Ventricular	0	11	B-Multi-tissue_structure
fibrillation	12	24	O
due	25	28	O
to	29	31	O
long	32	36	O
QT	37	39	O
syndrome	40	48	O
probably	49	57	O
caused	58	64	O
by	65	67	O
clindamycin	68	79	O
.	79	80	O

Prolongation	81	93	O
of	94	96	O
QT	97	99	O
time	100	104	O
interval	105	113	O
may	114	117	O
be	118	120	O
provoked	121	129	O
by	130	132	O
a	133	134	O
limited	135	142	O
number	143	149	O
of	150	152	O
drugs	153	158	O
,	158	159	O
especially	160	170	O
macrolide	171	180	O
antibiotics	181	192	O
.	192	193	O

We	194	196	O
describe	197	205	O
a	206	207	O
case	208	212	O
of	213	215	O
QT	216	218	O
time	219	223	O
interval	224	232	O
prolongation	233	245	O
induced	246	253	O
by	254	256	O
clindamycin	257	268	O
with	269	273	O
subsequent	274	284	O
repeated	285	293	O
ventricular	294	305	B-Multi-tissue_structure
fibrillation	306	318	O
and	319	322	O
resuscitation	323	336	O
;	336	337	O
there	338	343	O
is	344	346	O
no	347	349	O
previous	350	358	O
report	359	365	O
in	366	368	O
the	369	372	O
literature	373	383	O
of	384	386	O
QT	387	389	O
time	390	394	O
prolongation	395	407	O
caused	408	414	O
by	415	417	O
lincosamides	418	430	O
.	430	431	O

Decontamination	0	15	O
of	16	18	O
medical	19	26	O
equipment	27	36	O
-	36	37	O
-	37	38	O
manufacturer	38	50	O
'	50	51	O
s	51	52	O
problems	53	61	O
.	61	62	O

1	63	64	O
.	64	65	O

Small	66	71	O
items	72	77	O
sent	78	82	O
via	83	86	O
the	87	90	O
post	91	95	O
present	96	103	O
a	104	105	O
much	106	110	O
greater	111	118	O
hidden	119	125	O
hazard	126	132	O
and	133	136	O
a	137	138	O
higher	139	145	O
potential	146	155	O
for	156	159	O
catching	160	168	O
people	169	175	O
unawares	176	184	O
.	184	185	O

2	186	187	O
.	187	188	O

Large	189	194	O
items	195	200	O
accompanied	201	212	O
by	213	215	O
a	216	217	O
Decontamination	218	233	O
Certificate	234	245	O
need	246	250	O
to	251	253	O
be	254	256	O
treated	257	264	O
with	265	269	O
caution	270	277	O
because	278	285	O
only	286	290	O
those	291	296	O
surfaces	297	305	O
which	306	311	O
are	312	315	O
accessible	316	326	O
will	327	331	O
have	332	336	O
been	337	341	O
cleaned	342	349	O
;	349	350	O
as	351	353	O
soon	354	358	O
as	359	361	O
engineers	362	371	O
start	372	377	O
dismantling	378	389	O
equipment	390	399	O
,	399	400	O
areas	401	406	O
which	407	412	O
are	413	416	O
still	417	422	O
soiled	423	429	O
become	430	436	O
exposed	437	444	O
.	444	445	O

3	446	447	O
.	447	448	O

Total	449	454	O
co	455	457	O
-	457	458	O
operation	458	467	O
between	468	475	O
hospital	476	484	O
staff	485	490	O
and	491	494	O
service	495	502	O
engineers	503	512	O
is	513	515	O
necessary	516	525	O
to	526	528	O
resolve	529	536	O
these	537	542	O
problems	543	551	O
-	551	552	O
neither	552	559	O
can	560	563	O
work	564	568	O
safely	569	575	O
without	576	583	O
the	584	587	O
assistance	588	598	O
of	599	601	O
the	602	605	O
other	606	611	O
.	611	612	O

4	613	614	O
.	614	615	O

Many	616	620	O
products	621	629	O
in	630	632	O
use	633	636	O
in	637	639	O
hospitals	640	649	O
may	650	653	O
be	654	656	O
up	657	659	O
to	660	662	O
20	663	665	O
years	666	671	O
old	672	675	O
and	676	679	O
clearly	680	687	O
were	688	692	O
not	693	696	O
designed	697	705	O
to	706	708	O
facilitate	709	719	O
decontamination	720	735	O
and	736	739	O
therefore	740	749	O
present	750	757	O
far	758	761	O
greater	762	769	O
risk	770	774	O
to	775	777	O
all	778	781	O
concerned	782	791	O
.	791	792	O

5	793	794	O
.	794	795	O

For	796	799	O
the	800	803	O
future	804	810	O
there	811	816	O
a	817	818	O
clearly	819	826	O
a	827	828	O
responsibility	829	843	O
with	844	848	O
manufacturers	849	862	O
to	863	865	O
give	866	870	O
more	871	875	O
thought	876	883	O
to	884	886	O
the	887	890	O
design	891	897	O
of	898	900	O
their	901	906	O
equipment	907	916	O
so	917	919	O
that	920	924	O
decontamination	925	940	O
can	941	944	O
be	945	947	O
achieved	948	956	O
more	957	961	O
effectively	962	973	O
.	973	974	O

Enterococci	0	11	O
at	12	14	O
the	15	18	O
crossroads	19	29	O
of	30	32	O
food	33	37	O
safety	38	44	O
?	44	45	O

Enterococci	46	57	O
are	58	61	O
gram	62	66	O
-	66	67	O
positive	67	75	O
bacteria	76	84	O
and	85	88	O
fit	89	92	O
within	93	99	O
the	100	103	O
general	104	111	O
definition	112	122	O
of	123	125	O
lactic	126	132	O
acid	133	137	O
bacteria	138	146	O
.	146	147	O

Modern	148	154	O
classification	155	169	O
techniques	170	180	O
resulted	181	189	O
in	190	192	O
the	193	196	O
transfer	197	205	O
of	206	208	O
some	209	213	O
members	214	221	O
of	222	224	O
the	225	228	O
genus	229	234	O
Streptococcus	235	248	O
,	248	249	O
notably	250	257	O
some	258	262	O
of	263	265	O
the	266	269	O
Lancefield	270	280	O
'	280	281	O
s	281	282	O
group	283	288	O
D	289	290	O
streptococci	291	303	O
,	303	304	O
to	305	307	O
the	308	311	O
new	312	315	O
genus	316	321	O
Enterococcus	322	334	O
.	334	335	O

Enterococci	336	347	O
can	348	351	O
be	352	354	O
used	355	359	O
as	360	362	O
indicators	363	373	O
of	374	376	O
faecal	377	383	B-Organism_substance
contamination	384	397	O
.	397	398	O

They	399	403	O
have	404	408	O
been	409	413	O
implicated	414	424	O
in	425	427	O
outbreaks	428	437	O
of	438	440	O
foodborne	441	450	O
illness	451	458	O
,	458	459	O
and	460	463	O
they	464	468	O
have	469	473	O
been	474	478	O
ascribed	479	487	O
a	488	489	O
beneficial	490	500	O
or	501	503	O
detrimental	504	515	O
role	516	520	O
in	521	523	O
foods	524	529	O
.	529	530	O

In	531	533	O
processed	534	543	O
meats	544	549	B-Organism_subdivision
,	549	550	O
enterococci	551	562	O
may	563	566	O
survive	567	574	O
heat	575	579	O
processing	580	590	O
and	591	594	O
cause	595	600	O
spoilage	601	609	O
,	609	610	O
though	611	617	O
in	618	620	O
certain	621	628	O
cheeses	629	636	O
the	637	640	O
growth	641	647	O
of	648	650	O
enterococci	651	662	O
contributes	663	674	O
to	675	677	O
ripening	678	686	O
and	687	690	O
development	691	702	O
of	703	705	O
product	706	713	O
flavour	714	721	O
.	721	722	O

Some	723	727	O
enterococci	728	739	O
of	740	742	O
food	743	747	O
origin	748	754	O
produce	755	762	O
bacteriocins	763	775	O
that	776	780	O
exert	781	786	O
anti	787	791	O
-	791	792	O
Listeria	792	800	O
activity	801	809	O
.	809	810	O

Enterococci	811	822	O
are	823	826	O
used	827	831	O
as	832	834	O
probiotics	835	845	O
to	846	848	O
improve	849	856	O
the	857	860	O
microbial	861	870	O
balance	871	878	O
of	879	881	O
the	882	885	O
intestine	886	895	B-Organ
,	895	896	O
or	897	899	O
as	900	902	O
a	903	904	O
treatment	905	914	O
for	915	918	O
gastroenteritis	919	934	O
in	935	937	O
humans	938	944	O
and	945	948	O
animals	949	956	O
.	956	957	O

On	958	960	O
the	961	964	O
other	965	970	O
hand	971	975	O
,	975	976	O
enterococci	977	988	O
have	989	993	O
become	994	1000	O
recognised	1001	1011	O
as	1012	1014	O
serious	1015	1022	O
nosocomial	1023	1033	O
pathogens	1034	1043	O
causing	1044	1051	O
bacteraemia	1052	1063	O
,	1063	1064	O
endocarditis	1065	1077	O
,	1077	1078	O
urinary	1079	1086	B-Multi-tissue_structure
tract	1087	1092	I-Multi-tissue_structure
and	1093	1096	O
other	1097	1102	O
infections	1103	1113	O
.	1113	1114	O

This	1115	1119	O
is	1120	1122	O
in	1123	1125	O
part	1126	1130	O
explained	1131	1140	O
by	1141	1143	O
the	1144	1147	O
resistance	1148	1158	O
of	1159	1161	O
some	1162	1166	O
of	1167	1169	O
these	1170	1175	O
bacteria	1176	1184	O
to	1185	1187	O
most	1188	1192	O
antibiotics	1193	1204	O
that	1205	1209	O
are	1210	1213	O
currently	1214	1223	O
in	1224	1226	O
use	1227	1230	O
.	1230	1231	O

Resistance	1232	1242	O
is	1243	1245	O
acquired	1246	1254	O
by	1255	1257	O
gene	1258	1262	O
transfer	1263	1271	O
systems	1272	1279	O
,	1279	1280	O
such	1281	1285	O
as	1286	1288	O
conjugative	1289	1300	B-Cellular_component
or	1301	1303	O
nonconjugative	1304	1318	B-Cellular_component
plasmids	1319	1327	I-Cellular_component
or	1328	1330	O
transposons	1331	1342	O
.	1342	1343	O

Virulence	1344	1353	O
of	1354	1356	O
enterococci	1357	1368	O
is	1369	1371	O
not	1372	1375	O
well	1376	1380	O
understood	1381	1391	O
but	1392	1395	O
adhesins	1396	1404	O
,	1404	1405	O
haemolysin	1406	1416	O
,	1416	1417	O
hyaluronidase	1418	1431	O
,	1431	1432	O
aggregation	1433	1444	O
substance	1445	1454	O
and	1455	1458	O
gelatinase	1459	1469	O
are	1470	1473	O
putative	1474	1482	O
virulence	1483	1492	O
factors	1493	1500	O
.	1500	1501	O

It	1502	1504	O
appears	1505	1512	O
that	1513	1517	O
foods	1518	1523	O
could	1524	1529	O
be	1530	1532	O
a	1533	1534	O
source	1535	1541	O
of	1542	1544	O
vancomycin	1545	1555	O
-	1555	1556	O
resistant	1556	1565	O
enterococci	1566	1577	O
.	1577	1578	O

This	1579	1583	O
review	1584	1590	O
addresses	1591	1600	O
the	1601	1604	O
issue	1605	1610	O
of	1611	1613	O
the	1614	1617	O
health	1618	1624	O
risk	1625	1629	O
of	1630	1632	O
foods	1633	1638	O
containing	1639	1649	O
enterococci	1650	1661	O
.	1661	1662	O

Obstructive	0	11	O
nephropathy	12	23	O
:	23	24	O
lessons	25	32	O
from	33	37	O
cystic	38	44	O
kidney	45	51	B-Organ
disease	52	59	O
.	59	60	O

Obstructive	61	72	O
nephropathy	73	84	O
is	85	87	O
one	88	91	O
of	92	94	O
the	95	98	O
most	99	103	O
important	104	113	O
causes	114	120	O
of	121	123	O
renal	124	129	B-Organ
failure	130	137	O
in	138	140	O
infants	141	148	O
and	149	152	O
children	153	161	O
,	161	162	O
while	163	168	O
polycystic	169	179	O
kidney	180	186	B-Organ
disease	187	194	O
(	195	196	O
PKD	196	199	O
)	199	200	O
is	201	203	O
a	204	205	O
major	206	211	O
cause	212	217	O
of	218	220	O
renal	221	226	B-Organ
failure	227	234	O
in	235	237	O
the	238	241	O
adult	242	247	O
population	248	258	O
.	258	259	O

This	260	264	O
review	265	271	O
summarizes	272	282	O
the	283	286	O
evidence	287	295	O
that	296	300	O
there	301	306	O
may	307	310	O
be	311	313	O
a	314	315	O
number	316	322	O
of	323	325	O
mechanisms	326	336	O
common	337	343	O
to	344	346	O
the	347	350	O
pathophysiology	351	366	O
of	367	369	O
both	370	374	O
conditions	375	385	O
.	385	386	O

In	387	389	O
animal	390	396	O
models	397	403	O
of	404	406	O
obstructive	407	418	O
nephropathy	419	430	O
and	431	434	O
PKD	435	438	O
,	438	439	O
the	440	443	O
renal	444	449	B-Multi-tissue_structure
tubular	450	457	I-Multi-tissue_structure
expression	458	468	O
of	469	471	O
epidermal	472	481	O
growth	482	488	O
factor	489	495	O
is	496	498	O
suppressed	499	509	O
,	509	510	O
and	511	514	O
expression	515	525	O
of	526	528	O
clusterin	529	538	O
is	539	541	O
increased	542	551	O
,	551	552	O
both	553	557	O
of	558	560	O
which	561	566	O
suggest	567	574	O
arrested	575	583	O
maturation	584	594	O
or	595	597	O
dedifferentiation	598	615	O
of	616	618	O
the	619	622	O
tubular	623	630	B-Cell
cell	631	635	I-Cell
.	635	636	O

There	637	642	O
is	643	645	O
a	646	647	O
marked	648	654	O
increase	655	663	O
in	664	666	O
apoptosis	667	676	O
of	677	679	O
epithelial	680	690	B-Cell
cells	691	696	I-Cell
in	697	699	O
dilated	700	707	O
tubules	708	715	B-Multi-tissue_structure
,	715	716	O
associated	717	727	O
with	728	732	O
an	733	735	O
increase	736	744	O
in	745	747	O
apoptotic	748	757	O
stimuli	758	765	O
.	765	766	O

The	767	770	O
renin	771	776	O
-	776	777	O
angiotensin	777	788	O
system	789	795	O
is	796	798	O
activated	799	808	O
in	809	811	O
both	812	816	O
obstructive	817	828	O
nephropathy	829	840	O
and	841	844	O
PKD	845	848	O
,	848	849	O
which	850	855	O
may	856	859	O
contribute	860	870	O
to	871	873	O
tubular	874	881	B-Multi-tissue_structure
atrophy	882	889	O
and	890	893	O
interstitial	894	906	B-Immaterial_anatomical_entity
fibrosis	907	915	O
,	915	916	O
which	917	922	O
characterize	923	935	O
the	936	939	O
progression	940	951	O
of	952	954	O
both	955	959	O
conditions	960	970	O
.	970	971	O

Focal	972	977	O
cystic	978	984	O
dilatation	985	995	O
of	996	998	O
the	999	1002	O
tubule	1003	1009	B-Multi-tissue_structure
is	1010	1012	O
found	1013	1018	O
in	1019	1021	O
obstructive	1022	1033	O
nephropathy	1034	1045	O
,	1045	1046	O
while	1047	1052	O
tubular	1053	1060	B-Multi-tissue_structure
obstruction	1061	1072	O
is	1073	1075	O
present	1076	1083	O
in	1084	1086	O
cystic	1087	1093	O
kidney	1094	1100	B-Organ
disease	1101	1108	O
.	1108	1109	O

It	1110	1112	O
is	1113	1115	O
therefore	1116	1125	O
likely	1126	1132	O
that	1133	1137	O
elucidation	1138	1149	O
of	1150	1152	O
the	1153	1156	O
effects	1157	1164	O
of	1165	1167	O
mechanical	1168	1178	O
stretch	1179	1186	O
on	1187	1189	O
renal	1190	1195	B-Cell
tubular	1196	1203	I-Cell
epithelial	1204	1214	I-Cell
cells	1215	1220	I-Cell
will	1221	1225	O
contribute	1226	1236	O
to	1237	1239	O
our	1240	1243	O
understanding	1244	1257	O
of	1258	1260	O
both	1261	1265	O
conditions	1266	1276	O
.	1276	1277	O

Genuine	0	7	O
monovalent	8	18	O
ligands	19	26	O
of	27	29	O
TrkA	30	34	O
nerve	35	40	O
growth	41	47	O
factor	48	54	O
receptors	55	64	O
reveal	65	71	O
a	72	73	O
novel	74	79	O
pharmacological	80	95	O
mechanism	96	105	O
of	106	108	O
action	109	115	O
.	115	116	O

Developing	117	127	O
small	128	133	O
molecule	134	142	O
agonistic	143	152	O
ligands	153	160	O
for	161	164	O
tyrosine	165	173	O
kinase	174	180	O
receptors	181	190	O
has	191	194	O
been	195	199	O
difficult	200	209	O
,	209	210	O
and	211	214	O
it	215	217	O
is	218	220	O
generally	221	230	O
thought	231	238	O
that	239	243	O
such	244	248	O
ligands	249	256	O
require	257	264	O
bivalency	265	274	O
.	274	275	O

Moreover	276	284	O
,	284	285	O
multisubunit	286	298	O
receptors	299	308	O
are	309	312	O
difficult	313	322	O
to	323	325	O
target	326	332	O
,	332	333	O
because	334	341	O
each	342	346	O
subunit	347	354	O
contributes	355	366	O
to	367	369	O
ligand	370	376	O
affinity	377	385	O
,	385	386	O
and	387	390	O
each	391	395	O
subunit	396	403	O
may	404	407	O
have	408	412	O
distinct	413	421	O
and	422	425	O
sometimes	426	435	O
opposing	436	444	O
functions	445	454	O
.	454	455	O

Here	456	460	O
,	460	461	O
the	462	465	O
nerve	466	471	O
growth	472	478	O
factor	479	485	O
receptor	486	494	O
subunits	495	503	O
p75	504	507	O
and	508	511	O
the	512	515	O
tyrosine	516	524	O
kinase	525	531	O
TrkA	532	536	O
were	537	541	O
studied	542	549	O
using	550	555	O
artificial	556	566	O
ligands	567	574	O
that	575	579	O
bind	580	584	O
specifically	585	597	O
to	598	600	O
their	601	606	O
extracellular	607	620	B-Immaterial_anatomical_entity
domain	621	627	O
.	627	628	O

Bivalent	629	637	O
TrkA	638	642	O
ligands	643	650	O
afford	651	657	O
robust	658	664	O
signals	665	672	O
.	672	673	O

However	674	681	O
,	681	682	O
genuine	683	690	O
monomeric	691	700	O
and	701	704	O
monovalent	705	715	O
TrkA	716	720	O
ligands	721	728	O
afford	729	735	O
partial	736	743	O
agonism	744	751	O
,	751	752	O
activate	753	761	O
the	762	765	O
tyrosine	766	774	O
kinase	775	781	O
activity	782	790	O
,	790	791	O
cause	792	797	O
receptor	798	806	O
internalization	807	822	O
,	822	823	O
and	824	827	O
induce	828	834	O
survival	835	843	O
and	844	847	O
differentiation	848	863	O
in	864	866	O
cell	867	871	B-Cell
lines	872	877	I-Cell
and	878	881	O
primary	882	889	O
neurons	890	897	B-Cell
.	897	898	O

Monomeric	899	908	O
and	909	912	O
monovalent	913	923	O
TrkA	924	928	O
ligands	929	936	O
can	937	940	O
synergize	941	950	O
with	951	955	O
ligands	956	963	O
that	964	968	O
bind	969	973	O
the	974	977	O
p75	978	981	O
subunit	982	989	O
.	989	990	O

However	991	998	O
,	998	999	O
the	1000	1003	O
p75	1004	1007	O
ligands	1008	1015	O
used	1016	1020	O
in	1021	1023	O
this	1024	1028	O
study	1029	1034	O
must	1035	1039	O
be	1040	1042	O
bivalent	1043	1051	O
,	1051	1052	O
and	1053	1056	O
monovalent	1057	1067	O
p75	1068	1071	O
ligands	1072	1079	O
have	1080	1084	O
no	1085	1087	O
effect	1088	1094	O
.	1094	1095	O

These	1096	1101	O
findings	1102	1110	O
will	1111	1115	O
be	1116	1118	O
useful	1119	1125	O
in	1126	1128	O
designing	1129	1138	O
and	1139	1142	O
developing	1143	1153	O
screens	1154	1161	O
of	1162	1164	O
small	1165	1170	O
molecules	1171	1180	O
selective	1181	1190	O
for	1191	1194	O
tyrosine	1195	1203	O
kinase	1204	1210	O
receptors	1211	1220	O
and	1221	1224	O
indicate	1225	1233	O
that	1234	1238	O
strategies	1239	1249	O
for	1250	1253	O
designing	1254	1263	O
agonists	1264	1272	O
of	1273	1275	O
multisubunit	1276	1288	O
receptors	1289	1298	O
require	1299	1306	O
consideration	1307	1320	O
of	1321	1323	O
the	1324	1327	O
role	1328	1332	O
of	1333	1335	O
each	1336	1340	O
subunit	1341	1348	O
.	1348	1349	O

Last	1350	1354	O
,	1354	1355	O
the	1356	1359	O
strategy	1360	1368	O
of	1369	1371	O
using	1372	1377	O
anti	1378	1382	O
-	1382	1383	O
receptor	1383	1391	O
mAbs	1392	1396	O
and	1397	1400	O
small	1401	1406	O
molecule	1407	1415	O
hormone	1416	1423	O
mimics	1424	1430	O
as	1431	1433	O
receptor	1434	1442	O
ligands	1443	1450	O
could	1451	1456	O
be	1457	1459	O
applied	1460	1467	O
to	1468	1470	O
the	1471	1474	O
study	1475	1480	O
of	1481	1483	O
many	1484	1488	O
other	1489	1494	O
heteromeric	1495	1506	O
cell	1507	1511	B-Cellular_component
surface	1512	1519	I-Cellular_component
receptors	1520	1529	O
.	1529	1530	O

Application	0	11	O
of	12	14	O
microsatellite	15	29	O
PCR	30	33	O
techniques	34	44	O
in	45	47	O
the	48	51	O
identification	52	66	O
of	67	69	O
mixed	70	75	O
up	76	78	O
tissue	79	85	B-Tissue
specimens	86	95	I-Tissue
in	96	98	O
surgical	99	107	O
pathology	108	117	O
.	117	118	O

A	119	120	O
fragment	121	129	B-Pathological_formation
of	130	132	O
tumour	133	139	B-Pathological_formation
was	140	143	O
erroneously	144	155	O
mixed	156	161	O
up	162	164	O
with	165	169	O
an	170	172	O
endometrial	173	184	B-Tissue
biopsy	185	191	I-Tissue
.	191	192	O

Micro	193	198	O
-	198	199	O
satellite	199	208	O
polymerase	209	219	O
chain	220	225	O
reaction	226	234	O
(	235	236	O
PCR	236	239	O
)	239	240	O
clearly	241	248	O
demonstrated	249	261	O
the	262	265	O
extraneous	266	276	O
nature	277	283	O
of	284	286	O
the	287	290	O
fragment	291	299	B-Pathological_formation
.	299	300	O

Micro	301	306	O
-	306	307	O
satellite	307	316	O
PCR	317	320	O
may	321	324	O
be	325	327	O
useful	328	334	O
for	335	338	O
the	339	342	O
identification	343	357	O
of	358	360	O
mis	361	364	O
-	364	365	O
labelled	365	373	O
or	374	376	O
mismatched	377	387	O
tissue	388	394	B-Tissue
fragments	395	404	I-Tissue
in	405	407	O
surgical	408	416	O
pathology	417	426	O
specimens	427	436	B-Tissue
.	436	437	O

Specific	0	8	O
subgroup	9	17	O
B	18	19	O
adenovirus	20	30	O
diagnosis	31	40	O
by	41	43	O
PCR	44	47	O
of	48	50	O
the	51	54	O
fibre	55	60	O
gene	61	65	O
.	65	66	O

OBJECTIVE	67	76	O
:	76	77	O

A	78	79	O
highly	80	86	O
sensitive	87	96	O
and	97	100	O
specific	101	109	O
PCR	110	113	O
assay	114	119	O
targeting	120	129	O
regions	130	137	O
of	138	140	O
the	141	144	O
fibre	145	150	O
gene	151	155	O
was	156	159	O
developed	160	169	O
for	170	173	O
the	174	177	O
identification	178	192	O
of	193	195	O
subgroup	196	204	O
B	205	206	O
adenovirus	207	217	O
strains	218	225	O
.	225	226	O

This	227	231	O
is	232	234	O
critical	235	243	O
,	243	244	O
since	245	250	O
these	251	256	O
adenovirus	257	267	O
strains	268	275	O
are	276	279	O
frequently	280	290	O
associated	291	301	O
with	302	306	O
severe	307	313	O
respiratory	314	325	B-Anatomical_system
infections	326	336	O
in	337	339	O
infants	340	347	O
and	348	351	O
new	352	355	O
-	355	356	O
borns	356	361	O
.	361	362	O

METHODS	363	370	O
:	370	371	O

Clinical	372	380	O
samples	381	388	B-Organism_substance
from	389	393	O
nasopharyngeal	394	408	B-Organism_substance
aspirates	409	418	I-Organism_substance
were	419	423	O
analysed	424	432	O
by	433	435	O
PCR	436	439	O
using	440	445	O
several	446	453	O
sets	454	458	O
of	459	461	O
primers	462	469	O
corresponding	470	483	O
to	484	486	O
sequences	487	496	O
of	497	499	O
the	500	503	O
gene	504	508	O
coding	509	515	O
for	516	519	O
the	520	523	O
fibre	524	529	O
protein	530	537	O
.	537	538	O

RESULTS	539	546	O
:	546	547	O

The	548	551	O
assay	552	557	O
allowed	558	565	O
the	566	569	O
detection	570	579	O
and	580	583	O
identification	584	598	O
of	599	601	O
all	602	605	O
the	606	609	O
genotypes	610	619	O
of	620	622	O
adenovirus	623	633	O
subgroup	634	642	O
B	643	644	O
,	644	645	O
based	646	651	O
on	652	654	O
the	655	658	O
size	659	663	O
of	664	666	O
the	667	670	O
amplified	671	680	O
product	681	688	O
when	689	693	O
analysed	694	702	O
on	703	705	O
polyacrilamide	706	720	O
gel	721	724	O
electrophoresis	725	740	O
.	740	741	O

Specifically	742	754	O
,	754	755	O
one	756	759	O
set	760	763	O
of	764	766	O
primers	767	774	O
was	775	778	O
able	779	783	O
to	784	786	O
amplify	787	794	O
DNA	795	798	O
of	799	801	O
subgroup	802	810	O
B	811	812	O
but	813	816	O
not	817	820	O
subgroup	821	829	O
C	830	831	O
and	832	835	O
E	836	837	O
viruses	838	845	O
.	845	846	O

CONCLUSION	847	857	O
:	857	858	O

The	859	862	O
detection	863	872	O
of	873	875	O
adenovirus	876	886	O
and	887	890	O
the	891	894	O
genotyping	895	905	O
can	906	909	O
be	910	912	O
done	913	917	O
on	918	920	O
a	921	922	O
routine	923	930	O
basis	931	936	O
by	937	939	O
a	940	941	O
PCR	942	945	O
assay	946	951	O
using	952	957	O
the	958	961	O
fibre	962	967	O
gene	968	972	O
as	973	975	O
a	976	977	O
target	978	984	O
.	984	985	O

The	986	989	O
assay	990	995	O
allows	996	1002	O
the	1003	1006	O
identification	1007	1021	O
of	1022	1024	O
ADV	1025	1028	O
subgroup	1029	1037	O
B	1038	1039	O
,	1039	1040	O
including	1041	1050	O
genotype	1051	1059	O
7h	1060	1062	O
,	1062	1063	O
which	1064	1069	O
is	1070	1072	O
the	1073	1076	O
single	1077	1083	O
most	1084	1088	O
important	1089	1098	O
viral	1099	1104	O
pathogen	1105	1113	O
associated	1114	1124	O
with	1125	1129	O
respiratory	1130	1141	B-Anatomical_system
diseases	1142	1150	O
in	1151	1153	O
infants	1154	1161	O
and	1162	1165	O
young	1166	1171	O
children	1172	1180	O
in	1181	1183	O
the	1184	1187	O
southern	1188	1196	O
part	1197	1201	O
of	1202	1204	O
South	1205	1210	O
America	1211	1218	O
.	1218	1219	O

[	0	1	O
Anesthetic	1	11	O
management	12	22	O
of	23	25	O
a	26	27	O
patient	28	35	O
with	36	40	O
Dyggve	41	47	O
-	47	48	O
Melchior	48	56	O
-	56	57	O
Clausen	57	64	O
syndrome	65	73	O
]	73	74	O
.	74	75	O

The	76	79	O
Dyggve	80	86	O
-	86	87	O
Melchior	87	95	O
-	95	96	O
Clausen	96	103	O
syndrome	104	112	O
(	113	114	O
DMCS	114	118	O
)	118	119	O
is	120	122	O
a	123	124	O
rare	125	129	O
autosomal	130	139	O
recessive	140	149	O
skeletal	150	158	B-Anatomical_system
dysplasia	159	168	O
characterized	169	182	O
by	183	185	O
short	186	191	O
-	191	192	O
trunk	192	197	B-Organism_subdivision
dwarfism	198	206	O
and	207	210	O
mental	211	217	O
retardation	218	229	O
.	229	230	O

A	231	232	O
49	233	235	O
-	235	236	O
year	236	240	O
-	240	241	O
old	241	244	O
male	245	249	O
with	250	254	O
DMCS	255	259	O
underwent	260	269	O
resection	270	279	O
arthroplasty	280	292	O
for	293	296	O
contracture	297	308	O
of	309	311	O
the	312	315	O
right	316	321	B-Multi-tissue_structure
hip	322	325	I-Multi-tissue_structure
joint	326	331	I-Multi-tissue_structure
under	332	337	O
general	338	345	O
anesthesia	346	356	O
using	357	362	O
thiamylal	363	372	O
,	372	373	O
nitrous	374	381	O
oxide	382	387	O
,	387	388	O
sevoflurane	389	400	O
,	400	401	O
and	402	405	O
vecuronium	406	416	O
.	416	417	O

Although	418	426	O
he	427	429	O
was	430	433	O
assumed	434	441	O
to	442	444	O
have	445	449	O
difficult	450	459	O
airway	460	466	B-Multi-tissue_structure
due	467	470	O
to	471	473	O
short	474	479	O
neck	480	484	B-Organism_subdivision
,	484	485	O
macroglossia	486	498	O
,	498	499	O
and	500	503	O
disturbance	504	515	O
of	516	518	O
neck	519	523	B-Organism_subdivision
flexion	524	531	O
,	531	532	O
tracheal	533	541	B-Multi-tissue_structure
intubation	542	552	O
was	553	556	O
not	557	560	O
difficult	561	570	O
.	570	571	O

No	572	574	O
complications	575	588	O
including	589	598	O
malignant	599	608	O
hyperthermia	609	621	O
were	622	626	O
observed	627	635	O
during	636	642	O
the	643	646	O
95	647	649	O
min	650	653	O
of	654	656	O
the	657	660	O
operation	661	670	O
.	670	671	O

Assembly	0	8	O
strategies	9	19	O
and	20	23	O
GTPase	24	30	O
regulation	31	41	O
of	42	44	O
the	45	48	O
eukaryotic	49	59	O
and	60	63	O
Escherichia	64	75	O
coil	76	80	O
translocons	81	92	B-Cellular_component
.	92	93	O

The	94	97	O
translocation	98	111	O
of	112	114	O
most	115	119	O
proteins	120	128	O
across	129	135	O
the	136	139	O
endoplasmic	140	151	B-Cellular_component
reticulum	152	161	I-Cellular_component
or	162	164	O
bacterial	165	174	O
inner	175	180	B-Cellular_component
membrane	181	189	I-Cellular_component
occurs	190	196	O
through	197	204	O
an	205	207	O
aqueous	208	215	B-Cellular_component
pore	216	220	I-Cellular_component
that	221	225	O
spans	226	231	O
the	232	235	O
membrane	236	244	B-Cellular_component
.	244	245	O

Substrates	246	256	O
that	257	261	O
are	262	265	O
translocated	266	278	O
co	279	281	O
-	281	282	O
translationally	282	297	O
across	298	304	O
the	305	308	O
membrane	309	317	B-Cellular_component
are	318	321	O
directed	322	330	O
to	331	333	O
the	334	337	O
translocation	338	351	B-Cellular_component
pore	352	356	I-Cellular_component
via	357	360	O
an	361	363	O
interaction	364	375	O
between	376	383	O
the	384	387	O
cytosolic	388	397	B-Organism_substance
signal	398	404	O
recognition	405	416	O
particle	417	425	O
and	426	429	O
its	430	433	O
membrane	434	442	B-Cellular_component
-	442	443	O
bound	443	448	O
receptor	449	457	O
.	457	458	O

Together	459	467	O
the	468	471	O
translocation	472	485	B-Cellular_component
pore	486	490	I-Cellular_component
and	491	494	O
the	495	498	O
receptor	499	507	O
are	508	511	O
referred	512	520	O
to	521	523	O
as	524	526	O
a	527	528	O
translocon	529	539	B-Cellular_component
.	539	540	O

By	541	543	O
studying	544	552	O
the	553	556	O
biogenesis	557	567	O
of	568	570	O
the	571	574	O
translocon	575	585	B-Cellular_component
a	586	587	O
number	588	594	O
of	595	597	O
alternate	598	607	O
targeting	608	617	O
and	618	621	O
membrane	622	630	B-Cellular_component
-	630	631	O
integration	631	642	O
pathways	643	651	O
have	652	656	O
been	657	661	O
discovered	662	672	O
that	673	677	O
operate	678	685	O
independently	686	699	O
of	700	702	O
the	703	706	O
signal	707	713	O
recognition	714	725	O
particle	726	734	O
(	735	736	O
SRP	736	739	O
)	739	740	O
pathway	741	748	O
.	748	749	O

The	750	753	O
novel	754	759	O
assembly	760	768	O
strategies	769	779	O
of	780	782	O
the	783	786	O
translocon	787	797	B-Cellular_component
and	798	801	O
the	802	805	O
ways	806	810	O
in	811	813	O
which	814	819	O
these	820	825	O
components	826	836	O
interact	837	845	O
to	846	848	O
ensure	849	855	O
the	856	859	O
fidelity	860	868	O
and	869	872	O
unidirectionality	873	890	O
of	891	893	O
the	894	897	O
targeting	898	907	O
and	908	911	O
translocation	912	925	O
process	926	933	O
are	934	937	O
reviewed	938	946	O
here	947	951	O
.	951	952	O

Phonology	0	9	O
:	9	10	O
a	11	12	O
review	13	19	O
and	20	23	O
proposals	24	33	O
from	34	38	O
a	39	40	O
connectionist	41	54	O
perspective	55	66	O
.	66	67	O

A	68	69	O
parallel	70	78	O
distributed	79	90	O
processing	91	101	O
(	102	103	O
PDP	103	106	O
)	106	107	O
model	108	113	O
of	114	116	O
phonological	117	129	O
processing	130	140	O
is	141	143	O
developed	144	153	O
,	153	154	O
including	155	164	O
components	165	175	O
to	176	178	O
support	179	186	O
repetition	187	197	O
,	197	198	O
auditory	199	207	O
processing	208	218	O
,	218	219	O
comprehension	220	233	O
,	233	234	O
and	235	238	O
language	239	247	O
production	248	258	O
.	258	259	O

From	260	264	O
the	265	268	O
performance	269	280	O
of	281	283	O
the	284	287	O
PDP	288	291	O
reading	292	299	O
model	300	305	O
of	306	308	O
Plaut	309	314	O
,	314	315	O
McClelland	316	326	O
,	326	327	O
Seidenberg	328	338	O
,	338	339	O
and	340	343	O
Patterson	344	353	O
(	354	355	O
1996	355	359	O
)	359	360	O
,	360	361	O
it	362	364	O
is	365	367	O
inferred	368	376	O
that	377	381	O
the	382	385	O
acoustic	386	394	O
-	394	395	O
articulatory	395	407	O
motor	408	413	O
pattern	414	421	O
associator	422	432	O
that	433	437	O
supports	438	446	O
repetition	447	457	O
provides	458	466	O
the	467	470	O
basis	471	476	O
for	477	480	O
phonological	481	493	O
sequence	494	502	O
knowledge	503	512	O
.	512	513	O

From	514	518	O
the	519	522	O
observation	523	534	O
that	535	539	O
many	540	544	O
patients	545	553	O
make	554	558	O
phonemic	559	567	O
paraphasic	568	578	O
errors	579	585	O
in	586	588	O
language	589	597	O
production	598	608	O
,	608	609	O
as	610	612	O
in	613	615	O
repetition	616	626	O
,	626	627	O
it	628	630	O
is	631	633	O
argued	634	640	O
that	641	645	O
there	646	651	O
must	652	656	O
be	657	659	O
a	660	661	O
direct	662	668	O
link	669	673	O
between	674	681	O
distributed	682	693	O
concept	694	701	O
representations	702	717	O
(	718	719	O
lexical	719	726	O
semantic	727	735	O
knowledge	736	745	O
)	745	746	O
and	747	750	O
this	751	755	O
network	756	763	O
representation	764	778	O
of	779	781	O
sequence	782	790	O
knowledge	791	800	O
.	800	801	O

In	802	804	O
this	805	809	O
way	810	813	O
,	813	814	O
both	815	819	O
lexical	820	827	O
semantic	828	836	O
and	837	840	O
phonotactic	841	852	O
constraints	853	864	O
are	865	868	O
brought	869	876	O
to	877	879	O
bear	880	884	O
on	885	887	O
language	888	896	O
production	897	907	O
.	907	908	O

The	909	912	O
literature	913	923	O
on	924	926	O
phonological	927	939	O
function	940	948	O
in	949	951	O
normal	952	958	O
subjects	959	967	O
(	968	969	O
slip	969	973	O
-	973	974	O
of	974	976	O
-	976	977	O
the	977	980	O
-	980	981	O
tongue	981	987	O
corpora	988	995	O
)	995	996	O
and	997	1000	O
in	1001	1003	O
patients	1004	1012	O
with	1013	1017	O
aphasia	1018	1025	O
is	1026	1028	O
critically	1029	1039	O
reviewed	1040	1048	O
from	1049	1053	O
this	1054	1058	O
perspective	1059	1070	O
.	1070	1071	O

The	1072	1075	O
relationship	1076	1088	O
between	1089	1096	O
acoustic	1097	1105	O
and	1106	1109	O
articulatory	1110	1122	O
motor	1123	1128	O
representations	1129	1144	O
in	1145	1147	O
the	1148	1151	O
process	1152	1159	O
of	1160	1162	O
phonetic	1163	1171	O
perception	1172	1182	O
is	1183	1185	O
considered	1186	1196	O
.	1196	1197	O

Repetition	1198	1208	O
and	1209	1212	O
reproduction	1213	1225	O
conduction	1226	1236	O
aphasia	1237	1244	O
are	1245	1248	O
reviewed	1249	1257	O
in	1258	1260	O
detail	1261	1267	O
and	1268	1271	O
extended	1272	1280	O
consideration	1281	1294	O
is	1295	1297	O
given	1298	1303	O
to	1304	1306	O
the	1307	1310	O
representation	1311	1325	O
of	1326	1328	O
auditory	1329	1337	O
verbal	1338	1344	O
short	1345	1350	O
-	1350	1351	O
term	1351	1355	O
memory	1356	1362	O
in	1363	1365	O
the	1366	1369	O
model	1370	1375	O
.	1375	1376	O

Finally	1377	1384	O
,	1384	1385	O
the	1386	1389	O
PDP	1390	1393	O
model	1394	1399	O
is	1400	1402	O
reconciled	1403	1413	O
with	1414	1418	O
information	1419	1430	O
processing	1431	1441	O
models	1442	1448	O
of	1449	1451	O
phonological	1452	1464	O
processing	1465	1475	O
,	1475	1476	O
including	1477	1486	O
that	1487	1491	O
of	1492	1494	O
Lichtheim	1495	1504	O
,	1504	1505	O
and	1506	1509	O
with	1510	1514	O
current	1515	1522	O
knowledge	1523	1532	O
of	1533	1535	O
the	1536	1539	O
anatomic	1540	1548	O
localization	1549	1561	O
of	1562	1564	O
phonological	1565	1577	O
processing	1578	1588	O
.	1588	1589	O

Although	1590	1598	O
no	1599	1601	O
simulations	1602	1613	O
of	1614	1616	O
the	1617	1620	O
model	1621	1626	O
were	1627	1631	O
run	1632	1635	O
,	1635	1636	O
a	1637	1638	O
number	1639	1645	O
of	1646	1648	O
simulation	1649	1659	O
studies	1660	1667	O
are	1668	1671	O
proposed	1672	1680	O
.	1680	1681	O

Male	0	4	O
role	5	9	O
in	10	12	O
fertility	13	22	O
decisions	23	32	O
in	33	35	O
Robertsport	36	47	O
,	47	48	O
Liberia	49	56	O
:	56	57	O
an	58	60	O
experimental	61	73	O
exercise	74	82	O
for	83	86	O
policy	87	93	O
formulation	94	105	O
.	105	106	O

There	107	112	O
is	113	115	O
a	116	117	O
tendency	118	126	O
to	127	129	O
believe	130	137	O
that	138	142	O
in	143	145	O
African	146	153	O
societies	154	163	O
men	164	167	O
are	168	171	O
the	172	175	O
dominant	176	184	O
decision	185	193	O
makers	194	200	O
in	201	203	O
the	204	207	O
family	208	214	O
.	214	215	O

In	217	219	O
Robertsport	220	231	O
,	231	232	O
Liberia	233	240	O
,	240	241	O
there	242	247	O
are	248	251	O
indications	252	263	O
that	264	268	O
,	268	269	O
with	270	274	O
respect	275	282	O
to	283	285	O
fertility	286	295	O
regulation	296	306	O
,	306	307	O
the	308	311	O
dominance	312	321	O
of	322	324	O
the	325	328	O
husband	329	336	O
in	337	339	O
fertility	340	349	O
decisions	350	359	O
exists	360	366	O
,	366	367	O
but	368	371	O
it	372	374	O
is	375	377	O
also	378	382	O
apparent	383	391	O
that	392	396	O
many	397	401	O
of	402	404	O
these	405	410	O
decisions	411	420	O
are	421	424	O
made	425	429	O
jointly	430	437	O
by	438	440	O
both	441	445	O
husband	446	453	O
and	454	457	O
wife	458	462	O
.	462	463	O

Education	465	474	O
is	475	477	O
particularly	478	490	O
influential	491	502	O
in	503	505	O
the	506	509	O
joint	510	515	O
fertility	516	525	O
decision	526	534	O
-	534	535	O
making	535	541	O
process	542	549	O
.	549	550	O

The	552	555	O
100	556	559	O
husbands	560	568	O
sampled	569	576	O
in	577	579	O
1982	580	584	O
desired	585	592	O
a	593	594	O
large	595	600	O
number	601	607	O
of	608	610	O
children	611	619	O
and	620	623	O
had	624	627	O
experience	628	638	O
with	639	643	O
infant	644	650	O
and	651	654	O
child	655	660	O
mortality	661	670	O
.	670	671	O

If	673	675	O
family	676	682	O
planning	683	691	O
programs	692	700	O
should	701	707	O
attain	708	714	O
their	715	720	O
goals	721	726	O
,	726	727	O
men	728	731	O
should	732	738	O
be	739	741	O
more	742	746	O
involved	747	755	O
,	755	756	O
than	757	761	O
at	762	764	O
present	765	772	O
,	772	773	O
in	774	776	O
every	777	782	O
aspect	783	789	O
of	790	792	O
the	793	796	O
programs	797	805	O
.	805	806	O

Equally	808	815	O
important	816	825	O
is	826	828	O
the	829	832	O
urgency	833	840	O
for	841	844	O
studies	845	852	O
related	853	860	O
to	861	863	O
the	864	867	O
role	868	872	O
of	873	875	O
men	876	879	O
in	880	882	O
fertility	883	892	O
regulation	893	903	O
,	903	904	O
using	905	910	O
adequately	911	921	O
large	922	927	O
samples	928	935	O
.	935	936	O

Act	0	3	O
No	4	6	O
.	6	7	O
16	8	10	O
.	10	11	O
045	11	14	O
of	16	18	O
2	19	20	O
June	21	25	O
1989	26	30	O
prohibiting	31	42	O
all	43	46	O
discrimination	47	61	O
that	62	66	O
violates	67	75	O
the	76	79	O
principle	80	89	O
of	90	92	O
equality	93	101	O
of	102	104	O
treatment	105	114	O
and	115	118	O
opportunities	119	132	O
for	133	136	O
both	137	141	O
sexes	142	147	O
in	148	150	O
all	151	154	O
sectors	155	162	O
of	163	165	O
labor	166	171	O
activity	172	180	O
.	180	181	O

This	182	186	O
Uruguayan	187	196	O
Act	197	200	O
prohibits	201	210	O
discrimination	211	225	O
in	226	228	O
employment	229	239	O
with	240	244	O
respect	245	252	O
to	253	255	O
the	256	259	O
following	260	269	O
areas	270	275	O
,	275	276	O
among	277	282	O
others	283	289	O
:	289	290	O
1	291	292	O
)	292	293	O
advertising	294	305	O
for	306	309	O
the	310	313	O
provision	314	323	O
of	324	326	O
positions	327	336	O
;	336	337	O
2	338	339	O
)	339	340	O
selection	341	350	O
criteria	351	359	O
;	359	360	O
3	361	362	O
)	362	363	O
recruitment	364	375	O
and	376	379	O
hiring	380	386	O
;	386	387	O
4	388	389	O
)	389	390	O
evaluation	391	401	O
of	402	404	O
performance	405	416	O
criteria	417	425	O
;	425	426	O
5	427	428	O
)	428	429	O
the	430	433	O
right	434	439	O
to	440	442	O
advancement	443	454	O
and	455	458	O
promotion	459	468	O
;	468	469	O
6	470	471	O
)	471	472	O
labour	473	479	O
stability	480	489	O
;	489	490	O
7	491	492	O
)	492	493	O
social	494	500	O
benefits	501	509	O
;	509	510	O
8	511	512	O
)	512	513	O
suspension	514	524	O
and	525	528	O
dismissal	529	538	O
,	538	539	O
particularly	540	552	O
in	553	555	O
cases	556	561	O
involving	562	571	O
a	572	573	O
change	574	580	O
of	581	583	O
civil	584	589	O
status	590	596	O
,	596	597	O
pregnancy	598	607	O
,	607	608	O
or	609	611	O
nursing	612	619	O
;	619	620	O
9	621	622	O
)	622	623	O
possibilities	624	637	O
for	638	641	O
professional	642	654	O
and	655	658	O
technical	659	668	O
education	669	678	O
or	679	681	O
retraining	682	692	O
;	692	693	O
and	694	697	O
10	698	700	O
)	700	701	O
remuneration	702	714	O
criteria	715	723	O
.	723	724	O

Reserving	725	734	O
places	735	741	O
for	742	745	O
one	746	749	O
sex	750	753	O
because	754	761	O
of	762	764	O
the	765	768	O
presence	769	777	O
of	778	780	O
activities	781	791	O
in	792	794	O
which	795	800	O
the	801	804	O
sex	805	808	O
of	809	811	O
the	812	815	O
employee	816	824	O
is	825	827	O
essential	828	837	O
for	838	841	O
performance	842	853	O
or	854	856	O
to	857	859	O
comply	860	866	O
with	867	871	O
international	872	885	O
labor	886	891	O
treaties	892	900	O
does	901	905	O
not	906	909	O
constitute	910	920	O
discrimination	921	935	O
.	935	936	O

Nor	938	941	O
do	942	944	O
compensatory	945	957	O
acts	958	962	O
designed	963	971	O
to	972	974	O
promote	975	982	O
equality	983	991	O
of	992	994	O
opportunities	995	1008	O
and	1009	1012	O
treatment	1013	1022	O
of	1023	1025	O
both	1026	1030	O
sexes	1031	1036	O
in	1037	1039	O
concrete	1040	1048	O
situations	1049	1059	O
.	1059	1060	O

In	1061	1063	O
cases	1064	1069	O
where	1070	1075	O
the	1076	1079	O
provisions	1080	1090	O
of	1091	1093	O
this	1094	1098	O
Act	1099	1102	O
have	1103	1107	O
been	1108	1112	O
violated	1113	1121	O
,	1121	1122	O
specially	1123	1132	O
designated	1133	1143	O
judges	1144	1150	O
will	1151	1155	O
call	1156	1160	O
the	1161	1164	O
parties	1165	1172	O
together	1173	1181	O
and	1182	1185	O
may	1186	1189	O
adopt	1190	1195	O
measures	1196	1204	O
designed	1205	1213	O
to	1214	1216	O
end	1217	1220	O
the	1221	1224	O
situation	1225	1234	O
complained	1235	1245	O
of	1246	1248	O
.	1248	1249	O

If	1251	1253	O
they	1254	1258	O
deem	1259	1263	O
it	1264	1266	O
necessary	1267	1276	O
,	1276	1277	O
the	1278	1281	O
judges	1282	1288	O
may	1289	1292	O
institute	1293	1302	O
more	1303	1307	O
formal	1308	1314	O
proceedings	1315	1326	O
.	1326	1327	O

If	1329	1331	O
the	1332	1335	O
measures	1336	1344	O
adopted	1345	1352	O
are	1353	1356	O
not	1357	1360	O
carried	1361	1368	O
out	1369	1372	O
,	1372	1373	O
the	1374	1377	O
person	1378	1384	O
violating	1385	1394	O
the	1395	1398	O
law	1399	1402	O
is	1403	1405	O
subject	1406	1413	O
to	1414	1416	O
a	1417	1418	O
daily	1419	1424	O
fine	1425	1429	O
,	1429	1430	O
as	1431	1433	O
well	1434	1438	O
as	1439	1441	O
administrative	1442	1456	O
penalties	1457	1466	O
set	1467	1470	O
out	1471	1474	O
in	1475	1477	O
Act	1478	1481	O
15	1482	1484	O
.	1484	1485	O
903	1485	1488	O
of	1489	1491	O
10	1492	1494	O
November	1495	1503	O
1987	1504	1508	O
.	1508	1509	O

Adverse	1511	1518	O
decisions	1519	1528	O
may	1529	1532	O
be	1533	1535	O
appealed	1536	1544	O
.	1544	1545	O

The	1547	1550	O
state	1551	1556	O
is	1557	1559	O
also	1560	1564	O
to	1565	1567	O
undertake	1568	1577	O
educative	1578	1587	O
campaigns	1588	1597	O
to	1598	1600	O
create	1601	1607	O
interest	1608	1616	O
in	1617	1619	O
and	1620	1623	O
understanding	1624	1637	O
of	1638	1640	O
the	1641	1644	O
problems	1645	1653	O
affecting	1654	1663	O
women	1664	1669	O
workers	1670	1677	O
,	1677	1678	O
thus	1679	1683	O
promoting	1684	1693	O
awareness	1694	1703	O
in	1704	1706	O
such	1707	1711	O
workers	1712	1719	O
and	1720	1723	O
their	1724	1729	O
employers	1730	1739	O
of	1740	1742	O
their	1743	1748	O
situation	1749	1758	O
.	1758	1759	O

CXC	0	3	O
chemokine	4	13	O
receptors	14	23	O
in	24	26	O
the	27	30	O
central	31	38	B-Anatomical_system
nervous	39	46	I-Anatomical_system
system	47	53	I-Anatomical_system
:	53	54	O
Role	55	59	O
in	60	62	O
cerebellar	63	73	B-Multi-tissue_structure
neuromodulation	74	89	O
and	90	93	O
development	94	105	O
.	105	106	O

Chemokines	107	117	O
and	118	121	O
their	122	127	O
receptors	128	137	O
are	138	141	O
constitutively	142	156	O
present	157	164	O
in	165	167	O
the	168	171	O
central	172	179	B-Anatomical_system
nervous	180	187	I-Anatomical_system
system	188	194	I-Anatomical_system
(	195	196	O
CNS	196	199	B-Anatomical_system
)	199	200	O
,	200	201	O
expressed	202	211	O
in	212	214	O
neurons	215	222	B-Cell
and	223	226	O
glial	227	232	B-Cell
cells	233	238	I-Cell
.	238	239	O

Much	240	244	O
evidence	245	253	O
suggests	254	262	O
that	263	267	O
,	267	268	O
beyond	269	275	O
their	276	281	O
involvement	282	293	O
in	294	296	O
neuroinflammation	297	314	O
,	314	315	O
these	316	321	O
proteins	322	330	O
play	331	335	O
a	336	337	O
role	338	342	O
in	343	345	O
neurodevelopment	346	362	O
and	363	366	O
neurophysiological	367	385	O
signaling	386	395	O
.	395	396	O

The	397	400	O
goal	401	405	O
of	406	408	O
this	409	413	O
review	414	420	O
is	421	423	O
to	424	426	O
summarize	427	436	O
recent	437	443	O
information	444	455	O
concerning	456	466	O
expression	467	477	O
,	477	478	O
signaling	479	488	O
,	488	489	O
and	490	493	O
function	494	502	O
of	503	505	O
CXC	506	509	O
chemokine	510	519	O
receptor	520	528	O
in	529	531	O
the	532	535	O
CNS	536	539	B-Anatomical_system
,	539	540	O
with	541	545	O
the	546	549	O
main	550	554	O
focus	555	560	O
on	561	563	O
the	564	567	O
developmental	568	581	O
and	582	585	O
neuromodulatory	586	601	O
actions	602	609	O
of	610	612	O
chemokines	613	623	O
in	624	626	O
the	627	630	O
cerebellum	631	641	B-Multi-tissue_structure
.	641	642	O

Combined	0	8	O
tracheal	9	17	B-Multi-tissue_structure
and	18	21	O
esophageal	22	32	B-Multi-tissue_structure
stenting	33	41	O
for	42	45	O
palliation	46	56	O
of	57	59	O
tracheoesophageal	60	77	B-Multi-tissue_structure
symptoms	78	86	O
from	87	91	O
mediastinal	92	103	B-Pathological_formation
lymphoma	104	112	I-Pathological_formation
.	112	113	O

Mediastinal	114	125	B-Pathological_formation
lymphoma	126	134	I-Pathological_formation
as	135	137	O
a	138	139	O
cause	140	145	O
of	146	148	O
tracheobronchial	149	165	B-Multi-tissue_structure
obstruction	166	177	O
is	178	180	O
uncommon	181	189	O
,	189	190	O
and	191	194	O
a	195	196	O
malignant	197	206	O
tracheoesophageal	207	224	B-Immaterial_anatomical_entity
fistula	225	232	I-Immaterial_anatomical_entity
in	233	235	O
the	236	239	O
setting	240	247	O
of	248	250	O
mediastinal	251	262	B-Pathological_formation
lymphoma	263	271	I-Pathological_formation
is	272	274	O
rare	275	279	O
.	279	280	O

Malignant	281	290	O
tracheoesophageal	291	308	B-Immaterial_anatomical_entity
fistulas	309	317	I-Immaterial_anatomical_entity
are	318	321	O
associated	322	332	O
with	333	337	O
pronounced	338	348	O
morbidity	349	358	O
and	359	362	O
mortality	363	372	O
.	372	373	O

We	374	376	O
describe	377	385	O
a	386	387	O
patient	388	395	O
with	396	400	O
mediastinal	401	412	B-Pathological_formation
lymphomatous	413	425	I-Pathological_formation
infiltration	426	438	O
resulting	439	448	O
in	449	451	O
tracheal	452	460	B-Multi-tissue_structure
obstruction	461	472	O
,	472	473	O
esophageal	474	484	B-Multi-tissue_structure
obstruction	485	496	O
,	496	497	O
and	498	501	O
tracheoesophageal	502	519	B-Immaterial_anatomical_entity
fistula	520	527	I-Immaterial_anatomical_entity
that	528	532	O
were	533	537	O
successfully	538	550	O
palliated	551	560	O
with	561	565	O
combined	566	574	O
airway	575	581	B-Multi-tissue_structure
and	582	585	O
esophageal	586	596	B-Multi-tissue_structure
stent	597	602	O
placement	603	612	O
.	612	613	O

Rural	0	5	O
/	5	6	O
urban	6	11	O
differences	12	23	O
in	24	26	O
access	27	33	O
to	34	36	O
and	37	40	O
utilization	41	52	O
of	53	55	O
services	56	64	O
among	65	70	O
people	71	77	O
in	78	80	O
Alabama	81	88	O
with	89	93	O
sickle	94	100	B-Cell
cell	101	105	I-Cell
disease	106	113	O
.	113	114	O

OBJECTIVE	115	124	O
:	124	125	O

This	126	130	O
study	131	136	O
examined	137	145	O
relationships	146	159	O
between	160	167	O
socioeconomic	168	181	O
factors	182	189	O
and	190	193	O
the	194	197	O
geographic	198	208	O
distribution	209	221	O
of	222	224	O
662	225	228	O
cases	229	234	O
of	235	237	O
sickle	238	244	B-Cell
cell	245	249	I-Cell
disease	250	257	O
in	258	260	O
Alabama	261	268	O
in	269	271	O
1999	272	276	O
-	276	277	O
2001	277	281	O
.	281	282	O

METHODS	283	290	O
:	290	291	O

Measures	292	300	O
of	301	303	O
community	304	313	O
distress	314	322	O
,	322	323	O
physical	324	332	O
functioning	333	344	O
,	344	345	O
and	346	349	O
medical	350	357	O
problems	358	366	O
were	367	371	O
used	372	376	O
in	377	379	O
analyzing	380	389	O
utilization	390	401	O
differences	402	413	O
between	414	421	O
individuals	422	433	O
with	434	438	O
sickle	439	445	B-Cell
cell	446	450	I-Cell
disease	451	458	O
living	459	465	O
in	466	468	O
urban	469	474	O
and	475	478	O
rural	479	484	O
areas	485	490	O
.	490	491	O

RESULTS	492	499	O
:	499	500	O

Utilization	501	512	O
of	513	515	O
comprehensive	516	529	O
sickle	530	536	B-Cell
cells	537	542	I-Cell
disease	543	550	O
services	551	559	O
was	560	563	O
lower	564	569	O
for	570	573	O
individuals	574	585	O
with	586	590	O
sickle	591	597	B-Cell
cell	598	602	I-Cell
disease	603	610	O
living	611	617	O
in	618	620	O
rural	621	626	O
areas	627	632	O
than	633	637	O
for	638	641	O
those	642	647	O
living	648	654	O
in	655	657	O
urban	658	663	O
areas	664	669	O
.	669	670	O

Rural	671	676	O
clients	677	684	O
reported	685	693	O
significantly	694	707	O
more	708	712	O
limitations	713	724	O
than	725	729	O
urban	730	735	O
clients	736	743	O
on	744	746	O
several	747	754	O
measures	755	763	O
of	764	766	O
physical	767	775	O
functioning	776	787	O
.	787	788	O

The	789	792	O
results	793	800	O
also	801	805	O
suggest	806	813	O
that	814	818	O
utilization	819	830	O
of	831	833	O
services	834	842	O
was	843	846	O
higher	847	853	O
for	854	857	O
those	858	863	O
with	864	868	O
more	869	873	O
medical	874	881	O
problems	882	890	O
and	891	894	O
those	895	900	O
who	901	904	O
lived	905	910	O
in	911	913	O
high	914	918	O
distress	919	927	O
areas	928	933	O
,	933	934	O
although	935	943	O
these	944	949	O
findings	950	958	O
did	959	962	O
not	963	966	O
meet	967	971	O
the	972	975	O
criterion	976	985	O
for	986	989	O
statistical	990	1001	O
significance	1002	1014	O
.	1014	1015	O

CONCLUSIONS	1016	1027	O
:	1027	1028	O

Conclusions	1029	1040	O
based	1041	1046	O
on	1047	1049	O
statistical	1050	1061	O
evidence	1062	1070	O
that	1071	1075	O
geographic	1076	1086	O
location	1087	1095	O
and	1096	1099	O
socioeconomic	1100	1113	O
factors	1114	1121	O
relate	1122	1128	O
to	1129	1131	O
significantly	1132	1145	O
different	1146	1155	O
health	1156	1162	O
care	1163	1167	O
service	1168	1175	O
experience	1176	1186	O
bear	1187	1191	O
important	1192	1201	O
implications	1202	1214	O
for	1215	1218	O
medical	1219	1226	O
and	1227	1230	O
health	1231	1237	O
care	1238	1242	O
support	1243	1250	O
systems	1251	1258	O
,	1258	1259	O
especially	1260	1270	O
on	1271	1273	O
the	1274	1277	O
community	1278	1287	O
level	1288	1293	O
.	1293	1294	O

Impact	0	6	O
of	7	9	O
technology	10	20	O
on	21	23	O
the	24	27	O
utilisation	28	39	O
of	40	42	O
positron	43	51	O
emission	52	60	O
tomography	61	71	O
in	72	74	O
lymphoma	75	83	B-Pathological_formation
:	83	84	O
current	85	92	O
and	93	96	O
future	97	103	O
perspectives	104	116	O
.	116	117	O

Positron	118	126	O
emission	127	135	O
tomography	136	146	O
(	147	148	O
PET	148	151	O
)	151	152	O
has	153	156	O
now	157	160	O
gained	161	167	O
a	168	169	O
place	170	175	O
in	176	178	O
the	179	182	O
management	183	193	O
of	194	196	O
patients	197	205	O
with	206	210	O
cancer	211	217	B-Pathological_formation
,	217	218	O
including	219	228	O
those	229	234	O
with	235	239	O
Hodgkin	240	247	O
'	247	248	O
s	248	249	O
disease	250	257	O
and	258	261	O
non	262	265	B-Pathological_formation
-	265	266	I-Pathological_formation
Hodgkin	266	273	I-Pathological_formation
'	273	274	I-Pathological_formation
s	274	275	I-Pathological_formation
lymphoma	276	284	I-Pathological_formation
.	284	285	O

Restaging	286	295	O
studies	296	303	O
and	304	307	O
those	308	313	O
addressing	314	324	O
the	325	328	O
monitoring	329	339	O
of	340	342	O
response	343	351	O
to	352	354	O
treatment	355	364	O
are	365	368	O
especially	369	379	O
in	380	382	O
focus	383	388	O
.	388	389	O

Most	390	394	O
of	395	397	O
the	398	401	O
knowledge	402	411	O
gained	412	418	O
has	419	422	O
been	423	427	O
achieved	428	436	O
with	437	441	O
dedicated	442	451	O
BGO	452	455	O
-	455	456	O
based	456	461	O
PET	462	465	O
technology	466	476	O
,	476	477	O
but	478	481	O
there	482	487	O
are	488	491	O
a	492	493	O
number	494	500	O
of	501	503	O
developments	504	516	O
that	517	521	O
will	522	526	O
impact	527	533	O
on	534	536	O
the	537	540	O
use	541	544	O
of	545	547	O
this	548	552	O
metabolic	553	562	O
imaging	563	570	O
technique	571	580	O
in	581	583	O
the	584	587	O
investigation	588	601	O
of	602	604	O
patients	605	613	O
with	614	618	O
lymphoma	619	627	B-Pathological_formation
.	627	628	O

The	629	632	O
challenges	633	643	O
ahead	644	649	O
are	650	653	O
determined	654	664	O
by	665	667	O
the	668	671	O
need	672	676	O
for	677	680	O
high	681	685	O
-	685	686	O
quality	686	693	O
whole	694	699	O
-	699	700	O
body	700	704	O
imaging	705	712	O
associated	713	723	O
with	724	728	O
increased	729	738	O
patient	739	746	O
throughput	747	757	O
and	758	761	O
the	762	765	O
need	766	770	O
to	771	773	O
investigate	774	785	O
the	786	789	O
role	790	794	O
of	795	797	O
new	798	801	O
labelled	802	810	O
ligands	811	818	O
.	818	819	O

The	820	823	O
latter	824	830	O
are	831	834	O
likely	835	841	O
to	842	844	O
yield	845	850	O
new	851	854	O
insights	855	863	O
into	864	868	O
tumour	869	875	B-Cell
cell	876	880	I-Cell
characterisation	881	897	O
,	897	898	O
tumour	899	905	B-Pathological_formation
behaviour	906	915	O
and	916	919	O
tumour	920	926	B-Pathological_formation
outcome	927	934	O
assessment	935	945	O
.	945	946	O

The	947	950	O
study	951	956	O
of	957	959	O
new	960	963	O
radiolabelled	964	977	O
ligands	978	985	O
will	986	990	O
impose	991	997	O
further	998	1005	O
demands	1006	1013	O
for	1014	1017	O
rapid	1018	1023	O
dynamic	1024	1031	O
data	1032	1036	O
acquisition	1037	1048	O
and	1049	1052	O
accurate	1053	1061	O
tracer	1062	1068	O
quantification	1069	1083	O
.	1083	1084	O

Current	1085	1092	O
and	1093	1096	O
future	1097	1103	O
developments	1104	1116	O
in	1117	1119	O
PET	1120	1123	O
technology	1124	1134	O
range	1135	1140	O
from	1141	1145	O
the	1146	1149	O
use	1150	1153	O
of	1154	1156	O
new	1157	1160	O
detector	1161	1169	O
materials	1170	1179	O
to	1180	1182	O
different	1183	1192	O
detector	1193	1201	O
geometries	1202	1212	O
and	1213	1216	O
data	1217	1221	O
acquisition	1222	1233	O
modes	1234	1239	O
.	1239	1240	O

The	1241	1244	O
search	1245	1251	O
for	1252	1255	O
alternatives	1256	1268	O
to	1269	1271	O
BGO	1272	1275	O
scintillation	1276	1289	O
materials	1290	1299	O
for	1300	1303	O
PET	1304	1307	O
has	1308	1311	O
led	1312	1315	O
to	1316	1318	O
the	1319	1322	O
development	1323	1334	O
of	1335	1337	O
PET	1338	1341	O
instruments	1342	1353	O
utilising	1354	1363	O
new	1364	1367	O
crystals	1368	1376	O
such	1377	1381	O
as	1382	1384	O
LSO	1385	1388	O
and	1389	1392	O
GSO	1393	1396	O
.	1396	1397	O

The	1398	1401	O
use	1402	1405	O
of	1406	1408	O
these	1409	1414	O
new	1415	1418	O
detectors	1419	1428	O
and	1429	1432	O
the	1433	1436	O
increased	1437	1446	O
sensitivity	1447	1458	O
achieved	1459	1467	O
with	1468	1472	O
3D	1473	1475	O
data	1476	1480	O
acquisitions	1481	1493	O
represent	1494	1503	O
the	1504	1507	O
most	1508	1512	O
significant	1513	1524	O
current	1525	1532	O
developments	1533	1545	O
in	1546	1548	O
the	1549	1552	O
field	1553	1558	O
.	1558	1559	O

With	1560	1564	O
the	1565	1568	O
increasing	1569	1579	O
demands	1580	1587	O
imposed	1588	1595	O
on	1596	1598	O
the	1599	1602	O
clinical	1603	1611	O
utilisation	1612	1623	O
of	1624	1626	O
PET	1627	1630	O
,	1630	1631	O
issues	1632	1638	O
such	1639	1643	O
as	1644	1646	O
study	1647	1652	O
cost	1653	1657	O
and	1658	1661	O
patient	1662	1669	O
throughput	1670	1680	O
will	1681	1685	O
emerge	1686	1692	O
as	1693	1695	O
significant	1696	1707	O
future	1708	1714	O
factors	1715	1722	O
.	1722	1723	O

As	1724	1726	O
a	1727	1728	O
consequence	1729	1740	O
,	1740	1741	O
low	1742	1745	O
-	1745	1746	O
cost	1746	1750	O
units	1751	1756	O
are	1757	1760	O
being	1761	1766	O
offered	1767	1774	O
by	1775	1777	O
the	1778	1781	O
manufacturers	1782	1795	O
through	1796	1803	O
the	1804	1807	O
utilisation	1808	1819	O
of	1820	1822	O
gamma	1823	1828	O
camera	1829	1835	O
-	1835	1836	O
based	1836	1841	O
SPET	1842	1846	O
systems	1847	1854	O
for	1855	1858	O
PET	1859	1862	O
coincidence	1863	1874	O
imaging	1875	1882	O
.	1882	1883	O

Unfortunately	1884	1897	O
,	1897	1898	O
clinical	1899	1907	O
studies	1908	1915	O
in	1916	1918	O
lymphoma	1919	1927	B-Pathological_formation
and	1928	1931	O
other	1932	1937	O
cancers	1938	1945	B-Pathological_formation
have	1946	1950	O
already	1951	1958	O
demonstrated	1959	1971	O
the	1972	1975	O
limitations	1976	1987	O
of	1988	1990	O
this	1991	1995	O
technology	1996	2006	O
,	2006	2007	O
with	2008	2012	O
20	2013	2015	O
%	2015	2016	O
of	2017	2019	O
lesions	2020	2027	B-Pathological_formation
<	2028	2029	O
15	2029	2031	O
mm	2032	2034	O
in	2035	2037	O
size	2038	2042	O
escaping	2043	2051	O
detection	2052	2061	O
.	2061	2062	O

On	2063	2065	O
the	2066	2069	O
other	2070	2075	O
hand	2076	2080	O
,	2080	2081	O
the	2082	2085	O
recent	2086	2092	O
development	2093	2104	O
of	2105	2107	O
combined	2108	2116	O
PET	2117	2120	O
/	2120	2121	O
CT	2121	2123	O
devices	2124	2131	O
attempts	2132	2140	O
to	2141	2143	O
address	2144	2151	O
the	2152	2155	O
lack	2156	2160	O
of	2161	2163	O
anatomical	2164	2174	O
information	2175	2186	O
inherent	2187	2195	O
with	2196	2200	O
PET	2201	2204	O
images	2205	2211	O
,	2211	2212	O
taking	2213	2219	O
advantage	2220	2229	O
of	2230	2232	O
further	2233	2240	O
improvement	2241	2252	O
in	2253	2255	O
patient	2256	2263	O
throughput	2264	2274	O
and	2275	2278	O
hence	2279	2284	O
cost	2285	2289	O
-	2289	2290	O
effectiveness	2290	2303	O
.	2303	2304	O

Preliminary	2305	2316	O
studies	2317	2324	O
using	2325	2330	O
this	2331	2335	O
multimodality	2336	2349	O
imaging	2350	2357	O
approach	2358	2366	O
have	2367	2371	O
already	2372	2379	O
demonstrated	2380	2392	O
the	2393	2396	O
potential	2397	2406	O
of	2407	2409	O
the	2410	2413	O
technique	2414	2423	O
.	2423	2424	O

Although	2425	2433	O
the	2434	2437	O
potential	2438	2447	O
exists	2448	2454	O
,	2454	2455	O
certain	2456	2463	O
technical	2464	2473	O
issues	2474	2480	O
with	2481	2485	O
PET	2486	2489	O
/	2489	2490	O
CT	2490	2492	O
require	2493	2500	O
refinement	2501	2511	O
of	2512	2514	O
the	2515	2518	O
methodology	2519	2530	O
.	2530	2531	O

Such	2532	2536	O
issues	2537	2543	O
include	2544	2551	O
organ	2552	2557	B-Organ
movement	2558	2566	O
(	2567	2568	O
such	2568	2572	O
as	2573	2575	O
respiratory	2576	2587	B-Anatomical_system
motion	2588	2594	O
)	2594	2595	O
,	2595	2596	O
which	2597	2602	O
strongly	2603	2611	O
influences	2612	2622	O
the	2623	2626	O
image	2627	2632	O
fusion	2633	2639	O
of	2640	2642	O
a	2643	2644	O
rapidly	2645	2652	O
acquired	2653	2661	O
CT	2662	2664	O
scan	2665	2669	O
with	2670	2674	O
the	2675	2678	O
slower	2679	2685	O
acquisition	2686	2697	O
of	2698	2700	O
a	2701	2702	O
PET	2703	2706	O
dataset	2707	2714	O
,	2714	2715	O
and	2716	2719	O
the	2720	2723	O
derivation	2724	2734	O
of	2735	2737	O
CT	2738	2740	O
-	2740	2741	O
based	2741	2746	O
attenuation	2747	2758	O
coefficients	2759	2771	O
in	2772	2774	O
the	2775	2778	O
presence	2779	2787	O
of	2788	2790	O
contrast	2791	2799	O
agents	2800	2806	O
or	2807	2809	O
metallic	2810	2818	O
implants	2819	2827	O
.	2827	2828	O

The	2829	2832	O
application	2833	2844	O
of	2845	2847	O
the	2848	2851	O
technology	2852	2862	O
for	2863	2866	O
radiotherapy	2867	2879	O
planning	2880	2888	O
also	2889	2893	O
poses	2894	2899	O
a	2900	2901	O
number	2902	2908	O
of	2909	2911	O
associated	2912	2922	O
challenges	2923	2933	O
.	2933	2934	O

Finally	2935	2942	O
,	2942	2943	O
the	2944	2947	O
development	2948	2959	O
of	2960	2962	O
dedicated	2963	2972	O
PET	2973	2976	O
systems	2977	2984	O
based	2985	2990	O
on	2991	2993	O
planar	2994	3000	O
detector	3001	3009	O
arrangements	3010	3022	O
with	3023	3027	O
new	3028	3031	O
detector	3032	3040	O
components	3041	3051	O
has	3052	3055	O
the	3056	3059	O
potential	3060	3069	O
to	3070	3072	O
improve	3073	3080	O
clinical	3081	3089	O
throughput	3090	3100	O
by	3101	3103	O
over	3104	3108	O
100	3109	3112	O
%	3112	3113	O
,	3113	3114	O
but	3115	3118	O
clinical	3119	3127	O
trials	3128	3134	O
using	3135	3140	O
such	3141	3145	O
systems	3146	3153	O
have	3154	3158	O
still	3159	3164	O
to	3165	3167	O
be	3168	3170	O
carried	3171	3178	O
out	3179	3182	O
in	3183	3185	O
order	3186	3191	O
to	3192	3194	O
establish	3195	3204	O
the	3205	3208	O
associated	3209	3219	O
whole	3220	3225	O
-	3225	3226	O
body	3226	3230	B-Organism_subdivision
image	3231	3236	O
quality	3237	3244	O
.	3244	3245	O

Stereoselective	0	15	O
synthesis	16	25	O
of	26	28	O
1	29	30	O
-	30	31	O
aminoalkanephosphonic	31	52	O
acids	53	58	O
with	59	63	O
two	64	67	O
chiral	68	74	O
centers	75	82	O
and	83	86	O
their	87	92	O
activity	93	101	O
towards	102	109	O
leucine	110	117	O
aminopeptidase	118	132	O
.	132	133	O

The	134	137	O
stereoselective	138	153	O
synthesis	154	163	O
of	164	166	O
1	167	168	O
-	168	169	O
amino	169	174	O
-	174	175	O
2	175	176	O
-	176	177	O
alkylalkanephosphonic	177	198	O
acids	199	204	O
,	204	205	O
namely	206	212	O
,	212	213	O
compounds	214	223	O
bearing	224	231	O
two	232	235	O
chiral	236	242	O
centers	243	250	O
,	250	251	O
was	252	255	O
achieved	256	264	O
by	265	267	O
the	268	271	O
condensation	272	284	O
of	285	287	O
hypophosphorous	288	303	O
acid	304	308	O
salts	309	314	O
of	315	317	O
(	318	319	O
R	319	320	O
)	320	321	O
(	321	322	O
+	322	323	O
)	323	324	O
or	325	327	O
(	328	329	O
S	329	330	O
)	330	331	O
(	331	332	O
-	332	333	O
)	333	334	O
-	334	335	O
N	335	336	O
-	336	337	O
alpha	337	342	O
-	342	343	O
methylbenzylamine	343	360	O
with	361	365	O
the	366	369	O
appropriate	370	381	O
aldehydes	382	391	O
in	392	394	O
isopropanol	395	406	O
.	406	407	O

Simultaneous	408	420	O
deprotection	421	433	O
and	434	437	O
oxidation	438	447	O
by	448	450	O
the	451	454	O
action	455	461	O
of	462	464	O
bromine	465	472	O
water	473	478	O
provided	479	487	O
equimolar	488	497	O
mixtures	498	506	O
of	507	509	O
the	510	513	O
RS	514	516	O
:	516	517	O
RR	517	519	O
and	520	523	O
SR	524	526	O
:	526	527	O
SS	527	529	O
diastereomers	530	543	O
of	544	546	O
desired	547	554	O
acids	555	560	O
.	560	561	O

They	562	566	O
appeared	567	575	O
to	576	578	O
act	579	582	O
as	583	585	O
moderate	586	594	O
inhibitors	595	605	O
of	606	608	O
kidney	609	615	B-Organ
leucine	616	623	O
aminopeptidase	624	638	O
with	639	643	O
potency	644	651	O
dependent	652	661	O
on	662	664	O
the	665	668	O
absolute	669	677	O
configuration	678	691	O
of	692	694	O
both	695	699	O
centers	700	707	O
of	708	710	O
chirality	711	720	O
.	720	721	O

[	0	1	O
Community	1	10	O
intervention	11	23	O
on	24	26	O
hypertension	27	39	O
and	40	43	O
stroke	44	50	O
]	50	51	O
.	51	52	O

OBJECTIVE	53	62	O
:	62	63	O

To	64	66	O
evaluate	67	75	O
the	76	79	O
community	80	89	O
-	89	90	O
based	90	95	O
intervention	96	108	O
on	109	111	O
reduction	112	121	O
of	122	124	O
hypertension	125	137	O
and	138	141	O
stroke	142	148	O
in	149	151	O
different	152	161	O
age	162	165	O
groups	166	172	O
and	173	176	O
subtypes	177	185	O
hypertension	186	198	O
.	198	199	O

METHODS	200	207	O
:	207	208	O

In	209	211	O
6	212	213	O
cities	214	220	O
,	220	221	O
2	222	223	O
geographically	224	238	O
separated	239	248	O
communities	249	260	O
with	261	265	O
a	266	267	O
registered	268	278	O
population	279	289	O
about	290	295	O
10	296	298	O
000	299	302	O
of	303	305	O
each	306	310	O
were	311	315	O
selected	316	324	O
as	325	327	O
either	328	334	O
intervention	335	347	O
or	348	350	O
control	351	358	O
communities	359	370	O
.	370	371	O

A	372	373	O
cohort	374	380	O
containing	381	391	O
2	392	393	O
700	394	397	O
subjects	398	406	O
,	406	407	O
35	408	410	O
years	411	416	O
or	417	419	O
older	420	425	O
,	425	426	O
and	427	430	O
free	431	435	O
of	436	438	O
stroke	439	445	O
were	446	450	O
sampled	451	458	O
from	459	463	O
each	464	468	O
community	469	478	O
.	478	479	O

The	480	483	O
baseline	484	492	O
survey	493	499	O
was	500	503	O
conducted	504	513	O
to	514	516	O
screen	517	523	O
the	524	527	O
subjects	528	536	O
for	537	540	O
intervention	541	553	O
.	553	554	O

In	555	557	O
each	558	562	O
city	563	567	O
,	567	568	O
a	569	570	O
program	571	578	O
for	579	582	O
control	583	590	O
of	591	593	O
hypertension	594	606	O
,	606	607	O
heart	608	613	B-Organ
diseases	614	622	O
and	623	626	O
diabetes	627	635	O
was	636	639	O
initiated	640	649	O
in	650	652	O
the	653	656	O
intervention	657	669	O
cohort	670	676	O
and	677	680	O
health	681	687	O
education	688	697	O
was	698	701	O
provided	702	710	O
to	711	713	O
the	714	717	O
whole	718	723	O
intervention	724	736	O
community	737	746	O
.	746	747	O

A	748	749	O
follow	750	756	O
-	756	757	O
up	757	759	O
survey	760	766	O
was	767	770	O
conducted	771	780	O
3	781	782	O
years	783	788	O
later	789	794	O
.	794	795	O

RESULTS	796	803	O
:	803	804	O

Within	805	811	O
3	812	813	O
years	814	819	O
,	819	820	O
the	821	824	O
prevalence	825	835	O
of	836	838	O
hypertension	839	851	O
increased	852	861	O
in	862	864	O
both	865	869	O
intervention	870	882	O
and	883	886	O
control	887	894	O
cohorts	895	902	O
,	902	903	O
as	904	906	O
well	907	911	O
as	912	914	O
in	915	917	O
the	918	921	O
middle	922	928	O
and	929	932	O
elderly	933	940	O
cohorts	941	948	O
,	948	949	O
especially	950	960	O
in	961	963	O
the	964	967	O
middle	968	974	O
aged	975	979	O
in	980	982	O
control	983	990	O
group	991	996	O
.	996	997	O

Among	998	1003	O
hypertensives	1004	1017	O
in	1018	1020	O
the	1021	1024	O
intervention	1025	1037	O
cohort	1038	1044	O
,	1044	1045	O
the	1046	1049	O
rates	1050	1055	O
of	1056	1058	O
awareness	1059	1068	O
,	1068	1069	O
treatment	1070	1079	O
and	1080	1083	O
control	1084	1091	O
of	1092	1094	O
hypertension	1095	1107	O
got	1108	1111	O
improved	1112	1120	O
.	1120	1121	O

The	1122	1125	O
incidence	1126	1135	O
of	1136	1138	O
stroke	1139	1145	O
was	1146	1149	O
29	1150	1152	O
%	1152	1153	O
lower	1154	1159	O
(	1160	1161	O
HR	1161	1163	O
=	1164	1165	O
0	1166	1167	O
.	1167	1168	O
71	1168	1170	O
,	1170	1171	O
95	1172	1174	O
%	1174	1175	O
CI	1176	1178	O
:	1178	1179	O
0	1180	1181	O
.	1181	1182	O
58	1182	1184	O
-	1185	1186	O
0	1187	1188	O
.	1188	1189	O
87	1189	1191	O
)	1191	1192	O
and	1193	1196	O
mortality	1197	1206	O
of	1207	1209	O
stroke	1210	1216	O
was	1217	1220	O
40	1221	1223	O
%	1223	1224	O
lower	1225	1230	O
(	1231	1232	O
HR	1232	1234	O
=	1235	1236	O
0	1237	1238	O
.	1238	1239	O
60	1239	1241	O
,	1241	1242	O
95	1243	1245	O
%	1245	1246	O
CI	1247	1249	O
:	1249	1250	O
0	1251	1252	O
.	1252	1253	O
42	1253	1255	O
-	1256	1257	O
0	1258	1259	O
.	1259	1260	O
86	1260	1262	O
)	1262	1263	O
in	1264	1266	O
the	1267	1270	O
intervention	1271	1283	O
cohort	1284	1290	O
than	1291	1295	O
the	1296	1299	O
control	1300	1307	O
cohort	1308	1314	O
.	1314	1315	O

The	1316	1319	O
intervention	1320	1332	O
was	1333	1336	O
most	1337	1341	O
effective	1342	1351	O
in	1352	1354	O
reduction	1355	1364	O
of	1365	1367	O
stroke	1368	1374	O
for	1375	1378	O
those	1379	1384	O
with	1385	1389	O
isolated	1390	1398	O
systolic	1399	1407	O
hypertension	1408	1420	O
and	1421	1424	O
combined	1425	1433	O
systolic	1434	1442	O
and	1443	1446	O
diastolic	1447	1456	O
hypertension	1457	1469	O
(	1470	1471	O
All	1471	1474	O
P	1475	1476	O
<	1477	1478	O
0	1479	1480	O
.	1480	1481	O
05	1481	1483	O
)	1483	1484	O
.	1484	1485	O

Meanwhile	1486	1495	O
,	1495	1496	O
all	1497	1500	O
-	1500	1501	O
cause	1501	1506	O
mortality	1507	1516	O
was	1517	1520	O
11	1521	1523	O
%	1523	1524	O
lower	1525	1530	O
(	1531	1532	O
HR	1532	1534	O
=	1535	1536	O
0	1537	1538	O
.	1538	1539	O
89	1539	1541	O
,	1541	1542	O
95	1543	1545	O
%	1545	1546	O
CI	1547	1549	O
:	1549	1550	O
0	1551	1552	O
.	1552	1553	O
78	1553	1555	O
-	1556	1557	O
0	1558	1559	O
.	1559	1560	O
99	1560	1562	O
)	1562	1563	O
in	1564	1566	O
the	1567	1570	O
intervention	1571	1583	O
cohort	1584	1590	O
than	1591	1595	O
in	1596	1598	O
the	1599	1602	O
control	1603	1610	O
cohort	1611	1617	O
.	1617	1618	O

CONCLUSION	1619	1629	O
:	1629	1630	O

The	1631	1634	O
community	1635	1644	O
-	1644	1645	O
based	1645	1650	O
intervention	1651	1663	O
was	1664	1667	O
effective	1668	1677	O
in	1678	1680	O
controlling	1681	1692	O
the	1693	1696	O
development	1697	1708	O
of	1709	1711	O
hypertension	1712	1724	O
and	1725	1728	O
stroke	1729	1735	O
,	1735	1736	O
while	1737	1742	O
the	1743	1746	O
elderly	1747	1754	O
people	1755	1761	O
benefit	1762	1769	O
more	1770	1774	O
than	1775	1779	O
the	1780	1783	O
middle	1784	1790	O
aged	1791	1795	O
people	1796	1802	O
from	1803	1807	O
the	1808	1811	O
intervention	1812	1824	O
.	1824	1825	O

[	0	1	O
Laboratory	1	11	O
diagnostics	12	23	O
of	24	26	O
Crimean	27	34	O
hemorrhagic	35	46	O
fever	47	52	O
by	53	55	O
polymerase	56	66	O
chain	67	72	O
reaction	73	81	O
]	81	82	O
.	82	83	O

Our	84	87	O
group	88	93	O
developed	94	103	O
,	103	104	O
within	105	111	O
the	112	115	O
present	116	123	O
case	124	128	O
study	129	134	O
,	134	135	O
two	136	139	O
techniques	140	150	O
'	150	151	O
variations	152	162	O
,	162	163	O
i	164	165	O
.	165	166	O
e	166	167	O
.	167	168	O
a	169	170	O
single	171	177	O
-	177	178	O
step	178	182	O
RT	183	185	O
-	185	186	O
PCR	186	189	O
and	190	193	O
nested	194	200	O
RT	201	203	O
-	203	204	O
PCR	204	207	O
assays	208	214	O
,	214	215	O
for	216	219	O
the	220	223	O
purpose	224	231	O
of	232	234	O
detecting	235	244	O
the	245	248	O
Crimean	249	256	O
-	256	257	O
Congo	257	262	O
hemorrhagic	263	274	O
fever	275	280	O
RNA	281	284	O
virus	285	290	O
in	291	293	O
human	294	299	O
samples	300	307	O
.	307	308	O

The	309	312	O
above	313	318	O
assays	319	325	O
as	326	328	O
well	329	333	O
as	334	336	O
those	337	342	O
previously	343	353	O
recommended	354	365	O
by	366	368	O
the	369	372	O
Ministry	373	381	O
of	382	384	O
Health	385	391	O
of	392	394	O
the	395	398	O
Russian	399	406	O
Federation	407	417	O
were	418	422	O
simultaneously	423	437	O
used	438	442	O
in	443	445	O
14	446	448	O
clinical	449	457	O
samples	458	465	O
obtained	466	474	O
from	475	479	O
patients	480	488	O
with	489	493	O
Crimean	494	501	O
hemorrhagic	502	513	O
fever	514	519	O
.	519	520	O

After	521	526	O
assessing	527	536	O
the	537	540	O
detection	541	550	O
accuracy	551	559	O
,	559	560	O
it	561	563	O
was	564	567	O
found	568	573	O
that	574	578	O
the	579	582	O
developed	583	592	O
-	592	593	O
by	593	595	O
-	595	596	O
us	596	598	O
test	599	603	O
system	604	610	O
displayed	611	620	O
the	621	624	O
same	625	629	O
or	630	632	O
even	633	637	O
better	638	644	O
diagnostic	645	655	O
values	656	662	O
versus	663	669	O
the	670	673	O
previously	674	684	O
recommended	685	696	O
nested	697	703	O
RT	704	706	O
-	706	707	O
PCR	707	710	O
and	711	714	O
a	715	716	O
1000	717	721	O
-	721	722	O
fold	722	726	O
advantage	727	736	O
over	737	741	O
the	742	745	O
previously	746	756	O
recommended	757	768	O
single	769	775	O
-	775	776	O
step	776	780	O
RT	781	783	O
-	783	784	O
PCA	784	787	O
.	787	788	O

The	789	792	O
single	793	799	O
-	799	800	O
step	800	804	O
RT	805	807	O
-	807	808	O
PCR	808	811	O
assay	812	817	O
variation	818	827	O
is	828	830	O
always	831	837	O
more	838	842	O
preferable	843	853	O
in	854	856	O
sense	857	862	O
of	863	865	O
technical	866	875	O
and	876	879	O
economic	880	888	O
motivations	889	900	O
.	900	901	O

Finally	902	909	O
,	909	910	O
the	911	914	O
test	915	919	O
system	920	926	O
developed	927	936	O
by	937	939	O
us	940	942	O
has	943	946	O
every	947	952	O
reason	953	959	O
to	960	962	O
become	963	969	O
the	970	973	O
method	974	980	O
of	981	983	O
choice	984	990	O
in	991	993	O
routine	994	1001	O
PCR	1002	1005	O
diagnosis	1006	1015	O
of	1016	1018	O
Crimean	1019	1026	O
hemorrhagic	1027	1038	O
fever	1039	1044	O
after	1045	1050	O
all	1051	1054	O
official	1055	1063	O
trials	1064	1070	O
and	1071	1074	O
approvals	1075	1084	O
are	1085	1088	O
duly	1089	1093	O
complied	1094	1102	O
with	1103	1107	O
.	1107	1108	O

Prognostic	0	10	O
significance	11	23	O
and	24	27	O
correlation	28	39	O
with	40	44	O
survival	45	53	O
of	54	56	O
bcl	57	60	O
-	60	61	O
2	61	62	O
and	63	66	O
TGF	67	70	O
-	70	71	O
beta	71	75	O
RII	76	79	O
in	80	82	O
colon	83	88	B-Pathological_formation
cancer	89	95	I-Pathological_formation
.	95	96	O

Bcl	97	100	O
-	100	101	O
2	101	102	O
and	103	106	O
TGF	107	110	O
-	110	111	O
beta	111	115	O
receptors	116	125	O
type	126	130	O
II	131	133	O
(	134	135	O
RII	135	138	O
)	138	139	O
in	140	142	O
colon	143	148	B-Pathological_formation
carcinomas	149	159	I-Pathological_formation
were	160	164	O
studied	165	172	O
in	173	175	O
a	176	177	O
series	178	184	O
of	185	187	O
113	188	191	O
patients	192	200	O
,	200	201	O
to	202	204	O
determine	205	214	O
their	215	220	O
prognostic	221	231	O
significance	232	244	O
and	245	248	O
to	249	251	O
correlate	252	261	O
their	262	267	O
expression	268	278	O
with	279	283	O
other	284	289	O
prognostic	290	300	O
indicators	301	311	O
.	311	312	O

Bcl	313	316	O
-	316	317	O
2	317	318	O
expression	319	329	O
in	330	332	O
the	333	336	O
tumor	337	342	B-Cell
cells	343	348	I-Cell
showed	349	355	O
a	356	357	O
reverse	358	365	O
relation	366	374	O
with	375	379	O
tumor	380	385	B-Pathological_formation
size	386	390	O
(	391	392	O
P	392	393	O
=	394	395	O
0	396	397	O
.	397	398	O
018	398	401	O
)	401	402	O
,	402	403	O
histological	404	416	O
grade	417	422	O
(	423	424	O
P	424	425	O
=	426	427	O
0	428	429	O
.	429	430	O
04	430	432	O
)	432	433	O
,	433	434	O
and	435	438	O
stage	439	444	O
(	445	446	O
P	446	447	O
=	448	449	O
0	450	451	O
.	451	452	O
013	452	455	O
)	455	456	O
.	456	457	O

Univariate	458	468	O
survival	469	477	O
analysis	478	486	O
using	487	492	O
the	493	496	O
log	497	500	O
rank	501	505	O
test	506	510	O
showed	511	517	O
that	518	522	O
the	523	526	O
survival	527	535	O
of	536	538	O
patients	539	547	O
with	548	552	O
bcl	553	556	B-Pathological_formation
-	556	557	I-Pathological_formation
2	557	558	I-Pathological_formation
-	558	559	I-Pathological_formation
positive	559	567	I-Pathological_formation
tumors	568	574	I-Pathological_formation
was	575	578	O
significantly	579	592	O
better	593	599	O
than	600	604	O
the	605	608	O
survival	609	617	O
of	618	620	O
patients	621	629	O
with	630	634	O
bcl	635	638	B-Pathological_formation
-	638	639	I-Pathological_formation
2	639	640	I-Pathological_formation
-	640	641	I-Pathological_formation
negative	641	649	I-Pathological_formation
tumors	650	656	I-Pathological_formation
(	657	658	O
P	658	659	O
=	660	661	O
0	662	663	O
.	663	664	O
02	664	666	O
)	666	667	O
.	667	668	O

However	669	676	O
,	676	677	O
when	678	682	O
entered	683	690	O
into	691	695	O
a	696	697	O
multivariate	698	710	O
analysis	711	719	O
model	720	725	O
,	725	726	O
it	727	729	O
was	730	733	O
not	734	737	O
found	738	743	O
to	744	746	O
be	747	749	O
of	750	752	O
independent	753	764	O
prognostic	765	775	O
significance	776	788	O
.	788	789	O

TGF	790	793	O
-	793	794	O
beta	794	798	O
RII	799	802	O
expression	803	813	O
was	814	817	O
correlated	818	828	O
with	829	833	O
stage	834	839	O
(	840	841	O
P	841	842	O
=	843	844	O
0	845	846	O
.	846	847	O
03	847	849	O
)	849	850	O
,	850	851	O
while	852	857	O
no	858	860	O
statistically	861	874	O
significant	875	886	O
correlation	887	898	O
was	899	902	O
found	903	908	O
between	909	916	O
TGF	917	920	O
-	920	921	O
beta	921	925	O
RII	926	929	O
expression	930	940	O
and	941	944	O
histological	945	957	O
grade	958	963	O
or	964	966	O
survival	967	975	O
.	975	976	O

In	977	979	O
conclusion	980	990	O
,	990	991	O
these	992	997	O
results	998	1005	O
provide	1006	1013	O
additional	1014	1024	O
evidence	1025	1033	O
for	1034	1037	O
the	1038	1041	O
role	1042	1046	O
of	1047	1049	O
bcl	1050	1053	O
-	1053	1054	O
2	1054	1055	O
and	1056	1059	O
TGF	1060	1063	O
-	1063	1064	O
beta	1064	1068	O
RII	1069	1072	O
in	1073	1075	O
carcinogenesis	1076	1090	O
of	1091	1093	O
the	1094	1097	O
colon	1098	1103	B-Organ
,	1103	1104	O
while	1105	1110	O
they	1111	1115	O
do	1116	1118	O
not	1119	1122	O
support	1123	1130	O
the	1131	1134	O
use	1135	1138	O
of	1139	1141	O
these	1142	1147	O
factors	1148	1155	O
as	1156	1158	O
prognostic	1159	1169	O
markers	1170	1177	O
in	1178	1180	O
patients	1181	1189	O
with	1190	1194	O
colon	1195	1200	B-Pathological_formation
cancer	1201	1207	I-Pathological_formation
.	1207	1208	O

Antibiotic	0	10	O
-	10	11	O
induced	11	18	O
persistence	19	30	O
of	31	33	O
cytotoxic	34	43	O
Staphylococcus	44	58	O
aureus	59	65	O
in	66	68	O
non	69	72	B-Cell
-	72	73	I-Cell
phagocytic	73	83	I-Cell
cells	84	89	I-Cell
.	89	90	O

OBJECTIVES	91	101	O
:	101	102	O

After	103	108	O
infection	109	118	O
of	119	121	O
non	122	125	B-Cell
-	125	126	I-Cell
phagocytic	126	136	I-Cell
cells	137	142	I-Cell
,	142	143	O
some	144	148	O
Staphylococcus	149	163	O
aureus	164	170	O
strains	171	178	O
are	179	182	O
able	183	187	O
to	188	190	O
survive	191	198	O
and	199	202	O
kill	203	207	O
their	208	213	O
host	214	218	O
cells	219	224	B-Cell
.	224	225	O

The	226	229	O
purpose	230	237	O
of	238	240	O
this	241	245	O
study	246	251	O
was	252	255	O
to	256	258	O
determine	259	268	O
the	269	272	O
action	273	279	O
of	280	282	O
various	283	290	O
antibiotics	291	302	O
on	303	305	O
the	306	309	O
survival	310	318	O
of	319	321	O
host	322	326	O
cells	327	332	B-Cell
and	333	336	O
/	336	337	O
or	337	339	O
intracellular	340	353	B-Immaterial_anatomical_entity
S	354	355	O
.	355	356	O
aureus	357	363	O
.	363	364	O

METHODS	365	372	O
:	372	373	O

Murine	374	380	O
keratinocyte	381	393	B-Cell
(	394	395	O
PAM212	395	401	B-Cell
)	401	402	O
and	403	406	O
fibroblast	407	417	B-Cell
(	418	419	O
mKSA	419	423	B-Cell
)	423	424	I-Cell
cell	425	429	I-Cell
lines	430	435	I-Cell
were	436	440	O
infected	441	449	O
with	450	454	O
cytotoxic	455	464	O
S	465	466	O
.	466	467	O
aureus	468	474	O
and	475	478	O
cultured	479	487	O
in	488	490	O
the	491	494	O
presence	495	503	O
of	504	506	O
various	507	514	O
antibiotics	515	526	O
at	527	529	O
graded	530	536	O
concentrations	537	551	O
.	551	552	O

The	553	556	O
viability	557	566	O
of	567	569	O
host	570	574	O
cells	575	580	B-Cell
was	581	584	O
measured	585	593	O
24	594	596	O
h	597	598	O
after	599	604	O
infection	605	614	O
.	614	615	O

To	616	618	O
determine	619	628	O
the	629	632	O
bacterial	633	642	O
viability	643	652	O
within	653	659	O
host	660	664	O
cells	665	670	B-Cell
,	670	671	O
cellular	672	680	B-Organism_substance
lysates	681	688	I-Organism_substance
were	689	693	O
prepared	694	702	O
and	703	706	O
colony	707	713	O
forming	714	721	O
units	722	727	O
were	728	732	O
quantified	733	743	O
using	744	749	O
a	750	751	O
spiral	752	758	O
plater	759	765	O
.	765	766	O

Host	767	771	O
cells	772	777	B-Cell
infected	778	786	O
with	787	791	O
fluorescein	792	803	O
isothiocyanate	804	818	O
(	819	820	O
FITC	820	824	O
)	824	825	O
-	825	826	O
labelled	826	834	O
S	835	836	O
.	836	837	O
aureus	838	844	O
were	845	849	O
analysed	850	858	O
by	859	861	O
flow	862	866	O
cytometry	867	876	O
and	877	880	O
microscopy	881	891	O
to	892	894	O
determine	895	904	O
the	905	908	O
subcellular	909	920	B-Cellular_component
localization	921	933	O
S	934	935	O
.	935	936	O
aureus	937	943	O
.	943	944	O

RESULTS	945	952	O
:	952	953	O

Oxacillin	954	963	O
,	963	964	O
vancomycin	965	975	O
,	975	976	O
gentamicin	977	987	O
,	987	988	O
ciprofloxacin	989	1002	O
and	1003	1006	O
trimethoprim	1007	1019	O
/	1019	1020	O
sulfamethoxazole	1020	1036	O
did	1037	1040	O
not	1041	1044	O
rescue	1045	1051	O
host	1052	1056	O
cells	1057	1062	B-Cell
from	1063	1067	O
cell	1068	1072	B-Cell
death	1073	1078	O
induced	1079	1086	O
by	1087	1089	O
intracellular	1090	1103	B-Immaterial_anatomical_entity
S	1104	1105	O
.	1105	1106	O
aureus	1107	1113	O
.	1113	1114	O

In	1115	1117	O
contrast	1118	1126	O
,	1126	1127	O
linezolid	1128	1137	O
,	1137	1138	O
rifampicin	1139	1149	O
,	1149	1150	O
azithromycin	1151	1163	O
,	1163	1164	O
clindamycin	1165	1176	O
,	1176	1177	O
erythromycin	1178	1190	O
and	1191	1194	O
quinupristin	1195	1207	O
/	1207	1208	O
dalfopristin	1208	1220	O
suppressed	1221	1231	O
the	1232	1235	O
cytotoxic	1236	1245	O
action	1246	1252	O
of	1253	1255	O
S	1256	1257	O
.	1257	1258	O
aureus	1259	1265	O
.	1265	1266	O

After	1267	1272	O
withdrawal	1273	1283	O
of	1284	1286	O
antibiotics	1287	1298	O
,	1298	1299	O
intracellular	1300	1313	B-Immaterial_anatomical_entity
S	1314	1315	O
.	1315	1316	O
aureus	1317	1323	O
regained	1324	1332	O
cytotoxic	1333	1342	O
activity	1343	1351	O
and	1352	1355	O
killed	1356	1362	O
their	1363	1368	O
host	1369	1373	O
cells	1374	1379	B-Cell
.	1379	1380	O

Only	1381	1385	O
rifampicin	1386	1396	O
was	1397	1400	O
able	1401	1405	O
to	1406	1408	O
eliminate	1409	1418	O
intracellular	1419	1432	B-Immaterial_anatomical_entity
S	1433	1434	O
.	1434	1435	O
aureus	1436	1442	O
completely	1443	1453	O
within	1454	1460	O
72	1461	1463	O
h	1464	1465	O
.	1465	1466	O

In	1467	1469	O
contrast	1470	1478	O
,	1478	1479	O
clindamycin	1480	1491	O
,	1491	1492	O
azithromycin	1493	1505	O
and	1506	1509	O
linezolid	1510	1519	O
induced	1520	1527	O
a	1528	1529	O
state	1530	1535	O
of	1536	1538	O
intracellular	1539	1552	B-Immaterial_anatomical_entity
persistence	1553	1564	O
of	1565	1567	O
viable	1568	1574	O
S	1575	1576	O
.	1576	1577	O
aureus	1578	1584	O
.	1584	1585	O

CONCLUSIONS	1586	1597	O
:	1597	1598	O

Antibiotics	1599	1610	O
commonly	1611	1619	O
used	1620	1624	O
for	1625	1628	O
the	1629	1632	O
management	1633	1643	O
of	1644	1646	O
S	1647	1648	O
.	1648	1649	O
aureus	1650	1656	O
infections	1657	1667	O
appear	1668	1674	O
to	1675	1677	O
create	1678	1684	O
a	1685	1686	O
niche	1687	1692	O
for	1693	1696	O
invasive	1697	1705	O
intracellular	1706	1719	B-Immaterial_anatomical_entity
S	1720	1721	O
.	1721	1722	O
aureus	1723	1729	O
,	1729	1730	O
which	1731	1736	O
may	1737	1740	O
play	1741	1745	O
an	1746	1748	O
important	1749	1758	O
role	1759	1763	O
for	1764	1767	O
persistence	1768	1779	O
and	1780	1783	O
recurrence	1784	1794	O
of	1795	1797	O
infection	1798	1807	O
.	1807	1808	O

Because	1809	1816	O
of	1817	1819	O
its	1820	1823	O
unique	1824	1830	O
ability	1831	1838	O
to	1839	1841	O
eliminate	1842	1851	O
intracellular	1852	1865	B-Immaterial_anatomical_entity
S	1866	1867	O
.	1867	1868	O
aureus	1869	1875	O
,	1875	1876	O
rifampicin	1877	1887	O
appears	1888	1895	O
to	1896	1898	O
be	1899	1901	O
valuable	1902	1910	O
for	1911	1914	O
the	1915	1918	O
treatment	1919	1928	O
of	1929	1931	O
invasive	1932	1940	O
S	1941	1942	O
.	1942	1943	O
aureus	1944	1950	O
infections	1951	1961	O
.	1961	1962	O

Full	0	4	O
sequencing	5	15	O
analysis	16	24	O
of	25	27	O
estrogen	28	36	O
receptor	37	45	O
-	45	46	O
alpha	46	51	O
gene	52	56	O
polymorphism	57	69	O
and	70	73	O
its	74	77	O
association	78	89	O
with	90	94	O
breast	95	101	B-Pathological_formation
cancer	102	108	I-Pathological_formation
risk	109	113	O
.	113	114	O

BACKGROUND	115	125	O
:	125	126	O

The	127	130	O
estrogen	131	139	O
receptor	140	148	O
plays	149	154	O
a	155	156	O
critical	157	165	O
role	166	170	O
in	171	173	O
breast	174	180	B-Pathological_formation
cancer	181	187	I-Pathological_formation
development	188	199	O
and	200	203	O
progression	204	215	O
.	215	216	O

So	217	219	O
the	220	223	O
genetic	224	231	O
polymorphism	232	244	O
of	245	247	O
ER	248	250	O
-	250	251	O
alpha	251	256	O
gene	257	261	O
could	262	267	O
affect	268	274	O
cancer	275	281	B-Pathological_formation
risk	282	286	O
and	287	290	O
phenotype	291	300	O
.	300	301	O

MATERIALS	302	311	O
AND	312	315	O
METHODS	316	323	O
:	323	324	O

We	325	327	O
fully	328	333	O
sequenced	334	343	O
the	344	347	O
ER	348	350	O
-	350	351	O
alpha	351	356	O
gene	357	361	O
to	362	364	O
investigate	365	376	O
its	377	380	O
single	381	387	O
nucleotide	388	398	O
polymorphisms	399	412	O
(	413	414	O
SNPs	414	418	O
)	418	419	O
in	420	422	O
100	423	426	O
breast	427	433	B-Pathological_formation
cancer	434	440	I-Pathological_formation
patients	441	449	O
and	450	453	O
100	454	457	O
controls	458	466	O
.	466	467	O

RESULTS	468	475	O
:	475	476	O

Six	477	480	O
novel	481	486	O
polymorphism	487	499	O
in	500	502	O
the	503	506	O
control	507	514	O
and	515	518	O
11	519	521	O
in	522	524	O
cancer	525	531	B-Pathological_formation
patients	532	540	O
were	541	545	O
found	546	551	O
.	551	552	O

The	553	556	O
G	557	558	O
/	558	559	O
G	559	560	O
genotype	561	569	O
at	570	572	O
C975	573	577	O
G	578	579	O
and	580	583	O
A	584	585	O
/	585	586	O
A	586	587	O
genotype	588	596	O
at	597	599	O
G1782	600	605	O
A	606	607	O
had	608	611	O
a	612	613	O
protective	614	624	O
effect	625	631	O
against	632	639	O
breast	640	646	B-Pathological_formation
cancer	647	653	I-Pathological_formation
when	654	658	O
compared	659	667	O
to	668	670	O
other	671	676	O
genotypes	677	686	O
(	687	688	O
OR	688	690	O
=	691	692	O
0	693	694	O
.	694	695	O
3	695	696	O
and	697	700	O
0	701	702	O
.	702	703	O
3	703	704	O
,	704	705	O
respectively	706	718	O
)	718	719	O
.	719	720	O

975G	721	725	O
allele	726	732	O
was	733	736	O
associated	737	747	O
inversely	748	757	O
with	758	762	O
the	763	766	O
p53	767	770	O
expression	771	781	O
and	782	785	O
positively	786	796	O
with	797	801	O
the	802	805	O
bcl	806	809	O
-	809	810	O
2	810	811	O
expression	812	822	O
in	823	825	O
cancer	826	832	B-Pathological_formation
with	833	837	O
borderline	838	848	O
significance	849	861	O
.	861	862	O

Combining	863	872	O
this	873	877	O
result	878	884	O
with	885	889	O
our	890	893	O
previous	894	902	O
study	903	908	O
,	908	909	O
these	910	915	O
associations	916	928	O
became	929	935	O
more	936	940	O
significant	941	952	O
(	953	954	O
p	954	955	O
=	956	957	O
0	958	959	O
.	959	960	O
005	960	963	O
and	964	967	O
0	968	969	O
.	969	970	O
019	970	973	O
,	973	974	O
respectively	975	987	O
)	987	988	O
.	988	989	O

CONCLUSION	990	1000	O
:	1000	1001	O

Polymorphisms	1002	1015	O
in	1016	1018	O
ER	1019	1021	O
-	1021	1022	O
alpha	1022	1027	O
gene	1028	1032	O
can	1033	1036	O
affect	1037	1043	O
the	1044	1047	O
breast	1048	1054	B-Pathological_formation
cancer	1055	1061	I-Pathological_formation
susceptibility	1062	1076	O
and	1077	1080	O
may	1081	1084	O
be	1085	1087	O
related	1088	1095	O
to	1096	1098	O
other	1099	1104	O
protein	1105	1112	O
expression	1113	1123	O
,	1123	1124	O
such	1125	1129	O
as	1130	1132	O
p53	1133	1136	O
and	1137	1140	O
bcl	1141	1144	O
-	1144	1145	O
2	1145	1146	O
.	1146	1147	O

Covariance	0	10	O
structure	11	20	O
analysis	21	29	O
:	29	30	O
statistical	31	42	O
practice	43	51	O
,	51	52	O
theory	53	59	O
,	59	60	O
and	61	64	O
directions	65	75	O
.	75	76	O

Although	77	85	O
covariance	86	96	O
structure	97	106	O
analysis	107	115	O
is	116	118	O
used	119	123	O
increasingly	124	136	O
to	137	139	O
analyze	140	147	O
nonexperimental	148	163	O
data	164	168	O
,	168	169	O
important	170	179	O
statistical	180	191	O
requirements	192	204	O
for	205	208	O
its	209	212	O
proper	213	219	O
use	220	223	O
are	224	227	O
frequently	228	238	O
ignored	239	246	O
.	246	247	O

Valid	248	253	O
conclusions	254	265	O
about	266	271	O
the	272	275	O
adequacy	276	284	O
of	285	287	O
a	288	289	O
model	290	295	O
as	296	298	O
an	299	301	O
acceptable	302	312	O
representation	313	327	O
of	328	330	O
data	331	335	O
,	335	336	O
which	337	342	O
are	343	346	O
based	347	352	O
on	353	355	O
goodness	356	364	O
-	364	365	O
of	365	367	O
-	367	368	O
fit	368	371	O
test	372	376	O
statistics	377	387	O
and	388	391	O
standard	392	400	O
errors	401	407	O
of	408	410	O
parameter	411	420	O
estimates	421	430	O
,	430	431	O
rely	432	436	O
on	437	439	O
the	440	443	O
model	444	449	O
estimation	450	460	O
procedure	461	470	O
being	471	476	O
appropriate	477	488	O
for	489	492	O
the	493	496	O
data	497	501	O
.	501	502	O

Using	503	508	O
analogies	509	518	O
to	519	521	O
linear	522	528	O
regression	529	539	O
and	540	543	O
anova	544	549	O
,	549	550	O
this	551	555	O
review	556	562	O
examines	563	571	O
conditions	572	582	O
under	583	588	O
which	589	594	O
conclusions	595	606	O
drawn	607	612	O
from	613	617	O
various	618	625	O
estimation	626	636	O
methods	637	644	O
will	645	649	O
be	650	652	O
correct	653	660	O
and	661	664	O
the	665	668	O
consequences	669	681	O
of	682	684	O
ignoring	685	693	O
these	694	699	O
conditions	700	710	O
.	710	711	O

A	712	713	O
distinction	714	725	O
is	726	728	O
made	729	733	O
between	734	741	O
estimation	742	752	O
methods	753	760	O
that	761	765	O
are	766	769	O
either	770	776	O
correctly	777	786	O
or	787	789	O
incorrectly	790	801	O
specified	802	811	O
for	812	815	O
the	816	819	O
distribution	820	832	O
of	833	835	O
data	836	840	O
being	841	846	O
analyzed	847	855	O
,	855	856	O
and	857	860	O
it	861	863	O
is	864	866	O
shown	867	872	O
that	873	877	O
valid	878	883	O
conclusions	884	895	O
are	896	899	O
possible	900	908	O
even	909	913	O
under	914	919	O
misspecification	920	936	O
.	936	937	O

A	938	939	O
brief	940	945	O
example	946	953	O
illustrates	954	965	O
the	966	969	O
ideas	970	975	O
.	975	976	O

Internet	977	985	O
access	986	992	O
is	993	995	O
given	996	1001	O
to	1002	1004	O
a	1005	1006	O
computer	1007	1015	O
code	1016	1020	O
for	1021	1024	O
several	1025	1032	O
methods	1033	1040	O
that	1041	1045	O
are	1046	1049	O
not	1050	1053	O
available	1054	1063	O
in	1064	1066	O
programs	1067	1075	O
such	1076	1080	O
as	1081	1083	O
EQS	1084	1087	O
or	1088	1090	O
LISREL	1091	1097	O
.	1097	1098	O

Potent	0	6	O
antibacterial	7	20	O
activity	21	29	O
of	30	32	O
Y	33	34	O
-	34	35	O
754	35	38	O
,	38	39	O
a	40	41	O
novel	42	47	O
benzimidazole	48	61	O
compound	62	70	O
with	71	75	O
selective	76	85	O
action	86	92	O
against	93	100	O
Helicobacter	101	113	O
pylori	114	120	O
.	120	121	O

Y	122	123	O
-	123	124	O
754	124	127	O
,	127	128	O
a	129	130	O
novel	131	136	O
benzimidazole	137	150	O
compound	151	159	O
,	159	160	O
was	161	164	O
investigated	165	177	O
for	178	181	O
in	182	184	O
vitro	185	190	O
and	191	194	O
in	195	197	O
vivo	198	202	O
antibacterial	203	216	O
activity	217	225	O
.	225	226	O

Unlike	227	233	O
amoxicillin	234	245	O
,	245	246	O
clarithromycin	247	261	O
,	261	262	O
and	263	266	O
metronidazole	267	280	O
,	280	281	O
the	282	285	O
compound	286	294	O
had	295	298	O
no	299	301	O
activity	302	310	O
against	311	318	O
common	319	325	O
aerobic	326	333	O
and	334	337	O
anaerobic	338	347	O
bacteria	348	356	O
other	357	362	O
than	363	367	O
Helicobacter	368	380	O
pylori	381	387	O
.	387	388	O

The	389	392	O
minimum	393	400	O
inhibitory	401	411	O
concentration	412	425	O
of	426	428	O
Y	429	430	O
-	430	431	O
754	431	434	O
against	435	442	O
H	443	444	O
.	444	445	O
pylori	446	452	O
,	452	453	O
at	454	456	O
0	457	458	O
.	458	459	O
025	459	462	O
microg	463	469	O
/	469	470	O
ml	470	472	O
,	472	473	O
was	474	477	O
nearly	478	484	O
equal	485	490	O
to	491	493	O
that	494	498	O
of	499	501	O
amoxicillin	502	513	O
and	514	517	O
clarithromycin	518	532	O
.	532	533	O

The	534	537	O
respective	538	548	O
concentrations	549	563	O
of	564	566	O
Y	567	568	O
-	568	569	O
754	569	572	O
,	572	573	O
amoxicillin	574	585	O
,	585	586	O
clarithromycin	587	601	O
,	601	602	O
and	603	606	O
metronidazole	607	620	O
required	621	629	O
to	630	632	O
inhibit	633	640	O
90	641	643	O
%	643	644	O
of	645	647	O
39	648	650	O
isolates	651	659	O
of	660	662	O
H	663	664	O
.	664	665	O
pylori	666	672	O
were	673	677	O
0	678	679	O
.	679	680	O
05	680	682	O
,	682	683	O
0	684	685	O
.	685	686	O
39	686	688	O
,	688	689	O
6	690	691	O
.	691	692	O
25	692	694	O
,	694	695	O
and	696	699	O
25	700	702	O
microg	703	709	O
/	709	710	O
ml	710	712	O
,	712	713	O
indicating	714	724	O
the	725	728	O
potent	729	735	O
activity	736	744	O
of	745	747	O
Y	748	749	O
-	749	750	O
754	750	753	O
,	753	754	O
including	755	764	O
activity	765	773	O
against	774	781	O
clarithromycin	782	796	O
-	796	797	O
and	798	801	O
metronidazole	802	815	O
-	815	816	O
resistant	816	825	O
strains	826	833	O
.	833	834	O

The	835	838	O
anti	839	843	O
-	843	844	O
H	844	845	O
.	845	846	O
pylori	847	853	O
activity	854	862	O
of	863	865	O
Y	866	867	O
-	867	868	O
754	868	871	O
was	872	875	O
potent	876	882	O
even	883	887	O
at	888	890	O
pH	891	893	O
5	894	895	O
.	895	896	O
5	896	897	O
and	898	901	O
was	902	905	O
bactericidal	906	918	O
at	919	921	O
concentrations	922	936	O
of	937	939	O
0	940	941	O
.	941	942	O
1	942	943	O
microg	944	950	O
/	950	951	O
ml	951	953	O
and	954	957	O
above	958	963	O
.	963	964	O

Exposure	965	973	O
of	974	976	O
H	977	978	O
.	978	979	O
pylori	980	986	O
to	987	989	O
Y	990	991	O
-	991	992	O
754	992	995	O
did	996	999	O
not	1000	1003	O
result	1004	1010	O
in	1011	1013	O
the	1014	1017	O
induction	1018	1027	O
of	1028	1030	O
drug	1031	1035	O
-	1035	1036	O
resistant	1036	1045	O
mutation	1046	1054	O
.	1054	1055	O

Oral	1056	1060	O
administration	1061	1075	O
(	1076	1077	O
10	1077	1079	O
mg	1080	1082	O
/	1082	1083	O
kg	1083	1085	O
twice	1086	1091	O
a	1092	1093	O
day	1094	1097	O
for	1098	1101	O
7	1102	1103	O
days	1104	1108	O
)	1108	1109	O
to	1110	1112	O
Mongolian	1113	1122	O
gerbils	1123	1130	O
infected	1131	1139	O
with	1140	1144	O
strain	1145	1151	O
ATCC	1152	1156	O
43504	1157	1162	O
demonstrated	1163	1175	O
that	1176	1180	O
Y	1181	1182	O
-	1182	1183	O
754	1183	1186	O
was	1187	1190	O
effective	1191	1200	O
in	1201	1203	O
H	1204	1205	O
.	1205	1206	O
pylori	1207	1213	O
eradication	1214	1225	O
and	1226	1229	O
that	1230	1234	O
its	1235	1238	O
eradication	1239	1250	O
efficacy	1251	1259	O
increased	1260	1269	O
in	1270	1272	O
line	1273	1277	O
with	1278	1282	O
the	1283	1286	O
progress	1287	1295	O
of	1296	1298	O
damage	1299	1305	O
to	1306	1308	O
the	1309	1312	O
gastric	1313	1320	B-Multi-tissue_structure
mucosa	1321	1327	I-Multi-tissue_structure
caused	1328	1334	O
by	1335	1337	O
H	1338	1339	O
.	1339	1340	O
pylori	1341	1347	O
infection	1348	1357	O
.	1357	1358	O

Y	1359	1360	O
-	1360	1361	O
754	1361	1364	O
was	1365	1368	O
also	1369	1373	O
efficacious	1374	1385	O
in	1386	1388	O
the	1389	1392	O
treatment	1393	1402	O
of	1403	1405	O
infection	1406	1415	O
by	1416	1418	O
the	1419	1422	O
clarithromycin	1423	1437	O
-	1437	1438	O
resistant	1438	1447	O
strain	1448	1454	O
OIT	1455	1458	O
-	1458	1459	O
36	1459	1461	O
.	1461	1462	O

The	1463	1466	O
results	1467	1474	O
obtained	1475	1483	O
lead	1484	1488	O
to	1489	1491	O
the	1492	1495	O
expectation	1496	1507	O
that	1508	1512	O
the	1513	1516	O
new	1517	1520	O
benzimidazole	1521	1534	O
Y	1535	1536	O
-	1536	1537	O
754	1537	1540	O
will	1541	1545	O
,	1545	1546	O
in	1547	1549	O
the	1550	1553	O
near	1554	1558	O
future	1559	1565	O
,	1565	1566	O
be	1567	1569	O
used	1570	1574	O
for	1575	1578	O
H	1579	1580	O
.	1580	1581	O
pylori	1582	1588	O
eradication	1589	1600	O
therapy	1601	1608	O
in	1609	1611	O
peptic	1612	1618	B-Pathological_formation
ulcer	1619	1624	I-Pathological_formation
patients	1625	1633	O
.	1633	1634	O

Active	0	6	O
respiratory	7	18	O
syncytial	19	28	O
virus	29	34	O
purified	35	43	O
by	44	46	O
ion	47	50	O
-	50	51	O
exchange	51	59	O
chromatography	60	74	O
:	74	75	O
characterization	76	92	O
of	93	95	O
binding	96	103	O
and	104	107	O
elution	108	115	O
requirements	116	128	O
.	128	129	O

Two	130	133	O
viruses	134	141	O
,	141	142	O
respiratory	143	154	O
syncytial	155	164	O
virus	165	170	O
(	171	172	O
RSV	172	175	O
)	175	176	O
and	177	180	O
vesicular	181	190	O
stomatitis	191	201	O
virus	202	207	O
(	208	209	O
VSV	209	212	O
)	212	213	O
were	214	218	O
used	219	223	O
to	224	226	O
evaluate	227	235	O
viral	236	241	O
purification	242	254	O
by	255	257	O
an	258	260	O
affinity	261	269	O
resin	270	275	O
column	276	282	O
(	283	284	O
Matrex	284	290	O
Cellufine	291	300	O
Sulfate	301	308	O
(	309	310	O
MCS	310	313	O
)	313	314	O
;	314	315	O
Amicon	316	322	O
Division	323	331	O
,	331	332	O
WR	333	335	O
Grace	336	341	O
&	342	343	O
Co	344	346	O
.	346	347	O
)	347	348	O
.	348	349	O

Viable	350	356	O
RSV	357	360	O
was	361	364	O
purified	365	373	O
significantly	374	387	O
from	388	392	O
crude	393	398	O
cell	399	403	B-Organism_substance
lysate	404	410	I-Organism_substance
by	411	413	O
a	414	415	O
single	416	422	O
pass	423	427	O
through	428	435	O
a	436	437	O
column	438	444	O
containing	445	455	O
the	456	459	O
anionic	460	467	O
MCS	468	471	O
resin	472	477	O
.	477	478	O

Most	479	483	O
cell	484	488	B-Cell
protein	489	496	O
and	497	500	O
albumin	501	508	O
eluted	509	515	O
from	516	520	O
the	521	524	O
MCS	525	528	O
resin	529	534	O
with	535	539	O
phosphate	540	549	O
buffered	550	558	O
saline	559	565	O
(	566	567	O
PBS	567	570	O
)	570	571	O
but	572	575	O
RSV	576	579	O
eluted	580	586	O
at	587	589	O
high	590	594	O
ionic	595	600	O
strength	601	609	O
,	609	610	O
i	611	612	O
.	612	613	O
e	613	614	O
.	614	615	O
,	615	616	O
greater	617	624	O
than	625	629	O
or	630	632	O
equal	633	638	O
to	639	641	O
0	642	643	O
.	643	644	O
6	644	645	O
M	646	647	O
NaCl	648	652	O
.	652	653	O

Further	654	661	O
purification	662	674	O
was	675	678	O
possible	679	687	O
by	688	690	O
sucrose	691	698	O
step	699	703	O
gradient	704	712	O
centrifugation	713	727	O
.	727	728	O

The	729	732	O
RSV	733	736	O
prepared	737	745	O
by	746	748	O
column	749	755	O
purification	756	768	O
or	769	771	O
by	772	774	O
column	775	781	O
plus	782	786	O
sucrose	787	794	O
gradient	795	803	O
separation	804	814	O
was	815	818	O
both	819	823	O
intact	824	830	O
and	831	834	O
infective	835	844	O
.	844	845	O

RSV	846	849	O
and	850	853	O
pure	854	858	O
samples	859	866	O
of	867	869	O
VSV	870	873	O
were	874	878	O
used	879	883	O
to	884	886	O
optimize	887	895	O
ionic	896	901	O
strength	902	910	O
and	911	914	O
salts	915	920	O
for	921	924	O
elution	925	932	O
from	933	937	O
the	938	941	O
MCS	942	945	O
column	946	952	O
:	952	953	O
0	954	955	O
.	955	956	O
8	956	957	O
M	958	959	O
NaCl	960	964	O
removed	965	972	O
most	973	977	O
of	978	980	O
the	981	984	O
viral	985	990	O
protein	991	998	O
.	998	999	O

The	1000	1003	O
capacity	1004	1012	O
of	1013	1015	O
the	1016	1019	O
MCS	1020	1023	O
gel	1024	1027	O
for	1028	1031	O
RSV	1032	1035	O
or	1036	1038	O
VSV	1039	1042	O
was	1043	1046	O
found	1047	1052	O
to	1053	1055	O
be	1056	1058	O
about	1059	1064	O
0	1065	1066	O
.	1066	1067	O
6	1067	1068	O
-	1068	1069	O
0	1069	1070	O
.	1070	1071	O
8	1071	1072	O
mg	1073	1075	O
viral	1076	1081	O
protein	1082	1089	O
per	1090	1093	O
ml	1094	1096	O
of	1097	1099	O
hydrated	1100	1108	O
resin	1109	1114	O
.	1114	1115	O

Detergent	1116	1125	O
-	1125	1126	O
solubilized	1126	1137	O
viral	1138	1143	O
membrane	1144	1152	B-Cellular_component
proteins	1153	1161	O
bound	1162	1167	O
to	1168	1170	O
the	1171	1174	O
MCS	1175	1178	O
resin	1179	1184	O
in	1185	1187	O
0	1188	1189	O
.	1189	1190	O
145	1190	1193	O
M	1194	1195	O
NaCl	1196	1200	O
and	1201	1204	O
eluted	1205	1211	O
with	1212	1216	O
higher	1217	1223	O
salt	1224	1228	O
concentrations	1229	1243	O
.	1243	1244	O

Thus	1245	1249	O
,	1249	1250	O
this	1251	1255	O
resin	1256	1261	O
also	1262	1266	O
may	1267	1270	O
be	1271	1273	O
a	1274	1275	O
useful	1276	1282	O
aid	1283	1286	O
for	1287	1290	O
relatively	1291	1301	O
gentle	1302	1308	O
purification	1309	1321	O
of	1322	1324	O
these	1325	1330	O
proteins	1331	1339	O
.	1339	1340	O

Novel	0	5	O
insights	6	14	O
into	15	19	O
the	20	23	O
pathogenesis	24	36	O
of	37	39	O
uric	40	44	O
acid	45	49	O
nephrolithiasis	50	65	O
.	65	66	O

PURPOSE	67	74	O
OF	75	77	O
REVIEW	78	84	O
:	84	85	O

The	86	89	O
factors	90	97	O
involved	98	106	O
in	107	109	O
the	110	113	O
pathogenesis	114	126	O
of	127	129	O
uric	130	134	O
acid	135	139	O
nephrolithiasis	140	155	O
are	156	159	O
well	160	164	O
known	165	170	O
.	170	171	O

A	172	173	O
low	174	177	O
urinary	178	185	B-Organism_substance
pH	186	188	O
is	189	191	O
the	192	195	O
most	196	200	O
significant	201	212	O
element	213	220	O
in	221	223	O
the	224	227	O
generation	228	238	O
of	239	241	O
stones	242	248	B-Organism_substance
,	248	249	O
with	250	254	O
hyperuricosuria	255	270	O
being	271	276	O
a	277	278	O
less	279	283	O
common	284	290	O
finding	291	298	O
.	298	299	O

The	300	303	O
underlying	304	314	O
mechanism	315	324	O
(	324	325	O
s	325	326	O
)	326	327	O
responsible	328	339	O
for	340	343	O
these	344	349	O
disturbances	350	362	O
remain	363	369	O
poorly	370	376	O
characterized	377	390	O
.	390	391	O

This	392	396	O
review	397	403	O
summarizes	404	414	O
previous	415	423	O
knowledge	424	433	O
and	434	437	O
highlights	438	448	O
some	449	453	O
recent	454	460	O
developments	461	473	O
in	474	476	O
the	477	480	O
pathophysiology	481	496	O
of	497	499	O
low	500	503	O
urine	504	509	B-Organism_substance
pH	510	512	O
and	513	516	O
hyperuricosuria	517	532	O
.	532	533	O

RECENT	534	540	O
FINDINGS	541	549	O
:	549	550	O

Epidemiological	551	566	O
and	567	570	O
metabolic	571	580	O
studies	581	588	O
have	589	593	O
indicated	594	603	O
an	604	606	O
association	607	618	O
between	619	626	O
uric	627	631	O
acid	632	636	O
nephrolithiasis	637	652	O
and	653	656	O
insulin	657	664	O
resistance	665	675	O
.	675	676	O

Some	677	681	O
potential	682	691	O
mechanisms	692	702	O
include	703	710	O
impaired	711	719	O
ammoniagenesis	720	734	O
caused	735	741	O
by	742	744	O
resistance	745	755	O
to	756	758	O
insulin	759	766	O
action	767	773	O
in	774	776	O
the	777	780	O
renal	781	786	B-Multi-tissue_structure
proximal	787	795	I-Multi-tissue_structure
tubule	796	802	I-Multi-tissue_structure
,	802	803	O
or	804	806	O
substrate	807	816	O
competition	817	828	O
by	829	831	O
free	832	836	O
fatty	837	842	O
acids	843	848	O
.	848	849	O

The	850	853	O
evaluation	854	864	O
of	865	867	O
a	868	869	O
large	870	875	O
Sicilian	876	884	O
kindred	885	892	O
recently	893	901	O
revealed	902	910	O
a	911	912	O
putative	913	921	O
genetic	922	929	O
locus	930	935	O
linked	936	942	O
to	943	945	O
uric	946	950	B-Organism_substance
acid	951	955	I-Organism_substance
stone	956	961	I-Organism_substance
disease	962	969	O
.	969	970	O

The	971	974	O
identification	975	989	O
of	990	992	O
novel	993	998	O
complementary	999	1012	O
DNA	1013	1016	O
has	1017	1020	O
provided	1021	1029	O
an	1030	1032	O
interesting	1033	1044	O
insight	1045	1052	O
into	1053	1057	O
the	1058	1061	O
renal	1062	1067	B-Organ
handling	1068	1076	O
of	1077	1079	O
uric	1080	1084	O
acid	1085	1089	O
,	1089	1090	O
including	1091	1100	O
one	1101	1104	O
genetic	1105	1112	O
cause	1113	1118	O
of	1119	1121	O
renal	1122	1127	B-Organ
uric	1128	1132	O
acid	1133	1137	O
wasting	1138	1145	O
.	1145	1146	O

SUMMARY	1147	1154	O
:	1154	1155	O

The	1156	1159	O
recognition	1160	1171	O
of	1172	1174	O
metabolic	1175	1184	O
,	1184	1185	O
molecular	1186	1195	O
,	1195	1196	O
and	1197	1200	O
genetic	1201	1208	O
factors	1209	1216	O
that	1217	1221	O
influence	1222	1231	O
urinary	1232	1239	B-Organism_substance
pH	1240	1242	O
,	1242	1243	O
and	1244	1247	O
uric	1248	1252	O
acid	1253	1257	O
metabolism	1258	1268	O
and	1269	1272	O
excretion	1273	1282	O
,	1282	1283	O
will	1284	1288	O
provide	1289	1296	O
novel	1297	1302	O
insights	1303	1311	O
into	1312	1316	O
the	1317	1320	O
pathogenesis	1321	1333	O
of	1334	1336	O
uric	1337	1341	B-Organism_substance
acid	1342	1346	I-Organism_substance
stones	1347	1353	I-Organism_substance
,	1353	1354	O
and	1355	1358	O
open	1359	1363	O
the	1364	1367	O
way	1368	1371	O
for	1372	1375	O
new	1376	1379	O
therapeutic	1380	1391	O
strategies	1392	1402	O
.	1402	1403	O

Flow	0	4	O
dynamics	5	13	O
of	14	16	O
the	17	20	O
internal	21	29	B-Multi-tissue_structure
thoracic	30	38	I-Multi-tissue_structure
and	39	42	O
radial	43	49	B-Multi-tissue_structure
artery	50	56	I-Multi-tissue_structure
T	57	58	O
-	58	59	O
graft	59	64	O
.	64	65	O

BACKGROUND	66	76	O
:	76	77	O

Complex	78	85	O
use	86	89	O
of	90	92	O
arterial	93	101	B-Multi-tissue_structure
conduits	102	110	I-Multi-tissue_structure
has	111	114	O
resurrected	115	126	O
concerns	127	135	O
about	136	141	O
the	142	145	O
adequacy	146	154	O
of	155	157	O
conduit	158	165	B-Multi-tissue_structure
flow	166	170	O
.	170	171	O

The	172	175	O
T	176	177	O
-	177	178	O
graft	178	183	O
is	184	186	O
the	187	190	O
extreme	191	198	O
example	199	206	O
of	207	209	O
this	210	214	O
trend	215	220	O
.	220	221	O

Our	222	225	O
purpose	226	233	O
was	234	237	O
to	238	240	O
identify	241	249	O
the	250	253	O
limitation	254	264	O
of	265	267	O
single	268	274	O
source	275	281	O
inflow	282	288	O
and	289	292	O
to	293	295	O
compare	296	303	O
flow	304	308	O
capacity	309	317	O
with	318	322	O
completion	323	333	O
coronary	334	342	B-Multi-tissue_structure
flow	343	347	O
.	347	348	O

METHODS	349	356	O
:	356	357	O

Between	358	365	O
February	366	374	O
1999	375	379	O
and	380	383	O
November	384	392	O
2001	393	397	O
,	397	398	O
372	399	402	O
patients	403	411	O
underwent	412	421	O
total	422	427	O
arterial	428	436	B-Multi-tissue_structure
revascularization	437	454	O
with	455	459	O
the	460	463	O
T	464	465	O
-	465	466	O
graft	466	471	O
alone	472	477	O
.	477	478	O

Intraoperative	479	493	O
flows	494	499	O
were	500	504	O
recorded	505	513	O
for	514	517	O
each	518	522	O
limb	523	527	B-Multi-tissue_structure
of	528	530	O
the	531	534	O
T	535	536	O
-	536	537	O
graft	537	542	O
before	543	549	O
and	550	553	O
after	554	559	O
distal	560	566	O
anastomoses	567	578	O
in	579	581	O
204	582	585	O
patients	586	594	O
.	594	595	O

Independent	596	607	O
predictors	608	618	O
of	619	621	O
T	622	623	O
-	623	624	O
graft	624	629	O
flow	630	634	O
were	635	639	O
identified	640	650	O
by	651	653	O
multivariate	654	666	O
analysis	667	675	O
.	675	676	O

RESULTS	677	684	O
:	684	685	O

Free	686	690	O
flow	691	695	O
for	696	699	O
the	700	703	O
radial	704	710	B-Multi-tissue_structure
arterial	711	719	I-Multi-tissue_structure
(	720	721	I-Multi-tissue_structure
RA	721	723	I-Multi-tissue_structure
)	723	724	I-Multi-tissue_structure
limb	725	729	I-Multi-tissue_structure
was	730	733	O
161	734	737	O
+	738	739	O
/	739	740	O
-	740	741	O
81	742	744	O
mL	745	747	O
/	747	748	O
min	748	751	O
,	751	752	O
the	753	756	O
internal	757	765	B-Multi-tissue_structure
thoracic	766	774	I-Multi-tissue_structure
artery	775	781	I-Multi-tissue_structure
(	782	783	I-Multi-tissue_structure
ITA	783	786	I-Multi-tissue_structure
)	786	787	I-Multi-tissue_structure
limb	788	792	I-Multi-tissue_structure
137	793	796	O
+	797	798	O
/	798	799	O
-	799	800	O
57	801	803	O
mL	804	806	O
/	806	807	O
min	807	810	O
(	811	812	O
combined	812	820	O
298	821	824	O
+	825	826	O
/	826	827	O
-	827	828	O
101	829	832	O
mL	833	835	O
/	835	836	O
min	836	839	O
)	839	840	O
versus	841	847	O
simultaneous	848	860	O
limb	861	865	B-Multi-tissue_structure
flow	866	870	O
of	871	873	O
226	874	877	O
+	878	879	O
/	879	880	O
-	880	881	O
84	882	884	O
mL	885	887	O
/	887	888	O
min	888	891	O
giving	892	898	O
a	899	900	O
flow	901	905	O
restriction	906	917	O
of	918	920	O
24	921	923	O
%	923	924	O
+	925	926	O
/	926	927	O
-	927	928	O
14	929	931	O
%	931	932	O
.	932	933	O

Completion	934	944	O
coronary	945	953	B-Multi-tissue_structure
flow	954	958	O
was	959	962	O
88	963	965	O
+	966	967	O
/	967	968	O
-	968	969	O
49	970	972	O
mL	973	975	O
/	975	976	O
min	976	979	O
for	980	983	O
the	984	987	O
RA	988	990	B-Multi-tissue_structure
,	990	991	O
60	992	994	O
+	995	996	O
/	996	997	O
-	997	998	O
45	999	1001	O
mL	1002	1004	O
/	1004	1005	O
min	1005	1008	O
for	1009	1012	O
the	1013	1016	O
ITA	1017	1020	B-Multi-tissue_structure
,	1020	1021	O
and	1022	1025	O
140	1026	1029	O
+	1030	1031	O
/	1031	1032	O
-	1032	1033	O
70	1034	1036	O
mL	1037	1039	O
/	1039	1040	O
min	1040	1043	O
for	1044	1047	O
both	1048	1052	O
limbs	1053	1058	B-Multi-tissue_structure
simultaneously	1059	1073	O
to	1074	1076	O
give	1077	1081	O
a	1082	1083	O
flow	1084	1088	O
reserve	1089	1096	O
(	1097	1098	O
vs	1098	1100	O
simultaneous	1101	1113	O
free	1114	1118	O
flow	1119	1123	O
)	1123	1124	O
of	1125	1127	O
160	1128	1131	O
%	1131	1132	O
or	1133	1135	O
1	1136	1137	O
.	1137	1138	O
6	1138	1139	O
.	1139	1140	O

Independent	1141	1152	O
predictors	1153	1163	O
of	1164	1166	O
completion	1167	1177	O
RA	1178	1180	B-Multi-tissue_structure
limb	1181	1185	I-Multi-tissue_structure
flow	1186	1190	O
are	1191	1194	O
RA	1195	1197	B-Multi-tissue_structure
proximal	1198	1206	O
diameter	1207	1215	O
(	1216	1217	O
p	1217	1218	O
=	1219	1220	O
0	1221	1222	O
.	1222	1223	O
005	1223	1226	O
)	1226	1227	O
,	1227	1228	O
number	1229	1235	O
of	1236	1238	O
anastomoses	1239	1250	O
(	1251	1252	O
p	1252	1253	O
=	1254	1255	O
0	1256	1257	O
.	1257	1258	O
018	1258	1261	O
)	1261	1262	O
,	1262	1263	O
and	1264	1267	O
target	1268	1274	O
stenosis	1275	1283	O
(	1284	1285	O
p	1285	1286	O
=	1287	1288	O
0	1289	1290	O
.	1290	1291	O
005	1291	1294	O
)	1294	1295	O
.	1295	1296	O

CONCLUSIONS	1297	1308	O
:	1308	1309	O

A	1310	1311	O
flow	1312	1316	O
reserve	1317	1324	O
of	1325	1327	O
1	1328	1329	O
.	1329	1330	O
6	1330	1331	O
compares	1332	1340	O
favorably	1341	1350	O
with	1351	1355	O
an	1356	1358	O
ITA	1359	1362	B-Multi-tissue_structure
flow	1363	1367	O
reserve	1368	1375	O
of	1376	1378	O
1	1379	1380	O
.	1380	1381	O
8	1381	1382	O
at	1383	1385	O
1	1386	1387	O
-	1387	1388	O
month	1388	1393	O
postoperatively	1394	1409	O
and	1410	1413	O
1	1414	1415	O
.	1415	1416	O
8	1416	1417	O
for	1418	1421	O
both	1422	1426	O
the	1427	1430	O
ITA	1431	1434	B-Multi-tissue_structure
T	1435	1436	O
-	1436	1437	O
graft	1437	1442	O
and	1443	1446	O
the	1447	1450	O
ITA	1451	1454	B-Multi-tissue_structure
/	1454	1455	I-Multi-tissue_structure
RA	1455	1457	I-Multi-tissue_structure
T	1458	1459	O
-	1459	1460	O
graft	1460	1465	O
at	1466	1468	O
1	1469	1470	O
-	1470	1471	O
week	1471	1475	O
postoperatively	1476	1491	O
as	1492	1494	O
reported	1495	1503	O
by	1504	1506	O
others	1507	1513	O
.	1513	1514	O

Proximal	1515	1523	O
RA	1524	1526	B-Multi-tissue_structure
diameter	1527	1535	O
and	1536	1539	O
competitive	1540	1551	O
coronary	1552	1560	B-Multi-tissue_structure
flow	1561	1565	O
influence	1566	1575	O
completion	1576	1586	O
T	1587	1588	O
-	1588	1589	O
graft	1589	1594	O
flow	1595	1599	O
.	1599	1600	O

These	1601	1606	O
data	1607	1611	O
quantitate	1612	1622	O
the	1623	1626	O
limitation	1627	1637	O
of	1638	1640	O
single	1641	1647	O
source	1648	1654	O
inflow	1655	1661	O
of	1662	1664	O
the	1665	1668	O
T	1669	1670	O
-	1670	1671	O
graft	1671	1676	O
configuration	1677	1690	O
and	1691	1694	O
support	1695	1702	O
its	1703	1706	O
continued	1707	1716	O
use	1717	1720	O
.	1720	1721	O

Thiazole	0	8	O
orange	9	15	O
positive	16	24	O
platelets	25	34	B-Cell
in	35	37	O
a	38	39	O
dog	40	43	O
with	44	48	O
Evans	49	54	O
'	54	55	O
syndrome	56	64	O
.	64	65	O

We	66	68	O
examined	69	77	O
transition	78	88	O
for	89	92	O
the	93	96	O
percentage	97	107	O
of	108	110	O
reticulated	111	122	B-Cell
platelets	123	132	I-Cell
(	133	134	O
RP	134	136	B-Cell
%	136	137	O
)	137	138	O
and	139	142	O
platelet	143	151	B-Cell
count	152	157	O
in	158	160	O
a	161	162	O
canine	163	169	O
case	170	174	O
of	175	177	O
Evans	178	183	O
'	183	184	O
syndrome	185	193	O
.	193	194	O

The	195	198	O
result	199	205	O
demonstrated	206	218	O
that	219	223	O
measurement	224	235	O
of	236	238	O
the	239	242	O
RP	243	245	B-Cell
%	245	246	O
can	247	250	O
be	251	253	O
useful	254	260	O
in	261	263	O
evaluating	264	274	O
platelet	275	283	B-Cell
production	284	294	O
in	295	297	O
the	298	301	O
bone	302	306	B-Multi-tissue_structure
marrow	307	313	I-Multi-tissue_structure
and	314	317	O
response	318	326	O
to	327	329	O
treatment	330	339	O
.	339	340	O

Human	0	5	O
cytomegalovirus	6	21	O
5	22	23	O
-	23	24	O
kilobase	24	32	O
immediate	33	42	O
-	42	43	O
early	43	48	O
RNA	49	52	O
is	53	55	O
a	56	57	O
stable	58	64	O
intron	65	71	O
.	71	72	O

Immediate	73	82	O
-	82	83	O
early	83	88	O
viral	89	94	O
gene	95	99	O
products	100	108	O
of	109	111	O
human	112	117	O
cytomegalovirus	118	133	O
(	134	135	O
HCMV	135	139	O
)	139	140	O
are	141	144	O
derived	145	152	O
from	153	157	O
several	158	165	O
genomic	166	173	O
loci	174	178	O
and	179	182	O
largely	183	190	O
serve	191	196	O
to	197	199	O
establish	200	209	O
a	210	211	O
cellular	212	220	B-Cell
environment	221	232	O
conducive	233	242	O
to	243	245	O
viral	246	251	O
replication	252	263	O
.	263	264	O

We	265	267	O
have	268	272	O
further	273	280	O
examined	281	289	O
an	290	292	O
unusual	293	300	O
immediate	301	310	O
-	310	311	O
early	311	316	O
transcript	317	327	O
known	328	333	O
as	334	336	O
the	337	340	O
5	341	342	O
-	342	343	O
kb	343	345	O
RNA	346	349	O
,	349	350	O
concluding	351	361	O
that	362	366	O
it	367	369	O
is	370	372	O
a	373	374	O
stable	375	381	O
intron	382	388	O
encoded	389	396	O
by	397	399	O
HCMV	400	404	O
.	404	405	O

The	406	409	O
5	410	411	O
-	411	412	O
kb	412	414	O
RNA	415	418	O
is	419	421	O
highly	422	428	O
AT	429	431	O
rich	432	436	O
in	437	439	O
sequence	440	448	O
and	449	452	O
lacks	453	458	O
open	459	463	O
reading	464	471	O
frames	472	478	O
likely	479	485	O
to	486	488	O
be	489	491	O
translated	492	502	O
into	503	507	O
protein	508	515	O
.	515	516	O

We	517	519	O
confirmed	520	529	O
the	530	533	O
absence	534	541	O
of	542	544	O
polyadenylation	545	560	O
of	561	563	O
the	564	567	O
transcript	568	578	O
and	579	582	O
showed	583	589	O
that	590	594	O
it	595	597	O
is	598	600	O
primarily	601	610	O
nuclear	611	618	B-Cellular_component
localized	619	628	O
during	629	635	O
viral	636	641	O
infection	642	651	O
.	651	652	O

We	653	655	O
mapped	656	662	O
the	663	666	O
5	667	668	O
'	668	669	O
end	670	673	O
of	674	676	O
the	677	680	O
5	681	682	O
-	682	683	O
kb	683	685	O
RNA	686	689	O
to	690	692	O
a	693	694	O
consensus	695	704	O
splice	705	711	O
donor	712	717	O
site	718	722	O
and	723	726	O
localized	727	736	O
the	737	740	O
3	741	742	O
'	742	743	O
end	744	747	O
in	748	750	O
the	751	754	O
vicinity	755	763	O
of	764	766	O
a	767	768	O
splice	769	775	O
acceptor	776	784	O
site	785	789	O
.	789	790	O

In	791	793	O
transfection	794	806	O
studies	807	814	O
,	814	815	O
we	816	818	O
showed	819	825	O
that	826	830	O
the	831	834	O
5	835	836	O
-	836	837	O
kb	837	839	O
RNA	840	843	O
can	844	847	O
be	848	850	O
spliced	851	858	O
from	859	863	O
a	864	865	O
heterologous	866	878	O
primary	879	886	O
transcript	887	897	O
.	897	898	O

Using	899	904	O
bacterial	905	914	O
artificial	915	925	O
chromosome	926	936	B-Cellular_component
technology	937	947	O
,	947	948	O
we	949	951	O
constructed	952	963	O
a	964	965	O
viral	966	971	O
recombinant	972	983	O
containing	984	994	O
a	995	996	O
mutation	997	1005	O
in	1006	1008	O
the	1009	1012	O
5	1013	1014	O
'	1014	1015	O
splice	1016	1022	O
donor	1023	1028	O
site	1029	1033	O
that	1034	1038	O
defines	1039	1046	O
the	1047	1050	O
5	1051	1052	O
'	1052	1053	O
end	1054	1057	O
of	1058	1060	O
the	1061	1064	O
RNA	1065	1068	O
and	1069	1072	O
found	1073	1078	O
that	1079	1083	O
this	1084	1088	O
mutation	1089	1097	O
eliminates	1098	1108	O
expression	1109	1119	O
of	1120	1122	O
the	1123	1126	O
5	1127	1128	O
-	1128	1129	O
kb	1129	1131	O
RNA	1132	1135	O
during	1136	1142	O
viral	1143	1148	O
infection	1149	1158	O
.	1158	1159	O

This	1160	1164	O
mutant	1165	1171	O
grows	1172	1177	O
in	1178	1180	O
human	1181	1186	O
fibroblasts	1187	1198	B-Cell
without	1199	1206	O
complementation	1207	1222	O
.	1222	1223	O

Taken	1224	1229	O
together	1230	1238	O
,	1238	1239	O
these	1240	1245	O
data	1246	1250	O
support	1251	1258	O
the	1259	1262	O
conclusion	1263	1273	O
that	1274	1278	O
the	1279	1282	O
5	1283	1284	O
-	1284	1285	O
kb	1285	1287	O
RNA	1288	1291	O
is	1292	1294	O
a	1295	1296	O
stable	1297	1303	O
intron	1304	1310	O
expressed	1311	1320	O
by	1321	1323	O
HCMV	1324	1328	O
.	1328	1329	O

Reduced	0	7	O
prognostic	8	18	O
power	19	24	O
of	25	27	O
ventricular	28	39	B-Multi-tissue_structure
late	40	44	O
potentials	45	55	O
in	56	58	O
post	59	63	O
-	63	64	O
infarction	64	74	O
patients	75	83	O
of	84	86	O
the	87	90	O
reperfusion	91	102	O
era	103	106	O
.	106	107	O

AIMS	108	112	O
:	112	113	O

To	114	116	O
test	117	121	O
the	122	125	O
prognostic	126	136	O
value	137	142	O
of	143	145	O
ventricular	146	157	B-Multi-tissue_structure
late	158	162	O
potentials	163	173	O
(	174	175	O
LPs	175	178	O
)	178	179	O
in	180	182	O
a	183	184	O
large	185	190	O
cohort	191	197	O
of	198	200	O
post	201	205	O
-	205	206	O
infarction	206	216	O
patients	217	225	O
in	226	228	O
the	229	232	O
modern	233	239	O
reperfusion	240	251	O
era	252	255	O
.	255	256	O

METHODS	257	264	O
AND	265	268	O
RESULTS	269	276	O
:	276	277	O

1800	278	282	O
consecutive	283	294	O
survivors	295	304	O
of	305	307	O
acute	308	313	O
myocardial	314	324	B-Multi-tissue_structure
infarction	325	335	O
in	336	338	O
sinus	339	344	B-Immaterial_anatomical_entity
rhythm	345	351	O
and	352	355	O
under	356	361	O
76	362	364	O
years	365	370	O
of	371	373	O
age	374	377	O
were	378	382	O
enrolled	383	391	O
.	391	392	O

Many	393	397	O
(	398	399	O
99	399	401	O
%	401	402	O
)	402	403	O
of	404	406	O
the	407	410	O
patients	411	419	O
received	420	428	O
reperfusion	429	440	O
/	440	441	O
revascularization	441	458	O
therapy	459	466	O
(	467	468	O
91	468	470	O
%	470	471	O
percutaneous	472	484	O
coronary	485	493	B-Multi-tissue_structure
intervention	494	506	O
)	506	507	O
and	508	511	O
up	512	514	O
-	514	515	O
to	515	517	O
-	517	518	O
date	518	522	O
pharmacological	523	538	O
treatment	539	548	O
(	549	550	O
99	550	552	O
%	552	553	O
aspirin	554	561	O
,	561	562	O
93	563	565	O
%	565	566	O
beta	567	571	O
-	571	572	O
blockers	572	580	O
,	580	581	O
90	582	584	O
%	584	585	O
ACE	586	589	O
-	589	590	O
inhibitors	590	600	O
,	600	601	O
and	602	605	O
85	606	608	O
%	608	609	O
statins	610	617	O
)	617	618	O
.	618	619	O

LPs	620	623	O
were	624	628	O
calculated	629	639	O
in	640	642	O
968	643	646	O
patients	647	655	O
and	656	659	O
found	660	665	O
to	666	668	O
be	669	671	O
present	672	679	O
in	680	682	O
90	683	685	O
(	686	687	O
9	687	688	O
.	688	689	O
3	689	690	O
%	690	691	O
)	691	692	O
.	692	693	O

The	694	697	O
primary	698	705	O
endpoint	706	714	O
was	715	718	O
the	719	722	O
composite	723	732	O
of	733	735	O
cardiac	736	743	B-Organ
death	744	749	O
and	750	753	O
serious	754	761	O
arrhythmic	762	772	O
events	773	779	O
.	779	780	O

The	781	784	O
secondary	785	794	O
endpoint	795	803	O
was	804	807	O
the	808	811	O
composite	812	821	O
of	822	824	O
sudden	825	831	O
cardiac	832	839	B-Organ
death	840	845	O
and	846	849	O
serious	850	857	O
arrhythmic	858	868	O
events	869	875	O
.	875	876	O

During	877	883	O
follow	884	890	O
-	890	891	O
up	891	893	O
(	894	895	O
median	895	901	O
34	902	904	O
months	905	911	O
)	911	912	O
,	912	913	O
26	914	916	O
patients	917	925	O
reached	926	933	O
the	934	937	O
primary	938	945	O
endpoint	946	954	O
.	954	955	O

The	956	959	O
presence	960	968	O
of	969	971	O
LPs	972	975	O
was	976	979	O
not	980	983	O
significantly	984	997	O
associated	998	1008	O
with	1009	1013	O
the	1014	1017	O
primary	1018	1025	O
endpoint	1026	1034	O
in	1035	1037	O
univariable	1038	1049	O
or	1050	1052	O
multivariable	1053	1066	O
analysis	1067	1075	O
.	1075	1076	O

In	1077	1079	O
contrast	1080	1088	O
,	1088	1089	O
low	1090	1093	O
(	1094	1095	O
<	1095	1096	O
or	1097	1099	O
=	1100	1101	O
30	1102	1104	O
%	1104	1105	O
)	1105	1106	O
left	1107	1111	B-Multi-tissue_structure
ventricular	1112	1123	I-Multi-tissue_structure
ejection	1124	1132	O
fraction	1133	1141	O
(	1142	1143	O
hazard	1143	1149	O
ratio	1150	1155	O
9	1156	1157	O
.	1157	1158	O
6	1158	1159	O
,	1159	1160	O
95	1161	1163	O
%	1163	1164	O
confidence	1165	1175	O
interval	1176	1184	O
4	1185	1186	O
.	1186	1187	O
1	1187	1188	O
-	1188	1189	O
22	1189	1191	O
.	1191	1192	O
4	1192	1193	O
)	1193	1194	O
,	1194	1195	O
heart	1196	1201	B-Organ
rate	1202	1206	O
turbulence	1207	1217	O
category	1218	1226	O
2	1227	1228	O
(	1229	1230	O
7	1230	1231	O
.	1231	1232	O
5	1232	1233	O
,	1233	1234	O
2	1235	1236	O
.	1236	1237	O
4	1237	1238	O
-	1238	1239	O
23	1239	1241	O
.	1241	1242	O
9	1242	1243	O
)	1243	1244	O
and	1245	1248	O
category	1249	1257	O
1	1258	1259	O
(	1260	1261	O
5	1261	1262	O
.	1262	1263	O
3	1263	1264	O
,	1264	1265	O
1	1266	1267	O
.	1267	1268	O
9	1268	1269	O
-	1269	1270	O
14	1270	1272	O
.	1272	1273	O
9	1273	1274	O
)	1274	1275	O
were	1276	1280	O
significant	1281	1292	O
predictors	1293	1303	O
in	1304	1306	O
both	1307	1311	O
univariable	1312	1323	O
and	1324	1327	O
multivariable	1328	1341	O
analysis	1342	1350	O
.	1350	1351	O

CONCLUSION	1352	1362	O
:	1362	1363	O

Ventricular	1364	1375	B-Multi-tissue_structure
LPs	1376	1379	O
are	1380	1383	O
of	1384	1386	O
limited	1387	1394	O
use	1395	1398	O
for	1399	1402	O
risk	1403	1407	O
stratification	1408	1422	O
in	1423	1425	O
unselected	1426	1436	O
post	1437	1441	O
-	1441	1442	O
infarction	1442	1452	O
patients	1453	1461	O
in	1462	1464	O
the	1465	1468	O
modern	1469	1475	O
reperfusion	1476	1487	O
era	1488	1491	O
.	1491	1492	O

Bcl	0	3	O
-	3	4	O
2	4	5	O
decreases	6	15	O
cell	16	20	B-Cell
proliferation	21	34	O
and	35	38	O
promotes	39	47	O
accumulation	48	60	O
of	61	63	O
cells	64	69	B-Cell
in	70	72	O
S	73	74	O
phase	75	80	O
without	81	88	O
affecting	89	98	O
the	99	102	O
rate	103	107	O
of	108	110	O
apoptosis	111	120	O
in	121	123	O
human	124	129	O
ovarian	130	137	B-Cell
carcinoma	138	147	I-Cell
cells	148	153	I-Cell
.	153	154	O

OBJECTIVES	155	165	O
:	165	166	O

The	167	170	O
Bcl	171	174	O
-	174	175	O
2	175	176	O
protein	177	184	O
is	185	187	O
an	188	190	O
important	191	200	O
regulator	201	210	O
of	211	213	O
the	214	217	O
apoptotic	218	227	O
cascade	228	235	O
and	236	239	O
promotes	240	248	O
cell	249	253	B-Cell
survival	254	262	O
.	262	263	O

Bcl	264	267	O
-	267	268	O
2	268	269	O
can	270	273	O
also	274	278	O
delay	279	284	O
entry	285	290	O
into	291	295	O
the	296	299	O
cell	300	304	B-Cell
cycle	305	310	O
from	311	315	O
quiescence	316	326	O
.	326	327	O

In	328	330	O
the	331	334	O
present	335	342	O
study	343	348	O
,	348	349	O
we	350	352	O
used	353	357	O
two	358	361	O
isogenic	362	370	O
human	371	376	O
ovarian	377	384	B-Cell
carcinoma	385	394	I-Cell
cell	395	399	I-Cell
lines	400	405	I-Cell
,	405	406	O
which	407	412	O
expressed	413	422	O
differential	423	435	O
levels	436	442	O
of	443	445	O
Bcl	446	449	O
-	449	450	O
2	450	451	O
proteins	452	460	O
,	460	461	O
to	462	464	O
demonstrate	465	476	O
that	477	481	O
Bcl	482	485	O
-	485	486	O
2	486	487	O
may	488	491	O
regulate	492	500	O
the	501	504	O
growth	505	511	O
rates	512	517	O
of	518	520	O
adenocarcinoma	521	535	B-Cell
cells	536	541	I-Cell
.	541	542	O

METHODS	543	550	O
:	550	551	O

The	552	555	O
growth	556	562	O
rates	563	568	O
of	569	571	O
two	572	575	O
isogenic	576	584	O
ovarian	585	592	B-Cell
cancer	593	599	I-Cell
cell	600	604	I-Cell
lines	605	610	I-Cell
were	611	615	O
determined	616	626	O
by	627	629	O
XTT	630	633	O
assays	634	640	O
and	641	644	O
flow	645	649	O
cytometry	650	659	O
combined	660	668	O
with	669	673	O
PI	674	676	O
staining	677	685	O
.	685	686	O

Bcl	687	690	B-Cell
-	690	691	I-Cell
2	691	692	I-Cell
-	692	693	I-Cell
overexpressing	693	707	I-Cell
SKOV3	708	713	I-Cell
cells	714	719	I-Cell
were	720	724	O
modified	725	733	O
to	734	736	O
express	737	744	O
a	745	746	O
doxycycline	747	758	O
-	758	759	O
inducible	759	768	O
anti	769	773	O
-	773	774	O
Bcl	774	777	O
-	777	778	O
2	778	779	O
single	780	786	O
-	786	787	O
chain	787	792	O
antibody	793	801	O
and	802	805	O
the	806	809	O
effects	810	817	O
of	818	820	O
Bcl	821	824	O
-	824	825	O
2	825	826	O
protein	827	834	O
inhibition	835	845	O
on	846	848	O
cell	849	853	B-Cell
proliferation	854	867	O
and	868	871	O
apoptosis	872	881	O
were	882	886	O
assessed	887	895	O
.	895	896	O

RESULTS	897	904	O
:	904	905	O

We	906	908	O
demonstrate	909	920	O
that	921	925	O
Bcl	926	929	O
-	929	930	O
2	930	931	O
promotes	932	940	O
the	941	944	O
accumulation	945	957	O
of	958	960	O
proliferating	961	974	O
carcinoma	975	984	B-Cell
cells	985	990	I-Cell
in	991	993	O
S	994	995	O
phase	996	1001	O
.	1001	1002	O

The	1003	1006	O
Bcl	1007	1010	B-Cell
-	1010	1011	I-Cell
2	1011	1012	I-Cell
-	1012	1013	I-Cell
overexpressing	1013	1027	I-Cell
SKOV3	1028	1033	I-Cell
cell	1034	1038	I-Cell
line	1039	1043	I-Cell
proliferates	1044	1056	O
markedly	1057	1065	O
faster	1066	1072	O
and	1073	1076	O
shows	1077	1082	O
delayed	1083	1090	O
progression	1091	1102	O
to	1103	1105	O
G2M	1106	1109	O
phase	1110	1115	O
compared	1116	1124	O
to	1125	1127	O
its	1128	1131	O
low	1132	1135	O
Bcl	1136	1139	B-Cell
-	1139	1140	I-Cell
2	1140	1141	I-Cell
-	1141	1142	I-Cell
expressing	1142	1152	I-Cell
counterpart	1153	1164	I-Cell
SKOV3	1165	1170	I-Cell
.	1170	1171	I-Cell
ip1	1171	1174	I-Cell
cell	1175	1179	I-Cell
line	1180	1184	I-Cell
.	1184	1185	O

Single	1186	1192	O
-	1192	1193	O
chain	1193	1198	O
antibody	1199	1207	O
-	1207	1208	O
mediated	1208	1216	O
inhibition	1217	1227	O
of	1228	1230	O
Bcl	1231	1234	O
-	1234	1235	O
2	1235	1236	O
in	1237	1239	O
SKOV3	1240	1245	B-Cell
cells	1246	1251	I-Cell
was	1252	1255	O
associated	1256	1266	O
with	1267	1271	O
increased	1272	1281	O
growth	1282	1288	O
rates	1289	1294	O
and	1295	1298	O
more	1299	1303	O
rapid	1304	1309	O
cell	1310	1314	B-Cell
cycle	1315	1320	O
progression	1321	1332	O
.	1332	1333	O

Treatment	1334	1343	O
with	1344	1348	O
cisplatin	1349	1358	O
resulted	1359	1367	O
in	1368	1370	O
more	1371	1375	O
cells	1376	1381	B-Cell
accumulating	1382	1394	O
in	1395	1397	O
S	1398	1399	O
phase	1400	1405	O
in	1406	1408	O
Bcl	1409	1412	B-Cell
-	1412	1413	I-Cell
2	1413	1414	I-Cell
-	1414	1415	I-Cell
overexpressing	1415	1429	I-Cell
SKOV3	1430	1435	I-Cell
cells	1436	1441	I-Cell
,	1441	1442	O
while	1443	1448	O
the	1449	1452	O
inhibition	1453	1463	O
of	1464	1466	O
Bcl	1467	1470	O
-	1470	1471	O
2	1471	1472	O
abolished	1473	1482	O
delayed	1483	1490	O
entry	1491	1496	O
into	1497	1501	O
G2M	1502	1505	O
phase	1506	1511	O
without	1512	1519	O
affecting	1520	1529	O
cisplatin	1530	1539	O
-	1539	1540	O
induced	1540	1547	O
apoptosis	1548	1557	O
.	1557	1558	O

CONCLUSIONS	1559	1570	O
:	1570	1571	O

Our	1572	1575	O
results	1576	1583	O
suggest	1584	1591	O
that	1592	1596	O
,	1596	1597	O
in	1598	1600	O
ovarian	1601	1608	B-Cell
cancer	1609	1615	I-Cell
cells	1616	1621	I-Cell
,	1621	1622	O
Bcl	1623	1626	O
-	1626	1627	O
2	1627	1628	O
delays	1629	1635	O
cell	1636	1640	B-Cell
cycle	1641	1646	O
progression	1647	1658	O
by	1659	1661	O
promoting	1662	1671	O
accumulation	1672	1684	O
of	1685	1687	O
cells	1688	1693	B-Cell
in	1694	1696	O
S	1697	1698	O
phase	1699	1704	O
without	1705	1712	O
affecting	1713	1722	O
the	1723	1726	O
rate	1727	1731	O
of	1732	1734	O
apoptosis	1735	1744	O
.	1744	1745	O

Thus	1746	1750	O
,	1750	1751	O
in	1752	1754	O
addition	1755	1763	O
to	1764	1766	O
its	1767	1770	O
known	1771	1776	O
role	1777	1781	O
at	1782	1784	O
the	1785	1788	O
G0	1789	1791	O
/	1791	1792	O
G1	1792	1794	O
checkpoint	1795	1805	O
,	1805	1806	O
we	1807	1809	O
demonstrate	1810	1821	O
for	1822	1825	O
the	1826	1829	O
first	1830	1835	O
time	1836	1840	O
that	1841	1845	O
Bcl	1846	1849	O
-	1849	1850	O
2	1850	1851	O
also	1852	1856	O
regulates	1857	1866	O
the	1867	1870	O
S	1871	1872	O
phase	1873	1878	O
.	1878	1879	O

A	0	1	O
novel	2	7	O
conotoxin	8	17	O
from	18	22	O
Conus	23	28	O
delessertii	29	40	O
with	41	45	O
posttranslationally	46	65	O
modified	66	74	O
lysine	75	81	O
residues	82	90	O
.	90	91	O

A	92	93	O
major	94	99	O
peptide	100	107	O
,	107	108	O
de13a	109	114	O
from	115	119	O
the	120	123	O
crude	124	129	O
venom	130	135	B-Organism_substance
of	136	138	O
Conus	139	144	O
delessertii	145	156	O
collected	157	166	O
in	167	169	O
the	170	173	O
Yucatan	174	181	O
Channel	182	189	O
,	189	190	O
Mexico	191	197	O
,	197	198	O
was	199	202	O
purified	203	211	O
.	211	212	O

The	213	216	O
peptide	217	224	O
had	225	228	O
a	229	230	O
high	231	235	O
content	236	243	O
of	244	246	O
posttranslationally	247	266	O
modified	267	275	O
amino	276	281	O
acids	282	287	O
,	287	288	O
including	289	298	O
6	299	300	O
-	300	301	O
bromotryptophan	301	316	O
and	317	320	O
a	321	322	O
nonstandard	323	334	O
amino	335	340	O
acid	341	345	O
that	346	350	O
proved	351	357	O
to	358	360	O
be	361	363	O
5	364	365	O
-	365	366	O
hydroxylysine	366	379	O
.	379	380	O

This	381	385	O
is	386	388	O
the	389	392	O
first	393	398	O
report	399	405	O
of	406	408	O
5	409	410	O
-	410	411	O
hydroxylysine	411	424	O
residues	425	433	O
in	434	436	O
conotoxins	437	447	O
.	447	448	O

The	449	452	O
sequence	453	461	O
analysis	462	470	O
,	470	471	O
together	472	480	O
with	481	485	O
cDNA	486	490	O
cloning	491	498	O
and	499	502	O
a	503	504	O
mass	505	509	O
determination	510	523	O
(	524	525	O
monoisotopic	525	537	O
mass	538	542	O
of	543	545	O
3486	546	550	O
.	550	551	O
76	551	553	O
Da	554	556	O
)	556	557	O
,	557	558	O
established	559	570	O
that	571	575	O
the	576	579	O
mature	580	586	O
toxin	587	592	O
has	593	596	O
the	597	600	O
sequence	601	609	O
DCOTSCOTTCANGWECCKGYOCVNKACSGCTH	610	642	O
,	642	643	O
where	644	649	O
O	650	651	O
is	652	654	O
4	655	656	O
-	656	657	O
hydroxyproline	657	671	O
,	671	672	O
W	673	674	O
6	675	676	O
-	676	677	O
bromotryptophan	677	692	O
,	692	693	O
and	694	697	O
K	698	699	O
5	700	701	O
-	701	702	O
hydroxylysine	702	715	O
,	715	716	O
the	717	720	O
asterisk	721	729	O
represents	730	740	O
the	741	744	O
amidated	745	753	O
C	754	755	O
-	755	756	O
terminus	756	764	O
,	764	765	O
and	766	769	O
the	770	773	O
calculated	774	784	O
monoisotopic	785	797	O
mass	798	802	O
is	803	805	O
3487	806	810	O
.	810	811	O
09	811	813	O
Da	814	816	O
.	816	817	O

The	818	821	O
eight	822	827	O
Cys	828	831	O
residues	832	840	O
are	841	844	O
arranged	845	853	O
in	854	856	O
a	857	858	O
pattern	859	866	O
(	867	868	O
C	868	869	O
-	869	870	O
C	870	871	O
-	871	872	O
C	872	873	O
-	873	874	O
CC	874	876	O
-	876	877	O
C	877	878	O
-	878	879	O
C	879	880	O
-	880	881	O
C	881	882	O
)	882	883	O
not	884	887	O
described	888	897	O
previously	898	908	O
in	909	911	O
conotoxins	912	922	O
.	922	923	O

This	924	928	O
arrangement	929	940	O
,	940	941	O
for	942	945	O
which	946	951	O
we	952	954	O
propose	955	962	O
the	963	966	O
designation	967	978	O
of	979	981	O
framework	982	991	O
#	992	993	O
13	993	995	O
or	996	998	O
XIII	999	1003	O
,	1003	1004	O
differs	1005	1012	O
from	1013	1017	O
the	1018	1021	O
ones	1022	1026	O
(	1027	1028	O
C	1028	1029	O
-	1029	1030	O
C	1030	1031	O
-	1031	1032	O
CC	1032	1034	O
-	1034	1035	O
CC	1035	1037	O
-	1037	1038	O
C	1038	1039	O
-	1039	1040	O
C	1040	1041	O
and	1042	1045	O
C	1046	1047	O
-	1047	1048	O
C	1048	1049	O
-	1049	1050	O
C	1050	1051	O
-	1051	1052	O
C	1052	1053	O
-	1053	1054	O
CC	1054	1056	O
-	1056	1057	O
C	1057	1058	O
-	1058	1059	O
C	1059	1060	O
)	1060	1061	O
present	1062	1069	O
in	1070	1072	O
other	1073	1078	O
conotoxins	1079	1089	O
which	1090	1095	O
also	1096	1100	O
contain	1101	1108	O
eight	1109	1114	O
Cys	1115	1118	O
residues	1119	1127	O
.	1127	1128	O

This	1129	1133	O
peptide	1134	1141	O
thus	1142	1146	O
defines	1147	1154	O
a	1155	1156	O
novel	1157	1162	O
class	1163	1168	O
of	1169	1171	O
conotoxins	1172	1182	O
,	1182	1183	O
with	1184	1188	O
a	1189	1190	O
new	1191	1194	O
posttranslational	1195	1212	O
modification	1213	1225	O
not	1226	1229	O
previously	1230	1240	O
found	1241	1246	O
in	1247	1249	O
other	1250	1255	O
Conus	1256	1261	O
peptide	1262	1269	O
families	1270	1278	O
.	1278	1279	O

Enhancement	0	11	O
of	12	14	O
skin	15	19	B-Organ
permeation	20	30	O
of	31	33	O
ketotifen	34	43	O
by	44	46	O
supersaturation	47	62	O
generated	63	72	O
by	73	75	O
amorphous	76	85	O
form	86	90	O
of	91	93	O
the	94	97	O
drug	98	102	O
.	102	103	O

Pressure	104	112	O
sensitive	113	122	O
adhesive	123	131	O
(	132	133	O
PSA	133	136	O
)	136	137	O
matrices	138	146	O
containing	147	157	O
amorphous	158	167	O
ketotifen	168	177	O
were	178	182	O
prepared	183	191	O
and	192	195	O
evaluated	196	205	O
for	206	209	O
enhanced	210	218	O
skin	219	223	B-Organ
permeability	224	236	O
of	237	239	O
the	240	243	O
drug	244	248	O
.	248	249	O

A	250	251	O
solvent	252	259	O
casting	260	267	O
method	268	274	O
using	275	280	O
silicone	281	289	O
-	289	290	O
typed	290	295	O
PSA	296	299	O
was	300	303	O
employed	304	312	O
,	312	313	O
and	314	317	O
n	318	319	O
-	319	320	O
hexane	320	326	O
,	326	327	O
an	328	330	O
original	331	339	O
solvent	340	347	O
for	348	351	O
the	352	355	O
PSA	356	359	O
and	360	363	O
one	364	367	O
more	368	372	O
solvent	373	380	O
,	380	381	O
dichloromethane	382	397	O
,	397	398	O
tetrahydrofuran	399	414	O
,	414	415	O
acetone	416	423	O
,	423	424	O
ethyl	425	430	O
acetate	431	438	O
or	439	441	O
toluene	442	449	O
,	449	450	O
were	451	455	O
used	456	460	O
for	461	464	O
complete	465	473	O
dissolution	474	485	O
of	486	488	O
ketotifen	489	498	O
and	499	502	O
high	503	507	O
dispersion	508	518	O
in	519	521	O
an	522	524	O
amorphous	525	534	O
state	535	540	O
of	541	543	O
the	544	547	O
drug	548	552	O
.	552	553	O

Presence	554	562	O
of	563	565	O
the	566	569	O
amorphous	570	579	O
form	580	584	O
was	585	588	O
judged	589	595	O
based	596	601	O
on	602	604	O
the	605	608	O
in	609	611	O
vitro	612	617	O
drug	618	622	O
release	623	630	O
rate	631	635	O
from	636	640	O
the	641	644	O
matrix	645	651	O
.	651	652	O

As	653	655	O
a	656	657	O
result	658	664	O
,	664	665	O
dichloromethane	666	681	O
and	682	685	O
tetrahudrofuran	686	701	O
were	702	706	O
selected	707	715	O
as	716	718	O
appropriate	719	730	O
dilution	731	739	O
solvents	740	748	O
.	748	749	O

In	750	752	O
vitro	753	758	O
permeation	759	769	O
experiments	770	781	O
through	782	789	O
excised	790	797	O
hairless	798	806	O
mouse	807	812	O
skin	813	817	B-Organ
revealed	818	826	O
that	827	831	O
the	832	835	O
steady	836	842	O
-	842	843	O
state	843	848	O
flux	849	853	O
from	854	858	O
the	859	862	O
amorphous	863	872	O
ketotifen	873	882	O
-	882	883	O
dispersed	883	892	O
matrices	893	901	O
was	902	905	O
about	906	911	O
five	912	916	O
times	917	922	O
greater	923	930	O
than	931	935	O
that	936	940	O
of	941	943	O
the	944	947	O
crystalline	948	959	O
ketotifen	960	969	O
-	969	970	O
dispersed	970	979	O
matrices	980	988	O
,	988	989	O
and	990	993	O
that	994	998	O
the	999	1002	O
enhancement	1003	1014	O
ratio	1015	1020	O
was	1021	1024	O
in	1025	1027	O
good	1028	1032	O
agreement	1033	1042	O
with	1043	1047	O
the	1048	1051	O
solubility	1052	1062	O
ratio	1063	1068	O
of	1069	1071	O
the	1072	1075	O
amorphous	1076	1085	O
to	1086	1088	O
crystalline	1089	1100	O
form	1101	1105	O
of	1106	1108	O
the	1109	1112	O
drug	1113	1117	O
.	1117	1118	O

Comparison	1119	1129	O
of	1130	1132	O
the	1133	1136	O
skin	1137	1141	B-Organ
permeation	1142	1152	O
profiles	1153	1161	O
of	1162	1164	O
amorphous	1165	1174	O
ketotifen	1175	1184	O
-	1184	1185	O
dispersed	1185	1194	O
matrices	1195	1203	O
between	1204	1211	O
two	1212	1215	O
different	1216	1225	O
drug	1226	1230	O
contents	1231	1239	O
suggested	1240	1249	O
that	1250	1254	O
the	1255	1258	O
steady	1259	1265	O
-	1265	1266	O
state	1266	1271	O
flux	1272	1276	O
was	1277	1280	O
not	1281	1284	O
influenced	1285	1295	O
by	1296	1298	O
the	1299	1302	O
drug	1303	1307	O
content	1308	1315	O
.	1315	1316	O

In	1317	1319	O
addition	1320	1328	O
,	1328	1329	O
at	1330	1332	O
both	1333	1337	O
drug	1338	1342	O
contents	1343	1351	O
,	1351	1352	O
the	1353	1356	O
period	1357	1363	O
of	1364	1366	O
the	1367	1370	O
steady	1371	1377	O
-	1377	1378	O
state	1378	1383	O
permeation	1384	1394	O
coincided	1395	1404	O
with	1405	1409	O
the	1410	1413	O
time	1414	1418	O
until	1419	1424	O
the	1425	1428	O
amorphous	1429	1438	O
drug	1439	1443	O
was	1444	1447	O
depleted	1448	1456	O
from	1457	1461	O
the	1462	1465	O
matrix	1466	1472	O
.	1472	1473	O

These	1474	1479	O
results	1480	1487	O
suggest	1488	1495	O
that	1496	1500	O
the	1501	1504	O
increase	1505	1513	O
in	1514	1516	O
skin	1517	1521	B-Organ
permeation	1522	1532	O
of	1533	1535	O
ketotifen	1536	1545	O
from	1546	1550	O
PSA	1551	1554	O
matrix	1555	1561	O
was	1562	1565	O
due	1566	1569	O
to	1570	1572	O
the	1573	1576	O
supersaturation	1577	1592	O
generated	1593	1602	O
by	1603	1605	O
amorphous	1606	1615	O
form	1616	1620	O
,	1620	1621	O
and	1622	1625	O
that	1626	1630	O
the	1631	1634	O
amorphous	1635	1644	O
form	1645	1649	O
was	1650	1653	O
stable	1654	1660	O
during	1661	1667	O
the	1668	1671	O
application	1672	1683	O
period	1684	1690	O
.	1690	1691	O

Polybrominated	0	14	O
diphenyl	15	23	O
ethers	24	30	O
in	31	33	O
indoor	34	40	O
dust	41	45	O
in	46	48	O
Ottawa	49	55	O
,	55	56	O
Canada	57	63	O
:	63	64	O
implications	65	77	O
for	78	81	O
sources	82	89	O
and	90	93	O
exposure	94	102	O
.	102	103	O

Polybrominated	104	118	O
diphenyl	119	127	O
ethers	128	134	O
(	135	136	O
PBDEs	136	141	O
)	141	142	O
are	143	146	O
widely	147	153	O
used	154	158	O
as	159	161	O
additive	162	170	O
flame	171	176	O
retardants	177	187	O
in	188	190	O
plastics	191	199	O
,	199	200	O
soft	201	205	O
furnishings	206	217	O
,	217	218	O
electrical	219	229	O
and	230	233	O
electronic	234	244	O
equipment	245	254	O
,	254	255	O
and	256	259	O
insulation	260	270	O
in	271	273	O
the	274	277	O
indoor	278	284	O
environment	285	296	O
,	296	297	O
and	298	301	O
may	302	305	O
be	306	308	O
released	309	317	O
indoors	318	325	O
via	326	329	O
volatilization	330	344	O
or	345	347	O
as	348	350	O
dusts	351	356	O
.	356	357	O

The	358	361	O
penta	362	367	O
-	367	368	O
and	368	371	O
octa	372	376	O
-	376	377	O
brominated	377	387	O
mixes	388	393	O
are	394	397	O
now	398	401	O
banned	402	408	O
in	409	411	O
most	412	416	O
parts	417	422	O
of	423	425	O
Europe	426	432	O
,	432	433	O
and	434	437	O
phasing	438	445	O
out	446	449	O
of	450	452	O
their	453	458	O
use	459	462	O
has	463	466	O
recently	467	475	O
begun	476	481	O
in	482	484	O
North	485	490	O
America	491	498	O
.	498	499	O

This	500	504	O
study	505	510	O
follows	511	518	O
a	519	520	O
previous	521	529	O
investigation	530	543	O
into	544	548	O
indoor	549	555	O
air	556	559	O
levels	560	566	O
of	567	569	O
PBDEs	570	575	O
.	575	576	O

House	577	582	O
dust	583	587	O
was	588	591	O
analyzed	592	600	O
from	601	605	O
the	606	609	O
family	610	616	O
vacuum	617	623	O
cleaners	624	632	O
of	633	635	O
68	636	638	O
of	639	641	O
the	642	645	O
same	646	650	O
74	651	653	O
randomly	654	662	O
selected	663	671	O
homes	672	677	O
,	677	678	O
in	679	681	O
Ottawa	682	688	O
,	688	689	O
Canada	690	696	O
during	697	703	O
the	704	707	O
winter	708	714	O
of	715	717	O
2002	718	722	O
-	722	723	O
2003	723	727	O
.	727	728	O

PBDEs	729	734	O
,	734	735	O
comprising	736	746	O
on	747	749	O
average	750	757	O
42	758	760	O
%	760	761	O
BDE	762	765	O
-	765	766	O
209	766	769	O
,	769	770	O
were	771	775	O
found	776	781	O
in	782	784	O
all	785	788	O
samples	789	796	O
.	796	797	O

The	798	801	O
levels	802	808	O
were	809	813	O
log	814	817	O
-	817	818	O
normally	818	826	O
distributed	827	838	O
with	839	843	O
a	844	845	O
geometric	846	855	O
mean	856	860	O
sigmaPBDE	861	870	O
of	871	873	O
2000	874	878	O
ng	879	881	O
g	882	883	O
(	883	884	O
-	884	885	O
1	885	886	O
)	886	887	O
,	887	888	O
and	889	892	O
a	893	894	O
median	895	901	O
of	902	904	O
1800	905	909	O
ng	910	912	O
g	913	914	O
(	914	915	O
-	915	916	O
1	916	917	O
)	917	918	O
dust	919	923	O
.	923	924	O

The	925	928	O
levels	929	935	O
in	936	938	O
dust	939	943	O
did	944	947	O
not	948	951	O
correlate	952	961	O
with	962	966	O
questionnaire	967	980	O
information	981	992	O
on	993	995	O
house	996	1001	O
characteristics	1002	1017	O
.	1017	1018	O

Correlations	1019	1031	O
were	1032	1036	O
found	1037	1042	O
between	1043	1050	O
pentamix	1051	1059	O
congener	1060	1068	O
levels	1069	1075	O
in	1076	1078	O
dust	1079	1083	O
and	1084	1087	O
in	1088	1090	O
air	1091	1094	O
from	1095	1099	O
the	1100	1103	O
same	1104	1108	O
homes	1109	1114	O
,	1114	1115	O
but	1116	1119	O
not	1120	1123	O
for	1124	1127	O
congeners	1128	1137	O
of	1138	1140	O
the	1141	1144	O
more	1145	1149	O
highly	1150	1156	O
brominated	1157	1167	O
mixes	1168	1173	O
.	1173	1174	O

Exposure	1175	1183	O
scenarios	1184	1193	O
are	1194	1197	O
presented	1198	1207	O
for	1208	1211	O
mean	1212	1216	O
and	1217	1220	O
high	1221	1225	O
dust	1226	1230	O
ingestion	1231	1240	O
rates	1241	1246	O
,	1246	1247	O
and	1248	1251	O
compared	1252	1260	O
against	1261	1268	O
exposures	1269	1278	O
from	1279	1283	O
other	1284	1289	O
pathways	1290	1298	O
,	1298	1299	O
for	1300	1303	O
both	1304	1308	O
adults	1309	1315	O
and	1316	1319	O
toddlers	1320	1328	O
(	1329	1330	O
6	1330	1331	O
months	1332	1338	O
-	1338	1339	O
2	1339	1340	O
years	1341	1346	O
)	1346	1347	O
.	1347	1348	O

Assuming	1349	1357	O
a	1358	1359	O
mean	1360	1364	O
dust	1365	1369	O
ingestion	1370	1379	O
rate	1380	1384	O
and	1385	1388	O
median	1389	1395	O
dust	1396	1400	O
and	1401	1404	O
air	1405	1408	O
concentrations	1409	1423	O
,	1423	1424	O
adults	1425	1431	O
would	1432	1437	O
be	1438	1440	O
exposed	1441	1448	O
to	1449	1451	O
ca	1452	1454	O
.	1454	1455	O

7	1456	1457	O
.	1457	1458	O
5	1458	1459	O
ng	1460	1462	O
sigmaPBDE	1463	1472	O
d	1473	1474	O
(	1474	1475	O
-	1475	1476	O
1	1476	1477	O
)	1477	1478	O
via	1479	1482	O
the	1483	1486	O
dust	1487	1491	O
ingestion	1492	1501	O
pathway	1502	1509	O
,	1509	1510	O
which	1511	1516	O
represents	1517	1527	O
approximately	1528	1541	O
14	1542	1544	O
%	1544	1545	O
of	1546	1548	O
total	1549	1554	O
daily	1555	1560	O
exposure	1561	1569	O
when	1570	1574	O
compared	1575	1583	O
to	1584	1586	O
diet	1587	1591	O
(	1592	1593	O
82	1593	1595	O
%	1595	1596	O
)	1596	1597	O
and	1598	1601	O
inhalation	1602	1612	O
(	1613	1614	O
4	1614	1615	O
%	1615	1616	O
)	1616	1617	O
.	1617	1618	O

However	1619	1626	O
,	1626	1627	O
for	1628	1631	O
toddlers	1632	1640	O
the	1641	1644	O
equivalent	1645	1655	O
intakes	1656	1663	O
would	1664	1669	O
be	1670	1672	O
99	1673	1675	O
ng	1676	1678	O
d	1679	1680	O
(	1680	1681	O
-	1681	1682	O
1	1682	1683	O
)	1683	1684	O
,	1684	1685	O
representing	1686	1698	O
80	1699	1701	O
%	1701	1702	O
of	1703	1705	O
their	1706	1711	O
daily	1712	1717	O
PBDE	1718	1722	O
exposure	1723	1731	O
.	1731	1732	O

At	1733	1735	O
high	1736	1740	O
dust	1741	1745	O
ingestion	1746	1755	O
rates	1756	1761	O
these	1762	1767	O
values	1768	1774	O
increase	1775	1783	O
to	1784	1786	O
180	1787	1790	O
ng	1791	1793	O
d	1794	1795	O
(	1795	1796	O
-	1796	1797	O
1	1797	1798	O
)	1798	1799	O
(	1800	1801	O
80	1801	1803	O
%	1803	1804	O
daily	1805	1810	O
intake	1811	1817	O
)	1817	1818	O
for	1819	1822	O
adults	1823	1829	O
and	1830	1833	O
360	1834	1837	O
ng	1838	1840	O
d	1841	1842	O
(	1842	1843	O
-	1843	1844	O
1	1844	1845	O
)	1845	1846	O
(	1847	1848	O
89	1848	1850	O
%	1850	1851	O
daily	1852	1857	O
intake	1858	1864	O
)	1864	1865	O
for	1866	1869	O
toddlers	1870	1878	O
.	1878	1879	O

The	1880	1883	O
data	1884	1888	O
give	1889	1893	O
a	1894	1895	O
clearer	1896	1903	O
picture	1904	1911	O
of	1912	1914	O
sources	1915	1922	O
of	1923	1925	O
PBDE	1926	1930	O
exposure	1931	1939	O
in	1940	1942	O
the	1943	1946	O
home	1947	1951	O
environment	1952	1963	O
and	1964	1967	O
suggest	1968	1975	O
that	1976	1980	O
dust	1981	1985	O
could	1986	1991	O
be	1992	1994	O
a	1995	1996	O
significant	1997	2008	O
exposure	2009	2017	O
pathway	2018	2025	O
for	2026	2029	O
some	2030	2034	O
individuals	2035	2046	O
,	2046	2047	O
particularly	2048	2060	O
children	2061	2069	O
.	2069	2070	O

Pathogenesis	0	12	O
of	13	15	O
thrombosis	16	26	O
in	27	29	O
essential	30	39	O
thrombocythemia	40	55	O
and	56	59	O
polycythemia	60	72	O
vera	73	77	O
:	77	78	O
the	79	82	O
role	83	87	O
of	88	90	O
neutrophils	91	102	B-Cell
.	102	103	O

Thrombotic	104	114	O
complications	115	128	O
are	129	132	O
frequently	133	143	O
observed	144	152	O
in	153	155	O
patients	156	164	O
with	165	169	O
polycythemia	170	182	O
vera	183	187	O
(	188	189	O
PV	189	191	O
)	191	192	O
and	193	196	O
essential	197	206	O
thrombocythemia	207	222	O
(	223	224	O
ET	224	226	O
)	226	227	O
.	227	228	O

Abnormalities	229	242	O
of	243	245	O
red	246	249	B-Cell
blood	250	255	I-Cell
cells	256	261	I-Cell
and	262	265	O
platelets	266	275	B-Cell
arising	276	283	O
from	284	288	O
the	289	292	O
clonal	293	299	O
rearrangement	300	313	O
of	314	316	O
hematopoietic	317	330	B-Cell
cells	331	336	I-Cell
have	337	341	O
been	342	346	O
considered	347	357	O
,	357	358	O
although	359	367	O
causal	368	374	O
relationships	375	388	O
between	389	396	O
any	397	400	O
of	401	403	O
these	404	409	O
specific	410	418	O
abnormalities	419	432	O
and	433	436	O
thrombosis	437	447	O
have	448	452	O
not	453	456	O
been	457	461	O
clearly	462	469	O
established	470	481	O
.	481	482	O

The	483	486	O
involvement	487	498	O
of	499	501	O
neutrophils	502	513	B-Cell
and	514	517	O
macrophages	518	529	B-Cell
,	529	530	O
which	531	536	O
participate	537	548	O
in	549	551	O
thrombosis	552	562	O
and	563	566	O
hemostasis	567	577	O
,	577	578	O
has	579	582	O
been	583	587	O
insufficiently	588	602	O
explored	603	611	O
in	612	614	O
PV	615	617	O
and	618	621	O
ET	622	624	O
.	624	625	O

Persistent	626	636	O
activation	637	647	O
of	648	650	O
circulating	651	662	O
neutrophils	663	674	B-Cell
was	675	678	O
recently	679	687	O
demonstrated	688	700	O
in	701	703	O
ET	704	706	O
and	707	710	O
PV	711	713	O
patients	714	722	O
,	722	723	O
in	724	726	O
parallel	727	735	O
with	736	740	O
an	741	743	O
increase	744	752	O
in	753	755	O
plasma	756	762	B-Organism_substance
concentrations	763	777	O
of	778	780	O
endothelial	781	792	B-Tissue
damage	793	799	O
-	799	800	O
derived	800	807	O
and	808	811	O
prothrombotic	812	825	O
substances	826	836	O
.	836	837	O

Other	838	843	O
studies	844	851	O
have	852	856	O
explored	857	865	O
whether	866	873	O
the	874	877	O
augmentation	878	890	O
of	891	893	O
adhesion	894	902	O
of	903	905	O
neutrophils	906	917	B-Cell
may	918	921	O
affect	922	928	O
neutrophil	929	939	B-Cell
/	939	940	O
platelet	940	948	B-Cell
interaction	949	960	O
since	961	966	O
a	967	968	O
significant	969	980	O
increase	981	989	O
in	990	992	O
circulating	993	1004	O
neutrophil	1005	1015	B-Cell
/	1015	1016	O
platelet	1016	1024	B-Cell
aggregates	1025	1035	O
is	1036	1038	O
found	1039	1044	O
in	1045	1047	O
ET	1048	1050	O
and	1051	1054	O
PV	1055	1057	O
.	1057	1058	O

This	1059	1063	O
review	1064	1070	O
summarizes	1071	1081	O
the	1082	1085	O
current	1086	1093	O
knowledge	1094	1103	O
of	1104	1106	O
the	1107	1110	O
pathogenesis	1111	1123	O
of	1124	1126	O
thrombosis	1127	1137	O
in	1138	1140	O
PV	1141	1143	O
and	1144	1147	O
ET	1148	1150	O
,	1150	1151	O
with	1152	1156	O
emphasis	1157	1165	O
on	1166	1168	O
the	1169	1172	O
role	1173	1177	O
of	1178	1180	O
neutrophils	1181	1192	B-Cell
in	1193	1195	O
hemostasis	1196	1206	O
and	1207	1210	O
their	1211	1216	O
possible	1217	1225	O
involvement	1226	1237	O
in	1238	1240	O
the	1241	1244	O
mechanisms	1245	1255	O
of	1256	1258	O
the	1259	1262	O
acquired	1263	1271	O
thrombophilia	1272	1285	O
of	1286	1288	O
these	1289	1294	O
patients	1295	1303	O
.	1303	1304	O

Available	1305	1314	O
data	1315	1319	O
suggest	1320	1327	O
that	1328	1332	O
these	1333	1338	O
hemostatic	1339	1349	O
markers	1350	1357	O
deserve	1358	1365	O
to	1366	1368	O
be	1369	1371	O
included	1372	1380	O
in	1381	1383	O
prospective	1384	1395	O
clinical	1396	1404	O
studies	1405	1412	O
aimed	1413	1418	O
at	1419	1421	O
identifying	1422	1433	O
their	1434	1439	O
predictive	1440	1450	O
role	1451	1455	O
in	1456	1458	O
the	1459	1462	O
vascular	1463	1471	B-Multi-tissue_structure
complications	1472	1485	O
of	1486	1488	O
patients	1489	1497	O
with	1498	1502	O
ET	1503	1505	O
and	1506	1509	O
PV	1510	1512	O
.	1512	1513	O

Sensitivity	0	11	O
variation	12	21	O
in	22	24	O
two	25	28	O
-	28	29	O
center	29	35	O
holographic	36	47	O
recording	48	57	O
.	57	58	O

An	59	61	O
experimental	62	74	O
study	75	80	O
of	81	83	O
variation	84	93	O
of	94	96	O
sensitivity	97	108	O
with	109	113	O
recording	114	123	O
and	124	127	O
sensitizing	128	139	O
intensities	140	151	O
in	152	154	O
two	155	158	O
-	158	159	O
center	159	165	O
recording	166	175	O
is	176	178	O
presented	179	188	O
.	188	189	O

The	190	193	O
experimental	194	206	O
results	207	214	O
are	215	218	O
in	219	221	O
good	222	226	O
agreement	227	236	O
with	237	241	O
the	242	245	O
theoretical	246	257	O
predictions	258	269	O
.	269	270	O

It	271	273	O
is	274	276	O
shown	277	282	O
experimentally	283	297	O
,	297	298	O
for	299	302	O
what	303	307	O
is	308	310	O
to	311	313	O
our	314	317	O
knowledge	318	327	O
the	328	331	O
first	332	337	O
time	338	342	O
,	342	343	O
that	344	348	O
the	349	352	O
sensitivity	353	364	O
is	365	367	O
a	368	369	O
function	370	378	O
of	379	381	O
the	382	385	O
ratio	386	391	O
of	392	394	O
recording	395	404	O
to	405	407	O
sensitizing	408	419	O
intensities	420	431	O
and	432	435	O
not	436	439	O
the	440	443	O
absolute	444	452	O
intensities	453	464	O
.	464	465	O

Also	466	470	O
,	470	471	O
the	472	475	O
ratio	476	481	O
of	482	484	O
recording	485	494	O
to	495	497	O
sensitizing	498	509	O
intensities	510	521	O
should	522	528	O
be	529	531	O
small	532	537	O
to	538	540	O
obtain	541	547	O
high	548	552	O
sensitivity	553	564	O
values	565	571	O
.	571	572	O

We	573	575	O
also	576	580	O
report	581	587	O
the	588	591	O
highest	592	599	O
sensitivity	600	611	O
(	612	613	O
S	613	614	O
=	614	615	O
0	615	616	O
.	616	617	O
15	617	619	O
cm	620	622	O
/	622	623	O
J	623	624	O
)	624	625	O
that	626	630	O
has	631	634	O
been	635	639	O
achieved	640	648	O
to	649	651	O
date	652	656	O
for	657	660	O
a	661	662	O
LiNbO3	663	669	O
:	669	670	O
Fe	670	672	O
:	672	673	O
Mn	673	675	O
crystal	676	683	O
.	683	684	O

Recent	0	6	O
advances	7	15	O
in	16	18	O
minisatellite	19	32	O
biology	33	40	O
.	40	41	O

Highly	42	48	O
polymorphic	49	60	O
tandemly	61	69	O
repeated	70	78	O
'	79	80	O
minisatellite	80	93	O
'	93	94	O
loci	95	99	O
are	100	103	O
very	104	108	O
abundant	109	117	O
in	118	120	O
the	121	124	O
human	125	130	O
genome	131	137	O
,	137	138	O
and	139	142	O
of	143	145	O
considerable	146	158	O
utility	159	166	O
in	167	169	O
human	170	175	O
genetic	176	183	O
analysis	184	192	O
.	192	193	O

This	194	198	O
review	199	205	O
describes	206	215	O
the	216	219	O
use	220	223	O
of	224	226	O
an	227	229	O
ordered	230	237	O
-	237	238	O
array	238	243	O
Charomid	244	252	O
library	253	260	O
in	261	263	O
the	264	267	O
systematic	268	278	O
and	279	282	O
efficient	283	292	O
cloning	293	300	O
of	301	303	O
these	304	309	O
regions	310	317	O
,	317	318	O
and	319	322	O
in	323	325	O
the	326	329	O
analysis	330	338	O
of	339	341	O
the	342	345	O
relative	346	354	O
overlap	355	362	O
between	363	370	O
the	371	374	O
different	375	384	O
probes	385	391	O
used	392	396	O
to	397	399	O
screen	400	406	O
for	407	410	O
hypervariable	411	424	O
loci	425	429	O
.	429	430	O

Recent	431	437	O
work	438	442	O
on	443	445	O
the	446	449	O
process	450	457	O
of	458	460	O
mutation	461	469	O
leading	470	477	O
to	478	480	O
the	481	484	O
generation	485	495	O
of	496	498	O
new	499	502	O
-	502	503	O
length	503	509	O
alleles	510	517	O
is	518	520	O
also	521	525	O
discussed	526	535	O
,	535	536	O
including	537	546	O
the	547	550	O
observation	551	562	O
that	563	567	O
at	568	570	O
least	571	576	O
some	577	581	O
mutations	582	591	O
may	592	595	O
be	596	598	O
due	599	602	O
to	603	605	O
unequal	606	613	O
exchanges	614	623	O
.	623	624	O

The	0	3	O
ictal	4	9	O
bradycardia	10	21	O
syndrome	22	30	O
:	30	31	O
localization	32	44	O
and	45	48	O
lateralization	49	63	O
.	63	64	O

PURPOSE	65	72	O
:	72	73	O

Previous	74	82	O
studies	83	90	O
have	91	95	O
established	96	107	O
the	108	111	O
importance	112	122	O
of	123	125	O
the	126	129	O
insular	130	137	B-Multi-tissue_structure
cortex	138	144	I-Multi-tissue_structure
and	145	148	O
temporal	149	157	B-Multi-tissue_structure
lobe	158	162	I-Multi-tissue_structure
in	163	165	O
cardiovascular	166	180	B-Anatomical_system
autonomic	181	190	O
modulation	191	201	O
.	201	202	O

Some	203	207	O
investigators	208	221	O
,	221	222	O
based	223	228	O
on	229	231	O
the	232	235	O
results	236	243	O
of	244	246	O
cortical	247	255	B-Multi-tissue_structure
stimulation	256	267	O
response	268	276	O
,	276	277	O
functional	278	288	O
imaging	289	296	O
,	296	297	O
EEG	298	301	O
recordings	302	312	O
of	313	315	O
seizures	316	324	O
,	324	325	O
and	326	329	O
lesional	330	338	O
studies	339	346	O
,	346	347	O
have	348	352	O
suggested	353	362	O
that	363	367	O
cardiac	368	375	B-Organ
sympathetic	376	387	O
and	388	391	O
parasympathetic	392	407	O
function	408	416	O
may	417	420	O
be	421	423	O
lateralized	424	435	O
,	435	436	O
with	437	441	O
sympathetic	442	453	O
representation	454	468	O
lateralized	469	480	O
to	481	483	O
the	484	487	O
right	488	493	B-Multi-tissue_structure
insula	494	500	I-Multi-tissue_structure
,	500	501	O
and	502	505	O
parasympathetic	506	521	O
,	521	522	O
to	523	525	O
the	526	529	O
left	530	534	B-Multi-tissue_structure
.	534	535	O

These	536	541	O
studies	542	549	O
have	550	554	O
suggested	555	564	O
that	565	569	O
ictal	570	575	O
bradycardia	576	587	O
is	588	590	O
most	591	595	O
commonly	596	604	O
a	605	606	O
manifestation	607	620	O
of	621	623	O
activation	624	634	O
of	635	637	O
the	638	641	O
left	642	646	B-Multi-tissue_structure
temporal	647	655	I-Multi-tissue_structure
and	656	659	O
insular	660	667	B-Multi-tissue_structure
cortex	668	674	I-Multi-tissue_structure
.	674	675	O

However	676	683	O
,	683	684	O
the	685	688	O
evidence	689	697	O
for	698	701	O
this	702	706	O
is	707	709	O
inconsistent	710	722	O
.	722	723	O

We	724	726	O
sought	727	733	O
to	734	736	O
assess	737	743	O
critically	744	754	O
the	755	758	O
predictable	759	770	O
value	771	776	O
of	777	779	O
ictal	780	785	O
bradycardia	786	797	O
for	798	801	O
seizure	802	809	O
localization	810	822	O
and	823	826	O
lateralization	827	841	O
.	841	842	O

METHODS	843	850	O
:	850	851	O

In	852	854	O
this	855	859	O
study	860	865	O
,	865	866	O
we	867	869	O
reviewed	870	878	O
the	879	882	O
localization	883	895	O
of	896	898	O
seizure	899	906	O
activity	907	915	O
in	916	918	O
13	919	921	O
consecutive	922	933	O
patients	934	942	O
with	943	947	O
ictal	948	953	O
bradycardia	954	965	O
diagnosed	966	975	O
during	976	982	O
prolonged	983	992	O
video	993	998	O
-	998	999	O
EEG	999	1002	O
monitoring	1003	1013	O
at	1014	1016	O
Mayo	1017	1021	O
Clinic	1022	1028	O
Rochester	1029	1038	O
.	1038	1039	O

The	1040	1043	O
localization	1044	1056	O
of	1057	1059	O
electrographic	1060	1074	O
seizure	1075	1082	O
activity	1083	1091	O
at	1092	1094	O
seizure	1095	1102	O
onset	1103	1108	O
and	1109	1112	O
bradycardia	1113	1124	O
onset	1125	1130	O
was	1131	1134	O
identified	1135	1145	O
in	1146	1148	O
all	1149	1152	O
patients	1153	1161	O
.	1161	1162	O

In	1163	1165	O
addition	1166	1174	O
,	1174	1175	O
we	1176	1178	O
performed	1179	1188	O
a	1189	1190	O
comprehensive	1191	1204	O
review	1205	1211	O
of	1212	1214	O
the	1215	1218	O
ictal	1219	1224	O
bradycardia	1225	1236	O
literature	1237	1247	O
focusing	1248	1256	O
on	1257	1259	O
localization	1260	1272	O
of	1273	1275	O
seizure	1276	1283	O
activity	1284	1292	O
in	1293	1295	O
ictal	1296	1301	O
bradycardia	1302	1313	O
cases	1314	1319	O
.	1319	1320	O

RESULTS	1321	1328	O
:	1328	1329	O

All	1330	1333	O
occurrences	1334	1345	O
of	1346	1348	O
ictal	1349	1354	O
bradycardia	1355	1366	O
in	1367	1369	O
the	1370	1373	O
13	1374	1376	O
identified	1377	1387	O
patients	1388	1396	O
were	1397	1401	O
associated	1402	1412	O
with	1413	1417	O
temporal	1418	1426	O
lobe	1427	1431	O
-	1431	1432	O
onset	1432	1437	O
seizures	1438	1446	O
.	1446	1447	O

However	1448	1455	O
,	1455	1456	O
no	1457	1459	O
consistent	1460	1470	O
lateralization	1471	1485	O
of	1486	1488	O
seizure	1489	1496	O
activity	1497	1505	O
was	1506	1509	O
found	1510	1515	O
at	1516	1518	O
onset	1519	1524	O
of	1525	1527	O
seizure	1528	1535	O
activity	1536	1544	O
or	1545	1547	O
at	1548	1550	O
onset	1551	1556	O
of	1557	1559	O
bradycardia	1560	1571	O
in	1572	1574	O
this	1575	1579	O
population	1580	1590	O
.	1590	1591	O

Seizure	1592	1599	O
activity	1600	1608	O
was	1609	1612	O
bilateral	1613	1622	O
at	1623	1625	O
bradycardia	1626	1637	O
onset	1638	1643	O
in	1644	1646	O
nine	1647	1651	O
of	1652	1654	O
13	1655	1657	O
patients	1658	1666	O
.	1666	1667	O

The	1668	1671	O
results	1672	1679	O
from	1680	1684	O
the	1685	1688	O
literature	1689	1699	O
review	1700	1706	O
also	1707	1711	O
showed	1712	1718	O
that	1719	1723	O
a	1724	1725	O
predominance	1726	1738	O
of	1739	1741	O
patients	1742	1750	O
had	1751	1754	O
bilateral	1755	1764	O
activity	1765	1773	O
at	1774	1776	O
bradycardia	1777	1788	O
onset	1789	1794	O
;	1794	1795	O
however	1796	1803	O
,	1803	1804	O
more	1805	1809	O
of	1810	1812	O
the	1813	1816	O
ictal	1817	1822	O
bradycardia	1823	1834	O
cases	1835	1840	O
from	1841	1845	O
the	1846	1849	O
literature	1850	1860	O
had	1861	1864	O
left	1865	1869	B-Multi-tissue_structure
hemispheric	1870	1881	I-Multi-tissue_structure
localization	1882	1894	O
of	1895	1897	O
seizure	1898	1905	O
onset	1906	1911	O
.	1911	1912	O

CONCLUSIONS	1913	1924	O
:	1924	1925	O

Ictal	1926	1931	O
bradycardia	1932	1943	O
most	1944	1948	O
often	1949	1954	O
occurs	1955	1961	O
in	1962	1964	O
association	1965	1976	O
with	1977	1981	O
bilateral	1982	1991	O
hemispheric	1992	2003	O
seizure	2004	2011	O
activity	2012	2020	O
and	2021	2024	O
is	2025	2027	O
not	2028	2031	O
a	2032	2033	O
consistent	2034	2044	O
lateralizing	2045	2057	O
sign	2058	2062	O
in	2063	2065	O
localizing	2066	2076	O
seizure	2077	2084	O
onset	2085	2090	O
.	2090	2091	O

Our	2092	2095	O
data	2096	2100	O
do	2101	2103	O
not	2104	2107	O
support	2108	2115	O
the	2116	2119	O
existence	2120	2129	O
of	2130	2132	O
a	2133	2134	O
strictly	2135	2143	O
unilateral	2144	2154	O
parasympathetic	2155	2170	O
cardiomotor	2171	2182	O
representation	2183	2197	O
in	2198	2200	O
the	2201	2204	O
left	2205	2209	O
hemisphere	2210	2220	O
,	2220	2221	O
as	2222	2224	O
has	2225	2228	O
been	2229	2233	O
suggested	2234	2243	O
.	2243	2244	O

Dendrimer	0	9	O
-	9	10	O
templated	10	19	O
Fe	20	22	O
nanoparticles	23	36	O
for	37	40	O
the	41	44	O
growth	45	51	O
of	52	54	O
single	55	61	O
-	61	62	O
wall	62	66	O
carbon	67	73	O
nanotubes	74	83	O
by	84	86	O
plasma	87	93	O
-	93	94	O
enhanced	94	102	O
CVD	103	106	O
.	106	107	O

A	108	109	O
fourth	110	116	O
-	116	117	O
generation	117	127	O
(	128	129	O
G4	129	131	O
)	131	132	O
poly	133	137	O
(	137	138	O
amidoamine	138	148	O
)	148	149	O
(	150	151	O
PAMAM	151	156	O
)	156	157	O
dendrimer	158	167	O
(	168	169	O
G4	169	171	O
-	171	172	O
NH2	172	175	O
)	175	176	O
has	177	180	O
been	181	185	O
used	186	190	O
as	191	193	O
a	194	195	O
template	196	204	O
to	205	207	O
deliver	208	215	O
nearly	216	222	O
monodispersed	223	236	O
catalyst	237	245	O
nanoparticles	246	259	O
to	260	262	O
SiO2	263	267	O
/	267	268	O
Si	268	270	O
,	270	271	O
Ti	272	274	O
/	274	275	O
Si	275	277	O
,	277	278	O
sapphire	279	287	O
,	287	288	O
and	289	292	O
porous	293	299	O
anodic	300	306	O
alumina	307	314	O
(	315	316	O
PAA	316	319	O
)	319	320	O
substrates	321	331	O
.	331	332	O

Fe2O3	333	338	O
nanoparticles	339	352	O
obtained	353	361	O
after	362	367	O
calcination	368	379	O
of	380	382	O
the	383	386	O
immobilized	387	398	O
Fe3	399	402	O
+	402	403	O
/	403	404	O
G4	404	406	O
-	406	407	O
NH2	407	410	O
composite	411	420	O
served	421	427	O
as	428	430	O
catalytic	431	440	O
"	441	442	O
seeds	442	447	O
"	447	448	O
for	449	452	O
the	453	456	O
growth	457	463	O
of	464	466	O
single	467	473	O
-	473	474	O
wall	474	478	O
carbon	479	485	O
nanotubes	486	495	O
(	496	497	O
SWNTs	497	502	O
)	502	503	O
by	504	506	O
microwave	507	516	O
plasma	517	523	O
-	523	524	O
enhanced	524	532	O
CVD	533	536	O
(	537	538	O
PECVD	538	543	O
)	543	544	O
.	544	545	O

To	546	548	O
surmount	549	557	O
the	558	561	O
difficulty	562	572	O
associated	573	583	O
with	584	588	O
SWNT	589	593	O
growth	594	600	O
via	601	604	O
PECVD	605	610	O
,	610	611	O
reaction	612	620	O
conditions	621	631	O
that	632	636	O
promote	637	644	O
the	645	648	O
stabilization	649	662	O
of	663	665	O
Fe	666	668	O
nanoparticles	669	682	O
,	682	683	O
resulting	684	693	O
in	694	696	O
enhanced	697	705	O
SWNT	706	710	O
selectivity	711	722	O
and	723	726	O
quality	727	734	O
,	734	735	O
have	736	740	O
been	741	745	O
identified	746	756	O
.	756	757	O

In	758	760	O
particular	761	771	O
,	771	772	O
in	773	775	O
situ	776	780	O
annealing	781	790	O
of	791	793	O
Fe	794	796	O
catalyst	797	805	O
in	806	808	O
an	809	811	O
N2	812	814	O
atmosphere	815	825	O
was	826	829	O
found	830	835	O
to	836	838	O
improve	839	846	O
SWNT	847	851	O
selectivity	852	863	O
and	864	867	O
quality	868	875	O
.	875	876	O

H2	877	879	O
prereduction	880	892	O
at	893	895	O
900	896	899	O
degrees	900	907	O
C	908	909	O
for	910	913	O
5	914	915	O
min	916	919	O
was	920	923	O
also	924	928	O
found	929	934	O
to	935	937	O
enhance	938	945	O
SWNT	946	950	O
selectivity	951	962	O
and	963	966	O
quality	967	974	O
for	975	978	O
SiO2	979	983	O
/	983	984	O
Si	984	986	O
supported	987	996	O
catalyst	997	1005	O
,	1005	1006	O
albeit	1007	1013	O
of	1014	1016	O
lower	1017	1022	O
quality	1023	1030	O
for	1031	1034	O
sapphire	1035	1043	O
supported	1044	1053	O
catalyst	1054	1062	O
.	1062	1063	O

The	1064	1067	O
application	1068	1079	O
of	1080	1082	O
positive	1083	1091	O
dc	1092	1094	O
bias	1095	1099	O
voltage	1100	1107	O
(	1108	1109	O
+	1109	1110	O
200	1110	1113	O
V	1114	1115	O
)	1115	1116	O
during	1117	1123	O
SWNT	1124	1128	O
growth	1129	1135	O
was	1136	1139	O
shown	1140	1145	O
to	1146	1148	O
be	1149	1151	O
very	1152	1156	O
effective	1157	1166	O
in	1167	1169	O
removing	1170	1178	O
amorphous	1179	1188	O
carbon	1189	1195	O
impurities	1196	1206	O
while	1207	1212	O
enhancing	1213	1222	O
graphitization	1223	1237	O
,	1237	1238	O
SWNT	1239	1243	O
selectivity	1244	1255	O
,	1255	1256	O
and	1257	1260	O
vertical	1261	1269	O
alignment	1270	1279	O
.	1279	1280	O

The	1281	1284	O
results	1285	1292	O
of	1293	1295	O
this	1296	1300	O
study	1301	1306	O
should	1307	1313	O
promote	1314	1321	O
the	1322	1325	O
use	1326	1329	O
of	1330	1332	O
exposed	1333	1340	O
Fe	1341	1343	O
nanoparticles	1344	1357	O
supported	1358	1367	O
on	1368	1370	O
different	1371	1380	O
substrates	1381	1391	O
for	1392	1395	O
the	1396	1399	O
growth	1400	1406	O
of	1407	1409	O
high	1410	1414	O
-	1414	1415	O
quality	1415	1422	O
SWNTs	1423	1428	O
by	1429	1431	O
PECVD	1432	1437	O
.	1437	1438	O

Fluoro	0	6	O
-	6	7	O
Jade	7	11	O
B	12	13	O
staining	14	22	O
following	23	32	O
zymosan	33	40	O
microinjection	41	55	O
into	56	60	O
the	61	64	O
spinal	65	71	B-Multi-tissue_structure
cord	72	76	I-Multi-tissue_structure
white	77	82	I-Multi-tissue_structure
matter	83	89	I-Multi-tissue_structure
.	89	90	O

1	91	92	O
.	92	93	O

The	94	97	O
fluorescein	98	109	O
derivate	110	118	O
Fluoro	119	125	O
-	125	126	O
Jade	126	130	O
B	131	132	O
(	133	134	O
FJB	134	137	O
)	137	138	O
,	138	139	O
which	140	145	O
primarily	146	155	O
labels	156	162	O
dead	163	167	O
or	168	170	O
dying	171	176	O
neurons	177	184	B-Cell
,	184	185	O
was	186	189	O
used	190	194	O
to	195	197	O
study	198	203	O
the	204	207	O
acute	208	213	O
focal	214	219	O
inflammation	220	232	O
in	233	235	O
the	236	239	O
spinal	240	246	B-Multi-tissue_structure
cord	247	251	I-Multi-tissue_structure
white	252	257	I-Multi-tissue_structure
matter	258	264	I-Multi-tissue_structure
.	264	265	O

Inflammation	266	278	O
was	279	282	O
induced	283	290	O
by	291	293	O
microinjection	294	308	O
of	309	311	O
the	312	315	O
yeast	316	321	O
particulate	322	333	O
zymosan	334	341	O
to	342	344	O
evaluate	345	353	O
the	354	357	O
biological	358	368	O
effects	369	376	O
of	377	379	O
intraspinal	380	391	B-Cell
macrophages	392	403	I-Cell
activation	404	414	O
without	415	422	O
the	423	426	O
confounding	427	438	O
effects	439	446	O
of	447	449	O
physical	450	458	O
trauma	459	465	O
.	465	466	O

2	467	468	O
.	468	469	O

A	470	471	O
single	472	478	O
bolus	479	484	O
of	485	487	O
zymosan	488	495	O
(	496	497	O
Sigma	497	502	O
,	502	503	O
75	504	506	O
nL	507	509	O
)	509	510	O
was	511	514	O
stereotaxically	515	530	O
injected	531	539	O
at	540	542	O
the	543	546	O
thoracic	547	555	B-Multi-tissue_structure
level	556	561	O
into	562	566	O
the	567	570	O
lateral	571	578	B-Multi-tissue_structure
white	579	584	I-Multi-tissue_structure
matter	585	591	I-Multi-tissue_structure
of	592	594	O
rat	595	598	O
spinal	599	605	B-Organ
cord	606	610	I-Organ
.	610	611	O

A	612	613	O
standard	614	622	O
Fluoro	623	629	O
-	629	630	O
Jade	630	634	O
B	635	636	O
staining	637	645	O
protocol	646	654	O
was	655	658	O
applied	659	666	O
to	667	669	O
spinal	670	676	B-Organ
cord	677	681	I-Organ
sections	682	690	O
at	691	693	O
6	694	695	O
,	695	696	O
12	697	699	O
,	699	700	O
24	701	703	O
h	704	705	O
and	706	709	O
2	710	711	O
,	711	712	O
4	713	714	O
days	715	719	O
postinjection	720	733	O
.	733	734	O

Neutral	735	742	O
Red	743	746	O
,	746	747	O
NADPH	748	753	O
-	753	754	O
diaphorase	754	764	O
,	764	765	O
Iba1	766	770	O
-	770	771	O
IR	771	773	O
,	773	774	O
and	775	778	O
DAPI	779	783	O
staining	784	792	O
protocols	793	802	O
accomplished	803	815	O
examination	816	827	O
of	828	830	O
the	831	834	O
cells	835	840	B-Cell
participating	841	854	O
in	855	857	O
the	858	861	O
acute	862	867	O
inflammatory	868	880	O
response	881	889	O
.	889	890	O

3	891	892	O
.	892	893	O

Zymosan	894	901	O
caused	902	908	O
formation	909	918	O
of	919	921	O
clearly	922	929	O
delineated	930	940	O
inflammation	941	953	B-Pathological_formation
lesions	954	961	I-Pathological_formation
localized	962	971	O
in	972	974	O
the	975	978	O
lateral	979	986	B-Multi-tissue_structure
white	987	992	I-Multi-tissue_structure
matter	993	999	I-Multi-tissue_structure
of	1000	1002	O
the	1003	1006	O
spinal	1007	1013	B-Organ
cord	1014	1018	I-Organ
.	1018	1019	O

Fluoro	1020	1026	O
-	1026	1027	O
Jade	1027	1031	O
B	1032	1033	O
stained	1034	1041	O
cells	1042	1047	B-Cell
in	1048	1050	O
the	1051	1054	O
area	1055	1059	O
of	1060	1062	O
inflammation	1063	1075	B-Pathological_formation
were	1076	1080	O
not	1081	1084	O
observed	1085	1093	O
at	1094	1096	O
12	1097	1099	O
h	1100	1101	O
postinjection	1102	1115	O
while	1116	1121	O
mild	1122	1126	O
FJB	1127	1130	O
staining	1131	1139	O
appeared	1140	1148	O
at	1149	1151	O
24	1152	1154	O
h	1155	1156	O
and	1157	1160	O
intense	1161	1168	O
staining	1169	1177	O
was	1178	1181	O
observed	1182	1190	O
at	1191	1193	O
2	1194	1195	O
and	1196	1199	O
4	1200	1201	O
days	1202	1206	O
postinjection	1207	1220	O
.	1220	1221	O

4	1222	1223	O
.	1223	1224	O

This	1225	1229	O
study	1230	1235	O
shows	1236	1241	O
that	1242	1246	O
the	1247	1250	O
acute	1251	1256	O
response	1257	1265	O
to	1266	1268	O
zymosan	1269	1276	O
-	1276	1277	O
induced	1277	1284	O
inflammation	1285	1297	O
in	1298	1300	O
the	1301	1304	O
rat	1305	1308	O
spinal	1309	1315	B-Multi-tissue_structure
cord	1316	1320	I-Multi-tissue_structure
white	1321	1326	I-Multi-tissue_structure
matter	1327	1333	I-Multi-tissue_structure
causes	1334	1340	O
a	1341	1342	O
gradual	1343	1350	O
appearance	1351	1361	O
of	1362	1364	O
phagocytic	1365	1375	B-Cell
microglia	1376	1385	I-Cell
/	1385	1386	O
macrophages	1386	1397	B-Cell
and	1398	1401	O
delayed	1402	1409	O
FJB	1410	1413	O
staining	1414	1422	O
of	1423	1425	O
the	1426	1429	O
inflammatory	1430	1442	B-Cell
cells	1443	1448	I-Cell
.	1448	1449	O

5	1450	1451	O
.	1451	1452	O

FJB	1453	1456	O
,	1456	1457	O
a	1458	1459	O
reliable	1460	1468	O
marker	1469	1475	O
of	1476	1478	O
dying	1479	1484	O
neurons	1485	1492	B-Cell
,	1492	1493	O
is	1494	1496	O
a	1497	1498	O
more	1499	1503	O
universal	1504	1513	O
agent	1514	1519	O
than	1520	1524	O
formerly	1525	1533	O
believed	1534	1542	O
.	1542	1543	O

One	1544	1547	O
possible	1548	1556	O
explanation	1557	1568	O
for	1569	1572	O
the	1573	1576	O
gradual	1577	1584	O
appearance	1585	1595	O
of	1596	1598	O
FJB	1599	1602	O
-	1602	1603	O
stained	1603	1610	O
cells	1611	1616	B-Cell
in	1617	1619	O
the	1620	1623	O
area	1624	1628	O
of	1629	1631	O
inflammation	1632	1644	B-Pathological_formation
is	1645	1647	O
that	1648	1652	O
specific	1653	1661	O
time	1662	1666	O
is	1667	1669	O
required	1670	1678	O
for	1679	1682	O
sufficient	1683	1693	O
levels	1694	1700	O
of	1701	1703	O
proteins	1704	1712	O
and	1713	1716	O
/	1716	1717	O
or	1717	1719	O
myelin	1720	1726	O
debris	1727	1733	O
of	1734	1736	O
axonal	1737	1743	O
origin	1744	1750	O
to	1751	1753	O
appear	1754	1760	O
in	1761	1763	O
the	1764	1767	O
cytoplasm	1768	1777	B-Organism_substance
of	1778	1780	O
phagocytic	1781	1791	B-Cell
microglia	1792	1801	I-Cell
/	1801	1802	O
macrophages	1802	1813	B-Cell
.	1813	1814	O

Changes	0	7	O
of	8	10	O
lymphocyte	11	21	B-Cell
subsets	22	29	O
in	30	32	O
leukemia	33	41	O
patients	42	50	O
who	51	54	O
received	55	63	O
allogenic	64	73	O
bone	74	78	B-Multi-tissue_structure
marrow	79	85	I-Multi-tissue_structure
transplantation	86	101	O
.	101	102	O

Proportional	103	115	O
changes	116	123	O
of	124	126	O
lymphocyte	127	137	B-Cell
subsets	138	145	O
in	146	148	O
the	149	152	O
peripheral	153	163	B-Organism_substance
blood	164	169	I-Organism_substance
were	170	174	O
monitored	175	184	O
by	185	187	O
two	188	191	O
-	191	192	O
color	192	197	O
flow	198	202	O
-	202	203	O
cytometry	203	212	O
in	213	215	O
seven	216	221	O
leukemia	222	230	O
patients	231	239	O
who	240	243	O
had	244	247	O
received	248	256	O
allogenic	257	266	O
bone	267	271	B-Multi-tissue_structure
marrow	272	278	I-Multi-tissue_structure
transplantation	279	294	O
(	295	296	O
BMT	296	299	O
)	299	300	O
.	300	301	O

Lymphocyte	302	312	B-Cell
counts	313	319	O
,	319	320	O
and	321	324	O
proportions	325	336	O
of	337	339	O
T	340	341	B-Cell
and	342	345	O
B	346	347	B-Cell
-	347	348	I-Cell
cells	348	353	I-Cell
returned	354	362	O
to	363	365	O
normal	366	372	O
ranges	373	379	O
between	380	387	O
the	388	391	O
2nd	392	395	O
and	396	399	O
12th	400	404	O
months	405	411	O
after	412	417	O
BMT	418	421	O
.	421	422	O

Activated	423	432	O
T	433	434	B-Cell
-	434	435	I-Cell
cells	435	440	I-Cell
prominently	441	452	O
increased	453	462	O
after	463	468	O
BMT	469	472	O
,	472	473	O
and	474	477	O
the	478	481	O
values	482	488	O
gradually	489	498	O
returned	499	507	O
toward	508	514	O
normal	515	521	O
.	521	522	O

As	523	525	O
to	526	528	O
lymphocyte	529	539	B-Cell
subsets	540	547	O
,	547	548	O
the	549	552	O
proportions	553	564	O
of	565	567	O
CD	568	570	B-Cell
4	571	572	I-Cell
+	572	573	I-Cell
cells	574	579	I-Cell
had	580	583	O
remained	584	592	O
low	593	596	O
,	596	597	O
while	598	603	O
those	604	609	O
of	610	612	O
CD	613	615	B-Cell
8	616	617	I-Cell
+	617	618	I-Cell
cells	619	624	I-Cell
high	625	629	O
for	630	633	O
a	634	635	O
whole	636	641	O
observation	642	653	O
period	654	660	O
after	661	666	O
BMT	667	670	O
.	670	671	O

The	672	675	O
changes	676	683	O
of	684	686	O
CD	687	689	B-Cell
4	690	691	I-Cell
+	691	692	I-Cell
cells	693	698	I-Cell
were	699	703	O
caused	704	710	O
by	711	713	O
the	714	717	O
decrease	718	726	O
of	727	729	O
suppressor	730	740	B-Cell
-	740	741	I-Cell
inducer	741	748	I-Cell
T	749	750	I-Cell
-	750	751	I-Cell
cells	751	756	I-Cell
(	757	758	O
CD	758	760	O
4	761	762	O
+	762	763	O
Leu	764	767	O
8	768	769	O
+	769	770	O
)	770	771	O
.	771	772	O

High	773	777	O
proportion	778	788	O
of	789	791	O
CD	792	794	B-Cell
8	795	796	I-Cell
+	796	797	I-Cell
cells	798	803	I-Cell
was	804	807	O
mainly	808	814	O
associated	815	825	O
with	826	830	O
increased	831	840	O
suppressor	841	851	B-Cell
T	852	853	I-Cell
-	853	854	I-Cell
cells	854	859	I-Cell
(	860	861	O
CD	861	863	O
8	864	865	O
+	865	866	O
CD	867	869	O
11	870	872	O
+	872	873	O
)	873	874	O
.	874	875	O

Among	876	881	O
natural	882	889	B-Cell
killer	890	896	I-Cell
(	897	898	I-Cell
NK	898	900	I-Cell
)	900	901	I-Cell
cells	902	907	I-Cell
,	907	908	O
highly	909	915	O
active	916	922	O
NK	923	925	B-Cell
cells	926	931	I-Cell
(	932	933	O
CD	933	935	O
16	936	938	O
+	938	939	O
CD	940	942	O
57	943	945	O
-	945	946	O
)	946	947	O
markedly	948	956	O
increased	957	966	O
shortly	967	974	O
after	975	980	O
BMT	981	984	O
,	984	985	O
and	986	989	O
gradually	990	999	O
returned	1000	1008	O
to	1009	1011	O
normal	1012	1018	O
.	1018	1019	O

CD	1020	1022	B-Cell
16	1023	1025	I-Cell
-	1026	1027	I-Cell
CD	1027	1029	I-Cell
57	1030	1032	I-Cell
+	1032	1033	I-Cell
NK	1034	1036	I-Cell
cells	1037	1042	I-Cell
increased	1043	1052	O
beyond	1053	1059	O
normal	1060	1066	O
ranges	1067	1073	O
after	1074	1079	O
the	1080	1083	O
2nd	1084	1087	O
month	1088	1093	O
.	1093	1094	O

The	1095	1098	O
incidence	1099	1108	O
or	1109	1111	O
degree	1112	1118	O
of	1119	1121	O
acute	1122	1127	O
and	1128	1131	O
chronic	1132	1139	O
graft	1140	1145	B-Multi-tissue_structure
-	1145	1146	O
versus	1146	1152	O
-	1152	1153	O
host	1153	1157	O
diseases	1158	1166	O
(	1167	1168	O
GVHD	1168	1172	O
)	1172	1173	O
did	1174	1177	O
not	1178	1181	O
correlate	1182	1191	O
with	1192	1196	O
the	1197	1200	O
changes	1201	1208	O
of	1209	1211	O
any	1212	1215	O
lymphocyte	1216	1226	B-Cell
subsets	1227	1234	O
.	1234	1235	O

The	1236	1239	O
present	1240	1247	O
results	1248	1255	O
suggest	1256	1263	O
that	1264	1268	O
the	1269	1272	O
increase	1273	1281	O
of	1282	1284	O
activated	1285	1294	O
T	1295	1296	B-Cell
-	1296	1297	I-Cell
cells	1297	1302	I-Cell
shortly	1303	1310	O
after	1311	1316	O
BMT	1317	1320	O
reflects	1321	1329	O
lymphocyte	1330	1340	B-Cell
reconstitution	1341	1355	O
.	1355	1356	O

The	1357	1360	O
prolonged	1361	1370	O
immune	1371	1377	O
deficiency	1378	1388	O
after	1389	1394	O
BMT	1395	1398	O
might	1399	1404	O
be	1405	1407	O
related	1408	1415	O
to	1416	1418	O
either	1419	1425	O
deficient	1426	1435	O
expression	1436	1446	O
of	1447	1449	O
homing	1450	1456	O
receptor	1457	1465	O
(	1466	1467	O
Leu	1467	1470	O
8	1471	1472	O
antigen	1473	1480	O
)	1480	1481	O
on	1482	1484	O
CD	1485	1487	B-Cell
4	1488	1489	I-Cell
+	1489	1490	I-Cell
cells	1491	1496	I-Cell
or	1497	1499	O
increased	1500	1509	O
suppressor	1510	1520	B-Cell
T	1521	1522	I-Cell
-	1522	1523	I-Cell
cells	1523	1528	I-Cell
(	1529	1530	O
CD	1530	1532	O
8	1533	1534	O
+	1534	1535	O
CD	1536	1538	O
11	1539	1541	O
+	1541	1542	O
)	1542	1543	O
.	1543	1544	O

In	1545	1547	O
addition	1548	1556	O
,	1556	1557	O
the	1558	1561	O
early	1562	1567	O
increase	1568	1576	O
of	1577	1579	O
NK	1580	1582	B-Cell
cells	1583	1588	I-Cell
after	1589	1594	O
BMT	1595	1598	O
may	1599	1602	O
compensate	1603	1613	O
for	1614	1617	O
the	1618	1621	O
immune	1622	1628	O
deficiency	1629	1639	O
in	1640	1642	O
BMT	1643	1646	O
patients	1647	1655	O
.	1655	1656	O

Fluoroscopically	0	16	O
guided	17	23	O
cervical	24	32	B-Organism_subdivision
prolotherapy	33	45	O
for	46	49	O
instability	50	61	O
with	62	66	O
blinded	67	74	O
pre	75	78	O
and	79	82	O
post	83	87	O
radiographic	88	100	O
reading	101	108	O
.	108	109	O

BACKGROUND	110	120	O
:	120	121	O

Several	122	129	O
authors	130	137	O
have	138	142	O
postulated	143	153	O
that	154	158	O
cervical	159	167	B-Organism_subdivision
instability	168	179	O
is	180	182	O
a	183	184	O
major	185	190	O
cause	191	196	O
of	197	199	O
traumatic	200	209	O
spinal	210	216	B-Organism_subdivision
pain	217	221	O
.	221	222	O

OBJECTIVE	223	232	O
:	232	233	O

The	234	237	O
purpose	238	245	O
of	246	248	O
this	249	253	O
prospective	254	265	O
case	266	270	O
series	271	277	O
study	278	283	O
(	284	285	O
n	285	286	O
=	287	288	O
6	289	290	O
)	290	291	O
was	292	295	O
to	296	298	O
determine	299	308	O
if	309	311	O
proliferant	312	323	O
injections	324	334	O
have	335	339	O
an	340	342	O
effect	343	349	O
on	350	352	O
cervical	353	361	B-Organism_subdivision
translation	362	373	O
as	374	376	O
measured	377	385	O
by	386	388	O
a	389	390	O
blinded	391	398	O
reader	399	405	O
.	405	406	O

DESIGN	407	413	O
:	413	414	O

This	415	419	O
study	420	425	O
was	426	429	O
a	430	431	O
prospective	432	443	O
case	444	448	O
series	449	455	O
.	455	456	O

Study	457	462	O
participants	463	475	O
were	476	480	O
selected	481	489	O
from	490	494	O
patients	495	503	O
seen	504	508	O
for	509	512	O
the	513	516	O
primary	517	524	O
complaint	525	534	O
of	535	537	O
Motor	538	543	O
Vehicle	544	551	O
Collision	552	561	O
related	562	569	O
neck	570	574	B-Organism_subdivision
pain	575	579	O
in	580	582	O
a	583	584	O
private	585	592	O
sub	593	596	O
-	596	597	O
specialty	597	606	O
pain	607	611	O
clinic	612	618	O
.	618	619	O

METHODS	620	627	O
:	627	628	O

Flexion	629	636	O
and	637	640	O
extension	641	650	O
views	651	656	O
were	657	661	O
obtained	662	670	O
by	671	673	O
standard	674	682	O
radiographs	683	694	O
taken	695	700	O
with	701	705	O
a	706	707	O
C	708	709	O
-	709	710	O
Arm	710	713	O
fluoroscope	714	725	O
under	726	731	O
Valium	732	738	O
sedation	739	747	O
.	747	748	O

Patients	749	757	O
with	758	762	O
more	763	767	O
than	768	772	O
2	773	774	O
.	774	775	O
7	775	776	O
mm	777	779	O
of	780	782	O
absolute	783	791	O
cervical	792	800	B-Organism_subdivision
translation	801	812	O
and	813	816	O
at	817	819	O
least	820	825	O
50	826	828	O
%	828	829	O
reduction	830	839	O
of	840	842	O
cervical	843	851	B-Organism_subdivision
and	852	855	O
referred	856	864	O
pain	865	869	O
with	870	874	O
a	875	876	O
two	877	880	O
day	881	884	O
rigid	885	890	O
cervical	891	899	B-Organism_subdivision
immobilization	900	914	O
test	915	919	O
were	920	924	O
admitted	925	933	O
into	934	938	O
the	939	942	O
study	943	948	O
.	948	949	O

Participants	950	962	O
underwent	963	972	O
3	973	974	O
prolotherapy	975	987	O
injections	988	998	O
at	999	1001	O
all	1002	1005	O
sites	1006	1011	O
that	1012	1016	O
demonstrated	1017	1029	O
translation	1030	1041	O
.	1041	1042	O

The	1043	1046	O
difference	1047	1057	O
in	1058	1060	O
means	1061	1066	O
between	1067	1074	O
pre	1075	1078	O
-	1078	1079	O
test	1079	1083	O
and	1084	1087	O
post	1088	1092	O
-	1092	1093	O
test	1093	1097	O
measurements	1098	1110	O
(	1111	1112	O
flexion	1112	1119	O
translation	1120	1131	O
,	1131	1132	O
extension	1133	1142	O
translation	1143	1154	O
,	1154	1155	O
and	1156	1159	O
pain	1160	1164	O
VAS	1165	1168	O
scores	1169	1175	O
)	1175	1176	O
were	1177	1181	O
assessed	1182	1190	O
by	1191	1193	O
a	1194	1195	O
Wilcoxon	1196	1204	O
signed	1205	1211	O
ranks	1212	1217	O
test	1218	1222	O
(	1223	1224	O
alpha	1224	1229	O
=	1230	1231	O
0	1232	1233	O
.	1233	1234	O
05	1234	1236	O
)	1236	1237	O
.	1237	1238	O

RESULTS	1239	1246	O
:	1246	1247	O

The	1248	1251	O
mean	1252	1256	O
post	1257	1261	O
-	1261	1262	O
test	1262	1266	O
VAS	1267	1270	O
score	1271	1276	O
(	1277	1278	O
M	1278	1279	O
=	1279	1280	O
3	1281	1282	O
.	1282	1283	O
83	1283	1285	O
,	1285	1286	O
SD	1287	1289	O
=	1289	1290	O
2	1290	1291	O
.	1291	1292	O
3	1292	1293	O
,	1293	1294	O
t	1295	1296	O
=	1296	1297	O
2	1297	1298	O
.	1298	1299	O
889	1299	1302	O
)	1302	1303	O
was	1304	1307	O
significantly	1308	1321	O
less	1322	1326	O
(	1327	1328	O
p	1328	1329	O
=	1329	1330	O
0	1330	1331	O
.	1331	1332	O
04	1332	1334	O
)	1334	1335	O
than	1336	1340	O
the	1341	1344	O
mean	1345	1349	O
pre	1350	1353	O
-	1353	1354	O
test	1354	1358	O
VAS	1359	1362	O
score	1363	1368	O
(	1369	1370	O
M	1370	1371	O
=	1371	1372	O
5	1372	1373	O
.	1373	1374	O
75	1374	1376	O
,	1376	1377	O
SD	1378	1380	O
=	1380	1381	O
1	1381	1382	O
.	1382	1383	O
94	1383	1385	O
)	1385	1386	O
.	1386	1387	O

The	1388	1391	O
correlation	1392	1403	O
between	1404	1411	O
difference	1412	1422	O
in	1423	1425	O
mean	1426	1430	O
extension	1431	1440	O
at	1441	1443	O
C2	1444	1446	O
-	1446	1447	O
3	1447	1448	O
and	1449	1452	O
C5	1453	1455	O
-	1455	1456	O
6	1456	1457	O
and	1458	1461	O
difference	1462	1472	O
in	1473	1475	O
mean	1476	1480	O
extension	1481	1490	O
was	1491	1494	O
significant	1495	1506	O
(	1507	1508	O
rho	1508	1511	O
=	1511	1512	O
0	1512	1513	O
.	1513	1514	O
89	1514	1516	O
,	1516	1517	O
p	1518	1519	O
=	1519	1520	O
0	1520	1521	O
.	1521	1522	O
02	1522	1524	O
and	1525	1528	O
rho	1529	1532	O
=	1532	1533	O
0	1533	1534	O
.	1534	1535	O
85	1535	1537	O
,	1537	1538	O
p	1539	1540	O
=	1540	1541	O
0	1541	1542	O
.	1542	1543	O
03	1543	1545	O
respectively	1546	1558	O
)	1558	1559	O
.	1559	1560	O

Difference	1561	1571	O
in	1572	1574	O
mean	1575	1579	O
flexion	1580	1587	O
at	1588	1590	O
C3	1591	1593	O
-	1593	1594	O
4	1594	1595	O
and	1596	1599	O
C4	1600	1602	O
-	1602	1603	O
5	1603	1604	O
was	1605	1608	O
significantly	1609	1622	O
correlated	1623	1633	O
with	1634	1638	O
difference	1639	1649	O
in	1650	1652	O
mean	1653	1657	O
flexion	1658	1665	O
(	1666	1667	O
rho	1667	1670	O
=	1670	1671	O
0	1671	1672	O
.	1672	1673	O
88	1673	1675	O
,	1675	1676	O
p	1677	1678	O
=	1678	1679	O
0	1679	1680	O
.	1680	1681	O
02	1681	1683	O
and	1684	1687	O
rho	1688	1691	O
=	1691	1692	O
0	1692	1693	O
.	1693	1694	O
941	1694	1697	O
,	1697	1698	O
p	1699	1700	O
<	1701	1702	O
0	1702	1703	O
.	1703	1704	O
01	1704	1706	O
respectively	1707	1719	O
)	1719	1720	O
.	1720	1721	O

CONCLUSIONS	1722	1733	O
:	1733	1734	O

The	1735	1738	O
results	1739	1746	O
of	1747	1749	O
this	1750	1754	O
study	1755	1760	O
demonstrate	1761	1772	O
statistically	1773	1786	O
significant	1787	1798	O
correlations	1799	1811	O
between	1812	1819	O
proliferant	1820	1831	O
injections	1832	1842	O
,	1842	1843	O
a	1844	1845	O
reduction	1846	1855	O
of	1856	1858	O
both	1859	1863	O
cervical	1864	1872	B-Organism_subdivision
flexion	1873	1880	O
and	1881	1884	O
extension	1885	1894	O
translation	1895	1906	O
,	1906	1907	O
as	1908	1910	O
well	1911	1915	O
as	1916	1918	O
a	1919	1920	O
reduction	1921	1930	O
in	1931	1933	O
pain	1934	1938	O
VAS	1939	1942	O
score	1943	1948	O
.	1948	1949	O

Since	1950	1955	O
patients	1956	1964	O
with	1965	1969	O
traumatic	1970	1979	O
cervical	1980	1988	B-Organism_subdivision
instability	1989	2000	O
have	2001	2005	O
few	2006	2009	O
viable	2010	2016	O
treatment	2017	2026	O
options	2027	2034	O
other	2035	2040	O
than	2041	2045	O
surgical	2046	2054	O
fusion	2055	2061	O
,	2061	2062	O
cervical	2063	2071	B-Organism_subdivision
proliferant	2072	2083	O
injections	2084	2094	O
under	2095	2100	O
C	2101	2102	O
-	2102	2103	O
Arm	2103	2106	O
fluoroscope	2107	2118	O
may	2119	2122	O
be	2123	2125	O
a	2126	2127	O
viable	2128	2134	O
treatment	2135	2144	O
option	2145	2151	O
.	2151	2152	O

[	0	1	O
The	1	4	O
prevalence	5	15	O
of	16	18	O
ADHD	19	23	O
and	24	27	O
attention	28	37	O
problems	38	46	O
in	47	49	O
preschool	50	59	O
-	59	60	O
aged	60	64	O
children	65	73	O
.	73	74	O
A	75	76	O
comparison	77	87	O
of	88	90	O
two	91	94	O
diagnostic	95	105	O
instruments	106	117	O
]	117	118	O
.	118	119	O

OBJECTIVES	120	130	O
:	130	131	O

In	132	134	O
order	135	140	O
to	141	143	O
analyse	144	151	O
the	152	155	O
prevalence	156	166	O
of	167	169	O
ADHD	170	174	O
and	175	178	O
attention	179	188	O
problems	189	197	O
in	198	200	O
preschool	201	210	O
-	210	211	O
aged	211	215	O
children	216	224	O
,	224	225	O
mothers	226	233	O
were	234	238	O
asked	239	244	O
to	245	247	O
rate	248	252	O
their	253	258	O
children	259	267	O
using	268	273	O
two	274	277	O
measuring	278	287	O
instruments	288	299	O
.	299	300	O

METHODS	301	308	O
:	308	309	O

The	310	313	O
analysis	314	322	O
is	323	325	O
part	326	330	O
of	331	333	O
a	334	335	O
prospective	336	347	O
,	347	348	O
randomised	349	359	O
control	360	367	O
study	368	373	O
of	374	376	O
N	377	378	O
=	379	380	O
280	381	384	O
children	385	393	O
aged	394	398	O
three	399	404	O
to	405	407	O
six	408	411	O
years	412	417	O
,	417	418	O
whose	419	424	O
mothers	425	432	O
rated	433	438	O
them	439	443	O
using	444	449	O
the	450	453	O
Child	454	459	O
Behaviour	460	469	O
Checklist	470	479	O
/	479	480	O
CBCL	480	484	O
1	485	486	O
1	487	488	O
/	488	489	O
2	489	490	O
-	490	491	O
5	491	492	O
and	493	496	O
the	497	500	O
Parent	501	507	O
Rating	508	514	O
Scale	515	520	O
for	521	524	O
Attention	525	534	O
-	534	535	O
Deficit	535	542	O
Hyperactivity	543	556	O
Disorder	557	565	O
(	566	567	O
ADHD	567	571	O
)	571	572	O
.	572	573	O

RESULTS	574	581	O
:	581	582	O

The	583	586	O
prevalence	587	597	O
rates	598	603	O
ranged	604	610	O
from	611	615	O
2	616	617	O
.	617	618	O
7	618	619	O
%	619	620	O
to	621	623	O
9	624	625	O
.	625	626	O
9	626	627	O
%	627	628	O
.	628	629	O

There	630	635	O
was	636	639	O
no	640	642	O
significant	643	654	O
gender	655	661	O
effect	662	668	O
in	669	671	O
this	672	676	O
age	677	680	O
group	681	686	O
.	686	687	O

CONCLUSIONS	688	699	O
:	699	700	O

The	701	704	O
study	705	710	O
delivers	711	719	O
initial	720	727	O
findings	728	736	O
and	737	740	O
provides	741	749	O
support	750	757	O
for	758	761	O
decisions	762	771	O
to	772	774	O
implement	775	784	O
in	785	787	O
Germany	788	795	O
new	796	799	O
assessment	800	810	O
methods	811	818	O
for	819	822	O
preschool	823	832	O
-	832	833	O
aged	833	837	O
children	838	846	O
with	847	851	O
ADHD	852	856	O
or	857	859	O
hyperkinetic	860	872	O
syndrome	873	881	O
.	881	882	O

Finally	883	890	O
,	890	891	O
the	892	895	O
different	896	905	O
rates	906	911	O
of	912	914	O
prevalence	915	925	O
and	926	929	O
the	930	933	O
implications	934	946	O
of	947	949	O
the	950	953	O
findings	954	962	O
for	963	966	O
epidemiology	967	979	O
and	980	983	O
the	984	987	O
prevention	988	998	O
of	999	1001	O
ADHD	1002	1006	O
and	1007	1010	O
attention	1011	1020	O
problems	1021	1029	O
among	1030	1035	O
preschool	1036	1045	O
-	1045	1046	O
aged	1046	1050	O
children	1051	1059	O
are	1060	1063	O
discussed	1064	1073	O
.	1073	1074	O

Medical	0	7	O
adherence	8	17	O
and	18	21	O
childhood	22	31	O
chronic	32	39	O
illness	40	47	O
:	47	48	O
family	49	55	O
daily	56	61	O
management	62	72	O
skills	73	79	O
and	80	83	O
emotional	84	93	O
climate	94	101	O
as	102	104	O
emerging	105	113	O
contributors	114	126	O
.	126	127	O

PURPOSE	128	135	O
OF	136	138	O
REVIEW	139	145	O
:	145	146	O

To	147	149	O
describe	150	158	O
recent	159	165	O
research	166	174	O
that	175	179	O
examines	180	188	O
family	189	195	O
factors	196	203	O
that	204	208	O
promote	209	216	O
or	217	219	O
derail	220	226	O
adherence	227	236	O
to	237	239	O
medical	240	247	O
regimens	248	256	O
for	257	260	O
children	261	269	O
with	270	274	O
chronic	275	282	O
health	283	289	O
conditions	290	300	O
,	300	301	O
primarily	302	311	O
asthma	312	318	O
,	318	319	O
diabetes	320	328	O
,	328	329	O
and	330	333	O
cystic	334	340	O
fibrosis	341	349	O
.	349	350	O

From	351	355	O
the	356	359	O
past	360	364	O
2	365	366	O
years	367	372	O
,	372	373	O
eight	374	379	O
correlational	380	393	O
studies	394	401	O
were	402	406	O
identified	407	417	O
which	418	423	O
specifically	424	436	O
examined	437	445	O
the	446	449	O
links	450	455	O
between	456	463	O
family	464	470	O
management	471	481	O
strategies	482	492	O
,	492	493	O
family	494	500	O
climate	501	508	O
and	509	512	O
medical	513	520	O
adherence	521	530	O
.	530	531	O

RECENT	532	538	O
FINDINGS	539	547	O
:	547	548	O

Findings	549	557	O
from	558	562	O
the	563	566	O
studies	567	574	O
suggest	575	582	O
that	583	587	O
team	588	592	O
-	592	593	O
based	593	598	O
management	599	609	O
strategies	610	620	O
and	621	624	O
cohesive	625	633	O
family	634	640	O
climate	641	648	O
promote	649	656	O
adherence	657	666	O
to	667	669	O
medical	670	677	O
treatments	678	688	O
over	689	693	O
time	694	698	O
.	698	699	O

Family	700	706	O
interactions	707	719	O
that	720	724	O
are	725	728	O
characterized	729	742	O
by	743	745	O
conflict	746	754	O
and	755	758	O
disengagement	759	772	O
tend	773	777	O
to	778	780	O
disrupt	781	788	O
adherence	789	798	O
and	799	802	O
inevitably	803	813	O
cause	814	819	O
a	820	821	O
decline	822	829	O
in	830	832	O
child	833	838	O
health	839	845	O
.	845	846	O

Moreover	847	855	O
,	855	856	O
these	857	862	O
findings	863	871	O
seem	872	876	O
to	877	879	O
be	880	882	O
moderated	883	892	O
by	893	895	O
child	896	901	O
age	902	905	O
in	906	908	O
that	909	913	O
poorer	914	920	O
adherence	921	930	O
often	931	936	O
occurs	937	943	O
when	944	948	O
a	949	950	O
child	951	956	O
reaches	957	964	O
adolescence	965	976	O
and	977	980	O
is	981	983	O
searching	984	993	O
for	994	997	O
greater	998	1005	O
autonomy	1006	1014	O
.	1014	1015	O

SUMMARY	1016	1023	O
:	1023	1024	O

Future	1025	1031	O
research	1032	1040	O
should	1041	1047	O
consider	1048	1056	O
the	1057	1060	O
challenges	1061	1071	O
in	1072	1074	O
measuring	1075	1084	O
medical	1085	1092	O
adherence	1093	1102	O
in	1103	1105	O
the	1106	1109	O
family	1110	1116	O
context	1117	1124	O
as	1125	1127	O
well	1128	1132	O
as	1133	1135	O
incorporating	1136	1149	O
more	1150	1154	O
naturalistic	1155	1167	O
studies	1168	1175	O
of	1176	1178	O
family	1179	1185	O
interactions	1186	1198	O
.	1198	1199	O

Randomized	1200	1210	O
controlled	1211	1221	O
trials	1222	1228	O
using	1229	1234	O
family	1235	1241	O
-	1241	1242	O
based	1242	1247	O
interventions	1248	1261	O
may	1262	1265	O
consider	1266	1274	O
focusing	1275	1283	O
on	1284	1286	O
medical	1287	1294	O
adherence	1295	1304	O
as	1305	1307	O
an	1308	1310	O
important	1311	1320	O
mediator	1321	1329	O
between	1330	1337	O
family	1338	1344	O
process	1345	1352	O
and	1353	1356	O
child	1357	1362	O
health	1363	1369	O
outcomes	1370	1378	O
.	1378	1379	O

The	0	3	O
relationship	4	16	O
between	17	24	O
brain	25	30	B-Organ
activity	31	39	O
and	40	43	O
peak	44	48	O
grip	49	53	O
force	54	59	O
is	60	62	O
modulated	63	72	O
by	73	75	O
corticospinal	76	89	B-Anatomical_system
system	90	96	I-Anatomical_system
integrity	97	106	O
after	107	112	O
subcortical	113	124	B-Multi-tissue_structure
stroke	125	131	O
.	131	132	O

In	133	135	O
healthy	136	143	O
human	144	149	O
subjects	150	158	O
,	158	159	O
the	160	163	O
relative	164	172	O
contribution	173	185	O
of	186	188	O
cortical	189	197	B-Multi-tissue_structure
regions	198	205	I-Multi-tissue_structure
to	206	208	O
motor	209	214	O
performance	215	226	O
varies	227	233	O
with	234	238	O
the	239	242	O
task	243	247	O
parameters	248	258	O
.	258	259	O

Additionally	260	272	O
,	272	273	O
after	274	279	O
stroke	280	286	O
,	286	287	O
recruitment	288	299	O
of	300	302	O
cortical	303	311	B-Multi-tissue_structure
areas	312	317	I-Multi-tissue_structure
during	318	324	O
a	325	326	O
simple	327	333	O
motor	334	339	O
task	340	344	O
varies	345	351	O
with	352	356	O
corticospinal	357	370	B-Anatomical_system
system	371	377	I-Anatomical_system
integrity	378	387	O
.	387	388	O

We	389	391	O
investigated	392	404	O
whether	405	412	O
the	413	416	O
pattern	417	424	O
of	425	427	O
motor	428	433	O
system	434	440	O
recruitment	441	452	O
in	453	455	O
a	456	457	O
task	458	462	O
involving	463	472	O
increasingly	473	485	O
forceful	486	494	O
hand	495	499	B-Organism_subdivision
grips	500	505	O
is	506	508	O
influenced	509	519	O
by	520	522	O
the	523	526	O
degree	527	533	O
of	534	536	O
corticospinal	537	550	B-Anatomical_system
system	551	557	I-Anatomical_system
damage	558	564	O
.	564	565	O

Nine	566	570	O
chronic	571	578	O
subcortical	579	590	B-Multi-tissue_structure
stroke	591	597	O
patients	598	606	O
and	607	610	O
nine	611	615	O
age	616	619	O
-	619	620	O
matched	620	627	O
controls	628	636	O
underwent	637	646	O
functional	647	657	O
magnetic	658	666	O
brain	667	672	B-Organ
imaging	673	680	O
whilst	681	687	O
performing	688	698	O
repetitive	699	709	O
isometric	710	719	O
hand	720	724	B-Organism_subdivision
grips	725	730	O
.	730	731	O

Target	732	738	O
grip	739	743	O
forces	744	750	O
were	751	755	O
varied	756	762	O
between	763	770	O
15	771	773	O
%	773	774	O
and	775	778	O
45	779	781	O
%	781	782	O
of	783	785	O
individual	786	796	O
maximum	797	804	O
grip	805	809	O
force	810	815	O
.	815	816	O

Corticospinal	817	830	O
system	831	837	O
functional	838	848	O
integrity	849	858	O
was	859	862	O
assessed	863	871	O
with	872	876	O
transcranial	877	889	O
magnetic	890	898	O
stimulation	899	910	O
.	910	911	O

Averaged	912	920	O
across	921	927	O
all	928	931	O
forces	932	938	O
,	938	939	O
there	940	945	O
was	946	949	O
more	950	954	O
task	955	959	O
-	959	960	O
related	960	967	O
activation	968	978	O
compared	979	987	O
with	988	992	O
rest	993	997	O
in	998	1000	O
the	1001	1004	O
secondary	1005	1014	O
motor	1015	1020	O
areas	1021	1026	O
of	1027	1029	O
patients	1030	1038	O
with	1039	1043	O
greater	1044	1051	O
corticospinal	1052	1065	B-Anatomical_system
system	1066	1072	I-Anatomical_system
damage	1073	1079	O
,	1079	1080	O
confirming	1081	1091	O
previous	1092	1100	O
reports	1101	1108	O
.	1108	1109	O

However	1110	1117	O
,	1117	1118	O
here	1119	1123	O
we	1124	1126	O
were	1127	1131	O
primarily	1132	1141	O
interested	1142	1152	O
in	1153	1155	O
regional	1156	1164	O
brain	1165	1170	B-Organ
activation	1171	1181	O
,	1181	1182	O
which	1183	1188	O
covaried	1189	1197	O
with	1198	1202	O
the	1203	1206	O
amount	1207	1213	O
of	1214	1216	O
force	1217	1222	O
generated	1223	1232	O
,	1232	1233	O
implying	1234	1242	O
a	1243	1244	O
prominent	1245	1254	O
executive	1255	1264	O
role	1265	1269	O
in	1270	1272	O
force	1273	1278	O
production	1279	1289	O
.	1289	1290	O

We	1291	1293	O
found	1294	1299	O
that	1300	1304	O
in	1305	1307	O
control	1308	1315	O
subjects	1316	1324	O
and	1325	1328	O
patients	1329	1337	O
with	1338	1342	O
lesser	1343	1349	O
corticospinal	1350	1363	B-Anatomical_system
system	1364	1370	I-Anatomical_system
damage	1371	1377	O
,	1377	1378	O
signal	1379	1385	O
change	1386	1392	O
increased	1393	1402	O
linearly	1403	1411	O
with	1412	1416	O
increasing	1417	1427	O
force	1428	1433	O
output	1434	1440	O
in	1441	1443	O
contralateral	1444	1457	O
primary	1458	1465	O
motor	1466	1471	B-Multi-tissue_structure
cortex	1472	1478	I-Multi-tissue_structure
,	1478	1479	O
supplementary	1480	1493	O
motor	1494	1499	O
area	1500	1504	O
and	1505	1508	O
ipsilateral	1509	1520	O
cerebellum	1521	1531	B-Multi-tissue_structure
.	1531	1532	O

In	1533	1535	O
contrast	1536	1544	O
,	1544	1545	O
in	1546	1548	O
patients	1549	1557	O
with	1558	1562	O
greater	1563	1570	O
corticospinal	1571	1584	B-Anatomical_system
system	1585	1591	I-Anatomical_system
damage	1592	1598	O
,	1598	1599	O
force	1600	1605	O
-	1605	1606	O
related	1606	1613	O
signal	1614	1620	O
changes	1621	1628	O
were	1629	1633	O
seen	1634	1638	O
mainly	1639	1645	O
in	1646	1648	O
contralesional	1649	1663	B-Multi-tissue_structure
dorsolateral	1664	1676	I-Multi-tissue_structure
premotor	1677	1685	I-Multi-tissue_structure
cortex	1686	1692	I-Multi-tissue_structure
,	1692	1693	O
bilateral	1694	1703	B-Multi-tissue_structure
ventrolateral	1704	1717	I-Multi-tissue_structure
premotor	1718	1726	I-Multi-tissue_structure
cortices	1727	1735	I-Multi-tissue_structure
and	1736	1739	O
contralesional	1740	1754	B-Multi-tissue_structure
cerebellum	1755	1765	I-Multi-tissue_structure
,	1765	1766	O
but	1767	1770	O
not	1771	1774	O
ipsilesional	1775	1787	B-Multi-tissue_structure
primary	1788	1795	I-Multi-tissue_structure
motor	1796	1801	I-Multi-tissue_structure
cortex	1802	1808	I-Multi-tissue_structure
.	1808	1809	O

These	1810	1815	O
findings	1816	1824	O
suggest	1825	1832	O
that	1833	1837	O
the	1838	1841	O
premotor	1842	1850	B-Multi-tissue_structure
cortices	1851	1859	I-Multi-tissue_structure
might	1860	1865	O
play	1866	1870	O
a	1871	1872	O
new	1873	1876	O
and	1877	1880	O
functionally	1881	1893	O
relevant	1894	1902	O
role	1903	1907	O
in	1908	1910	O
controlling	1911	1922	O
force	1923	1928	O
production	1929	1939	O
in	1940	1942	O
patients	1943	1951	O
with	1952	1956	O
more	1957	1961	O
severe	1962	1968	O
corticospinal	1969	1982	B-Anatomical_system
system	1983	1989	I-Anatomical_system
disruption	1990	2000	O
.	2000	2001	O

Characterization	0	16	O
of	17	19	O
transferrin	20	31	O
glycoforms	32	42	O
in	43	45	O
human	46	51	O
serum	52	57	B-Organism_substance
by	58	60	O
CE	61	63	O
-	63	64	O
UV	64	66	O
and	67	70	O
CE	71	73	O
-	73	74	O
ESI	74	77	O
-	77	78	O
MS	78	80	O
.	80	81	O

Human	82	87	O
transferrin	88	99	O
(	100	101	O
Tf	101	103	O
)	103	104	O
is	105	107	O
a	108	109	O
model	110	115	O
glycoprotein	116	128	O
for	129	132	O
congenital	133	143	O
disorders	144	153	O
of	154	156	O
glycosylation	157	170	O
(	171	172	O
CDG	172	175	O
)	175	176	O
diagnosis	177	186	O
.	186	187	O

In	188	190	O
the	191	194	O
last	195	199	O
few	200	203	O
years	204	209	O
,	209	210	O
new	211	214	O
CE	215	217	O
-	217	218	O
UV	218	220	O
methods	221	228	O
for	229	232	O
intact	233	239	O
Tf	240	242	O
glycoforms	243	253	O
analysis	254	262	O
have	263	267	O
been	268	272	O
developed	273	282	O
using	283	288	O
nonvolatile	289	300	O
BGEs	301	305	O
and	306	309	O
organic	310	317	O
modifiers	318	327	O
.	327	328	O

However	329	336	O
,	336	337	O
the	338	341	O
use	342	345	O
of	346	348	O
these	349	354	O
BGEs	355	359	O
does	360	364	O
not	365	368	O
allow	369	374	O
the	375	378	O
coupling	379	387	O
of	388	390	O
these	391	396	O
procedures	397	407	O
with	408	412	O
electrospray	413	425	O
MS	426	428	O
(	429	430	O
ESI	430	433	O
-	433	434	O
MS	434	436	O
)	436	437	O
.	437	438	O

In	439	441	O
this	442	446	O
study	447	452	O
,	452	453	O
a	454	455	O
new	456	459	O
CE	460	462	O
-	462	463	O
UV	463	465	O
separation	466	476	O
method	477	483	O
of	484	486	O
Tf	487	489	O
glycoforms	490	500	O
is	501	503	O
developed	504	513	O
,	513	514	O
using	515	520	O
a	521	522	O
double	523	529	O
-	529	530	O
layer	530	535	O
stable	536	542	O
coating	543	550	O
and	551	554	O
a	555	556	O
volatile	557	565	O
BGE	566	569	O
based	570	575	O
on	576	578	O
ammonium	579	587	O
acetate	588	595	O
.	595	596	O

The	597	600	O
separation	601	611	O
method	612	618	O
is	619	621	O
optimized	622	631	O
using	632	637	O
standard	638	646	O
Tf	647	649	O
and	650	653	O
their	654	659	O
potential	660	669	O
is	670	672	O
demonstrated	673	685	O
applying	686	694	O
the	695	698	O
method	699	705	O
to	706	708	O
the	709	712	O
analysis	713	721	O
of	722	724	O
sera	725	729	B-Organism_substance
Tf	730	732	O
from	733	737	O
healthy	738	745	O
individuals	746	757	O
and	758	761	O
CDG	762	765	O
patients	766	774	O
.	774	775	O

The	776	779	O
CE	780	782	O
-	782	783	O
UV	783	785	O
separation	786	796	O
method	797	803	O
has	804	807	O
been	808	812	O
coupled	813	820	O
to	821	823	O
ESI	824	827	O
-	827	828	O
MS	828	830	O
detection	831	840	O
.	840	841	O

Main	842	846	O
parameters	847	857	O
such	858	862	O
as	863	865	O
sheath	866	872	O
liquid	873	879	O
composition	880	891	O
are	892	895	O
optimized	896	905	O
in	906	908	O
order	909	914	O
to	915	917	O
obtain	918	924	O
a	925	926	O
good	927	931	O
sensitivity	932	943	O
.	943	944	O

The	945	948	O
CE	949	951	O
-	951	952	O
ESI	952	955	O
-	955	956	O
MS	956	958	O
method	959	965	O
has	966	969	O
also	970	974	O
been	975	979	O
used	980	984	O
in	985	987	O
serum	988	993	B-Organism_substance
samples	994	1001	I-Organism_substance
obtaining	1002	1011	O
the	1012	1015	O
separation	1016	1026	O
of	1027	1029	O
the	1030	1033	O
different	1034	1043	O
proteins	1044	1052	O
present	1053	1060	O
in	1061	1063	O
serum	1064	1069	B-Organism_substance
and	1070	1073	O
partial	1074	1081	O
separation	1082	1092	O
of	1093	1095	O
Tf	1096	1098	O
glycoforms	1099	1109	O
.	1109	1110	O

Different	1111	1120	O
mass	1121	1125	O
spectra	1126	1133	O
and	1134	1137	O
deconvoluted	1138	1150	O
molecular	1151	1160	O
masses	1161	1167	O
were	1168	1172	O
obtained	1173	1181	O
for	1182	1185	O
each	1186	1190	O
sialoform	1191	1200	O
,	1200	1201	O
allowing	1202	1210	O
unequivocal	1211	1222	O
glycoform	1223	1232	O
identification	1233	1247	O
.	1247	1248	O

Selective	0	9	O
activation	10	20	O
of	21	23	O
mast	24	28	B-Cell
cells	29	34	I-Cell
in	35	37	O
rheumatoid	38	48	B-Tissue
synovial	49	57	I-Tissue
tissue	58	64	I-Tissue
results	65	72	O
in	73	75	O
production	76	86	O
of	87	89	O
TNF	90	93	O
-	93	94	O
alpha	94	99	O
,	99	100	O
IL	101	103	O
-	103	104	O
1beta	104	109	O
and	110	113	O
IL	114	116	O
-	116	117	O
1Ra	117	120	O
.	120	121	O

OBJECTIVES	122	132	O
AND	133	136	O
DESIGN	137	143	O
:	143	144	O

To	145	147	O
study	148	153	O
the	154	157	O
consequences	158	170	O
of	171	173	O
mast	174	178	B-Cell
cell	179	183	I-Cell
activation	184	194	O
in	195	197	O
human	198	203	O
synovial	204	212	B-Tissue
tissue	213	219	I-Tissue
.	219	220	O

METHODS	221	228	O
:	228	229	O

Synovial	230	238	B-Tissue
tissue	239	245	I-Tissue
was	246	249	O
obtained	250	258	O
from	259	263	O
18	264	266	O
RA	267	269	O
patients	270	278	O
and	279	282	O
mast	283	287	B-Cell
cells	288	293	I-Cell
was	294	297	O
selectively	298	309	O
activated	310	319	O
in	320	322	O
synovial	323	331	B-Tissue
tissue	332	338	I-Tissue
explant	339	346	O
cultures	347	355	O
.	355	356	O

Expression	357	367	O
of	368	370	O
TNF	371	374	O
-	374	375	O
alpha	375	380	O
,	380	381	O
IL	382	384	O
-	384	385	O
1beta	385	390	O
and	391	394	O
IL	395	397	O
-	397	398	O
1Ra	398	401	O
were	402	406	O
determined	407	417	O
and	418	421	O
tissue	422	428	B-Tissue
distribution	429	441	O
of	442	444	O
IL	445	447	O
-	447	448	O
1beta	448	453	O
was	454	457	O
studied	458	465	O
.	465	466	O

RESULTS	467	474	O
:	474	475	O

Compared	476	484	O
to	485	487	O
untreated	488	497	O
synovia	498	505	B-Tissue
,	505	506	O
selective	507	516	O
activation	517	527	O
of	528	530	O
synovial	531	539	B-Cell
mast	540	544	I-Cell
cells	545	550	I-Cell
increased	551	560	O
significantly	561	574	O
the	575	578	O
production	579	589	O
of	590	592	O
TNF	593	596	O
-	596	597	O
alpha	597	602	O
(	603	604	O
0	604	605	O
.	605	606	O
49	606	608	O
+	609	610	O
/	610	611	O
-	611	612	O
0	613	614	O
.	614	615	O
88	615	617	O
vs	618	620	O
.	620	621	O
4	622	623	O
.	623	624	O
56	624	626	O
+	627	628	O
/	628	629	O
-	629	630	O
3	631	632	O
.	632	633	O
18	633	635	O
pg	636	638	O
/	638	639	O
mg	639	641	O
wet	642	645	O
tissue	646	652	O
,	652	653	O
p	654	655	O
<	656	657	O
0	658	659	O
.	659	660	O
001	660	663	O
)	663	664	O
and	665	668	O
IL	669	671	O
-	671	672	O
1beta	672	677	O
(	678	679	O
0	679	680	O
.	680	681	O
058	681	684	O
+	685	686	O
/	686	687	O
-	687	688	O
0	689	690	O
.	690	691	O
032	691	694	O
vs	695	697	O
.	697	698	O
2	699	700	O
.	700	701	O
55	701	703	O
+	704	705	O
/	705	706	O
-	706	707	O
1	708	709	O
.	709	710	O
98	710	712	O
pg	713	715	O
/	715	716	O
mg	716	718	O
wet	719	722	O
tissue	723	729	O
,	729	730	O
p	731	732	O
=	733	734	O
0	735	736	O
.	736	737	O
013	737	740	O
)	740	741	O
.	741	742	O

The	743	746	O
expression	747	757	O
of	758	760	O
TNF	761	764	O
-	764	765	O
alpha	765	770	O
and	771	774	O
IL	775	777	O
-	777	778	O
1beta	778	783	O
mRNA	784	788	O
increased	789	798	O
significantly	799	812	O
(	813	814	O
19	814	816	O
-	816	817	O
fold	817	821	O
(	822	823	O
p	823	824	O
=	825	826	O
0	827	828	O
.	828	829	O
009	829	832	O
)	832	833	O
and	834	837	O
13	838	840	O
-	840	841	O
fold	841	845	O
(	846	847	O
p	847	848	O
=	849	850	O
0	851	852	O
.	852	853	O
031	853	856	O
)	856	857	O
,	857	858	O
respectively	859	871	O
)	871	872	O
.	872	873	O

Mast	874	878	B-Cell
cell	879	883	I-Cell
activation	884	894	O
induced	895	902	O
IL	903	905	O
-	905	906	O
1beta	906	911	O
expression	912	922	O
in	923	925	O
particular	926	936	O
in	937	939	O
nearby	940	946	O
CD68	947	951	B-Cell
positive	952	960	I-Cell
synovial	961	969	I-Cell
macrophages	970	981	I-Cell
.	981	982	O

Secretion	983	992	O
of	993	995	O
IL	996	998	O
-	998	999	O
1Ra	999	1002	O
was	1003	1006	O
also	1007	1011	O
increased	1012	1021	O
but	1022	1025	O
to	1026	1028	O
a	1029	1030	O
lesser	1031	1037	O
degree	1038	1044	O
than	1045	1049	O
that	1050	1054	O
of	1055	1057	O
IL	1058	1060	O
-	1060	1061	O
1beta	1061	1066	O
.	1066	1067	O

CONCLUSIONS	1068	1079	O
:	1079	1080	O

Synovial	1081	1089	B-Cell
mast	1090	1094	I-Cell
cells	1095	1100	I-Cell
produce	1101	1108	O
proinflammmatory	1109	1125	O
cytokines	1126	1135	O
and	1136	1139	O
may	1140	1143	O
thus	1144	1148	O
contribute	1149	1159	O
to	1160	1162	O
the	1163	1166	O
inflammation	1167	1179	O
in	1180	1182	O
RA	1183	1185	O
.	1185	1186	O

Rapid	0	5	O
mixing	6	12	O
between	13	20	O
old	21	24	O
and	25	28	O
new	29	32	O
C	33	34	O
pools	35	40	O
in	41	43	O
the	44	47	O
canopy	48	54	O
of	55	57	O
mature	58	64	O
forest	65	71	O
trees	72	77	O
.	77	78	O

Stable	79	85	O
C	86	87	O
isotope	88	95	O
signals	96	103	O
in	104	106	O
plant	107	112	O
tissues	113	120	B-Tissue
became	121	127	O
a	128	129	O
key	130	133	O
tool	134	138	O
in	139	141	O
explaining	142	152	O
growth	153	159	O
responses	160	169	O
to	170	172	O
the	173	176	O
environment	177	188	O
.	188	189	O

The	190	193	O
technique	194	203	O
is	204	206	O
based	207	212	O
on	213	215	O
the	216	219	O
fundamental	220	231	O
assumption	232	242	O
that	243	247	O
the	248	251	O
isotopic	252	260	O
composition	261	272	O
of	273	275	O
a	276	277	O
given	278	283	O
unit	284	288	O
of	289	291	O
tissue	292	298	B-Tissue
(	299	300	O
e	300	301	O
.	301	302	O
g	302	303	O
.	303	304	O
a	305	306	O
tree	307	311	B-Tissue
ring	312	316	I-Tissue
)	316	317	O
reflects	318	326	O
the	327	330	O
specific	331	339	O
C	340	341	O
uptake	342	348	O
conditions	349	359	O
in	360	362	O
the	363	366	O
leaf	367	371	B-Organ
at	372	374	O
a	375	376	O
given	377	382	O
time	383	387	O
.	387	388	O

Beyond	389	395	O
the	396	399	O
methodological	400	414	O
implications	415	427	O
of	428	430	O
any	431	434	O
deviation	435	444	O
from	445	449	O
this	450	454	O
assumption	455	465	O
,	465	466	O
it	467	469	O
is	470	472	O
of	473	475	O
physiological	476	489	O
interest	490	498	O
whether	499	506	O
new	507	510	O
C	511	512	O
is	513	515	O
transferred	516	527	O
directly	528	536	O
from	537	541	O
sources	542	549	O
(	550	551	O
a	551	552	O
photosynthesizing	553	570	O
leaf	571	575	B-Organ
)	575	576	O
to	577	579	O
structural	580	590	O
sinks	591	596	O
(	597	598	O
e	598	599	O
.	599	600	O
g	600	601	O
.	601	602	O
adjacent	603	611	O
stem	612	616	B-Tissue
tissue	617	623	I-Tissue
)	623	624	O
,	624	625	O
or	626	628	O
inherently	629	639	O
passes	640	646	O
through	647	654	O
existing	655	663	O
(	664	665	O
mobile	665	671	O
)	671	672	O
C	673	674	O
pools	675	680	O
,	680	681	O
which	682	687	O
may	688	691	O
be	692	694	O
of	695	697	O
variable	698	706	O
(	707	708	O
older	708	713	O
)	713	714	O
age	715	718	O
.	718	719	O

Here	720	724	O
,	724	725	O
we	726	728	O
explore	729	736	O
the	737	740	O
fate	741	745	O
of	746	748	O
(	749	750	O
13	750	752	O
)	752	753	O
C	753	754	O
-	754	755	O
labelled	755	763	O
photosynthates	764	778	O
in	779	781	O
the	782	785	O
crowns	786	792	B-Organism_subdivision
of	793	795	O
a	796	797	O
30	798	800	O
-	800	801	O
35	801	803	O
m	804	805	O
tall	806	810	O
,	810	811	O
mixed	812	817	O
forest	818	824	O
using	825	830	O
a	831	832	O
canopy	833	839	O
crane	840	845	O
.	845	846	O

In	847	849	O
all	850	853	O
nine	854	858	O
study	859	864	O
species	865	872	O
labelled	873	881	O
C	882	883	O
reached	884	891	O
woody	892	897	B-Tissue
tissue	898	904	I-Tissue
within	905	911	O
2	912	913	O
-	913	914	O
9	914	915	O
h	916	917	O
after	918	923	O
labelling	924	933	O
.	933	934	O

Four	935	939	O
months	940	946	O
later	947	952	O
,	952	953	O
very	954	958	O
small	959	964	O
signals	965	972	O
were	973	977	O
left	978	982	O
in	983	985	O
branch	986	992	O
wood	993	997	O
of	998	1000	O
Tilia	1001	1006	O
suggesting	1007	1017	O
that	1018	1022	O
low	1023	1026	O
mixing	1027	1033	O
of	1034	1036	O
new	1037	1040	O
,	1040	1041	O
labelled	1042	1050	O
C	1051	1052	O
with	1053	1057	O
old	1058	1061	O
C	1062	1063	O
had	1064	1067	O
taken	1068	1073	O
place	1074	1079	O
.	1079	1080	O

In	1081	1083	O
contrast	1084	1092	O
,	1092	1093	O
signals	1094	1101	O
in	1102	1104	O
Fagus	1105	1110	O
and	1111	1114	O
Quercus	1115	1122	O
had	1123	1126	O
increased	1127	1136	O
,	1136	1137	O
indicating	1138	1148	O
more	1149	1153	O
intense	1154	1161	O
mixing	1162	1168	O
.	1168	1169	O

This	1170	1174	O
species	1175	1182	O
-	1182	1183	O
specific	1183	1191	O
mixing	1192	1198	O
of	1199	1201	O
new	1202	1205	O
with	1206	1210	O
old	1211	1214	O
C	1215	1216	O
pools	1217	1222	O
is	1223	1225	O
likely	1226	1232	O
to	1233	1235	O
mask	1236	1240	O
year	1241	1245	O
-	1245	1246	O
or	1247	1249	O
season	1250	1256	O
-	1256	1257	O
specific	1257	1265	O
linkages	1266	1274	O
between	1275	1282	O
tree	1283	1287	B-Tissue
ring	1288	1292	I-Tissue
formation	1293	1302	O
and	1303	1306	O
climate	1307	1314	O
and	1315	1318	O
has	1319	1322	O
considerable	1323	1335	O
implications	1336	1348	O
for	1349	1352	O
climate	1353	1360	O
reconstruction	1361	1375	O
using	1376	1381	O
stable	1382	1388	O
isotopes	1389	1397	O
as	1398	1400	O
proxies	1401	1408	O
for	1409	1412	O
past	1413	1417	O
climatic	1418	1426	O
conditions	1427	1437	O
.	1437	1438	O

M	0	1	O
.	1	2	O
leprae	3	9	O
-	9	10	O
and	11	14	O
BCG	15	18	O
-	18	19	O
induced	19	26	O
chemiluminescence	27	44	O
response	45	53	O
of	54	56	O
monocytes	57	66	B-Cell
from	67	71	O
leprosy	72	79	O
patients	80	88	O
and	89	92	O
healthy	93	100	O
subjects	101	109	O
:	109	110	O
effects	111	118	O
of	119	121	O
gamma	122	127	O
-	127	128	O
interferon	128	138	O
and	139	142	O
GM	143	145	O
-	145	146	O
CSF	146	149	O
.	149	150	O

Mycobacterium	151	164	O
leprae	165	171	O
,	171	172	O
in	173	175	O
contrast	176	184	O
to	185	187	O
BCG	188	191	O
,	191	192	O
failed	193	199	O
to	200	202	O
trigger	203	210	O
any	211	214	O
chemiluminescence	215	232	O
(	233	234	O
CL	234	236	O
)	236	237	O
response	238	246	O
in	247	249	O
mononuclear	250	261	B-Cell
cells	262	267	I-Cell
from	268	272	O
either	273	279	O
leprosy	280	287	O
patients	288	296	O
or	297	299	O
healthy	300	307	O
subjects	308	316	O
,	316	317	O
a	318	319	O
deficit	320	327	O
not	328	331	O
reversed	332	340	O
by	341	343	O
either	344	350	O
interferon	351	361	O
-	361	362	O
gamma	362	367	O
or	368	370	O
GM	371	373	O
-	373	374	O
CSF	374	377	O
.	377	378	O

Chemiluminescence	379	396	O
responses	397	406	O
induced	407	414	O
without	415	422	O
mycobacteria	423	435	O
or	436	438	O
with	439	443	O
BCG	444	447	O
were	448	452	O
found	453	458	O
to	459	461	O
be	462	464	O
lower	465	470	O
in	471	473	O
leprosy	474	481	O
patients	482	490	O
than	491	495	O
in	496	498	O
controls	499	507	O
.	507	508	O

M	509	510	O
.	510	511	O
leprae	512	518	O
were	519	523	O
also	524	528	O
less	529	533	O
well	534	538	O
phagocytosed	539	551	O
than	552	556	O
BCG	557	560	O
.	560	561	O

However	562	569	O
,	569	570	O
there	571	576	O
was	577	580	O
a	581	582	O
significant	583	594	O
difference	595	605	O
in	606	608	O
phagocytosis	609	621	O
between	622	629	O
healthy	630	637	O
and	638	641	O
tuberculoid	642	653	O
leprosy	654	661	O
subjects	662	670	O
.	670	671	O

Phagocytosis	672	684	O
was	685	688	O
not	689	692	O
altered	693	700	O
by	701	703	O
the	704	707	O
addition	708	716	O
of	717	719	O
either	720	726	O
lymphokine	727	737	O
,	737	738	O
and	739	742	O
no	743	745	O
major	746	751	O
differences	752	763	O
between	764	771	O
healthy	772	779	O
subjects	780	788	O
and	789	792	O
patients	793	801	O
were	802	806	O
observed	807	815	O
.	815	816	O

Preincubating	817	830	O
mononuclear	831	842	B-Cell
cells	843	848	I-Cell
with	849	853	O
anti	854	858	O
-	858	859	O
mycobacteria	859	871	O
antibodies	872	882	O
(	883	884	O
lepromatous	884	895	O
patients	896	904	O
'	904	905	O
sera	906	910	B-Organism_substance
)	910	911	O
did	912	915	O
not	916	919	O
increase	920	928	O
the	929	932	O
CL	933	935	O
response	936	944	O
nor	945	948	O
the	949	952	O
phagocytosis	953	965	O
of	966	968	O
M	969	970	O
.	970	971	O
leprae	972	978	O
or	979	981	O
BCG	982	985	O
.	985	986	O

A	0	1	O
practical	2	11	O
interface	12	21	O
for	22	25	O
microfluidics	26	39	O
and	40	43	O
nanoelectrospray	44	60	O
mass	61	65	O
spectrometry	66	78	O
.	78	79	O

We	80	82	O
report	83	89	O
a	90	91	O
new	92	95	O
method	96	102	O
for	103	106	O
fabricating	107	118	O
nanospray	119	128	O
ionization	129	139	O
tips	140	144	O
for	145	148	O
MS	149	151	O
,	151	152	O
formed	153	159	O
from	160	164	O
glass	165	170	O
substrates	171	181	O
and	182	185	O
the	186	189	O
inert	190	195	O
polymer	196	203	O
,	203	204	O
parylene	205	213	O
-	213	214	O
C	214	215	O
.	215	216	O

Using	217	222	O
a	223	224	O
single	225	231	O
photolithography	232	248	O
step	249	253	O
,	253	254	O
the	255	258	O
emitters	259	267	O
are	268	271	O
formed	272	278	O
contiguously	279	291	O
with	292	296	O
microchannels	297	310	O
,	310	311	O
such	312	316	O
that	317	321	O
no	322	324	O
dead	325	329	O
volumes	330	337	O
are	338	341	O
observed	342	350	O
.	350	351	O

In	352	354	O
addition	355	363	O
,	363	364	O
because	365	372	O
the	373	376	O
devices	377	384	O
are	385	388	O
very	389	393	O
thin	394	398	O
(	399	400	O
approximately	400	413	O
0	414	415	O
.	415	416	O
3	416	417	O
mm	418	420	O
)	420	421	O
and	422	425	O
the	426	429	O
tips	430	434	O
are	435	438	O
formed	439	445	O
at	446	448	O
rectangular	449	460	O
corners	461	468	O
,	468	469	O
the	470	473	O
Taylor	474	480	O
cone	481	485	O
volumes	486	493	O
are	494	497	O
small	498	503	O
,	503	504	O
which	505	510	O
makes	511	516	O
the	517	520	O
method	521	527	O
attractive	528	538	O
for	539	542	O
future	543	549	O
integration	550	561	O
with	562	566	O
microfluidic	567	579	O
separations	580	591	O
.	591	592	O

Device	593	599	O
performance	600	611	O
was	612	615	O
demonstrated	616	628	O
by	629	631	O
evaluating	632	642	O
diverse	643	650	O
analytes	651	659	O
,	659	660	O
ranging	661	668	O
from	669	673	O
synthetic	674	683	O
polymers	684	692	O
,	692	693	O
to	694	696	O
peptides	697	705	O
,	705	706	O
to	707	709	O
nucleic	710	717	O
acids	718	723	O
.	723	724	O

For	725	728	O
all	729	732	O
analytes	733	741	O
,	741	742	O
performance	743	754	O
was	755	758	O
similar	759	766	O
to	767	769	O
that	770	774	O
of	775	777	O
conventional	778	790	O
emitters	791	799	O
(	800	801	O
pulled	801	807	O
-	807	808	O
glass	808	813	O
capillaries	814	825	O
and	826	829	O
the	830	833	O
Agilent	834	841	O
HPLC	842	846	O
Chip	847	851	O
)	851	852	O
with	853	857	O
the	858	861	O
advantage	862	871	O
of	872	874	O
rapid	875	880	O
,	880	881	O
batch	882	887	O
fabrication	888	899	O
of	900	902	O
identical	903	912	O
devices	913	920	O
.	920	921	O

Intraoperative	0	14	O
handling	15	23	O
and	24	27	O
wound	28	33	B-Pathological_formation
healing	34	41	O
of	42	44	O
arthroscopic	45	57	O
portal	58	64	O
wounds	65	71	B-Pathological_formation
:	71	72	O
a	73	74	O
clinical	75	83	O
study	84	89	O
comparing	90	99	O
nylon	100	105	O
suture	106	112	O
with	113	117	O
wound	118	123	B-Pathological_formation
closure	124	131	O
strips	132	138	O
.	138	139	O

This	140	144	O
prospective	145	156	O
,	156	157	O
single	158	164	O
-	164	165	O
centre	165	171	O
study	172	177	O
compared	178	186	O
wound	187	192	B-Pathological_formation
closure	193	200	O
methods	201	208	O
in	209	211	O
patients	212	220	O
undergoing	221	231	O
arthroscopy	232	243	O
.	243	244	O

Closure	245	252	O
of	253	255	O
arthroscopic	256	268	O
portal	269	275	O
wounds	276	282	B-Pathological_formation
with	283	287	O
sterile	288	295	O
adhesive	296	304	O
strips	305	311	O
is	312	314	O
effective	315	324	O
and	325	328	O
convenient	329	339	O
for	340	343	O
wound	344	349	B-Pathological_formation
management	350	360	O
.	360	361	O

The	362	365	O
method	366	372	O
was	373	376	O
associated	377	387	O
with	388	392	O
a	393	394	O
reduced	395	402	O
potential	403	412	O
for	413	416	O
infection	417	426	O
,	426	427	O
faster	428	434	O
renewal	435	442	O
of	443	445	O
tensile	446	453	O
strength	454	462	O
,	462	463	O
greater	464	471	O
cost	472	476	O
effectiveness	477	490	O
,	490	491	O
and	492	495	O
better	496	502	O
cosmetic	503	511	O
effects	512	519	O
comparing	520	529	O
with	530	534	O
suture	535	541	O
closure	542	549	O
.	549	550	O

This	551	555	O
method	556	562	O
of	563	565	O
wound	566	571	B-Pathological_formation
closure	572	579	O
may	580	583	O
also	584	588	O
reduce	589	595	O
the	596	599	O
incidence	600	609	O
of	610	612	O
needle	613	619	O
stick	620	625	O
injury	626	632	O
in	633	635	O
the	636	639	O
theatre	640	647	O
environment	648	659	O
.	659	660	O

Thereby	661	668	O
the	669	672	O
incidence	673	682	O
of	683	685	O
percutaneous	686	698	O
exposure	699	707	O
following	708	717	O
a	718	719	O
surgical	720	728	O
procedure	729	738	O
may	739	742	O
not	743	746	O
facilitate	747	757	O
transmission	758	770	O
of	771	773	O
blood	774	779	B-Organism_substance
borne	780	785	O
pathogens	786	795	O
such	796	800	O
as	801	803	O
human	804	809	O
immunodeficiency	810	826	O
virus	827	832	O
(	833	834	O
HIV	834	837	O
)	837	838	O
,	838	839	O
hepatitis	840	849	O
C	850	851	O
virus	852	857	O
and	858	861	O
hepatitis	862	871	O
B	872	873	O
virus	874	879	O
.	879	880	O

As	881	883	O
a	884	885	O
result	886	892	O
it	893	895	O
may	896	899	O
reduce	900	906	O
litigation	907	917	O
in	918	920	O
today	921	926	O
'	926	927	O
s	927	928	O
changing	929	937	O
healthcare	938	948	O
climate	949	956	O
.	956	957	O

Investigation	0	13	O
of	14	16	O
the	17	20	O
effect	21	27	O
of	28	30	O
kaolin	31	37	O
and	38	41	O
tissue	42	48	B-Tissue
-	48	49	O
factor	49	55	O
-	55	56	O
activated	56	65	O
citrated	66	74	O
whole	75	80	B-Organism_substance
blood	81	86	I-Organism_substance
,	86	87	O
on	88	90	O
clot	91	95	B-Organism_substance
-	95	96	O
forming	96	103	O
variables	104	113	O
,	113	114	O
as	115	117	O
evaluated	118	127	O
by	128	130	O
thromboelastography	131	150	O
.	150	151	O

BACKGROUND	152	162	O
:	162	163	O

The	164	167	O
Thrombelastograph	168	185	O
(	186	187	O
TEG	187	190	O
;	190	191	O
Haemoscope	192	202	O
Corp	203	207	O
.	207	208	O
)	208	209	O
analyzes	210	218	O
clot	219	223	B-Organism_substance
formation	224	233	O
in	234	236	O
whole	237	242	B-Organism_substance
blood	243	248	I-Organism_substance
(	249	250	O
WB	250	252	B-Organism_substance
)	252	253	O
and	254	257	O
treatment	258	267	O
based	268	273	O
on	274	276	O
this	277	281	O
analysis	282	290	O
has	291	294	O
been	295	299	O
shown	300	305	O
to	306	308	O
reduce	309	315	O
transfusion	316	327	O
requirements	328	340	O
in	341	343	O
liver	344	349	B-Organ
and	350	353	O
cardiac	354	361	B-Organ
surgery	362	369	O
when	370	374	O
compared	375	383	O
to	384	386	O
conventional	387	399	O
coagulation	400	411	O
analysis	412	420	O
.	420	421	O

Implementing	422	434	O
TEG	435	438	O
as	439	441	O
a	442	443	O
routine	444	451	O
laboratory	452	462	O
-	462	463	O
based	463	468	O
analysis	469	477	O
,	477	478	O
however	479	486	O
,	486	487	O
requires	488	496	O
validation	497	507	O
of	508	510	O
the	511	514	O
activators	515	525	O
employed	526	534	O
and	535	538	O
the	539	542	O
effect	543	549	O
of	550	552	O
storage	553	560	O
of	561	563	O
the	564	567	O
WB	568	570	B-Organism_substance
sample	571	577	O
in	578	580	O
citrate	581	588	O
before	589	595	O
analysis	596	604	O
.	604	605	O

STUDY	606	611	O
DESIGN	612	618	O
AND	619	622	O
METHODS	623	630	O
:	630	631	O

The	632	635	O
effect	636	642	O
of	643	645	O
kaolin	646	652	O
,	652	653	O
tissue	654	660	B-Tissue
factor	661	667	O
(	668	669	O
TF	669	671	O
)	671	672	O
1	673	674	O
:	674	675	O
17	675	677	O
,	677	678	O
000	678	681	O
,	681	682	O
or	683	685	O
TF	686	688	O
1	689	690	O
:	690	691	O
42	691	693	O
,	693	694	O
500	694	697	O
on	698	700	O
TEG	701	704	O
clotting	705	713	O
time	714	718	O
(	719	720	O
R	720	721	O
)	721	722	O
,	722	723	O
Angle	724	729	O
(	730	731	O
velocity	731	739	O
of	740	742	O
clot	743	747	B-Organism_substance
formation	748	757	O
)	757	758	O
,	758	759	O
and	760	763	O
maximum	764	771	O
clot	772	776	B-Organism_substance
strength	777	785	O
(	786	787	O
amplitude	787	796	O
[	797	798	O
MA	798	800	O
]	800	801	O
)	801	802	O
were	803	807	O
evaluated	808	817	O
,	817	818	O
together	819	827	O
with	828	832	O
day	833	836	O
-	836	837	O
to	837	839	O
-	839	840	O
day	840	843	O
variation	844	853	O
,	853	854	O
the	855	858	O
coefficient	859	870	O
of	871	873	O
variance	874	882	O
(	883	884	O
CV	884	886	O
%	886	887	O
)	887	888	O
,	888	889	O
and	890	893	O
the	894	897	O
effect	898	904	O
of	905	907	O
citrate	908	915	O
storage	916	923	O
time	924	928	O
.	928	929	O

RESULTS	930	937	O
:	937	938	O

Clot	939	943	B-Organism_substance
formation	944	953	O
variables	954	963	O
were	964	968	O
equally	969	976	O
affected	977	985	O
by	986	988	O
TF	989	991	O
1	992	993	O
:	993	994	O
17	994	996	O
,	996	997	O
000	997	1000	O
and	1001	1004	O
kaolin	1005	1011	O
activation	1012	1022	O
,	1022	1023	O
whereas	1024	1031	O
R	1032	1033	O
was	1034	1037	O
significantly	1038	1051	O
longer	1052	1058	O
when	1059	1063	O
TF	1064	1066	O
1	1067	1068	O
:	1068	1069	O
42	1069	1071	O
,	1071	1072	O
500	1072	1075	O
was	1076	1079	O
used	1080	1084	O
.	1084	1085	O

The	1086	1089	O
CV	1090	1092	O
for	1093	1096	O
the	1097	1100	O
different	1101	1110	O
variables	1111	1120	O
varied	1121	1127	O
from	1128	1132	O
3	1133	1134	O
to	1135	1137	O
13	1138	1140	O
percent	1141	1148	O
with	1149	1153	O
no	1154	1156	O
significant	1157	1168	O
differences	1169	1180	O
between	1181	1188	O
assays	1189	1195	O
.	1195	1196	O

Storage	1197	1204	O
of	1205	1207	O
citrated	1208	1216	O
WB	1217	1219	B-Organism_substance
significantly	1220	1233	O
affected	1234	1242	O
the	1243	1246	O
TEG	1247	1250	O
variables	1251	1260	O
in	1261	1263	O
a	1264	1265	O
hypercoagulable	1266	1281	O
direction	1282	1291	O
.	1291	1292	O

Only	1293	1297	O
the	1298	1301	O
R	1302	1303	O
,	1303	1304	O
however	1305	1312	O
,	1312	1313	O
was	1314	1317	O
significantly	1318	1331	O
affected	1332	1340	O
(	1341	1342	O
12	1342	1344	O
%	1344	1345	O
)	1345	1346	O
when	1347	1351	O
samples	1352	1359	O
rested	1360	1366	O
for	1367	1370	O
0	1371	1372	O
and	1373	1376	O
30	1377	1379	O
minutes	1380	1387	O
were	1388	1392	O
evaluated	1393	1402	O
with	1403	1407	O
kaolin	1408	1414	O
as	1415	1417	O
the	1418	1421	O
activator	1422	1431	O
.	1431	1432	O

CONCLUSION	1433	1443	O
:	1443	1444	O

The	1445	1448	O
TEG	1449	1452	O
assays	1453	1459	O
evaluated	1460	1469	O
were	1470	1474	O
reproducible	1475	1487	O
and	1488	1491	O
present	1492	1499	O
with	1500	1504	O
an	1505	1507	O
acceptable	1508	1518	O
CV	1519	1521	O
%	1521	1522	O
for	1523	1526	O
routine	1527	1534	O
clinical	1535	1543	O
practice	1544	1552	O
.	1552	1553	O

Kaolin	1554	1560	O
and	1561	1564	O
TF	1565	1567	O
1	1568	1569	O
:	1569	1570	O
17	1570	1572	O
,	1572	1573	O
000	1573	1576	O
equally	1577	1584	O
affected	1585	1593	O
the	1594	1597	O
clot	1598	1602	B-Organism_substance
formation	1603	1612	O
variables	1613	1622	O
.	1622	1623	O

Storage	1624	1631	O
of	1632	1634	O
WB	1635	1637	B-Organism_substance
for	1638	1641	O
up	1642	1644	O
to	1645	1647	O
30	1648	1650	O
minutes	1651	1658	O
in	1659	1661	O
citrate	1662	1669	O
did	1670	1673	O
not	1674	1677	O
,	1677	1678	O
except	1679	1685	O
for	1686	1689	O
R	1690	1691	O
,	1691	1692	O
affect	1693	1699	O
clot	1700	1704	B-Organism_substance
formation	1705	1714	O
variables	1715	1724	O
when	1725	1729	O
kaolin	1730	1736	O
was	1737	1740	O
used	1741	1745	O
as	1746	1748	O
activator	1749	1758	O
allowing	1759	1767	O
for	1768	1771	O
immediate	1772	1781	O
analysis	1782	1790	O
when	1791	1795	O
the	1796	1799	O
sample	1800	1806	O
arrives	1807	1814	O
in	1815	1817	O
the	1818	1821	O
laboratory	1822	1832	O
.	1832	1833	O

[	0	1	O
TESE	1	5	O
and	6	9	O
mTESE	10	15	O
.	15	16	O
Therapeutic	17	28	O
options	29	36	O
in	37	39	O
male	40	44	O
infertility	45	56	O
due	57	60	O
to	61	63	O
testicular	64	74	B-Organ
azoospermia	75	86	O
]	86	87	O
.	87	88	O

Modern	89	95	O
techniques	96	106	O
of	107	109	O
testicular	110	120	B-Cell
sperm	121	126	I-Cell
extraction	127	137	O
(	138	139	O
TESE	139	143	O
)	143	144	O
make	145	149	O
it	150	152	O
possible	153	161	O
for	162	165	O
an	166	168	O
infertile	169	178	O
man	179	182	O
to	183	185	O
father	186	192	O
a	193	194	O
child	195	200	O
.	200	201	O

The	202	205	O
operations	206	216	O
are	217	220	O
standardized	221	233	O
to	234	236	O
a	237	238	O
large	239	244	O
extent	245	251	O
and	252	255	O
the	256	259	O
underlying	260	270	O
morphological	271	284	O
alterations	285	296	O
of	297	299	O
spermatogenesis	300	315	O
also	316	320	O
appear	321	327	O
to	328	330	O
be	331	333	O
sufficiently	334	346	O
known	347	352	O
.	352	353	O

Current	354	361	O
research	362	370	O
is	371	373	O
focused	374	381	O
on	382	384	O
prognostic	385	395	O
factors	396	403	O
for	404	407	O
the	408	411	O
testicular	412	422	B-Organ
material	423	431	O
that	432	436	O
determine	437	446	O
the	447	450	O
sperm	451	456	B-Cell
retrieval	457	466	O
rate	467	471	O
and	472	475	O
success	476	483	O
rates	484	489	O
after	490	495	O
in	496	498	O
vitro	499	504	O
fertilization	505	518	O
/	518	519	O
intracytoplasmic	519	535	O
sperm	536	541	B-Cell
injection	542	551	O
(	552	553	O
IVF	553	556	O
-	556	557	O
ICSI	557	561	O
)	561	562	O
.	562	563	O
TESE	563	567	O
and	568	571	O
microTESE	572	581	O
are	582	585	O
accepted	586	594	O
standard	595	603	O
operations	604	614	O
for	615	618	O
testicular	619	629	B-Cell
sperm	630	635	I-Cell
retrieval	636	645	O
for	646	649	O
IVF	650	653	O
/	653	654	O
ICSI	654	658	O
.	658	659	O

Predictions	660	671	O
for	672	675	O
effective	676	685	O
sperm	686	691	B-Cell
recovery	692	700	O
are	701	704	O
addressed	705	714	O
.	714	715	O

Quantitative	0	12	O
retention	13	22	O
-	22	23	O
biological	23	33	O
activity	34	42	O
relationship	43	55	O
study	56	61	O
by	62	64	O
micellar	65	73	O
liquid	74	80	O
chromatography	81	95	O
.	95	96	O

In	97	99	O
a	100	101	O
previous	102	110	O
paper	111	116	O
,	116	117	O
the	118	121	O
usefulness	122	132	O
of	133	135	O
micellar	136	144	O
liquid	145	151	O
chromatography	152	166	O
(	167	168	O
MLC	168	171	O
)	171	172	O
in	173	175	O
predicting	176	186	O
octanol	187	194	O
-	194	195	O
water	195	200	O
partition	201	210	O
coefficients	211	223	O
of	224	226	O
organic	227	234	O
compounds	235	244	O
was	245	248	O
reported	249	257	O
.	257	258	O

This	259	263	O
paper	264	269	O
is	270	272	O
the	273	276	O
first	277	282	O
successful	283	293	O
report	294	300	O
of	301	303	O
a	304	305	O
quantitative	306	318	O
retention	319	328	O
-	328	329	O
activity	329	337	O
relationship	338	350	O
study	351	356	O
using	357	362	O
the	363	366	O
retention	367	376	O
factor	377	383	O
in	384	386	O
MLC	387	390	O
for	391	394	O
predicting	395	405	O
the	406	409	O
biological	410	420	O
activity	421	429	O
of	430	432	O
a	433	434	O
group	435	440	O
of	441	443	O
phenolic	444	452	O
compounds	453	462	O
.	462	463	O

Excellent	464	473	O
correlation	474	485	O
was	486	489	O
obtained	490	498	O
between	499	506	O
the	507	510	O
capacity	511	519	O
factor	520	526	O
in	527	529	O
MLC	530	533	O
and	534	537	O
the	538	541	O
bioactivity	542	553	O
(	554	555	O
measured	555	563	O
as	564	566	O
log	567	570	O
1	571	572	O
/	572	573	O
C	573	574	O
,	574	575	O
where	576	581	O
C	582	583	O
is	584	586	O
the	587	590	O
50	591	593	O
%	593	594	O
inhibitory	595	605	O
growth	606	612	O
concentration	613	626	O
)	626	627	O
of	628	630	O
26	631	633	O
para	634	638	O
-	638	639	O
substituted	639	650	O
phenols	651	658	O
.	658	659	O

A	660	661	O
single	662	668	O
MLC	669	672	O
retention	673	682	O
parameter	683	692	O
is	693	695	O
capable	696	703	O
of	704	706	O
describing	707	717	O
the	718	721	O
bioactivity	722	733	O
of	734	736	O
phenols	737	744	O
,	744	745	O
while	746	751	O
three	752	757	O
conventional	758	770	O
molecular	771	780	O
descriptors	781	792	O
(	793	794	O
log	794	797	O
P	798	799	O
(	799	800	O
ow	800	802	O
)	802	803	O
,	803	804	O
pKa	805	808	O
,	808	809	O
and	810	813	O
R	814	815	O
)	815	816	O
are	817	820	O
needed	821	827	O
to	828	830	O
achieve	831	838	O
a	839	840	O
similar	841	848	O
correlation	849	860	O
.	860	861	O

This	862	866	O
indicates	867	876	O
that	877	881	O
both	882	886	O
hydrophobic	887	898	O
and	899	902	O
electronic	903	913	O
interactions	914	926	O
are	927	930	O
incorporated	931	943	O
in	944	946	O
a	947	948	O
single	949	955	O
MLC	956	959	O
retention	960	969	O
parameter	970	979	O
,	979	980	O
which	981	986	O
is	987	989	O
due	990	993	O
to	994	996	O
the	997	1000	O
amphiphilic	1001	1012	O
nature	1013	1019	O
of	1020	1022	O
surfactants	1023	1034	O
in	1035	1037	O
the	1038	1041	O
system	1042	1048	O
.	1048	1049	O

In	1050	1052	O
situations	1053	1063	O
like	1064	1068	O
this	1069	1073	O
,	1073	1074	O
QRAR	1075	1079	O
is	1080	1082	O
a	1083	1084	O
suitable	1085	1093	O
alternative	1094	1105	O
to	1106	1108	O
QSAR	1109	1113	O
since	1114	1119	O
measuring	1120	1129	O
MLC	1130	1133	O
retention	1134	1143	O
is	1144	1146	O
much	1147	1151	O
easier	1152	1158	O
than	1159	1163	O
measuring	1164	1173	O
different	1174	1183	O
molecular	1184	1193	O
descriptors	1194	1205	O
needed	1206	1212	O
to	1213	1215	O
build	1216	1221	O
the	1222	1225	O
QSAR	1226	1230	O
model	1231	1236	O
.	1236	1237	O

Addition	1238	1246	O
of	1247	1249	O
10	1250	1252	O
%	1252	1253	O
2	1254	1255	O
-	1255	1256	O
propanol	1256	1264	O
to	1265	1267	O
a	1268	1269	O
micellar	1270	1278	O
system	1279	1285	O
(	1286	1287	O
hybrid	1287	1293	O
system	1294	1300	O
)	1300	1301	O
proved	1302	1308	O
to	1309	1311	O
be	1312	1314	O
the	1315	1318	O
best	1319	1323	O
chromatographic	1324	1339	O
system	1340	1346	O
for	1347	1350	O
the	1351	1354	O
best	1355	1359	O
estimation	1360	1370	O
of	1371	1373	O
the	1374	1377	O
phenols	1378	1385	O
bioactivity	1386	1397	O
.	1397	1398	O

Other	1399	1404	O
chromatographic	1405	1420	O
factors	1421	1428	O
such	1429	1433	O
as	1434	1436	O
pH	1437	1439	O
and	1440	1443	O
stationary	1444	1454	O
phase	1455	1460	O
also	1461	1465	O
showed	1466	1472	O
significant	1473	1484	O
effect	1485	1491	O
on	1492	1494	O
the	1495	1498	O
correlation	1499	1510	O
between	1511	1518	O
capacity	1519	1527	O
factor	1528	1534	O
k	1535	1536	O
'	1536	1537	O
and	1538	1541	O
log	1542	1545	O
1	1546	1547	O
/	1547	1548	O
C	1548	1549	O
.	1549	1550	O

Atypical	0	8	O
mycobacteriosis	9	24	O
of	25	27	O
the	28	31	O
larynx	32	38	B-Multi-tissue_structure
:	38	39	O
an	40	42	O
unusual	43	50	O
clinical	51	59	O
presentation	60	72	O
secondary	73	82	O
to	83	85	O
steroids	86	94	O
inhalation	95	105	O
.	105	106	O

Vocal	107	112	O
cords	113	118	O
stiffness	119	128	O
can	129	132	O
be	133	135	O
associated	136	146	O
with	147	151	O
a	152	153	O
variety	154	161	O
of	162	164	O
etiologic	165	174	O
agents	175	181	O
,	181	182	O
but	183	186	O
it	187	189	O
is	190	192	O
rarely	193	199	O
seen	200	204	O
with	205	209	O
atypical	210	218	O
mycobacteria	219	231	O
,	231	232	O
for	233	236	O
example	237	244	O
,	244	245	O
Mycobacterium	246	259	O
avium	260	265	O
complex	266	273	O
.	273	274	O

We	275	277	O
report	278	284	O
a	285	286	O
case	287	291	O
of	292	294	O
a	295	296	O
35	297	299	O
-	299	300	O
year	300	304	O
-	304	305	O
old	305	308	O
white	309	314	O
woman	315	320	O
who	321	324	O
is	325	327	O
and	328	331	O
was	332	335	O
maintained	336	346	O
on	347	349	O
inhaled	350	357	O
steroids	358	366	O
.	366	367	O

She	368	371	O
presented	372	381	O
with	382	386	O
hoarseness	387	397	O
and	398	401	O
low	402	405	O
-	405	406	O
grade	406	411	O
fever	412	417	O
,	417	418	O
but	419	422	O
her	423	426	O
medical	427	434	O
history	435	442	O
was	443	446	O
otherwise	447	456	O
unremarkable	457	469	O
.	469	470	O

Laryngoscopy	471	483	O
revealed	484	492	O
bilateral	493	502	O
scarring	503	511	O
of	512	514	O
the	515	518	O
vocal	519	524	B-Multi-tissue_structure
cords	525	530	I-Multi-tissue_structure
.	530	531	O

Vocal	532	537	B-Multi-tissue_structure
cord	538	542	I-Multi-tissue_structure
biopsies	543	551	O
were	552	556	O
performed	557	566	O
.	566	567	O

Histologic	568	578	O
examination	579	590	O
revealed	591	599	O
unremarkable	600	612	O
laryngeal	613	622	B-Multi-tissue_structure
mucosa	623	629	I-Multi-tissue_structure
,	629	630	O
except	631	637	O
for	638	641	O
abundant	642	650	O
subepithelial	651	664	B-Pathological_formation
non	665	668	I-Pathological_formation
-	668	669	I-Pathological_formation
necrotizing	669	680	I-Pathological_formation
granulomata	681	692	I-Pathological_formation
.	692	693	O

The	694	697	O
differential	698	710	O
diagnosis	711	720	O
included	721	729	O
sarcoid	730	737	B-Pathological_formation
,	737	738	O
Klebsiella	739	749	B-Pathological_formation
scleroma	750	758	I-Pathological_formation
,	758	759	O
and	760	763	O
tuberculosis	764	776	O
.	776	777	O

Special	778	785	O
stains	786	792	O
reviewed	793	801	O
abundant	802	810	O
acid	811	815	O
-	815	816	O
fast	816	820	O
bacilli	821	828	O
,	828	829	O
later	830	835	O
confirmed	836	845	O
by	846	848	O
a	849	850	O
DNA	851	854	O
assay	855	860	O
on	861	863	O
induced	864	871	O
deep	872	876	O
sputum	877	883	B-Organism_substance
,	883	884	O
consistent	885	895	O
with	896	900	O
M	901	902	O
avium	903	908	O
complex	909	916	O
.	916	917	O

Subsequently	918	930	O
,	930	931	O
steroids	932	940	O
were	941	945	O
withdrawn	946	955	O
,	955	956	O
and	957	960	O
the	961	964	O
patient	965	972	O
was	973	976	O
treated	977	984	O
with	985	989	O
a	990	991	O
multiple	992	1000	O
-	1000	1001	O
drug	1001	1005	O
antituberculous	1006	1021	O
regimen	1022	1029	O
and	1030	1033	O
had	1034	1037	O
a	1038	1039	O
full	1040	1044	O
recovery	1045	1053	O
.	1053	1054	O

This	1055	1059	O
unusual	1060	1067	O
clinical	1068	1076	O
presentation	1077	1089	O
of	1090	1092	O
the	1093	1096	O
atypical	1097	1105	O
mycobacteriosis	1106	1121	O
may	1122	1125	O
be	1126	1128	O
encountered	1129	1140	O
by	1141	1143	O
otolaryngologists	1144	1161	O
and	1162	1165	O
pathologists	1166	1178	O
,	1178	1179	O
and	1180	1183	O
it	1184	1186	O
is	1187	1189	O
critical	1190	1198	O
to	1199	1201	O
recognize	1202	1211	O
it	1212	1214	O
in	1215	1217	O
patients	1218	1226	O
immunocompromised	1227	1244	O
because	1245	1252	O
of	1253	1255	O
steroids	1256	1264	O
.	1264	1265	O

Are	0	3	O
former	4	10	O
female	11	17	O
elite	18	23	O
athletes	24	32	O
more	33	37	O
likely	38	44	O
to	45	47	O
experience	48	58	O
urinary	59	66	B-Organism_substance
incontinence	67	79	O
later	80	85	O
in	86	88	O
life	89	93	O
than	94	98	O
non	99	102	O
-	102	103	O
athletes	103	111	O
?	111	112	O

The	113	116	O
aim	117	120	O
of	121	123	O
the	124	127	O
present	128	135	O
study	136	141	O
was	142	145	O
to	146	148	O
investigate	149	160	O
whether	161	168	O
former	169	175	O
female	176	182	O
elite	183	188	O
athletes	189	197	O
are	198	201	O
more	202	206	O
likely	207	213	O
to	214	216	O
experience	217	227	O
urinary	228	235	B-Organism_substance
incontinence	236	248	O
(	249	250	O
UI	250	252	O
)	252	253	O
later	254	259	O
in	260	262	O
life	263	267	O
than	268	272	O
non	273	276	O
-	276	277	O
athletes	277	285	O
and	286	289	O
to	290	292	O
assess	293	299	O
possible	300	308	O
risk	309	313	O
factors	314	321	O
for	322	325	O
UI	326	328	O
in	329	331	O
athletes	332	340	O
.	340	341	O

Three	342	347	O
hundred	348	355	O
and	356	359	O
thirty	360	366	O
-	366	367	O
one	367	370	O
former	371	377	O
elite	378	383	O
athletes	384	392	O
(	393	394	O
response	394	402	O
rate	403	407	O
81	408	410	O
%	410	411	O
)	411	412	O
and	413	416	O
640	417	420	O
controls	421	429	O
replied	430	437	O
to	438	440	O
a	441	442	O
postal	443	449	O
questionnaire	450	463	O
including	464	473	O
validated	474	483	O
questions	484	493	O
on	494	496	O
UI	497	499	O
.	499	500	O

While	501	506	O
competing	507	516	O
in	517	519	O
sport	520	525	O
,	525	526	O
10	527	529	O
.	529	530	O
9	530	531	O
%	531	532	O
and	533	536	O
2	537	538	O
.	538	539	O
7	539	540	O
%	540	541	O
of	542	544	O
the	545	548	O
former	549	555	O
elite	556	561	O
athletes	562	570	O
reported	571	579	O
stress	580	586	O
urinary	587	594	B-Organism_substance
incontinence	595	607	O
(	608	609	O
SUI	609	612	O
)	612	613	O
and	614	617	O
urge	618	622	O
incontinence	623	635	O
,	635	636	O
respectively	637	649	O
.	649	650	O

Presently	651	660	O
,	660	661	O
36	662	664	O
.	664	665	O
5	665	666	O
%	666	667	O
of	668	670	O
the	671	674	O
former	675	681	O
elite	682	687	O
athletes	688	696	O
and	697	700	O
36	701	703	O
.	703	704	O
9	704	705	O
%	705	706	O
of	707	709	O
the	710	713	O
controls	714	722	O
reported	723	731	O
SUI	732	735	O
.	735	736	O

9	737	738	O
.	738	739	O
1	739	740	O
%	740	741	O
and	742	745	O
9	746	747	O
.	747	748	O
4	748	749	O
%	749	750	O
reported	751	759	O
urge	760	764	O
incontinence	765	777	O
.	777	778	O

Among	779	784	O
former	785	791	O
elite	792	797	O
athletes	798	806	O
,	806	807	O
those	808	813	O
with	814	818	O
two	819	822	O
or	823	825	O
three	826	831	O
children	832	840	O
were	841	845	O
more	846	850	O
likely	851	857	O
than	858	862	O
nulliparous	863	874	O
women	875	880	O
to	881	883	O
have	884	888	O
UI	889	891	O
now	892	895	O
.	895	896	O

Also	897	901	O
,	901	902	O
among	903	908	O
former	909	915	O
athletes	916	924	O
,	924	925	O
UI	926	928	O
was	929	932	O
more	933	937	O
common	938	944	O
in	945	947	O
women	948	953	O
with	954	958	O
vs	959	961	O
those	962	967	O
without	968	975	O
UI	976	978	O
while	979	984	O
competing	985	994	O
(	995	996	O
odds	996	1000	O
ratio	1001	1006	O
8	1007	1008	O
.	1008	1009	O
57	1009	1011	O
,	1011	1012	O
95	1013	1015	O
%	1015	1016	O
confidence	1017	1027	O
interval	1028	1036	O
:	1036	1037	O
3	1038	1039	O
.	1039	1040	O
55	1040	1042	O
-	1042	1043	O
20	1043	1045	O
.	1045	1046	O
71	1046	1048	O
)	1048	1049	O
.	1049	1050	O

Age	1051	1054	O
,	1054	1055	O
menopause	1056	1065	O
and	1066	1069	O
being	1070	1075	O
regularly	1076	1085	O
physically	1086	1096	O
active	1097	1103	O
now	1104	1107	O
were	1108	1112	O
not	1113	1116	O
associated	1117	1127	O
with	1128	1132	O
UI	1133	1135	O
in	1136	1138	O
either	1139	1145	O
group	1146	1151	O
.	1151	1152	O

Based	1153	1158	O
on	1159	1161	O
this	1162	1166	O
study	1167	1172	O
,	1172	1173	O
the	1174	1177	O
prevalence	1178	1188	O
of	1189	1191	O
UI	1192	1194	O
does	1195	1199	O
not	1200	1203	O
seem	1204	1208	O
to	1209	1211	O
be	1212	1214	O
higher	1215	1221	O
in	1222	1224	O
former	1225	1231	O
athletes	1232	1240	O
than	1241	1245	O
in	1246	1248	O
controls	1249	1257	O
.	1257	1258	O

However	1259	1266	O
,	1266	1267	O
the	1268	1271	O
results	1272	1279	O
indicate	1280	1288	O
that	1289	1293	O
UI	1294	1296	O
early	1297	1302	O
in	1303	1305	O
life	1306	1310	O
,	1310	1311	O
as	1312	1314	O
reported	1315	1323	O
during	1324	1330	O
elite	1331	1336	O
sport	1337	1342	O
,	1342	1343	O
is	1344	1346	O
a	1347	1348	O
strong	1349	1355	O
predictor	1356	1365	O
of	1366	1368	O
UI	1369	1371	O
later	1372	1377	O
in	1378	1380	O
life	1381	1385	O
.	1385	1386	O

Handling	0	8	O
within	9	15	O
run	16	19	O
retention	20	29	O
time	30	34	O
shifts	35	41	O
in	42	44	O
two	45	48	O
-	48	49	O
dimensional	49	60	O
chromatography	61	75	O
data	76	80	O
using	81	86	O
shift	87	92	O
correction	93	103	O
and	104	107	O
modeling	108	116	O
.	116	117	O

The	118	121	O
use	122	125	O
of	126	128	O
PARAFAC	129	136	O
for	137	140	O
modeling	141	149	O
GC	150	152	O
x	153	154	O
GC	155	157	O
-	157	158	O
TOFMS	158	163	O
peaks	164	169	O
is	170	172	O
well	173	177	O
documented	178	188	O
.	188	189	O

This	190	194	O
success	195	202	O
is	203	205	O
due	206	209	O
to	210	212	O
the	213	216	O
trilinear	217	226	O
structure	227	236	O
of	237	239	O
these	240	245	O
data	246	250	O
under	251	256	O
ideal	257	262	O
,	262	263	O
or	264	266	O
sufficiently	267	279	O
close	280	285	O
to	286	288	O
ideal	289	294	O
,	294	295	O
chromatographic	296	311	O
conditions	312	322	O
.	322	323	O

However	324	331	O
,	331	332	O
using	333	338	O
temperature	339	350	O
programming	351	362	O
to	363	365	O
cope	366	370	O
with	371	375	O
the	376	379	O
general	380	387	O
elution	388	395	O
problem	396	403	O
,	403	404	O
deviations	405	415	O
from	416	420	O
trilinearity	421	433	O
within	434	440	O
a	441	442	O
run	443	446	O
are	447	450	O
more	451	455	O
likely	456	462	O
to	463	465	O
be	466	468	O
seen	469	473	O
for	474	477	O
the	478	481	O
following	482	491	O
three	492	497	O
cases	498	503	O
:	503	504	O
(	505	506	O
1	506	507	O
)	507	508	O
compounds	509	518	O
(	519	520	O
i	520	521	O
.	521	522	O
e	522	523	O
.	523	524	O
,	524	525	O
analytes	526	534	O
)	534	535	O
severely	536	544	O
broadened	545	554	O
on	555	557	O
the	558	561	O
first	562	567	O
column	568	574	O
hence	575	580	O
defined	581	588	O
by	589	591	O
many	592	596	O
modulation	597	607	O
periods	608	615	O
,	615	616	O
(	617	618	O
2	618	619	O
)	619	620	O
analytes	621	629	O
with	630	634	O
a	635	636	O
very	637	641	O
high	642	646	O
retention	647	656	O
factor	657	663	O
on	664	666	O
the	667	670	O
second	671	677	O
column	678	684	O
and	685	688	O
likely	689	695	O
wrapped	696	703	O
around	704	710	O
in	711	713	O
that	714	718	O
dimension	719	728	O
,	728	729	O
or	730	732	O
(	733	734	O
3	734	735	O
)	735	736	O
with	737	741	O
fast	742	746	O
temperature	747	758	O
program	759	766	O
rates	767	772	O
.	772	773	O

This	774	778	O
deviation	779	788	O
from	789	793	O
trilinearity	794	806	O
is	807	809	O
seen	810	814	O
as	815	817	O
retention	818	827	O
time	828	832	O
-	832	833	O
shifted	833	840	O
peak	841	845	O
profiles	846	854	O
in	855	857	O
subsequent	858	868	O
modulation	869	879	O
periods	880	887	O
(	888	889	O
first	889	894	O
column	895	901	O
fractions	902	911	O
)	911	912	O
.	912	913	O

In	914	916	O
this	917	921	O
report	922	928	O
,	928	929	O
a	930	931	O
relaxed	932	939	O
yet	940	943	O
powerful	944	952	O
version	953	960	O
of	961	963	O
PARAFAC	964	971	O
,	971	972	O
known	973	978	O
as	979	981	O
PARAFAC2	982	990	O
has	991	994	O
been	995	999	O
applied	1000	1007	O
to	1008	1010	O
handle	1011	1017	O
this	1018	1022	O
shift	1023	1028	O
within	1029	1035	O
the	1036	1039	O
model	1040	1045	O
step	1046	1050	O
by	1051	1053	O
allowing	1054	1062	O
generation	1063	1073	O
of	1074	1076	O
individual	1077	1087	O
peak	1088	1092	O
profiles	1093	1101	O
in	1102	1104	O
subsequent	1105	1115	O
first	1116	1121	O
column	1122	1128	O
fractions	1129	1138	O
.	1138	1139	O

An	1140	1142	O
alternative	1143	1154	O
approach	1155	1163	O
was	1164	1167	O
also	1168	1172	O
studied	1173	1180	O
,	1180	1181	O
utilizing	1182	1191	O
a	1192	1193	O
standard	1194	1202	O
retention	1203	1212	O
time	1213	1217	O
shift	1218	1223	O
correction	1224	1234	O
to	1235	1237	O
restore	1238	1245	O
the	1246	1249	O
data	1250	1254	O
trilinearity	1255	1267	O
structure	1268	1277	O
followed	1278	1286	O
by	1287	1289	O
PARAFAC	1290	1297	O
.	1297	1298	O

These	1299	1304	O
two	1305	1308	O
approaches	1309	1319	O
are	1320	1323	O
compared	1324	1332	O
when	1333	1337	O
identifying	1338	1349	O
and	1350	1353	O
quantifying	1354	1365	O
a	1366	1367	O
known	1368	1373	O
analyte	1374	1381	O
over	1382	1386	O
a	1387	1388	O
large	1389	1394	O
concentration	1395	1408	O
series	1409	1415	O
where	1416	1421	O
a	1422	1423	O
certain	1424	1431	O
shift	1432	1437	O
is	1438	1440	O
simulated	1441	1450	O
in	1451	1453	O
the	1454	1457	O
successive	1458	1468	O
first	1469	1474	O
column	1475	1481	O
fractions	1482	1491	O
.	1491	1492	O

Finally	1493	1500	O
,	1500	1501	O
the	1502	1505	O
methods	1506	1513	O
are	1514	1517	O
applied	1518	1525	O
to	1526	1528	O
real	1529	1533	O
chromatographic	1534	1549	O
data	1550	1554	O
showing	1555	1562	O
severely	1563	1571	O
shifted	1572	1579	O
peak	1580	1584	O
profiles	1585	1593	O
.	1593	1594	O

The	1595	1598	O
pros	1599	1603	O
and	1604	1607	O
cons	1608	1612	O
of	1613	1615	O
the	1616	1619	O
presented	1620	1629	O
approaches	1630	1640	O
are	1641	1644	O
discussed	1645	1654	O
in	1655	1657	O
relation	1658	1666	O
to	1667	1669	O
the	1670	1673	O
model	1674	1679	O
parameters	1680	1690	O
,	1690	1691	O
the	1692	1695	O
signal	1696	1702	O
-	1702	1703	O
to	1703	1705	O
-	1705	1706	O
noise	1706	1711	O
ratio	1712	1717	O
and	1718	1721	O
the	1722	1725	O
degree	1726	1732	O
of	1733	1735	O
shift	1736	1741	O
.	1741	1742	O

[	0	1	O
Incidence	1	10	O
of	11	13	O
fungal	14	20	O
infection	21	30	O
in	31	33	O
surgical	34	42	O
diseases	43	51	O
of	52	54	O
the	55	58	O
pancreas	59	67	B-Organ
]	67	68	O
.	68	69	O

Recently	70	78	O
the	79	82	O
number	83	89	O
of	90	92	O
mycotic	93	100	O
infections	101	111	O
has	112	115	O
increased	116	125	O
significantly	126	139	O
.	139	140	O

Authors	141	148	O
have	149	153	O
observed	154	162	O
13	163	165	O
mycotic	166	173	O
infections	174	184	O
on	185	187	O
operated	188	196	O
patients	197	205	O
suffering	206	215	O
pancreatic	216	226	B-Organ
diseases	227	235	O
between	236	243	O
1984	244	248	O
and	249	252	O
1990	253	257	O
.	257	258	O

9	259	260	O
of	261	263	O
13	264	266	O
patients	267	275	O
had	276	279	O
pancreatic	280	290	B-Pathological_formation
abscesses	291	300	I-Pathological_formation
as	301	303	O
well	304	308	O
.	308	309	O

The	310	313	O
risk	314	318	O
factors	319	326	O
of	327	329	O
fungal	330	336	O
infections	337	347	O
are	348	351	O
analysed	352	360	O
.	360	361	O

It	362	364	O
is	365	367	O
important	368	377	O
to	378	380	O
take	381	385	O
differentiation	386	401	O
between	402	409	O
fungal	410	416	O
colonisation	417	429	O
and	430	433	O
septicaemia	434	445	O
caused	446	452	O
by	453	455	O
yeasts	456	462	O
.	462	463	O

Repeated	464	472	O
microbiological	473	488	O
examinations	489	501	O
can	502	505	O
promote	506	513	O
recognising	514	525	O
of	526	528	O
the	529	532	O
fungal	533	539	O
invasion	540	548	O
.	548	549	O

The	550	553	O
base	554	558	O
of	559	561	O
the	562	565	O
therapy	566	573	O
is	574	576	O
to	577	579	O
avoid	580	585	O
risk	586	590	O
factors	591	598	O
of	599	601	O
infections	602	612	O
and	613	616	O
to	617	619	O
use	620	623	O
antifungal	624	634	O
medication	635	645	O
in	646	648	O
time	649	653	O
.	653	654	O

[	0	1	O
Quantitative	1	13	O
analysis	14	22	O
of	23	25	O
regional	26	34	O
cerebral	35	43	B-Organ
blood	44	49	B-Organism_substance
flow	50	54	O
in	55	57	O
elderly	58	65	O
with	66	70	O
white	71	76	B-Pathological_formation
matter	77	83	I-Pathological_formation
lesions	84	91	I-Pathological_formation
]	91	92	O
.	92	93	O

OBJECTIVE	94	103	O
:	103	104	O

To	105	107	O
observe	108	115	O
whether	116	123	O
the	124	127	O
severity	128	136	O
of	137	139	O
white	140	145	B-Pathological_formation
matter	146	152	I-Pathological_formation
lesions	153	160	I-Pathological_formation
(	161	162	O
WML	162	165	B-Pathological_formation
)	165	166	O
is	167	169	O
related	170	177	O
to	178	180	O
ischemia	181	189	O
in	190	192	O
elderly	193	200	O
.	200	201	O

METHODS	202	209	O
:	209	210	O

WML	211	214	B-Pathological_formation
were	215	219	O
divided	220	227	O
into	228	232	O
2	233	234	O
categories	235	245	O
(	246	247	O
centrum	247	254	B-Multi-tissue_structure
semiovale	255	264	I-Multi-tissue_structure
and	265	268	O
periventricular	269	284	B-Multi-tissue_structure
regions	285	292	I-Multi-tissue_structure
)	292	293	O
and	294	297	O
four	298	302	O
grades	303	309	O
(	310	311	O
grade	311	316	O
0	317	318	O
,	318	319	O
grade	320	325	O
1	326	327	O
,	327	328	O
grade	329	334	O
2	335	336	O
and	337	340	O
grade	341	346	O
3	347	348	O
)	348	349	O
according	350	359	O
to	360	362	O
the	363	366	O
severity	367	375	O
of	376	378	O
WML	379	382	B-Pathological_formation
showing	383	390	O
on	391	393	O
the	394	397	O
FLAIR	398	403	O
sequence	404	412	O
of	413	415	O
MRI	416	419	O
using	420	425	O
modified	426	434	O
Fazekas	435	442	O
scale	443	448	O
.	448	449	O

The	450	453	O
values	454	460	O
of	461	463	O
regional	464	472	O
cerebral	473	481	B-Organ
blood	482	487	B-Organism_substance
flow	488	492	O
(	493	494	O
rCBF	494	498	O
)	498	499	O
within	500	506	O
WML	507	510	B-Pathological_formation
and	511	514	O
other	515	520	O
brain	521	526	B-Organ
regions	527	534	O
were	535	539	O
measured	540	548	O
using	549	554	O
Xenon	555	560	O
contrast	561	569	O
CT	570	572	O
.	572	573	O

RESULTS	574	581	O
:	581	582	O

Mean	583	587	O
rCBF	588	592	O
(	593	594	O
ml	594	596	O
x	597	598	O
100	599	602	O
g	603	604	O
(	604	605	O
-	605	606	O
1	606	607	O
)	607	608	O
x	609	610	O
min	611	614	O
(	614	615	O
-	615	616	O
1	616	617	O
)	617	618	O
)	618	619	O
within	620	626	O
lesions	627	634	B-Pathological_formation
around	635	641	O
periventricular	642	657	B-Multi-tissue_structure
areas	658	663	I-Multi-tissue_structure
,	663	664	O
in	665	667	O
right	668	673	O
and	674	677	O
left	678	682	O
centrum	683	690	B-Multi-tissue_structure
semiovale	691	700	I-Multi-tissue_structure
were	701	705	O
20	706	708	O
.	708	709	O
8	709	710	O
+	711	712	O
/	712	713	O
-	713	714	O
2	715	716	O
.	716	717	O
8	717	718	O
,	718	719	O
22	720	722	O
.	722	723	O
3	723	724	O
+	725	726	O
/	726	727	O
-	727	728	O
1	729	730	O
.	730	731	O
9	731	732	O
and	733	736	O
22	737	739	O
.	739	740	O
2	740	741	O
+	742	743	O
/	743	744	O
-	744	745	O
2	746	747	O
.	747	748	O
1	748	749	O
in	750	752	O
grade	753	758	O
0	759	760	O
;	760	761	O
20	762	764	O
.	764	765	O
3	765	766	O
+	767	768	O
/	768	769	O
-	769	770	O
2	771	772	O
.	772	773	O
5	773	774	O
,	774	775	O
21	776	778	O
.	778	779	O
3	779	780	O
+	781	782	O
/	782	783	O
-	783	784	O
1	785	786	O
.	786	787	O
0	787	788	O
and	789	792	O
21	793	795	O
.	795	796	O
0	796	797	O
+	798	799	O
/	799	800	O
-	800	801	O
1	802	803	O
.	803	804	O
8	804	805	O
in	806	808	O
grade1	809	815	O
;	815	816	O
16	817	819	O
.	819	820	O
3	820	821	O
+	822	823	O
/	823	824	O
-	824	825	O
2	826	827	O
.	827	828	O
0	828	829	O
,	829	830	O
15	831	833	O
.	833	834	O
6	834	835	O
+	836	837	O
/	837	838	O
-	838	839	O
1	840	841	O
.	841	842	O
7	842	843	O
and	844	847	O
15	848	850	O
.	850	851	O
9	851	852	O
+	853	854	O
/	854	855	O
-	855	856	O
0	857	858	O
.	858	859	O
9	859	860	O
in	861	863	O
grade	864	869	O
2	870	871	O
;	871	872	O
14	873	875	O
.	875	876	O
1	876	877	O
+	878	879	O
/	879	880	O
-	880	881	O
2	882	883	O
.	883	884	O
6	884	885	O
,	885	886	O
14	887	889	O
.	889	890	O
5	890	891	O
+	892	893	O
/	893	894	O
-	894	895	O
2	896	897	O
.	897	898	O
2	898	899	O
and	900	903	O
14	904	906	O
.	906	907	O
2	907	908	O
+	909	910	O
/	910	911	O
-	911	912	O
1	913	914	O
.	914	915	O
9	915	916	O
in	917	919	O
grade	920	925	O
3	926	927	O
respectively	928	940	O
.	940	941	O

The	942	945	O
severity	946	954	O
of	955	957	O
WML	958	961	B-Pathological_formation
is	962	964	O
associated	965	975	O
significantly	976	989	O
with	990	994	O
reduction	995	1004	O
of	1005	1007	O
rCBF	1008	1012	O
within	1013	1019	O
lesions	1020	1027	B-Pathological_formation
both	1028	1032	O
in	1033	1035	O
centrum	1036	1043	B-Multi-tissue_structure
semiovale	1044	1053	I-Multi-tissue_structure
and	1054	1057	O
periventricular	1058	1073	B-Multi-tissue_structure
regions	1074	1081	I-Multi-tissue_structure
(	1082	1083	O
all	1083	1086	O
P	1087	1088	O
<	1089	1090	O
0	1091	1092	O
.	1092	1093	O
05	1093	1095	O
)	1095	1096	O
.	1096	1097	O

There	1098	1103	O
was	1104	1107	O
no	1108	1110	O
significant	1111	1122	O
difference	1123	1133	O
in	1134	1136	O
rCBF	1137	1141	O
values	1142	1148	O
between	1149	1156	O
grade	1157	1162	O
0	1163	1164	O
and	1165	1168	O
1	1169	1170	O
,	1170	1171	O
but	1172	1175	O
significant	1176	1187	O
differences	1188	1199	O
existed	1200	1207	O
between	1208	1215	O
grade	1216	1221	O
0	1222	1223	O
and	1224	1227	O
grades	1228	1234	O
2	1235	1236	O
and	1237	1240	O
3	1241	1242	O
,	1242	1243	O
between	1244	1251	O
grade	1252	1257	O
1	1258	1259	O
and	1260	1263	O
grades	1264	1270	O
2	1271	1272	O
and	1273	1276	O
3	1277	1278	O
(	1279	1280	O
all	1280	1283	O
P	1284	1285	O
<	1286	1287	O
0	1288	1289	O
.	1289	1290	O
05	1290	1292	O
)	1292	1293	O
.	1293	1294	O

Statistical	1295	1306	O
significance	1307	1319	O
also	1320	1324	O
existed	1325	1332	O
between	1333	1340	O
the	1341	1344	O
severity	1345	1353	O
of	1354	1356	O
white	1357	1362	B-Pathological_formation
matter	1363	1369	I-Pathological_formation
lesions	1370	1377	I-Pathological_formation
and	1378	1381	O
rCBF	1382	1386	O
in	1387	1389	O
bilateral	1390	1399	O
temporal	1400	1408	B-Multi-tissue_structure
lobes	1409	1414	I-Multi-tissue_structure
and	1415	1418	O
lentiform	1419	1428	O
nucleases	1429	1438	O
(	1439	1440	O
P	1440	1441	O
<	1442	1443	O
0	1444	1445	O
.	1445	1446	O
05	1446	1448	O
)	1448	1449	O
.	1449	1450	O

CONCLUSIONS	1451	1462	O
:	1462	1463	O

The	1464	1467	O
severity	1468	1476	O
of	1477	1479	O
WML	1480	1483	B-Pathological_formation
both	1484	1488	O
in	1489	1491	O
centrum	1492	1499	B-Multi-tissue_structure
semiovale	1500	1509	I-Multi-tissue_structure
and	1510	1513	O
periventricular	1514	1529	B-Pathological_formation
regions	1530	1537	I-Pathological_formation
is	1538	1540	O
associated	1541	1551	O
significantly	1552	1565	O
with	1566	1570	O
reduction	1571	1580	O
of	1581	1583	O
rCBF	1584	1588	O
within	1589	1595	O
lesions	1596	1603	B-Pathological_formation
.	1603	1604	O

Aging	0	5	O
affects	6	13	O
the	14	17	O
cardiovascular	18	32	B-Anatomical_system
responses	33	42	O
to	43	45	O
cold	46	50	O
stress	51	57	O
in	58	60	O
humans	61	67	O
.	67	68	O

Cardiovascular	69	83	B-Anatomical_system
-	83	84	O
related	84	91	O
mortality	92	101	O
peaks	102	107	O
during	108	114	O
cold	115	119	O
winter	120	126	O
months	127	133	O
,	133	134	O
particularly	135	147	O
in	148	150	O
older	151	156	O
adults	157	163	O
.	163	164	O

Acute	165	170	O
physiological	171	184	O
responses	185	194	O
,	194	195	O
such	196	200	O
as	201	203	O
increases	204	213	O
in	214	216	O
blood	217	222	B-Organism_substance
pressure	223	231	O
,	231	232	O
in	233	235	O
response	236	244	O
to	245	247	O
cold	248	252	O
exposure	253	261	O
may	262	265	O
contribute	266	276	O
to	277	279	O
these	280	285	O
associations	286	298	O
.	298	299	O

To	300	302	O
determine	303	312	O
whether	313	320	O
the	321	324	O
blood	325	330	B-Organism_substance
pressure	331	339	O
-	339	340	O
raising	340	347	O
effect	348	354	O
(	355	356	O
pressor	356	363	O
response	364	372	O
)	372	373	O
of	374	376	O
non	377	380	O
-	380	381	O
internal	381	389	O
body	390	394	B-Organism_subdivision
temperature	395	406	O
-	406	407	O
reducing	407	415	O
cold	416	420	O
stress	421	427	O
is	428	430	O
greater	431	438	O
with	439	443	O
age	444	447	O
,	447	448	O
we	449	451	O
measured	452	460	O
physiological	461	474	O
responses	475	484	O
to	485	487	O
20	488	490	O
min	491	494	O
of	495	497	O
superficial	498	509	O
skin	510	514	B-Organ
cooling	515	522	O
,	522	523	O
via	524	527	O
water	528	533	O
-	533	534	O
perfused	534	542	O
suit	543	547	O
,	547	548	O
in	549	551	O
12	552	554	O
younger	555	562	O
[	563	564	O
25	564	566	O
+	567	568	O
/	568	569	O
-	569	570	O
1	571	572	O
(	573	574	O
SE	574	576	O
)	576	577	O
yr	578	580	O
old	581	584	O
]	584	585	O
and	586	589	O
12	590	592	O
older	593	598	O
(	599	600	O
65	600	602	O
+	603	604	O
/	604	605	O
-	605	606	O
2	607	608	O
yr	609	611	O
old	612	615	O
)	615	616	O
adults	617	623	O
.	623	624	O

We	625	627	O
found	628	633	O
that	634	638	O
superficial	639	650	O
skin	651	655	B-Organ
cooling	656	663	O
elicited	664	672	O
an	673	675	O
increase	676	684	O
in	685	687	O
blood	688	693	B-Organism_substance
pressure	694	702	O
from	703	707	O
resting	708	715	O
levels	716	722	O
(	723	724	O
pressor	724	731	O
response	732	740	O
;	740	741	O
P	742	743	O
<	744	745	O
0	746	747	O
.	747	748	O
05	748	750	O
)	750	751	O
in	752	754	O
younger	755	762	O
and	763	766	O
older	767	772	O
adults	773	779	O
.	779	780	O

However	781	788	O
,	788	789	O
the	790	793	O
magnitude	794	803	O
of	804	806	O
this	807	811	O
pressor	812	819	O
response	820	828	O
(	829	830	O
systolic	830	838	O
and	839	842	O
mean	843	847	O
blood	848	853	B-Organism_substance
pressure	854	862	O
)	862	863	O
was	864	867	O
more	868	872	O
than	873	877	O
twofold	878	885	O
higher	886	892	O
in	893	895	O
older	896	901	O
adults	902	908	O
(	909	910	O
P	910	911	O
<	912	913	O
0	914	915	O
.	915	916	O
05	916	918	O
vs	919	921	O
.	921	922	O
younger	923	930	O
adults	931	937	O
)	937	938	O
.	938	939	O

The	940	943	O
magnitude	944	953	O
of	954	956	O
the	957	960	O
pressor	961	968	O
response	969	977	O
was	978	981	O
similar	982	989	O
at	990	992	O
peripheral	993	1003	O
(	1004	1005	O
brachial	1005	1013	B-Organism_subdivision
)	1013	1014	O
and	1015	1018	O
central	1019	1026	O
(	1027	1028	O
estimated	1028	1037	O
in	1038	1040	O
the	1041	1044	O
aorta	1045	1050	B-Multi-tissue_structure
)	1050	1051	O
measurement	1052	1063	O
sites	1064	1069	O
.	1069	1070	O

Regression	1071	1081	O
analysis	1082	1090	O
revealed	1091	1099	O
that	1100	1104	O
aortic	1105	1111	B-Multi-tissue_structure
pulse	1112	1117	O
wave	1118	1122	O
velocity	1123	1131	O
,	1131	1132	O
a	1133	1134	O
measure	1135	1142	O
of	1143	1145	O
central	1146	1153	O
arterial	1154	1162	B-Multi-tissue_structure
stiffness	1163	1172	O
obtained	1173	1181	O
before	1182	1188	O
cooling	1189	1196	O
,	1196	1197	O
was	1198	1201	O
the	1202	1205	O
best	1206	1210	O
predictor	1211	1220	O
of	1221	1223	O
the	1224	1227	O
increased	1228	1237	O
pressor	1238	1245	O
response	1246	1254	O
to	1255	1257	O
superficial	1258	1269	O
skin	1270	1274	B-Organ
cooling	1275	1282	O
in	1283	1285	O
older	1286	1291	O
adults	1292	1298	O
,	1298	1299	O
explaining	1300	1310	O
approximately	1311	1324	O
63	1325	1327	O
%	1327	1328	O
of	1329	1331	O
its	1332	1335	O
variability	1336	1347	O
.	1347	1348	O

These	1349	1354	O
results	1355	1362	O
indicate	1363	1371	O
that	1372	1376	O
there	1377	1382	O
is	1383	1385	O
a	1386	1387	O
greater	1388	1395	O
pressor	1396	1403	O
response	1404	1412	O
to	1413	1415	O
non	1416	1419	O
-	1419	1420	O
internal	1420	1428	O
body	1429	1433	B-Organism_subdivision
temperature	1434	1445	O
-	1445	1446	O
reducing	1446	1454	O
cold	1455	1459	O
stress	1460	1466	O
with	1467	1471	O
age	1472	1475	O
in	1476	1478	O
humans	1479	1485	O
that	1486	1490	O
may	1491	1494	O
be	1495	1497	O
mediated	1498	1506	O
by	1507	1509	O
increased	1510	1519	O
levels	1520	1526	O
of	1527	1529	O
central	1530	1537	O
arterial	1538	1546	B-Multi-tissue_structure
stiffness	1547	1556	O
.	1556	1557	O

Magnesium	0	9	O
for	10	13	O
treatment	14	23	O
of	24	26	O
asthma	27	33	O
in	34	36	O
children	37	45	O
.	45	46	O

QUESTION	47	55	O
:	55	56	O
Magnesium	57	66	O
is	67	69	O
considered	70	80	O
adjuvant	81	89	O
therapy	90	97	O
for	98	101	O
moderate	102	110	O
to	111	113	O
severe	114	120	O
asthma	121	127	O
exacerbations	128	141	O
in	142	144	O
adults	145	151	O
,	151	152	O
but	153	156	O
can	157	160	O
it	161	163	O
be	164	166	O
used	167	171	O
to	172	174	O
treat	175	180	O
children	181	189	O
?	189	190	O

ANSWER	191	197	O
:	197	198	O
Magnesium	199	208	O
seems	209	214	O
to	215	217	O
be	218	220	O
beneficial	221	231	O
in	232	234	O
the	235	238	O
treatment	239	248	O
of	249	251	O
moderate	252	260	O
to	261	263	O
severe	264	270	O
asthma	271	277	O
in	278	280	O
children	281	289	O
.	289	290	O

It	291	293	O
is	294	296	O
a	297	298	O
safe	299	303	O
drug	304	308	O
to	309	311	O
administer	312	322	O
,	322	323	O
but	324	327	O
there	328	333	O
have	334	338	O
been	339	343	O
minor	344	349	O
side	350	354	O
effects	355	362	O
reported	363	371	O
,	371	372	O
such	373	377	O
as	378	380	O
epigastric	381	391	B-Organism_subdivision
or	392	394	O
facial	395	401	B-Organism_subdivision
warmth	402	408	O
,	408	409	O
flushing	410	418	O
,	418	419	O
pain	420	424	O
and	425	428	O
numbness	429	437	O
at	438	440	O
the	441	444	O
infusion	445	453	O
site	454	458	O
,	458	459	O
dry	460	463	O
mouth	464	469	B-Organism_subdivision
,	469	470	O
malaise	471	478	O
,	478	479	O
and	480	483	O
hypotension	484	495	O
.	495	496	O

Owing	497	502	O
to	503	505	O
its	506	509	O
bronchodilating	510	525	O
and	526	529	O
anti	530	534	O
-	534	535	O
inflammatory	535	547	O
effects	548	555	O
,	555	556	O
magnesium	557	566	O
is	567	569	O
an	570	572	O
encouraging	573	584	O
adjuvant	585	593	O
therapy	594	601	O
for	602	605	O
pediatric	606	615	O
patients	616	624	O
who	625	628	O
do	629	631	O
not	632	635	O
respond	636	643	O
to	644	646	O
conventional	647	659	O
treatment	660	669	O
in	670	672	O
acute	673	678	O
severe	679	685	O
exacerbations	686	699	O
.	699	700	O

Future	701	707	O
studies	708	715	O
should	716	722	O
focus	723	728	O
on	729	731	O
establishing	732	744	O
the	745	748	O
optimal	749	756	O
dosage	757	763	O
for	764	767	O
maximal	768	775	O
benefits	776	784	O
and	785	788	O
the	789	792	O
best	793	797	O
route	798	803	O
of	804	806	O
administration	807	821	O
.	821	822	O

Magnesium	823	832	O
should	833	839	O
also	840	844	O
be	845	847	O
considered	848	858	O
as	859	861	O
a	862	863	O
prophylactic	864	876	O
treatment	877	886	O
.	886	887	O

Effectiveness	0	13	O
of	14	16	O
different	17	26	O
approaches	27	37	O
for	38	41	O
establishing	42	54	O
cisplatin	55	64	O
-	64	65	O
induced	65	72	O
cochlear	73	81	B-Pathological_formation
lesions	82	89	I-Pathological_formation
in	90	92	O
mice	93	97	O
.	97	98	O

CONCLUSIONS	99	110	O
:	110	111	O

Mouse	112	117	O
cochleae	118	126	B-Multi-tissue_structure
are	127	130	O
highly	131	137	O
resistant	138	147	O
to	148	150	O
systemically	151	163	O
administered	164	176	O
cisplatin	177	186	O
.	186	187	O

However	188	195	O
,	195	196	O
cochlear	197	205	B-Pathological_formation
lesions	206	213	I-Pathological_formation
can	214	217	O
be	218	220	O
produced	221	229	O
effectively	230	241	O
in	242	244	O
mice	245	249	O
when	250	254	O
cisplatin	255	264	O
is	265	267	O
applied	268	275	O
locally	276	283	O
through	284	291	O
the	292	295	O
round	296	301	B-Immaterial_anatomical_entity
window	302	308	I-Immaterial_anatomical_entity
niche	309	314	I-Immaterial_anatomical_entity
or	315	317	O
tympanum	318	326	B-Multi-tissue_structure
.	326	327	O

OBJECTIVE	328	337	O
:	337	338	O

To	339	341	O
explore	342	349	O
the	350	353	O
optimal	354	361	O
approach	362	370	O
for	371	374	O
creating	375	383	O
cisplatin	384	393	O
-	393	394	O
induced	394	401	O
cochlear	402	410	B-Pathological_formation
lesions	411	418	I-Pathological_formation
in	419	421	O
mice	422	426	O
.	426	427	O

MATERIALS	428	437	O
AND	438	441	O
METHODS	442	449	O
:	449	450	O

Cisplatin	451	460	O
was	461	464	O
administered	465	477	O
to	478	480	O
adult	481	486	O
C57BL	487	492	O
/	492	493	O
6J	493	495	O
mice	496	500	O
via	501	504	O
four	505	509	O
approaches	510	520	O
:	520	521	O
(	522	523	O
1	523	524	O
)	524	525	O
transtympanic	526	539	O
injection	540	549	O
,	549	550	O
(	551	552	O
2	552	553	O
)	553	554	O
round	555	560	B-Immaterial_anatomical_entity
window	561	567	I-Immaterial_anatomical_entity
niche	568	573	I-Immaterial_anatomical_entity
injection	574	583	O
,	583	584	O
(	585	586	O
3	586	587	O
)	587	588	O
intraperitoneal	589	604	O
injection	605	614	O
(	615	616	O
i	616	617	O
.	617	618	O
p	618	619	O
.	619	620	O
)	620	621	O
at	622	624	O
4	625	626	O
mg	627	629	O
/	629	630	O
kg	630	632	O
/	632	633	O
day	633	636	O
for	637	640	O
4	641	642	O
consecutive	643	654	O
days	655	659	O
,	659	660	O
and	661	664	O
(	665	666	O
4	666	667	O
)	667	668	O
one	669	672	O
15	673	675	O
mg	676	678	O
/	678	679	O
kg	679	681	O
dose	682	686	O
i	687	688	O
.	688	689	O
p	689	690	O
.	690	691	O

The	692	695	O
hearing	696	703	O
was	704	707	O
monitored	708	717	O
using	718	723	O
frequency	724	733	O
-	733	734	O
specific	734	742	O
auditory	743	751	O
brainstem	752	761	B-Multi-tissue_structure
responses	762	771	O
(	772	773	O
ABRs	773	777	O
)	777	778	O
and	779	782	O
distortion	783	793	O
-	793	794	O
product	794	801	O
otoacoustic	802	813	O
emissions	814	823	O
(	824	825	O
DPOAEs	825	831	O
)	831	832	O
.	832	833	O

Cochlear	834	842	B-Multi-tissue_structure
pathology	843	852	O
was	853	856	O
observed	857	865	O
in	866	868	O
cochleograms	869	881	O
with	882	886	O
Harris	887	893	O
'	893	894	O
hematoxylin	895	906	O
staining	907	915	O
.	915	916	O

RESULTS	917	924	O
:	924	925	O

Cisplatin	926	935	O
applied	936	943	O
systemically	944	956	O
did	957	960	O
not	961	964	O
cause	965	970	O
any	971	974	O
significant	975	986	O
ABR	987	990	O
threshold	991	1000	O
elevation	1001	1010	O
across	1011	1017	O
the	1018	1021	O
frequencies	1022	1033	O
tested	1034	1040	O
(	1041	1042	O
2	1042	1043	O
-	1043	1044	O
32	1044	1046	O
kHz	1047	1050	O
)	1050	1051	O
,	1051	1052	O
whereas	1053	1060	O
local	1061	1066	O
application	1067	1078	O
of	1079	1081	O
cisplatin	1082	1091	O
through	1092	1099	O
the	1100	1103	O
round	1104	1109	B-Immaterial_anatomical_entity
window	1110	1116	I-Immaterial_anatomical_entity
niche	1117	1122	I-Immaterial_anatomical_entity
or	1123	1125	O
tympanum	1126	1134	B-Multi-tissue_structure
resulted	1135	1143	O
in	1144	1146	O
significant	1147	1158	O
ABR	1159	1162	O
threshold	1163	1172	O
elevations	1173	1183	O
from	1184	1188	O
high	1189	1193	O
to	1194	1196	O
medium	1197	1203	O
frequencies	1204	1215	O
.	1215	1216	O

The	1217	1220	O
functional	1221	1231	O
changes	1232	1239	O
were	1240	1244	O
consistent	1245	1255	O
with	1256	1260	O
the	1261	1264	O
cochlear	1265	1273	B-Multi-tissue_structure
pathology	1274	1283	O
across	1284	1290	O
groups	1291	1297	O
.	1297	1298	O

Further	0	7	O
Characterization	8	24	O
of	25	27	O
Activin	28	35	O
A	36	37	O
-	37	38	O
induced	38	45	O
IgA	46	49	O
Response	50	58	O
in	59	61	O
Murine	62	68	O
B	69	70	B-Cell
Lymphocytes	71	82	I-Cell
.	82	83	O

We	84	86	O
have	87	91	O
recently	92	100	O
shown	101	106	O
that	107	111	O
activin	112	119	O
A	120	121	O
,	121	122	O
a	123	124	O
member	125	131	O
of	132	134	O
TGF	135	138	O
-	138	139	O
beta	139	143	O
superfamily	144	155	O
,	155	156	O
stimulates	157	167	O
mouse	168	173	O
B	174	175	B-Cell
cells	176	181	I-Cell
to	182	184	O
express	185	192	O
IgA	193	196	O
isotype	197	204	O
but	205	208	O
other	209	214	O
isotypes	215	223	O
.	223	224	O

In	225	227	O
the	228	231	O
present	232	239	O
study	240	245	O
,	245	246	O
we	247	249	O
further	250	257	O
characterized	258	271	O
effects	272	279	O
of	280	282	O
activin	283	290	O
A	291	292	O
on	293	295	O
B	296	297	B-Cell
cell	298	302	I-Cell
growth	303	309	O
and	310	313	O
IgA	314	317	O
expression	318	328	O
.	328	329	O

We	330	332	O
found	333	338	O
that	339	343	O
activin	344	351	O
A	352	353	O
did	354	357	O
not	358	361	O
have	362	366	O
effect	367	373	O
on	374	376	O
LPS	377	380	O
-	380	381	O
stimulated	381	391	O
cell	392	396	B-Cell
viability	397	406	O
.	406	407	O

In	408	410	O
parallel	411	419	O
,	419	420	O
CFSE	421	425	O
staining	426	434	O
analysis	435	443	O
revealed	444	452	O
that	453	457	O
activin	458	465	O
A	466	467	O
did	468	471	O
not	472	475	O
alter	476	481	O
cell	482	486	B-Cell
division	487	495	O
.	495	496	O

An	497	499	O
increase	500	508	O
of	509	511	O
IgA	512	515	O
secretion	516	525	O
by	526	528	O
activin	529	536	O
A	537	538	O
was	539	542	O
completely	543	553	O
abrogated	554	563	O
by	564	566	O
anti	567	571	O
-	571	572	O
activin	572	579	O
A	580	581	O
Ab	582	584	O
but	585	588	O
not	589	592	O
by	593	595	O
anti	596	600	O
-	600	601	O
TGFbeta1	601	609	O
Ab	610	612	O
.	612	613	O

In	614	616	O
the	617	620	O
same	621	625	O
conditions	626	636	O
,	636	637	O
no	638	640	O
other	641	646	O
isotypes	647	655	O
are	656	659	O
significantly	660	673	O
affected	674	682	O
by	683	685	O
each	686	690	O
antibody	691	699	O
treatment	700	709	O
.	709	710	O

Finally	711	718	O
,	718	719	O
activin	720	727	O
A	728	729	O
,	729	730	O
as	731	733	O
similar	734	741	O
to	742	744	O
TGF	745	748	O
-	748	749	O
beta1	749	754	O
,	754	755	O
increased	756	765	O
IgA	766	769	O
secretion	770	779	O
by	780	782	O
mesenteric	783	793	O
lymph	794	799	B-Cell
node	800	804	I-Cell
cells	805	810	I-Cell
.	810	811	O

These	812	817	O
results	818	825	O
suggest	826	833	O
that	834	838	O
activin	839	846	O
A	847	848	O
can	849	852	O
specifically	853	865	O
stimulate	866	875	O
IgA	876	879	O
response	880	888	O
,	888	889	O
independent	890	901	O
of	902	904	O
TGF	905	908	O
-	908	909	O
beta	909	913	O
in	914	916	O
the	917	920	O
gut	921	924	B-Organism_subdivision
.	924	925	O

Posterior	0	9	O
stabilization	10	23	O
of	24	26	O
the	27	30	O
cervical	31	39	B-Organism_subdivision
spine	40	45	I-Organism_subdivision
with	46	50	O
hook	51	55	O
plates	56	62	O
.	62	63	O

Hook	64	68	O
-	68	69	O
plate	69	74	O
fixation	75	83	O
is	84	86	O
designed	87	95	O
for	96	99	O
posterior	100	109	O
cervical	110	118	B-Organism_subdivision
stabilization	119	132	O
from	133	137	O
C2	138	140	O
to	141	143	O
C7	144	146	O
.	146	147	O

Indications	148	159	O
remain	160	166	O
the	167	170	O
same	171	175	O
as	176	178	O
for	179	182	O
standard	183	191	O
posterior	192	201	O
fixations	202	211	O
.	211	212	O

The	213	216	O
prime	217	222	O
indications	223	234	O
are	235	238	O
discoligamentous	239	255	O
injuries	256	264	O
.	264	265	O

The	266	269	O
plates	270	276	O
are	277	280	O
hooked	281	287	O
under	288	293	O
the	294	297	O
lower	298	303	B-Multi-tissue_structure
laminas	304	311	I-Multi-tissue_structure
and	312	315	O
attached	316	324	O
to	325	327	O
the	328	331	O
articular	332	341	B-Multi-tissue_structure
masses	342	348	I-Multi-tissue_structure
of	349	351	O
the	352	355	O
upper	356	361	O
vertebra	362	370	B-Organ
by	371	373	O
oblique	374	381	O
screws	382	388	O
.	388	389	O

An	390	392	O
H	393	394	O
-	394	395	O
graft	395	400	O
is	401	403	O
placed	404	410	O
between	411	418	O
the	419	422	O
spinous	423	430	O
processes	431	440	O
.	440	441	O

The	442	445	O
vertebrae	446	455	B-Organ
are	456	459	O
compressed	460	470	O
together	471	479	O
by	480	482	O
the	483	486	O
plates	487	493	O
at	494	496	O
three	497	502	O
points	503	509	O
,	509	510	O
the	511	514	O
facet	515	520	O
joints	521	527	O
,	527	528	O
and	529	532	O
graft	533	538	O
.	538	539	O

The	540	543	O
resulting	544	553	O
pre	554	557	O
-	557	558	O
stressed	558	566	O
system	567	573	O
is	574	576	O
stable	577	583	O
in	584	586	O
all	587	590	O
directions	591	601	O
.	601	602	O

A	603	604	O
protocol	605	613	O
for	614	617	O
safe	618	622	O
reduction	623	632	O
of	633	635	O
cervical	636	644	B-Organism_subdivision
dislocations	645	657	O
is	658	660	O
observed	661	669	O
.	669	670	O

Of	671	673	O
70	674	676	O
patients	677	685	O
treated	686	693	O
from	694	698	O
1979	699	703	O
to	704	706	O
1986	707	711	O
,	711	712	O
51	713	715	O
were	716	720	O
examined	721	729	O
12	730	732	O
-	732	733	O
54	733	735	O
months	736	742	O
after	743	748	O
surgery	749	756	O
.	756	757	O

All	758	761	O
fusions	762	769	O
consolidated	770	782	O
.	782	783	O

Two	784	787	O
neurologic	788	798	B-Anatomical_system
complications	799	812	O
not	813	816	O
attributable	817	829	O
to	830	832	O
the	833	836	O
fixation	837	845	O
occurred	846	854	O
.	854	855	O

Other	856	861	O
major	862	867	O
complications	868	881	O
were	882	886	O
not	887	890	O
seen	891	895	O
.	895	896	O

Is	0	2	O
the	3	6	O
elimination	7	18	O
of	19	21	O
HIV	22	25	O
infection	26	35	O
within	36	42	O
reach	43	48	O
in	49	51	O
the	52	55	O
United	56	62	O
States	63	69	O
?	69	70	O

Lessons	71	78	O
from	79	83	O
an	84	86	O
epidemiologic	87	100	O
transmission	101	113	O
model	114	119	O
.	119	120	O

Recent	121	127	O
estimates	128	137	O
show	138	142	O
that	143	147	O
the	148	151	O
transmission	152	164	O
rate	165	169	O
of	170	172	O
human	173	178	O
immunodeficiency	179	195	O
virus	196	201	O
(	202	203	O
HIV	203	206	O
)	206	207	O
in	208	210	O
the	211	214	O
U	215	216	O
.	216	217	O
S	217	218	O
.	218	219	O
has	220	223	O
substantially	224	237	O
decreased	238	247	O
.	247	248	O

This	249	253	O
raises	254	260	O
the	261	264	O
question	265	273	O
,	273	274	O
is	275	277	O
elimination	278	289	O
of	290	292	O
HIV	293	296	O
infection	297	306	O
in	307	309	O
the	310	313	O
nation	314	320	O
feasible	321	329	O
in	330	332	O
the	333	336	O
foreseeable	337	348	O
future	349	355	O
?	355	356	O

We	357	359	O
demonstrate	360	371	O
that	372	376	O
if	377	379	O
the	380	383	O
HIV	384	387	O
transmission	388	400	O
rate	401	405	O
were	406	410	O
reduced	411	418	O
by	419	421	O
50	422	424	O
%	424	425	O
,	425	426	O
then	427	431	O
the	432	435	O
reproductive	436	448	O
rate	449	453	O
of	454	456	O
HIV	457	460	O
infection	461	470	O
would	471	476	O
drop	477	481	O
below	482	487	O
unity	488	493	O
and	494	497	O
lead	498	502	O
to	503	505	O
eventual	506	514	O
elimination	515	526	O
of	527	529	O
infection	530	539	O
.	539	540	O

In	541	543	O
recent	544	550	O
congressional	551	564	O
testimony	565	574	O
,	574	575	O
the	576	579	O
director	580	588	O
of	589	591	O
the	592	595	O
Centers	596	603	O
for	604	607	O
Disease	608	615	O
Control	616	623	O
and	624	627	O
Prevention	628	638	O
and	639	642	O
others	643	649	O
asserted	650	658	O
that	659	663	O
the	664	667	O
HIV	668	671	O
transmission	672	684	O
rate	685	689	O
can	690	693	O
be	694	696	O
halved	697	703	O
by	704	706	O
2020	707	711	O
,	711	712	O
if	713	715	O
not	716	719	O
earlier	720	727	O
,	727	728	O
provided	729	737	O
sufficient	738	748	O
investment	749	759	O
is	760	762	O
made	763	767	O
toward	768	774	O
achieving	775	784	O
this	785	789	O
goal	790	794	O
.	794	795	O

We	796	798	O
assert	799	805	O
that	806	810	O
if	811	813	O
adequate	814	822	O
investment	823	833	O
is	834	836	O
made	837	841	O
and	842	845	O
the	846	849	O
transmission	850	862	O
rate	863	867	O
is	868	870	O
in	871	873	O
fact	874	878	O
lowered	879	886	O
by	887	889	O
50	890	892	O
%	892	893	O
,	893	894	O
then	895	899	O
the	900	903	O
HIV	904	907	O
reproductive	908	920	O
rate	921	925	O
would	926	931	O
fall	932	936	O
below	937	942	O
unity	943	948	O
,	948	949	O
setting	950	957	O
the	958	961	O
stage	962	967	O
for	968	971	O
eventual	972	980	O
elimination	981	992	O
of	993	995	O
HIV	996	999	O
infection	1000	1009	O
in	1010	1012	O
the	1013	1016	O
U	1017	1018	O
.	1018	1019	O
S	1019	1020	O
.	1020	1021	O

Pain	0	4	O
assessment	5	15	O
by	16	18	O
continuous	19	29	O
EEG	30	33	O
:	33	34	O
association	35	46	O
between	47	54	O
subjective	55	65	O
perception	66	76	O
of	77	79	O
tonic	80	85	O
pain	86	90	O
and	91	94	O
peak	95	99	O
frequency	100	109	O
of	110	112	O
alpha	113	118	O
oscillations	119	131	O
during	132	138	O
stimulation	139	150	O
and	151	154	O
at	155	157	O
rest	158	162	O
.	162	163	O

Recordings	164	174	O
of	175	177	O
neurophysiological	178	196	O
brain	197	202	B-Organ
responses	203	212	O
to	213	215	O
noxious	216	223	O
stimuli	224	231	O
have	232	236	O
been	237	241	O
traditionally	242	255	O
based	256	261	O
on	262	264	O
short	265	270	O
stimuli	271	278	O
,	278	279	O
in	280	282	O
the	283	286	O
order	287	292	O
of	293	295	O
milliseconds	296	308	O
,	308	309	O
which	310	315	O
induce	316	322	O
distinct	323	331	O
event	332	337	O
-	337	338	O
related	338	345	O
potentials	346	356	O
(	357	358	O
ERPs	358	362	O
)	362	363	O
.	363	364	O

However	365	372	O
,	372	373	O
using	374	379	O
such	380	384	O
stimuli	385	392	O
in	393	395	O
the	396	399	O
experimental	400	412	O
setting	413	420	O
is	421	423	O
disadvantageous	424	439	O
as	440	442	O
they	443	447	O
are	448	451	O
too	452	455	O
brief	456	461	O
to	462	464	O
faithfully	465	475	O
simulate	476	484	O
clinical	485	493	O
pain	494	498	O
.	498	499	O

We	500	502	O
aimed	503	508	O
at	509	511	O
utilizing	512	521	O
continuous	522	532	O
EEG	533	536	O
to	537	539	O
investigate	540	551	O
the	552	555	O
properties	556	566	O
of	567	569	O
peak	570	574	O
alpha	575	580	O
frequency	581	590	O
(	591	592	O
PAF	592	595	O
)	595	596	O
as	597	599	O
an	600	602	O
objective	603	612	O
cortical	613	621	B-Multi-tissue_structure
measure	622	629	O
associated	630	640	O
with	641	645	O
subjective	646	656	O
perception	657	667	O
of	668	670	O
tonic	671	676	O
pain	677	681	O
.	681	682	O

Five	683	687	O
minute	688	694	O
long	695	699	O
continuous	700	710	O
EEG	711	714	O
was	715	718	O
recorded	719	727	O
in	728	730	O
18	731	733	O
healthy	734	741	O
volunteers	742	752	O
under	753	758	O
:	758	759	O
(	760	761	O
i	761	762	O
)	762	763	O
resting	764	771	O
-	771	772	O
state	772	777	O
;	777	778	O
(	779	780	O
ii	780	782	O
)	782	783	O
innocuous	784	793	O
temperature	794	805	O
;	805	806	O
and	807	810	O
(	811	812	O
iii	812	815	O
)	815	816	O
psychophysically	817	833	O
-	833	834	O
anchored	834	842	O
noxious	843	850	O
temperature	851	862	O
.	862	863	O

Numerical	864	873	O
pain	874	878	O
scores	879	885	O
(	886	887	O
NPSs	887	891	O
)	891	892	O
collected	893	902	O
during	903	909	O
the	910	913	O
application	914	925	O
of	926	928	O
tonic	929	934	O
noxious	935	942	O
stimuli	943	950	O
were	951	955	O
tested	956	962	O
for	963	966	O
correlation	967	978	O
with	979	983	O
peak	984	988	O
frequencies	989	1000	O
of	1001	1003	O
alpha	1004	1009	O
power	1010	1015	O
-	1015	1016	O
curves	1016	1022	O
derived	1023	1030	O
from	1031	1035	O
central	1036	1043	O
,	1043	1044	O
temporal	1045	1053	O
and	1054	1057	O
frontal	1058	1065	O
electrodes	1066	1076	O
.	1076	1077	O

NPSs	1078	1082	O
and	1083	1086	O
PAFs	1087	1091	O
remained	1092	1100	O
stable	1101	1107	O
throughout	1108	1118	O
the	1119	1122	O
recording	1123	1132	O
conditions	1133	1143	O
(	1144	1145	O
RM	1145	1147	O
-	1147	1148	O
ANOVAs	1148	1154	O
;	1154	1155	O
Ps	1156	1158	O
>	1158	1159	O
0	1159	1160	O
.	1160	1161	O
51	1161	1163	O
)	1163	1164	O
.	1164	1165	O

In	1166	1168	O
the	1169	1172	O
noxious	1173	1180	O
condition	1181	1190	O
,	1190	1191	O
PAFs	1192	1196	O
obtained	1197	1205	O
at	1206	1208	O
the	1209	1212	O
bilateral	1213	1222	O
temporal	1223	1231	B-Multi-tissue_structure
scalp	1232	1237	I-Multi-tissue_structure
were	1238	1242	O
correlated	1243	1253	O
with	1254	1258	O
NPSs	1259	1263	O
(	1264	1265	O
Ps	1265	1267	O
<	1267	1268	O
0	1268	1269	O
.	1269	1270	O
001	1270	1273	O
)	1273	1274	O
.	1274	1275	O

Moreover	1276	1284	O
,	1284	1285	O
resting	1286	1293	O
-	1293	1294	O
state	1294	1299	O
PAFs	1300	1304	O
recorded	1305	1313	O
at	1314	1316	O
the	1317	1320	O
bilateral	1321	1330	O
temporal	1331	1339	B-Multi-tissue_structure
scalp	1340	1345	I-Multi-tissue_structure
were	1346	1350	O
correlated	1351	1361	O
with	1362	1366	O
NPSs	1367	1371	O
reported	1372	1380	O
during	1381	1387	O
the	1388	1391	O
noxious	1392	1399	O
condition	1400	1409	O
(	1410	1411	O
Ps	1411	1413	O
<	1413	1414	O
0	1414	1415	O
.	1415	1416	O
01	1416	1418	O
)	1418	1419	O
.	1419	1420	O

These	1421	1426	O
psychophysical	1427	1441	O
-	1441	1442	O
neurophysiological	1442	1460	O
relations	1461	1470	O
attest	1471	1477	O
to	1478	1480	O
the	1481	1484	O
properties	1485	1495	O
of	1496	1498	O
PAF	1499	1502	O
as	1503	1505	O
a	1506	1507	O
novel	1508	1513	O
cortical	1514	1522	B-Multi-tissue_structure
objective	1523	1532	O
measure	1533	1540	O
of	1541	1543	O
subjective	1544	1554	O
perception	1555	1565	O
of	1566	1568	O
tonic	1569	1574	O
pain	1575	1579	O
.	1579	1580	O

Moreover	1581	1589	O
,	1589	1590	O
resting	1591	1598	O
-	1598	1599	O
state	1599	1604	O
PAFs	1605	1609	O
might	1610	1615	O
hold	1616	1620	O
inherent	1621	1629	O
pain	1630	1634	O
modulation	1635	1645	O
attributes	1646	1656	O
,	1656	1657	O
possibly	1658	1666	O
enabling	1667	1675	O
the	1676	1679	O
prediction	1680	1690	O
of	1691	1693	O
individual	1694	1704	O
responsiveness	1705	1719	O
to	1720	1722	O
prolonged	1723	1732	O
pain	1733	1737	O
.	1737	1738	O

The	1739	1742	O
relevance	1743	1752	O
of	1753	1755	O
PAF	1756	1759	O
to	1760	1762	O
the	1763	1766	O
neural	1767	1773	B-Cell
processing	1774	1784	O
of	1785	1787	O
tonic	1788	1793	O
pain	1794	1798	O
may	1799	1802	O
indicate	1803	1811	O
its	1812	1815	O
potential	1816	1825	O
to	1826	1828	O
advance	1829	1836	O
pain	1837	1841	O
research	1842	1850	O
as	1851	1853	O
well	1854	1858	O
as	1859	1861	O
clinical	1862	1870	O
pain	1871	1875	O
characterization	1876	1892	O
.	1892	1893	O

Acoustic	0	8	O
trauma	9	15	O
evokes	16	22	O
hyperactivity	23	36	O
and	37	40	O
changes	41	48	O
in	49	51	O
gene	52	56	O
expression	57	67	O
in	68	70	O
guinea	71	77	O
-	77	78	O
pig	78	81	O
auditory	82	90	O
brainstem	91	100	B-Multi-tissue_structure
.	100	101	O

Hearing	102	109	O
loss	110	114	O
from	115	119	O
acoustic	120	128	O
trauma	129	135	O
is	136	138	O
a	139	140	O
risk	141	145	O
factor	146	152	O
for	153	156	O
tinnitus	157	165	O
.	165	166	O

Animal	167	173	O
models	174	180	O
using	181	186	O
acoustic	187	195	O
trauma	196	202	O
have	203	207	O
demonstrated	208	220	O
hyperactivity	221	234	O
in	235	237	O
central	238	245	O
auditory	246	254	O
pathways	255	263	O
,	263	264	O
which	265	270	O
has	271	274	O
been	275	279	O
suggested	280	289	O
as	290	292	O
a	293	294	O
substrate	295	304	O
for	305	308	O
tinnitus	309	317	O
.	317	318	O

We	319	321	O
used	322	326	O
a	327	328	O
guinea	329	335	O
-	335	336	O
pig	336	339	O
model	340	345	O
of	346	348	O
unilateral	349	359	O
acoustic	360	368	O
trauma	369	375	O
.	375	376	O

Within	377	383	O
the	384	387	O
same	388	392	O
animals	393	400	O
,	400	401	O
measurements	402	414	O
of	415	417	O
peripheral	418	428	O
hearing	429	436	O
loss	437	441	O
,	441	442	O
spontaneous	443	454	O
activity	455	463	O
of	464	466	O
single	467	473	O
neurons	474	481	B-Cell
in	482	484	O
the	485	488	O
inferior	489	497	B-Multi-tissue_structure
colliculus	498	508	I-Multi-tissue_structure
and	509	512	O
gene	513	517	O
expression	518	528	O
in	529	531	O
cochlear	532	540	B-Multi-tissue_structure
nucleus	541	548	I-Multi-tissue_structure
and	549	552	O
inferior	553	561	B-Multi-tissue_structure
colliculus	562	572	I-Multi-tissue_structure
were	573	577	O
combined	578	586	O
,	586	587	O
acutely	588	595	O
and	596	599	O
after	600	605	O
recovery	606	614	O
from	615	619	O
acoustic	620	628	O
trauma	629	635	O
.	635	636	O

Genes	637	642	O
investigated	643	655	O
related	656	663	O
to	664	666	O
inhibitory	667	677	O
(	678	679	O
GABA	679	683	O
-	683	684	O
A	684	685	O
receptor	686	694	O
subunit	695	702	O
alpha	703	708	O
1	709	710	O
;	710	711	O
glycine	712	719	O
receptor	720	728	O
subunit	729	736	O
alpha	737	742	O
1	743	744	O
)	744	745	O
and	746	749	O
excitatory	750	760	O
neurotransmission	761	778	O
(	779	780	O
glutamate	780	789	O
decarboxylase	790	803	O
1	804	805	O
;	805	806	O
glutamate	807	816	O
receptor	817	825	O
AMPA	826	830	O
subunit	831	838	O
alpha	839	844	O
2	845	846	O
;	846	847	O
glutamate	848	857	O
receptor	858	866	O
NMDA	867	871	O
subunit	872	879	O
1	880	881	O
)	881	882	O
,	882	883	O
regulation	884	894	O
of	895	897	O
transmitter	898	909	O
release	910	917	O
(	918	919	O
member	919	925	O
of	926	928	O
RAB	929	932	O
family	933	939	O
of	940	942	O
small	943	948	O
GTPase	949	955	O
;	955	956	O
RAB3	957	961	O
GTPase	962	968	O
activating	969	979	O
protein	980	987	O
subunit	988	995	O
1	996	997	O
)	997	998	O
and	999	1002	O
neuronal	1003	1011	B-Cell
excitability	1012	1024	O
(	1025	1026	O
potassium	1026	1035	O
channel	1036	1043	O
subfamily	1044	1053	O
K	1054	1055	O
member	1056	1062	O
15	1063	1065	O
)	1065	1066	O
.	1066	1067	O

Acoustic	1068	1076	O
trauma	1077	1083	O
resulted	1084	1092	O
in	1093	1095	O
unilateral	1096	1106	O
hearing	1107	1114	O
loss	1115	1119	O
and	1120	1123	O
hyperactivity	1124	1137	O
bilaterally	1138	1149	O
in	1150	1152	O
inferior	1153	1161	B-Multi-tissue_structure
colliculus	1162	1172	I-Multi-tissue_structure
.	1172	1173	O

Changes	1174	1181	O
in	1182	1184	O
expression	1185	1195	O
of	1196	1198	O
different	1199	1208	O
mRNAs	1209	1214	O
were	1215	1219	O
observed	1220	1228	O
in	1229	1231	O
ipsilateral	1232	1243	O
cochlear	1244	1252	B-Multi-tissue_structure
nucleus	1253	1260	I-Multi-tissue_structure
and	1261	1264	O
in	1265	1267	O
ipsi	1268	1272	O
-	1272	1273	O
and	1274	1277	O
contralateral	1278	1291	O
inferior	1292	1300	B-Multi-tissue_structure
colliculus	1301	1311	I-Multi-tissue_structure
,	1311	1312	O
immediately	1313	1324	O
after	1325	1330	O
acoustic	1331	1339	O
trauma	1340	1346	O
,	1346	1347	O
and	1348	1351	O
after	1352	1357	O
2	1358	1359	O
and	1360	1363	O
4	1364	1365	O
weeks	1366	1371	O
'	1371	1372	O
recovery	1373	1381	O
.	1381	1382	O

Gene	1383	1387	O
expression	1388	1398	O
was	1399	1402	O
generally	1403	1412	O
reduced	1413	1420	O
immediately	1421	1432	O
after	1433	1438	O
trauma	1439	1445	O
,	1445	1446	O
followed	1447	1455	O
by	1456	1458	O
a	1459	1460	O
return	1461	1467	O
to	1468	1470	O
near	1471	1475	O
normal	1476	1482	O
levels	1483	1489	O
or	1490	1492	O
over	1493	1497	O
-	1497	1498	O
expression	1498	1508	O
as	1509	1511	O
recovery	1512	1520	O
time	1521	1525	O
increased	1526	1535	O
.	1535	1536	O

Different	1537	1546	O
mechanisms	1547	1557	O
appear	1558	1564	O
to	1565	1567	O
underlie	1568	1576	O
the	1577	1580	O
spontaneous	1581	1592	O
hyperactivity	1593	1606	O
observed	1607	1615	O
.	1615	1616	O

There	1617	1622	O
is	1623	1625	O
evidence	1626	1634	O
of	1635	1637	O
down	1638	1642	O
-	1642	1643	O
regulation	1643	1653	O
of	1654	1656	O
genes	1657	1662	O
associated	1663	1673	O
with	1674	1678	O
neuronal	1679	1687	B-Cell
inhibition	1688	1698	O
in	1699	1701	O
the	1702	1705	O
contralateral	1706	1719	O
inferior	1720	1728	B-Multi-tissue_structure
colliculus	1729	1739	I-Multi-tissue_structure
,	1739	1740	O
whereas	1741	1748	O
in	1749	1751	O
ipsilateral	1752	1763	O
cochlear	1764	1772	B-Multi-tissue_structure
nucleus	1773	1780	I-Multi-tissue_structure
,	1780	1781	O
competing	1782	1791	O
actions	1792	1799	O
of	1800	1802	O
inhibitory	1803	1813	O
and	1814	1817	O
excitatory	1818	1828	O
systems	1829	1836	O
seem	1837	1841	O
to	1842	1844	O
play	1845	1849	O
a	1850	1851	O
major	1852	1857	O
role	1858	1862	O
in	1863	1865	O
determining	1866	1877	O
overall	1878	1885	O
excitability	1886	1898	O
.	1898	1899	O

Yellow	0	6	O
-	6	7	O
green	7	12	O
52	13	15	O
.	15	16	O
3W	16	18	O
laser	19	24	O
at	25	27	O
556nm	28	33	O
based	34	39	O
on	40	42	O
frequency	43	52	O
doubling	53	61	O
of	62	64	O
a	65	66	O
diode	67	72	O
side	73	77	O
-	77	78	O
pumped	78	84	O
Q	85	86	O
-	86	87	O
switched	87	95	O
Nd	96	98	O
:	98	99	O
YAG	99	102	O
laser	103	108	O
.	108	109	O

We	110	112	O
demonstrate	113	124	O
a	125	126	O
high	127	131	O
-	131	132	O
power	132	137	O
556nm	138	143	O
yellow	144	150	O
-	150	151	O
green	151	156	O
laser	157	162	O
generated	163	172	O
by	173	175	O
intracavity	176	187	O
frequency	188	197	O
doubling	198	206	O
of	207	209	O
a	210	211	O
diode	212	217	O
side	218	222	O
-	222	223	O
pumped	223	229	O
Nd	230	232	O
:	232	233	O
YAG	233	236	O
laser	237	242	O
at	243	245	O
1112nm	246	252	O
.	252	253	O

A	254	255	O
symmetrical	256	267	O
L	268	269	O
-	269	270	O
shaped	270	276	O
flat	277	281	O
-	281	282	O
flat	282	286	O
cavity	287	293	O
was	294	297	O
employed	298	306	O
to	307	309	O
implement	310	319	O
efficient	320	329	O
operation	330	339	O
of	340	342	O
the	343	346	O
low	347	350	O
-	350	351	O
gain	351	355	O
1112nm	356	362	O
transition	363	373	O
and	374	377	O
to	378	380	O
achieve	381	388	O
good	389	393	O
power	394	399	O
scalability	400	411	O
.	411	412	O

The	413	416	O
coatings	417	425	O
of	426	428	O
the	429	432	O
cavity	433	439	O
mirrors	440	447	O
were	448	452	O
carefully	453	462	O
designed	463	471	O
to	472	474	O
optimize	475	483	O
the	484	487	O
performance	488	499	O
of	500	502	O
the	503	506	O
laser	507	512	O
,	512	513	O
and	514	517	O
a	518	519	O
92W	520	523	O
continuous	524	534	O
wave	535	539	O
laser	540	545	O
output	546	552	O
at	553	555	O
1112nm	556	562	O
was	563	566	O
achieved	567	575	O
when	576	580	O
the	581	584	O
pumping	585	592	O
power	593	598	O
of	599	601	O
the	602	605	O
laser	606	611	O
diodes	612	618	O
reached	619	626	O
960W	627	631	O
.	631	632	O

By	633	635	O
intracavity	636	647	O
frequency	648	657	O
doubling	658	666	O
of	667	669	O
the	670	673	O
fundamental	674	685	O
laser	686	691	O
in	692	694	O
a	695	696	O
lithium	697	704	O
triborate	705	714	O
crystal	715	722	O
,	722	723	O
the	724	727	O
maximum	728	735	O
power	736	741	O
of	742	744	O
the	745	748	O
frequency	749	758	O
-	758	759	O
doubled	759	766	O
output	767	773	O
at	774	776	O
556nm	777	782	O
was	783	786	O
found	787	792	O
to	793	795	O
be	796	798	O
as	799	801	O
high	802	806	O
as	807	809	O
52	810	812	O
.	812	813	O
3W	813	815	O
with	816	820	O
a	821	822	O
pulse	823	828	O
repetition	829	839	O
frequency	840	849	O
of	850	852	O
10kHz	853	858	O
.	858	859	O

This	860	864	O
corresponds	865	876	O
to	877	879	O
an	880	882	O
optical	883	890	O
-	890	891	O
to	891	893	O
-	893	894	O
optical	894	901	O
conversion	902	912	O
efficiency	913	923	O
of	924	926	O
about	927	932	O
5	933	934	O
.	934	935	O
4	935	936	O
%	936	937	O
.	937	938	O

Ventral	0	7	B-Multi-tissue_structure
and	8	11	O
dorsal	12	18	B-Multi-tissue_structure
striatal	19	27	I-Multi-tissue_structure
dopamine	28	36	O
efflux	37	43	O
and	44	47	O
behavior	48	56	O
in	57	59	O
rats	60	64	O
with	65	69	O
simple	70	76	O
vs	77	79	O
.	79	80	O
co	81	83	O
-	83	84	O
morbid	84	90	O
histories	91	100	O
of	101	103	O
cocaine	104	111	O
sensitization	112	125	O
and	126	129	O
neonatal	130	138	B-Pathological_formation
ventral	139	146	I-Pathological_formation
hippocampal	147	158	I-Pathological_formation
lesions	159	166	I-Pathological_formation
.	166	167	O

UNLABELLED	168	178	O
:	178	179	O

RATIONAL	180	188	O
:	188	189	O
Exposing	190	198	O
animal	199	205	O
models	206	212	O
of	213	215	O
mental	216	222	O
illness	223	230	O
to	231	233	O
addictive	234	243	O
drugs	244	249	O
provides	250	258	O
an	259	261	O
approach	262	270	O
to	271	273	O
understanding	274	287	O
the	288	291	O
neural	292	298	B-Multi-tissue_structure
etiology	299	307	O
of	308	310	O
dual	311	315	O
diagnosis	316	325	O
disorders	326	335	O
.	335	336	O

Previous	337	345	O
studies	346	353	O
have	354	358	O
shown	359	364	O
that	365	369	O
neonatal	370	378	B-Pathological_formation
ventral	379	386	I-Pathological_formation
hippocampal	387	398	I-Pathological_formation
lesions	399	406	I-Pathological_formation
(	407	408	O
NVHL	408	412	B-Pathological_formation
)	412	413	O
in	414	416	O
rats	417	421	O
produce	422	429	O
features	430	438	O
of	439	441	O
both	442	446	O
schizophrenia	447	460	O
and	461	464	O
addiction	465	474	O
vulnerability	475	488	O
.	488	489	O

OBJECTIVE	490	499	O
:	499	500	O

This	501	505	O
study	506	511	O
investigated	512	524	O
ventral	525	532	B-Multi-tissue_structure
and	533	536	O
dorsal	537	543	B-Multi-tissue_structure
striatal	544	552	I-Multi-tissue_structure
dopamine	553	561	O
(	562	563	O
DA	563	565	O
)	565	566	O
efflux	567	573	O
in	574	576	O
NVHL	577	581	B-Pathological_formation
rats	582	586	O
combined	587	595	O
with	596	600	O
behavioral	601	611	O
sensitization	612	625	O
to	626	628	O
cocaine	629	636	O
.	636	637	O

METHODS	638	645	O
:	645	646	O

Adult	647	652	O
NVHL	653	657	B-Pathological_formation
vs	658	660	O
.	660	661	O
SHAM	662	666	O
-	666	667	O
operated	667	675	O
rats	676	680	O
underwent	681	690	O
a	691	692	O
5	693	694	O
-	694	695	O
day	695	698	O
injection	699	708	O
series	709	715	O
of	716	718	O
cocaine	719	726	O
(	727	728	O
15	728	730	O
mg	731	733	O
/	733	734	O
kg	734	736	O
/	736	737	O
day	737	740	O
)	740	741	O
vs	742	744	O
.	744	745	O
saline	746	752	O
.	752	753	O

One	754	757	O
week	758	762	O
later	763	768	O
,	768	769	O
rats	770	774	O
were	775	779	O
cannulated	780	790	O
in	791	793	O
nucleus	794	801	B-Multi-tissue_structure
accumbens	802	811	I-Multi-tissue_structure
SHELL	812	817	O
,	817	818	O
CORE	819	823	O
,	823	824	O
or	825	827	O
caudate	828	835	B-Multi-tissue_structure
-	835	836	I-Multi-tissue_structure
putamen	836	843	I-Multi-tissue_structure
.	843	844	O

Another	845	852	O
week	853	857	O
later	858	863	O
,	863	864	O
in	865	867	O
vivo	868	872	O
microdialysis	873	886	O
sampled	887	894	O
DA	895	897	O
during	898	904	O
locomotor	905	914	O
testing	915	922	O
in	923	925	O
which	926	931	O
a	932	933	O
single	934	940	O
cocaine	941	948	O
injection	949	958	O
(	959	960	O
15	960	962	O
mg	963	965	O
/	965	966	O
kg	966	968	O
)	968	969	O
was	970	973	O
delivered	974	983	O
.	983	984	O

RESULTS	985	992	O
:	992	993	O

NVHLs	994	999	B-Pathological_formation
and	1000	1003	O
cocaine	1004	1011	O
history	1012	1019	O
significantly	1020	1033	O
increased	1034	1043	O
behavioral	1044	1054	O
activation	1055	1065	O
approximately	1066	1079	O
2	1080	1081	O
-	1081	1082	O
fold	1082	1086	O
over	1087	1091	O
SHAM	1092	1096	O
-	1096	1097	O
saline	1097	1103	O
history	1104	1111	O
rats	1112	1116	O
.	1116	1117	O

DA	1118	1120	O
efflux	1121	1127	O
curves	1128	1134	O
corresponded	1135	1147	O
time	1148	1152	O
dependently	1153	1164	O
with	1165	1169	O
the	1170	1173	O
cocaine	1174	1181	O
injection	1182	1191	O
and	1192	1195	O
locomotor	1196	1205	O
curves	1206	1212	O
and	1213	1216	O
varied	1217	1223	O
significantly	1224	1237	O
by	1238	1240	O
striatal	1241	1249	B-Multi-tissue_structure
region	1250	1256	I-Multi-tissue_structure
:	1256	1257	O
Baseline	1258	1266	O
DA	1267	1269	O
levels	1270	1276	O
increased	1277	1286	O
5	1287	1288	O
-	1288	1289	O
fold	1289	1293	O
while	1294	1299	O
cocaine	1300	1307	O
-	1307	1308	O
stimulated	1308	1318	O
DA	1319	1321	O
efflux	1322	1328	O
decreased	1329	1338	O
by	1339	1341	O
half	1342	1346	O
across	1347	1353	O
a	1354	1355	O
ventral	1356	1363	B-Multi-tissue_structure
to	1364	1366	O
dorsal	1367	1373	B-Multi-tissue_structure
striatal	1374	1382	I-Multi-tissue_structure
gradient	1383	1391	O
.	1391	1392	O

However	1393	1400	O
,	1400	1401	O
NVHLs	1402	1407	B-Pathological_formation
,	1407	1408	O
prior	1409	1414	O
cocaine	1415	1422	O
history	1423	1430	O
,	1430	1431	O
and	1432	1435	O
individual	1436	1446	O
differences	1447	1458	O
in	1459	1461	O
behavior	1462	1470	O
were	1471	1475	O
not	1476	1479	O
underpinned	1480	1491	O
by	1492	1494	O
differential	1495	1507	O
DA	1508	1510	O
efflux	1511	1517	O
overall	1518	1525	O
or	1526	1528	O
within	1529	1535	O
any	1536	1539	O
striatal	1540	1548	B-Multi-tissue_structure
region	1549	1555	I-Multi-tissue_structure
.	1555	1556	O

CONCLUSION	1557	1567	O
:	1567	1568	O

Differences	1569	1580	O
in	1581	1583	O
ventral	1584	1591	B-Multi-tissue_structure
/	1591	1592	O
dorsal	1592	1598	B-Multi-tissue_structure
striatal	1599	1607	I-Multi-tissue_structure
DA	1608	1610	O
efflux	1611	1617	O
are	1618	1621	O
not	1622	1625	O
present	1626	1633	O
in	1634	1636	O
and	1637	1640	O
are	1641	1644	O
not	1645	1648	O
required	1649	1657	O
for	1658	1661	O
producing	1662	1671	O
differential	1672	1684	O
levels	1685	1691	O
of	1692	1694	O
acute	1695	1700	O
cocaine	1701	1708	O
-	1708	1709	O
induced	1709	1716	O
behavioral	1717	1727	O
activation	1728	1738	O
in	1739	1741	O
NVHLs	1742	1747	B-Pathological_formation
with	1748	1752	O
and	1753	1756	O
without	1757	1764	O
a	1765	1766	O
behaviorally	1767	1779	O
sensitizing	1780	1791	O
cocaine	1792	1799	O
history	1800	1807	O
.	1807	1808	O

These	1809	1814	O
findings	1815	1823	O
suggest	1824	1831	O
other	1832	1837	O
neurotransmitter	1838	1854	O
systems	1855	1862	O
,	1862	1863	O
and	1864	1867	O
alterations	1868	1879	O
in	1880	1882	O
striatal	1883	1891	B-Multi-tissue_structure
network	1892	1899	O
function	1900	1908	O
post	1909	1913	O
-	1913	1914	O
synaptic	1914	1922	O
to	1923	1925	O
DA	1926	1928	O
transmission	1929	1941	O
are	1942	1945	O
more	1946	1950	O
important	1951	1960	O
to	1961	1963	O
understanding	1964	1977	O
the	1978	1981	O
interactive	1982	1993	O
effects	1994	2001	O
of	2002	2004	O
addictive	2005	2014	O
drugs	2015	2020	O
and	2021	2024	O
mental	2025	2031	O
illness	2032	2039	O
.	2039	2040	O

Predictive	0	10	O
value	11	16	O
of	17	19	O
serum	20	25	B-Organism_substance
carbohydrate	26	38	O
antigen	39	46	O
19	47	49	O
-	49	50	O
9	50	51	O
in	52	54	O
malignant	55	64	O
intraductal	65	76	O
papillary	77	86	B-Pathological_formation
mucinous	87	95	I-Pathological_formation
neoplasms	96	105	I-Pathological_formation
.	105	106	O

BACKGROUND	107	117	O
:	117	118	O

The	119	122	O
goal	123	127	O
of	128	130	O
the	131	134	O
present	135	142	O
study	143	148	O
was	149	152	O
to	153	155	O
evaluate	156	164	O
the	165	168	O
predictive	169	179	O
value	180	185	O
of	186	188	O
serum	189	194	B-Organism_substance
carbohydrate	195	207	O
antigen	208	215	O
19	216	218	O
-	218	219	O
9	219	220	O
(	221	222	O
CA	222	224	O
19	225	227	O
-	227	228	O
9	228	229	O
)	229	230	O
in	231	233	O
the	234	237	O
diagnosis	238	247	O
of	248	250	O
malignant	251	260	O
intraductal	261	272	B-Pathological_formation
papillary	273	282	I-Pathological_formation
mucinous	283	291	I-Pathological_formation
neoplasms	292	301	I-Pathological_formation
of	302	304	O
pancreas	305	313	B-Organ
(	314	315	O
IPMNs	315	320	B-Pathological_formation
)	320	321	O
.	321	322	O

METHODS	323	330	O
:	330	331	O

Eighty	332	338	O
-	338	339	O
six	339	342	O
patients	343	351	O
with	352	356	O
pathological	357	369	O
diagnosis	370	379	O
of	380	382	O
IPMNs	383	388	B-Pathological_formation
in	389	391	O
Zhongshan	392	401	O
Hospital	402	410	O
between	411	418	O
March	419	424	O
1999	425	429	O
and	430	433	O
November	434	442	O
2008	443	447	O
were	448	452	O
retrospectively	453	468	O
reviewed	469	477	O
.	477	478	O

Data	479	483	O
reflecting	484	494	O
clinical	495	503	O
characteristics	504	519	O
,	519	520	O
tumor	521	526	B-Pathological_formation
marker	527	533	O
level	534	539	O
,	539	540	O
and	541	544	O
prognosis	545	554	O
were	555	559	O
collected	560	569	O
.	569	570	O

The	571	574	O
potential	575	584	O
predictive	585	595	O
value	596	601	O
of	602	604	O
CA	605	607	O
19	608	610	O
-	610	611	O
9	611	612	O
was	613	616	O
analyzed	617	625	O
by	626	628	O
receiver	629	637	O
operating	638	647	O
characteristic	648	662	O
(	663	664	O
ROC	664	667	O
)	667	668	O
curve	669	674	O
.	674	675	O

RESULTS	676	683	O
:	683	684	O

Eighty	685	691	O
-	691	692	O
six	692	695	O
consecutive	696	707	O
patients	708	716	O
with	717	721	O
IPMNs	722	727	B-Pathological_formation
all	728	731	O
underwent	732	741	O
surgical	742	750	O
intervention	751	763	O
.	763	764	O

A	765	766	O
high	767	771	O
level	772	777	O
of	778	780	O
CA	781	783	O
19	784	786	O
-	786	787	O
9	787	788	O
or	789	791	O
carcinoembryonic	792	808	O
antigen	809	816	O
(	817	818	O
CEA	818	821	O
)	821	822	O
was	823	826	O
associated	827	837	O
with	838	842	O
more	843	847	O
advanced	848	856	O
stage	857	862	O
of	863	865	O
malignant	866	875	O
IPMNs	876	881	B-Pathological_formation
.	881	882	O

Carbohydrate	883	895	O
antigen	896	903	O
19	904	906	O
-	906	907	O
9	907	908	O
was	909	912	O
significant	913	924	O
for	925	928	O
judging	929	936	O
malignant	937	946	O
IPMNs	947	952	B-Pathological_formation
in	953	955	O
the	956	959	O
binary	960	966	O
logistic	967	975	O
regression	976	986	O
model	987	992	O
(	993	994	O
p	994	995	O
=	995	996	O
0	996	997	O
.	997	998	O
047	998	1001	O
)	1001	1002	O
.	1002	1003	O

The	1004	1007	O
hazard	1008	1014	O
ratio	1015	1020	O
was	1021	1024	O
1	1025	1026	O
.	1026	1027	O
014	1027	1030	O
,	1030	1031	O
whose	1032	1037	O
95	1038	1040	O
.	1040	1041	O
0	1041	1042	O
%	1042	1043	O
confidence	1044	1054	O
interval	1055	1063	O
was	1064	1067	O
0	1068	1069	O
.	1069	1070	O
91	1070	1072	O
-	1072	1073	O
1	1073	1074	O
.	1074	1075	O
028	1075	1078	O
.	1078	1079	O

Receiver	1080	1088	O
operating	1089	1098	O
characteristic	1099	1113	O
analysis	1114	1122	O
showed	1123	1129	O
that	1130	1134	O
the	1135	1138	O
serum	1139	1144	B-Organism_substance
CA	1145	1147	O
19	1148	1150	O
-	1150	1151	O
9	1151	1152	O
level	1153	1158	O
had	1159	1162	O
good	1163	1167	O
predictive	1168	1178	O
value	1179	1184	O
for	1185	1188	O
malignant	1189	1198	O
or	1199	1201	O
invasive	1202	1210	O
IPMNs	1211	1216	B-Pathological_formation
,	1216	1217	O
postoperative	1218	1231	O
survival	1232	1240	O
,	1240	1241	O
and	1242	1245	O
disease	1246	1253	O
-	1253	1254	O
specific	1254	1262	O
recurrence	1263	1273	O
.	1273	1274	O

The	1275	1278	O
area	1279	1283	O
under	1284	1289	O
the	1290	1293	O
curve	1294	1299	O
(	1300	1301	O
AUC	1301	1304	O
)	1304	1305	O
was	1306	1309	O
0	1310	1311	O
.	1311	1312	O
856	1312	1315	O
,	1315	1316	O
0	1317	1318	O
.	1318	1319	O
893	1319	1322	O
,	1322	1323	O
0	1324	1325	O
.	1325	1326	O
815	1326	1329	O
,	1329	1330	O
and	1331	1334	O
0	1335	1336	O
.	1336	1337	O
857	1337	1340	O
(	1341	1342	O
p	1342	1343	O
<	1343	1344	O
0	1344	1345	O
.	1345	1346	O
05	1346	1348	O
)	1348	1349	O
,	1349	1350	O
respectively	1351	1363	O
.	1363	1364	O

According	1365	1374	O
to	1375	1377	O
the	1378	1381	O
follow	1382	1388	O
-	1388	1389	O
up	1389	1391	O
,	1391	1392	O
mean	1393	1397	O
survival	1398	1406	O
time	1407	1411	O
for	1412	1415	O
groups	1416	1422	O
with	1423	1427	O
CA	1428	1430	O
19	1431	1433	O
-	1433	1434	O
9	1434	1435	O
>	1435	1436	O
63	1436	1438	O
.	1438	1439	O
60	1439	1441	O
U	1442	1443	O
/	1443	1444	O
ml	1444	1446	O
was	1447	1450	O
dramatically	1451	1463	O
shorter	1464	1471	O
than	1472	1476	O
that	1477	1481	O
for	1482	1485	O
groups	1486	1492	O
with	1493	1497	O
CA	1498	1500	O
19	1501	1503	O
-	1503	1504	O
9	1504	1505	O
<	1505	1506	O
=	1506	1507	O
63	1507	1509	O
.	1509	1510	O
60	1510	1512	O
U	1513	1514	O
/	1514	1515	O
ml	1515	1517	O
(	1518	1519	O
57	1519	1521	O
.	1521	1522	O
38	1522	1524	O
+	1524	1525	O
/	1525	1526	O
-	1526	1527	O
2	1527	1528	O
.	1528	1529	O
85	1529	1531	O
versus	1532	1538	O
29	1539	1541	O
.	1541	1542	O
24	1542	1544	O
+	1544	1545	O
/	1545	1546	O
-	1546	1547	O
5	1547	1548	O
.	1548	1549	O
82	1549	1551	O
[	1552	1553	O
months	1553	1559	O
]	1559	1560	O
;	1560	1561	O
p	1562	1563	O
<	1563	1564	O
0	1564	1565	O
.	1565	1566	O
01	1566	1568	O
)	1568	1569	O
.	1569	1570	O

CONCLUSIONS	1571	1582	O
:	1582	1583	O

Serum	1584	1589	B-Organism_substance
CA	1590	1592	O
19	1593	1595	O
-	1595	1596	O
9	1596	1597	O
level	1598	1603	O
has	1604	1607	O
good	1608	1612	O
predictive	1613	1623	O
value	1624	1629	O
for	1630	1633	O
malignant	1634	1643	O
or	1644	1646	O
invasive	1647	1655	O
IPMNs	1656	1661	B-Pathological_formation
.	1661	1662	O

Patients	1663	1671	O
with	1672	1676	O
CA	1677	1679	O
19	1680	1682	O
-	1682	1683	O
9	1683	1684	O
>	1685	1686	O
63	1687	1689	O
.	1689	1690	O
60	1690	1692	O
U	1693	1694	O
/	1694	1695	O
ml	1695	1697	O
had	1698	1701	O
poor	1702	1706	O
postoperative	1707	1720	O
prognosis	1721	1730	O
in	1731	1733	O
IPMNs	1734	1739	B-Pathological_formation
.	1739	1740	O

Preoperative	1741	1753	O
abnormal	1754	1762	O
serum	1763	1768	B-Organism_substance
CA	1769	1771	O
19	1772	1774	O
-	1774	1775	O
9	1775	1776	O
might	1777	1782	O
be	1783	1785	O
predictive	1786	1796	O
for	1797	1800	O
an	1801	1803	O
aggressive	1804	1814	O
surgical	1815	1823	O
intervention	1824	1836	O
in	1837	1839	O
IPMNs	1840	1845	B-Pathological_formation
.	1845	1846	O

Saliva	0	6	O
proteins	7	15	O
of	16	18	O
vector	19	25	O
Culicoides	26	36	O
modify	37	43	O
structure	44	53	O
and	54	57	O
infectivity	58	69	O
of	70	72	O
bluetongue	73	83	O
virus	84	89	O
particles	90	99	O
.	99	100	O

Bluetongue	101	111	O
virus	112	117	O
(	118	119	O
BTV	119	122	O
)	122	123	O
and	124	127	O
epizootic	128	137	O
haemorrhagic	138	150	O
disease	151	158	O
virus	159	164	O
(	165	166	O
EHDV	166	170	O
)	170	171	O
are	172	175	O
related	176	183	O
orbiviruses	184	195	O
,	195	196	O
transmitted	197	208	O
between	209	216	O
their	217	222	O
ruminant	223	231	O
hosts	232	237	O
primarily	238	247	O
by	248	250	O
certain	251	258	O
haematophagous	259	273	O
midge	274	279	O
vectors	280	287	O
(	288	289	O
Culicoides	289	299	O
spp	300	303	O
.	303	304	O
)	304	305	O
.	305	306	O

The	307	310	O
larger	311	317	O
of	318	320	O
the	321	324	O
BTV	325	328	O
outer	329	334	O
-	334	335	O
capsid	335	341	O
proteins	342	350	O
,	350	351	O
'	352	353	O
VP2	353	356	O
'	356	357	O
,	357	358	O
can	359	362	O
be	363	365	O
cleaved	366	373	O
by	374	376	O
proteases	377	386	O
(	387	388	O
including	388	397	O
trypsin	398	405	O
or	406	408	O
chymotrypsin	409	421	O
)	421	422	O
,	422	423	O
forming	424	431	O
infectious	432	442	O
subviral	443	451	O
particles	452	461	O
(	462	463	O
ISVP	463	467	O
)	467	468	O
which	469	474	O
have	475	479	O
enhanced	480	488	O
infectivity	489	500	O
for	501	504	O
adult	505	510	O
Culicoides	511	521	O
,	521	522	O
or	523	525	O
KC	526	528	B-Cell
cells	529	534	I-Cell
(	535	536	O
a	536	537	O
cell	538	542	B-Cell
-	542	543	I-Cell
line	543	547	I-Cell
derived	548	555	O
from	556	560	O
C	561	562	O
.	562	563	O
sonorensis	564	574	O
)	574	575	O
.	575	576	O

We	577	579	O
demonstrate	580	591	O
that	592	596	O
VP2	597	600	O
present	601	608	O
on	609	611	O
purified	612	620	O
virus	621	626	O
particles	627	636	O
from	637	641	O
3	642	643	O
different	644	653	O
BTV	654	657	O
strains	658	665	O
can	666	669	O
also	670	674	O
be	675	677	O
cleaved	678	685	O
by	686	688	O
treatment	689	698	O
with	699	703	O
saliva	704	710	O
from	711	715	O
adult	716	721	O
Culicoides	722	732	O
.	732	733	O

The	734	737	O
saliva	738	744	O
proteins	745	753	O
from	754	758	O
C	759	760	O
.	760	761	O
sonorensis	762	772	O
(	773	774	O
a	774	775	O
competent	776	785	O
BTV	786	789	O
vector	790	796	O
)	796	797	O
,	797	798	O
cleaved	799	806	O
BTV	807	810	O
-	810	811	O
VP2	811	814	O
more	815	819	O
efficiently	820	831	O
than	832	836	O
those	837	842	O
from	843	847	O
C	848	849	O
.	849	850	O
nubeculosus	851	862	O
(	863	864	O
a	864	865	O
less	866	870	O
competent	871	880	O
/	880	881	O
non	881	884	O
-	884	885	O
vector	885	891	O
species	892	899	O
)	899	900	O
.	900	901	O

Electrophoresis	902	917	O
and	918	921	O
mass	922	926	O
spectrometry	927	939	O
identified	940	950	O
a	951	952	O
trypsin	953	960	O
-	960	961	O
like	961	965	O
protease	966	974	O
in	975	977	O
C	978	979	O
.	979	980	O
sonorensis	981	991	O
saliva	992	998	O
,	998	999	O
which	1000	1005	O
was	1006	1009	O
significantly	1010	1023	O
reduced	1024	1031	O
or	1032	1034	O
absent	1035	1041	O
from	1042	1046	O
C	1047	1048	O
.	1048	1049	O
nubeculosus	1050	1061	O
saliva	1062	1068	O
.	1068	1069	O

Incubating	1070	1080	O
purified	1081	1089	O
BTV	1090	1093	O
-	1093	1094	O
1	1094	1095	O
with	1096	1100	O
C	1101	1102	O
.	1102	1103	O
sonorensis	1104	1114	O
saliva	1115	1121	O
proteins	1122	1130	O
also	1131	1135	O
increased	1136	1145	O
their	1146	1151	O
infectivity	1152	1163	O
for	1164	1167	O
KC	1168	1170	B-Cell
cells	1171	1176	I-Cell
~	1177	1178	O
10	1178	1180	O
fold	1181	1185	O
,	1185	1186	O
while	1187	1192	O
infectivity	1193	1204	O
for	1205	1208	O
BHK	1209	1212	B-Cell
cells	1213	1218	I-Cell
was	1219	1222	O
reduced	1223	1230	O
by	1231	1233	O
2	1234	1235	O
-	1235	1236	O
6	1236	1237	O
fold	1238	1242	O
.	1242	1243	O

Treatment	1244	1253	O
of	1254	1256	O
an	1257	1259	O
'	1260	1261	O
eastern	1261	1268	O
'	1268	1269	O
strain	1270	1276	O
of	1277	1279	O
EHDV	1280	1284	O
-	1284	1285	O
2	1285	1286	O
with	1287	1291	O
saliva	1292	1298	O
proteins	1299	1307	O
of	1308	1310	O
either	1311	1317	O
C	1318	1319	O
.	1319	1320	O
sonorensis	1321	1331	O
or	1332	1334	O
C	1335	1336	O
.	1336	1337	O
nubeculosus	1338	1349	O
cleaved	1350	1357	O
VP2	1358	1361	O
,	1361	1362	O
but	1363	1366	O
a	1367	1368	O
'	1369	1370	O
western	1370	1377	O
'	1377	1378	O
strain	1379	1385	O
of	1386	1388	O
EHDV	1389	1393	O
-	1393	1394	O
2	1394	1395	O
remained	1396	1404	O
unmodified	1405	1415	O
.	1415	1416	O

These	1417	1422	O
results	1423	1430	O
indicate	1431	1439	O
that	1440	1444	O
temperature	1445	1456	O
,	1456	1457	O
strain	1458	1464	O
of	1465	1467	O
virus	1468	1473	O
and	1474	1477	O
protein	1478	1485	O
composition	1486	1497	O
of	1498	1500	O
Culicoides	1501	1511	O
saliva	1512	1518	O
(	1519	1520	O
particularly	1520	1532	O
its	1533	1536	O
protease	1537	1545	O
content	1546	1553	O
which	1554	1559	O
is	1560	1562	O
dependent	1563	1572	O
upon	1573	1577	O
vector	1578	1584	O
species	1585	1592	O
)	1592	1593	O
,	1593	1594	O
can	1595	1598	O
all	1599	1602	O
play	1603	1607	O
a	1608	1609	O
significant	1610	1621	O
role	1622	1626	O
in	1627	1629	O
the	1630	1633	O
efficiency	1634	1644	O
of	1645	1647	O
VP2	1648	1651	O
cleavage	1652	1660	O
,	1660	1661	O
influencing	1662	1673	O
virus	1674	1679	O
infectivity	1680	1691	O
.	1691	1692	O

Saliva	1693	1699	O
of	1700	1702	O
several	1703	1710	O
other	1711	1716	O
arthropod	1717	1726	O
species	1727	1734	O
has	1735	1738	O
previously	1739	1749	O
been	1750	1754	O
shown	1755	1760	O
to	1761	1763	O
increase	1764	1772	O
transmission	1773	1785	O
,	1785	1786	O
infectivity	1787	1798	O
and	1799	1802	O
virulence	1803	1812	O
of	1813	1815	O
certain	1816	1823	O
arboviruses	1824	1835	O
,	1835	1836	O
by	1837	1839	O
modulating	1840	1850	O
and	1851	1854	O
/	1854	1855	O
or	1855	1857	O
suppressing	1858	1869	O
the	1870	1873	O
mammalian	1874	1883	O
immune	1884	1890	O
response	1891	1899	O
.	1899	1900	O

The	1901	1904	O
findings	1905	1913	O
presented	1914	1923	O
here	1924	1928	O
,	1928	1929	O
however	1930	1937	O
,	1937	1938	O
demonstrate	1939	1950	O
a	1951	1952	O
novel	1953	1958	O
mechanism	1959	1968	O
by	1969	1971	O
which	1972	1977	O
proteases	1978	1987	O
in	1988	1990	O
Culicoides	1991	2001	O
saliva	2002	2008	O
can	2009	2012	O
also	2013	2017	O
directly	2018	2026	O
modify	2027	2033	O
the	2034	2037	O
orbivirus	2038	2047	O
particle	2048	2056	O
structure	2057	2066	O
,	2066	2067	O
leading	2068	2075	O
to	2076	2078	O
increased	2079	2088	O
infectivity	2089	2100	O
specifically	2101	2113	O
for	2114	2117	O
Culicoides	2118	2128	O
cells	2129	2134	B-Cell
and	2135	2138	O
,	2138	2139	O
in	2140	2142	O
turn	2143	2147	O
,	2147	2148	O
efficiency	2149	2159	O
of	2160	2162	O
transmission	2163	2175	O
to	2176	2178	O
the	2179	2182	O
insect	2183	2189	O
vector	2190	2196	O
.	2196	2197	O

mirAct	0	6	O
:	6	7	O
a	8	9	O
web	10	13	O
tool	14	18	O
for	19	22	O
evaluating	23	33	O
microRNA	34	42	O
activity	43	51	O
based	52	57	O
on	58	60	O
gene	61	65	O
expression	66	76	O
data	77	81	O
.	81	82	O

MicroRNAs	83	92	O
(	93	94	O
miRNAs	94	100	O
)	100	101	O
are	102	105	O
critical	106	114	O
regulators	115	125	O
in	126	128	O
the	129	132	O
complex	133	140	O
cellular	141	149	B-Cell
networks	150	158	O
.	158	159	O

The	160	163	O
mirAct	164	170	O
web	171	174	O
server	175	181	O
(	182	183	O
http	183	187	O
:	187	188	O
/	188	189	O
/	189	190	O
sysbio	190	196	O
.	196	197	O
ustc	197	201	O
.	201	202	O
edu	202	205	O
.	205	206	O
cn	206	208	O
/	208	209	O
software	209	217	O
/	217	218	O
mirAct	218	224	O
)	224	225	O
is	226	228	O
a	229	230	O
tool	231	235	O
designed	236	244	O
to	245	247	O
investigate	248	259	O
miRNA	260	265	O
activity	266	274	O
based	275	280	O
on	281	283	O
gene	284	288	O
-	288	289	O
expression	289	299	O
data	300	304	O
by	305	307	O
using	308	313	O
the	314	317	O
negative	318	326	O
regulation	327	337	O
relationship	338	350	O
between	351	358	O
miRNAs	359	365	O
and	366	369	O
their	370	375	O
target	376	382	O
genes	383	388	O
.	388	389	O

mirAct	390	396	O
supports	397	405	O
multiple	406	414	O
-	414	415	O
class	415	420	O
data	421	425	O
and	426	429	O
enables	430	437	O
clustering	438	448	O
analysis	449	457	O
based	458	463	O
on	464	466	O
computationally	467	482	O
determined	483	493	O
miRNA	494	499	O
activity	500	508	O
.	508	509	O

Here	510	514	O
,	514	515	O
we	516	518	O
describe	519	527	O
the	528	531	O
framework	532	541	O
of	542	544	O
mirAct	545	551	O
,	551	552	O
demonstrate	553	564	O
its	565	568	O
performance	569	580	O
by	581	583	O
comparing	584	593	O
with	594	598	O
other	599	604	O
similar	605	612	O
programs	613	621	O
and	622	625	O
exemplify	626	635	O
its	636	639	O
applications	640	652	O
using	653	658	O
case	659	663	O
studies	664	671	O
.	671	672	O

Non	0	3	O
-	3	4	O
heart	4	9	B-Organ
-	9	10	O
beating	10	17	O
organ	18	23	B-Organ
donation	24	32	O
in	33	35	O
Italy	36	41	O
.	41	42	O

In	43	45	O
2007	46	50	O
the	51	54	O
non	55	58	O
-	58	59	O
heart	59	64	B-Organ
-	64	65	O
beating	65	72	O
organ	73	78	B-Organ
donation	79	87	O
(	88	89	O
NHBD	89	93	O
)	93	94	O
"	95	96	O
Programma	96	105	O
Alba	106	110	O
"	110	111	O
(	112	113	O
Sunrise	113	120	O
Programme	121	130	O
)	130	131	O
started	132	139	O
in	140	142	O
Pavia	143	148	O
,	148	149	O
Italy	150	155	O
.	155	156	O

The	157	160	O
initial	161	168	O
plan	169	173	O
was	174	177	O
to	178	180	O
cut	181	184	O
down	185	189	O
waiting	190	197	O
list	198	202	O
for	203	206	O
kidney	207	213	B-Organ
transplantation	214	229	O
,	229	230	O
while	231	236	O
its	237	240	O
final	241	246	O
aim	247	250	O
is	251	253	O
to	254	256	O
shorten	257	264	O
organ	265	270	B-Organ
transplantation	271	286	O
waiting	287	294	O
lists	295	300	O
.	300	301	O

When	302	306	O
compared	307	315	O
to	316	318	O
European	319	327	O
countries	328	337	O
and	338	341	O
the	342	345	O
USA	346	349	O
,	349	350	O
the	351	354	O
Italian	355	362	O
NHBD	363	367	O
program	368	375	O
has	376	379	O
taken	380	385	O
longer	386	392	O
to	393	395	O
get	396	399	O
established	400	411	O
.	411	412	O

Initially	413	422	O
Italian	423	430	O
physicians	431	441	O
were	442	446	O
not	447	450	O
entirely	451	459	O
aware	460	465	O
of	466	468	O
the	469	472	O
NHBD	473	477	O
organ	478	483	B-Organ
viability	484	493	O
for	494	497	O
transplantation	498	513	O
,	513	514	O
furthermore	515	526	O
ethical	527	534	O
issues	535	541	O
and	542	545	O
the	546	549	O
need	550	554	O
to	555	557	O
regulate	558	566	O
medical	567	574	O
requirements	575	587	O
to	588	590	O
Italian	591	598	O
law	599	602	O
slowed	603	609	O
down	610	614	O
the	615	618	O
NHBD	619	623	O
program	624	631	O
.	631	632	O

In	633	635	O
particular	636	646	O
,	646	647	O
Italian	648	655	O
legislation	656	667	O
provides	668	676	O
for	677	680	O
death	681	686	O
ascertainment	687	700	O
after	701	706	O
irreversible	707	719	O
cardiac	720	727	B-Organ
arrest	728	734	O
,	734	735	O
20	736	738	O
-	738	739	O
minute	739	745	O
flat	746	750	O
electrocardiogram	751	768	O
.	768	769	O

This	770	774	O
no	775	777	O
-	777	778	O
touch	778	783	O
period	784	790	O
is	791	793	O
longer	794	800	O
when	801	805	O
compared	806	814	O
to	815	817	O
worldwide	818	827	O
legislation	828	839	O
,	839	840	O
and	841	844	O
organ	845	850	B-Organ
viability	851	860	O
has	861	864	O
been	865	869	O
a	870	871	O
main	872	876	O
concern	877	884	O
for	885	888	O
Italian	889	896	O
transplant	897	907	O
doctors	908	915	O
over	916	920	O
the	921	924	O
years	925	930	O
.	930	931	O

However	932	939	O
,	939	940	O
recent	941	947	O
data	948	952	O
let	953	956	O
up	957	959	O
to	960	962	O
40	963	965	O
-	965	966	O
minute	966	972	O
warm	973	977	O
ischemia	978	986	O
time	987	991	O
to	992	994	O
preserve	995	1003	O
organ	1004	1009	B-Organ
viability	1010	1019	O
;	1019	1020	O
this	1021	1025	O
has	1026	1029	O
encouraged	1030	1040	O
Pavia	1041	1046	O
'	1046	1047	O
s	1047	1048	O
group	1049	1054	O
to	1055	1057	O
establish	1058	1067	O
the	1068	1071	O
NHBD	1072	1076	O
"	1077	1078	O
Programma	1078	1087	O
Alba	1088	1092	O
"	1092	1093	O
.	1093	1094	O

It	1095	1097	O
was	1098	1101	O
designed	1102	1110	O
according	1111	1120	O
to	1121	1123	O
Italian	1124	1131	O
legislation	1132	1143	O
from	1144	1148	O
death	1149	1154	O
diagnosis	1155	1164	O
to	1165	1167	O
graft	1168	1173	B-Organ
placement	1174	1183	O
,	1183	1184	O
from	1185	1189	O
this	1190	1194	O
perspective	1195	1206	O
must	1207	1211	O
the	1212	1215	O
significant	1216	1227	O
role	1228	1232	O
of	1233	1235	O
the	1236	1239	O
Transplant	1240	1250	O
coordinator	1251	1262	O
be	1263	1265	O
recognized	1266	1276	O
.	1276	1277	O

Since	1278	1283	O
2007	1284	1288	O
seven	1289	1294	O
kidneys	1295	1302	B-Organ
have	1303	1307	O
been	1308	1312	O
gathered	1313	1321	O
from	1322	1326	O
seven	1327	1332	O
NHBD	1333	1337	O
.	1337	1338	O

Of	1339	1341	O
these	1342	1347	O
,	1347	1348	O
six	1349	1352	O
NHBD	1353	1357	O
kidneys	1358	1365	B-Organ
have	1366	1370	O
been	1371	1375	O
transplanted	1376	1388	O
.	1388	1389	O

Currently	1390	1399	O
,	1399	1400	O
four	1401	1405	O
patients	1406	1414	O
are	1415	1418	O
out	1419	1422	O
of	1423	1425	O
dialysis	1426	1434	O
.	1434	1435	O

This	1436	1440	O
report	1441	1447	O
is	1448	1450	O
a	1451	1452	O
detailed	1453	1461	O
description	1462	1473	O
of	1474	1476	O
NHBD	1477	1481	O
"	1482	1483	O
Programma	1483	1492	O
Alba	1493	1497	O
"	1497	1498	O
and	1499	1502	O
its	1503	1506	O
preliminary	1507	1518	O
results	1519	1526	O
.	1526	1527	O

Massive	0	7	O
osteolysis	8	18	O
in	19	21	O
a	22	23	O
dog	24	27	O
resembling	28	38	O
Gorham	39	45	O
'	45	46	O
s	46	47	O
disease	48	55	O
in	56	58	O
humans	59	65	O
.	65	66	O

An	67	69	O
eight	70	75	O
-	75	76	O
month	76	81	O
-	81	82	O
old	82	85	O
mixed	86	91	O
-	91	92	O
breed	92	97	O
dog	98	101	O
was	102	105	O
presented	106	115	O
with	116	120	O
a	121	122	O
history	123	130	O
of	131	133	O
sudden	134	140	O
onset	141	146	O
pelvic	147	153	B-Organism_subdivision
limb	154	158	I-Organism_subdivision
lameness	159	167	O
.	167	168	O

Radiographic	169	181	O
and	182	185	O
computed	186	194	O
tomographic	195	206	O
examinations	207	219	O
demonstrated	220	232	O
an	233	235	O
osteolytic	236	246	O
process	247	254	O
involving	255	264	O
the	265	268	O
lumbar	269	275	B-Organ
spine	276	281	I-Organ
and	282	285	O
pelvis	286	292	B-Organ
.	292	293	O

A	294	295	O
comprehensive	296	309	O
work	310	314	O
-	314	315	O
up	315	317	O
including	318	327	O
serial	328	334	O
radiographic	335	347	O
skeletal	348	356	B-Anatomical_system
survey	357	363	O
,	363	364	O
biopsy	365	371	O
,	371	372	O
routine	373	380	O
laboratory	381	391	O
investigation	392	405	O
and	406	409	O
evaluation	410	420	O
of	421	423	O
parathyroid	424	435	O
hormone	436	443	O
(	444	445	O
PTH	445	448	O
)	448	449	O
and	450	453	O
25	454	456	O
-	456	457	O
hydroxy	457	464	O
-	464	465	O
vitamin	465	472	O
D	473	474	O
levels	475	481	O
failed	482	488	O
to	489	491	O
reveal	492	498	O
any	499	502	O
underlying	503	513	O
cause	514	519	O
for	520	523	O
the	524	527	O
osteolysis	528	538	O
.	538	539	O

Conservative	540	552	O
treatment	553	562	O
using	563	568	O
the	569	572	O
bisphosphonate	573	587	O
drug	588	592	O
alendronate	593	604	O
and	605	608	O
oral	609	613	O
analgesic	614	623	O
medications	624	635	O
resulted	636	644	O
in	645	647	O
a	648	649	O
return	650	656	O
to	657	659	O
nearly	660	666	O
normal	667	673	O
long	674	678	O
-	678	679	O
term	679	683	O
function	684	692	O
,	692	693	O
despite	694	701	O
massive	702	709	O
lumbar	710	716	O
and	717	720	O
pelvic	721	727	O
osteolysis	728	738	O
.	738	739	O

The	740	743	O
clinical	744	752	O
,	752	753	O
radiological	754	766	O
and	767	770	O
histopathological	771	788	O
features	789	797	O
in	798	800	O
this	801	805	O
dog	806	809	O
are	810	813	O
reported	814	822	O
,	822	823	O
and	824	827	O
similarities	828	840	O
with	841	845	O
the	846	849	O
human	850	855	O
condition	856	865	O
known	866	871	O
as	872	874	O
Gorham	875	881	O
'	881	882	O
s	882	883	O
disease	884	891	O
are	892	895	O
discussed	896	905	O
.	905	906	O

[	0	1	O
Rubella	1	8	O
in	9	11	O
Poland	12	18	O
in	19	21	O
2009	22	26	O
]	26	27	O
.	27	28	O

In	29	31	O
Poland	32	38	O
,	38	39	O
7	40	41	O
,	41	42	O
587	42	45	O
cases	46	51	O
of	52	54	O
rubella	55	62	O
were	63	67	O
registered	68	78	O
in	79	81	O
2009	82	86	O
(	87	88	O
incidence	88	97	O
19	98	100	O
.	100	101	O
9	101	102	O
per	103	106	O
100	107	110	O
,	110	111	O
000	111	114	O
population	115	125	O
)	125	126	O
.	126	127	O

According	128	137	O
to	138	140	O
a	141	142	O
new	143	146	O
rubella	147	154	O
case	155	159	O
definition	160	170	O
,	170	171	O
introduced	172	182	O
in	183	185	O
2009	186	190	O
,	190	191	O
7	192	193	O
(	194	195	O
0	195	196	O
.	196	197	O
1	197	198	O
%	198	199	O
)	199	200	O
cases	201	206	O
were	207	211	O
classified	212	222	O
as	223	225	O
confirmed	226	235	O
cases	236	241	O
,	241	242	O
30	243	245	O
(	246	247	O
0	247	248	O
.	248	249	O
4	249	250	O
%	250	251	O
)	251	252	O
as	253	255	O
probable	256	264	O
.	264	265	O

One	266	269	O
case	270	274	O
of	275	277	O
congenital	278	288	O
rubella	289	296	O
syndrome	297	305	O
was	306	309	O
reported	310	318	O
.	318	319	O

The	320	323	O
incidence	324	333	O
in	334	336	O
men	337	340	O
(	341	342	O
26	342	344	O
.	344	345	O
6	345	346	O
)	346	347	O
was	348	351	O
1	352	353	O
.	353	354	O
9	354	355	O
-	355	356	O
times	356	361	O
higher	362	368	O
than	369	373	O
in	374	376	O
women	377	382	O
(	383	384	O
13	384	386	O
.	386	387	O
6	387	388	O
)	388	389	O
.	389	390	O

The	391	394	O
highest	395	402	O
incidence	403	412	O
was	413	416	O
observed	417	425	O
in	426	428	O
children	429	437	O
aged	438	442	O
7	443	444	O
and	445	448	O
8	449	450	O
years	451	456	O
(	457	458	O
180	458	461	O
.	461	462	O
3	462	463	O
and	464	467	O
175	468	471	O
.	471	472	O
6	472	473	O
,	473	474	O
respectively	475	487	O
)	487	488	O
.	488	489	O

No	490	492	O
rubella	493	500	O
deaths	501	507	O
were	508	512	O
registered	513	523	O
.	523	524	O

An	525	527	O
improvement	528	539	O
of	540	542	O
laboratory	543	553	O
diagnosis	554	563	O
of	564	566	O
reported	567	575	O
cases	576	581	O
is	582	584	O
necessary	585	594	O
to	595	597	O
assess	598	604	O
the	605	608	O
impact	609	615	O
of	616	618	O
2	619	620	O
-	620	621	O
dose	621	625	O
immunization	626	638	O
implemented	639	650	O
in	651	653	O
2003	654	658	O
on	659	661	O
rubella	662	669	O
epidemiology	670	682	O
in	683	685	O
Poland	686	692	O
.	692	693	O

Burns	0	5	O
from	6	10	O
hot	11	14	O
wheat	15	20	O
bags	21	25	O
:	25	26	O
a	27	28	O
public	29	35	O
safety	36	42	O
issue	43	48	O
.	48	49	O

Introduction	50	62	O
:	62	63	O
Wheat	64	69	O
bags	70	74	O
are	75	78	O
therapeutic	79	90	O
devices	91	98	O
that	99	103	O
are	104	107	O
heated	108	114	O
in	115	117	O
microwaves	118	128	O
and	129	132	O
commonly	133	141	O
used	142	146	O
to	147	149	O
provide	150	157	O
relief	158	164	O
from	165	169	O
muscle	170	176	B-Organ
and	177	180	O
joint	181	186	B-Multi-tissue_structure
pain	187	191	O
.	191	192	O

The	193	196	O
Royal	197	202	O
Adelaide	203	211	O
Hospital	212	220	O
Burns	221	226	O
Unit	227	231	O
has	232	235	O
observed	236	244	O
a	245	246	O
number	247	253	O
of	254	256	O
patients	257	265	O
with	266	270	O
significant	271	282	O
burn	283	287	O
injuries	288	296	O
resulting	297	306	O
from	307	311	O
their	312	317	O
use	318	321	O
.	321	322	O

Despite	323	330	O
their	331	336	O
dangers	337	344	O
,	344	345	O
the	346	349	O
products	350	358	O
come	359	363	O
with	364	368	O
limited	369	376	O
safety	377	383	O
information	384	395	O
.	395	396	O

Methods	397	404	O
:	404	405	O
Data	406	410	O
were	411	415	O
collected	416	425	O
from	426	430	O
the	431	434	O
Burns	435	440	O
Unit	441	445	O
database	446	454	O
for	455	458	O
all	459	462	O
patients	463	471	O
admitted	472	480	O
with	481	485	O
burns	486	491	O
due	492	495	O
to	496	498	O
hot	499	502	O
wheat	503	508	O
bags	509	513	O
from	514	518	O
2004	519	523	O
to	524	526	O
2009	527	531	O
.	531	532	O

This	533	537	O
was	538	541	O
analyzed	542	550	O
to	551	553	O
determine	554	563	O
the	564	567	O
severity	568	576	O
of	577	579	O
the	580	583	O
burn	584	588	O
injury	589	595	O
and	596	599	O
identify	600	608	O
any	609	612	O
predisposing	613	625	O
factors	626	633	O
.	633	634	O

An	635	637	O
experimental	638	650	O
study	651	656	O
was	657	660	O
performed	661	670	O
to	671	673	O
measure	674	681	O
the	682	685	O
temperature	686	697	O
of	698	700	O
wheat	701	706	O
bags	707	711	O
when	712	716	O
heated	717	723	O
to	724	726	O
determine	727	736	O
their	737	742	O
potential	743	752	O
for	753	756	O
causing	757	764	O
thermal	765	772	O
injury	773	779	O
.	779	780	O

Results	781	788	O
:	788	789	O
11	790	792	O
patients	793	801	O
were	802	806	O
admitted	807	815	O
with	816	820	O
burns	821	826	O
due	827	830	O
to	831	833	O
hot	834	837	O
wheat	838	843	O
bags	844	848	O
.	848	849	O

The	850	853	O
median	854	860	O
age	861	864	O
was	865	868	O
52	869	871	O
years	872	877	O
and	878	881	O
the	882	885	O
mean	886	890	O
total	891	896	O
body	897	901	B-Organism_subdivision
surface	902	909	I-Organism_subdivision
area	910	914	I-Organism_subdivision
was	915	918	O
1	919	920	O
.	920	921	O
1	921	922	O
%	922	923	O
.	923	924	O

All	925	928	O
burns	929	934	O
were	935	939	O
either	940	946	O
deep	947	951	O
dermal	952	958	B-Multi-tissue_structure
(	959	960	O
45	960	962	O
.	962	963	O
5	963	964	O
%	964	965	O
)	965	966	O
or	967	969	O
full	970	974	O
thickness	975	984	O
(	985	986	O
54	986	988	O
.	988	989	O
5	989	990	O
%	990	991	O
)	991	992	O
.	992	993	O

Ten	994	997	O
patients	998	1006	O
required	1007	1015	O
operative	1016	1025	O
management	1026	1036	O
.	1036	1037	O

Predisposing	1038	1050	O
factors	1051	1058	O
(	1059	1060	O
eg	1060	1062	O
,	1062	1063	O
neuropathy	1064	1074	O
)	1074	1075	O
to	1076	1078	O
thermal	1079	1086	O
injury	1087	1093	O
were	1094	1098	O
identified	1099	1109	O
in	1110	1112	O
7	1113	1114	O
patients	1115	1123	O
.	1123	1124	O

The	1125	1128	O
experimental	1129	1141	O
study	1142	1147	O
showed	1148	1154	O
that	1155	1159	O
hot	1160	1163	O
wheat	1164	1169	O
bags	1170	1174	O
reached	1175	1182	O
temperatures	1183	1195	O
of	1196	1198	O
57	1199	1201	O
.	1201	1202	O
3degreesC	1202	1211	O
(	1212	1213	O
135	1213	1216	O
.	1216	1217	O
1degreesF	1217	1226	O
)	1226	1227	O
when	1228	1232	O
heated	1233	1239	O
according	1240	1249	O
to	1250	1252	O
instructions	1253	1265	O
,	1265	1266	O
63	1267	1269	O
.	1269	1270	O
3degreesC	1270	1279	O
(	1280	1281	O
145	1281	1284	O
.	1284	1285	O
9degreesF	1285	1294	O
)	1294	1295	O
in	1296	1298	O
a	1299	1300	O
1000	1301	1305	O
W	1306	1307	O
microwave	1308	1317	O
and	1318	1321	O
69	1322	1324	O
.	1324	1325	O
6degreesC	1325	1334	O
(	1335	1336	O
157	1336	1339	O
.	1339	1340	O
3degreesF	1340	1349	O
)	1349	1350	O
on	1351	1353	O
reheating	1354	1363	O
.	1363	1364	O

Conclusions	1365	1376	O
:	1376	1377	O
Hot	1378	1381	O
wheat	1382	1387	O
bags	1388	1392	O
cause	1393	1398	O
serious	1399	1406	O
burn	1407	1411	O
injury	1412	1418	O
.	1418	1419	O

When	1420	1424	O
heated	1425	1431	O
improperly	1432	1442	O
,	1442	1443	O
they	1444	1448	O
can	1449	1452	O
reach	1453	1458	O
temperatures	1459	1471	O
high	1472	1476	O
enough	1477	1483	O
to	1484	1486	O
cause	1487	1492	O
epidermal	1493	1502	B-Multi-tissue_structure
necrosis	1503	1511	O
in	1512	1514	O
a	1515	1516	O
short	1517	1522	O
period	1523	1529	O
of	1530	1532	O
time	1533	1537	O
.	1537	1538	O

Patients	1539	1547	O
with	1548	1552	O
impaired	1553	1561	O
temperature	1562	1573	O
sensation	1574	1583	O
are	1584	1587	O
particularly	1588	1600	O
at	1601	1603	O
risk	1604	1608	O
.	1608	1609	O

There	1610	1615	O
should	1616	1622	O
be	1623	1625	O
greater	1626	1633	O
public	1634	1640	O
awareness	1641	1650	O
of	1651	1653	O
the	1654	1657	O
dangers	1658	1665	O
of	1666	1668	O
wheat	1669	1674	O
bag	1675	1678	O
use	1679	1682	O
and	1683	1686	O
more	1687	1691	O
specific	1692	1700	O
safety	1701	1707	O
warnings	1708	1716	O
on	1717	1719	O
the	1720	1723	O
products	1724	1732	O
.	1732	1733	O

The	0	3	O
enlarging	4	13	O
clinical	14	22	O
spectrum	23	31	O
of	32	34	O
Lyme	35	39	O
disease	40	47	O
:	47	48	O
Lyme	49	53	O
cerebral	54	62	B-Organ
vasculitis	63	73	O
,	73	74	O
a	75	76	O
new	77	80	O
disease	81	88	O
entity	89	95	O
.	95	96	O

The	97	100	O
case	101	105	O
of	106	108	O
a	109	110	O
patient	111	118	O
with	119	123	O
cerebral	124	132	B-Organ
vasculitis	133	143	O
with	144	148	O
a	149	150	O
right	151	156	B-Multi-tissue_structure
thalamic	157	165	I-Multi-tissue_structure
infarct	166	173	O
associated	174	184	O
with	185	189	O
cerebral	190	198	B-Organism_substance
spinal	199	205	I-Organism_substance
fluid	206	211	I-Organism_substance
Lyme	212	216	O
disease	217	224	O
is	225	227	O
presented	228	237	O
.	237	238	O

This	239	243	O
entity	244	250	O
has	251	254	O
not	255	258	O
been	259	263	O
described	264	273	O
in	274	276	O
the	277	280	O
United	281	287	O
States	288	294	O
,	294	295	O
and	296	299	O
only	300	304	O
one	305	308	O
similar	309	316	O
case	317	321	O
in	322	324	O
the	325	328	O
world	329	334	O
literature	335	345	O
could	346	351	O
be	352	354	O
found	355	360	O
.	360	361	O

The	362	365	O
patient	366	373	O
presented	374	383	O
with	384	388	O
a	389	390	O
progressive	391	402	O
headache	403	411	O
and	412	415	O
subsequent	416	426	O
development	427	438	O
of	439	441	O
grand	442	447	O
mal	448	451	O
seizure	452	459	O
activity	460	468	O
.	468	469	O

Lyme	470	474	O
disease	475	482	O
has	483	486	O
been	487	491	O
associated	492	502	O
with	503	507	O
cranial	508	515	B-Multi-tissue_structure
nerve	516	521	I-Multi-tissue_structure
palsies	522	529	O
,	529	530	O
peripheral	531	541	O
and	542	545	O
cranial	546	553	B-Organism_subdivision
radiculopathies	554	569	O
,	569	570	O
aseptic	571	578	O
meningitis	579	589	O
,	589	590	O
encephalitic	591	603	O
symptoms	604	612	O
,	612	613	O
chorea	614	620	O
,	620	621	O
and	622	625	O
demyelinating	626	639	O
polyneuropathy	640	654	O
presenting	655	665	O
like	666	670	O
Guillain	671	679	O
-	679	680	O
Barre	680	685	O
syndrome	686	694	O
.	694	695	O

These	696	701	O
syndromes	702	711	O
can	712	715	O
occur	716	721	O
separately	722	732	O
or	733	735	O
in	736	738	O
combination	739	750	O
.	750	751	O

Stroke	752	758	O
and	759	762	O
strokelike	763	773	O
syndromes	774	783	O
have	784	788	O
been	789	793	O
attributed	794	804	O
to	805	807	O
Lyme	808	812	O
disease	813	820	O
.	820	821	O

The	822	825	O
literature	826	836	O
concerning	837	847	O
the	848	851	O
neurologic	852	862	B-Anatomical_system
manifestations	863	877	O
of	878	880	O
Lyme	881	885	O
disease	886	893	O
is	894	896	O
reviewed	897	905	O
.	905	906	O

Gastric	0	7	B-Organ
microcirculatory	8	24	O
change	25	31	O
and	32	35	O
development	36	47	O
of	48	50	O
acute	51	56	O
gastric	57	64	B-Pathological_formation
mucosal	65	72	I-Pathological_formation
lesions	73	80	I-Pathological_formation
(	81	82	O
stress	82	88	B-Pathological_formation
ulcer	89	94	I-Pathological_formation
)	94	95	O
.	95	96	O

Concerning	97	107	O
the	108	111	O
pathogenesis	112	124	O
of	125	127	O
acute	128	133	O
gastric	134	141	B-Pathological_formation
mucosal	142	149	I-Pathological_formation
lesions	150	157	I-Pathological_formation
,	157	158	O
gastric	159	166	B-Organ
microcirculatory	167	183	O
change	184	190	O
has	191	194	O
drawn	195	200	O
attention	201	210	O
as	211	213	O
an	214	216	O
important	217	226	O
factor	227	233	O
.	233	234	O

In	235	237	O
view	238	242	O
of	243	245	O
this	246	250	O
fact	251	255	O
,	255	256	O
gastric	257	264	B-Multi-tissue_structure
mucosal	265	272	I-Multi-tissue_structure
blood	273	278	B-Organism_substance
flow	279	283	O
and	284	287	O
microvascular	288	301	B-Tissue
structure	302	311	O
were	312	316	O
investigated	317	329	O
in	330	332	O
normal	333	339	O
and	340	343	O
in	344	346	O
burn	347	351	O
stressed	352	360	O
rats	361	365	O
.	365	366	O

Moreover	367	375	O
,	375	376	O
alterations	377	388	O
in	389	391	O
acid	392	396	O
and	397	400	O
pepsin	401	407	O
activities	408	418	O
in	419	421	O
by	422	424	O
morphological	425	438	O
and	439	442	O
biochemical	443	454	O
procedures	455	465	O
in	466	468	O
order	469	474	O
to	475	477	O
evaluate	478	486	O
the	487	490	O
relationship	491	503	O
between	504	511	O
defensive	512	521	O
and	522	525	O
aggressive	526	536	O
factors	537	544	O
of	545	547	O
the	548	551	O
gastric	552	559	B-Multi-tissue_structure
mucosa	560	566	I-Multi-tissue_structure
.	566	567	O

Gastric	568	575	B-Multi-tissue_structure
mucosal	576	583	I-Multi-tissue_structure
blood	584	589	B-Organism_substance
flow	590	594	O
decreased	595	604	O
significantly	605	618	O
in	619	621	O
early	622	627	O
period	628	634	O
after	635	640	O
induction	641	650	O
of	651	653	O
stress	654	660	O
(	661	662	O
p	662	663	O
less	664	668	O
than	669	673	O
0	674	675	O
.	675	676	O
01	676	678	O
)	678	679	O
.	679	680	O

The	681	684	O
incidence	685	694	O
of	695	697	O
ulceration	698	708	O
showed	709	715	O
a	716	717	O
correlative	718	729	O
relation	730	738	O
with	739	743	O
the	744	747	O
decrease	748	756	O
of	757	759	O
mucosal	760	767	B-Multi-tissue_structure
blood	768	773	B-Organism_substance
flow	774	778	O
.	778	779	O

Reduction	780	789	O
of	790	792	O
blood	793	798	B-Organism_substance
flow	799	803	O
in	804	806	O
burn	807	811	O
was	812	815	O
due	816	819	O
to	820	822	O
opening	823	830	O
of	831	833	O
arteriovenular	834	848	B-Multi-tissue_structure
shunt	849	854	O
and	855	858	O
it	859	861	O
appeared	862	870	O
that	871	875	O
this	876	880	O
was	881	884	O
responsible	885	896	O
for	897	900	O
mucosal	901	908	B-Multi-tissue_structure
ischemia	909	917	O
and	918	921	O
congestion	922	932	O
.	932	933	O

Following	934	943	O
the	944	947	O
decrease	948	956	O
of	957	959	O
blood	960	965	B-Organism_substance
flow	966	970	O
,	970	971	O
acid	972	976	O
output	977	983	O
was	984	987	O
lower	988	993	O
in	994	996	O
stress	997	1003	O
than	1004	1008	O
that	1009	1013	O
in	1014	1016	O
control	1017	1024	O
.	1024	1025	O

Finally	1026	1033	O
,	1033	1034	O
the	1035	1038	O
results	1039	1046	O
of	1047	1049	O
these	1050	1055	O
studies	1056	1063	O
demonstrated	1064	1076	O
the	1077	1080	O
importance	1081	1091	O
of	1092	1094	O
defensive	1095	1104	O
factors	1105	1112	O
.	1112	1113	O

The	1114	1117	O
reduction	1118	1127	O
of	1128	1130	O
mucosal	1131	1138	B-Multi-tissue_structure
blood	1139	1144	B-Organism_substance
flow	1145	1149	O
resulted	1150	1158	O
in	1159	1161	O
the	1162	1165	O
sequence	1166	1174	O
of	1175	1177	O
events	1178	1184	O
that	1185	1189	O
led	1190	1193	O
to	1194	1196	O
formation	1197	1206	O
of	1207	1209	O
acute	1210	1215	O
gastric	1216	1223	B-Pathological_formation
mucosal	1224	1231	I-Pathological_formation
lesion	1232	1238	I-Pathological_formation
.	1238	1239	O

Type	0	4	O
-	4	5	O
A	5	6	O
cholecystokinin	7	22	O
receptors	23	32	O
in	33	35	O
CHP212	36	42	B-Cell
neuroblastoma	43	56	I-Cell
cells	57	62	I-Cell
:	62	63	O
evidence	64	72	O
for	73	76	O
association	77	88	O
with	89	93	O
G	94	95	O
protein	96	103	O
and	104	107	O
activation	108	118	O
of	119	121	O
phosphoinositide	122	138	O
hydrolysis	139	149	O
.	149	150	O

125I	151	155	O
-	155	156	O
Bolton	156	162	O
Hunter	163	169	O
-	169	170	O
cholecystokinin	170	185	O
octapeptide	186	197	O
(	198	199	O
BH	199	201	O
-	201	202	O
CCK8	202	206	O
)	206	207	O
and	208	211	O
(	212	213	O
-	213	214	O
)	214	215	O
-	215	216	O
[	216	217	O
3H	217	219	O
]	219	220	O
L	220	221	O
-	221	222	O
364718	222	228	O
membrane	229	237	B-Cellular_component
binding	238	245	O
assays	246	252	O
were	253	257	O
used	258	262	O
to	263	265	O
identify	266	274	O
and	275	278	O
characterize	279	291	O
cholecystokinin	292	307	O
(	308	309	O
CCK	309	312	O
)	312	313	O
receptors	314	323	O
in	324	326	O
CHP212	327	333	B-Cell
human	334	339	O
neuroblastoma	340	353	B-Cell
cells	354	359	I-Cell
.	359	360	O

The	361	364	O
ligand	365	371	O
binding	372	379	O
properties	380	390	O
of	391	393	O
CCK	394	397	O
receptors	398	407	O
in	408	410	O
these	411	416	O
cells	417	422	B-Cell
are	423	426	O
similar	427	434	O
to	435	437	O
those	438	443	O
found	444	449	O
in	450	452	O
pancreas	453	461	B-Organ
(	462	463	O
CCK	463	466	O
-	466	467	O
A	467	468	O
sites	469	474	O
)	474	475	O
and	476	479	O
differ	480	486	O
from	487	491	O
the	492	495	O
predominant	496	507	O
type	508	512	O
of	513	515	O
CCK	516	519	O
binding	520	527	O
site	528	532	O
found	533	538	O
in	539	541	O
brain	542	547	B-Organ
(	548	549	O
CCK	549	552	O
-	552	553	O
B	553	554	O
sites	555	560	O
)	560	561	O
.	561	562	O

The	563	566	O
specific	567	575	O
binding	576	583	O
of	584	586	O
125I	587	591	O
-	591	592	O
BH	592	594	O
-	594	595	O
CCK8	595	599	O
but	600	603	O
not	604	607	O
(	608	609	O
-	609	610	O
)	610	611	O
-	611	612	O
[	612	613	O
3H	613	615	O
]	615	616	O
L	616	617	O
-	617	618	O
364718	618	624	O
was	625	628	O
reduced	629	636	O
by	637	639	O
the	640	643	O
metabolically	644	657	O
stable	658	664	O
GTP	665	668	O
analog	669	675	O
guanosine	676	685	O
5	686	687	O
'	687	688	O
-	688	689	O
(	689	690	O
beta	690	694	O
-	694	695	O
delta	695	700	O
-	700	701	O
imido	701	706	O
)	706	707	O
trisphosphate	707	720	O
.	720	721	O

A	722	723	O
substantial	724	735	O
difference	736	746	O
in	747	749	O
the	750	753	O
Bmax	754	758	O
for	759	762	O
the	763	766	O
radiolabeled	767	779	O
agonist	780	787	O
(	788	789	O
125I	789	793	O
-	793	794	O
BH	794	796	O
-	796	797	O
CCK8	797	801	O
)	801	802	O
and	803	806	O
antagonist	807	817	O
[	818	819	O
(	819	820	O
-	820	821	O
)	821	822	O
-	822	823	O
[	823	824	O
3H	824	826	O
]	826	827	O
L	827	828	O
-	828	829	O
364718	829	835	O
]	835	836	O
was	837	840	O
noted	841	846	O
.	846	847	O

These	848	853	O
observations	854	866	O
are	867	870	O
consistent	871	881	O
with	882	886	O
CCK	887	890	O
receptors	891	900	O
existing	901	909	O
in	910	912	O
guanine	913	920	O
nucleotide	921	931	O
-	931	932	O
binding	932	939	O
protein	940	947	O
-	947	948	O
coupled	948	955	O
and	956	959	O
-	960	961	O
uncoupled	961	970	O
states	971	977	O
.	977	978	O

Similar	979	986	O
to	987	989	O
its	990	993	O
action	994	1000	O
in	1001	1003	O
pancreatic	1004	1014	B-Cell
acinar	1015	1021	I-Cell
cells	1022	1027	I-Cell
,	1027	1028	O
CCK8	1029	1033	O
(	1033	1034	O
S	1034	1035	O
)	1035	1036	O
stimulated	1037	1047	O
the	1048	1051	O
accumulation	1052	1064	O
of	1065	1067	O
[	1068	1069	O
3H	1069	1071	O
]	1071	1072	O
inositol	1072	1080	O
phosphates	1081	1091	O
in	1092	1094	O
cells	1095	1100	B-Cell
prelabeled	1101	1111	O
with	1112	1116	O
[	1117	1118	O
3H	1118	1120	O
]	1120	1121	O
myo	1121	1124	O
-	1124	1125	O
inositol	1125	1133	O
(	1134	1135	O
EC50	1135	1139	O
=	1140	1141	O
3	1142	1143	O
.	1143	1144	O
2	1144	1145	O
+	1146	1147	O
/	1147	1148	O
-	1148	1149	O
0	1150	1151	O
.	1151	1152	O
4	1152	1153	O
nM	1154	1156	O
;	1156	1157	O
maximum	1158	1165	O
response	1166	1174	O
=	1175	1176	O
4	1177	1178	O
.	1178	1179	O
5	1179	1180	O
+	1181	1182	O
/	1182	1183	O
-	1183	1184	O
0	1185	1186	O
.	1186	1187	O
4	1187	1188	O
x	1189	1190	O
basal	1191	1196	O
)	1196	1197	O
.	1197	1198	O

The	1199	1202	O
intrinsic	1203	1212	O
activity	1213	1221	O
of	1222	1224	O
CCK	1225	1228	O
analogues	1229	1238	O
in	1239	1241	O
stimulating	1242	1253	O
phosphoinositide	1254	1270	O
hydrolysis	1271	1281	O
was	1282	1285	O
substantially	1286	1299	O
less	1300	1304	O
than	1305	1309	O
their	1310	1315	O
reported	1316	1324	O
intrinsic	1325	1334	O
activity	1335	1343	O
in	1344	1346	O
stimulating	1347	1358	O
phosphoinositide	1359	1375	O
hydrolysis	1376	1386	O
in	1387	1389	O
pancreatic	1390	1400	B-Cell
acinar	1401	1407	I-Cell
cells	1408	1413	I-Cell
.	1413	1414	O

The	1415	1418	O
CHP212	1419	1425	B-Cell
neuroblastoma	1426	1439	I-Cell
cell	1440	1444	I-Cell
may	1445	1448	O
serve	1449	1454	O
as	1455	1457	O
a	1458	1459	O
useful	1460	1466	O
model	1467	1472	O
for	1473	1476	O
the	1477	1480	O
recently	1481	1489	O
reported	1490	1498	O
CCK	1499	1502	O
-	1502	1503	O
A	1503	1504	O
binding	1505	1512	O
site	1513	1517	O
found	1518	1523	O
in	1524	1526	O
the	1527	1530	O
central	1531	1538	B-Anatomical_system
nervous	1539	1546	I-Anatomical_system
system	1547	1553	I-Anatomical_system
.	1553	1554	O

Screening	0	9	O
method	10	16	O
for	17	20	O
insecticidal	21	33	O
activity	34	42	O
using	43	48	O
first	49	54	O
instars	55	62	O
of	63	65	O
black	66	71	O
blow	72	76	O
fly	77	80	O
(	81	82	O
Diptera	82	89	O
:	89	90	O
Calliphoridae	91	104	O
)	104	105	O
.	105	106	O

A	107	108	O
bioassay	109	117	O
method	118	124	O
suitable	125	133	O
for	134	137	O
rapid	138	143	O
mass	144	148	O
screening	149	158	O
of	159	161	O
fermentation	162	174	O
and	175	178	O
synthetic	179	188	O
organic	189	196	O
compounds	197	206	O
for	207	210	O
insecticidal	211	223	O
activity	224	232	O
is	233	235	O
described	236	245	O
.	245	246	O

The	247	250	O
test	251	255	O
,	255	256	O
which	257	262	O
uses	263	267	O
first	268	273	O
instars	274	281	O
of	282	284	O
susceptible	285	296	O
black	297	302	O
blow	303	307	O
fly	308	311	O
,	311	312	O
Phormia	313	320	O
regina	321	327	O
(	328	329	O
Meigen	329	335	O
)	335	336	O
,	336	337	O
in	338	340	O
a	341	342	O
bovine	343	349	O
serum	350	355	B-Organism_substance
medium	356	362	O
,	362	363	O
detects	364	371	O
insecticidal	372	384	O
activity	385	393	O
with	394	398	O
reproducible	399	411	O
results	412	419	O
.	419	420	O

It	421	423	O
is	424	426	O
capable	427	434	O
of	435	437	O
selecting	438	447	O
the	448	451	O
most	452	456	O
active	457	463	O
compound	464	472	O
in	473	475	O
structure	476	485	O
-	485	486	O
activity	486	494	O
relationships	495	508	O
by	509	511	O
minimum	512	519	O
effective	520	529	O
dose	530	534	O
concentration	535	548	O
studies	549	556	O
.	556	557	O

The	558	561	O
bioassay	562	570	O
system	571	577	O
is	578	580	O
easy	581	585	O
to	586	588	O
operate	589	596	O
and	597	600	O
requires	601	609	O
only	610	614	O
a	615	616	O
minute	617	623	O
quantity	624	632	O
of	633	635	O
chemical	636	644	O
compound	645	653	O
.	653	654	O

Early	0	5	O
post	6	10	O
-	10	11	O
mortem	11	17	O
metabolism	18	28	O
and	29	32	O
muscle	33	39	B-Organ
shortening	40	50	O
in	51	53	O
the	54	57	O
Pectoralis	58	68	O
major	69	74	O
muscle	75	81	B-Organ
of	82	84	O
broiler	85	92	O
chickens	93	101	O
.	101	102	O

Three	103	108	O
experiments	109	120	O
were	121	125	O
conducted	126	135	O
to	136	138	O
examine	139	146	O
the	147	150	O
effects	151	158	O
of	159	161	O
sodium	162	168	O
pentobarbital	169	182	O
(	183	184	O
SP	184	186	O
)	186	187	O
,	187	188	O
iodoacetate	189	200	O
(	201	202	O
IO	202	204	O
)	204	205	O
,	205	206	O
tubocurarine	207	219	O
(	220	221	O
TC	221	223	O
)	223	224	O
,	224	225	O
and	226	229	O
surgical	230	238	O
denervation	239	250	O
(	251	252	O
DN	252	254	O
)	254	255	O
on	256	258	O
early	259	264	O
rigor	265	270	O
development	271	282	O
in	283	285	O
broiler	286	293	O
breast	294	300	B-Organ
muscle	301	307	I-Organ
.	307	308	O

In	309	311	O
Experiment	312	322	O
1	323	324	O
,	324	325	O
birds	326	331	O
were	332	336	O
either	337	343	O
anesthetized	344	356	O
or	357	359	O
not	360	363	O
with	364	368	O
SP	369	371	O
before	372	378	O
receiving	379	388	O
an	389	391	O
injection	392	401	O
of	402	404	O
IO	405	407	O
or	408	410	O
TC	411	413	O
or	414	416	O
maintained	417	427	O
as	428	430	O
noninjected	431	442	O
controls	443	451	O
.	451	452	O

Experiment	453	463	O
2	464	465	O
was	466	469	O
identical	470	479	O
except	480	486	O
that	487	491	O
a	492	493	O
treatment	494	503	O
of	504	506	O
denervation	507	518	O
of	519	521	O
the	522	525	O
breast	526	532	B-Organ
muscle	533	539	I-Organ
was	540	543	O
added	544	549	O
.	549	550	O

Experiment	551	561	O
3	562	563	O
was	564	567	O
conducted	568	577	O
to	578	580	O
contrast	581	589	O
birds	590	595	O
at	596	598	O
1	599	600	O
day	601	604	O
(	605	606	O
DN1	606	609	O
)	609	610	O
and	611	614	O
3	615	616	O
days	617	621	O
(	622	623	O
DN3	623	626	O
)	626	627	O
denervation	628	639	O
prior	640	645	O
to	646	648	O
slaughter	649	658	O
to	659	661	O
nonoperated	662	673	O
controls	674	682	O
.	682	683	O

Measurements	684	696	O
of	697	699	O
muscle	700	706	B-Organ
lactate	707	714	O
,	714	715	O
ATP	716	719	O
,	719	720	O
R	721	722	O
value	723	728	O
(	729	730	O
ratio	730	735	O
of	736	738	O
inosine	739	746	O
to	747	749	O
adenine	750	757	O
nucleotides	758	769	O
)	769	770	O
,	770	771	O
pH	772	774	O
,	774	775	O
sarcomere	776	785	B-Tissue
lengths	786	793	O
,	793	794	O
and	795	798	O
shear	799	804	O
were	805	809	O
used	810	814	O
to	815	817	O
evaluate	818	826	O
treatment	827	836	O
effects	837	844	O
.	844	845	O

Results	846	853	O
for	854	857	O
Experiment	858	868	O
1	869	870	O
showed	871	877	O
no	878	880	O
significant	881	892	O
differences	893	904	O
among	905	910	O
treatment	911	920	O
and	921	924	O
control	925	932	O
groups	933	939	O
for	940	943	O
ATP	944	947	O
and	948	951	O
lactate	952	959	O
contents	960	968	O
,	968	969	O
R	970	971	O
values	972	978	O
,	978	979	O
or	980	982	O
sarcomere	983	992	B-Tissue
lengths	993	1000	O
;	1000	1001	O
however	1002	1009	O
,	1009	1010	O
significantly	1011	1024	O
lower	1025	1030	O
pH	1031	1033	O
and	1034	1037	O
higher	1038	1044	O
shear	1045	1050	O
values	1051	1057	O
were	1058	1062	O
observed	1063	1071	O
for	1072	1075	O
control	1076	1083	O
birds	1084	1089	O
.	1089	1090	O

In	1091	1093	O
Experiment	1094	1104	O
2	1105	1106	O
,	1106	1107	O
no	1108	1110	O
significant	1111	1122	O
differences	1123	1134	O
were	1135	1139	O
observed	1140	1148	O
among	1149	1154	O
the	1155	1158	O
treatment	1159	1168	O
groups	1169	1175	O
for	1176	1179	O
ATP	1180	1183	O
,	1183	1184	O
R	1185	1186	O
values	1187	1193	O
,	1193	1194	O
or	1195	1197	O
sarcomere	1198	1207	B-Tissue
lengths	1208	1215	O
.	1215	1216	O

However	1217	1224	O
,	1224	1225	O
lactate	1226	1233	O
and	1234	1237	O
shear	1238	1243	O
values	1244	1250	O
were	1251	1255	O
significantly	1256	1269	O
lower	1270	1275	O
,	1275	1276	O
and	1277	1280	O
pH	1281	1283	O
higher	1284	1290	O
,	1290	1291	O
for	1292	1295	O
the	1296	1299	O
DN	1300	1302	O
and	1303	1306	O
SP	1307	1309	O
treated	1310	1317	O
birds	1318	1323	O
.	1323	1324	O

Experiment	1325	1335	O
3	1336	1337	O
resulted	1338	1346	O
in	1347	1349	O
lower	1350	1355	O
lactate	1356	1363	O
and	1364	1367	O
higher	1368	1374	O
pH	1375	1377	O
values	1378	1384	O
for	1385	1388	O
the	1389	1392	O
DN3	1393	1396	O
treatment	1397	1406	O
in	1407	1409	O
comparison	1410	1420	O
with	1421	1425	O
both	1426	1430	O
DN1	1431	1434	O
and	1435	1438	O
control	1439	1446	O
groups	1447	1453	O
.	1453	1454	O

Results	1455	1462	O
of	1463	1465	O
these	1466	1471	O
studies	1472	1479	O
indicate	1480	1488	O
that	1489	1493	O
the	1494	1497	O
use	1498	1501	O
of	1502	1504	O
SP	1505	1507	O
and	1508	1511	O
DN	1512	1514	O
can	1515	1518	O
be	1519	1521	O
used	1522	1526	O
to	1527	1529	O
alter	1530	1535	O
the	1536	1539	O
early	1540	1545	O
profiles	1546	1554	O
of	1555	1557	O
rigor	1558	1563	O
development	1564	1575	O
.	1575	1576	O

Anaplastic	0	10	B-Pathological_formation
and	11	14	I-Pathological_formation
sarcomatoid	15	26	I-Pathological_formation
carcinoma	27	36	I-Pathological_formation
of	37	39	O
the	40	43	O
small	44	49	B-Organ
intestine	50	59	I-Organ
:	59	60	O
a	61	62	O
clinicopathologic	63	80	O
study	81	86	O
.	86	87	O

Carcinomas	88	98	B-Pathological_formation
involving	99	108	O
the	109	112	O
jejunum	113	120	B-Multi-tissue_structure
and	121	124	O
ileum	125	130	B-Multi-tissue_structure
are	131	134	O
rare	135	139	O
tumors	140	146	B-Pathological_formation
.	146	147	O

During	148	154	O
a	155	156	O
review	157	163	O
of	164	166	O
small	167	172	B-Pathological_formation
intestinal	173	183	I-Pathological_formation
neoplasms	184	193	I-Pathological_formation
,	193	194	O
six	195	198	O
primary	199	206	O
carcinomas	207	217	B-Pathological_formation
of	218	220	O
jejunum	221	228	B-Multi-tissue_structure
or	229	231	O
ileum	232	237	B-Multi-tissue_structure
with	238	242	O
an	243	245	O
anaplastic	246	256	O
and	257	260	O
sarcomatoid	261	272	B-Pathological_formation
histology	273	282	O
were	283	287	O
identified	288	298	O
.	298	299	O

At	300	302	O
presentation	303	315	O
,	315	316	O
three	317	322	O
of	323	325	O
the	326	329	O
patients	330	338	O
had	339	342	O
symptoms	343	351	O
related	352	359	O
to	360	362	O
metastatic	363	373	O
disease	374	381	O
and	382	385	O
three	386	391	O
had	392	395	O
symptoms	396	404	O
referable	405	414	O
to	415	417	O
the	418	421	O
local	422	427	O
tumor	428	433	B-Pathological_formation
.	433	434	O

The	435	438	O
tumors	439	445	B-Pathological_formation
were	446	450	O
large	451	456	O
(	457	458	O
greater	458	465	O
than	466	470	O
4	471	472	O
.	472	473	O
5	473	474	O
cm	475	477	O
in	478	480	O
diameter	481	489	O
)	489	490	O
,	490	491	O
usually	492	499	O
endophytic	500	510	O
masses	511	517	O
composed	518	526	O
of	527	529	O
large	530	535	O
cells	536	541	B-Cell
with	542	546	O
eosinophilic	547	559	B-Organism_substance
cytoplasm	560	569	I-Organism_substance
,	569	570	O
anaplastic	571	581	O
nuclei	582	588	B-Cellular_component
,	588	589	O
and	590	593	O
prominent	594	603	O
nucleoli	604	612	B-Cellular_component
.	612	613	O

In	614	616	O
many	617	621	O
areas	622	627	O
,	627	628	O
the	629	632	O
cells	633	638	B-Cell
had	639	642	O
a	643	644	O
spindled	645	653	O
configuration	654	667	O
.	667	668	O

Mucin	669	674	O
positivity	675	685	O
was	686	689	O
identified	690	700	O
in	701	703	O
all	704	707	O
six	708	711	O
cases	712	717	O
.	717	718	O

Electron	719	727	O
microscopic	728	739	O
findings	740	748	O
in	749	751	O
two	752	755	O
cases	756	761	O
were	762	766	O
indicative	767	777	O
of	778	780	O
epithelial	781	791	B-Tissue
differentiation	792	807	O
.	807	808	O

The	809	812	O
tumors	813	819	B-Pathological_formation
behaved	820	827	O
aggressively	828	840	O
;	840	841	O
all	842	845	O
five	846	850	O
patients	851	859	O
for	860	863	O
whom	864	868	O
there	869	874	O
was	875	878	O
clinical	879	887	O
follow	888	894	O
-	894	895	O
up	895	897	O
died	898	902	O
of	903	905	O
metastases	906	916	B-Pathological_formation
within	917	923	O
40	924	926	O
months	927	933	O
.	933	934	O

The	935	938	O
six	939	942	O
anaplastic	943	953	B-Pathological_formation
and	954	957	I-Pathological_formation
sarcomatoid	958	969	I-Pathological_formation
carcinomas	970	980	I-Pathological_formation
were	981	985	O
compared	986	994	O
with	995	999	O
29	1000	1002	O
typical	1003	1010	O
adenocarcinomas	1011	1026	B-Pathological_formation
arising	1027	1034	O
in	1035	1037	O
the	1038	1041	O
jejunum	1042	1049	B-Multi-tissue_structure
or	1050	1052	O
ileum	1053	1058	B-Multi-tissue_structure
.	1058	1059	O

Only	1060	1064	O
two	1065	1068	O
of	1069	1071	O
the	1072	1075	O
latter	1076	1082	O
group	1083	1088	O
had	1089	1092	O
symptoms	1093	1101	O
referable	1102	1111	O
to	1112	1114	O
distant	1115	1122	O
metastases	1123	1133	B-Pathological_formation
at	1134	1136	O
presentation	1137	1149	O
.	1149	1150	O

These	1151	1156	O
tumors	1157	1163	B-Pathological_formation
also	1164	1168	O
tended	1169	1175	O
to	1176	1178	O
be	1179	1181	O
smaller	1182	1189	O
at	1190	1192	O
presentation	1193	1205	O
(	1206	1207	O
11	1207	1209	O
tumors	1210	1216	B-Pathological_formation
were	1217	1221	O
less	1222	1226	O
than	1227	1231	O
4	1232	1233	O
cm	1234	1236	O
in	1237	1239	O
greatest	1240	1248	O
dimension	1249	1258	O
)	1258	1259	O
.	1259	1260	O

Of	1261	1263	O
25	1264	1266	O
patients	1267	1275	O
with	1276	1280	O
typical	1281	1288	O
adenocarcinomas	1289	1304	B-Pathological_formation
who	1305	1308	O
had	1309	1312	O
acceptable	1313	1323	O
follow	1324	1330	O
-	1330	1331	O
up	1331	1333	O
,	1333	1334	O
18	1335	1337	O
(	1338	1339	O
72	1339	1341	O
%	1341	1342	O
)	1342	1343	O
died	1344	1348	O
of	1349	1351	O
disease	1352	1359	O
and	1360	1363	O
five	1364	1368	O
(	1369	1370	O
20	1370	1372	O
%	1372	1373	O
)	1373	1374	O
were	1375	1379	O
alive	1380	1385	O
with	1386	1390	O
no	1391	1393	O
evidence	1394	1402	O
of	1403	1405	O
disease	1406	1413	O
after	1414	1419	O
5	1420	1421	O
years	1422	1427	O
.	1427	1428	O

We	1429	1431	O
conclude	1432	1440	O
that	1441	1445	O
anaplastic	1446	1456	B-Pathological_formation
and	1457	1460	I-Pathological_formation
sarcomatoid	1461	1472	I-Pathological_formation
carcinoma	1473	1482	I-Pathological_formation
is	1483	1485	O
a	1486	1487	O
rare	1488	1492	O
variant	1493	1500	O
of	1501	1503	O
small	1504	1509	B-Pathological_formation
intestinal	1510	1520	I-Pathological_formation
carcinoma	1521	1530	I-Pathological_formation
with	1531	1535	O
an	1536	1538	O
aggressive	1539	1549	O
clinical	1550	1558	O
course	1559	1565	O
.	1565	1566	O

Time	0	4	O
course	5	11	O
of	12	14	O
transmitter	15	26	O
action	27	33	O
at	34	36	O
the	37	40	O
sympathetic	41	52	B-Tissue
neuroeffector	53	66	I-Tissue
junction	67	75	I-Tissue
in	76	78	O
rodent	79	85	O
vascular	86	94	B-Organ
and	95	98	O
non	99	102	B-Organ
-	102	103	I-Organ
vascular	103	111	I-Organ
smooth	112	118	I-Organ
muscle	119	125	I-Organ
.	125	126	O

1	127	128	O
.	128	129	O

Transmitter	130	141	O
release	142	149	O
from	150	154	O
sympathetic	155	166	B-Multi-tissue_structure
postganglionic	167	181	I-Multi-tissue_structure
nerve	182	187	I-Multi-tissue_structure
terminals	188	197	O
innervating	198	209	O
the	210	213	O
guinea	214	220	O
-	220	221	O
pig	221	224	O
and	225	228	O
mouse	229	234	O
vas	235	238	B-Multi-tissue_structure
deferens	239	247	I-Multi-tissue_structure
and	248	251	O
the	252	255	O
rat	256	259	O
tail	260	264	B-Multi-tissue_structure
artery	265	271	I-Multi-tissue_structure
has	272	275	O
been	276	280	O
studied	281	288	O
in	289	291	O
vitro	292	297	O
by	298	300	O
focal	301	306	O
extracellular	307	320	B-Immaterial_anatomical_entity
recording	321	330	O
with	331	335	O
particular	336	346	O
emphasis	347	355	O
on	356	358	O
the	359	362	O
time	363	367	O
course	368	374	O
of	375	377	O
transmitter	378	389	O
action	390	396	O
underlying	397	407	O
the	408	411	O
intracellular	412	425	B-Immaterial_anatomical_entity
potential	426	435	O
changes	436	443	O
.	443	444	O

2	445	446	O
.	446	447	O

In	448	450	O
the	451	454	O
absence	455	462	O
of	463	465	O
stimulation	466	477	O
,	477	478	O
spontaneous	479	490	O
excitatory	491	501	B-Tissue
junction	502	510	I-Tissue
currents	511	519	O
(	520	521	O
SEJCs	521	526	O
)	526	527	O
were	528	532	O
recorded	533	541	O
with	542	546	O
amplitudes	547	557	O
up	558	560	O
to	561	563	O
500	564	567	O
microV	568	574	O
and	575	578	O
durations	579	588	O
between	589	596	O
40	597	599	O
and	600	603	O
100	604	607	O
ms	608	610	O
.	610	611	O

SEJCs	612	617	O
were	618	622	O
unaffected	623	633	O
by	634	636	O
the	637	640	O
competitive	641	652	O
alpha	653	658	O
-	658	659	O
adrenoceptor	659	671	O
antagonist	672	682	O
prazosin	683	691	O
but	692	695	O
blocked	696	703	O
by	704	706	O
alpha	707	712	O
,	712	713	O
beta	714	718	O
-	718	719	O
methylene	719	728	O
ATP	729	732	O
which	733	738	O
desensitizes	739	751	O
P2	752	754	O
-	754	755	O
purinoceptors	755	768	O
.	768	769	O

3	770	771	O
.	771	772	O

During	773	779	O
trains	780	786	O
of	787	789	O
supramaximal	790	802	O
stimuli	803	810	O
at	811	813	O
0	814	815	O
.	815	816	O
1	816	817	O
-	817	818	O
4	818	819	O
Hz	820	822	O
stimulus	823	831	O
locked	832	838	O
excitatory	839	849	B-Tissue
junction	850	858	I-Tissue
currents	859	867	O
(	868	869	O
EJCs	869	873	O
)	873	874	O
were	875	879	O
evoked	880	886	O
intermittently	887	901	O
from	902	906	O
the	907	910	O
population	911	921	O
of	922	924	O
varicosities	925	937	O
located	938	945	O
under	946	951	O
the	952	955	O
suction	956	963	O
electrode	964	973	O
.	973	974	O

4	975	976	O
.	976	977	O

SEJCs	978	983	O
were	984	988	O
similar	989	996	O
in	997	999	O
amplitude	1000	1009	O
and	1010	1013	O
time	1014	1018	O
course	1019	1025	O
to	1026	1028	O
EJCs	1029	1033	O
evoked	1034	1040	O
by	1041	1043	O
low	1044	1047	O
-	1047	1048	O
frequency	1048	1057	O
stimulation	1058	1069	O
in	1070	1072	O
the	1073	1076	O
same	1077	1081	O
attachment	1082	1092	O
in	1093	1095	O
all	1096	1099	O
three	1100	1105	O
tissues	1106	1113	B-Tissue
.	1113	1114	O

5	1115	1116	O
.	1116	1117	O

SEJCs	1118	1123	O
recorded	1124	1132	O
using	1133	1138	O
either	1139	1145	O
a	1146	1147	O
conventional	1148	1160	O
AC	1161	1163	O
amplifier	1164	1173	O
or	1174	1176	O
a	1177	1178	O
patch	1179	1184	O
clamp	1185	1190	O
amplifier	1191	1200	O
had	1201	1204	O
the	1205	1208	O
same	1209	1213	O
time	1214	1218	O
course	1219	1225	O
.	1225	1226	O

6	1227	1228	O
.	1228	1229	O

These	1230	1235	O
studies	1236	1243	O
show	1244	1248	O
that	1249	1253	O
the	1254	1257	O
time	1258	1262	O
course	1263	1269	O
of	1270	1272	O
the	1273	1276	O
current	1277	1284	O
underlying	1285	1295	O
the	1296	1299	O
excitatory	1300	1310	B-Tissue
junction	1311	1319	I-Tissue
potential	1320	1329	O
is	1330	1332	O
brief	1333	1338	O
and	1339	1342	O
essentially	1343	1354	O
the	1355	1358	O
same	1359	1363	O
in	1364	1366	O
three	1367	1372	O
different	1373	1382	O
tissues	1383	1390	B-Tissue
.	1390	1391	O

The	1392	1395	O
prolonged	1396	1405	O
time	1406	1410	O
course	1411	1417	O
of	1418	1420	O
the	1421	1424	O
excitatory	1425	1435	B-Tissue
junction	1436	1444	I-Tissue
potential	1445	1454	O
in	1455	1457	O
different	1458	1467	O
tissues	1468	1475	B-Tissue
can	1476	1479	O
be	1480	1482	O
accounted	1483	1492	O
for	1493	1496	O
by	1497	1499	O
the	1500	1503	O
passive	1504	1511	O
membrane	1512	1520	B-Multi-tissue_structure
properties	1521	1531	O
.	1531	1532	O

Differential	0	12	O
secretion	13	22	O
of	23	25	O
proteins	26	34	O
and	35	38	O
glycoproteins	39	52	O
by	53	55	O
livers	56	62	B-Organ
of	63	65	O
immature	66	74	O
and	75	78	O
adult	79	84	O
rats	85	89	O
.	89	90	O

Effect	91	97	O
of	98	100	O
antimicrotubule	101	116	B-Cellular_component
drugs	117	122	O
.	122	123	O

This	124	128	O
study	129	134	O
was	135	138	O
initiated	139	148	O
to	149	151	O
re	152	154	O
-	154	155	O
examine	155	162	O
reported	163	171	O
differences	172	183	O
in	184	186	O
the	187	190	O
action	191	197	O
of	198	200	O
antimicrotubule	201	216	B-Cellular_component
agents	217	223	O
on	224	226	O
plasma	227	233	B-Organism_substance
protein	234	241	O
secretion	242	251	O
from	252	256	O
livers	257	263	B-Organ
of	264	266	O
immature	267	275	O
versus	276	282	O
adult	283	288	O
rats	289	293	O
.	293	294	O

The	295	298	O
aim	299	302	O
was	303	306	O
(	307	308	O
1	308	309	O
)	309	310	O
to	311	313	O
determine	314	323	O
the	324	327	O
composition	328	339	O
and	340	343	O
to	344	346	O
monitor	347	354	O
the	355	358	O
secretion	359	368	O
of	369	371	O
various	372	379	O
plasma	380	386	B-Organism_substance
proteins	387	395	O
and	396	399	O
glycoproteins	400	413	O
from	414	418	O
liver	419	424	B-Multi-tissue_structure
slices	425	431	I-Multi-tissue_structure
labeled	432	439	O
in	440	442	O
vitro	443	448	O
with	449	453	O
specific	454	462	O
amino	463	468	O
acids	469	474	O
and	475	478	O
sugar	479	484	O
residues	485	493	O
,	493	494	O
and	495	498	O
(	499	500	O
2	500	501	O
)	501	502	O
to	503	505	O
correlate	506	515	O
observed	516	524	O
differences	525	536	O
in	537	539	O
secretion	540	549	O
of	550	552	O
these	553	558	O
proteins	559	567	O
with	568	572	O
structural	573	583	O
changes	584	591	O
in	592	594	O
the	595	598	O
hepatocytes	599	610	B-Cell
of	611	613	O
the	614	617	O
different	618	627	O
aged	628	632	O
animals	633	640	O
.	640	641	O

For	642	645	O
the	646	649	O
most	650	654	O
part	655	659	O
,	659	660	O
slices	661	667	B-Multi-tissue_structure
of	668	670	O
liver	671	676	B-Organ
from	677	681	O
fetal	682	687	B-Developing_anatomical_structure
(	688	689	O
term	689	693	O
)	693	694	O
,	694	695	O
neonatal	696	704	O
(	705	706	O
4	706	707	O
-	707	708	O
to	709	711	O
5	712	713	O
days	714	718	O
old	719	722	O
)	722	723	O
,	723	724	O
and	725	728	O
adult	729	734	O
rats	735	739	O
(	740	741	O
70	741	743	O
days	744	748	O
old	749	752	O
)	752	753	O
were	754	758	O
incubated	759	768	O
with	769	773	O
radioactive	774	785	O
amino	786	791	O
acids	792	797	O
or	798	800	O
various	801	808	O
tritiated	809	818	O
sugars	819	825	O
specific	826	834	O
for	835	838	O
N	839	840	O
-	840	841	O
linked	841	847	O
core	848	852	O
oligosaccharide	853	868	O
and	869	872	O
/	872	873	O
or	873	875	O
N	876	877	O
-	877	878	O
linked	878	884	O
terminal	885	893	O
oligosaccharide	894	909	O
chains	910	916	O
.	916	917	O

Our	918	921	O
findings	922	930	O
indicate	931	939	O
that	940	944	O
liver	945	950	B-Multi-tissue_structure
slices	951	957	I-Multi-tissue_structure
of	958	960	O
fetal	961	966	B-Developing_anatomical_structure
and	967	970	O
neonatal	971	979	O
rats	980	984	O
are	985	988	O
efficient	989	998	O
in	999	1001	O
synthesizing	1002	1014	O
plasma	1015	1021	B-Organism_substance
proteins	1022	1030	O
including	1031	1040	O
fully	1041	1046	O
glycosylated	1047	1059	O
glycoproteins	1060	1073	O
.	1073	1074	O

The	1075	1078	O
secretion	1079	1088	O
of	1089	1091	O
glycosylated	1092	1104	O
and	1105	1108	O
nonglycosylated	1109	1124	O
proteins	1125	1133	O
believed	1134	1142	O
to	1143	1145	O
be	1146	1148	O
processed	1149	1158	O
through	1159	1166	O
Golgi	1167	1172	B-Cellular_component
complexes	1173	1182	I-Cellular_component
was	1183	1186	O
inhibited	1187	1196	O
to	1197	1199	O
the	1200	1203	O
same	1204	1208	O
extent	1209	1215	O
(	1216	1217	O
approximately	1217	1230	O
70	1231	1233	O
-	1233	1234	O
80	1234	1236	O
%	1236	1237	O
)	1237	1238	O
by	1239	1241	O
antimicrotubule	1242	1257	B-Cellular_component
agents	1258	1264	O
,	1264	1265	O
regardless	1266	1276	O
of	1277	1279	O
the	1280	1283	O
age	1284	1287	O
of	1288	1290	O
the	1291	1294	O
host	1295	1299	O
animal	1300	1306	O
.	1306	1307	O

However	1308	1315	O
,	1315	1316	O
other	1317	1322	O
proteins	1323	1331	O
and	1332	1335	O
glycoproteins	1336	1349	O
secreted	1350	1358	O
by	1359	1361	O
livers	1362	1368	B-Organ
of	1369	1371	O
immature	1372	1380	O
rats	1381	1385	O
were	1386	1390	O
found	1391	1396	O
to	1397	1399	O
be	1400	1402	O
relatively	1403	1413	O
insensitive	1414	1425	O
(	1426	1427	O
i	1427	1428	O
.	1428	1429	O
e	1429	1430	O
.	1430	1431	O
inhibited	1432	1441	O
to	1442	1444	O
only	1445	1449	O
30	1450	1452	O
-	1452	1453	O
40	1453	1455	O
%	1455	1456	O
)	1456	1457	O
to	1458	1460	O
the	1461	1464	O
action	1465	1471	O
of	1472	1474	O
various	1475	1482	O
antimicrotubule	1483	1498	B-Cellular_component
drugs	1499	1504	O
.	1504	1505	O

The	1506	1509	O
glycoproteins	1510	1523	O
were	1524	1528	O
found	1529	1534	O
to	1535	1537	O
lack	1538	1542	O
N	1543	1544	O
-	1544	1545	O
linked	1545	1551	O
terminal	1552	1560	O
sugars	1561	1567	O
(	1568	1569	O
although	1569	1577	O
the	1578	1581	O
glycoproteins	1582	1595	O
did	1596	1599	O
contain	1600	1607	O
N	1608	1609	O
-	1609	1610	O
linked	1610	1616	O
core	1617	1621	O
sugars	1622	1628	O
)	1628	1629	O
,	1629	1630	O
and	1631	1634	O
it	1635	1637	O
is	1638	1640	O
likely	1641	1647	O
that	1648	1652	O
the	1653	1656	O
drug	1657	1661	O
-	1661	1662	O
insensitive	1662	1673	O
proteins	1674	1682	O
bypassed	1683	1691	O
critical	1692	1700	O
glycosylating	1701	1714	O
sites	1715	1720	O
in	1721	1723	O
the	1724	1727	O
Golgi	1728	1733	B-Cellular_component
compartment	1734	1745	I-Cellular_component
prior	1746	1751	O
to	1752	1754	O
release	1755	1762	O
.	1762	1763	O

Overall	1764	1771	O
,	1771	1772	O
these	1773	1778	O
findings	1779	1787	O
support	1788	1795	O
earlier	1796	1803	O
data	1804	1808	O
showing	1809	1816	O
that	1817	1821	O
antimicrotubule	1822	1837	B-Cellular_component
drugs	1838	1843	O
have	1844	1848	O
a	1849	1850	O
special	1851	1858	O
impact	1859	1865	O
on	1866	1868	O
Golgi	1869	1874	B-Cellular_component
-	1874	1875	O
associated	1875	1885	O
events	1886	1892	O
in	1893	1895	O
liver	1896	1901	B-Cell
cells	1902	1907	I-Cell
.	1907	1908	O

To	1909	1911	O
what	1912	1916	O
extent	1917	1923	O
these	1924	1929	O
findings	1930	1938	O
are	1939	1942	O
related	1943	1950	O
to	1951	1953	O
the	1954	1957	O
action	1958	1964	O
of	1965	1967	O
microtubules	1968	1980	B-Cellular_component
remains	1981	1988	O
to	1989	1991	O
be	1992	1994	O
seen	1995	1999	O
.	1999	2000	O

Torsade	0	7	O
de	8	10	O
pointes	11	18	O
during	19	25	O
loading	26	33	O
with	34	38	O
amiodarone	39	49	O
.	49	50	O

Torsade	51	58	O
de	59	61	O
pointes	62	69	O
represents	70	80	O
a	81	82	O
potential	83	92	O
complication	93	105	O
of	106	108	O
chronic	109	116	O
amiodarone	117	127	O
therapy	128	135	O
.	135	136	O

Several	137	144	O
reports	145	152	O
have	153	157	O
emphasized	158	168	O
the	169	172	O
need	173	177	O
for	178	181	O
a	182	183	O
loading	184	191	O
dose	192	196	O
in	197	199	O
order	200	205	O
to	206	208	O
achieve	209	216	O
therapeutic	217	228	O
blood	229	234	B-Organism_substance
levels	235	241	O
rapidly	242	249	O
.	249	250	O

We	251	253	O
report	254	260	O
a	261	262	O
case	263	267	O
of	268	270	O
torsade	271	278	O
de	279	281	O
pointes	282	289	O
following	290	299	O
a	300	301	O
single	302	308	O
oral	309	313	O
dose	314	318	O
of	319	321	O
amiodarone	322	332	O
(	333	334	O
1400	334	338	O
mg	339	341	O
or	342	344	O
30	345	347	O
mg	348	350	O
kg	351	353	O
-	353	354	O
1	354	355	O
)	355	356	O
administered	357	369	O
after	370	375	O
short	376	381	O
intravenous	382	393	B-Multi-tissue_structure
loading	394	401	O
for	402	405	O
prevention	406	416	O
of	417	419	O
paroxysmal	420	430	O
atrial	431	437	B-Multi-tissue_structure
flutter	438	445	O
.	445	446	O

Torsades	447	455	O
de	456	458	O
pointes	459	466	O
were	467	471	O
preceded	472	480	O
and	481	484	O
associated	485	495	O
with	496	500	O
marked	501	507	O
QT	508	510	O
prolongation	511	523	O
and	524	527	O
bradycardia	528	539	O
.	539	540	O

This	541	545	O
report	546	552	O
suggests	553	561	O
that	562	566	O
careful	567	574	O
monitoring	575	585	O
of	586	588	O
patients	589	597	O
undergoing	598	608	O
oral	609	613	O
amiodarone	614	624	O
loading	625	632	O
is	633	635	O
necessary	636	645	O
.	645	646	O

Unsatisfactory	0	14	O
forehead	15	23	B-Pathological_formation
scar	24	28	I-Pathological_formation
following	29	38	O
face	39	43	B-Organism_subdivision
lift	44	48	O
.	48	49	O

The	50	53	O
W	54	55	O
-	55	56	O
plasty	56	62	O
scar	63	67	B-Pathological_formation
revision	68	76	O
technique	77	86	O
has	87	90	O
been	91	95	O
found	96	101	O
to	102	104	O
be	105	107	O
effective	108	117	O
in	118	120	O
the	121	124	O
repair	125	131	O
of	132	134	O
the	135	138	O
difficult	139	148	O
and	149	152	O
cosmetically	153	165	O
unsatisfactory	166	180	O
hairline	181	189	B-Pathological_formation
scar	190	194	I-Pathological_formation
following	195	204	O
the	205	208	O
ill	209	212	O
-	212	213	O
advised	213	220	O
face	221	225	B-Organism_subdivision
lift	226	230	O
technique	231	240	O
that	241	245	O
excises	246	253	O
forehead	254	262	B-Multi-tissue_structure
skin	263	267	I-Multi-tissue_structure
.	267	268	O

Clinical	0	8	O
evaluation	9	19	O
of	20	22	O
radiotherapy	23	35	O
for	36	39	O
Graves	40	46	O
'	46	47	O
ophthalmopathy	48	62	O
.	62	63	O

Seventeen	64	73	O
patients	74	82	O
with	83	87	O
moderately	88	98	O
severe	99	105	O
ophthalmopathy	106	120	O
due	121	124	O
to	125	127	O
Graves	128	134	O
'	134	135	O
disease	136	143	O
were	144	148	O
treated	149	156	O
by	157	159	O
cobalt	160	166	O
or	167	169	O
supervoltage	170	182	O
radiotherapy	183	195	O
.	195	196	O

All	197	200	O
patients	201	209	O
complained	210	220	O
of	221	223	O
diplopia	224	232	O
.	232	233	O

The	234	237	O
mean	238	242	O
proptosis	243	252	O
value	253	258	O
was	259	262	O
21	263	265	O
.	265	266	O
4	266	267	O
mm	268	270	O
.	270	271	O

Three	272	277	O
patients	278	286	O
(	287	288	O
18	288	290	O
%	290	291	O
)	291	292	O
showed	293	299	O
good	300	304	O
response	305	313	O
,	313	314	O
7	315	316	O
(	317	318	O
41	318	320	O
%	320	321	O
)	321	322	O
moderate	323	331	O
and	332	335	O
7	336	337	O
minimal	338	345	O
or	346	348	O
no	349	351	O
response	352	360	O
.	360	361	O

Improvement	362	373	O
was	374	377	O
noted	378	383	O
mainly	384	390	O
in	391	393	O
soft	394	398	B-Tissue
tissue	399	405	I-Tissue
changes	406	413	O
and	414	417	O
diplopia	418	426	O
,	426	427	O
while	428	433	O
proptosis	434	443	O
decreased	444	453	O
in	454	456	O
only	457	461	O
5	462	463	O
patients	464	472	O
.	472	473	O

All	474	477	O
except	478	484	O
one	485	488	O
patient	489	496	O
who	497	500	O
had	501	504	O
marked	505	511	O
extraocular	512	523	B-Multi-tissue_structure
muscle	524	530	I-Multi-tissue_structure
involvement	531	542	O
revealed	543	551	O
by	552	554	O
computed	555	563	O
tomography	564	574	O
responded	575	584	O
to	585	587	O
treatment	588	597	O
.	597	598	O

These	599	604	O
data	605	609	O
indicate	610	618	O
that	619	623	O
radiotherapy	624	636	O
may	637	640	O
be	641	643	O
indicated	644	653	O
in	654	656	O
patients	657	665	O
with	666	670	O
progressive	671	682	O
ophthalmopathy	683	697	O
,	697	698	O
especially	699	709	O
in	710	712	O
those	713	718	O
who	719	722	O
are	723	726	O
associated	727	737	O
with	738	742	O
extraocular	743	754	B-Multi-tissue_structure
muscle	755	761	I-Multi-tissue_structure
enlargement	762	773	O
.	773	774	O

Management	0	10	O
of	11	13	O
the	14	17	O
tortuous	18	26	B-Multi-tissue_structure
internal	27	35	I-Multi-tissue_structure
carotid	36	43	I-Multi-tissue_structure
artery	44	50	I-Multi-tissue_structure
.	50	51	O

The	52	55	O
tortuous	56	64	B-Multi-tissue_structure
internal	65	73	I-Multi-tissue_structure
carotid	74	81	I-Multi-tissue_structure
artery	82	88	I-Multi-tissue_structure
as	89	91	O
the	92	95	O
basis	96	101	O
of	102	104	O
cerebral	105	113	B-Multi-tissue_structure
vascular	114	122	I-Multi-tissue_structure
insufficiency	123	136	O
is	137	139	O
a	140	141	O
controversial	142	155	O
entity	156	162	O
,	162	163	O
as	164	166	O
such	167	171	O
lesions	172	179	B-Pathological_formation
frequently	180	190	O
occur	191	196	O
without	197	204	O
neurologic	205	215	B-Anatomical_system
symptoms	216	224	O
.	224	225	O

However	226	233	O
,	233	234	O
some	235	239	O
tortuous	240	248	B-Multi-tissue_structure
vessels	249	256	I-Multi-tissue_structure
are	257	260	O
associated	261	271	O
with	272	276	O
significant	277	288	O
carotid	289	296	B-Multi-tissue_structure
atherosclerotic	297	312	O
disease	313	320	O
requiring	321	330	O
a	331	332	O
specific	333	341	O
surgical	342	350	O
approach	351	359	O
.	359	360	O

This	361	365	O
formed	366	372	O
the	373	376	O
basis	377	382	O
of	383	385	O
our	386	389	O
report	390	396	O
.	396	397	O

Symptoms	398	406	O
of	407	409	O
cerebrovascular	410	425	B-Multi-tissue_structure
insufficiency	426	439	O
in	440	442	O
association	443	454	O
with	455	459	O
a	460	461	O
tortuous	462	470	B-Multi-tissue_structure
internal	471	479	I-Multi-tissue_structure
carotid	480	487	I-Multi-tissue_structure
artery	488	494	I-Multi-tissue_structure
was	495	498	O
encountered	499	510	O
in	511	513	O
27	514	516	O
of	517	519	O
853	520	523	O
carotid	524	531	B-Multi-tissue_structure
endarterectomies	532	548	O
over	549	553	O
a	554	555	O
22	556	558	O
year	559	563	O
period	564	570	O
.	570	571	O

Stenosis	572	580	O
of	581	583	O
hemodynamic	584	595	O
significance	596	608	O
was	609	612	O
noted	613	618	O
in	619	621	O
nine	622	626	O
patients	627	635	O
and	636	639	O
irregularities	640	654	O
or	655	657	O
ulceration	658	668	O
were	669	673	O
noted	674	679	O
in	680	682	O
the	683	686	O
rest	687	691	O
.	691	692	O

With	693	697	O
the	698	701	O
standard	702	710	O
technique	711	720	O
of	721	723	O
carotid	724	731	B-Multi-tissue_structure
endarterectomy	732	746	O
,	746	747	O
removal	748	755	O
of	756	758	O
plaque	759	765	B-Cell
from	766	770	O
a	771	772	O
tortuous	773	781	B-Multi-tissue_structure
vessel	782	788	I-Multi-tissue_structure
leads	789	794	O
to	795	797	O
loss	798	802	O
of	803	805	O
the	806	809	O
stenting	810	818	O
effect	819	825	O
provided	826	834	O
by	835	837	O
the	838	841	O
plaque	842	848	B-Cell
such	849	853	O
that	854	858	O
angulation	859	869	O
occlusion	870	879	O
is	880	882	O
likely	883	889	O
to	890	892	O
occur	893	898	O
.	898	899	O

The	900	903	O
optimal	904	911	O
reconstruction	912	926	O
in	927	929	O
our	930	933	O
experience	934	944	O
is	945	947	O
eversion	948	956	O
endarterectomy	957	971	O
by	972	974	O
transection	975	986	O
and	987	990	O
lower	991	996	O
reimplantation	997	1011	O
of	1012	1014	O
the	1015	1018	O
internal	1019	1027	B-Multi-tissue_structure
carotid	1028	1035	I-Multi-tissue_structure
artery	1036	1042	I-Multi-tissue_structure
on	1043	1045	O
the	1046	1049	O
common	1050	1056	B-Multi-tissue_structure
carotid	1057	1064	I-Multi-tissue_structure
artery	1065	1071	I-Multi-tissue_structure
.	1071	1072	O

Our	1073	1076	O
experience	1077	1087	O
with	1088	1092	O
17	1093	1095	O
such	1096	1100	O
procedures	1101	1111	O
in	1112	1114	O
15	1115	1117	O
patients	1118	1126	O
has	1127	1130	O
been	1131	1135	O
presented	1136	1145	O
.	1145	1146	O

Rapid	0	5	O
enzyme	6	12	O
analysis	13	21	O
of	22	24	O
amniotic	25	33	B-Organism_substance
fluid	34	39	I-Organism_substance
phospholipids	40	53	O
containing	54	64	O
choline	65	72	O
:	72	73	O
a	74	75	O
comparison	76	86	O
with	87	91	O
the	92	95	O
lecithin	96	104	O
to	105	107	O
sphingomyelin	108	121	O
ratio	122	127	O
in	128	130	O
prenatal	131	139	O
assessment	140	150	O
of	151	153	O
fetal	154	159	B-Organ
lung	160	164	I-Organ
maturity	165	173	O
.	173	174	O

The	175	178	O
relation	179	187	O
between	188	195	O
the	196	199	O
choline	200	207	O
containing	208	218	O
surfactant	219	229	O
phospholipids	230	243	O
lecithin	244	252	O
and	253	256	O
sphingomyelin	257	270	O
in	271	273	O
amniotic	274	282	B-Organism_substance
fluid	283	288	I-Organism_substance
and	289	292	O
fetal	293	298	B-Organ
lung	299	303	I-Organ
maturity	304	312	O
is	313	315	O
well	316	320	O
established	321	332	O
.	332	333	O

An	334	336	O
enzymatic	337	346	O
method	347	353	O
that	354	358	O
had	359	362	O
been	363	367	O
automated	368	377	O
and	378	381	O
optimised	382	391	O
for	392	395	O
use	396	399	O
on	400	402	O
a	403	404	O
centrifugal	405	416	O
analyser	417	425	O
was	426	429	O
used	430	434	O
to	435	437	O
measure	438	445	O
the	446	449	O
total	450	455	O
choline	456	463	O
containing	464	474	O
phospholipids	475	488	O
in	489	491	O
amniotic	492	500	B-Organism_substance
fluid	501	506	I-Organism_substance
.	506	507	O

The	508	511	O
total	512	517	O
time	518	522	O
taken	523	528	O
for	529	532	O
this	533	537	O
assay	538	543	O
was	544	547	O
10	548	550	O
minutes	551	558	O
.	558	559	O

The	560	563	O
results	564	571	O
obtained	572	580	O
from	581	585	O
100	586	589	O
patient	590	597	O
samples	598	605	O
,	605	606	O
using	607	612	O
this	613	617	O
procedure	618	627	O
,	627	628	O
compared	629	637	O
favourably	638	648	O
with	649	653	O
the	654	657	O
results	658	665	O
obtained	666	674	O
by	675	677	O
the	678	681	O
thin	682	686	O
layer	687	692	O
chromatography	693	707	O
procedure	708	717	O
used	718	722	O
to	723	725	O
determine	726	735	O
the	736	739	O
lecithin	740	748	O
to	749	751	O
sphingomyelin	752	765	O
ratio	766	771	O
(	772	773	O
r	773	774	O
=	775	776	O
0	777	778	O
.	778	779	O
93	779	781	O
)	781	782	O
.	782	783	O

A	784	785	O
clinical	786	794	O
study	795	800	O
of	801	803	O
60	804	806	O
patients	807	815	O
showed	816	822	O
that	823	827	O
this	828	832	O
assay	833	838	O
predicted	839	848	O
prenatal	849	857	O
respiratory	858	869	B-Anatomical_system
distress	870	878	O
syndrome	879	887	O
as	888	890	O
well	891	895	O
as	896	898	O
the	899	902	O
lecithin	903	911	O
to	912	914	O
sphingomyelin	915	928	O
ratios	929	935	O
.	935	936	O

The	937	940	O
advantage	941	950	O
of	951	953	O
this	954	958	O
assay	959	964	O
over	965	969	O
existing	970	978	O
procedures	979	989	O
is	990	992	O
that	993	997	O
it	998	1000	O
requires	1001	1009	O
minimum	1010	1017	O
preparation	1018	1029	O
of	1030	1032	O
the	1033	1036	O
specimen	1037	1045	B-Organism_substance
and	1046	1049	O
no	1050	1052	O
extraction	1053	1063	O
,	1063	1064	O
is	1065	1067	O
quick	1068	1073	O
,	1073	1074	O
and	1075	1078	O
shows	1079	1084	O
a	1085	1086	O
high	1087	1091	O
degree	1092	1098	O
of	1099	1101	O
precision	1102	1111	O
.	1111	1112	O

Differences	0	11	O
between	12	19	O
the	20	23	O
arterial	24	32	B-Multi-tissue_structure
and	33	36	O
the	37	40	O
venous	41	47	B-Multi-tissue_structure
pathomorphology	48	63	O
in	64	66	O
Buerger	67	74	O
'	74	75	O
s	75	76	O
disease	77	84	O
.	84	85	O

Morphological	86	99	O
lesions	100	107	B-Pathological_formation
were	108	112	O
found	113	118	O
to	119	121	O
be	122	124	O
different	125	134	O
in	135	137	O
arteries	138	146	B-Multi-tissue_structure
and	147	150	O
in	151	153	O
veins	154	159	B-Multi-tissue_structure
,	159	160	O
in	161	163	O
9	164	165	O
cases	166	171	O
of	172	174	O
Buerger	175	182	O
'	182	183	O
s	183	184	O
disease	185	192	O
.	192	193	O

The	194	197	O
arterial	198	206	B-Pathological_formation
lesions	207	214	I-Pathological_formation
were	215	219	O
not	220	223	O
characteristic	224	238	O
and	239	242	O
consisted	243	252	O
of	253	255	O
non	256	259	O
-	259	260	O
specific	260	268	O
inflammation	269	281	O
,	281	282	O
thrombosis	283	293	O
and	294	297	O
obliteration	298	310	O
which	311	316	O
also	317	321	O
occur	322	327	O
in	328	330	O
many	331	335	O
other	336	341	O
disease	342	349	O
.	349	350	O

In	351	353	O
contrast	354	362	O
,	362	363	O
in	364	366	O
addition	367	375	O
to	376	378	O
wall	379	383	B-Multi-tissue_structure
infiltration	384	396	O
and	397	400	O
thrombosis	401	411	O
,	411	412	O
the	413	416	O
veins	417	422	B-Multi-tissue_structure
showed	423	429	O
microabscesses	430	444	B-Pathological_formation
and	445	448	O
giant	449	454	B-Pathological_formation
cell	455	459	I-Pathological_formation
granulomas	460	470	I-Pathological_formation
,	470	471	O
which	472	477	O
we	478	480	O
believe	481	488	O
to	489	491	O
be	492	494	O
absent	495	501	O
in	502	504	O
all	505	508	O
other	509	514	O
known	515	520	O
diseases	521	529	O
.	529	530	O

The	531	534	O
affected	535	543	O
venous	544	550	B-Multi-tissue_structure
segment	551	558	O
exhibited	559	568	O
a	569	570	O
variety	571	578	O
of	579	581	O
lesions	582	589	B-Pathological_formation
.	589	590	O

In	591	593	O
the	594	597	O
earliest	598	606	O
period	607	613	O
,	613	614	O
the	615	618	O
morphological	619	632	O
aspect	633	639	O
of	640	642	O
inflammation	643	655	O
in	656	658	O
arteries	659	667	B-Multi-tissue_structure
and	668	671	O
veins	672	677	B-Multi-tissue_structure
was	678	681	O
fairly	682	688	O
similar	689	696	O
.	696	697	O

In	698	700	O
a	701	702	O
late	703	707	O
periods	708	715	O
,	715	716	O
that	717	721	O
is	722	724	O
those	725	730	O
of	731	733	O
vascular	734	742	B-Multi-tissue_structure
obliteration	743	755	O
,	755	756	O
the	757	760	O
arteries	761	769	B-Multi-tissue_structure
and	770	773	O
veins	774	779	B-Multi-tissue_structure
did	780	783	O
not	784	787	O
show	788	792	O
any	793	796	O
distinguishing	797	811	O
morphological	812	825	O
differences	826	837	O
.	837	838	O

Phosphorylation	0	15	O
-	15	16	O
induced	16	23	O
mobility	24	32	O
shift	33	38	O
in	39	41	O
phospholamban	42	55	O
in	56	58	O
sodium	59	65	O
dodecyl	66	73	O
sulfate	74	81	O
-	81	82	O
polyacrylamide	82	96	O
gels	97	101	O
.	101	102	O

Evidence	103	111	O
for	112	115	O
a	116	117	O
protein	118	125	O
structure	126	135	O
consisting	136	146	O
of	147	149	O
multiple	150	158	O
identical	159	168	O
phosphorylatable	169	185	O
subunits	186	194	O
.	194	195	O

Phosphorylation	196	211	O
of	212	214	O
purified	215	223	O
phospholamban	224	237	O
isolated	238	246	O
from	247	251	O
canine	252	258	O
cardiac	259	266	B-Cellular_component
sarcoplasmic	267	279	I-Cellular_component
reticulum	280	289	I-Cellular_component
vesicles	290	298	I-Cellular_component
decreased	299	308	O
the	309	312	O
electrophoretic	313	328	O
mobility	329	337	O
of	338	340	O
the	341	344	O
protein	345	352	O
in	353	355	O
sodium	356	362	O
dodecyl	363	370	O
sulfate	371	378	O
(	379	380	O
SDS	380	383	O
)	383	384	O
-	384	385	O
polyacrylamide	385	399	O
gels	400	404	O
.	404	405	O

Different	406	415	O
mobility	416	424	O
forms	425	430	O
of	431	433	O
phospholamban	434	447	O
in	448	450	O
SDS	451	454	O
gels	455	459	O
were	460	464	O
visualized	465	475	O
both	476	480	O
by	481	483	O
direct	484	490	O
protein	491	498	O
staining	499	507	O
and	508	511	O
by	512	514	O
autoradiography	515	530	O
.	530	531	O

Unphosphorylated	532	548	O
phospholamban	549	562	O
migrated	563	571	O
with	572	576	O
an	577	579	O
apparent	580	588	O
Mr	589	591	O
=	592	593	O
25	594	596	O
,	596	597	O
000	597	600	O
in	601	603	O
SDS	604	607	O
gels	608	612	O
;	612	613	O
maximal	614	621	O
phosphorylation	622	637	O
of	638	640	O
phospholamban	641	654	O
by	655	657	O
cAMP	658	662	O
-	662	663	O
or	664	666	O
Ca2	667	670	O
+	670	671	O
-	671	672	O
calmodulin	672	682	O
-	682	683	O
dependent	683	692	O
protein	693	700	O
kinase	701	707	O
increased	708	717	O
the	718	721	O
apparent	722	730	O
Mr	731	733	O
to	734	736	O
27	737	739	O
,	739	740	O
000	740	743	O
.	743	744	O

Partial	745	752	O
phosphorylation	753	768	O
of	769	771	O
phospholamban	772	785	O
by	786	788	O
either	789	795	O
protein	796	803	O
kinase	804	810	O
gave	811	815	O
intermediate	816	828	O
mobility	829	837	O
forms	838	843	O
of	844	846	O
molecular	847	856	O
weights	857	864	O
between	865	872	O
25	873	875	O
,	875	876	O
000	876	879	O
and	880	883	O
27	884	886	O
,	886	887	O
000	887	890	O
,	890	891	O
suggesting	892	902	O
that	903	907	O
more	908	912	O
than	913	917	O
one	918	921	O
phosphorylation	922	937	O
site	938	942	O
was	943	946	O
present	947	954	O
on	955	957	O
the	958	961	O
holoprotein	962	973	O
for	974	977	O
each	978	982	O
activity	983	991	O
.	991	992	O

Boiling	993	1000	O
of	1001	1003	O
phospholamban	1004	1017	O
in	1018	1020	O
SDS	1021	1024	O
dissociated	1025	1036	O
the	1037	1040	O
holoprotein	1041	1052	O
into	1053	1057	O
an	1058	1060	O
apparently	1061	1071	O
homogeneous	1072	1083	O
class	1084	1089	O
of	1090	1092	O
low	1093	1096	O
molecular	1097	1106	O
weight	1107	1113	O
"	1114	1115	O
monomers	1115	1123	O
.	1123	1124	O
"	1124	1125	O
Only	1126	1130	O
two	1131	1134	O
mobility	1135	1143	O
forms	1144	1149	O
of	1150	1152	O
monomeric	1153	1162	O
phospholamban	1163	1176	O
were	1177	1181	O
observed	1182	1190	O
in	1191	1193	O
SDS	1194	1197	O
gels	1198	1202	O
after	1203	1208	O
phosphorylation	1209	1224	O
by	1225	1227	O
cAMP	1228	1232	O
-	1232	1233	O
dependent	1233	1242	O
protein	1243	1250	O
kinase	1251	1257	O
,	1257	1258	O
corresponding	1259	1272	O
to	1273	1275	O
9	1276	1277	O
-	1277	1278	O
kDa	1278	1281	O
dephospho	1282	1291	O
-	1291	1292	O
and	1293	1296	O
11	1297	1299	O
-	1299	1300	O
kDa	1300	1303	O
phosphoproteins	1304	1319	O
.	1319	1320	O

All	1321	1324	O
of	1325	1327	O
the	1328	1331	O
9	1332	1333	O
-	1333	1334	O
kDa	1334	1337	O
protein	1338	1345	O
could	1346	1351	O
be	1352	1354	O
phosphorylated	1355	1369	O
and	1370	1373	O
converted	1374	1383	O
into	1384	1388	O
the	1389	1392	O
11	1393	1395	O
-	1395	1396	O
kDa	1396	1399	O
mobility	1400	1408	O
form	1409	1413	O
,	1413	1414	O
suggesting	1415	1425	O
the	1426	1429	O
presence	1430	1438	O
of	1439	1441	O
only	1442	1446	O
one	1447	1450	O
site	1451	1455	O
of	1456	1458	O
phosphorylation	1459	1474	O
on	1475	1477	O
a	1478	1479	O
single	1480	1486	O
type	1487	1491	O
of	1492	1494	O
monomer	1495	1502	O
for	1503	1506	O
cAMP	1507	1511	O
-	1511	1512	O
dependent	1512	1521	O
protein	1522	1529	O
kinase	1530	1536	O
.	1536	1537	O

Simultaneous	1538	1550	O
phosphorylation	1551	1566	O
of	1567	1569	O
monomeric	1570	1579	O
phospholamban	1580	1593	O
by	1594	1596	O
cAMP	1597	1601	O
-	1601	1602	O
dependent	1602	1611	O
protein	1612	1619	O
kinase	1620	1626	O
and	1627	1630	O
Ca2	1631	1634	O
+	1634	1635	O
-	1635	1636	O
calmodulin	1636	1646	O
-	1646	1647	O
dependent	1647	1656	O
protein	1657	1664	O
kinase	1665	1671	O
gave	1672	1676	O
an	1677	1679	O
additional	1680	1690	O
mobility	1691	1699	O
form	1700	1704	O
of	1705	1707	O
the	1708	1711	O
protein	1712	1719	O
,	1719	1720	O
suggesting	1721	1731	O
that	1732	1736	O
different	1737	1746	O
sites	1747	1752	O
of	1753	1755	O
phosphorylation	1756	1771	O
were	1772	1776	O
present	1777	1784	O
for	1785	1788	O
each	1789	1793	O
activity	1794	1802	O
on	1803	1805	O
each	1806	1810	O
monomer	1811	1818	O
.	1818	1819	O

Incomplete	1820	1830	O
dissociation	1831	1843	O
of	1844	1846	O
the	1847	1850	O
holoprotein	1851	1862	O
by	1863	1865	O
boiling	1866	1873	O
it	1874	1876	O
in	1877	1879	O
a	1880	1881	O
relatively	1882	1892	O
low	1893	1896	O
concentration	1897	1910	O
of	1911	1913	O
SDS	1914	1917	O
facilitated	1918	1929	O
the	1930	1933	O
detection	1934	1943	O
of	1944	1946	O
five	1947	1951	O
major	1952	1957	O
mobility	1958	1966	O
forms	1967	1972	O
of	1973	1975	O
the	1976	1979	O
protein	1980	1987	O
in	1988	1990	O
SDS	1991	1994	O
gels	1995	1999	O
,	1999	2000	O
and	2001	2004	O
the	2005	2008	O
mobilities	2009	2019	O
of	2020	2022	O
all	2023	2026	O
of	2027	2029	O
these	2030	2035	O
forms	2036	2041	O
were	2042	2046	O
decreased	2047	2056	O
by	2057	2059	O
phosphorylation	2060	2075	O
.	2075	2076	O

We	2077	2079	O
propose	2080	2087	O
that	2088	2092	O
the	2093	2096	O
high	2097	2101	O
molecular	2102	2111	O
weight	2112	2118	O
form	2119	2123	O
of	2124	2126	O
phospholamban	2127	2140	O
is	2141	2143	O
a	2144	2145	O
multimer	2146	2154	O
of	2155	2157	O
electrophoretically	2158	2177	O
indistinguishable	2178	2195	O
monomers	2196	2204	O
,	2204	2205	O
each	2206	2210	O
of	2211	2213	O
which	2214	2219	O
contains	2220	2228	O
a	2229	2230	O
different	2231	2240	O
phosphorylation	2241	2256	O
site	2257	2261	O
for	2262	2265	O
cAMP	2266	2270	O
-	2270	2271	O
dependent	2271	2280	O
protein	2281	2288	O
kinase	2289	2295	O
activity	2296	2304	O
and	2305	2308	O
Ca2	2309	2312	O
+	2312	2313	O
-	2313	2314	O
calmodulin	2314	2324	O
-	2324	2325	O
dependent	2325	2334	O
protein	2335	2342	O
kinase	2343	2349	O
activity	2350	2358	O
.	2358	2359	O

Phosphorylation	2360	2375	O
of	2376	2378	O
phospholamban	2379	2392	O
at	2393	2395	O
multiple	2396	2404	O
sites	2405	2410	O
is	2411	2413	O
responsible	2414	2425	O
for	2426	2429	O
the	2430	2433	O
various	2434	2441	O
mobility	2442	2450	O
forms	2451	2456	O
of	2457	2459	O
the	2460	2463	O
holoprotein	2464	2475	O
detected	2476	2484	O
in	2485	2487	O
SDS	2488	2491	O
-	2491	2492	O
polyacrylamide	2492	2506	O
gels	2507	2511	O
.	2511	2512	O

Preliminary	0	11	O
evidence	12	20	O
for	21	24	O
a	25	26	O
pyridine	27	35	O
nucleotide	36	46	O
cycle	47	52	O
in	53	55	O
Bordetella	56	66	O
pertussis	67	76	O
.	76	77	O

Preliminary	78	89	O
evidence	90	98	O
that	99	103	O
Bordetella	104	114	O
pertussis	115	124	O
has	125	128	O
a	129	130	O
functional	131	141	O
pyridine	142	150	O
nucleotide	151	161	O
cycle	162	167	O
was	168	171	O
the	172	175	O
observation	176	187	O
that	188	192	O
[	193	194	O
14C	194	197	O
]	197	198	O
-	198	199	O
nicotinic	199	208	O
acid	209	213	O
was	214	217	O
rapidly	218	225	O
metabolized	226	237	O
during	238	244	O
its	245	248	O
uptake	249	255	O
by	256	258	O
the	259	262	O
bacteria	263	271	O
to	272	274	O
pyridine	275	283	O
nucleotides	284	295	O
and	296	299	O
nicotinamide	300	312	O
.	312	313	O

Nicotinamide	314	326	O
deamidase	327	336	O
activity	337	345	O
,	345	346	O
necessary	347	356	O
for	357	360	O
the	361	364	O
completion	365	375	O
of	376	378	O
the	379	382	O
cycle	383	388	O
by	389	391	O
conversion	392	402	O
of	403	405	O
nicotinamide	406	418	O
to	419	421	O
nicotinic	422	431	O
acid	432	436	O
,	436	437	O
was	438	441	O
found	442	447	O
in	448	450	O
a	451	452	O
soluble	453	460	O
extract	461	468	O
(	469	470	O
20	470	472	O
000	473	476	O
X	477	478	O
g	479	480	O
supernatant	481	492	O
)	492	493	O
of	494	496	O
B	497	498	O
.	498	499	O
pertussis	500	509	O
cell	510	514	B-Organism_substance
lysates	515	522	I-Organism_substance
.	522	523	O

Use	0	3	O
of	4	6	O
monoclonal	7	17	O
antibodies	18	28	O
to	29	31	O
investigate	32	43	O
a	44	45	O
possible	46	54	O
role	55	59	O
of	60	62	O
thyroglobulin	63	76	O
in	77	79	O
the	80	83	O
pathogenesis	84	96	O
of	97	99	O
Graves	100	106	O
'	106	107	O
ophthalmopathy	108	122	O
.	122	123	O

One	124	127	O
possible	128	136	O
mechanism	137	146	O
for	147	150	O
Graves	151	157	O
'	157	158	O
ophthalmopathy	159	173	O
is	174	176	O
that	177	181	O
the	182	185	O
progressive	186	197	O
orbital	198	205	B-Immaterial_anatomical_entity
inflammation	206	218	O
is	219	221	O
initiated	222	231	O
by	232	234	O
formation	235	244	O
of	245	247	O
thyroglobulin	248	261	O
(	262	263	O
Tg	263	265	O
)	265	266	O
-	266	267	O
anti	267	271	O
-	271	272	O
Tg	272	274	O
immune	275	281	O
complexes	282	291	O
at	292	294	O
sites	295	300	O
of	301	303	O
Tg	304	306	O
binding	307	314	O
to	315	317	O
extraocular	318	329	B-Tissue
muscle	330	336	I-Tissue
membranes	337	346	I-Tissue
.	346	347	O

In	348	350	O
this	351	355	O
study	356	361	O
monoclonal	362	372	O
antibodies	373	383	O
(	384	385	O
MCAB	385	389	O
)	389	390	O
against	391	398	O
human	399	404	O
Tg	405	407	O
were	408	412	O
used	413	417	O
as	418	420	O
probes	421	427	O
(	428	429	O
1	429	430	O
)	430	431	O
to	432	434	O
identify	435	443	O
Tg	444	446	O
in	447	449	O
eye	450	453	B-Tissue
muscle	454	460	I-Tissue
membranes	461	470	I-Tissue
prepared	471	479	O
from	480	484	O
normal	485	491	O
subjects	492	500	O
and	501	504	O
(	505	506	O
2	506	507	O
)	507	508	O
to	509	511	O
measure	512	519	O
binding	520	527	O
of	528	530	O
human	531	536	O
Tg	537	539	O
and	540	543	O
Tg	544	546	O
-	546	547	O
anti	547	551	O
-	551	552	O
Tg	552	554	O
immune	555	561	O
complexes	562	571	O
to	572	574	O
eye	575	578	B-Tissue
muscle	579	585	I-Tissue
membranes	586	595	I-Tissue
.	595	596	O

Reactivity	597	607	O
of	608	610	O
anti	611	615	O
-	615	616	O
Tg	616	618	O
MCAB	619	623	O
with	624	628	O
Tg	629	631	O
,	631	632	O
thyroid	633	640	B-Tissue
,	640	641	O
and	642	645	O
eye	646	649	B-Tissue
muscle	650	656	I-Tissue
membranes	657	666	I-Tissue
was	667	670	O
determined	671	681	O
by	682	684	O
binding	685	692	O
of	693	695	O
[	696	697	O
125I	697	701	O
]	701	702	O
anti	702	706	O
-	706	707	O
Tg	707	709	O
monoclonal	710	720	O
antibody	721	729	O
,	729	730	O
an	731	733	O
enzyme	734	740	O
-	740	741	O
linked	741	747	O
immunosorbent	748	761	O
assay	762	767	O
(	768	769	O
ELISA	769	774	O
)	774	775	O
,	775	776	O
and	777	780	O
the	781	784	O
indirect	785	793	O
immunofluorescence	794	812	O
technique	813	822	O
.	822	823	O

Seven	824	829	O
membrane	830	838	B-Tissue
fractions	839	848	I-Tissue
,	848	849	O
prepared	850	858	O
by	859	861	O
differential	862	874	O
sucrose	875	882	O
gradient	883	891	O
centrifugation	892	906	O
,	906	907	O
were	908	912	O
used	913	917	O
.	917	918	O

Whereas	919	926	O
[	927	928	O
125I	928	932	O
]	932	933	O
anti	933	937	O
-	937	938	O
Tg	938	940	O
MCAB	941	945	O
bound	946	951	O
to	952	954	O
all	955	958	O
thyroid	959	966	B-Tissue
membrane	967	975	I-Tissue
fractions	976	985	I-Tissue
tested	986	992	O
,	992	993	O
no	994	996	O
[	997	998	O
125I	998	1002	O
]	1002	1003	O
anti	1003	1007	O
-	1007	1008	O
Tg	1008	1010	O
bound	1011	1016	O
to	1017	1019	O
eye	1020	1023	B-Tissue
muscle	1024	1030	I-Tissue
membranes	1031	1040	I-Tissue
.	1040	1041	O

Similarly	1042	1051	O
,	1051	1052	O
reactivity	1053	1063	O
of	1064	1066	O
anti	1067	1071	O
-	1071	1072	O
Tg	1072	1074	O
MCAB	1075	1079	O
with	1080	1084	O
eye	1085	1088	B-Tissue
muscle	1089	1095	I-Tissue
membranes	1096	1105	I-Tissue
was	1106	1109	O
not	1110	1113	O
demonstrated	1114	1126	O
in	1127	1129	O
ELISA	1130	1135	O
or	1136	1138	O
immunofluorescence	1139	1157	O
tests	1158	1163	O
.	1163	1164	O

Although	1165	1173	O
Tg	1174	1176	O
-	1176	1177	O
anti	1177	1181	O
-	1181	1182	O
Tg	1182	1184	O
immune	1185	1191	O
complexes	1192	1201	O
bound	1202	1207	O
to	1208	1210	O
thyroid	1211	1218	B-Tissue
membranes	1219	1228	I-Tissue
,	1228	1229	O
such	1230	1234	O
complexes	1235	1244	O
did	1245	1248	O
not	1249	1252	O
bind	1253	1257	O
to	1258	1260	O
eye	1261	1264	B-Tissue
muscle	1265	1271	I-Tissue
membranes	1272	1281	I-Tissue
.	1281	1282	O

Significant	1283	1294	O
binding	1295	1302	O
of	1303	1305	O
[	1306	1307	O
125I	1307	1311	O
]	1311	1312	O
human	1312	1317	O
Tg	1318	1320	O
to	1321	1323	O
eye	1324	1327	B-Tissue
muscle	1328	1334	I-Tissue
or	1335	1337	O
thyroid	1338	1345	B-Tissue
membranes	1346	1355	I-Tissue
was	1356	1359	O
not	1360	1363	O
demonstrated	1364	1376	O
for	1377	1380	O
any	1381	1384	O
membrane	1385	1393	B-Tissue
preparation	1394	1405	I-Tissue
.	1405	1406	O

On	1407	1409	O
the	1410	1413	O
other	1414	1419	O
hand	1420	1424	O
moderate	1425	1433	O
,	1433	1434	O
but	1435	1438	O
significant	1439	1450	O
,	1450	1451	O
binding	1452	1459	O
to	1460	1462	O
skeletal	1463	1471	B-Organ
muscle	1472	1478	I-Organ
was	1479	1482	O
shown	1483	1488	O
.	1488	1489	O

Similar	1490	1497	O
results	1498	1505	O
were	1506	1510	O
found	1511	1516	O
using	1517	1522	O
an	1523	1525	O
ELISA	1526	1531	O
.	1531	1532	O

Binding	1533	1540	O
of	1541	1543	O
[	1544	1545	O
125I	1545	1549	O
]	1549	1550	O
anti	1550	1554	O
-	1554	1555	O
Tg	1555	1557	O
-	1557	1558	O
Tg	1558	1560	O
complexes	1561	1570	O
of	1571	1573	O
[	1574	1575	O
125I	1575	1579	O
]	1579	1580	O
Tg	1580	1582	O
to	1583	1585	O
thyroid	1586	1593	B-Tissue
and	1594	1597	O
eye	1598	1601	B-Tissue
muscle	1602	1608	I-Tissue
membranes	1609	1618	I-Tissue
was	1619	1622	O
not	1623	1626	O
affected	1627	1635	O
by	1636	1638	O
the	1639	1642	O
presence	1643	1651	O
of	1652	1654	O
normal	1655	1661	O
human	1662	1667	O
serum	1668	1673	B-Organism_substance
,	1673	1674	O
phosphate	1675	1684	O
ions	1685	1689	O
,	1689	1690	O
pH	1691	1693	O
,	1693	1694	O
or	1695	1697	O
incubation	1698	1708	O
temperature	1709	1720	O
,	1720	1721	O
conditions	1722	1732	O
claimed	1733	1740	O
by	1741	1743	O
others	1744	1750	O
to	1751	1753	O
be	1754	1756	O
critical	1757	1765	O
for	1766	1769	O
Tg	1770	1772	O
and	1773	1776	O
Tg	1777	1779	O
-	1779	1780	O
anti	1780	1784	O
-	1784	1785	O
Tg	1785	1787	O
immune	1788	1794	O
complex	1795	1802	O
binding	1803	1810	O
.	1810	1811	O

Since	1812	1817	O
Tg	1818	1820	O
is	1821	1823	O
not	1824	1827	O
present	1828	1835	O
in	1836	1838	O
normal	1839	1845	O
human	1846	1851	O
eye	1852	1855	B-Tissue
muscle	1856	1862	I-Tissue
a	1863	1864	O
major	1865	1870	O
role	1871	1875	O
of	1876	1878	O
Tg	1879	1881	O
,	1881	1882	O
or	1883	1885	O
Tg	1886	1888	O
-	1888	1889	O
anti	1889	1893	O
-	1893	1894	O
Tg	1894	1896	O
immune	1897	1903	O
complexes	1904	1913	O
,	1913	1914	O
in	1915	1917	O
the	1918	1921	O
pathogenesis	1922	1934	O
of	1935	1937	O
Graves	1938	1944	O
'	1944	1945	O
ophthalmopathy	1946	1960	O
appears	1961	1968	O
to	1969	1971	O
have	1972	1976	O
been	1977	1981	O
excluded	1982	1990	O
by	1991	1993	O
these	1994	1999	O
findings	2000	2008	O
.	2008	2009	O

Purification	0	12	O
and	13	16	O
characterization	17	33	O
of	34	36	O
various	37	44	O
esterases	45	54	O
from	55	59	O
rat	60	63	O
liver	64	69	B-Organ
.	69	70	O

The	71	74	O
major	75	80	O
rat	81	84	O
liver	85	90	B-Cellular_component
microsomal	91	101	I-Cellular_component
esterases	102	111	O
acting	112	118	O
on	119	121	O
o	122	123	O
-	123	124	O
nitrophenylacetate	124	142	O
with	143	147	O
isoelectric	148	159	O
points	160	166	O
5	167	168	O
.	168	169	O
0	169	170	O
,	170	171	O
5	172	173	O
.	173	174	O
5	174	175	O
,	175	176	O
6	177	178	O
.	178	179	O
1	179	180	O
and	181	184	O
6	185	186	O
.	186	187	O
4	187	188	O
were	189	193	O
resolved	194	202	O
by	203	205	O
isoelectric	206	217	O
focusing	218	226	O
.	226	227	O

Molecular	228	237	O
weights	238	245	O
were	246	250	O
determined	251	261	O
by	262	264	O
sedimentation	265	278	O
analysis	279	287	O
in	288	290	O
isokinetic	291	301	O
gradients	302	311	O
of	312	314	O
sucrose	315	322	O
and	323	326	O
,	326	327	O
after	328	333	O
purification	334	346	O
,	346	347	O
in	348	350	O
sodium	351	357	O
dodecyl	358	365	O
sulphate	366	374	O
/	374	375	O
polyacrylamide	375	389	O
gel	390	393	O
electrophoresis	394	409	O
.	409	410	O

Their	411	416	O
subunit	417	424	O
molecular	425	434	O
weights	435	442	O
were	443	447	O
between	448	455	O
57	456	458	O
000	459	462	O
and	463	466	O
60	467	469	O
000	470	473	O
.	473	474	O

They	475	479	O
behaved	480	487	O
as	488	490	O
monomers	491	499	O
except	500	506	O
the	507	510	O
pI	511	513	O
-	513	514	O
6	514	515	O
.	515	516	O
1	516	517	O
enzyme	518	524	O
which	525	530	O
behaved	531	538	O
as	539	541	O
a	542	543	O
trimer	544	550	O
.	550	551	O

Esterases	552	561	O
of	562	564	O
pI	565	567	O
5	568	569	O
.	569	570	O
0	570	571	O
,	571	572	O
pI	573	575	O
6	576	577	O
.	577	578	O
1	578	579	O
and	580	583	O
pI	584	586	O
6	587	588	O
.	588	589	O
4	589	590	O
behaved	591	598	O
like	599	603	O
glycoproteins	604	617	O
of	618	620	O
the	621	624	O
polymannose	625	636	O
type	637	641	O
in	642	644	O
the	645	648	O
presence	649	657	O
of	658	660	O
125I	661	665	O
-	665	666	O
labelled	666	674	O
concanavalin	675	687	O
A	688	689	O
.	689	690	O

Preparations	691	703	O
of	704	706	O
the	707	710	O
pI	711	713	O
-	713	714	O
5	714	715	O
.	715	716	O
0	716	717	O
enzyme	718	724	O
contained	725	734	O
two	735	738	O
esterases	739	748	O
of	749	751	O
highly	752	758	O
homologous	759	769	O
structure	770	779	O
.	779	780	O

Antibodies	781	791	O
directed	792	800	O
against	801	808	O
this	809	813	O
preparation	814	825	O
did	826	829	O
not	830	833	O
inhibit	834	841	O
but	842	845	O
precipitated	846	858	O
pI	859	861	O
-	861	862	O
5	862	863	O
.	863	864	O
0	864	865	O
esterase	866	874	O
activity	875	883	O
quantitatively	884	898	O
.	898	899	O

They	900	904	O
did	905	908	O
not	909	912	O
react	913	918	O
with	919	923	O
the	924	927	O
pI	928	930	O
-	930	931	O
6	931	932	O
.	932	933	O
1	933	934	O
and	935	938	O
pI	939	941	O
-	941	942	O
6	942	943	O
.	943	944	O
4	944	945	O
esterases	946	955	O
but	956	959	O
precipitated	960	972	O
several	973	980	O
nonimmunologically	981	999	O
related	1000	1007	O
esterases	1008	1017	O
.	1017	1018	O

Two	1019	1022	O
of	1023	1025	O
these	1026	1031	O
enzymes	1032	1039	O
were	1040	1044	O
inducible	1045	1054	O
by	1055	1057	O
phenobarbital	1058	1071	O
.	1071	1072	O

Total	1073	1078	O
activity	1079	1087	O
was	1088	1091	O
very	1092	1096	O
low	1097	1100	O
in	1101	1103	O
3	1104	1105	O
-	1105	1106	O
day	1106	1109	O
-	1109	1110	O
old	1110	1113	O
animals	1114	1121	O
.	1121	1122	O

Individual	1123	1133	O
esterase	1134	1142	O
activities	1143	1153	O
rose	1154	1158	O
at	1159	1161	O
different	1162	1171	O
rates	1172	1177	O
during	1178	1184	O
development	1185	1196	O
;	1196	1197	O
the	1198	1201	O
enzyme	1202	1208	O
focusing	1209	1217	O
near	1218	1222	O
pI	1223	1225	O
5	1226	1227	O
.	1227	1228	O
0	1228	1229	O
was	1230	1233	O
about	1234	1239	O
three	1240	1245	O
times	1246	1251	O
more	1252	1256	O
active	1257	1263	O
in	1264	1266	O
adult	1267	1272	O
females	1273	1280	O
than	1281	1285	O
in	1286	1288	O
males	1289	1294	O
.	1294	1295	O

All	1296	1299	O
microsomal	1300	1310	O
esterases	1311	1320	O
are	1321	1324	O
located	1325	1332	O
on	1333	1335	O
the	1336	1339	O
luminal	1340	1347	O
side	1348	1352	O
of	1353	1355	O
the	1356	1359	O
endoplasmic	1360	1371	B-Cellular_component
reticulum	1372	1381	I-Cellular_component
.	1381	1382	O

Hippocampal	0	11	B-Multi-tissue_structure
afterdischarge	12	26	O
interferes	27	37	O
with	38	42	O
storage	43	50	O
of	51	53	O
spatial	54	61	O
information	62	73	O
in	74	76	O
a	77	78	O
working	79	86	O
memory	87	93	O
test	94	98	O
.	98	99	O

In	100	102	O
an	103	105	O
attempt	106	113	O
to	114	116	O
impair	117	123	O
spatial	124	131	O
working	132	139	O
memory	140	146	O
by	147	149	O
reversible	150	160	O
functional	161	171	O
blockade	172	180	O
rather	181	187	O
than	188	192	O
by	193	195	O
irreversible	196	208	O
lesion	209	215	B-Pathological_formation
of	216	218	O
the	219	222	O
hippocampus	223	234	B-Multi-tissue_structure
,	234	235	O
eight	236	241	O
male	242	246	O
hooded	247	253	O
rats	254	258	O
were	259	263	O
trained	264	271	O
to	272	274	O
asymptotic	275	285	O
performance	286	297	O
of	298	300	O
1	301	302	O
.	302	303	O
2	303	304	O
to	305	307	O
1	308	309	O
.	309	310	O
4	310	311	O
errors	312	318	O
per	319	322	O
trial	323	328	O
in	329	331	O
the	332	335	O
spatial	336	343	O
12	344	346	O
-	346	347	O
choice	347	353	O
apparatus	354	363	O
(	364	365	O
Bure	366	370	O
s	371	372	O
et	373	375	O
al	376	378	O
.	378	379	O
1982	380	384	O
)	384	385	O
,	385	386	O
formally	387	395	O
similar	396	403	O
to	404	406	O
the	407	410	O
radial	411	417	O
maze	418	422	O
.	422	423	O

The	424	427	O
rats	428	432	O
were	433	437	O
implanted	438	447	O
with	448	452	O
hippocampal	453	464	B-Multi-tissue_structure
stimulating	465	476	O
and	477	480	O
recording	481	490	O
electrodes	491	501	O
,	501	502	O
which	503	508	O
were	509	513	O
used	514	518	O
for	519	522	O
eliciting	523	532	O
and	533	536	O
monitoring	537	547	O
hippocampal	548	559	B-Multi-tissue_structure
afterdischarge	560	574	O
(	575	576	O
HAD	576	579	O
)	579	580	O
lasting	581	588	O
for	589	592	O
at	593	595	O
least	596	601	O
20	602	604	O
s	605	606	O
.	606	607	O

In	608	610	O
Experiment	611	621	O
1	622	623	O
,	623	624	O
HAD	625	628	O
elicited	629	637	O
1	638	639	O
or	640	642	O
10	643	645	O
min	646	649	O
before	650	656	O
testing	657	664	O
increased	665	674	O
the	675	678	O
incidence	679	688	O
of	689	691	O
errors	692	698	O
to	699	701	O
2	702	703	O
.	703	704	O
75	704	706	O
or	707	709	O
2	710	711	O
.	711	712	O
50	712	714	O
per	715	718	O
trial	719	724	O
,	724	725	O
respectively	726	738	O
,	738	739	O
but	740	743	O
the	744	747	O
performance	748	759	O
still	760	765	O
remained	766	774	O
above	775	780	O
chance	781	787	O
level	788	793	O
(	794	795	O
4	795	796	O
.	796	797	O
18	797	799	O
)	799	800	O
.	800	801	O

In	802	804	O
Experiment	805	815	O
2	816	817	O
,	817	818	O
interruption	819	831	O
of	832	834	O
the	835	838	O
trial	839	844	O
by	845	847	O
1	848	849	O
,	849	850	O
10	851	853	O
,	853	854	O
20	855	857	O
and	858	861	O
30	862	864	O
min	865	868	O
intervals	869	878	O
inserted	879	887	O
between	888	895	O
choices	896	903	O
6	904	905	O
and	906	909	O
7	910	911	O
increased	912	921	O
the	922	925	O
incidence	926	935	O
of	936	938	O
errors	939	945	O
in	946	948	O
choices	949	956	O
7	957	958	O
to	959	961	O
12	962	964	O
to	965	967	O
1	968	969	O
.	969	970	O
0	970	971	O
,	971	972	O
1	973	974	O
.	974	975	O
5	975	976	O
,	976	977	O
2	978	979	O
.	979	980	O
1	980	981	O
and	982	985	O
2	986	987	O
.	987	988	O
5	988	989	O
,	989	990	O
respectively	991	1003	O
.	1003	1004	O

HAD	1005	1008	O
elicited	1009	1017	O
immediately	1018	1029	O
after	1030	1035	O
choice	1036	1042	O
6	1043	1044	O
increased	1045	1054	O
error	1055	1060	O
incidence	1061	1070	O
in	1071	1073	O
the	1074	1077	O
subsequent	1078	1088	O
6	1089	1090	O
choices	1091	1098	O
performed	1099	1108	O
after	1109	1114	O
1	1115	1116	O
-	1116	1117	O
min	1117	1120	O
or	1121	1123	O
10	1124	1126	O
-	1126	1127	O
min	1127	1130	O
intervals	1131	1140	O
to	1141	1143	O
3	1144	1145	O
.	1145	1146	O
1	1146	1147	O
or	1148	1150	O
2	1151	1152	O
.	1152	1153	O
75	1153	1155	O
,	1155	1156	O
respectively	1157	1169	O
,	1169	1170	O
i	1171	1172	O
.	1172	1173	O
e	1173	1174	O
.	1174	1175	O
to	1176	1178	O
the	1179	1182	O
chance	1183	1189	O
level	1190	1195	O
of	1196	1198	O
3	1199	1200	O
errors	1201	1207	O
in	1208	1210	O
6	1211	1212	O
choices	1213	1220	O
.	1220	1221	O

It	1222	1224	O
is	1225	1227	O
concluded	1228	1237	O
that	1238	1242	O
HAD	1243	1246	O
elicits	1247	1254	O
transient	1255	1264	O
shortening	1265	1275	O
of	1276	1278	O
the	1279	1282	O
memory	1283	1289	O
span	1290	1294	O
for	1295	1298	O
newly	1299	1304	O
acquired	1305	1313	O
spatial	1314	1321	O
information	1322	1333	O
(	1334	1335	O
anterograde	1335	1346	O
effect	1347	1353	O
)	1353	1354	O
and	1355	1358	O
erases	1359	1365	O
the	1366	1369	O
current	1370	1377	O
spatial	1378	1385	O
working	1386	1393	O
memory	1394	1400	O
record	1401	1407	O
(	1408	1409	O
retrograde	1409	1419	O
effect	1420	1426	O
)	1426	1427	O
.	1427	1428	O

[	0	1	O
In	1	3	O
vitro	4	9	O
studies	10	17	O
of	18	20	O
the	21	24	O
thyroid	25	32	B-Organ
gland	33	38	I-Organ
regulation	39	49	O
principles	50	60	O
and	61	64	O
their	65	70	O
evaluation	71	81	O
]	81	82	O
.	82	83	O

The	84	87	O
free	88	92	O
fractions	93	102	O
of	103	105	O
the	106	109	O
thyroid	110	117	O
hormone	118	125	O
further	126	133	O
the	134	137	O
metabolism	138	148	O
of	149	151	O
the	152	155	O
body	156	160	B-Cell
cells	161	166	I-Cell
and	167	170	O
regulate	171	179	O
the	180	183	O
synthesis	184	193	O
of	194	196	O
the	197	200	O
thyroid	201	208	O
hormone	209	216	O
.	216	217	O

Once	218	222	O
the	223	226	O
level	227	232	O
of	233	235	O
FT3	236	239	O
and	240	243	O
FT4	244	247	O
decreases	248	257	O
.	257	258	O

With	259	263	O
the	264	267	O
help	268	272	O
of	273	275	O
a	276	277	O
liberation	278	288	O
of	289	291	O
the	292	295	O
hormone	296	303	O
stimulating	304	315	O
the	316	319	O
thyroid	320	327	B-Organ
gland	328	333	I-Organ
from	334	338	O
the	339	342	O
anterior	343	351	B-Multi-tissue_structure
lobe	352	356	I-Multi-tissue_structure
of	357	359	O
the	360	363	O
pituitary	364	373	B-Organ
gland	374	379	I-Organ
the	380	383	O
lack	384	388	O
of	389	391	O
thyroid	392	399	O
hormone	400	407	O
is	408	410	O
corrected	411	420	O
.	420	421	O

The	422	425	O
synthesis	426	435	O
and	436	439	O
secretion	440	449	O
of	450	452	O
the	453	456	O
thyroid	457	464	B-Organ
gland	465	470	I-Organ
stimulating	471	482	O
hormone	483	490	O
is	491	493	O
induced	494	501	O
by	502	504	O
the	505	508	O
thyreotropin	509	521	O
releasing	522	531	O
hormone	532	539	O
which	540	545	O
is	546	548	O
given	549	554	O
by	555	557	O
the	558	561	O
hypothalamus	562	574	B-Multi-tissue_structure
.	574	575	O

Moreover	576	584	O
,	584	585	O
the	586	589	O
organism	590	598	O
is	599	601	O
able	602	606	O
as	607	609	O
needed	610	616	O
to	617	619	O
carry	620	625	O
out	626	629	O
the	630	633	O
monodiodation	634	647	O
of	648	650	O
LT4	651	654	O
to	655	657	O
biologically	658	670	O
active	671	677	O
LT3	678	681	O
or	682	684	O
biologically	685	697	O
inactive	698	706	O
so	707	709	O
-	709	710	O
called	710	716	O
revers	717	723	O
T3	724	726	O
(	727	728	O
RT3	728	731	O
)	731	732	O
.	732	733	O

The	734	737	O
estimation	738	748	O
of	749	751	O
thyroid	752	759	B-Organ
gland	760	765	I-Organ
stimulating	766	777	O
hormone	778	785	O
before	786	792	O
and	793	796	O
30	797	799	O
minutes	800	807	O
after	808	813	O
intravenous	814	825	B-Multi-tissue_structure
application	826	837	O
of	838	840	O
thyreotropin	841	853	O
releasing	854	863	O
hormone	864	871	O
has	872	875	O
its	876	879	O
main	880	884	O
importance	885	895	O
for	896	899	O
the	900	903	O
early	904	909	O
recognition	910	921	O
of	922	924	O
a	925	926	O
disturbance	927	938	O
of	939	941	O
the	942	945	O
regulating	946	956	O
circle	957	963	O
hypophysis	964	974	O
-	974	975	O
thyroid	975	982	B-Organ
gland	983	988	I-Organ
,	988	989	O
above	990	995	O
all	996	999	O
in	1000	1002	O
the	1003	1006	O
diagnosis	1007	1016	O
of	1017	1019	O
clinically	1020	1030	O
not	1031	1034	O
yet	1035	1038	O
manifest	1039	1047	O
clinical	1048	1056	O
pictures	1057	1065	O
,	1065	1066	O
such	1067	1071	O
as	1072	1074	O
the	1075	1078	O
latent	1079	1085	O
hypothyreosis	1086	1099	O
and	1100	1103	O
the	1104	1107	O
latent	1108	1114	O
hyperthyreosis	1115	1129	O
,	1129	1130	O
respectively	1131	1143	O
(	1144	1145	O
Basedow	1145	1152	O
hyperthyreosis	1153	1167	O
and	1168	1171	O
thyroidal	1172	1181	O
autonomy	1182	1190	O
)	1190	1191	O
.	1191	1192	O

According	1193	1202	O
to	1203	1205	O
the	1206	1209	O
questioning	1210	1221	O
the	1222	1225	O
estimations	1226	1237	O
of	1238	1240	O
the	1241	1244	O
levels	1245	1251	O
of	1252	1254	O
the	1255	1258	O
thyroid	1259	1266	O
hormones	1267	1275	O
and	1276	1279	O
of	1280	1282	O
the	1283	1286	O
thyroid	1287	1294	B-Organ
gland	1295	1300	I-Organ
stimulating	1301	1312	O
hormone	1313	1320	O
should	1321	1327	O
be	1328	1330	O
used	1331	1335	O
stepwise	1336	1344	O
.	1344	1345	O

Relationship	0	12	O
of	13	15	O
self	16	20	O
-	20	21	O
concept	21	28	O
during	29	35	O
late	36	40	O
pregnancy	41	50	O
to	51	53	O
neonatal	54	62	O
perception	63	73	O
and	74	77	O
parenting	78	87	O
profile	88	95	O
.	95	96	O

Thirty	97	103	O
-	103	104	O
one	104	107	O
gravidas	108	116	O
were	117	121	O
studied	122	129	O
to	130	132	O
examine	133	140	O
the	141	144	O
relationship	145	157	O
between	158	165	O
a	166	167	O
woman	168	173	O
'	173	174	O
s	174	175	O
feelings	176	184	O
about	185	190	O
herself	191	198	O
during	199	205	O
late	206	210	O
pregnancy	211	220	O
,	220	221	O
her	222	225	O
perception	226	236	O
of	237	239	O
her	240	243	O
newborn	244	251	O
,	251	252	O
and	253	256	O
her	257	260	O
profile	261	268	O
of	269	271	O
parenting	272	281	O
.	281	282	O

The	283	286	O
Tennessee	287	296	O
Self	297	301	O
-	301	302	O
Concept	302	309	O
Scale	310	315	O
was	316	319	O
completed	320	329	O
during	330	336	O
the	337	340	O
third	341	346	O
trimester	347	356	O
of	357	359	O
pregnancy	360	369	O
,	369	370	O
the	371	374	O
Neonatal	375	383	O
Perception	384	394	O
Inventory	395	404	O
I	405	406	O
at	407	409	O
one	410	413	O
-	413	414	O
to	414	416	O
-	416	417	O
two	417	420	O
days	421	425	O
postpartum	426	436	O
,	436	437	O
and	438	441	O
the	442	445	O
Neonatal	446	454	O
Perception	455	465	O
Inventory	466	475	O
II	476	478	O
and	479	482	O
the	483	486	O
Michigan	487	495	O
Screening	496	505	O
Profile	506	513	O
of	514	516	O
Parenting	517	526	O
at	527	529	O
four	530	534	O
-	534	535	O
to	535	537	O
-	537	538	O
six	538	541	O
weeks	542	547	O
postpartum	548	558	O
.	558	559	O

When	560	564	O
considered	565	575	O
separately	576	586	O
,	586	587	O
no	588	590	O
positive	591	599	O
significant	600	611	O
relationships	612	625	O
were	626	630	O
found	631	636	O
between	637	644	O
scores	645	651	O
on	652	654	O
these	655	660	O
variables	661	670	O
.	670	671	O

However	672	679	O
,	679	680	O
all	681	684	O
subjects	685	693	O
with	694	698	O
negative	699	707	O
scores	708	714	O
on	715	717	O
both	718	722	O
self	723	727	O
-	727	728	O
concept	728	735	O
and	736	739	O
neonatal	740	748	O
perception	749	759	O
had	760	763	O
negative	764	772	O
scores	773	779	O
on	780	782	O
at	783	785	O
least	786	791	O
two	792	795	O
subscales	796	805	O
of	806	808	O
the	809	812	O
parenting	813	822	O
profile	823	830	O
.	830	831	O

Verrucous	0	9	B-Pathological_formation
carcinoma	10	19	I-Pathological_formation
of	20	22	O
the	23	26	O
endometrium	27	38	B-Multi-tissue_structure
-	38	39	O
-	39	40	O
a	40	41	O
unique	42	48	O
neoplasm	49	57	B-Pathological_formation
with	58	62	O
long	63	67	O
survival	68	76	O
.	76	77	O

A	78	79	O
case	80	84	O
of	85	87	O
verrucous	88	97	B-Pathological_formation
carcinoma	98	107	I-Pathological_formation
of	108	110	O
the	111	114	O
endometrium	115	126	B-Multi-tissue_structure
with	127	131	O
long	132	136	O
survival	137	145	O
is	146	148	O
described	149	158	O
.	158	159	O

It	160	162	O
represents	163	173	O
the	174	177	O
first	178	183	O
of	184	186	O
its	187	190	O
type	191	195	O
to	196	198	O
be	199	201	O
recorded	202	210	O
in	211	213	O
this	214	218	O
site	219	223	O
.	223	224	O

The	225	228	O
literature	229	239	O
on	240	242	O
verrucous	243	252	B-Pathological_formation
carcinoma	253	262	I-Pathological_formation
and	263	266	O
on	267	269	O
other	270	275	O
cases	276	281	O
of	282	284	O
squamous	285	293	B-Pathological_formation
carcinoma	294	303	I-Pathological_formation
of	304	306	O
the	307	310	O
endometrium	311	322	B-Multi-tissue_structure
is	323	325	O
briefly	326	333	O
reviewed	334	342	O
.	342	343	O

[	0	1	O
Organization	1	13	O
of	14	16	O
pectoral	17	25	B-Cell
muscle	26	32	I-Cell
motor	33	38	I-Cell
neurons	39	46	I-Cell
in	47	49	O
the	50	53	O
rat	54	57	O
.	57	58	O
Contribution	59	71	O
to	72	74	O
the	75	78	O
study	79	84	O
of	85	87	O
the	88	91	O
axillary	92	100	B-Multi-tissue_structure
arch	101	105	I-Multi-tissue_structure
(	106	107	O
Achselbogen	107	118	O
)	118	119	O
]	119	120	O
.	120	121	O

In	122	124	O
spite	125	130	O
of	131	133	O
their	134	139	O
role	140	144	O
of	145	147	O
the	148	151	O
forelimb	152	160	B-Organism_subdivision
activity	161	169	O
,	169	170	O
the	171	174	O
organization	175	187	O
of	188	190	O
the	191	194	O
mammalian	195	204	O
pectoral	205	213	B-Organ
muscles	214	221	I-Organ
remains	222	229	O
unclear	230	237	O
.	237	238	O

In	239	241	O
order	242	247	O
to	248	250	O
get	251	254	O
more	255	259	O
information	260	271	O
,	271	272	O
we	273	275	O
have	276	280	O
studied	281	288	O
,	288	289	O
qualitatively	290	303	O
and	304	307	O
quantitatively	308	322	O
,	322	323	O
the	324	327	O
motor	328	333	O
pools	334	339	O
of	340	342	O
the	343	346	O
various	347	354	O
pectoral	355	363	B-Organ
muscles	364	371	I-Organ
in	372	374	O
the	375	378	O
rat	379	382	O
(	383	384	O
musculus	384	392	B-Organ
pectoralis	393	403	I-Organ
major	404	409	I-Organ
,	409	410	O
musculus	411	419	B-Organ
pectoralis	420	430	I-Organ
minor	431	436	I-Organ
and	437	440	O
musculus	441	449	B-Organ
panniculus	450	460	I-Organ
carnosus	461	469	I-Organ
)	469	470	O
.	470	471	O

The	472	475	O
method	476	482	O
applied	483	490	O
was	491	494	O
the	495	498	O
retrograde	499	509	O
transport	510	519	O
of	520	522	O
horseradish	523	534	O
peroxidase	535	545	O
by	546	548	O
the	549	552	O
peripheral	553	563	B-Multi-tissue_structure
nerves	564	570	I-Multi-tissue_structure
supplying	571	580	O
the	581	584	O
various	585	592	O
muscles	593	600	B-Organ
.	600	601	O

The	602	605	O
results	606	613	O
provided	614	622	O
the	623	626	O
precise	627	634	O
localization	635	647	O
within	648	654	O
the	655	658	O
ventral	659	666	B-Cellular_component
horn	667	671	I-Cellular_component
of	672	674	O
the	675	678	O
motor	679	684	B-Cell
neurons	685	692	I-Cell
from	693	697	O
the	698	701	O
pectoral	702	710	B-Organ
muscles	711	718	I-Organ
which	719	724	O
were	725	729	O
all	730	733	O
in	734	736	O
the	737	740	O
most	741	745	O
ventral	746	753	B-Multi-tissue_structure
part	754	758	I-Multi-tissue_structure
of	759	761	O
the	762	765	O
gray	766	770	B-Multi-tissue_structure
matter	771	777	I-Multi-tissue_structure
.	777	778	O

Three	779	784	O
distinct	785	793	O
motor	794	799	O
pools	800	805	O
were	806	810	O
observed	811	819	O
,	819	820	O
which	821	826	O
confirms	827	835	O
the	836	839	O
functional	840	850	O
identity	851	859	O
of	860	862	O
each	863	867	O
muscle	868	874	B-Organ
.	874	875	O

The	876	879	O
motor	880	885	B-Cell
neurons	886	893	I-Cell
of	894	896	O
m	897	898	O
.	898	899	O
panniculus	900	910	O
carnosus	911	919	O
exhibited	920	929	O
some	930	934	O
particularities	935	950	O
.	950	951	O

They	952	956	O
were	957	961	O
4	962	963	O
times	964	969	O
more	970	974	O
numerous	975	983	O
than	984	988	O
those	989	994	O
from	995	999	O
m	1000	1001	O
.	1001	1002	O
pectoralis	1003	1013	O
major	1014	1019	O
,	1019	1020	O
they	1021	1025	O
occupied	1026	1034	O
the	1035	1038	O
whole	1039	1044	O
ventral	1045	1052	B-Cellular_component
edge	1053	1057	I-Cellular_component
of	1058	1060	O
the	1061	1064	O
ventral	1065	1072	B-Cellular_component
horn	1073	1077	I-Cellular_component
,	1077	1078	O
from	1079	1083	O
its	1084	1087	O
medial	1088	1094	O
part	1095	1099	O
to	1100	1102	O
its	1103	1106	O
lateral	1107	1114	O
tip	1115	1118	O
.	1118	1119	O

The	1120	1123	O
cell	1124	1128	B-Cell
size	1129	1133	O
was	1134	1137	O
different	1138	1147	O
from	1148	1152	O
that	1153	1157	O
of	1158	1160	O
the	1161	1164	O
other	1165	1170	O
muscles	1171	1178	B-Organ
.	1178	1179	O

These	1180	1185	O
results	1186	1193	O
were	1194	1198	O
discussed	1199	1208	O
,	1208	1209	O
according	1210	1219	O
to	1220	1222	O
the	1223	1226	O
role	1227	1231	O
of	1232	1234	O
this	1235	1239	O
muscle	1240	1246	B-Organ
,	1246	1247	O
which	1248	1253	O
links	1254	1259	O
the	1260	1263	O
forelimb	1264	1272	B-Organism_subdivision
to	1273	1275	O
the	1276	1279	O
whole	1280	1285	O
trunk	1286	1291	B-Organism_subdivision
.	1291	1292	O

In	1293	1295	O
mammals	1296	1303	O
,	1303	1304	O
m	1305	1306	O
.	1306	1307	O
panniculus	1308	1318	O
carnosus	1319	1327	O
constitutes	1328	1339	O
,	1339	1340	O
with	1341	1345	O
musculus	1346	1354	B-Organ
latissimus	1355	1365	I-Organ
dorsi	1366	1371	I-Organ
,	1371	1372	O
the	1373	1376	O
axillary	1377	1385	B-Multi-tissue_structure
arch	1386	1390	I-Multi-tissue_structure
(	1391	1392	O
Achselbogen	1392	1403	O
)	1403	1404	O
.	1404	1405	O

A	1406	1407	O
small	1408	1413	O
area	1414	1418	O
of	1419	1421	O
overlapping	1422	1433	O
between	1434	1441	O
the	1442	1445	O
motor	1446	1451	O
pools	1452	1457	O
of	1458	1460	O
these	1461	1466	O
two	1467	1470	O
muscles	1471	1478	B-Organ
was	1479	1482	O
observed	1483	1491	O
.	1491	1492	O

It	1493	1495	O
was	1496	1499	O
suggested	1500	1509	O
that	1510	1514	O
the	1515	1518	O
muscular	1519	1527	B-Cell
fibers	1528	1534	I-Cell
from	1535	1539	O
the	1540	1543	O
axillary	1544	1552	B-Multi-tissue_structure
arch	1553	1557	I-Multi-tissue_structure
were	1558	1562	O
innervated	1563	1573	O
by	1574	1576	O
the	1577	1580	O
same	1581	1585	O
,	1585	1586	O
well	1587	1591	O
-	1591	1592	O
defined	1592	1599	O
spinal	1600	1606	B-Organism_subdivision
area	1607	1611	I-Organism_subdivision
,	1611	1612	O
independent	1613	1624	O
of	1625	1627	O
the	1628	1631	O
muscle	1632	1638	B-Organ
from	1639	1643	O
which	1644	1649	O
they	1650	1654	O
originate	1655	1664	O
.	1664	1665	O

Additional	0	10	O
tests	11	16	O
of	17	19	O
interest	20	28	O
to	29	31	O
the	32	35	O
dermatologist	36	49	O
.	49	50	O

The	51	54	O
carcinoid	55	64	O
syndrome	65	73	O
and	74	77	O
its	78	81	O
clinical	82	90	O
manifestations	91	105	O
have	106	110	O
been	111	115	O
discussed	116	125	O
.	125	126	O

The	127	130	O
standard	131	139	O
laboratory	140	150	O
test	151	155	O
for	156	159	O
making	160	166	O
that	167	171	O
diagnosis	172	181	O
is	182	184	O
urinary	185	192	B-Organism_substance
5	193	194	O
-	194	195	O
HIAA	195	199	O
levels	200	206	O
but	207	210	O
newer	211	216	O
,	216	217	O
more	218	222	O
sensitive	223	232	O
tests	233	238	O
may	239	242	O
also	243	247	O
be	248	250	O
available	251	260	O
.	260	261	O

Central	0	7	B-Anatomical_system
nervous	8	15	I-Anatomical_system
system	16	22	I-Anatomical_system
infection	23	32	O
with	33	37	O
Eikenella	38	47	O
corrodens	48	57	O
:	57	58	O
report	59	65	O
of	66	68	O
two	69	72	O
cases	73	78	O
.	78	79	O

Two	80	83	O
cases	84	89	O
of	90	92	O
central	93	100	B-Anatomical_system
nervous	101	108	I-Anatomical_system
system	109	115	I-Anatomical_system
infections	116	126	O
from	127	131	O
which	132	137	O
E	138	139	O
.	139	140	O
corrodens	141	150	O
has	151	154	O
been	155	159	O
isolated	160	168	O
are	169	172	O
reported	173	181	O
.	181	182	O

The	183	186	O
portals	187	194	O
of	195	197	O
entry	198	203	O
,	203	204	O
clinical	205	213	O
course	214	220	O
,	220	221	O
and	222	225	O
antimicrobial	226	239	O
responses	240	249	O
conform	250	257	O
to	258	260	O
other	261	266	O
reports	267	274	O
in	275	277	O
the	278	281	O
literature	282	292	O
.	292	293	O

The	294	297	O
importance	298	308	O
of	309	311	O
obtaining	312	321	O
careful	322	329	O
anaerobic	330	339	O
cultures	340	348	O
is	349	351	O
emphasized	352	362	O
.	362	363	O

Comparative	0	11	O
immunohistochemical	12	31	O
study	32	37	O
of	38	40	O
primary	41	48	B-Pathological_formation
and	49	52	O
metastatic	53	63	B-Pathological_formation
carcinomas	64	74	I-Pathological_formation
of	75	77	O
the	78	81	O
liver	82	87	B-Organ
.	87	88	O

Distinguishing	89	103	O
primary	104	111	B-Pathological_formation
hepatocellular	112	126	I-Pathological_formation
carcinoma	127	136	I-Pathological_formation
(	137	138	O
HCC	138	141	B-Pathological_formation
)	141	142	O
from	143	147	O
metastatic	148	158	B-Pathological_formation
carcinomas	159	169	I-Pathological_formation
to	170	172	O
the	173	176	O
liver	177	182	B-Organ
is	183	185	O
often	186	191	O
difficult	192	201	O
,	201	202	O
if	203	205	O
not	206	209	O
impossible	210	220	O
,	220	221	O
particularly	222	234	O
in	235	237	O
needle	238	244	B-Multi-tissue_structure
biopsy	245	251	I-Multi-tissue_structure
and	252	255	O
fine	256	260	B-Multi-tissue_structure
-	260	261	I-Multi-tissue_structure
needle	261	267	I-Multi-tissue_structure
aspiration	268	278	I-Multi-tissue_structure
specimens	279	288	I-Multi-tissue_structure
.	288	289	O

In	290	292	O
an	293	295	O
attempt	296	303	O
to	304	306	O
identify	307	315	O
a	316	317	O
specific	318	326	O
immunohistochemical	327	346	O
profile	347	354	O
that	355	359	O
would	360	365	O
distinguish	366	377	O
HCC	378	381	B-Pathological_formation
from	382	386	O
metastatic	387	397	B-Pathological_formation
carcinomas	398	408	I-Pathological_formation
,	408	409	O
we	410	412	O
studied	413	420	O
56	421	423	O
HCCs	424	428	O
,	428	429	O
8	430	431	O
cholangiocarcinomas	432	451	B-Pathological_formation
,	451	452	O
and	453	456	O
24	457	459	O
metastatic	460	470	B-Pathological_formation
adenocarcinomas	471	486	I-Pathological_formation
with	487	491	O
monoclonal	492	502	O
antibodies	503	513	O
to	514	516	O
alpha	517	522	O
-	522	523	O
fetoprotein	523	534	O
(	535	536	O
AFP	536	539	O
)	539	540	O
,	540	541	O
keratin	542	549	O
(	550	551	O
AE1	551	554	O
,	554	555	O
AE3	556	559	O
,	559	560	O
and	561	564	O
CAM5	565	569	O
.	569	570	O
2	570	571	O
)	571	572	O
,	572	573	O
Leu	574	577	O
-	577	578	O
M1	578	580	O
,	580	581	O
human	582	587	O
milk	588	592	O
fat	593	596	O
globule	597	604	O
(	605	606	O
HMFG	606	610	O
-	610	611	O
2	611	612	O
)	612	613	O
,	613	614	O
tumor	615	620	B-Pathological_formation
-	620	621	O
associated	621	631	O
glycoprotein	632	644	O
-	644	645	O
72	645	647	O
(	647	648	O
B72	648	651	O
.	651	652	O
3	652	653	O
)	653	654	O
,	654	655	O
epithelial	656	666	B-Tissue
specific	667	675	O
membrane	676	684	B-Cellular_component
antigen	685	692	O
(	693	694	O
Ber	694	697	O
-	697	698	O
EP4	698	701	O
)	701	702	O
,	702	703	O
and	704	707	O
BCA	708	711	O
-	711	712	O
225	712	715	O
(	716	717	O
CU	717	719	O
-	719	720	O
18	720	722	O
)	722	723	O
.	723	724	O

Both	725	729	O
monoclonal	730	740	O
and	741	744	O
polyclonal	745	755	O
(	756	757	O
mCEA	757	761	O
and	762	765	O
pCEA	766	770	O
)	770	771	O
antibodies	772	782	O
to	783	785	O
carcinoembryonic	786	802	O
antigen	803	810	O
also	811	815	O
were	816	820	O
used	821	825	O
.	825	826	O

Metastatic	827	837	B-Pathological_formation
adenocarcinomas	838	853	I-Pathological_formation
were	854	858	O
often	859	864	O
positive	865	873	O
for	874	877	O
CU	878	880	O
-	880	881	O
18	881	883	O
(	883	884	O
71	884	886	O
%	886	887	O
)	887	888	O
,	888	889	O
Leu	890	893	O
-	893	894	O
M1	894	896	O
(	897	898	O
75	898	900	O
%	900	901	O
)	901	902	O
,	902	903	O
B72	904	907	O
.	907	908	O
3	908	909	O
(	910	911	O
50	911	913	O
%	913	914	O
)	914	915	O
,	915	916	O
HMFG	917	921	O
-	921	922	O
2	922	923	O
(	924	925	O
67	925	927	O
%	927	928	O
)	928	929	O
,	929	930	O
Ber	931	934	O
-	934	935	O
EP4	935	938	O
(	938	939	O
83	939	941	O
%	941	942	O
)	942	943	O
and	944	947	O
mCEA	948	952	O
(	952	953	O
71	953	955	O
%	955	956	O
)	956	957	O
.	957	958	O

Using	959	964	O
these	965	970	O
antibodies	971	981	O
,	981	982	O
the	983	986	O
frequency	987	996	O
of	997	999	O
positivity	1000	1010	O
for	1011	1014	O
HCC	1015	1018	B-Pathological_formation
was	1019	1022	O
9	1023	1024	O
%	1024	1025	O
,	1025	1026	O
16	1027	1029	O
%	1029	1030	O
,	1030	1031	O
11	1032	1034	O
%	1034	1035	O
,	1035	1036	O
20	1037	1039	O
%	1039	1040	O
,	1040	1041	O
36	1042	1044	O
%	1044	1045	O
,	1045	1046	O
and	1047	1050	O
11	1051	1053	O
%	1053	1054	O
,	1054	1055	O
respectively	1056	1068	O
.	1068	1069	O

CU	1070	1072	O
-	1072	1073	O
18	1073	1075	O
was	1076	1079	O
the	1080	1083	O
only	1084	1088	O
monoclonal	1089	1099	O
antibody	1100	1108	O
in	1109	1111	O
which	1112	1117	O
there	1118	1123	O
was	1124	1127	O
a	1128	1129	O
significant	1130	1141	O
difference	1142	1152	O
in	1153	1155	O
positive	1156	1164	O
rates	1165	1170	O
between	1171	1178	O
HCC	1179	1182	B-Pathological_formation
and	1183	1186	O
metastatic	1187	1197	B-Pathological_formation
adenocarcinomas	1198	1213	I-Pathological_formation
.	1213	1214	O

Most	1215	1219	O
HCCs	1220	1224	B-Pathological_formation
(	1225	1226	O
71	1226	1228	O
%	1228	1229	O
)	1229	1230	O
revealed	1231	1239	O
a	1240	1241	O
bile	1242	1246	B-Multi-tissue_structure
canalicular	1247	1258	I-Multi-tissue_structure
staining	1259	1267	O
pattern	1268	1275	O
with	1276	1280	O
pCEA	1281	1285	O
.	1285	1286	O

Because	1287	1294	O
this	1295	1299	O
staining	1300	1308	O
pattern	1309	1316	O
was	1317	1320	O
absent	1321	1327	O
in	1328	1330	O
metastatic	1331	1341	B-Pathological_formation
carcinomas	1342	1352	I-Pathological_formation
,	1352	1353	O
pCEA	1354	1358	O
appears	1359	1366	O
to	1367	1369	O
be	1370	1372	O
useful	1373	1379	O
in	1380	1382	O
confirming	1383	1393	O
a	1394	1395	O
diagnosis	1396	1405	O
of	1406	1408	O
HCC	1409	1412	O
.	1412	1413	O

AE1	1414	1417	O
,	1417	1418	O
AE3	1419	1422	O
and	1423	1426	O
CAM5	1427	1431	O
.	1431	1432	O
2	1432	1433	O
antibodies	1434	1444	O
were	1445	1449	O
not	1450	1453	O
useful	1454	1460	O
in	1461	1463	O
distinguishing	1464	1478	O
HCC	1479	1482	B-Pathological_formation
from	1483	1487	O
metastatic	1488	1498	B-Pathological_formation
carcinomas	1499	1509	I-Pathological_formation
.	1509	1510	O

Each	1511	1515	O
cholangiocarcinoma	1516	1534	B-Pathological_formation
shared	1535	1541	O
a	1542	1543	O
staining	1544	1552	O
profile	1553	1560	O
similar	1561	1568	O
to	1569	1571	O
that	1572	1576	O
of	1577	1579	O
metastatic	1580	1590	B-Pathological_formation
carcinomas	1591	1601	I-Pathological_formation
.	1601	1602	O

Differential	0	12	O
effects	13	20	O
of	21	23	O
carbachol	24	33	O
on	34	36	O
calcium	37	44	O
entry	45	50	O
and	51	54	O
release	55	62	O
in	63	65	O
CHO	66	69	B-Cell
cells	70	75	I-Cell
expressing	76	86	O
the	87	90	O
m3	91	93	O
muscarinic	94	104	O
receptor	105	113	O
.	113	114	O

Calcium	115	122	O
signalling	123	133	O
was	134	137	O
examined	138	146	O
in	147	149	O
CHO	150	153	B-Cell
-	153	154	I-Cell
k1	154	156	I-Cell
cells	157	162	I-Cell
that	163	167	O
stably	168	174	O
express	175	182	O
the	183	186	O
m3	187	189	O
subtype	190	197	O
of	198	200	O
the	201	204	O
muscarinic	205	215	O
receptor	216	224	O
.	224	225	O

The	226	229	O
calcium	230	237	O
indicator	238	247	O
Fura	248	252	O
-	252	253	O
2	253	254	O
was	255	258	O
retained	259	267	O
in	268	270	O
these	271	276	O
cells	277	282	B-Cell
only	283	287	O
in	288	290	O
the	291	294	O
presence	295	303	O
of	304	306	O
probenecid	307	317	O
(	318	319	O
1	319	320	O
mM	321	323	O
)	323	324	O
,	324	325	O
suggesting	326	336	O
that	337	341	O
Fura	342	346	O
-	346	347	O
2	347	348	O
efflux	349	355	O
was	356	359	O
mediated	360	368	O
by	369	371	O
an	372	374	O
organic	375	382	O
anion	383	388	O
transporter	389	400	O
.	400	401	O

The	402	405	O
addition	406	414	O
of	415	417	O
carbachol	418	427	O
(	428	429	O
CCh	429	432	O
)	432	433	O
to	434	436	O
Fura	437	441	O
-	441	442	O
2	442	443	O
loaded	444	450	O
cells	451	456	B-Cell
in	457	459	O
suspension	460	470	O
caused	471	477	O
a	478	479	O
rapid	480	485	O
transient	486	495	O
increase	496	504	O
in	505	507	O
intracellular	508	521	B-Immaterial_anatomical_entity
calcium	522	529	O
[	530	531	O
Ca	531	533	O
]	533	534	O
i	534	535	O
followed	536	544	O
by	545	547	O
a	548	549	O
smaller	550	557	O
sustained	558	567	O
plateau	568	575	O
phase	576	581	O
.	581	582	O

The	583	586	O
transient	587	596	O
rise	597	601	O
in	602	604	O
[	605	606	O
Ca	606	608	O
]	608	609	O
i	609	610	O
was	611	614	O
dose	615	619	O
-	619	620	O
dependent	620	629	O
with	630	634	O
a	635	636	O
threshold	637	646	O
response	647	655	O
of	656	658	O
89	659	661	O
+	662	663	O
/	663	664	O
-	664	665	O
18	666	668	O
nM	669	671	O
above	672	677	O
baseline	678	686	O
with	687	691	O
10	692	694	O
nM	695	697	O
CCh	698	701	O
and	702	705	O
a	706	707	O
maximum	708	715	O
stimulation	716	727	O
of	728	730	O
734	731	734	O
+	735	736	O
/	736	737	O
-	737	738	O
46	739	741	O
nM	742	744	O
with	745	749	O
10	750	752	O
microM	753	759	O
CCh	760	763	O
.	763	764	O

This	765	769	O
phase	770	775	O
was	776	779	O
accompanied	780	791	O
by	792	794	O
a	795	796	O
similar	797	804	O
dose	805	809	O
-	809	810	O
dependent	810	819	O
stimulation	820	831	O
of	832	834	O
total	835	840	O
inositol	841	849	O
phosphate	850	859	O
production	860	870	O
and	871	874	O
was	875	878	O
assumed	879	886	O
to	887	889	O
be	890	892	O
generated	893	902	O
by	903	905	O
release	906	913	O
from	914	918	O
intracellular	919	932	B-Immaterial_anatomical_entity
stores	933	939	O
of	940	942	O
the	943	946	O
endoplasmic	947	958	B-Cellular_component
reticulum	959	968	I-Cellular_component
(	969	970	O
ER	970	972	B-Cellular_component
)	972	973	O
.	973	974	O

The	975	978	O
sustained	979	988	O
increase	989	997	O
in	998	1000	O
[	1001	1002	O
Ca	1002	1004	O
]	1004	1005	O
i	1005	1006	O
was	1007	1010	O
generated	1011	1020	O
by	1021	1023	O
entry	1024	1029	O
from	1030	1034	O
the	1035	1038	O
extracellular	1039	1052	B-Immaterial_anatomical_entity
bath	1053	1057	O
since	1058	1063	O
it	1064	1066	O
was	1067	1070	O
blocked	1071	1078	O
by	1079	1081	O
pretreatment	1082	1094	O
with	1095	1099	O
La3	1100	1103	O
+	1103	1104	O
(	1105	1106	O
1	1106	1107	O
microM	1108	1114	O
)	1114	1115	O
and	1116	1119	O
was	1120	1123	O
absent	1124	1130	O
when	1131	1135	O
bath	1136	1140	O
calcium	1141	1148	O
was	1149	1152	O
chelated	1153	1161	O
with	1162	1166	O
EGTA	1167	1171	O
.	1171	1172	O

This	1173	1177	O
phase	1178	1183	O
was	1184	1187	O
not	1188	1191	O
dependent	1192	1201	O
on	1202	1204	O
CCh	1205	1208	O
dose	1209	1213	O
,	1213	1214	O
and	1215	1218	O
a	1219	1220	O
stimulation	1221	1232	O
of	1233	1235	O
[	1236	1237	O
Ca	1237	1239	O
]	1239	1240	O
i	1240	1241	O
of	1242	1244	O
approximately	1245	1258	O
90	1259	1261	O
nM	1262	1264	O
above	1265	1270	O
baseline	1271	1279	O
was	1280	1283	O
observed	1284	1292	O
with	1293	1297	O
CCh	1298	1301	O
concentrations	1302	1316	O
between	1317	1324	O
50	1325	1327	O
nM	1328	1330	O
and	1331	1334	O
10	1335	1337	O
microM	1338	1344	O
.	1344	1345	O

With	1346	1350	O
this	1351	1355	O
dose	1356	1360	O
range	1361	1366	O
,	1366	1367	O
the	1368	1371	O
rate	1372	1376	O
of	1377	1379	O
Mn2	1380	1383	O
+	1383	1384	O
quenching	1385	1394	O
of	1395	1397	O
Fura	1398	1402	O
-	1402	1403	O
2	1403	1404	O
at	1405	1407	O
the	1408	1411	O
Ca	1412	1414	O
-	1414	1415	O
insensitive	1415	1426	O
excitation	1427	1437	O
wavelength	1438	1448	O
of	1449	1451	O
360	1452	1455	O
nm	1456	1458	O
was	1459	1462	O
likewise	1463	1471	O
maximally	1472	1481	O
stimulated	1482	1492	O
.	1492	1493	O

At	1494	1496	O
lower	1497	1502	O
CCh	1503	1506	O
concentrations	1507	1521	O
(	1522	1523	O
10	1523	1525	O
-	1525	1526	O
50	1526	1528	O
nM	1529	1531	O
)	1531	1532	O
,	1532	1533	O
it	1534	1536	O
was	1537	1540	O
clear	1541	1546	O
that	1547	1551	O
the	1552	1555	O
activation	1556	1566	O
of	1567	1569	O
Ca	1570	1572	O
entry	1573	1578	O
could	1579	1584	O
not	1585	1588	O
be	1589	1591	O
dissociated	1592	1603	O
from	1604	1608	O
a	1609	1610	O
threshold	1611	1620	O
release	1621	1628	O
of	1629	1631	O
Ca	1632	1634	O
from	1635	1639	O
intracellular	1640	1653	B-Immaterial_anatomical_entity
stores	1654	1660	O
.	1660	1661	O

The	1662	1665	O
phorbol	1666	1673	O
ester	1674	1679	O
PMA	1680	1683	O
,	1683	1684	O
which	1685	1690	O
uncouples	1691	1700	O
the	1701	1704	O
muscarinic	1705	1715	O
receptor	1716	1724	O
from	1725	1729	O
phospholipase	1730	1743	O
C	1744	1745	O
,	1745	1746	O
reduced	1747	1754	O
the	1755	1758	O
transient	1759	1768	O
rise	1769	1773	O
in	1774	1776	O
[	1777	1778	O
Ca	1778	1780	O
]	1780	1781	O
i	1781	1782	O
by	1783	1785	O
approximately	1786	1799	O
50	1800	1802	O
%	1802	1803	O
with	1804	1808	O
little	1809	1815	O
or	1816	1818	O
no	1819	1821	O
effect	1822	1828	O
on	1829	1831	O
Ca	1832	1834	O
entry	1835	1840	O
at	1841	1843	O
higher	1844	1850	O
CCh	1851	1854	O
levels	1855	1861	O
(	1862	1863	O
>	1863	1864	O
or	1865	1867	O
=	1868	1869	O
1	1870	1871	O
microM	1872	1878	O
)	1878	1879	O
.	1879	1880	O

At	1881	1883	O
lower	1884	1889	O
CCh	1890	1893	O
concentrations	1894	1908	O
(	1909	1910	O
<	1910	1911	O
or	1912	1914	O
=	1915	1916	O
100	1917	1920	O
nM	1921	1923	O
)	1923	1924	O
however	1925	1932	O
,	1932	1933	O
pretreatment	1934	1946	O
with	1947	1951	O
PMA	1952	1955	O
completely	1956	1966	O
blocked	1967	1974	O
all	1975	1978	O
Ca	1979	1981	O
mobilization	1982	1994	O
and	1995	1998	O
supports	1999	2007	O
the	2008	2011	O
contention	2012	2022	O
that	2023	2027	O
Ca	2028	2030	O
entry	2031	2036	O
is	2037	2039	O
coupled	2040	2047	O
to	2048	2050	O
Ca	2051	2053	O
release	2054	2061	O
from	2062	2066	O
stores	2067	2073	O
or	2074	2076	O
to	2077	2079	O
store	2080	2085	O
depletion	2086	2095	O
.	2095	2096	O

The	2097	2100	O
emptying	2101	2109	O
of	2110	2112	O
inositol	2113	2121	O
trisphosphate	2122	2135	O
-	2135	2136	O
sensitive	2136	2145	O
stores	2146	2152	O
with	2153	2157	O
thapsigargin	2158	2170	O
(	2171	2172	O
10	2172	2174	O
nM	2175	2177	O
)	2177	2178	O
stimulated	2179	2189	O
Ca	2190	2192	O
entry	2193	2198	O
and	2199	2202	O
also	2203	2207	O
the	2208	2211	O
rate	2212	2216	O
of	2217	2219	O
Mn2	2220	2223	O
+	2223	2224	O
quenching	2225	2234	O
.	2234	2235	O

Store	2236	2241	O
depletion	2242	2251	O
by	2252	2254	O
incubation	2255	2265	O
in	2266	2268	O
Ca	2269	2271	O
-	2271	2272	O
free	2272	2276	O
media	2277	2282	O
likewise	2283	2291	O
stimulated	2292	2302	O
Mn2	2303	2306	O
+	2306	2307	O
uptake	2308	2314	O
without	2315	2322	O
a	2323	2324	O
rise	2325	2329	O
in	2330	2332	O
[	2333	2334	O
Ca	2334	2336	O
]	2336	2337	O
i	2337	2338	O
.	2338	2339	O

Our	2340	2343	O
data	2344	2348	O
are	2349	2352	O
therefore	2353	2362	O
consistent	2363	2373	O
with	2374	2378	O
a	2379	2380	O
'	2381	2382	O
capacitative	2382	2394	O
'	2394	2395	O
coupling	2396	2404	O
model	2405	2410	O
,	2410	2411	O
whereby	2412	2419	O
the	2420	2423	O
activation	2424	2434	O
of	2435	2437	O
the	2438	2441	O
plasma	2442	2448	B-Cellular_component
membrane	2449	2457	I-Cellular_component
receptor	2458	2466	O
leads	2467	2472	O
to	2473	2475	O
an	2476	2478	O
InsP3	2479	2484	O
-	2484	2485	O
induced	2485	2492	O
change	2493	2499	O
in	2500	2502	O
the	2503	2506	O
degree	2507	2513	O
of	2514	2516	O
filling	2517	2524	O
of	2525	2527	O
the	2528	2531	O
ER	2532	2534	B-Cellular_component
Ca	2535	2537	O
pool	2538	2542	O
.	2542	2543	O
(	2543	2544	O
ABSTRACT	2544	2552	O
TRUNCATED	2553	2562	O
AT	2563	2565	O
400	2566	2569	O
WORDS	2570	2575	O
)	2575	2576	O

Appetite	0	8	O
regulation	9	19	O
by	20	22	O
serotoninergic	23	37	O
mechanisms	38	48	O
and	49	52	O
effects	53	60	O
of	61	63	O
d	64	65	O
-	65	66	O
fenfluramine	66	78	O
.	78	79	O

In	80	82	O
this	83	87	O
literature	88	98	O
review	99	105	O
,	105	106	O
evidence	107	115	O
is	116	118	O
presented	119	128	O
for	129	132	O
the	133	136	O
theory	137	143	O
that	144	148	O
the	149	152	O
neurotransmitter	153	169	O
,	169	170	O
serotonin	171	180	O
(	181	182	O
5	182	183	O
-	183	184	O
hydroxytryptamine	184	201	O
,	201	202	O
5HT	203	206	O
)	206	207	O
,	207	208	O
in	209	211	O
medial	212	218	B-Multi-tissue_structure
hypothalamic	219	231	I-Multi-tissue_structure
centres	232	239	I-Multi-tissue_structure
is	240	242	O
an	243	245	O
important	246	255	O
regulator	256	265	O
for	266	269	O
appetite	270	278	O
and	279	282	O
for	283	286	O
the	287	290	O
selection	291	300	O
of	301	303	O
major	304	309	O
food	310	314	O
constituents	315	327	O
.	327	328	O

High	329	333	O
local	334	339	O
levels	340	346	O
of	347	349	O
5HT	350	353	O
cause	354	359	O
a	360	361	O
reduction	362	371	O
of	372	374	O
appetite	375	383	O
and	384	387	O
a	388	389	O
preference	390	400	O
for	401	404	O
protein	405	412	O
,	412	413	O
low	414	417	O
levels	418	424	O
the	425	428	O
opposite	429	437	O
.	437	438	O

The	439	442	O
main	443	447	O
antagonistic	448	460	O
system	461	467	O
is	468	470	O
noradrenergic	471	484	O
.	484	485	O

The	486	489	O
drug	490	494	O
d	495	496	O
-	496	497	O
fenfluramine	497	509	O
mimics	510	516	O
the	517	520	O
effects	521	528	O
of	529	531	O
5HT	532	535	O
by	536	538	O
releasing	539	548	O
5HT	549	552	O
from	553	557	O
serotoninergic	558	572	O
nerve	573	578	B-Multi-tissue_structure
endings	579	586	O
and	587	590	O
inhibiting	591	601	O
its	602	605	O
neuronal	606	614	B-Cell
re	615	617	O
-	617	618	O
uptake	618	624	O
.	624	625	O

Further	626	633	O
experimental	634	646	O
data	647	651	O
prove	652	657	O
that	658	662	O
a	663	664	O
high	665	669	O
-	669	670	O
carbohydrate	670	682	O
,	682	683	O
low	684	687	O
-	687	688	O
protein	688	695	O
diet	696	700	O
promotes	701	709	O
uptake	710	716	O
of	717	719	O
serum	720	725	B-Organism_substance
tryptophan	726	736	O
in	737	739	O
the	740	743	O
brain	744	749	B-Organ
and	750	753	O
its	754	757	O
conversion	758	768	O
into	769	773	O
5HT	774	777	O
.	777	778	O

Hence	779	784	O
,	784	785	O
this	786	790	O
serotoninergic	791	805	O
system	806	812	O
may	813	816	O
function	817	825	O
as	826	828	O
a	829	830	O
self	831	835	O
-	835	836	O
regulatory	836	846	O
mechanism	847	856	O
.	856	857	O

In	858	860	O
patients	861	869	O
with	870	874	O
decreased	875	884	O
peripheral	885	895	O
insulin	896	903	O
sensitivity	904	915	O
,	915	916	O
the	917	920	O
system	921	927	O
may	928	931	O
be	932	934	O
disturbed	935	944	O
,	944	945	O
causing	946	953	O
overconsumption	954	969	O
of	970	972	O
carbohydrates	973	986	O
.	986	987	O

This	988	992	O
is	993	995	O
sometimes	996	1005	O
compulsive	1006	1016	O
(	1017	1018	O
"	1018	1019	O
carbohydrate	1019	1031	O
craving	1032	1039	O
"	1039	1040	O
)	1040	1041	O
.	1041	1042	O

It	1043	1045	O
may	1046	1049	O
be	1050	1052	O
presumed	1053	1061	O
that	1062	1066	O
in	1067	1069	O
the	1070	1073	O
treatment	1074	1083	O
of	1084	1086	O
obesity	1087	1094	O
,	1094	1095	O
in	1096	1098	O
addition	1099	1107	O
to	1108	1110	O
the	1111	1114	O
use	1115	1118	O
of	1119	1121	O
serotoninergic	1122	1136	O
drugs	1137	1142	O
,	1142	1143	O
successes	1144	1153	O
with	1154	1158	O
reducing	1159	1167	O
diets	1168	1173	O
may	1174	1177	O
be	1178	1180	O
enhanced	1181	1189	O
by	1190	1192	O
including	1193	1202	O
periods	1203	1210	O
of	1211	1213	O
high	1214	1218	O
-	1218	1219	O
carbohydrate	1219	1231	O
,	1231	1232	O
low	1233	1236	O
-	1236	1237	O
protein	1237	1244	O
intake	1245	1251	O
.	1251	1252	O

It	1253	1255	O
would	1256	1261	O
be	1262	1264	O
worthwhile	1265	1275	O
to	1276	1278	O
explore	1279	1286	O
whether	1287	1294	O
similar	1295	1302	O
alimentary	1303	1313	O
self	1314	1318	O
-	1318	1319	O
regulatory	1319	1329	O
mechanisms	1330	1340	O
of	1341	1343	O
neurotransmitter	1344	1360	O
function	1361	1369	O
exist	1370	1375	O
in	1376	1378	O
other	1379	1384	O
regulatory	1385	1395	O
systems	1396	1403	O
.	1403	1404	O

[	0	1	O
Preliminary	1	12	O
results	13	20	O
of	21	23	O
observing	24	33	O
18	34	36	O
cases	37	42	O
of	43	45	O
retinoblastoma	46	60	B-Pathological_formation
carried	61	68	O
within	69	75	O
the	76	79	O
international	80	93	O
research	94	102	O
program	103	110	O
RICS	111	115	O
]	115	116	O
.	116	117	O

In	118	120	O
the	121	124	O
years	125	130	O
1988	131	135	O
-	135	136	O
1989	136	140	O
,	140	141	O
the	142	145	O
Ophthalmological	146	162	O
Clinic	163	169	O
in	170	172	O
Cracow	173	179	O
took	180	184	O
part	185	189	O
in	190	192	O
the	193	196	O
International	197	210	O
Research	211	219	O
Programme	220	229	O
on	230	232	O
Retinoblastoma	233	247	B-Pathological_formation
as	248	250	O
one	251	254	O
of	255	257	O
28	258	260	O
clinical	261	269	O
centres	270	277	O
in	278	280	O
14	281	283	O
countries	284	293	O
.	293	294	O

The	295	298	O
study	299	304	O
included	305	313	O
18	314	316	O
children	317	325	O
with	326	330	O
retinoblastoma	331	345	B-Pathological_formation
,	345	346	O
in	347	349	O
most	350	354	O
cases	355	360	O
in	361	363	O
the	364	367	O
advanced	368	376	O
stadium	377	384	O
of	385	387	O
the	388	391	O
disease	392	399	O
.	399	400	O

As	401	403	O
a	404	405	O
rule	406	410	O
,	410	411	O
the	412	415	O
eyes	416	420	B-Organ
filled	421	427	O
with	428	432	O
tumours	433	440	B-Pathological_formation
were	441	445	O
enucleated	446	456	O
,	456	457	O
and	458	461	O
the	462	465	O
less	466	470	O
advanced	471	479	O
cases	480	485	O
were	486	490	O
treated	491	498	O
with	499	503	O
combined	504	512	O
methods	513	520	O
applying	521	529	O
radiation	530	539	O
with	540	544	O
60Co	545	549	O
plaques	550	557	O
with	558	562	O
xenon	563	568	O
arc	569	572	O
photocoagulation	573	589	O
,	589	590	O
cryopexy	591	599	O
,	599	600	O
and	601	604	O
chemotherapy	605	617	O
.	617	618	O

In	619	621	O
18	622	624	O
treated	625	632	O
children	633	641	O
23	642	644	O
eyes	645	649	B-Organ
were	650	654	O
enucleated	655	665	O
(	666	667	O
in	667	669	O
5	670	671	O
children	672	680	O
both	681	685	O
eyes	686	690	B-Organ
,	690	691	O
in	692	694	O
6	695	696	O
children	697	705	O
with	706	710	O
bilateral	711	720	O
retinoblastoma	721	735	B-Pathological_formation
1	736	737	O
eye	738	741	B-Organ
,	741	742	O
and	743	746	O
7	747	748	O
eyes	749	753	B-Organ
in	754	756	O
all	757	760	O
unilateral	761	771	O
cases	772	777	O
)	777	778	O
.	778	779	O

Six	780	783	O
eyes	784	788	B-Organ
with	789	793	O
less	794	798	O
advanced	799	807	O
lesions	808	815	B-Pathological_formation
were	816	820	O
treated	821	828	O
with	829	833	O
combined	834	842	O
methods	843	850	O
.	850	851	O

One	852	855	O
child	856	861	O
died	862	866	O
because	867	874	O
of	875	877	O
metastases	878	888	B-Pathological_formation
to	889	891	O
the	892	895	O
brain	896	901	B-Organ
.	901	902	O

The	903	906	O
obtained	907	915	O
data	916	920	O
reveal	921	927	O
that	928	932	O
retinoblastoma	933	947	B-Pathological_formation
is	948	950	O
diagnosed	951	960	O
too	961	964	O
late	965	969	O
,	969	970	O
which	971	976	O
decreases	977	986	O
the	987	990	O
chance	991	997	O
of	998	1000	O
cure	1001	1005	O
and	1006	1009	O
causes	1010	1016	O
great	1017	1022	O
danger	1023	1029	O
for	1030	1033	O
the	1034	1037	O
life	1038	1042	O
of	1043	1045	O
the	1046	1049	O
child	1050	1055	O
.	1055	1056	O

Epilepsy	0	8	O
in	9	11	O
Down	12	16	O
syndrome	17	25	O
:	25	26	O
clinical	27	35	O
aspects	36	43	O
and	44	47	O
possible	48	56	O
mechanisms	57	67	O
.	67	68	O

Although	69	77	O
epilepsy	78	86	O
is	87	89	O
more	90	94	O
common	95	101	O
in	102	104	O
persons	105	112	O
with	113	117	O
trisomy	118	125	O
21	126	128	O
(	129	130	O
Down	130	134	O
syndrome	135	143	O
)	143	144	O
than	145	149	O
in	150	152	O
the	153	156	O
general	157	164	O
population	165	175	O
,	175	176	O
the	177	180	O
mechanisms	181	191	O
by	192	194	O
which	195	200	O
seizures	201	209	O
are	210	213	O
generated	214	223	O
in	224	226	O
this	227	231	O
population	232	242	O
have	243	247	O
received	248	256	O
little	257	263	O
attention	264	273	O
.	273	274	O

It	275	277	O
is	278	280	O
likely	281	287	O
that	288	292	O
this	293	297	O
increased	298	307	O
seizure	308	315	O
susceptibility	316	330	O
is	331	333	O
due	334	337	O
to	338	340	O
a	341	342	O
combination	343	354	O
of	355	357	O
medical	358	365	O
risk	366	370	O
factors	371	378	O
and	379	382	O
inherent	383	391	O
neurologic	392	402	B-Anatomical_system
abnormalities	403	416	O
characteristic	417	431	O
of	432	434	O
Down	435	439	O
syndrome	440	448	O
.	448	449	O

In	450	452	O
this	453	457	O
review	458	464	O
clinical	465	473	O
aspects	474	481	O
of	482	484	O
seizures	485	493	O
among	494	499	O
individuals	500	511	O
with	512	516	O
Down	517	521	O
syndrome	522	530	O
were	531	535	O
described	536	545	O
and	546	549	O
possible	550	558	O
mechanisms	559	569	O
by	570	572	O
which	573	578	O
the	579	582	O
trisomy	583	590	O
21	591	593	O
brain	594	599	B-Organ
may	600	603	O
generate	604	612	O
seizures	613	621	O
were	622	626	O
explored	627	635	O
.	635	636	O

Chelation	0	9	O
treatment	10	19	O
of	20	22	O
neurological	23	35	B-Anatomical_system
Wilson	36	42	O
'	42	43	O
s	43	44	O
disease	45	52	O
.	52	53	O

The	54	57	O
results	58	65	O
of	66	68	O
chelation	69	78	O
treatment	79	88	O
of	89	91	O
137	92	95	O
patients	96	104	O
presenting	105	115	O
with	116	120	O
neurological	121	133	B-Anatomical_system
Wilson	134	140	O
'	140	141	O
s	141	142	O
disease	143	150	O
are	151	154	O
described	155	164	O
,	164	165	O
together	166	174	O
with	175	179	O
the	180	183	O
more	184	188	O
commonly	189	197	O
observed	198	206	O
toxic	207	212	O
reactions	213	222	O
to	223	225	O
the	226	229	O
various	230	237	O
drugs	238	243	O
employed	244	252	O
.	252	253	O

Fifty	254	259	O
-	259	260	O
seven	260	265	O
patients	266	274	O
made	275	279	O
an	280	282	O
excellent	283	292	O
response	293	301	O
to	302	304	O
treatment	305	314	O
and	315	318	O
became	319	325	O
symptom	326	333	O
free	334	338	O
.	338	339	O

Thirty	340	346	O
-	346	347	O
six	347	350	O
patients	351	359	O
made	360	364	O
a	365	366	O
good	367	371	O
recovery	372	380	O
,	380	381	O
but	382	385	O
were	386	390	O
left	391	395	O
with	396	400	O
some	401	405	O
minor	406	411	O
neurological	412	424	B-Anatomical_system
deficit	425	432	O
.	432	433	O

Twenty	434	440	O
-	440	441	O
four	441	445	O
patients	446	454	O
had	455	458	O
a	459	460	O
poor	461	465	O
response	466	474	O
:	474	475	O
although	476	484	O
the	485	488	O
disease	489	496	O
process	497	504	O
was	505	508	O
arrested	509	517	O
they	518	522	O
were	523	527	O
left	528	532	O
more	533	537	O
or	538	540	O
less	541	545	O
disabled	546	554	O
.	554	555	O

Twenty	556	562	O
patients	563	571	O
died	572	576	O
:	576	577	O
nine	578	582	O
had	583	586	O
little	587	593	O
or	594	596	O
no	597	599	O
treatment	600	609	O
,	609	610	O
but	611	614	O
11	615	617	O
died	618	622	O
despite	623	630	O
apparently	631	641	O
adequate	642	650	O
chelation	651	660	O
therapy	661	668	O
.	668	669	O

There	670	675	O
was	676	679	O
no	680	682	O
obvious	683	690	O
reason	691	697	O
for	698	701	O
this	702	706	O
failure	707	714	O
.	714	715	O

The	716	719	O
liver	720	725	B-Organ
copper	726	732	O
level	733	738	O
was	739	742	O
estimated	743	752	O
in	753	755	O
six	756	759	O
of	760	762	O
these	763	768	O
patients	769	777	O
:	777	778	O
it	779	781	O
was	782	785	O
still	786	791	O
significantly	792	805	O
elevated	806	814	O
in	815	817	O
only	818	822	O
one	823	826	O
,	826	827	O
but	828	831	O
in	832	834	O
all	835	838	O
four	839	843	O
in	844	846	O
whom	847	851	O
it	852	854	O
was	855	858	O
possible	859	867	O
to	868	870	O
make	871	875	O
the	876	879	O
determination	880	893	O
,	893	894	O
the	895	898	O
concentration	899	912	O
of	913	915	O
copper	916	922	O
in	923	925	O
the	926	929	O
basal	930	935	B-Multi-tissue_structure
ganglia	936	943	I-Multi-tissue_structure
was	944	947	O
in	948	950	O
excess	951	957	O
of	958	960	O
45	961	963	O
micrograms	964	974	O
/	974	975	O
g	975	976	O
wet	977	980	O
weight	981	987	O
.	987	988	O

It	989	991	O
was	992	995	O
not	996	999	O
apparent	1000	1008	O
why	1009	1012	O
adequate	1013	1021	O
therapy	1022	1029	O
failed	1030	1036	O
to	1037	1039	O
remove	1040	1046	O
copper	1047	1053	O
from	1054	1058	O
the	1059	1062	O
brains	1063	1069	B-Organ
of	1070	1072	O
these	1073	1078	O
patients	1079	1087	O
.	1087	1088	O

There	1089	1094	O
was	1095	1098	O
no	1099	1101	O
obvious	1102	1109	O
clinical	1110	1118	O
,	1118	1119	O
histological	1120	1132	O
or	1133	1135	O
biochemical	1136	1147	O
indicator	1148	1157	O
of	1158	1160	O
failure	1161	1168	O
to	1169	1171	O
respond	1172	1179	O
to	1180	1182	O
treatment	1183	1192	O
.	1192	1193	O

Initial	1194	1201	O
deterioration	1202	1215	O
before	1216	1222	O
improvement	1223	1234	O
was	1235	1238	O
seen	1239	1243	O
in	1244	1246	O
30	1247	1249	O
patients	1250	1258	O
:	1258	1259	O
the	1260	1263	O
prognosis	1264	1273	O
for	1274	1277	O
a	1278	1279	O
useful	1280	1286	O
recovery	1287	1295	O
was	1296	1299	O
not	1300	1303	O
necessarily	1304	1315	O
worse	1316	1321	O
than	1322	1326	O
that	1327	1331	O
in	1332	1334	O
patients	1335	1343	O
who	1344	1347	O
did	1348	1351	O
not	1352	1355	O
show	1356	1360	O
this	1361	1365	O
phenomenon	1366	1376	O
.	1376	1377	O

[	0	1	O
Prehospital	1	12	O
service	13	20	O
in	21	23	O
Denmark	24	31	O
]	31	32	O
.	32	33	O

In	34	36	O
Denmark	37	44	O
,	44	45	O
emergency	46	55	O
ambulances	56	66	O
are	67	70	O
dispatched	71	81	O
by	82	84	O
41	85	87	O
centres	88	95	O
manned	96	102	O
either	103	109	O
by	110	112	O
trained	113	120	O
firemen	121	128	O
(	129	130	O
in	130	132	O
Copenhagen	133	143	O
)	143	144	O
or	145	147	O
policemen	148	157	O
(	158	159	O
outside	159	166	O
Copenhagen	167	177	O
)	177	178	O
.	178	179	O

In	180	182	O
1990	183	187	O
,	187	188	O
emergency	189	198	O
ambulance	199	208	O
calls	209	214	O
totalled	215	223	O
284	224	227	O
,	227	228	O
000	228	231	O
.	231	232	O

Utilisation	233	244	O
of	245	247	O
emergency	248	257	O
ambulance	258	267	O
services	268	276	O
increases	277	286	O
with	287	291	O
urbanisation	292	304	O
.	304	305	O

A	306	307	O
doctor	308	314	O
-	314	315	O
manned	315	321	O
ambulance	322	331	O
is	332	334	O
in	335	337	O
operation	338	347	O
in	348	350	O
Copenhagen	351	361	O
,	361	362	O
and	363	366	O
in	367	369	O
some	370	374	O
other	375	380	O
large	381	386	O
towns	387	392	O
anaesthesiology	393	408	O
and	409	412	O
intensive	413	422	O
care	423	427	O
teams	428	433	O
can	434	437	O
be	438	440	O
dispatched	441	451	O
from	452	456	O
hospital	457	465	O
to	466	468	O
give	469	473	O
on	474	476	O
-	476	477	O
the	477	480	O
-	480	481	O
spot	481	485	O
care	486	490	O
.	490	491	O

In	492	494	O
less	495	499	O
populated	500	509	O
areas	510	515	O
,	515	516	O
some	517	521	O
general	522	529	O
practitioners	530	543	O
give	544	548	O
advanced	549	557	O
life	558	562	O
-	562	563	O
support	563	570	O
.	570	571	O

Although	572	580	O
many	581	585	O
areas	586	591	O
are	592	595	O
serviced	596	604	O
by	605	607	O
ambulances	608	618	O
equipped	619	627	O
with	628	632	O
defibrillators	633	647	O
,	647	648	O
the	649	652	O
majority	653	661	O
of	662	664	O
patients	665	673	O
receive	674	681	O
only	682	686	O
basic	687	692	O
life	693	697	O
-	697	698	O
support	698	705	O
from	706	710	O
ambulance	711	720	O
personnel	721	730	O
.	730	731	O

New	732	735	O
initiatives	736	747	O
resulting	748	757	O
from	758	762	O
a	763	764	O
recent	765	771	O
report	772	778	O
by	779	781	O
a	782	783	O
commission	784	794	O
appointed	795	804	O
by	805	807	O
central	808	815	O
authorities	816	827	O
,	827	828	O
and	829	832	O
focused	833	840	O
on	841	843	O
prehospital	844	855	O
treatment	856	865	O
,	865	866	O
are	867	870	O
expected	871	879	O
to	880	882	O
improve	883	890	O
the	891	894	O
service	895	902	O
by	903	905	O
raising	906	913	O
the	914	917	O
level	918	923	O
of	924	926	O
training	927	935	O
given	936	941	O
to	942	944	O
ambulance	945	954	O
personnel	955	964	O
.	964	965	O

Cell	0	4	B-Cellular_component
surface	5	12	I-Cellular_component
binding	13	20	O
characteristics	21	36	O
correlate	37	46	O
with	47	51	O
consensus	52	61	O
type	62	66	O
I	67	68	O
interferon	69	79	O
enhanced	80	88	O
activity	89	97	O
.	97	98	O

The	99	102	O
binding	103	110	O
characteristics	111	126	O
of	127	129	O
a	130	131	O
genetically	132	143	O
engineered	144	154	O
consensus	155	164	O
interferon	165	175	O
with	176	180	O
unusually	181	190	O
high	191	195	O
biologic	196	204	O
activity	205	213	O
were	214	218	O
compared	219	227	O
to	228	230	O
the	231	234	O
characteristics	235	250	O
of	251	253	O
recombinant	254	265	O
interferon	266	276	O
-	276	277	O
alpha	277	282	O
2	283	284	O
.	284	285	O

Both	286	290	O
interferon	291	301	O
-	301	302	O
alpha	302	307	O
2	308	309	O
and	310	313	O
the	314	317	O
consensus	318	327	O
interferon	328	338	O
produced	339	347	O
typical	348	355	O
biphasic	356	364	O
Scatchard	365	374	O
plots	375	380	O
,	380	381	O
indicating	382	392	O
multiple	393	401	O
independent	402	413	O
binding	414	421	O
sites	422	427	O
.	427	428	O

The	429	432	O
consensus	433	442	O
interferon	443	453	O
,	453	454	O
which	455	460	O
exhibited	461	470	O
a	471	472	O
biologic	473	481	O
potency	482	489	O
more	490	494	O
than	495	499	O
10	500	502	O
-	502	503	O
fold	503	507	O
greater	508	515	O
than	516	520	O
all	521	524	O
other	525	530	O
type	531	535	O
I	536	537	O
interferons	538	549	O
,	549	550	O
also	551	555	O
exhibited	556	565	O
binding	566	573	O
site	574	578	O
affinities	579	589	O
greater	590	597	O
than	598	602	O
those	603	608	O
for	609	612	O
IFN	613	616	O
-	616	617	O
alpha	617	622	O
2b	623	625	O
.	625	626	O

In	627	629	O
addition	630	638	O
,	638	639	O
a	640	641	O
larger	642	648	O
number	649	655	O
of	656	658	O
high	659	663	O
,	663	664	O
and	665	668	O
low	669	672	O
-	672	673	O
affinity	673	681	O
cell	682	686	B-Cellular_component
surface	687	694	I-Cellular_component
sites	695	700	O
were	701	705	O
recognized	706	716	O
by	717	719	O
the	720	723	O
consensus	724	733	O
interferon	734	744	O
,	744	745	O
resulting	746	755	O
in	756	758	O
equivalent	759	769	O
numbers	770	777	O
of	778	780	O
sites	781	786	O
at	787	789	O
reduced	790	797	O
molar	798	803	O
concentrations	804	818	O
compared	819	827	O
to	828	830	O
IFN	831	834	O
-	834	835	O
a2b	835	838	O
.	838	839	O

Thus	840	844	O
,	844	845	O
at	846	848	O
any	849	852	O
given	853	858	O
biologic	859	867	O
activity	868	876	O
,	876	877	O
similar	878	885	O
numbers	886	893	O
of	894	896	O
sites	897	902	O
were	903	907	O
bound	908	913	O
by	914	916	O
the	917	920	O
consensus	921	930	O
interferon	931	941	O
and	942	945	O
IFN	946	949	O
-	949	950	O
alpha	950	955	O
2	956	957	O
,	957	958	O
despite	959	966	O
differences	967	978	O
in	979	981	O
their	982	987	O
molar	988	993	O
concentrations	994	1008	O
.	1008	1009	O

No	1010	1012	O
differences	1013	1024	O
in	1025	1027	O
internalization	1028	1043	O
kinetics	1044	1052	O
were	1053	1057	O
identified	1058	1068	O
between	1069	1076	O
the	1077	1080	O
two	1081	1084	O
interferons	1085	1096	O
,	1096	1097	O
indicating	1098	1108	O
that	1109	1113	O
the	1114	1117	O
differences	1118	1129	O
in	1130	1132	O
cell	1133	1137	B-Cellular_component
surface	1138	1145	I-Cellular_component
binding	1146	1153	O
may	1154	1157	O
be	1158	1160	O
sufficient	1161	1171	O
to	1172	1174	O
produce	1175	1182	O
the	1183	1186	O
differences	1187	1198	O
in	1199	1201	O
biologic	1202	1210	O
activity	1211	1219	O
.	1219	1220	O

Human	0	5	O
immunodeficiency	6	22	O
virus	23	28	O
type	29	33	O
1	34	35	O
viral	36	41	O
background	42	52	O
plays	53	58	O
a	59	60	O
major	61	66	O
role	67	71	O
in	72	74	O
development	75	86	O
of	87	89	O
resistance	90	100	O
to	101	103	O
protease	104	112	O
inhibitors	113	123	O
.	123	124	O

The	125	128	O
observed	129	137	O
in	138	140	O
vitro	141	146	O
and	147	150	O
in	151	153	O
vivo	154	158	O
benefit	159	166	O
of	167	169	O
combination	170	181	O
treatment	182	191	O
with	192	196	O
anti	197	201	O
-	201	202	O
human	202	207	O
immunodeficiency	208	224	O
virus	225	230	O
(	231	232	O
HIV	232	235	O
)	235	236	O
agents	237	243	O
prompted	244	252	O
us	253	255	O
to	256	258	O
examine	259	266	O
the	267	270	O
potential	271	280	O
of	281	283	O
resistance	284	294	O
development	295	306	O
when	307	311	O
two	312	315	O
protease	316	324	O
inhibitors	325	335	O
are	336	339	O
used	340	344	O
concurrently	345	357	O
.	357	358	O

Recombinant	359	370	O
HIV	371	374	O
-	374	375	O
1	375	376	O
(	377	378	O
NL4	378	381	O
-	381	382	O
3	382	383	O
)	383	384	O
proteases	385	394	O
containing	395	405	O
combined	406	414	O
resistance	415	425	O
mutations	426	435	O
associated	436	446	O
with	447	451	O
BMS	452	455	O
-	455	456	O
186318	456	462	O
and	463	466	O
A	467	468	O
-	468	469	O
77003	469	474	O
(	475	476	O
or	476	478	O
saquinavir	479	489	O
)	489	490	O
were	491	495	O
either	496	502	O
inactive	503	511	O
or	512	514	O
had	515	518	O
impaired	519	527	O
enzyme	528	534	O
activity	535	543	O
.	543	544	O

Subsequent	545	555	O
construction	556	568	O
of	569	571	O
HIV	572	575	O
-	575	576	O
1	576	577	O
(	578	579	O
NL4	579	582	O
-	582	583	O
3	583	584	O
)	584	585	O
proviral	586	594	O
clones	595	601	O
containing	602	612	O
the	613	616	O
same	617	621	O
mutations	622	631	O
yielded	632	639	O
viruses	640	647	O
that	648	652	O
were	653	657	O
severely	658	666	O
impaired	667	675	O
in	676	678	O
growth	679	685	O
or	686	688	O
nonviable	689	698	O
,	698	699	O
confirming	700	710	O
that	711	715	O
combination	716	727	O
therapy	728	735	O
may	736	739	O
be	740	742	O
advantageous	743	755	O
.	755	756	O

However	757	764	O
,	764	765	O
passage	766	773	O
of	774	776	O
BMS	777	780	O
-	780	781	O
186318	781	787	O
-	787	788	O
resistant	788	797	O
HIV	798	801	O
-	801	802	O
1	802	803	O
(	804	805	O
RF	805	807	O
)	807	808	O
in	809	811	O
the	812	815	O
presence	816	824	O
of	825	827	O
either	828	834	O
saquinavir	835	845	O
or	846	848	O
SC52151	849	856	O
,	856	857	O
which	858	863	O
represented	864	875	O
sequential	876	886	O
drug	887	891	O
treatment	892	901	O
,	901	902	O
produced	903	911	O
viable	912	918	O
viruses	919	926	O
resistant	927	936	O
to	937	939	O
both	940	944	O
BMS	945	948	O
-	948	949	O
186318	949	955	O
and	956	959	O
the	960	963	O
second	964	970	O
compound	971	979	O
.	979	980	O

The	981	984	O
predominant	985	996	O
breakthrough	997	1009	O
virus	1010	1015	O
contained	1016	1025	O
the	1026	1029	O
G48V	1030	1034	O
/	1034	1035	O
A71T	1035	1039	O
/	1039	1040	O
V82A	1040	1044	O
protease	1045	1053	O
mutations	1054	1063	O
.	1063	1064	O

The	1065	1068	O
clone	1069	1074	O
-	1074	1075	O
purified	1075	1083	O
RF	1084	1086	O
(	1087	1088	O
G48V	1088	1092	O
/	1092	1093	O
A71T	1093	1097	O
/	1097	1098	O
V82A	1098	1102	O
)	1102	1103	O
virus	1104	1109	O
,	1109	1110	O
unlike	1111	1117	O
the	1118	1121	O
corresponding	1122	1135	O
defective	1136	1145	O
NL4	1146	1149	O
-	1149	1150	O
3	1150	1151	O
triple	1152	1158	O
mutant	1159	1165	O
,	1165	1166	O
grew	1167	1171	O
well	1172	1176	O
and	1177	1180	O
displayed	1181	1190	O
cross	1191	1196	O
-	1196	1197	O
resistance	1197	1207	O
to	1208	1210	O
four	1211	1215	O
distinct	1216	1224	O
protease	1225	1233	O
inhibitors	1234	1244	O
.	1244	1245	O

Chimeric	1246	1254	O
virus	1255	1260	O
and	1261	1264	O
in	1265	1267	O
vitro	1268	1273	O
mutagenesis	1274	1285	O
studies	1286	1293	O
indicated	1294	1303	O
that	1304	1308	O
the	1309	1312	O
RF	1313	1315	O
-	1315	1316	O
specific	1316	1324	O
protease	1325	1333	O
sequence	1334	1342	O
,	1342	1343	O
specifically	1344	1356	O
the	1357	1360	O
Ile	1361	1364	O
at	1365	1367	O
residue	1368	1375	O
10	1376	1378	O
,	1378	1379	O
enabled	1380	1387	O
the	1388	1391	O
NL4	1392	1395	O
-	1395	1396	O
3	1396	1397	O
strain	1398	1404	O
with	1405	1409	O
the	1410	1413	O
triple	1414	1420	O
mutant	1421	1427	O
to	1428	1430	O
grow	1431	1435	O
.	1435	1436	O

Our	1437	1440	O
results	1441	1448	O
clearly	1449	1456	O
indicate	1457	1465	O
that	1466	1470	O
viral	1471	1476	O
genetic	1477	1484	O
background	1485	1495	O
will	1496	1500	O
play	1501	1505	O
a	1506	1507	O
key	1508	1511	O
role	1512	1516	O
in	1517	1519	O
determining	1520	1531	O
whether	1532	1539	O
cross	1540	1545	O
-	1545	1546	O
resistance	1546	1556	O
variants	1557	1565	O
will	1566	1570	O
arise	1571	1576	O
.	1576	1577	O

Referral	0	8	O
bias	9	13	O
among	14	19	O
health	20	26	O
workers	27	34	O
in	35	37	O
studies	38	45	O
using	46	51	O
hospitalization	52	67	O
as	68	70	O
a	71	72	O
proxy	73	78	O
measure	79	86	O
of	87	89	O
the	90	93	O
underlying	94	104	O
incidence	105	114	O
rate	115	119	O
.	119	120	O

Contacts	121	129	O
with	130	134	O
health	135	141	O
services	142	150	O
like	151	155	O
hospitals	156	165	O
or	166	168	O
general	169	176	O
practitioners	177	190	O
are	191	194	O
usually	195	202	O
the	203	206	O
only	207	211	O
available	212	221	O
proxy	222	227	O
measure	228	235	O
of	236	238	O
incidence	239	248	O
of	249	251	O
disease	252	259	O
in	260	262	O
studies	263	270	O
based	271	276	O
on	277	279	O
secondary	280	289	O
data	290	294	O
and	295	298	O
differential	299	311	O
referrals	312	321	O
or	322	324	O
care	325	329	O
-	329	330	O
seeking	330	337	O
behavior	338	346	O
often	347	352	O
bias	353	357	O
such	358	362	O
proxy	363	368	O
measures	369	377	O
.	377	378	O

In	379	381	O
former	382	388	O
analyses	389	397	O
based	398	403	O
on	404	406	O
the	407	410	O
Occupational	411	423	O
Hospitalization	424	439	O
Register	440	448	O
in	449	451	O
Denmark	452	459	O
assisting	460	469	O
nurses	470	476	O
had	477	480	O
high	481	485	O
Standardized	486	498	O
Hospitalization	499	514	O
Ratios	515	521	O
for	522	525	O
many	526	530	O
diseases	531	539	O
.	539	540	O

It	541	543	O
was	544	547	O
,	547	548	O
however	549	556	O
,	556	557	O
suspected	558	567	O
that	568	572	O
it	573	575	O
fully	576	581	O
or	582	584	O
partly	585	591	O
was	592	595	O
due	596	599	O
to	600	602	O
a	603	604	O
referral	605	613	O
bias	614	618	O
or	619	621	O
self	622	626	O
-	626	627	O
selection	627	636	O
to	637	639	O
hospital	640	648	O
treatment	649	658	O
rather	659	665	O
than	666	670	O
exposures	671	680	O
to	681	683	O
occupational	684	696	O
hazards	697	704	O
.	704	705	O

The	706	709	O
aim	710	713	O
of	714	716	O
the	717	720	O
present	721	728	O
study	729	734	O
is	735	737	O
to	738	740	O
evaluate	741	749	O
the	750	753	O
referral	754	762	O
bias	763	767	O
hypothesis	768	778	O
by	779	781	O
comparing	782	791	O
hospitalization	792	807	O
and	808	811	O
mortality	812	821	O
data	822	826	O
for	827	830	O
health	831	837	O
workers	838	845	O
for	846	849	O
a	850	851	O
disease	852	859	O
category	860	868	O
with	869	873	O
a	874	875	O
high	876	880	O
mortality	881	890	O
.	890	891	O

Cohorts	892	899	O
of	900	902	O
all	903	906	O
gainfully	907	916	O
employed	917	925	O
20	926	928	O
-	928	929	O
to	930	932	O
59	933	935	O
-	935	936	O
year	936	940	O
-	940	941	O
old	941	944	O
Danes	945	950	O
were	951	955	O
formed	956	962	O
in	963	965	O
order	966	971	O
to	972	974	O
compare	975	982	O
Standardized	983	995	O
Mortality	996	1005	O
Ratios	1006	1012	O
and	1013	1016	O
Standardized	1017	1029	O
Hospitalization	1030	1045	O
Ratios	1046	1052	O
of	1053	1055	O
ischemic	1056	1064	O
heart	1065	1070	B-Organ
disease	1071	1078	O
(	1079	1080	O
IHD	1080	1083	O
)	1083	1084	O
in	1085	1087	O
occupational	1088	1100	O
groups	1101	1107	O
.	1107	1108	O

The	1109	1112	O
follow	1113	1119	O
-	1119	1120	O
up	1120	1122	O
period	1123	1129	O
was	1130	1133	O
10	1134	1136	O
years	1137	1142	O
.	1142	1143	O

For	1144	1147	O
most	1148	1152	O
of	1153	1155	O
the	1156	1159	O
investigated	1160	1172	O
occupational	1173	1185	O
groups	1186	1192	O
a	1193	1194	O
similar	1195	1202	O
disease	1203	1210	O
pattern	1211	1218	O
was	1219	1222	O
found	1223	1228	O
whether	1229	1236	O
hospitalization	1237	1252	O
or	1253	1255	O
death	1256	1261	O
was	1262	1265	O
used	1266	1270	O
as	1271	1273	O
the	1274	1277	O
outcome	1278	1285	O
measure	1286	1293	O
.	1293	1294	O

In	1295	1297	O
"	1298	1299	O
nurse	1299	1304	O
assistants	1305	1315	O
"	1315	1316	O
a	1317	1318	O
statistically	1319	1332	O
significant	1333	1344	O
higher	1345	1351	O
risk	1352	1356	O
was	1357	1360	O
,	1360	1361	O
however	1362	1369	O
,	1369	1370	O
found	1371	1376	O
using	1377	1382	O
hospitalization	1383	1398	O
due	1399	1402	O
to	1403	1405	O
IHD	1406	1409	O
as	1410	1412	O
the	1413	1416	O
end	1417	1420	O
point	1421	1426	O
rather	1427	1433	O
than	1434	1438	O
mortality	1439	1448	O
.	1448	1449	O

Additional	1450	1460	O
analysis	1461	1469	O
did	1470	1473	O
not	1474	1477	O
support	1478	1485	O
the	1486	1489	O
hypothesis	1490	1500	O
that	1501	1505	O
the	1506	1509	O
finding	1510	1517	O
could	1518	1523	O
be	1524	1526	O
explained	1527	1536	O
by	1537	1539	O
differentiated	1540	1554	O
hospitalization	1555	1570	O
due	1571	1574	O
to	1575	1577	O
social	1578	1584	O
factors	1585	1592	O
.	1592	1593	O

The	1594	1597	O
true	1598	1602	O
incidence	1603	1612	O
rates	1613	1618	O
of	1619	1621	O
the	1622	1625	O
disease	1626	1633	O
need	1634	1638	O
not	1639	1642	O
be	1643	1645	O
equally	1646	1653	O
well	1654	1658	O
described	1659	1668	O
by	1669	1671	O
proxy	1672	1677	O
measures	1678	1686	O
such	1687	1691	O
as	1692	1694	O
hospitalization	1695	1710	O
diagnosis	1711	1720	O
or	1721	1723	O
death	1724	1729	O
diagnosis	1730	1739	O
in	1740	1742	O
all	1743	1746	O
occupational	1747	1759	O
groups	1760	1766	O
.	1766	1767	O

Differential	1768	1780	O
access	1781	1787	O
to	1788	1790	O
medical	1791	1798	O
treatment	1799	1808	O
in	1809	1811	O
some	1812	1816	O
groups	1817	1823	O
may	1824	1827	O
lead	1828	1832	O
to	1833	1835	O
bias	1836	1840	O
when	1841	1845	O
hospital	1846	1854	O
data	1855	1859	O
are	1860	1863	O
used	1864	1868	O
as	1869	1871	O
proxy	1872	1877	O
measures	1878	1886	O
for	1887	1890	O
the	1891	1894	O
underlying	1895	1905	O
incidence	1906	1915	O
rates	1916	1921	O
.	1921	1922	O

Induction	0	9	O
of	10	12	O
p18INK4c	13	21	O
and	22	25	O
its	26	29	O
predominant	30	41	O
association	42	53	O
with	54	58	O
CDK4	59	63	O
and	64	67	O
CDK6	68	72	O
during	73	79	O
myogenic	80	88	O
differentiation	89	104	O
.	104	105	O

Terminal	106	114	O
cell	115	119	B-Cell
differentiation	120	135	O
involves	136	144	O
permanent	145	154	O
withdrawal	155	165	O
from	166	170	O
the	171	174	O
cell	175	179	B-Cell
division	180	188	O
cycle	189	194	O
.	194	195	O

The	196	199	O
inhibitors	200	210	O
of	211	213	O
cyclin	214	220	O
-	220	221	O
dependent	221	230	O
kinases	231	238	O
(	239	240	O
CDKs	240	244	O
)	244	245	O
are	246	249	O
potential	250	259	O
molecules	260	269	O
functioning	270	281	O
to	282	284	O
couple	285	291	O
cell	292	296	B-Cell
cycle	297	302	O
arrest	303	309	O
and	310	313	O
cell	314	318	B-Cell
differentiation	319	334	O
.	334	335	O

In	336	338	O
murine	339	345	O
C2C12	346	351	B-Cell
myoblast	352	360	I-Cell
cells	361	366	I-Cell
,	366	367	O
G1	368	370	O
CDK	371	374	O
enzymes	375	382	O
(	383	384	O
CDK2	384	388	O
,	388	389	O
CDK4	390	394	O
,	394	395	O
and	396	399	O
CDK6	400	404	O
)	404	405	O
associate	406	415	O
with	416	420	O
four	421	425	O
CDK	426	429	O
inhibitors	430	440	O
:	440	441	O
p18INK4c	442	450	O
,	450	451	O
p19INK4d	452	460	O
,	460	461	O
p21	462	465	O
,	465	466	O
and	467	470	O
p27Kip1	471	478	O
.	478	479	O

During	480	486	O
induced	487	494	O
myogenesis	495	505	O
,	505	506	O
p21	507	510	O
and	511	514	O
its	515	518	O
associated	519	529	O
CDK	530	533	O
proteins	534	542	O
underwent	543	552	O
an	553	555	O
initial	556	563	O
increase	564	572	O
followed	573	581	O
by	582	584	O
a	585	586	O
decrease	587	595	O
as	596	598	O
cells	599	604	B-Cell
became	605	611	O
terminally	612	622	O
differentiated	623	637	O
.	637	638	O

The	639	642	O
level	643	648	O
of	649	651	O
p27	652	655	O
protein	656	663	O
gradually	664	673	O
increased	674	683	O
,	683	684	O
but	685	688	O
the	689	692	O
amount	693	699	O
of	700	702	O
total	703	708	O
associated	709	719	O
CDK	720	723	O
proteins	724	732	O
remained	733	741	O
unchanged	742	751	O
.	751	752	O

p19	753	756	O
protein	757	764	O
decreased	765	774	O
gradually	775	784	O
during	785	791	O
differentiation	792	807	O
,	807	808	O
as	809	811	O
did	812	815	O
its	816	819	O
associated	820	830	O
CDK4	831	835	O
protein	836	843	O
.	843	844	O

In	845	847	O
contrast	848	856	O
,	856	857	O
p18	858	861	O
protein	862	869	O
increased	870	879	O
50	880	882	O
-	882	883	O
fold	883	887	O
,	887	888	O
from	889	893	O
negligible	894	904	O
levels	905	911	O
in	912	914	O
proliferating	915	928	O
myoblasts	929	938	B-Cell
to	939	941	O
clearly	942	949	O
detectable	950	960	O
levels	961	967	O
within	968	974	O
8	975	976	O
-	976	977	O
12	977	979	O
h	980	981	O
of	982	984	O
myogenic	985	993	O
induction	994	1003	O
.	1003	1004	O

This	1005	1009	O
initial	1010	1017	O
rise	1018	1022	O
was	1023	1026	O
followed	1027	1035	O
by	1036	1038	O
a	1039	1040	O
precipitous	1041	1052	O
increase	1053	1061	O
between	1062	1069	O
12	1070	1072	O
and	1073	1076	O
24	1077	1079	O
h	1080	1081	O
postinduction	1082	1095	O
,	1095	1096	O
with	1097	1101	O
p18	1102	1105	O
protein	1106	1113	O
finally	1114	1121	O
accumulating	1122	1134	O
to	1135	1137	O
its	1138	1141	O
highest	1142	1149	O
level	1150	1155	O
in	1156	1158	O
terminally	1159	1169	O
differentiated	1170	1184	O
cells	1185	1190	B-Cell
.	1190	1191	O

Induction	1192	1201	O
of	1202	1204	O
p18	1205	1208	O
correlated	1209	1219	O
with	1220	1224	O
increased	1225	1234	O
and	1235	1238	O
sequential	1239	1249	O
complex	1250	1257	O
formation	1258	1267	O
-	1267	1268	O
-	1268	1269	O
first	1269	1274	O
increasing	1275	1285	O
association	1286	1297	O
with	1298	1302	O
CDK6	1303	1307	O
and	1308	1311	O
then	1312	1316	O
with	1317	1321	O
CDK4	1322	1326	O
over	1327	1331	O
the	1332	1335	O
course	1336	1342	O
of	1343	1345	O
myogenic	1346	1354	O
differentiation	1355	1370	O
.	1370	1371	O

All	1372	1375	O
of	1376	1378	O
the	1379	1382	O
CDK6	1383	1387	O
and	1388	1391	O
half	1392	1396	O
of	1397	1399	O
the	1400	1403	O
CDK4	1404	1408	O
were	1409	1413	O
complexed	1414	1423	O
with	1424	1428	O
p18	1429	1432	O
in	1433	1435	O
terminally	1436	1446	O
differentiated	1447	1461	O
C2C12	1462	1467	B-Cell
cells	1468	1473	I-Cell
as	1474	1476	O
well	1477	1481	O
as	1482	1484	O
in	1485	1487	O
adult	1488	1493	O
mouse	1494	1499	O
muscle	1500	1506	B-Tissue
tissue	1507	1513	I-Tissue
.	1513	1514	O

Finally	1515	1522	O
,	1522	1523	O
kinase	1524	1530	O
activity	1531	1539	O
of	1540	1542	O
CDK2	1543	1547	O
and	1548	1551	O
CDK4	1552	1556	O
decreases	1557	1566	O
as	1567	1569	O
C2C12	1570	1575	B-Cell
cells	1576	1581	I-Cell
differentiate	1582	1595	O
,	1595	1596	O
whereas	1597	1604	O
the	1605	1608	O
CDK6	1609	1613	O
kinase	1614	1620	O
activity	1621	1629	O
is	1630	1632	O
low	1633	1636	O
in	1637	1639	O
both	1640	1644	O
proliferating	1645	1658	O
myoblasts	1659	1668	B-Cell
and	1669	1672	O
differentiated	1673	1687	O
myotubes	1688	1696	B-Tissue
.	1696	1697	O

Our	1698	1701	O
results	1702	1709	O
indicate	1710	1718	O
that	1719	1723	O
p18	1724	1727	O
may	1728	1731	O
play	1732	1736	O
a	1737	1738	O
critical	1739	1747	O
role	1748	1752	O
in	1753	1755	O
causing	1756	1763	O
and	1764	1767	O
/	1767	1768	O
or	1768	1770	O
maintaining	1771	1782	O
permanent	1783	1792	O
cell	1793	1797	B-Cell
cycle	1798	1803	O
arrest	1804	1810	O
associated	1811	1821	O
with	1822	1826	O
mature	1827	1833	O
muscle	1834	1840	B-Tissue
formation	1841	1850	O
.	1850	1851	O

Functional	0	10	O
model	11	16	O
of	17	19	O
benign	20	26	O
paroxysmal	27	37	O
positional	38	48	O
vertigo	49	56	O
using	57	62	O
an	63	65	O
isolated	66	74	O
frog	75	79	O
semicircular	80	92	B-Multi-tissue_structure
canal	93	98	I-Multi-tissue_structure
.	98	99	O

Bull	100	104	O
frogs	105	110	O
posterior	111	120	B-Multi-tissue_structure
semicircular	121	133	I-Multi-tissue_structure
canals	134	140	I-Multi-tissue_structure
(	141	142	O
psc	142	145	B-Multi-tissue_structure
)	145	146	O
wee	147	150	O
used	151	155	O
to	156	158	O
simulate	159	167	O
the	168	171	O
condition	172	181	O
of	182	184	O
benign	185	191	O
paroxysmal	192	202	O
positional	203	213	O
vertigo	214	221	O
(	222	223	O
BPPV	223	227	O
)	227	228	O
.	228	229	O

The	230	233	O
psc	234	237	B-Multi-tissue_structure
was	238	241	O
isolated	242	250	O
in	251	253	O
frog	254	258	O
Ringer	259	265	O
'	265	266	O
s	266	267	O
solution	268	276	O
,	276	277	O
and	278	281	O
the	282	285	O
saccular	286	294	B-Organism_substance
otoconia	295	303	I-Organism_substance
were	304	308	O
used	309	313	O
as	314	316	O
a	317	318	O
responsible	319	330	O
material	331	339	O
to	340	342	O
stimulate	343	352	O
the	353	356	O
cupula	357	363	B-Multi-tissue_structure
.	363	364	O

When	365	369	O
the	370	373	O
otoconia	374	382	B-Organism_substance
were	383	387	O
placed	388	394	O
on	395	397	O
the	398	401	O
cupular	402	409	B-Multi-tissue_structure
surface	410	417	I-Multi-tissue_structure
to	418	420	O
mimic	421	426	O
the	427	430	O
condition	431	440	O
of	441	443	O
cupulolithiasis	444	459	O
,	459	460	O
the	461	464	O
psc	465	468	B-Multi-tissue_structure
ampullary	469	478	I-Multi-tissue_structure
nerve	479	484	I-Multi-tissue_structure
action	485	491	O
potentials	492	502	O
instantaneously	503	518	O
changed	519	526	O
according	527	536	O
to	537	539	O
the	540	543	O
direction	544	553	O
of	554	556	O
the	557	560	O
gravity	561	568	O
produced	569	577	O
by	578	580	O
otoconia	581	589	B-Organism_substance
.	589	590	O

When	591	595	O
the	596	599	O
otoconia	600	608	B-Organism_substance
were	609	613	O
dropped	614	621	O
into	622	626	O
the	627	630	O
canal	631	636	B-Multi-tissue_structure
to	637	639	O
mimic	640	645	O
the	646	649	O
condition	650	659	O
of	660	662	O
moving	663	669	O
otoconia	670	678	B-Organism_substance
in	679	681	O
the	682	685	O
canal	686	691	B-Multi-tissue_structure
,	691	692	O
the	693	696	O
action	697	703	O
potentials	704	714	O
changed	715	722	O
together	723	731	O
with	732	736	O
the	737	740	O
otoconial	741	750	B-Organism_substance
flow	751	755	O
after	756	761	O
a	762	763	O
latent	764	770	O
period	771	777	O
.	777	778	O

Both	779	783	O
cupulolithiasis	784	799	O
and	800	803	O
moving	804	810	O
otoconia	811	819	B-Organism_substance
are	820	823	O
possibly	824	832	O
valid	833	838	O
mechanisms	839	849	O
of	850	852	O
BPPV	853	857	O
,	857	858	O
since	859	864	O
they	865	869	O
effectively	870	881	O
stimulate	882	891	O
the	892	895	O
cupula	896	902	B-Multi-tissue_structure
.	902	903	O

However	904	911	O
,	911	912	O
moving	913	919	O
otoconia	920	928	B-Organism_substance
with	929	933	O
a	934	935	O
latent	936	942	O
period	943	949	O
would	950	955	O
better	956	962	O
explain	963	970	O
clinical	971	979	O
features	980	988	O
of	989	991	O
BPPV	992	996	O
.	996	997	O

[	0	1	O
Considerations	1	15	O
regarding	16	25	O
two	26	29	O
cases	30	35	O
of	36	38	O
macromastia	39	50	O
(	51	52	O
author	52	58	O
'	58	59	O
s	59	60	O
transl	61	67	O
)	67	68	O
]	68	69	O
.	69	70	O

Two	71	74	O
cases	75	80	O
of	81	83	O
macromastia	84	95	O
have	96	100	O
been	101	105	O
shown	106	111	O
;	111	112	O
one	113	116	O
which	117	122	O
appeared	123	131	O
during	132	138	O
puberty	139	146	O
,	146	147	O
the	148	151	O
other	152	157	O
during	158	164	O
menopause	165	174	O
.	174	175	O

Histopathological	176	193	O
examination	194	205	O
has	206	209	O
demonstrated	210	222	O
for	223	226	O
the	227	230	O
both	231	235	O
cases	236	241	O
a	242	243	O
cystic	244	250	O
degeneracy	251	261	O
of	262	264	O
the	265	268	O
glandular	269	278	B-Tissue
tissue	279	285	I-Tissue
with	286	290	O
a	291	292	O
hyperplazia	293	304	O
and	305	308	O
hypertrophy	309	320	O
of	321	323	O
the	324	327	O
conjunctive	328	339	B-Tissue
tissue	340	346	I-Tissue
.	346	347	O

The	348	351	O
pathogeny	352	361	O
of	362	364	O
macromastia	365	376	O
is	377	379	O
being	380	385	O
discussed	386	395	O
and	396	399	O
it	400	402	O
is	403	405	O
demonstrated	406	418	O
both	419	423	O
the	424	427	O
role	428	432	O
of	433	435	O
hypophysis	436	446	O
hormones	447	455	O
(	456	457	O
prolactine	457	467	O
and	468	471	O
growth	472	478	O
hormone	479	486	O
)	486	487	O
and	488	491	O
of	492	494	O
ovarian	495	502	B-Organ
hormones	503	511	O
(	512	513	O
estrogens	513	522	O
)	522	523	O
.	523	524	O

The	525	528	O
treatment	529	538	O
was	539	542	O
surgical	543	551	O
for	552	555	O
the	556	559	O
both	560	564	O
cases	565	570	O
.	570	571	O

Procedural	0	10	O
memory	11	17	O
stimulation	18	29	O
in	30	32	O
Alzheimer	33	42	O
'	42	43	O
s	43	44	O
disease	45	52	O
:	52	53	O
impact	54	60	O
of	61	63	O
a	64	65	O
training	66	74	O
programme	75	84	O
.	84	85	O

The	86	89	O
study	90	95	O
evaluates	96	105	O
the	106	109	O
efficacy	110	118	O
of	119	121	O
a	122	123	O
procedural	124	134	O
memory	135	141	O
stimulation	142	153	O
programme	154	163	O
in	164	166	O
mild	167	171	O
and	172	175	O
mild	176	180	O
-	180	181	O
moderate	181	189	O
Alzheimer	190	199	O
'	199	200	O
s	200	201	O
disease	202	209	O
(	210	211	O
AD	211	213	O
)	213	214	O
.	214	215	O

Twenty	216	222	O
basic	223	228	O
and	229	232	O
instrumental	233	245	O
activities	246	256	O
of	257	259	O
daily	260	265	O
living	266	272	O
have	273	277	O
been	278	282	O
selected	283	291	O
,	291	292	O
and	293	296	O
divided	297	304	O
into	305	309	O
two	310	313	O
groups	314	320	O
,	320	321	O
comparable	322	332	O
for	333	336	O
difficulty	337	347	O
.	347	348	O

Ten	349	352	O
normal	353	359	O
elderly	360	367	O
subjects	368	376	O
(	377	378	O
age	378	381	O
68	382	384	O
.	384	385	O
0	385	386	O
+	387	388	O
/	388	389	O
-	389	390	O
4	391	392	O
.	392	393	O
8	393	394	O
years	395	400	O
;	400	401	O
MMSE	402	406	O
score	407	412	O
:	412	413	O
28	414	416	O
.	416	417	O
7	417	418	O
+	419	420	O
/	420	421	O
-	421	422	O
0	423	424	O
.	424	425	O
9	425	426	O
;	426	427	O
education	428	437	O
:	437	438	O
7	439	440	O
.	440	441	O
6	441	442	O
+	443	444	O
/	444	445	O
-	445	446	O
3	447	448	O
.	448	449	O
5	449	450	O
years	451	456	O
)	456	457	O
were	458	462	O
asked	463	468	O
to	469	471	O
perform	472	479	O
the	480	483	O
two	484	487	O
groups	488	494	O
of	495	497	O
daily	498	503	O
activities	504	514	O
and	515	518	O
the	519	522	O
time	523	527	O
required	528	536	O
to	537	539	O
perform	540	547	O
the	548	551	O
tasks	552	557	O
of	558	560	O
each	561	565	O
group	566	571	O
was	572	575	O
recorded	576	584	O
and	585	588	O
used	589	593	O
as	594	596	O
a	597	598	O
reference	599	608	O
.	608	609	O

Ten	610	613	O
mild	614	618	O
and	619	622	O
mild	623	627	O
-	627	628	O
moderate	628	636	O
AD	637	639	O
patients	640	648	O
(	649	650	O
age	650	653	O
77	654	656	O
.	656	657	O
2	657	658	O
+	659	660	O
/	660	661	O
-	661	662	O
5	663	664	O
.	664	665	O
3	665	666	O
years	667	672	O
;	672	673	O
MMSE	674	678	O
score	679	684	O
:	684	685	O
19	686	688	O
.	688	689	O
8	689	690	O
+	691	692	O
/	692	693	O
-	693	694	O
3	695	696	O
.	696	697	O
5	697	698	O
;	698	699	O
education	700	709	O
:	709	710	O
7	711	712	O
.	712	713	O
3	713	714	O
+	715	716	O
/	716	717	O
-	717	718	O
4	719	720	O
.	720	721	O
7	721	722	O
years	723	728	O
)	728	729	O
without	730	737	O
major	738	743	O
behavioural	744	755	O
disturbances	756	768	O
constituted	769	780	O
the	781	784	O
experimental	785	797	O
group	798	803	O
.	803	804	O

Patients	805	813	O
were	814	818	O
evaluated	819	828	O
in	829	831	O
all	832	835	O
20	836	838	O
daily	839	844	O
activities	845	855	O
and	856	859	O
the	860	863	O
time	864	868	O
employed	869	877	O
was	878	881	O
recorded	882	890	O
at	891	893	O
baseline	894	902	O
and	903	906	O
after	907	912	O
a	913	914	O
3	915	916	O
-	916	917	O
week	917	921	O
training	922	930	O
(	931	932	O
1	932	933	O
h	934	935	O
/	935	936	O
d	936	937	O
,	937	938	O
5	939	940	O
d	941	942	O
/	942	943	O
week	943	947	O
)	947	948	O
period	949	955	O
.	955	956	O

Five	957	961	O
patients	962	970	O
were	971	975	O
trained	976	983	O
during	984	990	O
the	991	994	O
3	995	996	O
weeks	997	1002	O
on	1003	1005	O
half	1006	1010	O
of	1011	1013	O
the	1014	1017	O
20	1018	1020	O
daily	1021	1026	O
activities	1027	1037	O
and	1038	1041	O
the	1042	1045	O
other	1046	1051	O
five	1052	1056	O
patients	1057	1065	O
were	1066	1070	O
trained	1071	1078	O
on	1079	1081	O
the	1082	1085	O
remainder	1086	1095	O
.	1095	1096	O

This	1097	1101	O
procedure	1102	1111	O
was	1112	1115	O
adopted	1116	1123	O
in	1124	1126	O
order	1127	1132	O
to	1133	1135	O
detect	1136	1142	O
separately	1143	1153	O
the	1154	1157	O
improvement	1158	1169	O
in	1170	1172	O
"	1173	1174	O
trained	1174	1181	O
"	1181	1182	O
and	1183	1186	O
"	1187	1188	O
not	1188	1191	O
trained	1192	1199	O
"	1199	1200	O
activities	1201	1211	O
,	1211	1212	O
allowing	1213	1221	O
to	1222	1224	O
control	1225	1232	O
better	1233	1239	O
the	1240	1243	O
effects	1244	1251	O
of	1252	1254	O
the	1255	1258	O
intervention	1259	1271	O
.	1271	1272	O

The	1273	1276	O
assessment	1277	1287	O
of	1288	1290	O
the	1291	1294	O
functional	1295	1305	O
impact	1306	1312	O
of	1313	1315	O
the	1316	1319	O
training	1320	1328	O
was	1329	1332	O
directly	1333	1341	O
measured	1342	1350	O
,	1350	1351	O
through	1352	1359	O
the	1360	1363	O
variation	1364	1373	O
of	1374	1376	O
time	1377	1381	O
employed	1382	1390	O
to	1391	1393	O
perform	1394	1401	O
tasks	1402	1407	O
before	1408	1414	O
and	1415	1418	O
after	1419	1424	O
training	1425	1433	O
.	1433	1434	O

After	1435	1440	O
3	1441	1442	O
weeks	1443	1448	O
of	1449	1451	O
training	1452	1460	O
a	1461	1462	O
significant	1463	1474	O
improvement	1475	1486	O
was	1487	1490	O
observed	1491	1499	O
for	1500	1503	O
the	1504	1507	O
trained	1508	1515	O
activities	1516	1526	O
,	1526	1527	O
from	1528	1532	O
3	1533	1534	O
.	1534	1535	O
6	1535	1536	O
to	1537	1539	O
1	1540	1541	O
.	1541	1542	O
9	1542	1543	O
standard	1544	1552	O
deviations	1553	1563	O
below	1564	1569	O
the	1570	1573	O
performance	1574	1585	O
of	1586	1588	O
the	1589	1592	O
normal	1593	1599	O
elderly	1600	1607	O
controls	1608	1616	O
(	1617	1618	O
P	1618	1619	O
<	1620	1621	O
0	1622	1623	O
.	1623	1624	O
05	1624	1626	O
)	1626	1627	O
.	1627	1628	O

AD	1629	1631	O
patients	1632	1640	O
improved	1641	1649	O
also	1650	1654	O
in	1655	1657	O
not	1658	1661	O
-	1661	1662	O
trained	1662	1669	O
activities	1670	1680	O
from	1681	1685	O
3	1686	1687	O
.	1687	1688	O
5	1688	1689	O
to	1690	1692	O
2	1693	1694	O
.	1694	1695	O
7	1695	1696	O
standard	1697	1705	O
deviations	1706	1716	O
below	1717	1722	O
the	1723	1726	O
controls	1727	1735	O
'	1735	1736	O
performance	1737	1748	O
(	1749	1750	O
P	1750	1751	O
<	1752	1753	O
0	1754	1755	O
.	1755	1756	O
05	1756	1758	O
)	1758	1759	O
.	1759	1760	O

The	1761	1764	O
rehabilitation	1765	1779	O
of	1780	1782	O
activities	1783	1793	O
of	1794	1796	O
daily	1797	1802	O
living	1803	1809	O
through	1810	1817	O
developing	1818	1828	O
procedural	1829	1839	O
memory	1840	1846	O
strategies	1847	1857	O
may	1858	1861	O
be	1862	1864	O
effective	1865	1874	O
in	1875	1877	O
mild	1878	1882	O
and	1883	1886	O
mild	1887	1891	O
-	1891	1892	O
moderate	1892	1900	O
AD	1901	1903	O
patients	1904	1912	O
.	1912	1913	O

Some	0	4	O
findings	5	13	O
concerning	14	24	O
beliefs	25	32	O
about	33	38	O
alcoholism	39	49	O
.	49	50	O

The	51	54	O
beliefs	55	62	O
that	63	67	O
alcoholics	68	78	O
hold	79	83	O
about	84	89	O
alcoholism	90	100	O
and	101	104	O
themselves	105	115	O
,	115	116	O
and	117	120	O
the	121	124	O
beliefs	125	132	O
that	133	137	O
hospital	138	146	O
staff	147	152	O
and	153	156	O
other	157	162	O
personnel	163	172	O
hold	173	177	O
about	178	183	O
alcoholism	184	194	O
,	194	195	O
were	196	200	O
investigated	201	213	O
using	214	219	O
methods	220	227	O
derived	228	235	O
from	236	240	O
the	241	244	O
repertory	245	254	O
grid	255	259	O
,	259	260	O
with	261	265	O
anonymous	266	275	O
facial	276	282	B-Organism_subdivision
photographs	283	294	O
as	295	297	O
elements	298	306	O
.	306	307	O

Data	308	312	O
are	313	316	O
presented	317	326	O
as	327	329	O
to	330	332	O
the	333	336	O
degree	337	343	O
of	344	346	O
association	347	358	O
of	359	361	O
various	362	369	O
characteristics	370	385	O
with	386	390	O
alcoholism	391	401	O
for	402	405	O
the	406	409	O
various	410	417	O
groups	418	424	O
.	424	425	O

Differences	426	437	O
between	438	445	O
groups	446	452	O
,	452	453	O
and	454	457	O
overall	458	465	O
changes	466	473	O
during	474	480	O
group	481	486	O
psychotherapy	487	500	O
for	501	504	O
patients	505	513	O
were	514	518	O
small	519	524	O
.	524	525	O

The	526	529	O
relative	530	538	O
contribution	539	551	O
of	552	554	O
personal	555	563	O
and	564	567	O
shared	568	574	O
aspects	575	582	O
of	583	585	O
belief	586	592	O
was	593	596	O
measured	597	605	O
.	605	606	O

It	607	609	O
was	610	613	O
found	614	619	O
that	620	624	O
the	625	628	O
agreement	629	638	O
between	639	646	O
groups	647	653	O
was	654	657	O
high	658	662	O
and	663	666	O
closely	667	674	O
similar	675	682	O
to	683	685	O
that	686	690	O
predictable	691	702	O
from	703	707	O
consistencies	708	721	O
within	722	728	O
groups	729	735	O
.	735	736	O

It	737	739	O
is	740	742	O
concluded	743	752	O
that	753	757	O
there	758	763	O
may	764	767	O
be	768	770	O
a	771	772	O
very	773	777	O
general	778	785	O
stereotype	786	796	O
of	797	799	O
alcoholism	800	810	O
,	810	811	O
consistent	812	822	O
with	823	827	O
a	828	829	O
personality	830	841	O
disorder	842	850	O
concept	851	858	O
which	859	864	O
is	865	867	O
implicitly	868	878	O
held	879	883	O
even	884	888	O
in	889	891	O
the	892	895	O
face	896	900	O
of	901	903	O
nominal	904	911	O
acceptance	912	922	O
of	923	925	O
other	926	931	O
concepts	932	940	O
.	940	941	O

The	942	945	O
self	946	950	O
constructs	951	961	O
of	962	964	O
alcoholics	965	975	O
were	976	980	O
found	981	986	O
to	987	989	O
be	990	992	O
complex	993	1000	O
.	1000	1001	O

In	1002	1004	O
a	1005	1006	O
small	1007	1012	O
follow	1013	1019	O
-	1019	1020	O
up	1020	1022	O
study	1023	1028	O
of	1029	1031	O
patients	1032	1040	O
,	1040	1041	O
there	1042	1047	O
was	1048	1051	O
found	1052	1057	O
to	1058	1060	O
be	1061	1063	O
a	1064	1065	O
relationship	1066	1078	O
of	1079	1081	O
poor	1082	1086	O
outcome	1087	1094	O
with	1095	1099	O
tightness	1100	1109	O
of	1110	1112	O
construing	1113	1123	O
for	1124	1127	O
key	1128	1131	O
constructs	1132	1142	O
after	1143	1148	O
psychotherapy	1149	1162	O
.	1162	1163	O

The	1164	1167	O
implications	1168	1180	O
of	1181	1183	O
the	1184	1187	O
findings	1188	1196	O
are	1197	1200	O
discussed	1201	1210	O
briefly	1211	1218	O
.	1218	1219	O

Monitoring	0	10	O
the	11	14	O
efficiency	15	25	O
of	26	28	O
interferon	29	39	O
-	39	40	O
alpha	40	45	O
therapy	46	53	O
in	54	56	O
chronic	57	64	O
myelogenous	65	76	O
leukemia	77	85	O
(	86	87	O
CML	87	90	O
)	90	91	O
patients	92	100	O
by	101	103	O
competitive	104	115	O
polymerase	116	126	O
chain	127	132	O
reaction	133	141	O
.	141	142	O

Interferon	143	153	O
alpha	154	159	O
(	160	161	O
IFN	161	164	O
-	164	165	O
alpha	165	170	O
)	170	171	O
induces	172	179	O
cytogenetic	180	191	O
responses	192	201	O
of	202	204	O
variable	205	213	O
degree	214	220	O
in	221	223	O
patients	224	232	O
with	233	237	O
CML	238	241	O
.	241	242	O

We	243	245	O
sought	246	252	O
to	253	255	O
establish	256	265	O
the	266	269	O
relationship	270	282	O
between	283	290	O
BCR	291	294	O
-	294	295	O
ABL	295	298	O
transcript	299	309	O
numbers	310	317	O
measured	318	326	O
by	327	329	O
competitive	330	341	O
two	342	345	O
-	345	346	O
step	346	350	O
reverse	351	358	O
transcription	359	372	O
polymerase	373	383	O
chain	384	389	O
reaction	390	398	O
(	399	400	O
RT	400	402	O
-	402	403	O
PCR	403	406	O
)	406	407	O
and	408	411	O
cytogenetic	412	423	O
status	424	430	O
in	431	433	O
CML	434	437	O
patients	438	446	O
treated	447	454	O
with	455	459	O
IFN	460	463	O
-	463	464	O
alpha	464	469	O
.	469	470	O

All	471	474	O
398	475	478	O
samples	479	486	O
from	487	491	O
163	492	495	O
patients	496	504	O
investigated	505	517	O
by	518	520	O
RT	521	523	O
-	523	524	O
PCR	524	527	O
were	528	532	O
positive	533	541	O
for	542	545	O
BCR	546	549	O
-	549	550	O
ABL	550	553	O
transcripts	554	565	O
.	565	566	O

In	567	569	O
order	570	575	O
to	576	578	O
standardize	579	590	O
results	591	598	O
for	599	602	O
variability	603	614	O
in	615	617	O
RNA	618	621	O
and	622	625	O
cDNA	626	630	O
quality	631	638	O
,	638	639	O
we	640	642	O
quantified	643	653	O
total	654	659	O
ABL	660	663	O
transcripts	664	675	O
in	676	678	O
each	679	683	O
sample	684	690	O
as	691	693	O
internal	694	702	O
control	703	710	O
.	710	711	O

The	712	715	O
BCR	716	719	O
-	719	720	O
ABL	720	723	O
/	723	724	O
ABL	724	727	O
ratios	728	734	O
correlated	735	745	O
with	746	750	O
the	751	754	O
cytogenetic	755	766	O
results	767	774	O
.	774	775	O

Quantitative	776	788	O
nested	789	795	O
PCR	796	799	O
allowed	800	807	O
the	808	811	O
detection	812	821	O
of	822	824	O
residual	825	833	O
BCR	834	837	O
-	837	838	O
ABL	838	841	O
transcripts	842	853	O
in	854	856	O
all	857	860	O
complete	861	869	O
cytogenetic	870	881	O
responders	882	892	O
on	893	895	O
IFN	896	899	O
-	899	900	O
alpha	900	905	O
.	905	906	O

We	907	909	O
conclude	910	918	O
that	919	923	O
competitive	924	935	O
PCR	936	939	O
with	940	944	O
internal	945	953	O
controls	954	962	O
is	963	965	O
a	966	967	O
reliable	968	976	O
method	977	983	O
for	984	987	O
monitoring	988	998	O
patients	999	1007	O
on	1008	1010	O
IFN	1011	1014	O
-	1014	1015	O
alpha	1015	1020	O
and	1021	1024	O
reduces	1025	1032	O
the	1033	1036	O
need	1037	1041	O
for	1042	1045	O
repeated	1046	1054	O
marrow	1055	1061	B-Multi-tissue_structure
investigations	1062	1076	O
.	1076	1077	O

[	0	1	O
Treatment	1	10	O
of	11	13	O
acute	14	19	O
liver	20	25	B-Organ
failure	26	33	O
in	34	36	O
children	37	45	O
]	45	46	O
.	46	47	O

Among	48	53	O
the	54	57	O
main	58	62	O
causes	63	69	O
of	70	72	O
acute	73	78	O
liver	79	84	B-Organ
failure	85	92	O
(	93	94	O
ALF	94	97	O
)	97	98	O
in	99	101	O
children	102	110	O
,	110	111	O
metabolic	112	121	O
diseases	122	130	O
(	131	132	O
especially	132	142	O
in	143	145	O
infants	146	153	O
)	153	154	O
,	154	155	O
viral	156	161	O
and	162	165	O
toxin	166	171	O
or	172	174	O
drug	175	179	O
induced	180	187	O
hepatitis	188	197	O
are	198	201	O
the	202	205	O
most	206	210	O
frequent	211	219	O
.	219	220	O

The	221	224	O
cause	225	230	O
remains	231	238	O
,	238	239	O
however	240	247	O
,	247	248	O
undetermined	249	261	O
in	262	264	O
about	265	270	O
30	271	273	O
%	273	274	O
of	275	277	O
the	278	281	O
cases	282	287	O
.	287	288	O

Management	289	299	O
must	300	304	O
be	305	307	O
conducted	308	317	O
in	318	320	O
a	321	322	O
pediatric	323	332	O
hepatology	333	343	O
unit	344	348	O
or	349	351	O
intensive	352	361	O
care	362	366	O
unit	367	371	O
in	372	374	O
relation	375	383	O
with	384	388	O
a	389	390	O
pediatric	391	400	O
transplant	401	411	O
team	412	416	O
in	417	419	O
order	420	425	O
:	425	426	O
1	427	428	O
)	428	429	O
to	430	432	O
perform	433	440	O
urgent	441	447	O
etiological	448	459	O
diagnosis	460	469	O
;	469	470	O
2	471	472	O
)	472	473	O
to	474	476	O
initiate	477	485	O
specific	486	494	O
therapy	495	502	O
and	503	506	O
symptomatic	507	518	O
treatment	519	528	O
;	528	529	O
3	530	531	O
)	531	532	O
to	533	535	O
evaluate	536	544	O
the	545	548	O
severity	549	557	O
and	558	561	O
prognosis	562	571	O
of	572	574	O
liver	575	580	B-Organ
disease	581	588	O
for	589	592	O
selection	593	602	O
of	603	605	O
children	606	614	O
for	615	618	O
emergency	619	628	O
liver	629	634	B-Organ
transplantation	635	650	O
;	650	651	O
4	652	653	O
)	653	654	O
to	655	657	O
evaluate	658	666	O
contraindications	667	684	O
to	685	687	O
liver	688	693	B-Organ
transplantation	694	709	O
.	709	710	O

The	711	714	O
overall	715	722	O
survival	723	731	O
of	732	734	O
post	735	739	O
-	739	740	O
emergency	740	749	O
liver	750	755	B-Organ
transplantation	756	771	O
for	772	775	O
ALF	776	779	O
in	780	782	O
children	783	791	O
averages	792	800	O
65	801	803	O
%	803	804	O
.	804	805	O

Blind	0	5	O
separation	6	16	O
of	17	19	O
auditory	20	28	O
event	29	34	O
-	34	35	O
related	35	42	O
brain	43	48	B-Organ
responses	49	58	O
into	59	63	O
independent	64	75	O
components	76	86	O
.	86	87	O

Averaged	88	96	O
event	97	102	O
-	102	103	O
related	103	110	O
potential	111	120	O
(	121	122	O
ERP	122	125	O
)	125	126	O
data	127	131	O
recorded	132	140	O
from	141	145	O
the	146	149	O
human	150	155	O
scalp	156	161	B-Multi-tissue_structure
reveal	162	168	O
electroencephalographic	169	192	O
(	193	194	O
EEG	194	197	O
)	197	198	O
activity	199	207	O
that	208	212	O
is	213	215	O
reliably	216	224	O
time	225	229	O
-	229	230	O
locked	230	236	O
and	237	240	O
phase	241	246	O
-	246	247	O
locked	247	253	O
to	254	256	O
experimental	257	269	O
events	270	276	O
.	276	277	O

We	278	280	O
report	281	287	O
here	288	292	O
the	293	296	O
application	297	308	O
of	309	311	O
a	312	313	O
method	314	320	O
based	321	326	O
on	327	329	O
information	330	341	O
theory	342	348	O
that	349	353	O
decomposes	354	364	O
one	365	368	O
or	369	371	O
more	372	376	O
ERPs	377	381	O
recorded	382	390	O
at	391	393	O
multiple	394	402	O
scalp	403	408	B-Multi-tissue_structure
sensors	409	416	O
into	417	421	O
a	422	423	O
sum	424	427	O
of	428	430	O
components	431	441	O
with	442	446	O
fixed	447	452	O
scalp	453	458	B-Multi-tissue_structure
distributions	459	472	O
and	473	476	O
sparsely	477	485	O
activated	486	495	O
,	495	496	O
maximally	497	506	O
independent	507	518	O
time	519	523	O
courses	524	531	O
.	531	532	O

Independent	533	544	O
component	545	554	O
analysis	555	563	O
(	564	565	O
ICA	565	568	O
)	568	569	O
decomposes	570	580	O
ERP	581	584	O
data	585	589	O
into	590	594	O
a	595	596	O
number	597	603	O
of	604	606	O
components	607	617	O
equal	618	623	O
to	624	626	O
the	627	630	O
number	631	637	O
of	638	640	O
sensors	641	648	O
.	648	649	O

The	650	653	O
derived	654	661	O
components	662	672	O
have	673	677	O
distinct	678	686	O
but	687	690	O
not	691	694	O
necessarily	695	706	O
orthogonal	707	717	O
scalp	718	723	B-Multi-tissue_structure
projections	724	735	O
.	735	736	O

Unlike	737	743	O
dipole	744	750	O
-	750	751	O
fitting	751	758	O
methods	759	766	O
,	766	767	O
the	768	771	O
algorithm	772	781	O
does	782	786	O
not	787	790	O
model	791	796	O
the	797	800	O
locations	801	810	O
of	811	813	O
their	814	819	O
generators	820	830	O
in	831	833	O
the	834	837	O
head	838	842	B-Organism_subdivision
.	842	843	O

Unlike	844	850	O
methods	851	858	O
that	859	863	O
remove	864	870	O
second	871	877	O
-	877	878	O
order	878	883	O
correlations	884	896	O
,	896	897	O
such	898	902	O
as	903	905	O
principal	906	915	O
component	916	925	O
analysis	926	934	O
(	935	936	O
PCA	936	939	O
)	939	940	O
,	940	941	O
ICA	942	945	O
also	946	950	O
minimizes	951	960	O
higher	961	967	O
-	967	968	O
order	968	973	O
dependencies	974	986	O
.	986	987	O

Applied	988	995	O
to	996	998	O
detected	999	1007	O
-	1007	1008	O
and	1008	1011	O
undetected	1012	1022	O
-	1022	1023	O
target	1023	1029	O
ERPs	1030	1034	O
from	1035	1039	O
an	1040	1042	O
auditory	1043	1051	O
vigilance	1052	1061	O
experiment	1062	1072	O
,	1072	1073	O
the	1074	1077	O
algorithm	1078	1087	O
derived	1088	1095	O
ten	1096	1099	O
components	1100	1110	O
that	1111	1115	O
decomposed	1116	1126	O
each	1127	1131	O
of	1132	1134	O
the	1135	1138	O
major	1139	1144	O
response	1145	1153	O
peaks	1154	1159	O
into	1160	1164	O
one	1165	1168	O
or	1169	1171	O
more	1172	1176	O
ICA	1177	1180	O
components	1181	1191	O
with	1192	1196	O
relatively	1197	1207	O
simple	1208	1214	O
scalp	1215	1220	B-Multi-tissue_structure
distributions	1221	1234	O
.	1234	1235	O

Three	1236	1241	O
of	1242	1244	O
these	1245	1250	O
components	1251	1261	O
were	1262	1266	O
active	1267	1273	O
only	1274	1278	O
when	1279	1283	O
the	1284	1287	O
subject	1288	1295	O
detected	1296	1304	O
the	1305	1308	O
targets	1309	1316	O
,	1316	1317	O
three	1318	1323	O
other	1324	1329	O
components	1330	1340	O
only	1341	1345	O
when	1346	1350	O
the	1351	1354	O
target	1355	1361	O
went	1362	1366	O
undetected	1367	1377	O
,	1377	1378	O
and	1379	1382	O
one	1383	1386	O
in	1387	1389	O
both	1390	1394	O
cases	1395	1400	O
.	1400	1401	O

Three	1402	1407	O
additional	1408	1418	O
components	1419	1429	O
accounted	1430	1439	O
for	1440	1443	O
the	1444	1447	O
steady	1448	1454	O
-	1454	1455	O
state	1455	1460	O
brain	1461	1466	B-Organ
response	1467	1475	O
to	1476	1478	O
a	1479	1480	O
39	1481	1483	O
-	1483	1484	O
Hz	1484	1486	O
background	1487	1497	O
click	1498	1503	O
train	1504	1509	O
.	1509	1510	O

Major	1511	1516	O
features	1517	1525	O
of	1526	1528	O
the	1529	1532	O
decomposition	1533	1546	O
proved	1547	1553	O
robust	1554	1560	O
across	1561	1567	O
sessions	1568	1576	O
and	1577	1580	O
changes	1581	1588	O
in	1589	1591	O
sensor	1592	1598	O
number	1599	1605	O
and	1606	1609	O
placement	1610	1619	O
.	1619	1620	O

This	1621	1625	O
method	1626	1632	O
of	1633	1635	O
ERP	1636	1639	O
analysis	1640	1648	O
can	1649	1652	O
be	1653	1655	O
used	1656	1660	O
to	1661	1663	O
compare	1664	1671	O
responses	1672	1681	O
from	1682	1686	O
multiple	1687	1695	O
stimuli	1696	1703	O
,	1703	1704	O
task	1705	1709	O
conditions	1710	1720	O
,	1720	1721	O
and	1722	1725	O
subject	1726	1733	O
states	1734	1740	O
.	1740	1741	O

[	0	1	O
Extra	1	6	O
-	6	7	O
anatomic	7	15	O
bypass	16	22	O
from	23	27	O
the	28	31	O
ascending	32	41	B-Multi-tissue_structure
aorta	42	47	I-Multi-tissue_structure
to	48	50	O
the	51	54	O
supraceliac	55	66	O
abdominal	67	76	B-Multi-tissue_structure
aorta	77	82	I-Multi-tissue_structure
-	82	83	O
-	83	84	O
surgical	84	92	O
option	93	99	O
applied	100	107	O
to	108	110	O
reoperation	111	122	O
for	123	126	O
aortic	127	133	B-Multi-tissue_structure
coarctation	134	145	O
or	146	148	O
interruption	149	161	O
]	161	162	O
.	162	163	O

The	164	167	O
optimal	168	175	O
approach	176	184	O
for	185	188	O
reoperation	189	200	O
following	201	210	O
repair	211	217	O
of	218	220	O
aortic	221	227	B-Multi-tissue_structure
coarctation	228	239	O
(	240	241	O
CoA	241	244	O
)	244	245	O
or	246	248	O
interruption	249	261	O
(	262	263	O
IAA	263	266	O
)	266	267	O
remains	268	275	O
controversial	276	289	O
.	289	290	O

Four	291	295	O
patients	296	304	O
underwent	305	314	O
extra	315	320	O
-	320	321	O
anatomic	321	329	O
bypass	330	336	O
for	337	340	O
restenosis	341	351	O
after	352	357	O
repair	358	364	O
of	365	367	O
CoA	368	371	O
or	372	374	O
IAA	375	378	O
.	378	379	O

The	380	383	O
age	384	387	O
ranged	388	394	O
from	395	399	O
4	400	401	O
to	402	404	O
12	405	407	O
years	408	413	O
.	413	414	O

The	415	418	O
initial	419	426	O
repairs	427	434	O
for	435	438	O
two	439	442	O
CoA	443	446	O
,	446	447	O
one	448	451	O
type	452	456	O
A	457	458	O
-	458	459	O
IAA	459	462	O
,	462	463	O
and	464	467	O
one	468	471	O
type	472	476	O
B	477	478	O
-	478	479	O
IAA	479	482	O
consisted	483	492	O
of	493	495	O
two	496	499	O
grafting	500	508	O
,	508	509	O
one	510	513	O
subclavian	514	524	O
arterial	525	533	B-Multi-tissue_structure
turning	534	541	O
-	541	542	O
down	542	546	O
aortoplasty	547	558	O
,	558	559	O
and	560	563	O
one	564	567	O
subclavian	568	578	O
flap	579	583	B-Multi-tissue_structure
aortoplasty	584	595	O
.	595	596	O

All	597	600	O
of	601	603	O
them	604	608	O
underwent	609	618	O
during	619	625	O
infancy	626	633	O
.	633	634	O

Preoperative	635	647	O
right	648	653	B-Organism_subdivision
arm	654	657	I-Organism_subdivision
systolic	658	666	O
pressure	667	675	O
ranged	676	682	O
from	683	687	O
140	688	691	O
to	692	694	O
190	695	698	O
mmHg	699	703	O
ar	704	706	O
rest	707	711	O
.	711	712	O

Through	713	720	O
a	721	722	O
midline	723	730	O
sternotomy	731	741	O
and	742	745	O
an	746	748	O
upper	749	754	O
laparotmy	755	764	O
incision	765	773	O
,	773	774	O
an	775	777	O
extra	778	783	O
-	783	784	O
anatomic	784	792	O
bypass	793	799	O
from	800	804	O
the	805	808	O
ascending	809	818	B-Multi-tissue_structure
aorta	819	824	I-Multi-tissue_structure
to	825	827	O
the	828	831	O
supraceliac	832	843	O
abdominal	844	853	B-Multi-tissue_structure
aorta	854	859	I-Multi-tissue_structure
was	860	863	O
employed	864	872	O
using	873	878	O
a	879	880	O
12	881	883	O
to	884	886	O
18	887	889	O
mm	890	892	O
tube	893	897	O
graft	898	903	O
.	903	904	O

All	905	908	O
patients	909	917	O
survived	918	926	O
surgeries	927	936	O
,	936	937	O
and	938	941	O
their	942	947	O
hypertension	948	960	O
markedly	961	969	O
improved	970	978	O
.	978	979	O

Our	980	983	O
experience	984	994	O
confirms	995	1003	O
safety	1004	1010	O
and	1011	1014	O
effectiveness	1015	1028	O
of	1029	1031	O
this	1032	1036	O
option	1037	1043	O
in	1044	1046	O
selected	1047	1055	O
young	1056	1061	O
patients	1062	1070	O
with	1071	1075	O
re	1076	1078	O
-	1078	1079	O
stenosis	1079	1087	O
of	1088	1090	O
following	1091	1100	O
repair	1101	1107	O
of	1108	1110	O
CoA	1111	1114	O
or	1115	1117	O
IAA	1118	1121	O
.	1121	1122	O

Effect	0	6	O
of	7	9	O
a	10	11	O
mutation	12	20	O
in	21	23	O
the	24	27	O
anticodon	28	37	O
of	38	40	O
human	41	46	O
mitochondrial	47	60	B-Cellular_component
tRNAPro	61	68	O
on	69	71	O
its	72	75	O
post	76	80	O
-	80	81	O
transcriptional	81	96	O
modification	97	109	O
pattern	110	117	O
.	117	118	O

Although	119	127	O
the	128	131	O
gene	132	136	O
sequences	137	146	O
of	147	149	O
all	150	153	O
22	154	156	O
tRNAs	157	162	O
encoded	163	170	O
in	171	173	O
the	174	177	O
human	178	183	O
mitochondrial	184	197	B-Cellular_component
genome	198	204	I-Cellular_component
are	205	208	O
known	209	214	O
,	214	215	O
little	216	222	O
information	223	234	O
exists	235	241	O
about	242	247	O
their	248	253	O
sequences	254	263	O
at	264	266	O
the	267	270	O
RNA	271	274	O
level	275	280	O
.	280	281	O

This	282	286	O
becomes	287	294	O
a	295	296	O
crucial	297	304	O
limitation	305	315	O
when	316	320	O
searching	321	330	O
for	331	334	O
a	335	336	O
molecular	337	346	O
understanding	347	360	O
of	361	363	O
the	364	367	O
growing	368	375	O
number	376	382	O
of	383	385	O
maternally	386	396	O
inherited	397	406	O
human	407	412	O
diseases	413	421	O
correlated	422	432	O
with	433	437	O
point	438	443	O
mutations	444	453	O
in	454	456	O
tRNA	457	461	O
genes	462	467	O
.	467	468	O

Here	469	473	O
we	474	476	O
describe	477	485	O
the	486	489	O
sequence	490	498	O
of	499	501	O
human	502	507	O
mt	508	510	O
-	510	511	O
tRNAPropurified	511	526	O
from	527	531	O
placenta	532	540	B-Organ
.	540	541	O

It	542	544	O
shows	545	550	O
absence	551	558	O
of	559	561	O
editing	562	569	O
events	570	576	O
in	577	579	O
this	580	584	O
tRNA	585	589	O
and	590	593	O
highlights	594	604	O
the	605	608	O
presence	609	617	O
of	618	620	O
eight	621	626	O
post	627	631	O
-	631	632	O
transcriptional	632	647	O
modifications	648	661	O
.	661	662	O

These	663	668	O
include	669	676	O
T54	677	680	O
,	680	681	O
never	682	687	O
found	688	693	O
so	694	696	O
far	697	700	O
in	701	703	O
an	704	706	O
animal	707	713	O
mt	714	716	O
-	716	717	O
tRNA	717	721	O
,	721	722	O
and	723	726	O
m1G37	727	732	O
,	732	733	O
a	734	735	O
modification	736	748	O
known	749	754	O
to	755	757	O
have	758	762	O
fundamental	763	774	O
functional	775	785	O
properties	786	796	O
in	797	799	O
a	800	801	O
number	802	808	O
of	809	811	O
canonical	812	821	O
tRNAs	822	827	O
.	827	828	O

Occurrence	829	839	O
of	840	842	O
m1G37	843	848	O
was	849	852	O
further	853	860	O
investigated	861	873	O
in	874	876	O
an	877	879	O
analysis	880	888	O
of	889	891	O
the	892	895	O
substrate	896	905	O
properties	906	916	O
of	917	919	O
in	920	922	O
vitro	923	928	O
transcripts	929	940	O
of	941	943	O
human	944	949	O
mt	950	952	O
-	952	953	O
tRNAProtowards	953	967	O
pure	968	972	O
Escherichia	973	984	O
coli	985	989	O
methylguanosine	990	1005	O
transferase	1006	1017	O
.	1017	1018	O

This	1019	1023	O
enzyme	1024	1030	O
properly	1031	1039	O
methylates	1040	1050	O
G37	1051	1054	O
in	1055	1057	O
mt	1058	1060	O
-	1060	1061	O
tRNA	1061	1065	O
and	1066	1069	O
is	1070	1072	O
sensitive	1073	1082	O
to	1083	1085	O
the	1086	1089	O
presence	1090	1098	O
of	1099	1101	O
a	1102	1103	O
second	1104	1110	O
G	1111	1112	O
at	1113	1115	O
position	1116	1124	O
36	1125	1127	O
,	1127	1128	O
neighboring	1129	1140	O
the	1141	1144	O
target	1145	1151	O
nucleotide	1152	1162	O
for	1163	1166	O
methylation	1167	1178	O
.	1178	1179	O

Since	1180	1185	O
mutation	1186	1194	O
of	1195	1197	O
nt	1198	1200	O
36	1201	1203	O
was	1204	1207	O
shown	1208	1213	O
to	1214	1216	O
be	1217	1219	O
correlated	1220	1230	O
with	1231	1235	O
myopathy	1236	1244	O
,	1244	1245	O
the	1246	1249	O
potential	1250	1259	O
consequences	1260	1272	O
of	1273	1275	O
non	1276	1279	O
-	1279	1280	O
modification	1280	1292	O
or	1293	1295	O
under	1296	1301	O
-	1301	1302	O
modification	1302	1314	O
of	1315	1317	O
mt	1318	1320	O
-	1320	1321	O
tRNA	1321	1325	O
nucleotides	1326	1337	O
in	1338	1340	O
expression	1341	1351	O
of	1352	1354	O
the	1355	1358	O
particular	1359	1369	O
myopathy	1370	1378	O
and	1379	1382	O
of	1383	1385	O
mitochondrial	1386	1399	B-Cellular_component
diseases	1400	1408	O
in	1409	1411	O
general	1412	1419	O
are	1420	1423	O
discussed	1424	1433	O
.	1433	1434	O

Clozapine	0	9	O
-	9	10	O
induced	10	17	O
agranulocytosis	18	33	O
and	34	37	O
thrombopenia	38	50	O
in	51	53	O
a	54	55	O
patient	56	63	O
with	64	68	O
dopaminergic	69	81	O
psychosis	82	91	O
.	91	92	O

In	93	95	O
patients	96	104	O
with	105	109	O
Parkinson	110	119	O
'	119	120	O
disease	121	128	O
and	129	132	O
dopaminergic	133	145	O
psychosis	146	155	O
,	155	156	O
clozapine	157	166	O
treatment	167	176	O
is	177	179	O
recommended	180	191	O
as	192	194	O
the	195	198	O
drug	199	203	O
is	204	206	O
free	207	211	O
from	212	216	O
extrapyramidal	217	231	O
side	232	236	O
effects	237	244	O
and	245	248	O
does	249	253	O
not	254	257	O
worsen	258	264	O
motor	265	270	O
symptoms	271	279	O
of	280	282	O
the	283	286	O
underlying	287	297	O
disease	298	305	O
.	305	306	O

The	307	310	O
use	311	314	O
of	315	317	O
clozapine	318	327	O
,	327	328	O
however	329	336	O
,	336	337	O
is	338	340	O
limited	341	348	O
due	349	352	O
to	353	355	O
its	356	359	O
hematotoxic	360	371	O
side	372	376	O
effects	377	384	O
.	384	385	O

For	386	389	O
treatment	390	399	O
of	400	402	O
clozapine	403	412	O
-	412	413	O
induced	413	420	O
agranulocytosis	421	436	O
,	436	437	O
granulocyte	438	449	O
colony	450	456	O
-	456	457	O
stimulating	457	468	O
factors	469	476	O
(	477	478	O
G	478	479	O
-	479	480	O
CSF	480	483	O
)	483	484	O
are	485	488	O
recommended	489	500	O
.	500	501	O

We	502	504	O
report	505	511	O
the	512	515	O
case	516	520	O
of	521	523	O
a	524	525	O
72	526	528	O
-	528	529	O
years	529	534	O
-	534	535	O
old	535	538	O
male	539	543	O
patient	544	551	O
with	552	556	O
clozapine	557	566	O
-	566	567	O
induced	567	574	O
agranulocytosis	575	590	O
and	591	594	O
thrombopenia	595	607	O
.	607	608	O

Neutropenia	609	620	O
was	621	624	O
successfully	625	637	O
treated	638	645	O
with	646	650	O
G	651	652	O
-	652	653	O
CSF	653	656	O
,	656	657	O
but	658	661	O
thrombopenia	662	674	O
persisted	675	684	O
and	685	688	O
resolved	689	697	O
spontaneously	698	711	O
after	712	717	O
14	718	720	O
days	721	725	O
.	725	726	O

Bone	727	731	B-Multi-tissue_structure
marrow	732	738	I-Multi-tissue_structure
toxicity	739	747	O
of	748	750	O
clozapine	751	760	O
is	761	763	O
not	764	767	O
restricted	768	778	O
to	779	781	O
white	782	787	B-Cell
cell	788	792	I-Cell
maturation	793	803	O
,	803	804	O
but	805	808	O
may	809	812	O
also	813	817	O
impair	818	824	O
thrombocytopoesis	825	842	O
.	842	843	O

Acylase	0	7	O
I	8	9	O
-	9	10	O
catalyzed	10	19	O
deacetylation	20	33	O
of	34	36	O
N	37	38	O
-	38	39	O
acetyl	39	45	O
-	45	46	O
L	46	47	O
-	47	48	O
cysteine	48	56	O
and	57	60	O
S	61	62	O
-	62	63	O
alkyl	63	68	O
-	68	69	O
N	69	70	O
-	70	71	O
acetyl	71	77	O
-	77	78	O
L	78	79	O
-	79	80	O
cysteines	80	89	O
.	89	90	O

The	91	94	O
aminoacylase	95	107	O
that	108	112	O
catalyzes	113	122	O
the	123	126	O
hydrolysis	127	137	O
of	138	140	O
N	141	142	O
-	142	143	O
acetyl	143	149	O
-	149	150	O
L	150	151	O
-	151	152	O
cysteine	152	160	O
(	161	162	O
NAC	162	165	O
)	165	166	O
was	167	170	O
identified	171	181	O
as	182	184	O
acylase	185	192	O
I	193	194	O
after	195	200	O
purification	201	213	O
by	214	216	O
column	217	223	O
chromatography	224	238	O
and	239	242	O
electrophoretic	243	258	O
analysis	259	267	O
.	267	268	O

Rat	269	272	O
kidney	273	279	B-Organism_substance
cytosol	280	287	I-Organism_substance
was	288	291	O
fractionated	292	304	O
by	305	307	O
ammonium	308	316	O
sulfate	317	324	O
precipitation	325	338	O
,	338	339	O
and	340	343	O
the	344	347	O
proteins	348	356	O
were	357	361	O
separated	362	371	O
by	372	374	O
ion	375	378	O
-	378	379	O
exchange	379	387	O
column	388	394	O
chromatography	395	409	O
,	409	410	O
gel	411	414	O
-	414	415	O
filtration	415	425	O
column	426	432	O
chromatography	433	447	O
,	447	448	O
and	449	452	O
hydrophobic	453	464	O
interaction	465	476	O
column	477	483	O
chromatography	484	498	O
.	498	499	O

Acylase	500	507	O
activity	508	516	O
with	517	521	O
NAC	522	525	O
and	526	529	O
N	530	531	O
-	531	532	O
acetyl	532	538	O
-	538	539	O
L	539	540	O
-	540	541	O
methionine	541	551	O
(	552	553	O
NAM	553	556	O
)	556	557	O
,	557	558	O
a	559	560	O
known	561	566	O
substrate	567	576	O
for	577	580	O
acylase	581	588	O
I	589	590	O
,	590	591	O
as	592	594	O
substrates	595	605	O
coeluted	606	614	O
during	615	621	O
all	622	625	O
chromatographic	626	641	O
steps	642	647	O
.	647	648	O

Sodium	649	655	O
dodecyl	656	663	O
sulfate	664	671	O
-	671	672	O
polyacrylamide	672	686	O
gel	687	690	O
electrophoresis	691	706	O
showed	707	713	O
that	714	718	O
the	719	722	O
protein	723	730	O
was	731	734	O
purified	735	743	O
to	744	746	O
near	747	751	O
homogeneity	752	763	O
and	764	767	O
had	768	771	O
a	772	773	O
subunit	774	781	O
Mr	782	784	O
of	785	787	O
43	788	790	O
000	791	794	O
,	794	795	O
which	796	801	O
is	802	804	O
identical	805	814	O
with	815	819	O
the	820	823	O
Mr	824	826	O
of	827	829	O
acylase	830	837	O
I	838	839	O
from	840	844	O
porcine	845	852	O
kidney	853	859	B-Organ
and	860	863	O
bovine	864	870	O
liver	871	876	B-Organ
.	876	877	O

n	878	879	O
-	879	880	O
Butylmalonic	880	892	O
acid	893	897	O
was	898	901	O
a	902	903	O
slow	904	908	O
-	908	909	O
binding	909	916	O
inhibitor	917	926	O
of	927	929	O
acylase	930	937	O
I	938	939	O
and	940	943	O
inhibited	944	953	O
the	954	957	O
deacetylation	958	971	O
of	972	974	O
NAC	975	978	O
with	979	983	O
a	984	985	O
Ki	986	988	O
of	989	991	O
192	992	995	O
+	996	997	O
/	997	998	O
-	998	999	O
27	1000	1002	O
microM	1003	1009	O
.	1009	1010	O

These	1011	1016	O
results	1017	1024	O
show	1025	1029	O
that	1030	1034	O
acylase	1035	1042	O
I	1043	1044	O
catalyzes	1045	1054	O
the	1055	1058	O
deacetylation	1059	1072	O
of	1073	1075	O
NAC	1076	1079	O
.	1079	1080	O

The	1081	1084	O
acylase	1085	1092	O
I	1093	1094	O
-	1094	1095	O
catalyzed	1095	1104	O
deacetylation	1105	1118	O
of	1119	1121	O
a	1122	1123	O
range	1124	1129	O
of	1130	1132	O
S	1133	1134	O
-	1134	1135	O
alkyl	1135	1140	O
-	1140	1141	O
N	1141	1142	O
-	1142	1143	O
acetyl	1143	1149	O
-	1149	1150	O
L	1150	1151	O
-	1151	1152	O
cysteines	1152	1161	O
,	1161	1162	O
their	1163	1168	O
carbon	1169	1175	O
and	1176	1179	O
oxygen	1180	1186	O
analogues	1187	1196	O
,	1196	1197	O
and	1198	1201	O
the	1202	1205	O
selenium	1206	1214	O
analogue	1215	1223	O
of	1224	1226	O
NAM	1227	1230	O
was	1231	1234	O
also	1235	1239	O
studied	1240	1247	O
with	1248	1252	O
porcine	1253	1260	O
kidney	1261	1267	B-Organ
acylase	1268	1275	O
I	1276	1277	O
.	1277	1278	O

The	1279	1282	O
specific	1283	1291	O
activity	1292	1300	O
of	1301	1303	O
the	1304	1307	O
acylase	1308	1315	O
I	1316	1317	O
-	1317	1318	O
catalyzed	1318	1327	O
deacetylation	1328	1341	O
of	1342	1344	O
these	1345	1350	O
substrates	1351	1361	O
was	1362	1365	O
related	1366	1373	O
to	1374	1376	O
their	1377	1382	O
calculated	1383	1393	O
molar	1394	1399	O
volumes	1400	1407	O
and	1408	1411	O
log	1412	1415	O
P	1416	1417	O
values	1418	1424	O
.	1424	1425	O

The	1426	1429	O
S	1430	1431	O
-	1431	1432	O
alkyl	1432	1437	O
-	1437	1438	O
N	1438	1439	O
-	1439	1440	O
acetyl	1440	1446	O
-	1446	1447	O
L	1447	1448	O
-	1448	1449	O
cysteines	1449	1458	O
with	1459	1463	O
short	1464	1469	O
(	1470	1471	O
C0	1471	1473	O
-	1473	1474	O
C3	1474	1476	O
)	1476	1477	O
and	1478	1481	O
unbranched	1482	1492	O
S	1493	1494	O
-	1494	1495	O
alkyl	1495	1500	O
substituents	1501	1513	O
were	1514	1518	O
good	1519	1523	O
acylase	1524	1531	O
I	1532	1533	O
substrates	1534	1544	O
,	1544	1545	O
whereas	1546	1553	O
the	1554	1557	O
S	1558	1559	O
-	1559	1560	O
alkyl	1560	1565	O
-	1565	1566	O
N	1566	1567	O
-	1567	1568	O
acetyl	1568	1574	O
-	1574	1575	O
L	1575	1576	O
-	1576	1577	O
cysteines	1577	1586	O
with	1587	1591	O
long	1592	1596	O
(	1597	1598	O
>	1598	1599	O
C3	1599	1601	O
)	1601	1602	O
and	1603	1606	O
branched	1607	1615	O
S	1616	1617	O
-	1617	1618	O
alkyl	1618	1623	O
substituents	1624	1636	O
were	1637	1641	O
poLr	1642	1646	O
acylase	1647	1654	O
I	1655	1656	O
substrates	1657	1667	O
.	1667	1668	O

The	1669	1672	O
carbon	1673	1679	O
and	1680	1683	O
oxygen	1684	1690	O
analogues	1691	1700	O
of	1701	1703	O
S	1704	1705	O
-	1705	1706	O
methyl	1706	1712	O
-	1712	1713	O
N	1713	1714	O
-	1714	1715	O
acetyl	1715	1721	O
-	1721	1722	O
L	1722	1723	O
-	1723	1724	O
cysteine	1724	1732	O
and	1733	1736	O
the	1737	1740	O
carbon	1741	1747	O
analogue	1748	1756	O
of	1757	1759	O
S	1760	1761	O
-	1761	1762	O
ethyl	1762	1767	O
-	1767	1768	O
N	1768	1769	O
-	1769	1770	O
acetyl	1770	1776	O
-	1776	1777	O
L	1777	1778	O
-	1778	1779	O
cysteine	1779	1787	O
were	1788	1792	O
poor	1793	1797	O
acylase	1798	1805	O
I	1806	1807	O
substrates	1808	1818	O
,	1818	1819	O
whereas	1820	1827	O
the	1828	1831	O
selenium	1832	1840	O
analogue	1841	1849	O
of	1850	1852	O
NAM	1853	1856	O
was	1857	1860	O
a	1861	1862	O
good	1863	1867	O
acylase	1868	1875	O
I	1876	1877	O
substrate	1878	1887	O
.	1887	1888	O

Hemispheric	0	11	O
control	12	19	O
of	20	22	O
motor	23	28	O
function	29	37	O
:	37	38	O
a	39	40	O
whole	41	46	O
brain	47	52	B-Organ
echo	53	57	O
planar	58	64	O
fMRI	65	69	O
study	70	75	O
.	75	76	O

The	77	80	O
aim	81	84	O
of	85	87	O
this	88	92	O
study	93	98	O
was	99	102	O
to	103	105	O
explore	106	113	O
whether	114	121	O
recruitment	122	133	O
of	134	136	O
the	137	140	O
ipsilateral	141	152	B-Multi-tissue_structure
motor	153	158	I-Multi-tissue_structure
cortex	159	165	I-Multi-tissue_structure
during	166	172	O
non	173	176	O
-	176	177	O
dominant	177	185	O
motor	186	191	O
movement	192	200	O
reflects	201	209	O
left	210	214	B-Multi-tissue_structure
hemispheric	215	226	I-Multi-tissue_structure
control	227	234	O
of	235	237	O
motor	238	243	O
function	244	252	O
or	253	255	O
simply	256	262	O
the	263	266	O
greater	267	274	O
complexity	275	285	O
or	286	288	O
unfamiliarity	289	302	O
of	303	305	O
the	306	309	O
motor	310	315	O
task	316	320	O
.	320	321	O

BOLD	322	326	O
fMRI	327	331	O
was	332	335	O
performed	336	345	O
in	346	348	O
normal	349	355	O
right	356	361	O
-	361	362	O
handers	362	369	O
during	370	376	O
two	377	380	O
motor	381	386	O
tasks	387	392	O
:	392	393	O
(	394	395	O
1	395	396	O
)	396	397	O
sequential	398	408	O
finger	409	415	B-Organism_subdivision
movements	416	425	O
(	426	427	O
SM	427	429	O
task	430	434	O
)	434	435	O
with	436	440	O
the	441	444	O
right	445	450	O
or	451	453	O
left	454	458	O
hand	459	463	B-Organism_subdivision
;	463	464	O
and	465	468	O
(	469	470	O
2	470	471	O
)	471	472	O
random	473	479	O
finger	480	486	B-Organism_subdivision
movements	487	496	O
(	497	498	O
RM	498	500	O
task	501	505	O
)	505	506	O
with	507	511	O
the	512	515	O
right	516	521	O
hand	522	526	B-Organism_subdivision
.	526	527	O

In	528	530	O
all	531	534	O
subjects	535	543	O
,	543	544	O
activation	545	555	O
was	556	559	O
predominantly	560	573	O
in	574	576	O
the	577	580	O
contralateral	581	594	O
motor	595	600	O
areas	601	606	O
(	607	608	O
primary	608	615	O
sensorimotor	616	628	O
,	628	629	O
lateral	630	637	O
premotor	638	646	O
,	646	647	O
parietal	648	656	O
and	657	660	O
supplementary	661	674	O
motor	675	680	O
regions	681	688	O
)	688	689	O
and	690	693	O
ipsilateral	694	705	B-Multi-tissue_structure
cerebellum	706	716	I-Multi-tissue_structure
.	716	717	O

While	718	723	O
the	724	727	O
ipsilateral	728	739	B-Multi-tissue_structure
motor	740	745	I-Multi-tissue_structure
areas	746	751	I-Multi-tissue_structure
were	752	756	O
also	757	761	O
activated	762	771	O
,	771	772	O
single	773	779	O
subject	780	787	O
analysis	788	796	O
revealed	797	805	O
these	806	811	O
areas	812	817	O
to	818	820	O
be	821	823	O
more	824	828	O
extensive	829	838	O
and	839	842	O
to	843	845	O
be	846	848	O
seen	849	853	O
in	854	856	O
more	857	861	O
subjects	862	870	O
during	871	877	O
the	878	881	O
non	882	885	O
-	885	886	O
dominant	886	894	O
hand	895	899	B-Organism_subdivision
SM	900	902	O
task	903	907	O
and	908	911	O
dominant	912	920	O
hand	921	925	B-Organism_subdivision
RM	926	928	O
task	929	933	O
than	934	938	O
during	939	945	O
the	946	949	O
more	950	954	O
familiar	955	963	O
dominant	964	972	O
hand	973	977	B-Organism_subdivision
SM	978	980	O
task	981	985	O
.	985	986	O

Similarly	987	996	O
,	996	997	O
group	998	1003	O
analysis	1004	1012	O
also	1013	1017	O
revealed	1018	1026	O
ipsilateral	1027	1038	O
activation	1039	1049	O
in	1050	1052	O
the	1053	1056	O
primary	1057	1064	O
sensorimotor	1065	1077	O
and	1078	1081	O
lateral	1082	1089	B-Multi-tissue_structure
premotor	1090	1098	I-Multi-tissue_structure
areas	1099	1104	I-Multi-tissue_structure
,	1104	1105	O
but	1106	1109	O
only	1110	1114	O
during	1115	1121	O
the	1122	1125	O
non	1126	1129	O
-	1129	1130	O
dominant	1130	1138	O
SM	1139	1141	O
task	1142	1146	O
and	1147	1150	O
the	1151	1154	O
dominant	1155	1163	O
hand	1164	1168	B-Organism_subdivision
RM	1169	1171	O
task	1172	1176	O
.	1176	1177	O

Non	1178	1181	O
-	1181	1182	O
dominant	1182	1190	O
hand	1191	1195	B-Organism_subdivision
movements	1196	1205	O
,	1205	1206	O
perhaps	1207	1214	O
because	1215	1222	O
they	1223	1227	O
are	1228	1231	O
less	1232	1236	O
'	1237	1238	O
automatic	1238	1247	O
'	1247	1248	O
,	1248	1249	O
appear	1250	1256	O
to	1257	1259	O
require	1260	1267	O
more	1268	1272	O
cortical	1273	1281	B-Multi-tissue_structure
activity	1282	1290	O
similar	1291	1298	O
to	1299	1301	O
complex	1302	1309	O
tasks	1310	1315	O
with	1316	1320	O
the	1321	1324	O
dominant	1325	1333	O
hand	1334	1338	B-Organism_subdivision
,	1338	1339	O
and	1340	1343	O
result	1344	1350	O
in	1351	1353	O
greater	1354	1361	O
recruitment	1362	1373	O
of	1374	1376	O
ipsilateral	1377	1388	B-Multi-tissue_structure
cortical	1389	1397	I-Multi-tissue_structure
motor	1398	1403	I-Multi-tissue_structure
areas	1404	1409	I-Multi-tissue_structure
and	1410	1413	O
striatum	1414	1422	B-Multi-tissue_structure
.	1422	1423	O

The	1424	1427	O
study	1428	1433	O
also	1434	1438	O
illustrates	1439	1450	O
how	1451	1454	O
potentially	1455	1466	O
meaningful	1467	1477	O
subtleties	1478	1488	O
seen	1489	1493	O
on	1494	1496	O
individual	1497	1507	O
maps	1508	1512	O
may	1513	1516	O
be	1517	1519	O
obscured	1520	1528	O
with	1529	1533	O
group	1534	1539	O
averaging	1540	1549	O
approaches	1550	1560	O
.	1560	1561	O

Selective	0	9	O
inhibition	10	20	O
of	21	23	O
the	24	27	O
renal	28	33	B-Organ
dopamine	34	42	O
subtype	43	50	O
D1A	51	54	O
receptor	55	63	O
induces	64	71	O
antinatriuresis	72	87	O
in	88	90	O
conscious	91	100	O
rats	101	105	O
.	105	106	O

Both	107	111	O
dopamine	112	120	O
D1	121	123	O
-	123	124	O
like	124	128	O
(	129	130	O
D1A	130	133	O
and	134	137	O
D1B	138	141	O
)	141	142	O
and	143	146	O
D2	147	149	O
-	149	150	O
like	150	154	O
(	155	156	O
D2	156	158	O
,	158	159	O
D3	160	162	O
,	162	163	O
and	164	167	O
D4	168	170	O
)	170	171	O
receptor	172	180	O
subfamilies	181	192	O
are	193	196	O
present	197	204	O
in	205	207	O
the	208	211	O
kidney	212	218	B-Organ
.	218	219	O

Blockade	220	228	O
of	229	231	O
the	232	235	O
intrarenal	236	246	O
D1	247	249	O
-	249	250	O
like	250	254	O
receptor	255	263	O
family	264	270	O
is	271	273	O
associated	274	284	O
with	285	289	O
natriuresis	290	301	O
and	302	305	O
diuresis	306	314	O
.	314	315	O

Because	316	323	O
the	324	327	O
D1A	328	331	O
and	332	335	O
D1B	336	339	O
receptor	340	348	O
subtypes	349	357	O
are	358	361	O
not	362	365	O
distinguishable	366	381	O
by	382	384	O
currently	385	394	O
available	395	404	O
dopaminergic	405	417	O
agents	418	424	O
,	424	425	O
their	426	431	O
functional	432	442	O
role	443	447	O
remains	448	455	O
undefined	456	465	O
.	465	466	O

In	467	469	O
the	470	473	O
present	474	481	O
study	482	487	O
,	487	488	O
the	489	492	O
effect	493	499	O
of	500	502	O
selective	503	512	O
inhibition	513	523	O
of	524	526	O
the	527	530	O
renal	531	536	B-Organ
D1A	537	540	O
receptor	541	549	O
with	550	554	O
phosphorothioated	555	572	O
antisense	573	582	O
oligodeoxynucleotide	583	603	O
(	604	605	O
AS	605	607	O
-	607	608	O
ODN	608	611	O
)	611	612	O
was	613	616	O
investigated	617	629	O
in	630	632	O
conscious	633	642	O
uninephrectomized	643	660	O
rats	661	665	O
.	665	666	O

After	667	672	O
renal	673	678	B-Immaterial_anatomical_entity
interstitial	679	691	I-Immaterial_anatomical_entity
administration	692	706	O
of	707	709	O
Texas	710	715	O
red	716	719	O
-	719	720	O
labeled	720	727	O
D1A	728	731	O
receptor	732	740	O
AS	741	743	O
-	743	744	O
ODN	744	747	O
,	747	748	O
intense	749	756	O
fluorescent	757	768	O
signal	769	775	O
was	776	779	O
localized	780	789	O
in	790	792	O
the	793	796	O
renal	797	802	B-Tissue
tubular	803	810	I-Tissue
epithelium	811	821	I-Tissue
and	822	825	O
vasculature	826	837	B-Multi-tissue_structure
.	837	838	O

In	839	841	O
rats	842	846	O
on	847	849	O
normal	850	856	O
salt	857	861	O
intake	862	868	O
,	868	869	O
AS	870	872	O
-	872	873	O
ODN	873	876	O
injected	877	885	O
interstitially	886	900	O
into	901	905	O
the	906	909	O
kidney	910	916	B-Organ
reduced	917	924	O
daily	925	930	O
urinary	931	938	B-Organism_substance
sodium	939	945	O
excretion	946	955	O
(	956	957	O
1	957	958	O
.	958	959	O
4	959	960	O
+	960	961	O
/	961	962	O
-	962	963	O
0	963	964	O
.	964	965	O
04	965	967	O
versus	968	974	O
0	975	976	O
.	976	977	O
8	977	978	O
+	978	979	O
/	979	980	O
-	980	981	O
0	981	982	O
.	982	983	O
2	983	984	O
mEq	985	988	O
/	988	989	O
d	989	990	O
,	990	991	O
n	992	993	O
=	993	994	O
5	994	995	O
,	995	996	O
P	997	998	O
<	998	999	O
0	999	1000	O
.	1000	1001	O
05	1001	1003	O
)	1003	1004	O
and	1005	1008	O
urine	1009	1014	B-Organism_substance
output	1015	1021	O
(	1022	1023	O
16	1023	1025	O
.	1025	1026	O
9	1026	1027	O
+	1027	1028	O
/	1028	1029	O
-	1029	1030	O
3	1030	1031	O
.	1031	1032	O
8	1032	1033	O
versus	1034	1040	O
12	1041	1043	O
.	1043	1044	O
5	1044	1045	O
+	1045	1046	O
/	1046	1047	O
-	1047	1048	O
3	1048	1049	O
.	1049	1050	O
6	1050	1051	O
mL	1052	1054	O
/	1054	1055	O
d	1055	1056	O
,	1056	1057	O
n	1058	1059	O
=	1059	1060	O
5	1060	1061	O
,	1061	1062	O
P	1063	1064	O
<	1064	1065	O
0	1065	1066	O
.	1066	1067	O
05	1067	1069	O
)	1069	1070	O
.	1070	1071	O

In	1072	1074	O
rats	1075	1079	O
on	1080	1082	O
high	1083	1087	O
sodium	1088	1094	O
intake	1095	1101	O
,	1101	1102	O
continuous	1103	1113	O
renal	1114	1119	B-Immaterial_anatomical_entity
interstitial	1120	1132	I-Immaterial_anatomical_entity
administration	1133	1147	O
of	1148	1150	O
D1A	1151	1154	O
receptor	1155	1163	O
AS	1164	1166	O
-	1166	1167	O
ODN	1167	1170	O
transiently	1171	1182	O
decreased	1183	1192	O
daily	1193	1198	O
urinary	1199	1206	B-Organism_substance
sodium	1207	1213	O
excretion	1214	1223	O
(	1224	1225	O
5	1225	1226	O
.	1226	1227	O
4	1227	1228	O
+	1228	1229	O
/	1229	1230	O
-	1230	1231	O
0	1231	1232	O
.	1232	1233	O
5	1233	1234	O
versus	1235	1241	O
4	1242	1243	O
.	1243	1244	O
2	1244	1245	O
+	1245	1246	O
/	1246	1247	O
-	1247	1248	O
0	1248	1249	O
.	1249	1250	O
3	1250	1251	O
mEq	1252	1255	O
/	1255	1256	O
d	1256	1257	O
,	1257	1258	O
n	1259	1260	O
=	1260	1261	O
7	1261	1262	O
,	1262	1263	O
P	1264	1265	O
<	1265	1266	O
0	1266	1267	O
.	1267	1268	O
01	1268	1270	O
)	1270	1271	O
and	1272	1275	O
urine	1276	1281	B-Organism_substance
output	1282	1288	O
(	1289	1290	O
27	1290	1292	O
.	1292	1293	O
6	1293	1294	O
+	1294	1295	O
/	1295	1296	O
-	1296	1297	O
4	1297	1298	O
.	1298	1299	O
5	1299	1300	O
versus	1301	1307	O
18	1308	1310	O
.	1310	1311	O
1	1311	1312	O
+	1312	1313	O
/	1313	1314	O
-	1314	1315	O
1	1315	1316	O
.	1316	1317	O
8	1317	1318	O
mL	1319	1321	O
/	1321	1322	O
d	1322	1323	O
,	1323	1324	O
n	1325	1326	O
=	1326	1327	O
7	1327	1328	O
,	1328	1329	O
P	1330	1331	O
<	1331	1332	O
0	1332	1333	O
.	1333	1334	O
01	1334	1336	O
)	1336	1337	O
.	1337	1338	O

Neither	1339	1346	O
vehicle	1347	1354	O
nor	1355	1358	O
sense	1359	1364	O
oligodeoxynucleotide	1365	1385	O
had	1386	1389	O
significant	1390	1401	O
effects	1402	1409	O
.	1409	1410	O

Systolic	1411	1419	O
blood	1420	1425	B-Organism_substance
pressure	1426	1434	O
remained	1435	1443	O
unchanged	1444	1453	O
.	1453	1454	O

The	1455	1458	O
renal	1459	1464	B-Organ
D1A	1465	1468	O
receptor	1469	1477	O
protein	1478	1485	O
was	1486	1489	O
significantly	1490	1503	O
decreased	1504	1513	O
by	1514	1516	O
35	1517	1519	O
%	1519	1520	O
and	1521	1524	O
46	1525	1527	O
%	1527	1528	O
at	1529	1531	O
the	1532	1535	O
end	1536	1539	O
of	1540	1542	O
the	1543	1546	O
study	1547	1552	O
in	1553	1555	O
AS	1556	1558	O
-	1558	1559	O
ODN	1559	1562	O
-	1562	1563	O
treated	1563	1570	O
rats	1571	1575	O
on	1576	1578	O
normal	1579	1585	O
and	1586	1589	O
high	1590	1594	O
salt	1595	1599	O
intake	1600	1606	O
,	1606	1607	O
respectively	1608	1620	O
,	1620	1621	O
whereas	1622	1629	O
the	1630	1633	O
D1B	1634	1637	O
receptor	1638	1646	O
and	1647	1650	O
beta	1651	1655	O
-	1655	1656	O
actin	1656	1661	O
were	1662	1666	O
not	1667	1670	O
affected	1671	1679	O
.	1679	1680	O

These	1681	1686	O
results	1687	1694	O
provide	1695	1702	O
the	1703	1706	O
first	1707	1712	O
direct	1713	1719	O
evidence	1720	1728	O
that	1729	1733	O
the	1734	1737	O
renal	1738	1743	B-Organ
D1A	1744	1747	O
receptor	1748	1756	O
subtype	1757	1764	O
plays	1765	1770	O
an	1771	1773	O
important	1774	1783	O
role	1784	1788	O
in	1789	1791	O
the	1792	1795	O
control	1796	1803	O
of	1804	1806	O
sodium	1807	1813	O
excretion	1814	1823	O
.	1823	1824	O

[	0	1	O
Epidemiology	1	13	O
of	14	16	O
respiratory	17	28	B-Anatomical_system
allergy	29	36	O
in	37	39	O
children	40	48	O
]	48	49	O
.	49	50	O

Epidemiology	51	63	O
of	64	66	O
paediatric	67	77	O
respiratory	78	89	B-Anatomical_system
allergic	90	98	O
disorders	99	108	O
allows	109	115	O
the	116	119	O
approach	120	128	O
to	129	131	O
causal	132	138	O
and	139	142	O
preventive	143	153	O
risk	154	158	O
factors	159	166	O
by	167	169	O
studying	170	178	O
groups	179	185	O
or	186	188	O
sub	189	192	O
groups	193	199	O
of	200	202	O
children	203	211	O
in	212	214	O
different	215	224	O
locations	225	234	O
and	235	238	O
under	239	244	O
different	245	254	O
conditions	255	265	O
.	265	266	O

This	267	271	O
is	272	274	O
,	274	275	O
however	276	283	O
,	283	284	O
complicated	285	296	O
by	297	299	O
the	300	303	O
lack	304	308	O
of	309	311	O
consensus	312	321	O
on	322	324	O
disease	325	332	O
definitions	333	344	O
,	344	345	O
which	346	351	O
renders	352	359	O
comparisons	360	371	O
between	372	379	O
studies	380	387	O
difficult	388	397	O
.	397	398	O

Atopy	399	404	O
is	405	407	O
usually	408	415	O
defined	416	423	O
by	424	426	O
the	427	430	O
presence	431	439	O
of	440	442	O
positive	443	451	O
skin	452	456	B-Organ
tests	457	462	O
(	463	464	O
wheal	464	469	O
size	470	474	O
of	475	477	O
at	478	480	O
least	481	486	O
a	487	488	O
mean	489	493	O
diameter	494	502	O
>	503	504	O
or	505	507	O
=	508	509	O
3	510	511	O
mm	512	514	O
)	514	515	O
,	515	516	O
by	517	519	O
the	520	523	O
presence	524	532	O
of	533	535	O
specific	536	544	O
IgE	545	548	O
,	548	549	O
or	550	552	O
by	553	555	O
the	556	559	O
presence	560	568	O
of	569	571	O
increased	572	581	O
total	582	587	O
IgE	588	591	O
(	592	593	O
>	593	594	O
or	595	597	O
=	598	599	O
100	600	603	O
UI	604	606	O
/	606	607	O
mL	607	609	O
)	609	610	O
.	610	611	O

Infantile	612	621	O
asthma	622	628	O
is	629	631	O
not	632	635	O
well	636	640	O
defined	641	648	O
,	648	649	O
complicated	650	661	O
by	662	664	O
the	665	668	O
high	669	673	O
prevalence	674	684	O
of	685	687	O
bronchiolitis	688	701	O
;	701	702	O
one	703	706	O
thus	707	711	O
questions	712	721	O
between	722	729	O
wheezing	730	738	O
or	739	741	O
wheezy	742	748	O
bronchitis	749	759	O
.	759	760	O

Prevalence	761	771	O
is	772	774	O
high	775	779	O
:	779	780	O
among	781	786	O
early	787	792	O
wheezers	793	801	O
,	801	802	O
two	803	806	O
populations	807	818	O
will	819	823	O
be	824	826	O
defined	827	834	O
by	835	837	O
the	838	841	O
medium	842	848	O
term	849	853	O
evolution	854	863	O
:	863	864	O
transient	865	874	O
wheezers	875	883	O
and	884	887	O
persistent	888	898	O
wheezers	899	907	O
.	907	908	O

Risk	909	913	O
factors	914	921	O
for	922	925	O
these	926	931	O
two	932	935	O
conditions	936	946	O
are	947	950	O
different	951	960	O
.	960	961	O

Childhood	962	971	O
asthma	972	978	O
may	979	982	O
be	983	985	O
defined	986	993	O
by	994	996	O
the	997	1000	O
diagnosis	1001	1010	O
of	1011	1013	O
asthma	1014	1020	O
(	1021	1022	O
specific	1022	1030	O
but	1031	1034	O
fairly	1035	1041	O
non	1042	1045	O
-	1045	1046	O
sensitive	1046	1055	O
)	1055	1056	O
,	1056	1057	O
by	1058	1060	O
asthmatic	1061	1070	O
symptoms	1071	1079	O
(	1080	1081	O
wheezing	1081	1089	O
,	1089	1090	O
waking	1091	1097	O
by	1098	1100	O
an	1101	1103	O
attack	1104	1110	O
of	1111	1113	O
shortness	1114	1123	O
of	1124	1126	O
breath	1127	1133	O
)	1133	1134	O
(	1135	1136	O
sensitive	1136	1145	O
but	1146	1149	O
not	1150	1153	O
very	1154	1158	O
specific	1159	1167	O
)	1167	1168	O
,	1168	1169	O
or	1170	1172	O
by	1173	1175	O
the	1176	1179	O
combination	1180	1191	O
of	1192	1194	O
symptoms	1195	1203	O
and	1204	1207	O
airway	1208	1214	B-Multi-tissue_structure
hyperresponsiveness	1215	1234	O
.	1234	1235	O

The	1236	1239	O
ISAAC	1240	1245	O
study	1246	1251	O
has	1252	1255	O
standardised	1256	1268	O
a	1269	1270	O
questionnaire	1271	1284	O
to	1285	1287	O
assess	1288	1294	O
the	1295	1298	O
prevalence	1299	1309	O
of	1310	1312	O
asthma	1313	1319	O
.	1319	1320	O

The	1321	1324	O
preliminary	1325	1336	O
results	1337	1344	O
show	1345	1349	O
that	1350	1354	O
there	1355	1360	O
are	1361	1364	O
wide	1365	1369	O
variations	1370	1380	O
across	1381	1387	O
the	1388	1391	O
world	1392	1397	O
.	1397	1398	O

The	1399	1402	O
prevalence	1403	1413	O
is	1414	1416	O
low	1417	1420	O
in	1421	1423	O
Africa	1424	1430	O
and	1431	1434	O
Asia	1435	1439	O
,	1439	1440	O
intermediate	1441	1453	O
in	1454	1456	O
Europe	1457	1463	O
,	1463	1464	O
and	1465	1468	O
high	1469	1473	O
in	1474	1476	O
Anglo	1477	1482	O
-	1482	1483	O
Saxon	1483	1488	O
countries	1489	1498	O
.	1498	1499	O

The	1500	1503	O
prevalence	1504	1514	O
of	1515	1517	O
asthma	1518	1524	O
has	1525	1528	O
gradually	1529	1538	O
increased	1539	1548	O
over	1549	1553	O
the	1554	1557	O
past	1558	1562	O
20	1563	1565	O
years	1566	1571	O
in	1572	1574	O
developed	1575	1584	O
countries	1585	1594	O
.	1594	1595	O

Asthma	1596	1602	O
and	1603	1606	O
atopy	1607	1612	O
are	1613	1616	O
closely	1617	1624	O
associated	1625	1635	O
in	1636	1638	O
children	1639	1647	O
.	1647	1648	O

Risk	1649	1653	O
factors	1654	1661	O
are	1662	1665	O
genetic	1666	1673	O
,	1673	1674	O
associated	1675	1685	O
with	1686	1690	O
sex	1691	1694	O
and	1695	1698	O
environmental	1699	1712	O
factors	1713	1720	O
.	1720	1721	O

Among	1722	1727	O
these	1728	1733	O
,	1733	1734	O
allergic	1735	1743	O
sensitisation	1744	1757	O
is	1758	1760	O
associated	1761	1771	O
with	1772	1776	O
the	1777	1780	O
degree	1781	1787	O
of	1788	1790	O
exposure	1791	1799	O
to	1800	1802	O
allergens	1803	1812	O
.	1812	1813	O

Westernization	1814	1828	O
of	1829	1831	O
way	1832	1835	O
of	1836	1838	O
life	1839	1843	O
is	1844	1846	O
associated	1847	1857	O
with	1858	1862	O
increased	1863	1872	O
prevalence	1873	1883	O
of	1884	1886	O
atopy	1887	1892	O
,	1892	1893	O
allergic	1894	1902	O
rhinitis	1903	1911	O
and	1912	1915	O
asthma	1916	1922	O
.	1922	1923	O

Atopy	1924	1929	O
seems	1930	1935	O
inversely	1936	1945	O
correlated	1946	1956	O
to	1957	1959	O
certain	1960	1967	O
infections	1968	1978	O
.	1978	1979	O

Passive	1980	1987	O
smoking	1988	1995	O
is	1996	1998	O
clearly	1999	2006	O
associated	2007	2017	O
with	2018	2022	O
early	2023	2028	O
wheezing	2029	2037	O
.	2037	2038	O

This	2039	2043	O
and	2044	2047	O
atmospheric	2048	2059	O
pollution	2060	2069	O
aggravate	2070	2079	O
childhood	2080	2089	O
asthma	2090	2096	O
.	2096	2097	O

However	2098	2105	O
,	2105	2106	O
the	2107	2110	O
inducing	2111	2119	O
role	2120	2124	O
of	2125	2127	O
pollution	2128	2137	O
on	2138	2140	O
asthma	2141	2147	O
is	2148	2150	O
still	2151	2156	O
controversial	2157	2170	O
.	2170	2171	O

Novel	0	5	O
mechanism	6	15	O
for	16	19	O
the	20	23	O
impairment	24	34	O
of	35	37	O
cell	38	42	B-Cell
proliferation	43	56	O
in	57	59	O
HIV	60	63	O
-	63	64	O
1	64	65	O
infection	66	75	O
.	75	76	O

The	77	80	O
synthesis	81	90	O
of	91	93	O
ribonucleotides	94	109	O
is	110	112	O
essential	113	122	O
to	123	125	O
cell	126	130	B-Cell
proliferation	131	144	O
.	144	145	O

Defects	146	153	O
in	154	156	O
the	157	160	O
relevant	161	169	O
metabolic	170	179	O
pathways	180	188	O
have	189	193	O
been	194	198	O
demonstrated	199	211	O
in	212	214	O
stimulated	215	225	O
T	226	227	B-Cell
cells	228	233	I-Cell
from	234	238	O
AIDS	239	243	O
patients	244	252	O
and	253	256	O
are	257	260	O
associated	261	271	O
with	272	276	O
lymphocyte	277	287	B-Cell
necrotic	288	296	O
death	297	302	O
.	302	303	O

Here	304	308	O
,	308	309	O
Margarita	310	319	O
Bofill	320	326	O
and	327	330	O
colleagues	331	341	O
discuss	342	349	O
the	350	353	O
possibility	354	365	O
that	366	370	O
an	371	373	O
impaired	374	382	O
ribonucleotide	383	397	O
metabolism	398	408	O
might	409	414	O
be	415	417	O
common	418	424	O
to	425	427	O
all	428	431	O
rapidly	432	439	O
dividing	440	448	O
cells	449	454	B-Cell
and	455	458	O
thus	459	463	O
contribute	464	474	O
to	475	477	O
other	478	483	O
recognized	484	494	O
symptoms	495	503	O
of	504	506	O
HIV	507	510	O
-	510	511	O
1	511	512	O
infection	513	522	O
.	522	523	O

A	0	1	O
pancreatic	2	12	B-Cell
beta	13	17	I-Cell
-	18	19	I-Cell
cell	19	23	I-Cell
-	23	24	O
specific	24	32	O
enhancer	33	41	O
in	42	44	O
the	45	48	O
human	49	54	O
PDX	55	58	O
-	58	59	O
1	59	60	O
gene	61	65	O
is	66	68	O
regulated	69	78	O
by	79	81	O
hepatocyte	82	92	O
nuclear	93	100	O
factor	101	107	O
3beta	108	113	O
(	114	115	O
HNF	115	118	O
-	118	119	O
3beta	119	124	O
)	125	126	O
,	126	127	O
HNF	128	131	O
-	131	132	O
1alpha	132	138	O
,	138	139	O
and	140	143	O
SPs	144	147	O
transcription	148	161	O
factors	162	169	O
.	169	170	O

The	171	174	O
PDX	175	178	O
-	178	179	O
1	179	180	O
transcription	181	194	O
factor	195	201	O
plays	202	207	O
a	208	209	O
key	210	213	O
role	214	218	O
in	219	221	O
pancreas	222	230	B-Organ
development	231	242	O
.	242	243	O

Although	244	252	O
expressed	253	262	O
in	263	265	O
all	266	269	O
cells	270	275	B-Cell
at	276	278	O
the	279	282	O
early	283	288	O
stages	289	295	O
,	295	296	O
in	297	299	O
the	300	303	O
adult	304	309	O
it	310	312	O
is	313	315	O
mainly	316	322	O
restricted	323	333	O
to	334	336	O
the	337	340	O
beta	341	345	B-Cell
-	345	346	I-Cell
cell	346	350	I-Cell
.	350	351	O

To	352	354	O
characterize	355	367	O
the	368	371	O
regulatory	372	382	O
elements	383	391	O
and	392	395	O
potential	396	405	O
transcription	406	419	O
factors	420	427	O
necessary	428	437	O
for	438	441	O
human	442	447	O
PDX	448	451	O
-	451	452	O
1	452	453	O
gene	454	458	O
expression	459	469	O
in	470	472	O
beta	473	477	B-Cell
-	477	478	I-Cell
cells	478	483	I-Cell
,	483	484	O
we	485	487	O
constructed	488	499	O
a	500	501	O
series	502	508	O
of	509	511	O
5	512	513	O
'	513	514	O
and	515	518	O
3	519	520	O
'	520	521	O
deletion	522	530	O
fragments	531	540	O
of	541	543	O
the	544	547	O
5	548	549	O
'	549	550	O
-	550	551	O
flanking	551	559	O
region	560	566	O
of	567	569	O
the	570	573	O
gene	574	578	O
,	578	579	O
fused	580	585	O
to	586	588	O
the	589	592	O
luciferase	593	603	O
reporter	604	612	O
gene	613	617	O
.	617	618	O

In	619	621	O
this	622	626	O
report	627	633	O
,	633	634	O
we	635	637	O
identify	638	646	O
by	647	649	O
transient	650	659	O
transfections	660	673	O
in	674	676	O
beta	677	681	B-Cell
-	681	682	I-Cell
and	683	686	O
non	687	690	B-Cell
-	690	691	I-Cell
beta	691	695	I-Cell
-	695	696	I-Cell
cells	696	701	I-Cell
a	702	703	O
novel	704	709	O
beta	710	714	B-Cell
-	714	715	I-Cell
cell	715	719	I-Cell
-	719	720	O
specific	720	728	O
distal	729	735	O
enhancer	736	744	O
element	745	752	O
located	753	760	O
between	761	768	O
-	769	770	O
3	770	771	O
.	771	772	O
7	772	773	O
and	774	777	O
-	778	779	O
3	779	780	O
.	780	781	O
45	781	783	O
kilobases	784	793	O
.	793	794	O

DNase	795	800	O
I	801	802	O
footprinting	803	815	O
analysis	816	824	O
revealed	825	833	O
two	834	837	O
protected	838	847	O
regions	848	855	O
,	855	856	O
one	857	860	O
binding	861	868	O
the	869	872	O
transcription	873	886	O
factors	887	894	O
SP1	895	898	O
and	899	902	O
SP3	903	906	O
and	907	910	O
the	911	914	O
other	915	920	O
hepatocyte	921	931	O
nuclear	932	939	O
factor	940	946	O
3beta	947	952	O
(	953	954	O
HNF	954	957	O
-	957	958	O
3beta	958	963	O
)	963	964	O
and	965	968	O
HNF	969	972	O
-	972	973	O
1alpha	973	979	O
.	979	980	O

Cotransfection	981	995	O
experiments	996	1007	O
suggest	1008	1015	O
that	1016	1020	O
HNF	1021	1024	O
-	1024	1025	O
3beta	1025	1030	O
,	1030	1031	O
HNF	1032	1035	O
-	1035	1036	O
1alpha	1036	1042	O
,	1042	1043	O
and	1044	1047	O
SP1	1048	1051	O
are	1052	1055	O
positive	1056	1064	O
regulators	1065	1075	O
of	1076	1078	O
the	1079	1082	O
herein	1083	1089	O
-	1089	1090	O
described	1090	1099	O
human	1100	1105	O
PDX	1106	1109	O
-	1109	1110	O
1	1110	1111	O
enhancer	1112	1120	O
element	1121	1128	O
.	1128	1129	O

Furthermore	1130	1141	O
,	1141	1142	O
mutations	1143	1152	O
within	1153	1159	O
each	1160	1164	O
motif	1165	1170	O
abolished	1171	1180	O
the	1181	1184	O
binding	1185	1192	O
of	1193	1195	O
the	1196	1199	O
corresponding	1200	1213	O
factor	1214	1220	O
(	1220	1221	O
s	1221	1222	O
)	1222	1223	O
and	1224	1227	O
dramatically	1228	1240	O
impaired	1241	1249	O
the	1250	1253	O
enhancer	1254	1262	O
activity	1263	1271	O
,	1271	1272	O
therefore	1273	1282	O
suggesting	1283	1293	O
cooperativity	1294	1307	O
between	1308	1315	O
these	1316	1321	O
factors	1322	1329	O
.	1329	1330	O

[	0	1	O
A	1	2	O
decline	3	10	O
in	11	13	O
the	14	17	O
French	18	24	O
demographic	25	36	O
situation	37	46	O
in	47	49	O
the	50	53	O
context	54	61	O
of	62	64	O
a	65	66	O
Europe	67	73	O
also	74	78	O
in	79	81	O
demographic	82	93	O
decline	94	101	O
]	101	102	O
.	102	103	O

The	104	107	O
author	108	114	O
analyzes	115	123	O
the	124	127	O
decline	128	135	O
in	136	138	O
French	139	145	O
fertility	146	155	O
which	156	161	O
has	162	165	O
occurred	166	174	O
over	175	179	O
the	180	183	O
past	184	188	O
two	189	192	O
years	193	198	O
using	199	204	O
data	205	209	O
from	210	214	O
official	215	223	O
sources	224	231	O
.	231	232	O

Some	234	238	O
comparisons	239	250	O
are	251	254	O
made	255	259	O
with	260	264	O
fertility	265	274	O
trends	275	281	O
in	282	284	O
other	285	290	O
European	291	299	O
countries	300	309	O
.	309	310	O

The	0	3	O
patterns	4	12	O
of	13	15	O
internal	16	24	O
migration	25	34	O
in	35	37	O
Maharashtra	38	49	O
:	49	50	O
an	52	54	O
analysis	55	63	O
of	64	66	O
1971	67	71	O
census	72	78	O
data	79	83	O
.	83	84	O

Patterns	85	93	O
of	94	96	O
internal	97	105	O
migration	106	115	O
in	116	118	O
the	119	122	O
state	123	128	O
of	129	131	O
Maharashtra	132	143	O
,	143	144	O
India	145	150	O
,	150	151	O
for	152	155	O
the	156	159	O
period	160	166	O
1961	167	171	O
-	171	172	O
1971	172	176	O
are	177	180	O
analyzed	181	189	O
using	190	195	O
1971	196	200	O
census	201	207	O
data	208	212	O
.	212	213	O

The	215	218	O
nature	219	225	O
,	225	226	O
volume	227	233	O
,	233	234	O
and	235	238	O
direction	239	248	O
of	249	251	O
migration	252	261	O
are	262	265	O
examined	266	274	O
.	274	275	O

Migrants	277	285	O
are	286	289	O
characterized	290	303	O
according	304	313	O
to	314	316	O
factors	317	324	O
including	325	334	O
age	335	338	O
,	338	339	O
sex	340	343	O
,	343	344	O
marital	345	352	O
status	353	359	O
,	359	360	O
occupation	361	371	O
,	371	372	O
and	373	376	O
areas	377	382	O
of	383	385	O
origin	386	392	O
and	393	396	O
destination	397	408	O
.	408	409	O

Deletion	0	8	O
of	9	11	O
guanine	12	19	O
nucleotide	20	30	O
binding	31	38	O
protein	39	46	O
alpha	47	52	O
z	53	54	O
subunit	55	62	O
in	63	65	O
mice	66	70	O
induces	71	78	O
a	79	80	O
gene	81	85	O
dose	86	90	O
dependent	91	100	O
tolerance	101	110	O
to	111	113	O
morphine	114	122	O
.	122	123	O

The	124	127	O
mechanism	128	137	O
underlying	138	148	O
the	149	152	O
development	153	164	O
of	165	167	O
tolerance	168	177	O
to	178	180	O
morphine	181	189	O
is	190	192	O
still	193	198	O
incompletely	199	211	O
understood	212	222	O
.	222	223	O

Morphine	224	232	O
binds	233	238	O
to	239	241	O
opioid	242	248	O
receptors	249	258	O
,	258	259	O
which	260	265	O
in	266	268	O
turn	269	273	O
activates	274	283	O
downstream	284	294	O
second	295	301	O
messenger	302	311	O
cascades	312	320	O
through	321	328	O
heterotrimeric	329	343	O
guanine	344	351	O
nucleotide	352	362	O
binding	363	370	O
proteins	371	379	O
(	380	381	O
G	381	382	O
proteins	383	391	O
)	391	392	O
.	392	393	O

In	394	396	O
this	397	401	O
paper	402	407	O
,	407	408	O
we	409	411	O
show	412	416	O
that	417	421	O
G	422	423	O
(	423	424	O
z	424	425	O
)	425	426	O
,	426	427	O
a	428	429	O
member	430	436	O
of	437	439	O
the	440	443	O
inhibitory	444	454	O
G	455	456	O
protein	457	464	O
family	465	471	O
,	471	472	O
plays	473	478	O
an	479	481	O
important	482	491	O
role	492	496	O
in	497	499	O
mediating	500	509	O
the	510	513	O
analgesic	514	523	O
and	524	527	O
lethality	528	537	O
effects	538	545	O
of	546	548	O
morphine	549	557	O
after	558	563	O
tolerance	564	573	O
development	574	585	O
.	585	586	O

We	587	589	O
blocked	590	597	O
signaling	598	607	O
through	608	615	O
the	616	619	O
G	620	621	O
(	621	622	O
z	622	623	O
)	623	624	O
second	625	631	O
messenger	632	641	O
cascade	642	649	O
by	650	652	O
genetic	653	660	O
ablation	661	669	O
of	670	672	O
the	673	676	O
alpha	677	682	O
subunit	683	690	O
of	691	693	O
the	694	697	O
G	698	699	O
protein	700	707	O
in	708	710	O
mice	711	715	O
.	715	716	O

The	717	720	O
Galpha	721	727	O
(	727	728	O
z	728	729	O
)	729	730	O
knockout	731	739	O
mouse	740	745	O
develops	746	754	O
significantly	755	768	O
increased	769	778	O
tolerance	779	788	O
to	789	791	O
morphine	792	800	O
,	800	801	O
which	802	807	O
depends	808	815	O
on	816	818	O
Galpha	819	825	O
(	825	826	O
z	826	827	O
)	827	828	O
gene	829	833	O
dosage	834	840	O
.	840	841	O

Further	842	849	O
experiments	850	861	O
demonstrate	862	873	O
that	874	878	O
the	879	882	O
enhanced	883	891	O
morphine	892	900	O
tolerance	901	910	O
is	911	913	O
not	914	917	O
caused	918	924	O
by	925	927	O
pharmacokinetic	928	943	O
and	944	947	O
behavioural	948	959	O
learning	960	968	O
mechanisms	969	979	O
.	979	980	O

The	981	984	O
results	985	992	O
suggest	993	1000	O
that	1001	1005	O
G	1006	1007	O
(	1007	1008	O
z	1008	1009	O
)	1009	1010	O
signaling	1011	1020	O
pathways	1021	1029	O
are	1030	1033	O
involved	1034	1042	O
in	1043	1045	O
transducing	1046	1057	O
the	1058	1061	O
analgesic	1062	1071	O
and	1072	1075	O
lethality	1076	1085	O
effects	1086	1093	O
of	1094	1096	O
morphine	1097	1105	O
following	1106	1115	O
chronic	1116	1123	O
morphine	1124	1132	O
treatment	1133	1142	O
.	1142	1143	O

Effects	0	7	O
of	8	10	O
buffer	11	17	O
properties	18	28	O
on	29	31	O
cyclodextrin	32	44	O
glucanotransferase	45	63	O
reactions	64	73	O
and	74	77	O
cyclodextrin	78	90	O
production	91	101	O
from	102	106	O
raw	107	110	O
sago	111	115	O
(	116	117	O
Cycas	117	122	O
revoluta	123	131	O
)	131	132	O
starch	133	139	B-Organism_substance
.	139	140	O

Results	141	148	O
from	149	153	O
the	154	157	O
present	158	165	O
study	166	171	O
have	172	176	O
shown	177	182	O
that	183	187	O
the	188	191	O
ionic	192	197	O
species	198	205	O
of	206	208	O
buffers	209	216	O
,	216	217	O
pH	218	220	O
values	221	227	O
and	228	231	O
reaction	232	240	O
temperature	241	252	O
can	253	256	O
affect	257	263	O
the	264	267	O
enzyme	268	274	O
unit	275	279	O
activities	280	290	O
and	291	294	O
product	295	302	O
specificity	303	314	O
of	315	317	O
Toruzyme	318	326	O
(	327	328	O
Novo	328	332	O
Nordisk	333	340	O
A	341	342	O
/	342	343	O
S	343	344	O
Bagsvaerd	345	354	O
,	354	355	O
Denmark	356	363	O
)	363	364	O
CGTase	365	371	O
(	372	373	O
cyclodextrin	373	385	O
glucanotransferase	386	404	O
)	404	405	O
.	405	406	O

Applying	407	415	O
a	416	417	O
similar	418	425	O
reaction	426	434	O
environment	435	446	O
(	447	448	O
acetate	448	455	O
buffer	456	462	O
,	462	463	O
pH	464	466	O
6	467	468	O
.	468	469	O
0	469	470	O
;	470	471	O
temperature	472	483	O
,	483	484	O
60	485	487	O
degrees	488	495	O
C	496	497	O
)	497	498	O
,	498	499	O
the	500	503	O
CGTase	504	510	O
was	511	514	O
found	515	520	O
to	521	523	O
be	524	526	O
capable	527	534	O
of	535	537	O
producing	538	547	O
pre	548	551	O
dominantly	552	562	O
beta	563	567	O
-	567	568	O
cyclodextrin	568	580	O
from	581	585	O
either	586	592	O
raw	593	596	O
or	597	599	O
gelatinized	600	611	O
sago	612	616	O
(	617	618	O
Cycas	618	623	O
revoluta	624	632	O
)	632	633	O
starch	634	640	B-Organism_substance
.	640	641	O

Changing	642	650	O
the	651	654	O
buffer	655	661	O
from	662	666	O
acetate	667	674	O
to	675	677	O
phosphate	678	687	O
reduced	688	695	O
the	696	699	O
yield	700	705	O
of	706	708	O
beta	709	713	O
-	713	714	O
cyclodextrin	714	726	O
from	727	731	O
2	732	733	O
.	733	734	O
48	734	736	O
to	737	739	O
1	740	741	O
.	741	742	O
42	742	744	O
mg	745	747	O
/	747	748	O
ml	748	750	O
and	751	754	O
also	755	759	O
affected	760	768	O
the	769	772	O
product	773	780	O
specificity	781	792	O
,	792	793	O
where	794	799	O
production	800	810	O
of	811	813	O
both	814	818	O
alpha	819	824	O
-	824	825	O
and	826	829	O
beta	830	834	O
-	834	835	O
cyclodextrins	835	848	O
were	849	853	O
more	854	858	O
pronounced	859	869	O
.	869	870	O

The	871	874	O
decrease	875	883	O
in	884	886	O
the	887	890	O
production	891	901	O
of	902	904	O
cyclodextrins	905	918	O
in	919	921	O
phosphate	922	931	O
buffer	932	938	O
was	939	942	O
significant	943	954	O
at	955	957	O
both	958	962	O
pH	963	965	O
6	966	967	O
.	967	968	O
0	968	969	O
and	970	973	O
7	974	975	O
.	975	976	O
0	976	977	O
.	977	978	O

However	979	986	O
,	986	987	O
changing	988	996	O
the	997	1000	O
buffer	1001	1007	O
to	1008	1010	O
Tris	1011	1015	O
/	1015	1016	O
HCl	1016	1019	O
(	1020	1021	O
pH	1021	1023	O
7	1024	1025	O
.	1025	1026	O
0	1026	1027	O
)	1027	1028	O
showed	1029	1035	O
a	1036	1037	O
significant	1038	1049	O
increase	1050	1058	O
in	1059	1061	O
beta	1062	1066	O
-	1066	1067	O
cyclodextrin	1067	1079	O
production	1080	1090	O
.	1090	1091	O

Increasing	1092	1102	O
the	1103	1106	O
ionic	1107	1112	O
strength	1113	1121	O
of	1122	1124	O
sodium	1125	1131	O
acetate	1132	1139	O
and	1140	1143	O
Tris	1144	1148	O
/	1148	1149	O
HCl	1149	1152	O
buffers	1153	1160	O
at	1161	1163	O
pH	1164	1166	O
6	1167	1168	O
.	1168	1169	O
0	1169	1170	O
and	1171	1174	O
7	1175	1176	O
.	1176	1177	O
0	1177	1178	O
to	1179	1181	O
equivalent	1182	1192	O
ionic	1193	1198	O
strength	1199	1207	O
of	1208	1210	O
phosphate	1211	1220	O
buffers	1221	1228	O
showed	1229	1235	O
no	1236	1238	O
significant	1239	1250	O
effects	1251	1258	O
on	1259	1261	O
cyclodextrin	1262	1274	O
production	1275	1285	O
.	1285	1286	O

Higher	1287	1293	O
yield	1294	1299	O
of	1300	1302	O
cyclodextrins	1303	1316	O
at	1317	1319	O
pH	1320	1322	O
7	1323	1324	O
.	1324	1325	O
0	1325	1326	O
when	1327	1331	O
Tris	1332	1336	O
/	1336	1337	O
HCl	1337	1340	O
was	1341	1344	O
used	1345	1349	O
might	1350	1355	O
be	1356	1358	O
due	1359	1362	O
to	1363	1365	O
the	1366	1369	O
binding	1370	1377	O
of	1378	1380	O
chloride	1381	1389	O
ions	1390	1394	O
at	1395	1397	O
the	1398	1401	O
calcium	1402	1409	O
-	1409	1410	O
binding	1410	1417	O
sites	1418	1423	O
of	1424	1426	O
the	1427	1430	O
CGTase	1431	1437	O
,	1437	1438	O
resulting	1439	1448	O
in	1449	1451	O
the	1452	1455	O
shift	1456	1461	O
of	1462	1464	O
the	1465	1468	O
optimum	1469	1476	O
pH	1477	1479	O
close	1480	1485	O
to	1486	1488	O
physiological	1489	1502	O
environment	1503	1514	O
,	1514	1515	O
leading	1516	1523	O
to	1524	1526	O
an	1527	1529	O
increase	1530	1538	O
in	1539	1541	O
the	1542	1545	O
activities	1546	1556	O
and	1557	1560	O
specificity	1561	1572	O
.	1572	1573	O

Rational	0	8	O
synthesis	9	18	O
of	19	21	O
multicyclic	22	33	O
bis	34	37	O
[	37	38	O
2	38	39	O
]	39	40	O
catenanes	40	49	O
.	49	50	O

Bis	51	54	O
-	54	55	O
loop	55	59	O
tetraurea	60	69	O
calix	70	75	O
[	75	76	O
4	76	77	O
]	77	78	O
arene	78	83	O
6	84	85	O
has	86	89	O
been	90	94	O
prepared	95	103	O
by	104	106	O
acylation	107	116	O
of	117	119	O
the	120	123	O
wide	124	128	O
-	128	129	O
rim	129	132	O
calix	133	138	O
[	138	139	O
4	139	140	O
]	140	141	O
arene	141	146	O
tetraamine	147	157	O
1	158	159	O
with	160	164	O
the	165	168	O
activated	169	178	O
bis	179	182	O
(	182	183	O
urethane	183	191	O
)	191	192	O
8	193	194	O
under	195	200	O
dilution	201	209	O
conditions	210	220	O
.	220	221	O

Similarly	222	231	O
the	232	235	O
bis	236	239	O
(	239	240	O
Boc	240	243	O
-	243	244	O
protected	244	253	O
)	253	254	O
tetraamine	255	265	O
2	266	267	O
is	268	270	O
converted	271	280	O
into	281	285	O
the	286	289	O
mono	290	294	O
-	294	295	O
loop	295	299	O
derivative	300	310	O
3	311	312	O
which	313	318	O
after	319	324	O
deprotection	325	337	O
and	338	341	O
acylation	342	351	O
gives	352	357	O
the	358	361	O
bisalkenyl	362	372	O
derivative	373	383	O
5	384	385	O
.	385	386	O

In	387	389	O
apolar	390	396	O
solvents	397	405	O
this	406	410	O
tetraurea	411	420	O
calix	421	426	O
[	426	427	O
4	427	428	O
]	428	429	O
arene	429	434	O
5	435	436	O
forms	437	442	O
regioselectively	443	459	O
a	460	461	O
single	462	468	O
hydrogen	469	477	O
-	477	478	O
bonded	478	484	O
homodimer	485	494	O
,	494	495	O
from	496	500	O
which	501	506	O
the	507	510	O
bis	511	514	O
[	514	515	O
2	515	516	O
]	516	517	O
catenane	517	525	O
10a	526	529	O
is	530	532	O
formed	533	539	O
in	540	542	O
49	543	545	O
%	545	546	O
by	547	549	O
a	550	551	O
metathesis	552	562	O
reaction	563	571	O
followed	572	580	O
by	581	583	O
hydrogenation	584	597	O
.	597	598	O

Bis	599	602	O
-	602	603	O
loop	603	607	O
derivative	608	618	O
6	619	620	O
forms	621	626	O
no	627	629	O
homodimers	630	640	O
for	641	644	O
steric	645	651	O
reasons	652	659	O
,	659	660	O
but	661	664	O
a	665	666	O
stoichiometric	667	681	O
mixture	682	689	O
with	690	694	O
the	695	698	O
open	699	703	O
-	703	704	O
chain	704	709	O
tetraalkenyl	710	722	O
derivative	723	733	O
7a	734	736	O
contains	737	745	O
exclusively	746	757	O
the	758	761	O
heterodimer	762	773	O
.	773	774	O

Metathesis	775	785	O
and	786	789	O
subsequent	790	800	O
hydrogenation	801	814	O
now	815	818	O
yields	819	825	O
65	826	828	O
%	829	830	O
of	831	833	O
the	834	837	O
pure	838	842	O
bis	843	846	O
[	846	847	O
2	847	848	O
]	848	849	O
catenane	849	857	O
10a	858	861	O
which	862	867	O
could	868	873	O
not	874	877	O
be	878	880	O
isolated	881	889	O
from	890	894	O
the	895	898	O
complex	899	906	O
reaction	907	915	O
mixture	916	923	O
obtained	924	932	O
from	933	937	O
the	938	941	O
homodimer	942	951	O
7a	952	954	O
.	954	955	O
7a	955	957	O
.	957	958	O

The	959	962	O
chirality	963	972	O
of	973	975	O
10a	976	979	O
(	980	981	O
D	981	982	O
(	982	983	O
2	983	984	O
)	984	985	O
symmetry	986	994	O
)	994	995	O
has	996	999	O
been	1000	1004	O
verified	1005	1013	O
by	1014	1016	O
optical	1017	1024	O
resolution	1025	1035	O
using	1036	1041	O
HPLC	1042	1046	O
on	1047	1049	O
a	1050	1051	O
chiral	1052	1058	O
stationary	1059	1069	O
phase	1070	1075	O
.	1075	1076	O

Sciatic	0	7	B-Multi-tissue_structure
nerve	8	13	I-Multi-tissue_structure
repair	14	20	O
by	21	23	O
microgrooved	24	36	O
nerve	37	42	B-Multi-tissue_structure
conduits	43	51	O
made	52	56	O
of	57	59	O
chitosan	60	68	O
-	68	69	O
gold	69	73	O
nanocomposites	74	88	O
.	88	89	O

BACKGROUND	90	100	O
:	100	101	O

To	102	104	O
better	105	111	O
direct	112	118	O
the	119	122	O
repair	123	129	O
of	130	132	O
peripheral	133	143	B-Multi-tissue_structure
nerve	144	149	I-Multi-tissue_structure
after	150	155	O
injury	156	162	O
,	162	163	O
an	164	166	O
implant	167	174	O
consisting	175	185	O
of	186	188	O
a	189	190	O
multicomponent	191	205	O
micropatterned	206	220	O
conduit	221	228	B-Multi-tissue_structure
seeded	229	235	O
with	236	240	O
NSC	241	244	B-Cell
was	245	248	O
designed	249	257	O
.	257	258	O

METHODS	259	266	O
:	266	267	O

The	268	271	O
mechanical	272	282	O
properties	283	293	O
of	294	296	O
the	297	300	O
chi	301	304	O
-	304	305	O
Au	305	307	O
nanocomposites	308	322	O
were	323	327	O
tested	328	334	O
.	334	335	O

In	336	338	O
vitro	339	344	O
,	344	345	O
the	346	349	O
effect	350	356	O
of	357	359	O
chi	360	363	O
-	363	364	O
Au	364	366	O
on	367	369	O
cell	370	374	B-Cell
behavior	375	383	O
(	384	385	O
NSC	385	388	B-Cell
and	389	392	O
glial	393	398	B-Cell
cell	399	403	I-Cell
line	404	408	I-Cell
C6	409	411	I-Cell
)	411	412	O
and	413	416	O
the	417	420	O
influence	421	430	O
of	431	433	O
micropattern	434	446	O
on	447	449	O
cell	450	454	B-Cell
alignment	455	464	O
were	465	469	O
evaluated	470	479	O
.	479	480	O

In	481	483	O
vivo	484	488	O
,	488	489	O
the	490	493	O
micropatterned	494	508	O
conduits	509	517	O
with	518	522	O
/	522	523	O
without	523	530	O
the	531	534	O
preseeded	535	544	O
NSC	545	548	B-Cell
were	549	553	O
implanted	554	563	O
to	564	566	O
bridge	567	573	O
a	574	575	O
10	576	578	O
-	578	579	O
mm	579	581	O
-	581	582	O
long	582	586	O
defect	587	593	O
of	594	596	O
the	597	600	O
sciatic	601	608	B-Multi-tissue_structure
nerve	609	614	I-Multi-tissue_structure
in	615	617	O
9	618	619	O
male	620	624	O
Sprague	625	632	O
-	632	633	O
Dawley	633	639	O
rats	640	644	O
.	644	645	O

The	646	649	O
repair	650	656	O
outcome	657	664	O
was	665	668	O
investigated	669	681	O
6	682	683	O
weeks	684	689	O
after	690	695	O
the	696	699	O
surgery	700	707	O
.	707	708	O

RESULTS	709	716	O
:	716	717	O

Based	718	723	O
on	724	726	O
the	727	730	O
dynamic	731	738	O
modulus	739	746	O
,	746	747	O
chitosan	748	756	O
with	757	761	O
50	762	764	O
ppm	765	768	O
or	769	771	O
more	772	776	O
gold	777	781	O
was	782	785	O
a	786	787	O
stronger	788	796	O
material	797	805	O
than	806	810	O
others	811	817	O
.	817	818	O

In	819	821	O
vitro	822	827	O
,	827	828	O
gold	829	833	O
at	834	836	O
25	837	839	O
or	840	842	O
50	843	845	O
ppm	846	849	O
led	850	853	O
to	854	856	O
better	857	863	O
cell	864	868	B-Cell
performance	869	880	O
for	881	884	O
NSC	885	888	B-Cell
;	888	889	O
and	890	893	O
gold	894	898	O
at	899	901	O
50	902	904	O
ppm	905	908	O
gave	909	913	O
better	914	920	O
cell	921	925	B-Cell
performance	926	937	O
for	938	941	O
C6	942	944	B-Cell
.	944	945	O

On	946	948	O
the	949	952	O
microgrooved	953	965	O
substrate	966	975	O
,	975	976	O
the	977	980	O
NSC	981	984	B-Cell
had	985	988	O
elongated	989	998	O
processes	999	1008	O
oriented	1009	1017	O
parallel	1018	1026	O
to	1027	1029	O
the	1030	1033	O
grooves	1034	1041	O
,	1041	1042	O
whereas	1043	1050	O
the	1051	1054	O
NSC	1055	1058	B-Cell
on	1059	1061	O
the	1062	1065	O
nonpatterned	1066	1078	O
surfaces	1079	1087	O
did	1088	1091	O
not	1092	1095	O
exhibit	1096	1103	O
a	1104	1105	O
particular	1106	1116	O
bias	1117	1121	O
in	1122	1124	O
alignment	1125	1134	O
.	1134	1135	O

In	1136	1138	O
vivo	1139	1143	O
,	1143	1144	O
the	1145	1148	O
number	1149	1155	O
of	1156	1158	O
regenerated	1159	1170	O
axons	1171	1176	O
,	1176	1177	O
the	1178	1181	O
regenerated	1182	1193	O
area	1194	1198	O
,	1198	1199	O
and	1200	1203	O
the	1204	1207	O
number	1208	1214	O
of	1215	1217	O
blood	1218	1223	B-Multi-tissue_structure
vessels	1224	1231	I-Multi-tissue_structure
were	1232	1236	O
significantly	1237	1250	O
higher	1251	1257	O
in	1258	1260	O
the	1261	1264	O
NSC	1265	1268	B-Cell
-	1268	1269	O
preseeded	1269	1278	O
conduit	1279	1286	O
.	1286	1287	O

CONCLUSION	1288	1298	O
:	1298	1299	O

Modification	1300	1312	O
of	1313	1315	O
the	1316	1319	O
chitosan	1320	1328	O
matrix	1329	1335	O
by	1336	1338	O
gold	1339	1343	O
nanoparticles	1344	1357	O
not	1358	1361	O
only	1362	1366	O
provides	1367	1375	O
the	1376	1379	O
mechanical	1380	1390	O
strength	1391	1399	O
but	1400	1403	O
also	1404	1408	O
affects	1409	1416	O
the	1417	1420	O
cellular	1421	1429	B-Cell
response	1430	1438	O
.	1438	1439	O

The	1440	1443	O
preliminary	1444	1455	O
in	1456	1458	O
vivo	1459	1463	O
data	1464	1468	O
demonstrated	1469	1481	O
that	1482	1486	O
the	1487	1490	O
biodegradable	1491	1504	O
micropatterned	1505	1519	O
conduits	1520	1528	O
preseeded	1529	1538	O
with	1539	1543	O
NSC	1544	1547	B-Cell
provided	1548	1556	O
a	1557	1558	O
combination	1559	1570	O
of	1571	1573	O
physical	1574	1582	O
and	1583	1586	O
biological	1587	1597	O
guidance	1598	1606	O
cues	1607	1611	O
for	1612	1615	O
regenerating	1616	1628	O
axons	1629	1634	B-Cellular_component
at	1635	1637	O
the	1638	1641	O
cellular	1642	1650	B-Cell
level	1651	1656	O
and	1657	1660	O
offered	1661	1668	O
a	1669	1670	O
better	1671	1677	O
alternative	1678	1689	O
for	1690	1693	O
repairing	1694	1703	O
sciatic	1704	1711	B-Multi-tissue_structure
nerve	1712	1717	I-Multi-tissue_structure
transactions	1718	1730	O
.	1730	1731	O

[	0	1	O
The	1	4	O
clinical	5	13	O
and	14	17	O
laboratory	18	28	O
features	29	37	O
of	38	40	O
acute	41	46	O
promyelocytic	47	60	O
leukemia	61	69	O
:	69	70	O
an	71	73	O
analysis	74	82	O
of	83	85	O
513	86	89	O
cases	90	95	O
]	95	96	O
.	96	97	O

OBJECTIVE	98	107	O
:	107	108	O

To	109	111	O
investigate	112	123	O
the	124	127	O
clinical	128	136	O
and	137	140	O
laboratory	141	151	O
features	152	160	O
of	161	163	O
acute	164	169	O
promyelocytic	170	183	O
leukemia	184	192	O
(	193	194	O
APL	194	197	O
)	197	198	O
.	198	199	O

METHODS	200	207	O
:	207	208	O

513	209	212	O
APL	213	216	O
patients	217	225	O
in	226	228	O
the	229	232	O
last	233	237	O
two	238	241	O
decades	242	249	O
were	250	254	O
retrospectively	255	270	O
analyzed	271	279	O
in	280	282	O
this	283	287	O
research	288	296	O
.	296	297	O

We	298	300	O
investigated	301	313	O
the	314	317	O
clinical	318	326	O
features	327	335	O
including	336	345	O
age	346	349	O
,	349	350	O
sex	351	354	O
,	354	355	O
abnormality	356	367	O
of	368	370	O
peripheral	371	381	O
hemogram	382	390	O
before	391	397	O
treatment	398	407	O
,	407	408	O
therapeutic	409	420	O
effect	421	427	O
and	428	431	O
follow	432	438	O
-	438	439	O
up	439	441	O
and	442	445	O
laboratory	446	456	O
data	457	461	O
such	462	466	O
as	467	469	O
morphology	470	480	O
,	480	481	O
immunology	482	492	O
,	492	493	O
cytogenetics	494	506	O
and	507	510	O
molecular	511	520	O
biology	521	528	O
(	529	530	O
MICM	530	534	O
)	534	535	O
.	535	536	O

RESULTS	537	544	O
:	544	545	O

The	546	549	O
median	550	556	O
age	557	560	O
of	561	563	O
the	564	567	O
APL	568	571	O
patients	572	580	O
was	581	584	O
33	585	587	O
years	588	593	O
old	594	597	O
and	598	601	O
the	602	605	O
ratio	606	611	O
of	612	614	O
male	615	619	O
and	620	623	O
female	624	630	O
was	631	634	O
1	635	636	O
.	636	637	O
21	637	639	O
:	639	640	O
1	640	641	O
.	641	642	O

Before	643	649	O
treatment	650	659	O
,	659	660	O
the	661	664	O
median	665	671	O
level	672	677	O
of	678	680	O
WBC	681	684	B-Cell
was	685	688	O
4	689	690	O
.	690	691	O
3	691	692	O
x	693	694	O
10	695	697	O
(	697	698	O
9	698	699	O
)	699	700	O
/	700	701	O
L	701	702	O
and	703	706	O
the	707	710	O
detection	711	720	O
rate	721	725	O
of	726	728	O
abnormal	729	737	O
promyelocyte	738	750	B-Cell
on	751	753	O
blood	754	759	B-Organism_substance
film	760	764	O
was	765	768	O
85	769	771	O
.	771	772	O
8	772	773	O
%	773	774	O
;	774	775	O
with	776	780	O
immunophenotypic	781	797	O
detection	798	807	O
,	807	808	O
the	809	812	O
expression	813	823	O
levels	824	830	O
of	831	833	O
CD117	834	839	O
,	839	840	O
CD34	841	845	O
,	845	846	O
HLA	847	850	O
-	850	851	O
DR	851	853	O
,	853	854	O
CD7	855	858	O
,	858	859	O
CD14	860	864	O
and	865	868	O
CD19	869	873	O
in	874	876	O
APL	877	880	O
were	881	885	O
found	886	891	O
to	892	894	O
be	895	897	O
lower	898	903	O
and	904	907	O
the	908	911	O
expression	912	922	O
levels	923	929	O
of	930	932	O
CD2	933	936	O
,	936	937	O
CD33	938	942	O
and	943	946	O
MPO	947	950	O
higher	951	957	O
than	958	962	O
those	963	968	O
in	969	971	O
other	972	977	O
subtypes	978	986	O
of	987	989	O
acute	990	995	O
myelocytic	996	1006	O
leukemia	1007	1015	O
(	1016	1017	O
AML	1017	1020	O
)	1020	1021	O
(	1022	1023	O
both	1023	1027	O
P	1028	1029	O
<	1030	1031	O
0	1032	1033	O
.	1033	1034	O
01	1034	1036	O
)	1036	1037	O
.	1037	1038	O

Specific	1039	1047	O
abnormal	1048	1056	O
chromosome	1057	1067	B-Cellular_component
t	1068	1069	O
(	1070	1071	O
15	1071	1073	O
;	1073	1074	O
17	1074	1076	O
)	1076	1077	O
was	1078	1081	O
detected	1082	1090	O
in	1091	1093	O
91	1094	1096	O
.	1096	1097	O
7	1097	1098	O
%	1098	1099	O
of	1100	1102	O
the	1103	1106	O
patients	1107	1115	O
,	1115	1116	O
of	1117	1119	O
whom	1120	1124	O
75	1125	1127	O
.	1127	1128	O
9	1128	1129	O
%	1129	1130	O
had	1131	1134	O
standard	1135	1143	O
translocation	1144	1157	O
of	1158	1160	O
t	1161	1162	O
(	1163	1164	O
15	1164	1166	O
;	1166	1167	O
17	1167	1169	O
)	1169	1170	O
,	1170	1171	O
being	1172	1177	O
the	1178	1181	O
most	1182	1186	O
common	1187	1193	O
one	1194	1197	O
and	1198	1201	O
15	1202	1204	O
.	1204	1205	O
8	1205	1206	O
%	1206	1207	O
of	1208	1210	O
the	1211	1214	O
patients	1215	1223	O
had	1224	1227	O
t	1228	1229	O
(	1230	1231	O
15	1231	1233	O
;	1233	1234	O
17	1234	1236	O
)	1236	1237	O
with	1238	1242	O
additional	1243	1253	O
abnormal	1254	1262	O
chromosome	1263	1273	B-Cellular_component
.	1273	1274	O

There	1275	1280	O
was	1281	1284	O
only	1285	1289	O
7	1290	1291	O
.	1291	1292	O
5	1292	1293	O
%	1293	1294	O
of	1295	1297	O
the	1298	1301	O
patients	1302	1310	O
with	1311	1315	O
normal	1316	1322	O
karyotype	1323	1332	O
.	1332	1333	O

However	1334	1341	O
,	1341	1342	O
the	1343	1346	O
presence	1347	1355	O
of	1356	1358	O
both	1359	1363	O
simple	1364	1370	O
translocation	1371	1384	O
and	1385	1388	O
complex	1389	1396	O
translocation	1397	1410	O
was	1411	1414	O
seldom	1415	1421	O
seen	1422	1426	O
.	1426	1427	O

With	1428	1432	O
molecular	1433	1442	O
biological	1443	1453	O
detection	1454	1463	O
,	1463	1464	O
PML	1465	1468	O
/	1468	1469	O
RARalpha	1469	1477	O
fusion	1478	1484	O
gene	1485	1489	O
positive	1490	1498	O
rate	1499	1503	O
was	1504	1507	O
99	1508	1510	O
.	1510	1511	O
6	1511	1512	O
%	1512	1513	O
.	1513	1514	O

In	1515	1517	O
a	1518	1519	O
relatively	1520	1530	O
long	1531	1535	O
clinical	1536	1544	O
follow	1545	1551	O
-	1551	1552	O
up	1552	1554	O
,	1554	1555	O
we	1556	1558	O
found	1559	1564	O
that	1565	1569	O
the	1570	1573	O
complete	1574	1582	O
remission	1583	1592	O
(	1593	1594	O
CR	1594	1596	O
)	1596	1597	O
rate	1598	1602	O
in	1603	1605	O
APL	1606	1609	O
patients	1610	1618	O
was	1619	1622	O
84	1623	1625	O
.	1625	1626	O
7	1626	1627	O
%	1627	1628	O
,	1628	1629	O
incidence	1630	1639	O
of	1640	1642	O
DIC	1643	1646	O
was	1647	1650	O
13	1651	1653	O
.	1653	1654	O
4	1654	1655	O
%	1655	1656	O
and	1657	1660	O
five	1661	1665	O
-	1665	1666	O
year	1666	1670	O
survival	1671	1679	O
rate	1680	1684	O
was	1685	1688	O
30	1689	1691	O
.	1691	1692	O
7	1692	1693	O
%	1693	1694	O
.	1694	1695	O

The	1696	1699	O
median	1700	1706	O
count	1707	1712	O
of	1713	1715	O
WBC	1716	1719	B-Cell
in	1720	1722	O
CR	1723	1725	O
group	1726	1731	O
was	1732	1735	O
lower	1736	1741	O
than	1742	1746	O
that	1747	1751	O
non	1752	1755	O
-	1755	1756	O
remission	1756	1765	O
group	1766	1771	O
(	1772	1773	O
P	1773	1774	O
<	1775	1776	O
0	1777	1778	O
.	1778	1779	O
01	1779	1781	O
)	1781	1782	O
.	1782	1783	O

There	1784	1789	O
were	1790	1794	O
no	1795	1797	O
significant	1798	1809	O
differences	1810	1821	O
on	1822	1824	O
expressions	1825	1836	O
of	1837	1839	O
CD34	1840	1844	O
and	1845	1848	O
CD2	1849	1852	O
and	1853	1856	O
changes	1857	1864	O
of	1865	1867	O
cytogenetics	1868	1880	O
between	1881	1888	O
the	1889	1892	O
two	1893	1896	O
groups	1897	1903	O
(	1904	1905	O
P	1905	1906	O
>	1907	1908	O
0	1909	1910	O
.	1910	1911	O
05	1911	1913	O
)	1913	1914	O
.	1914	1915	O

CONCLUSIONS	1916	1927	O
:	1927	1928	O

Comprehensive	1929	1942	O
evaluation	1943	1953	O
of	1954	1956	O
MICM	1957	1961	O
could	1962	1967	O
be	1968	1970	O
of	1971	1973	O
important	1974	1983	O
significance	1984	1996	O
in	1997	1999	O
the	2000	2003	O
diagnosis	2004	2013	O
and	2014	2017	O
prognosis	2018	2027	O
judgment	2028	2036	O
for	2037	2040	O
APL	2041	2044	O
patients	2045	2053	O
.	2053	2054	O

The	2055	2058	O
CR	2059	2061	O
rate	2062	2066	O
in	2067	2069	O
these	2070	2075	O
patients	2076	2084	O
with	2085	2089	O
high	2090	2094	O
WBC	2095	2098	B-Cell
count	2099	2104	O
was	2105	2108	O
considerable	2109	2121	O
low	2122	2125	O
.	2125	2126	O

Cognitive	0	9	O
function	10	18	O
and	19	22	O
number	23	29	O
of	30	32	O
teeth	33	38	B-Organ
in	39	41	O
a	42	43	O
community	44	53	O
-	53	54	O
dwelling	54	62	O
elderly	63	70	O
population	71	81	O
without	82	89	O
dementia	90	98	O
.	98	99	O

Although	100	108	O
the	109	112	O
number	113	119	O
of	120	122	O
sound	123	128	O
or	129	131	O
decayed	132	139	O
teeth	140	145	B-Organ
has	146	149	O
been	150	154	O
reported	155	163	O
to	164	166	O
be	167	169	O
associated	170	180	O
with	181	185	O
cognitive	186	195	O
function	196	204	O
in	205	207	O
elderly	208	215	O
populations	216	227	O
with	228	232	O
dementia	233	241	O
,	241	242	O
little	243	249	O
is	250	252	O
known	253	258	O
about	259	264	O
this	265	269	O
association	270	281	O
in	282	284	O
elderly	285	292	O
populations	293	304	O
without	305	312	O
dementia	313	321	O
.	321	322	O

We	323	325	O
evaluated	326	335	O
this	336	340	O
relationship	341	353	O
,	353	354	O
with	355	359	O
adjustment	360	370	O
for	371	374	O
confounding	375	386	O
factors	387	394	O
,	394	395	O
in	396	398	O
Japanese	399	407	O
populations	408	419	O
of	420	422	O
60	423	425	O
-	425	426	O
year	426	430	O
-	430	431	O
old	431	434	O
(	435	436	O
n	436	437	O
=	438	439	O
270	440	443	O
;	443	444	O
120	445	448	O
males	449	454	O
and	455	458	O
150	459	462	O
females	463	470	O
)	470	471	O
and	472	475	O
65	476	478	O
-	478	479	O
year	479	483	O
-	483	484	O
old	484	487	O
(	488	489	O
n	489	490	O
=	491	492	O
123	493	496	O
;	496	497	O
57	498	500	O
males	501	506	O
and	507	510	O
66	511	513	O
females	514	521	O
)	521	522	O
individuals	523	534	O
residing	535	543	O
in	544	546	O
Fukuoka	547	554	O
Prefecture	555	565	O
of	566	568	O
Japan	569	574	O
.	574	575	O

Dental	576	582	O
examinations	583	595	O
were	596	600	O
performed	601	610	O
in	611	613	O
all	614	617	O
subjects	618	626	O
,	626	627	O
along	628	633	O
with	634	638	O
the	639	642	O
Mini	643	647	O
-	647	648	O
mental	648	654	O
state	655	660	O
examination	661	672	O
(	673	674	O
MMSE	674	678	O
)	678	679	O
for	680	683	O
assessing	684	693	O
cognitive	694	703	O
function	704	712	O
.	712	713	O

Among	714	719	O
the	720	723	O
total	724	729	O
of	730	732	O
393	733	736	O
subjects	737	745	O
,	745	746	O
the	747	750	O
mean	751	755	O
MMSE	756	760	O
score	761	766	O
was	767	770	O
27	771	773	O
.	773	774	O
9	774	775	O
+	776	777	O
/	777	778	O
-	778	779	O
1	780	781	O
.	781	782	O
9	782	783	O
,	783	784	O
and	785	788	O
391	789	792	O
subjects	793	801	O
scored	802	808	O
24	809	811	O
or	812	814	O
higher	815	821	O
.	821	822	O

The	823	826	O
mean	827	831	O
numbers	832	839	O
of	840	842	O
sound	843	848	O
and	849	852	O
decayed	853	860	O
teeth	861	866	B-Organ
were	867	871	O
12	872	874	O
.	874	875	O
0	875	876	O
+	877	878	O
/	878	879	O
-	879	880	O
6	881	882	O
.	882	883	O
3	883	884	O
and	885	888	O
0	889	890	O
.	890	891	O
5	891	892	O
+	893	894	O
/	894	895	O
-	895	896	O
1	897	898	O
.	898	899	O
2	899	900	O
,	900	901	O
respectively	902	914	O
.	914	915	O

Associations	916	928	O
were	929	933	O
found	934	939	O
between	940	947	O
the	948	951	O
numbers	952	959	O
of	960	962	O
sound	963	968	O
and	969	972	O
decayed	973	980	O
teeth	981	986	B-Organ
and	987	990	O
MMSE	991	995	O
in	996	998	O
total	999	1004	O
subjects	1005	1013	O
and	1014	1017	O
males	1018	1023	O
,	1023	1024	O
but	1025	1028	O
not	1029	1032	O
in	1033	1035	O
females	1036	1043	O
,	1043	1044	O
by	1045	1047	O
multiple	1048	1056	O
regression	1057	1067	O
analysis	1068	1076	O
adjusted	1077	1085	O
for	1086	1089	O
gender	1090	1096	O
,	1096	1097	O
age	1098	1101	O
,	1101	1102	O
level	1103	1108	O
of	1109	1111	O
education	1112	1121	O
,	1121	1122	O
marital	1123	1130	O
status	1131	1137	O
,	1137	1138	O
smoking	1139	1146	O
,	1146	1147	O
alcohol	1148	1155	O
drinking	1156	1164	O
,	1164	1165	O
working	1166	1173	O
status	1174	1180	O
,	1180	1181	O
systolic	1182	1190	O
blood	1191	1196	B-Organism_substance
pressure	1197	1205	O
and	1206	1209	O
blood	1210	1215	B-Organism_substance
glucose	1216	1223	O
.	1223	1224	O

An	1225	1227	O
association	1228	1239	O
was	1240	1243	O
also	1244	1248	O
found	1249	1254	O
between	1255	1262	O
MMSE	1263	1267	O
and	1268	1271	O
the	1272	1275	O
number	1276	1282	O
of	1283	1285	O
sound	1286	1291	O
teeth	1292	1297	B-Organ
in	1298	1300	O
a	1301	1302	O
logistic	1303	1311	O
regression	1312	1322	O
analysis	1323	1331	O
.	1331	1332	O

In	1333	1335	O
conclusion	1336	1346	O
,	1346	1347	O
associations	1348	1360	O
were	1361	1365	O
found	1366	1371	O
between	1372	1379	O
normal	1380	1386	O
-	1386	1387	O
range	1387	1392	O
cognitive	1393	1402	O
function	1403	1411	O
and	1412	1415	O
the	1416	1419	O
numbers	1420	1427	O
of	1428	1430	O
sound	1431	1436	O
and	1437	1440	O
decayed	1441	1448	O
teeth	1449	1454	B-Organ
,	1454	1455	O
after	1456	1461	O
adjustment	1462	1472	O
for	1473	1476	O
various	1477	1484	O
confounding	1485	1496	O
factors	1497	1504	O
,	1504	1505	O
in	1506	1508	O
an	1509	1511	O
elderly	1512	1519	O
Japanese	1520	1528	O
population	1529	1539	O
.	1539	1540	O

Comment	0	7	O
on	8	10	O
"	11	12	O
Why	12	15	O
reduced	16	23	O
-	23	24	O
form	24	28	O
regression	29	39	O
models	40	46	O
of	47	49	O
health	50	56	O
effects	57	64	O
versus	65	71	O
exposures	72	81	O
should	82	88	O
not	89	92	O
replace	93	100	O
QRA	101	104	O
:	104	105	O
livestock	106	115	O
production	116	126	O
and	127	130	O
infant	131	137	O
mortality	138	147	O
as	148	150	O
an	151	153	O
example	154	161	O
,	161	162	O
"	162	163	O
by	164	166	O
Louis	167	172	O
Anthony	173	180	O
(	181	182	O
Tony	182	186	O
)	186	187	O
Cox	188	191	O
,	191	192	O
Jr	193	195	O
.	195	196	O
,	196	197	O
Risk	198	202	O
Analysis	203	211	O
2009	212	216	O
,	216	217	O
Vol	218	221	O
.	221	222	O

29	223	225	O
,	225	226	O
No	227	229	O
.	229	230	O
12	231	233	O
.	233	234	O

While	235	240	O
a	241	242	O
recent	243	249	O
paper	250	255	O
by	256	258	O
Cox	259	262	O
in	263	265	O
this	266	270	O
journal	271	278	O
uses	279	283	O
as	284	286	O
its	287	290	O
motivating	291	301	O
factor	302	308	O
the	309	312	O
benefits	313	321	O
of	322	324	O
quantitative	325	337	O
risk	338	342	O
assessment	343	353	O
,	353	354	O
its	355	358	O
content	359	366	O
is	367	369	O
entirely	370	378	O
devoted	379	386	O
to	387	389	O
critiquing	390	400	O
Sneeringer	401	411	O
'	411	412	O
s	412	413	O
article	414	421	O
in	422	424	O
the	425	428	O
American	429	437	O
Journal	438	445	O
of	446	448	O
Agricultural	449	461	O
Economics	462	471	O
.	471	472	O

Cox	473	476	O
'	476	477	O
s	477	478	O
two	479	482	O
main	483	487	O
critiques	488	497	O
of	498	500	O
Sneeringer	501	511	O
are	512	515	O
fundamentally	516	529	O
flawed	530	536	O
and	537	540	O
misrepresent	541	553	O
the	554	557	O
original	558	566	O
article	567	574	O
.	574	575	O

Cox	576	579	O
posits	580	586	O
that	587	591	O
Sneeringer	592	602	O
did	603	606	O
A	607	608	O
and	609	612	O
B	613	614	O
,	614	615	O
and	616	619	O
then	620	624	O
argues	625	631	O
why	632	635	O
A	636	637	O
and	638	641	O
B	642	643	O
are	644	647	O
incorrect	648	657	O
.	657	658	O

However	659	666	O
,	666	667	O
Sneeringer	668	678	O
in	679	681	O
fact	682	686	O
did	687	690	O
C	691	692	O
and	693	696	O
D	697	698	O
;	698	699	O
thus	700	704	O
critiques	705	714	O
of	715	717	O
A	718	719	O
and	720	723	O
B	724	725	O
are	726	729	O
not	730	733	O
applicable	734	744	O
to	745	747	O
Sneeringer	748	758	O
'	758	759	O
s	759	760	O
analysis	761	769	O
.	769	770	O

Prognostic	0	10	O
significance	11	23	O
of	24	26	O
TRAIL	27	32	O
signaling	33	42	O
molecules	43	52	O
in	53	55	O
stage	56	61	B-Pathological_formation
II	62	64	I-Pathological_formation
and	65	68	I-Pathological_formation
III	69	72	I-Pathological_formation
colorectal	73	83	I-Pathological_formation
cancer	84	90	I-Pathological_formation
.	90	91	O

PURPOSE	92	99	O
:	99	100	O

We	101	103	O
previously	104	114	O
found	115	120	O
that	121	125	O
cellular	126	134	O
FLICE	135	140	O
-	140	141	O
inhibitory	141	151	O
protein	152	159	O
(	160	161	O
c	161	162	O
-	162	163	O
FLIP	163	167	O
)	167	168	O
,	168	169	O
caspase	170	177	O
8	178	179	O
,	179	180	O
and	181	184	O
tumor	185	190	O
necrosis	191	199	O
factor	200	206	O
-	206	207	O
related	207	214	O
apoptosis	215	224	O
-	224	225	O
inducing	225	233	O
ligand	234	240	O
(	241	242	O
TRAIL	242	247	O
)	247	248	O
receptor	249	257	O
2	258	259	O
(	260	261	O
DR5	261	264	O
)	264	265	O
are	266	269	O
major	270	275	O
regulators	276	286	O
of	287	289	O
cell	290	294	B-Cell
viability	295	304	O
and	305	308	O
chemotherapy	309	321	O
-	321	322	O
induced	322	329	O
apoptosis	330	339	O
in	340	342	O
colorectal	343	353	B-Pathological_formation
cancer	354	360	I-Pathological_formation
.	360	361	O

In	362	364	O
this	365	369	O
study	370	375	O
,	375	376	O
we	377	379	O
determined	380	390	O
the	391	394	O
prognostic	395	405	O
significance	406	418	O
of	419	421	O
c	422	423	O
-	423	424	O
FLIP	424	428	O
,	428	429	O
caspase	430	437	O
8	438	439	O
,	439	440	O
TRAIL	441	446	O
and	447	450	O
DR5	451	454	O
expression	455	465	O
in	466	468	O
tissues	469	476	B-Tissue
from	477	481	O
patients	482	490	O
with	491	495	O
stage	496	501	B-Pathological_formation
II	502	504	I-Pathological_formation
and	505	508	I-Pathological_formation
III	509	512	I-Pathological_formation
colorectal	513	523	I-Pathological_formation
cancer	524	530	I-Pathological_formation
.	530	531	O

EXPERIMENTAL	532	544	O
DESIGN	545	551	O
:	551	552	O

Tissue	553	559	B-Tissue
microarrays	560	571	O
were	572	576	O
constructed	577	588	O
from	589	593	O
matched	594	601	O
normal	602	608	B-Tissue
and	609	612	O
tumor	613	618	B-Tissue
tissue	619	625	I-Tissue
derived	626	633	O
from	634	638	O
patients	639	647	O
(	648	649	O
n	649	650	O
=	651	652	O
253	653	656	O
)	656	657	O
enrolled	658	666	O
in	667	669	O
a	670	671	O
phase	672	677	O
III	678	681	O
trial	682	687	O
of	688	690	O
adjuvant	691	699	O
5	700	701	O
-	701	702	O
fluorouracil	702	714	O
-	714	715	O
based	715	720	O
chemotherapy	721	733	O
versus	734	740	O
postoperative	741	754	O
observation	755	766	O
alone	767	772	O
.	772	773	O

TRAIL	774	779	O
,	779	780	O
DR5	781	784	O
,	784	785	O
caspase	786	793	O
8	794	795	O
,	795	796	O
and	797	800	O
c	801	802	O
-	802	803	O
FLIP	803	807	O
expression	808	818	O
levels	819	825	O
were	826	830	O
determined	831	841	O
by	842	844	O
immunohistochemistry	845	865	O
.	865	866	O

RESULTS	867	874	O
:	874	875	O

Colorectal	876	886	B-Pathological_formation
tumors	887	893	I-Pathological_formation
displayed	894	903	O
significantly	904	917	O
higher	918	924	O
expression	925	935	O
levels	936	942	O
of	943	945	O
c	946	947	O
-	947	948	O
FLIP	948	952	O
(	953	954	O
P	954	955	O
<	956	957	O
0	958	959	O
.	959	960	O
001	960	963	O
)	963	964	O
,	964	965	O
caspase	966	973	O
8	974	975	O
(	976	977	O
P	977	978	O
=	979	980	O
0	981	982	O
.	982	983	O
01	983	985	O
)	985	986	O
,	986	987	O
and	988	991	O
DR5	992	995	O
(	996	997	O
P	997	998	O
<	999	1000	O
0	1001	1002	O
.	1002	1003	O
001	1003	1006	O
)	1006	1007	O
,	1007	1008	O
but	1009	1012	O
lower	1013	1018	O
levels	1019	1025	O
of	1026	1028	O
TRAIL	1029	1034	O
(	1035	1036	O
P	1036	1037	O
<	1038	1039	O
0	1040	1041	O
.	1041	1042	O
001	1042	1045	O
)	1045	1046	O
compared	1047	1055	O
with	1056	1060	O
matched	1061	1068	O
normal	1069	1075	B-Tissue
tissue	1076	1082	I-Tissue
.	1082	1083	O

In	1084	1086	O
univariate	1087	1097	O
analysis	1098	1106	O
,	1106	1107	O
higher	1108	1114	O
TRAIL	1115	1120	O
expression	1121	1131	O
in	1132	1134	O
the	1135	1138	O
tumor	1139	1144	B-Pathological_formation
was	1145	1148	O
associated	1149	1159	O
with	1160	1164	O
worse	1165	1170	O
overall	1171	1178	O
survival	1179	1187	O
(	1188	1189	O
P	1189	1190	O
=	1191	1192	O
0	1193	1194	O
.	1194	1195	O
026	1195	1198	O
)	1198	1199	O
,	1199	1200	O
with	1201	1205	O
a	1206	1207	O
trend	1208	1213	O
to	1214	1216	O
decreased	1217	1226	O
relapse	1227	1234	O
-	1234	1235	O
free	1235	1239	O
survival	1240	1248	O
(	1249	1250	O
RFS	1250	1253	O
;	1253	1254	O
P	1255	1256	O
=	1257	1258	O
0	1259	1260	O
.	1260	1261	O
06	1261	1263	O
)	1263	1264	O
,	1264	1265	O
and	1266	1269	O
higher	1270	1276	O
tumor	1277	1282	B-Pathological_formation
c	1283	1284	O
-	1284	1285	O
FLIP	1285	1289	O
expression	1290	1300	O
was	1301	1304	O
associated	1305	1315	O
with	1316	1320	O
a	1321	1322	O
significantly	1323	1336	O
decreased	1337	1346	O
RFS	1347	1350	O
(	1351	1352	O
P	1352	1353	O
=	1354	1355	O
0	1356	1357	O
.	1357	1358	O
015	1358	1361	O
)	1361	1362	O
.	1362	1363	O

Using	1364	1369	O
multivariate	1370	1382	O
predictive	1383	1393	O
modeling	1394	1402	O
for	1403	1406	O
RFS	1407	1410	O
in	1411	1413	O
all	1414	1417	O
patients	1418	1426	O
and	1427	1430	O
including	1431	1440	O
all	1441	1444	O
biomarkers	1445	1455	O
,	1455	1456	O
age	1457	1460	O
,	1460	1461	O
treatment	1462	1471	O
,	1471	1472	O
and	1473	1476	O
stage	1477	1482	O
,	1482	1483	O
we	1484	1486	O
found	1487	1492	O
that	1493	1497	O
the	1498	1501	O
model	1502	1507	O
was	1508	1511	O
significant	1512	1523	O
when	1524	1528	O
the	1529	1532	O
mean	1533	1537	O
tumor	1538	1543	B-Pathological_formation
c	1544	1545	O
-	1545	1546	O
FLIP	1546	1550	O
expression	1551	1561	O
score	1562	1567	O
and	1568	1571	O
disease	1572	1579	O
stage	1580	1585	O
were	1586	1590	O
included	1591	1599	O
(	1600	1601	O
P	1601	1602	O
<	1603	1604	O
0	1605	1606	O
.	1606	1607	O
001	1607	1610	O
)	1610	1611	O
.	1611	1612	O

As	1613	1615	O
regards	1616	1623	O
overall	1624	1631	O
survival	1632	1640	O
,	1640	1641	O
the	1642	1645	O
overall	1646	1653	O
model	1654	1659	O
was	1660	1663	O
predictive	1664	1674	O
when	1675	1679	O
both	1680	1684	O
TRAIL	1685	1690	O
expression	1691	1701	O
and	1702	1705	O
disease	1706	1713	O
stage	1714	1719	O
were	1720	1724	O
included	1725	1733	O
(	1734	1735	O
P	1735	1736	O
<	1737	1738	O
0	1739	1740	O
.	1740	1741	O
001	1741	1744	O
)	1744	1745	O
.	1745	1746	O

CONCLUSIONS	1747	1758	O
:	1758	1759	O

High	1760	1764	O
c	1765	1766	O
-	1766	1767	O
FLIP	1767	1771	O
and	1772	1775	O
TRAIL	1776	1781	O
expression	1782	1792	O
may	1793	1796	O
be	1797	1799	O
independent	1800	1811	O
adverse	1812	1819	O
prognostic	1820	1830	O
markers	1831	1838	O
in	1839	1841	O
stage	1842	1847	B-Pathological_formation
II	1848	1850	I-Pathological_formation
and	1851	1854	I-Pathological_formation
III	1855	1858	I-Pathological_formation
colorectal	1859	1869	I-Pathological_formation
cancer	1870	1876	I-Pathological_formation
and	1877	1880	O
might	1881	1886	O
identify	1887	1895	O
patients	1896	1904	O
most	1905	1909	O
at	1910	1912	O
risk	1913	1917	O
of	1918	1920	O
relapse	1921	1928	O
.	1928	1929	O

Influences	0	10	O
on	11	13	O
the	14	17	O
pharmacokinetics	18	34	O
of	35	37	O
oxycodone	38	47	O
:	47	48	O
a	49	50	O
multicentre	51	62	O
cross	63	68	O
-	68	69	O
sectional	69	78	O
study	79	84	O
in	85	87	O
439	88	91	O
adult	92	97	O
cancer	98	104	B-Pathological_formation
patients	105	113	O
.	113	114	O

OBJECTIVE	115	124	O
:	124	125	O

Oxycodone	126	135	O
is	136	138	O
widely	139	145	O
used	146	150	O
for	151	154	O
the	155	158	O
treatment	159	168	O
of	169	171	O
cancer	172	178	B-Pathological_formation
pain	179	183	O
,	183	184	O
but	185	188	O
little	189	195	O
is	196	198	O
known	199	204	O
of	205	207	O
its	208	211	O
pharmacokinetics	212	228	O
in	229	231	O
cancer	232	238	B-Pathological_formation
pain	239	243	O
patients	244	252	O
.	252	253	O

The	254	257	O
aim	258	261	O
of	262	264	O
this	265	269	O
study	270	275	O
was	276	279	O
to	280	282	O
explore	283	290	O
the	291	294	O
relationships	295	308	O
between	309	316	O
ordinary	317	325	O
patient	326	333	O
characteristics	334	349	O
and	350	353	O
serum	354	359	B-Organism_substance
concentrations	360	374	O
of	375	377	O
oxycodone	378	387	O
and	388	391	O
the	392	395	O
ratios	396	402	O
noroxycodone	403	415	O
or	416	418	O
oxymorphone	419	430	O
/	430	431	O
oxycodone	431	440	O
in	441	443	O
cancer	444	450	B-Pathological_formation
patients	451	459	O
.	459	460	O

METHODS	461	468	O
:	468	469	O

Four	470	474	O
hundred	475	482	O
and	483	486	O
thirty	487	493	O
-	493	494	O
nine	494	498	O
patients	499	507	O
using	508	513	O
oral	514	518	O
oxycodone	519	528	O
for	529	532	O
cancer	533	539	B-Pathological_formation
pain	540	544	O
were	545	549	O
included	550	558	O
.	558	559	O

The	560	563	O
patients	564	572	O
'	572	573	O
characteristics	574	589	O
(	590	591	O
sex	591	594	O
,	594	595	O
age	596	599	O
,	599	600	O
body	601	605	B-Organism_subdivision
mass	606	610	O
index	611	616	O
[	617	618	O
BMI	618	621	O
]	621	622	O
,	622	623	O
Karnofsky	624	633	O
performance	634	645	O
status	646	652	O
,	652	653	O
"	654	655	O
time	655	659	O
since	660	665	O
starting	666	674	O
opioids	675	682	O
"	682	683	O
,	683	684	O
"	685	686	O
oxycodone	686	695	O
total	696	701	O
daily	702	707	O
dose	708	712	O
"	712	713	O
,	713	714	O
"	715	716	O
time	716	720	O
from	721	725	O
last	726	730	O
oxycodone	731	740	O
dose	741	745	O
"	745	746	O
,	746	747	O
use	748	751	O
of	752	754	O
CYP3A4	755	761	O
inducer	762	769	O
/	769	770	O
inhibitor	770	779	O
,	779	780	O
"	781	782	O
use	782	785	O
of	786	788	O
systemic	789	797	O
steroids	798	806	O
"	806	807	O
,	807	808	O
"	809	810	O
number	810	816	O
of	817	819	O
medications	820	831	O
taken	832	837	O
in	838	840	O
the	841	844	O
last	845	849	O
24	850	852	O
h	853	854	O
"	854	855	O
,	855	856	O
glomerular	857	867	B-Multi-tissue_structure
filtration	868	878	O
rate	879	883	O
(	884	885	O
GFR	885	888	O
)	888	889	O
and	890	893	O
albumin	894	901	O
serum	902	907	B-Organism_substance
concentrations	908	922	O
)	922	923	O
influence	924	933	O
on	934	936	O
oxycodone	937	946	O
serum	947	952	B-Organism_substance
concentrations	953	967	O
or	968	970	O
metabolite	971	981	O
/	981	982	O
oxycodone	982	991	O
ratios	992	998	O
were	999	1003	O
explored	1004	1012	O
by	1013	1015	O
multiple	1016	1024	O
regression	1025	1035	O
analyses	1036	1044	O
.	1044	1045	O

RESULTS	1046	1053	O
:	1053	1054	O

Sex	1055	1058	O
,	1058	1059	O
CYP3A4	1060	1066	O
inducers	1067	1075	O
/	1075	1076	O
inhibitors	1076	1086	O
,	1086	1087	O
total	1088	1093	O
daily	1094	1099	O
dose	1100	1104	O
,	1104	1105	O
and	1106	1109	O
"	1110	1111	O
time	1111	1115	O
from	1116	1120	O
last	1121	1125	O
oxycodone	1126	1135	O
dose	1136	1140	O
"	1140	1141	O
predicted	1142	1151	O
oxycodone	1152	1161	O
concentrations	1162	1176	O
.	1176	1177	O

CYP3A4	1178	1184	O
inducers	1185	1193	O
,	1193	1194	O
total	1195	1200	O
daily	1201	1206	O
dose	1207	1211	O
,	1211	1212	O
and	1213	1216	O
"	1217	1218	O
number	1218	1224	O
of	1225	1227	O
medications	1228	1239	O
taken	1240	1245	O
in	1246	1248	O
the	1249	1252	O
last	1253	1257	O
24	1258	1260	O
h	1261	1262	O
"	1262	1263	O
predicted	1264	1273	O
the	1274	1277	O
oxymorphone	1278	1289	O
/	1289	1290	O
oxycodone	1290	1299	O
ratio	1300	1305	O
.	1305	1306	O

Total	1307	1312	O
daily	1313	1318	O
dose	1319	1323	O
,	1323	1324	O
"	1325	1326	O
time	1326	1330	O
from	1331	1335	O
last	1336	1340	O
dose	1341	1345	O
to	1346	1348	O
blood	1349	1354	B-Organism_substance
sample	1355	1361	I-Organism_substance
"	1361	1362	O
,	1362	1363	O
albumin	1364	1371	O
,	1371	1372	O
sex	1373	1376	O
,	1376	1377	O
CYP3A4	1378	1384	O
inducers	1385	1393	O
/	1393	1394	O
inhibitors	1394	1404	O
,	1404	1405	O
steroids	1406	1414	O
,	1414	1415	O
BMI	1416	1419	O
and	1420	1423	O
GFR	1424	1427	O
predicted	1428	1437	O
the	1438	1441	O
noroxycodone	1442	1454	O
/	1454	1455	O
oxycodone	1455	1464	O
ratio	1465	1470	O
.	1470	1471	O

CONCLUSION	1472	1482	O
:	1482	1483	O

Women	1484	1489	O
had	1490	1493	O
lower	1494	1499	O
oxycodone	1500	1509	O
serum	1510	1515	B-Organism_substance
concentrations	1516	1530	O
than	1531	1535	O
men	1536	1539	O
.	1539	1540	O

CYP3A4	1541	1547	O
inducers	1548	1556	O
/	1556	1557	O
inhibitors	1557	1567	O
should	1568	1574	O
be	1575	1577	O
used	1578	1582	O
with	1583	1587	O
caution	1588	1595	O
as	1596	1598	O
these	1599	1604	O
are	1605	1608	O
predicted	1609	1618	O
to	1619	1621	O
have	1622	1626	O
a	1627	1628	O
significant	1629	1640	O
impact	1641	1647	O
on	1648	1650	O
oxycodone	1651	1660	O
pharmacokinetics	1661	1677	O
.	1677	1678	O

Other	1679	1684	O
characteristics	1685	1700	O
explained	1701	1710	O
only	1711	1715	O
minor	1716	1721	O
parts	1722	1727	O
of	1728	1730	O
the	1731	1734	O
variability	1735	1746	O
of	1747	1749	O
the	1750	1753	O
outcomes	1754	1762	O
.	1762	1763	O

Phase	0	5	O
II	6	8	O
trial	9	14	O
with	15	19	O
D	20	21	O
-	21	22	O
Trp	22	25	O
-	25	26	O
6	26	27	O
-	27	28	O
LH	28	30	O
-	30	31	O
RH	31	33	O
in	34	36	O
prostatic	37	46	B-Pathological_formation
carcinoma	47	56	I-Pathological_formation
:	56	57	O
comparison	58	68	O
with	69	73	O
other	74	79	O
hormonal	80	88	O
agents	89	95	O
.	95	96	O

Various	97	104	O
approaches	105	115	O
to	116	118	O
hormonal	119	127	O
treatment	128	137	O
of	138	140	O
prostate	141	149	B-Pathological_formation
carcinoma	150	159	I-Pathological_formation
are	160	163	O
discussed	164	173	O
.	173	174	O

Eighty	175	181	O
-	181	182	O
one	182	185	O
patients	186	194	O
with	195	199	O
prostatic	200	209	B-Pathological_formation
carcinoma	210	219	I-Pathological_formation
,	219	220	O
eight	221	226	O
with	227	231	O
stage	232	237	O
B	238	239	O
,	239	240	O
nine	241	245	O
with	246	250	O
stage	251	256	O
C	257	258	O
,	258	259	O
and	260	263	O
64	264	266	O
with	267	271	O
stage	272	277	O
D	278	279	O
disease	280	287	O
,	287	288	O
were	289	293	O
treated	294	301	O
subcutaneously	302	316	O
daily	317	322	O
for	323	326	O
3	327	328	O
months	329	335	O
with	336	340	O
the	341	344	O
LH	345	347	O
-	347	348	O
RH	348	350	O
agonist	351	358	O
D	359	360	O
-	360	361	O
Trp	361	364	O
-	364	365	O
6	365	366	O
-	366	367	O
LH	367	369	O
-	369	370	O
RH	370	372	O
(	373	374	O
Decapeptyl	374	384	O
)	384	385	O
in	386	388	O
order	389	394	O
to	395	397	O
evaluate	398	406	O
the	407	410	O
incidence	411	420	O
of	421	423	O
remissions	424	434	O
according	435	444	O
to	445	447	O
WHO	448	451	O
recommendations	452	467	O
for	468	471	O
oncologic	472	481	O
trials	482	488	O
.	488	489	O

The	490	493	O
findings	494	502	O
were	503	507	O
compared	508	516	O
to	517	519	O
those	520	525	O
obtained	526	534	O
with	535	539	O
other	540	545	O
hormonal	546	554	O
therapies	555	564	O
of	565	567	O
prostatic	568	577	B-Pathological_formation
carcinoma	578	587	I-Pathological_formation
according	588	597	O
to	598	600	O
the	601	604	O
statistical	605	616	O
method	617	623	O
of	624	626	O
"	627	628	O
expected	628	636	O
response	637	645	O
rate	646	650	O
"	650	651	O
as	652	654	O
adapted	655	662	O
by	663	665	O
Lee	666	669	O
and	670	673	O
Wesley	674	680	O
for	681	684	O
phase	685	690	O
II	691	693	O
trials	694	700	O
.	700	701	O

Treatment	702	711	O
with	712	716	O
D	717	718	O
-	718	719	O
Trp	719	722	O
-	722	723	O
6	723	724	O
-	724	725	O
LH	725	727	O
-	727	728	O
RH	728	730	O
greatly	731	738	O
reduced	739	746	O
serum	747	752	B-Organism_substance
LH	753	755	O
and	756	759	O
testosterone	760	772	O
levels	773	779	O
without	780	787	O
raising	788	795	O
serum	796	801	B-Organism_substance
prolactin	802	811	O
.	811	812	O

After	813	818	O
1	819	820	O
-	820	821	O
2	821	822	O
weeks	823	828	O
of	829	831	O
therapy	832	839	O
,	839	840	O
there	841	846	O
was	847	850	O
relief	851	857	O
of	858	860	O
subjective	861	871	O
symptoms	872	880	O
and	881	884	O
a	885	886	O
reversal	887	895	O
of	896	898	O
the	899	902	O
signs	903	908	O
of	909	911	O
prostatism	912	922	O
as	923	925	O
well	926	930	O
as	931	933	O
a	934	935	O
marked	936	942	O
decrease	943	951	O
in	952	954	O
bone	955	959	B-Organ
pain	960	964	O
.	964	965	O

At	966	968	O
90	969	971	O
days	972	976	O
52	977	979	O
patients	980	988	O
had	989	992	O
complete	993	1001	O
relief	1002	1008	O
of	1009	1011	O
prostatism	1012	1022	O
and	1023	1026	O
21	1027	1029	O
had	1030	1033	O
only	1034	1038	O
mild	1039	1043	O
signs	1044	1049	O
and	1050	1053	O
symptoms	1054	1062	O
.	1062	1063	O

Seventy	1064	1071	O
patients	1072	1080	O
were	1081	1085	O
experiencing	1086	1098	O
no	1099	1101	O
bone	1102	1106	B-Organ
pain	1107	1111	O
and	1112	1115	O
an	1116	1118	O
additional	1119	1129	O
six	1130	1133	O
had	1134	1137	O
only	1138	1142	O
mild	1143	1147	O
pain	1148	1152	O
.	1152	1153	O

Prostatic	1154	1163	B-Organ
size	1164	1168	O
,	1168	1169	O
evaluated	1170	1179	O
by	1180	1182	O
rectal	1183	1189	O
examination	1190	1201	O
and	1202	1205	O
transabdominal	1206	1220	B-Organism_subdivision
ultrasonography	1221	1236	O
,	1236	1237	O
reverted	1238	1246	O
to	1247	1249	O
normal	1250	1256	O
in	1257	1259	O
26	1260	1262	O
.	1262	1263	O
4	1263	1264	O
%	1264	1265	O
of	1266	1268	O
patients	1269	1277	O
(	1278	1279	O
complete	1279	1287	O
remission	1288	1297	O
)	1297	1298	O
and	1299	1302	O
was	1303	1306	O
reduced	1307	1314	O
by	1315	1317	O
more	1318	1322	O
than	1323	1327	O
50	1328	1330	O
%	1330	1331	O
in	1332	1334	O
an	1335	1337	O
additional	1338	1348	O
17	1349	1351	O
.	1351	1352	O
6	1352	1353	O
%	1353	1354	O
(	1355	1356	O
partial	1356	1363	O
remission	1364	1373	O
)	1373	1374	O
,	1374	1375	O
the	1376	1379	O
overall	1380	1387	O
rate	1388	1392	O
of	1393	1395	O
complete	1396	1404	O
plus	1405	1409	O
partial	1410	1417	O
regression	1418	1428	O
of	1429	1431	O
prostatic	1432	1441	B-Organ
enlargement	1442	1453	O
being	1454	1459	O
44	1460	1462	O
%	1462	1463	O
.	1463	1464	O

Scans	1465	1470	O
showed	1471	1477	O
a	1478	1479	O
major	1480	1485	O
improvement	1486	1497	O
of	1498	1500	O
bone	1501	1505	B-Pathological_formation
lesions	1506	1513	I-Pathological_formation
in	1514	1516	O
14	1517	1519	O
.	1519	1520	O
8	1520	1521	O
%	1521	1522	O
of	1523	1525	O
cases	1526	1531	O
.	1531	1532	O

This	1533	1537	O
response	1538	1546	O
increased	1547	1556	O
to	1557	1559	O
37	1560	1562	O
%	1562	1563	O
after	1564	1569	O
more	1570	1574	O
than	1575	1579	O
6	1580	1581	O
months	1582	1588	O
of	1589	1591	O
follow	1592	1598	O
-	1598	1599	O
up	1599	1601	O
.	1601	1602	O

Prostatic	1603	1612	B-Organ
acid	1613	1617	O
phosphatase	1618	1629	O
levels	1630	1636	O
were	1637	1641	O
decreased	1642	1651	O
by	1652	1654	O
more	1655	1659	O
than	1660	1664	O
50	1665	1667	O
%	1667	1668	O
in	1669	1671	O
61	1672	1674	O
%	1674	1675	O
of	1676	1678	O
the	1679	1682	O
patients	1683	1691	O
,	1691	1692	O
but	1693	1696	O
this	1697	1701	O
test	1702	1706	O
appears	1707	1714	O
to	1715	1717	O
be	1718	1720	O
a	1721	1722	O
less	1723	1727	O
valid	1728	1733	O
marker	1734	1740	O
than	1741	1745	O
the	1746	1749	O
lipid	1750	1755	O
-	1755	1756	O
associated	1756	1766	O
sialic	1767	1773	O
acid	1774	1778	O
(	1779	1780	O
LASA	1780	1784	O
)	1784	1785	O
.	1785	1786	O

The	1787	1790	O
increase	1791	1799	O
in	1800	1802	O
LASA	1803	1807	O
before	1808	1814	O
treatment	1815	1824	O
and	1825	1828	O
a	1829	1830	O
reduction	1831	1840	O
after	1841	1846	O
treatment	1847	1856	O
can	1857	1860	O
frequently	1861	1871	O
be	1872	1874	O
correlated	1875	1885	O
with	1886	1890	O
the	1891	1894	O
objective	1895	1904	O
volume	1905	1911	O
of	1912	1914	O
the	1915	1918	O
neoplasms	1919	1928	B-Pathological_formation
.	1928	1929	O

No	1930	1932	O
flare	1933	1938	O
-	1938	1939	O
up	1939	1941	O
of	1942	1944	O
the	1945	1948	O
disease	1949	1956	O
was	1957	1960	O
encountered	1961	1972	O
,	1972	1973	O
and	1974	1977	O
there	1978	1983	O
were	1984	1988	O
no	1989	1991	O
side	1992	1996	O
effects	1997	2004	O
except	2005	2011	O
for	2012	2015	O
impotence	2016	2025	O
.	2025	2026	O

Statistical	2027	2038	O
analyses	2039	2047	O
of	2048	2050	O
results	2051	2058	O
by	2059	2061	O
the	2062	2065	O
method	2066	2072	O
of	2073	2075	O
Lee	2076	2079	O
and	2080	2083	O
Wesley	2084	2090	O
indicated	2091	2100	O
that	2101	2105	O
the	2106	2109	O
incidence	2110	2119	O
of	2120	2122	O
complete	2123	2131	O
and	2132	2135	O
partial	2136	2143	O
regression	2144	2154	O
(	2155	2156	O
CR	2156	2158	O
and	2159	2162	O
PR	2163	2165	O
)	2165	2166	O
observed	2167	2175	O
with	2176	2180	O
D	2181	2182	O
-	2182	2183	O
Trp	2183	2186	O
-	2186	2187	O
6	2187	2188	O
-	2188	2189	O
LH	2189	2191	O
-	2191	2192	O
RH	2192	2194	O
was	2195	2198	O
not	2199	2202	O
significantly	2203	2216	O
different	2217	2226	O
from	2227	2231	O
that	2232	2236	O
recorded	2237	2245	O
in	2246	2248	O
previous	2249	2257	O
studies	2258	2265	O
for	2266	2269	O
another	2270	2277	O
LH	2278	2280	O
-	2280	2281	O
RH	2281	2283	O
analog	2284	2290	O
,	2290	2291	O
Buserelin	2292	2301	O
.	2301	2302	O

However	2303	2310	O
,	2310	2311	O
CR	2312	2314	O
and	2315	2318	O
PR	2319	2321	O
obtained	2322	2330	O
with	2331	2335	O
D	2336	2337	O
-	2337	2338	O
Trp	2338	2341	O
-	2341	2342	O
6	2342	2343	O
-	2343	2344	O
LH	2344	2346	O
-	2346	2347	O
RH	2347	2349	O
(	2350	2351	O
44	2351	2353	O
%	2353	2354	O
)	2354	2355	O
were	2356	2360	O
significantly	2361	2374	O
higher	2375	2381	O
than	2382	2386	O
with	2387	2391	O
subcapsular	2392	2403	O
orchiectomy	2404	2415	O
(	2416	2417	O
22	2417	2419	O
%	2419	2420	O
)	2420	2421	O
.	2421	2422	O

Hormonal	2423	2431	O
effects	2432	2439	O
and	2440	2443	O
some	2444	2448	O
other	2449	2454	O
actions	2455	2462	O
of	2463	2465	O
D	2466	2467	O
-	2467	2468	O
Trp	2468	2471	O
-	2471	2472	O
6	2472	2473	O
-	2473	2474	O
LH	2474	2476	O
-	2476	2477	O
RH	2477	2479	O
were	2480	2484	O
compared	2485	2493	O
and	2494	2497	O
contrasted	2498	2508	O
with	2509	2513	O
those	2514	2519	O
produced	2520	2528	O
by	2529	2531	O
castration	2532	2542	O
,	2542	2543	O
estrogens	2544	2553	O
,	2553	2554	O
antiandrogens	2555	2568	O
,	2568	2569	O
and	2570	2573	O
progestogens	2574	2586	O
.	2586	2587	O
(	2587	2588	O
ABSTRACT	2588	2596	O
TRUNCATED	2597	2606	O
AT	2607	2609	O
400	2610	2613	O
WORDS	2614	2619	O
)	2619	2620	O

[	0	1	O
Histophysiology	1	16	O
and	17	20	O
histopathology	21	35	O
of	36	38	O
the	39	42	O
adrenals	43	51	B-Organ
in	52	54	O
experimental	55	67	O
hypokinesia	68	79	O
]	79	80	O
.	80	81	O

In	82	84	O
experiments	85	96	O
on	97	99	O
male	100	104	O
rats	105	109	O
in	110	112	O
the	113	116	O
course	117	123	O
of	124	126	O
3	127	128	O
-	128	129	O
month	129	134	O
hypokinesia	135	146	O
phasic	147	153	O
changes	154	161	O
were	162	166	O
observed	167	175	O
in	176	178	O
the	179	182	O
relative	183	191	O
adrenal	192	199	B-Organ
gland	200	205	I-Organ
weight	206	212	O
,	212	213	O
in	214	216	O
the	217	220	O
volume	221	227	O
of	228	230	O
the	231	234	O
cell	235	239	B-Cellular_component
nuclei	240	246	I-Cellular_component
of	247	249	O
the	250	253	O
glomerular	254	264	B-Multi-tissue_structure
,	264	265	O
fasicular	266	275	B-Multi-tissue_structure
zones	276	281	I-Multi-tissue_structure
and	282	285	O
the	286	289	O
medulla	290	297	B-Multi-tissue_structure
,	297	298	O
in	299	301	O
the	302	305	O
activity	306	314	O
of	315	317	O
the	318	321	O
succinic	322	330	O
dehydrogenase	331	344	O
,	344	345	O
alkaline	346	354	O
and	355	358	O
acid	359	363	O
phosphatases	364	376	O
,	376	377	O
in	378	380	O
the	381	384	O
RNA	385	388	O
and	389	392	O
catecholamine	393	406	O
content	407	414	O
.	414	415	O

These	416	421	O
changes	422	429	O
are	430	433	O
associated	434	444	O
with	445	449	O
variations	450	460	O
in	461	463	O
the	464	467	O
secretion	468	477	O
and	478	481	O
biosynthesis	482	494	O
of	495	497	O
the	498	501	O
hormones	502	510	O
of	511	513	O
the	514	517	O
cortical	518	526	B-Multi-tissue_structure
and	527	530	O
the	531	534	O
medullary	535	544	B-Multi-tissue_structure
layer	545	550	I-Multi-tissue_structure
of	551	553	O
the	554	557	O
adrenal	558	565	B-Organ
glands	566	572	I-Organ
during	573	579	O
the	580	583	O
hypokinetic	584	595	O
stress	596	602	O
development	603	614	O
.	614	615	O

Dynorphin	0	9	O
is	10	12	O
contained	13	22	O
within	23	29	O
hippocampal	30	41	B-Tissue
mossy	42	47	I-Tissue
fibers	48	54	I-Tissue
:	54	55	O
immunochemical	56	70	O
alterations	71	82	O
after	83	88	O
kainic	89	95	O
acid	96	100	O
administration	101	115	O
and	116	119	O
colchicine	120	130	O
-	130	131	O
induced	131	138	O
neurotoxicity	139	152	O
.	152	153	O

Antisera	154	162	B-Organism_substance
raised	163	169	O
against	170	177	O
synthetic	178	187	O
dynorphin	188	197	O
or	198	200	O
[	201	202	O
Leu5	202	206	O
]	206	207	O
enkephalin	207	217	O
demonstrate	218	229	O
immunostaining	230	244	O
in	245	247	O
hippocampal	248	259	B-Tissue
mossy	260	265	I-Tissue
fibers	266	272	I-Tissue
and	273	276	O
in	277	279	O
dentate	280	287	B-Cell
granule	288	295	I-Cell
cells	296	301	I-Cell
.	301	302	O

However	303	310	O
,	310	311	O
dynorphin	312	321	O
immunoreactivity	322	338	O
(	339	340	O
ir	340	342	O
)	342	343	O
appears	344	351	O
to	352	354	O
be	355	357	O
denser	358	364	O
in	365	367	O
immunocytochemical	368	386	O
preparations	387	399	O
and	400	403	O
is	404	406	O
quantitatively	407	421	O
greater	422	429	O
by	430	432	O
radioimmunoassay	433	449	O
than	450	454	O
enkephalin	455	465	O
-	465	466	O
ir	466	468	O
.	468	469	O

Immunostaining	470	484	O
with	485	489	O
dynorphin	490	499	O
antisera	500	508	O
is	509	511	O
eliminated	512	522	O
by	523	525	O
adsorption	526	536	O
with	537	541	O
1	542	543	O
-	543	544	O
100	544	547	O
microM	548	554	O
dynorphin	555	564	O
-	564	565	O
17	565	567	O
whereas	568	575	O
immunostaining	576	590	O
with	591	595	O
enkephalin	596	606	O
antisera	607	615	O
is	616	618	O
eliminated	619	629	O
by	630	632	O
adsorption	633	643	O
with	644	648	O
1	649	650	O
-	650	651	O
100	651	654	O
microM	655	661	O
[	662	663	O
Leu5	663	667	O
]	667	668	O
enkephalin	668	678	O
,	678	679	O
dynorphin	680	689	O
-	689	690	O
17	690	692	O
,	692	693	O
dynorphin	694	703	O
-	703	704	O
(	704	705	O
1	705	706	O
-	706	707	O
13	707	709	O
)	709	710	O
,	710	711	O
or	712	714	O
alpha	715	720	O
-	720	721	O
neo	721	724	O
-	724	725	O
endorphin	725	734	O
.	734	735	O

Intrahippocampal	736	752	B-Multi-tissue_structure
colchicine	753	763	O
injections	764	774	O
,	774	775	O
which	776	781	O
selectively	782	793	O
destroy	794	801	O
dentate	802	809	O
granule	810	817	O
cells	818	823	O
,	823	824	O
significantly	825	838	O
decrease	839	847	O
the	848	851	O
dynorphin	852	861	O
-	861	862	O
ir	862	864	O
and	865	868	O
enkephalin	869	879	O
-	879	880	O
ir	880	882	O
levels	883	889	O
in	890	892	O
rat	893	896	O
hippocampus	897	908	B-Multi-tissue_structure
.	908	909	O

Intraventricularly	910	928	B-Multi-tissue_structure
administered	929	941	O
kainic	942	948	O
acid	949	953	O
,	953	954	O
which	955	960	O
selectively	961	972	O
destroys	973	981	O
CA3	982	985	B-Cell
-	985	986	I-Cell
4	986	987	I-Cell
pyramidal	988	997	I-Cell
cells	998	1003	I-Cell
,	1003	1004	O
results	1005	1012	O
in	1013	1015	O
an	1016	1018	O
increase	1019	1027	O
of	1028	1030	O
enkephalin	1031	1041	O
immunostaining	1042	1056	O
in	1057	1059	O
mossy	1060	1065	B-Tissue
fibers	1066	1072	I-Tissue
and	1073	1076	O
a	1077	1078	O
significant	1079	1090	O
increase	1091	1099	O
in	1100	1102	O
enkephalin	1103	1113	O
-	1113	1114	O
ir	1114	1116	O
by	1117	1119	O
radioimmunoassay	1120	1136	O
in	1137	1139	O
whole	1140	1145	O
hippocampus	1146	1157	B-Multi-tissue_structure
.	1157	1158	O

The	1159	1162	O
enkephalin	1163	1173	B-Cell
-	1173	1174	I-Cell
ir	1174	1176	I-Cell
cells	1177	1182	I-Cell
and	1183	1186	O
fibers	1187	1193	B-Tissue
in	1194	1196	O
entorhinal	1197	1207	B-Multi-tissue_structure
/	1207	1208	O
perirhinal	1208	1218	B-Multi-tissue_structure
cortex	1219	1225	I-Multi-tissue_structure
,	1225	1226	O
which	1227	1232	O
innervate	1233	1242	O
rat	1243	1246	O
hippocampus	1247	1258	B-Multi-tissue_structure
and	1259	1262	O
dentate	1263	1270	B-Multi-tissue_structure
gyrus	1271	1276	I-Multi-tissue_structure
,	1276	1277	O
do	1278	1280	O
not	1281	1284	O
contain	1285	1292	O
dynorphin	1293	1302	O
-	1302	1303	O
ir	1303	1305	O
.	1305	1306	O

Differential	0	12	O
reactivity	13	23	O
of	24	26	O
the	27	30	O
functional	31	41	O
sulfhydryl	42	52	O
groups	53	59	O
of	60	62	O
cysteine	63	71	O
-	71	72	O
32	72	74	O
and	75	78	O
cysteine	79	87	O
-	87	88	O
35	88	90	O
present	91	98	O
in	99	101	O
the	102	105	O
reduced	106	113	O
form	114	118	O
of	119	121	O
thioredoxin	122	133	O
from	134	138	O
Escherichia	139	150	O
coli	151	155	O
.	155	156	O

Only	157	161	O
one	162	165	O
of	166	168	O
the	169	172	O
sulfhydryl	173	183	O
groups	184	190	O
from	191	195	O
Cys	196	199	O
-	199	200	O
32	200	202	O
and	203	206	O
Cys	207	210	O
-	210	211	O
35	211	213	O
in	214	216	O
the	217	220	O
active	221	227	O
center	228	234	O
of	235	237	O
native	238	244	O
Escherichia	245	256	O
coli	257	261	O
thioredoxin	262	273	O
-	273	274	O
(	274	275	O
SH	275	277	O
)	277	278	O
2	278	279	O
was	280	283	O
alkylated	284	293	O
by	294	296	O
excess	297	303	O
iodoacetic	304	314	O
acid	315	319	O
at	320	322	O
pH	323	325	O
values	326	332	O
below	333	338	O
8	339	340	O
.	340	341	O
0	341	342	O
.	342	343	O

Both	344	348	O
groups	349	355	O
reacted	356	363	O
in	364	366	O
the	367	370	O
protein	371	378	O
denatured	379	388	O
with	389	393	O
4	394	395	O
.	395	396	O
5	396	397	O
M	398	399	O
guanidine	400	409	O
hydrochloride	410	423	O
.	423	424	O

The	425	428	O
second	429	435	O
order	436	441	O
rate	442	446	O
of	447	449	O
alkylation	450	460	O
of	461	463	O
thioredoxin	464	475	O
-	475	476	O
(	476	477	O
SH	477	479	O
)	479	480	O
2	480	481	O
with	482	486	O
1	487	488	O
eq	489	491	O
of	492	494	O
iodoacetic	495	505	O
acid	506	510	O
was	511	514	O
pH	515	517	O
-	517	518	O
dependent	518	527	O
and	528	531	O
showed	532	538	O
independent	539	550	O
initial	551	558	O
reactions	559	568	O
of	569	571	O
one	572	575	O
thiolate	576	584	O
ion	585	588	O
with	589	593	O
a	594	595	O
pK	596	598	O
value	599	604	O
of	605	607	O
6	608	609	O
.	609	610	O
7	610	611	O
and	612	615	O
a	616	617	O
second	618	624	O
with	625	629	O
a	630	631	O
pK	632	634	O
value	635	640	O
close	641	646	O
to	647	649	O
9	650	651	O
.	651	652	O
0	652	653	O
.	653	654	O

The	655	658	O
same	659	663	O
pH	664	666	O
dependence	667	677	O
was	678	681	O
observed	682	690	O
for	691	694	O
alkylation	695	705	O
with	706	710	O
iodoacetamide	711	724	O
but	725	728	O
the	729	732	O
apparent	733	741	O
rate	742	746	O
constant	747	755	O
,	755	756	O
107	757	760	O
M	761	762	O
-	762	763	O
1	763	764	O
S	765	766	O
-	766	767	O
1	767	768	O
at	769	771	O
pH	772	774	O
7	775	776	O
.	776	777	O
2	777	778	O
,	778	779	O
was	780	783	O
about	784	789	O
20	790	792	O
-	792	793	O
fold	793	797	O
higher	798	804	O
than	805	809	O
the	810	813	O
corresponding	814	827	O
rate	828	832	O
with	833	837	O
iodoacetate	838	849	O
.	849	850	O

The	851	854	O
sulfhydryl	855	865	O
group	866	871	O
with	872	876	O
a	877	878	O
pK	879	881	O
value	882	887	O
of	888	890	O
6	891	892	O
.	892	893	O
7	893	894	O
was	895	898	O
shown	899	904	O
to	905	907	O
belong	908	914	O
to	915	917	O
Cys	918	921	O
-	921	922	O
32	922	924	O
by	925	927	O
labeling	928	936	O
thioredoxin	937	948	O
with	949	953	O
[	954	955	O
14C	955	958	O
]	958	959	O
iodoacetic	959	969	O
acid	970	974	O
followed	975	983	O
by	984	986	O
complete	987	995	O
alkylation	996	1006	O
with	1007	1011	O
[	1012	1013	O
3H	1013	1015	O
]	1015	1016	O
iodoacetate	1016	1027	O
and	1028	1031	O
amino	1032	1037	O
acid	1038	1042	O
sequence	1043	1051	O
analysis	1052	1060	O
of	1061	1063	O
peptides	1064	1072	O
from	1073	1077	O
the	1078	1081	O
active	1082	1088	O
center	1089	1095	O
.	1095	1096	O

The	1097	1100	O
abnormally	1101	1111	O
low	1112	1115	O
pK	1116	1118	O
value	1119	1124	O
of	1125	1127	O
Cys	1128	1131	O
-	1131	1132	O
32	1132	1134	O
is	1135	1137	O
suggested	1138	1147	O
to	1148	1150	O
arise	1151	1156	O
by	1157	1159	O
electrostatic	1160	1173	O
influence	1174	1183	O
from	1184	1188	O
a	1189	1190	O
positive	1191	1199	O
charge	1200	1206	O
on	1207	1209	O
the	1210	1213	O
amino	1214	1219	O
group	1220	1225	O
of	1226	1228	O
Lys	1229	1232	O
-	1232	1233	O
36	1233	1235	O
.	1235	1236	O

A	1237	1238	O
mechanism	1239	1248	O
of	1249	1251	O
action	1252	1258	O
for	1259	1262	O
thioredoxin	1263	1274	O
-	1274	1275	O
(	1275	1276	O
SH	1276	1278	O
)	1278	1279	O
2	1279	1280	O
as	1281	1283	O
a	1284	1285	O
protein	1286	1293	O
disulfide	1294	1303	O
reductase	1304	1313	O
has	1314	1317	O
been	1318	1322	O
formulated	1323	1333	O
.	1333	1334	O

This	1335	1339	O
is	1340	1342	O
based	1343	1348	O
on	1349	1351	O
an	1352	1354	O
initial	1355	1362	O
nucleophilic	1363	1375	O
attack	1376	1382	O
by	1383	1385	O
the	1386	1389	O
thiolate	1390	1398	O
of	1399	1401	O
Cys	1402	1405	O
-	1405	1406	O
32	1406	1408	O
with	1409	1413	O
the	1414	1417	O
formation	1418	1427	O
of	1428	1430	O
an	1431	1433	O
unstable	1434	1442	O
transient	1443	1452	O
mixed	1453	1458	O
disulfide	1459	1468	O
involving	1469	1478	O
Cys	1479	1482	O
-	1482	1483	O
32	1483	1485	O
and	1486	1489	O
one	1490	1493	O
of	1494	1496	O
the	1497	1500	O
sulfurs	1501	1508	O
in	1509	1511	O
the	1512	1515	O
substrate	1516	1525	O
.	1525	1526	O

This	1527	1531	O
is	1532	1534	O
followed	1535	1543	O
by	1544	1546	O
a	1547	1548	O
conformational	1549	1563	O
change	1564	1570	O
and	1571	1574	O
a	1575	1576	O
nucleophilic	1577	1589	O
attack	1590	1596	O
of	1597	1599	O
Cys	1600	1603	O
-	1603	1604	O
35	1604	1606	O
to	1607	1609	O
give	1610	1614	O
the	1615	1618	O
14	1619	1621	O
-	1621	1622	O
membered	1622	1630	O
disulfide	1631	1640	O
ring	1641	1645	O
in	1646	1648	O
thioredoxin	1649	1660	O
-	1660	1661	O
S2	1661	1663	O
and	1664	1667	O
the	1668	1671	O
dithiol	1672	1679	O
of	1680	1682	O
the	1683	1686	O
substrate	1687	1696	O
.	1696	1697	O

Identification	0	14	O
of	15	17	O
NAB1	18	22	O
,	22	23	O
a	24	25	O
repressor	26	35	O
of	36	38	O
NGFI	39	43	O
-	43	44	O
A	44	45	O
-	45	46	O
and	47	50	O
Krox20	51	57	O
-	57	58	O
mediated	58	66	O
transcription	67	80	O
.	80	81	O

NGFI	82	86	O
-	86	87	O
A	87	88	O
(	89	90	O
also	90	94	O
called	95	101	O
Egr1	102	106	O
,	106	107	O
Zif268	108	114	O
,	114	115	O
or	116	118	O
Krox24	119	125	O
)	125	126	O
and	127	130	O
the	131	134	O
closely	135	142	O
related	143	150	O
proteins	151	159	O
Krox20	160	166	O
,	166	167	O
NGFI	168	172	O
-	172	173	O
C	173	174	O
,	174	175	O
and	176	179	O
Egr3	180	184	O
are	185	188	O
zinc	189	193	O
-	193	194	O
finger	194	200	O
transcription	201	214	O
factors	215	222	O
encoded	223	230	O
by	231	233	O
immediate	234	243	O
-	243	244	O
early	244	249	O
genes	250	255	O
which	256	261	O
are	262	265	O
induced	266	273	O
by	274	276	O
a	277	278	O
wide	279	283	O
variety	284	291	O
of	292	294	O
extracellular	295	308	B-Immaterial_anatomical_entity
stimuli	309	316	O
.	316	317	O

NGFI	318	322	O
-	322	323	O
A	323	324	O
has	325	328	O
been	329	333	O
implicated	334	344	O
in	345	347	O
cell	348	352	B-Cell
proliferation	353	366	O
,	366	367	O
macrophage	368	378	B-Cell
differentiation	379	394	O
,	394	395	O
synaptic	396	404	B-Cellular_component
activation	405	415	O
,	415	416	O
and	417	420	O
long	421	425	O
-	425	426	O
term	426	430	O
potentiation	431	443	O
,	443	444	O
whereas	445	452	O
Krox20	453	459	O
is	460	462	O
critical	463	471	O
for	472	475	O
proper	476	482	O
hindbrain	483	492	O
segmentation	493	505	O
and	506	509	O
peripheral	510	520	B-Multi-tissue_structure
nerve	521	526	I-Multi-tissue_structure
myelination	527	538	O
.	538	539	O

In	540	542	O
previous	543	551	O
work	552	556	O
,	556	557	O
a	558	559	O
structure	560	569	O
/	569	570	O
function	570	578	O
analysis	579	587	O
of	588	590	O
NGFI	591	595	O
-	595	596	O
A	596	597	O
revealed	598	606	O
a	607	608	O
34	609	611	O
-	611	612	O
aa	612	614	O
inhibitory	615	625	O
domain	626	632	O
that	633	637	O
was	638	641	O
hypothesized	642	654	O
to	655	657	O
be	658	660	O
the	661	664	O
target	665	671	O
of	672	674	O
a	675	676	O
cellular	677	685	B-Cell
factor	686	692	O
that	693	697	O
represses	698	707	O
NGFI	708	712	O
-	712	713	O
A	713	714	O
transcriptional	715	730	O
activity	731	739	O
.	739	740	O

Using	741	746	O
the	747	750	O
yeast	751	756	O
two	757	760	O
-	760	761	O
hybrid	761	767	O
system	768	774	O
,	774	775	O
we	776	778	O
have	779	783	O
isolated	784	792	O
a	793	794	O
cDNA	795	799	O
clone	800	805	O
which	806	811	O
encodes	812	819	O
a	820	821	O
protein	822	829	O
that	830	834	O
interacts	835	844	O
with	845	849	O
this	850	854	O
inhibitory	855	865	O
domain	866	872	O
and	873	876	O
inhibits	877	885	O
the	886	889	O
ability	890	897	O
of	898	900	O
NGFI	901	905	O
-	905	906	O
A	906	907	O
to	908	910	O
activate	911	919	O
transcription	920	933	O
.	933	934	O

This	935	939	O
NGFI	940	944	O
-	944	945	O
A	945	946	O
-	946	947	O
binding	947	954	O
protein	955	962	O
,	962	963	O
NAB1	964	968	O
,	968	969	O
is	970	972	O
a	973	974	O
570	975	978	O
-	978	979	O
aa	979	981	O
nuclear	982	989	B-Cellular_component
protein	990	997	O
that	998	1002	O
bears	1003	1008	O
no	1009	1011	O
obvious	1012	1019	O
sequence	1020	1028	O
homology	1029	1037	O
to	1038	1040	O
known	1041	1046	O
proteins	1047	1055	O
.	1055	1056	O

NAB1	1057	1061	O
also	1062	1066	O
represses	1067	1076	O
Krox20	1077	1083	O
activity	1084	1092	O
,	1092	1093	O
but	1094	1097	O
it	1098	1100	O
does	1101	1105	O
not	1106	1109	O
influence	1110	1119	O
Egr3	1120	1124	O
or	1125	1127	O
NGFI	1128	1132	O
-	1132	1133	O
G	1133	1134	O
,	1134	1135	O
thus	1136	1140	O
providing	1141	1150	O
a	1151	1152	O
mechanism	1153	1162	O
for	1163	1166	O
the	1167	1170	O
differential	1171	1183	O
regulation	1184	1194	O
of	1195	1197	O
this	1198	1202	O
family	1203	1209	O
of	1210	1212	O
immediate	1213	1222	O
-	1222	1223	O
early	1223	1228	O
transcription	1229	1242	O
factors	1243	1250	O
.	1250	1251	O

Comparison	0	10	O
of	11	13	O
image	14	19	O
(	20	21	O
CAS	21	24	O
200	25	28	O
)	28	29	O
and	30	33	O
flow	34	38	O
cytometry	39	48	O
determined	49	59	O
DNA	60	63	O
content	64	71	O
of	72	74	O
paraffin	75	83	O
-	83	84	O
embedded	84	92	O
Hodgkin	93	100	B-Tissue
'	100	101	I-Tissue
s	101	102	I-Tissue
disease	103	110	I-Tissue
tissue	111	117	I-Tissue
.	117	118	O

To	119	121	O
assess	122	128	O
the	129	132	O
reliability	133	144	O
of	145	147	O
DNA	148	151	O
estimation	152	162	O
using	163	168	O
image	169	174	O
cytometry	175	184	O
,	184	185	O
deparaffinized	186	200	O
lymph	201	206	B-Multi-tissue_structure
nodes	207	212	I-Multi-tissue_structure
from	213	217	O
70	218	220	O
patients	221	229	O
with	230	234	O
Hodgkin	235	242	O
'	242	243	O
s	243	244	O
disease	245	252	O
were	253	257	O
examined	258	266	O
and	267	270	O
the	271	274	O
results	275	282	O
obtained	283	291	O
were	292	296	O
compared	297	305	O
with	306	310	O
those	311	316	O
from	317	321	O
flow	322	326	O
cytometry	327	336	O
.	336	337	O

Image	338	343	O
analysis	344	352	O
without	353	360	O
discriminating	361	375	O
between	376	383	O
the	384	387	O
various	388	395	O
cell	396	400	B-Cell
types	401	406	O
,	406	407	O
as	408	410	O
found	411	416	O
in	417	419	O
Hodgkin	420	427	O
'	427	428	O
s	428	429	O
disease	430	437	O
,	437	438	O
revealed	439	447	O
no	448	450	O
separate	451	459	O
aneuploid	460	469	O
peak	470	474	O
.	474	475	O

Selecting	476	485	O
on	486	488	O
morphologically	489	504	O
defined	505	512	O
nuclear	513	520	B-Cellular_component
types	521	526	O
DNA	527	530	O
aneuploidy	531	541	O
was	542	545	O
detected	546	554	O
in	555	557	O
20	558	560	O
%	560	561	O
of	562	564	O
the	565	568	O
cases	569	574	O
(	575	576	O
14	576	578	O
/	578	579	O
70	579	581	O
)	581	582	O
.	582	583	O

The	584	587	O
aneuploid	588	597	O
populations	598	609	O
were	610	614	O
limited	615	622	O
to	623	625	O
the	626	629	O
population	630	640	O
of	641	643	O
nuclei	644	650	B-Cellular_component
defined	651	658	O
as	659	661	O
Reed	662	666	O
-	666	667	O
Sternberg	667	676	O
(	677	678	O
RS	678	680	O
)	680	681	O
-	681	682	O
like	682	686	O
or	687	689	O
medium	690	696	O
-	696	697	O
sized	697	702	O
lymphocytes	703	714	B-Cell
.	714	715	O

Benign	716	722	B-Pathological_formation
lymph	723	728	I-Pathological_formation
nodes	729	734	I-Pathological_formation
DNA	735	738	O
aneuploidy	739	749	O
was	750	753	O
not	754	757	O
found	758	763	O
in	764	766	O
any	767	770	O
of	771	773	O
the	774	777	O
controls	778	786	O
.	786	787	O

Comparison	788	798	O
of	799	801	O
DNA	802	805	O
histograms	806	816	O
obtained	817	825	O
by	826	828	O
image	829	834	O
and	835	838	O
flow	839	843	O
cytometry	844	853	O
showed	854	860	O
aneuploid	861	870	O
peaks	871	876	O
using	877	882	O
image	883	888	O
cytometry	889	898	O
in	899	901	O
4	902	903	O
of	904	906	O
30	907	909	O
diploid	910	917	O
and	918	921	O
10	922	924	O
of	925	927	O
40	928	930	O
aneuploid	931	940	O
flow	941	945	O
histograms	946	956	O
.	956	957	O

In	958	960	O
conclusion	961	971	O
,	971	972	O
image	973	978	O
analysis	979	987	O
using	988	993	O
the	994	997	O
CAS	998	1001	O
200	1002	1005	O
system	1006	1012	O
as	1013	1015	O
compared	1016	1024	O
to	1025	1027	O
flow	1028	1032	O
cytometry	1033	1042	O
is	1043	1045	O
more	1046	1050	O
time	1051	1055	O
-	1055	1056	O
consuming	1056	1065	O
and	1066	1069	O
less	1070	1074	O
sensitive	1075	1084	O
to	1085	1087	O
assess	1088	1094	O
ploidy	1095	1101	O
status	1102	1108	O
,	1108	1109	O
although	1110	1118	O
it	1119	1121	O
may	1122	1125	O
provide	1126	1133	O
extra	1134	1139	O
information	1140	1151	O
in	1152	1154	O
some	1155	1159	O
selected	1160	1168	O
cases	1169	1174	O
.	1174	1175	O

Evidence	1176	1184	O
is	1185	1187	O
obtained	1188	1196	O
that	1197	1201	O
DNA	1202	1205	O
aneuploidy	1206	1216	O
in	1217	1219	O
Hodgkin	1220	1227	O
'	1227	1228	O
s	1228	1229	O
disease	1230	1237	O
is	1238	1240	O
preferentially	1241	1255	O
expressed	1256	1265	O
by	1266	1268	O
cells	1269	1274	B-Cell
with	1275	1279	O
the	1280	1283	O
RS	1284	1286	O
/	1286	1287	O
H	1287	1288	O
-	1288	1289	O
like	1289	1293	O
and	1294	1297	O
medium	1298	1304	O
-	1304	1305	O
sized	1305	1310	O
lymphocyte	1311	1321	B-Cell
morphology	1322	1332	O
.	1332	1333	O

Imaging	0	7	O
techniques	8	18	O
for	19	22	O
the	23	26	O
assessment	27	37	O
of	38	40	O
body	41	45	B-Organism_subdivision
composition	46	57	O
.	57	58	O

Three	59	64	O
imaging	65	72	O
methods	73	80	O
,	80	81	O
ultrasound	82	92	O
imaging	93	100	O
(	101	102	O
UI	102	104	O
)	104	105	O
,	105	106	O
computer	107	115	O
-	115	116	O
assisted	116	124	O
axial	125	130	O
tomography	131	141	O
(	142	143	O
CAT	143	146	O
)	146	147	O
and	148	151	O
magnetic	152	160	O
resonance	161	170	O
imaging	171	178	O
(	179	180	O
MRI	180	183	O
)	183	184	O
,	184	185	O
are	186	189	O
widely	190	196	O
used	197	201	O
in	202	204	O
medicine	205	213	O
.	213	214	O

Their	215	220	O
application	221	232	O
to	233	235	O
the	236	239	O
assessment	240	250	O
of	251	253	O
body	254	258	B-Organism_subdivision
composition	259	270	O
in	271	273	O
nutrition	274	283	O
research	284	292	O
is	293	295	O
still	296	301	O
being	302	307	O
explored	308	316	O
and	317	320	O
developed	321	330	O
.	330	331	O

Ultrasound	332	342	O
imaging	343	350	O
yields	351	357	O
poor	358	362	O
image	363	368	O
quality	369	376	O
but	377	380	O
,	380	381	O
because	382	389	O
it	390	392	O
is	393	395	O
cheap	396	401	O
and	402	405	O
safe	406	410	O
,	410	411	O
deserves	412	420	O
further	421	428	O
exploration	429	440	O
.	440	441	O

Both	442	446	O
CAT	447	450	O
and	451	454	O
MRI	455	458	O
can	459	462	O
produce	463	470	O
images	471	477	O
with	478	482	O
good	483	487	O
discrimination	488	502	O
among	503	508	O
bone	509	513	B-Organ
,	513	514	O
muscle	515	521	B-Organ
and	522	525	O
adipose	526	533	B-Tissue
tissue	534	540	I-Tissue
.	540	541	O

Movement	542	550	O
artifacts	551	560	O
tend	561	565	O
to	566	568	O
be	569	571	O
more	572	576	O
serious	577	584	O
in	585	587	O
MRI	588	591	O
than	592	596	O
in	597	599	O
CAT	600	603	O
due	604	607	O
to	608	610	O
the	611	614	O
longer	615	621	O
imaging	622	629	O
time	630	634	O
.	634	635	O

On	636	638	O
the	639	642	O
other	643	648	O
hand	649	653	O
,	653	654	O
the	655	658	O
X	659	660	O
-	660	661	O
ray	661	664	O
exposure	665	673	O
in	674	676	O
CAT	677	680	O
is	681	683	O
likely	684	690	O
to	691	693	O
limit	694	699	O
its	700	703	O
use	704	707	O
in	708	710	O
human	711	716	O
nutrition	717	726	O
research	727	735	O
.	735	736	O

Repeated	737	745	O
measurements	746	758	O
of	759	761	O
tissue	762	768	B-Tissue
volumes	769	776	O
by	777	779	O
CAT	780	783	O
and	784	787	O
MRI	788	791	O
give	792	796	O
similar	797	804	O
CV	805	807	O
.	807	808	O

In	809	811	O
both	812	816	O
CAT	817	820	O
and	821	824	O
MRI	825	828	O
,	828	829	O
intra	830	835	O
-	835	836	O
abdominal	836	845	B-Tissue
adipose	846	853	I-Tissue
tissue	854	860	I-Tissue
presents	861	869	O
greater	870	877	O
problems	878	886	O
of	887	889	O
measurement	890	901	O
than	902	906	O
subcutaneous	907	919	B-Tissue
adipose	920	927	I-Tissue
tissue	928	934	I-Tissue
.	934	935	O

Validation	936	946	O
studies	947	954	O
with	955	959	O
77	960	962	O
-	962	963	O
kg	963	965	O
pigs	966	970	O
of	971	973	O
MRI	974	977	O
,	977	978	O
using	979	984	O
13	985	987	O
slices	988	994	O
,	994	995	O
predicted	996	1005	O
total	1006	1011	O
body	1012	1016	B-Organism_subdivision
lipid	1017	1022	O
with	1023	1027	O
residual	1028	1036	O
standard	1037	1045	O
deviation	1046	1055	O
of	1056	1058	O
1	1059	1060	O
.	1060	1061	O
9	1061	1062	O
%	1062	1063	O
.	1063	1064	O

In	1065	1067	O
validating	1068	1078	O
any	1079	1082	O
of	1083	1085	O
these	1086	1091	O
methods	1092	1099	O
,	1099	1100	O
account	1101	1108	O
should	1109	1115	O
be	1116	1118	O
take	1119	1123	O
of	1124	1126	O
the	1127	1130	O
extent	1131	1137	O
to	1138	1140	O
which	1141	1146	O
the	1147	1150	O
information	1151	1162	O
they	1163	1167	O
give	1168	1172	O
can	1173	1176	O
augment	1177	1184	O
that	1185	1189	O
given	1190	1195	O
by	1196	1198	O
more	1199	1203	O
simple	1204	1210	O
measures	1211	1219	O
like	1220	1224	O
age	1225	1228	O
and	1229	1232	O
weight	1233	1239	O
.	1239	1240	O

Defective	0	9	O
biliary	10	17	O
copper	18	24	O
excretion	25	34	O
in	35	37	O
Wilson	38	44	O
'	44	45	O
s	45	46	O
disease	47	54	O
:	54	55	O
the	56	59	O
role	60	64	O
of	65	67	O
caeruloplasmin	68	82	O
.	82	83	O

Previous	84	92	O
studies	93	100	O
have	101	105	O
failed	106	112	O
to	113	115	O
explain	116	123	O
the	124	127	O
link	128	132	O
between	133	140	O
copper	141	147	O
accumulation	148	160	O
and	161	164	O
abnormal	165	173	O
caeruloplasmin	174	188	O
expression	189	199	O
in	200	202	O
Wilson	203	209	O
'	209	210	O
s	210	211	O
disease	212	219	O
.	219	220	O

Furthermore	221	232	O
,	232	233	O
despite	234	241	O
the	242	245	O
isolation	246	255	O
of	256	258	O
a	259	260	O
candidate	261	270	O
gene	271	275	O
for	276	279	O
Wilson	280	286	O
'	286	287	O
s	287	288	O
disease	289	296	O
,	296	297	O
which	298	303	O
predicts	304	312	O
a	313	314	O
defective	315	324	O
copper	325	331	O
transport	332	341	O
protein	342	349	O
,	349	350	O
the	351	354	O
localization	355	367	O
of	368	370	O
this	371	375	O
putative	376	384	O
protein	385	392	O
and	393	396	O
its	397	400	O
relationship	401	413	O
to	414	416	O
the	417	420	O
pathway	421	428	O
involved	429	437	O
in	438	440	O
copper	441	447	O
excretion	448	457	O
and	458	461	O
to	462	464	O
caeruloplasmin	465	479	O
remain	480	486	O
unknown	487	494	O
.	494	495	O

We	496	498	O
now	499	502	O
present	503	510	O
evidence	511	519	O
that	520	524	O
caeruloplasmin	525	539	O
,	539	540	O
the	541	544	O
major	545	550	O
plasma	551	557	B-Organism_substance
copper	558	564	O
-	564	565	O
carrying	565	573	O
protein	574	581	O
,	581	582	O
is	583	585	O
present	586	593	O
in	594	596	O
the	597	600	O
liver	601	606	B-Organ
in	607	609	O
Wilson	610	616	O
'	616	617	O
s	617	618	O
disease	619	626	O
,	626	627	O
and	628	631	O
thus	632	636	O
that	637	641	O
reduced	642	649	O
circulating	650	661	O
levels	662	668	O
of	669	671	O
the	672	675	O
protein	676	683	O
result	684	690	O
from	691	695	O
a	696	697	O
post	698	702	O
-	702	703	O
translational	703	716	O
defect	717	723	O
in	724	726	O
the	727	730	O
secretory	731	740	O
pathway	741	748	O
.	748	749	O

We	750	752	O
have	753	757	O
also	758	762	O
identified	763	773	O
a	774	775	O
novel	776	781	O
form	782	786	O
of	787	789	O
caeruloplasmin	790	804	O
,	804	805	O
molecular	806	815	O
weight	816	822	O
125	823	826	O
kD	827	829	O
,	829	830	O
which	831	836	O
we	837	839	O
propose	840	847	O
may	848	851	O
act	852	855	O
as	856	858	O
the	859	862	O
carrier	863	870	O
for	871	874	O
excretory	875	884	O
copper	885	891	O
into	892	896	O
bile	897	901	B-Organism_substance
,	901	902	O
since	903	908	O
it	909	911	O
is	912	914	O
normally	915	923	O
present	924	931	O
in	932	934	O
both	935	939	O
liver	940	945	B-Organ
and	946	949	O
bile	950	954	B-Organism_substance
,	954	955	O
although	956	964	O
largely	965	972	O
absent	973	979	O
from	980	984	O
serum	985	990	B-Organism_substance
,	990	991	O
and	992	995	O
undetectable	996	1008	O
in	1009	1011	O
bile	1012	1016	B-Organism_substance
from	1017	1021	O
Wilson	1022	1028	O
'	1028	1029	O
s	1029	1030	O
disease	1031	1038	O
patients	1039	1047	O
.	1047	1048	O

The	1049	1052	O
presence	1053	1061	O
of	1062	1064	O
this	1065	1069	O
form	1070	1074	O
of	1075	1077	O
caeruloplasmin	1078	1092	O
in	1093	1095	O
Wilson	1096	1102	O
'	1102	1103	O
s	1103	1104	O
disease	1105	1112	O
liver	1113	1118	B-Organ
suggests	1119	1127	O
that	1128	1132	O
a	1133	1134	O
related	1135	1142	O
post	1143	1147	O
-	1147	1148	O
translational	1148	1161	O
defect	1162	1168	O
may	1169	1172	O
also	1173	1177	O
be	1178	1180	O
responsible	1181	1192	O
for	1193	1196	O
its	1197	1200	O
absence	1201	1208	O
from	1209	1213	O
bile	1214	1218	B-Organism_substance
in	1219	1221	O
Wilson	1222	1228	O
'	1228	1229	O
s	1229	1230	O
disease	1231	1238	O
.	1238	1239	O

This	1240	1244	O
study	1245	1250	O
thus	1251	1255	O
provides	1256	1264	O
the	1265	1268	O
first	1269	1274	O
plausible	1275	1284	O
explanation	1285	1296	O
of	1297	1299	O
a	1300	1301	O
link	1302	1306	O
between	1307	1314	O
the	1315	1318	O
defective	1319	1328	O
copper	1329	1335	O
excretion	1336	1345	O
and	1346	1349	O
the	1350	1353	O
reduced	1354	1361	O
plasma	1362	1368	B-Organism_substance
caeruloplasmin	1369	1383	O
,	1383	1384	O
which	1385	1390	O
characterize	1391	1403	O
Wilson	1404	1410	O
'	1410	1411	O
s	1411	1412	O
disease	1413	1420	O
.	1420	1421	O

Conservative	0	12	O
treatment	13	22	O
of	23	25	O
endometriosis	26	39	O
:	39	40	O
the	41	44	O
effects	45	52	O
of	53	55	O
limited	56	63	O
surgery	64	71	O
and	72	75	O
hormonal	76	84	O
pseudopregnancy	85	100	O
.	100	101	O

This	102	106	O
study	107	112	O
compares	113	121	O
the	122	125	O
effects	126	133	O
of	134	136	O
limited	137	144	O
surgery	145	152	O
or	153	155	O
hormonal	156	164	O
pseudopregnancy	165	180	O
,	180	181	O
or	182	184	O
a	185	186	O
combination	187	198	O
of	199	201	O
these	202	207	O
two	208	211	O
,	211	212	O
upon	213	217	O
fertility	218	227	O
and	228	231	O
the	232	235	O
need	236	240	O
for	241	244	O
subsequent	245	255	O
surgery	256	263	O
with	264	268	O
respect	269	276	O
to	277	279	O
the	280	283	O
extent	284	290	O
of	291	293	O
the	294	297	O
disease	298	305	O
at	306	308	O
the	309	312	O
time	313	317	O
of	318	320	O
initial	321	328	O
diagnosis	329	338	O
in	339	341	O
patients	342	350	O
with	351	355	O
endometriosis	356	369	O
externa	370	377	O
.	377	378	O

Of	379	381	O
the	382	385	O
61	386	388	O
patients	389	397	O
who	398	401	O
desired	402	409	O
to	410	412	O
enhance	413	420	O
or	421	423	O
preserve	424	432	O
reproductive	433	445	O
capacity	446	454	O
,	454	455	O
20	456	458	O
patients	459	467	O
became	468	474	O
pregnant	475	483	O
,	483	484	O
for	485	488	O
a	489	490	O
pregnancy	491	500	O
rate	501	505	O
of	506	508	O
33	509	511	O
%	511	512	O
.	512	513	O

The	514	517	O
pregnancy	518	527	O
rate	528	532	O
in	533	535	O
all	536	539	O
categories	540	550	O
,	550	551	O
that	552	556	O
is	557	559	O
,	559	560	O
those	561	566	O
patients	567	575	O
treated	576	583	O
with	584	588	O
pseudopregnancy	589	604	O
,	604	605	O
conservative	606	618	O
surgery	619	626	O
,	626	627	O
and	628	631	O
combined	632	640	O
pseudopregnancy	641	656	O
and	657	660	O
surgery	661	668	O
,	668	669	O
was	670	673	O
found	674	679	O
to	680	682	O
be	683	685	O
in	686	688	O
direct	689	695	O
relationship	696	708	O
to	709	711	O
the	712	715	O
initial	716	723	O
extent	724	730	O
of	731	733	O
disease	734	741	O
.	741	742	O

In	743	745	O
such	746	750	O
patients	751	759	O
,	759	760	O
conservative	761	773	O
surgery	774	781	O
alone	782	787	O
seemed	788	794	O
to	795	797	O
give	798	802	O
the	803	806	O
best	807	811	O
results	812	819	O
in	820	822	O
the	823	826	O
achievement	827	838	O
of	839	841	O
pregnancy	842	851	O
.	851	852	O

There	853	858	O
seemed	859	865	O
to	866	868	O
be	869	871	O
little	872	878	O
difference	879	889	O
between	890	897	O
pseudopregnancy	898	913	O
alone	914	919	O
and	920	923	O
conservative	924	936	O
surgery	937	944	O
in	945	947	O
regard	948	954	O
to	955	957	O
the	958	961	O
need	962	966	O
for	967	970	O
subsequent	971	981	O
surgery	982	989	O
after	990	995	O
initial	996	1003	O
therapy	1004	1011	O
,	1011	1012	O
although	1013	1021	O
there	1022	1027	O
seemed	1028	1034	O
to	1035	1037	O
be	1038	1040	O
a	1041	1042	O
significantly	1043	1056	O
greater	1057	1064	O
chance	1065	1071	O
for	1072	1075	O
the	1076	1079	O
need	1080	1084	O
for	1085	1088	O
subsequent	1089	1099	O
surgery	1100	1107	O
in	1108	1110	O
patients	1111	1119	O
receiving	1120	1129	O
a	1130	1131	O
combination	1132	1143	O
of	1144	1146	O
the	1147	1150	O
two	1151	1154	O
forms	1155	1160	O
of	1161	1163	O
therapy	1164	1171	O
.	1171	1172	O

The	1173	1176	O
need	1177	1181	O
for	1182	1185	O
subsequent	1186	1196	O
surgery	1197	1204	O
after	1205	1210	O
initial	1211	1218	O
therapy	1219	1226	O
in	1227	1229	O
80	1230	1232	O
patients	1233	1241	O
increased	1242	1251	O
in	1252	1254	O
direct	1255	1261	O
relationship	1262	1274	O
to	1275	1277	O
the	1278	1281	O
initial	1282	1289	O
extent	1290	1296	O
of	1297	1299	O
disease	1300	1307	O
present	1308	1315	O
,	1315	1316	O
despite	1317	1324	O
the	1325	1328	O
form	1329	1333	O
of	1334	1336	O
therapy	1337	1344	O
used	1345	1349	O
.	1349	1350	O

Fifty	1351	1356	O
-	1356	1357	O
nine	1357	1361	O
other	1362	1367	O
patients	1368	1376	O
with	1377	1381	O
endometriosis	1382	1395	O
,	1395	1396	O
who	1397	1400	O
did	1401	1404	O
not	1405	1408	O
desire	1409	1415	O
to	1416	1418	O
preserve	1419	1427	O
fertility	1428	1437	O
and	1438	1441	O
presented	1442	1451	O
for	1452	1455	O
relief	1456	1462	O
of	1463	1465	O
other	1466	1471	O
symptoms	1472	1480	O
,	1480	1481	O
underwent	1482	1491	O
initial	1492	1499	O
"	1500	1501	O
radical	1501	1508	O
"	1508	1509	O
therapy	1510	1517	O
.	1517	1518	O

Forty	1519	1524	O
-	1524	1525	O
six	1525	1528	O
patients	1529	1537	O
underwent	1538	1547	O
complete	1548	1556	O
operation	1557	1566	O
,	1566	1567	O
including	1568	1577	O
removal	1578	1585	O
of	1586	1588	O
uterus	1589	1595	B-Organ
,	1595	1596	O
tubes	1597	1602	B-Multi-tissue_structure
and	1603	1606	O
ovaries	1607	1614	B-Organ
,	1614	1615	O
and	1616	1619	O
none	1620	1624	O
required	1625	1633	O
subsequent	1634	1644	O
reoperation	1645	1656	O
.	1656	1657	O

Of	1658	1660	O
the	1661	1664	O
13	1665	1667	O
remaining	1668	1677	O
patients	1678	1686	O
,	1686	1687	O
who	1688	1691	O
underwent	1692	1701	O
incomplete	1702	1712	O
surgical	1713	1721	O
removal	1722	1729	O
,	1729	1730	O
leaving	1731	1738	O
one	1739	1742	O
or	1743	1745	O
both	1746	1750	O
ovaries	1751	1758	B-Organ
in	1759	1761	O
situ	1762	1766	O
,	1766	1767	O
11	1768	1770	O
required	1771	1779	O
subsequent	1780	1790	O
reoperation	1791	1802	O
for	1803	1806	O
recurrent	1807	1816	O
pelvic	1817	1823	O
endometriosis	1824	1837	O
.	1837	1838	O

Lack	0	4	O
of	5	7	O
developmental	8	21	O
and	22	25	O
reproductive	26	38	O
toxicity	39	47	O
of	48	50	O
2	51	52	O
,	52	53	O
3	53	54	O
,	54	55	O
3	55	56	O
'	56	57	O
,	57	58	O
4	58	59	O
,	59	60	O
4	61	62	O
'	62	63	O
-	63	64	O
pentachlorobiphenyl	64	83	O
(	84	85	O
PCB	85	88	O
105	89	92	O
)	92	93	O
in	94	96	O
ring	97	101	O
-	101	102	O
necked	102	108	O
pheasants	109	118	O
.	118	119	O

Mono	120	124	O
-	124	125	O
ortho	125	130	O
PCBs	131	135	O
are	136	139	O
global	140	146	O
contaminants	147	159	O
of	160	162	O
wildlife	163	171	O
with	172	176	O
the	177	180	O
potential	181	190	O
to	191	193	O
produce	194	201	O
toxicity	202	210	O
by	211	213	O
an	214	216	O
aryl	217	221	O
hydrocarbon	222	233	O
receptor	234	242	O
(	243	244	O
AhR	244	247	O
)	247	248	O
-	248	249	O
mediated	249	257	O
mechanism	258	267	O
.	267	268	O

To	269	271	O
determine	272	281	O
the	282	285	O
potency	286	293	O
of	294	296	O
2	297	298	O
,	298	299	O
3	299	300	O
,	300	301	O
3	301	302	O
'	302	303	O
,	303	304	O
4	304	305	O
,	305	306	O
4	307	308	O
'	308	309	O
-	309	310	O
pentachlorobiphenyl	310	329	O
(	330	331	O
PCB	331	334	O
105	335	338	O
)	338	339	O
for	340	343	O
producing	344	353	O
reproductive	354	366	O
and	367	370	O
developmental	371	384	O
toxicity	385	393	O
,	393	394	O
adult	395	400	O
ring	401	405	O
-	405	406	O
necked	406	412	O
pheasant	413	421	O
hens	422	426	O
(	427	428	O
Phasianus	428	437	O
colchicus	438	447	O
)	447	448	O
were	449	453	O
orally	454	460	O
dosed	461	466	O
with	467	471	O
0	472	473	O
,	473	474	O
0	475	476	O
.	476	477	O
06	477	479	O
,	479	480	O
0	481	482	O
.	482	483	O
6	483	484	O
,	484	485	O
or	486	488	O
6	489	490	O
mg	491	493	O
PCB	494	497	O
105	498	501	O
/	501	502	O
kg	502	504	O
hen	505	508	O
/	508	509	O
week	509	513	O
for	514	517	O
10	518	520	O
weeks	521	526	O
to	527	529	O
achieve	530	537	O
cumulative	538	548	O
doses	549	554	O
of	555	557	O
0	558	559	O
,	559	560	O
0	561	562	O
.	562	563	O
6	563	564	O
,	564	565	O
6	566	567	O
,	567	568	O
or	569	571	O
60	572	574	O
mg	575	577	O
PCB	578	581	O
105	582	585	O
/	585	586	O
kg	586	588	O
hen	589	592	O
after	593	598	O
which	599	604	O
hens	605	609	O
were	610	614	O
bred	615	619	O
with	620	624	O
untreated	625	634	O
roosters	635	643	O
once	644	648	O
per	649	652	O
week	653	657	O
for	658	661	O
8	662	663	O
weeks	664	669	O
.	669	670	O

Except	671	677	O
at	678	680	O
week	681	685	O
6	686	687	O
of	688	690	O
the	691	694	O
egg	695	698	B-Developing_anatomical_structure
-	698	699	O
laying	699	705	O
period	706	712	O
when	713	717	O
cumulative	718	728	O
egg	729	732	B-Developing_anatomical_structure
production	733	743	O
in	744	746	O
the	747	750	O
6	751	752	O
mg	753	755	O
PCB	756	759	O
105	760	763	O
/	763	764	O
kg	764	766	O
hen	767	770	O
group	771	776	O
was	777	780	O
greater	781	788	O
than	789	793	O
controls	794	802	O
,	802	803	O
fertilized	804	814	O
egg	815	818	B-Developing_anatomical_structure
production	819	829	O
was	830	833	O
not	834	837	O
significantly	838	851	O
different	852	861	O
between	862	869	O
treatment	870	879	O
groups	880	886	O
.	886	887	O

Embryo	888	894	B-Developing_anatomical_structure
mortality	895	904	O
and	905	908	O
chick	909	914	O
mortality	915	924	O
were	925	929	O
not	930	933	O
significantly	934	947	O
different	948	957	O
between	958	965	O
treatment	966	975	O
groups	976	982	O
.	982	983	O

Total	984	989	O
body	990	994	B-Organism_subdivision
and	995	998	O
heart	999	1004	B-Organ
weights	1005	1012	O
of	1013	1015	O
all	1016	1019	O
chicks	1020	1026	O
1	1027	1028	O
day	1029	1032	O
posthatch	1033	1042	O
(	1043	1044	O
dph	1044	1047	O
)	1047	1048	O
were	1049	1053	O
not	1054	1057	O
different	1058	1067	O
between	1068	1075	O
groups	1076	1082	O
,	1082	1083	O
however	1084	1091	O
,	1091	1092	O
liver	1093	1098	B-Organ
weights	1099	1106	O
of	1107	1109	O
chicks	1110	1116	O
from	1117	1121	O
the	1122	1125	O
60	1126	1128	O
mg	1129	1131	O
/	1131	1132	O
kg	1132	1134	O
treatment	1135	1144	O
group	1145	1150	O
were	1151	1155	O
greater	1156	1163	O
than	1164	1168	O
controls	1169	1177	O
at	1178	1180	O
1	1181	1182	O
dph	1183	1186	O
.	1186	1187	O

The	1188	1191	O
first	1192	1197	O
chick	1198	1203	O
to	1204	1206	O
hatch	1207	1212	O
from	1213	1217	O
each	1218	1222	O
hen	1223	1226	O
was	1227	1230	O
reared	1231	1237	O
to	1238	1240	O
21	1241	1243	O
dph	1244	1247	O
and	1248	1251	O
among	1252	1257	O
these	1258	1263	O
birds	1264	1269	O
,	1269	1270	O
the	1271	1274	O
total	1275	1280	O
body	1281	1285	B-Organism_subdivision
,	1285	1286	O
liver	1287	1292	B-Organ
,	1292	1293	O
and	1294	1297	O
heart	1298	1303	B-Organ
weights	1304	1311	O
were	1312	1316	O
not	1317	1320	O
different	1321	1330	O
between	1331	1338	O
groups	1339	1345	O
.	1345	1346	O

There	1347	1352	O
were	1353	1357	O
no	1358	1360	O
dose	1361	1365	O
-	1365	1366	O
related	1366	1373	O
malformations	1374	1387	O
of	1388	1390	O
the	1391	1394	O
beak	1395	1399	B-Organism_subdivision
or	1400	1402	O
limbs	1403	1408	B-Organism_subdivision
,	1408	1409	O
and	1410	1413	O
no	1414	1416	O
signs	1417	1422	O
of	1423	1425	O
subcutaneous	1426	1438	B-Pathological_formation
edema	1439	1444	I-Pathological_formation
,	1444	1445	O
ascites	1446	1453	B-Organism_substance
,	1453	1454	O
or	1455	1457	O
pericardial	1458	1469	B-Pathological_formation
edema	1470	1475	I-Pathological_formation
in	1476	1478	O
chicks	1479	1485	O
at	1486	1488	O
1	1489	1490	O
or	1491	1493	O
21	1494	1496	O
dph	1497	1500	O
.	1500	1501	O

Hepatic	1502	1509	O
microsomal	1510	1520	O
monooxygenase	1521	1534	O
activities	1535	1545	O
[	1546	1547	O
ethoxyresorufin	1547	1562	O
-	1562	1563	O
O	1563	1564	O
-	1564	1565	O
dealkylase	1565	1575	O
(	1576	1577	O
EROD	1577	1581	O
)	1581	1582	O
,	1582	1583	O
benzyloxyresorufin	1584	1602	O
-	1602	1603	O
O	1603	1604	O
-	1604	1605	O
dealkylase	1605	1615	O
(	1616	1617	O
BROD	1617	1621	O
)	1621	1622	O
,	1622	1623	O
and	1624	1627	O
methyloxyresorufin	1628	1646	O
-	1646	1647	O
O	1647	1648	O
-	1648	1649	O
dealkylase	1649	1659	O
(	1660	1661	O
MROD	1661	1665	O
)	1665	1666	O
]	1666	1667	O
were	1668	1672	O
significantly	1673	1686	O
elevated	1687	1695	O
in	1696	1698	O
chicks	1699	1705	O
at	1706	1708	O
1	1709	1710	O
dph	1711	1714	O
from	1715	1719	O
hens	1720	1724	O
given	1725	1730	O
a	1731	1732	O
cumulative	1733	1743	O
PCB	1744	1747	O
105	1748	1751	O
dose	1752	1756	O
of	1757	1759	O
6	1760	1761	O
mg	1762	1764	O
/	1764	1765	O
kg	1765	1767	O
and	1768	1771	O
in	1772	1774	O
chicks	1775	1781	O
at	1782	1784	O
21	1785	1787	O
dph	1788	1791	O
from	1792	1796	O
hens	1797	1801	O
given	1802	1807	O
a	1808	1809	O
cumulative	1810	1820	O
PCB	1821	1824	O
dose	1825	1829	O
of	1830	1832	O
60	1833	1835	O
mg	1836	1838	O
/	1838	1839	O
kg	1839	1841	O
.	1841	1842	O

These	1843	1848	O
results	1849	1856	O
indicate	1857	1865	O
that	1866	1870	O
a	1871	1872	O
cumulative	1873	1883	O
PCB	1884	1887	O
105	1888	1891	O
dose	1892	1896	O
up	1897	1899	O
to	1900	1902	O
60	1903	1905	O
mg	1906	1908	O
/	1908	1909	O
kg	1909	1911	O
hen	1912	1915	O
does	1916	1920	O
not	1921	1924	O
decrease	1925	1933	O
the	1934	1937	O
production	1938	1948	O
of	1949	1951	O
fertilized	1952	1962	O
eggs	1963	1967	B-Developing_anatomical_structure
or	1968	1970	O
increase	1971	1979	O
embryo	1980	1986	B-Developing_anatomical_structure
or	1987	1989	O
chick	1990	1995	O
mortality	1996	2005	O
in	2006	2008	O
ring	2009	2013	O
-	2013	2014	O
necked	2014	2020	O
pheasants	2021	2030	O
,	2030	2031	O
but	2032	2035	O
does	2036	2040	O
increase	2041	2049	O
chick	2050	2055	O
hepatic	2056	2063	B-Organ
monooxygenase	2064	2077	O
activity	2078	2086	O
.	2086	2087	O

Detection	0	9	O
of	10	12	O
total	13	18	O
assist	19	25	O
and	26	29	O
sucking	30	37	O
points	38	44	O
based	45	50	O
on	51	53	O
the	54	57	O
pulsatility	58	69	O
of	70	72	O
a	73	74	O
continuous	75	85	O
flow	86	90	O
artificial	91	101	O
heart	102	107	O
:	107	108	O
in	109	111	O
vivo	112	116	O
evaluation	117	127	O
.	127	128	O

Our	129	132	O
novel	133	138	O
control	139	146	O
strategy	147	155	O
for	156	159	O
a	160	161	O
continuous	162	172	O
flow	173	177	O
artificial	178	188	O
heart	189	194	O
by	195	197	O
detecting	198	207	O
the	208	211	O
total	212	217	O
assist	218	224	O
and	225	228	O
sucking	229	236	O
points	237	243	O
based	244	249	O
on	250	252	O
pump	253	257	O
pulsatility	258	269	O
was	270	273	O
evaluated	274	283	O
in	284	286	O
acute	287	292	O
animal	293	299	O
experiments	300	311	O
using	312	317	O
beagle	318	324	O
dogs	325	329	O
and	330	333	O
our	334	337	O
mixed	338	343	O
flow	344	348	O
pump	349	353	O
.	353	354	O

The	355	358	O
pump	359	363	O
was	364	367	O
installed	368	377	O
as	378	380	O
a	381	382	O
left	383	387	B-Multi-tissue_structure
ventricular	388	399	I-Multi-tissue_structure
(	400	401	O
LV	401	403	B-Multi-tissue_structure
)	403	404	O
bypass	405	411	O
through	412	419	O
a	420	421	O
left	422	426	O
thoracotomy	427	438	O
.	438	439	O

To	440	442	O
change	443	449	O
LV	450	452	B-Multi-tissue_structure
contractility	453	466	O
,	466	467	O
the	468	471	O
left	472	476	O
coronary	477	485	B-Multi-tissue_structure
arteries	486	494	I-Multi-tissue_structure
were	495	499	O
occluded	500	508	O
for	509	512	O
30	513	515	O
min	516	519	O
,	519	520	O
followed	521	529	O
by	530	532	O
a	533	534	O
120	535	538	O
min	539	542	O
reperfusion	543	554	O
.	554	555	O

To	556	558	O
change	559	565	O
LV	566	568	B-Multi-tissue_structure
end	569	572	O
diastolic	573	582	O
pressure	583	591	O
(	592	593	O
LVEDP	593	598	O
)	598	599	O
,	599	600	O
dextran	601	608	O
solution	609	617	O
was	618	621	O
rapidly	622	629	O
infused	630	637	O
.	637	638	O

To	639	641	O
estimate	642	650	O
the	651	654	O
pump	655	659	O
pulsatility	660	671	O
without	672	679	O
any	680	683	O
specific	684	692	O
sensor	693	699	O
,	699	700	O
we	701	703	O
calculated	704	714	O
the	715	718	O
index	719	724	O
of	725	727	O
current	728	735	O
amplitude	736	745	O
(	746	747	O
ICA	747	750	O
)	750	751	O
,	751	752	O
which	753	758	O
was	759	762	O
obtained	763	771	O
from	772	776	O
the	777	780	O
amplitude	781	790	O
of	791	793	O
the	794	797	O
motor	798	803	O
current	804	811	O
waveform	812	820	O
divided	821	828	O
by	829	831	O
the	832	835	O
simultaneous	836	848	O
mean	849	853	O
value	854	859	O
.	859	860	O

To	861	863	O
investigate	864	875	O
the	876	879	O
basic	880	885	O
characteristics	886	901	O
of	902	904	O
the	905	908	O
ICA	909	912	O
,	912	913	O
the	914	917	O
pump	918	922	O
speed	923	928	O
was	929	932	O
changed	933	940	O
temporarily	941	952	O
from	953	957	O
2	958	959	O
,	959	960	O
300	960	963	O
rpm	964	967	O
to	968	970	O
5	971	972	O
,	972	973	O
000	973	976	O
rpm	977	980	O
.	980	981	O

In	982	984	O
92	985	987	O
%	987	988	O
of	989	991	O
all	992	995	O
measurements	996	1008	O
,	1008	1009	O
the	1010	1013	O
ICA	1014	1017	O
plotted	1018	1025	O
against	1026	1033	O
the	1034	1037	O
pump	1038	1042	O
speed	1043	1048	O
had	1049	1052	O
a	1053	1054	O
peak	1055	1059	O
point	1060	1065	O
(	1066	1067	O
t	1067	1068	O
-	1068	1069	O
point	1069	1074	O
)	1074	1075	O
that	1076	1080	O
corresponded	1081	1093	O
highly	1094	1100	O
with	1101	1105	O
the	1106	1109	O
turning	1110	1117	O
point	1118	1123	O
from	1124	1128	O
partial	1129	1136	O
to	1137	1139	O
total	1140	1145	O
assistance	1146	1156	O
.	1156	1157	O

The	1158	1161	O
ICA	1162	1165	O
also	1166	1170	O
had	1171	1174	O
a	1175	1176	O
trough	1177	1183	O
(	1184	1185	O
s	1185	1186	O
-	1186	1187	O
point	1187	1192	O
)	1192	1193	O
that	1194	1198	O
corresponded	1199	1211	O
with	1212	1216	O
the	1217	1220	O
beginning	1221	1230	O
of	1231	1233	O
severe	1234	1240	O
sucking	1241	1248	O
in	1249	1251	O
most	1252	1256	O
cases	1257	1262	O
.	1262	1263	O

Only	1264	1268	O
preload	1269	1276	O
significantly	1277	1290	O
influenced	1291	1301	O
pump	1302	1306	O
flow	1307	1311	O
rate	1312	1316	O
at	1317	1319	O
the	1320	1323	O
t	1324	1325	O
-	1325	1326	O
point	1326	1331	O
from	1332	1336	O
among	1337	1342	O
preload	1343	1350	O
(	1351	1352	O
LVEDP	1352	1357	O
)	1357	1358	O
,	1358	1359	O
afterload	1360	1369	O
(	1370	1371	O
SAoP	1371	1375	O
)	1375	1376	O
,	1376	1377	O
and	1378	1381	O
contractility	1382	1395	O
(	1396	1397	O
max	1397	1400	O
LV	1401	1403	B-Multi-tissue_structure
dP	1404	1406	O
/	1406	1407	O
dt	1407	1409	O
)	1409	1410	O
,	1410	1411	O
by	1412	1414	O
which	1415	1420	O
we	1421	1423	O
can	1424	1427	O
simulate	1428	1436	O
Starling	1437	1445	O
'	1445	1446	O
s	1446	1447	O
law	1448	1451	O
of	1452	1454	O
the	1455	1458	O
natural	1459	1466	O
heart	1467	1472	B-Organ
.	1472	1473	O

We	1474	1476	O
concluded	1477	1486	O
that	1487	1491	O
a	1492	1493	O
continuous	1494	1504	O
flow	1505	1509	O
artificial	1510	1520	O
heart	1521	1526	O
could	1527	1532	O
be	1533	1535	O
well	1536	1540	O
controlled	1541	1551	O
by	1552	1554	O
detecting	1555	1564	O
the	1565	1568	O
t	1569	1570	O
-	1570	1571	O
point	1571	1576	O
and	1577	1580	O
s	1581	1582	O
-	1582	1583	O
point	1583	1588	O
.	1588	1589	O

Immunostaining	0	14	O
and	15	18	O
confocal	19	27	O
analysis	28	36	O

DNA	37	40	O
labelling	41	50	O
and	51	54	O
staining	55	63	O
with	64	68	O
5	69	70	O
-	70	71	O
bromo	71	76	O
-	76	77	O
2	77	78	O
'	78	79	O
-	79	80	O
deoxyuridine	80	92	O
(	93	94	O
BrdU	94	98	O
labelling	99	108	O
and	109	112	O
detection	113	122	O
kit	123	126	O
I	127	128	O
;	128	129	O
Boehringer	130	140	O
Mannheim	141	149	O
,	149	150	O
Germany	151	158	O
)	158	159	O
was	160	163	O
performed	164	173	O
according	174	183	O
to	184	186	O
the	187	190	O
manufacturer	191	203	O
'	203	204	O
s	204	205	O
instructions	206	218	O
.	218	219	O

The	220	223	O
nucleoli	224	232	B-Cellular_component
were	233	237	O
detected	238	246	O
with	247	251	O
an	252	254	O
anti	255	259	O
-	259	260	O
nucleolin	260	269	O
antibody	270	278	O
(	279	280	O
clone	280	285	O
3G4B2	286	291	O
;	291	292	O
Upstate	293	300	O
biotechnology	301	314	O
,	314	315	O
Lake	316	320	O
Placid	321	327	O
,	327	328	O
NY	329	331	O
)	331	332	O
on	333	335	O
cells	336	341	B-Cell
fixed	342	347	O
in	348	350	O
2	351	352	O
%	352	353	O
formalin	354	362	O
for	363	366	O
10	367	369	O
min	370	373	O
followed	374	382	O
by	383	385	O
permeabilization	386	402	O
with	403	407	O
ice	408	411	O
-	411	412	O
cold	412	416	O
methanol	417	425	O
for	426	429	O
30	430	432	O
min	433	436	O
.	436	437	O

The	438	441	O
secondary	442	451	O
antibody	452	460	O
used	461	465	O
for	466	469	O
both	470	474	O
BrdU	475	479	O
and	480	483	O
nucleoli	484	492	B-Cellular_component
staining	493	501	O
was	502	505	O
a	506	507	O
rhodamine	508	517	O
(	518	519	O
tetra	519	524	O
-	524	525	O
methyl	525	531	O
)	531	532	O
-	532	533	O
conjugated	533	543	O
goat	544	548	O
anti	549	553	O
-	553	554	O
mouse	554	559	O
antibody	560	568	O
(	569	570	O
T	570	571	O
-	571	572	O
2762	572	576	O
)	576	577	O
from	578	582	O
Molecular	583	592	O
Probe	593	598	O
(	599	600	O
Eugene	600	606	O
,	606	607	O
OR	608	610	O
)	610	611	O
.	611	612	O

The	613	616	O
cells	617	622	B-Cell
were	623	627	O
examined	628	636	O
in	637	639	O
a	640	641	O
Zeiss	642	647	O
LSM	648	651	O
510	652	655	O
laser	656	661	O
scanning	662	670	O
microscope	671	681	O
equipped	682	690	O
with	691	695	O
a	696	697	O
Plan	698	702	O
-	702	703	O
Apochromate	703	714	O
63x	715	718	O
/	718	719	O
1	719	720	O
.	720	721	O
4	721	722	O
oil	723	726	O
immersion	727	736	O
objective	737	746	O
.	746	747	O

We	748	750	O
used	751	755	O
the	756	759	O
488	760	763	O
nm	764	766	O
laser	767	772	O
line	773	777	O
for	778	781	O
excitation	782	792	O
of	793	795	O
EGFP	796	800	O
(	801	802	O
detected	802	810	O
at	811	813	O
505	814	817	O
nm	818	820	O
<	821	822	O
lambdaEGFP	823	833	O
<	834	835	O
530	836	839	O
nm	840	842	O
)	842	843	O
and	844	847	O
the	848	851	O
543	852	855	O
nm	856	858	O
laser	859	864	O
line	865	869	O
for	870	873	O
rhodamine	874	883	O
(	884	885	O
tetra	885	890	O
-	890	891	O
methyl	891	897	O
)	897	898	O
(	899	900	O
detected	900	908	O
at	909	911	O
lambdaRhodamine	912	927	O
>	928	929	O
560	930	933	O
nm	934	936	O
)	936	937	O
.	937	938	O

ECFP	939	943	O
fusion	944	950	O
protein	951	958	O
was	959	962	O
excited	963	970	O
with	971	975	O
a	976	977	O
458	978	981	O
nm	982	984	O
laser	985	990	O
line	991	995	O
(	996	997	O
detected	997	1005	O
at	1006	1008	O
480	1009	1012	O
nm	1013	1015	O
<	1016	1017	O
lambdaECFP	1018	1028	O
<	1029	1030	O
520	1031	1034	O
nm	1035	1037	O
)	1037	1038	O
,	1038	1039	O
EYFP	1040	1044	O
fusion	1045	1051	O
protein	1052	1059	O
was	1060	1063	O
excited	1064	1071	O
with	1072	1076	O
a	1077	1078	O
514	1079	1082	O
nm	1083	1085	O
laser	1086	1091	O
line	1092	1096	O
(	1097	1098	O
lambdaEGFP	1098	1108	O
>	1109	1110	O
560	1111	1114	O
nm	1115	1117	O
)	1117	1118	O
and	1119	1122	O
HcRed	1123	1128	O
fusion	1129	1135	O
protein	1136	1143	O
was	1144	1147	O
excited	1148	1155	O
with	1156	1160	O
a	1161	1162	O
543	1163	1166	O
nm	1167	1169	O
laser	1170	1175	O
line	1176	1180	O
and	1181	1184	O
detected	1185	1193	O
at	1194	1196	O
>	1197	1198	O
585	1198	1201	O
or	1202	1204	O
650	1205	1208	O
nm	1209	1211	O
.	1211	1212	O

The	1213	1216	O
images	1217	1223	O
were	1224	1228	O
from	1229	1233	O
1	1234	1235	O
mum	1236	1239	O
thick	1240	1245	O
slices	1246	1252	B-Cell
of	1253	1255	O
the	1256	1259	O
cells	1260	1265	B-Cell
.	1265	1266	O

The	1267	1270	O
images	1271	1277	O
were	1278	1282	O
exported	1283	1291	O
into	1292	1296	O
Adobe	1297	1302	O
Photoshop	1303	1312	O
(	1313	1314	O
Adobe	1314	1319	O
Systems	1320	1327	O
Inc	1328	1331	O
.	1331	1332	O
,	1332	1333	O
San	1334	1337	O
Jose	1338	1342	O
,	1342	1343	O
CA	1344	1346	O
)	1346	1347	O
.	1347	1348	O

Conclusions	0	11	O

Only	12	16	O
after	17	22	O
careful	23	30	O
consideration	31	44	O
of	45	47	O
the	48	51	O
biological	52	62	O
underpinnings	63	76	O
of	77	79	O
a	80	81	O
truly	82	87	O
beneficial	88	98	O
response	99	107	O
can	108	111	O
an	112	114	O
exposure	115	123	O
be	124	126	O
considered	127	137	O
for	138	141	O
the	142	145	O
general	146	153	O
population	154	164	O
,	164	165	O
such	166	170	O
as	171	173	O
the	174	177	O
addition	178	186	O
of	187	189	O
folic	190	195	O
acid	196	200	O
to	201	203	O
cereals	204	211	O
.	211	212	O

If	213	215	O
a	216	217	O
toxic	218	223	O
or	224	226	O
hazardous	227	236	O
pollutant	237	246	O
were	247	251	O
found	252	257	O
to	258	260	O
have	261	265	O
truly	266	271	O
beneficial	272	282	O
effects	283	290	O
at	291	293	O
low	294	297	O
dose	298	302	O
,	302	303	O
then	304	308	O
that	309	313	O
agent	314	319	O
should	320	326	O
be	327	329	O
tested	330	336	O
clinically	337	347	O
,	347	348	O
go	349	351	O
through	352	359	O
the	360	363	O
U	364	365	O
.	365	366	O
S	366	367	O
.	367	368	O

Food	369	373	O
and	374	377	O
Drug	378	382	O
Administration	383	397	O
(	398	399	O
FDA	399	402	O
)	402	403	O
approval	404	412	O
process	413	420	O
,	420	421	O
and	422	425	O
be	426	428	O
regulated	429	438	O
as	439	441	O
a	442	443	O
pharmaceutical	444	458	O
for	459	462	O
those	463	468	O
who	469	472	O
might	473	478	O
benefit	479	486	O
from	487	491	O
its	492	495	O
use	496	499	O
.	499	500	O

Certainly	501	510	O
,	510	511	O
the	512	515	O
general	516	523	O
population	524	534	O
should	535	541	O
not	542	545	O
be	546	548	O
exposed	549	556	O
to	557	559	O
chemotherapeutic	560	576	O
agents	577	583	O
that	584	588	O
benefit	589	596	O
cancer	597	603	B-Pathological_formation
patients	604	612	O
.	612	613	O

For	614	617	O
pharmaceuticals	618	633	O
,	633	634	O
it	635	637	O
is	638	640	O
understood	641	651	O
that	652	656	O
there	657	662	O
are	663	666	O
trade	667	672	O
offs	673	677	O
between	678	685	O
benefits	686	694	O
and	695	698	O
risks	699	704	O
.	704	705	O

For	706	709	O
example	710	717	O
,	717	718	O
although	719	727	O
aspirin	728	735	O
is	736	738	O
a	739	740	O
generally	741	750	O
well	751	755	O
-	755	756	O
tolerated	756	765	O
pain	766	770	O
reliever	771	779	O
and	780	783	O
is	784	786	O
increasingly	787	799	O
advocated	800	809	O
as	810	812	O
a	813	814	O
preventative	815	827	O
tool	828	832	O
for	833	836	O
heart	837	842	B-Organ
attacks	843	850	O
and	851	854	O
colorectal	855	865	B-Pathological_formation
cancer	866	872	I-Pathological_formation
(	873	874	O
Vainio	874	880	O
and	881	884	O
Miller	885	891	O
2003	892	896	O
;	896	897	O
Werner	898	904	O
et	905	907	O
al	908	910	O
.	910	911	O
2004	912	916	O
)	916	917	O
,	917	918	O
it	919	921	O
is	922	924	O
also	925	929	O
linked	930	936	O
to	937	939	O
increased	940	949	O
risk	950	954	O
of	955	957	O
gastrointestinal	958	974	B-Organism_subdivision
bleeding	975	983	O
,	983	984	O
cerebral	985	993	B-Organ
hemorrhage	994	1004	O
(	1005	1006	O
Werner	1006	1012	O
et	1013	1015	O
al	1016	1018	O
.	1018	1019	O
2004	1020	1024	O
)	1024	1025	O
,	1025	1026	O
and	1027	1030	O
asthma	1031	1037	O
attacks	1038	1045	O
(	1046	1047	O
Jenkins	1047	1054	O
et	1055	1057	O
al	1058	1060	O
.	1060	1061	O
2004	1062	1066	O
)	1066	1067	O
.	1067	1068	O

In	1069	1071	O
addition	1072	1080	O
,	1080	1081	O
aspirin	1082	1089	O
is	1090	1092	O
not	1093	1096	O
recommended	1097	1108	O
for	1109	1112	O
children	1113	1121	O
or	1122	1124	O
teenagers	1125	1134	O
who	1135	1138	O
have	1139	1143	O
or	1144	1146	O
are	1147	1150	O
recovering	1151	1161	O
from	1162	1166	O
chicken	1167	1174	O
pox	1175	1178	O
or	1179	1181	O
flulike	1182	1189	O
symptoms	1190	1198	O
because	1199	1206	O
it	1207	1209	O
can	1210	1213	O
cause	1214	1219	O
debilitating	1220	1232	O
and	1233	1236	O
sometimes	1237	1246	O
lethal	1247	1253	O
Reyes	1254	1259	O
syndrome	1260	1268	O
(	1269	1270	O
U	1270	1271	O
.	1271	1272	O
S	1272	1273	O
.	1273	1274	O
FDA	1275	1278	O
2003	1279	1283	O
)	1283	1284	O
.	1284	1285	O

Individual	1286	1296	O
risks	1297	1302	O
to	1303	1305	O
pharmaceutical	1306	1320	O
agents	1321	1327	O
can	1328	1331	O
be	1332	1334	O
controlled	1335	1345	O
with	1346	1350	O
proper	1351	1357	O
usage	1358	1363	O
;	1363	1364	O
however	1365	1372	O
,	1372	1373	O
increased	1374	1383	O
exposure	1384	1392	O
to	1393	1395	O
environmental	1396	1409	O
toxins	1410	1416	O
presents	1417	1425	O
additional	1426	1436	O
involuntary	1437	1448	O
risks	1449	1454	O
for	1455	1458	O
the	1459	1462	O
general	1463	1470	O
population	1471	1481	O
.	1481	1482	O

Under	1483	1488	O
the	1489	1492	O
latter	1493	1499	O
condition	1500	1509	O
,	1509	1510	O
exposure	1511	1519	O
is	1520	1522	O
inadequately	1523	1535	O
controlled	1536	1546	O
,	1546	1547	O
and	1548	1551	O
there	1552	1557	O
is	1558	1560	O
no	1561	1563	O
mechanism	1564	1573	O
to	1574	1576	O
correct	1577	1584	O
for	1585	1588	O
individual	1589	1599	O
circumstances	1600	1613	O
(	1614	1615	O
e	1615	1616	O
.	1616	1617	O
g	1617	1618	O
.	1618	1619	O
,	1619	1620	O
medical	1621	1628	O
condition	1629	1638	O
or	1639	1641	O
age	1642	1645	O
)	1645	1646	O
that	1647	1651	O
may	1652	1655	O
result	1656	1662	O
in	1663	1665	O
harm	1666	1670	O
.	1670	1671	O

Although	1672	1680	O
hormetic	1681	1689	O
effects	1690	1697	O
may	1698	1701	O
occur	1702	1707	O
in	1708	1710	O
some	1711	1715	O
instances	1716	1725	O
,	1725	1726	O
it	1727	1729	O
is	1730	1732	O
indeed	1733	1739	O
rare	1740	1744	O
that	1745	1749	O
exposures	1750	1759	O
to	1760	1762	O
toxic	1763	1768	O
,	1768	1769	O
mutagenic	1770	1779	O
,	1779	1780	O
teratogenic	1781	1792	O
,	1792	1793	O
and	1794	1797	O
carcinogenic	1798	1810	O
chemicals	1811	1820	O
,	1820	1821	O
even	1822	1826	O
at	1827	1829	O
low	1830	1833	O
exposure	1834	1842	O
levels	1843	1849	O
,	1849	1850	O
would	1851	1856	O
be	1857	1859	O
risk	1860	1864	O
free	1865	1869	O
and	1870	1873	O
provide	1874	1881	O
health	1882	1888	O
benefits	1889	1897	O
for	1898	1901	O
the	1902	1905	O
general	1906	1913	O
public	1914	1920	O
.	1920	1921	O

Portraying	1922	1932	O
chemicals	1933	1942	O
with	1943	1947	O
numerous	1948	1956	O
adverse	1957	1964	O
effects	1965	1972	O
as	1973	1975	O
having	1976	1982	O
benefits	1983	1991	O
while	1992	1997	O
ignoring	1998	2006	O
their	2007	2012	O
hazards	2013	2020	O
is	2021	2023	O
irresponsible	2024	2037	O
and	2038	2041	O
does	2042	2046	O
not	2047	2050	O
provide	2051	2058	O
full	2059	2063	O
and	2064	2067	O
objective	2068	2077	O
disclosure	2078	2088	O
.	2088	2089	O

In	2090	2092	O
the	2093	2096	O
1950s	2097	2102	O
doctors	2103	2110	O
prescribed	2111	2121	O
DES	2122	2125	O
to	2126	2128	O
pregnant	2129	2137	O
women	2138	2143	O
to	2144	2146	O
prevent	2147	2154	O
miscarriage	2155	2166	O
and	2167	2170	O
premature	2171	2180	O
births	2181	2187	O
and	2188	2191	O
to	2192	2194	O
produce	2195	2202	O
"	2203	2204	O
bigger	2204	2210	O
and	2211	2214	O
stronger	2215	2223	O
babies	2224	2230	O
"	2230	2231	O
even	2232	2236	O
though	2237	2243	O
DES	2244	2247	O
had	2248	2251	O
been	2252	2256	O
shown	2257	2262	O
to	2263	2265	O
cause	2266	2271	O
damage	2272	2278	O
to	2279	2281	O
reproductive	2282	2294	O
tissues	2295	2302	B-Tissue
in	2303	2305	O
animals	2306	2313	O
(	2314	2315	O
Dinusson	2315	2323	O
et	2324	2326	O
al	2327	2329	O
.	2329	2330	O
1948	2331	2335	O
;	2335	2336	O
Dunn	2337	2341	O
and	2342	2345	O
Green	2346	2351	O
1963	2352	2356	O
;	2356	2357	O
Takasugi	2358	2366	O
and	2367	2370	O
Bern	2371	2375	O
1964	2376	2380	O
)	2380	2381	O
.	2381	2382	O

Human	2383	2388	O
use	2389	2392	O
of	2393	2395	O
DES	2396	2399	O
was	2400	2403	O
banned	2404	2410	O
in	2411	2413	O
the	2414	2417	O
United	2418	2424	O
States	2425	2431	O
in	2432	2434	O
1971	2435	2439	O
after	2440	2445	O
the	2446	2449	O
discovery	2450	2459	O
of	2460	2462	O
high	2463	2467	O
rates	2468	2473	O
of	2474	2476	O
rare	2477	2481	O
,	2481	2482	O
clear	2483	2488	O
-	2488	2489	O
cell	2489	2493	O
adenocarcinomas	2494	2509	B-Pathological_formation
of	2510	2512	O
the	2513	2516	O
vagina	2517	2523	B-Multi-tissue_structure
and	2524	2527	O
cervix	2528	2534	B-Multi-tissue_structure
in	2535	2537	O
DES	2538	2541	O
-	2541	2542	O
exposed	2542	2549	O
daughters	2550	2559	O
(	2560	2561	O
Herbst	2561	2567	O
1981	2568	2572	O
)	2572	2573	O
,	2573	2574	O
and	2575	2578	O
later	2579	2584	O
studies	2585	2592	O
showed	2593	2599	O
elevated	2600	2608	O
breast	2609	2615	B-Pathological_formation
cancer	2616	2622	I-Pathological_formation
risk	2623	2627	O
in	2628	2630	O
women	2631	2636	O
who	2637	2640	O
took	2641	2645	O
DES	2646	2649	O
during	2650	2656	O
pregnancy	2657	2666	O
(	2667	2668	O
Titus	2668	2673	O
-	2673	2674	O
Ernstoff	2674	2682	O
et	2683	2685	O
al	2686	2688	O
.	2688	2689	O
2001	2690	2694	O
)	2694	2695	O
.	2695	2696	O

Certainly	2697	2706	O
,	2706	2707	O
health	2708	2714	O
policy	2715	2721	O
decisions	2722	2731	O
should	2732	2738	O
be	2739	2741	O
based	2742	2747	O
on	2748	2750	O
scientific	2751	2761	O
evidence	2762	2770	O
and	2771	2774	O
not	2775	2778	O
on	2779	2781	O
speculation	2782	2793	O
of	2794	2796	O
health	2797	2803	O
benefits	2804	2812	O
in	2813	2815	O
order	2816	2821	O
for	2822	2825	O
the	2826	2829	O
general	2830	2837	O
population	2838	2848	O
to	2849	2851	O
avoid	2852	2857	O
repeating	2858	2867	O
the	2868	2871	O
mistakes	2872	2880	O
of	2881	2883	O
the	2884	2887	O
past	2888	2892	O
similar	2893	2900	O
to	2901	2903	O
that	2904	2908	O
of	2909	2911	O
the	2912	2915	O
DES	2916	2919	O
tragedy	2920	2927	O
.	2927	2928	O

The	2929	2932	O
claims	2933	2939	O
and	2940	2943	O
projections	2944	2955	O
of	2956	2958	O
health	2959	2965	O
benefits	2966	2974	O
from	2975	2979	O
exposures	2980	2989	O
to	2990	2992	O
environmental	2993	3006	O
toxicants	3007	3016	O
and	3017	3020	O
carcinogens	3021	3032	O
are	3033	3036	O
based	3037	3042	O
on	3043	3045	O
untested	3046	3054	O
assumptions	3055	3066	O
and	3067	3070	O
disregard	3071	3080	O
numerous	3081	3089	O
well	3090	3094	O
-	3094	3095	O
established	3095	3106	O
scientific	3107	3117	O
principles	3118	3128	O
that	3129	3133	O
underpin	3134	3142	O
a	3143	3144	O
public	3145	3151	O
health	3152	3158	O
-	3158	3159	O
protective	3159	3169	O
approach	3170	3178	O
to	3179	3181	O
regulating	3182	3192	O
exposure	3193	3201	O
to	3202	3204	O
toxic	3205	3210	O
substances	3211	3221	O
.	3221	3222	O

If	3223	3225	O
hormesis	3226	3234	O
were	3235	3239	O
used	3240	3244	O
in	3245	3247	O
the	3248	3251	O
decision	3252	3260	O
-	3260	3261	O
making	3261	3267	O
process	3268	3275	O
to	3276	3278	O
allow	3279	3284	O
higher	3285	3291	O
exposures	3292	3301	O
to	3302	3304	O
toxic	3305	3310	O
and	3311	3314	O
carcinogenic	3315	3327	O
agents	3328	3334	O
,	3334	3335	O
this	3336	3340	O
would	3341	3346	O
substantially	3347	3360	O
increase	3361	3369	O
health	3370	3376	O
risks	3377	3382	O
for	3383	3386	O
many	3387	3391	O
,	3391	3392	O
if	3393	3395	O
not	3396	3399	O
most	3400	3404	O
,	3404	3405	O
segments	3406	3414	O
of	3415	3417	O
the	3418	3421	O
general	3422	3429	O
population	3430	3440	O
.	3440	3441	O

Measured	0	8	O
analytes	9	17	O
in	18	20	O
five	21	25	O
biologic	26	34	O
sample	35	41	O
matrices	42	50	O
.	50	51	O
a	51	52	O

Competing	0	9	O
interests	10	19	O

None	20	24	O
declared	25	33	O
.	33	34	O

This	35	39	O
article	40	47	O
is	48	50	O
the	51	54	O
third	55	60	O
in	61	63	O
an	64	66	O
ongoing	67	74	O
,	74	75	O
educational	76	87	O
review	88	94	O
series	95	101	O
on	102	104	O
medical	105	112	O
statistics	113	123	O
in	124	126	O
critical	127	135	O
care	136	140	O
.	140	141	O

Previous	142	150	O
articles	151	159	O
have	160	164	O
covered	165	172	O
'	173	174	O
presenting	174	184	O
and	185	188	O
summarising	189	200	O
data	201	205	O
'	205	206	O
[	207	208	O
3	208	209	O
]	209	210	O
and	211	214	O
'	215	216	O
samples	216	223	O
and	224	227	O
populations	228	239	O
'	239	240	O
[	241	242	O
4	242	243	O
]	243	244	O
.	244	245	O

Future	246	252	O
topics	253	259	O
to	260	262	O
be	263	265	O
covered	266	273	O
include	274	281	O
power	282	287	O
calculations	288	300	O
,	300	301	O
comparison	302	312	O
of	313	315	O
means	316	321	O
,	321	322	O
comparison	323	333	O
of	334	336	O
proportions	337	348	O
,	348	349	O
and	350	353	O
analysis	354	362	O
of	363	365	O
survival	366	374	O
data	375	379	O
to	380	382	O
name	383	387	O
but	388	391	O
a	392	393	O
few	394	397	O
.	397	398	O

If	399	401	O
there	402	407	O
is	408	410	O
a	411	412	O
medical	413	420	O
statistics	421	431	O
topic	432	437	O
you	438	441	O
would	442	447	O
like	448	452	O
explained	453	462	O
contact	463	470	O
us	471	473	O
on	474	476	O
editorial	477	486	O
@	486	487	O
ccforum	487	494	O
.	494	495	O
com	495	498	O
.	499	500	O

Results	0	7	O

The	8	11	O
set	12	15	O
of	16	18	O
E	19	20	O
.	20	21	O
coli	22	26	O
expression	27	37	O
vectors	38	45	O
,	45	46	O
encode	47	53	O
for	54	57	O
either	58	64	O
a	65	66	O
hexa	67	71	O
-	71	72	O
histidine	72	81	O
tag	82	85	O
or	86	88	O
the	89	92	O
three	93	98	O
most	99	103	O
commonly	104	112	O
used	113	117	O
solubility	118	128	O
tags	129	133	O
(	134	135	O
GST	135	138	O
,	138	139	O
MBP	140	143	O
,	143	144	O
NusA	145	149	O
)	149	150	O
and	151	154	O
all	155	158	O
with	159	163	O
an	164	166	O
N	167	168	O
-	168	169	O
terminal	169	177	O
hexa	178	182	O
-	182	183	O
histidine	183	192	O
sequence	193	201	O
.	201	202	O

The	203	206	O
result	207	213	O
is	214	216	O
two	217	220	O
-	220	221	O
fold	221	225	O
:	225	226	O
the	227	230	O
His	231	234	O
-	234	235	O
tag	235	238	O
facilitates	239	250	O
purification	251	263	O
by	264	266	O
immobilised	267	278	O
metal	279	284	O
affinity	285	293	O
chromatography	294	308	O
,	308	309	O
whilst	310	316	O
the	317	320	O
fusion	321	327	O
domains	328	335	O
act	336	339	O
primarily	340	349	O
as	350	352	O
solubility	353	363	O
aids	364	368	O
during	369	375	O
expression	376	386	O
,	386	387	O
in	388	390	O
addition	391	399	O
to	400	402	O
providing	403	412	O
an	413	415	O
optional	416	424	O
purification	425	437	O
step	438	442	O
.	442	443	O

We	444	446	O
have	447	451	O
also	452	456	O
incorporated	457	469	O
a	470	471	O
TEV	472	475	O
recognition	476	487	O
sequence	488	496	O
following	497	506	O
the	507	510	O
solubility	511	521	O
tag	522	525	O
domain	526	532	O
,	532	533	O
which	534	539	O
allows	540	546	O
for	547	550	O
highly	551	557	O
specific	558	566	O
cleavage	567	575	O
(	576	577	O
using	577	582	O
TEV	583	586	O
protease	587	595	O
)	595	596	O
of	597	599	O
the	600	603	O
fusion	604	610	O
protein	611	618	O
to	619	621	O
yield	622	627	O
native	628	634	O
protein	635	642	O
.	642	643	O

These	644	649	O
vectors	650	657	O
are	658	661	O
also	662	666	O
designed	667	675	O
for	676	679	O
ligation	680	688	O
-	688	689	O
independent	689	700	O
cloning	701	708	O
and	709	712	O
they	713	717	O
possess	718	725	O
a	726	727	O
high	728	732	O
-	732	733	O
level	733	738	O
expressing	739	749	O
T7	750	752	O
promoter	753	761	O
,	761	762	O
which	763	768	O
is	769	771	O
suitable	772	780	O
for	781	784	O
auto	785	789	O
-	789	790	O
induction	790	799	O
.	799	800	O

To	801	803	O
validate	804	812	O
our	813	816	O
vector	817	823	O
system	824	830	O
,	830	831	O
we	832	834	O
have	835	839	O
cloned	840	846	O
four	847	851	O
different	852	861	O
genes	862	867	O
and	868	871	O
also	872	876	O
one	877	880	O
gene	881	885	O
into	886	890	O
all	891	894	O
four	895	899	O
vectors	900	907	O
and	908	911	O
used	912	916	O
small	917	922	O
-	922	923	O
scale	923	928	O
expression	929	939	O
and	940	943	O
purification	944	956	O
techniques	957	967	O
.	967	968	O

We	969	971	O
demonstrate	972	983	O
that	984	988	O
the	989	992	O
vectors	993	1000	O
are	1001	1004	O
capable	1005	1012	O
of	1013	1015	O
high	1016	1020	O
levels	1021	1027	O
of	1028	1030	O
expression	1031	1041	O
and	1042	1045	O
that	1046	1050	O
efficient	1051	1060	O
screening	1061	1070	O
of	1071	1073	O
new	1074	1077	O
proteins	1078	1086	O
can	1087	1090	O
be	1091	1093	O
readily	1094	1101	O
achieved	1102	1110	O
at	1111	1113	O
the	1114	1117	O
laboratory	1118	1128	O
level	1129	1134	O
.	1134	1135	O

Inflammation	0	12	O
-	12	13	O
modulating	13	23	O
effect	24	30	O
of	31	33	O
antithrombin	34	46	O
on	47	49	O
the	50	53	O
endothelium	54	65	B-Tissue
.	65	66	O

Ligation	67	75	O
of	76	78	O
heparan	79	86	O
sulfate	87	94	O
proteoglycans	95	108	O
(	109	110	O
HSPGs	110	115	O
)	115	116	O
of	117	119	O
endothelium	120	131	B-Tissue
with	132	136	O
antithrombin	137	149	O
(	150	151	O
AT	151	153	O
)	153	154	O
induces	155	162	O
cellular	163	171	B-Cell
signalling	172	182	O
events	183	189	O
that	190	194	O
alter	195	200	O
the	201	204	O
cell	205	209	B-Cell
'	209	210	O
s	210	211	O
biochemical	212	223	O
and	224	227	O
functional	228	238	O
responses	239	248	O
to	249	251	O
inflammatory	252	264	O
stimuli	265	272	O
(	273	274	O
e	274	275	O
.	275	276	O
g	276	277	O
.	277	278	O
bacterial	279	288	O
lipopolysaccharide	289	307	O
[	308	309	O
LPS	309	312	O
]	312	313	O
)	313	314	O
.	314	315	O

Changes	316	323	O
include	324	331	O
reduced	332	339	O
release	340	347	O
of	348	350	O
inflammatory	351	363	O
and	364	367	O
procoagulatory	368	382	O
mediators	383	392	O
(	393	394	O
e	394	395	O
.	395	396	O
g	396	397	O
.	397	398	O
interleukin	399	410	O
[	411	412	O
IL	412	414	O
]	414	415	O
-	415	416	O
1	416	417	O
,	417	418	O
IL	419	421	O
-	421	422	O
6	422	423	O
,	423	424	O
tumour	425	431	O
necrosis	432	440	O
factor	441	447	O
-	447	448	O
alpha	448	453	O
[	453	454	O
TNF	454	457	O
]	457	458	O
)	458	459	O
,	459	460	O
tissue	461	467	O
factor	468	474	O
(	475	476	O
TF	476	478	O
)	478	479	O
,	479	480	O
adenosine	481	490	O
diphosphate	491	502	O
(	503	504	O
ADP	504	507	O
)	507	508	O
and	509	512	O
cellular	513	521	B-Cell
adhesion	522	530	O
molecules	531	540	O
(	541	542	O
not	542	545	O
shown	546	551	O
)	551	552	O
,	552	553	O
as	554	556	O
well	557	561	O
as	562	564	O
increased	565	574	O
release	575	582	O
of	583	585	O
anticoagulatory	586	601	O
prostacyclin	602	614	O
(	615	616	O
prostaglandin	616	629	O
[	630	631	O
PG	631	633	O
]	633	634	O
I	634	635	O
)	635	636	O
or	637	639	O
CD39	640	644	O
/	644	645	O
ATPDase	645	652	O
.	652	653	O

In	654	656	O
neuronal	657	665	B-Tissue
tissue	666	672	I-Tissue
,	672	673	O
protective	674	684	O
mechanisms	685	695	O
may	696	699	O
by	700	702	O
mediated	703	711	O
via	712	715	O
the	716	719	O
release	720	727	O
of	728	730	O
calcitonin	731	741	O
gene	742	746	O
-	746	747	O
related	747	754	O
peptide	755	762	O
and	763	766	O
nitric	767	773	O
oxide	774	779	O
with	780	784	O
the	785	788	O
potential	789	798	O
to	799	801	O
affect	802	808	O
prostacyclin	809	821	O
release	822	829	O
[	830	831	O
55	831	833	O
]	833	834	O
.	834	835	O

Background	0	10	O

Hallucinations	11	25	O
may	26	29	O
occur	30	35	O
in	36	38	O
any	39	42	O
sensory	43	50	O
modalities	51	61	O
.	61	62	O

Formed	63	69	O
musical	70	77	O
hallucinations	78	92	O
(	93	94	O
i	94	95	O
.	95	96	O
e	96	97	O
.	97	98	O
Perception	99	109	O
of	110	112	O
either	113	119	O
vocal	120	125	O
or	126	128	O
instrumental	129	141	O
melodies	142	150	O
)	150	151	O
reported	152	160	O
in	161	163	O
English	164	171	O
literature	172	182	O
to	183	185	O
date	186	190	O
have	191	195	O
typically	196	205	O
been	206	210	O
associated	211	221	O
with	222	226	O
marked	227	233	O
hearing	234	241	O
loss	242	246	O
,	246	247	O
advanced	248	256	O
age	257	260	O
,	260	261	O
female	262	268	O
sex	269	272	O
(	273	274	O
71	274	276	O
%	276	277	O
)	277	278	O
,	278	279	O
lack	280	284	O
of	285	287	O
response	288	296	O
to	297	299	O
treatment	300	309	O
and	310	313	O
associated	314	324	O
psychopathology	325	340	O
[	341	342	O
1	342	343	O
]	343	344	O
but	345	348	O
has	349	352	O
been	353	357	O
concluded	358	367	O
that	368	372	O
hearing	373	380	O
loss	381	385	O
is	386	388	O
neither	389	396	O
a	397	398	O
necessary	399	408	O
nor	409	412	O
sufficient	413	423	O
condition	424	433	O
for	434	437	O
the	438	441	O
occurrence	442	452	O
of	453	455	O
musical	456	463	O
hallucinations	464	478	O
[	479	480	O
1	480	481	O
]	481	482	O
.	482	483	O

Tumor	484	489	B-Pathological_formation
like	490	494	O
Astrocytoma	495	506	B-Pathological_formation
,	506	507	O
Temporal	508	516	B-Multi-tissue_structure
lobe	517	521	I-Multi-tissue_structure
epilepsy	522	530	O
,	530	531	O
raised	532	538	O
intra	539	544	O
cranial	545	552	B-Organism_subdivision
tension	553	560	O
,	560	561	O
drug	562	566	O
induced	567	574	O
(	575	576	O
tricyclics	576	586	O
,	586	587	O
Propronolol	588	599	O
etc	600	603	O
;	604	605	O
)	605	606	O
,	606	607	O
meningitis	608	618	O
and	619	622	O
psychotic	623	632	O
illness	633	640	O
were	641	645	O
shown	646	651	O
to	652	654	O
cause	655	660	O
palinacousis	661	673	O
and	674	677	O
musical	678	685	O
hallucinations	686	700	O
[	701	702	O
2	702	703	O
,	703	704	O
3	704	705	O
]	705	706	O
.	706	707	O

Musical	708	715	O
hallucinations	716	730	O
are	731	734	O
pseudo	735	741	O
hallucinations	742	756	O
that	757	761	O
originate	762	771	O
in	772	774	O
memory	775	781	O
representations	782	797	O
and	798	801	O
they	802	806	O
may	807	810	O
undergo	811	818	O
a	819	820	O
transition	821	831	O
to	832	834	O
true	835	839	O
hallucination	840	853	O
.	853	854	O

In	855	857	O
musical	858	865	O
hallucination	866	879	O
spatial	880	887	O
projection	888	898	O
is	899	901	O
less	902	906	O
definite	907	915	O
.	915	916	O

Sometimes	917	926	O
they	927	931	O
are	932	935	O
perceived	936	945	O
like	946	950	O
the	951	954	O
tinnitus	955	963	O
in	964	966	O
patient	967	974	O
'	974	975	O
s	975	976	O
own	977	980	O
head	981	985	B-Organism_subdivision
.	985	986	O

The	987	990	O
quality	991	998	O
is	999	1001	O
usually	1002	1009	O
very	1010	1014	O
intense	1015	1022	O
and	1023	1026	O
distinct	1027	1035	O
often	1036	1041	O
very	1042	1046	O
loud	1047	1051	O
.	1051	1052	O

They	1053	1057	O
vary	1058	1062	O
from	1063	1067	O
elementary	1068	1078	O
sounds	1079	1085	O
to	1086	1088	O
instrumental	1089	1101	O
music	1102	1107	O
,	1107	1108	O
vocal	1109	1114	O
music	1115	1120	O
,	1120	1121	O
bird	1122	1126	O
songs	1127	1132	O
,	1132	1133	O
bells	1134	1139	O
,	1139	1140	O
pieces	1141	1147	O
of	1148	1150	O
melodies	1151	1159	O
or	1160	1162	O
sentences	1163	1172	O
,	1172	1173	O
religious	1174	1183	O
music	1184	1189	O
etc	1190	1193	O
:	1193	1194	O
-	1194	1195	O
We	1196	1198	O
report	1199	1205	O
an	1206	1208	O
unusual	1209	1216	O
presentation	1217	1229	O
of	1230	1232	O
an	1233	1235	O
elderly	1236	1243	O
lady	1244	1248	O
who	1249	1252	O
had	1253	1256	O
experienced	1257	1268	O
musical	1269	1276	O
hallucinations	1277	1291	O
whilst	1292	1298	O
being	1299	1304	O
treated	1305	1312	O
with	1313	1317	O
Electro	1318	1325	O
Convulsive	1326	1336	O
Therapy	1337	1344	O
.	1344	1345	O

Though	1346	1352	O
this	1353	1357	O
has	1358	1361	O
never	1362	1367	O
been	1368	1372	O
reported	1373	1381	O
earlier	1382	1389	O
,	1389	1390	O
there	1391	1396	O
seemed	1397	1403	O
to	1404	1406	O
have	1407	1411	O
a	1412	1413	O
good	1414	1418	O
association	1419	1430	O
between	1431	1438	O
the	1439	1442	O
initiation	1443	1453	O
of	1454	1456	O
Electro	1457	1464	O
convulsive	1465	1475	O
therapy	1476	1483	O
and	1484	1487	O
musical	1488	1495	O
hallucination	1496	1509	O
in	1510	1512	O
our	1513	1516	O
patient	1517	1524	O
.	1524	1525	O

Correlation	0	11	O
between	12	19	O
sperm	20	25	B-Cell
morphology	26	36	O
and	37	40	O
seminal	41	48	B-Organism_substance
plasma	49	55	I-Organism_substance
NO	56	58	O
(	59	60	O
a	60	61	O
)	61	62	O
and	63	66	O
TBARS	67	72	O
(	73	74	O
b	74	75	O
)	75	76	O
levels	77	83	O
in	84	86	O
both	87	91	O
groups	92	98	O
.	98	99	O

Conclusion	0	10	O

The	11	14	O
survey	15	21	O
indicated	22	31	O
that	32	36	O
,	36	37	O
the	38	41	O
study	42	47	O
area	48	52	O
has	53	56	O
plenty	57	63	O
of	64	66	O
medicinal	67	76	O
plants	77	83	O
to	84	86	O
treat	87	92	O
a	93	94	O
wide	95	99	O
spectrum	100	108	O
of	109	111	O
human	112	117	O
ailments	118	126	O
.	126	127	O

Earlier	128	135	O
studies	136	143	O
on	144	146	O
traditional	147	158	O
medicinal	159	168	O
plants	169	175	O
also	176	180	O
revealed	181	189	O
that	190	194	O
the	195	198	O
economically	199	211	O
backward	212	220	O
local	221	226	O
and	227	230	O
tribal	231	237	O
people	238	244	O
of	245	247	O
Tamil	248	253	O
Nadu	254	258	O
prefer	259	265	O
folk	266	270	O
medicine	271	279	O
due	280	283	O
to	284	286	O
low	287	290	O
cost	291	295	O
and	296	299	O
sometimes	300	309	O
it	310	312	O
is	313	315	O
a	316	317	O
part	318	322	O
of	323	325	O
their	326	331	O
social	332	338	O
life	339	343	O
and	344	347	O
culture	348	355	O
[	356	357	O
40	357	359	O
-	359	360	O
45	360	362	O
]	362	363	O
.	363	364	O

It	365	367	O
is	368	370	O
evident	371	378	O
from	379	383	O
the	384	387	O
interviews	388	398	O
conducted	399	408	O
in	409	411	O
different	412	421	O
villages	422	430	O
,	430	431	O
knowledge	432	441	O
of	442	444	O
medicinal	445	454	O
plants	455	461	O
is	462	464	O
limited	465	472	O
to	473	475	O
traditional	476	487	O
healers	488	495	O
,	495	496	O
herbalists	497	507	O
and	508	511	O
elderly	512	519	O
persons	520	527	O
who	528	531	O
are	532	535	O
living	536	542	O
in	543	545	O
rural	546	551	O
areas	552	557	O
.	557	558	O

This	559	563	O
study	564	569	O
also	570	574	O
points	575	581	O
out	582	585	O
that	586	590	O
certain	591	598	O
species	599	606	O
of	607	609	O
medicinal	610	619	O
plants	620	626	O
are	627	630	O
being	631	636	O
exploited	637	646	O
by	647	649	O
the	650	653	O
local	654	659	O
residents	660	669	O
who	670	673	O
are	674	677	O
unaware	678	685	O
of	686	688	O
the	689	692	O
importance	693	703	O
of	704	706	O
medicinal	707	716	O
plants	717	723	O
in	724	726	O
the	727	730	O
ecosystem	731	740	O
.	740	741	O

This	742	746	O
study	747	752	O
concluded	753	762	O
that	763	767	O
even	768	772	O
though	773	779	O
the	780	783	O
accessibility	784	797	O
of	798	800	O
Western	801	808	O
medicine	809	817	O
for	818	821	O
simple	822	828	O
and	829	832	O
complicated	833	844	O
diseases	845	853	O
is	854	856	O
available	857	866	O
,	866	867	O
many	868	872	O
people	873	879	O
in	880	882	O
the	883	886	O
studied	887	894	O
parts	895	900	O
of	901	903	O
Kancheepuram	904	916	O
district	917	925	O
is	926	928	O
still	929	934	O
continue	935	943	O
to	944	946	O
depend	947	953	O
on	954	956	O
medicinal	957	966	O
plants	967	973	O
,	973	974	O
at	975	977	O
least	978	983	O
for	984	987	O
the	988	991	O
treatment	992	1001	O
of	1002	1004	O
some	1005	1009	O
simple	1010	1016	O
diseases	1017	1025	O
such	1026	1030	O
as	1031	1033	O
,	1033	1034	O
cold	1035	1039	O
,	1039	1040	O
cough	1041	1046	O
,	1046	1047	O
fever	1048	1053	O
,	1053	1054	O
headache	1055	1063	O
,	1063	1064	O
poison	1065	1071	O
bites	1072	1077	O
,	1077	1078	O
skin	1079	1083	B-Organ
diseases	1084	1092	O
and	1093	1096	O
tooth	1097	1102	B-Organ
infections	1103	1113	O
.	1113	1114	O

Well	1115	1119	O
-	1119	1120	O
knowledged	1120	1130	O
healers	1131	1138	O
have	1139	1143	O
good	1144	1148	O
interactions	1149	1161	O
with	1162	1166	O
patients	1167	1175	O
and	1176	1179	O
this	1180	1184	O
would	1185	1190	O
improve	1191	1198	O
the	1199	1202	O
quality	1203	1210	O
of	1211	1213	O
healthcare	1214	1224	O
delivery	1225	1233	O
.	1233	1234	O

The	1235	1238	O
present	1239	1246	O
-	1246	1247	O
day	1247	1250	O
traditional	1251	1262	O
healers	1263	1270	O
are	1271	1274	O
very	1275	1279	O
old	1280	1283	O
.	1283	1284	O

Due	1285	1288	O
to	1289	1291	O
lack	1292	1296	O
of	1297	1299	O
interest	1300	1308	O
among	1309	1314	O
the	1315	1318	O
younger	1319	1326	O
generation	1327	1337	O
as	1338	1340	O
well	1341	1345	O
as	1346	1348	O
their	1349	1354	O
tendency	1355	1363	O
to	1364	1366	O
migrate	1367	1374	O
to	1375	1377	O
cities	1378	1384	O
for	1385	1388	O
lucrative	1389	1398	O
jobs	1399	1403	O
,	1403	1404	O
there	1405	1410	O
is	1411	1413	O
a	1414	1415	O
possibility	1416	1427	O
of	1428	1430	O
losing	1431	1437	O
this	1438	1442	O
wealth	1443	1449	O
of	1450	1452	O
knowledge	1453	1462	O
in	1463	1465	O
the	1466	1469	O
near	1470	1474	O
future	1475	1481	O
.	1481	1482	O

It	1483	1485	O
thus	1486	1490	O
becomes	1491	1498	O
necessary	1499	1508	O
to	1509	1511	O
acquire	1512	1519	O
and	1520	1523	O
preserve	1524	1532	O
this	1533	1537	O
traditional	1538	1549	O
system	1550	1556	O
of	1557	1559	O
medicine	1560	1568	O
by	1569	1571	O
proper	1572	1578	O
documentation	1579	1592	O
and	1593	1596	O
identification	1597	1611	O
of	1612	1614	O
specimens	1615	1624	O
.	1624	1625	O

Figures	0	7	O
and	8	11	O
Tables	12	18	O

Figure	19	25	O
1	26	27	O

Modular	28	35	O
crosstalking	36	48	O
in	49	51	O
synthetic	52	61	O
gene	62	66	O
networks	67	75	O
.	75	76	O

A	77	78	O
promoter	79	87	O
with	88	92	O
binding	93	100	O
sites	101	106	O
for	107	110	O
lambda	111	117	O
cI	118	120	O
dimers	121	127	O
(	128	129	O
OR1	129	132	O
and	133	136	O
OR2	137	140	O
)	140	141	O
and	142	145	O
for	146	149	O
the	150	153	O
lac	154	157	O
repressor	158	167	O
(	168	169	O
Olac	169	173	O
)	173	174	O
controls	175	183	O
the	184	187	O
production	188	198	O
of	199	201	O
the	202	205	O
lac	206	209	O
repressor	210	219	O
(	220	221	O
encoded	221	228	O
by	229	231	O
lacI	232	236	O
)	236	237	O
in	238	240	O
module	241	247	O
1	248	249	O
and	250	253	O
lambda	254	260	O
cI	261	263	O
(	264	265	O
encoded	265	272	O
by	273	275	O
cI	276	278	O
)	278	279	O
in	280	282	O
module	283	289	O
2	290	291	O
.	291	292	O

The	293	296	O
lac	297	300	O
repressor	301	310	O
and	311	314	O
lambda	315	321	O
cI	322	324	O
dimers	325	331	O
are	332	335	O
represented	336	347	O
by	348	350	O
blue	351	355	O
ellipsoids	356	366	O
and	367	370	O
red	371	374	O
circles	375	382	O
,	382	383	O
respectively	384	396	O
.	396	397	O

When	398	402	O
the	403	406	O
two	407	410	O
modules	411	418	O
are	419	422	O
put	423	426	O
together	427	435	O
,	435	436	O
two	437	440	O
pairs	441	446	O
of	447	449	O
lambda	450	456	O
cI	457	459	O
dimers	460	466	O
bound	467	472	O
at	473	475	O
different	476	485	O
operators	486	495	O
can	496	499	O
loop	500	504	O
DNA	505	508	O
and	509	512	O
octamerize	513	523	O
,	523	524	O
forming	525	532	O
a	533	534	O
tetramer	535	543	O
of	544	546	O
dimers	547	553	O
.	553	554	O

Comparison	0	10	O
of	11	13	O
the	14	17	O
Predicted	18	27	O
Irr	28	31	O
Regulon	32	39	O
and	40	43	O
ICE	44	47	O
Motifs	48	54	O
with	55	59	O
the	60	63	O
Published	64	73	O
Expression	74	84	O
Microarray	85	95	O
Data	96	100	O
for	101	104	O
Iron	105	109	O
-	109	110	O
and	111	114	O
Irr	115	118	O
-	118	119	O
Affected	119	127	O
Genes	128	133	O
in	134	136	O
Bradyrhizobium	137	151	O
japonicum	152	161	O

Mass	0	4	O
casualty	5	13	O
estimation	14	24	O
on	25	27	O
a	28	29	O
geographic	30	40	O
basis	41	46	O

The	47	50	O
Defense	51	58	O
Threat	59	65	O
Reduction	66	75	O
Agency	76	82	O
(	83	84	O
DTRA	84	88	O
)	88	89	O
has	90	93	O
expended	94	102	O
considerable	103	115	O
effort	116	122	O
to	123	125	O
develop	126	133	O
models	134	140	O
for	141	144	O
calculating	145	156	O
mass	157	161	O
casualties	162	172	O
from	173	177	O
a	178	179	O
nuclear	180	187	O
detonation	188	198	O
.	198	199	O

In	200	202	O
order	203	208	O
to	209	211	O
specifically	212	224	O
evaluate	225	233	O
urban	234	239	O
medical	240	247	O
systems	248	255	O
vulnerability	256	269	O
we	270	272	O
are	273	276	O
employing	277	286	O
the	287	290	O
PC	291	293	O
based	294	299	O
Consequence	300	311	O
Assessment	312	322	O
Tool	323	327	O
Set	328	331	O
(	332	333	O
CATS	333	337	O
)	337	338	O
v6	339	341	O
,	341	342	O
with	343	347	O
ESRI	348	352	O
'	352	353	O
s	353	354	O
ArcGIS9	355	362	O
[	363	364	O
14	364	366	O
]	366	367	O
,	367	368	O
CATS	369	373	O
/	373	374	O
JACE	374	378	O
(	379	380	O
Joint	380	385	O
Assessment	386	396	O
of	397	399	O
Catastrophic	400	412	O
Events	413	419	O
)	419	420	O
v5	421	423	O
with	424	428	O
ESRI	429	433	O
'	433	434	O
s	434	435	O
ArcView	436	443	O
3	444	445	O
.	445	446	O
3	446	447	O
,	447	448	O
Hazard	449	455	O
Prediction	456	466	O
and	467	470	O
Assessment	471	481	O
Capability	482	492	O
(	493	494	O
HPAC	494	498	O
)	498	499	O
V4	500	502	O
.	502	503	O
04SP3	503	508	O
[	509	510	O
15	510	512	O
]	512	513	O
,	513	514	O
as	515	517	O
well	518	522	O
as	523	525	O
custom	526	532	O
GIS	533	536	O
and	537	540	O
database	541	549	O
software	550	558	O
applications	559	571	O
.	571	572	O

HPAC	573	577	O
does	578	582	O
excellent	583	592	O
Chemical	593	601	O
Biological	602	612	O
and	613	616	O
Nuclear	617	624	O
(	625	626	O
CBN	626	629	O
)	629	630	O
modeling	631	639	O
,	639	640	O
although	641	649	O
output	650	656	O
could	657	662	O
provide	663	670	O
more	671	675	O
flexibility	676	687	O
.	687	688	O

Additionally	689	701	O
,	701	702	O
results	703	710	O
can	711	714	O
be	715	717	O
exported	718	726	O
to	727	729	O
CATS	730	734	O
for	735	738	O
further	739	746	O
analysis	747	755	O
and	756	759	O
display	760	767	O
.	767	768	O

All	769	772	O
three	773	778	O
programs	779	787	O
can	788	791	O
access	792	798	O
the	799	802	O
current	803	810	O
weather	811	818	O
data	819	823	O
from	824	828	O
both	829	833	O
classified	834	844	O
and	845	848	O
unclassified	849	861	O
weather	862	869	O
servers	870	877	O
.	877	878	O

Examples	879	887	O
of	888	890	O
uses	891	895	O
of	896	898	O
CATS	899	903	O
/	903	904	O
HPAC	904	908	O
are	909	912	O
hurricane	913	922	O
,	922	923	O
tidal	924	929	O
surge	930	935	O
and	936	939	O
earthquake	940	950	O
damage	951	957	O
,	957	958	O
prediction	959	969	O
of	970	972	O
the	973	976	O
results	977	984	O
from	985	989	O
nuclear	990	997	O
,	997	998	O
biological	999	1009	O
and	1010	1013	O
chemical	1014	1022	O
releases	1023	1031	O
,	1031	1032	O
assessment	1033	1043	O
of	1044	1046	O
persons	1047	1054	O
and	1055	1058	O
infrastructure	1059	1073	O
affected	1074	1082	O
and	1083	1086	O
at	1087	1089	O
risk	1090	1094	O
(	1095	1096	O
e	1096	1097	O
.	1097	1098	O
g	1098	1099	O
.	1099	1100	O
which	1101	1106	O
hospitals	1107	1116	O
and	1117	1120	O
pharmacies	1121	1131	O
are	1132	1135	O
under	1136	1141	O
a	1142	1143	O
CBN	1144	1147	O
plume	1148	1153	O
and	1154	1157	O
are	1158	1161	O
thus	1162	1166	O
out	1167	1170	O
of	1171	1173	O
commission	1174	1184	O
)	1184	1185	O
,	1185	1186	O
and	1187	1190	O
mobilization	1191	1203	O
of	1204	1206	O
surviving	1207	1216	O
and	1217	1220	O
nearby	1221	1227	O
infrastructure	1228	1242	O
outside	1243	1250	O
the	1251	1254	O
plume	1255	1260	O
that	1261	1265	O
would	1266	1271	O
be	1272	1274	O
needed	1275	1281	O
to	1282	1284	O
address	1285	1292	O
healthcare	1293	1303	O
and	1304	1307	O
other	1308	1313	O
emergency	1314	1323	O
response	1324	1332	O
needs	1333	1338	O
of	1339	1341	O
the	1342	1345	O
community	1346	1355	O
.	1355	1356	O

These	1357	1362	O
models	1363	1369	O
have	1370	1374	O
been	1375	1379	O
,	1379	1380	O
and	1381	1384	O
continue	1385	1393	O
to	1394	1396	O
be	1397	1399	O
,	1399	1400	O
developed	1401	1410	O
with	1411	1415	O
a	1416	1417	O
view	1418	1422	O
to	1423	1425	O
better	1426	1432	O
estimating	1433	1443	O
the	1444	1447	O
impact	1448	1454	O
of	1455	1457	O
WMD	1458	1461	O
weapons	1462	1469	O
in	1470	1472	O
an	1473	1475	O
offensive	1476	1485	O
setting	1486	1493	O
.	1493	1494	O

However	1495	1502	O
,	1502	1503	O
recent	1504	1510	O
DTRA	1511	1515	O
enhancements	1516	1528	O
and	1529	1532	O
our	1533	1536	O
modifications	1537	1550	O
have	1551	1555	O
facilitated	1556	1567	O
their	1568	1573	O
use	1574	1577	O
in	1578	1580	O
helping	1581	1588	O
estimate	1589	1597	O
potential	1598	1607	O
casualties	1608	1618	O
from	1619	1623	O
a	1624	1625	O
WMD	1626	1629	O
terrorist	1630	1639	O
incident	1640	1648	O
.	1648	1649	O

One	1650	1653	O
area	1654	1658	O
of	1659	1661	O
intense	1662	1669	O
interest	1670	1678	O
,	1678	1679	O
and	1680	1683	O
somewhat	1684	1692	O
of	1693	1695	O
a	1696	1697	O
vacuum	1698	1704	O
in	1705	1707	O
public	1708	1714	O
health	1715	1721	O
planning	1722	1730	O
,	1730	1731	O
has	1732	1735	O
been	1736	1740	O
the	1741	1744	O
utility	1745	1752	O
of	1753	1755	O
this	1756	1760	O
approach	1761	1769	O
in	1770	1772	O
estimating	1773	1783	O
medical	1784	1791	O
care	1792	1796	O
vulnerabilities	1797	1812	O
in	1813	1815	O
such	1816	1820	O
an	1821	1823	O
attack	1824	1830	O
,	1830	1831	O
and	1832	1835	O
for	1836	1839	O
the	1840	1843	O
calculation	1844	1855	O
of	1856	1858	O
the	1859	1862	O
distribution	1863	1875	O
of	1876	1878	O
surviving	1879	1888	O
medical	1889	1896	O
care	1897	1901	O
resources	1902	1911	O
.	1911	1912	O

While	1913	1918	O
much	1919	1923	O
work	1924	1928	O
has	1929	1932	O
already	1933	1940	O
occurred	1941	1949	O
in	1950	1952	O
estimating	1953	1963	O
the	1964	1967	O
impact	1968	1974	O
of	1975	1977	O
chemical	1978	1986	O
weapons	1987	1994	O
(	1995	1996	O
due	1996	1999	O
to	2000	2002	O
the	2003	2006	O
dual	2007	2011	O
use	2012	2015	O
in	2016	2018	O
chemical	2019	2027	O
spill	2028	2033	O
management	2034	2044	O
from	2045	2049	O
transportation	2050	2064	O
and	2065	2068	O
industrial	2069	2079	O
accidents	2080	2089	O
)	2089	2090	O
,	2090	2091	O
or	2092	2094	O
in	2095	2097	O
nuclear	2098	2105	O
power	2106	2111	O
plant	2112	2117	O
accident	2118	2126	O
management	2127	2137	O
,	2137	2138	O
much	2139	2143	O
less	2144	2148	O
research	2149	2157	O
and	2158	2161	O
development	2162	2173	O
has	2174	2177	O
gone	2178	2182	O
into	2183	2187	O
estimating	2188	2198	O
the	2199	2202	O
impact	2203	2209	O
on	2210	2212	O
our	2213	2216	O
civilian	2217	2225	O
population	2226	2236	O
of	2237	2239	O
a	2240	2241	O
nuclear	2242	2249	O
weapon	2250	2256	O
detonation	2257	2267	O
from	2268	2272	O
a	2273	2274	O
terrorist	2275	2284	O
incident	2285	2293	O
in	2294	2296	O
a	2297	2298	O
large	2299	2304	O
urban	2305	2310	O
area	2311	2315	O
.	2315	2316	O

The	2317	2320	O
models	2321	2327	O
already	2328	2335	O
calculate	2336	2345	O
such	2346	2350	O
factors	2351	2358	O
as	2359	2361	O
the	2362	2365	O
impact	2366	2372	O
of	2373	2375	O
blast	2376	2381	O
,	2381	2382	O
thermal	2383	2390	O
effects	2391	2398	O
and	2399	2402	O
fallout	2403	2410	O
,	2410	2411	O
but	2412	2415	O
results	2416	2423	O
are	2424	2427	O
often	2428	2433	O
not	2434	2437	O
available	2438	2447	O
at	2448	2450	O
the	2451	2454	O
detail	2455	2461	O
level	2462	2467	O
needed	2468	2474	O
for	2475	2478	O
civil	2479	2484	O
defense	2485	2492	O
purposes	2493	2501	O
,	2501	2502	O
casualty	2503	2511	O
management	2512	2522	O
,	2522	2523	O
and	2524	2527	O
planning	2528	2536	O
the	2537	2540	O
use	2541	2544	O
of	2545	2547	O
scarce	2548	2554	O
health	2555	2561	O
resources	2562	2571	O
in	2572	2574	O
response	2575	2583	O
to	2584	2586	O
a	2587	2588	O
nuclear	2589	2596	O
weapon	2597	2603	O
detonation	2604	2614	O
.	2614	2615	O

Furthermore	2616	2627	O
,	2627	2628	O
the	2629	2632	O
models	2633	2639	O
do	2640	2642	O
not	2643	2646	O
readily	2647	2654	O
facilitate	2655	2665	O
the	2666	2669	O
calculation	2670	2681	O
of	2682	2684	O
injuries	2685	2693	O
from	2694	2698	O
multiple	2699	2707	O
effects	2708	2715	O
such	2716	2720	O
as	2721	2723	O
burns	2724	2729	O
and	2730	2733	O
blast	2734	2739	O
with	2740	2744	O
fallout	2745	2752	O
or	2753	2755	O
prompt	2756	2762	O
radiation	2763	2772	O
.	2772	2773	O

The	2774	2777	O
complexity	2778	2788	O
of	2789	2791	O
the	2792	2795	O
urban	2796	2801	O
three	2802	2807	O
-	2807	2808	O
dimensional	2808	2819	O
landscape	2820	2829	O
and	2830	2833	O
its	2834	2837	O
local	2838	2843	O
impact	2844	2850	O
on	2851	2853	O
thermal	2854	2861	O
,	2861	2862	O
blast	2863	2868	O
and	2869	2872	O
radiation	2873	2882	O
is	2883	2885	O
also	2886	2890	O
poorly	2891	2897	O
understood	2898	2908	O
.	2908	2909	O

Additionally	2910	2922	O
,	2922	2923	O
given	2924	2929	O
their	2930	2935	O
traditional	2936	2947	O
world	2948	2953	O
-	2953	2954	O
wide	2954	2958	O
focus	2959	2964	O
,	2964	2965	O
and	2966	2969	O
the	2970	2973	O
increased	2974	2983	O
sensitivity	2984	2995	O
to	2996	2998	O
providing	2999	3008	O
information	3009	3020	O
on	3021	3023	O
the	3024	3027	O
U	3028	3029	O
.	3029	3030	O
S	3030	3031	O
.	3031	3032	O
A	3032	3033	O
.	3033	3034	O
of	3035	3037	O
use	3038	3041	O
to	3042	3044	O
terrorists	3045	3055	O
,	3055	3056	O
the	3057	3060	O
models	3061	3067	O
do	3068	3070	O
not	3071	3074	O
provide	3075	3082	O
detailed	3083	3091	O
or	3092	3094	O
current	3095	3102	O
data	3103	3107	O
that	3108	3112	O
exists	3113	3119	O
for	3120	3123	O
the	3124	3127	O
United	3128	3134	O
States	3135	3141	O
that	3142	3146	O
would	3147	3152	O
help	3153	3157	O
provide	3158	3165	O
better	3166	3172	O
casualty	3173	3181	O
estimates	3182	3191	O
and	3192	3195	O
response	3196	3204	O
.	3204	3205	O

The	3206	3209	O
models	3210	3216	O
can	3217	3220	O
be	3221	3223	O
customized	3224	3234	O
locally	3235	3242	O
and	3243	3246	O
data	3247	3251	O
updated	3252	3259	O
if	3260	3262	O
the	3263	3266	O
user	3267	3271	O
has	3272	3275	O
sufficient	3276	3286	O
expertise	3287	3296	O
.	3296	3297	O

However	3298	3305	O
,	3305	3306	O
there	3307	3312	O
is	3313	3315	O
often	3316	3321	O
a	3322	3323	O
significant	3324	3335	O
duplication	3336	3347	O
of	3348	3350	O
effort	3351	3357	O
due	3358	3361	O
to	3362	3364	O
overlapping	3365	3376	O
jurisdictions	3377	3390	O
and	3391	3394	O
the	3395	3398	O
lack	3399	3403	O
of	3404	3406	O
data	3407	3411	O
sharing	3412	3419	O
due	3420	3423	O
to	3424	3426	O
security	3427	3435	O
and	3436	3439	O
other	3440	3445	O
considerations	3446	3460	O
.	3460	3461	O

CATS	3462	3466	O
and	3467	3470	O
HPAC	3471	3475	O
are	3476	3479	O
also	3480	3484	O
useful	3485	3491	O
for	3492	3495	O
creating	3496	3504	O
realistic	3505	3514	O
scenarios	3515	3524	O
for	3525	3528	O
training	3529	3537	O
and	3538	3541	O
planning	3542	3550	O
before	3551	3557	O
a	3558	3559	O
disaster	3560	3568	O
strikes	3569	3576	O
,	3576	3577	O
thus	3578	3582	O
enabling	3583	3591	O
responders	3592	3602	O
to	3603	3605	O
drill	3606	3611	O
and	3612	3615	O
exercise	3616	3624	O
so	3625	3627	O
they	3628	3632	O
know	3633	3637	O
roughly	3638	3645	O
what	3646	3650	O
to	3651	3653	O
expect	3654	3660	O
and	3661	3664	O
how	3665	3668	O
to	3669	3671	O
react	3672	3677	O
.	3677	3678	O

Contingency	3679	3690	O
plans	3691	3696	O
can	3697	3700	O
be	3701	3703	O
created	3704	3711	O
using	3712	3717	O
comprehensive	3718	3731	O
national	3732	3740	O
and	3741	3744	O
more	3745	3749	O
detailed	3750	3758	O
population	3759	3769	O
and	3770	3773	O
infrastructure	3774	3788	O
data	3789	3793	O
.	3793	3794	O

Should	3795	3801	O
disaster	3802	3810	O
strike	3811	3817	O
,	3817	3818	O
the	3819	3822	O
affected	3823	3831	O
population	3832	3842	O
and	3843	3846	O
the	3847	3850	O
impact	3851	3857	O
on	3858	3860	O
critical	3861	3869	O
facilities	3870	3880	O
can	3881	3884	O
be	3885	3887	O
quickly	3888	3895	O
assessed	3896	3904	O
,	3904	3905	O
although	3906	3914	O
efforts	3915	3922	O
frequently	3923	3933	O
need	3934	3938	O
to	3939	3941	O
be	3942	3944	O
expended	3945	3953	O
to	3954	3956	O
ensure	3957	3963	O
regional	3964	3972	O
and	3973	3976	O
local	3977	3982	O
databases	3983	3992	O
are	3993	3996	O
current	3997	4004	O
and	4005	4008	O
useful	4009	4015	O
.	4015	4016	O

Case	0	4	O
Presentation	5	17	O

The	18	21	O
patient	22	29	O
is	30	32	O
an	33	35	O
80	36	38	O
year	39	43	O
old	44	47	O
male	48	52	O
with	53	57	O
diabetes	58	66	O
mellitus	67	75	O
and	76	79	O
hypertension	80	92	O
,	92	93	O
who	94	97	O
at	98	100	O
age	101	104	O
74	105	107	O
(	108	109	O
March	109	114	O
2001	115	119	O
)	119	120	O
had	121	124	O
received	125	133	O
a	134	135	O
living	136	142	O
non	143	146	O
-	146	147	O
related	147	154	O
donor	155	160	O
kidney	161	167	B-Organ
transplant	168	178	O
.	178	179	O

At	180	182	O
that	183	187	O
time	188	192	O
he	193	195	O
was	196	199	O
discharged	200	210	O
with	211	215	O
a	216	217	O
double	218	224	O
immunosuppressive	225	242	O
therapy	243	250	O
consisting	251	261	O
of	262	264	O
prednisone	265	275	O
20	276	278	O
mg	279	281	O
/	281	282	O
day	282	285	O
and	286	289	O
mophetil	290	298	O
mycophenolate	299	312	O
1	313	314	O
.	314	315	O
5	315	316	O
gr	317	319	O
/	319	320	O
day	320	323	O
.	323	324	O

No	325	327	O
calcineurin	328	339	O
inhibitor	340	349	O
was	350	353	O
administered	354	366	O
.	366	367	O

His	368	371	O
prednisone	372	382	O
dose	383	387	O
was	388	391	O
further	392	399	O
decreased	400	409	O
to	410	412	O
5	413	414	O
mg	415	417	O
/	417	418	O
day	418	421	O
and	422	425	O
mophetil	426	434	O
mycophenolate	435	448	O
doses	449	454	O
sustained	455	464	O
.	464	465	O

In	466	468	O
November	469	477	O
2001	478	482	O
he	483	485	O
developed	486	495	O
cutaneous	496	505	O
purple	506	512	O
elevated	513	521	O
lesions	522	529	B-Pathological_formation
in	530	532	O
his	533	536	O
lower	537	542	B-Organism_subdivision
limbs	543	548	I-Organism_subdivision
that	549	553	O
were	554	558	O
diagnosed	559	568	O
as	569	571	O
KS	572	574	B-Pathological_formation
by	575	577	O
skin	578	582	B-Organ
biopsy	583	589	O
.	589	590	O

He	591	593	O
received	594	602	O
19	603	605	O
administrations	606	621	O
of	622	624	O
vincristine	625	636	O
(	637	638	O
1	638	639	O
mg	640	642	O
)	642	643	O
and	644	647	O
bleomycin	648	657	O
(	658	659	O
15	659	661	O
mg	662	664	O
)	664	665	O
weekly	666	672	O
that	673	677	O
resulted	678	686	O
in	687	689	O
flattening	690	700	O
and	701	704	O
fading	705	711	O
of	712	714	O
the	715	718	O
lesions	719	726	B-Pathological_formation
.	726	727	O

Treatment	728	737	O
was	738	741	O
discontinued	742	754	O
for	755	758	O
two	759	762	O
months	763	769	O
,	769	770	O
and	771	774	O
KS	775	777	B-Pathological_formation
recurred	778	786	O
,	786	787	O
with	788	792	O
pain	793	797	O
and	798	801	O
edema	802	807	B-Pathological_formation
in	808	810	O
both	811	815	O
legs	816	820	B-Organism_subdivision
.	820	821	O

On	822	824	O
July	825	829	O
2002	830	834	O
,	834	835	O
with	836	840	O
an	841	843	O
almost	844	850	O
100	851	854	O
%	854	855	O
involvement	856	867	O
of	868	870	O
his	871	874	O
lower	875	880	B-Organ
limbs	881	886	I-Organ
skin	887	891	I-Organ
with	892	896	O
KS	897	899	B-Pathological_formation
but	900	903	O
no	904	906	O
visceral	907	915	O
involvement	916	927	O
he	928	930	O
received	931	939	O
50	940	942	O
mg	943	945	O
of	946	948	O
liposomal	949	958	O
-	958	959	O
adriamycin	959	969	O
.	969	970	O

In	971	973	O
addition	974	982	O
,	982	983	O
he	984	986	O
was	987	990	O
then	991	995	O
prescribed	996	1006	O
valganciclovir	1007	1021	O
450	1022	1025	O
mg	1026	1028	O
BID	1029	1032	O
(	1033	1034	O
corrected	1034	1043	O
for	1044	1047	O
creatinine	1048	1058	O
clearance	1059	1068	O
)	1068	1069	O
[	1070	1071	O
7	1071	1072	O
]	1072	1073	O
and	1074	1077	O
three	1078	1083	O
additional	1084	1094	O
administrations	1095	1110	O
of	1111	1113	O
liposomal	1114	1123	O
-	1123	1124	O
adriamycin	1124	1134	O
,	1134	1135	O
up	1136	1138	O
to	1139	1141	O
December	1142	1150	O
2002	1151	1155	O
.	1155	1156	O

He	1157	1159	O
showed	1160	1166	O
40	1167	1169	O
%	1169	1170	O
response	1171	1179	O
again	1180	1185	O
with	1186	1190	O
early	1191	1196	O
relapse	1197	1204	O
.	1204	1205	O

On	1206	1208	O
January	1209	1216	O
2003	1217	1221	O
the	1222	1225	O
patient	1226	1233	O
developed	1234	1243	O
disseminated	1244	1256	O
herpes	1257	1263	O
zoster	1264	1270	O
,	1270	1271	O
which	1272	1277	O
was	1278	1281	O
treated	1282	1289	O
with	1290	1294	O
IV	1295	1297	O
acyclovir	1298	1307	O
.	1307	1308	O

In	1309	1311	O
May	1312	1315	O
2003	1316	1320	O
KS	1321	1323	B-Pathological_formation
progression	1324	1335	O
was	1336	1339	O
observed	1340	1348	O
and	1349	1352	O
received	1353	1361	O
radiotherapy	1362	1374	O
with	1375	1379	O
no	1380	1382	O
benefit	1383	1390	O
Figure	1391	1397	O
1	1398	1399	O
.	1399	1400	O

In	1401	1403	O
August	1404	1410	O
2003	1411	1415	O
he	1416	1418	O
started	1419	1426	O
oral	1427	1431	O
etoposide	1432	1441	O
at	1442	1444	O
50	1445	1447	O
mg	1448	1450	O
QD	1451	1453	O
for	1454	1457	O
two	1458	1461	O
weeks	1462	1467	O
followed	1468	1476	O
by	1477	1479	O
two	1480	1483	O
weeks	1484	1489	O
off	1490	1493	O
until	1494	1499	O
May	1500	1503	O
2004	1504	1508	O
achieving	1509	1518	O
a	1519	1520	O
very	1521	1525	O
slow	1526	1530	O
50	1531	1533	O
%	1533	1534	O
response	1535	1543	O
.	1543	1544	O

Tolerance	1545	1554	O
was	1555	1558	O
good	1559	1563	O
and	1564	1567	O
serum	1568	1573	B-Organism_substance
creatinine	1574	1584	O
remain	1585	1591	O
stable	1592	1598	O
at	1599	1601	O
around	1602	1608	O
1	1609	1610	O
,	1610	1611	O
4	1611	1612	O
mg	1613	1615	O
/	1615	1616	O
dl	1616	1618	O
.	1618	1619	O

Mophetil	1620	1628	O
mycophenolate	1629	1642	O
dose	1643	1647	O
was	1648	1651	O
reduced	1652	1659	O
to	1660	1662	O
1	1663	1664	O
g	1665	1666	O
/	1666	1667	O
day	1667	1670	O
and	1671	1674	O
prednisone	1675	1685	O
to	1686	1688	O
2	1689	1690	O
.	1690	1691	O
5	1691	1692	O
mg	1693	1695	O
/	1695	1696	O
day	1696	1699	O
.	1699	1700	O

Figure	1701	1707	O
1	1708	1709	O

Kaposi	1710	1716	B-Pathological_formation
'	1716	1717	I-Pathological_formation
s	1717	1718	I-Pathological_formation
sarcoma	1719	1726	I-Pathological_formation
progressions	1727	1739	O
after	1740	1745	O
chemotherapy	1746	1758	O
withdrawal	1759	1769	O
,	1769	1770	O
both	1771	1775	O
lower	1776	1781	B-Organism_subdivision
limbs	1782	1787	I-Organism_subdivision
were	1788	1792	O
completely	1793	1803	O
covered	1804	1811	O
with	1812	1816	O
Kaposi	1817	1823	B-Pathological_formation
'	1823	1824	I-Pathological_formation
s	1824	1825	I-Pathological_formation
Sarcoma	1826	1833	I-Pathological_formation
(	1834	1835	O
June	1835	1839	O
2003	1840	1844	O
)	1844	1845	O
.	1845	1846	O

On	1847	1849	O
May	1850	1853	O
2004	1854	1858	O
the	1859	1862	O
patient	1863	1870	O
requested	1871	1880	O
a	1881	1882	O
second	1883	1889	O
opinion	1890	1897	O
and	1898	1901	O
was	1902	1905	O
prescribed	1906	1916	O
Imatinib	1917	1925	O
200	1926	1929	O
mg	1930	1932	O
qd	1933	1935	O
for	1936	1939	O
two	1940	1943	O
weeks	1944	1949	O
followed	1950	1958	O
by	1959	1961	O
400	1962	1965	O
mg	1966	1968	O
qd	1969	1971	O
.	1971	1972	O

After	1973	1978	O
four	1979	1983	O
weeks	1984	1989	O
of	1990	1992	O
Imatinib	1993	2001	O
,	2001	2002	O
his	2003	2006	O
health	2007	2013	O
deteriorated	2014	2026	O
rapidly	2027	2034	O
,	2034	2035	O
he	2036	2038	O
developed	2039	2048	O
anasarca	2049	2057	B-Pathological_formation
,	2057	2058	O
worsening	2059	2068	O
of	2069	2071	O
KS	2072	2074	O
,	2074	2075	O
his	2076	2079	O
serum	2080	2085	B-Organism_substance
creatinine	2086	2096	O
increased	2097	2106	O
from	2107	2111	O
1	2112	2113	O
.	2113	2114	O
4	2114	2115	O
mg	2116	2118	O
/	2118	2119	O
dl	2119	2121	O
to	2122	2124	O
2	2125	2126	O
.	2126	2127	O
3	2127	2128	O
mg	2129	2131	O
/	2131	2132	O
dl	2132	2134	O
and	2135	2138	O
he	2139	2141	O
developed	2142	2151	O
grade	2152	2157	O
4	2158	2159	O
granulocytopenia	2160	2176	O
(	2177	2178	O
Figure	2178	2184	O
2	2185	2186	O
)	2186	2187	O
.	2187	2188	O

The	2189	2192	O
patient	2193	2200	O
was	2201	2204	O
hospitalized	2205	2217	O
with	2218	2222	O
fever	2223	2228	O
and	2229	2232	O
was	2233	2236	O
started	2237	2244	O
on	2245	2247	O
IV	2248	2250	O
antibiotics	2251	2262	O
and	2263	2266	O
daily	2267	2272	O
G	2273	2274	O
-	2274	2275	O
CSF	2275	2278	O
for	2279	2282	O
four	2283	2287	O
days	2288	2292	O
after	2293	2298	O
which	2299	2304	O
his	2305	2308	O
WBC	2309	2312	B-Cell
count	2313	2318	O
normalized	2319	2329	O
.	2329	2330	O

Two	2331	2334	O
weeks	2335	2340	O
later	2341	2346	O
the	2347	2350	O
creatinine	2351	2361	O
level	2362	2367	O
returned	2368	2376	O
to	2377	2379	O
1	2380	2381	O
.	2381	2382	O
5	2382	2383	O
mg	2384	2386	O
/	2386	2387	O
dl	2387	2389	O
.	2389	2390	O

On	2391	2393	O
February	2394	2402	O
2005	2403	2407	O
he	2408	2410	O
was	2411	2414	O
started	2415	2422	O
on	2423	2425	O
30	2426	2428	O
mg	2429	2431	O
of	2432	2434	O
paclitaxel	2435	2445	O
IV	2446	2448	O
every	2449	2454	O
three	2455	2460	O
weeks	2461	2466	O
.	2466	2467	O

After	2468	2473	O
three	2474	2479	O
courses	2480	2487	O
with	2488	2492	O
no	2493	2495	O
clinical	2496	2504	O
benefit	2505	2512	O
he	2513	2515	O
developed	2516	2525	O
a	2526	2527	O
skin	2528	2532	B-Organ
rash	2533	2537	O
that	2538	2542	O
prompted	2543	2551	O
discontinuation	2552	2567	O
.	2567	2568	O

Figure	2569	2575	O
2	2576	2577	O

Patient	2578	2585	O
developed	2586	2595	O
anasarca	2596	2604	B-Pathological_formation
with	2605	2609	O
rapid	2610	2615	O
progression	2616	2627	O
of	2628	2630	O
Kaposi	2631	2637	B-Pathological_formation
'	2637	2638	I-Pathological_formation
s	2638	2639	I-Pathological_formation
Sarcoma	2640	2647	I-Pathological_formation
after	2648	2653	O
four	2654	2658	O
weeks	2659	2664	O
of	2665	2667	O
taking	2668	2674	O
Imatinib	2675	2683	O
(	2684	2685	O
June	2685	2689	O
2004	2690	2694	O
)	2694	2695	O
.	2695	2696	O

On	2697	2699	O
April	2700	2705	O
2005	2706	2710	O
,	2710	2711	O
he	2712	2714	O
was	2715	2718	O
started	2719	2726	O
on	2727	2729	O
Sirolimus	2730	2739	O
2	2740	2741	O
mg	2742	2744	O
a	2745	2746	O
day	2747	2750	O
,	2750	2751	O
and	2752	2755	O
after	2756	2761	O
8	2762	2763	O
weeks	2764	2769	O
escalated	2770	2779	O
to	2780	2782	O
4	2783	2784	O
mg	2785	2787	O
a	2788	2789	O
day	2790	2793	O
.	2793	2794	O

Three	2795	2800	O
weeks	2801	2806	O
later	2807	2812	O
mophetil	2813	2821	O
mycophenolate	2822	2835	O
and	2836	2839	O
prednisone	2840	2850	O
were	2851	2855	O
discontinued	2856	2868	O
.	2868	2869	O

Sustained	2870	2879	O
and	2880	2883	O
significant	2884	2895	O
KS	2896	2898	B-Pathological_formation
regression	2899	2909	O
was	2910	2913	O
evident	2914	2921	O
after	2922	2927	O
16	2928	2930	O
weeks	2931	2936	O
,	2936	2937	O
but	2938	2941	O
he	2942	2944	O
developed	2945	2954	O
a	2955	2956	O
basal	2957	2962	B-Pathological_formation
cell	2963	2967	I-Pathological_formation
carcinoma	2968	2977	I-Pathological_formation
and	2978	2981	O
pneumonia	2982	2991	O
that	2992	2996	O
required	2997	3005	O
hospital	3006	3014	O
admission	3015	3024	O
;	3024	3025	O
Sirolimus	3026	3035	O
dose	3036	3040	O
was	3041	3044	O
lowered	3045	3052	O
to	3053	3055	O
2	3056	3057	O
mg	3058	3060	O
a	3061	3062	O
day	3063	3066	O
.	3066	3067	O

Thereafter	3068	3078	O
his	3079	3082	O
clinical	3083	3091	O
course	3092	3098	O
has	3099	3102	O
been	3103	3107	O
satisfactory	3108	3120	O
with	3121	3125	O
continuous	3126	3136	O
and	3137	3140	O
progressive	3141	3152	O
regression	3153	3163	O
of	3164	3166	O
KS	3167	3169	B-Pathological_formation
lesions	3170	3177	I-Pathological_formation
(	3178	3179	O
Figure	3179	3185	O
3	3186	3187	O
)	3187	3188	O
.	3188	3189	O

His	3190	3193	O
serum	3194	3199	B-Organism_substance
creatinine	3200	3210	O
has	3211	3214	O
remained	3215	3223	O
under	3224	3229	O
1	3230	3231	O
.	3231	3232	O
6	3232	3233	O
mg	3234	3236	O
/	3236	3237	O
dl	3237	3239	O
and	3240	3243	O
he	3244	3246	O
has	3247	3250	O
not	3251	3254	O
developed	3255	3264	O
new	3265	3268	O
infectious	3269	3279	O
episodes	3280	3288	O
.	3288	3289	O

Figure	3290	3296	O
3	3297	3298	O

Extensive	3299	3308	O
regression	3309	3319	O
of	3320	3322	O
Kaposi	3323	3329	B-Pathological_formation
Sarcoma	3330	3337	I-Pathological_formation
after	3338	3343	O
immune	3344	3350	O
-	3350	3351	O
suppression	3351	3362	O
was	3363	3366	O
changed	3367	3374	O
to	3375	3377	O
Sirolimus	3378	3387	O
,	3387	3388	O
(	3389	3390	O
14	3390	3392	O
months	3393	3399	O
later	3400	3405	O
)	3405	3406	O
,	3406	3407	O
he	3408	3410	O
only	3411	3415	O
has	3416	3419	O
hyperpigmented	3420	3434	O
areas	3435	3440	O
at	3441	3443	O
knee	3444	3448	B-Organism_subdivision
levels	3449	3455	O
,	3455	3456	O
skin	3457	3461	B-Organ
looks	3462	3467	O
thin	3468	3472	O
and	3473	3476	O
delicate	3477	3485	O
and	3486	3489	O
easily	3490	3496	O
bruised	3497	3504	O
(	3505	3506	O
July	3506	3510	O
2006	3511	3515	O
)	3515	3516	O
.	3516	3517	O

Hypothetical	0	12	O
distribution	13	25	O
patterns	26	34	O
of	35	37	O
the	38	41	O
meadow	42	48	O
brown	49	54	O
Maniola	55	62	O
jurtina	63	70	O
in	71	73	O
Europe	74	80	O
during	81	87	O
the	88	91	O
last	92	96	O
glacial	97	104	O
maximum	105	112	O
(	113	114	O
dark	114	118	O
hatched	119	126	O
areas	127	132	O
)	132	133	O
.	133	134	O

Postglacial	135	146	O
expansions	147	157	O
are	158	161	O
indicated	162	171	O
by	172	174	O
solid	175	180	O
arrows	181	187	O
.	187	188	O

The	189	192	O
postulated	193	203	O
actual	204	210	O
hybrid	211	217	O
zone	218	222	O
is	223	225	O
shown	226	231	O
by	232	234	O
the	235	238	O
hatched	239	246	O
area	247	251	O
.	251	252	O

Question	253	261	O
marks	262	267	O
indicate	268	276	O
lack	277	281	O
of	282	284	O
information	285	296	O
concerning	297	307	O
ancient	308	315	O
distribution	316	328	O
patterns	329	337	O
in	338	340	O
the	341	344	O
South	345	350	O
and	351	354	O
present	355	362	O
distribution	363	375	O
of	376	378	O
hybrid	379	385	O
populations	386	397	O
in	398	400	O
the	401	404	O
North	405	410	O
.	410	411	O

Redrawn	412	419	O
from	420	424	O
Schmitt	425	432	O
et	433	435	O
.	435	436	O

al	437	439	O
.	439	440	O

[	441	442	O
36	442	444	O
]	444	445	O
;	445	446	O
based	447	452	O
on	453	455	O
Thomson	456	463	O
[	464	465	O
37	465	467	O
]	467	468	O
and	469	472	O
Schmitt	473	480	O
et	481	483	O
al	484	486	O
.	486	487	O

[	488	489	O
36	489	491	O
]	491	492	O
.	492	493	O

Supporting	0	10	O
Information	11	22	O

Alternate	23	32	O
Language	33	41	O
Article	42	49	O
S1	50	52	O

Translation	53	64	O
of	65	67	O
the	68	71	O
manuscript	72	82	O
into	83	87	O
French	88	94	O
by	95	97	O
EL	98	100	O

(	101	102	O
201	102	105	O
KB	106	108	O
DOC	109	112	O
)	112	113	O
.	113	114	O

Click	115	120	O
here	121	125	O
for	126	129	O
additional	130	140	O
data	141	145	O
file	146	150	O
.	150	151	O

Extrapyramidal	0	14	O
symptoms	15	23	O
based	24	29	O
on	30	32	O
Extrapyramidal	33	47	O
Symptoms	48	56	O
Rating	57	63	O
Scale	64	69	O

Etiology	0	8	O

Anorectal	9	18	B-Organism_subdivision
malformations	19	32	O
(	33	34	O
ARM	34	37	O
)	37	38	O
represent	39	48	O
a	49	50	O
spectrum	51	59	O
of	60	62	O
abnormalities	63	76	O
ranging	77	84	O
from	85	89	O
mild	90	94	O
anal	95	99	B-Immaterial_anatomical_entity
anomalies	100	109	O
to	110	112	O
complex	113	120	O
cloacal	121	128	O
malformations	129	142	O
.	142	143	O

The	144	147	O
etiology	148	156	O
of	157	159	O
such	160	164	O
malformations	165	178	O
remains	179	186	O
unclear	187	194	O
and	195	198	O
is	199	201	O
likely	202	208	O
multifactorial	209	223	O
.	223	224	O

There	225	230	O
are	231	234	O
however	235	242	O
reasons	243	250	O
to	251	253	O
believe	254	261	O
there	262	267	O
is	268	270	O
a	271	272	O
genetic	273	280	O
componenet	281	291	O
.	291	292	O

As	293	295	O
early	296	301	O
as	302	304	O
the	305	308	O
1950s	309	314	O
,	314	315	O
it	316	318	O
was	319	322	O
recognized	323	333	O
that	334	338	O
there	339	344	O
was	345	348	O
an	349	351	O
increased	352	361	O
risk	362	366	O
for	367	370	O
a	371	372	O
sibling	373	380	O
of	381	383	O
a	384	385	O
patient	386	393	O
with	394	398	O
ARM	399	402	O
to	403	405	O
be	406	408	O
born	409	413	O
with	414	418	O
a	419	420	O
malformation	421	433	O
,	433	434	O
as	435	437	O
much	438	442	O
as	443	445	O
1	446	447	O
in	448	450	O
100	451	454	O
,	454	455	O
compared	456	464	O
with	465	469	O
the	470	473	O
incidence	474	483	O
of	484	486	O
about	487	492	O
1	493	494	O
in	495	497	O
5000	498	502	O
in	503	505	O
the	506	509	O
general	510	517	O
population	518	528	O
.	528	529	O

Since	530	535	O
that	536	540	O
time	541	545	O
there	546	551	O
have	552	556	O
been	557	561	O
reports	562	569	O
of	570	572	O
families	573	581	O
with	582	586	O
2	587	588	O
or	589	591	O
more	592	596	O
affected	597	605	O
members	606	613	O
and	614	617	O
associations	618	630	O
of	631	633	O
ARMs	634	638	O
with	639	643	O
multisystem	644	655	O
syndromes	656	665	O
.	665	666	O

In	667	669	O
particular	670	680	O
,	680	681	O
mutations	682	691	O
in	692	694	O
specific	695	703	O
genes	704	709	O
encoding	710	718	O
transcription	719	732	O
factors	733	740	O
have	741	745	O
been	746	750	O
described	751	760	O
in	761	763	O
patients	764	772	O
having	773	779	O
Townes	780	786	O
-	786	787	O
Broks	787	792	O
syndrome	793	801	O
,	801	802	O
Currarino	803	812	O
'	812	813	O
s	813	814	O
syndrome	815	823	O
,	823	824	O
and	825	828	O
Pallister	829	838	O
-	838	839	O
Hall	839	843	O
syndrome	844	852	O
,	852	853	O
each	854	858	O
of	859	861	O
which	862	867	O
have	868	872	O
autosomal	873	882	O
dominant	883	891	O
modes	892	897	O
of	898	900	O
inheritance	901	912	O
.	912	913	O

In	914	916	O
addition	917	925	O
,	925	926	O
it	927	929	O
has	930	933	O
been	934	938	O
found	939	944	O
that	945	949	O
there	950	955	O
is	956	958	O
not	959	962	O
only	963	967	O
an	968	970	O
increased	971	980	O
incidence	981	990	O
of	991	993	O
ARM	994	997	O
in	998	1000	O
patient	1001	1008	O
with	1009	1013	O
trisomy	1014	1021	O
21	1022	1024	O
(	1025	1026	O
Down	1026	1030	O
'	1030	1031	O
s	1031	1032	O
syndrome	1033	1041	O
)	1041	1042	O
,	1042	1043	O
but	1044	1047	O
that	1048	1052	O
95	1053	1055	O
%	1055	1056	O
of	1057	1059	O
patients	1060	1068	O
with	1069	1073	O
trisomy	1074	1081	O
21	1082	1084	O
and	1085	1088	O
ARM	1089	1092	O
have	1093	1097	O
imperforate	1098	1109	O
anus	1110	1114	B-Immaterial_anatomical_entity
without	1115	1122	O
fistula	1123	1130	B-Pathological_formation
,	1130	1131	O
compared	1132	1140	O
with	1141	1145	O
only	1146	1150	O
5	1151	1152	O
%	1152	1153	O
of	1154	1156	O
all	1157	1160	O
patients	1161	1169	O
with	1170	1174	O
ARM	1175	1178	O
.	1178	1179	O

Based	1180	1185	O
on	1186	1188	O
this	1189	1193	O
evidence	1194	1202	O
,	1202	1203	O
it	1204	1206	O
is	1207	1209	O
likely	1210	1216	O
that	1217	1221	O
the	1222	1225	O
mutation	1226	1234	O
of	1235	1237	O
a	1238	1239	O
variety	1240	1247	O
of	1248	1250	O
different	1251	1260	O
genes	1261	1266	O
can	1267	1270	O
result	1271	1277	O
in	1278	1280	O
ARM	1281	1284	O
,	1284	1285	O
or	1286	1288	O
that	1289	1293	O
the	1294	1297	O
etiology	1298	1306	O
of	1307	1309	O
ARM	1310	1313	O
is	1314	1316	O
multigenic	1317	1327	O
[	1328	1329	O
13	1329	1331	O
]	1331	1332	O
.	1332	1333	O

Images	0	6	O

Fig	7	10	O
.	10	11	O

1	12	13	O

Fig	14	17	O
.	17	18	O

2	19	20	O

Fig	21	24	O
.	24	25	O

3	26	27	O

Images	0	6	O

Figure	7	13	O
1	14	15	O

Results	0	7	O

The	8	11	O
observation	12	23	O
that	24	28	O
AP	29	31	O
-	31	32	O
3	32	33	O
is	34	36	O
found	37	42	O
in	43	45	O
both	46	50	O
cytosolic	51	60	B-Organism_substance
and	61	64	O
membrane	65	73	B-Organism_substance
subcellular	74	85	I-Organism_substance
fractions	86	95	I-Organism_substance
,	95	96	O
and	97	100	O
that	101	105	O
membrane	106	114	B-Cellular_component
-	114	115	O
associated	115	125	O
AP	126	128	O
-	128	129	O
3	129	130	O
can	131	134	O
be	135	137	O
extracted	138	147	O
with	148	152	O
salts	153	158	O
(	159	160	O
Dell	160	164	O
'	164	165	O
Angelica	165	173	O
et	174	176	O
al	177	179	O
.	179	180	O
,	180	181	O
1997a	182	187	O
)	187	188	O
is	189	191	O
consistent	192	202	O
with	203	207	O
its	208	211	O
role	212	216	O
as	217	219	O
a	220	221	O
membrane	222	230	B-Cellular_component
coat	231	235	O
that	236	240	O
can	241	244	O
be	245	247	O
recruited	248	257	O
from	258	262	O
a	263	264	O
cytosolic	265	274	B-Organism_substance
pool	275	279	I-Organism_substance
.	279	280	O

In	281	283	O
addition	284	292	O
,	292	293	O
the	294	297	O
punctate	298	306	O
staining	307	315	O
of	316	318	O
AP	319	321	O
-	321	322	O
3	322	323	O
by	324	326	O
immunofluorescence	327	345	O
microscopy	346	356	O
,	356	357	O
its	358	361	O
redistribution	362	376	O
to	377	379	O
the	380	383	O
cytosol	384	391	B-Organism_substance
by	392	394	O
BFA	395	398	O
,	398	399	O
and	400	403	O
the	404	407	O
reversibility	408	421	O
of	422	424	O
the	425	428	O
BFA	429	432	O
effect	433	439	O
(	440	441	O
Dell	441	445	O
'	445	446	O
Angelica	446	454	O
et	455	457	O
al	458	460	O
.	460	461	O
,	461	462	O
1997a	463	468	O
;	468	469	O
Simpson	470	477	O
et	478	480	O
al	481	483	O
.	483	484	O
,	484	485	O
1997	486	490	O
)	490	491	O
also	492	496	O
indicate	497	505	O
that	506	510	O
AP	511	513	O
-	513	514	O
3	514	515	O
can	516	519	O
cycle	520	525	O
between	526	533	O
the	534	537	O
cytosol	538	545	B-Organism_substance
and	546	549	O
membranes	550	559	B-Cellular_component
.	559	560	O

The	561	564	O
sensitivity	565	576	O
of	577	579	O
AP	580	582	O
-	582	583	O
3	583	584	O
to	585	587	O
BFA	588	591	O
in	592	594	O
cells	595	600	B-Cell
suggests	601	609	O
that	610	614	O
its	615	618	O
membrane	619	627	B-Cellular_component
association	628	639	O
may	640	643	O
be	644	646	O
regulated	647	656	O
by	657	659	O
ARF1	660	664	O
,	664	665	O
since	666	671	O
BFA	672	675	O
inhibits	676	684	O
ARF1	685	689	O
guanine	690	697	O
nucleotide	698	708	O
exchange	709	717	O
,	717	718	O
and	719	722	O
has	723	726	O
been	727	731	O
shown	732	737	O
to	738	740	O
prevent	741	748	O
ARF1	749	753	O
membrane	754	762	B-Cellular_component
binding	763	770	O
in	771	773	O
vitro	774	779	O
(	780	781	O
Donaldson	781	790	O
et	791	793	O
al	794	796	O
.	796	797	O
,	797	798	O
1992	799	803	O
;	803	804	O
Helms	805	810	O
and	811	814	O
Rothman	815	822	O
,	822	823	O
1992	824	828	O
;	828	829	O
Randazzo	830	838	O
et	839	841	O
al	842	844	O
.	844	845	O
,	845	846	O
1993	847	851	O
)	851	852	O
.	852	853	O

Immunocytochemistry	0	19	O

C2C12	20	25	B-Cell
cells	26	31	I-Cell
grown	32	37	O
in	38	40	O
8	41	42	O
-	42	43	O
chamber	43	50	O
slides	51	57	O
(	58	59	O
Nunc	59	63	O
)	63	64	O
were	65	69	O
fixed	70	75	O
in	76	78	O
4	79	80	O
%	80	81	O
PFA	82	85	O
/	85	86	O
PBS	86	89	O
for	90	93	O
10	94	96	O
min	97	100	O
and	101	104	O
permeabilized	105	118	O
in	119	121	O
0	122	123	O
.	123	124	O
1	124	125	O
%	125	126	O
Triton	127	133	O
X	134	135	O
-	135	136	O
100	136	139	O
for	140	143	O
20	144	146	O
min	147	150	O
.	150	151	O

In	152	154	O
some	155	159	O
cases	160	165	O
,	165	166	O
they	167	171	O
were	172	176	O
fixed	177	182	O
and	183	186	O
permeabilized	187	200	O
in	201	203	O
methanol	204	212	O
at	213	215	O
-	216	217	O
20degreesC	217	227	O
for	228	231	O
2	232	233	O
min	234	237	O
.	237	238	O

The	239	242	O
fixed	243	248	O
and	249	252	O
permeabilized	253	266	O
cells	267	272	B-Cell
were	273	277	O
blocked	278	285	O
in	286	288	O
PBS	289	292	O
containing	293	303	O
3	304	305	O
%	305	306	O
BSA	307	310	O
(	311	312	O
Jackson	312	319	O
ImmunoResearch	320	334	O
Laboratories	335	347	O
)	347	348	O
and	349	352	O
incubated	353	362	O
overnight	363	372	O
at	373	375	O
4degreesC	376	385	O
with	386	390	O
primary	391	398	O
antibodies	399	409	O
in	410	412	O
blocking	413	421	O
solution	422	430	O
.	430	431	O

Immunoreactivity	432	448	O
was	449	452	O
detected	453	461	O
with	462	466	O
either	467	473	O
Alexa	474	479	O
-	479	480	O
conjugated	480	490	O
secondary	491	500	O
antibody	501	509	O
(	510	511	O
Molecular	511	520	O
Probes	521	527	O
)	527	528	O
or	529	531	O
a	532	533	O
combination	534	545	O
of	546	548	O
biotin	549	555	O
-	555	556	O
conjugated	556	566	O
secondary	567	576	O
antibody	577	585	O
(	586	587	O
Vector	587	593	O
Laboratories	594	606	O
)	606	607	O
and	608	611	O
Alexa	612	617	O
-	617	618	O
conjugated	618	628	O
streptavidin	629	641	O
(	642	643	O
Molecular	643	652	O
Probes	653	659	O
)	659	660	O
.	660	661	O

Cytology	0	8	O
and	9	12	O
Histology	13	22	O

For	23	26	O
semithin	27	35	O
sections	36	44	O
,	44	45	O
embryoid	46	54	B-Developing_anatomical_structure
bodies	55	61	I-Developing_anatomical_structure
were	62	66	O
washed	67	73	O
twice	74	79	O
in	80	82	O
PBS	83	86	O
,	86	87	O
fixed	88	93	O
in	94	96	O
4	97	98	O
%	98	99	O
paraformaldehyde	100	116	O
at	117	119	O
4degreesC	120	129	O
overnight	130	139	O
,	139	140	O
and	141	144	O
after	145	150	O
dehydration	151	162	O
in	163	165	O
ethanol	166	173	O
were	174	178	O
embedded	179	187	O
in	188	190	O
JB	191	193	O
-	193	194	O
4	194	195	O
resin	196	201	O
(	202	203	O
Polysciences	203	215	O
,	215	216	O
Inc	217	220	O
.	220	221	O
)	221	222	O
.	222	223	O

1	224	225	O
-	225	226	O
4	226	227	O
-	227	228	O
mum	228	231	O
sections	232	240	O
were	241	245	O
cut	246	249	O
with	250	254	O
a	255	256	O
glass	257	262	O
knife	263	268	O
.	268	269	O

For	270	273	O
cytology	274	282	O
,	282	283	O
the	284	287	O
sections	288	296	O
were	297	301	O
stained	302	309	O
with	310	314	O
toluidine	315	324	O
blue	325	329	O
.	329	330	O

In	331	333	O
cell	334	338	B-Cell
mixing	339	345	O
experiments	346	357	O
,	357	358	O
the	359	362	O
embryoid	363	371	B-Developing_anatomical_structure
bodies	372	378	I-Developing_anatomical_structure
were	379	383	O
prefixed	384	392	O
and	393	396	O
stained	397	404	O
for	405	408	O
beta	409	413	O
-	413	414	O
galactosidase	414	427	O
and	428	431	O
the	432	435	O
sections	436	444	O
were	445	449	O
counterstained	450	464	O
with	465	469	O
neutral	470	477	O
red	478	481	O
.	481	482	O

Teratocarcinomas	483	499	O
were	500	504	O
fixed	505	510	O
in	511	513	O
Bouin	514	519	O
fixative	520	528	O
,	528	529	O
embedded	530	538	O
in	539	541	O
Paraplast	542	551	O
,	551	552	O
and	553	556	O
the	557	560	O
sections	561	569	O
were	570	574	O
stained	575	582	O
with	583	587	O
hematoxylin	588	599	O
and	600	603	O
eosin	604	609	O
.	609	610	O

Microphotography	611	627	O
was	628	631	O
with	632	636	O
a	637	638	O
ZEISS	639	644	O
Axiomat	645	652	O
microscope	653	663	O
.	663	664	O

Films	665	670	O
were	671	675	O
scanned	676	683	O
and	684	687	O
figures	688	695	O
were	696	700	O
prepared	701	709	O
with	710	714	O
Photoshop	715	724	O
5	725	726	O
.	726	727	O
5	727	728	O
software	729	737	O
.	737	738	O

Stimulation	0	11	O
/	11	12	O
Inhibition	12	22	O
of	23	25	O
iDC	26	29	B-Cell
Functions	30	39	O
by	40	42	O
Activated	43	52	O
NK	53	55	B-Cell
Cells	56	61	I-Cell
.	61	62	O

Two	63	66	O
previous	67	75	O
studies	76	83	O
have	84	88	O
shown	89	94	O
that	95	99	O
both	100	104	O
resting	105	112	O
and	113	116	O
activated	117	126	O
NK	127	129	B-Cell
cells	130	135	I-Cell
partially	136	145	O
kill	146	150	O
autologous	151	161	O
DCs	162	165	B-Cell
,	165	166	O
as	167	169	O
measured	170	178	O
by	179	181	O
3	182	183	O
-	183	184	O
4	184	185	O
-	185	186	O
h	186	187	O
chromium	188	196	O
release	197	204	O
assays	205	211	O
using	212	217	O
high	218	222	O
NK	223	225	B-Cell
/	225	226	O
DC	226	228	B-Cell
ratios	229	235	O
(	236	237	O
11	237	239	O
,	239	240	O
12	241	243	O
)	243	244	O
.	244	245	O

However	246	253	O
,	253	254	O
in	255	257	O
our	258	261	O
long	262	266	O
-	266	267	O
term	267	271	O
cultures	272	280	O
(	281	282	O
24	282	284	O
-	284	285	O
48	285	287	O
h	288	289	O
)	289	290	O
the	291	294	O
NK	295	297	B-Cell
cells	298	303	I-Cell
stimulated	304	314	O
the	315	318	O
iDCs	319	323	B-Cell
rather	324	330	O
than	331	335	O
lysing	336	342	O
them	343	347	O
.	347	348	O

Based	349	354	O
on	355	357	O
these	358	363	O
conflicting	364	375	O
results	376	383	O
,	383	384	O
we	385	387	O
examined	388	396	O
in	397	399	O
more	400	404	O
detail	405	411	O
the	412	415	O
apparent	416	424	O
stimulation	425	436	O
of	437	439	O
iDCs	440	444	B-Cell
after	445	450	O
contact	451	458	O
with	459	463	O
NK	464	466	B-Cell
cells	467	472	I-Cell
.	472	473	O

We	474	476	O
reasoned	477	485	O
that	486	490	O
activated	491	500	O
NK	501	503	B-Cell
cells	504	509	I-Cell
would	510	515	O
be	516	518	O
more	519	523	O
useful	524	530	O
for	531	534	O
these	535	540	O
experiments	541	552	O
because	553	560	O
(	561	562	O
i	562	563	O
)	563	564	O
an	565	567	O
encounter	568	577	O
in	578	580	O
vivo	581	585	O
between	586	593	O
NK	594	596	B-Cell
cells	597	602	I-Cell
that	603	607	O
normally	608	616	O
traffic	617	624	O
in	625	627	O
the	628	631	O
blood	632	637	B-Organism_substance
(	638	639	O
4	639	640	O
)	640	641	O
and	642	645	O
iDCs	646	650	B-Cell
which	651	656	O
reside	657	663	O
in	664	666	O
the	667	670	O
tissues	671	678	B-Tissue
(	679	680	O
1	680	681	O
,	681	682	O
3	683	684	O
)	684	685	O
,	685	686	O
should	687	693	O
only	694	698	O
occur	699	704	O
when	705	709	O
both	710	714	O
cells	715	720	B-Cell
are	721	724	O
activated	725	734	O
;	734	735	O
(	736	737	O
ii	737	739	O
)	739	740	O
activated	741	750	O
NK	751	753	B-Cell
cells	754	759	I-Cell
mediate	760	767	O
more	768	772	O
potent	773	779	O
lysis	780	785	O
of	786	788	O
iDCs	789	793	B-Cell
(	794	795	O
11	795	797	O
-	797	798	O
13	798	800	O
)	800	801	O
,	801	802	O
thereby	803	810	O
allowing	811	819	O
for	820	823	O
a	824	825	O
more	826	830	O
rigorous	831	839	O
examination	840	851	O
of	852	854	O
a	855	856	O
potential	857	866	O
cytotoxic	867	876	O
effect	877	883	O
;	883	884	O
and	885	888	O
(	889	890	O
iii	890	893	O
)	893	894	O
the	895	898	O
number	899	905	O
of	906	908	O
NK	909	911	B-Cell
cells	912	917	I-Cell
obtained	918	926	O
after	927	932	O
short	933	938	O
-	938	939	O
term	939	943	O
in	944	946	O
vitro	947	952	O
culture	953	960	O
would	961	966	O
be	967	969	O
far	970	973	O
greater	974	981	O
providing	982	991	O
more	992	996	O
cells	997	1002	B-Cell
for	1003	1006	O
analysis	1007	1015	O
(	1016	1017	O
9	1017	1018	O
)	1018	1019	O
.	1019	1020	O

The	1021	1024	O
DC	1025	1027	B-Cell
maturation	1028	1038	O
induced	1039	1046	O
by	1047	1049	O
resting	1050	1057	O
NK	1058	1060	B-Cell
cells	1061	1066	I-Cell
we	1067	1069	O
observed	1070	1078	O
was	1079	1082	O
dependent	1083	1092	O
on	1093	1095	O
endogenous	1096	1106	O
TNF	1107	1110	O
-	1110	1111	O
alpha	1111	1116	O
production	1117	1127	O
.	1127	1128	O

Furthermore	1129	1140	O
,	1140	1141	O
TNF	1142	1145	O
-	1145	1146	O
alpha	1146	1151	O
and	1152	1155	O
other	1156	1161	O
proinflammatory	1162	1177	O
cytokines	1178	1187	O
are	1188	1191	O
important	1192	1201	O
amplifiers	1202	1212	O
of	1213	1215	O
immune	1216	1222	O
responses	1223	1232	O
(	1233	1234	O
14	1234	1236	O
)	1236	1237	O
.	1237	1238	O

Therefore	1239	1248	O
,	1248	1249	O
we	1250	1252	O
used	1253	1257	O
TNF	1258	1261	O
-	1261	1262	O
alpha	1262	1267	O
production	1268	1278	O
as	1279	1281	O
a	1282	1283	O
readout	1284	1291	O
for	1292	1295	O
DC	1296	1298	B-Cell
stimulation	1299	1310	O
in	1311	1313	O
our	1314	1317	O
culture	1318	1325	O
system	1326	1332	O
.	1332	1333	O

Culturing	1334	1343	O
activated	1344	1353	O
NK	1354	1356	B-Cell
cells	1357	1362	I-Cell
with	1363	1367	O
DCs	1368	1371	B-Cell
at	1372	1374	O
low	1375	1378	O
NK	1379	1381	B-Cell
/	1381	1382	O
DC	1382	1384	B-Cell
ratios	1385	1391	O
(	1392	1393	O
1	1393	1394	O
:	1394	1395	O
5	1395	1396	O
)	1396	1397	O
led	1398	1401	O
to	1402	1404	O
increases	1405	1414	O
in	1415	1417	O
TNF	1418	1421	O
-	1421	1422	O
alpha	1422	1427	O
production	1428	1438	O
,	1438	1439	O
which	1440	1445	O
were	1446	1450	O
augmented	1451	1460	O
dramatically	1461	1473	O
by	1474	1476	O
the	1477	1480	O
addition	1481	1489	O
of	1490	1492	O
suboptimal	1493	1503	O
doses	1504	1509	O
(	1510	1511	O
10	1511	1513	O
ng	1514	1516	O
/	1516	1517	O
ml	1517	1519	O
)	1519	1520	O
of	1521	1523	O
LPS	1524	1527	O
(	1528	1529	O
Fig	1529	1532	O
.	1532	1533	O
2	1534	1535	O
A	1536	1537	O
)	1537	1538	O
.	1538	1539	O

The	1540	1543	O
increased	1544	1553	O
TNF	1554	1557	O
-	1557	1558	O
alpha	1558	1563	O
production	1564	1574	O
was	1575	1578	O
dependent	1579	1588	O
on	1589	1591	O
cell	1592	1596	B-Cell
-	1596	1597	O
to	1597	1599	O
-	1599	1600	O
cell	1600	1604	B-Cell
contact	1605	1612	O
because	1613	1620	O
when	1621	1625	O
the	1626	1629	O
two	1630	1633	O
cell	1634	1638	B-Cell
types	1639	1644	O
were	1645	1649	O
separated	1650	1659	O
in	1660	1662	O
trans	1663	1668	O
-	1668	1669	O
wells	1669	1674	O
,	1674	1675	O
no	1676	1678	O
stimulation	1679	1690	O
was	1691	1694	O
observed	1695	1703	O
(	1704	1705	O
Fig	1705	1708	O
.	1708	1709	O
2	1710	1711	O
B	1712	1713	O
)	1713	1714	O
.	1714	1715	O

In	1716	1718	O
separate	1719	1727	O
experiments	1728	1739	O
we	1740	1742	O
observed	1743	1751	O
this	1752	1756	O
NK	1757	1759	B-Cell
-	1759	1760	O
stimulatory	1760	1771	O
effect	1772	1778	O
on	1779	1781	O
TNF	1782	1785	O
-	1785	1786	O
alpha	1786	1791	O
production	1792	1802	O
at	1803	1805	O
NK	1806	1808	B-Cell
/	1808	1809	O
DC	1809	1811	B-Cell
ratios	1812	1818	O
as	1819	1821	O
low	1822	1825	O
as	1826	1828	O
1	1829	1830	O
:	1830	1831	O
20	1831	1833	O
and	1834	1837	O
1	1838	1839	O
:	1839	1840	O
40	1840	1842	O
(	1843	1844	O
data	1844	1848	O
not	1849	1852	O
shown	1853	1858	O
)	1858	1859	O
.	1859	1860	O

Raising	1861	1868	O
the	1869	1872	O
NK	1873	1875	B-Cell
/	1875	1876	O
DC	1876	1878	B-Cell
ratio	1879	1884	O
to	1885	1887	O
5	1888	1889	O
:	1889	1890	O
1	1890	1891	O
changes	1892	1899	O
the	1900	1903	O
interaction	1904	1915	O
from	1916	1920	O
one	1921	1924	O
of	1925	1927	O
potent	1928	1934	O
DC	1935	1937	B-Cell
stimulation	1938	1949	O
to	1950	1952	O
that	1953	1957	O
of	1958	1960	O
complete	1961	1969	O
inhibition	1970	1980	O
in	1981	1983	O
the	1984	1987	O
presence	1988	1996	O
or	1997	1999	O
absence	2000	2007	O
of	2008	2010	O
LPS	2011	2014	O
(	2015	2016	O
Fig	2016	2019	O
.	2019	2020	O
2	2021	2022	O
C	2023	2024	O
)	2024	2025	O
.	2025	2026	O

An	2027	2029	O
identical	2030	2039	O
pattern	2040	2047	O
is	2048	2050	O
seen	2051	2055	O
for	2056	2059	O
IL	2060	2062	O
-	2062	2063	O
12	2063	2065	O
p40	2066	2069	O
production	2070	2080	O
(	2081	2082	O
Fig	2082	2085	O
.	2085	2086	O
2	2087	2088	O
D	2089	2090	O
)	2090	2091	O
.	2091	2092	O

No	2093	2095	O
IL	2096	2098	O
-	2098	2099	O
10	2099	2101	O
production	2102	2112	O
in	2113	2115	O
the	2116	2119	O
cultures	2120	2128	O
was	2129	2132	O
detected	2133	2141	O
under	2142	2147	O
any	2148	2151	O
of	2152	2154	O
the	2155	2158	O
conditions	2159	2169	O
tested	2170	2176	O
(	2177	2178	O
data	2178	2182	O
not	2183	2186	O
shown	2187	2192	O
)	2192	2193	O
.	2193	2194	O

The	2195	2198	O
massive	2199	2206	O
production	2207	2217	O
of	2218	2220	O
TNF	2221	2224	O
-	2224	2225	O
alpha	2225	2230	O
in	2231	2233	O
the	2234	2237	O
cultures	2238	2246	O
at	2247	2249	O
the	2250	2253	O
lowest	2254	2260	O
ratios	2261	2267	O
was	2268	2271	O
mediated	2272	2280	O
primarily	2281	2290	O
by	2291	2293	O
DCs	2294	2297	B-Cell
in	2298	2300	O
the	2301	2304	O
culture	2305	2312	O
due	2313	2316	O
to	2317	2319	O
the	2320	2323	O
low	2324	2327	O
number	2328	2334	O
of	2335	2337	O
NK	2338	2340	B-Cell
cells	2341	2346	I-Cell
(	2347	2348	O
2	2348	2349	O
x	2350	2351	O
104	2352	2355	O
cells	2356	2361	B-Cell
per	2362	2365	O
well	2366	2370	O
)	2370	2371	O
used	2372	2376	O
in	2377	2379	O
these	2380	2385	O
experiments	2386	2397	O
.	2397	2398	O

In	2399	2401	O
addition	2402	2410	O
,	2410	2411	O
efforts	2412	2419	O
to	2420	2422	O
stimulate	2423	2432	O
NK	2433	2435	B-Cell
cells	2436	2441	I-Cell
directly	2442	2450	O
with	2451	2455	O
optimal	2456	2463	O
doses	2464	2469	O
of	2470	2472	O
anti	2473	2477	O
-	2477	2478	O
CD16	2478	2482	O
,	2482	2483	O
rIL	2484	2487	O
-	2487	2488	O
2	2488	2489	O
,	2489	2490	O
rIL	2491	2494	O
-	2494	2495	O
12	2495	2497	O
,	2497	2498	O
and	2499	2502	O
PMA	2503	2506	O
/	2506	2507	O
ionomycin	2507	2516	O
alone	2517	2522	O
or	2523	2525	O
in	2526	2528	O
combination	2529	2540	O
induced	2541	2548	O
only	2549	2553	O
moderate	2554	2562	O
(	2563	2564	O
<	2564	2565	O
500	2565	2568	O
pg	2569	2571	O
/	2571	2572	O
ml	2572	2574	O
)	2574	2575	O
TNF	2576	2579	O
-	2579	2580	O
alpha	2580	2585	O
production	2586	2596	O
by	2597	2599	O
the	2600	2603	O
NK	2604	2606	B-Cell
cells	2607	2612	I-Cell
alone	2613	2618	O
which	2619	2624	O
were	2625	2629	O
present	2630	2637	O
at	2638	2640	O
2	2641	2642	O
x	2643	2644	O
105	2645	2648	O
cells	2649	2654	B-Cell
per	2655	2658	O
well	2659	2663	O
(	2664	2665	O
data	2665	2669	O
not	2670	2673	O
shown	2674	2679	O
)	2679	2680	O
.	2680	2681	O

Figure	2682	2688	O
2	2689	2690	O
.	2690	2691	O

Activated	2692	2701	O
/	2701	2702	O
cultured	2702	2710	O
NK	2711	2713	B-Cell
cell	2714	2718	I-Cell
-	2718	2719	O
mediated	2719	2727	O
amplification	2728	2741	O
/	2741	2742	O
inhibition	2742	2752	O
of	2753	2755	O
DC	2756	2758	B-Cell
cytokine	2759	2767	O
production	2768	2778	O
.	2778	2779	O

Results	2780	2787	O
are	2788	2791	O
presented	2792	2801	O
on	2802	2804	O
log	2805	2808	O
scales	2809	2815	O
.	2815	2816	O

Cultured	2817	2825	O
iDCs	2826	2830	B-Cell
were	2831	2835	O
incubated	2836	2845	O
alone	2846	2851	O
or	2852	2854	O
with	2855	2859	O
cultured	2860	2868	O
/	2868	2869	O
purified	2869	2877	O
NK	2878	2880	B-Cell
cells	2881	2886	I-Cell
for	2887	2890	O
24	2891	2893	O
h	2894	2895	O
(	2896	2897	O
A	2897	2898	O
and	2899	2902	O
B	2903	2904	O
)	2904	2905	O
or	2906	2908	O
48	2909	2911	O
h	2912	2913	O
(	2914	2915	O
C	2915	2916	O
-	2916	2917	O
E	2917	2918	O
)	2918	2919	O
in	2920	2922	O
the	2923	2926	O
presence	2927	2935	O
or	2936	2938	O
absence	2939	2946	O
of	2947	2949	O
the	2950	2953	O
indicated	2954	2963	O
concentrations	2964	2978	O
of	2979	2981	O
LPS	2982	2985	O
.	2985	2986	O

After	2987	2992	O
culture	2993	3000	O
the	3001	3004	O
supernatants	3005	3017	O
were	3018	3022	O
removed	3023	3030	O
and	3031	3034	O
analyzed	3035	3043	O
by	3044	3046	O
ELISA	3047	3052	O
for	3053	3056	O
TNF	3057	3060	O
-	3060	3061	O
alpha	3061	3066	O
or	3067	3069	O
IL	3070	3072	O
-	3072	3073	O
12	3073	3075	O
p40	3076	3079	O
.	3079	3080	O

(	3081	3082	O
A	3082	3083	O
)	3083	3084	O
TNF	3085	3088	O
-	3088	3089	O
alpha	3089	3094	O
production	3095	3105	O
was	3106	3109	O
measured	3110	3118	O
in	3119	3121	O
the	3122	3125	O
supernatants	3126	3138	O
from	3139	3143	O
cultures	3144	3152	O
of	3153	3155	O
:	3155	3156	O
DCs	3157	3160	B-Cell
alone	3161	3166	O
(	3167	3168	O
gray	3168	3172	O
bars	3173	3177	O
)	3177	3178	O
;	3178	3179	O
NK	3180	3182	B-Cell
+	3182	3183	O
DC	3183	3185	B-Cell
(	3186	3187	O
1	3187	3188	O
:	3188	3189	O
5	3189	3190	O
)	3190	3191	O
(	3192	3193	O
black	3193	3198	O
bars	3199	3203	O
)	3203	3204	O
.	3204	3205	O

LPS	3206	3209	O
concentrations	3210	3224	O
used	3225	3229	O
were	3230	3234	O
:	3234	3235	O
0	3236	3237	O
,	3237	3238	O
10	3239	3241	O
,	3241	3242	O
and	3243	3246	O
1	3247	3248	O
,	3248	3249	O
000	3249	3252	O
ng	3253	3255	O
/	3255	3256	O
ml	3256	3258	O
(	3259	3260	O
DCs	3260	3263	B-Cell
alone	3264	3269	O
only	3270	3274	O
)	3274	3275	O
.	3275	3276	O

(	3277	3278	O
B	3278	3279	O
)	3279	3280	O
Contact	3281	3288	O
-	3288	3289	O
dependent	3289	3298	O
stimulation	3299	3310	O
of	3311	3313	O
iDC	3314	3317	B-Cell
TNF	3318	3321	O
-	3321	3322	O
alpha	3322	3327	O
production	3328	3338	O
by	3339	3341	O
NK	3342	3344	B-Cell
cells	3345	3350	I-Cell
was	3351	3354	O
tested	3355	3361	O
under	3362	3367	O
the	3368	3371	O
following	3372	3381	O
conditions	3382	3392	O
:	3392	3393	O
DCs	3394	3397	B-Cell
alone	3398	3403	O
(	3404	3405	O
gray	3405	3409	O
bars	3410	3414	O
)	3414	3415	O
;	3415	3416	O
NK	3417	3419	B-Cell
+	3419	3420	O
DC	3420	3422	B-Cell
(	3423	3424	O
1	3424	3425	O
:	3425	3426	O
5	3426	3427	O
)	3427	3428	O
(	3429	3430	O
black	3430	3435	O
bars	3436	3440	O
)	3440	3441	O
;	3441	3442	O
NK	3443	3445	B-Cell
/	3445	3446	O
DC	3446	3448	B-Cell
(	3449	3450	O
1	3450	3451	O
:	3451	3452	O
5	3452	3453	O
)	3453	3454	O
trans	3455	3460	O
-	3460	3461	O
wells	3461	3466	O
(	3467	3468	O
striped	3468	3475	O
bars	3476	3480	O
)	3480	3481	O
.	3481	3482	O

LPS	3483	3486	O
concentrations	3487	3501	O
used	3502	3506	O
were	3507	3511	O
:	3511	3512	O
10	3513	3515	O
ng	3516	3518	O
/	3518	3519	O
ml	3519	3521	O
(	3522	3523	O
donor	3523	3528	O
1	3529	3530	O
)	3530	3531	O
and	3532	3535	O
20	3536	3538	O
ng	3539	3541	O
/	3541	3542	O
ml	3542	3544	O
(	3545	3546	O
donor	3546	3551	O
2	3552	3553	O
)	3553	3554	O
.	3554	3555	O

(	3556	3557	O
C	3557	3558	O
and	3559	3562	O
D	3563	3564	O
)	3564	3565	O
Effect	3566	3572	O
of	3573	3575	O
increasing	3576	3586	O
the	3587	3590	O
NK	3591	3593	B-Cell
/	3593	3594	O
DC	3594	3596	B-Cell
ratio	3597	3602	O
(	3603	3604	O
DCs	3604	3607	B-Cell
alone	3608	3613	O
;	3613	3614	O
NK	3615	3617	B-Cell
:	3617	3618	O
DC	3618	3620	B-Cell
-	3620	3621	O
1	3621	3622	O
:	3622	3623	O
5	3623	3624	O
;	3624	3625	O
1	3626	3627	O
:	3627	3628	O
1	3628	3629	O
;	3629	3630	O
5	3631	3632	O
:	3632	3633	O
1	3633	3634	O
)	3634	3635	O
on	3636	3638	O
(	3639	3640	O
C	3640	3641	O
)	3641	3642	O
TNF	3643	3646	O
-	3646	3647	O
alpha	3647	3652	O
and	3653	3656	O
(	3657	3658	O
D	3658	3659	O
)	3659	3660	O
IL	3661	3663	O
-	3663	3664	O
12	3664	3666	O
p40	3667	3670	O
production	3671	3681	O
.	3681	3682	O

LPS	3683	3686	O
concentrations	3687	3701	O
used	3702	3706	O
were	3707	3711	O
:	3711	3712	O
0	3713	3714	O
ng	3715	3717	O
/	3717	3718	O
ml	3718	3720	O
(	3721	3722	O
*	3722	3723	O
)	3723	3724	O
;	3724	3725	O
20	3726	3728	O
ng	3729	3731	O
/	3731	3732	O
ml	3732	3734	O
(	3735	3736	O
*	3736	3737	O
)	3737	3738	O
;	3738	3739	O
50	3740	3742	O
ng	3743	3745	O
/	3745	3746	O
ml	3746	3748	O
(	3749	3750	O
^	3750	3751	O
)	3751	3752	O
;	3752	3753	O
and	3754	3757	O
1	3758	3759	O
,	3759	3760	O
000	3760	3763	O
ng	3764	3766	O
/	3766	3767	O
ml	3767	3769	O
-	3769	3770	O
LPS	3770	3773	O
(	3774	3775	O
*	3775	3776	O
)	3776	3777	O
(	3778	3779	O
DCs	3779	3782	B-Cell
alone	3783	3788	O
only	3789	3793	O
)	3793	3794	O
.	3794	3795	O

(	3796	3797	O
E	3797	3798	O
)	3798	3799	O
The	3800	3803	O
effect	3804	3810	O
of	3811	3813	O
neutralizing	3814	3826	O
IFN	3827	3830	O
-	3830	3831	O
gamma	3831	3836	O
production	3837	3847	O
was	3848	3851	O
tested	3852	3858	O
under	3859	3864	O
the	3865	3868	O
following	3869	3878	O
conditions	3879	3889	O
:	3889	3890	O
DCs	3891	3894	B-Cell
alone	3895	3900	O
(	3901	3902	O
gray	3902	3906	O
bars	3907	3911	O
)	3911	3912	O
;	3912	3913	O
NK	3914	3916	B-Cell
+	3916	3917	O
DC	3917	3919	B-Cell
(	3920	3921	O
1	3921	3922	O
:	3922	3923	O
5	3923	3924	O
)	3924	3925	O
(	3926	3927	O
black	3927	3932	O
bars	3933	3937	O
)	3937	3938	O
;	3938	3939	O
NK	3940	3942	B-Cell
+	3942	3943	O
DC	3943	3945	B-Cell
(	3946	3947	O
1	3947	3948	O
:	3948	3949	O
5	3949	3950	O
)	3950	3951	O
and	3952	3955	O
10	3956	3958	O
mug	3959	3962	O
/	3962	3963	O
ml	3963	3965	O
of	3966	3968	O
blocking	3969	3977	O
anti	3978	3982	O
-	3982	3983	O
IFN	3983	3986	O
-	3986	3987	O
gamma	3987	3992	O
mAb	3993	3996	O
(	3997	3998	O
stippled	3998	4006	O
bars	4007	4011	O
)	4011	4012	O
.	4012	4013	O

LPS	4014	4017	O
concentrations	4018	4032	O
used	4033	4037	O
were	4038	4042	O
:	4042	4043	O
0	4044	4045	O
ng	4046	4048	O
/	4048	4049	O
ml	4049	4051	O
(	4052	4053	O
NO	4053	4055	O
LPS	4056	4059	O
)	4059	4060	O
and	4061	4064	O
20	4065	4067	O
ng	4068	4070	O
/	4070	4071	O
ml	4071	4073	O
(	4074	4075	O
LPS	4075	4078	O
20	4079	4081	O
)	4081	4082	O
.	4082	4083	O

Blocking	4084	4092	O
reagents	4093	4101	O
for	4102	4105	O
CD80	4106	4110	O
,	4110	4111	O
CD86	4112	4116	O
,	4116	4117	O
CD154	4118	4123	O
,	4123	4124	O
CD95	4125	4129	O
,	4129	4130	O
CD11a	4131	4136	O
,	4136	4137	O
CD50	4138	4142	O
,	4142	4143	O
or	4144	4146	O
IL	4147	4149	O
-	4149	4150	O
12	4150	4152	O
,	4152	4153	O
had	4154	4157	O
no	4158	4160	O
effect	4161	4167	O
on	4168	4170	O
the	4171	4174	O
NK	4175	4177	B-Cell
cell	4178	4182	I-Cell
-	4182	4183	O
induced	4183	4190	O
TNF	4191	4194	O
-	4194	4195	O
alpha	4195	4200	O
or	4201	4203	O
IL	4204	4206	O
-	4206	4207	O
12	4207	4209	O
p40	4210	4213	O
production	4214	4224	O
,	4224	4225	O
whereas	4226	4233	O
a	4234	4235	O
neutralizing	4236	4248	O
antibody	4249	4257	O
for	4258	4261	O
IFN	4262	4265	O
-	4265	4266	O
gamma	4266	4271	O
while	4272	4277	O
not	4278	4281	O
affecting	4282	4291	O
TNF	4292	4295	O
-	4295	4296	O
alpha	4296	4301	O
production	4302	4312	O
partially	4313	4322	O
blocked	4323	4330	O
(	4331	4332	O
<	4332	4333	O
20	4333	4335	O
%	4335	4336	O
)	4336	4337	O
IL	4338	4340	O
-	4340	4341	O
12	4341	4343	O
p40	4344	4347	O
production	4348	4358	O
induced	4359	4366	O
by	4367	4369	O
the	4370	4373	O
NK	4374	4376	B-Cell
cells	4377	4382	I-Cell
(	4383	4384	O
Fig	4384	4387	O
.	4387	4388	O
2	4389	4390	O
E	4391	4392	O
)	4392	4393	O
.	4393	4394	O

This	4395	4399	O
partial	4400	4407	O
inhibition	4408	4418	O
is	4419	4421	O
consistent	4422	4432	O
with	4433	4437	O
numerous	4438	4446	O
previous	4447	4455	O
reports	4456	4463	O
demonstrating	4464	4477	O
a	4478	4479	O
central	4480	4487	O
role	4488	4492	O
for	4493	4496	O
an	4497	4499	O
IL	4500	4502	O
-	4502	4503	O
12	4503	4505	O
/	4505	4506	O
IFN	4506	4509	O
-	4509	4510	O
gamma	4510	4515	O
positive	4516	4524	O
feedback	4525	4533	O
loop	4534	4538	O
active	4539	4545	O
between	4546	4553	O
NK	4554	4556	B-Cell
cells	4557	4562	I-Cell
and	4563	4566	O
IL	4567	4569	B-Cell
-	4569	4570	I-Cell
12	4570	4572	I-Cell
-	4572	4573	I-Cell
producing	4573	4582	I-Cell
cells	4583	4588	I-Cell
(	4589	4590	O
15	4590	4592	O
-	4592	4593	O
17	4593	4595	O
)	4595	4596	O
.	4596	4597	O

Clearly	4598	4605	O
,	4605	4606	O
however	4607	4614	O
,	4614	4615	O
this	4616	4620	O
well	4621	4625	O
-	4625	4626	O
described	4626	4635	O
cytokine	4636	4644	O
cross	4645	4650	O
-	4650	4651	O
talk	4651	4655	O
mechanism	4656	4665	O
is	4666	4668	O
secondary	4669	4678	O
to	4679	4681	O
the	4682	4685	O
contact	4686	4693	O
-	4693	4694	O
dependent	4694	4703	O
activation	4704	4714	O
of	4715	4717	O
DCs	4718	4721	B-Cell
by	4722	4724	O
NK	4725	4727	B-Cell
cells	4728	4733	I-Cell
described	4734	4743	O
here	4744	4748	O
.	4748	4749	O

Taken	4750	4755	O
together	4756	4764	O
these	4765	4770	O
results	4771	4778	O
indicate	4779	4787	O
that	4788	4792	O
novel	4793	4798	O
mechanisms	4799	4809	O
control	4810	4817	O
cognate	4818	4825	O
interactions	4826	4838	O
between	4839	4846	O
NK	4847	4849	B-Cell
cells	4850	4855	I-Cell
and	4856	4859	O
DCs	4860	4863	B-Cell
and	4864	4867	O
that	4868	4872	O
NK	4873	4875	B-Cell
-	4875	4876	O
DC	4876	4878	B-Cell
contact	4879	4886	O
has	4887	4890	O
the	4891	4894	O
potential	4895	4904	O
to	4905	4907	O
serve	4908	4913	O
as	4914	4916	O
an	4917	4919	O
important	4920	4929	O
control	4930	4937	O
switch	4938	4944	O
for	4945	4948	O
both	4949	4953	O
amplifying	4954	4964	O
and	4965	4968	O
attenuating	4969	4980	O
innate	4981	4987	O
immune	4988	4994	O
responses	4995	5004	O
in	5005	5007	O
vivo	5008	5012	O
.	5012	5013	O

We	5014	5016	O
next	5017	5021	O
tested	5022	5028	O
directly	5029	5037	O
whether	5038	5045	O
NK	5046	5048	B-Cell
cell	5049	5053	I-Cell
killing	5054	5061	O
was	5062	5065	O
active	5066	5072	O
in	5073	5075	O
our	5076	5079	O
system	5080	5086	O
using	5087	5092	O
both	5093	5097	O
short	5098	5103	O
-	5103	5104	O
term	5104	5108	O
(	5109	5110	O
4	5110	5111	O
-	5111	5112	O
h	5112	5113	O
)	5113	5114	O
chromium	5115	5123	O
release	5124	5131	O
assays	5132	5138	O
(	5139	5140	O
data	5140	5144	O
not	5145	5148	O
shown	5149	5154	O
)	5154	5155	O
and	5156	5159	O
a	5160	5161	O
flow	5162	5166	O
cytometric	5167	5177	O
assay	5178	5183	O
which	5184	5189	O
allowed	5190	5197	O
us	5198	5200	O
to	5201	5203	O
follow	5204	5210	O
the	5211	5214	O
survival	5215	5223	O
of	5224	5226	O
the	5227	5230	O
autologous	5231	5241	O
iDCs	5242	5246	B-Cell
in	5247	5249	O
the	5250	5253	O
presence	5254	5262	O
of	5263	5265	O
NK	5266	5268	B-Cell
cells	5269	5274	I-Cell
over	5275	5279	O
longer	5280	5286	O
periods	5287	5294	O
(	5295	5296	O
Fig	5296	5299	O
.	5299	5300	O
3	5301	5302	O
)	5302	5303	O
.	5303	5304	O

The	5305	5308	O
results	5309	5316	O
demonstrate	5317	5328	O
that	5329	5333	O
NK	5334	5336	B-Cell
cells	5337	5342	I-Cell
kill	5343	5347	O
autologous	5348	5358	O
iDCs	5359	5363	B-Cell
(	5364	5365	O
Fig	5365	5368	O
.	5368	5369	O
3	5370	5371	O
A	5372	5373	O
)	5373	5374	O
at	5375	5377	O
all	5378	5381	O
NK	5382	5384	B-Cell
/	5384	5385	O
DC	5385	5387	B-Cell
ratios	5388	5394	O
tested	5395	5401	O
after	5402	5407	O
4	5408	5409	O
h	5410	5411	O
and	5412	5415	O
the	5416	5419	O
level	5420	5425	O
of	5426	5428	O
killing	5429	5436	O
is	5437	5439	O
similar	5440	5447	O
to	5448	5450	O
the	5451	5454	O
lysis	5455	5460	O
of	5461	5463	O
K562	5464	5468	B-Cell
cells	5469	5474	I-Cell
over	5475	5479	O
the	5480	5483	O
same	5484	5488	O
time	5489	5493	O
(	5494	5495	O
Fig	5495	5498	O
.	5498	5499	O
3	5500	5501	O
B	5502	5503	O
)	5503	5504	O
.	5504	5505	O

After	5506	5511	O
24	5512	5514	O
h	5515	5516	O
,	5516	5517	O
however	5518	5525	O
,	5525	5526	O
the	5527	5530	O
presence	5531	5539	O
of	5540	5542	O
NK	5543	5545	B-Cell
cells	5546	5551	I-Cell
led	5552	5555	O
to	5556	5558	O
completely	5559	5569	O
divergent	5570	5579	O
effects	5580	5587	O
on	5588	5590	O
the	5591	5594	O
DCs	5595	5598	B-Cell
.	5598	5599	O

At	5600	5602	O
the	5603	5606	O
5	5607	5608	O
:	5608	5609	O
1	5609	5610	O
(	5611	5612	O
NK	5612	5614	B-Cell
/	5614	5615	O
DC	5615	5617	B-Cell
)	5617	5618	O
ratio	5619	5624	O
,	5624	5625	O
NK	5626	5628	B-Cell
cell	5629	5633	I-Cell
-	5633	5634	O
mediated	5634	5642	O
destruction	5643	5654	O
of	5655	5657	O
the	5658	5661	O
iDCs	5662	5666	B-Cell
was	5667	5670	O
the	5671	5674	O
dominant	5675	5683	O
feature	5684	5691	O
,	5691	5692	O
whereas	5693	5700	O
at	5701	5703	O
the	5704	5707	O
low	5708	5711	O
ratio	5712	5717	O
(	5718	5719	O
1	5719	5720	O
:	5720	5721	O
5	5721	5722	O
)	5722	5723	O
the	5724	5727	O
same	5728	5732	O
NK	5733	5735	B-Cell
cells	5736	5741	I-Cell
promoted	5742	5750	O
iDCs	5751	5755	B-Cell
survival	5756	5764	O
compared	5765	5773	O
with	5774	5778	O
iDCs	5779	5783	B-Cell
alone	5784	5789	O
over	5790	5794	O
the	5795	5798	O
same	5799	5803	O
period	5804	5810	O
(	5811	5812	O
Fig	5812	5815	O
.	5815	5816	O
3	5817	5818	O
A	5819	5820	O
)	5820	5821	O
.	5821	5822	O

The	5823	5826	O
equal	5827	5832	O
ratio	5833	5838	O
of	5839	5841	O
NK	5842	5844	B-Cell
/	5844	5845	O
DC	5845	5847	B-Cell
(	5848	5849	O
1	5849	5850	O
:	5850	5851	O
1	5851	5852	O
)	5852	5853	O
fell	5854	5858	O
between	5859	5866	O
these	5867	5872	O
two	5873	5876	O
extremes	5877	5885	O
.	5885	5886	O

The	5887	5890	O
NK	5891	5893	B-Cell
cell	5894	5898	I-Cell
-	5898	5899	O
mediated	5899	5907	O
lysis	5908	5913	O
of	5914	5916	O
the	5917	5920	O
K562	5921	5925	B-Cell
targets	5926	5933	O
increased	5934	5943	O
at	5944	5946	O
all	5947	5950	O
ratios	5951	5957	O
tested	5958	5964	O
after	5965	5970	O
the	5971	5974	O
24	5975	5977	O
-	5977	5978	O
h	5978	5979	O
incubation	5980	5990	O
.	5990	5991	O

These	5992	5997	O
striking	5998	6006	O
differences	6007	6018	O
between	6019	6026	O
death	6027	6032	O
and	6033	6036	O
survival	6037	6045	O
of	6046	6048	O
DCs	6049	6052	B-Cell
upon	6053	6057	O
encountering	6058	6070	O
NK	6071	6073	B-Cell
cells	6074	6079	I-Cell
correlate	6080	6089	O
precisely	6090	6099	O
with	6100	6104	O
our	6105	6108	O
previous	6109	6117	O
results	6118	6125	O
on	6126	6128	O
TNF	6129	6132	O
-	6132	6133	O
alpha	6133	6138	O
and	6139	6142	O
IL	6143	6145	O
-	6145	6146	O
12	6146	6148	O
p40	6149	6152	O
production	6153	6163	O
where	6164	6169	O
increasing	6170	6180	O
numbers	6181	6188	O
of	6189	6191	O
NK	6192	6194	B-Cell
cells	6195	6200	I-Cell
in	6201	6203	O
the	6204	6207	O
culture	6208	6215	O
shifts	6216	6222	O
the	6223	6226	O
NK	6227	6229	B-Cell
effect	6230	6236	O
from	6237	6241	O
potent	6242	6248	O
stimulation	6249	6260	O
to	6261	6263	O
complete	6264	6272	O
inhibition	6273	6283	O
(	6284	6285	O
Fig	6285	6288	O
.	6288	6289	O
2	6290	6291	O
)	6291	6292	O
.	6292	6293	O

Figure	6294	6300	O
3	6301	6302	O
.	6302	6303	O

Activated	6304	6313	O
/	6313	6314	O
cultured	6314	6322	O
NK	6323	6325	B-Cell
cell	6326	6330	I-Cell
-	6330	6331	O
mediated	6331	6339	O
death	6340	6345	O
/	6345	6346	O
survival	6346	6354	O
of	6355	6357	O
DCs	6358	6361	B-Cell
and	6362	6365	O
NK	6366	6368	B-Cell
-	6368	6369	O
DC	6369	6371	B-Cell
conjugate	6372	6381	O
formation	6382	6391	O
.	6391	6392	O

NK	6393	6395	B-Cell
cell	6396	6400	I-Cell
mediated	6401	6409	O
killing	6410	6417	O
/	6417	6418	O
survival	6418	6426	O
of	6427	6429	O
CFDA	6430	6434	O
.	6434	6435	O
SE	6435	6437	O
-	6437	6438	O
loaded	6438	6444	O
iDCs	6445	6449	B-Cell
(	6450	6451	O
A	6451	6452	O
)	6452	6453	O
and	6454	6457	O
K562	6458	6462	B-Cell
cells	6463	6468	I-Cell
(	6469	6470	O
B	6470	6471	O
)	6471	6472	O
was	6473	6476	O
measured	6477	6485	O
by	6486	6488	O
flow	6489	6493	O
cytometry	6494	6503	O
over	6504	6508	O
4	6509	6510	O
h	6511	6512	O
(	6513	6514	O
*	6514	6515	O
)	6515	6516	O
or	6517	6519	O
24	6520	6522	O
h	6523	6524	O
(	6525	6526	O
*	6526	6527	O
)	6527	6528	O
at	6529	6531	O
the	6532	6535	O
indicated	6536	6545	O
NK	6546	6548	B-Cell
/	6548	6549	O
DC	6549	6551	B-Cell
ratios	6552	6558	O
as	6559	6561	O
described	6562	6571	O
in	6572	6574	O
Materials	6575	6584	O
and	6585	6588	O
Methods	6589	6596	O
.	6596	6597	O

Results	6598	6605	O
are	6606	6609	O
presented	6610	6619	O
as	6620	6622	O
percentage	6623	6633	O
of	6634	6636	O
specific	6637	6645	O
lysis	6646	6651	O
+	6652	6653	O
/	6653	6654	O
-	6654	6655	O
SEM	6656	6659	O
(	6660	6661	O
n	6661	6662	O
=	6663	6664	O
3	6665	6666	O
independent	6667	6678	O
experiments	6679	6690	O
)	6690	6691	O
.	6691	6692	O

NK	6693	6695	B-Cell
-	6695	6696	O
DC	6696	6698	B-Cell
(	6699	6700	O
C	6700	6701	O
-	6701	6702	O
E	6702	6703	O
)	6703	6704	O
or	6705	6707	O
NK	6708	6710	B-Cell
-	6710	6711	O
K562	6711	6715	B-Cell
(	6716	6717	O
F	6717	6718	O
-	6718	6719	O
H	6719	6720	O
)	6720	6721	O
conjugate	6722	6731	O
formation	6732	6741	O
was	6742	6745	O
measured	6746	6754	O
by	6755	6757	O
flow	6758	6762	O
cytometry	6763	6772	O
,	6772	6773	O
at	6774	6776	O
the	6777	6780	O
following	6781	6790	O
ratios	6791	6797	O
(	6798	6799	O
NK	6799	6801	B-Cell
/	6801	6802	O
DC	6802	6804	B-Cell
or	6805	6807	O
NK	6808	6810	B-Cell
/	6810	6811	O
K562	6811	6815	B-Cell
)	6815	6816	O
:	6816	6817	O
1	6818	6819	O
:	6819	6820	O
5	6820	6821	O
(	6822	6823	O
C	6823	6824	O
and	6825	6828	O
F	6829	6830	O
)	6830	6831	O
;	6831	6832	O
1	6833	6834	O
:	6834	6835	O
1	6835	6836	O
(	6837	6838	O
D	6838	6839	O
and	6840	6843	O
G	6844	6845	O
)	6845	6846	O
;	6846	6847	O
and	6848	6851	O
5	6852	6853	O
:	6853	6854	O
1	6854	6855	O
(	6856	6857	O
E	6857	6858	O
and	6859	6862	O
H	6863	6864	O
)	6864	6865	O
.	6865	6866	O

Snarf	6867	6872	O
-	6872	6873	O
1	6873	6874	O
(	6875	6876	O
FL3	6876	6879	O
)	6879	6880	O
-	6880	6881	O
labeled	6881	6888	O
iDCs	6889	6893	B-Cell
or	6894	6896	O
K562	6897	6901	B-Cell
cells	6902	6907	I-Cell
were	6908	6912	O
incubated	6913	6922	O
(	6923	6924	O
30	6924	6926	O
min	6927	6930	O
)	6930	6931	O
with	6932	6936	O
CFDA	6937	6941	O
.	6941	6942	O
SE	6942	6944	O
(	6945	6946	O
FL1	6946	6949	O
)	6949	6950	O
-	6950	6951	O
labeled	6951	6958	O
NK	6959	6961	B-Cell
cells	6962	6967	I-Cell
at	6968	6970	O
the	6971	6974	O
different	6975	6984	O
ratios	6985	6991	O
.	6991	6992	O

The	6993	6996	O
percentage	6997	7007	O
of	7008	7010	O
conjugates	7011	7021	O
formed	7022	7028	O
(	7029	7030	O
top	7030	7033	O
right	7034	7039	O
quadrant	7040	7048	O
)	7048	7049	O
was	7050	7053	O
calculated	7054	7064	O
by	7065	7067	O
determining	7068	7079	O
the	7080	7083	O
percentage	7084	7094	O
of	7095	7097	O
FL3	7098	7101	O
+	7101	7102	O
(	7103	7104	O
Snarf	7104	7109	O
-	7109	7110	O
1	7110	7111	O
)	7111	7112	O
events	7113	7119	O
which	7120	7125	O
were	7126	7130	O
also	7131	7135	O
positive	7136	7144	O
for	7145	7148	O
FL1	7149	7152	O
(	7153	7154	O
CFDA	7154	7158	O
.	7158	7159	O
SE	7159	7161	O
)	7161	7162	O
.	7162	7163	O

The	7164	7167	O
results	7168	7175	O
are	7176	7179	O
representative	7180	7194	O
of	7195	7197	O
four	7198	7202	O
experiments	7203	7214	O
performed	7215	7224	O
with	7225	7229	O
activated	7230	7239	O
NK	7240	7242	B-Cell
cells	7243	7248	I-Cell
.	7248	7249	O

Resting	7250	7257	O
NK	7258	7260	B-Cell
cells	7261	7266	I-Cell
also	7267	7271	O
readily	7272	7279	O
formed	7280	7286	O
conjugates	7287	7297	O
with	7298	7302	O
autologous	7303	7313	O
iDCs	7314	7318	B-Cell
(	7319	7320	O
data	7320	7324	O
not	7325	7328	O
shown	7329	7334	O
)	7334	7335	O
.	7335	7336	O

NK	7337	7339	B-Cell
cells	7340	7345	I-Cell
can	7346	7349	O
both	7350	7354	O
efficiently	7355	7366	O
kill	7367	7371	O
and	7372	7375	O
potently	7376	7384	O
stimulate	7385	7394	O
DCs	7395	7398	B-Cell
in	7399	7401	O
our	7402	7405	O
model	7406	7411	O
system	7412	7418	O
and	7419	7422	O
each	7423	7427	O
of	7428	7430	O
these	7431	7436	O
opposing	7437	7445	O
effects	7446	7453	O
appear	7454	7460	O
dependent	7461	7470	O
on	7471	7473	O
cell	7474	7478	B-Cell
-	7478	7479	O
to	7479	7481	O
-	7481	7482	O
cell	7482	7486	B-Cell
contact	7487	7494	O
.	7494	7495	O

To	7496	7498	O
quantify	7499	7507	O
these	7508	7513	O
apparent	7514	7522	O
cognate	7523	7530	O
interactions	7531	7543	O
we	7544	7546	O
measured	7547	7555	O
the	7556	7559	O
formation	7560	7569	O
of	7570	7572	O
NK	7573	7575	B-Cell
-	7575	7576	O
DC	7576	7578	B-Cell
conjugates	7579	7589	O
and	7590	7593	O
compared	7594	7602	O
them	7603	7607	O
to	7608	7610	O
conjugates	7611	7621	O
formed	7622	7628	O
by	7629	7631	O
NK	7632	7634	B-Cell
cells	7635	7640	I-Cell
and	7641	7644	O
tumor	7645	7650	B-Pathological_formation
targets	7651	7658	O
.	7658	7659	O

Our	7660	7663	O
analysis	7664	7672	O
revealed	7673	7681	O
that	7682	7686	O
NK	7687	7689	B-Cell
cells	7690	7695	I-Cell
bound	7696	7701	O
DC	7702	7704	B-Cell
(	7705	7706	O
Fig	7706	7709	O
.	7709	7710	O
3	7711	7712	O
C	7713	7714	O
-	7714	7715	O
E	7715	7716	O
)	7716	7717	O
with	7718	7722	O
an	7723	7725	O
efficiency	7726	7736	O
almost	7737	7743	O
equal	7744	7749	O
to	7750	7752	O
that	7753	7757	O
of	7758	7760	O
NK	7761	7763	B-Cell
cell	7764	7768	I-Cell
binding	7769	7776	O
to	7777	7779	O
the	7780	7783	O
classical	7784	7793	O
NK	7794	7796	B-Cell
-	7796	7797	O
target	7797	7803	O
,	7803	7804	O
K562	7805	7809	B-Cell
(	7810	7811	O
Fig	7811	7814	O
.	7814	7815	O
3	7816	7817	O
F	7818	7819	O
-	7819	7820	O
H	7820	7821	O
)	7821	7822	O
.	7822	7823	O

Binding	7824	7831	O
was	7832	7835	O
detectable	7836	7846	O
even	7847	7851	O
at	7852	7854	O
the	7855	7858	O
lowest	7859	7865	O
NK	7866	7868	B-Cell
/	7868	7869	O
DC	7869	7871	B-Cell
ratio	7872	7877	O
tested	7878	7884	O
(	7885	7886	O
1	7886	7887	O
:	7887	7888	O
5	7888	7889	O
)	7889	7890	O
indicating	7891	7901	O
that	7902	7906	O
NK	7907	7909	B-Cell
-	7909	7910	O
DC	7910	7912	B-Cell
conjugates	7913	7923	O
are	7924	7927	O
formed	7928	7934	O
in	7935	7937	O
our	7938	7941	O
other	7942	7947	O
experiments	7948	7959	O
measuring	7960	7969	O
cytokine	7970	7978	O
production	7979	7989	O
and	7990	7993	O
cell	7994	7998	B-Cell
killing	7999	8006	O
.	8006	8007	O

Our	8008	8011	O
initial	8012	8019	O
experiments	8020	8031	O
using	8032	8037	O
resting	8038	8045	O
NK	8046	8048	B-Cell
cells	8049	8054	I-Cell
(	8055	8056	O
Fig	8056	8059	O
.	8059	8060	O
1	8061	8062	O
)	8062	8063	O
demonstrated	8064	8076	O
a	8077	8078	O
contact	8079	8086	O
-	8086	8087	O
dependent	8087	8096	O
NK	8097	8099	B-Cell
effect	8100	8106	O
driving	8107	8114	O
iDCs	8115	8119	B-Cell
to	8120	8122	O
mature	8123	8129	O
.	8129	8130	O

Therefore	8131	8140	O
,	8140	8141	O
we	8142	8144	O
tested	8145	8151	O
what	8152	8156	O
effects	8157	8164	O
activated	8165	8174	O
NK	8175	8177	B-Cell
cells	8178	8183	I-Cell
mediated	8184	8192	O
on	8193	8195	O
DC	8196	8198	B-Cell
maturation	8199	8209	O
(	8210	8211	O
Fig	8211	8214	O
.	8214	8215	O
4	8216	8217	O
)	8217	8218	O
.	8218	8219	O

Similar	8220	8227	O
to	8228	8230	O
our	8231	8234	O
previous	8235	8243	O
results	8244	8251	O
with	8252	8256	O
activated	8257	8266	O
NK	8267	8269	B-Cell
cells	8270	8275	I-Cell
(	8276	8277	O
Figs	8277	8281	O
.	8281	8282	O
2	8283	8284	O
and	8285	8288	O
3	8289	8290	O
)	8290	8291	O
,	8291	8292	O
addition	8293	8301	O
of	8302	8304	O
NK	8305	8307	B-Cell
cells	8308	8313	I-Cell
to	8314	8316	O
the	8317	8320	O
culture	8321	8328	O
leads	8329	8334	O
to	8335	8337	O
opposing	8338	8346	O
effects	8347	8354	O
on	8355	8357	O
the	8358	8361	O
iDC	8362	8365	B-Cell
population	8366	8376	O
depending	8377	8386	O
on	8387	8389	O
the	8390	8393	O
NK	8394	8396	B-Cell
/	8396	8397	O
DC	8397	8399	B-Cell
ratio	8400	8405	O
.	8405	8406	O

Compared	8407	8415	O
with	8416	8420	O
the	8421	8424	O
untreated	8425	8434	O
DCs	8435	8438	B-Cell
(	8439	8440	O
Fig	8440	8443	O
.	8443	8444	O
4	8445	8446	O
A	8447	8448	O
-	8448	8449	O
C	8449	8450	O
)	8450	8451	O
,	8451	8452	O
low	8453	8456	O
NK	8457	8459	B-Cell
/	8459	8460	O
DC	8460	8462	B-Cell
ratios	8463	8469	O
(	8470	8471	O
1	8471	8472	O
:	8472	8473	O
5	8473	8474	O
or	8475	8477	O
1	8478	8479	O
:	8479	8480	O
1	8480	8481	O
)	8481	8482	O
consistently	8483	8495	O
augmented	8496	8505	O
expression	8506	8516	O
of	8517	8519	O
the	8520	8523	O
maturation	8524	8534	O
markers	8535	8542	O
:	8542	8543	O
CD86	8544	8548	O
(	8549	8550	O
Fig	8550	8553	O
.	8553	8554	O
4	8555	8556	O
D	8557	8558	O
-	8558	8559	O
I	8559	8560	O
)	8560	8561	O
,	8561	8562	O
CD83	8563	8567	O
,	8567	8568	O
and	8569	8572	O
HLA	8573	8576	O
-	8576	8577	O
DR	8577	8579	O
(	8580	8581	O
data	8581	8585	O
not	8586	8589	O
shown	8590	8595	O
)	8595	8596	O
.	8596	8597	O

At	8598	8600	O
a	8601	8602	O
5	8603	8604	O
:	8604	8605	O
1	8605	8606	O
ratio	8607	8612	O
(	8613	8614	O
NK	8614	8616	B-Cell
/	8616	8617	O
DC	8617	8619	B-Cell
)	8619	8620	O
most	8621	8625	O
of	8626	8628	O
the	8629	8632	O
DCs	8633	8636	B-Cell
are	8637	8640	O
nonviable	8641	8650	O
(	8651	8652	O
Fig	8652	8655	O
.	8655	8656	O
4	8657	8658	O
J	8659	8660	O
-	8660	8661	O
L	8661	8662	O
)	8662	8663	O
.	8663	8664	O

Addition	8665	8673	O
of	8674	8676	O
suboptimal	8677	8687	O
doses	8688	8693	O
of	8694	8696	O
LPS	8697	8700	O
(	8701	8702	O
Fig	8702	8705	O
.	8705	8706	O
4	8707	8708	O
C	8709	8710	O
,	8710	8711	O
F	8712	8713	O
,	8713	8714	O
I	8715	8716	O
,	8716	8717	O
and	8718	8721	O
L	8722	8723	O
)	8723	8724	O
augmented	8725	8734	O
the	8735	8738	O
NK	8739	8741	B-Cell
-	8741	8742	O
induced	8742	8749	O
maturation	8750	8760	O
at	8761	8763	O
NK	8764	8766	B-Cell
/	8766	8767	O
DC	8767	8769	B-Cell
ratios	8770	8776	O
of	8777	8779	O
1	8780	8781	O
:	8781	8782	O
5	8782	8783	O
and	8784	8787	O
1	8788	8789	O
:	8789	8790	O
1	8790	8791	O
,	8791	8792	O
but	8793	8796	O
had	8797	8800	O
no	8801	8803	O
effect	8804	8810	O
at	8811	8813	O
the	8814	8817	O
5	8818	8819	O
:	8819	8820	O
1	8820	8821	O
ratio	8822	8827	O
.	8827	8828	O

Again	8829	8834	O
,	8834	8835	O
DC	8836	8838	B-Cell
maturation	8839	8849	O
was	8850	8853	O
dependent	8854	8863	O
on	8864	8866	O
NK	8867	8869	B-Cell
cell	8870	8874	I-Cell
contact	8875	8882	O
and	8883	8886	O
endogenously	8887	8899	O
produced	8900	8908	O
TNF	8909	8912	O
-	8912	8913	O
alpha	8913	8918	O
,	8918	8919	O
because	8920	8927	O
it	8928	8930	O
did	8931	8934	O
not	8935	8938	O
occur	8939	8944	O
when	8945	8949	O
the	8950	8953	O
two	8954	8957	O
cell	8958	8962	B-Cell
types	8963	8968	O
were	8969	8973	O
separated	8974	8983	O
in	8984	8986	O
trans	8987	8992	O
-	8992	8993	O
wells	8993	8998	O
or	8999	9001	O
upon	9002	9006	O
the	9007	9010	O
addition	9011	9019	O
of	9020	9022	O
a	9023	9024	O
neutralizing	9025	9037	O
antibody	9038	9046	O
for	9047	9050	O
TNF	9051	9054	O
-	9054	9055	O
alpha	9055	9060	O
(	9061	9062	O
Fig	9062	9065	O
.	9065	9066	O
5	9067	9068	O
)	9068	9069	O
.	9069	9070	O

Moreover	9071	9079	O
,	9079	9080	O
addition	9081	9089	O
of	9090	9092	O
blocking	9093	9101	O
reagents	9102	9110	O
for	9111	9114	O
CD80	9115	9119	O
,	9119	9120	O
CD86	9121	9125	O
,	9125	9126	O
CD154	9127	9132	O
,	9132	9133	O
CD95	9134	9138	O
,	9138	9139	O
CD11a	9140	9145	O
,	9145	9146	O
CD50	9147	9151	O
,	9151	9152	O
IL	9153	9155	O
-	9155	9156	O
12	9156	9158	O
,	9158	9159	O
IFN	9160	9163	O
-	9163	9164	O
gamma	9164	9169	O
,	9169	9170	O
IFN	9171	9174	O
-	9174	9175	O
alpha	9175	9180	O
,	9180	9181	O
or	9182	9184	O
IFN	9185	9188	O
-	9188	9189	O
beta	9189	9193	O
had	9194	9197	O
no	9198	9200	O
effect	9201	9207	O
on	9208	9210	O
the	9211	9214	O
NK	9215	9217	B-Cell
-	9217	9218	O
induced	9218	9225	O
maturation	9226	9236	O
(	9237	9238	O
data	9238	9242	O
not	9243	9246	O
shown	9247	9252	O
)	9252	9253	O
.	9253	9254	O

Figure	9255	9261	O
4	9262	9263	O
.	9263	9264	O

Activated	9265	9274	O
/	9274	9275	O
cultured	9275	9283	O
NK	9284	9286	B-Cell
cell	9287	9291	I-Cell
-	9291	9292	O
mediated	9292	9300	O
maturation	9301	9311	O
/	9311	9312	O
death	9312	9317	O
of	9318	9320	O
DCs	9321	9324	B-Cell
.	9324	9325	O

Cultured	9326	9334	O
iDCs	9335	9339	B-Cell
were	9340	9344	O
incubated	9345	9354	O
for	9355	9358	O
48	9359	9361	O
h	9362	9363	O
,	9363	9364	O
alone	9365	9370	O
(	9371	9372	O
A	9372	9373	O
-	9373	9374	O
C	9374	9375	O
)	9375	9376	O
,	9376	9377	O
or	9378	9380	O
with	9381	9385	O
NK	9386	9388	B-Cell
cells	9389	9394	I-Cell
at	9395	9397	O
the	9398	9401	O
following	9402	9411	O
ratios	9412	9418	O
(	9419	9420	O
NK	9420	9422	B-Cell
/	9422	9423	O
DC	9423	9425	B-Cell
)	9425	9426	O
,	9426	9427	O
1	9428	9429	O
:	9429	9430	O
5	9430	9431	O
(	9432	9433	O
D	9433	9434	O
-	9434	9435	O
F	9435	9436	O
)	9436	9437	O
,	9437	9438	O
1	9439	9440	O
:	9440	9441	O
1	9441	9442	O
(	9443	9444	O
G	9444	9445	O
-	9445	9446	O
I	9446	9447	O
)	9447	9448	O
,	9448	9449	O
and	9450	9453	O
5	9454	9455	O
:	9455	9456	O
1	9456	9457	O
(	9458	9459	O
J	9459	9460	O
-	9460	9461	O
L	9461	9462	O
)	9462	9463	O
.	9463	9464	O

Forward	9465	9472	O
versus	9473	9479	O
side	9480	9484	O
scatter	9485	9492	O
plots	9493	9498	O
(	9499	9500	O
A	9500	9501	O
,	9501	9502	O
D	9503	9504	O
,	9504	9505	O
G	9506	9507	O
,	9507	9508	O
and	9509	9512	O
J	9513	9514	O
)	9514	9515	O
show	9516	9520	O
the	9521	9524	O
gating	9525	9531	O
on	9532	9534	O
the	9535	9538	O
DC	9539	9541	B-Cell
subset	9542	9548	O
and	9549	9552	O
demonstrate	9553	9564	O
its	9565	9568	O
disappearance	9569	9582	O
at	9583	9585	O
the	9586	9589	O
5	9590	9591	O
:	9591	9592	O
1	9592	9593	O
(	9594	9595	O
NK	9595	9597	B-Cell
/	9597	9598	O
DC	9598	9600	B-Cell
)	9600	9601	O
ratio	9602	9607	O
(	9608	9609	O
J	9609	9610	O
)	9610	9611	O
.	9611	9612	O

Propidium	9613	9622	O
iodide	9623	9629	O
staining	9630	9638	O
of	9639	9641	O
the	9642	9645	O
NK	9646	9648	B-Cell
/	9648	9649	O
DC	9649	9651	B-Cell
(	9652	9653	O
5	9653	9654	O
:	9654	9655	O
1	9655	9656	O
)	9656	9657	O
cultures	9658	9666	O
confirmed	9667	9676	O
the	9677	9680	O
almost	9681	9687	O
complete	9688	9696	O
absence	9697	9704	O
of	9705	9707	O
viable	9708	9714	O
DCs	9715	9718	B-Cell
(	9719	9720	O
data	9720	9724	O
not	9725	9728	O
shown	9729	9734	O
)	9734	9735	O
.	9735	9736	O

Staining	9737	9745	O
for	9746	9749	O
CD86	9750	9754	O
expression	9755	9765	O
was	9766	9769	O
performed	9770	9779	O
as	9780	9782	O
described	9783	9792	O
in	9793	9795	O
Fig	9796	9799	O
.	9799	9800	O

1	9801	9802	O
and	9803	9806	O
the	9807	9810	O
histograms	9811	9821	O
are	9822	9825	O
shown	9826	9831	O
for	9832	9835	O
DCs	9836	9839	B-Cell
cultured	9840	9848	O
in	9849	9851	O
the	9852	9855	O
presence	9856	9864	O
(	9865	9866	O
C	9866	9867	O
,	9867	9868	O
F	9869	9870	O
,	9870	9871	O
I	9872	9873	O
,	9873	9874	O
and	9875	9878	O
L	9879	9880	O
)	9880	9881	O
or	9882	9884	O
absence	9885	9892	O
(	9893	9894	O
B	9894	9895	O
,	9895	9896	O
E	9897	9898	O
,	9898	9899	O
H	9900	9901	O
,	9901	9902	O
and	9903	9906	O
K	9907	9908	O
)	9908	9909	O
of	9910	9912	O
1	9913	9914	O
ng	9915	9917	O
/	9917	9918	O
ml	9918	9920	O
of	9921	9923	O
LPS	9924	9927	O
.	9927	9928	O

Results	9929	9936	O
are	9937	9940	O
representative	9941	9955	O
of	9956	9958	O
six	9959	9962	O
experiments	9963	9974	O
performed	9975	9984	O
.	9984	9985	O

Figure	9986	9992	O
5	9993	9994	O
.	9994	9995	O

Activated	9996	10005	O
/	10005	10006	O
cultured	10006	10014	O
NK	10015	10017	B-Cell
cell	10018	10022	I-Cell
-	10022	10023	O
induced	10023	10030	O
DC	10031	10033	B-Cell
maturation	10034	10044	O
is	10045	10047	O
dependent	10048	10057	O
on	10058	10060	O
cell	10061	10065	B-Cell
-	10065	10066	O
to	10066	10068	O
-	10068	10069	O
cell	10069	10073	B-Cell
contact	10074	10081	O
and	10082	10085	O
endogenous	10086	10096	O
TNF	10097	10100	O
-	10100	10101	O
alpha	10101	10106	O
production	10107	10117	O
.	10117	10118	O

Cultured	10119	10127	O
iDCs	10128	10132	B-Cell
were	10133	10137	O
incubated	10138	10147	O
alone	10148	10153	O
(	10154	10155	O
A	10155	10156	O
,	10156	10157	O
D	10158	10159	O
,	10159	10160	O
and	10161	10164	O
G	10165	10166	O
)	10166	10167	O
;	10167	10168	O
with	10169	10173	O
activated	10174	10183	O
NK	10184	10186	B-Cell
cells	10187	10192	I-Cell
at	10193	10195	O
an	10196	10198	O
NK	10199	10201	B-Cell
/	10201	10202	O
DC	10202	10204	B-Cell
ratio	10205	10210	O
of	10211	10213	O
1	10214	10215	O
:	10215	10216	O
5	10216	10217	O
(	10218	10219	O
B	10219	10220	O
,	10220	10221	O
E	10222	10223	O
,	10223	10224	O
and	10225	10228	O
H	10229	10230	O
)	10230	10231	O
;	10231	10232	O
with	10233	10237	O
activated	10238	10247	O
NK	10248	10250	B-Cell
cells	10251	10256	I-Cell
(	10257	10258	O
NK	10258	10260	B-Cell
/	10260	10261	O
DC	10261	10263	B-Cell
;	10263	10264	O
1	10265	10266	O
:	10266	10267	O
5	10267	10268	O
)	10268	10269	O
separated	10270	10279	O
in	10280	10282	O
trans	10283	10288	O
-	10288	10289	O
wells	10289	10294	O
(	10295	10296	O
C	10296	10297	O
and	10298	10301	O
F	10302	10303	O
)	10303	10304	O
;	10304	10305	O
or	10306	10308	O
with	10309	10313	O
activated	10314	10323	O
NK	10324	10326	B-Cell
cells	10327	10332	I-Cell
and	10333	10336	O
10	10337	10339	O
mug	10340	10343	O
/	10343	10344	O
ml	10344	10346	O
of	10347	10349	O
a	10350	10351	O
neutralizing	10352	10364	O
antibody	10365	10373	O
for	10374	10377	O
TNF	10378	10381	O
-	10381	10382	O
alpha	10382	10387	O
(	10388	10389	O
I	10389	10390	O
)	10390	10391	O
.	10391	10392	O

LPS	10393	10396	O
concentrations	10397	10411	O
used	10412	10416	O
were	10417	10421	O
:	10421	10422	O
0	10423	10424	O
ng	10425	10427	O
/	10427	10428	O
ml	10428	10430	O
(	10431	10432	O
A	10432	10433	O
-	10433	10434	O
C	10434	10435	O
)	10435	10436	O
;	10436	10437	O
10	10438	10440	O
ng	10441	10443	O
/	10443	10444	O
ml	10444	10446	O
(	10447	10448	O
D	10448	10449	O
-	10449	10450	O
F	10450	10451	O
)	10451	10452	O
and	10453	10456	O
50	10457	10459	O
ng	10460	10462	O
/	10462	10463	O
ml	10463	10465	O
(	10466	10467	O
G	10467	10468	O
-	10468	10469	O
I	10469	10470	O
)	10470	10471	O
.	10471	10472	O

CD86	10473	10477	O
staining	10478	10486	O
of	10487	10489	O
the	10490	10493	O
DC	10494	10496	B-Cell
subset	10497	10503	O
was	10504	10507	O
performed	10508	10517	O
as	10518	10520	O
in	10521	10523	O
Figs	10524	10528	O
.	10528	10529	O

1	10530	10531	O
and	10532	10535	O
4	10536	10537	O
.	10537	10538	O

Results	10539	10546	O
are	10547	10550	O
representative	10551	10565	O
of	10566	10568	O
four	10569	10573	O
experiments	10574	10585	O
performed	10586	10595	O
.	10595	10596	O

Acknowledgements	0	16	O

We	17	19	O
would	20	25	O
like	26	30	O
to	31	33	O
thank	34	39	O
our	40	43	O
colleague	44	53	O
Dr	54	56	O
.	56	57	O
Nikolaos	58	66	O
Papathanasiou	67	80	O
for	81	84	O
his	85	88	O
assistance	89	99	O
in	100	102	O
performing	103	113	O
the	114	117	O
statistical	118	129	O
analysis	130	138	O
.	138	139	O

Anion	0	5	O
to	6	8	O
cation	9	15	O
selectivity	16	27	O
ratio	28	33	O
determined	34	44	O
from	45	49	O
the	50	53	O
relative	54	62	O
rates	63	68	O
of	69	71	O
reaction	72	80	O
of	81	83	O
MTSES	84	89	O
-	89	90	O
and	91	94	O
MTSET	95	100	O
+	100	101	O
with	102	106	O
the	107	110	O
water	111	116	O
exposed	117	124	O
residues	125	133	O
in	134	136	O
the	137	140	O
M6	141	143	O
segment	144	151	O
.	151	152	O

The	153	156	O
anion	157	162	O
selectivity	163	174	O
ratio	175	180	O
is	181	183	O
calculated	184	194	O
as	195	197	O
described	198	207	O
in	208	210	O
Table	211	216	O
II	217	219	O
,	219	220	O
column	221	227	O
5	228	229	O
.	229	230	O

Note	231	235	O
the	236	239	O
marked	240	246	O
increase	247	255	O
in	256	258	O
anion	259	264	O
selectivity	265	276	O
at	277	279	O
the	280	283	O
residues	284	292	O
T351C	293	298	O
and	299	302	O
Q353C	303	308	O
.	308	309	O

A	310	311	O
ratio	312	317	O
of	318	320	O
1	321	322	O
indicates	323	332	O
no	333	335	O
selectivity	336	347	O
between	348	355	O
anions	356	362	O
and	363	366	O
cations	367	374	O
.	374	375	O

The	376	379	O
larger	380	386	O
the	387	390	O
ratio	391	396	O
the	397	400	O
greater	401	408	O
the	409	412	O
anion	413	418	O
selectivity	419	430	O
.	430	431	O

Authors	0	7	O
'	7	8	O
contributions	9	22	O

All	23	26	O
authors	27	34	O
contributed	35	46	O
to	47	49	O
the	50	53	O
development	54	65	O
of	66	68	O
the	69	72	O
methodology	73	84	O
.	84	85	O

CY	86	88	O
and	89	92	O
NZ	93	95	O
led	96	99	O
method	100	106	O
conceptualization	107	124	O
and	125	128	O
prepared	129	137	O
the	138	141	O
original	142	150	O
draft	151	156	O
,	156	157	O
which	158	163	O
was	164	167	O
revised	168	175	O
by	176	178	O
JR	179	181	O
.	181	182	O

CY	183	185	O
and	186	189	O
VD	190	192	O
performed	193	202	O
most	203	207	O
implementations	208	223	O
.	223	224	O

All	225	228	O
authors	229	236	O
read	237	241	O
and	242	245	O
approved	246	254	O
the	255	258	O
final	259	264	O
manuscript	265	275	O
.	275	276	O

Background	0	10	O

Potato	11	17	O
late	18	22	O
blight	23	29	O
,	29	30	O
a	31	32	O
disease	33	40	O
caused	41	47	O
by	48	50	O
the	51	54	O
oomycete	55	63	O
pathogen	64	72	O
Phytophthora	73	85	O
infestans	86	95	O
,	95	96	O
is	97	99	O
one	100	103	O
of	104	106	O
the	107	110	O
world	111	116	O
'	116	117	O
s	117	118	O
most	119	123	O
devastating	124	135	O
crop	136	140	O
diseases	141	149	O
.	149	150	O

World	151	156	O
-	156	157	O
wide	157	161	O
losses	162	168	O
due	169	172	O
to	173	175	O
late	176	180	O
blight	181	187	O
exceed	188	194	O
several	195	202	O
billion	203	210	O
dollars	211	218	O
annually	219	227	O
[	228	229	O
1	229	230	O
]	230	231	O
.	231	232	O

Most	233	237	O
of	238	240	O
the	241	244	O
potato	245	251	O
cultivars	252	261	O
currently	262	271	O
grown	272	277	O
in	278	280	O
the	281	284	O
United	285	291	O
States	292	298	O
are	299	302	O
highly	303	309	O
susceptible	310	321	O
to	322	324	O
late	325	329	O
blight	330	336	O
and	337	340	O
control	341	348	O
of	349	351	O
this	352	356	O
disease	357	364	O
relies	365	371	O
almost	372	378	O
exclusively	379	390	O
on	391	393	O
fungicide	394	403	O
applications	404	416	O
.	416	417	O

The	418	421	O
most	422	426	O
effective	427	436	O
and	437	440	O
environmentally	441	456	O
sound	457	462	O
way	463	466	O
for	467	470	O
controlling	471	482	O
late	483	487	O
blight	488	494	O
is	495	497	O
to	498	500	O
incorporate	501	512	O
natural	513	520	O
resistance	521	531	O
into	532	536	O
potato	537	543	O
cultivars	544	553	O
.	553	554	O

The	555	558	O
pedigrees	559	568	O
of	569	571	O
many	572	576	O
potato	577	583	O
cultivars	584	593	O
currently	594	603	O
used	604	608	O
in	609	611	O
different	612	621	O
countries	622	631	O
include	632	639	O
late	640	644	O
blight	645	651	O
resistant	652	661	O
germplasm	662	671	O
derived	672	679	O
from	680	684	O
Solanum	685	692	O
demissum	693	701	O
,	701	702	O
Solanum	703	710	O
andigena	711	719	O
,	719	720	O
and	721	724	O
other	725	730	O
wild	731	735	O
species	736	743	O
.	743	744	O

However	745	752	O
,	752	753	O
most	754	758	O
of	759	761	O
the	762	765	O
resistance	766	776	O
derived	777	784	O
from	785	789	O
these	790	795	O
wild	796	800	O
species	801	808	O
is	809	811	O
controlled	812	822	O
by	823	825	O
single	826	832	O
dominant	833	841	O
resistance	842	852	O
genes	853	858	O
(	859	860	O
R	860	861	O
genes	862	867	O
)	867	868	O
.	868	869	O

These	870	875	O
R	876	877	O
genes	878	883	O
are	884	887	O
only	888	892	O
effective	893	902	O
in	903	905	O
preventing	906	916	O
the	917	920	O
development	921	932	O
of	933	935	O
late	936	940	O
blight	941	947	O
if	948	950	O
the	951	954	O
invading	955	963	O
P	964	965	O
.	965	966	O
infestans	967	976	O
race	977	981	O
contains	982	990	O
the	991	994	O
corresponding	995	1008	O
avirulence	1009	1019	O
genes	1020	1025	O
.	1025	1026	O

This	1027	1031	O
R	1032	1033	O
gene	1034	1038	O
-	1038	1039	O
mediated	1039	1047	O
resistance	1048	1058	O
is	1059	1061	O
often	1062	1067	O
short	1068	1073	O
-	1073	1074	O
lived	1074	1079	O
and	1080	1083	O
is	1084	1086	O
rapidly	1087	1094	O
overcome	1095	1103	O
by	1104	1106	O
new	1107	1110	O
races	1111	1116	O
of	1117	1119	O
the	1120	1123	O
late	1124	1128	O
blight	1129	1135	O
pathogen	1136	1144	O
.	1144	1145	O

Solanum	1146	1153	O
bulbocastanum	1154	1167	O
(	1168	1169	O
2n	1169	1171	O
=	1172	1173	O
2x	1174	1176	O
=	1177	1178	O
24	1179	1181	O
)	1181	1182	O
is	1183	1185	O
a	1186	1187	O
diploid	1188	1195	O
species	1196	1203	O
that	1204	1208	O
has	1209	1212	O
adapted	1213	1220	O
in	1221	1223	O
the	1224	1227	O
same	1228	1232	O
environment	1233	1244	O
as	1245	1247	O
the	1248	1251	O
late	1252	1256	O
blight	1257	1263	O
pathogen	1264	1272	O
.	1272	1273	O

This	1274	1278	O
wild	1279	1283	O
species	1284	1291	O
was	1292	1295	O
characterized	1296	1309	O
as	1310	1312	O
possessing	1313	1323	O
durable	1324	1331	O
resistance	1332	1342	O
against	1343	1350	O
P	1351	1352	O
.	1352	1353	O
infestans	1354	1363	O
,	1363	1364	O
even	1365	1369	O
under	1370	1375	O
high	1376	1380	O
disease	1381	1388	O
pressure	1389	1397	O
[	1398	1399	O
2	1399	1400	O
,	1400	1401	O
3	1401	1402	O
]	1402	1403	O
.	1403	1404	O

Two	1405	1408	O
resistance	1409	1419	O
genes	1420	1425	O
,	1425	1426	O
RB	1427	1429	O
(	1430	1431	O
Rpi	1431	1434	O
-	1434	1435	O
blb1	1435	1439	O
)	1439	1440	O
and	1441	1444	O
Rpi	1445	1448	O
-	1448	1449	O
blb2	1449	1453	O
,	1453	1454	O
have	1455	1459	O
been	1460	1464	O
cloned	1465	1471	O
from	1472	1476	O
S	1477	1478	O
.	1478	1479	O
bulbocastanum	1480	1493	O
[	1494	1495	O
4	1495	1496	O
-	1496	1497	O
6	1497	1498	O
]	1498	1499	O
.	1499	1500	O

Both	1501	1505	O
genes	1506	1511	O
confer	1512	1518	O
broad	1519	1524	O
-	1524	1525	O
spectrum	1525	1533	O
resistance	1534	1544	O
against	1545	1552	O
a	1553	1554	O
wide	1555	1559	O
range	1560	1565	O
of	1566	1568	O
known	1569	1574	O
P	1575	1576	O
.	1576	1577	O
infestans	1578	1587	O
races	1588	1593	O
.	1593	1594	O

Transgenic	1595	1605	O
potato	1606	1612	O
lines	1613	1618	O
containing	1619	1629	O
a	1630	1631	O
single	1632	1638	O
RB	1639	1641	O
gene	1642	1646	O
showed	1647	1653	O
a	1654	1655	O
high	1656	1660	O
-	1660	1661	O
level	1661	1666	O
resistance	1667	1677	O
in	1678	1680	O
the	1681	1684	O
Toluca	1685	1691	O
Valley	1692	1698	O
,	1698	1699	O
Mexico	1700	1706	O
,	1706	1707	O
where	1708	1713	O
the	1714	1717	O
potato	1718	1724	O
fields	1725	1731	O
are	1732	1735	O
naturally	1736	1745	O
intensively	1746	1757	O
infested	1758	1766	O
with	1767	1771	O
the	1772	1775	O
most	1776	1780	O
diversified	1781	1792	O
P	1793	1794	O
.	1794	1795	O
infestans	1796	1805	O
populations	1806	1817	O
[	1818	1819	O
7	1819	1820	O
]	1820	1821	O
.	1821	1822	O

Most	1823	1827	O
interestingly	1828	1841	O
,	1841	1842	O
transgenic	1843	1853	O
RB	1854	1856	O
plants	1857	1863	O
did	1864	1867	O
not	1868	1871	O
show	1872	1876	O
total	1877	1882	O
immunity	1883	1891	O
to	1892	1894	O
late	1895	1899	O
blight	1900	1906	O
,	1906	1907	O
but	1908	1911	O
instead	1912	1919	O
showed	1920	1926	O
a	1927	1928	O
marked	1929	1935	O
delay	1936	1941	O
in	1942	1944	O
both	1945	1949	O
onset	1950	1955	O
of	1956	1958	O
symptoms	1959	1967	O
and	1968	1971	O
development	1972	1983	O
of	1984	1986	O
lesions	1987	1994	B-Pathological_formation
.	1994	1995	O

Such	1996	2000	O
rate	2001	2005	O
-	2005	2006	O
limiting	2006	2014	O
resistance	2015	2025	O
may	2026	2029	O
put	2030	2033	O
less	2034	2038	O
selection	2039	2048	O
pressure	2049	2057	O
on	2058	2060	O
the	2061	2064	O
P	2065	2066	O
.	2066	2067	O
infestans	2068	2077	O
populations	2078	2089	O
and	2090	2093	O
protect	2094	2101	O
the	2102	2105	O
durability	2106	2116	O
of	2117	2119	O
this	2120	2124	O
resistance	2125	2135	O
gene	2136	2140	O
.	2140	2141	O

The	2142	2145	O
RB	2146	2148	O
gene	2149	2153	O
therefore	2154	2163	O
provides	2164	2172	O
an	2173	2175	O
excellent	2176	2185	O
model	2186	2191	O
to	2192	2194	O
study	2195	2200	O
the	2201	2204	O
mechanism	2205	2214	O
of	2215	2217	O
broad	2218	2223	O
-	2223	2224	O
spectrum	2224	2232	O
and	2233	2236	O
rate	2237	2241	O
-	2241	2242	O
limiting	2242	2250	O
disease	2251	2258	O
resistances	2259	2270	O
.	2270	2271	O

An	2272	2274	O
understanding	2275	2288	O
of	2289	2291	O
the	2292	2295	O
underlying	2296	2306	O
mechanism	2307	2316	O
of	2317	2319	O
this	2320	2324	O
type	2325	2329	O
of	2330	2332	O
resistance	2333	2343	O
is	2344	2346	O
important	2347	2356	O
for	2357	2360	O
developing	2361	2371	O
strategies	2372	2382	O
to	2383	2385	O
breed	2386	2391	O
durable	2392	2399	O
and	2400	2403	O
sustainable	2404	2415	O
disease	2416	2423	O
resistance	2424	2434	O
.	2434	2435	O

Several	2436	2443	O
genes	2444	2449	O
have	2450	2454	O
been	2455	2459	O
implicated	2460	2470	O
in	2471	2473	O
the	2474	2477	O
regulation	2478	2488	O
of	2489	2491	O
R	2492	2493	O
gene	2494	2498	O
function	2499	2507	O
.	2507	2508	O

Of	2509	2511	O
these	2512	2517	O
genes	2518	2523	O
,	2523	2524	O
Rar1	2525	2529	O
and	2530	2533	O
Sgt1	2534	2538	O
are	2539	2542	O
among	2543	2548	O
the	2549	2552	O
most	2553	2557	O
extensively	2558	2569	O
studied	2570	2577	O
genes	2578	2583	O
.	2583	2584	O

The	2585	2588	O
Rar1	2589	2593	O
(	2594	2595	O
required	2595	2603	O
for	2604	2607	O
Mla12	2608	2613	O
resistance	2614	2624	O
)	2624	2625	O
gene	2626	2630	O
was	2631	2634	O
first	2635	2640	O
identified	2641	2651	O
for	2652	2655	O
its	2656	2659	O
essential	2660	2669	O
role	2670	2674	O
in	2675	2677	O
the	2678	2681	O
function	2682	2690	O
of	2691	2693	O
a	2694	2695	O
subset	2696	2702	O
of	2703	2705	O
Mla	2706	2709	O
genes	2710	2715	O
that	2716	2720	O
confer	2721	2727	O
resistance	2728	2738	O
to	2739	2741	O
barley	2742	2748	O
powdery	2749	2756	O
mildew	2757	2763	O
[	2764	2765	O
8	2765	2766	O
]	2766	2767	O
.	2767	2768	O

The	2769	2772	O
RAR1	2773	2777	O
protein	2778	2785	O
contains	2786	2794	O
two	2795	2798	O
highly	2799	2805	O
similar	2806	2813	O
but	2814	2817	O
distinct	2818	2826	O
cysteine	2827	2835	O
-	2835	2836	O
and	2837	2840	O
histidine	2841	2850	O
-	2850	2851	O
rich	2851	2855	O
(	2856	2857	O
CHORD	2857	2862	O
)	2862	2863	O
Zn2	2864	2867	O
+	2867	2868	O
-	2868	2869	O
binding	2869	2876	O
domains	2877	2884	O
and	2885	2888	O
was	2889	2892	O
proposed	2893	2901	O
to	2902	2904	O
play	2905	2909	O
a	2910	2911	O
role	2912	2916	O
in	2917	2919	O
stabilizing	2920	2931	O
R	2932	2933	O
proteins	2934	2942	O
in	2943	2945	O
a	2946	2947	O
confirmation	2948	2960	O
that	2961	2965	O
is	2966	2968	O
implicated	2969	2979	O
in	2980	2982	O
receiving	2983	2992	O
pathogen	2993	3001	O
signals	3002	3009	O
[	3010	3011	O
9	3011	3012	O
]	3012	3013	O
.	3013	3014	O

The	3015	3018	O
Sgt1	3019	3023	O
gene	3024	3028	O
(	3029	3030	O
suppressor	3030	3040	O
of	3041	3043	O
the	3044	3047	O
G2	3048	3050	O
allele	3051	3057	O
of	3058	3060	O
skp1	3061	3065	O
)	3065	3066	O
is	3067	3069	O
an	3070	3072	O
essential	3073	3082	O
gene	3083	3087	O
with	3088	3092	O
multiple	3093	3101	O
functions	3102	3111	O
in	3112	3114	O
yeast	3115	3120	O
.	3120	3121	O

SGT1	3122	3126	O
protein	3127	3134	O
was	3135	3138	O
initially	3139	3148	O
identified	3149	3159	O
as	3160	3162	O
a	3163	3164	O
RAR1	3165	3169	O
-	3169	3170	O
interacting	3170	3181	O
partner	3182	3189	O
in	3190	3192	O
a	3193	3194	O
yeast	3195	3200	O
two	3201	3204	O
-	3204	3205	O
hybrid	3205	3211	O
screen	3212	3218	O
[	3219	3220	O
10	3220	3222	O
]	3222	3223	O
.	3223	3224	O

SGT1	3225	3229	O
may	3230	3233	O
play	3234	3238	O
a	3239	3240	O
role	3241	3245	O
in	3246	3248	O
R	3249	3250	O
protein	3251	3258	O
accumulation	3259	3271	O
[	3272	3273	O
11	3273	3275	O
]	3275	3276	O
.	3276	3277	O

Rar1	3278	3282	O
and	3283	3286	O
Sgt1	3287	3291	O
genes	3292	3297	O
are	3298	3301	O
required	3302	3310	O
in	3311	3313	O
various	3314	3321	O
R	3322	3323	O
-	3323	3324	O
gene	3324	3328	O
mediated	3329	3337	O
resistance	3338	3348	O
against	3349	3356	O
viral	3357	3362	O
,	3362	3363	O
bacterial	3364	3373	O
,	3373	3374	O
oomycete	3375	3383	O
or	3384	3386	O
fungal	3387	3393	O
pathogens	3394	3403	O
[	3404	3405	O
12	3405	3407	O
]	3407	3408	O
.	3408	3409	O

However	3410	3417	O
,	3417	3418	O
none	3419	3423	O
of	3424	3426	O
the	3427	3430	O
previously	3431	3441	O
studied	3442	3449	O
R	3450	3451	O
genes	3452	3457	O
showed	3458	3464	O
a	3465	3466	O
race	3467	3471	O
-	3471	3472	O
non	3472	3475	O
-	3475	3476	O
specific	3476	3484	O
and	3485	3488	O
rate	3489	3493	O
-	3493	3494	O
limiting	3494	3502	O
resistance	3503	3513	O
phenotype	3514	3523	O
as	3524	3526	O
the	3527	3530	O
RB	3531	3533	O
gene	3534	3538	O
.	3538	3539	O

In	3540	3542	O
addition	3543	3551	O
,	3551	3552	O
the	3553	3556	O
role	3557	3561	O
the	3562	3565	O
Rar1	3566	3570	O
and	3571	3574	O
Sgt1	3575	3579	O
genes	3580	3585	O
are	3586	3589	O
not	3590	3593	O
universal	3594	3603	O
and	3604	3607	O
these	3608	3613	O
genes	3614	3619	O
are	3620	3623	O
not	3624	3627	O
essential	3628	3637	O
for	3638	3641	O
resistance	3642	3652	O
involving	3653	3662	O
some	3663	3667	O
R	3668	3669	O
genes	3670	3675	O
[	3676	3677	O
12	3677	3679	O
,	3679	3680	O
13	3680	3682	O
]	3682	3683	O
.	3683	3684	O

Besides	3685	3692	O
the	3693	3696	O
two	3697	3700	O
broad	3701	3706	O
-	3706	3707	O
spectrum	3707	3715	O
resistance	3716	3726	O
genes	3727	3732	O
RB	3733	3735	O
and	3736	3739	O
Rpi	3740	3743	O
-	3743	3744	O
blb2	3744	3748	O
,	3748	3749	O
several	3750	3757	O
race	3758	3762	O
-	3762	3763	O
specific	3763	3771	O
late	3772	3776	O
blight	3777	3783	O
resistance	3784	3794	O
genes	3795	3800	O
have	3801	3805	O
also	3806	3810	O
been	3811	3815	O
cloned	3816	3822	O
[	3823	3824	O
14	3824	3826	O
-	3826	3827	O
16	3827	3829	O
]	3829	3830	O
.	3830	3831	O

Numerous	3832	3840	O
late	3841	3845	O
blight	3846	3852	O
resistance	3853	3863	O
genes	3864	3869	O
have	3870	3874	O
recently	3875	3883	O
been	3884	3888	O
mapped	3889	3895	O
in	3896	3898	O
various	3899	3906	O
potato	3907	3913	O
species	3914	3921	O
or	3922	3924	O
populations	3925	3936	O
[	3937	3938	O
17	3938	3940	O
-	3940	3941	O
25	3941	3943	O
]	3943	3944	O
.	3944	3945	O

However	3946	3953	O
,	3953	3954	O
there	3955	3960	O
is	3961	3963	O
almost	3964	3970	O
no	3971	3973	O
information	3974	3985	O
available	3986	3995	O
about	3996	4001	O
the	4002	4005	O
resistance	4006	4016	O
pathways	4017	4025	O
mediated	4026	4034	O
by	4035	4037	O
any	4038	4041	O
of	4042	4044	O
these	4045	4050	O
genes	4051	4056	O
.	4056	4057	O

As	4058	4060	O
an	4061	4063	O
initial	4064	4071	O
effort	4072	4078	O
to	4079	4081	O
understand	4082	4092	O
the	4093	4096	O
RB	4097	4099	O
-	4099	4100	O
mediated	4100	4108	O
late	4109	4113	O
blight	4114	4120	O
resistance	4121	4131	O
pathway	4132	4139	O
,	4139	4140	O
we	4141	4143	O
silenced	4144	4152	O
the	4153	4156	O
Rar1	4157	4161	O
and	4162	4165	O
Sgt1	4166	4170	O
genes	4171	4176	O
using	4177	4182	O
an	4183	4185	O
RNAi	4186	4190	O
-	4190	4191	O
based	4191	4196	O
approach	4197	4205	O
in	4206	4208	O
a	4209	4210	O
potato	4211	4217	O
line	4218	4222	O
containing	4223	4233	O
the	4234	4237	O
RB	4238	4240	O
gene	4241	4245	O
.	4245	4246	O

We	4247	4249	O
demonstrated	4250	4262	O
that	4263	4267	O
SGT1	4268	4272	O
,	4272	4273	O
but	4274	4277	O
not	4278	4281	O
RAR1	4282	4286	O
,	4286	4287	O
is	4288	4290	O
essential	4291	4300	O
for	4301	4304	O
the	4305	4308	O
RB	4309	4311	O
-	4311	4312	O
mediated	4312	4320	O
broad	4321	4326	O
-	4326	4327	O
spectrum	4327	4335	O
resistance	4336	4346	O
to	4347	4349	O
potato	4350	4356	O
late	4357	4361	O
blight	4362	4368	O
.	4368	4369	O

Ovariectomy	0	11	O

Based	12	17	O
on	18	20	O
the	21	24	O
uterine	25	32	B-Organ
weight	33	39	O
,	39	40	O
we	41	43	O
determined	44	54	O
seven	55	60	O
unsuccessful	61	73	O
OVXs	74	78	O
.	78	79	O

The	80	83	O
rats	84	88	O
concerned	89	98	O
were	99	103	O
removed	104	111	O
from	112	116	O
further	117	124	O
analyses	125	133	O
,	133	134	O
which	135	140	O
left	141	145	O
nine	146	150	O
rats	151	155	O
in	156	158	O
the	159	162	O
control	163	170	O
group	171	176	O
,	176	177	O
five	178	182	O
in	183	185	O
the	186	189	O
OVX	190	193	O
group	194	199	O
,	199	200	O
seven	201	206	O
in	207	209	O
the	210	213	O
OVX	214	217	O
and	218	221	O
late	222	226	O
ZOL	227	230	O
group	231	236	O
,	236	237	O
and	238	241	O
eight	242	247	O
in	248	250	O
the	251	254	O
OVX	255	258	O
and	259	262	O
early	263	268	O
ZOL	269	272	O
group	273	278	O
.	278	279	O

For	280	283	O
each	284	288	O
animal	289	295	O
,	295	296	O
we	297	299	O
determined	300	310	O
the	311	314	O
percentage	315	325	O
change	326	332	O
in	333	335	O
structural	336	346	O
parameters	347	357	O
compared	358	366	O
to	367	369	O
the	370	373	O
values	374	380	O
at	381	383	O
week	384	388	O
0	389	390	O
.	390	391	O

Figure	392	398	O
1	399	400	O
shows	401	406	O
the	407	410	O
average	411	418	O
percentage	419	429	O
change	430	436	O
and	437	440	O
upper	441	446	O
standard	447	455	O
deviation	456	465	O
for	466	469	O
all	470	473	O
groups	474	480	O
for	481	484	O
BV	485	487	O
/	487	488	O
TV	488	490	O
,	490	491	O
Conn	492	496	O
.	496	497	O
D	497	498	O
,	498	499	O
SMI	500	503	O
,	503	504	O
Tb	505	507	O
.	507	508	O
N	508	509	O
,	509	510	O
Tb	511	513	O
.	513	514	O
Th	514	516	O
,	516	517	O
and	518	521	O
Tb	522	524	O
.	524	525	O
Sp	525	527	O
.	527	528	O

The	529	532	O
OVX	533	536	O
group	537	542	O
without	543	550	O
treatment	551	560	O
showed	561	567	O
large	568	573	O
changes	574	581	O
in	582	584	O
structural	585	595	O
parameters	596	606	O
,	606	607	O
indicating	608	618	O
the	619	622	O
development	623	634	O
of	635	637	O
OVX	638	641	O
-	641	642	O
induced	642	649	O
bone	650	654	B-Tissue
loss	655	659	O
(	660	661	O
Figs	661	665	O
.	665	666	O
1	667	668	O
and	669	672	O
2	673	674	O
)	674	675	O
.	675	676	O

Paired	677	683	O
Student	684	691	O
'	691	692	O
s	692	693	O
t	694	695	O
-	695	696	O
test	696	700	O
indicated	701	710	O
significant	711	722	O
changes	723	730	O
within	731	737	O
2	738	739	O
weeks	740	745	O
after	746	751	O
OVX	752	755	O
for	756	759	O
all	760	763	O
structural	764	774	O
parameters	775	785	O
.	785	786	O

BV	787	789	O
/	789	790	O
TV	790	792	O
,	792	793	O
Conn	794	798	O
.	798	799	O
D	799	800	O
,	800	801	O
and	802	805	O
Tb	806	808	O
.	808	809	O
N	809	810	O
decreased	811	820	O
during	821	827	O
the	828	831	O
experiment	832	842	O
and	843	846	O
SMI	847	850	O
and	851	854	O
Tb	855	857	O
.	857	858	O
Sp	858	860	O
increased	861	870	O
.	870	871	O

Both	872	876	O
Tb	877	879	O
.	879	880	O
Th	880	882	O
and	883	886	O
Tb	887	889	O
.	889	890	O
N	890	891	O
decreased	892	901	O
within	902	908	O
2	909	910	O
weeks	911	916	O
,	916	917	O
indicating	918	928	O
that	929	933	O
both	934	938	O
thinning	939	947	O
and	948	951	O
complete	952	960	O
resorption	961	971	O
of	972	974	O
trabeculae	975	985	O
started	986	993	O
directly	994	1002	O
after	1003	1008	O
OVX	1009	1012	O
.	1012	1013	O

The	1014	1017	O
initial	1018	1025	O
rapid	1026	1031	O
loss	1032	1036	O
of	1037	1039	O
bone	1040	1044	B-Tissue
and	1045	1048	O
connectivity	1049	1061	O
was	1062	1065	O
largely	1066	1073	O
accompanied	1074	1085	O
by	1086	1088	O
trabecular	1089	1099	B-Organ
thinning	1100	1108	O
,	1108	1109	O
while	1110	1115	O
secondary	1116	1125	O
,	1125	1126	O
slower	1127	1133	O
loss	1134	1138	O
of	1139	1141	O
bone	1142	1146	B-Tissue
was	1147	1150	O
concomitant	1151	1162	O
with	1163	1167	O
a	1168	1169	O
decrease	1170	1178	O
in	1179	1181	O
Tb	1182	1184	O
.	1184	1185	O
N	1185	1186	O
.	1186	1187	O

While	1188	1193	O
BV	1194	1196	O
/	1196	1197	O
TV	1197	1199	O
,	1199	1200	O
Conn	1201	1205	O
.	1205	1206	O
D	1206	1207	O
,	1207	1208	O
SMI	1209	1212	O
,	1212	1213	O
Tb	1214	1216	O
.	1216	1217	O
N	1217	1218	O
,	1218	1219	O
and	1220	1223	O
Tb	1224	1226	O
.	1226	1227	O
Sp	1227	1229	O
showed	1230	1236	O
continuous	1237	1247	O
changes	1248	1255	O
in	1256	1258	O
the	1259	1262	O
same	1263	1267	O
direction	1268	1277	O
throughout	1278	1288	O
the	1289	1292	O
experiment	1293	1303	O
,	1303	1304	O
Tb	1305	1307	O
.	1307	1308	O
Th	1308	1310	O
initially	1311	1320	O
decreased	1321	1330	O
significantly	1331	1344	O
until	1345	1350	O
4	1351	1352	O
weeks	1353	1358	O
after	1359	1364	O
OVX	1365	1368	O
and	1369	1372	O
then	1373	1377	O
increased	1378	1387	O
again	1388	1393	O
until	1394	1399	O
after	1400	1405	O
16	1406	1408	O
weeks	1409	1414	O
Tb	1415	1417	O
.	1417	1418	O
Th	1418	1420	O
was	1421	1424	O
significantly	1425	1438	O
higher	1439	1445	O
than	1446	1450	O
in	1451	1453	O
the	1454	1457	O
control	1458	1465	O
group	1466	1471	O
.	1471	1472	O

Fig	1474	1477	O
.	1477	1478	O

1	1479	1480	O

Average	1481	1488	O
percentage	1489	1499	O
change	1500	1506	O
in	1507	1509	O
structural	1510	1520	O
parameters	1521	1531	O
in	1532	1534	O
the	1535	1538	O
metaphyseal	1539	1550	O
proximal	1551	1559	O
tibia	1560	1565	B-Organ
and	1566	1569	O
upper	1570	1575	O
standard	1576	1584	O
deviation	1585	1594	O
for	1595	1598	O
all	1599	1602	O
groups	1603	1609	O
at	1610	1612	O
all	1613	1616	O
time	1617	1621	O
points	1622	1628	O
.	1628	1629	O

Brackets	1630	1638	O
indicate	1639	1647	O
P	1648	1649	O
<	1650	1651	O
0	1652	1653	O
.	1653	1654	O
05	1654	1656	O
at	1657	1659	O
week	1660	1664	O
16	1665	1667	O

Fig	1668	1671	O
.	1671	1672	O

2	1673	1674	O

Same	1675	1679	O
slice	1680	1685	O
of	1686	1688	O
an	1689	1691	O
unprocessed	1692	1703	O
CT	1704	1706	O
scan	1707	1711	O
of	1712	1714	O
the	1715	1718	O
same	1719	1723	O
rat	1724	1727	O
in	1728	1730	O
the	1731	1734	O
OVX	1735	1738	O
group	1739	1744	O
taken	1745	1750	O
at	1751	1753	O
weeks	1754	1759	O
0	1760	1761	O
(	1762	1763	O
a	1763	1764	O
)	1764	1765	O
,	1765	1766	O
2	1767	1768	O
(	1769	1770	O
b	1770	1771	O
)	1771	1772	O
,	1772	1773	O
4	1774	1775	O
(	1776	1777	O
c	1777	1778	O
)	1778	1779	O
,	1779	1780	O
8	1781	1782	O
(	1783	1784	O
d	1784	1785	O
)	1785	1786	O
,	1786	1787	O
12	1788	1790	O
(	1791	1792	O
e	1792	1793	O
)	1793	1794	O
,	1794	1795	O
and	1796	1799	O
16	1800	1802	O
(	1803	1804	O
f	1804	1805	O
)	1805	1806	O
.	1806	1807	O

Images	1808	1814	O
show	1815	1819	O
typical	1820	1827	O
trabecular	1828	1838	B-Tissue
bone	1839	1843	I-Tissue
loss	1844	1848	O
due	1849	1852	O
to	1853	1855	O
OVX	1856	1859	O
in	1860	1862	O
the	1863	1866	O
metaphysis	1867	1877	O
.	1877	1878	O

Green	1879	1884	O
line	1885	1889	O
shows	1890	1895	O
the	1896	1899	O
analyzed	1900	1908	O
metaphyseal	1909	1920	O
bone	1921	1925	B-Tissue

The	1926	1929	O
absolute	1930	1938	O
average	1939	1946	O
values	1947	1953	O
and	1954	1957	O
standard	1958	1966	O
deviations	1967	1977	O
for	1978	1981	O
all	1982	1985	O
structural	1986	1996	O
parameters	1997	2007	O
of	2008	2010	O
all	2011	2014	O
measurements	2015	2027	O
are	2028	2031	O
shown	2032	2037	O
in	2038	2040	O
Table	2041	2046	O
1	2047	2048	O
.	2048	2049	O

At	2050	2052	O
the	2053	2056	O
starting	2057	2065	O
point	2066	2071	O
,	2071	2072	O
some	2073	2077	O
differences	2078	2089	O
in	2090	2092	O
the	2093	2096	O
values	2097	2103	O
between	2104	2111	O
the	2112	2115	O
groups	2116	2122	O
were	2123	2127	O
present	2128	2135	O
.	2135	2136	O

This	2137	2141	O
was	2142	2145	O
due	2146	2149	O
to	2150	2152	O
the	2153	2156	O
fact	2157	2161	O
that	2162	2166	O
some	2167	2171	O
animals	2172	2179	O
,	2179	2180	O
which	2181	2186	O
mostly	2187	2193	O
had	2194	2197	O
a	2198	2199	O
relatively	2200	2210	O
low	2211	2214	O
BV	2215	2217	O
/	2217	2218	O
TV	2218	2220	O
,	2220	2221	O
were	2222	2226	O
removed	2227	2234	O
from	2235	2239	O
the	2240	2243	O
study	2244	2249	O
because	2250	2257	O
they	2258	2262	O
did	2263	2266	O
not	2267	2270	O
respond	2271	2278	O
to	2279	2281	O
the	2282	2285	O
OVX	2286	2289	O
.	2289	2290	O

However	2291	2298	O
,	2298	2299	O
since	2300	2305	O
we	2306	2308	O
compared	2309	2317	O
the	2318	2321	O
relative	2322	2330	O
changes	2331	2338	O
in	2339	2341	O
each	2342	2346	O
animal	2347	2353	O
,	2353	2354	O
the	2355	2358	O
results	2359	2366	O
were	2367	2371	O
most	2372	2376	O
likely	2377	2383	O
not	2384	2387	O
affected	2388	2396	O
by	2397	2399	O
the	2400	2403	O
difference	2404	2414	O
in	2415	2417	O
absolute	2418	2426	O
values	2427	2433	O
.	2433	2434	O

Table	2436	2441	O
1	2442	2443	O

Mean	2444	2448	O
values	2449	2455	O
and	2456	2459	O
standard	2460	2468	O
deviation	2469	2478	O
of	2479	2481	O
all	2482	2485	O
structural	2486	2496	O
parameters	2497	2507	O
of	2508	2510	O
all	2511	2514	O
groups	2515	2521	O
at	2522	2524	O
the	2525	2528	O
start	2529	2534	O
of	2535	2537	O
the	2538	2541	O
experiment	2542	2552	O

Group	2553	2558	O
BV	2559	2561	O
/	2561	2562	O
TV	2562	2564	O
(	2565	2566	O
1	2566	2567	O
)	2567	2568	O
Conn	2569	2573	O
.	2573	2574	O
D	2574	2575	O
(	2576	2577	O
1	2577	2578	O
/	2578	2579	O
mm	2579	2581	O
)	2581	2582	O
SMI	2583	2586	O
(	2587	2588	O
1	2588	2589	O
)	2589	2590	O
Tb	2591	2593	O
.	2593	2594	O
N	2594	2595	O
(	2596	2597	O
1	2597	2598	O
/	2598	2599	O
mm	2599	2601	O
)	2601	2602	O
Tb	2603	2605	O
.	2605	2606	O
Th	2606	2608	O
(	2609	2610	O
mum	2610	2613	O
)	2613	2614	O
Tb	2615	2617	O
.	2617	2618	O
Sp	2618	2620	O
(	2621	2622	O
mum	2622	2625	O
)	2625	2626	O

Control	2627	2634	O
0	2635	2636	O
.	2636	2637	O
17	2637	2639	O
(	2640	2641	O
0	2641	2642	O
.	2642	2643	O
056	2643	2646	O
)	2646	2647	O
41	2648	2650	O
(	2651	2652	O
47	2652	2654	O
)	2654	2655	O
1	2656	2657	O
.	2657	2658	O
52	2658	2660	O
(	2661	2662	O
0	2662	2663	O
.	2663	2664	O
53	2664	2666	O
)	2666	2667	O
1	2668	2669	O
.	2669	2670	O
89	2670	2672	O
(	2673	2674	O
1	2674	2675	O
.	2675	2676	O
38	2676	2678	O
)	2678	2679	O
105	2680	2683	O
(	2684	2685	O
49	2685	2687	O
)	2687	2688	O
613	2689	2692	O
(	2693	2694	O
368	2694	2697	O
)	2697	2698	O

OVX	2699	2702	O
0	2703	2704	O
.	2704	2705	O
26	2705	2707	O
(	2708	2709	O
0	2709	2710	O
.	2710	2711	O
055	2711	2714	O
)	2714	2715	O
141	2716	2719	O
(	2720	2721	O
76	2721	2723	O
)	2723	2724	O
1	2725	2726	O
.	2726	2727	O
22	2727	2729	O
(	2730	2731	O
0	2731	2732	O
.	2732	2733	O
39	2733	2735	O
)	2735	2736	O
3	2737	2738	O
.	2738	2739	O
77	2739	2741	O
(	2742	2743	O
1	2743	2744	O
.	2744	2745	O
66	2745	2747	O
)	2747	2748	O
84	2749	2751	O
(	2752	2753	O
10	2753	2755	O
)	2755	2756	O
335	2757	2760	O
(	2761	2762	O
174	2762	2765	O
)	2765	2766	O

OVX	2767	2770	O
+	2771	2772	O
late	2773	2777	O
ZOL	2778	2781	O
0	2782	2783	O
.	2783	2784	O
23	2784	2786	O
(	2787	2788	O
0	2788	2789	O
.	2789	2790	O
062	2790	2793	O
)	2793	2794	O
86	2795	2797	O
(	2798	2799	O
66	2799	2801	O
)	2801	2802	O
1	2803	2804	O
.	2804	2805	O
23	2805	2807	O
(	2808	2809	O
0	2809	2810	O
.	2810	2811	O
34	2811	2813	O
)	2813	2814	O
2	2815	2816	O
.	2816	2817	O
77	2817	2819	O
(	2820	2821	O
1	2821	2822	O
.	2822	2823	O
55	2823	2825	O
)	2825	2826	O
89	2827	2829	O
(	2830	2831	O
13	2831	2833	O
)	2833	2834	O
482	2835	2838	O
(	2839	2840	O
227	2840	2843	O
)	2843	2844	O

OVX	2845	2848	O
+	2849	2850	O
early	2851	2856	O
ZOL	2857	2860	O
0	2861	2862	O
.	2862	2863	O
17	2863	2865	O
(	2866	2867	O
0	2867	2868	O
.	2868	2869	O
056	2869	2872	O
)	2872	2873	O
38	2874	2876	O
(	2877	2878	O
21	2878	2880	O
)	2880	2881	O
1	2882	2883	O
.	2883	2884	O
70	2884	2886	O
(	2887	2888	O
0	2888	2889	O
.	2889	2890	O
39	2890	2892	O
)	2892	2893	O
1	2894	2895	O
.	2895	2896	O
86	2896	2898	O
(	2899	2900	O
0	2900	2901	O
.	2901	2902	O
80	2902	2904	O
)	2904	2905	O
95	2906	2908	O
(	2909	2910	O
7	2910	2911	O
)	2911	2912	O
647	2913	2916	O
(	2917	2918	O
207	2918	2921	O
)	2921	2922	O

Click	0	5	O
here	6	10	O
for	11	14	O
file	15	19	O

Aim	0	3	O

This	4	8	O
study	9	14	O
reports	15	22	O
the	23	26	O
results	27	34	O
of	35	37	O
a	38	39	O
large	40	45	O
prospective	46	57	O
single	58	64	O
-	64	65	O
blinded	65	72	O
clinical	73	81	O
trial	82	87	O
of	88	90	O
3	91	92	O
SSRI	93	97	O
(	98	99	O
paroxetine	99	109	O
,	109	110	O
fluoxetine	111	121	O
and	122	125	O
escitalopram	126	138	O
)	138	139	O
in	140	142	O
PE	143	145	O
using	146	151	O
a	152	153	O
validated	154	163	O
questionnaire	164	177	O
.	177	178	O

Summary	0	7	O
of	8	10	O
studies	11	18	O
reporting	19	28	O
comorbidities	29	42	O
with	43	47	O
diabetes	48	56	O
.	56	57	O

Click	0	5	O
here	6	10	O
for	11	14	O
additional	15	25	O
data	26	30	O
file	31	35	O
.	35	36	O

Images	0	6	O

Figure	7	13	O
1	14	15	O

Figure	16	22	O
5	23	24	O

Figure	25	31	O
6	32	33	O

Characteristics	0	15	O
of	16	18	O
cases	19	24	O
with	25	29	O
childhood	30	39	O
leukaemia	40	49	O
(	50	51	O
n	51	52	O
=	52	53	O
162	53	56	O
)	56	57	O
and	58	61	O
matched	62	69	O
controls	70	78	O
(	79	80	O
n	80	81	O
=	81	82	O
2125	82	86	O
)	86	87	O
,	87	88	O
all	89	92	O
registered	93	103	O
within	104	110	O
3	111	112	O
months	113	119	O
of	120	122	O
birth	123	128	O

Appendix	0	8	O
Table	9	14	O

Detection	15	24	O
of	25	27	O
Nipah	28	33	O
virus	34	39	O
antibody	40	48	O
among	49	54	O
bat	55	58	O
serum	59	64	B-Organism_substance
samples	65	72	I-Organism_substance
collected	73	82	O
from	83	87	O
10	88	90	O
provinces	91	100	O
in	101	103	O
China	104	109	O
,	109	110	O
2004	111	115	O
-	115	116	O
2007	116	120	O
*	120	121	O

Whole	0	5	O
-	5	6	O
Body	6	10	O
gamma	11	16	O
-	16	17	O
Irradiation	17	28	O

To	29	31	O
evaluate	32	40	O
differential	41	53	O
sensitivity	54	65	O
to	66	68	O
irradiation	69	80	O
,	80	81	O
mice	82	86	O
were	87	91	O
exposed	92	99	O
to	100	102	O
gamma	103	108	O
-	108	109	O
irradiation	109	120	O
(	121	122	O
4	122	123	O
-	123	124	O
10	124	126	O
Gy	127	129	O
,	129	130	O
single	131	137	O
dose	138	142	O
)	142	143	O
and	144	147	O
closely	148	155	O
monitored	156	165	O
throughout	166	176	O
the	177	180	O
experimentation	181	196	O
period	197	203	O
.	203	204	O

Animals	205	212	O
were	213	217	O
killed	218	224	O
at	225	227	O
the	228	231	O
first	232	237	O
appearance	238	248	O
of	249	251	O
signs	252	257	O
of	258	260	O
poor	261	265	O
health	266	272	O
.	272	273	O

Recipients	274	284	O
of	285	287	O
bone	288	292	B-Multi-tissue_structure
marrow	293	299	I-Multi-tissue_structure
transplants	300	311	O
were	312	316	O
pre	317	320	O
-	320	321	O
irradiated	321	331	O
with	332	336	O
a	337	338	O
total	339	344	O
dose	345	349	O
of	350	352	O
10	353	355	O
.	355	356	O
2	356	357	O
Gy	358	360	O
(	361	362	O
two	362	365	O
doses	366	371	O
of	372	374	O
5	375	376	O
.	376	377	O
1	377	378	O
Gy	379	381	O
,	381	382	O
3	383	384	O
h	385	386	O
apart	387	392	O
)	392	393	O
.	393	394	O

For	395	398	O
in	399	401	O
vivo	402	406	O
DNA	407	410	O
damage	411	417	O
experiments	418	429	O
,	429	430	O
mice	431	435	O
were	436	440	O
irradiated	441	451	O
with	452	456	O
a	457	458	O
single	459	465	O
dose	466	470	O
of	471	473	O
5Gy	474	477	O
and	478	481	O
killed	482	488	O
after	489	494	O
1	495	496	O
,	496	497	O
3	498	499	O
or	500	502	O
6	503	504	O
hours	505	510	O
.	510	511	O

All	512	515	O
irradiations	516	528	O
were	529	533	O
carried	534	541	O
out	542	545	O
in	546	548	O
a	549	550	O
Cesium	551	557	O
Mark1	558	563	O
irradiator	564	574	O
(	575	576	O
Shepherd	576	584	O
Associates	585	595	O
)	595	596	O
.	596	597	O

Background	0	10	O

Sealant	0	7	O
application	8	19	O
criteria	20	28	O
for	29	32	O
molar	33	38	B-Organ
fissures	39	47	O

Power	0	5	O
(	6	7	O
Y	7	8	O
-	8	9	O
axis	9	13	O
)	13	14	O
as	15	17	O
a	18	19	O
function	20	28	O
of	29	31	O
main	32	36	O
effects	37	44	O
(	45	46	O
x	46	47	O
-	47	48	O
axis	48	52	O
)	52	53	O
.	53	54	O

For	55	58	O
a	59	60	O
pure	61	65	O
main	66	70	O
-	70	71	O
effects	71	78	O
model	79	84	O
(	85	86	O
x	86	87	O
-	87	88	O
axis	88	92	O
=	93	94	O
a1	95	97	O
>	98	99	O
0	100	101	O
;	101	102	O
interaction	103	114	O
effects	115	122	O
a2	123	125	O
=	126	127	O
a3	128	130	O
=	131	132	O
0	133	134	O
are	135	138	O
all	139	142	O
zero	143	147	O
)	147	148	O
,	148	149	O
Figure	150	156	O
1	157	158	O
shows	159	164	O
that	165	169	O
pattern	170	177	O
(	178	179	O
solid	179	184	O
red	185	188	O
line	189	193	O
)	193	194	O
and	195	198	O
single	199	205	O
-	205	206	O
locus	206	211	O
(	212	213	O
broken	213	219	O
blue	220	224	O
line	225	229	O
)	229	230	O
approaches	231	241	O
have	242	246	O
virtually	247	256	O
the	257	260	O
same	261	265	O
power	266	271	O
.	271	272	O

Peptide	0	7	O
-	7	8	O
BSA	8	11	O
conjugates	12	22	O
as	23	25	O
diagnostic	26	36	O
antigens	37	45	O

To	46	48	O
analyse	49	56	O
the	57	60	O
potential	61	70	O
of	71	73	O
the	74	77	O
peptides	78	86	O
to	87	89	O
behave	90	96	O
as	97	99	O
antigen	100	107	O
mimics	108	114	O
,	114	115	O
their	116	121	O
ability	122	129	O
to	130	132	O
react	133	138	O
with	139	143	O
IgM	144	147	O
antibodies	148	158	O
from	159	163	O
individuals	164	175	O
infected	176	184	O
with	185	189	O
EBV	190	193	O
was	194	197	O
assessed	198	206	O
.	206	207	O

In	208	210	O
our	211	214	O
previous	215	223	O
study	224	229	O
,	229	230	O
we	231	233	O
demonstrated	234	246	O
that	247	251	O
the	252	255	O
sensitivity	256	267	O
of	268	270	O
detection	271	280	O
was	281	284	O
greatly	285	292	O
improved	293	301	O
when	302	306	O
the	307	310	O
peptides	311	319	O
were	320	324	O
coupled	325	332	O
to	333	335	O
a	336	337	O
carrier	338	345	O
molecule	346	354	O
such	355	359	O
as	360	362	O
BSA	363	366	O
prior	367	372	O
to	373	375	O
immobilisation	376	390	O
onto	391	395	O
a	396	397	O
solid	398	403	O
surface	404	411	O
(	412	413	O
Casey	413	418	O
et	419	421	O
al	422	424	O
.	424	425	O
,	425	426	O
2006	427	431	O
)	431	432	O
.	432	433	O

This	434	438	O
strategy	439	447	O
was	448	451	O
adopted	452	459	O
to	460	462	O
test	463	467	O
peptides	468	476	O
Eb1	477	480	O
-	480	481	O
4	481	482	O
and	483	486	O
H1	487	489	O
.	489	490	O

A	491	492	O
set	493	496	O
of	497	499	O
40	500	502	O
clinical	503	511	O
samples	512	519	O
that	520	524	O
were	525	529	O
classified	530	540	O
as	541	543	O
EBV	544	547	O
seropositive	548	560	O
(	561	562	O
n	562	563	O
=	564	565	O
16	566	568	O
)	568	569	O
,	569	570	O
seronegative	571	583	O
(	584	585	O
n	585	586	O
=	587	588	O
16	589	591	O
)	591	592	O
or	593	595	O
potentially	596	607	O
cross	608	613	O
-	613	614	O
reactive	614	622	O
sera	623	627	B-Organism_substance
(	628	629	O
n	629	630	O
=	631	632	O
8	633	634	O
)	634	635	O
were	636	640	O
assessed	641	649	O
for	650	653	O
reactivity	654	664	O
with	665	669	O
Eb1	670	673	O
-	673	674	O
4	674	675	O
and	676	679	O
H1	680	682	O
peptides	683	691	O
individually	692	704	O
.	704	705	O

The	706	709	O
cut	710	713	O
-	713	714	O
off	714	717	O
level	718	723	O
was	724	727	O
defined	728	735	O
as	736	738	O
the	739	742	O
mean	743	747	O
optical	748	755	O
density	756	763	O
of	764	766	O
the	767	770	O
seronegative	771	783	O
samples	784	791	O
plus	792	796	O
3	797	798	O
standard	799	807	O
deviations	808	818	O
shown	819	824	O
as	825	827	O
a	828	829	O
line	830	834	O
on	835	837	O
the	838	841	O
graphs	842	848	O
in	849	851	O
Fig	852	855	O
.	855	856	O

5	857	858	O
.	858	859	O

Readings	860	868	O
above	869	874	O
this	875	879	O
level	880	885	O
were	886	890	O
defined	891	898	O
as	899	901	O
positive	902	910	O
and	911	914	O
below	915	920	O
this	921	925	O
level	926	931	O
negative	932	940	O
.	940	941	O

The	942	945	O
same	946	950	O
set	951	954	O
of	955	957	O
samples	958	965	O
were	966	970	O
analysed	971	979	O
on	980	982	O
BSA	983	986	O
alone	987	992	O
and	993	996	O
these	997	1002	O
values	1003	1009	O
were	1010	1014	O
subtracted	1015	1025	O
from	1026	1030	O
the	1031	1034	O
peptide	1035	1042	O
-	1042	1043	O
BSA	1043	1046	O
conjugate	1047	1056	O
readings	1057	1065	O
and	1066	1069	O
the	1070	1073	O
corrected	1074	1083	O
absorbance	1084	1094	O
readings	1095	1103	O
were	1104	1108	O
plotted	1109	1116	O
individually	1117	1129	O
for	1130	1133	O
our	1134	1137	O
new	1138	1141	O
peptides	1142	1150	O
Eb1	1151	1154	O
-	1154	1155	O
4	1155	1156	O
and	1157	1160	O
H1	1161	1163	O
in	1164	1166	O
Fig	1167	1170	O
.	1170	1171	O

5	1172	1173	O
.	1173	1174	O

There	1175	1180	O
was	1181	1184	O
a	1185	1186	O
clear	1187	1192	O
difference	1193	1203	O
in	1204	1206	O
the	1207	1210	O
detection	1211	1220	O
of	1221	1223	O
seropositive	1224	1236	O
antibodies	1237	1247	O
by	1248	1250	O
all	1251	1254	O
the	1255	1258	O
peptides	1259	1267	O
(	1268	1269	O
Fig	1269	1272	O
.	1272	1273	O
5A	1274	1276	O
-	1276	1277	O
E	1277	1278	O
)	1278	1279	O
compared	1280	1288	O
with	1289	1293	O
the	1294	1297	O
analysis	1298	1306	O
of	1307	1309	O
BSA	1310	1313	O
alone	1314	1319	O
(	1320	1321	O
Fig	1321	1324	O
.	1324	1325	O
5F	1326	1328	O
)	1328	1329	O
,	1329	1330	O
with	1331	1335	O
the	1336	1339	O
majority	1340	1348	O
of	1349	1351	O
absorbance	1352	1362	O
readings	1363	1371	O
above	1372	1377	O
the	1378	1381	O
cut	1382	1385	O
-	1385	1386	O
off	1386	1389	O
level	1390	1395	O
.	1395	1396	O

We	1397	1399	O
compared	1400	1408	O
the	1409	1412	O
ability	1413	1420	O
of	1421	1423	O
our	1424	1427	O
panel	1428	1433	O
of	1434	1436	O
peptide	1437	1444	O
mimotopes	1445	1454	O
to	1455	1457	O
be	1458	1460	O
recognised	1461	1471	O
by	1472	1474	O
antibodies	1475	1485	O
in	1486	1488	O
the	1489	1492	O
same	1493	1497	O
set	1498	1501	O
of	1502	1504	O
seropositive	1505	1517	O
samples	1518	1525	O
in	1526	1528	O
Fig	1529	1532	O
.	1532	1533	O

6A	1534	1536	O
and	1537	1540	O
the	1541	1544	O
sensitivity	1545	1556	O
of	1557	1559	O
detection	1560	1569	O
is	1570	1572	O
shown	1573	1578	O
in	1579	1581	O
Fig	1582	1585	O
.	1585	1586	O

6B	1587	1589	O
.	1589	1590	O

We	1591	1593	O
also	1594	1598	O
included	1599	1607	O
F1	1608	1610	O
and	1611	1614	O
Gp125	1615	1620	O
mimotopes	1621	1630	O
specific	1631	1639	O
for	1640	1643	O
two	1644	1647	O
mAbs	1648	1652	O
in	1653	1655	O
our	1656	1659	O
previous	1660	1668	O
study	1669	1674	O
(	1675	1676	O
Casey	1676	1681	O
et	1682	1684	O
al	1685	1687	O
.	1687	1688	O
,	1688	1689	O
2006	1690	1694	O
)	1694	1695	O
.	1695	1696	O

Of	1697	1699	O
the	1700	1703	O
peptides	1704	1712	O
identified	1713	1723	O
from	1724	1728	O
polyclonal	1729	1739	O
sera	1740	1744	B-Organism_substance
Eb1	1745	1748	O
,	1748	1749	O
Gp125	1750	1755	O
and	1756	1759	O
F1	1760	1762	O
had	1763	1766	O
the	1767	1770	O
highest	1771	1778	O
sensitivity	1779	1790	O
(	1791	1792	O
94	1792	1794	O
%	1794	1795	O
)	1795	1796	O
.	1796	1797	O

Slightly	1798	1806	O
lower	1807	1812	O
sensitivity	1813	1824	O
was	1825	1828	O
observed	1829	1837	O
for	1838	1841	O
Eb2	1842	1845	O
,	1845	1846	O
3	1847	1848	O
and	1849	1852	O
4	1853	1854	O
(	1855	1856	O
88	1856	1858	O
%	1858	1859	O
)	1859	1860	O
and	1861	1864	O
H1	1865	1867	O
peptide	1868	1875	O
had	1876	1879	O
the	1880	1883	O
lowest	1884	1890	O
sensitivity	1891	1902	O
(	1903	1904	O
81	1904	1906	O
%	1906	1907	O
)	1907	1908	O
as	1909	1911	O
summarised	1912	1922	O
in	1923	1925	O
Fig	1926	1929	O
.	1929	1930	O

6B	1931	1933	O
.	1933	1934	O

The	1935	1938	O
sensitivity	1939	1950	O
of	1951	1953	O
F1	1954	1956	O
and	1957	1960	O
Gp125	1961	1966	O
was	1967	1970	O
similar	1971	1978	O
to	1979	1981	O
that	1982	1986	O
produced	1987	1995	O
by	1996	1998	O
the	1999	2002	O
mimotopes	2003	2012	O
selected	2013	2021	O
in	2022	2024	O
our	2025	2028	O
previous	2029	2037	O
study	2038	2043	O
,	2043	2044	O
95	2045	2047	O
%	2047	2048	O
for	2049	2052	O
F1	2053	2055	O
and	2056	2059	O
92	2060	2062	O
%	2062	2063	O
for	2064	2067	O
Gp125	2068	2073	O
.	2073	2074	O

Fig	2075	2078	O
.	2078	2079	O

5	2080	2081	O

Evaluation	2082	2092	O
of	2093	2095	O
peptides	2096	2104	O
Eb1	2105	2108	O
-	2108	2109	O
4	2109	2110	O
and	2111	2114	O
H1	2115	2117	O
coupled	2118	2125	O
to	2126	2128	O
BSA	2129	2132	O
as	2133	2135	O
EBV	2136	2139	O
diagnostic	2140	2150	O
reagents	2151	2159	O
.	2159	2160	O

Human	2161	2166	O
serum	2167	2172	B-Organism_substance
(	2173	2174	O
n	2174	2175	O
=	2176	2177	O
40	2178	2180	O
)	2180	2181	O
previously	2182	2192	O
analysed	2193	2201	O
using	2202	2207	O
a	2208	2209	O
diagnostic	2210	2220	O
test	2221	2225	O
for	2226	2229	O
VCA	2230	2233	O
IgM	2234	2237	O
was	2238	2241	O
allowed	2242	2249	O
to	2250	2252	O
react	2253	2258	O
with	2259	2263	O
the	2264	2267	O
peptides	2268	2276	O
and	2277	2280	O
the	2281	2284	O
bound	2285	2290	O
IgM	2291	2294	O
antibodies	2295	2305	O
were	2306	2310	O
detected	2311	2319	O
using	2320	2325	O
anti	2326	2330	O
-	2330	2331	O
human	2331	2336	O
IgM	2337	2340	O
HRP	2341	2344	O
.	2344	2345	O

The	2346	2349	O
absorbance	2350	2360	O
readings	2361	2369	O
for	2370	2373	O
1	2374	2375	O
(	2376	2377	O
positive	2377	2385	O
)	2385	2386	O
,	2386	2387	O
2	2388	2389	O
(	2390	2391	O
negative	2391	2399	O
)	2399	2400	O
and	2401	2404	O
putative	2405	2413	O
cross	2414	2419	O
-	2419	2420	O
reactive	2420	2428	O
sera	2429	2433	B-Organism_substance
for	2434	2437	O
3	2438	2439	O
(	2440	2441	O
Parvo	2441	2446	O
)	2446	2447	O
,	2447	2448	O
4	2449	2450	O
(	2451	2452	O
HSV	2452	2455	O
)	2455	2456	O
,	2456	2457	O
5	2458	2459	O
(	2460	2461	O
CMV	2461	2464	O
)	2464	2465	O
and	2466	2469	O
6	2470	2471	O
(	2472	2473	O
RF	2473	2475	O
)	2475	2476	O
are	2477	2480	O
plotted	2481	2488	O
for	2489	2492	O
(	2493	2494	O
A	2494	2495	O
)	2495	2496	O
Eb1	2497	2500	O
,	2500	2501	O
(	2502	2503	O
B	2503	2504	O
)	2504	2505	O
Eb2	2506	2509	O
,	2509	2510	O
(	2511	2512	O
C	2512	2513	O
)	2513	2514	O
Eb3	2515	2518	O
,	2518	2519	O
(	2520	2521	O
D	2521	2522	O
)	2522	2523	O
Eb4	2524	2527	O
,	2527	2528	O
(	2529	2530	O
E	2530	2531	O
)	2531	2532	O
H1	2533	2535	O
and	2536	2539	O
(	2540	2541	O
F	2541	2542	O
)	2542	2543	O
BSA	2544	2547	O
,	2547	2548	O
respectively	2549	2561	O
.	2561	2562	O

The	2563	2566	O
cut	2567	2570	O
-	2570	2571	O
off	2571	2574	O
value	2575	2580	O
is	2581	2583	O
defined	2584	2591	O
as	2592	2594	O
the	2595	2598	O
mean	2599	2603	O
of	2604	2606	O
the	2607	2610	O
negative	2611	2619	O
population	2620	2630	O
+	2631	2632	O
3SD	2632	2635	O
indicated	2636	2645	O
by	2646	2648	O
a	2649	2650	O
solid	2651	2656	O
horizontal	2657	2667	O
line	2668	2672	O
;	2672	2673	O
since	2674	2679	O
there	2680	2685	O
were	2686	2690	O
no	2691	2693	O
false	2694	2699	O
positives	2700	2709	O
,	2709	2710	O
the	2711	2714	O
specificity	2715	2726	O
for	2727	2730	O
each	2731	2735	O
mimotope	2736	2744	O
was	2745	2748	O
100	2749	2752	O
%	2752	2753	O
.	2753	2754	O

Fig	2755	2758	O
.	2758	2759	O

6	2760	2761	O

Comparison	2762	2772	O
of	2773	2775	O
the	2776	2779	O
reactivities	2780	2792	O
of	2793	2795	O
our	2796	2799	O
panel	2800	2805	O
of	2806	2808	O
mimotopes	2809	2818	O
Eb1	2819	2822	O
-	2822	2823	O
4	2823	2824	O
,	2824	2825	O
H1	2826	2828	O
,	2828	2829	O
F1	2830	2832	O
and	2833	2836	O
Gp125	2837	2842	O
conjugated	2843	2853	O
to	2854	2856	O
BSA	2857	2860	O
with	2861	2865	O
EBV	2866	2869	O
IgM	2870	2873	O
-	2873	2874	O
positive	2874	2882	O
sera	2883	2887	B-Organism_substance
(	2888	2889	O
n	2889	2890	O
=	2891	2892	O
16	2893	2895	O
)	2895	2896	O
absorbance	2897	2907	O
values	2908	2914	O
are	2915	2918	O
plotted	2919	2926	O
and	2927	2930	O
the	2931	2934	O
cut	2935	2938	O
-	2938	2939	O
off	2939	2942	O
levels	2943	2949	O
are	2950	2953	O
depicted	2954	2962	O
by	2963	2965	O
a	2966	2967	O
horizontal	2968	2978	O
line	2979	2983	O
in	2984	2986	O
(	2987	2988	O
A	2988	2989	O
)	2989	2990	O
.	2990	2991	O

(	2992	2993	O
B	2993	2994	O
)	2994	2995	O
Summary	2996	3003	O
of	3004	3006	O
the	3007	3010	O
false	3011	3016	O
-	3016	3017	O
negative	3017	3025	O
results	3026	3033	O
from	3034	3038	O
the	3039	3042	O
5	3043	3044	O
/	3044	3045	O
16	3045	3047	O
serum	3048	3053	B-Organism_substance
samples	3054	3061	I-Organism_substance
seropositive	3062	3074	O
for	3075	3078	O
IgM	3079	3082	O
EBV	3083	3086	O
and	3087	3090	O
the	3091	3094	O
overall	3095	3102	O
sensitivity	3103	3114	O
for	3115	3118	O
each	3119	3123	O
mimotope	3124	3132	O
for	3133	3136	O
diagnosis	3137	3146	O
of	3147	3149	O
EBV	3150	3153	O
IgM	3154	3157	O
antibodies	3158	3168	O
.	3168	3169	O

We	3170	3172	O
also	3173	3177	O
considered	3178	3188	O
which	3189	3194	O
seropositive	3195	3207	O
EBV	3208	3211	O
samples	3212	3219	B-Organism_substance
contained	3220	3229	O
antibodies	3230	3240	O
that	3241	3245	O
did	3246	3249	O
not	3250	3253	O
recognise	3254	3263	O
the	3264	3267	O
panel	3268	3273	O
of	3274	3276	O
peptides	3277	3285	O
,	3285	3286	O
i	3287	3288	O
.	3288	3289	O
e	3289	3290	O
.	3290	3291	O
false	3292	3297	O
-	3297	3298	O
negative	3298	3306	O
readings	3307	3315	O
,	3315	3316	O
listed	3317	3323	O
in	3324	3326	O
Fig	3327	3330	O
.	3330	3331	O

6B	3332	3334	O
.	3334	3335	O

The	3336	3339	O
antibodies	3340	3350	O
in	3351	3353	O
serum	3354	3359	B-Organism_substance
1	3360	3361	O
(	3362	3363	O
s1	3363	3365	O
)	3365	3366	O
were	3367	3371	O
unreactive	3372	3382	O
with	3383	3387	O
all	3388	3391	O
of	3392	3394	O
the	3395	3398	O
peptides	3399	3407	O
identified	3408	3418	O
in	3419	3421	O
this	3422	3426	O
study	3427	3432	O
,	3432	3433	O
s2	3434	3436	O
was	3437	3440	O
not	3441	3444	O
reactive	3445	3453	O
with	3454	3458	O
Eb3	3459	3462	O
,	3462	3463	O
Eb4	3464	3467	O
and	3468	3471	O
H1	3472	3474	O
and	3475	3478	O
s3	3479	3481	O
was	3482	3485	O
unreactive	3486	3496	O
with	3497	3501	O
H1	3502	3504	O
.	3504	3505	O

Gp125	3506	3511	O
and	3512	3515	O
F1	3516	3518	O
that	3519	3523	O
were	3524	3528	O
selected	3529	3537	O
in	3538	3540	O
our	3541	3544	O
previous	3545	3553	O
study	3554	3559	O
were	3560	3564	O
recognised	3565	3575	O
by	3576	3578	O
s1	3579	3581	O
,	3581	3582	O
2	3583	3584	O
and	3585	3588	O
3	3589	3590	O
;	3590	3591	O
however	3592	3599	O
,	3599	3600	O
two	3601	3604	O
different	3605	3614	O
serum	3615	3620	B-Organism_substance
samples	3621	3628	I-Organism_substance
(	3629	3630	O
s4	3630	3632	O
and	3633	3636	O
5	3637	3638	O
)	3638	3639	O
did	3640	3643	O
not	3644	3647	O
recognise	3648	3657	O
F1	3658	3660	O
or	3661	3663	O
Gp125	3664	3669	O
,	3669	3670	O
respectively	3671	3683	O
.	3683	3684	O

This	3685	3689	O
demonstrates	3690	3702	O
that	3703	3707	O
individual	3708	3718	O
peptides	3719	3727	O
are	3728	3731	O
not	3732	3735	O
recognised	3736	3746	O
by	3747	3749	O
all	3750	3753	O
EBV	3754	3757	O
antibodies	3758	3768	O
and	3769	3772	O
confirms	3773	3781	O
that	3782	3786	O
different	3787	3796	O
peptides	3797	3805	O
are	3806	3809	O
required	3810	3818	O
to	3819	3821	O
represent	3822	3831	O
different	3832	3841	O
epitopes	3842	3850	O
.	3850	3851	O

Therefore	3852	3861	O
,	3861	3862	O
a	3863	3864	O
combination	3865	3876	O
of	3877	3879	O
Eb1	3880	3883	O
peptide	3884	3891	O
F1	3892	3894	O
and	3895	3898	O
Gp125	3899	3904	O
peptides	3905	3913	O
could	3914	3919	O
be	3920	3922	O
recognised	3923	3933	O
by	3934	3936	O
antibodies	3937	3947	O
present	3948	3955	O
in	3956	3958	O
all	3959	3962	O
this	3963	3967	O
set	3968	3971	O
of	3972	3974	O
EBV	3975	3978	O
clinical	3979	3987	O
samples	3988	3995	O
resulting	3996	4005	O
in	4006	4008	O
100	4009	4012	O
%	4012	4013	O
sensitivity	4014	4025	O
.	4025	4026	O

For	4027	4030	O
the	4031	4034	O
samples	4035	4042	O
defined	4043	4050	O
as	4051	4053	O
EBV	4054	4057	O
-	4057	4058	O
seronegative	4058	4070	O
,	4070	4071	O
there	4072	4077	O
were	4078	4082	O
no	4083	4085	O
readings	4086	4094	O
above	4095	4100	O
the	4101	4104	O
cut	4105	4108	O
-	4108	4109	O
off	4109	4112	O
level	4113	4118	O
and	4119	4122	O
therefore	4123	4132	O
no	4133	4135	O
false	4136	4141	O
positives	4142	4151	O
,	4151	4152	O
resulting	4153	4162	O
in	4163	4165	O
100	4166	4169	O
%	4169	4170	O
specificity	4171	4182	O
.	4182	4183	O

In	4184	4186	O
addition	4187	4195	O
,	4195	4196	O
there	4197	4202	O
were	4203	4207	O
no	4208	4210	O
absorbance	4211	4221	O
readings	4222	4230	O
above	4231	4236	O
the	4237	4240	O
cut	4241	4244	O
-	4244	4245	O
off	4245	4248	O
levels	4249	4255	O
for	4256	4259	O
the	4260	4263	O
potentially	4264	4275	O
cross	4276	4281	O
-	4281	4282	O
reactive	4282	4290	O
serum	4291	4296	B-Organism_substance
samples	4297	4304	I-Organism_substance
,	4304	4305	O
inferring	4306	4315	O
that	4316	4320	O
the	4321	4324	O
peptides	4325	4333	O
identified	4334	4344	O
in	4345	4347	O
this	4348	4352	O
study	4353	4358	O
have	4359	4363	O
high	4364	4368	O
specificity	4369	4380	O
for	4381	4384	O
EBV	4385	4388	O
antibodies	4389	4399	O
.	4399	4400	O

Additional	0	10	O
File	11	15	O
2	16	17	O

Full	18	22	O
Model	23	28	O
Code	29	33	O
.	33	34	O

Full	35	39	O
model	40	45	O
code	46	50	O
plus	51	55	O
instructions	56	68	O
for	69	72	O
running	73	80	O
in	81	83	O
Berkeley	84	92	O
Madonna	93	100	O
(	100	101	O
TM	101	103	O
)	103	104	O
.	104	105	O

Secchi	0	6	O
depth	7	12	O
in	13	15	O
the	16	19	O
Baltic	20	26	O
Proper	27	33	O
,	33	34	O
June	35	39	O
-	39	40	O
August	40	46	O
,	46	47	O
1957	48	52	O
-	52	53	O
1998	53	57	O
.	57	58	O

Number	59	65	O
of	66	68	O
data	69	73	O
:	73	74	O
3	75	76	O
,	76	77	O
452	77	80	O
.	80	81	O

Nucleotide	0	10	O
features	11	19	O
of	20	22	O
free	23	27	O
-	27	28	O
standing	28	36	O
homing	37	43	O
-	43	44	O
endonucleases	44	57	O

Gene	58	62	O
control	63	70	O
elements	71	79	O
were	80	84	O
identified	85	95	O
for	96	99	O
several	100	107	O
members	108	115	O
of	116	118	O
each	119	123	O
type	124	128	O
of	129	131	O
intervening	132	143	O
homing	144	150	O
endonuclease	151	163	O
genes	164	169	O
described	170	179	O
in	180	182	O
this	183	187	O
study	188	193	O
.	193	194	O

In	195	197	O
15	198	200	O
out	201	204	O
of	205	207	O
16	208	210	O
,	210	211	O
5	212	213	O
'	213	214	O
untranslated	215	227	O
regions	228	235	O
of	236	238	O
the	239	242	O
endonucleases	243	256	O
we	257	259	O
identified	260	270	O
RNA	271	274	O
hairpin	275	282	O
structures	283	293	O
upstream	294	302	O
of	303	305	O
initiation	306	316	O
codons	317	323	O
(	324	325	O
Figures	325	332	O
1	333	334	O
and	335	338	O
4A	339	341	O
)	341	342	O
.	342	343	O

This	344	348	O
may	349	352	O
be	353	355	O
a	356	357	O
translational	358	371	O
regulatory	372	382	O
hairpin	383	390	O
structure	391	400	O
known	401	406	O
from	407	411	O
various	412	419	O
phage	420	425	O
genes	426	431	O
,	431	432	O
including	433	442	O
homing	443	449	O
endonucleases	450	463	O
(	464	465	O
22	465	467	O
,	467	468	O
47	468	470	O
-	470	471	O
49	471	473	O
)	473	474	O
.	474	475	O

The	476	479	O
hairpins	480	488	O
we	489	491	O
found	492	497	O
are	498	501	O
in	502	504	O
fractured	505	514	O
gene	515	519	O
loci	520	524	O
with	525	529	O
different	530	539	O
protein	540	547	O
host	548	552	O
types	553	558	O
,	558	559	O
including	560	569	O
gp41	570	574	O
,	574	575	O
IMPDH	576	581	O
,	581	582	O
DnaE	583	587	O
,	587	588	O
NrdJ	589	593	O
and	594	597	O
NrdA	598	602	O
.	602	603	O

Ten	604	607	O
of	608	610	O
these	611	616	O
hairpins	617	625	O
also	626	630	O
include	631	638	O
a	639	640	O
conserved	641	650	O
sequence	651	659	O
of	660	662	O
Aeh1	663	667	O
phage	668	673	O
late	674	678	O
promoter	679	687	O
element	688	695	O
(	696	697	O
TATAAATA	697	705	O
)	705	706	O
,	706	707	O
which	708	713	O
was	714	717	O
recently	718	726	O
shown	727	732	O
to	733	735	O
inhibit	736	743	O
the	744	747	O
translation	748	759	O
of	760	762	O
a	763	764	O
gene	765	769	O
-	769	770	O
fracturing	770	780	O
endonuclease	781	793	O
gene	794	798	O
,	798	799	O
by	800	802	O
sequestering	803	815	O
its	816	819	O
ribosome	820	828	B-Cellular_component
binding	829	836	O
site	837	841	O
(	842	843	O
22	843	845	O
,	845	846	O
23	846	848	O
)	848	849	O
.	849	850	O

Analysis	851	859	O
of	860	862	O
the	863	866	O
endonuclease	867	879	O
5	880	881	O
'	881	882	O
untranslated	883	895	O
regions	896	903	O
revealed	904	912	O
two	913	916	O
conserved	917	926	O
motifs	927	933	O
(	934	935	O
Figures	935	942	O
4A	943	945	O
and	946	949	O
Supplementary	950	963	O
Figure	964	970	O
S4	971	973	O
)	973	974	O
,	974	975	O
which	976	981	O
usually	982	989	O
complement	990	1000	O
each	1001	1005	O
other	1006	1011	O
on	1012	1014	O
the	1015	1018	O
stem	1019	1023	O
of	1024	1026	O
the	1027	1030	O
conserved	1031	1040	O
hairpin	1041	1048	O
structures	1049	1059	O
.	1059	1060	O

Figure	1062	1068	O
4	1069	1070	O
.	1070	1071	O

Nucleotide	1072	1082	O
features	1083	1091	O
of	1092	1094	O
endonuclease	1095	1107	O
genes	1108	1113	O
.	1113	1114	O

(	1115	1116	O
A	1116	1117	O
)	1117	1118	O
RNA	1119	1122	O
hairpin	1123	1130	O
structures	1131	1141	O
at	1142	1144	O
the	1145	1148	O
5	1149	1150	O
'	1150	1151	O
untranslated	1152	1164	O
region	1165	1171	O
of	1172	1174	O
endonuclease	1175	1187	O
ORFs	1188	1192	O
in	1193	1195	O
the	1196	1199	O
gp41	1200	1204	O
-	1204	1205	O
1	1205	1206	O
(	1207	1208	O
representing	1208	1220	O
the	1221	1224	O
very	1225	1229	O
similar	1230	1237	O
sequences	1238	1247	O
of	1248	1250	O
gp41	1251	1255	O
-	1255	1256	O
1	1256	1257	O
-	1257	1258	O
7	1258	1259	O
)	1259	1260	O
,	1260	1261	O
nrdA	1262	1266	O
-	1266	1267	O
5	1267	1268	O
and	1269	1272	O
DnaE	1273	1277	O
-	1277	1278	O
1	1278	1279	O
gene	1280	1284	O
loci	1285	1289	O
.	1289	1290	O

Initiator	1291	1300	O
codons	1301	1307	O
are	1308	1311	O
marked	1312	1318	O
by	1319	1321	O
arrows	1322	1328	O
,	1328	1329	O
conserved	1330	1339	O
putative	1340	1348	O
T4	1349	1351	O
late	1352	1356	O
promoter	1357	1365	O
elements	1366	1374	O
are	1375	1378	O
boxed	1379	1384	O
,	1384	1385	O
and	1386	1389	O
conserved	1390	1399	O
sequence	1400	1408	O
motifs	1409	1415	O
(	1416	1417	O
Supplementary	1417	1430	O
Figure	1431	1437	O
S4	1438	1440	O
)	1440	1441	O
are	1442	1445	O
highlighted	1446	1457	O
in	1458	1460	O
grey	1461	1465	O
.	1465	1466	O

The	1467	1470	O
expected	1471	1479	O
values	1480	1486	O
for	1487	1490	O
motifs	1491	1497	O
1	1498	1499	O
and	1500	1503	O
2	1504	1505	O
are	1506	1509	O
1	1510	1511	O
.	1511	1512	O
7	1512	1513	O
-	1513	1514	O
10	1514	1516	O
and	1517	1520	O
9	1521	1522	O
.	1522	1523	O
9	1523	1524	O
-	1524	1525	O
3	1525	1526	O
,	1526	1527	O
respectively	1528	1540	O
.	1540	1541	O

RNA	1542	1545	O
structures	1546	1556	O
were	1557	1561	O
calculated	1562	1572	O
using	1573	1578	O
the	1579	1582	O
Vienna	1583	1589	O
package	1590	1597	O
(	1598	1599	O
http	1599	1603	O
:	1603	1604	O
/	1604	1605	O
/	1605	1606	O
rna	1606	1609	O
.	1609	1610	O
tbi	1610	1613	O
.	1613	1614	O
univie	1614	1620	O
.	1620	1621	O
ac	1621	1623	O
.	1623	1624	O
at	1624	1626	O
/	1626	1627	O
cgi	1627	1630	O
-	1630	1631	O
bin	1631	1634	O
/	1634	1635	O
RNAfold	1635	1642	O
.	1642	1643	O
cgi	1643	1646	O
)	1646	1647	O
,	1647	1648	O
and	1649	1652	O
sequence	1653	1661	O
motifs	1662	1668	O
were	1669	1673	O
identified	1674	1684	O
using	1685	1690	O
the	1691	1694	O
MEME	1695	1699	O
program	1700	1707	O
.	1707	1708	O

(	1709	1710	O
B	1710	1711	O
)	1711	1712	O
Overlapping	1713	1724	O
#	1724	1725	O
protein	1725	1732	O
coding	1733	1739	O
regions	1740	1747	O
of	1748	1750	O
endonuclease	1751	1763	O
3	1764	1765	O
'	1765	1766	O
termini	1767	1774	O
and	1775	1778	O
the	1779	1782	O
5	1783	1784	O
'	1784	1785	O
termini	1786	1793	O
of	1794	1796	O
their	1797	1802	O
downstream	1803	1813	O
genes	1814	1819	O
.	1819	1820	O

Additionally	1821	1833	O
,	1833	1834	O
15	1835	1837	O
loci	1838	1842	O
included	1843	1851	O
an	1852	1854	O
overlapping	1855	1866	O
region	1867	1873	O
of	1874	1876	O
6	1877	1878	O
-	1878	1879	O
69	1879	1881	O
bp	1882	1884	O
between	1885	1892	O
the	1893	1896	O
coding	1897	1903	O
regions	1904	1911	O
of	1912	1914	O
the	1915	1918	O
probable	1919	1927	O
endonuclease	1928	1940	O
C	1941	1942	O
-	1942	1943	O
termini	1943	1950	O
and	1951	1954	O
the	1955	1958	O
downstream	1959	1969	O
N	1970	1971	O
-	1971	1972	O
termini	1972	1979	O
of	1980	1982	O
the	1983	1986	O
split	1987	1992	O
-	1992	1993	O
intein	1993	1999	O
part	2000	2004	O
(	2005	2006	O
Figures	2006	2013	O
1	2014	2015	O
and	2016	2019	O
4B	2020	2022	O
)	2022	2023	O
.	2023	2024	O

This	2025	2029	O
overlap	2030	2037	O
is	2038	2040	O
present	2041	2048	O
in	2049	2051	O
both	2052	2056	O
types	2057	2062	O
of	2063	2065	O
endonucleases	2066	2079	O
,	2079	2080	O
and	2081	2084	O
is	2085	2087	O
independent	2088	2099	O
on	2100	2102	O
the	2103	2106	O
presence	2107	2115	O
of	2116	2118	O
a	2119	2120	O
split	2121	2126	O
-	2126	2127	O
intein	2127	2133	O
part	2134	2138	O
in	2139	2141	O
the	2142	2145	O
fractured	2146	2155	O
gene	2156	2160	O
,	2160	2161	O
also	2162	2166	O
occurring	2167	2176	O
in	2177	2179	O
the	2180	2183	O
putative	2184	2192	O
sbcD	2193	2197	O
DNA	2198	2201	O
-	2201	2202	O
repair	2202	2208	O
gene	2209	2213	O
that	2214	2218	O
we	2219	2221	O
found	2222	2227	O
,	2227	2228	O
as	2229	2231	O
well	2232	2236	O
as	2237	2239	O
in	2240	2242	O
the	2243	2246	O
Aeh1	2247	2251	O
fractured	2252	2261	O
nrdA	2262	2266	O
found	2267	2272	O
by	2273	2275	O
Gibb	2276	2280	O
and	2281	2284	O
Edgell	2285	2291	O
(	2292	2293	O
22	2293	2295	O
)	2295	2296	O
.	2296	2297	O

Efficacy	0	8	O
of	9	11	O
MMF	12	15	O
in	16	18	O
current	19	26	O
immunosuppressive	27	44	O
regimens	45	53	O
after	54	59	O
kidney	60	66	B-Organ
transplantation	67	82	O

Current	83	90	O
established	91	102	O
immunosuppressive	103	120	O
strategies	121	131	O
in	132	134	O
kidney	135	141	B-Organ
transplantation	142	157	O
often	158	163	O
include	164	171	O
an	172	174	O
induction	175	184	O
agent	185	190	O
(	191	192	O
monoclonal	192	202	O
or	203	205	O
polyclonal	206	216	O
anti	217	221	O
-	221	222	O
T	222	223	B-Cell
-	223	224	I-Cell
cell	224	228	I-Cell
antibodies	229	239	O
)	239	240	O
based	241	246	O
on	247	249	O
the	250	253	O
immunologic	254	265	O
risk	266	270	O
of	271	273	O
the	274	277	O
recipient	278	287	O
,	287	288	O
followed	289	297	O
by	298	300	O
a	301	302	O
maintenance	303	314	O
regimen	315	322	O
combining	323	332	O
a	333	334	O
CNI	335	338	O
and	339	342	O
an	343	345	O
anti	346	350	O
-	350	351	O
proliferative	351	364	O
agent	365	370	O
,	370	371	O
with	372	376	O
or	377	379	O
without	380	387	O
corticosteroids	388	403	O
.	403	404	O
2	404	405	O
-	405	406	O
4	406	407	O
As	408	410	O
MMF	411	414	O
was	415	418	O
the	419	422	O
first	423	428	O
MPA	429	432	O
formulation	433	444	O
approved	445	453	O
in	454	456	O
clinical	457	465	O
kidney	466	472	B-Organ
transplantation	473	488	O
,	488	489	O
more	490	494	O
extensive	495	504	O
clinical	505	513	O
data	514	518	O
are	519	522	O
available	523	532	O
with	533	537	O
this	538	542	O
drug	543	547	O
in	548	550	O
comparison	551	561	O
to	562	564	O
EC	565	567	O
-	567	568	O
MPS	568	571	O
.	571	572	O

Sex	0	3	O
and	4	7	O
age	8	11	O
distributions	12	25	O
of	26	28	O
confirmed	29	38	O
cases	39	44	O

Of	45	47	O
480	48	51	O
confirmed	52	61	O
cases	62	67	O
,	67	68	O
56	69	71	O
%	71	72	O
(	73	74	O
269	74	77	O
/	77	78	O
480	78	81	O
)	81	82	O
were	83	87	O
male	88	92	O
patients	93	101	O
and	102	105	O
44	106	108	O
%	108	109	O
(	110	111	O
211	111	114	O
/	114	115	O
480	115	118	O
)	118	119	O
were	120	124	O
female	125	131	O
,	131	132	O
respectively	133	145	O
.	145	146	O

The	147	150	O
percentage	151	161	O
of	162	164	O
male	165	169	O
cases	170	175	O
was	176	179	O
higher	180	186	O
than	187	191	O
that	192	196	O
of	197	199	O
females	200	207	O
in	208	210	O
all	211	214	O
groups	215	221	O
except	222	228	O
for	229	232	O
the	233	236	O
group	237	242	O
aged	243	247	O
31	248	250	O
-	250	251	O
40	251	253	O
(	254	255	O
chi2	255	259	O
=	260	261	O
42	262	264	O
.	264	265	O
4	265	266	O
,	266	267	O
P	268	269	O
<	270	271	O
0	272	273	O
.	273	274	O
001	274	277	O
)	277	278	O
.	278	279	O

278	280	283	O
(	284	285	O
57	285	287	O
.	287	288	O
9	288	289	O
%	289	290	O
)	290	291	O
cases	292	297	O
were	298	302	O
in	303	305	O
the	306	309	O
group	310	315	O
aged	316	320	O
21	321	323	O
-	323	324	O
50	324	326	O
,	326	327	O
followed	328	336	O
by	337	339	O
102	340	343	O
(	344	345	O
21	345	347	O
.	347	348	O
3	348	349	O
%	349	350	O
)	350	351	O
,	351	352	O
79	353	355	O
(	356	357	O
16	357	359	O
.	359	360	O
5	360	361	O
%	361	362	O
)	362	363	O
and	364	367	O
21	368	370	O
(	371	372	O
4	372	373	O
.	373	374	O
4	374	375	O
%	375	376	O
)	376	377	O
cases	378	383	O
in	384	386	O
the	387	390	O
group	391	396	O
aged	397	401	O
51	402	404	O
-	404	405	O
70	405	407	O
,	407	408	O
0	409	410	O
-	410	411	O
20	411	413	O
,	413	414	O
and	415	418	O
>	419	420	O
=	420	421	O
71	422	424	O
,	424	425	O
respectively	426	438	O
.	438	439	O

The	440	443	O
youngest	444	452	O
and	453	456	O
oldest	457	463	O
cases	464	469	O
were	470	474	O
1	475	476	O
.	476	477	O
5	477	478	O
and	479	482	O
81	483	485	O
years	486	491	O
old	492	495	O
,	495	496	O
respectively	497	509	O
(	510	511	O
Table	511	516	O
2	517	518	O
)	518	519	O
.	519	520	O

Table	521	526	O
2	527	528	O

Age	529	532	O
and	533	536	O
occupational	537	549	O
distributions	550	563	O
and	564	567	O
activities	568	578	O
(	579	580	O
1	580	581	O
-	581	582	O
3	582	583	O
weeks	584	589	O
prior	590	595	O
to	596	598	O
symptom	599	606	O
appearance	607	617	O
)	617	618	O
of	619	621	O
confirmed	622	631	O
cases	632	637	O

Cases	638	643	O
(	644	645	O
%	645	646	O
)	646	647	O
(	648	649	O
Male	649	653	O
:	653	654	O
Female	655	661	O
,	661	662	O
%	663	664	O
)	664	665	O

Age	666	669	O
(	670	671	O
Years	671	676	O
)	676	677	O

0	678	679	O
-	679	680	O
10	680	682	O
46	683	685	O
(	686	687	O
9	687	688	O
.	688	689	O
6	689	690	O
)	690	691	O
(	692	693	O
76	693	695	O
:	695	696	O
24	696	698	O
)	698	699	O

11	700	702	O
-	702	703	O
20	703	705	O
33	706	708	O
(	709	710	O
6	710	711	O
.	711	712	O
9	712	713	O
)	713	714	O
(	715	716	O
79	716	718	O
:	718	719	O
21	719	721	O
)	721	722	O

21	723	725	O
-	725	726	O
30	726	728	O
78	729	731	O
(	732	733	O
16	733	735	O
.	735	736	O
3	736	737	O
)	737	738	O
(	739	740	O
51	740	742	O
:	742	743	O
49	743	745	O
)	745	746	O

31	747	749	O
-	749	750	O
40	750	752	O
99	753	755	O
(	756	757	O
20	757	759	O
.	759	760	O
6	760	761	O
)	761	762	O
(	763	764	O
46	764	766	O
:	766	767	O
54	767	769	O
)	769	770	O

41	771	773	O
-	773	774	O
50	774	776	O
101	777	780	O
(	781	782	O
21	782	784	O
.	784	785	O
0	785	786	O
)	786	787	O
(	788	789	O
56	789	791	O
:	791	792	O
44	792	794	O
)	794	795	O

51	796	798	O
-	798	799	O
60	799	801	O
47	802	804	O
(	805	806	O
9	806	807	O
.	807	808	O
8	808	809	O
)	809	810	O
(	811	812	O
55	812	814	O
:	814	815	O
45	815	817	O
)	817	818	O

61	819	821	O
-	821	822	O
70	822	824	O
55	825	827	O
(	828	829	O
11	829	831	O
.	831	832	O
5	832	833	O
)	833	834	O
(	835	836	O
53	836	838	O
:	838	839	O
47	839	841	O
)	841	842	O

>	843	844	O
=	844	845	O
71	846	848	O
21	849	851	O
(	852	853	O
4	853	854	O
.	854	855	O
4	855	856	O
)	856	857	O
(	858	859	O
52	859	861	O
:	861	862	O
48	862	864	O
)	864	865	O

Occupation	866	876	O

Children	877	885	O
at	886	888	O
preschool	889	898	O
age	899	902	O
20	903	905	O
(	906	907	O
4	907	908	O
.	908	909	O
2	909	910	O
)	910	911	O
(	912	913	O
75	913	915	O
:	915	916	O
25	916	918	O
)	918	919	O

Pupils	920	926	O
50	927	929	O
(	930	931	O
10	931	933	O
.	933	934	O
4	934	935	O
)	935	936	O
(	937	938	O
78	938	940	O
:	940	941	O
22	941	943	O
)	943	944	O

Farmers	945	952	O
408	953	956	O
(	957	958	O
85	958	960	O
.	960	961	O
0	961	962	O
)	962	963	O
(	964	965	O
52	965	967	O
:	967	968	O
48	968	970	O
)	970	971	O

Others	972	978	O
2	979	980	O
(	981	982	O
0	982	983	O
.	983	984	O
4	984	985	O
)	985	986	O
(	987	988	O
50	988	990	O
:	990	991	O
50	991	993	O
)	993	994	O

Activities	995	1005	O

Farm	1006	1010	O
work	1011	1015	O
325	1016	1019	O
(	1020	1021	O
67	1021	1023	O
.	1023	1024	O
7	1024	1025	O
)	1025	1026	O
(	1027	1028	O
53	1028	1030	O
:	1030	1031	O
47	1031	1033	O
)	1033	1034	O

Play	1035	1039	O
on	1040	1042	O
grassland	1043	1052	O
65	1053	1055	O
(	1056	1057	O
13	1057	1059	O
.	1059	1060	O
5	1060	1061	O
)	1061	1062	O
(	1063	1064	O
75	1064	1066	O
:	1066	1067	O
25	1067	1069	O
)	1069	1070	O

Recreation	1071	1081	O
20	1082	1084	O
(	1085	1086	O
4	1086	1087	O
.	1087	1088	O
2	1088	1089	O
)	1089	1090	O
(	1091	1092	O
65	1092	1094	O
:	1094	1095	O
35	1095	1097	O
)	1097	1098	O

Housework	1099	1108	O
25	1109	1111	O
(	1112	1113	O
5	1113	1114	O
.	1114	1115	O
2	1115	1116	O
)	1116	1117	O
(	1118	1119	O
8	1119	1120	O
:	1120	1121	O
92	1121	1123	O
)	1123	1124	O

Unknown	1125	1132	O
45	1133	1135	O
(	1136	1137	O
9	1137	1138	O
.	1138	1139	O
4	1139	1140	O
)	1140	1141	O
(	1142	1143	O
71	1143	1145	O
:	1145	1146	O
29	1146	1148	O
)	1148	1149	O

Discussion	0	10	O

Because	11	18	O
Netherton	19	28	O
syndrome	29	37	O
exhibits	38	46	O
allergic	47	55	O
phenotype	56	65	O
,	65	66	O
it	67	69	O
is	70	72	O
reasonable	73	83	O
to	84	86	O
speculate	87	96	O
that	97	101	O
SPINK5	102	108	O
,	108	109	O
which	110	115	O
is	116	118	O
mutated	119	126	O
in	127	129	O
Netherton	130	139	O
syndrome	140	148	O
,	148	149	O
may	150	153	O
act	154	157	O
as	158	160	O
a	161	162	O
candidate	163	172	O
gene	173	177	O
for	178	181	O
asthma	182	188	O
and	189	192	O
other	193	198	O
allergic	199	207	O
diseases	208	216	O
[	217	218	O
9	218	219	O
]	219	220	O
.	220	221	O

An	222	224	O
extensive	225	234	O
search	235	241	O
for	242	245	O
single	246	252	O
nucleotide	253	263	O
polymorphisms	264	277	O
in	278	280	O
the	281	284	O
SPINK5	285	291	O
led	292	295	O
to	296	298	O
the	299	302	O
identification	303	317	O
of	318	320	O
a	321	322	O
number	323	329	O
of	330	332	O
SNPs	333	337	O
,	337	338	O
including	339	348	O
six	349	352	O
nonsynonymous	353	366	O
SNPs	367	371	O
in	372	374	O
coding	375	381	O
region	382	388	O
that	389	393	O
might	394	399	O
perturb	400	407	O
its	408	411	O
immune	412	418	O
function	419	427	O
.	427	428	O

Subsequent	429	439	O
genotyping	440	450	O
of	451	453	O
three	454	459	O
nonsynonymous	460	473	O
SNPs	474	478	O
,	478	479	O
A1103G	480	486	O
,	486	487	O
G1156A	488	494	O
and	495	498	O
G1258A	499	505	O
in	506	508	O
two	509	512	O
independent	513	524	O
panels	525	531	O
of	532	534	O
British	535	542	O
families	543	551	O
showed	552	558	O
a	559	560	O
significant	561	572	O
association	573	584	O
between	585	592	O
SNP	593	596	O
G1258A	597	603	O
(	604	605	O
Glu420Lys	605	614	O
)	614	615	O
and	616	619	O
atopy	620	625	O
,	625	626	O
atopic	627	633	O
dermatitis	634	644	O
,	644	645	O
elevated	646	654	O
serum	655	660	B-Organism_substance
IgE	661	664	O
levels	665	671	O
and	672	675	O
asthma	676	682	O
[	683	684	O
10	684	686	O
]	686	687	O
.	687	688	O

This	689	693	O
association	694	705	O
was	706	709	O
confirmed	710	719	O
in	720	722	O
a	723	724	O
large	725	730	O
German	731	737	O
population	738	748	O
and	749	752	O
two	753	756	O
Japanese	757	765	O
populations	766	777	O
[	778	779	O
16	779	781	O
-	781	782	O
18	782	784	O
]	784	785	O
.	785	786	O

Kato	787	791	O
et	792	794	O
al	795	797	O
analyzed	798	806	O
eight	807	812	O
SNPs	813	817	O
in	818	820	O
exon	821	825	O
13	826	828	O
and	829	832	O
14	833	835	O
of	836	838	O
the	839	842	O
SPINK5	843	849	O
including	850	859	O
G1258A	860	866	O
(	867	868	O
Glu420Lys	868	877	O
)	877	878	O
,	878	879	O
and	880	883	O
found	884	889	O
a	890	891	O
positive	892	900	O
association	901	912	O
of	913	915	O
seven	916	921	O
SNPs	922	926	O
with	927	931	O
atopic	932	938	O
dermatitis	939	949	O
in	950	952	O
a	953	954	O
Japanese	955	963	O
study	964	969	O
sample	970	976	O
using	977	982	O
a	983	984	O
case	985	989	O
-	989	990	O
control	990	997	O
study	998	1003	O
design	1004	1010	O
[	1011	1012	O
16	1012	1014	O
]	1014	1015	O
.	1015	1016	O

Nishio	1017	1023	O
et	1024	1026	O
al	1027	1029	O
surveyed	1030	1038	O
five	1039	1043	O
of	1044	1046	O
six	1047	1050	O
previously	1051	1061	O
reported	1062	1070	O
nonsynonymous	1071	1084	O
SPINK5	1085	1091	O
SNPs	1092	1096	O
in	1097	1099	O
Japanese	1100	1108	O
atopic	1109	1115	O
families	1116	1124	O
identified	1125	1135	O
through	1136	1143	O
asthmatic	1144	1153	O
children	1154	1162	O
or	1163	1165	O
subjects	1166	1174	O
with	1175	1179	O
atopic	1180	1186	O
dermatitis	1187	1197	O
and	1198	1201	O
found	1202	1207	O
that	1208	1212	O
SPINK5	1213	1219	O
was	1220	1223	O
associated	1224	1234	O
with	1235	1239	O
development	1240	1251	O
of	1252	1254	O
atopic	1255	1261	O
dermatitis	1262	1272	O
but	1273	1276	O
not	1277	1280	O
asthma	1281	1287	O
[	1288	1289	O
17	1289	1291	O
]	1291	1292	O
.	1292	1293	O

Kabesch	1294	1301	O
M	1302	1303	O
et	1304	1306	O
al	1307	1309	O
.	1309	1310	O
analyzed	1311	1319	O
G1258A	1320	1326	O
(	1327	1328	O
Glu420Lys	1328	1337	O
)	1337	1338	O
in	1339	1341	O
a	1342	1343	O
German	1344	1350	O
population	1351	1361	O
of	1362	1364	O
school	1365	1371	O
children	1372	1380	O
,	1380	1381	O
and	1382	1385	O
found	1386	1391	O
its	1392	1395	O
association	1396	1407	O
with	1408	1412	O
asthma	1413	1419	O
as	1420	1422	O
well	1423	1427	O
as	1428	1430	O
a	1431	1432	O
concomitant	1433	1444	O
occurrence	1445	1455	O
of	1456	1458	O
asthma	1459	1465	O
and	1466	1469	O
atopic	1470	1476	O
dermatitis	1477	1487	O
[	1488	1489	O
18	1489	1491	O
]	1491	1492	O
.	1492	1493	O

However	1494	1501	O
,	1501	1502	O
two	1503	1506	O
subsequent	1507	1517	O
studies	1518	1525	O
failed	1526	1532	O
to	1533	1535	O
replicate	1536	1545	O
the	1546	1549	O
original	1550	1558	O
SPINK5	1559	1565	O
findings	1566	1574	O
for	1575	1578	O
allergic	1579	1587	O
diseases	1588	1596	O
[	1597	1598	O
19	1598	1600	O
,	1600	1601	O
20	1601	1603	O
]	1603	1604	O
.	1604	1605	O

Folster	1606	1613	O
-	1613	1614	O
Holst	1614	1619	O
et	1620	1622	O
al	1623	1625	O
genotyped	1626	1635	O
four	1636	1640	O
nonsynonymous	1641	1654	O
SNPs	1655	1659	O
(	1660	1661	O
Asp106Asn	1661	1670	O
,	1670	1671	O
Asn368Ser	1672	1681	O
,	1681	1682	O
Asp386Asn	1683	1692	O
,	1692	1693	O
and	1694	1697	O
Glu420Lys	1698	1707	O
)	1707	1708	O
,	1708	1709	O
and	1710	1713	O
detected	1714	1722	O
no	1723	1725	O
association	1726	1737	O
between	1738	1745	O
SPINK5	1746	1752	O
and	1753	1756	O
atopic	1757	1763	O
dermatitis	1764	1774	O
in	1775	1777	O
populations	1778	1789	O
of	1790	1792	O
Northern	1793	1801	O
German	1802	1808	O
origin	1809	1815	O
[	1816	1817	O
20	1817	1819	O
]	1819	1820	O
.	1820	1821	O

Jongepier	1822	1831	O
H	1832	1833	O
et	1834	1836	O
al	1837	1839	O
.	1839	1840	O
failed	1841	1847	O
to	1848	1850	O
detect	1851	1857	O
any	1858	1861	O
association	1862	1873	O
between	1874	1881	O
SPINK5	1882	1888	O
and	1889	1892	O
asthma	1893	1899	O
,	1899	1900	O
atopic	1901	1907	O
phenotypes	1908	1918	O
and	1919	1922	O
atopic	1923	1929	O
dermatitis	1930	1940	O
in	1941	1943	O
a	1944	1945	O
Dutch	1946	1951	O
population	1952	1962	O
[	1963	1964	O
19	1964	1966	O
]	1966	1967	O
.	1967	1968	O

These	1969	1974	O
discordant	1975	1985	O
findings	1986	1994	O
probably	1995	2003	O
reflect	2004	2011	O
different	2012	2021	O
genetic	2022	2029	O
and	2030	2033	O
environmental	2034	2047	O
backgrounds	2048	2059	O
in	2060	2062	O
various	2063	2070	O
populations	2071	2082	O
.	2082	2083	O

To	2084	2086	O
determine	2087	2096	O
whether	2097	2104	O
nonsynonymous	2105	2118	O
SNPs	2119	2123	O
of	2124	2126	O
the	2127	2130	O
SPINK5	2131	2137	O
are	2138	2141	O
involved	2142	2150	O
in	2151	2153	O
the	2154	2157	O
pathogenesis	2158	2170	O
of	2171	2173	O
asthma	2174	2180	O
in	2181	2183	O
the	2184	2187	O
Chinese	2188	2195	O
Han	2196	2199	O
population	2200	2210	O
,	2210	2211	O
we	2212	2214	O
performed	2215	2224	O
a	2225	2226	O
case	2227	2231	O
-	2231	2232	O
control	2232	2239	O
study	2240	2245	O
by	2246	2248	O
genotyping	2249	2259	O
four	2260	2264	O
nonsynonymous	2265	2278	O
SNPs	2279	2283	O
in	2284	2286	O
the	2287	2290	O
SPINK5	2291	2297	O
.	2297	2298	O

We	2299	2301	O
did	2302	2305	O
not	2306	2309	O
detect	2310	2316	O
any	2317	2320	O
significant	2321	2332	O
association	2333	2344	O
between	2345	2352	O
these	2353	2358	O
nonsynonymous	2359	2372	O
SNPs	2373	2377	O
and	2378	2381	O
asthma	2382	2388	O
in	2389	2391	O
our	2392	2395	O
Chinese	2396	2403	O
samples	2404	2411	O
.	2411	2412	O

With	2413	2417	O
our	2418	2421	O
sample	2422	2428	O
size	2429	2433	O
,	2433	2434	O
we	2435	2437	O
expected	2438	2446	O
a	2447	2448	O
power	2449	2454	O
of	2455	2457	O
at	2458	2460	O
least	2461	2466	O
80	2467	2469	O
%	2469	2470	O
in	2471	2473	O
detecting	2474	2483	O
an	2484	2486	O
effect	2487	2493	O
of	2494	2496	O
OR	2497	2499	O
>	2500	2501	O
=	2501	2502	O
1	2502	2503	O
.	2503	2504	O
3	2504	2505	O
for	2506	2509	O
each	2510	2514	O
of	2515	2517	O
these	2518	2523	O
SNPs	2524	2528	O
.	2528	2529	O

Therefore	2530	2539	O
,	2539	2540	O
our	2541	2544	O
failure	2545	2552	O
to	2553	2555	O
detect	2556	2562	O
an	2563	2565	O
association	2566	2577	O
for	2578	2581	O
these	2582	2587	O
4	2588	2589	O
SNPs	2590	2594	O
was	2595	2598	O
not	2599	2602	O
due	2603	2606	O
to	2607	2609	O
the	2610	2613	O
sample	2614	2620	O
size	2621	2625	O
.	2625	2626	O

These	2627	2632	O
results	2633	2640	O
suggest	2641	2648	O
that	2649	2653	O
the	2654	2657	O
polymorphisms	2658	2671	O
in	2672	2674	O
the	2675	2678	O
coding	2679	2685	O
region	2686	2692	O
of	2693	2695	O
the	2696	2699	O
SPINK5	2700	2706	O
are	2707	2710	O
unlikely	2711	2719	O
to	2720	2722	O
contribute	2723	2733	O
to	2734	2736	O
asthma	2737	2743	O
risk	2744	2748	O
in	2749	2751	O
the	2752	2755	O
Chinese	2756	2763	O
Han	2764	2767	O
population	2768	2778	O
.	2778	2779	O

However	2780	2787	O
,	2787	2788	O
because	2789	2796	O
our	2797	2800	O
patients	2801	2809	O
were	2810	2814	O
ascertained	2815	2826	O
for	2827	2830	O
asthma	2831	2837	O
,	2837	2838	O
we	2839	2841	O
could	2842	2847	O
not	2848	2851	O
exclude	2852	2859	O
a	2860	2861	O
role	2862	2866	O
of	2867	2869	O
the	2870	2873	O
coding	2874	2880	O
SNPs	2881	2885	O
of	2886	2888	O
the	2889	2892	O
SPINK5	2893	2899	O
in	2900	2902	O
atopic	2903	2909	O
dermatitis	2910	2920	O
in	2921	2923	O
our	2924	2927	O
population	2928	2938	O
.	2938	2939	O

The	2940	2943	O
variations	2944	2954	O
in	2955	2957	O
the	2958	2961	O
regulatory	2962	2972	O
sequences	2973	2982	O
of	2983	2985	O
genes	2986	2991	O
may	2992	2995	O
determine	2996	3005	O
risks	3006	3011	O
to	3012	3014	O
common	3015	3021	O
diseases	3022	3030	O
by	3031	3033	O
causing	3034	3041	O
different	3042	3051	O
levels	3052	3058	O
of	3059	3061	O
expression	3062	3072	O
.	3072	3073	O

Therefore	3074	3083	O
,	3083	3084	O
the	3085	3088	O
identification	3089	3103	O
and	3104	3107	O
functional	3108	3118	O
evaluation	3119	3129	O
of	3130	3132	O
polymorphisms	3133	3146	O
in	3147	3149	O
promoter	3150	3158	O
region	3159	3165	O
are	3166	3169	O
of	3170	3172	O
great	3173	3178	O
value	3179	3184	O
in	3185	3187	O
understanding	3188	3201	O
the	3202	3205	O
genetic	3206	3213	O
susceptibility	3214	3228	O
to	3229	3231	O
asthma	3232	3238	O
.	3238	3239	O

In	3240	3242	O
order	3243	3248	O
to	3249	3251	O
determine	3252	3261	O
the	3262	3265	O
role	3266	3270	O
of	3271	3273	O
the	3274	3277	O
SPINK5	3278	3284	O
promoter	3285	3293	O
polymorphism	3294	3306	O
in	3307	3309	O
the	3310	3313	O
pathogenesis	3314	3326	O
of	3327	3329	O
asthma	3330	3336	O
,	3336	3337	O
we	3338	3340	O
genotyped	3341	3350	O
a	3351	3352	O
promoter	3353	3361	O
polymorphism	3362	3374	O
,	3374	3375	O
-	3376	3377	O
206G	3377	3381	O
>	3381	3382	O
A	3382	3383	O
,	3383	3384	O
in	3385	3387	O
422	3388	3391	O
asthma	3392	3398	O
patients	3399	3407	O
and	3408	3411	O
410	3412	3415	O
controls	3416	3424	O
,	3424	3425	O
and	3426	3429	O
found	3430	3435	O
a	3436	3437	O
marginal	3438	3446	O
association	3447	3458	O
.	3458	3459	O

The	3460	3463	O
frequency	3464	3473	O
of	3474	3476	O
allele	3477	3483	O
G	3484	3485	O
was	3486	3489	O
significantly	3490	3503	O
higher	3504	3510	O
in	3511	3513	O
asthmatic	3514	3523	O
patients	3524	3532	O
than	3533	3537	O
that	3538	3542	O
in	3543	3545	O
controls	3546	3554	O
(	3555	3556	O
p	3556	3557	O
=	3558	3559	O
0	3560	3561	O
.	3561	3562	O
022	3562	3565	O
)	3565	3566	O
.	3566	3567	O

To	3568	3570	O
confirm	3571	3578	O
the	3579	3582	O
association	3583	3594	O
,	3594	3595	O
additional	3596	3606	O
267	3607	3610	O
asthma	3611	3617	O
patients	3618	3626	O
and	3627	3630	O
301	3631	3634	O
controls	3635	3643	O
newly	3644	3649	O
recruited	3650	3659	O
from	3660	3664	O
the	3665	3668	O
same	3669	3673	O
hospital	3674	3682	O
were	3683	3687	O
genotyped	3688	3697	O
,	3697	3698	O
and	3699	3702	O
the	3703	3706	O
-	3707	3708	O
206G	3708	3712	O
>	3712	3713	O
A	3713	3714	O
polymorphism	3715	3727	O
remained	3728	3736	O
significantly	3737	3750	O
associated	3751	3761	O
with	3762	3766	O
asthma	3767	3773	O
(	3774	3775	O
P	3775	3776	O
=	3777	3778	O
0	3779	3780	O
.	3780	3781	O
001	3781	3784	O
)	3784	3785	O
,	3785	3786	O
even	3787	3791	O
after	3792	3797	O
Bonferroni	3798	3808	O
correction	3809	3819	O
(	3819	3820	O
adjusted	3820	3828	O
P	3829	3830	O
=	3831	3832	O
0	3833	3834	O
.	3834	3835	O
01	3835	3837	O
)	3837	3838	O
.	3838	3839	O

To	3840	3842	O
our	3843	3846	O
knowledge	3847	3856	O
,	3856	3857	O
this	3858	3862	O
is	3863	3865	O
the	3866	3869	O
first	3870	3875	O
report	3876	3882	O
of	3883	3885	O
an	3886	3888	O
association	3889	3900	O
of	3901	3903	O
-	3904	3905	O
206G	3905	3909	O
>	3909	3910	O
A	3910	3911	O
polymorphism	3912	3924	O
with	3925	3929	O
asthma	3930	3936	O
.	3936	3937	O

We	3938	3940	O
further	3941	3948	O
examined	3949	3957	O
the	3958	3961	O
potential	3962	3971	O
functional	3972	3982	O
role	3983	3987	O
of	3988	3990	O
this	3991	3995	O
promoter	3996	4004	O
polymorphism	4005	4017	O
,	4017	4018	O
and	4019	4022	O
found	4023	4028	O
that	4029	4033	O
the	4034	4037	O
G	4038	4039	O
to	4040	4042	O
A	4043	4044	O
substitution	4045	4057	O
at	4058	4060	O
-	4061	4062	O
206	4062	4065	O
generated	4066	4075	O
a	4076	4077	O
GATA	4078	4082	O
-	4082	4083	O
3	4083	4084	O
transcription	4085	4098	O
factor	4099	4105	O
binding	4106	4113	O
site	4114	4118	O
.	4118	4119	O

Major	4120	4125	O
transcription	4126	4139	O
factors	4140	4147	O
controlling	4148	4159	O
Th1	4160	4163	O
and	4164	4167	O
Th2	4168	4171	O
development	4172	4183	O
,	4183	4184	O
such	4185	4189	O
as	4190	4192	O
T	4193	4194	O
-	4194	4195	O
box	4195	4198	O
transcription	4199	4212	O
factor	4213	4219	O
and	4220	4223	O
GATA3	4224	4229	O
,	4229	4230	O
are	4231	4234	O
possibly	4235	4243	O
involved	4244	4252	O
in	4253	4255	O
asthma	4256	4262	O
and	4263	4266	O
atopic	4267	4273	O
diseases	4274	4282	O
.	4282	4283	O

GATA	4284	4288	O
-	4288	4289	O
3	4289	4290	O
,	4290	4291	O
a	4292	4293	O
transcription	4294	4307	O
factor	4308	4314	O
specifically	4315	4327	O
expressed	4328	4337	O
in	4338	4340	O
T	4341	4342	B-Cell
helper	4343	4349	I-Cell
2	4350	4351	I-Cell
(	4352	4353	I-Cell
Th2	4353	4356	I-Cell
)	4356	4357	I-Cell
cells	4358	4363	I-Cell
,	4363	4364	O
plays	4365	4370	O
a	4371	4372	O
critical	4373	4381	O
role	4382	4386	O
in	4387	4389	O
the	4390	4393	O
differentiation	4394	4409	O
of	4410	4412	O
Th2	4413	4416	B-Cell
cells	4417	4422	I-Cell
from	4423	4427	O
uncommitted	4428	4439	O
CD4	4440	4443	B-Cell
+	4443	4444	I-Cell
lymphocytes	4445	4456	I-Cell
.	4456	4457	O

In	4458	4460	O
addition	4461	4469	O
,	4469	4470	O
GATA	4471	4475	O
-	4475	4476	O
3	4476	4477	O
is	4478	4480	O
essential	4481	4490	O
for	4491	4494	O
the	4495	4498	O
expression	4499	4509	O
of	4510	4512	O
the	4513	4516	O
cytokines	4517	4526	O
IL	4527	4529	O
-	4529	4530	O
4	4530	4531	O
,	4531	4532	O
IL	4533	4535	O
-	4535	4536	O
5	4536	4537	O
and	4538	4541	O
IL	4542	4544	O
-	4544	4545	O
13	4545	4547	O
that	4548	4552	O
mediate	4553	4560	O
allergic	4561	4569	O
inflammation	4570	4582	O
[	4583	4584	O
23	4584	4586	O
]	4586	4587	O
.	4587	4588	O

Our	4589	4592	O
luciferase	4593	4603	O
reporter	4604	4612	O
assay	4613	4618	O
confirmed	4619	4628	O
that	4629	4633	O
SNP	4634	4637	O
-	4638	4639	O
206G	4639	4643	O
>	4643	4644	O
A	4644	4645	O
is	4646	4648	O
associated	4649	4659	O
with	4660	4664	O
the	4665	4668	O
transcriptional	4669	4684	O
activity	4685	4693	O
of	4694	4696	O
SPINK5	4697	4703	O
.	4703	4704	O

The	4705	4708	O
G	4709	4710	O
allele	4711	4717	O
was	4718	4721	O
associated	4722	4732	O
with	4733	4737	O
decreased	4738	4747	O
transcriptional	4748	4763	O
activity	4764	4772	O
of	4773	4775	O
the	4776	4779	O
SPINK5	4780	4786	O
.	4786	4787	O

The	4788	4791	O
mechanism	4792	4801	O
by	4802	4804	O
which	4805	4810	O
the	4811	4814	O
-	4815	4816	O
206G	4816	4820	O
>	4820	4821	O
A	4821	4822	O
SNP	4823	4826	O
affects	4827	4834	O
SPINK5	4835	4841	O
expression	4842	4852	O
may	4853	4856	O
be	4857	4859	O
explained	4860	4869	O
by	4870	4872	O
the	4873	4876	O
potential	4877	4886	O
differential	4887	4899	O
transcription	4900	4913	O
factor	4914	4920	O
binding	4921	4928	O
of	4929	4931	O
GATA	4932	4936	O
binding	4937	4944	O
factor	4945	4951	O
,	4951	4952	O
since	4953	4958	O
-	4959	4960	O
206G	4960	4964	O
>	4964	4965	O
A	4965	4966	O
is	4967	4969	O
located	4970	4977	O
at	4978	4980	O
the	4981	4984	O
core	4985	4989	O
sequence	4990	4998	O
of	4999	5001	O
GATA	5002	5006	O
binding	5007	5014	O
factor	5015	5021	O
binding	5022	5029	O
site	5030	5034	O
.	5034	5035	O

Electrophoretic	5036	5051	O
mobility	5052	5060	O
shift	5061	5066	O
assay	5067	5072	O
confirmed	5073	5082	O
that	5083	5087	O
the	5088	5091	O
A	5092	5093	O
to	5094	5096	O
G	5097	5098	O
substitution	5099	5111	O
at	5112	5114	O
-	5115	5116	O
206	5116	5119	O
significantly	5120	5133	O
reduced	5134	5141	O
the	5142	5145	O
binding	5146	5153	O
efficiency	5154	5164	O
of	5165	5167	O
nuclear	5168	5175	B-Cellular_component
proteins	5176	5184	O
to	5185	5187	O
this	5188	5192	O
element	5193	5200	O
.	5200	5201	O

Our	5202	5205	O
data	5206	5210	O
suggest	5211	5218	O
that	5219	5223	O
loss	5224	5228	O
of	5229	5231	O
GATA	5232	5236	O
transcription	5237	5250	O
factor	5251	5257	O
regulation	5258	5268	O
with	5269	5273	O
the	5274	5277	O
-	5278	5279	O
206G	5279	5283	O
may	5284	5287	O
decrease	5288	5296	O
the	5297	5300	O
SPINK5	5301	5307	O
expression	5308	5318	O
and	5319	5322	O
thereby	5323	5330	O
potentially	5331	5342	O
perturb	5343	5350	O
the	5351	5354	O
immunosuppressive	5355	5372	O
function	5373	5381	O
of	5382	5384	O
LEKTI	5385	5390	O
.	5390	5391	O

Statistical	0	11	O
Analysis	12	20	O

Mitochondrial	21	34	B-Cellular_component
DNA	35	38	O
haplogroup	39	49	O
frequencies	50	61	O
were	62	66	O
calculated	67	77	O
by	78	80	O
counting	81	89	O
from	90	94	O
the	95	98	O
observed	99	107	O
genotypes	108	117	O
.	117	118	O

The	119	122	O
Pearson	123	130	O
chi	131	134	O
-	134	135	O
square	135	141	O
test	142	146	O
and	147	150	O
the	151	154	O
chi	155	158	O
-	158	159	O
square	159	165	O
test	166	170	O
for	171	174	O
linear	175	181	O
-	181	182	O
by	182	184	O
-	184	185	O
linear	185	191	O
association	192	203	O
were	204	208	O
used	209	213	O
to	214	216	O
analyze	217	224	O
the	225	228	O
significances	229	242	O
between	243	250	O
the	251	254	O
prevalence	255	265	O
of	266	268	O
haplogroups	269	280	O
and	281	284	O
different	285	294	O
age	295	298	O
groups	299	305	O
.	305	306	O

SPSS	307	311	O
software	312	320	O
(	321	322	O
version	322	329	O
10	330	332	O
.	332	333	O
0	333	334	O
)	334	335	O
was	336	339	O
used	340	344	O
.	344	345	O

Duplicated	0	10	O
HGT	11	14	O
candidates	15	25	O
in	26	28	O
K	29	30	O
.	30	31	O
thermotolerans	32	46	O
.	46	47	O

(	48	49	O
A	49	50	O
)	50	51	O
Part	52	56	O
of	57	59	O
the	60	63	O
conserved	64	73	O
synteny	74	81	O
block	82	87	O
surrounding	88	99	O
KLTH0C07700g	100	112	O
and	113	116	O
KLTH0C07722g	117	129	O
tandem	130	136	O
genes	137	142	O
.	142	143	O

Same	144	148	O
legend	149	155	O
as	156	158	O
Figure	159	165	O
3A	166	168	O
.	168	169	O

(	170	171	O
B	171	172	O
)	172	173	O
Part	174	178	O
of	179	181	O
the	182	185	O
conserved	186	195	O
synteny	196	203	O
block	204	209	O
surrounding	210	221	O
KLTH0F12276g	222	234	O
gene	235	239	O
.	239	240	O

Same	241	245	O
legend	246	252	O
as	253	255	O
Figure	256	262	O
3A	263	265	O
.	265	266	O

(	267	268	O
C	268	269	O
)	269	270	O
Sequence	271	279	O
alignment	280	289	O
of	290	292	O
proteins	293	301	O
from	302	306	O
K	307	308	O
.	308	309	O
thermotolerans	310	324	O
and	325	328	O
K	329	330	O
.	330	331	O
waltii	332	338	O
.	338	339	O

(	340	341	O
D	341	342	O
)	342	343	O
Phylogenetic	344	356	O
tree	357	361	O
reconstructed	362	375	O
from	376	380	O
sequence	381	389	O
alignment	390	399	O
of	400	402	O
100	403	406	O
sites	407	412	O
of	413	415	O
K	416	417	O
.	417	418	O
thermotolerans	419	433	O
protein	434	441	O
family	442	448	O
members	449	456	O
,	456	457	O
K	458	459	O
.	459	460	O
waltii	461	467	O
gene	468	472	O
,	472	473	O
bacterial	474	483	O
(	484	485	O
green	485	490	O
)	490	491	O
and	492	495	O
amoebal	496	503	O
(	504	505	O
blue	505	509	O
)	509	510	O
proteins	511	519	O
.	519	520	O

Bootstrap	521	530	O
values	531	537	O
are	538	541	O
indicated	542	551	O
next	552	556	O
to	557	559	O
the	560	563	O
nodes	564	569	O
and	570	573	O
branch	574	580	O
length	581	587	O
scale	588	593	O
is	594	596	O
shown	597	602	O
at	603	605	O
bottom	606	612	O
left	613	617	O
.	617	618	O

Quantitative	0	12	O
reverse	13	20	O
transcription	21	34	O
PCR	35	38	O

Reverse	39	46	O
transcription	47	60	O
was	61	64	O
performed	65	74	O
using	75	80	O
0	81	82	O
.	82	83	O
2	83	84	O
mug	85	88	O
of	89	91	O
total	92	97	O
RNA	98	101	O
from	102	106	O
muscle	107	113	B-Tissue
of	114	116	O
10	117	119	O
week	120	124	O
-	124	125	O
old	125	128	O
and	129	132	O
19	133	135	O
month	136	141	O
-	141	142	O
old	142	145	O
C57Bl6	146	152	O
mice	153	157	O
(	158	159	O
five	159	163	O
animals	164	171	O
per	172	175	O
group	176	181	O
)	181	182	O
,	182	183	O
a	184	185	O
Core	186	190	O
kit	191	194	O
(	195	196	O
RT	196	198	O
-	198	199	O
RTCK	199	203	O
-	203	204	O
03	204	206	O
,	206	207	O
Eurogentec	208	218	O
)	218	219	O
according	220	229	O
to	230	232	O
manufacturer	233	245	O
'	245	246	O
s	246	247	O
instruction	248	259	O
and	260	263	O
a	264	265	O
mix	266	269	O
of	270	272	O
random	273	279	O
primers	280	287	O
(	288	289	O
9	289	290	O
mers	291	295	O
)	295	296	O
and	297	300	O
oligodT	301	308	O
.	308	309	O

qPCR	310	314	O
was	315	318	O
performed	319	328	O
on	329	331	O
SDS7900HT	332	341	O
(	342	343	O
Applied	343	350	O
Biosystem	351	360	O
)	360	361	O
using	362	367	O
Mesagreen	368	377	O
qPCR	378	382	O
kit	383	386	O
for	387	390	O
SYBR	391	395	O
(	396	397	O
Eurogentec	397	407	O
)	407	408	O
and	409	412	O
the	413	416	O
following	417	426	O
primers	427	434	O
:	434	435	O

PPARbeta	437	445	O
:	445	446	O
5	447	448	O
'	448	449	O
-	449	450	O
AGATGGTGGCAGAGCTATGACC	450	472	O
-	472	473	O
3	473	474	O
'	474	475	O
;	475	476	O
5	477	478	O
'	478	479	O
-	479	480	O
TCCTCCTGTGGCTGTTCC	480	498	O
-	498	499	O
3	499	500	O
'	500	501	O
.	501	502	O

Catalase	503	511	O
:	511	512	O
5	513	514	O
'	514	515	O
-	515	516	O
GGATCCTGACATGGTCTGGG	516	536	O
-	536	537	O
3	537	538	O
'	538	539	O
;	539	540	O
5	541	542	O
'	542	543	O
-	543	544	O
TGGAGAGACTCGGGACGAAG	544	564	O
-	564	565	O
3	565	566	O
'	566	567	O
.	567	568	O

PDK4	569	573	O
:	573	574	O
5	575	576	O
'	576	577	O
-	577	578	O
GCATTTCTACTCGGATGCTCAATG	578	602	O
-	602	603	O
3	603	604	O
'	604	605	O
;	605	606	O
5	607	608	O
'	608	609	O
-	609	610	O
CCAATGTGGCTTGGGTTTCC	610	630	O
-	630	631	O
3	631	632	O
'	632	633	O
.	633	634	O

36B4	635	639	O
:	639	640	O
5	641	642	O
'	642	643	O
-	643	644	O
TCCAGGCTTTGGGCATCA	644	662	O
-	662	663	O
3	663	664	O
'	664	665	O
;	665	666	O
5	667	668	O
'	668	669	O
-	669	670	O
CTTTATCAGCTGCACATCACTCAGA	670	695	O
-	695	696	O
3	696	697	O
'	697	698	O
.	698	699	O

Data	700	704	O
were	705	709	O
all	710	713	O
normalised	714	724	O
using	725	730	O
36B4	731	735	O
as	736	738	O
housekeeping	739	751	O
gene	752	756	O
.	756	757	O

Chicken	0	7	O
CCN3	8	12	O
expression	13	23	O
in	24	26	O
embryonic	27	36	B-Tissue
and	37	40	O
extraembryonic	41	55	B-Tissue
tissues	56	63	I-Tissue

Expression	64	74	O
of	75	77	O
CCN3	78	82	O
in	83	85	O
axial	86	91	O
structure	92	101	O
becomes	102	109	O
visible	110	117	O
in	118	120	O
the	121	124	O
presegmentation	125	140	O
stage	141	146	O
and	147	150	O
reaches	151	158	O
to	159	161	O
the	162	165	O
highest	166	173	O
level	174	179	O
at	180	182	O
the	183	186	O
beginning	187	196	O
of	197	199	O
somitogenesis	200	213	O
(	214	215	O
HH	215	217	O
stage	218	223	O
7	224	225	O
,	225	226	O
Fig	227	230	O
.	230	231	O
1a	232	234	O
)	234	235	O
.	235	236	O

Strong	237	243	O
similarity	244	254	O
between	255	262	O
CCN3	263	267	O
and	268	271	O
Sonic	272	277	O
Hedgehog	278	286	O
was	287	290	O
observed	291	299	O
for	300	303	O
the	304	307	O
expression	308	318	O
pattern	319	326	O
in	327	329	O
axial	330	335	O
structure	336	345	O
(	346	347	O
notochord	347	356	O
and	357	360	O
floor	361	366	O
plate	367	372	O
)	372	373	O
,	373	374	O
in	375	377	O
which	378	383	O
the	384	387	O
left	388	392	O
-	392	393	O
right	393	398	O
asymmetrical	399	411	O
pattern	412	419	O
in	420	422	O
the	423	426	O
node	427	431	O
area	432	436	O
is	437	439	O
also	440	444	O
conserved	445	454	O
(	455	456	O
Fig	456	459	O
.	459	460	O
1b	461	463	O
)	463	464	O
.	464	465	O

However	466	473	O
,	473	474	O
Sonic	475	480	O
Hedgehog	481	489	O
expression	490	500	O
is	501	503	O
slightly	504	512	O
broader	513	520	O
than	521	525	O
that	526	530	O
of	531	533	O
CCN3	534	538	O
.	538	539	O

Since	540	545	O
CCN3	546	550	O
stimulates	551	561	O
Notch	562	567	O
signaling	568	577	O
(	578	579	O
Sakamoto	579	587	O
et	588	590	O
al	591	593	O
.	593	594	O
2002	595	599	O
)	599	600	O
,	600	601	O
we	602	604	O
investigated	605	617	O
the	618	621	O
expression	622	632	O
of	633	635	O
Notch	636	641	O
signal	642	648	O
genes	649	654	O
.	654	655	O

Among	656	661	O
them	662	666	O
,	666	667	O
Serrate1	668	676	O
,	676	677	O
a	678	679	O
ligand	680	686	O
of	687	689	O
Notch	690	695	O
is	696	698	O
unique	699	705	O
because	706	713	O
its	714	717	O
expression	718	728	O
is	729	731	O
apparently	732	742	O
a	743	744	O
right	745	750	O
deviated	751	759	O
pattern	760	767	O
in	768	770	O
the	771	774	O
node	775	779	O
area	780	784	O
(	785	786	O
Fig	786	789	O
.	789	790	O
1c	791	793	O
)	793	794	O
.	794	795	O

Another	796	803	O
Notch	804	809	O
ligand	810	816	O
,	816	817	O
Delta1	818	824	O
shows	825	830	O
a	831	832	O
right	833	838	O
deviated	839	847	O
pattern	848	855	O
,	855	856	O
but	857	860	O
is	861	863	O
more	864	868	O
caudal	869	875	O
area	876	880	O
of	881	883	O
the	884	887	O
node	888	892	O
extending	893	902	O
to	903	905	O
the	906	909	O
primitive	910	919	O
streak	920	926	O
(	927	928	O
data	928	932	O
not	933	936	O
shown	937	942	O
)	942	943	O
.	943	944	O

The	945	948	O
expression	949	959	O
of	960	962	O
CCN3	963	967	O
in	968	970	O
axial	971	976	O
structure	977	986	O
was	987	990	O
followed	991	999	O
by	1000	1002	O
the	1003	1006	O
presomitic	1007	1017	O
mesoderm	1018	1026	O
although	1027	1035	O
it	1036	1038	O
is	1039	1041	O
diminished	1042	1052	O
(	1053	1054	O
Sakamoto	1054	1062	O
et	1063	1065	O
al	1066	1068	O
.	1068	1069	O
2002	1070	1074	O
)	1074	1075	O
.	1075	1076	O

Fig	1078	1081	O
.	1081	1082	O

1	1083	1084	O

Expression	1085	1095	O
of	1096	1098	O
mRNA	1099	1103	O
in	1104	1106	O
early	1107	1112	O
stage	1113	1118	O
chicken	1119	1126	O
embryo	1127	1133	B-Developing_anatomical_structure
;	1133	1134	O
CCN3	1135	1139	O
(	1140	1141	O
a	1141	1142	O
)	1142	1143	O
,	1143	1144	O
Sonic	1145	1150	O
Hedgehog	1151	1159	O
(	1160	1161	O
b	1161	1162	O
)	1162	1163	O
and	1164	1167	O
Serrate1	1168	1176	O
(	1177	1178	O
c	1178	1179	O
)	1179	1180	O
at	1181	1183	O
the	1184	1187	O
beginning	1188	1197	O
stage	1198	1203	O
of	1204	1206	O
somitogenesis	1207	1220	O
(	1221	1222	O
Hamburger	1222	1231	O
and	1232	1235	O
Hamilton	1236	1244	O
(	1245	1246	O
HH	1246	1248	O
)	1248	1249	O
Stage	1250	1255	O
7	1256	1257	O
)	1257	1258	O
.	1258	1259	O

Arrowheads	1260	1270	O
indicate	1271	1279	O
Hensen	1280	1286	O
'	1286	1287	O
s	1287	1288	O
node	1289	1293	O
.	1293	1294	O

Demonstrates	1295	1307	O
the	1308	1311	O
schematic	1312	1321	O
view	1322	1326	O
of	1327	1329	O
tissue	1330	1336	B-Tissue
organization	1337	1349	O
at	1350	1352	O
this	1353	1357	O
stage	1358	1363	O
(	1364	1365	O
d	1365	1366	O
)	1366	1367	O
.	1367	1368	O

Expression	1369	1379	O
of	1380	1382	O
CCN3	1383	1387	O
mRNA	1388	1392	O
in	1393	1395	O
blood	1396	1401	B-Organism_substance
islands	1402	1409	I-Organism_substance
of	1410	1412	O
chicken	1413	1420	O
extraembryonic	1421	1435	B-Tissue
tissue	1436	1442	I-Tissue
(	1443	1444	O
HH	1444	1446	O
stage	1447	1452	O
10	1453	1455	O
)	1455	1456	O
(	1457	1458	O
e	1458	1459	O
)	1459	1460	O
.	1460	1461	O

Ventral	1462	1469	B-Multi-tissue_structure
part	1470	1474	O
of	1475	1477	O
the	1478	1481	O
endothelial	1482	1493	B-Cell
precursor	1494	1503	I-Cell
cells	1504	1509	I-Cell
in	1510	1512	O
blood	1513	1518	B-Organism_substance
islands	1519	1526	I-Organism_substance
is	1527	1529	O
positive	1530	1538	O
for	1539	1542	O
CCN3	1543	1547	O
expression	1548	1558	O
.	1558	1559	O

Coloration	1560	1570	O
was	1571	1574	O
stopped	1575	1582	O
before	1583	1589	O
the	1590	1593	O
background	1594	1604	O
staining	1605	1613	O
started	1614	1621	O
in	1622	1624	O
sense	1625	1630	O
probes	1631	1637	O
(	1638	1639	O
negative	1639	1647	O
control	1648	1655	O
)	1655	1656	O

There	1657	1662	O
is	1663	1665	O
accumulating	1666	1678	O
evidence	1679	1687	O
of	1688	1690	O
CCN3	1691	1695	O
commitment	1696	1706	O
to	1707	1709	O
hematopoiesis	1710	1723	O
and	1724	1727	O
therefore	1728	1737	O
we	1738	1740	O
investigated	1741	1753	O
the	1754	1757	O
CCN3	1758	1762	O
expression	1763	1773	O
in	1774	1776	O
extraembryonic	1777	1791	B-Tissue
tissues	1792	1799	I-Tissue
.	1799	1800	O

Blood	1801	1806	B-Organism_substance
islands	1807	1814	I-Organism_substance
are	1815	1818	O
formed	1819	1825	O
in	1826	1828	O
the	1829	1832	O
yolk	1833	1837	B-Tissue
sac	1838	1841	I-Tissue
mesodermal	1842	1852	I-Tissue
area	1853	1857	O
just	1858	1862	O
between	1863	1870	O
the	1871	1874	O
visceral	1875	1883	B-Tissue
endodermal	1884	1894	I-Tissue
and	1895	1898	O
ectodermal	1899	1909	B-Tissue
layers	1910	1916	I-Tissue
,	1916	1917	O
which	1918	1923	O
supply	1924	1930	O
the	1931	1934	O
red	1935	1938	B-Cell
blood	1939	1944	I-Cell
cells	1945	1950	I-Cell
at	1951	1953	O
the	1954	1957	O
primary	1958	1965	O
stage	1966	1971	O
.	1971	1972	O

The	1973	1976	O
cells	1977	1982	B-Cell
in	1983	1985	O
blood	1986	1991	B-Organism_substance
islands	1992	1999	I-Organism_substance
are	2000	2003	O
called	2004	2010	O
hemangioblasts	2011	2025	B-Cell
since	2026	2031	O
they	2032	2036	O
also	2037	2041	O
differentiate	2042	2055	O
into	2056	2060	O
the	2061	2064	O
endothelial	2065	2076	B-Cell
cells	2077	2082	I-Cell
of	2083	2085	O
extraembryonic	2086	2100	B-Developing_anatomical_structure
blood	2101	2106	I-Developing_anatomical_structure
vessel	2107	2113	I-Developing_anatomical_structure
structure	2114	2123	I-Developing_anatomical_structure
.	2123	2124	O

In	2125	2127	O
chicken	2128	2135	O
embryo	2136	2142	B-Developing_anatomical_structure
,	2142	2143	O
differentiating	2144	2159	O
endothelial	2160	2171	B-Cell
cells	2172	2177	I-Cell
in	2178	2180	O
the	2181	2184	O
ventral	2185	2192	B-Multi-tissue_structure
part	2193	2197	O
of	2198	2200	O
blood	2201	2206	B-Organism_substance
islands	2207	2214	I-Organism_substance
express	2215	2222	O
CCN3	2223	2227	O
from	2228	2232	O
the	2233	2236	O
initial	2237	2244	O
stage	2245	2250	O
(	2251	2252	O
Fig	2252	2255	O
.	2255	2256	O
1e	2257	2259	O
)	2259	2260	O
.	2260	2261	O

Erythroblasts	2262	2275	B-Cell
in	2276	2278	O
the	2279	2282	O
center	2283	2289	O
of	2290	2292	O
blood	2293	2298	B-Organism_substance
islands	2299	2306	I-Organism_substance
(	2307	2308	O
spherical	2308	2317	O
cells	2318	2323	B-Cell
in	2324	2326	O
Fig	2327	2330	O
.	2330	2331	O
1e	2332	2334	O
)	2334	2335	O
weakly	2336	2342	O
express	2343	2350	O
CCN3	2351	2355	O
and	2356	2359	O
their	2360	2365	O
expression	2366	2376	O
is	2377	2379	O
mildly	2380	2386	O
enhanced	2387	2395	O
in	2396	2398	O
later	2399	2404	O
stage	2405	2410	O
(	2411	2412	O
data	2412	2416	O
not	2417	2420	O
shown	2421	2426	O
)	2426	2427	O
.	2427	2428	O

Assessment	0	10	O
of	11	13	O
various	14	21	O
forms	22	27	O
of	28	30	O
bevavioural	31	42	O
addictions	43	53	O

A	54	55	O
first	56	61	O
approach	62	70	O
for	71	74	O
the	75	78	O
comprehensive	79	92	O
and	93	96	O
standardized	97	109	O
assessment	110	120	O
of	121	123	O
different	124	133	O
forms	134	139	O
of	140	142	O
behavioural	143	154	O
addictions	155	165	O
(	166	167	O
e	167	168	O
.	168	169	O
g	169	170	O
.	170	171	O
,	171	172	O
pathological	173	185	O
gambling	186	194	O
,	194	195	O
workaholism	196	207	O
,	207	208	O
compulsive	209	219	O
buying	220	226	O
)	226	227	O
is	228	230	O
the	231	234	O
German	235	241	O
self	242	246	O
-	246	247	O
assessment	247	257	O
questionnaire	258	271	O
"	272	273	O
Fragebogen	273	283	O
zur	284	287	O
Differenzierten	288	303	O
Anamnese	304	312	O
exzessiver	313	323	O
Verhaltensweisen	324	340	O
"	340	341	O
(	342	343	O
FDAV	343	347	O
,	347	348	O
Questionnaire	349	362	O
on	363	365	O
Differentiated	366	380	O
Assessment	381	391	O
of	392	394	O
Excessive	395	404	O
Behaviours	405	415	O
)	415	416	O
[	417	418	O
96	418	420	O
]	420	421	O
.	421	422	O

The	423	426	O
FDAV	427	431	O
is	432	434	O
based	435	440	O
on	441	443	O
the	444	447	O
criteria	448	456	O
of	457	459	O
substance	460	469	O
-	469	470	O
related	470	477	O
addictions	478	488	O
,	488	489	O
pathological	490	502	O
gambling	503	511	O
and	512	515	O
impulse	516	523	O
control	524	531	O
disorders	532	541	O
of	542	544	O
the	545	548	O
ICD	549	552	O
-	552	553	O
10	553	555	O
[	556	557	O
3	557	558	O
]	558	559	O
and	560	563	O
the	564	567	O
DSM	568	571	O
-	571	572	O
IV	572	574	O
-	574	575	O
TR	575	577	O
[	578	579	O
2	579	580	O
]	580	581	O
.	581	582	O

The	583	586	O
FDAV	587	591	O
is	592	594	O
a	595	596	O
modified	597	605	O
version	606	613	O
of	614	616	O
the	617	620	O
"	621	622	O
Fragebogen	622	632	O
zur	633	636	O
Differenzierten	637	652	O
Drogenanamnese	653	667	O
"	667	668	O
(	669	670	O
FDDA	670	674	O
;	674	675	O
Questionnaire	676	689	O
on	690	692	O
Differentiated	693	707	O
Assessment	708	718	O
of	719	721	O
Addiction	722	731	O
,	731	732	O
QDAA	733	737	O
)	737	738	O
[	739	740	O
97	740	742	O
]	742	743	O
.	743	744	O

Its	745	748	O
seven	749	754	O
modules	755	762	O
obtain	763	769	O
"	770	771	O
sociodemographic	771	787	O
information	788	799	O
"	799	800	O
(	801	802	O
e	802	803	O
.	803	804	O
g	804	805	O
.	805	806	O
,	806	807	O
age	808	811	O
,	811	812	O
profession	813	823	O
,	823	824	O
marital	825	832	O
status	833	839	O
)	839	840	O
,	840	841	O
"	842	843	O
history	843	850	O
of	851	853	O
excessive	854	863	O
behaviour	864	873	O
"	873	874	O
(	875	876	O
e	876	877	O
.	877	878	O
g	878	879	O
.	879	880	O
,	880	881	O
diagnostic	882	892	O
criteria	893	901	O
for	902	905	O
addictions	906	916	O
and	917	920	O
impulse	921	928	O
control	929	936	O
disorder	937	945	O
,	945	946	O
individual	947	957	O
patterns	958	966	O
of	967	969	O
behaviour	970	979	O
,	979	980	O
craving	981	988	O
symptoms	989	997	O
)	997	998	O
,	998	999	O
"	1000	1001	O
critical	1001	1009	O
life	1010	1014	O
events	1015	1021	O
"	1021	1022	O
(	1023	1024	O
stress	1024	1030	O
caused	1031	1037	O
by	1038	1040	O
traumatic	1041	1050	O
events	1051	1057	O
)	1057	1058	O
,	1058	1059	O
"	1060	1061	O
legal	1061	1066	O
situation	1067	1076	O
"	1076	1077	O
,	1077	1078	O
"	1079	1080	O
medical	1080	1087	O
history	1088	1095	O
"	1095	1096	O
,	1096	1097	O
"	1098	1099	O
physical	1099	1107	O
and	1108	1111	O
psychological	1112	1125	O
complaints	1126	1136	O
"	1136	1137	O
,	1137	1138	O
and	1139	1142	O
"	1143	1144	O
emotional	1144	1153	O
state	1154	1159	O
"	1159	1160	O
(	1161	1162	O
triggering	1162	1172	O
psychological	1173	1186	O
conditions	1187	1197	O
,	1197	1198	O
or	1199	1201	O
consequences	1202	1214	O
of	1215	1217	O
the	1218	1221	O
addictive	1222	1231	O
behaviour	1232	1241	O
,	1241	1242	O
respectively	1243	1255	O
)	1255	1256	O
.	1256	1257	O

Every	1258	1263	O
module	1264	1270	O
can	1271	1274	O
be	1275	1277	O
administered	1278	1290	O
separately	1291	1301	O
according	1302	1311	O
to	1312	1314	O
the	1315	1318	O
suspected	1319	1328	O
behavioural	1329	1340	O
addiction	1341	1350	O
,	1350	1351	O
thereby	1352	1359	O
making	1360	1366	O
the	1367	1370	O
FDAV	1371	1375	O
an	1376	1378	O
economical	1379	1389	O
tool	1390	1394	O
in	1395	1397	O
assessing	1398	1407	O
behavioural	1408	1419	O
addictions	1420	1430	O
.	1430	1431	O

The	1432	1435	O
FDAV	1436	1440	O
is	1441	1443	O
suitable	1444	1452	O
for	1453	1456	O
diagnostics	1457	1468	O
,	1468	1469	O
evaluation	1470	1480	O
of	1481	1483	O
therapy	1484	1491	O
and	1492	1495	O
follow	1496	1502	O
-	1502	1503	O
up	1503	1505	O
in	1506	1508	O
clinical	1509	1517	O
practice	1518	1526	O
and	1527	1530	O
research	1531	1539	O
.	1539	1540	O

Currently	1541	1550	O
,	1550	1551	O
the	1552	1555	O
FDAV	1556	1560	O
is	1561	1563	O
being	1564	1569	O
validated	1570	1579	O
in	1580	1582	O
clinical	1583	1591	O
and	1592	1595	O
non	1596	1599	O
-	1599	1600	O
clinical	1600	1608	O
samples	1609	1616	O
.	1616	1617	O

Click	0	5	O
here	6	10	O
for	11	14	O
file	15	19	O

Method	0	6	O

Results	0	7	O
:	7	8	O

All	9	12	O
fractures	13	22	O
united	23	29	O
.	29	30	O

Individual	31	41	O
movement	42	50	O
of	51	53	O
dorsiflexion	54	66	O
,	66	67	O
palmar	68	74	B-Organism_subdivision
flexion	75	82	O
,	82	83	O
supination	84	94	O
,	94	95	O
pronation	96	105	O
and	106	109	O
radial	110	116	B-Organ
-	116	117	O
ulnar	117	122	B-Organ
deviation	123	132	O
were	133	137	O
all	138	141	O
significantly	142	155	O
better	156	162	O
in	163	165	O
the	166	169	O
dorsiflexed	170	181	O
-	181	182	O
immobilized	182	193	O
group	194	199	O
as	200	202	O
compared	203	211	O
with	212	216	O
the	217	220	O
palmar	221	227	B-Organism_subdivision
flexed	228	234	O
immobilized	235	246	O
group	247	252	O
.	252	253	O

Grip	254	258	O
strength	259	267	O
recovery	268	276	O
with	277	281	O
subjective	282	292	O
assessment	293	303	O
was	304	307	O
better	308	314	O
in	315	317	O
the	318	321	O
dorsiflexed	322	333	O
group	334	339	O
(	340	341	O
77	341	343	O
%	343	344	O
)	344	345	O
as	346	348	O
compared	349	357	O
to	358	360	O
the	361	364	O
palmar	365	371	B-Organism_subdivision
flexed	372	378	O
group	379	384	O
(	385	386	O
23	386	388	O
%	388	389	O
)	389	390	O
.	390	391	O

Radiological	392	404	O
parameters	405	415	O
were	416	420	O
markedly	421	429	O
better	430	436	O
in	437	439	O
the	440	443	O
dorsiflexed	444	455	O
group	456	461	O
.	461	462	O

Ninety	463	469	O
-	469	470	O
one	470	473	O
per	474	477	O
cent	478	482	O
of	483	485	O
patients	486	494	O
in	495	497	O
the	498	501	O
dorsiflexed	502	513	O
group	514	519	O
had	520	523	O
excellent	524	533	O
to	534	536	O
good	537	541	O
results	542	549	O
as	550	552	O
compared	553	561	O
to	562	564	O
66	565	567	O
%	567	568	O
in	569	571	O
the	572	575	O
palmar	576	582	B-Organism_subdivision
flexed	583	589	O
group	590	595	O
.	595	596	O

3	0	1	O
.	1	2	O
2	2	3	O
.	3	4	O

Cell	5	9	B-Cell
line	10	14	I-Cell
and	15	18	O
culture	19	26	O

DU145	27	32	B-Cell
(	33	34	I-Cell
prostate	34	42	I-Cell
cancer	43	49	I-Cell
)	49	50	I-Cell
cell	51	55	I-Cell
line	56	60	I-Cell
was	61	64	O
used	65	69	O
in	70	72	O
this	73	77	O
assay	78	83	O
.	83	84	O

DU145	85	90	B-Cell
was	91	94	O
grown	95	100	O
in	101	103	O
DMEM	104	108	O
/	108	109	O
F	109	110	O
-	110	111	O
12	111	113	O
medium	114	120	O
(	121	122	O
Gibco	122	127	O
BRL	128	131	O
Life	132	136	O
Technologies	137	149	O
,	149	150	O
San	151	154	O
Diego	155	160	O
,	160	161	O
CA	162	164	O
.	164	165	O
,	165	166	O
USA	167	170	O
)	170	171	O
supplemented	172	184	O
with	185	189	O
10	190	192	O
%	192	193	O
fetal	194	199	B-Developing_anatomical_structure
calf	200	204	O
serum	205	210	B-Organism_substance
and	211	214	O
kept	215	219	O
in	220	222	O
a	223	224	O
humidified	225	235	O
37	236	238	O
degreesC	239	247	O
,	247	248	O
5	249	250	O
%	250	251	O
CO2	252	255	O
incubator	256	265	O
.	265	266	O

Target	0	6	O
volumes	7	14	O
'	14	15	O
coverage	16	24	O

The	25	28	O
mean	29	33	O
PTV1	34	38	O
and	39	42	O
PTV2	43	47	O
volumes	48	55	O
were	56	60	O
452	61	64	O
cm3	65	68	O
(	69	70	O
range	70	75	O
276	76	79	O
-	79	80	O
1074	80	84	O
cm3	85	88	O
)	88	89	O
and	90	93	O
300	94	97	O
cm3	98	101	O
(	102	103	O
range	103	108	O
137	109	112	O
-	112	113	O
567	113	116	O
cm3	117	120	O
)	120	121	O
respectively	122	134	O
.	134	135	O

A	136	137	O
mean	138	142	O
of	143	145	O
>	146	147	O
98	147	149	O
%	149	150	O
(	151	152	O
range	152	157	O
92	158	160	O
-	160	161	O
100	161	164	O
%	164	165	O
)	165	166	O
of	167	169	O
the	170	173	O
PTV1	174	178	O
received	179	187	O
100	188	191	O
%	191	192	O
of	193	195	O
the	196	199	O
prescribed	200	210	O
dose	211	215	O
in	216	218	O
all	219	222	O
planning	223	231	O
methods	232	239	O
.	239	240	O

A	241	242	O
mean	243	247	O
of	248	250	O
95	251	253	O
.	253	254	O
5	254	255	O
%	255	256	O
and	257	260	O
95	261	263	O
.	263	264	O
7	264	265	O
%	265	266	O
of	267	269	O
the	270	273	O
PTV2	274	278	O
received	279	287	O
100	288	291	O
%	291	292	O
of	293	295	O
the	296	299	O
prescribed	300	310	O
dose	311	315	O
with	316	320	O
TOMO	321	325	O
and	326	329	O
IMRT	330	334	O
plans	335	340	O
respectively	341	353	O
.	353	354	O

A	355	356	O
mean	357	361	O
of	362	364	O
94	365	367	O
%	367	368	O
and	369	372	O
92	373	375	O
%	375	376	O
of	377	379	O
the	380	383	O
PTV2	384	388	O
received	389	397	O
100	398	401	O
%	401	402	O
of	403	405	O
the	406	409	O
prescribed	410	420	O
dose	421	425	O
with	426	430	O
IB	431	433	O
and	434	437	O
3D	438	440	O
treatment	441	450	O
plans	451	456	O
,	456	457	O
respectively	458	470	O
.	470	471	O

The	472	475	O
mean	476	480	O
IB	481	483	O
and	484	487	O
3D	488	490	O
plans	491	496	O
PTV2	497	501	O
coverage	502	510	O
was	511	514	O
significantly	515	528	O
inferior	529	537	O
then	538	542	O
the	543	546	O
IMRT	547	551	O
and	552	555	O
TOMO	556	560	O
plans	561	566	O
(	567	568	O
p	568	569	O
<	570	571	O
0	572	573	O
.	573	574	O
02	574	576	O
,	576	577	O
for	578	581	O
all	582	585	O
comparisons	586	597	O
)	597	598	O
.	598	599	O

The	600	603	O
mean	604	608	O
Inhomogeneity	609	622	O
Coefficient	623	634	O
(	635	636	O
IC	636	638	O
)	638	639	O
was	640	643	O
significantly	644	657	O
lower	658	663	O
(	664	665	O
better	665	671	O
)	671	672	O
with	673	677	O
the	678	681	O
TOMO	682	686	O
plans	687	692	O
,	692	693	O
compared	694	702	O
to	703	705	O
all	706	709	O
other	710	715	O
plans	716	721	O
for	722	725	O
both	726	730	O
PTV1	731	735	O
and	736	739	O
PTV2	740	744	O
(	745	746	O
p	746	747	O
<	748	749	O
0	750	751	O
.	751	752	O
0003	752	756	O
for	757	760	O
all	761	764	O
comparisons	765	776	O
)	776	777	O
(	778	779	O
figure	779	785	O
3	786	787	O
)	787	788	O
.	788	789	O

The	790	793	O
mean	794	798	O
IC	799	801	O
of	802	804	O
the	805	808	O
IMRT	809	813	O
plans	814	819	O
was	820	823	O
significantly	824	837	O
higher	838	844	O
(	845	846	O
worse	846	851	O
)	851	852	O
than	853	857	O
the	858	861	O
mean	862	866	O
IC	867	869	O
of	870	872	O
the	873	876	O
3D	877	879	O
plans	880	885	O
regarding	886	895	O
PTV	896	899	O
1	900	901	O
(	902	903	O
p	903	904	O
<	905	906	O
0	907	908	O
.	908	909	O
02	909	911	O
)	911	912	O
and	913	916	O
higher	917	923	O
(	924	925	O
worse	925	930	O
)	930	931	O
then	932	936	O
the	937	940	O
mean	941	945	O
IC	946	948	O
of	949	951	O
the	952	955	O
IB	956	958	O
plans	959	964	O
regarding	965	974	O
PTV2	975	979	O
(	980	981	O
p	981	982	O
<	983	984	O
0	985	986	O
.	986	987	O
03	987	989	O
)	989	990	O
(	991	992	O
figure	992	998	O
3	999	1000	O
)	1000	1001	O
.	1001	1002	O

No	1003	1005	O
significant	1006	1017	O
difference	1018	1028	O
was	1029	1032	O
found	1033	1038	O
between	1039	1046	O
the	1047	1050	O
means	1051	1056	O
of	1057	1059	O
the	1060	1063	O
IC	1064	1066	O
of	1067	1069	O
the	1070	1073	O
3D	1074	1076	O
and	1077	1080	O
IB	1081	1083	O
plans	1084	1089	O
.	1089	1090	O

Figure	1091	1097	O
3	1098	1099	O

The	1100	1103	O
mean	1104	1108	O
Inhomogeneity	1109	1122	O
Coefficient	1123	1134	O
(	1135	1136	O
IC	1136	1138	O
)	1138	1139	O
achieved	1140	1148	O
by	1149	1151	O
the	1152	1155	O
different	1156	1165	O
planning	1166	1174	O
methods	1175	1182	O
.	1182	1183	O

The	1184	1187	O
mean	1188	1192	O
of	1193	1195	O
the	1196	1199	O
Inhomogeneity	1200	1213	O
Coefficient	1214	1225	O
is	1226	1228	O
a	1229	1230	O
measure	1231	1238	O
of	1239	1241	O
dose	1242	1246	O
inhomogeneity	1247	1260	O
in	1261	1263	O
the	1264	1267	O
target	1268	1274	O
volumes	1275	1282	O
.	1282	1283	O

The	1284	1287	O
closer	1288	1294	O
the	1295	1298	O
IC	1299	1301	O
to	1302	1304	O
zero	1305	1309	O
,	1309	1310	O
the	1311	1314	O
more	1315	1319	O
homogenous	1320	1330	O
the	1331	1334	O
dose	1335	1339	O
is	1340	1342	O
.	1342	1343	O

RESEARCH	0	8	O
DESIGN	9	15	O
AND	16	19	O
METHODS	20	27	O

For	28	31	O
this	32	36	O
study	37	42	O
,	42	43	O
20	44	46	O
individuals	47	58	O
(	59	60	O
mean	60	64	O
age	65	68	O
39	69	71	O
.	71	72	O
5	72	73	O
+	74	75	O
/	75	76	O
-	76	77	O
11	78	80	O
.	80	81	O
1	81	82	O
years	83	88	O
)	88	89	O
with	90	94	O
long	95	99	O
-	99	100	O
standing	100	108	O
type	109	113	O
1	114	115	O
diabetes	116	124	O
(	125	126	O
21	126	128	O
.	128	129	O
3	129	130	O
+	131	132	O
/	132	133	O
-	133	134	O
10	135	137	O
.	137	138	O
7	138	139	O
years	140	145	O
)	145	146	O
were	147	151	O
enrolled	152	160	O
in	161	163	O
this	164	168	O
prospective	169	180	O
open	181	185	O
-	185	186	O
label	186	191	O
crossover	192	201	O
trial	202	207	O
.	207	208	O

After	209	214	O
achieving	215	224	O
optimal	225	232	O
blood	233	238	B-Organism_substance
glucose	239	246	O
control	247	254	O
,	254	255	O
16	256	258	O
subjects	259	267	O
were	268	272	O
randomized	273	283	O
to	284	286	O
exenatide	287	296	O
with	297	301	O
or	302	304	O
without	305	312	O
daclizumab	313	323	O
.	323	324	O

Endogenous	325	335	O
insulin	336	343	O
production	344	354	O
was	355	358	O
determined	359	369	O
by	370	372	O
repeatedly	373	383	O
measuring	384	393	O
serum	394	399	B-Organism_substance
C	400	401	O
-	401	402	O
peptide	402	409	O
.	409	410	O

Subjects	0	8	O
and	9	12	O
Methods	13	20	O

ABPM	21	25	O
was	26	29	O
conducted	30	39	O
for	40	43	O
60	44	46	O
selected	47	55	O
patients	56	64	O
who	65	68	O
had	69	72	O
visited	73	80	O
Sunlin	81	87	O
Hospital	88	96	O
between	97	104	O
January	105	112	O
2008	113	117	O
and	118	121	O
August	122	128	O
2008	129	133	O
.	133	134	O

Patients	135	143	O
were	144	148	O
classified	149	159	O
into	160	164	O
3	165	166	O
groups	167	173	O
;	173	174	O
an	175	177	O
obese	178	183	O
group	184	189	O
whose	190	195	O
body	196	200	B-Organism_subdivision
mass	201	205	O
index	206	211	O
(	212	213	O
BMI	213	216	O
)	216	217	O
was	218	221	O
>	222	223	O
the	224	227	O
95th	228	232	O
percentile	233	243	O
,	243	244	O
an	245	247	O
overweight	248	258	O
group	259	264	O
whose	265	270	O
BMI	271	274	O
was	275	278	O
>	279	280	O
the	281	284	O
85th	285	289	O
percentile	290	300	O
but	301	304	O
less	305	309	O
than	310	314	O
the	315	318	O
95th	319	323	O
percentile	324	334	O
,	334	335	O
and	336	339	O
a	340	341	O
normal	342	348	O
group	349	354	O
whose	355	360	O
BMI	361	364	O
was	365	368	O
below	369	374	O
the	375	378	O
85th	379	383	O
percentile	384	394	O
.	394	395	O

Overall	396	403	O
mean	404	408	O
BP	409	411	O
,	411	412	O
day	413	416	O
and	417	420	O
night	421	426	O
BP	427	429	O
and	430	433	O
BP	434	436	O
load	437	441	O
were	442	446	O
measured	447	455	O
by	456	458	O
ABPM	459	463	O
.	463	464	O

Surgery	0	7	O

Trabeculectomy	8	22	O
should	23	29	O
be	30	32	O
considered	33	43	O
in	44	46	O
all	47	50	O
patients	51	59	O
,	59	60	O
when	61	65	O
the	66	69	O
'	70	71	O
target	71	77	O
IOP	78	81	O
'	81	82	O
is	83	85	O
not	86	89	O
achieved	90	98	O
with	99	103	O
glaucoma	104	112	O
medications	113	124	O
and	125	128	O
if	129	131	O
the	132	135	O
expected	136	144	O
rate	145	149	O
of	150	152	O
visual	153	159	O
loss	160	164	O
could	165	170	O
affect	171	177	O
the	178	181	O
patient	182	189	O
during	190	196	O
their	197	202	O
lifetime	203	211	O
.	211	212	O

In	213	215	O
this	216	220	O
procedure	221	230	O
,	230	231	O
an	232	234	O
opening	235	242	O
is	243	245	O
made	246	250	O
in	251	253	O
the	254	257	O
trabecular	258	268	B-Organ
meshwork	269	277	O
,	277	278	O
so	279	281	O
that	282	286	O
aqueous	287	294	O
humor	295	300	B-Organism_substance
can	301	304	O
drain	305	310	O
into	311	315	O
the	316	319	O
sclera	320	326	B-Multi-tissue_structure
.	326	327	O

Many	328	332	O
patients	333	341	O
can	342	345	O
discontinue	346	357	O
glaucoma	358	366	O
medications	367	378	O
after	379	384	O
surgery	385	392	O
.	392	393	O

Approximately	394	407	O
one	408	411	O
-	411	412	O
third	412	417	O
of	418	420	O
the	421	424	O
trabeculectomy	425	439	O
patients	440	448	O
develop	449	456	O
cataract	457	465	O
within	466	472	O
five	473	477	O
years	478	483	O
.	483	484	O

If	485	487	O
trabeculectomy	488	502	O
fails	503	508	O
,	508	509	O
another	510	517	O
type	518	522	O
of	523	525	O
surgery	526	533	O
places	534	540	O
a	541	542	O
drainage	543	551	O
tube	552	556	O
(	557	558	O
Molteno	558	565	O
tube	566	570	O
)	570	571	O
in	572	574	O
the	575	578	O
eye	579	582	B-Organ
,	582	583	O
between	584	591	O
the	592	595	O
cornea	596	602	B-Multi-tissue_structure
and	603	606	O
iris	607	611	B-Multi-tissue_structure
,	611	612	O
which	613	618	O
exits	619	624	O
at	625	627	O
the	628	631	O
junction	632	640	O
of	641	643	O
the	644	647	O
cornea	648	654	B-Multi-tissue_structure
and	655	658	O
sclera	659	665	B-Multi-tissue_structure
.	665	666	O

Cyclodestructive	667	683	O
procedures	684	694	O
,	694	695	O
which	696	701	O
lower	702	707	O
IOP	708	711	O
by	712	714	O
destroying	715	725	O
the	726	729	O
ciliary	730	737	B-Multi-tissue_structure
body	738	742	I-Multi-tissue_structure
,	742	743	O
are	744	747	O
typically	748	757	O
reserved	758	766	O
for	767	770	O
eyes	771	775	B-Organ
,	775	776	O
which	777	782	O
are	783	786	O
refractory	787	797	O
to	798	800	O
all	801	804	O
other	805	810	O
forms	811	816	O
of	817	819	O
therapy	820	827	O
.	827	828	O

These	829	834	O
procedures	835	845	O
include	846	853	O
cyclocryotherapy	854	870	O
,	870	871	O
cylcodiathermy	872	886	O
and	887	890	O
laser	891	896	O
cyclophotocoagulation	897	918	O
.	918	919	O
[	919	920	O
91	920	922	O
-	922	923	O
93	923	925	O
]	925	926	O

Follow	0	6	O
-	6	7	O
up	7	9	O

Patients	10	18	O
were	19	23	O
followed	24	32	O
up	33	35	O
at	36	38	O
the	39	42	O
outpatient	43	53	O
clinic	54	60	O
at	61	63	O
1	64	65	O
,	65	66	O
4	67	68	O
,	68	69	O
and	70	73	O
7	74	75	O
months	76	82	O
after	83	88	O
the	89	92	O
ablation	93	101	O
procedure	102	111	O
and	112	115	O
every	116	121	O
6	122	123	O
months	124	130	O
thereafter	131	141	O
.	141	142	O

Routine	143	150	O
24	151	153	O
or	154	156	O
48	157	159	O
h	160	161	O
Holter	162	168	O
monitoring	169	179	O
was	180	183	O
performed	184	193	O
before	194	200	O
each	201	205	O
appointment	206	217	O
,	217	218	O
and	219	222	O
a	223	224	O
12	225	227	O
-	227	228	O
lead	228	232	O
electrocardiogram	233	250	O
was	251	254	O
obtained	255	263	O
at	264	266	O
each	267	271	O
visit	272	277	O
.	277	278	O

Patients	279	287	O
were	288	292	O
asked	293	298	O
to	299	301	O
report	302	308	O
to	309	311	O
the	312	315	O
emergency	316	325	O
room	326	330	O
or	331	333	O
our	334	337	O
arrhythmia	338	348	O
unit	349	353	O
for	354	357	O
an	358	360	O
ECG	361	364	O
if	365	367	O
any	368	371	O
symptom	372	379	O
suggestive	380	390	O
of	391	393	O
recurrence	394	404	O
occurred	405	413	O
between	414	421	O
scheduled	422	431	O
visits	432	438	O
.	438	439	O

After	440	445	O
the	446	449	O
ablation	450	458	O
procedure	459	468	O
,	468	469	O
all	470	473	O
patients	474	482	O
received	483	491	O
anti	492	496	O
-	496	497	O
arrhythmic	497	507	O
treatment	508	517	O
for	518	521	O
at	522	524	O
least	525	530	O
1	531	532	O
month	533	538	O
to	539	541	O
protect	542	549	O
against	550	557	O
early	558	563	O
recurrences	564	575	O
and	576	579	O
continued	580	589	O
oral	590	594	O
anticoagulation	595	610	O
for	611	614	O
a	615	616	O
minimum	617	624	O
of	625	627	O
2	628	629	O
months	630	636	O
to	637	639	O
maintain	640	648	O
an	649	651	O
international	652	665	O
normalized	666	676	O
ratio	677	682	O
between	683	690	O
2	691	692	O
.	692	693	O
0	693	694	O
and	695	698	O
3	699	700	O
.	700	701	O
0	701	702	O
.	702	703	O

Additionally	704	716	O
,	716	717	O
magnetic	718	726	O
resonance	727	736	O
angiography	737	748	O
was	749	752	O
repeated	753	761	O
at	762	764	O
3	765	766	O
-	766	767	O
6	767	768	O
months	769	775	O
after	776	781	O
the	782	785	O
procedure	786	795	O
to	796	798	O
evaluate	799	807	O
the	808	811	O
presence	812	820	O
of	821	823	O
PV	824	826	O
stenosis	827	835	O
.	835	836	O

Arrhythmia	837	847	O
recurrence	848	858	O
was	859	862	O
defined	863	870	O
as	871	873	O
a	874	875	O
documented	876	886	O
AF	887	889	O
or	890	892	O
atrial	893	899	B-Multi-tissue_structure
flutter	900	907	O
episode	908	915	O
of	916	918	O
>	919	920	O
30	920	922	O
s	923	924	O
.	924	925	O

Arrhythmic	926	936	O
episodes	937	945	O
within	946	952	O
the	953	956	O
first	957	962	O
3	963	964	O
months	965	971	O
after	972	977	O
the	978	981	O
CPVA	982	986	O
(	987	988	O
healing	988	995	O
period	996	1002	O
)	1002	1003	O
were	1004	1008	O
not	1009	1012	O
considered	1013	1023	O
in	1024	1026	O
the	1027	1030	O
evaluation	1031	1041	O
of	1042	1044	O
final	1045	1050	O
success	1051	1058	O
rates	1059	1064	O
because	1065	1072	O
they	1073	1077	O
are	1078	1081	O
often	1082	1087	O
described	1088	1097	O
as	1098	1100	O
transient	1101	1110	O
recurrences	1111	1122	O
related	1123	1130	O
to	1131	1133	O
atrial	1134	1140	B-Multi-tissue_structure
inflammatory	1141	1153	O
processes	1154	1163	O
following	1164	1173	O
RF	1174	1176	O
lesions	1177	1184	O
.	1184	1185	O
26	1185	1187	O

The	1188	1191	O
endpoint	1192	1200	O
of	1201	1203	O
the	1204	1207	O
study	1208	1213	O
was	1214	1217	O
freedom	1218	1225	O
from	1226	1230	O
arrhythmia	1231	1241	O
recurrence	1242	1252	O
after	1253	1258	O
a	1259	1260	O
single	1261	1267	O
CPVA	1268	1272	O
procedure	1273	1282	O
,	1282	1283	O
without	1284	1291	O
anti	1292	1296	O
-	1296	1297	O
arrhythmic	1297	1307	O
medication	1308	1318	O
.	1318	1319	O

A	1320	1321	O
minimum	1322	1329	O
follow	1330	1336	O
-	1336	1337	O
up	1337	1339	O
of	1340	1342	O
3	1343	1344	O
months	1345	1351	O
was	1352	1355	O
required	1356	1364	O
.	1364	1365	O

Electrostatic	0	13	O
interaction	14	25	O
energies	26	34	O
between	35	42	O
the	43	46	O
SNARE	47	52	O
complex	53	60	O
and	61	64	O
fusing	65	71	O
membranes	72	81	B-Cellular_component
.	81	82	O

(	83	84	O
A	84	85	O
)	85	86	O
Schematic	87	96	O
diagram	97	104	O
and	105	108	O
definitions	109	120	O
of	121	123	O
intermolecular	124	138	O
interaction	139	150	O
energies	151	159	O
presented	160	169	O
in	170	172	O
(	173	174	O
B	174	175	O
)	175	176	O
and	177	180	O
(	181	182	O
C	182	183	O
)	183	184	O
.	184	185	O

In	186	188	O
(	189	190	O
A	190	191	O
)	191	192	O
through	193	200	O
(	201	202	O
C	202	203	O
)	203	204	O
,	204	205	O
only	206	210	O
the	211	214	O
SNARE	215	220	O
core	221	225	O
complex	226	233	O
is	234	236	O
considered	237	247	O
.	247	248	O

Interaction	249	260	O
free	261	265	O
energies	266	274	O
are	275	278	O
calculated	279	289	O
for	290	293	O
(	294	295	O
B	295	296	O
)	296	297	O
a	298	299	O
series	300	306	O
of	307	309	O
SNARE	310	315	O
/	315	316	O
membrane	316	324	B-Cellular_component
distances	325	334	O
and	335	338	O
(	339	340	O
C	340	341	O
)	341	342	O
different	343	352	O
membrane	353	361	B-Cellular_component
lipid	362	367	O
compositions	368	380	O
.	380	381	O

Arrow	382	387	O
in	388	390	O
(	391	392	O
B	392	393	O
)	393	394	O
indicates	395	404	O
the	405	408	O
most	409	413	O
physiologically	414	429	O
relevant	430	438	O
distance	439	447	O
when	448	452	O
the	453	456	O
closest	457	464	O
points	465	471	O
between	472	479	O
SNARE	480	485	O
and	486	489	O
membranes	490	499	B-Cellular_component
are	500	503	O
3	504	505	O
A	506	507	O
,	507	508	O
the	509	512	O
thickness	513	522	O
of	523	525	O
a	526	527	O
layer	528	533	O
of	534	536	O
water	537	542	O
.	542	543	O
[	543	544	O
19	544	546	O
]	546	547	O
In	548	550	O
(	551	552	O
D	552	553	O
)	553	554	O
through	555	562	O
(	563	564	O
F	564	565	O
)	565	566	O
,	566	567	O
TMDs	568	572	O
of	573	575	O
VAMP	576	580	O
and	581	584	O
syntaxin	585	593	O
are	594	597	O
present	598	605	O
and	606	609	O
embedded	610	618	O
in	619	621	O
membranes	622	631	B-Cellular_component
.	631	632	O

Furthermore	633	644	O
,	644	645	O
the	646	649	O
C	650	651	O
-	651	652	O
terminus	652	660	O
of	661	663	O
the	664	667	O
SNARE	668	673	O
motif	674	679	O
is	680	682	O
partially	683	692	O
unraveled	693	702	O
into	703	707	O
individual	708	718	O
alpha	719	724	O
-	724	725	O
helices	725	732	O
by	733	735	O
molecular	736	745	O
dynamics	746	754	O
simulations	755	766	O
to	767	769	O
represent	770	779	O
trans	780	785	O
-	785	786	O
SNARE	786	791	O
complex	792	799	O
.	799	800	O

Interaction	801	812	O
free	813	817	O
energies	818	826	O
are	827	830	O
then	831	835	O
calculated	836	846	O
for	847	850	O
(	851	852	O
E	852	853	O
)	853	854	O
a	855	856	O
series	857	863	O
of	864	866	O
SNARE	867	872	O
motif	873	878	O
C	879	880	O
-	880	881	O
terminus	881	889	O
separation	890	900	O
distances	901	910	O
and	911	914	O
(	915	916	O
F	916	917	O
)	917	918	O
different	919	928	O
lipid	929	934	O
compositions	935	947	O
of	948	950	O
the	951	954	O
membranes	955	964	B-Cellular_component
.	964	965	O

Conclusions	966	977	O
drawn	978	983	O
from	984	988	O
both	989	993	O
groups	994	1000	O
of	1001	1003	O
studies	1004	1011	O
are	1012	1015	O
essentially	1016	1027	O
the	1028	1031	O
same	1032	1036	O
.	1036	1037	O

V	1038	1039	O
(	1040	1041	O
circles	1041	1048	O
)	1048	1049	O
:	1049	1050	O
Interaction	1051	1062	O
energies	1063	1071	O
between	1072	1079	O
the	1080	1083	O
SNARE	1084	1089	O
complex	1090	1097	O
and	1098	1101	O
the	1102	1105	O
v	1106	1107	B-Cellular_component
-	1107	1108	I-Cellular_component
membrane	1108	1116	I-Cellular_component
.	1116	1117	O

T	1118	1119	O
(	1120	1121	O
squares	1121	1128	O
)	1128	1129	O
:	1129	1130	O
Interaction	1131	1142	O
energies	1143	1151	O
between	1152	1159	O
SNARE	1160	1165	O
and	1166	1169	O
the	1170	1173	O
t	1174	1175	B-Cellular_component
-	1175	1176	I-Cellular_component
membrane	1176	1184	I-Cellular_component
.	1184	1185	O

VT	1186	1188	O
(	1189	1190	O
triangles	1190	1199	O
)	1199	1200	O
:	1200	1201	O
Interaction	1202	1213	O
energies	1214	1222	O
between	1223	1230	O
the	1231	1234	O
v	1235	1236	B-Cellular_component
-	1236	1237	I-Cellular_component
and	1238	1241	O
the	1242	1245	O
t	1246	1247	B-Cellular_component
-	1247	1248	I-Cellular_component
membranes	1248	1257	I-Cellular_component
if	1258	1260	O
the	1261	1264	O
SNARE	1265	1270	O
complex	1271	1278	O
were	1279	1283	O
extracted	1284	1293	O
.	1293	1294	O

Demographic	0	11	O
data	12	16	O
of	17	19	O
subjects	20	28	O

1	0	1	O
.	1	2	O

Background	3	13	O

The	14	17	O
United	18	24	O
Republic	25	33	O
of	34	36	O
Tanzania	37	45	O
,	45	46	O
is	47	49	O
among	50	55	O
the	56	59	O
many	60	64	O
countries	65	74	O
in	75	77	O
sub	78	81	O
-	81	82	O
Saharan	82	89	O
Africa	90	96	O
facing	97	103	O
a	104	105	O
human	106	111	O
resources	112	121	O
crisis	122	128	O
in	129	131	O
its	132	135	O
health	136	142	O
sector	143	149	O
,	149	150	O
with	151	155	O
a	156	157	O
small	158	163	O
and	164	167	O
inequitably	168	179	O
distributed	180	191	O
health	192	198	O
workforce	199	208	O
[	209	210	O
1	210	211	O
]	211	212	O
that	213	217	O
shoulders	218	227	O
a	228	229	O
disproportionately	230	248	O
high	249	253	O
burden	254	260	O
of	261	263	O
disease	264	271	O
[	271	272	O
2	272	273	O
]	273	274	O
.	274	275	O

Although	276	284	O
all	285	288	O
poor	289	293	O
countries	294	303	O
in	304	306	O
the	307	310	O
world	311	316	O
face	317	321	O
a	322	323	O
severe	324	330	O
human	331	336	O
resource	337	345	O
crisis	346	352	O
in	353	355	O
their	356	361	O
health	362	368	O
sectors	369	376	O
[	377	378	O
3	378	379	O
,	379	380	O
4	380	381	O
]	381	382	O
,	382	383	O
the	384	387	O
problem	388	395	O
is	396	398	O
most	399	403	O
acute	404	409	O
in	410	412	O
Sub	413	416	O
-	416	417	O
Saharan	417	424	O
Africa	425	431	O
,	431	432	O
in	433	435	O
which	436	441	O
an	442	444	O
estimated	445	454	O
workforce	455	464	O
of	465	467	O
750	468	471	O
000	472	475	O
health	476	482	O
workers	483	490	O
in	491	493	O
the	494	497	O
region	498	504	O
serves	505	511	O
682	512	515	O
million	516	523	O
people	524	530	O
[	531	532	O
2	532	533	O
]	533	534	O
.	534	535	O

By	536	538	O
comparison	539	549	O
,	549	550	O
the	551	554	O
ratio	555	560	O
is	561	563	O
10	564	566	O
to	567	569	O
15	570	572	O
times	573	578	O
higher	579	585	O
in	586	588	O
developed	589	598	O
countries	599	608	O
.	608	609	O

Moreover	610	618	O
,	618	619	O
this	620	624	O
estimated	625	634	O
workforce	635	644	O
of	645	647	O
doctors	648	655	O
,	655	656	O
nurses	657	663	O
and	664	667	O
allied	668	674	O
health	675	681	O
workers	682	689	O
in	690	692	O
Sub	693	696	O
-	696	697	O
Saharan	697	704	O
Africa	705	711	O
constitutes	712	723	O
1	724	725	O
.	725	726	O
3	726	727	O
%	727	728	O
of	729	731	O
the	732	735	O
world	736	741	O
'	741	742	O
s	742	743	O
health	744	750	O
workforce	751	760	O
,	760	761	O
while	762	767	O
Africa	768	774	O
suffers	775	782	O
from	783	787	O
25	788	790	O
%	790	791	O
of	792	794	O
the	795	798	O
world	799	804	O
'	804	805	O
s	805	806	O
burden	807	813	O
of	814	816	O
disease	817	824	O
[	825	826	O
2	826	827	O
]	827	828	O
.	828	829	O

A	830	831	O
minimum	832	839	O
level	840	845	O
of	846	848	O
a	849	850	O
health	851	857	O
workforce	858	867	O
of	868	870	O
2	871	872	O
.	872	873	O
5	873	874	O
health	875	881	O
workers	882	889	O
per	890	893	O
1000	894	898	O
people	899	905	O
is	906	908	O
required	909	917	O
to	918	920	O
achieve	921	928	O
the	929	932	O
Millennium	933	943	O
Development	944	955	O
Goals	956	961	O
[	962	963	O
5	963	964	O
]	964	965	O
.	965	966	O

Africa	967	973	O
is	974	976	O
far	977	980	O
from	981	985	O
this	986	990	O
level	991	996	O
with	997	1001	O
a	1002	1003	O
health	1004	1010	O
workforce	1011	1020	O
density	1021	1028	O
that	1029	1033	O
only	1034	1038	O
averages	1039	1047	O
0	1048	1049	O
.	1049	1050	O
8	1050	1051	O
worker	1052	1058	O
per	1059	1062	O
1000	1063	1067	O
people	1068	1074	O
,	1074	1075	O
while	1076	1081	O
the	1082	1085	O
world	1086	1091	O
median	1092	1098	O
density	1099	1106	O
of	1107	1109	O
health	1110	1116	O
personnel	1117	1126	O
is	1127	1129	O
5	1130	1131	O
per	1132	1135	O
1000	1136	1140	O
people	1141	1147	O
[	1148	1149	O
5	1149	1150	O
]	1150	1151	O
.	1151	1152	O

There	1153	1158	O
is	1159	1161	O
a	1162	1163	O
positive	1164	1172	O
correlation	1173	1184	O
between	1185	1192	O
health	1193	1199	O
worker	1200	1206	O
density	1207	1214	O
and	1215	1218	O
various	1219	1226	O
health	1227	1233	O
indices	1234	1241	O
,	1241	1242	O
most	1243	1247	O
notably	1248	1255	O
infant	1256	1262	O
mortality	1263	1272	O
rate	1273	1277	O
,	1277	1278	O
maternal	1279	1287	O
mortality	1288	1297	O
rates	1298	1303	O
,	1303	1304	O
and	1305	1308	O
various	1309	1316	O
disease	1317	1324	O
specific	1325	1333	O
mortality	1334	1343	O
and	1344	1347	O
morbidity	1348	1357	O
rates	1358	1363	O
[	1364	1365	O
6	1365	1366	O
,	1366	1367	O
7	1367	1368	O
]	1368	1369	O
.	1369	1370	O

An	1371	1373	O
increase	1374	1382	O
in	1383	1385	O
the	1386	1389	O
number	1390	1396	O
of	1397	1399	O
health	1400	1406	O
workers	1407	1414	O
per	1415	1418	O
capita	1419	1425	O
is	1426	1428	O
associated	1429	1439	O
with	1440	1444	O
a	1445	1446	O
notable	1447	1454	O
decline	1455	1462	O
in	1463	1465	O
the	1466	1469	O
rates	1470	1475	O
mentioned	1476	1485	O
above	1486	1491	O
.	1491	1492	O

As	1493	1495	O
a	1496	1497	O
consequence	1498	1509	O
,	1509	1510	O
it	1511	1513	O
has	1514	1517	O
been	1518	1522	O
argued	1523	1529	O
that	1530	1534	O
health	1535	1541	O
worker	1542	1548	O
shortages	1549	1558	O
have	1559	1563	O
impeded	1564	1571	O
the	1572	1575	O
implementation	1576	1590	O
of	1591	1593	O
development	1594	1605	O
goals	1606	1611	O
in	1612	1614	O
many	1615	1619	O
poor	1620	1624	O
countries	1625	1634	O
[	1635	1636	O
8	1636	1637	O
]	1637	1638	O
.	1638	1639	O

CASE	0	4	O
:	4	5	O

Here	6	10	O
for	11	14	O
the	15	18	O
first	19	24	O
time	25	29	O
a	30	31	O
case	32	36	O
of	37	39	O
CDLS	40	44	O
from	45	49	O
Iran	50	54	O
,	54	55	O
a	56	57	O
15	58	60	O
-	60	61	O
week	61	65	O
-	65	66	O
old	66	69	O
male	70	74	O
infant	75	81	O
who	82	85	O
was	86	89	O
refereed	90	98	O
as	99	101	O
a	102	103	O
case	104	108	O
of	109	111	O
multiple	112	120	O
congenital	121	131	O
anomalies	132	141	O
.	141	142	O

Clinical	143	151	O
investigation	152	165	O
showed	166	172	O
that	173	177	O
the	178	181	O
child	182	187	O
was	188	191	O
a	192	193	O
case	194	198	O
of	199	201	O
CDLS	202	206	O
.	206	207	O

Applying	0	8	O
A1C	9	12	O
cut	13	16	O
offs	17	21	O
to	22	24	O
the	25	28	O
AusDiab	29	36	O
population	37	47	O
(	48	49	O
4	49	50	O
.	50	51	O
6	51	52	O
%	52	53	O
undiagnosed	54	65	O
diabetes	66	74	O
)	74	75	O

Applying	76	84	O
the	85	88	O
same	89	93	O
cut	94	97	O
offs	98	102	O
,	102	103	O
a	104	105	O
total	106	111	O
75	112	114	O
.	114	115	O
9	115	116	O
%	116	117	O
of	118	120	O
the	121	124	O
AusDiab	125	132	O
population	133	143	O
had	144	147	O
diabetes	148	156	O
ruled	157	162	O
in	163	165	O
or	166	168	O
ruled	169	174	O
out	175	178	O
(	179	180	O
Fig	180	183	O
.	183	184	O
1B	185	187	O
)	187	188	O
,	188	189	O
while	190	195	O
the	196	199	O
remaining	200	209	O
24	210	212	O
.	212	213	O
1	213	214	O
%	214	215	O
had	216	219	O
impaired	220	228	O
A1C	229	232	O
.	232	233	O

From	234	238	O
those	239	244	O
with	245	249	O
impaired	250	258	O
A1C	259	262	O
,	262	263	O
69	264	266	O
.	266	267	O
3	267	268	O
%	268	269	O
had	270	273	O
abnormal	274	282	O
glucose	283	290	O
status	291	297	O
.	297	298	O

For	299	302	O
diabetes	303	311	O
,	311	312	O
A1C	313	316	O
at	317	319	O
5	320	321	O
.	321	322	O
5	322	323	O
%	323	324	O
provided	325	333	O
moderate	334	342	O
sensitivity	343	354	O
(	355	356	O
83	356	358	O
.	358	359	O
5	359	360	O
%	360	361	O
)	361	362	O
but	363	366	O
high	367	371	O
NPV	372	375	O
(	376	377	O
99	377	379	O
.	379	380	O
0	380	381	O
%	381	382	O
)	382	383	O
,	383	384	O
since	385	390	O
diabetes	391	399	O
prevalence	400	410	O
was	411	414	O
lower	415	420	O
in	421	423	O
the	424	427	O
AusDiab	428	435	O
than	436	440	O
in	441	443	O
the	444	447	O
MP	448	450	O
population	451	461	O
.	461	462	O

A1C	463	466	O
at	467	469	O
7	470	471	O
.	471	472	O
0	472	473	O
%	473	474	O
gave	475	479	O
100	480	483	O
%	483	484	O
specificity	485	496	O
and	497	500	O
100	501	504	O
%	504	505	O
PPV	506	509	O
.	509	510	O

By	511	513	O
dropping	514	522	O
the	523	526	O
cut	527	530	O
off	531	534	O
to	535	537	O
6	538	539	O
.	539	540	O
5	540	541	O
%	541	542	O
,	542	543	O
specificity	544	555	O
remained	556	564	O
99	565	567	O
.	567	568	O
9	568	569	O
%	569	570	O
,	570	571	O
with	572	576	O
PPV	577	580	O
near	581	585	O
100	586	589	O
%	589	590	O
.	590	591	O

Calcium	0	7	O
intake	8	14	O
and	15	18	O
effects	19	26	O
on	27	29	O
QUS	30	33	O
T	34	35	O
-	35	36	O
score	36	41	O

Figure	42	48	O
5	49	50	O
shows	51	56	O
the	57	60	O
amounts	61	68	O
of	69	71	O
dietary	72	79	O
calcium	80	87	O
intake	88	94	O
according	95	104	O
to	105	107	O
menopausal	108	118	O
status	119	125	O
.	125	126	O

Calcium	127	134	O
consumption	135	146	O
in	147	149	O
most	150	154	O
groups	155	161	O
,	161	162	O
like	163	167	O
that	168	172	O
in	173	175	O
the	176	179	O
study	180	185	O
population	186	196	O
as	197	199	O
a	200	201	O
whole	202	207	O
,	207	208	O
was	209	212	O
inadequate	213	223	O
.	223	224	O

Fewer	225	230	O
than	231	235	O
one	236	239	O
third	240	245	O
of	246	248	O
premenopausal	249	262	O
and	263	266	O
postmenopausal	267	281	O
women	282	287	O
received	288	296	O
more	297	301	O
than	302	306	O
800	307	310	O
mg	311	313	O
calcium	314	321	O
daily	322	327	O
,	327	328	O
and	329	332	O
fewer	333	338	O
than	339	343	O
16	344	346	O
%	346	347	O
of	348	350	O
premenopausal	351	364	O
women	365	370	O
in	371	373	O
the	374	377	O
50	378	380	O
-	380	381	O
59	381	383	O
age	384	387	O
decade	388	394	O
(	395	396	O
n	396	397	O
=	398	399	O
38	400	402	O
)	402	403	O
consumed	404	412	O
more	413	417	O
than	418	422	O
800	423	426	O
mg	427	429	O
calcium	430	437	O
daily	438	443	O
.	443	444	O

Figure	445	451	O
5	452	453	O

Daily	454	459	O
calcium	460	467	O
intake	468	474	O
in	475	477	O
premenopausal	478	491	O
and	492	495	O
postmenopausal	496	510	O
women	511	516	O
.	516	517	O

This	518	522	O
figure	523	529	O
depicts	530	537	O
the	538	541	O
daily	542	547	O
amounts	548	555	O
of	556	558	O
dietary	559	566	O
calcium	567	574	O
intake	575	581	O
(	582	583	O
and	583	586	O
percent	587	594	O
)	594	595	O
according	596	605	O
to	606	608	O
menopausal	609	619	O
status	620	626	O
using	627	632	O
800	633	636	O
mg	637	639	O
daily	640	645	O
as	646	648	O
cut	649	652	O
off	653	656	O
point	657	662	O
.	662	663	O

QUS	664	667	O
T	668	669	O
-	669	670	O
score	670	675	O
were	676	680	O
then	681	685	O
calculated	686	696	O
according	697	706	O
to	707	709	O
daily	710	715	O
calcium	716	723	O
intake	724	730	O
in	731	733	O
all	734	737	O
premenopausal	738	751	O
and	752	755	O
postmenopausal	756	770	O
activity	771	779	O
groups	780	786	O
using	787	792	O
800	793	796	O
mg	797	799	O
daily	800	805	O
calcium	806	813	O
as	814	816	O
cutoff	817	823	O
point	824	829	O
.	829	830	O

As	831	833	O
shown	834	839	O
in	840	842	O
Tables	843	849	O
3	850	851	O
and	852	855	O
4	856	857	O
and	858	861	O
Figure	862	868	O
6	869	870	O
,	870	871	O
premenopausal	872	885	O
women	886	891	O
who	892	895	O
were	896	900	O
systematically	901	915	O
active	916	922	O
and	923	926	O
consumed	927	935	O
more	936	940	O
than	941	945	O
800	946	949	O
mg	950	952	O
calcium	953	960	O
daily	961	966	O
had	967	970	O
significantly	971	984	O
higher	985	991	O
QUS	992	995	O
T	996	997	O
-	997	998	O
scores	998	1004	O
compared	1005	1013	O
with	1014	1018	O
all	1019	1022	O
other	1023	1028	O
activity	1029	1037	O
groups	1038	1044	O
(	1045	1046	O
p	1046	1047	O
<	1048	1049	O
0	1050	1051	O
.	1051	1052	O
05	1052	1054	O
)	1054	1055	O
.	1055	1056	O

Among	1057	1062	O
systematically	1063	1077	O
active	1078	1084	O
premenopausal	1085	1098	O
women	1099	1104	O
who	1105	1108	O
received	1109	1117	O
more	1118	1122	O
than	1123	1127	O
800	1128	1131	O
mg	1132	1134	O
calcium	1135	1142	O
per	1143	1146	O
day	1147	1150	O
,	1150	1151	O
this	1152	1156	O
difference	1157	1167	O
was	1168	1171	O
separately	1172	1182	O
significant	1183	1194	O
verses	1195	1201	O
sedentary	1202	1211	O
(	1212	1213	O
p	1213	1214	O
=	1215	1216	O
0	1217	1218	O
.	1218	1219	O
028	1219	1222	O
)	1222	1223	O
and	1224	1227	O
moderately	1228	1238	O
active	1239	1245	O
(	1246	1247	O
p	1247	1248	O
=	1249	1250	O
0	1251	1252	O
.	1252	1253	O
04	1253	1255	O
)	1255	1256	O
women	1257	1262	O
.	1262	1263	O

In	1264	1266	O
contrast	1267	1275	O
,	1275	1276	O
postmenopausal	1277	1291	O
women	1292	1297	O
showed	1298	1304	O
no	1305	1307	O
difference	1308	1318	O
in	1319	1321	O
QUS	1322	1325	O
T	1326	1327	O
-	1327	1328	O
scores	1328	1334	O
regardless	1335	1345	O
of	1346	1348	O
the	1349	1352	O
amount	1353	1359	O
of	1360	1362	O
daily	1363	1368	O
calcium	1369	1376	O
intake	1377	1383	O
.	1383	1384	O

Figure	1385	1391	O
6	1392	1393	O

Synergy	1394	1401	O
between	1402	1409	O
physical	1410	1418	O
activity	1419	1427	O
and	1428	1431	O
dietary	1432	1439	O
calcium	1440	1447	O
intake	1448	1454	O
in	1455	1457	O
women	1458	1463	O
consuming	1464	1473	O
calcium	1474	1481	O
amounts	1482	1489	O
greater	1490	1497	O
than	1498	1502	O
800	1503	1506	O
mg	1507	1509	O
/	1509	1510	O
day	1510	1513	O
.	1513	1514	O

This	1515	1519	O
graphic	1520	1527	O
depicts	1528	1535	O
mean	1536	1540	O
QUS	1541	1544	O
T	1545	1546	O
-	1546	1547	O
score	1547	1552	O
values	1553	1559	O
calculated	1560	1570	O
according	1571	1580	O
to	1581	1583	O
daily	1584	1589	O
calcium	1590	1597	O
intake	1598	1604	O
in	1605	1607	O
all	1608	1611	O
premenopausal	1612	1625	O
and	1626	1629	O
postmenopausal	1630	1644	O
activity	1645	1653	O
groups	1654	1660	O
using	1661	1666	O
800	1667	1670	O
mg	1671	1673	O
daily	1674	1679	O
as	1680	1682	O
cut	1683	1686	O
off	1687	1690	O
point	1691	1696	O
(	1697	1698	O
for	1698	1701	O
statistical	1702	1713	O
significant	1714	1725	O
values	1726	1732	O
see	1733	1736	O
text	1737	1741	O
)	1741	1742	O
.	1742	1743	O

CONCLUSIONS	0	11	O

The	12	15	O
lack	16	20	O
of	21	23	O
association	24	35	O
between	36	43	O
depression	44	54	O
and	55	58	O
glycemic	59	67	O
control	68	75	O
is	76	78	O
not	79	82	O
due	83	86	O
to	87	89	O
the	90	93	O
use	94	97	O
of	98	100	O
a	101	102	O
binary	103	109	O
measure	110	117	O
of	118	120	O
depression	121	131	O
.	131	132	O

Findings	133	141	O
further	142	149	O
clarify	150	157	O
the	158	161	O
significant	162	173	O
association	174	185	O
between	186	193	O
distress	194	202	O
and	203	206	O
A1C	207	210	O
.	210	211	O

Discussion	0	10	O

This	11	15	O
is	16	18	O
the	19	22	O
first	23	28	O
study	29	34	O
to	35	37	O
employ	38	44	O
such	45	49	O
a	50	51	O
large	52	57	O
number	58	64	O
of	65	67	O
replicated	68	78	O
samples	79	86	O
in	87	89	O
order	90	95	O
to	96	98	O
assess	99	105	O
the	106	109	O
bacterial	110	119	O
communities	120	131	O
of	132	134	O
healthy	135	142	O
and	143	146	O
diseased	147	155	O
corals	156	162	O
,	162	163	O
and	164	167	O
the	168	171	O
first	172	177	O
culture	178	185	O
-	185	186	O
independent	186	197	O
assessment	198	208	O
of	209	211	O
bacterial	212	221	O
communities	222	233	O
on	234	236	O
Acroporid	237	246	O
WS	247	249	O
corals	250	256	O
on	257	259	O
the	260	263	O
GBR	264	267	O
.	267	268	O

Despite	269	276	O
the	277	280	O
potential	281	290	O
of	291	293	O
not	294	297	O
capturing	298	307	O
rare	308	312	O
or	313	315	O
very	316	320	O
low	321	324	O
abundance	325	334	O
bacterial	335	344	O
ribotypes	345	354	O
,	354	355	O
the	356	359	O
DGGE	360	364	O
analysis	365	373	O
used	374	378	O
in	379	381	O
this	382	386	O
study	387	392	O
indicated	393	402	O
similar	403	410	O
results	411	418	O
of	419	421	O
captured	422	430	O
bacterial	431	440	O
ribotypes	441	450	O
and	451	454	O
tentative	455	464	O
bacterial	465	474	O
species	475	482	O
replacement	483	494	O
in	495	497	O
unhealthy	498	507	O
corals	508	514	O
to	515	517	O
that	518	522	O
of	523	525	O
less	526	530	O
replicated	531	541	O
studies	542	549	O
using	550	555	O
other	556	561	O
non	562	565	O
-	565	566	O
culture	566	573	O
based	574	579	O
techniques	580	590	O
(	591	592	O
e	592	593	O
.	593	594	O
g	594	595	O
.	595	596	O
[	597	598	O
3	598	599	O
]	599	600	O
,	600	601	O
[	602	603	O
54	603	605	O
]	605	606	O
,	606	607	O
[	608	609	O
69	609	611	O
]	611	612	O
;	612	613	O
Figure	614	620	O
4	621	622	O
)	622	623	O
.	623	624	O

The	625	628	O
results	629	636	O
from	637	641	O
this	642	646	O
research	647	655	O
reinforce	656	665	O
,	665	666	O
with	667	671	O
statistically	672	685	O
relevant	686	694	O
data	695	699	O
,	699	700	O
that	701	705	O
corals	706	712	O
harbour	713	720	O
bacterial	721	730	O
communities	731	742	O
different	743	752	O
to	753	755	O
the	756	759	O
water	760	765	O
column	766	772	O
[	773	774	O
7	774	775	O
]	775	776	O
,	776	777	O
[	778	779	O
9	779	780	O
]	780	781	O
,	781	782	O
[	783	784	O
42	784	786	O
]	786	787	O
,	787	788	O
corroborate	789	800	O
findings	801	809	O
that	810	814	O
corals	815	821	O
associate	822	831	O
only	832	836	O
with	837	841	O
certain	842	849	O
specific	850	858	O
bacterial	859	868	O
groups	869	875	O
,	875	876	O
and	877	880	O
that	881	885	O
these	886	891	O
coral	892	897	O
-	897	898	O
associated	898	908	O
bacterial	909	918	O
communities	919	930	O
are	931	934	O
'	935	936	O
host	936	940	O
'	940	941	O
species	942	949	O
-	949	950	O
specific	950	958	O
[	959	960	O
2	960	961	O
]	961	962	O
.	962	963	O

The	964	967	O
data	968	972	O
presented	973	982	O
here	983	987	O
highlight	988	997	O
a	998	999	O
cluster	1000	1007	O
of	1008	1010	O
bacterial	1011	1020	O
ribotypes	1021	1030	O
frequently	1031	1041	O
associated	1042	1052	O
with	1053	1057	O
corals	1058	1064	O
,	1064	1065	O
and	1066	1069	O
the	1070	1073	O
distribution	1074	1086	O
of	1087	1089	O
these	1090	1095	O
bacterial	1096	1105	O
ribotypes	1106	1115	O
on	1116	1118	O
healthy	1119	1126	O
and	1127	1130	O
diseased	1131	1139	O
corals	1140	1146	O
,	1146	1147	O
which	1148	1153	O
allows	1154	1160	O
for	1161	1164	O
further	1165	1172	O
targeted	1173	1181	O
research	1182	1190	O
into	1191	1195	O
a	1196	1197	O
tentative	1198	1207	O
link	1208	1212	O
between	1213	1220	O
these	1221	1226	O
common	1227	1233	O
coral	1234	1239	O
associates	1240	1250	O
and	1251	1254	O
coral	1255	1260	O
health	1261	1267	O
.	1267	1268	O

This	1269	1273	O
study	1274	1279	O
indicates	1280	1289	O
that	1290	1294	O
coral	1295	1300	O
bacterial	1301	1310	O
community	1311	1320	O
assessments	1321	1332	O
require	1333	1340	O
a	1341	1342	O
number	1343	1349	O
of	1350	1352	O
replicates	1353	1363	O
per	1364	1367	O
coral	1368	1373	O
species	1374	1381	O
and	1382	1385	O
site	1386	1390	O
to	1391	1393	O
accurately	1394	1404	O
describe	1405	1413	O
the	1414	1417	O
diversity	1418	1427	O
present	1428	1435	O
across	1436	1442	O
the	1443	1446	O
population	1447	1457	O
and	1458	1461	O
in	1462	1464	O
order	1465	1470	O
to	1471	1473	O
draw	1474	1478	O
inferences	1479	1489	O
on	1490	1492	O
health	1493	1499	O
-	1499	1500	O
related	1500	1507	O
changes	1508	1515	O
in	1516	1518	O
the	1519	1522	O
community	1523	1532	O
composition	1533	1544	O
.	1544	1545	O

In	1546	1548	O
addition	1549	1557	O
,	1557	1558	O
the	1559	1562	O
comparisons	1563	1574	O
of	1575	1577	O
healthy	1578	1585	O
and	1586	1589	O
diseased	1590	1598	O
Acropora	1599	1607	O
hyacinthus	1608	1618	O
samples	1619	1626	O
showed	1627	1633	O
that	1634	1638	O
bacterial	1639	1648	O
communities	1649	1660	O
can	1661	1664	O
change	1665	1671	O
dramatically	1672	1684	O
in	1685	1687	O
diseased	1688	1696	O
individuals	1697	1708	O
.	1708	1709	O

The	1710	1713	O
DGGE	1714	1718	O
profiles	1719	1727	O
observed	1728	1736	O
for	1737	1740	O
corals	1741	1747	O
displaying	1748	1758	O
signs	1759	1764	O
of	1765	1767	O
White	1768	1773	O
Syndrome	1774	1782	O
comprised	1783	1792	O
a	1793	1794	O
range	1795	1800	O
of	1801	1803	O
bacterial	1804	1813	O
ribotypes	1814	1823	O
not	1824	1827	O
generally	1828	1837	O
found	1838	1843	O
on	1844	1846	O
healthy	1847	1854	O
corals	1855	1861	O
,	1861	1862	O
including	1863	1872	O
close	1873	1878	O
relatives	1879	1888	O
of	1889	1891	O
bacteria	1892	1900	O
previously	1901	1911	O
found	1912	1917	O
on	1918	1920	O
Black	1921	1926	O
Band	1927	1931	O
Diseased	1932	1940	O
corals	1941	1947	O
.	1947	1948	O

However	1949	1956	O
the	1957	1960	O
community	1961	1970	O
profiles	1971	1979	O
across	1980	1986	O
the	1987	1990	O
samples	1991	1998	O
taken	1999	2004	O
from	2005	2009	O
diseased	2010	2018	O
coral	2019	2024	O
colonies	2025	2033	O
were	2034	2038	O
inconsistent	2039	2051	O
and	2052	2055	O
not	2056	2059	O
indicative	2060	2070	O
of	2071	2073	O
a	2074	2075	O
single	2076	2082	O
bacterial	2083	2092	O
causative	2093	2102	O
agent	2103	2108	O
.	2108	2109	O

The	0	3	O
eukaryotic	4	14	O
parasite	15	23	O
Trypanosoma	24	35	O
brucei	36	42	O
is	43	45	O
able	46	50	O
to	51	53	O
import	54	60	O
inositol	61	69	O
from	70	74	O
the	75	78	O
environment	79	90	O
or	91	93	O
synthesize	94	104	O
it	105	107	O
de	108	110	O
novo	111	115	O
.	115	116	O

However	117	124	O
,	124	125	O
according	126	135	O
to	136	138	O
the	139	142	O
current	143	150	O
model	151	156	O
,	156	157	O
inositol	158	166	O
imported	167	175	O
from	176	180	O
the	181	184	O
environment	185	196	O
is	197	199	O
utilized	200	208	O
primarily	209	218	O
in	219	221	O
bulk	222	226	O
phosphatidylinositol	227	247	O
(	248	249	O
red	249	252	O
and	253	256	O
yellow	257	263	O
phospholipid	264	276	O
)	276	277	O
production	278	288	O
via	289	292	O
a	293	294	O
phosphatidylinositol	295	315	O
synthase	316	324	O
(	325	326	O
PIS	326	329	O
)	329	330	O
localized	331	340	O
to	341	343	O
the	344	347	O
Golgi	348	353	B-Cellular_component
complex	354	361	I-Cellular_component
.	361	362	O

Inositol	363	371	O
synthesized	372	383	O
de	384	386	O
novo	387	391	O
is	392	394	O
primarily	395	404	O
used	405	409	O
to	410	412	O
generate	413	421	O
phosphatidylinositol	422	442	O
that	443	447	O
is	448	450	O
used	451	455	O
for	456	459	O
production	460	470	O
of	471	473	O
glycosylphosphatidylinositols	474	503	O
(	504	505	O
GPIs	505	509	O
)	509	510	O
.	510	511	O

The	512	515	O
de	516	518	O
novo	519	523	O
-	523	524	O
synthesized	524	535	O
inositol	536	544	O
is	545	547	O
believed	548	556	O
to	557	559	O
be	560	562	O
utilized	563	571	O
mostly	572	578	O
for	579	582	O
GPI	583	586	O
production	587	597	O
because	598	605	O
the	606	609	O
IMPase	610	616	O
that	617	621	O
dephosphorylates	622	638	O
inositol	639	647	O
3	648	649	O
-	649	650	O
phosphate	650	659	O
to	660	662	O
inositol	663	671	O
is	672	674	O
localized	675	684	O
to	685	687	O
the	688	691	O
ER	692	694	O
,	694	695	O
where	696	701	O
GPI	702	705	O
synthesis	706	715	O
occurs	716	722	O
.	722	723	O

Mutants	724	731	O
lacking	732	739	O
TbINO1	740	746	O
are	747	750	O
inviable	751	759	O
because	760	767	O
of	768	770	O
diminished	771	781	O
GPI	782	785	O
production	786	796	O
.	796	797	O

Large	0	5	O
nodular	6	13	B-Pathological_formation
hepatic	14	21	I-Pathological_formation
flexure	22	29	I-Pathological_formation
lesions	30	37	I-Pathological_formation
as	38	40	O
seen	41	45	O
on	46	48	O
Colonoscopy	49	60	O
.	60	61	O

Water	0	5	O
emerging	6	14	O
from	15	19	O
the	20	23	O
yoke	24	28	O
adapter	29	36	O
of	37	39	O
the	40	43	O
nitrous	44	51	O
oxide	52	57	O
hose	58	62	O

The	0	3	O
pedigree	4	12	O
of	13	15	O
a	16	17	O
Korean	18	24	O
family	25	31	O
with	32	36	O
macular	37	44	B-Tissue
dystrophy	45	54	O
demonstrating	55	68	O
the	69	72	O
characteristics	73	88	O
of	89	91	O
an	92	94	O
autosomal	95	104	O
dominant	105	113	O
inheritance	114	125	O
trait	126	131	O
.	131	132	O

Histological	0	12	O
analysis	13	21	O

A	22	23	O
cross	24	29	O
-	29	30	O
section	30	37	O
of	38	40	O
the	41	44	O
distal	45	51	B-Multi-tissue_structure
colon	52	57	I-Multi-tissue_structure
(	58	59	O
2	59	60	O
cm	61	63	O
)	63	64	O
was	65	68	O
fixed	69	74	O
in	75	77	O
10	78	80	O
%	80	81	O
paraformaldehyde	82	98	O
solution	99	107	O
.	107	108	O

Afterwards	109	119	O
,	119	120	O
it	121	123	O
was	124	127	O
cut	128	131	O
into	132	136	O
small	137	142	O
fragments	143	152	O
,	152	153	O
dehydrated	154	164	O
through	165	172	O
an	173	175	O
ethanol	176	183	O
series	184	190	O
(	191	192	O
70	192	194	O
%	194	195	O
-	195	196	O
100	196	199	O
%	199	200	O
)	200	201	O
,	201	202	O
cleared	203	210	O
in	211	213	O
xylol	214	219	O
and	220	223	O
embedded	224	232	O
in	233	235	O
paraffin	236	244	O
.	244	245	O

The	246	249	O
fragments	250	259	B-Multi-tissue_structure
were	260	264	O
sliced	265	271	O
into	272	276	O
5	277	278	O
mum	279	282	O
thick	283	288	O
sections	289	297	O
and	298	301	O
stained	302	309	O
with	310	314	O
hematoxylin	315	326	O
-	326	327	O
eosin	327	332	O
.	332	333	O

Histological	334	346	O
evaluation	347	357	O
was	358	361	O
done	362	366	O
by	367	369	O
a	370	371	O
pathologist	372	383	O
who	384	387	O
was	388	391	O
blinded	392	399	O
to	400	402	O
the	403	406	O
experimental	407	419	O
groups	420	426	O
,	426	427	O
and	428	431	O
it	432	434	O
was	435	438	O
based	439	444	O
on	445	447	O
the	448	451	O
intensity	452	461	O
of	462	464	O
mononuclear	465	476	O
and	477	480	O
polymorphonuclear	481	498	O
infiltrates	499	510	O
in	511	513	O
the	514	517	O
lamina	518	524	B-Tissue
propria	525	532	I-Tissue
,	532	533	O
crypt	534	539	B-Immaterial_anatomical_entity
dilation	540	548	O
,	548	549	O
cellular	550	558	B-Cell
destruction	559	570	O
and	571	574	O
mucosal	575	582	B-Multi-tissue_structure
ulceration	583	593	O
.	593	594	O

Histopathological	595	612	O
changes	613	620	O
were	621	625	O
graded	626	632	O
according	633	642	O
to	643	645	O
the	646	649	O
degree	650	656	O
of	657	659	O
inflammation	660	672	O
using	673	678	O
the	679	682	O
following	683	692	O
scale	693	698	O
:	698	699	O
absent	700	706	O
(	707	708	O
0	708	709	O
)	709	710	O
,	710	711	O
light	712	717	O
(	718	719	O
1	719	720	O
)	720	721	O
,	721	722	O
moderate	723	731	O
(	732	733	O
2	733	734	O
)	734	735	O
and	736	739	O
intense	740	747	O
(	748	749	O
3	749	750	O
)	750	751	O
,	751	752	O
and	753	756	O
the	757	760	O
numbers	761	768	O
represented	769	780	O
the	781	784	O
inflammation	785	797	O
score	798	803	O
(	804	805	O
IS	805	807	O
)	807	808	O
.	808	809	O

Results	810	817	O
were	818	822	O
expressed	823	832	O
as	833	835	O
mean	836	840	O
values	841	847	O
of	848	850	O
IS	851	853	O
+	854	855	O
/	855	856	O
-	856	857	O
standard	858	866	O
error	867	872	O
of	873	875	O
the	876	879	O
mean	880	884	O
(	885	886	O
SEM	886	889	O
)	889	890	O
for	891	894	O
each	895	899	O
experimental	900	912	O
group	913	918	O
.	918	919	O

Pteris	0	6	O
vittata	7	14	O

Intervention	0	12	O

Patients	13	21	O
'	21	22	O
initial	23	30	O
introduction	31	43	O
to	44	46	O
the	47	50	O
Wrist	51	56	B-Organism_subdivision
Extension	57	66	O
Dynasplint	67	77	O
(	78	79	O
WED	79	82	O
)	82	83	O
system	84	90	O
,	90	91	O
[	92	93	O
Dynasplint	93	103	O
Systems	104	111	O
,	111	112	O
Inc	113	116	O
.	116	117	O
,	117	118	O
Severna	119	126	O
Park	127	131	O
,	131	132	O
MD	133	135	O
,	135	136	O
USA	137	140	O
]	140	141	O
included	142	150	O
customized	151	161	O
fitting	162	169	O
(	170	171	O
wrist	171	176	B-Organism_subdivision
length	177	183	O
,	183	184	O
width	185	190	O
,	190	191	O
and	192	195	O
girth	196	201	O
so	202	204	O
that	205	209	O
the	210	213	O
force	214	219	O
and	220	223	O
counter	224	231	O
force	232	237	O
straps	238	244	O
could	245	250	O
be	251	253	O
properly	254	262	O
aligned	263	270	O
)	270	271	O
and	272	275	O
training	276	284	O
on	285	287	O
donning	288	295	O
and	296	299	O
doffing	300	307	O
of	308	310	O
the	311	314	O
device	315	321	O
.	321	322	O

(	323	324	O
See	324	327	O
figure	328	334	O
1	335	336	O
.	336	337	O
)	337	338	O
Verbal	339	345	O
and	346	349	O
written	350	357	O
instructions	358	370	O
were	371	375	O
provided	376	384	O
throughout	385	395	O
the	396	399	O
duration	400	408	O
of	409	411	O
treatment	412	421	O
for	422	425	O
safety	426	432	O
,	432	433	O
general	434	441	O
wear	442	446	O
and	447	450	O
care	451	455	O
,	455	456	O
and	457	460	O
tension	461	468	O
setting	469	476	O
goals	477	482	O
based	483	488	O
on	489	491	O
patient	492	499	O
tolerance	500	509	O
.	509	510	O

Figure	511	517	O
1	518	519	O

Wrist	520	525	B-Organism_subdivision
Extension	526	535	O
Dynasplint	536	546	O
.	546	547	O

Each	548	552	O
patient	553	560	O
initially	561	570	O
wore	571	575	O
the	576	579	O
WED	580	583	O
for	584	587	O
4	588	589	O
-	589	590	O
6	590	591	O
continuous	592	602	O
hours	603	608	O
at	609	611	O
an	612	614	O
initial	615	622	O
tension	623	630	O
setting	631	638	O
of	639	641	O
#	642	643	O
2	643	644	O
(	645	646	O
0	646	647	O
.	647	648	O
1	648	649	O
foot	650	654	O
pounds	655	661	O
of	662	664	O
torque	665	671	O
)	671	672	O
.	672	673	O

This	674	678	O
duration	679	687	O
was	688	691	O
for	692	695	O
acclimatization	696	711	O
to	712	714	O
the	715	718	O
system	719	725	O
;	725	726	O
then	727	731	O
patients	732	740	O
were	741	745	O
instructed	746	756	O
to	757	759	O
wear	760	764	O
the	765	768	O
WED	769	772	O
system	773	779	O
at	780	782	O
night	783	788	O
while	789	794	O
sleeping	795	803	O
for	804	807	O
6	808	809	O
-	809	810	O
8	810	811	O
hours	812	817	O
of	818	820	O
continuous	821	831	O
wear	832	836	O
.	836	837	O

After	838	843	O
each	844	848	O
patient	849	856	O
was	857	860	O
comfortable	861	872	O
wearing	873	880	O
the	881	884	O
unit	885	889	O
for	890	893	O
one	894	897	O
week	898	902	O
at	903	905	O
tension	906	913	O
level	914	919	O
#	920	921	O
2	921	922	O
,	922	923	O
they	924	928	O
were	929	933	O
instructed	934	944	O
to	945	947	O
increase	948	956	O
the	957	960	O
tension	961	968	O
level	969	974	O
to	975	977	O
#	978	979	O
3	979	980	O
(	981	982	O
0	982	983	O
.	983	984	O
3	984	985	O
ft	986	988	O
lbs	989	992	O
.	992	993	O
)	993	994	O
and	995	998	O
make	999	1003	O
continual	1004	1013	O
increases	1014	1023	O
every	1024	1029	O
two	1030	1033	O
weeks	1034	1039	O
.	1039	1040	O

If	1041	1043	O
prolonged	1044	1053	O
soreness	1054	1062	O
followed	1063	1071	O
a	1072	1073	O
session	1074	1081	O
(	1082	1083	O
soreness	1083	1091	O
for	1092	1095	O
more	1096	1100	O
than	1101	1105	O
15	1106	1108	O
minutes	1109	1116	O
)	1116	1117	O
the	1118	1121	O
patient	1122	1129	O
was	1130	1133	O
instructed	1134	1144	O
to	1145	1147	O
decrease	1148	1156	O
the	1157	1160	O
tension	1161	1168	O
one	1169	1172	O
half	1173	1177	O
a	1178	1179	O
setting	1180	1187	O
for	1188	1191	O
two	1192	1195	O
days	1196	1200	O
until	1201	1206	O
they	1207	1211	O
were	1212	1216	O
comfortable	1217	1228	O
wearing	1229	1236	O
it	1237	1239	O
for	1240	1243	O
6	1244	1245	O
-	1245	1246	O
8	1246	1247	O
hours	1248	1253	O
at	1254	1256	O
the	1257	1260	O
new	1261	1264	O
tension	1265	1272	O
setting	1273	1280	O
.	1280	1281	O

The	1282	1285	O
majority	1286	1294	O
of	1295	1297	O
all	1298	1301	O
patients	1302	1310	O
reached	1311	1318	O
level	1319	1324	O
#	1325	1326	O
5	1326	1327	O
(	1328	1329	O
0	1329	1330	O
.	1330	1331	O
8	1331	1332	O
foot	1333	1337	O
pounds	1338	1344	O
of	1345	1347	O
torque	1348	1354	O
)	1354	1355	O
by	1356	1358	O
the	1359	1362	O
end	1363	1366	O
of	1367	1369	O
two	1370	1373	O
months	1374	1380	O
.	1380	1381	O

All	1382	1385	O
range	1386	1391	O
of	1392	1394	O
motion	1395	1401	O
measurements	1402	1414	O
were	1415	1419	O
recorded	1420	1428	O
by	1429	1431	O
the	1432	1435	O
prescribing	1436	1447	O
clinician	1448	1457	O
.	1457	1458	O

Animals	0	7	O

STOP	8	12	O
null	13	17	O
mice	18	22	O
and	23	26	O
their	27	32	O
WT	33	35	O
littermates	36	47	O
were	48	52	O
generated	53	62	O
on	63	65	O
a	66	67	O
mixed	68	73	O
BALBc	74	79	O
/	79	80	O
129	80	83	O
SvPas	84	89	O
and	90	93	O
on	94	96	O
a	97	98	O
pure	99	103	O
129	104	107	O
SvPas	108	113	O
background	114	124	O
as	125	127	O
previously	128	138	O
reported	139	147	O
by	148	150	O
Andrieux	151	159	O
et	160	162	O
al	163	165	O
.	165	166	O

[	167	168	O
4	168	169	O
]	169	170	O
.	170	171	O

All	172	175	O
animals	176	183	O
used	184	188	O
in	189	191	O
the	192	195	O
study	196	201	O
underwent	202	211	O
immunohistochemistry	212	232	O
for	233	236	O
the	237	240	O
detection	241	250	O
of	251	253	O
STOP	254	258	O
protein	259	266	O
,	266	267	O
resulting	268	277	O
in	278	280	O
no	281	283	O
staining	284	292	O
in	293	295	O
STOP	296	300	O
null	301	305	O
mice	306	310	O
,	310	311	O
and	312	315	O
genotyping	316	326	O
by	327	329	O
PCR	330	333	O
as	334	336	O
described	337	346	O
by	347	349	O
Andrieux	350	358	O
et	359	361	O
al	362	364	O
.	364	365	O

[	366	367	O
4	367	368	O
]	368	369	O
.	369	370	O

All	371	374	O
mice	375	379	O
were	380	384	O
kept	385	389	O
under	390	395	O
standard	396	404	O
housing	405	412	O
conditions	413	423	O
with	424	428	O
a	429	430	O
12	431	433	O
-	433	434	O
hour	434	438	O
/	438	439	O
12	439	441	O
-	441	442	O
hour	442	446	O
dark	447	451	O
-	451	452	O
light	452	457	O
cycle	458	463	O
.	463	464	O

The	465	468	O
experiments	469	480	O
were	481	485	O
carried	486	493	O
out	494	497	O
in	498	500	O
accordance	501	511	O
with	512	516	O
the	517	520	O
European	521	529	O
Communities	530	541	O
Council	542	549	O
Directive	550	559	O
of	560	562	O
24	563	565	O
November	566	574	O
1986	575	579	O
(	580	581	O
86	581	583	O
/	583	584	O
609	584	587	O
/	587	588	O
EEC	588	591	O
)	591	592	O
,	592	593	O
and	594	597	O
the	598	601	O
French	602	608	O
Department	609	619	O
of	620	622	O
Agriculture	623	634	O
(	635	636	O
License	636	643	O
Ndegrees	644	652	O
67	653	655	O
-	655	656	O
95	656	658	O
)	658	659	O
.	659	660	O

The	661	664	O
protocol	665	673	O
was	674	677	O
approved	678	686	O
by	687	689	O
the	690	693	O
ethical	694	701	O
Animal	702	708	O
Research	709	717	O
Committee	718	727	O
of	728	730	O
Louis	731	736	O
Pasteur	737	744	O
University	745	755	O
(	756	757	O
CREMEAS	757	764	O
#	765	766	O
AL	766	768	O
/	768	769	O
01	769	771	O
/	771	772	O
19	772	774	O
/	774	775	O
10	775	777	O
/	777	778	O
07	778	780	O
)	780	781	O
.	781	782	O

In	783	785	O
a	786	787	O
first	788	793	O
experiment	794	804	O
,	804	805	O
we	806	808	O
searched	809	817	O
for	818	821	O
differences	822	833	O
in	834	836	O
glomerular	837	847	B-Multi-tissue_structure
ultrastructure	848	862	O
and	863	866	O
peripheral	867	877	O
neurogenesis	878	890	O
between	891	898	O
WT	899	901	O
and	902	905	O
STOP	906	910	O
null	911	915	O
mice	916	920	O
:	920	921	O
a	922	923	O
first	924	929	O
group	930	935	O
of	936	938	O
24	939	941	O
mice	942	946	O
,	946	947	O
3	948	949	O
-	949	950	O
to	951	953	O
6	954	955	O
-	955	956	O
month	957	962	O
-	962	963	O
old	963	966	O
,	966	967	O
was	968	971	O
used	972	976	O
for	977	980	O
ultrastructural	981	996	O
study	997	1002	O
of	1003	1005	O
the	1006	1009	O
OBs	1010	1013	O
;	1013	1014	O
a	1015	1016	O
second	1017	1023	O
group	1024	1029	O
of	1030	1032	O
13	1033	1035	O
animals	1036	1043	O
was	1044	1047	O
used	1048	1052	O
to	1053	1055	O
analyse	1056	1063	O
proliferation	1064	1077	O
and	1078	1081	O
apoptosis	1082	1091	O
in	1092	1094	O
the	1095	1098	O
OE	1099	1101	B-Tissue
and	1102	1105	O
VNE	1106	1109	B-Tissue
on	1110	1112	O
paraffin	1113	1121	B-Tissue
sections	1122	1130	I-Tissue
in	1131	1133	O
3	1134	1135	O
-	1135	1136	O
month	1136	1141	O
-	1141	1142	O
old	1142	1145	O
mice	1146	1150	O
.	1150	1151	O

In	1152	1154	O
a	1155	1156	O
second	1157	1163	O
experiment	1164	1174	O
we	1175	1177	O
analysed	1178	1186	O
,	1186	1187	O
in	1188	1190	O
WT	1191	1193	O
and	1194	1197	O
STOP	1198	1202	O
null	1203	1207	O
mice	1208	1212	O
,	1212	1213	O
the	1214	1217	O
effect	1218	1224	O
of	1225	1227	O
OE	1228	1230	B-Tissue
regeneration	1231	1243	O
on	1244	1246	O
glomeruli	1247	1256	B-Multi-tissue_structure
structure	1257	1266	O
and	1267	1270	O
ultrastructure	1271	1285	O
and	1286	1289	O
on	1290	1292	O
peripheral	1293	1303	O
neurogenesis	1304	1316	O
at	1317	1319	O
two	1320	1323	O
age	1324	1327	O
times	1328	1333	O
(	1334	1335	O
3	1335	1336	O
and	1337	1340	O
10	1341	1343	O
months	1344	1350	O
)	1350	1351	O
.	1351	1352	O

Effect	0	6	O
of	7	9	O
the	10	13	O
deletion	14	22	O
of	23	25	O
IRE1alpha	26	35	O
on	36	38	O
the	39	42	O
liver	43	48	B-Organ
.	48	49	O

(	50	51	O
A	51	52	O
)	52	53	O
HE	54	56	O
-	56	57	O
stained	57	64	O
sections	65	73	B-Tissue
of	74	76	O
the	77	80	O
liver	81	86	B-Tissue
tissue	87	93	I-Tissue
(	94	95	O
scale	95	100	O
bar	101	104	O
:	104	105	O
50	106	108	O
mum	109	112	O
)	112	113	O
.	113	114	O

(	115	116	O
B	116	117	O
)	117	118	O
Comparison	119	129	O
of	130	132	O
the	133	136	O
serum	137	142	B-Organism_substance
AST	143	146	O
and	147	150	O
ALT	151	154	O
levels	155	161	O
between	162	169	O
the	170	173	O
IRE1alpha	174	183	O
CKO	184	187	O
mice	188	192	O
and	193	196	O
the	197	200	O
control	201	208	O
mice	209	213	O
.	213	214	O

Data	215	219	O
are	220	223	O
expressed	224	233	O
as	234	236	O
mean	237	241	O
+	242	243	O
/	243	244	O
-	244	245	O
S	246	247	O
.	247	248	O
E	248	249	O
.	249	250	O
M	250	251	O
(	252	253	O
n	253	254	O
=	255	256	O
5	257	258	O
)	258	259	O
.	259	260	O

(	261	262	O
C	262	263	O
)	263	264	O
Quantitative	265	277	O
PCR	278	281	O
analysis	282	290	O
of	291	293	O
lipid	294	299	O
synthesis	300	309	O
genes	310	315	O
in	316	318	O
the	319	322	O
liver	323	328	B-Organ
of	329	331	O
mice	332	336	O
fed	337	340	O
normal	341	347	O
or	348	350	O
high	351	355	O
-	355	356	O
fructose	356	364	O
feed	365	369	O
.	369	370	O

Columns	371	378	O
indicate	379	387	O
mean	388	392	O
and	393	396	O
error	397	402	O
bars	403	407	O
denote	408	414	O
S	415	416	O
.	416	417	O
E	417	418	O
.	418	419	O
M	419	420	O
(	421	422	O
n	422	423	O
=	424	425	O
3	426	427	O
)	427	428	O
.	428	429	O

All	430	433	O
the	434	437	O
data	438	442	O
were	443	447	O
obtained	448	456	O
from	457	461	O
20	462	464	O
weeks	465	470	O
old	471	474	O
male	475	479	O
mice	480	484	O
.	484	485	O

2	0	1	O
.	1	2	O

Methods	3	10	O

Summary	0	7	O
of	8	10	O
instrument	11	21	O
characteristics	22	37	O

Histology	0	9	O
of	10	12	O
the	13	16	O
lung	17	21	B-Organ

The	22	25	O
left	26	30	O
lung	31	35	B-Organ
was	36	39	O
fixed	40	45	O
by	46	48	O
gentle	49	55	O
infusion	56	64	O
of	65	67	O
fixative	68	76	O
(	77	78	O
4	78	79	O
%	79	80	O
paraformaldehyde	81	97	O
)	97	98	O
through	99	106	O
the	107	110	O
tracheal	111	119	B-Multi-tissue_structure
cannula	120	127	O
[	128	129	O
24	129	131	O
]	131	132	O
.	132	133	O

After	134	139	O
excision	140	148	O
,	148	149	O
the	150	153	O
lung	154	158	B-Organ
was	159	162	O
immersed	163	171	O
in	172	174	O
a	175	176	O
fresh	177	182	O
fixative	183	191	O
for	192	195	O
2	196	197	O
h	198	199	O
.	199	200	O

The	201	204	O
lung	205	209	B-Multi-tissue_structure
lobe	210	214	I-Multi-tissue_structure
was	215	218	O
embedded	219	227	O
in	228	230	O
paraffin	231	239	O
and	240	243	O
cut	244	247	O
into	248	252	O
3	253	254	O
mum	255	258	O
transverse	259	269	O
sections	270	278	O
,	278	279	O
followed	280	288	O
by	289	291	O
immunohistochemical	292	311	O
and	312	315	O
chemical	316	324	O
staining	325	333	O
.	333	334	O

Photomicrographs	335	351	O
were	352	356	O
captured	357	365	O
using	366	371	O
KS400	372	377	O
image	378	383	O
analyze	384	391	O
platform	392	400	O
(	401	402	O
Zeiss	402	407	O
,	407	408	O
Oberkochen	409	419	O
,	419	420	O
Germany	421	428	O
)	428	429	O
and	430	433	O
analyzed	434	442	O
quantitatively	443	457	O
.	457	458	O

Data	0	4	O
collection	5	15	O
:	15	16	O
CrystalClear	17	29	O
(	30	31	O
Rigaku	31	37	O
/	37	38	O
MSC	38	41	O
,	41	42	O
2005	43	47	O
>	48	49	O
)	49	50	O
;	50	51	O
cell	52	56	B-Cell
refinement	57	67	O
:	67	68	O
CrystalClear	69	81	O
;	81	82	O
data	83	87	O
reduction	88	97	O
:	97	98	O
CrystalClear	99	111	O
;	111	112	O
program	113	120	O
(	120	121	O
s	121	122	O
)	122	123	O
used	124	128	O
to	129	131	O
solve	132	137	O
structure	138	147	O
:	147	148	O
SHELXS97	149	157	O
(	158	159	O
Sheldrick	159	168	O
,	168	169	O
2008	170	174	O
>	175	176	O
)	176	177	O
;	177	178	O
program	179	186	O
(	186	187	O
s	187	188	O
)	188	189	O
used	190	194	O
to	195	197	O
refine	198	204	O
structure	205	214	O
:	214	215	O
SHELXL97	216	224	O
(	225	226	O
Sheldrick	226	235	O
,	235	236	O
2008	237	241	O
>	242	243	O
)	243	244	O
;	244	245	O
molecular	246	255	O
graphics	256	264	O
:	264	265	O
ORTEPII	266	273	O
(	274	275	O
Johnson	275	282	O
,	282	283	O
1976	284	288	O
>	289	290	O
)	290	291	O
;	291	292	O
software	293	301	O
used	302	306	O
to	307	309	O
prepare	310	317	O
material	318	326	O
for	327	330	O
publication	331	342	O
:	342	343	O
SHELXL97	344	352	O
.	352	353	O

Experimental	0	12	O

The	0	3	O
molecular	4	13	O
structure	14	23	O
of	24	26	O
(	27	28	O
I	28	29	O
)	29	30	O
,	30	31	O
showing	32	39	O
displacement	40	52	O
ellipsoids	53	63	O
at	64	66	O
the	67	70	O
30	71	73	O
%	73	74	O
probability	75	86	O
level	87	92	O
for	93	96	O
non	97	100	O
-	100	101	O
H	101	102	O
atoms	103	108	O
.	108	109	O

Discussion	0	10	O

Our	11	14	O
results	15	22	O
indicate	23	31	O
beneficial	32	42	O
effects	43	50	O
of	51	53	O
motivational	54	66	O
incentives	67	77	O
on	78	80	O
cognitive	81	90	O
performance	91	102	O
and	103	106	O
alleviating	107	118	O
effects	119	126	O
on	127	129	O
cognitive	130	139	O
decline	140	147	O
.	147	148	O

These	149	154	O
beneficial	155	165	O
effects	166	173	O
were	174	178	O
evident	179	186	O
in	187	189	O
healthy	190	197	O
young	198	203	O
and	204	207	O
older	208	213	O
adults	214	220	O
and	221	224	O
in	225	227	O
patients	228	236	O
with	237	241	O
Parkinson	242	251	O
'	251	252	O
s	252	253	O
disease	254	261	O
.	261	262	O

Young	263	268	O
adults	269	275	O
showed	276	282	O
improved	283	291	O
antisaccade	292	303	O
preparation	304	315	O
when	316	320	O
a	321	322	O
reward	323	329	O
was	330	333	O
at	334	336	O
stake	337	342	O
;	342	343	O
older	344	349	O
adults	350	356	O
and	357	360	O
PD	361	363	O
patients	364	372	O
could	373	378	O
utilize	379	386	O
reward	387	393	O
prospect	394	402	O
to	403	405	O
improve	406	413	O
their	414	419	O
impaired	420	428	O
antisaccade	429	440	O
preparation	441	452	O
.	452	453	O

Elderly	454	461	O
participants	462	474	O
and	475	478	O
PD	479	481	O
patients	482	490	O
were	491	495	O
not	496	499	O
only	500	504	O
better	505	511	O
prepared	512	520	O
by	521	523	O
means	524	529	O
of	530	532	O
commonly	533	541	O
used	542	546	O
preparatory	547	558	O
aids	559	563	O
(	564	565	O
i	565	566	O
.	566	567	O
e	567	568	O
.	568	569	O
,	569	570	O
more	571	575	O
preparation	576	587	O
time	588	592	O
and	593	596	O
advance	597	604	O
information	605	616	O
on	617	619	O
the	620	623	O
upcoming	624	632	O
response	633	641	O
)	641	642	O
but	643	646	O
also	647	651	O
by	652	654	O
means	655	660	O
of	661	663	O
motivational	664	676	O
incentives	677	687	O
.	687	688	O

These	689	694	O
beneficial	695	705	O
effects	706	713	O
of	714	716	O
motivational	717	729	O
incentives	730	740	O
on	741	743	O
cognitive	744	753	O
action	754	760	O
preparation	761	772	O
in	773	775	O
healthy	776	783	O
and	784	787	O
pathological	788	800	O
aging	801	806	O
further	807	814	O
support	815	822	O
views	823	828	O
that	829	833	O
question	834	842	O
the	843	846	O
notion	847	853	O
of	854	856	O
monotonic	857	866	O
deterioration	867	880	O
of	881	883	O
cognitive	884	893	O
function	894	902	O
with	903	907	O
age	908	911	O
(	912	913	O
Allen	913	918	O
et	919	921	O
al	922	924	O
.	924	925	O
,	925	926	O
2001	927	931	O
)	931	932	O
.	932	933	O

They	934	938	O
indicate	939	947	O
that	948	952	O
age	953	956	O
-	956	957	O
related	957	964	O
declines	965	973	O
can	974	977	O
be	978	980	O
modulated	981	990	O
by	991	993	O
emotion	994	1001	O
-	1001	1002	O
cognition	1002	1011	O
interactions	1012	1024	O
.	1024	1025	O

In	1026	1028	O
line	1029	1033	O
with	1034	1038	O
the	1039	1042	O
predominant	1043	1054	O
view	1055	1059	O
that	1060	1064	O
cognitive	1065	1074	O
control	1075	1082	O
deteriorates	1083	1095	O
in	1096	1098	O
aging	1099	1104	O
and	1105	1108	O
Parkinson	1109	1118	O
'	1118	1119	O
s	1119	1120	O
disease	1121	1128	O
,	1128	1129	O
and	1130	1133	O
in	1134	1136	O
line	1137	1141	O
with	1142	1146	O
previous	1147	1155	O
findings	1156	1164	O
on	1165	1167	O
age	1168	1171	O
-	1171	1172	O
related	1172	1179	O
changes	1180	1187	O
in	1188	1190	O
antisaccade	1191	1202	O
control	1203	1210	O
specifically	1211	1223	O
(	1224	1225	O
Eenshuistra	1225	1236	O
et	1237	1239	O
al	1240	1242	O
.	1242	1243	O
,	1243	1244	O
2004	1245	1249	O
;	1249	1250	O
Chan	1251	1255	O
et	1256	1258	O
al	1259	1261	O
.	1261	1262	O
,	1262	1263	O
2005	1264	1268	O
;	1268	1269	O
Amador	1270	1276	O
et	1277	1279	O
al	1280	1282	O
.	1282	1283	O
,	1283	1284	O
2006	1285	1289	O
;	1289	1290	O
Abel	1291	1295	O
and	1296	1299	O
Douglas	1300	1307	O
,	1307	1308	O
2007	1309	1313	O
)	1313	1314	O
,	1314	1315	O
the	1316	1319	O
current	1320	1327	O
results	1328	1335	O
showed	1336	1342	O
decline	1343	1350	O
in	1351	1353	O
antisaccade	1354	1365	O
preparation	1366	1377	O
in	1378	1380	O
PD	1381	1383	O
patients	1384	1392	O
with	1393	1397	O
severe	1398	1404	O
motor	1405	1410	O
symptoms	1411	1419	O
as	1420	1422	O
compared	1423	1431	O
to	1432	1434	O
healthy	1435	1442	O
seniors	1443	1450	O
.	1450	1451	O

Mild	1452	1456	O
-	1456	1457	O
symptom	1457	1464	O
patients	1465	1473	O
and	1474	1477	O
healthy	1478	1485	O
elderly	1486	1493	O
did	1494	1497	O
not	1498	1501	O
differ	1502	1508	O
in	1509	1511	O
antisaccade	1512	1523	O
preparation	1524	1535	O
.	1535	1536	O

Healthy	1537	1544	O
seniors	1545	1552	O
showed	1553	1559	O
declining	1560	1569	O
antisaccade	1570	1581	O
preparation	1582	1593	O
as	1594	1596	O
compared	1597	1605	O
to	1606	1608	O
young	1609	1614	O
adults	1615	1621	O
.	1621	1622	O

Decline	1623	1630	O
was	1631	1634	O
evident	1635	1642	O
on	1643	1645	O
several	1646	1653	O
oculomotor	1654	1664	B-Multi-tissue_structure
parameters	1665	1675	O
and	1676	1679	O
most	1680	1684	O
pronounced	1685	1695	O
on	1696	1698	O
antisaccade	1699	1710	O
onset	1711	1716	O
latencies	1717	1726	O
.	1726	1727	O

In	1728	1730	O
line	1731	1735	O
with	1736	1740	O
the	1741	1744	O
notion	1745	1751	O
that	1752	1756	O
in	1757	1759	O
general	1760	1767	O
,	1767	1768	O
elderly	1769	1776	O
tend	1777	1781	O
to	1782	1784	O
prefer	1785	1791	O
accuracy	1792	1800	O
over	1801	1805	O
speed	1806	1811	O
,	1811	1812	O
elderly	1813	1820	O
showed	1821	1827	O
no	1828	1830	O
decreased	1831	1840	O
antisaccade	1841	1852	O
accuracy	1853	1861	O
as	1862	1864	O
compared	1865	1873	O
to	1874	1876	O
young	1877	1882	O
adults	1883	1889	O
.	1889	1890	O

As	1891	1893	O
compared	1894	1902	O
to	1903	1905	O
the	1906	1909	O
young	1910	1915	O
group	1916	1921	O
,	1921	1922	O
elderly	1923	1930	O
and	1931	1934	O
PD	1935	1937	O
patients	1938	1946	O
exhibited	1947	1956	O
slightly	1957	1965	O
,	1965	1966	O
but	1967	1970	O
not	1971	1974	O
significantly	1975	1988	O
more	1989	1993	O
premature	1994	2003	O
eye	2004	2007	B-Organ
movements	2008	2017	O
.	2017	2018	O

Premature	2019	2028	O
eye	2029	2032	B-Organ
movements	2033	2042	O
,	2042	2043	O
however	2044	2051	O
significantly	2052	2065	O
increased	2066	2075	O
in	2076	2078	O
elderly	2079	2086	O
and	2087	2090	O
PD	2091	2093	O
patients	2094	2102	O
but	2103	2106	O
only	2107	2111	O
slightly	2112	2120	O
in	2121	2123	O
the	2124	2127	O
young	2128	2133	O
,	2133	2134	O
when	2135	2139	O
more	2140	2144	O
specific	2145	2153	O
information	2154	2165	O
on	2166	2168	O
the	2169	2172	O
upcoming	2173	2181	O
movement	2182	2190	O
was	2191	2194	O
available	2195	2204	O
in	2205	2207	O
advance	2208	2215	O
.	2215	2216	O

Presumably	2217	2227	O
,	2227	2228	O
this	2229	2233	O
increase	2234	2242	O
in	2243	2245	O
premature	2246	2255	O
eye	2256	2259	B-Organ
movements	2260	2269	O
reflects	2270	2278	O
difficulties	2279	2291	O
with	2292	2296	O
the	2297	2300	O
inhibition	2301	2311	O
of	2312	2314	O
externally	2315	2325	O
guided	2326	2332	O
movement	2333	2341	O
and	2342	2345	O
/	2345	2346	O
or	2346	2348	O
the	2349	2352	O
suppression	2353	2364	O
of	2365	2367	O
strongly	2368	2376	O
activated	2377	2386	O
prepotent	2387	2396	O
action	2397	2403	O
plans	2404	2409	O
.	2409	2410	O

On	2411	2413	O
the	2414	2417	O
one	2418	2421	O
hand	2422	2426	O
,	2426	2427	O
the	2428	2431	O
choice	2432	2438	O
for	2439	2442	O
medicated	2443	2452	O
PD	2453	2455	O
patients	2456	2464	O
represents	2465	2475	O
a	2476	2477	O
limitation	2478	2488	O
of	2489	2491	O
the	2492	2495	O
current	2496	2503	O
study	2504	2509	O
as	2510	2512	O
we	2513	2515	O
cannot	2516	2522	O
exclude	2523	2530	O
differential	2531	2543	O
effects	2544	2551	O
of	2552	2554	O
medication	2555	2565	O
on	2566	2568	O
behavior	2569	2577	O
.	2577	2578	O

On	2579	2581	O
the	2582	2585	O
other	2586	2591	O
hand	2592	2596	O
,	2596	2597	O
PD	2598	2600	O
patients	2601	2609	O
generally	2610	2619	O
take	2620	2624	O
medication	2625	2635	O
in	2636	2638	O
their	2639	2644	O
daily	2645	2650	O
routine	2651	2658	O
,	2658	2659	O
such	2660	2664	O
that	2665	2669	O
the	2670	2673	O
results	2674	2681	O
can	2682	2685	O
be	2686	2688	O
generalized	2689	2700	O
to	2701	2703	O
clinical	2704	2712	O
practice	2713	2721	O
.	2721	2722	O

Exploratory	2723	2734	O
analysis	2735	2743	O
within	2744	2750	O
the	2751	2754	O
PD	2755	2757	O
patient	2758	2765	O
group	2766	2771	O
revealed	2772	2780	O
that	2781	2785	O
patients	2786	2794	O
with	2795	2799	O
more	2800	2804	O
severe	2805	2811	O
motoric	2812	2819	O
symptoms	2820	2828	O
(	2829	2830	O
as	2830	2832	O
indexed	2833	2840	O
by	2841	2843	O
their	2844	2849	O
motoric	2850	2857	O
subscore	2858	2866	O
on	2867	2869	O
the	2870	2873	O
UPDRS	2874	2879	O
)	2879	2880	O
displayed	2881	2890	O
more	2891	2895	O
signs	2896	2901	O
of	2902	2904	O
antisaccade	2905	2916	O
decline	2917	2924	O
,	2924	2925	O
such	2926	2930	O
as	2931	2933	O
longer	2934	2940	O
antisaccade	2941	2952	O
latencies	2953	2962	O
and	2963	2966	O
lower	2967	2972	O
accuracy	2973	2981	O
compared	2982	2990	O
to	2991	2993	O
mildly	2994	3000	O
affected	3001	3009	O
patients	3010	3018	O
,	3018	3019	O
who	3020	3023	O
initiated	3024	3033	O
saccades	3034	3042	O
equally	3043	3050	O
fast	3051	3055	O
as	3056	3058	O
healthy	3059	3066	O
adults	3067	3073	O
.	3073	3074	O

This	3075	3079	O
suggests	3080	3088	O
that	3089	3093	O
dopaminergic	3094	3106	O
medication	3107	3117	O
was	3118	3121	O
not	3122	3125	O
sufficient	3126	3136	O
to	3137	3139	O
raise	3140	3145	O
the	3146	3149	O
patient	3150	3157	O
'	3157	3158	O
s	3158	3159	O
antisaccadic	3160	3172	O
preparation	3173	3184	O
up	3185	3187	O
to	3188	3190	O
the	3191	3194	O
level	3195	3200	O
of	3201	3203	O
the	3204	3207	O
healthy	3208	3215	O
older	3216	3221	O
adults	3222	3228	O
.	3228	3229	O

One	3230	3233	O
intriguing	3234	3244	O
observation	3245	3256	O
was	3257	3260	O
that	3261	3265	O
despite	3266	3273	O
the	3274	3277	O
different	3278	3287	O
extents	3288	3295	O
of	3296	3298	O
observed	3299	3307	O
antisaccade	3308	3319	O
performance	3320	3331	O
decline	3332	3339	O
in	3340	3342	O
elderly	3343	3350	O
and	3351	3354	O
PD	3355	3357	O
patients	3358	3366	O
,	3366	3367	O
reward	3368	3374	O
prospect	3375	3383	O
led	3384	3387	O
to	3388	3390	O
beneficial	3391	3401	O
effects	3402	3409	O
on	3410	3412	O
antisaccade	3413	3424	O
latency	3425	3432	O
and	3433	3436	O
accuracy	3437	3445	O
in	3446	3448	O
young	3449	3454	O
,	3454	3455	O
elderly	3456	3463	O
,	3463	3464	O
and	3465	3468	O
PD	3469	3471	O
patients	3472	3480	O
alike	3481	3486	O
.	3486	3487	O

Young	3488	3493	O
,	3493	3494	O
elderly	3495	3502	O
and	3503	3506	O
PD	3507	3509	O
patients	3510	3518	O
benefited	3519	3528	O
from	3529	3533	O
reward	3534	3540	O
prospect	3541	3549	O
to	3550	3552	O
the	3553	3556	O
same	3557	3561	O
extent	3562	3568	O
,	3568	3569	O
confirming	3570	3580	O
that	3581	3585	O
the	3586	3589	O
expectancy	3590	3600	O
of	3601	3603	O
reward	3604	3610	O
is	3611	3613	O
a	3614	3615	O
powerful	3616	3624	O
mediator	3625	3633	O
of	3634	3636	O
cognitive	3637	3646	O
control	3647	3654	O
,	3654	3655	O
even	3656	3660	O
if	3661	3663	O
cognitive	3664	3673	O
control	3674	3681	O
suffers	3682	3689	O
from	3690	3694	O
decline	3695	3702	O
.	3702	3703	O

The	3704	3707	O
expectation	3708	3719	O
of	3720	3722	O
rewarding	3723	3732	O
incentives	3733	3743	O
thus	3744	3748	O
seems	3749	3754	O
to	3755	3757	O
support	3758	3765	O
older	3766	3771	O
adults	3772	3778	O
'	3778	3779	O
and	3780	3783	O
PD	3784	3786	O
patients	3787	3795	O
'	3795	3796	O
ability	3797	3804	O
to	3805	3807	O
anticipate	3808	3818	O
,	3818	3819	O
prepare	3820	3827	O
and	3828	3831	O
initiate	3832	3840	O
goal	3841	3845	O
-	3845	3846	O
directed	3846	3854	O
behavior	3855	3863	O
.	3863	3864	O

These	3865	3870	O
findings	3871	3879	O
imply	3880	3885	O
that	3886	3890	O
despite	3891	3898	O
a	3899	3900	O
general	3901	3908	O
decline	3909	3916	O
in	3917	3919	O
the	3920	3923	O
action	3924	3930	O
preparation	3931	3942	O
system	3943	3949	O
as	3950	3952	O
indexed	3953	3960	O
by	3961	3963	O
increased	3964	3973	O
antisaccade	3974	3985	O
latency	3986	3993	O
,	3993	3994	O
action	3995	4001	O
preparation	4002	4013	O
processes	4014	4023	O
remain	4024	4030	O
susceptible	4031	4042	O
to	4043	4045	O
the	4046	4049	O
prospect	4050	4058	O
of	4059	4061	O
future	4062	4068	O
reward	4069	4075	O
.	4075	4076	O

It	4077	4079	O
could	4080	4085	O
thus	4086	4090	O
be	4091	4093	O
argued	4094	4100	O
that	4101	4105	O
the	4106	4109	O
neural	4110	4116	B-Multi-tissue_structure
representations	4117	4132	O
of	4133	4135	O
upcoming	4136	4144	O
rewards	4145	4152	O
influence	4153	4162	O
neural	4163	4169	B-Anatomical_system
systems	4170	4177	I-Anatomical_system
concerned	4178	4187	O
with	4188	4192	O
action	4193	4199	O
preparation	4200	4211	O
and	4212	4215	O
oculomotor	4216	4226	B-Multi-tissue_structure
control	4227	4234	O
.	4234	4235	O

Although	4236	4244	O
the	4245	4248	O
current	4249	4256	O
behavioral	4257	4267	O
results	4268	4275	O
cannot	4276	4282	O
exclude	4283	4290	O
or	4291	4293	O
confirm	4294	4301	O
neural	4302	4308	B-Multi-tissue_structure
links	4309	4314	O
between	4315	4322	O
reward	4323	4329	O
anticipation	4330	4342	O
and	4343	4346	O
action	4347	4353	O
preparation	4354	4365	O
systems	4366	4373	O
in	4374	4376	O
the	4377	4380	O
brain	4381	4386	B-Organ
,	4386	4387	O
they	4388	4392	O
suggest	4393	4400	O
intact	4401	4407	O
cross	4408	4413	O
-	4413	4414	O
talk	4414	4418	O
among	4419	4424	O
subcortical	4425	4436	B-Multi-tissue_structure
circuits	4437	4445	O
that	4446	4450	O
allow	4451	4456	O
goal	4457	4461	O
-	4461	4462	O
directed	4462	4470	O
action	4471	4477	O
to	4478	4480	O
be	4481	4483	O
modified	4484	4492	O
by	4493	4495	O
motivational	4496	4508	O
factors	4509	4516	O
.	4516	4517	O

The	4518	4521	O
motivational	4522	4534	O
neural	4535	4541	B-Multi-tissue_structure
reward	4542	4548	O
anticipation	4549	4561	O
signal	4562	4568	O
presumably	4569	4579	O
activates	4580	4589	O
the	4590	4593	O
reward	4594	4600	O
network	4601	4608	O
including	4609	4618	O
the	4619	4622	O
amygdala	4623	4631	O
,	4631	4632	O
orbitofrontal	4633	4646	B-Multi-tissue_structure
cortex	4647	4653	I-Multi-tissue_structure
,	4653	4654	O
the	4655	4658	O
more	4659	4663	O
ventral	4664	4671	B-Multi-tissue_structure
and	4672	4675	O
dorsal	4676	4682	B-Multi-tissue_structure
striatum	4683	4691	I-Multi-tissue_structure
(	4692	4693	O
nucleus	4693	4700	B-Multi-tissue_structure
accumbens	4701	4710	I-Multi-tissue_structure
,	4710	4711	O
putamen	4712	4719	B-Multi-tissue_structure
,	4719	4720	O
and	4721	4724	O
caudate	4725	4732	B-Multi-tissue_structure
)	4732	4733	O
,	4733	4734	O
leading	4735	4742	O
to	4743	4745	O
an	4746	4748	O
release	4749	4756	O
of	4757	4759	O
caudate	4760	4767	O
/	4767	4768	O
SNr	4768	4771	O
inhibition	4772	4782	O
on	4783	4785	O
the	4786	4789	O
executive	4790	4799	O
oculomotor	4800	4810	B-Multi-tissue_structure
structure	4811	4820	I-Multi-tissue_structure
superior	4821	4829	I-Multi-tissue_structure
colliculus	4830	4840	I-Multi-tissue_structure
.	4840	4841	O

This	4842	4846	O
transiently	4847	4858	O
decreased	4859	4868	O
inhibitory	4869	4879	O
force	4880	4885	O
on	4886	4888	O
superior	4889	4897	B-Multi-tissue_structure
colliculus	4898	4908	I-Multi-tissue_structure
may	4909	4912	O
improve	4913	4920	O
goal	4921	4925	O
-	4925	4926	O
directed	4926	4934	O
oculomotor	4935	4945	B-Multi-tissue_structure
control	4946	4953	O
.	4953	4954	O

Thus	4955	4959	O
reward	4960	4966	O
anticipation	4967	4979	O
might	4980	4985	O
compensate	4986	4996	O
for	4997	5000	O
the	5001	5004	O
age	5005	5008	O
-	5008	5009	O
and	5010	5013	O
disease	5014	5021	O
-	5021	5022	O
related	5022	5029	O
dopaminergic	5030	5042	O
loss	5043	5047	O
in	5048	5050	O
the	5051	5054	O
SNc	5055	5058	O
projections	5059	5070	O
to	5071	5073	O
the	5074	5077	O
caudate	5078	5085	O
/	5085	5086	O
SNr	5086	5089	O
and	5090	5093	O
may	5094	5097	O
thus	5098	5102	O
play	5103	5107	O
a	5108	5109	O
compensatory	5110	5122	O
role	5123	5127	O
in	5128	5130	O
"	5131	5132	O
boosting	5132	5140	O
"	5140	5141	O
the	5142	5145	O
efficiency	5146	5156	O
of	5157	5159	O
interactions	5160	5172	O
between	5173	5180	O
motivational	5181	5193	O
and	5194	5197	O
impaired	5198	5206	O
cognitive	5207	5216	O
control	5217	5224	O
processes	5225	5234	O
.	5234	5235	O

However	5236	5243	O
the	5244	5247	O
reward	5248	5254	O
-	5254	5255	O
related	5255	5262	O
modulation	5263	5273	O
of	5274	5276	O
the	5277	5280	O
oculomotor	5281	5291	B-Multi-tissue_structure
control	5292	5299	I-Multi-tissue_structure
system	5300	5306	I-Multi-tissue_structure
may	5307	5310	O
not	5311	5314	O
only	5315	5319	O
apply	5320	5325	O
to	5326	5328	O
the	5329	5332	O
basal	5333	5338	B-Multi-tissue_structure
ganglia	5339	5346	I-Multi-tissue_structure
part	5347	5351	O
of	5352	5354	O
the	5355	5358	O
oculomotor	5359	5369	B-Multi-tissue_structure
network	5370	5377	I-Multi-tissue_structure
.	5377	5378	O

Although	5379	5387	O
speculative	5388	5399	O
,	5399	5400	O
it	5401	5403	O
could	5404	5409	O
extend	5410	5416	O
to	5417	5419	O
the	5420	5423	O
cortical	5424	5432	B-Multi-tissue_structure
eyefields	5433	5442	I-Multi-tissue_structure
(	5443	5444	O
frontal	5444	5451	B-Multi-tissue_structure
,	5451	5452	O
supplementary	5453	5466	B-Multi-tissue_structure
,	5466	5467	O
and	5468	5471	O
parietal	5472	5480	B-Multi-tissue_structure
eyefields	5481	5490	I-Multi-tissue_structure
)	5490	5491	O
and	5492	5495	O
to	5496	5498	O
parts	5499	5504	O
of	5505	5507	O
the	5508	5511	O
visual	5512	5518	B-Multi-tissue_structure
cortex	5519	5525	I-Multi-tissue_structure
.	5525	5526	O

Human	5527	5532	O
research	5533	5541	O
shows	5542	5547	O
that	5548	5552	O
more	5553	5557	O
preparatory	5558	5569	O
activation	5570	5580	O
in	5581	5583	O
the	5584	5587	O
frontal	5588	5595	B-Multi-tissue_structure
eyefields	5596	5605	I-Multi-tissue_structure
leads	5606	5611	O
to	5612	5614	O
a	5615	5616	O
faster	5617	5623	O
antisaccade	5624	5635	O
latency	5636	5643	O
(	5644	5645	O
Connolly	5645	5653	O
et	5654	5656	O
al	5657	5659	O
.	5659	5660	O
,	5660	5661	O
2002	5662	5666	O
,	5666	5667	O
2005	5668	5672	O
)	5672	5673	O
.	5673	5674	O

The	5675	5678	O
compensatory	5679	5691	O
effect	5692	5698	O
on	5699	5701	O
the	5702	5705	O
antisaccade	5706	5717	O
latency	5718	5725	O
,	5725	5726	O
therefore	5727	5736	O
,	5736	5737	O
could	5738	5743	O
theoretically	5744	5757	O
stem	5758	5762	O
from	5763	5767	O
a	5768	5769	O
propagation	5770	5781	O
of	5782	5784	O
reward	5785	5791	O
anticipation	5792	5804	O
signal	5805	5811	O
in	5812	5814	O
the	5815	5818	O
caudate	5819	5826	B-Multi-tissue_structure
to	5827	5829	O
the	5830	5833	O
frontal	5834	5841	B-Multi-tissue_structure
eyefields	5842	5851	I-Multi-tissue_structure
.	5851	5852	O

Complex	5853	5860	O
structural	5861	5871	O
connections	5872	5883	O
enable	5884	5890	O
the	5891	5894	O
striatum	5895	5903	B-Multi-tissue_structure
to	5904	5906	O
exert	5907	5912	O
a	5913	5914	O
controlling	5915	5926	O
influence	5927	5936	O
over	5937	5941	O
the	5942	5945	O
cerebral	5946	5954	B-Multi-tissue_structure
cortex	5955	5961	I-Multi-tissue_structure
via	5962	5965	O
a	5966	5967	O
series	5968	5974	O
of	5975	5977	O
reentrant	5978	5987	B-Multi-tissue_structure
corticobasal	5988	6000	I-Multi-tissue_structure
ganglia	6001	6008	I-Multi-tissue_structure
circuits	6009	6017	O
.	6017	6018	O

Thus	6019	6023	O
reward	6024	6030	O
anticipation	6031	6043	O
may	6044	6047	O
increase	6048	6056	O
the	6057	6060	O
level	6061	6066	O
of	6067	6069	O
preparation	6070	6081	O
in	6082	6084	O
the	6085	6088	O
intact	6089	6095	O
cortical	6096	6104	B-Multi-tissue_structure
eyefields	6105	6114	I-Multi-tissue_structure
and	6115	6118	O
thereby	6119	6126	O
compensate	6127	6137	O
for	6138	6141	O
age	6142	6145	O
-	6145	6146	O
and	6147	6150	O
disease	6151	6158	O
-	6158	6159	O
related	6159	6166	O
subcortical	6167	6178	B-Multi-tissue_structure
decrements	6179	6189	O
in	6190	6192	O
the	6193	6196	O
oculomotor	6197	6207	B-Multi-tissue_structure
network	6208	6215	I-Multi-tissue_structure
.	6215	6216	O

Taken	6217	6222	O
together	6223	6231	O
,	6231	6232	O
it	6233	6235	O
seems	6236	6241	O
plausible	6242	6251	O
that	6252	6256	O
motivational	6257	6269	O
reward	6270	6276	O
processes	6277	6286	O
in	6287	6289	O
the	6290	6293	O
caudate	6294	6301	B-Multi-tissue_structure
enhance	6302	6309	O
preparatory	6310	6321	O
activation	6322	6332	O
in	6333	6335	O
subcortical	6336	6347	B-Multi-tissue_structure
as	6348	6350	O
well	6351	6355	O
as	6356	6358	O
in	6359	6361	O
cortical	6362	6370	B-Multi-tissue_structure
nodes	6371	6376	I-Multi-tissue_structure
of	6377	6379	O
the	6380	6383	O
oculomotor	6384	6394	B-Multi-tissue_structure
network	6395	6402	I-Multi-tissue_structure
.	6402	6403	O

Several	6404	6411	O
neurotransmission	6412	6429	O
mechanisms	6430	6440	O
may	6441	6444	O
underlie	6445	6453	O
the	6454	6457	O
remedial	6458	6466	O
effect	6467	6473	O
of	6474	6476	O
positive	6477	6485	O
incentives	6486	6496	O
on	6497	6499	O
declining	6500	6509	O
antisaccadic	6510	6522	O
control	6523	6530	O
.	6530	6531	O

Given	6532	6537	O
the	6538	6541	O
convergence	6542	6553	O
of	6554	6556	O
dopamine	6557	6565	O
and	6566	6569	O
glutamate	6570	6579	O
inputs	6580	6586	O
at	6587	6589	O
the	6590	6593	O
spiny	6594	6599	B-Cell
projection	6600	6610	I-Cell
neurons	6611	6618	I-Cell
in	6619	6621	O
the	6622	6625	O
striatum	6626	6634	B-Multi-tissue_structure
(	6635	6636	O
Burns	6636	6641	O
et	6642	6644	O
al	6645	6647	O
.	6647	6648	O
,	6648	6649	O
1994	6650	6654	O
)	6654	6655	O
,	6655	6656	O
an	6657	6659	O
interaction	6660	6671	O
between	6672	6679	O
dopamine	6680	6688	O
and	6689	6692	O
glutamate	6693	6702	O
might	6703	6708	O
underlie	6709	6717	O
striatal	6718	6726	B-Multi-tissue_structure
processes	6727	6736	O
of	6737	6739	O
reward	6740	6746	O
anticipation	6747	6759	O
and	6760	6763	O
action	6764	6770	O
preparation	6771	6782	O
.	6782	6783	O

However	6784	6791	O
,	6791	6792	O
it	6793	6795	O
cannot	6796	6802	O
be	6803	6805	O
fully	6806	6811	O
excluded	6812	6820	O
that	6821	6825	O
alterations	6826	6837	O
in	6838	6840	O
other	6841	6846	O
neurotransmitter	6847	6863	O
systems	6864	6871	O
may	6872	6875	O
also	6876	6880	O
have	6881	6885	O
an	6886	6888	O
effect	6889	6895	O
on	6896	6898	O
declining	6899	6908	O
oculomotor	6909	6919	B-Multi-tissue_structure
control	6920	6927	O
and	6928	6931	O
on	6932	6934	O
remediating	6935	6946	O
incentive	6947	6956	O
effects	6957	6964	O
.	6964	6965	O

Non	6966	6969	O
-	6969	6970	O
dopaminergic	6970	6982	O
changes	6983	6990	O
such	6991	6995	O
as	6996	6998	O
noradrenergic	6999	7012	O
,	7012	7013	O
serotonergic	7014	7026	O
,	7026	7027	O
and	7028	7031	O
cholinergic	7032	7043	O
deafferentation	7044	7059	O
of	7060	7062	O
the	7063	7066	O
cortex	7067	7073	B-Multi-tissue_structure
also	7074	7078	O
occur	7079	7084	O
in	7085	7087	O
PD	7088	7090	O
and	7091	7094	O
can	7095	7098	O
inflict	7099	7106	O
cognitive	7107	7116	O
deficits	7117	7125	O
(	7126	7127	O
Agid	7127	7131	O
et	7132	7134	O
al	7135	7137	O
.	7137	7138	O
,	7138	7139	O
1987	7140	7144	O
)	7144	7145	O
.	7145	7146	O

Evidence	7147	7155	O
from	7156	7160	O
non	7161	7164	O
-	7164	7165	O
human	7165	7170	O
primates	7171	7179	O
suggests	7180	7188	O
that	7189	7193	O
basal	7194	7199	B-Multi-tissue_structure
ganglia	7200	7207	I-Multi-tissue_structure
dopamine	7208	7216	O
acts	7217	7221	O
to	7222	7224	O
speed	7225	7230	B-Multi-tissue_structure
motor	7231	7236	I-Multi-tissue_structure
responding	7237	7247	O
in	7248	7250	O
response	7251	7259	O
to	7260	7262	O
rewarding	7263	7272	O
cues	7273	7277	O
(	7278	7279	O
Niv	7279	7282	O
,	7282	7283	O
2007	7284	7288	O
;	7288	7289	O
Niv	7290	7293	O
et	7294	7296	O
al	7297	7299	O
.	7299	7300	O
,	7300	7301	O
2007	7302	7306	O
)	7306	7307	O
.	7307	7308	O

Among	7309	7314	O
at	7315	7317	O
least	7318	7323	O
five	7324	7328	O
types	7329	7334	O
of	7335	7337	O
DA	7338	7340	O
receptors	7341	7350	O
,	7350	7351	O
mainly	7352	7358	O
D1	7359	7361	O
and	7362	7365	O
D2	7366	7368	O
receptors	7369	7378	O
are	7379	7382	O
expressed	7383	7392	O
in	7393	7395	O
caudate	7396	7403	B-Cell
projection	7404	7414	I-Cell
neurons	7415	7422	I-Cell
(	7423	7424	O
Nakamura	7424	7432	O
and	7433	7436	O
Hikosaka	7437	7445	O
,	7445	7446	O
2006	7447	7451	O
)	7451	7452	O
.	7452	7453	O

Tendencies	7454	7464	O
to	7465	7467	O
speed	7468	7473	O
responses	7474	7483	O
to	7484	7486	O
obtain	7487	7493	O
large	7494	7499	O
rewards	7500	7507	O
have	7508	7512	O
been	7513	7517	O
found	7518	7523	O
to	7524	7526	O
be	7527	7529	O
dependent	7530	7539	O
on	7540	7542	O
striatal	7543	7551	B-Multi-tissue_structure
D1	7552	7554	O
receptors	7555	7564	O
(	7565	7566	O
Dalley	7566	7572	O
et	7573	7575	O
al	7576	7578	O
.	7578	7579	O
,	7579	7580	O
2005	7581	7585	O
;	7585	7586	O
Berridge	7587	7595	O
,	7595	7596	O
2007	7597	7601	O
)	7601	7602	O
.	7602	7603	O

In	7604	7606	O
contrast	7607	7615	O
to	7616	7618	O
this	7619	7623	O
D1	7624	7626	O
modulated	7627	7636	O
speeding	7637	7645	O
in	7646	7648	O
reward	7649	7655	O
-	7655	7656	O
motor	7656	7661	O
tasks	7662	7667	O
,	7667	7668	O
evidence	7669	7677	O
from	7678	7682	O
saccade	7683	7690	O
tasks	7691	7696	O
in	7697	7699	O
non	7700	7703	O
-	7703	7704	O
human	7704	7709	O
primates	7710	7718	O
suggests	7719	7727	O
D2	7728	7730	O
receptor	7731	7739	O
modulation	7740	7750	O
of	7751	7753	O
reward	7754	7760	O
dependent	7761	7770	O
improvements	7771	7783	O
of	7784	7786	O
performance	7787	7798	O
(	7799	7800	O
Nakamura	7800	7808	O
and	7809	7812	O
Hikosaka	7813	7821	O
,	7821	7822	O
2006	7823	7827	O
)	7827	7828	O
.	7828	7829	O

Injections	7830	7840	O
of	7841	7843	O
a	7844	7845	O
D1	7846	7848	O
antagonist	7849	7859	O
and	7860	7863	O
a	7864	7865	O
D2	7866	7868	O
antagonist	7869	7879	O
into	7880	7884	O
the	7885	7888	O
region	7889	7895	O
of	7896	7898	O
the	7899	7902	O
caudate	7903	7910	B-Multi-tissue_structure
where	7911	7916	O
saccade	7917	7924	O
-	7924	7925	O
related	7925	7932	O
neurons	7933	7940	B-Cell
are	7941	7944	O
clustered	7945	7954	O
while	7955	7960	O
the	7961	7964	O
monkey	7965	7971	O
performed	7972	7981	O
a	7982	7983	O
reward	7984	7990	O
-	7990	7991	O
biased	7991	7997	O
saccade	7998	8005	O
task	8006	8010	O
showed	8011	8017	O
that	8018	8022	O
D1	8023	8025	O
antagonists	8026	8037	O
attenuate	8038	8047	O
the	8048	8051	O
reward	8052	8058	O
modulation	8059	8069	O
of	8070	8072	O
saccade	8073	8080	O
behavior	8081	8089	O
whereas	8090	8097	O
D2	8098	8100	O
antagonists	8101	8112	O
into	8113	8117	O
the	8118	8121	O
same	8122	8126	O
region	8127	8133	O
enhanced	8134	8142	O
the	8143	8146	O
reward	8147	8153	O
-	8153	8154	O
dependent	8154	8163	O
changes	8164	8171	O
.	8171	8172	O

Future	8173	8179	O
studies	8180	8187	O
of	8188	8190	O
Parkinson	8191	8200	O
patients	8201	8209	O
on	8210	8212	O
versus	8213	8219	O
off	8220	8223	O
medication	8224	8234	O
,	8234	8235	O
could	8236	8241	O
provide	8242	8249	O
some	8250	8254	O
information	8255	8266	O
on	8267	8269	O
the	8270	8273	O
role	8274	8278	O
of	8279	8281	O
dopaminergic	8282	8294	O
mechanisms	8295	8305	O
in	8306	8308	O
the	8309	8312	O
remedial	8313	8321	O
effects	8322	8329	O
on	8330	8332	O
antisaccadic	8333	8345	O
performance	8346	8357	O
.	8357	8358	O

A	8359	8360	O
recent	8361	8367	O
study	8368	8373	O
of	8374	8376	O
reward	8377	8383	O
learning	8384	8392	O
in	8393	8395	O
Parkinson	8396	8405	O
patients	8406	8414	O
on	8415	8417	O
/	8417	8418	O
off	8418	8421	O
dopaminergic	8422	8434	O
medication	8435	8445	O
showed	8446	8452	O
that	8453	8457	O
patients	8458	8466	O
adapted	8467	8474	O
their	8475	8480	O
behavior	8481	8489	O
to	8490	8492	O
maximize	8493	8501	O
expected	8502	8510	O
reward	8511	8517	O
value	8518	8523	O
dependent	8524	8533	O
on	8534	8536	O
their	8537	8542	O
medication	8543	8553	O
status	8554	8560	O
(	8561	8562	O
Moustafa	8562	8570	O
et	8571	8573	O
al	8574	8576	O
.	8576	8577	O
,	8577	8578	O
2008	8579	8583	O
)	8583	8584	O
.	8584	8585	O

Whilst	8586	8592	O
off	8593	8596	O
dopaminergic	8597	8609	O
medication	8610	8620	O
,	8620	8621	O
patients	8622	8630	O
slowed	8631	8637	O
their	8638	8643	O
responses	8644	8653	O
to	8654	8656	O
avoid	8657	8662	O
low	8663	8666	O
expected	8667	8675	O
values	8676	8682	O
,	8682	8683	O
but	8684	8687	O
succeeded	8688	8697	O
less	8698	8702	O
well	8703	8707	O
in	8708	8710	O
speeding	8711	8719	O
responses	8720	8729	O
when	8730	8734	O
a	8735	8736	O
reward	8737	8743	O
was	8744	8747	O
at	8748	8750	O
stake	8751	8756	O
.	8756	8757	O

The	8758	8761	O
opposite	8762	8770	O
pattern	8771	8778	O
emerged	8779	8786	O
when	8787	8791	O
the	8792	8795	O
same	8796	8800	O
patients	8801	8809	O
were	8810	8814	O
on	8815	8817	O
medication	8818	8828	O
;	8828	8829	O
patients	8830	8838	O
showed	8839	8845	O
better	8846	8852	O
response	8853	8861	O
speeding	8862	8870	O
,	8870	8871	O
and	8872	8875	O
worse	8876	8881	O
response	8882	8890	O
slowing	8891	8898	O
,	8898	8899	O
to	8900	8902	O
maximize	8903	8911	O
expected	8912	8920	O
value	8921	8926	O
.	8926	8927	O

The	8928	8931	O
current	8932	8939	O
behavioral	8940	8950	O
findings	8951	8959	O
are	8960	8963	O
in	8964	8966	O
line	8967	8971	O
with	8972	8976	O
neuroimaging	8977	8989	O
research	8990	8998	O
showing	8999	9006	O
intact	9007	9013	O
neural	9014	9020	B-Multi-tissue_structure
representations	9021	9036	O
of	9037	9039	O
future	9040	9046	O
reward	9047	9053	O
in	9054	9056	O
the	9057	9060	O
aging	9061	9066	O
striatum	9067	9075	B-Multi-tissue_structure
(	9076	9077	O
Samanez	9077	9084	O
-	9084	9085	O
Larkin	9085	9091	O
et	9092	9094	O
al	9095	9097	O
.	9097	9098	O
,	9098	9099	O
2007	9100	9104	O
)	9104	9105	O
.	9105	9106	O

The	9107	9110	O
observation	9111	9122	O
however	9123	9130	O
that	9131	9135	O
older	9136	9141	O
adults	9142	9148	O
and	9149	9152	O
PD	9153	9155	O
patients	9156	9164	O
can	9165	9168	O
use	9169	9172	O
this	9173	9177	O
intact	9178	9184	O
neural	9185	9191	B-Multi-tissue_structure
representation	9192	9206	O
of	9207	9209	O
reward	9210	9216	O
anticipation	9217	9229	O
(	9230	9231	O
a	9231	9232	O
positive	9233	9241	O
motivational	9242	9254	O
incentive	9255	9264	O
)	9264	9265	O
to	9266	9268	O
optimize	9269	9277	O
their	9278	9283	O
preparatory	9284	9295	O
processes	9296	9305	O
,	9305	9306	O
cannot	9307	9313	O
necessarily	9314	9325	O
be	9326	9328	O
generalized	9329	9340	O
to	9341	9343	O
cognitive	9344	9353	O
contexts	9354	9362	O
with	9363	9367	O
negative	9368	9376	O
motivational	9377	9389	O
incentives	9390	9400	O
.	9400	9401	O

Samanez	9402	9409	O
-	9409	9410	O
Larkin	9410	9416	O
et	9417	9419	O
al	9420	9422	O
.	9422	9423	O
(	9423	9424	O
2010	9424	9428	O
)	9428	9429	O
recently	9430	9438	O
showed	9439	9445	O
that	9446	9450	O
older	9451	9456	O
adults	9457	9463	O
were	9464	9468	O
not	9469	9472	O
able	9473	9477	O
to	9478	9480	O
optimally	9481	9490	O
use	9491	9494	O
their	9495	9500	O
intact	9501	9507	O
neural	9508	9514	B-Multi-tissue_structure
reward	9515	9521	O
anticipation	9522	9534	O
system	9535	9541	O
in	9542	9544	O
risky	9545	9550	O
financial	9551	9560	O
decision	9561	9569	O
making	9570	9576	O
.	9576	9577	O

Elderly	9578	9585	O
made	9586	9590	O
more	9591	9595	O
suboptimal	9596	9606	O
choices	9607	9614	O
when	9615	9619	O
they	9620	9624	O
were	9625	9629	O
to	9630	9632	O
choose	9633	9639	O
risky	9640	9645	O
assets	9646	9652	O
.	9652	9653	O

The	9654	9657	O
authors	9658	9665	O
deemed	9666	9672	O
it	9673	9675	O
likely	9676	9682	O
that	9683	9687	O
these	9688	9693	O
decrements	9694	9704	O
in	9705	9707	O
value	9708	9713	O
-	9713	9714	O
based	9714	9719	O
decision	9720	9728	O
making	9729	9735	O
are	9736	9739	O
explained	9740	9749	O
by	9750	9752	O
the	9753	9756	O
fact	9757	9761	O
that	9762	9766	O
value	9767	9772	O
-	9772	9773	O
based	9773	9778	O
decision	9779	9787	O
making	9788	9794	O
requires	9795	9803	O
the	9804	9807	O
weighting	9808	9817	O
of	9818	9820	O
behavioral	9821	9831	O
alternatives	9832	9844	O
,	9844	9845	O
that	9846	9850	O
may	9851	9854	O
lead	9855	9859	O
to	9860	9862	O
either	9863	9869	O
gain	9870	9874	O
or	9875	9877	O
loss	9878	9882	O
.	9882	9883	O

During	9884	9890	O
anticipation	9891	9903	O
of	9904	9906	O
rewards	9907	9914	O
older	9915	9920	O
adults	9921	9927	O
show	9928	9932	O
similar	9933	9940	O
neural	9941	9947	B-Multi-tissue_structure
responses	9948	9957	O
as	9958	9960	O
young	9961	9966	O
adults	9967	9973	O
but	9974	9977	O
they	9978	9982	O
show	9983	9987	O
reduced	9988	9995	O
neural	9996	10002	B-Multi-tissue_structure
activation	10003	10013	O
during	10014	10020	O
the	10021	10024	O
anticipation	10025	10037	O
of	10038	10040	O
losses	10041	10047	O
(	10048	10049	O
Samanez	10049	10056	O
-	10056	10057	O
Larkin	10057	10063	O
et	10064	10066	O
al	10067	10069	O
.	10069	10070	O
,	10070	10071	O
2007	10072	10076	O
)	10076	10077	O
.	10077	10078	O

The	10079	10082	O
latter	10083	10089	O
,	10089	10090	O
together	10091	10099	O
with	10100	10104	O
the	10105	10108	O
observation	10109	10120	O
that	10121	10125	O
older	10126	10131	O
adults	10132	10138	O
tend	10139	10143	O
to	10144	10146	O
shift	10147	10152	O
their	10153	10158	O
attention	10159	10168	O
away	10169	10173	O
from	10174	10178	O
negative	10179	10187	O
stimuli	10188	10195	O
and	10196	10199	O
attend	10200	10206	O
to	10207	10209	O
positive	10210	10218	O
information	10219	10230	O
instead	10231	10238	O
(	10239	10240	O
Mather	10240	10246	O
and	10247	10250	O
Carstensen	10251	10261	O
,	10261	10262	O
2003	10263	10267	O
,	10267	10268	O
2005	10269	10273	O
)	10273	10274	O
,	10274	10275	O
may	10276	10279	O
have	10280	10284	O
led	10285	10288	O
to	10289	10291	O
the	10292	10295	O
underestimation	10296	10311	O
of	10312	10314	O
loss	10315	10319	O
and	10320	10323	O
therefore	10324	10333	O
to	10334	10336	O
more	10337	10341	O
risky	10342	10347	O
and	10348	10351	O
suboptimal	10352	10362	O
decisions	10363	10372	O
.	10372	10373	O

In	10374	10376	O
this	10377	10381	O
respect	10382	10389	O
,	10389	10390	O
one	10391	10394	O
limitation	10395	10405	O
of	10406	10408	O
the	10409	10412	O
current	10413	10420	O
task	10421	10425	O
is	10426	10428	O
that	10429	10433	O
it	10434	10436	O
built	10437	10442	O
solely	10443	10449	O
on	10450	10452	O
reward	10453	10459	O
prospect	10460	10468	O
and	10469	10472	O
not	10473	10476	O
on	10477	10479	O
the	10480	10483	O
prospect	10484	10492	O
of	10493	10495	O
loss	10496	10500	O
,	10500	10501	O
such	10502	10506	O
that	10507	10511	O
the	10512	10515	O
question	10516	10524	O
of	10525	10527	O
how	10528	10531	O
the	10532	10535	O
anticipation	10536	10548	O
of	10549	10551	O
loss	10552	10556	O
influences	10557	10567	O
action	10568	10574	O
preparation	10575	10586	O
was	10587	10590	O
not	10591	10594	O
tested	10595	10601	O
.	10601	10602	O

The	10603	10606	O
impact	10607	10613	O
of	10614	10616	O
negative	10617	10625	O
incentives	10626	10636	O
might	10637	10642	O
be	10643	10645	O
an	10646	10648	O
intriguing	10649	10659	O
question	10660	10668	O
for	10669	10672	O
future	10673	10679	O
research	10680	10688	O
,	10688	10689	O
as	10690	10692	O
due	10693	10696	O
to	10697	10699	O
the	10700	10703	O
decreased	10704	10713	O
activation	10714	10724	O
of	10725	10727	O
the	10728	10731	O
neural	10732	10738	B-Multi-tissue_structure
loss	10739	10743	O
anticipation	10744	10756	O
system	10757	10763	O
(	10764	10765	O
Samanez	10765	10772	O
-	10772	10773	O
Larkin	10773	10779	O
et	10780	10782	O
al	10783	10785	O
.	10785	10786	O
,	10786	10787	O
2007	10788	10792	O
)	10792	10793	O
together	10794	10802	O
with	10803	10807	O
the	10808	10811	O
observed	10812	10820	O
differential	10821	10833	O
attentional	10834	10845	O
bias	10846	10850	O
for	10851	10854	O
negative	10855	10863	O
and	10864	10867	O
positive	10868	10876	O
information	10877	10888	O
(	10889	10890	O
Mather	10890	10896	O
and	10897	10900	O
Carstensen	10901	10911	O
,	10911	10912	O
2003	10913	10917	O
)	10917	10918	O
,	10918	10919	O
it	10920	10922	O
seems	10923	10928	O
likely	10929	10935	O
that	10936	10940	O
negative	10941	10949	O
motivational	10950	10962	O
incentives	10963	10973	O
,	10973	10974	O
i	10975	10976	O
.	10976	10977	O
e	10977	10978	O
.	10978	10979	O
,	10979	10980	O
the	10981	10984	O
prospect	10985	10993	O
of	10994	10996	O
loss	10997	11001	O
,	11001	11002	O
might	11003	11008	O
have	11009	11013	O
a	11014	11015	O
different	11016	11025	O
impact	11026	11032	O
on	11033	11035	O
action	11036	11042	O
preparation	11043	11054	O
in	11055	11057	O
older	11058	11063	O
adults	11064	11070	O
than	11071	11075	O
in	11076	11078	O
the	11079	11082	O
young	11083	11088	O
.	11088	11089	O

Future	11090	11096	O
approaches	11097	11107	O
to	11108	11110	O
the	11111	11114	O
effect	11115	11121	O
of	11122	11124	O
loss	11125	11129	O
anticipation	11130	11142	O
on	11143	11145	O
declining	11146	11155	O
antisaccade	11156	11167	O
control	11168	11175	O
may	11176	11179	O
ideally	11180	11187	O
contain	11188	11195	O
a	11196	11197	O
sequence	11198	11206	O
of	11207	11209	O
experiments	11210	11221	O
,	11221	11222	O
starting	11223	11231	O
with	11232	11236	O
a	11237	11238	O
separate	11239	11247	O
(	11248	11249	O
punishment	11249	11259	O
only	11260	11264	O
)	11264	11265	O
approach	11266	11274	O
before	11275	11281	O
moving	11282	11288	O
to	11289	11291	O
combined	11292	11300	O
reward	11301	11307	O
-	11307	11308	O
punishment	11308	11318	O
designs	11319	11326	O
.	11326	11327	O

This	11328	11332	O
might	11333	11338	O
be	11339	11341	O
necessary	11342	11351	O
as	11352	11354	O
previous	11355	11363	O
evidence	11364	11372	O
(	11373	11374	O
from	11374	11378	O
healthy	11379	11386	O
young	11387	11392	O
adults	11393	11399	O
)	11399	11400	O
suggests	11401	11409	O
that	11410	11414	O
the	11415	11418	O
reward	11419	11425	O
effect	11426	11432	O
on	11433	11435	O
oculomotor	11436	11446	B-Multi-tissue_structure
control	11447	11454	O
disappears	11455	11465	O
in	11466	11468	O
the	11469	11472	O
presence	11473	11481	O
of	11482	11484	O
punishment	11485	11495	O
trials	11496	11502	O
.	11502	11503	O

The	11504	11507	O
authors	11508	11515	O
deemed	11516	11522	O
it	11523	11525	O
likely	11526	11532	O
that	11533	11537	O
the	11538	11541	O
participants	11542	11554	O
increased	11555	11564	O
caution	11565	11572	O
to	11573	11575	O
all	11576	11579	O
incentive	11580	11589	O
(	11590	11591	O
reward	11591	11597	O
and	11598	11601	O
punishment	11602	11612	O
)	11612	11613	O
trials	11614	11620	O
(	11621	11622	O
Blaukopf	11622	11630	O
and	11631	11634	O
DiGirolamo	11635	11645	O
,	11645	11646	O
2006	11647	11651	O
)	11651	11652	O
.	11652	11653	O

As	11654	11656	O
of	11657	11659	O
yet	11660	11663	O
,	11663	11664	O
age	11665	11668	O
-	11668	11669	O
related	11669	11676	O
changes	11677	11684	O
in	11685	11687	O
neural	11688	11694	B-Multi-tissue_structure
reward	11695	11701	O
anticipation	11702	11714	O
have	11715	11719	O
mainly	11720	11726	O
been	11727	11731	O
studied	11732	11739	O
in	11740	11742	O
isolation	11743	11752	O
.	11752	11753	O

Recently	11754	11762	O
however	11763	11770	O
,	11770	11771	O
the	11772	11775	O
interaction	11776	11787	O
of	11788	11790	O
neural	11791	11797	B-Multi-tissue_structure
reward	11798	11804	O
processing	11805	11815	O
with	11816	11820	O
other	11821	11826	O
cognitive	11827	11836	O
functions	11837	11846	O
and	11847	11850	O
their	11851	11856	O
underlying	11857	11867	O
neural	11868	11874	B-Anatomical_system
systems	11875	11882	I-Anatomical_system
,	11882	11883	O
such	11884	11888	O
as	11889	11891	O
the	11892	11895	O
action	11896	11902	B-Anatomical_system
control	11903	11910	I-Anatomical_system
system	11911	11917	I-Anatomical_system
,	11917	11918	O
has	11919	11922	O
gained	11923	11929	O
increasing	11930	11940	O
interest	11941	11949	O
(	11950	11951	O
Haber	11951	11956	O
and	11957	11960	O
Knutson	11961	11968	O
,	11968	11969	O
2010	11970	11974	O
)	11974	11975	O
.	11975	11976	O

Initial	11977	11984	O
evidence	11985	11993	O
suggests	11994	12002	O
coordinated	12003	12014	O
activity	12015	12023	O
between	12024	12031	O
distant	12032	12039	O
brain	12040	12045	B-Organ
regions	12046	12053	O
responsible	12054	12065	O
for	12066	12069	O
reward	12070	12076	O
processing	12077	12087	O
(	12088	12089	O
Cohen	12089	12094	O
et	12095	12097	O
al	12098	12100	O
.	12100	12101	O
,	12101	12102	O
2009	12103	12107	O
)	12107	12108	O
.	12108	12109	O

The	12110	12113	O
current	12114	12121	O
results	12122	12129	O
encourage	12130	12139	O
further	12140	12147	O
neural	12148	12154	B-Multi-tissue_structure
network	12155	12162	I-Multi-tissue_structure
investigations	12163	12177	O
on	12178	12180	O
the	12181	12184	O
role	12185	12189	O
of	12190	12192	O
coordinated	12193	12204	O
brain	12205	12210	B-Organ
network	12211	12218	O
activity	12219	12227	O
in	12228	12230	O
motivated	12231	12240	O
behavior	12241	12249	O
.	12249	12250	O

Behavioral	12251	12261	O
benefits	12262	12270	O
from	12271	12275	O
motivation	12276	12286	O
might	12287	12292	O
be	12293	12295	O
associated	12296	12306	O
with	12307	12311	O
changes	12312	12319	O
in	12320	12322	O
functional	12323	12333	O
brain	12334	12339	B-Organ
connectivity	12340	12352	O
on	12353	12355	O
a	12356	12357	O
larger	12358	12364	O
scale	12365	12370	O
,	12370	12371	O
e	12372	12373	O
.	12373	12374	O
g	12374	12375	O
.	12375	12376	O
,	12376	12377	O
between	12378	12385	O
frontostriatal	12386	12400	B-Multi-tissue_structure
reward	12401	12407	O
and	12408	12411	O
action	12412	12418	O
preparation	12419	12430	O
structures	12431	12441	O
.	12441	12442	O

Another	12443	12450	O
important	12451	12460	O
factor	12461	12467	O
that	12468	12472	O
emerges	12473	12480	O
from	12481	12485	O
the	12486	12489	O
present	12490	12497	O
and	12498	12501	O
previous	12502	12510	O
results	12511	12518	O
,	12518	12519	O
is	12520	12522	O
the	12523	12526	O
importance	12527	12537	O
of	12538	12540	O
the	12541	12544	O
training	12545	12553	O
of	12554	12556	O
the	12557	12560	O
motivational	12561	12573	O
aspects	12574	12581	O
of	12582	12584	O
the	12585	12588	O
instructions	12589	12601	O
that	12602	12606	O
need	12607	12611	O
to	12612	12614	O
be	12615	12617	O
kept	12618	12622	O
in	12623	12625	O
working	12626	12633	O
memory	12634	12640	O
when	12641	12645	O
performing	12646	12656	O
a	12657	12658	O
cognitive	12659	12668	O
task	12669	12673	O
.	12673	12674	O

Samanez	12675	12682	O
-	12682	12683	O
Larkin	12683	12689	O
et	12690	12692	O
al	12693	12695	O
.	12695	12696	O

(	12697	12698	O
2007	12698	12702	O
)	12702	12703	O
found	12704	12709	O
intact	12710	12716	O
neural	12717	12723	B-Multi-tissue_structure
reward	12724	12730	O
anticipation	12731	12743	O
processes	12744	12753	O
specifically	12754	12766	O
in	12767	12769	O
the	12770	12773	O
absence	12774	12781	O
of	12782	12784	O
learning	12785	12793	O
(	12794	12795	O
after	12795	12800	O
the	12801	12804	O
learning	12805	12813	O
process	12814	12821	O
of	12822	12824	O
reward	12825	12831	O
cue	12832	12835	O
-	12835	12836	O
reward	12836	12842	O
associations	12843	12855	O
was	12856	12859	O
completed	12860	12869	O
)	12869	12870	O
.	12870	12871	O

Therefore	12872	12881	O
it	12882	12884	O
might	12885	12890	O
be	12891	12893	O
important	12894	12903	O
for	12904	12907	O
researchers	12908	12919	O
doing	12920	12925	O
experiments	12926	12937	O
with	12938	12942	O
motivation	12943	12953	O
based	12954	12959	O
instructions	12960	12972	O
to	12973	12975	O
keep	12976	12980	O
in	12981	12983	O
mind	12984	12988	O
that	12989	12993	O
,	12993	12994	O
compared	12995	13003	O
to	13004	13006	O
young	13007	13012	O
adults	13013	13019	O
,	13019	13020	O
elderly	13021	13028	O
and	13029	13032	O
PD	13033	13035	O
patients	13036	13044	O
are	13045	13048	O
generally	13049	13058	O
hampered	13059	13067	O
on	13068	13070	O
stimulus	13071	13079	O
-	13079	13080	O
response	13080	13088	O
learning	13089	13097	O
(	13098	13099	O
Shohamy	13099	13106	O
et	13107	13109	O
al	13110	13112	O
.	13112	13113	O
,	13113	13114	O
2004	13115	13119	O
;	13119	13120	O
Marschner	13121	13130	O
et	13131	13133	O
al	13134	13136	O
.	13136	13137	O
,	13137	13138	O
2005	13139	13143	O
)	13143	13144	O
.	13144	13145	O

Reward	13146	13152	O
instruction	13153	13164	O
cues	13165	13169	O
,	13169	13170	O
as	13171	13173	O
they	13174	13178	O
were	13179	13183	O
used	13184	13188	O
in	13189	13191	O
the	13192	13195	O
current	13196	13203	O
study	13204	13209	O
require	13210	13217	O
participants	13218	13230	O
to	13231	13233	O
form	13234	13238	O
reward	13239	13245	O
cue	13246	13249	O
-	13249	13250	O
reward	13250	13256	O
associations	13257	13269	O
.	13269	13270	O

Impairments	13271	13282	O
in	13283	13285	O
the	13286	13289	O
learning	13290	13298	O
of	13299	13301	O
associations	13302	13314	O
between	13315	13322	O
the	13323	13326	O
cue	13327	13330	O
signaling	13331	13340	O
reward	13341	13347	O
and	13348	13351	O
the	13352	13355	O
actual	13356	13362	O
reward	13363	13369	O
might	13370	13375	O
conceal	13376	13383	O
intact	13384	13390	O
reward	13391	13397	O
anticipation	13398	13410	O
processes	13411	13420	O
.	13420	13421	O

When	13422	13426	O
the	13427	13430	O
formation	13431	13440	O
of	13441	13443	O
associations	13444	13456	O
is	13457	13459	O
weakened	13460	13468	O
,	13468	13469	O
it	13470	13472	O
could	13473	13478	O
appear	13479	13485	O
as	13486	13488	O
a	13489	13490	O
failure	13491	13498	O
to	13499	13501	O
capitalize	13502	13512	O
on	13513	13515	O
the	13516	13519	O
neural	13520	13526	B-Multi-tissue_structure
reward	13527	13533	O
anticipation	13534	13546	O
system	13547	13553	O
,	13553	13554	O
whereas	13555	13562	O
it	13563	13565	O
represents	13566	13576	O
an	13577	13579	O
indirect	13580	13588	O
effect	13589	13595	O
of	13596	13598	O
non	13599	13602	O
-	13602	13603	O
available	13603	13612	O
reward	13613	13619	O
associations	13620	13632	O
in	13633	13635	O
working	13636	13643	O
memory	13644	13650	O
when	13651	13655	O
preparing	13656	13665	O
the	13666	13669	O
response	13670	13678	O
.	13678	13679	O

Hence	13680	13685	O
,	13685	13686	O
one	13687	13690	O
might	13691	13696	O
circumvent	13697	13707	O
the	13708	13711	O
effect	13712	13718	O
of	13719	13721	O
potential	13722	13731	O
learning	13732	13740	O
impairments	13741	13752	O
on	13753	13755	O
reward	13756	13762	O
anticipation	13763	13775	O
processes	13776	13785	O
by	13786	13788	O
the	13789	13792	O
training	13793	13801	O
of	13802	13804	O
abstract	13805	13813	O
reward	13814	13820	O
cues	13821	13825	O
(	13826	13827	O
as	13827	13829	O
in	13830	13832	O
the	13833	13836	O
current	13837	13844	O
and	13845	13848	O
in	13849	13851	O
Samanez	13852	13859	O
-	13859	13860	O
Larkin	13860	13866	O
'	13866	13867	O
s	13867	13868	O
study	13869	13874	O
)	13874	13875	O
or	13876	13878	O
by	13879	13881	O
using	13882	13887	O
explicit	13888	13896	O
and	13897	13900	O
concrete	13901	13909	O
rewards	13910	13917	O
.	13917	13918	O

Once	13919	13923	O
the	13924	13927	O
learning	13928	13936	O
of	13937	13939	O
reward	13940	13946	O
cues	13947	13951	O
is	13952	13954	O
accomplished	13955	13967	O
the	13968	13971	O
intact	13972	13978	O
reward	13979	13985	O
anticipation	13986	13998	O
processes	13999	14008	O
might	14009	14014	O
become	14015	14021	O
evident	14022	14029	O
.	14029	14030	O

In	14031	14033	O
sum	14034	14037	O
,	14037	14038	O
the	14039	14042	O
results	14043	14050	O
confirmed	14051	14060	O
that	14061	14065	O
the	14066	14069	O
preparation	14070	14081	O
of	14082	14084	O
goal	14085	14089	O
-	14089	14090	O
directed	14090	14098	O
actions	14099	14106	O
declined	14107	14115	O
in	14116	14118	O
PD	14119	14121	O
patients	14122	14130	O
compared	14131	14139	O
to	14140	14142	O
healthy	14143	14150	O
seniors	14151	14158	O
,	14158	14159	O
and	14160	14163	O
in	14164	14166	O
healthy	14167	14174	O
seniors	14175	14182	O
compared	14183	14191	O
to	14192	14194	O
young	14195	14200	O
adults	14201	14207	O
.	14207	14208	O

Due	14209	14212	O
perhaps	14213	14220	O
to	14221	14223	O
deterioration	14224	14237	O
in	14238	14240	O
dopaminergic	14241	14253	O
striatal	14254	14262	B-Multi-tissue_structure
circuitry	14263	14272	O
,	14272	14273	O
antisaccade	14274	14285	O
performance	14286	14297	O
is	14298	14300	O
subject	14301	14308	O
to	14309	14311	O
decline	14312	14319	O
in	14320	14322	O
healthy	14323	14330	O
seniors	14331	14338	O
,	14338	14339	O
and	14340	14343	O
even	14344	14348	O
more	14349	14353	O
in	14354	14356	O
individuals	14357	14368	O
with	14369	14373	O
Parkinson	14374	14383	O
'	14383	14384	O
s	14384	14385	O
disease	14386	14393	O
.	14393	14394	O

The	14395	14398	O
prospect	14399	14407	O
of	14408	14410	O
future	14411	14417	O
reward	14418	14424	O
however	14425	14432	O
provided	14433	14441	O
a	14442	14443	O
motivational	14444	14456	O
incentive	14457	14466	O
for	14467	14470	O
optimizing	14471	14481	O
oculomotor	14482	14492	B-Multi-tissue_structure
preparation	14493	14504	O
in	14505	14507	O
all	14508	14511	O
groups	14512	14518	O
alike	14519	14524	O
.	14524	14525	O

These	14526	14531	O
results	14532	14539	O
suggest	14540	14547	O
that	14548	14552	O
reward	14553	14559	O
-	14559	14560	O
processing	14560	14570	O
networks	14571	14579	O
and	14580	14583	O
oculomotor	14584	14594	B-Multi-tissue_structure
-	14594	14595	I-Multi-tissue_structure
control	14595	14602	I-Multi-tissue_structure
networks	14603	14611	I-Multi-tissue_structure
in	14612	14614	O
the	14615	14618	O
brain	14619	14624	B-Organ
are	14625	14628	O
connected	14629	14638	O
in	14639	14641	O
such	14642	14646	O
a	14647	14648	O
way	14649	14652	O
(	14653	14654	O
presumably	14654	14664	O
with	14665	14669	O
the	14670	14673	O
dorsal	14674	14680	B-Multi-tissue_structure
striatum	14681	14689	I-Multi-tissue_structure
as	14690	14692	O
a	14693	14694	O
common	14695	14701	O
nexus	14702	14707	O
)	14707	14708	O
that	14709	14713	O
reward	14714	14720	O
anticipation	14721	14733	O
can	14734	14737	O
facilitate	14738	14748	O
oculomotor	14749	14759	B-Multi-tissue_structure
control	14760	14767	O
and	14768	14771	O
alleviate	14772	14781	O
the	14782	14785	O
deficiencies	14786	14798	O
experienced	14799	14810	O
by	14811	14813	O
healthy	14814	14821	O
seniors	14822	14829	O
and	14830	14833	O
PD	14834	14836	O
patients	14837	14845	O
.	14845	14846	O

Future	14847	14853	O
investigations	14854	14868	O
should	14869	14875	O
examine	14876	14883	O
whether	14884	14891	O
the	14892	14895	O
observed	14896	14904	O
effects	14905	14912	O
are	14913	14916	O
specific	14917	14925	O
for	14926	14929	O
the	14930	14933	O
current	14934	14941	O
task	14942	14946	O
or	14947	14949	O
generalize	14950	14960	O
to	14961	14963	O
other	14964	14969	O
tasks	14970	14975	O
that	14976	14980	O
show	14981	14985	O
age	14986	14989	O
-	14989	14990	O
and	14991	14994	O
PD	14995	14997	O
-	14997	14998	O
related	14998	15005	O
cognitive	15006	15015	O
decrements	15016	15026	O
(	15027	15028	O
e	15028	15029	O
.	15029	15030	O
g	15030	15031	O
.	15031	15032	O
,	15032	15033	O
in	15034	15036	O
task	15037	15041	O
switching	15042	15051	O
)	15051	15052	O
and	15053	15056	O
have	15057	15061	O
been	15062	15066	O
related	15067	15074	O
to	15075	15077	O
dopaminergic	15078	15090	O
denervation	15091	15102	O
in	15103	15105	O
the	15106	15109	O
caudate	15110	15117	B-Multi-tissue_structure
(	15118	15119	O
e	15119	15120	O
.	15120	15121	O
g	15121	15122	O
.	15122	15123	O
,	15123	15124	O
impaired	15125	15133	O
verbal	15134	15140	O
episodic	15141	15149	O
memory	15150	15156	O
,	15156	15157	O
attention	15158	15167	O
,	15167	15168	O
and	15169	15172	O
response	15173	15181	O
inhibition	15182	15192	O
;	15192	15193	O
Rinne	15194	15199	O
et	15200	15202	O
al	15203	15205	O
.	15205	15206	O
,	15206	15207	O
2000	15208	15212	O
;	15212	15213	O
Bruck	15214	15219	O
et	15220	15222	O
al	15223	15225	O
.	15225	15226	O
,	15226	15227	O
2005	15228	15232	O
)	15232	15233	O
.	15233	15234	O

Future	15235	15241	O
studies	15242	15249	O
on	15250	15252	O
network	15253	15260	O
processes	15261	15270	O
may	15271	15274	O
help	15275	15279	O
to	15280	15282	O
localize	15283	15291	O
the	15292	15295	O
neural	15296	15302	B-Multi-tissue_structure
link	15303	15307	O
between	15308	15315	O
reward	15316	15322	O
prospect	15323	15331	O
and	15332	15335	O
action	15336	15342	O
preparation	15343	15354	O
that	15355	15359	O
enables	15360	15367	O
alleviating	15368	15379	O
effects	15380	15387	O
of	15388	15390	O
motivational	15391	15403	O
incentives	15404	15414	O
on	15415	15417	O
cognitive	15418	15427	O
decline	15428	15435	O
.	15435	15436	O

Crystal	0	7	O
data	8	12	O

C24H21ClN4O2S	13	26	O

M	27	28	O
r	29	30	O
=	31	32	O
464	33	36	O
.	36	37	O
96	37	39	O

Triclinic	40	49	O
,	49	50	O

a	52	53	O
=	54	55	O
8	56	57	O
.	57	58	O
6798	58	62	O
(	63	64	O
18	64	66	O
)	66	67	O
A	68	69	O

b	70	71	O
=	72	73	O
11	74	76	O
.	76	77	O
078	77	80	O
(	81	82	O
2	82	83	O
)	83	84	O
A	85	86	O

c	87	88	O
=	89	90	O
11	91	93	O
.	93	94	O
372	94	97	O
(	98	99	O
2	99	100	O
)	100	101	O
A	102	103	O

alpha	104	109	O
=	110	111	O
78	112	114	O
.	114	115	O
984	115	118	O
(	119	120	O
7	120	121	O
)	121	122	O
degrees	122	129	O

beta	130	134	O
=	135	136	O
81	137	139	O
.	139	140	O
867	140	143	O
(	144	145	O
10	145	147	O
)	147	148	O
degrees	148	155	O

gamma	156	161	O
=	162	163	O
81	164	166	O
.	166	167	O
718	167	170	O
(	171	172	O
11	172	174	O
)	174	175	O
degrees	175	182	O

V	183	184	O
=	185	186	O
1054	187	191	O
.	191	192	O
8	192	193	O
(	194	195	O
4	195	196	O
)	196	197	O
A3	198	200	O

Z	201	202	O
=	203	204	O
2	205	206	O

Cu	207	209	O
Kalpha	210	216	O
radiation	217	226	O

mu	227	229	O
=	230	231	O
2	232	233	O
.	233	234	O
78	234	236	O
mm	237	239	O
-	239	240	O
1	240	241	O

T	242	243	O
=	244	245	O
113	246	249	O
K	250	251	O

0	252	253	O
.	253	254	O
28	254	256	O
x	257	258	O
0	259	260	O
.	260	261	O
24	261	263	O
x	264	265	O
0	266	267	O
.	267	268	O
20	268	270	O
mm	271	273	O

Characteristics	0	15	O
of	16	18	O
fistula	19	26	B-Pathological_formation
lesions	27	34	I-Pathological_formation

Selective	0	9	O
SMA	10	13	O
angiography	14	25	O
was	26	29	O
performed	30	39	O
5	40	41	O
h	42	43	O
from	44	48	O
onset	49	54	O
.	54	55	O

Before	56	62	O
therapy	63	70	O
,	70	71	O
the	72	75	O
SMA	76	79	O
was	80	83	O
completely	84	94	O
occluded	95	103	O
by	104	106	O
an	107	109	O
embolus	110	117	B-Organism_substance
at	118	120	O
the	121	124	O
proximal	125	133	O
portion	134	141	O
(	142	143	O
a	143	144	O
)	144	145	O
,	145	146	O
and	147	150	O
after	151	156	O
the	157	160	O
bolus	161	166	B-Organism_substance
infusion	167	175	O
of	176	178	O
urokinase	179	188	O
(	189	190	O
600	190	193	O
,	193	194	O
000	194	197	O
IU	198	200	O
)	200	201	O
into	202	206	O
the	207	210	O
SMA	211	214	O
,	214	215	O
peripheral	216	226	B-Organism_substance
blood	227	232	I-Organism_substance
flow	233	237	O
was	238	241	O
improved	242	250	O
.	250	251	O

However	252	259	O
,	259	260	O
the	261	264	O
thrombus	265	273	B-Organism_substance
decreased	274	283	O
in	284	286	O
size	287	291	O
,	291	292	O
but	293	296	O
remained	297	305	O
(	306	307	O
b	307	308	O
)	308	309	O
.	309	310	O

Asterisks	311	320	O
indicate	321	329	O
thrombus	330	338	B-Organism_substance
.	338	339	O

Measurement	0	11	O
of	12	14	O
IgA1	15	19	O
content	20	27	O

IgA1	28	32	O
content	33	40	O
in	41	43	O
the	44	47	O
supernatant	48	59	B-Organism_substance
from	60	64	O
each	65	69	O
culture	70	77	O
well	78	82	O
was	83	86	O
measured	87	95	O
in	96	98	O
duplicate	99	108	O
using	109	114	O
enzyme	115	121	O
-	121	122	O
linked	122	128	O
immunosorbent	129	142	O
assay	143	148	O
(	149	150	O
ELISA	150	155	O
)	155	156	O
.	156	157	O

All	158	161	O
incubations	162	173	O
were	174	178	O
performed	179	188	O
at	189	191	O
room	192	196	O
temperature	197	208	O
except	209	215	O
for	216	219	O
capture	220	227	O
antibody	228	236	O
coating	237	244	O
.	244	245	O

Briefly	246	253	O
,	253	254	O
96	255	257	O
-	257	258	O
well	258	262	O
immunoplates	263	275	O
(	276	277	O
Thermo	277	283	O
Fisher	284	290	O
Scientific	291	301	O
,	301	302	O
Waltham	303	310	O
,	310	311	O
MA	312	314	O
,	314	315	O
USA	316	319	O
)	319	320	O
were	321	325	O
coated	326	332	O
with	333	337	O
5	338	339	O
microg	340	346	O
/	346	347	O
mL	347	349	O
of	350	352	O
F	353	354	O
(	354	355	O
ab	355	357	O
'	357	358	O
)	358	359	O
2	359	360	O
fragment	361	369	O
goat	370	374	O
anti	375	379	O
-	379	380	O
human	380	385	O
IgA	386	389	O
antibody	390	398	O
(	399	400	O
Jackson	400	407	O
ImmunoResearch	408	422	O
Laboratories	423	435	O
,	435	436	O
West	437	441	O
Grove	442	447	O
,	447	448	O
PA	449	451	O
,	451	452	O
USA	453	456	O
)	456	457	O
,	457	458	O
in	459	461	O
phosphate	462	471	O
-	471	472	O
buffered	472	480	O
saline	481	487	O
(	488	489	O
PBS	489	492	O
)	492	493	O
at	494	496	O
4degreesC	497	506	O
overnight	507	516	O
.	516	517	O

After	518	523	O
three	524	529	O
washes	530	536	O
with	537	541	O
PBS	542	545	O
containing	546	556	O
0	557	558	O
.	558	559	O
05	559	561	O
%	561	562	O
Tween	563	568	O
-	568	569	O
20	569	571	O
(	572	573	O
PBST	573	577	O
)	577	578	O
,	578	579	O
plates	580	586	O
were	587	591	O
blocked	592	599	O
by	600	602	O
adding	603	609	O
PBS	610	613	O
containing	614	624	O
1	625	626	O
%	626	627	O
bovine	628	634	O
serum	635	640	B-Organism_substance
albumin	641	648	O
(	649	650	O
BSA	650	653	O
)	653	654	O
to	655	657	O
the	658	661	O
wells	662	667	O
for	668	671	O
90	672	674	O
min	675	678	O
.	678	679	O

Next	680	684	O
,	684	685	O
50	686	688	O
microL	689	695	O
of	696	698	O
supernatant	699	710	B-Organism_substance
sample	711	717	I-Organism_substance
or	718	720	O
standard	721	729	O
human	730	735	O
IgA1	736	740	O
(	741	742	O
CALBIOCHEM	742	752	O
,	752	753	O
La	754	756	O
Jolla	757	762	O
,	762	763	O
CA	764	766	O
,	766	767	O
USA	768	771	O
)	771	772	O
was	773	776	O
added	777	782	O
to	783	785	O
the	786	789	O
reaction	790	798	O
wells	799	804	O
and	805	808	O
then	809	813	O
incubated	814	823	O
for	824	827	O
90	828	830	O
min	831	834	O
.	834	835	O

After	836	841	O
three	842	847	O
washes	848	854	O
,	854	855	O
0	856	857	O
.	857	858	O
75	858	860	O
microg	861	867	O
/	867	868	O
mL	868	870	O
alkaline	871	879	O
phosphatase	880	891	O
conjugated	892	902	O
goat	903	907	O
anti	908	912	O
-	912	913	O
human	913	918	O
IgA	919	922	O
(	923	924	O
Southern	924	932	O
Biotechnology	933	946	O
Associates	947	957	O
,	957	958	O
Birmingham	959	969	O
,	969	970	O
AL	971	973	O
,	973	974	O
USA	975	978	O
)	978	979	O
in	980	982	O
1	983	984	O
%	984	985	O
BSA	986	989	O
/	989	990	O
PBS	990	993	O
was	994	997	O
added	998	1003	O
to	1004	1006	O
the	1007	1010	O
reaction	1011	1019	O
wells	1020	1025	O
and	1026	1029	O
then	1030	1034	O
incubated	1035	1044	O
for	1045	1048	O
90	1049	1051	O
min	1052	1055	O
.	1055	1056	O

Plates	1057	1063	O
were	1064	1068	O
washed	1069	1075	O
three	1076	1081	O
times	1082	1087	O
and	1088	1091	O
developed	1092	1101	O
with	1102	1106	O
a	1107	1108	O
substrate	1109	1118	O
solution	1119	1127	O
of	1128	1130	O
1	1131	1132	O
mg	1133	1135	O
/	1135	1136	O
mL	1136	1138	O
p	1139	1140	O
-	1140	1141	O
nitrophenyl	1141	1152	O
phosphate	1153	1162	O
disodium	1163	1171	O
salt	1172	1176	O
(	1177	1178	O
SIGMA	1178	1183	O
,	1183	1184	O
St	1185	1187	O
.	1187	1188	O
Louis	1189	1194	O
,	1194	1195	O
MO	1196	1198	O
,	1198	1199	O
USA	1200	1203	O
)	1203	1204	O
in	1205	1207	O
0	1208	1209	O
.	1209	1210	O
1	1210	1211	O
M	1212	1213	O
glycine	1214	1221	O
buffer	1222	1228	O
containing	1229	1239	O
1	1240	1241	O
mM	1242	1244	O
MgCl2	1245	1250	O
,	1250	1251	O
1	1252	1253	O
mM	1254	1256	O
ZnCl2	1257	1262	O
,	1262	1263	O
pH	1264	1266	O
10	1267	1269	O
.	1269	1270	O
4	1270	1271	O
.	1271	1272	O

The	1273	1276	O
optical	1277	1284	O
density	1285	1292	O
at	1293	1295	O
405	1296	1299	O
nm	1300	1302	O
was	1303	1306	O
determined	1307	1317	O
in	1318	1320	O
a	1321	1322	O
microplate	1323	1333	O
reader	1334	1340	O
(	1341	1342	O
Benchmark	1342	1351	O
PlusTM	1352	1358	O
Bio	1359	1362	O
-	1362	1363	O
Rad	1363	1366	O
Laboratories	1367	1379	O
,	1379	1380	O
Hercules	1381	1389	O
,	1389	1390	O
CA	1391	1393	O
,	1393	1394	O
USA	1395	1398	O
)	1398	1399	O
.	1399	1400	O

IgA1	1401	1405	O
concentration	1406	1419	O
in	1420	1422	O
unknown	1423	1430	O
duplicate	1431	1440	O
samples	1441	1448	O
was	1449	1452	O
determined	1453	1463	O
by	1464	1466	O
interpolation	1467	1480	O
of	1481	1483	O
the	1484	1487	O
respective	1488	1498	O
optical	1499	1506	O
density	1507	1514	O
into	1515	1519	O
the	1520	1523	O
appropriate	1524	1535	O
standard	1536	1544	O
curve	1545	1550	O
.	1550	1551	O

IgG	1552	1555	O
and	1556	1559	O
IgM	1560	1563	O
contents	1564	1572	O
in	1573	1575	O
the	1576	1579	O
supernatant	1580	1591	B-Organism_substance
were	1592	1596	O
measured	1597	1605	O
using	1606	1611	O
sandwich	1612	1620	O
ELISA	1621	1626	O
(	1627	1628	O
IMMUNOtek	1628	1637	O
(	1637	1638	O
R	1638	1639	O
)	1639	1640	O
,	1640	1641	O
ZeptoMetrix	1642	1653	O
Corporation	1654	1665	O
,	1665	1666	O
Buffalo	1667	1674	O
,	1674	1675	O
NY	1676	1678	O
,	1678	1679	O
USA	1680	1683	O
)	1683	1684	O
according	1685	1694	O
to	1695	1697	O
the	1698	1701	O
manufacturer	1702	1714	O
'	1714	1715	O
s	1715	1716	O
instructions	1717	1729	O
.	1729	1730	O

The	0	3	O
thickness	4	13	O
of	14	16	O
the	17	20	O
inner	21	26	B-Multi-tissue_structure
retina	27	33	I-Multi-tissue_structure
was	34	37	O
established	38	49	O
as	50	52	O
the	53	56	O
distance	57	65	O
between	66	73	O
retinal	74	81	B-Tissue
nerve	82	87	I-Tissue
fiber	88	93	I-Tissue
layer	94	99	I-Tissue
and	100	103	O
inner	104	109	B-Tissue
nuclear	110	117	I-Tissue
layer	118	123	I-Tissue
and	124	127	O
was	128	131	O
measured	132	140	O
using	141	146	O
the	147	150	O
1	151	152	O
,	152	153	O
000	153	156	O
mum	157	160	O
caliper	161	168	O
available	169	178	O
in	179	181	O
the	182	185	O
OCT	186	189	O
-	189	190	O
SLO	190	193	O
Spectralis	194	204	O
.	204	205	O

Ten	206	209	O
age	210	213	O
-	213	214	O
matched	214	221	O
normal	222	228	O
eyes	229	233	B-Organ
were	234	238	O
used	239	243	O
as	244	246	O
controls	247	255	O
.	255	256	O

Observe	257	264	O
the	265	268	O
decrease	269	277	O
in	278	280	O
the	281	284	O
nasal	285	290	B-Organism_subdivision
and	291	294	O
temporal	295	303	O
inner	304	309	B-Multi-tissue_structure
retinal	310	317	I-Multi-tissue_structure
thickness	318	327	O
in	328	330	O
the	331	334	O
right	335	340	O
eye	341	344	B-Organ
in	345	347	O
comparison	348	358	O
to	359	361	O
the	362	365	O
left	366	370	O
and	371	374	O
normal	375	381	O
control	382	389	O
eyes	390	394	B-Organ
.	394	395	O

Real	0	4	O
time	5	9	O
RT	10	12	O
-	12	13	O
PCR	13	16	O

RNA	17	20	O
extraction	21	31	O
and	32	35	O
real	36	40	O
-	40	41	O
time	41	45	O
RT	46	48	O
-	48	49	O
PCR	49	52	O
were	53	57	O
performed	58	67	O
as	68	70	O
we	71	73	O
described	74	83	O
previously	84	94	O
[	95	96	O
22	96	98	O
]	98	99	O
.	99	100	O

The	101	104	O
sequences	105	114	O
of	115	117	O
ABCG2	118	123	O
primers	124	131	O
are	132	135	O
5	136	137	O
'	137	138	O
-	138	139	O
GGCTTTCTACCTGCACGAAAACCAGTTGAG	139	169	O
-	169	170	O
3	170	171	O
'	171	172	O
(	173	174	O
forward	174	181	O
)	181	182	O
and	183	186	O
5	187	188	O
'	188	189	O
-	189	190	O
ATGGCGTTGAGACCAG	190	206	O
-	206	207	O
3	207	208	O
'	208	209	O
(	210	211	O
reverse	211	218	O
)	218	219	O
.	219	220	O

The	221	224	O
sequences	225	234	O
of	235	237	O
GAPDH	238	243	O
primers	244	251	O
are	252	255	O
5	256	257	O
'	257	258	O
-	258	259	O
AAGGACTCATGACCACAGTCCAT	259	282	O
-	282	283	O
3	283	284	O
'	284	285	O
(	286	287	O
forward	287	294	O
)	294	295	O
and	296	299	O
5	300	301	O
'	301	302	O
-	302	303	O
CCATCACGCCACAGTTTCC	303	322	O
-	322	323	O
3	323	324	O
'	324	325	O
(	326	327	O
reverse	327	334	O
)	334	335	O
.	335	336	O

The	337	340	O
relative	341	349	O
ABCG2	350	355	O
RNA	356	359	O
level	360	365	O
(	366	367	O
2DeltaCT	367	375	O
)	375	376	O
treated	377	384	O
with	385	389	O
inhibitors	390	400	O
was	401	404	O
expressed	405	414	O
as	415	417	O
percentage	418	428	O
of	429	431	O
the	432	435	O
control	436	443	O
(	444	445	O
in	445	447	O
the	448	451	O
presence	452	460	O
of	461	463	O
0	464	465	O
.	465	466	O
1	466	467	O
%	467	468	O
DMSO	469	473	O
)	473	474	O
where	475	480	O
DeltaCT	481	488	O
(	489	490	O
threshold	490	499	O
cycle	500	505	O
)	505	506	O
=	507	508	O
(	509	510	O
CTABCG2	510	517	O
-	517	518	O
CTGAPDH	518	525	O
)	525	526	O
.	526	527	O

Introduction	0	12	O

Adipose	13	20	B-Tissue
tissue	21	27	I-Tissue
,	27	28	O
once	29	33	O
viewed	34	40	O
as	41	43	O
simply	44	50	O
a	51	52	O
storage	53	60	O
and	61	64	O
release	65	72	O
depot	73	78	O
for	79	82	O
lipids	83	89	O
,	89	90	O
is	91	93	O
now	94	97	O
considered	98	108	O
an	109	111	O
endocrine	112	121	B-Tissue
tissue	122	128	I-Tissue
[	129	130	O
1	130	131	O
,	131	132	O
2	132	133	O
]	133	134	O
that	135	139	O
secretes	140	148	O
various	149	156	O
substances	157	167	O
(	168	169	O
adipokines	169	179	O
)	179	180	O
,	180	181	O
including	182	191	O
tumor	192	197	O
necrosis	198	206	O
factor	207	213	O
-	213	214	O
alpha	214	219	O
(	220	221	O
TNF	221	224	O
-	224	225	O
alpha	225	230	O
)	230	231	O
,	231	232	O
interleukin	233	244	O
(	245	246	O
IL	246	248	O
)	248	249	O
-	249	250	O
6	250	251	O
,	251	252	O
leptin	253	259	O
,	259	260	O
adiponectin	261	272	O
,	272	273	O
resistin	274	282	O
,	282	283	O
visfatin	284	292	O
,	292	293	O
and	294	297	O
omenetin	298	306	O
[	307	308	O
3	308	309	O
,	309	310	O
4	310	311	O
]	311	312	O
.	312	313	O

Among	314	319	O
these	320	325	O
adipokines	326	336	O
,	336	337	O
much	338	342	O
attention	343	352	O
has	353	356	O
been	357	361	O
paid	362	366	O
to	367	369	O
adiponectin	370	381	O
'	381	382	O
s	382	383	O
relationship	384	396	O
with	397	401	O
insulin	402	409	O
sensitivity	410	421	O
and	422	425	O
glucose	426	433	O
and	434	437	O
lipid	438	443	O
metabolism	444	454	O
in	455	457	O
the	458	461	O
past	462	466	O
10	467	469	O
years	470	475	O
.	475	476	O

In	477	479	O
addition	480	488	O
,	488	489	O
adiponectin	490	501	O
is	502	504	O
known	505	510	O
to	511	513	O
exhibit	514	521	O
potent	522	528	O
anti	529	533	O
-	533	534	O
inflammatory	534	546	O
[	547	548	O
5	548	549	O
]	549	550	O
,	550	551	O
atheroprotective	552	568	O
[	569	570	O
6	570	571	O
]	571	572	O
,	572	573	O
and	574	577	O
antidiabetic	578	590	O
[	591	592	O
7	592	593	O
]	593	594	O
effects	595	602	O
.	602	603	O

Recent	604	610	O
findings	611	619	O
suggest	620	627	O
that	628	632	O
adiponectin	633	644	O
may	645	648	O
be	649	651	O
involved	652	660	O
in	661	663	O
the	664	667	O
pathogenesis	668	680	O
of	681	683	O
rheumatoid	684	694	O
arthritis	695	704	O
(	705	706	O
RA	706	708	O
)	708	709	O
.	709	710	O

Levels	711	717	O
of	718	720	O
adiponectin	721	732	O
in	733	735	O
synovial	736	744	B-Organism_substance
fluid	745	750	I-Organism_substance
and	751	754	O
sera	755	759	B-Organism_substance
were	760	764	O
elevated	765	773	O
in	774	776	O
patients	777	785	O
with	786	790	O
RA	791	793	O
[	794	795	O
8	795	796	O
,	796	797	O
9	797	798	O
]	798	799	O
.	799	800	O

Adiponectin	801	812	O
also	813	817	O
induces	818	825	O
the	826	829	O
production	830	840	O
of	841	843	O
proinflammatory	844	859	O
cytokines	860	869	O
,	869	870	O
IL	871	873	O
-	873	874	O
6	874	875	O
,	875	876	O
matrix	877	883	O
metalloproteinase	884	901	O
(	902	903	O
MMP	903	906	O
)	906	907	O
-	907	908	O
1	908	909	O
,	909	910	O
and	911	914	O
IL	915	917	O
-	917	918	O
8	918	919	O
from	920	924	O
RA	925	927	O
synovial	928	936	B-Cell
fibroblasts	937	948	I-Cell
in	949	951	O
vitro	952	957	O
[	958	959	O
10	959	961	O
,	961	962	O
11	962	964	O
]	964	965	O
.	965	966	O

Thus	967	971	O
,	971	972	O
it	973	975	O
was	976	979	O
suggested	980	989	O
that	990	994	O
adiponectin	995	1006	O
can	1007	1010	O
also	1011	1015	O
exert	1016	1021	O
significant	1022	1033	O
proinflammatory	1034	1049	O
and	1050	1053	O
matrix	1054	1060	O
-	1060	1061	O
degrading	1061	1070	O
effects	1071	1078	O
.	1078	1079	O

However	1080	1087	O
,	1087	1088	O
the	1089	1092	O
role	1093	1097	O
of	1098	1100	O
adiponectin	1101	1112	O
in	1113	1115	O
the	1116	1119	O
pathogenesis	1120	1132	O
of	1133	1135	O
RA	1136	1138	O
is	1139	1141	O
still	1142	1147	O
controversial	1148	1161	O
because	1162	1169	O
of	1170	1172	O
conflicting	1173	1184	O
reports	1185	1192	O
about	1193	1198	O
its	1199	1202	O
function	1203	1211	O
[	1212	1213	O
10	1213	1215	O
,	1215	1216	O
12	1216	1218	O
-	1218	1219	O
15	1219	1221	O
]	1221	1222	O
.	1222	1223	O

In	1224	1226	O
particular	1227	1237	O
,	1237	1238	O
adiponectin	1239	1250	O
seems	1251	1256	O
to	1257	1259	O
play	1260	1264	O
an	1265	1267	O
anti	1268	1272	O
-	1272	1273	O
inflammatory	1273	1285	O
role	1286	1290	O
because	1291	1298	O
it	1299	1301	O
significantly	1302	1315	O
inhibited	1316	1325	O
IL	1326	1328	O
-	1328	1329	O
1beta	1329	1334	O
-	1334	1335	O
stimulated	1335	1345	O
synovial	1346	1354	B-Cell
cell	1355	1359	I-Cell
proliferation	1360	1373	O
in	1374	1376	O
collagen	1377	1385	O
-	1385	1386	O
induced	1386	1393	O
arthritic	1394	1403	O
mice	1404	1408	O
,	1408	1409	O
despite	1410	1417	O
increased	1418	1427	O
IL	1428	1430	O
-	1430	1431	O
6	1431	1432	O
expression	1433	1443	O
[	1444	1445	O
16	1445	1447	O
]	1447	1448	O
.	1448	1449	O

In	1450	1452	O
contrast	1453	1461	O
,	1461	1462	O
high	1463	1467	O
-	1467	1468	O
grade	1468	1473	O
inflammation	1474	1486	O
in	1487	1489	O
RA	1490	1492	O
patients	1493	1501	O
was	1502	1505	O
negatively	1506	1516	O
correlated	1517	1527	O
with	1528	1532	O
circulating	1533	1544	O
adiponectin	1545	1556	O
concentrations	1557	1571	O
[	1572	1573	O
17	1573	1575	O
]	1575	1576	O
.	1576	1577	O

Rather	1578	1584	O
,	1584	1585	O
it	1586	1588	O
was	1589	1592	O
suggested	1593	1602	O
that	1603	1607	O
circulating	1608	1619	O
adiponectin	1620	1631	O
may	1632	1635	O
be	1636	1638	O
involved	1639	1647	O
in	1648	1650	O
cardiovascular	1651	1665	B-Multi-tissue_structure
disease	1666	1673	O
in	1674	1676	O
RA	1677	1679	O
patients	1680	1688	O
.	1688	1689	O

Although	1690	1698	O
this	1699	1703	O
contradiction	1704	1717	O
was	1718	1721	O
partly	1722	1728	O
explained	1729	1738	O
by	1739	1741	O
the	1742	1745	O
induction	1746	1755	O
of	1756	1758	O
tolerance	1759	1768	O
to	1769	1771	O
inflammatory	1772	1784	O
stimuli	1785	1792	O
by	1793	1795	O
adiponectin	1796	1807	O
[	1808	1809	O
18	1809	1811	O
]	1811	1812	O
,	1812	1813	O
the	1814	1817	O
pro	1818	1821	O
-	1821	1822	O
or	1823	1825	O
anti	1826	1830	O
-	1830	1831	O
inflammatory	1831	1843	O
effects	1844	1851	O
of	1852	1854	O
adiponectin	1855	1866	O
on	1867	1869	O
the	1870	1873	O
pathogenesis	1874	1886	O
of	1887	1889	O
RA	1890	1892	O
remain	1893	1899	O
unknown	1900	1907	O
.	1907	1908	O

With	1909	1913	O
regard	1914	1920	O
to	1921	1923	O
adiponectin	1924	1935	O
'	1935	1936	O
s	1936	1937	O
proinflammatory	1938	1953	O
effects	1954	1961	O
,	1961	1962	O
we	1963	1965	O
wondered	1966	1974	O
whether	1975	1982	O
adiponectin	1983	1994	O
might	1995	2000	O
stimulate	2001	2010	O
the	2011	2014	O
production	2015	2025	O
of	2026	2028	O
vascular	2029	2037	O
endothelial	2038	2049	O
growth	2050	2056	O
factor	2057	2063	O
(	2064	2065	O
VEGF	2065	2069	O
)	2069	2070	O
and	2071	2074	O
MMPs	2075	2079	O
as	2080	2082	O
well	2083	2087	O
as	2088	2090	O
proinflammatory	2091	2106	O
mediators	2107	2116	O
like	2117	2121	O
IL	2122	2124	O
-	2124	2125	O
1beta	2125	2130	O
and	2131	2134	O
TNF	2135	2138	O
-	2138	2139	O
alpha	2139	2144	O
do	2145	2147	O
.	2147	2148	O

In	2149	2151	O
this	2152	2156	O
study	2157	2162	O
,	2162	2163	O
we	2164	2166	O
investigated	2167	2179	O
the	2180	2183	O
stimulatory	2184	2195	O
effect	2196	2202	O
of	2203	2205	O
adiponectin	2206	2217	O
on	2218	2220	O
the	2221	2224	O
production	2225	2235	O
of	2236	2238	O
IL	2239	2241	O
-	2241	2242	O
6	2242	2243	O
,	2243	2244	O
IL	2245	2247	O
-	2247	2248	O
8	2248	2249	O
,	2249	2250	O
prostaglandin	2251	2264	O
E2	2265	2267	O
(	2268	2269	O
PGE2	2269	2273	O
)	2273	2274	O
,	2274	2275	O
VEGF	2276	2280	O
,	2280	2281	O
and	2282	2285	O
MMPs	2286	2290	O
.	2290	2291	O

In	2292	2294	O
addition	2295	2303	O
,	2303	2304	O
the	2305	2308	O
correlation	2309	2320	O
between	2321	2328	O
adiponectin	2329	2340	O
and	2341	2344	O
VEGF	2345	2349	O
or	2350	2352	O
MMPs	2353	2357	O
was	2358	2361	O
investigated	2362	2374	O
by	2375	2377	O
measuring	2378	2387	O
the	2388	2391	O
levels	2392	2398	O
of	2399	2401	O
these	2402	2407	O
three	2408	2413	O
proteins	2414	2422	O
in	2423	2425	O
the	2426	2429	O
joint	2430	2435	B-Organism_substance
fluid	2436	2441	I-Organism_substance
of	2442	2444	O
patients	2445	2453	O
with	2454	2458	O
RA	2459	2461	O
or	2462	2464	O
osteoarthritis	2465	2479	O
(	2480	2481	O
OA	2481	2483	O
)	2483	2484	O
.	2484	2485	O

Refinement	0	10	O

The	11	14	O
H	15	16	O
-	16	17	O
atoms	17	22	O
were	23	27	O
positioned	28	38	O
geometrically	39	52	O
(	53	54	O
O	54	55	O
-	55	56	O
H	56	57	O
=	58	59	O
0	60	61	O
.	61	62	O
82	62	64	O
,	64	65	O
C	66	67	O
-	67	68	O
H	68	69	O
=	70	71	O
0	72	73	O
.	73	74	O
93	74	76	O
A	77	78	O
)	78	79	O
and	80	83	O
were	84	88	O
included	89	97	O
in	98	100	O
the	101	104	O
refinement	105	115	O
in	116	118	O
the	119	122	O
riding	123	129	O
model	130	135	O
approximation	136	149	O
,	149	150	O
with	151	155	O
Uiso	156	160	O
(	160	161	O
H	161	162	O
)	162	163	O
=	164	165	O
xUeq	166	170	O
(	170	171	O
C	171	172	O
,	172	173	O
O	174	175	O
)	175	176	O
,	176	177	O
where	178	183	O
x	184	185	O
=	186	187	O
1	188	189	O
.	189	190	O
2	190	191	O
for	192	195	O
all	196	199	O
H	200	201	O
-	201	202	O
atoms	202	207	O
.	207	208	O

Reagents	0	8	O
and	9	12	O
antibodies	13	23	O

Maxisorp	24	32	O
strips	33	39	O
(	40	41	O
NunC	41	45	O
,	45	46	O
Roskilde	47	55	O
,	55	56	O
Denmark	57	64	O
)	64	65	O
,	65	66	O
GST	67	70	O
-	70	71	O
PNMA2	71	76	O
recombinant	77	88	O
protein	89	96	O
(	97	98	O
Abnova	98	104	O
,	104	105	O
Taipei	106	112	O
,	112	113	O
Taiwan	114	120	O
)	120	121	O
;	121	122	O
3	123	124	O
,	124	125	O
3	125	126	O
'	126	127	O
,	127	128	O
5	128	129	O
,	129	130	O
5	130	131	O
-	131	132	O
tetramethylbenzidine	132	152	O
(	153	154	O
TMB	154	157	O
)	157	158	O
+	159	160	O
substrate	161	170	O
(	171	172	O
Dako	172	176	O
,	176	177	O
Glostrup	178	186	O
,	186	187	O
Denmark	188	195	O
)	195	196	O
,	196	197	O
Peroxidase	198	208	O
with	209	213	O
dakocytomation	214	228	O
peroxidase	229	239	O
block	240	245	O
(	246	247	O
Dako	247	251	O
)	251	252	O
,	252	253	O
Dakocytomation	254	268	O
envision	269	277	O
(	277	278	O
R	278	279	O
)	279	280	O
system	281	287	O
labeled	288	295	O
polymer	296	303	O
-	303	304	O
HRP	304	307	O
anti	308	312	O
-	312	313	O
rabbit	313	319	O
kit	320	323	O
and	324	327	O
3	328	329	O
-	329	330	O
3	330	331	O
'	331	332	O
-	332	333	O
diaminobenzidine	333	349	O
(	350	351	O
Dako	351	355	O
)	355	356	O
,	356	357	O
Mayer	358	363	O
'	363	364	O
s	364	365	O
hematoxylin	366	377	O
(	378	379	O
Histolab	379	387	O
Product	388	395	O
AB	396	398	O
,	398	399	O
Gothenburg	400	410	O
,	410	411	O
Sweden	412	418	O
)	418	419	O
,	419	420	O
Graded	421	427	O
alcohol	428	435	O
(	436	437	O
Kemetyl	437	444	O
,	444	445	O
Vestby	446	452	O
,	452	453	O
Norway	454	460	O
)	460	461	O
,	461	462	O
Xylen	463	468	O
(	469	470	O
Solveco	470	477	O
,	477	478	O
Rosersberg	479	489	O
,	489	490	O
Sweden	491	497	O
)	497	498	O
,	498	499	O
Pertex	500	506	O
(	506	507	O
R	507	508	O
)	508	509	O
(	510	511	O
Histolab	511	519	O
,	519	520	O
Gothenburg	521	531	O
,	531	532	O
Sweden	533	539	O
)	539	540	O
,	540	541	O
Tris	542	546	O
-	546	547	O
Glycine	547	554	O
blotting	555	563	O
buffer	564	570	O
(	571	572	O
Amresco	572	579	O
,	579	580	O
Solon	581	586	O
,	586	587	O
OH	588	590	O
)	590	591	O
,	591	592	O
Western	593	600	O
blotting	601	609	O
(	610	611	O
WB	611	613	O
)	613	614	O
reagent	615	622	O
and	623	626	O
Lumi	627	631	O
-	631	632	O
Light	632	637	O
WB	638	640	O
substrate	641	650	O
(	651	652	O
Roche	652	657	O
,	657	658	O
Basel	659	664	O
,	664	665	O
Switzerland	666	677	O
)	677	678	O
,	678	679	O
EasyTag	680	687	O
Methionine	688	698	O
-	698	699	O
L	699	700	O
-	700	701	O
35S	701	704	O
,	704	705	O
NEG709A005MC	706	718	O
(	719	720	O
PerkinElmer	720	731	O
,	731	732	O
Waltham	733	740	O
,	740	741	O
MA	742	744	O
)	744	745	O
,	745	746	O
Full	747	751	O
-	751	752	O
length	752	758	O
cDNA	759	763	O
clone	764	769	O
for	770	773	O
human	774	779	O
PNMA2	780	785	O
,	785	786	O
ID6580976	787	796	O
(	797	798	O
BioScience	798	808	O
Geneservice	809	820	O
,	820	821	O
Cambridge	822	831	O
,	831	832	O
UK	833	835	O
)	835	836	O
,	836	837	O
TnT	838	841	O
(	841	842	O
R	842	843	O
)	843	844	O
SP6	845	848	O
Quick	849	854	O
Coupled	855	862	O
Transcription	863	876	O
/	876	877	O
Translation	877	888	O
System	889	895	O
(	896	897	O
Promega	897	904	O
,	904	905	O
Madison	906	913	O
,	913	914	O
WI	915	917	O
)	917	918	O
,	918	919	O
Protein	920	927	O
G	928	929	O
-	929	930	O
Sepharose	930	939	O
beads	940	945	O
(	946	947	O
GE	947	949	O
Healthcare	950	960	O
,	960	961	O
Little	962	968	O
Chalfont	969	977	O
,	977	978	O
Buckinghamshire	979	994	O
,	994	995	O
UK	996	998	O
)	998	999	O
,	999	1000	O
Peroxidase	1001	1011	O
(	1012	1013	O
HRP	1013	1016	O
)	1016	1017	O
-	1017	1018	O
conjugated	1018	1028	O
rabbit	1029	1035	O
anti	1036	1040	O
human	1041	1046	O
IgG	1047	1050	O
(	1051	1052	O
anti	1052	1056	O
-	1056	1057	O
IgG	1057	1060	O
)	1060	1061	O
(	1062	1063	O
Dako	1063	1067	O
)	1067	1068	O
,	1068	1069	O
rabbit	1070	1076	O
polyclonal	1077	1087	O
antibody	1088	1096	O
anti	1097	1101	O
-	1101	1102	O
PNMA2	1102	1107	O
(	1108	1109	O
Atlas	1109	1114	O
Antibodies	1115	1125	O
,	1125	1126	O
Stockholm	1127	1136	O
,	1136	1137	O
Sweden	1138	1144	O
)	1144	1145	O
,	1145	1146	O
monoclonal	1147	1157	O
mouse	1158	1163	O
anti	1164	1168	O
-	1168	1169	O
GST	1169	1172	O
,	1172	1173	O
sc	1174	1176	O
-	1176	1177	O
138	1177	1180	O
,	1180	1181	O
polyclonal	1182	1192	O
goat	1193	1197	O
anti	1198	1202	O
-	1202	1203	O
human	1203	1208	O
Ma2	1209	1212	O
,	1212	1213	O
sc	1214	1216	O
-	1216	1217	O
68099	1217	1222	O
,	1222	1223	O
HRP	1224	1227	O
-	1227	1228	O
donkey	1228	1234	O
anti	1235	1239	O
-	1239	1240	O
goat	1240	1244	O
,	1244	1245	O
sc	1246	1248	O
-	1248	1249	O
2020	1249	1253	O
,	1253	1254	O
(	1255	1256	O
Santa	1256	1261	O
Cruz	1262	1266	O
Biotechnology	1267	1280	O
,	1280	1281	O
Santa	1282	1287	O
Cruz	1288	1292	O
,	1292	1293	O
CA	1294	1296	O
)	1296	1297	O
,	1297	1298	O
HRP	1299	1302	O
-	1302	1303	O
goat	1303	1307	O
anti	1308	1312	O
-	1312	1313	O
rabbit	1313	1319	O
,	1319	1320	O
P0448	1321	1326	O
,	1326	1327	O
(	1328	1329	O
Dako	1329	1333	O
)	1333	1334	O
and	1335	1338	O
Ravo	1339	1343	O
PNS	1344	1347	O
-	1347	1348	O
Blot	1348	1352	O
,	1352	1353	O
(	1354	1355	O
Ravo	1355	1359	O
Diagnostika	1360	1371	O
GmbH	1372	1376	O
,	1376	1377	O
Freiburg	1378	1386	O
,	1386	1387	O
Germany	1388	1395	O
)	1395	1396	O
.	1396	1397	O

Statistical	0	11	O
analysis	12	20	O

All	21	24	O
statistical	25	36	O
analyses	37	45	O
were	46	50	O
performed	51	60	O
using	61	66	O
SPSS13	67	73	O
.	73	74	O
0	74	75	O
software	76	84	O
.	84	85	O

The	86	89	O
differences	90	101	O
between	102	109	O
groups	110	116	O
were	117	121	O
compared	122	130	O
using	131	136	O
Student	137	144	O
'	144	145	O
s	145	146	O
t	147	148	O
-	148	149	O
test	149	153	O
,	153	154	O
and	155	158	O
data	159	163	O
were	164	168	O
expressed	169	178	O
as	179	181	O
mean	182	186	O
+	187	188	O
/	188	189	O
-	189	190	O
SD	191	193	O
.	193	194	O

Statistical	195	206	O
difference	207	217	O
was	218	221	O
accepted	222	230	O
at	231	233	O
P	234	235	O
<	235	236	O
0	236	237	O
.	237	238	O
05	238	240	O
.	240	241	O

The	0	3	O
importance	4	14	O
in	15	17	O
identifying	18	29	O
genes	30	35	O
involved	36	44	O
in	45	47	O
spinal	48	54	B-Organism_subdivision
curvature	55	64	O

Spinal	65	71	B-Organism_subdivision
curvature	72	81	O
is	82	84	O
a	85	86	O
prevalent	87	96	O
and	97	100	O
costly	101	107	O
deformity	108	117	O
among	118	123	O
humans	124	130	O
and	131	134	O
teleosts	135	143	O
.	143	144	O

The	145	148	O
estimated	149	158	O
annual	159	165	O
cost	166	170	O
of	171	173	O
treating	174	182	O
children	183	191	O
hospitalized	192	204	O
with	205	209	O
idiopathic	210	220	O
scoliosis	221	230	O
(	231	232	O
IS	232	234	O
)	234	235	O
in	236	238	O
the	239	242	O
United	243	249	O
States	250	256	O
alone	257	262	O
is	263	265	O
over	266	270	O
$	271	272	O
3	272	273	O
billion	274	281	O
.	281	282	O

This	283	287	O
cost	288	292	O
estimate	293	301	O
does	302	306	O
not	307	310	O
consider	311	319	O
Scheuermann	320	331	O
kyphosis	332	340	O
,	340	341	O
or	342	344	O
adults	345	351	O
with	352	356	O
idiopathic	357	367	O
-	367	368	O
type	368	372	O
spinal	373	379	B-Organism_subdivision
curvature	380	389	O
who	390	393	O
suffer	394	400	O
from	401	405	O
chronic	406	413	O
back	414	418	B-Organism_subdivision
pain	419	423	O
,	423	424	O
contributing	425	437	O
to	438	440	O
the	441	444	O
estimated	445	454	O
$	455	456	O
849	456	459	O
billion	460	467	O
cost	468	472	O
of	473	475	O
treatment	476	485	O
and	486	489	O
lost	490	494	O
wages	495	500	O
associated	501	511	O
with	512	516	O
musculoskeletal	517	532	B-Anatomical_system
disease	533	540	O
[	541	542	O
24	542	544	O
]	544	545	O
.	545	546	O

Among	547	552	O
teleosts	553	561	O
,	561	562	O
spinal	563	569	B-Organism_subdivision
column	570	576	I-Organism_subdivision
deformities	577	588	O
reduce	589	595	O
total	596	601	O
production	602	612	O
in	613	615	O
the	616	619	O
aquaculture	620	631	O
industry	632	640	O
substantially	641	654	O
[	655	656	O
12	656	658	O
]	658	659	O
.	659	660	O

In	661	663	O
contrast	664	672	O
to	673	675	O
humans	676	682	O
,	682	683	O
teleost	684	691	O
curve	692	697	O
phenotypes	698	708	O
are	709	712	O
less	713	717	O
well	718	722	O
characterized	723	736	O
;	736	737	O
although	738	746	O
heritable	747	756	O
curves	757	763	O
are	764	767	O
acknowledged	768	780	O
to	781	783	O
account	784	791	O
for	792	795	O
many	796	800	O
cases	801	806	O
among	807	812	O
cultured	813	821	O
stocks	822	828	O
,	828	829	O
whether	830	837	O
these	838	843	O
cases	844	849	O
are	850	853	O
from	854	858	O
congenital	859	869	O
defects	870	877	O
or	878	880	O
are	881	884	O
idiopathic	885	895	O
-	895	896	O
type	896	900	O
is	901	903	O
often	904	909	O
not	910	913	O
known	914	919	O
.	919	920	O

Despite	921	928	O
the	929	932	O
prevalence	933	943	O
and	944	947	O
impact	948	954	O
of	955	957	O
this	958	962	O
type	963	967	O
of	968	970	O
deformity	971	980	O
,	980	981	O
the	982	985	O
genetic	986	993	O
architecture	994	1006	O
and	1007	1010	O
specific	1011	1019	O
genes	1020	1025	O
involved	1026	1034	O
are	1035	1038	O
unknown	1039	1046	O
.	1046	1047	O

The	1048	1051	O
current	1052	1059	O
view	1060	1064	O
is	1065	1067	O
that	1068	1072	O
human	1073	1078	O
idiopathic	1079	1089	O
-	1089	1090	O
type	1090	1094	O
scoliosis	1095	1104	O
is	1105	1107	O
a	1108	1109	O
complex	1110	1117	O
genetic	1118	1125	O
disorder	1126	1134	O
with	1135	1139	O
multiple	1140	1148	O
genes	1149	1154	O
segregating	1155	1166	O
in	1167	1169	O
the	1170	1173	O
population	1174	1184	O
exhibiting	1185	1195	O
complex	1196	1203	O
genotype	1204	1212	O
by	1213	1215	O
environment	1216	1227	O
interactions	1228	1240	O
[	1241	1242	O
25	1242	1244	O
-	1244	1245	O
30	1245	1247	O
]	1247	1248	O
.	1248	1249	O

In	1250	1252	O
aquaculture	1253	1264	O
stocks	1265	1271	O
,	1271	1272	O
inheritance	1273	1284	O
for	1285	1288	O
spinal	1289	1295	B-Organism_subdivision
curvature	1296	1305	O
has	1306	1309	O
been	1310	1314	O
described	1315	1324	O
as	1325	1327	O
Mendelian	1328	1337	O
recessive	1338	1347	O
or	1348	1350	O
dominant	1351	1359	O
,	1359	1360	O
as	1361	1363	O
well	1364	1368	O
as	1369	1371	O
polygenic	1372	1381	O
,	1381	1382	O
depending	1383	1392	O
on	1393	1395	O
how	1396	1399	O
well	1400	1404	O
the	1405	1408	O
phenotype	1409	1418	O
is	1419	1421	O
characterized	1422	1435	O
and	1436	1439	O
what	1440	1444	O
stock	1445	1450	O
is	1451	1453	O
considered	1454	1464	O
(	1465	1466	O
reviewed	1466	1474	O
in	1475	1477	O
[	1478	1479	O
13	1479	1481	O
]	1481	1482	O
,	1482	1483	O
[	1484	1485	O
16	1485	1487	O
]	1487	1488	O
)	1488	1489	O
.	1489	1490	O

The	1491	1494	O
guppy	1495	1500	O
curveback	1501	1510	O
phenotype	1511	1520	O
has	1521	1524	O
been	1525	1529	O
extensively	1530	1541	O
characterized	1542	1555	O
so	1556	1558	O
that	1559	1563	O
the	1564	1567	O
lineage	1568	1575	O
can	1576	1579	O
be	1580	1582	O
applied	1583	1590	O
as	1591	1593	O
a	1594	1595	O
model	1596	1601	O
for	1602	1605	O
understanding	1606	1619	O
the	1620	1623	O
biological	1624	1634	O
context	1635	1642	O
of	1643	1645	O
heritable	1646	1655	O
spinal	1656	1662	B-Organism_subdivision
curvature	1663	1672	O
[	1673	1674	O
1	1674	1675	O
,	1675	1676	O
7	1676	1677	O
-	1677	1678	O
9	1678	1679	O
]	1679	1680	O
.	1680	1681	O

Future	1682	1688	O
studies	1689	1696	O
can	1697	1700	O
use	1701	1704	O
approaches	1705	1715	O
to	1716	1718	O
map	1719	1722	O
QTL	1723	1726	O
affecting	1727	1736	O
shape	1737	1742	O
based	1743	1748	O
on	1749	1751	O
digital	1752	1759	O
photos	1760	1766	O
[	1767	1768	O
31	1768	1770	O
,	1770	1771	O
32	1771	1773	O
]	1773	1774	O
,	1774	1775	O
rather	1776	1782	O
than	1783	1787	O
the	1788	1791	O
qualitative	1792	1803	O
scale	1804	1809	O
used	1810	1814	O
in	1815	1817	O
the	1818	1821	O
present	1822	1829	O
study	1830	1835	O
.	1835	1836	O

The	1837	1840	O
identification	1841	1855	O
of	1856	1858	O
QTL	1859	1862	O
in	1863	1865	O
this	1866	1870	O
study	1871	1876	O
is	1877	1879	O
a	1880	1881	O
first	1882	1887	O
step	1888	1892	O
in	1893	1895	O
understanding	1896	1909	O
the	1910	1913	O
genetics	1914	1922	O
of	1923	1925	O
this	1926	1930	O
type	1931	1935	O
of	1936	1938	O
deformity	1939	1948	O
and	1949	1952	O
will	1953	1957	O
lead	1958	1962	O
to	1963	1965	O
the	1966	1969	O
identification	1970	1984	O
of	1985	1987	O
biological	1988	1998	O
pathways	1999	2007	O
associated	2008	2018	O
with	2019	2023	O
spinal	2024	2030	B-Organism_subdivision
integrity	2031	2040	O
.	2040	2041	O

Intact	0	6	O
mass	7	11	O
analysis	12	20	O
of	21	23	O
a	24	25	O
mixed	26	31	O
population	32	42	O
of	43	45	O
proteins	46	54	O
.	54	55	O

A	56	57	O
mixture	58	65	O
of	66	68	O
the	69	72	O
membrane	73	81	B-Cellular_component
protein	82	89	O
KCNJ12	90	96	O
,	96	97	O
the	98	101	O
soluble	102	109	O
TEV	110	113	O
protease	114	122	O
used	123	127	O
to	128	130	O
cleave	131	137	O
the	138	141	O
fusion	142	148	O
tag	149	152	O
,	152	153	O
and	154	157	O
the	158	161	O
membrane	162	170	B-Cellular_component
protein	171	178	O
HVCN1	179	184	O
,	184	185	O
which	186	191	O
occurred	192	200	O
as	201	203	O
a	204	205	O
contaminant	206	217	O
from	218	222	O
an	223	225	O
earlier	226	233	O
analysis	234	242	O
on	243	245	O
the	246	249	O
same	250	254	O
LC	255	257	O
column	258	264	O
.	264	265	O

The	0	3	O
asymmetric	4	14	O
unit	15	19	O
of	20	22	O
the	23	26	O
title	27	32	O
compound	33	41	O
with	42	46	O
the	47	50	O
atomic	51	57	O
labelling	58	67	O
scheme	68	74	O
.	74	75	O
Displacement	75	87	O
are	88	91	O
drawn	92	97	O
at	98	100	O
the	101	104	O
50	105	107	O
%	107	108	O
probability	109	120	O
level	121	126	O
.	126	127	O

H	128	129	O
atoms	130	135	O
are	136	139	O
represented	140	151	O
as	152	154	O
small	155	160	O
spheres	161	168	O
of	169	171	O
arbitrary	172	181	O
radii	182	187	O
.	187	188	O

Hydrogen	189	197	O
bonds	198	203	O
are	204	207	O
shown	208	213	O
as	214	216	O
dashed	217	223	O
lines	224	229	O
.	229	230	O

Modified	0	8	O
radiology	9	18	O
-	18	19	O
guided	19	25	O
percutaneous	26	38	O
gastrostomy	39	50	O
technique	51	60	O
.	60	61	O

A	62	63	O
.	63	64	O

21G	65	68	O
fine	69	73	O
needle	74	80	O
punctured	81	90	O
localized	91	100	O
collection	101	111	O
of	112	114	O
air	115	118	O
,	118	119	O
which	120	125	O
was	126	129	O
visible	130	137	O
in	138	140	O
collapsed	141	150	O
stomach	151	158	B-Organ
under	159	164	O
fluoroscopy	165	176	O
-	176	177	O
guided	177	183	O
gastrostomy	184	195	O
.	195	196	O

Needle	197	203	O
tip	204	207	O
is	208	210	O
then	211	215	O
gradually	216	225	O
withdrawn	226	235	O
while	236	241	O
injecting	242	251	O
small	252	257	O
amounts	258	265	O
of	266	268	O
water	269	274	O
-	274	275	O
soluble	275	282	O
contrast	283	291	O
medium	292	298	O
.	298	299	O

Location	300	308	O
of	309	311	O
stomach	312	319	B-Organ
is	320	322	O
confirmed	323	332	O
by	333	335	O
visualization	336	349	O
of	350	352	O
opacified	353	362	O
gastric	363	370	B-Organ
rugae	371	376	O
.	376	377	O

B	378	379	O
.	379	380	O

Stomach	381	388	B-Organ
was	389	392	O
inflated	393	401	O
with	402	406	O
approximately	407	420	O
600	421	424	O
-	424	425	O
800	425	428	O
mL	429	431	O
of	432	434	O
room	435	439	O
air	440	443	O
through	444	451	O
21G	452	455	O
fine	456	460	O
needle	461	467	O
.	467	468	O

C	469	470	O
.	470	471	O

100	472	475	O
-	475	476	O
cm	476	478	O
stainless	479	488	O
steel	489	494	O
guide	495	500	O
wire	501	505	O
is	506	508	O
inserted	509	517	O
through	518	525	O
needle	526	532	O
,	532	533	O
and	534	537	O
gastro	538	544	B-Organ
-	544	545	O
percutaneous	545	557	O
tract	558	563	O
is	564	566	O
gradually	567	576	O
dilated	577	584	O
.	584	585	O

D	586	587	O
.	587	588	O

Insertion	589	598	O
of	599	601	O
14	602	604	O
-	604	605	O
Fr	605	607	O
pigtail	608	615	O
gastrostomy	616	627	O
catheter	628	636	O
and	637	640	O
injection	641	650	O
of	651	653	O
small	654	659	O
amount	660	666	O
of	667	669	O
water	670	675	O
-	675	676	O
soluble	676	683	O
contrast	684	692	O
medium	693	699	O
via	700	703	O
pigtail	704	711	O
catheter	712	720	O
confirmed	721	730	O
that	731	735	O
gastrostomy	736	747	O
catheter	748	756	O
is	757	759	O
correctly	760	769	O
placed	770	776	O
within	777	783	O
stomach	784	791	B-Organ
.	791	792	O

Loss	0	4	O
of	5	7	O
body	8	12	B-Organism_subdivision
weight	13	19	O
after	20	25	O
challenge	26	35	O
-	35	36	O
infection	36	45	O
with	46	50	O
WNV	51	54	O
.	54	55	O

Mice	56	60	O
(	61	62	O
n	62	63	O
=	64	65	O
8	66	67	O
)	67	68	O
were	69	73	O
vaccinated	74	84	O
intranasally	85	97	B-Immaterial_anatomical_entity
with	98	102	O
Flu	103	106	O
-	106	107	O
NA	107	109	O
-	109	110	O
DIII	110	114	O
(	115	116	O
*	116	117	O
)	117	118	O
or	119	121	O
Flu	122	125	O
-	125	126	O
NA	126	128	O
-	128	129	O
GFP	129	132	O
(	133	134	O
o	134	135	O
)	135	136	O
or	137	139	O
by	140	142	O
the	143	146	O
subcutaneous	147	159	O
route	160	165	O
(	166	167	O
^	167	168	O
and	169	172	O
^	173	174	O
,	174	175	O
respectively	176	188	O
)	188	189	O
.	189	190	O

The	191	194	O
daily	195	200	O
weights	201	208	O
of	209	211	O
each	212	216	O
animal	217	223	O
were	224	228	O
calculated	229	239	O
compared	240	248	O
to	249	251	O
their	252	257	O
respective	258	268	O
weight	269	275	O
on	276	278	O
the	279	282	O
day	283	286	O
of	287	289	O
challenge	290	299	O
,	299	300	O
and	301	304	O
data	305	309	O
are	310	313	O
shown	314	319	O
as	320	322	O
the	323	326	O
average	327	334	O
percentage	335	345	O
of	346	348	O
initial	349	356	O
weight	357	363	O
for	364	367	O
each	368	372	O
group	373	378	O
.	378	379	O

Error	380	385	O
bars	386	390	O
represent	391	400	O
the	401	404	O
standard	405	413	O
error	414	419	O
for	420	423	O
all	424	427	O
samples	428	435	O
available	436	445	O
at	446	448	O
that	449	453	O
time	454	458	O
point	459	464	O
.	464	465	O

Subsequently	466	478	O
,	478	479	O
the	480	483	O
mice	484	488	O
were	489	493	O
challenged	494	504	O
subcutaneously	505	519	O
with	520	524	O
106	525	528	O
TCID50	529	535	O
WNV	536	539	O
-	539	540	O
NY99	540	544	O
and	545	548	O
weighed	549	556	O
daily	557	562	O
.	562	563	O

The	564	567	O
mean	568	572	O
body	573	577	B-Organism_subdivision
weight	578	584	O
is	585	587	O
expressed	588	597	O
as	598	600	O
the	601	604	O
percentage	605	615	O
of	616	618	O
the	619	622	O
body	623	627	B-Organism_subdivision
weight	628	634	O
before	635	641	O
challenge	642	651	O
infection	652	661	O
(	662	663	O
A	663	664	O
)	664	665	O
.	665	666	O

The	667	670	O
survival	671	679	O
rates	680	685	O
of	686	688	O
mice	689	693	O
after	694	699	O
challenge	700	709	O
infection	710	719	O
with	720	724	O
WNV	725	728	O
-	728	729	O
NY99	729	733	O
are	734	737	O
depicted	738	746	O
as	747	749	O
Kaplan	750	756	O
-	756	757	O
Meier	757	762	O
survival	763	771	O
curves	772	778	O
(	779	780	O
B	780	781	O
)	781	782	O
.	782	783	O

The	784	787	O
difference	788	798	O
in	799	801	O
survival	802	810	O
rate	811	815	O
between	816	823	O
Flu	824	827	O
-	827	828	O
NA	828	830	O
-	830	831	O
DIII	831	835	O
and	836	839	O
Flu	840	843	O
-	843	844	O
NA	844	846	O
-	846	847	O
GFP	847	850	O
vaccinated	851	861	O
mice	862	866	O
was	867	870	O
statistically	871	884	O
significant	885	896	O
as	897	899	O
determined	900	910	O
by	911	913	O
the	914	917	O
logrank	918	925	O
test	926	930	O
.	930	931	O

The	932	935	O
symbols	936	943	O
for	944	947	O
the	948	951	O
respective	952	962	O
groups	963	969	O
are	970	973	O
the	974	977	O
same	978	982	O
as	983	985	O
in	986	988	O
panel	989	994	O
A	995	996	O
.	996	997	O

Representative	0	14	O
time	15	19	O
histories	20	29	O
of	30	32	O
the	33	36	O
estimated	37	46	O
SatO2	47	52	O
levels	53	59	O
of	60	62	O
normal	63	69	O
cortex	70	76	B-Multi-tissue_structure
(	77	78	O
black	78	83	O
)	83	84	O
and	85	88	O
tumor	89	94	B-Pathological_formation
(	95	96	O
grey	96	100	O
)	100	101	O
from	102	106	O
all	107	110	O
six	111	114	O
patients	115	123	O
.	123	124	O

Etymology	0	9	O
.	9	10	O

Professor	11	20	O
Stephen	21	28	O
Lane	29	33	O
Wood	34	38	O
worked	39	45	O
extensively	46	57	O
on	58	60	O
collections	61	72	O
of	73	75	O
Scolytinae	76	86	O
preserved	87	96	O
in	97	99	O
Indian	100	106	O
museums	107	114	O
,	114	115	O
and	116	119	O
described	120	129	O
a	130	131	O
number	132	138	O
of	139	141	O
new	142	145	O
Scolytinae	146	156	O
species	157	164	O
from	165	169	O
India	170	175	O
.	175	176	O

In	177	179	O
this	180	184	O
paper	185	190	O
we	191	193	O
describe	194	202	O
one	203	206	O
more	207	211	O
new	212	215	O
bark	216	220	O
-	220	221	O
beetle	221	227	O
species	228	235	O
from	236	240	O
India	241	246	O
kept	247	251	O
in	252	254	O
the	255	258	O
Natural	259	266	O
History	267	274	O
Museum	275	281	O
in	282	284	O
Vienna	285	291	O
(	292	293	O
NHMW	293	297	O
)	297	298	O
and	299	302	O
dedicate	303	311	O
this	312	316	O
species	317	324	O
to	325	327	O
the	328	331	O
late	332	336	O
Professor	337	346	O
Stephen	347	354	O
Lane	355	359	O
Wood	360	364	O
.	364	365	O

Statistics	0	10	O

The	11	14	O
survival	15	23	O
of	24	26	O
mice	27	31	O
was	32	35	O
analyzed	36	44	O
using	45	50	O
Kaplan	51	57	O
-	57	58	O
Meier	58	63	O
survival	64	72	O
analysis	73	81	O
.	81	82	O

All	83	86	O
other	87	92	O
data	93	97	O
were	98	102	O
analyzed	103	111	O
by	112	114	O
one	115	118	O
-	118	119	O
way	119	122	O
ANOVA	123	128	O
,	128	129	O
followed	130	138	O
by	139	141	O
the	142	145	O
Student	146	153	O
-	153	154	O
Newman	154	160	O
-	160	161	O
Keuls	161	166	O
test	167	171	O
for	172	175	O
all	176	179	O
pairwise	180	188	O
comparisons	189	200	O
.	200	201	O

Prior	202	207	O
to	208	210	O
ANOVA	211	216	O
,	216	217	O
Levene	218	224	O
'	224	225	O
s	225	226	O
Test	227	231	O
for	232	235	O
Equality	236	244	O
of	245	247	O
Variances	248	257	O
was	258	261	O
performed	262	271	O
.	271	272	O

All	273	276	O
statistical	277	288	O
analyses	289	297	O
were	298	302	O
performed	303	312	O
using	313	318	O
MedCalc	319	326	O
software	327	335	O
,	335	336	O
version	337	344	O
11	345	347	O
.	347	348	O
2	348	349	O
.	349	350	O
1	350	351	O
.	351	352	O
0	352	353	O
.	353	354	O

Acknowledgements	0	16	O

The	17	20	O
authors	21	28	O
gratefully	29	39	O
acknowledge	40	51	O
the	52	55	O
support	56	63	O
of	64	66	O
DRUID	67	72	O
study	73	78	O
participants	79	91	O
,	91	92	O
study	93	98	O
staff	99	104	O
,	104	105	O
members	106	113	O
of	114	116	O
the	117	120	O
Indigenous	121	131	O
Steering	132	140	O
Group	141	146	O
,	146	147	O
and	148	151	O
partner	152	159	O
organisations	160	173	O
.	173	174	O

The	175	178	O
DRUID	179	184	O
Study	185	190	O
was	191	194	O
funded	195	201	O
by	202	204	O
the	205	208	O
National	209	217	O
Health	218	224	O
and	225	228	O
Medical	229	236	O
Research	237	245	O
Council	246	253	O
(	254	255	O
NHMRC	255	260	O
Project	261	268	O
Grant	269	274	O
#	275	276	O
236207	276	282	O
)	282	283	O
,	283	284	O
with	285	289	O
additional	290	300	O
support	301	308	O
from	309	313	O
the	314	317	O
Australian	318	328	O
Government	329	339	O
Department	340	350	O
of	351	353	O
Employment	354	364	O
and	365	368	O
Workplace	369	378	O
Relations	379	388	O
,	388	389	O
the	390	393	O
Clive	394	399	O
and	400	403	O
Vera	404	408	O
Ramaciotti	409	419	O
Foundation	420	430	O
,	430	431	O
the	432	435	O
Vincent	436	443	O
Fairfax	444	451	O
Family	452	458	O
Foundation	459	469	O
,	469	470	O
the	471	474	O
International	475	488	O
Diabetes	489	497	O
Institute	498	507	O
(	508	509	O
AusDiab	509	516	O
Partnership	517	528	O
)	528	529	O
,	529	530	O
and	531	534	O
Bayer	535	540	O
HealthCare	541	551	O
.	551	552	O

The	553	556	O
DRUID	557	562	O
Study	563	568	O
is	569	571	O
an	572	574	O
in	575	577	O
-	577	578	O
kind	578	582	O
project	583	590	O
of	591	593	O
the	594	597	O
Cooperative	598	609	O
Research	610	618	O
Centre	619	625	O
for	626	629	O
Aboriginal	630	640	O
Health	641	647	O
.	647	648	O

LMB	649	652	O
had	653	656	O
a	657	658	O
NHMRC	659	664	O
Scholarship	665	676	O
2003	677	681	O
-	681	682	O
5	682	683	O
and	684	687	O
is	688	690	O
supported	691	700	O
by	701	703	O
NHMRC	704	709	O
Training	710	718	O
Fellowship	719	729	O
(	730	731	O
#	731	732	O
605837	732	738	O
)	738	739	O
,	739	740	O
NHMRC	741	746	O
#	747	748	O
320860	748	754	O
and	755	758	O
the	759	762	O
Centre	763	769	O
of	770	772	O
Clinical	773	781	O
Research	782	790	O
Excellence	791	801	O
in	802	804	O
Clinical	805	813	O
Science	814	821	O
in	822	824	O
Diabetes	825	833	O
,	833	834	O
University	835	845	O
of	846	848	O
Melbourne	849	858	O
.	858	859	O

JC	860	862	O
was	863	866	O
supported	867	876	O
by	877	879	O
a	880	881	O
NHMRC	882	887	O
Career	888	894	O
Development	895	906	O
Award	907	912	O
(	913	914	O
#	914	915	O
283310	915	921	O
)	921	922	O
and	923	926	O
a	927	928	O
NHMRC	929	934	O
Research	935	943	O
Fellowship	944	954	O
(	955	956	O
#	956	957	O
545200	957	963	O
)	963	964	O
.	964	965	O

AH	966	968	O
is	969	971	O
supported	972	981	O
by	982	984	O
NHMRC	985	990	O
Fellowship	991	1001	O
(	1002	1003	O
#	1003	1004	O
520316	1004	1010	O
)	1010	1011	O
.	1011	1012	O

Thank	1013	1018	O
you	1019	1022	O
to	1023	1025	O
Dr	1026	1028	O
Jaquelyne	1029	1038	O
Hughes	1039	1045	O
for	1046	1049	O
comments	1050	1058	O
on	1059	1061	O
the	1062	1065	O
manuscript	1066	1076	O
.	1076	1077	O

Funding	1078	1085	O
sources	1086	1093	O
played	1094	1100	O
no	1101	1103	O
role	1104	1108	O
in	1109	1111	O
the	1112	1115	O
study	1116	1121	O
design	1122	1128	O
,	1128	1129	O
in	1130	1132	O
the	1133	1136	O
collection	1137	1147	O
,	1147	1148	O
analysis	1149	1157	O
and	1158	1161	O
interpretation	1162	1176	O
of	1177	1179	O
the	1180	1183	O
data	1184	1188	O
,	1188	1189	O
in	1190	1192	O
the	1193	1196	O
writing	1197	1204	O
of	1205	1207	O
the	1208	1211	O
manuscript	1212	1222	O
,	1222	1223	O
or	1224	1226	O
in	1227	1229	O
the	1230	1233	O
decision	1234	1242	O
to	1243	1245	O
submit	1246	1252	O
the	1253	1256	O
manuscript	1257	1267	O
for	1268	1271	O
publication	1272	1283	O
.	1283	1284	O

Concurrent	0	10	O
disease	11	18	O
in	19	21	O
33	22	24	O
cows	25	29	O
with	30	34	O
LDA	35	38	O
.	38	39	O

Parkin	0	6	O
regulates	7	16	O
the	17	20	O
proteasomal	21	32	B-Cellular_component
degradation	33	44	O
of	45	47	O
PARIS	48	53	O
and	54	57	O
PGC	58	61	O
-	61	62	O
1alpha	62	68	O
-	68	69	O
dependent	69	78	O
mitochondrial	79	92	B-Cellular_component
biogenesis	93	103	O
.	103	104	O

(	105	106	O
A	106	107	O
)	107	108	O
Normal	109	115	O
physiological	116	129	O
conditions	130	140	O
that	141	145	O
maintain	146	154	O
mitochondrial	155	168	B-Cellular_component
homeostasis	169	180	O
:	180	181	O
PINK1	182	187	O
recruits	188	196	O
parkin	197	203	O
to	204	206	O
the	207	210	O
mitochondria	211	223	B-Cellular_component
,	223	224	O
where	225	230	O
these	231	236	O
two	237	240	O
proteins	241	249	O
interact	250	258	O
to	259	261	O
eliminate	262	271	O
abnormal	272	280	O
mitochondria	281	293	B-Cellular_component
through	294	301	O
mitophagy	302	311	O
.	311	312	O

Alterations	313	324	O
in	325	327	O
mitochondrial	328	341	B-Cellular_component
membrane	342	350	I-Cellular_component
potential	351	360	O
(	361	362	O
DeltaPsim	362	371	O
;	371	372	O
a	373	374	O
key	375	378	O
indicator	379	388	O
of	389	391	O
mitochondrial	392	405	B-Cellular_component
physiology	406	416	O
and	417	420	O
cell	421	425	B-Cell
viability	426	435	O
)	435	436	O
initiate	437	445	O
the	446	449	O
PINK1	450	455	O
-	455	456	O
parkin	456	462	O
cascade	463	470	O
of	471	473	O
events	474	480	O
that	481	485	O
lead	486	490	O
to	491	493	O
mitophagy	494	503	O
.	503	504	O

Furthermore	505	516	O
,	516	517	O
parkin	518	524	O
ubiquitylates	525	538	O
and	539	542	O
thereby	543	550	O
promotes	551	559	O
proteasomal	560	571	B-Cellular_component
degradation	572	583	O
of	584	586	O
PARIS	587	592	O
.	592	593	O

Because	594	601	O
PARIS	602	607	O
represses	608	617	O
the	618	621	O
expression	622	632	O
of	633	635	O
PGC	636	639	O
-	639	640	O
1alpha	640	646	O
,	646	647	O
degradation	648	659	O
of	660	662	O
PARIS	663	668	O
by	669	671	O
parkin	672	678	O
allows	679	685	O
PGC	686	689	O
-	689	690	O
1alpha	690	696	O
-	696	697	O
dependent	697	706	O
gene	707	711	O
expression	712	722	O
and	723	726	O
enables	727	734	O
mitochondrial	735	748	B-Cellular_component
biogenesis	749	759	O
.	759	760	O

Parkin	761	767	O
seems	768	773	O
to	774	776	O
be	777	779	O
an	780	782	O
integral	783	791	O
regulator	792	801	O
of	802	804	O
mitochondrial	805	818	B-Cellular_component
homeostasis	819	830	O
,	830	831	O
controlling	832	843	O
both	844	848	O
degradation	849	860	O
and	861	864	O
biogenesis	865	875	O
.	875	876	O

(	877	878	O
B	878	879	O
)	879	880	O
Loss	881	885	O
of	886	888	O
parkin	889	895	O
function	896	904	O
as	905	907	O
a	908	909	O
result	910	916	O
of	917	919	O
familial	920	928	O
mutations	929	938	O
(	939	940	O
in	940	942	O
the	943	946	O
case	947	951	O
of	952	954	O
AR	955	957	O
-	957	958	O
PD	958	960	O
)	960	961	O
or	962	964	O
aging	965	970	O
,	970	971	O
environmental	972	985	O
or	986	988	O
cellular	989	997	B-Cell
stress	998	1004	O
(	1005	1006	O
in	1006	1008	O
the	1009	1012	O
case	1013	1017	O
of	1018	1020	O
sporadic	1021	1029	O
PD	1030	1032	O
)	1032	1033	O
leads	1034	1039	O
to	1040	1042	O
the	1043	1046	O
accumulation	1047	1059	O
of	1060	1062	O
abnormal	1063	1071	O
mitochondria	1072	1084	B-Cellular_component
,	1084	1085	O
owing	1086	1091	O
to	1092	1094	O
faulty	1095	1101	O
mitophagy	1102	1111	O
.	1111	1112	O

In	1113	1115	O
addition	1116	1124	O
,	1124	1125	O
PARIS	1126	1131	O
accumulates	1132	1143	O
and	1144	1147	O
represses	1148	1157	O
PGC	1158	1161	O
-	1161	1162	O
1alpha	1162	1168	O
,	1168	1169	O
preventing	1170	1180	O
mitochondrial	1181	1194	B-Cellular_component
biogenesis	1195	1205	O
.	1205	1206	O

Loss	1207	1211	O
of	1212	1214	O
parkin	1215	1221	O
function	1222	1230	O
does	1231	1235	O
not	1236	1239	O
tip	1240	1243	O
the	1244	1247	O
balance	1248	1255	O
between	1256	1263	O
mitochondrial	1264	1277	B-Cellular_component
biogenesis	1278	1288	O
and	1289	1292	O
degradation	1293	1304	O
to	1305	1307	O
either	1308	1314	O
side	1315	1319	O
,	1319	1320	O
but	1321	1324	O
leads	1325	1330	O
to	1331	1333	O
a	1334	1335	O
general	1336	1343	O
breakdown	1344	1353	O
of	1354	1356	O
mitochondrial	1357	1370	B-Cellular_component
homeostasis	1371	1382	O
that	1383	1387	O
can	1388	1391	O
ultimately	1392	1402	O
lead	1403	1407	O
to	1408	1410	O
PD	1411	1413	O
.	1413	1414	O

4	0	1	O
.	1	2	O
2	2	3	O
.	3	4	O

Histological	5	17	O
Findings	18	26	O

Microscopy	27	37	O
revealed	38	46	O
features	47	55	O
of	56	58	O
a	59	60	O
diffusely	61	70	O
growing	71	78	O
discohesive	79	90	B-Pathological_formation
carcinoma	91	100	I-Pathological_formation
,	100	101	O
exclusively	102	113	O
growing	114	121	O
in	122	124	O
the	125	128	O
alveolar	129	137	B-Multi-tissue_structure
interstitium	138	150	I-Multi-tissue_structure
,	150	151	O
thus	152	156	O
expanding	157	166	O
it	167	169	O
,	169	170	O
while	171	176	O
leaving	177	184	O
the	185	188	O
original	189	197	O
alveolar	198	206	B-Multi-tissue_structure
architecture	207	219	O
intact	220	226	O
(	227	228	O
Figure	228	234	O
2	235	236	O
)	236	237	O
.	237	238	O

There	239	244	O
was	245	248	O
local	249	254	O
ulceration	255	265	O
of	266	268	O
the	269	272	O
pleura	273	279	B-Multi-tissue_structure
,	279	280	O
while	281	286	O
,	286	287	O
beyond	288	294	O
this	295	299	O
ulcer	300	305	B-Pathological_formation
,	305	306	O
the	307	310	O
tumor	311	316	B-Pathological_formation
formed	317	323	O
a	324	325	O
thick	326	331	O
cake	332	336	O
of	337	339	O
discohesive	340	351	B-Cell
tumor	352	357	I-Cell
cells	358	363	I-Cell
lining	364	370	O
the	371	374	O
pleural	375	382	B-Multi-tissue_structure
membrane	383	391	I-Multi-tissue_structure
(	392	393	O
Figure	393	399	O
2	400	401	O
(	401	402	O
c	402	403	O
)	403	404	O
)	404	405	O
,	405	406	O
with	407	411	O
only	412	416	O
focal	417	422	O
,	422	423	O
microscopic	424	435	O
invasion	436	444	O
into	445	449	O
the	450	453	O
fatty	454	459	B-Tissue
tissue	460	466	I-Tissue
of	467	469	O
the	470	473	O
parietal	474	482	B-Multi-tissue_structure
pleura	483	489	I-Multi-tissue_structure
.	489	490	O

The	491	494	O
tumor	495	500	B-Pathological_formation
consisted	501	510	O
of	511	513	O
atypical	514	522	O
,	522	523	O
moderately	524	534	O
polymorphous	535	547	O
,	547	548	O
and	549	552	O
irregularly	553	564	O
shaped	565	571	O
tumor	572	577	B-Cell
cells	578	583	I-Cell
with	584	588	O
marked	589	595	O
discohesiveness	596	611	O
.	611	612	O

They	613	617	O
featured	618	626	O
scant	627	632	O
eosinophilic	633	645	B-Organism_substance
cytoplasm	646	655	I-Organism_substance
and	656	659	O
irregularly	660	671	O
contoured	672	681	O
and	682	685	O
hyperchromatic	686	700	O
nuclei	701	707	B-Cellular_component
,	707	708	O
often	709	714	O
containing	715	725	O
one	726	729	O
or	730	732	O
more	733	737	O
prominent	738	747	O
nucleoli	748	756	B-Cellular_component
(	757	758	O
Figure	758	764	O
2	765	766	O
(	766	767	O
b	767	768	O
)	768	769	O
)	769	770	O
.	770	771	O

There	772	777	O
were	778	782	O
many	783	787	O
mitoses	788	795	O
and	796	799	O
apoptoses	800	809	O
present	810	817	O
,	817	818	O
but	819	822	O
necrosis	823	831	O
was	832	835	O
not	836	839	O
observed	840	848	O
.	848	849	O

No	850	852	O
squamous	853	861	B-Cell
or	862	864	O
glandular	865	874	B-Cell
differentiation	875	890	O
was	891	894	O
observed	895	903	O
,	903	904	O
and	905	908	O
mucin	909	914	O
stains	915	921	O
(	922	923	O
PAS	923	926	O
-	926	927	O
D	927	928	O
and	929	932	O
alcian	933	939	O
blue	940	944	O
)	944	945	O
were	946	950	O
negative	951	959	O
.	959	960	O

Within	961	967	O
the	968	971	O
tumor	972	977	B-Pathological_formation
,	977	978	O
there	979	984	O
were	985	989	O
multiple	990	998	O
small	999	1004	O
blood	1005	1010	B-Organism_substance
-	1010	1011	O
filled	1011	1017	O
clefts	1018	1024	O
and	1025	1028	O
blood	1029	1034	B-Organism_substance
lakes	1035	1040	O
.	1040	1041	O

Angioinvasion	1042	1055	O
in	1056	1058	O
medium	1059	1065	O
-	1065	1066	O
sized	1066	1071	O
vessels	1072	1079	B-Multi-tissue_structure
,	1079	1080	O
including	1081	1090	O
an	1091	1093	O
artery	1094	1100	B-Multi-tissue_structure
,	1100	1101	O
was	1102	1105	O
demonstrated	1106	1118	O
(	1119	1120	O
Figure	1120	1126	O
2	1127	1128	O
(	1128	1129	O
d	1129	1130	O
)	1130	1131	O
)	1131	1132	O
.	1132	1133	O

Of	1134	1136	O
note	1137	1141	O
,	1141	1142	O
the	1143	1146	O
broadened	1147	1156	O
alveolar	1157	1165	B-Multi-tissue_structure
septa	1166	1171	I-Multi-tissue_structure
were	1172	1176	O
lined	1177	1182	O
by	1183	1185	O
markedly	1186	1194	O
atypical	1195	1203	O
epithelial	1204	1214	B-Cell
cells	1215	1220	I-Cell
,	1220	1221	O
yet	1222	1225	O
less	1226	1230	O
atypical	1231	1239	O
than	1240	1244	O
the	1245	1248	O
interstitial	1249	1261	B-Pathological_formation
carcinoma	1262	1271	I-Pathological_formation
(	1272	1273	O
Figures	1273	1280	O
2	1281	1282	O
(	1282	1283	O
a	1283	1284	O
)	1284	1285	O
and	1286	1289	O
2	1290	1291	O
(	1291	1292	O
b	1292	1293	O
)	1293	1294	O
)	1294	1295	O
.	1295	1296	O

The	1297	1300	O
atypia	1301	1307	O
of	1308	1310	O
the	1311	1314	O
lining	1315	1321	B-Cell
cells	1322	1327	I-Cell
extended	1328	1336	O
beyond	1337	1343	O
the	1344	1347	O
tumor	1348	1353	B-Pathological_formation
front	1354	1359	O
,	1359	1360	O
showing	1361	1368	O
a	1369	1370	O
sharp	1371	1376	O
demarcation	1377	1388	O
with	1389	1393	O
normal	1394	1400	O
type	1401	1405	B-Cell
I	1406	1407	I-Cell
pneumocytes	1408	1419	I-Cell
(	1420	1421	O
Figure	1421	1427	O
2	1428	1429	O
(	1429	1430	O
a	1430	1431	O
)	1431	1432	O
)	1432	1433	O
,	1433	1434	O
a	1435	1436	O
feature	1437	1444	O
characteristic	1445	1459	O
to	1460	1462	O
nonmucinous	1463	1474	B-Pathological_formation
adenocarcinoma	1475	1489	I-Pathological_formation
in	1490	1492	O
situ	1493	1497	O
with	1498	1502	O
lepidic	1503	1510	O
growth	1511	1517	O
pattern	1518	1525	O
(	1526	1527	O
former	1527	1533	O
bronchioloalveolar	1534	1552	B-Pathological_formation
carcinoma	1553	1562	I-Pathological_formation
,	1562	1563	O
BAC	1564	1567	B-Pathological_formation
)	1567	1568	O
[	1569	1570	O
3	1570	1571	O
]	1571	1572	O
.	1572	1573	O

Paederus	0	8	O
dermatitis	9	19	O
involving	20	29	O
the	30	33	O
neck	34	38	B-Organism_subdivision

Introduction	0	12	O

During	13	19	O
the	20	23	O
weaning	24	31	O
period	32	38	O
and	39	42	O
transition	43	53	O
to	54	56	O
solid	57	62	O
foods	63	68	O
in	69	71	O
the	72	75	O
first	76	81	O
year	82	86	O
of	87	89	O
life	90	94	O
,	94	95	O
infants	96	103	O
take	104	108	O
a	109	110	O
critical	111	119	O
step	120	124	O
in	125	127	O
their	128	133	O
eating	134	140	O
behavior	141	149	O
and	150	153	O
need	154	158	O
to	159	161	O
meet	162	166	O
high	167	171	O
nutrient	172	180	O
requirements	181	193	O
[	194	195	O
1	195	196	O
,	196	197	O
2	198	199	O
]	199	200	O
.	200	201	O

They	202	206	O
are	207	210	O
exposed	211	218	O
to	219	221	O
new	222	225	O
foods	226	231	O
and	232	235	O
food	236	240	O
combinations	241	253	O
,	253	254	O
which	255	260	O
should	261	267	O
ensure	268	274	O
a	275	276	O
smooth	277	283	O
transition	284	294	O
to	295	297	O
the	298	301	O
family	302	308	O
diet	309	313	O
later	314	319	O
in	320	322	O
life	323	327	O
.	327	328	O

At	329	331	O
this	332	336	O
stage	337	342	O
,	342	343	O
either	344	350	O
homemade	351	359	O
or	360	362	O
commercially	363	375	O
prepared	376	384	O
foods	385	390	O
may	391	394	O
be	395	397	O
fed	398	401	O
.	401	402	O

It	403	405	O
is	406	408	O
worth	409	414	O
noting	415	421	O
that	422	426	O
in	427	429	O
prosperous	430	440	O
countries	441	450	O
the	451	454	O
modern	455	461	O
diet	462	466	O
differs	467	474	O
considerably	475	487	O
from	488	492	O
that	493	497	O
of	498	500	O
previous	501	509	O
generations	510	521	O
,	521	522	O
now	523	526	O
dominated	527	536	O
by	537	539	O
products	540	548	O
that	549	553	O
have	554	558	O
been	559	563	O
processed	564	573	O
,	573	574	O
stored	575	581	O
,	581	582	O
and	583	586	O
transported	587	598	O
over	599	603	O
great	604	609	O
distances	610	619	O
.	619	620	O

Traditional	621	632	O
,	632	633	O
cold	634	638	O
-	638	639	O
pressed	639	646	O
vegetable	647	656	B-Organism_substance
oils	657	661	I-Organism_substance
of	662	664	O
the	665	668	O
highest	669	676	O
nutritional	677	688	O
quality	689	696	O
,	696	697	O
e	698	699	O
.	699	700	O
g	700	701	O
.	701	702	O
extra	703	708	O
virgin	709	715	O
olive	716	721	O
oil	722	725	B-Organism_substance
,	725	726	O
may	727	730	O
therefore	731	740	O
constitute	741	751	O
an	752	754	O
important	755	764	O
part	765	769	O
of	770	772	O
the	773	776	O
modern	777	783	O
diet	784	788	O
[	789	790	O
3	790	791	O
,	791	792	O
4	793	794	O
]	794	795	O
.	795	796	O

In	797	799	O
Poland	800	806	O
,	806	807	O
many	808	812	O
infants	813	820	O
do	821	823	O
not	824	827	O
receive	828	835	O
any	836	839	O
traditional	840	851	O
homemade	852	860	O
foods	861	866	O
and	867	870	O
even	871	875	O
fruits	876	882	B-Organism_subdivision
come	883	887	O
from	888	892	O
purchased	893	902	O
jars	903	907	O
.	907	908	O

Commercial	909	919	O
baby	920	924	O
foods	925	930	O
are	931	934	O
regarded	935	943	O
by	944	946	O
some	947	951	O
parents	952	959	O
and	960	963	O
medical	964	971	O
professionals	972	985	O
to	986	988	O
be	989	991	O
more	992	996	O
appropriate	997	1008	O
for	1009	1012	O
several	1013	1020	O
reasons	1021	1028	O
:	1028	1029	O
they	1030	1034	O
undergo	1035	1042	O
intense	1043	1050	O
screening	1051	1060	O
for	1061	1064	O
contaminants	1065	1077	O
in	1078	1080	O
comparison	1081	1091	O
to	1092	1094	O
foods	1095	1100	O
sold	1101	1105	O
for	1106	1109	O
the	1110	1113	O
general	1114	1121	O
population	1122	1132	O
,	1132	1133	O
contain	1134	1141	O
no	1142	1144	O
additives	1145	1154	O
of	1155	1157	O
certain	1158	1165	O
types	1166	1171	O
,	1171	1172	O
and	1173	1176	O
are	1177	1180	O
thought	1181	1188	O
to	1189	1191	O
be	1192	1194	O
designed	1195	1203	O
to	1204	1206	O
help	1207	1211	O
infants	1212	1219	O
meet	1220	1224	O
nutrient	1225	1233	O
requirements	1234	1246	O
[	1247	1248	O
5	1248	1249	O
]	1249	1250	O
.	1250	1251	O

The	1252	1255	O
process	1256	1263	O
of	1264	1266	O
peeling	1267	1274	O
,	1274	1275	O
however	1276	1283	O
,	1283	1284	O
was	1285	1288	O
identified	1289	1299	O
as	1300	1302	O
the	1303	1306	O
most	1307	1311	O
effective	1312	1321	O
,	1321	1322	O
and	1323	1326	O
simple	1327	1333	O
,	1333	1334	O
procedure	1335	1344	O
in	1345	1347	O
reducing	1348	1356	O
residues	1357	1365	O
,	1365	1366	O
e	1367	1368	O
.	1368	1369	O
g	1369	1370	O
.	1370	1371	O
pesticides	1372	1382	O
,	1382	1383	O
in	1384	1386	O
fruits	1387	1393	B-Organism_subdivision
and	1394	1397	O
vegetables	1398	1408	B-Organism_subdivision
[	1409	1410	O
6	1410	1411	O
]	1411	1412	O
.	1412	1413	O

Moreover	1414	1422	O
,	1422	1423	O
contrary	1424	1432	O
to	1433	1435	O
homemade	1436	1444	O
food	1445	1449	O
,	1449	1450	O
which	1451	1456	O
does	1457	1461	O
not	1462	1465	O
contain	1466	1473	O
furan	1474	1479	O
,	1479	1480	O
the	1481	1484	O
highest	1485	1492	O
average	1493	1500	O
content	1501	1508	O
of	1509	1511	O
this	1512	1516	O
chemical	1517	1525	O
was	1526	1529	O
found	1530	1535	O
in	1536	1538	O
ready	1539	1544	O
-	1544	1545	O
to	1545	1547	O
-	1547	1548	O
eat	1548	1551	O
baby	1552	1556	O
foods	1557	1562	O
with	1563	1567	O
pasta	1568	1573	O
meals	1574	1579	O
,	1579	1580	O
followed	1581	1589	O
by	1590	1592	O
vegetable	1593	1602	B-Organism_subdivision
meals	1603	1608	O
and	1609	1612	O
meals	1613	1618	O
with	1619	1623	O
meat	1624	1628	B-Organism_subdivision
[	1629	1630	O
7	1630	1631	O
]	1631	1632	O
.	1632	1633	O

Furan	1634	1639	O
is	1640	1642	O
considered	1643	1653	O
to	1654	1656	O
be	1657	1659	O
potentially	1660	1671	O
hazardous	1672	1681	O
chemical	1682	1690	O
and	1691	1694	O
is	1695	1697	O
classified	1698	1708	O
as	1709	1711	O
a	1712	1713	O
possible	1714	1722	O
carcinogen	1723	1733	O
.	1733	1734	O

The	1735	1738	O
problem	1739	1746	O
of	1747	1749	O
this	1750	1754	O
chemical	1755	1763	O
in	1764	1766	O
homemade	1767	1775	O
food	1776	1780	O
may	1781	1784	O
only	1785	1789	O
arise	1790	1795	O
if	1796	1798	O
meals	1799	1804	O
with	1805	1809	O
potatoes	1810	1818	O
are	1819	1822	O
stored	1823	1829	O
and	1830	1833	O
then	1834	1838	O
hardly	1839	1845	O
re	1846	1848	O
-	1848	1849	O
heated	1849	1855	O
[	1856	1857	O
7	1857	1858	O
]	1858	1859	O
.	1859	1860	O

There	1861	1866	O
is	1867	1869	O
a	1870	1871	O
growing	1872	1879	O
body	1880	1884	B-Organism_subdivision
of	1885	1887	O
evidence	1888	1896	O
that	1897	1901	O
flavor	1902	1908	O
experiences	1909	1920	O
and	1921	1924	O
dietary	1925	1932	O
patterns	1933	1941	O
in	1942	1944	O
childhood	1945	1954	O
influence	1955	1964	O
these	1965	1970	O
patterns	1971	1979	O
later	1980	1985	O
in	1986	1988	O
life	1989	1993	O
[	1994	1995	O
1	1995	1996	O
,	1996	1997	O
8	1998	1999	O
,	1999	2000	O
9	2001	2002	O
]	2002	2003	O
.	2003	2004	O

It	2005	2007	O
is	2008	2010	O
most	2011	2015	O
likely	2016	2022	O
early	2023	2028	O
in	2029	2031	O
life	2032	2036	O
that	2037	2041	O
culture	2042	2049	O
-	2049	2050	O
specific	2050	2058	O
flavor	2059	2065	O
preferences	2066	2077	O
are	2078	2081	O
initiated	2082	2091	O
[	2092	2093	O
10	2093	2095	O
,	2095	2096	O
11	2097	2099	O
]	2099	2100	O
.	2100	2101	O

Consequently	2102	2114	O
,	2114	2115	O
exposure	2116	2124	O
to	2125	2127	O
flavors	2128	2135	O
and	2136	2139	O
smells	2140	2146	O
of	2147	2149	O
transitory	2150	2160	O
foods	2161	2166	O
may	2167	2170	O
serve	2171	2176	O
to	2177	2179	O
heighten	2180	2188	O
preferences	2189	2200	O
for	2201	2204	O
"	2205	2206	O
known	2206	2211	O
tastes	2212	2218	O
"	2218	2219	O
in	2220	2222	O
the	2223	2226	O
family	2227	2233	O
diet	2234	2238	O
later	2239	2244	O
in	2245	2247	O
adulthood	2248	2257	O
.	2257	2258	O

Moreover	2259	2267	O
,	2267	2268	O
adopting	2269	2277	O
elements	2278	2286	O
of	2287	2289	O
childhood	2290	2299	O
dinner	2300	2306	O
patterns	2307	2315	O
was	2316	2319	O
recognized	2320	2330	O
to	2331	2333	O
be	2334	2336	O
an	2337	2339	O
important	2340	2349	O
part	2350	2354	O
of	2355	2357	O
the	2358	2361	O
social	2362	2368	O
reproduction	2369	2381	O
of	2382	2384	O
family	2385	2391	O
identities	2392	2402	O
across	2403	2409	O
generations	2410	2421	O
[	2422	2423	O
12	2423	2425	O
]	2425	2426	O
.	2426	2427	O

Processing	2428	2438	O
industries	2439	2449	O
have	2450	2454	O
been	2455	2459	O
successful	2460	2470	O
in	2471	2473	O
manufacturing	2474	2487	O
and	2488	2491	O
marketing	2492	2501	O
jarred	2502	2508	O
baby	2509	2513	O
foods	2514	2519	O
on	2520	2522	O
a	2523	2524	O
commercial	2525	2535	O
scale	2536	2541	O
.	2541	2542	O

Available	2543	2552	O
products	2553	2561	O
contain	2562	2569	O
different	2570	2579	O
ingredients	2580	2591	O
and	2592	2595	O
depend	2596	2602	O
on	2603	2605	O
the	2606	2609	O
manufacturer	2610	2622	O
,	2622	2623	O
country	2624	2631	O
,	2631	2632	O
traditional	2633	2644	O
cuisine	2645	2652	O
,	2652	2653	O
income	2654	2660	O
rate	2661	2665	O
,	2665	2666	O
and	2667	2670	O
lastly	2671	2677	O
,	2677	2678	O
personal	2679	2687	O
beliefs	2688	2695	O
and	2696	2699	O
values	2700	2706	O
of	2707	2709	O
parents	2710	2717	O
[	2718	2719	O
9	2719	2720	O
,	2720	2721	O
11	2722	2724	O
]	2724	2725	O
.	2725	2726	O

Jarred	2727	2733	O
foods	2734	2739	O
with	2740	2744	O
vegetables	2745	2755	B-Organism_subdivision
,	2755	2756	O
meats	2757	2762	B-Organism_subdivision
,	2762	2763	O
and	2764	2767	O
desserts	2768	2776	O
may	2777	2780	O
contain	2781	2788	O
added	2789	2794	O
fat	2795	2798	O
from	2799	2803	O
a	2804	2805	O
variety	2806	2813	O
of	2814	2816	O
sources	2817	2824	O
:	2824	2825	O
vegetable	2826	2835	B-Organism_substance
oils	2836	2840	I-Organism_substance
,	2840	2841	O
cow	2842	2845	O
milk	2846	2850	B-Organism_substance
butter	2851	2857	O
,	2857	2858	O
or	2859	2861	O
cream	2862	2867	O
.	2867	2868	O

Manufacturer	2869	2881	O
advertising	2882	2893	O
makes	2894	2899	O
the	2900	2903	O
majority	2904	2912	O
of	2913	2915	O
consumers	2916	2925	O
feel	2926	2930	O
safe	2931	2935	O
,	2935	2936	O
causing	2937	2944	O
them	2945	2949	O
to	2950	2952	O
believe	2953	2960	O
that	2961	2965	O
they	2966	2970	O
are	2971	2974	O
doing	2975	2980	O
the	2981	2984	O
best	2985	2989	O
possible	2990	2998	O
in	2999	3001	O
buying	3002	3008	O
given	3009	3014	O
products	3015	3023	O
[	3024	3025	O
11	3025	3027	O
]	3027	3028	O
.	3028	3029	O

A	3030	3031	O
noteworthy	3032	3042	O
fact	3043	3047	O
is	3048	3050	O
that	3051	3055	O
many	3056	3060	O
types	3061	3066	O
of	3067	3069	O
baby	3070	3074	O
foods	3075	3080	O
produced	3081	3089	O
by	3090	3092	O
international	3093	3106	O
manufacturers	3107	3120	O
are	3121	3124	O
,	3124	3125	O
in	3126	3128	O
essence	3129	3136	O
,	3136	3137	O
the	3138	3141	O
same	3142	3146	O
mixtures	3147	3155	O
with	3156	3160	O
different	3161	3170	O
names	3171	3176	O
;	3176	3177	O
this	3178	3182	O
procedure	3183	3192	O
aims	3193	3197	O
to	3198	3200	O
exploit	3201	3208	O
the	3209	3212	O
specifics	3213	3222	O
of	3223	3225	O
local	3226	3231	O
markets	3232	3239	O
without	3240	3247	O
delivering	3248	3258	O
any	3259	3262	O
new	3263	3266	O
,	3266	3267	O
real	3268	3272	O
value	3273	3278	O
[	3279	3280	O
11	3280	3282	O
]	3282	3283	O
.	3283	3284	O

In	3285	3287	O
the	3288	3291	O
book	3292	3296	O
,	3296	3297	O
How	3298	3301	O
to	3302	3304	O
Eat	3305	3308	O
Well	3309	3313	O
and	3314	3317	O
Stay	3318	3322	O
Well	3323	3327	O
the	3328	3331	O
Mediterranean	3332	3345	O
Way	3346	3349	O
by	3350	3352	O
Keys	3353	3357	O
[	3358	3359	O
13	3359	3361	O
]	3361	3362	O
first	3363	3368	O
used	3369	3373	O
the	3374	3377	O
term	3378	3382	O
"	3383	3384	O
good	3384	3388	O
Mediterranean	3389	3402	O
diet	3403	3407	O
"	3407	3408	O
to	3409	3411	O
describe	3412	3420	O
the	3421	3424	O
eating	3425	3431	O
patterns	3432	3440	O
of	3441	3443	O
populations	3444	3455	O
dwelling	3456	3464	O
in	3465	3467	O
southern	3468	3476	O
Europe	3477	3483	O
,	3483	3484	O
where	3485	3490	O
the	3491	3494	O
olive	3495	3500	O
tree	3501	3505	O
(	3506	3507	O
Olea	3507	3511	O
europaea	3512	3520	O
)	3520	3521	O
is	3522	3524	O
an	3525	3527	O
emblematic	3528	3538	O
species	3539	3546	O
[	3547	3548	O
4	3548	3549	O
,	3549	3550	O
14	3551	3553	O
]	3553	3554	O
.	3554	3555	O

There	3556	3561	O
is	3562	3564	O
variation	3565	3574	O
between	3575	3582	O
the	3583	3586	O
exact	3587	3592	O
diet	3593	3597	O
in	3598	3600	O
different	3601	3610	O
parts	3611	3616	O
of	3617	3619	O
the	3620	3623	O
Mediterranean	3624	3637	O
region	3638	3644	O
.	3644	3645	O

However	3646	3653	O
,	3653	3654	O
generalized	3655	3666	O
and	3667	3670	O
distinctive	3671	3682	O
dietary	3683	3690	O
patterns	3691	3699	O
do	3700	3702	O
exist	3703	3708	O
,	3708	3709	O
including	3710	3719	O
olive	3720	3725	O
oil	3726	3729	B-Organism_substance
as	3730	3732	O
the	3733	3736	O
main	3737	3741	O
source	3742	3748	O
of	3749	3751	O
visible	3752	3759	O
fat	3760	3763	O
,	3763	3764	O
employed	3765	3773	O
both	3774	3778	O
in	3779	3781	O
cooking	3782	3789	O
and	3790	3793	O
as	3794	3796	O
a	3797	3798	O
dressing	3799	3807	O
,	3807	3808	O
moderate	3809	3817	O
fish	3818	3822	O
and	3823	3826	O
poultry	3827	3834	O
but	3835	3838	O
low	3839	3842	O
red	3843	3846	B-Organism_subdivision
meat	3847	3851	I-Organism_subdivision
consumption	3852	3863	O
,	3863	3864	O
high	3865	3869	O
intake	3870	3876	O
of	3877	3879	O
vegetables	3880	3890	B-Organism_subdivision
,	3890	3891	O
fruits	3892	3898	B-Organism_subdivision
,	3898	3899	O
legumes	3900	3907	O
,	3907	3908	O
nuts	3909	3913	B-Organism_subdivision
,	3913	3914	O
and	3915	3918	O
whole	3919	3924	O
-	3924	3925	O
grain	3925	3930	O
cereals	3931	3938	O
[	3939	3940	O
4	3940	3941	O
,	3941	3942	O
14	3943	3945	O
-	3945	3946	O
16	3946	3948	O
]	3948	3949	O
.	3949	3950	O

When	3951	3955	O
dietary	3956	3963	B-Organism_substance
fats	3964	3968	I-Organism_substance
are	3969	3972	O
added	3973	3978	O
,	3978	3979	O
in	3980	3982	O
accordance	3983	3993	O
with	3994	3998	O
the	3999	4002	O
traditional	4003	4014	O
Mediterranean	4015	4028	O
diet	4029	4033	O
,	4033	4034	O
olive	4035	4040	O
oil	4041	4044	B-Organism_substance
is	4045	4047	O
the	4048	4051	O
choice	4052	4058	O
for	4059	4062	O
children	4063	4071	O
[	4072	4073	O
17	4073	4075	O
]	4075	4076	O
.	4076	4077	O

It	4078	4080	O
has	4081	4084	O
been	4085	4089	O
repeatedly	4090	4100	O
observed	4101	4109	O
that	4110	4114	O
individuals	4115	4126	O
applying	4127	4135	O
the	4136	4139	O
Mediterranean	4140	4153	O
diet	4154	4158	O
have	4159	4163	O
reduced	4164	4171	O
risks	4172	4177	O
of	4178	4180	O
type	4181	4185	O
2	4186	4187	O
diabetes	4188	4196	O
and	4197	4200	O
other	4201	4206	O
diseases	4207	4215	O
associated	4216	4226	O
with	4227	4231	O
the	4232	4235	O
metabolic	4236	4245	O
syndrome	4246	4254	O
,	4254	4255	O
autoimmunological	4256	4273	O
diseases	4274	4282	O
,	4282	4283	O
and	4284	4287	O
certain	4288	4295	O
forms	4296	4301	O
of	4302	4304	O
cancer	4305	4311	B-Pathological_formation
[	4312	4313	O
18	4313	4315	O
]	4315	4316	O
.	4316	4317	O

Moreover	4318	4326	O
,	4326	4327	O
considerable	4328	4340	O
evidence	4341	4349	O
exists	4350	4356	O
that	4357	4361	O
the	4362	4365	O
Mediterranean	4366	4379	O
diet	4380	4384	O
increases	4385	4394	O
quality	4395	4402	O
of	4403	4405	O
life	4406	4410	O
in	4411	4413	O
the	4414	4417	O
course	4418	4424	O
of	4425	4427	O
ageing	4428	4434	O
,	4434	4435	O
as	4436	4438	O
well	4439	4443	O
as	4444	4446	O
longevity	4447	4456	O
[	4457	4458	O
13	4458	4460	O
,	4460	4461	O
19	4462	4464	O
]	4464	4465	O
.	4465	4466	O

The	4467	4470	O
health	4471	4477	O
benefits	4478	4486	O
of	4487	4489	O
olive	4490	4495	O
oil	4496	4499	B-Organism_substance
have	4500	4504	O
been	4505	4509	O
attributed	4510	4520	O
to	4521	4523	O
two	4524	4527	O
main	4528	4532	O
constituents	4533	4545	O
:	4545	4546	O
a	4547	4548	O
high	4549	4553	O
oleic	4554	4559	O
acid	4560	4564	O
(	4565	4566	O
monounsaturated	4566	4581	O
fatty	4582	4587	O
acid	4588	4592	O
,	4592	4593	O
18	4594	4596	O
:	4596	4597	O
1n	4597	4599	O
-	4599	4600	O
9	4600	4601	O
)	4601	4602	O
content	4603	4610	O
(	4611	4612	O
70	4612	4614	O
-	4614	4615	O
85	4615	4617	O
%	4617	4618	O
)	4618	4619	O
and	4620	4623	O
a	4624	4625	O
large	4626	4631	O
amount	4632	4638	O
of	4639	4641	O
antioxidant	4642	4653	O
compounds	4654	4663	O
,	4663	4664	O
which	4665	4670	O
also	4671	4675	O
possess	4676	4683	O
antiviral	4684	4693	O
,	4693	4694	O
antibacterial	4695	4708	O
,	4708	4709	O
and	4710	4713	O
immunomodulating	4714	4730	O
effects	4731	4738	O
[	4739	4740	O
3	4740	4741	O
,	4741	4742	O
4	4743	4744	O
,	4744	4745	O
14	4746	4748	O
,	4748	4749	O
16	4750	4752	O
]	4752	4753	O
.	4753	4754	O

Polyphenols	4755	4766	O
found	4767	4772	O
in	4773	4775	O
virgin	4776	4782	O
olive	4783	4788	O
oil	4789	4792	B-Organism_substance
are	4793	4796	O
linked	4797	4803	O
to	4804	4806	O
both	4807	4811	O
its	4812	4815	O
flavor	4816	4822	O
and	4823	4826	O
its	4827	4830	O
remarkable	4831	4841	O
stability	4842	4851	O
[	4852	4853	O
3	4853	4854	O
]	4854	4855	O
.	4855	4856	O

The	4857	4860	O
introduction	4861	4873	O
of	4874	4876	O
solid	4877	4882	O
foods	4883	4888	O
in	4889	4891	O
infancy	4892	4899	O
is	4900	4902	O
one	4903	4906	O
of	4907	4909	O
the	4910	4913	O
primary	4914	4921	O
matters	4922	4929	O
often	4930	4935	O
discussed	4936	4945	O
by	4946	4948	O
parents	4949	4956	O
with	4957	4961	O
their	4962	4967	O
child	4968	4973	O
'	4973	4974	O
s	4974	4975	O
pediatrician	4976	4988	O
.	4988	4989	O

However	4990	4997	O
,	4997	4998	O
many	4999	5003	O
parents	5004	5011	O
do	5012	5014	O
not	5015	5018	O
feel	5019	5023	O
that	5024	5028	O
the	5029	5032	O
diet	5033	5037	O
of	5038	5040	O
their	5041	5046	O
child	5047	5052	O
may	5053	5056	O
be	5057	5059	O
linked	5060	5066	O
to	5067	5069	O
poor	5070	5074	O
health	5075	5081	O
outcomes	5082	5090	O
in	5091	5093	O
the	5094	5097	O
future	5098	5104	O
.	5104	5105	O

Parents	5106	5113	O
should	5114	5120	O
be	5121	5123	O
educated	5124	5132	O
about	5133	5138	O
the	5139	5142	O
interplay	5143	5152	O
of	5153	5155	O
environmental	5156	5169	O
and	5170	5173	O
genetic	5174	5181	O
influences	5182	5192	O
on	5193	5195	O
children	5196	5204	O
,	5204	5205	O
specifically	5206	5218	O
during	5219	5225	O
the	5226	5229	O
early	5230	5235	O
years	5236	5241	O
of	5242	5244	O
development	5245	5256	O
when	5257	5261	O
the	5262	5265	O
child	5266	5271	O
is	5272	5274	O
maturing	5275	5283	O
and	5284	5287	O
taking	5288	5294	O
control	5295	5302	O
of	5303	5305	O
its	5306	5309	O
own	5310	5313	O
diet	5314	5318	O
[	5319	5320	O
11	5320	5322	O
]	5322	5323	O
.	5323	5324	O

Nutrition	5325	5334	O
educators	5335	5344	O
should	5345	5351	O
increase	5352	5360	O
the	5361	5364	O
critical	5365	5373	O
awareness	5374	5383	O
of	5384	5386	O
parents	5387	5394	O
in	5395	5397	O
relation	5398	5406	O
to	5407	5409	O
their	5410	5415	O
child	5416	5421	O
'	5421	5422	O
s	5422	5423	O
solid	5424	5429	O
food	5430	5434	O
choices	5435	5442	O
.	5442	5443	O

It	5444	5446	O
is	5447	5449	O
important	5450	5459	O
to	5460	5462	O
emphasize	5463	5472	O
to	5473	5475	O
parents	5476	5483	O
the	5484	5487	O
fundamental	5488	5499	O
role	5500	5504	O
that	5505	5509	O
the	5510	5513	O
Mediterranean	5514	5527	O
diet	5528	5532	O
and	5533	5536	O
consumption	5537	5548	O
of	5549	5551	O
foods	5552	5557	O
with	5558	5562	O
olive	5563	5568	O
oil	5569	5572	B-Organism_substance
play	5573	5577	O
in	5578	5580	O
a	5581	5582	O
healthy	5583	5590	O
life	5591	5595	O
style	5596	5601	O
[	5602	5603	O
14	5603	5605	O
,	5605	5606	O
20	5607	5609	O
]	5609	5610	O
.	5610	5611	O

Parental	5612	5620	O
management	5621	5631	O
of	5632	5634	O
the	5635	5638	O
family	5639	5645	O
food	5646	5650	O
environment	5651	5662	O
may	5663	5666	O
be	5667	5669	O
complicated	5670	5681	O
by	5682	5684	O
numerous	5685	5693	O
mitigating	5694	5704	O
factors	5705	5712	O
,	5712	5713	O
e	5714	5715	O
.	5715	5716	O
g	5716	5717	O
.	5717	5718	O
health	5719	5725	O
literacy	5726	5734	O
,	5734	5735	O
time	5736	5740	O
availability	5741	5753	O
,	5753	5754	O
and	5755	5758	O
financial	5759	5768	O
resources	5769	5778	O
.	5778	5779	O

Considering	5780	5791	O
the	5792	5795	O
role	5796	5800	O
baby	5801	5805	O
food	5806	5810	O
manufacturers	5811	5824	O
play	5825	5829	O
in	5830	5832	O
the	5833	5836	O
infant	5837	5843	O
'	5843	5844	O
s	5844	5845	O
contextual	5846	5856	O
environment	5857	5868	O
,	5868	5869	O
their	5870	5875	O
products	5876	5884	O
,	5884	5885	O
as	5886	5888	O
well	5889	5893	O
as	5894	5896	O
the	5897	5900	O
manufacturers	5901	5914	O
themselves	5915	5925	O
,	5925	5926	O
should	5927	5933	O
also	5934	5938	O
be	5939	5941	O
viewed	5942	5948	O
as	5949	5951	O
key	5952	5955	O
players	5956	5963	O
and	5964	5967	O
central	5968	5975	O
agents	5976	5982	O
in	5983	5985	O
establishing	5986	5998	O
dietary	5999	6006	O
habits	6007	6013	O
.	6013	6014	O

Consequently	6015	6027	O
,	6027	6028	O
we	6029	6031	O
attempted	6032	6041	O
to	6042	6044	O
survey	6045	6051	O
manufacturer	6052	6064	O
claims	6065	6071	O
concerning	6072	6082	O
added	6083	6088	O
fat	6089	6092	O
in	6093	6095	O
jarred	6096	6102	O
infant	6103	6109	O
foods	6110	6115	O
supplied	6116	6124	O
to	6125	6127	O
the	6128	6131	O
Polish	6132	6138	O
market	6139	6145	O
.	6145	6146	O

2	0	1	O
.	1	2	O
1	2	3	O
.	3	4	O
3	4	5	O

Pixel	6	11	O
Classification	12	26	O

The	27	30	O
feature	31	38	O
vector	39	45	O
of	46	48	O
a	49	50	O
grid	51	55	O
,	55	56	O
which	57	62	O
consists	63	71	O
of	72	74	O
nine	75	79	O
features	80	88	O
,	88	89	O
is	90	92	O
normalized	93	103	O
to	104	106	O
[	107	108	O
0	108	109	O
,	109	110	O
1	111	112	O
]	112	113	O
,	113	114	O
and	115	118	O
the	119	122	O
position	123	131	O
features	132	140	O
are	141	144	O
scaled	145	151	O
by	152	154	O
the	155	158	O
weighting	159	168	O
coefficient	169	180	O
wpos	181	185	O
.	185	186	O

Then	187	191	O
,	191	192	O
taking	193	199	O
the	200	203	O
nine	204	208	O
dimensional	209	220	O
vector	221	227	O
of	228	230	O
each	231	235	O
grid	236	240	O
as	241	243	O
the	244	247	O
input	248	253	O
of	254	256	O
the	257	260	O
classifier	261	271	O
,	271	272	O
the	273	276	O
ROI	277	280	O
and	281	284	O
non	285	288	O
-	288	289	O
ROI	289	292	O
background	293	303	O
in	304	306	O
ultrasonic	307	317	O
breast	318	324	B-Pathological_formation
tumor	325	330	I-Pathological_formation
images	331	337	O
can	338	341	O
be	342	344	O
distinguished	345	358	O
.	358	359	O

In	360	362	O
this	363	367	O
section	368	375	O
,	375	376	O
the	377	380	O
self	381	385	O
-	385	386	O
organizing	386	396	O
feature	397	404	O
map	405	408	O
neural	409	415	O
network	416	423	O
(	424	425	O
SOMNN	425	430	O
)	430	431	O
[	432	433	O
25	433	435	O
]	435	436	O
,	436	437	O
proposed	438	446	O
by	447	449	O
Kohonen	450	457	O
according	458	467	O
to	468	470	O
characteristics	471	486	O
of	487	489	O
the	490	493	O
nervous	494	501	B-Anatomical_system
system	502	508	I-Anatomical_system
,	508	509	O
is	510	512	O
used	513	517	O
for	518	521	O
the	522	525	O
classification	526	540	O
of	541	543	O
these	544	549	O
grids	550	555	O
to	556	558	O
detect	559	565	O
the	566	569	O
ROI	570	573	O
automatically	574	587	O
.	587	588	O

The	589	592	O
SOM	593	596	O
is	597	599	O
trained	600	607	O
by	608	610	O
the	611	614	O
unsupervised	615	627	O
learning	628	636	O
to	637	639	O
produce	640	647	O
a	648	649	O
low	650	653	O
-	653	654	O
dimensional	654	665	O
discretized	666	677	O
representation	678	692	O
of	693	695	O
the	696	699	O
input	700	705	O
space	706	711	O
of	712	714	O
the	715	718	O
training	719	727	O
samples	728	735	O
,	735	736	O
and	737	740	O
it	741	743	O
uses	744	748	O
a	749	750	O
neighborhood	751	763	O
function	764	772	O
to	773	775	O
preserve	776	784	O
the	785	788	O
topological	789	800	O
properties	801	811	O
of	812	814	O
the	815	818	O
input	819	824	O
space	825	830	O
,	830	831	O
which	832	837	O
makes	838	843	O
it	844	846	O
different	847	856	O
from	857	861	O
other	862	867	O
artificial	868	878	O
neural	879	885	O
networks	886	894	O
.	894	895	O

In	896	898	O
this	899	903	O
way	904	907	O
,	907	908	O
the	909	912	O
SOM	913	916	O
is	917	919	O
able	920	924	O
to	925	927	O
classify	928	936	O
the	937	940	O
sub	941	944	O
-	944	945	O
blocks	945	951	O
into	952	956	O
n	957	958	O
clusters	959	967	O
only	968	972	O
by	973	975	O
the	976	979	O
unsupervised	980	992	O
learning	993	1001	O
.	1001	1002	O

In	1003	1005	O
our	1006	1009	O
study	1010	1015	O
,	1015	1016	O
the	1017	1020	O
output	1021	1027	O
layer	1028	1033	O
number	1034	1040	O
n	1041	1042	O
is	1043	1045	O
set	1046	1049	O
to	1050	1052	O
2	1053	1054	O
(	1055	1056	O
ROI	1056	1059	O
and	1060	1063	O
non	1064	1067	O
-	1067	1068	O
ROI	1068	1071	O
output	1072	1078	O
)	1078	1079	O
and	1080	1083	O
the	1084	1087	O
feature	1088	1095	O
vector	1096	1102	O
extracted	1103	1112	O
from	1113	1117	O
each	1118	1122	O
grid	1123	1127	O
is	1128	1130	O
taken	1131	1136	O
as	1137	1139	O
the	1140	1143	O
input	1144	1149	O
.	1149	1150	O

To	1151	1153	O
map	1154	1157	O
the	1158	1161	O
sorted	1162	1168	O
sub	1169	1172	O
-	1172	1173	O
blocks	1173	1179	O
back	1180	1184	O
to	1185	1187	O
the	1188	1191	O
size	1192	1196	O
of	1197	1199	O
the	1200	1203	O
original	1204	1212	O
ultrasonic	1213	1223	O
images	1224	1230	O
,	1230	1231	O
the	1232	1235	O
initial	1236	1243	O
result	1244	1250	O
of	1251	1253	O
ROI	1254	1257	O
detection	1258	1267	O
can	1268	1271	O
be	1272	1274	O
represented	1275	1286	O
by	1287	1289	O
a	1290	1291	O
binary	1292	1298	O
image	1299	1304	O
as	1305	1307	O
shown	1308	1313	O
in	1314	1316	O
Fig	1317	1320	O
.	1320	1321	O

(	1322	1323	O
2d	1323	1325	O
)	1325	1326	O
,	1326	1327	O
where	1328	1333	O
white	1334	1339	O
areas	1340	1345	O
indicate	1346	1354	O
the	1355	1358	O
ROI	1359	1362	O
candidates	1363	1373	O
while	1374	1379	O
black	1380	1385	O
areas	1386	1391	O
the	1392	1395	O
non	1396	1399	O
-	1399	1400	O
ROIs	1400	1404	O
.	1404	1405	O

Materials	0	9	O
and	10	13	O
Methods	14	21	O
:	21	22	O

A	23	24	O
total	25	30	O
of	31	33	O
75	34	36	O
brain	37	42	B-Multi-tissue_structure
abscess	43	50	I-Multi-tissue_structure
pus	51	54	I-Multi-tissue_structure
specimens	55	64	I-Multi-tissue_structure
were	65	69	O
collected	70	79	O
during	80	86	O
neurosurgery	87	99	O
,	99	100	O
either	101	107	O
by	108	110	O
burr	111	115	O
hole	116	120	O
or	121	123	O
by	124	126	O
craniotomy	127	137	O
.	137	138	O

These	139	144	O
specimens	145	154	B-Multi-tissue_structure
were	155	159	O
further	160	167	O
subjected	168	177	O
to	178	180	O
Gram	181	185	O
stain	186	191	O
,	191	192	O
Ziehl	193	198	O
-	198	199	O
Neelsen	199	206	O
(	207	208	O
ZN	208	210	O
)	210	211	O
stain	212	217	O
,	217	218	O
and	219	222	O
conventional	223	235	O
microbiological	236	251	O
culture	252	259	O
.	259	260	O

Only	261	265	O
those	266	271	O
cases	272	277	O
which	278	283	O
showed	284	290	O
presence	291	299	O
of	300	302	O
AFB	303	306	O
on	307	309	O
ZN	310	312	O
stain	313	318	O
along	319	324	O
with	325	329	O
the	330	333	O
growth	334	340	O
of	341	343	O
Mycobacterium	344	357	O
tuberculosis	358	370	O
were	371	375	O
considered	376	386	O
as	387	389	O
TBAs	390	394	O
.	394	395	O

Such	396	400	O
TBA	401	404	O
cases	405	410	O
were	411	415	O
further	416	423	O
presented	424	433	O
along	434	439	O
with	440	444	O
their	445	450	O
In	451	453	O
vitro	454	459	O
Proton	460	466	O
Magnetic	467	475	O
Resonance	476	485	O
(	486	487	O
MR	487	489	O
)	489	490	O
Spectroscopic	491	504	O
findings	505	513	O
.	513	514	O

Challenges	0	10	O
to	11	13	O
creating	14	22	O
and	23	26	O
implementing	27	39	O
a	40	41	O
perioperative	42	55	O
glycemic	56	64	O
control	65	72	O
protocol	73	81	O
.	81	82	O

Parameters	0	10	O
derived	11	18	O
from	19	23	O
normalized	24	34	O
averaged	35	43	O
data	44	48	O
across	49	55	O
participants	56	68	O

Absolute	0	8	O
responder	9	18	O
rates	19	24	O
for	25	28	O
medical	29	36	O
management	37	47	O
recommendations	48	63	O
.	63	64	O

Conclusions	0	11	O

This	12	16	O
is	17	19	O
the	20	23	O
first	24	29	O
prospective	30	41	O
evaluation	42	52	O
of	53	55	O
parents	56	63	O
'	63	64	O
preferences	65	76	O
in	77	79	O
newly	80	85	O
diagnosed	86	95	O
juvenile	96	104	O
idiopathic	105	115	O
arthritis	116	125	O
patients	126	134	O
participating	135	148	O
in	149	151	O
the	152	155	O
BeSt	156	160	O
for	161	164	O
Kids	165	169	O
trial	170	175	O
.	175	176	O

Within	177	183	O
the	184	187	O
limitations	188	199	O
of	200	202	O
the	203	206	O
small	207	212	O
amounts	213	220	O
,	220	221	O
patients	222	230	O
clearly	231	238	O
preferred	239	248	O
initial	249	256	O
combination	257	268	O
therapy	269	276	O
with	277	281	O
etanercept	282	292	O
and	293	296	O
disliked	297	305	O
taking	306	312	O
prednisone	313	323	O
.	323	324	O

After	325	330	O
actual	331	337	O
exposure	338	346	O
and	347	350	O
follow	351	357	O
up	358	360	O
,	360	361	O
this	362	366	O
questionnaire	367	380	O
will	381	385	O
be	386	388	O
repeated	389	397	O
to	398	400	O
see	401	404	O
if	405	407	O
preferences	408	419	O
remain	420	426	O
the	427	430	O
same	431	435	O
.	435	436	O

Patients	0	8	O
and	9	12	O
Study	13	18	O
Design	19	25	O

A	26	27	O
prospective	28	39	O
evaluation	40	50	O
of	51	53	O
the	54	57	O
different	58	67	O
CMR	68	71	O
parameters	72	82	O
for	83	86	O
predicting	87	97	O
LV	98	100	B-Multi-tissue_structure
segmental	101	110	O
and	111	114	O
global	115	121	O
functional	122	132	O
recovery	133	141	O
was	142	145	O
performed	146	155	O
in	156	158	O
46	159	161	O
patients	162	170	O
(	171	172	O
63	172	174	O
+	175	176	O
/	176	177	O
-	177	178	O
10	179	181	O
years	182	187	O
old	188	191	O
,	191	192	O
3	193	194	O
with	195	199	O
previous	200	208	O
CABG	209	213	O
,	213	214	O
35	215	217	O
with	218	222	O
three	223	228	O
-	228	229	O
vessel	229	235	O
disease	236	243	O
,	243	244	O
3	245	246	O
with	247	251	O
one	252	255	O
-	255	256	O
vessel	256	262	O
disease	263	270	O
)	270	271	O
with	272	276	O
LV	277	279	B-Multi-tissue_structure
systolic	280	288	O
dysfunction	289	300	O
(	301	302	O
LVEF	302	306	O
35	307	309	O
+	310	311	O
/	311	312	O
-	312	313	O
8	314	315	O
%	315	316	O
)	316	317	O
before	318	324	O
they	325	329	O
underwent	330	339	O
surgical	340	348	O
(	349	350	O
n	350	351	O
=	352	353	O
34	354	356	O
)	356	357	O
or	358	360	O
percutaneous	361	373	O
(	374	375	O
n	375	376	O
=	377	378	O
12	379	381	O
)	381	382	O
revascularisation	383	400	O
.	400	401	O

Sixty	402	407	O
patients	408	416	O
without	417	424	O
contraindications	425	442	O
for	443	446	O
CMR	447	450	O
were	451	455	O
screened	456	464	O
for	465	468	O
the	469	472	O
following	473	482	O
inclusion	483	492	O
criteria	493	501	O
:	501	502	O
(	503	504	O
1	504	505	O
)	505	506	O
CAD	507	510	O
(	511	512	O
>	512	513	O
70	514	516	O
%	516	517	O
stenosis	518	526	O
in	527	529	O
one	530	533	O
or	534	536	O
more	537	541	O
major	542	547	O
epicardial	548	558	B-Multi-tissue_structure
vessels	559	566	I-Multi-tissue_structure
)	566	567	O
,	567	568	O
scheduled	569	578	O
for	579	582	O
a	583	584	O
revascularisation	585	602	O
procedure	603	612	O
;	612	613	O
(	614	615	O
2	615	616	O
)	616	617	O
LVEF	618	622	O
<	623	624	O
=	624	625	O
45	626	628	O
%	628	629	O
;	629	630	O
(	631	632	O
3	632	633	O
)	633	634	O
at	635	637	O
least	638	643	O
two	644	647	O
adjacent	648	656	O
segments	657	665	O
with	666	670	O
wall	671	675	B-Multi-tissue_structure
motion	676	682	O
abnormalities	683	696	O
at	697	699	O
rest	700	704	O
;	704	705	O
and	706	709	O
(	710	711	O
4	711	712	O
)	712	713	O
no	714	716	O
infarction	717	727	O
or	728	730	O
revascularisation	731	748	O
within	749	755	O
the	756	759	O
last	760	764	O
two	765	768	O
months	769	775	O
.	775	776	O

Patients	777	785	O
were	786	790	O
included	791	799	O
in	800	802	O
the	803	806	O
study	807	812	O
only	813	817	O
after	818	823	O
a	824	825	O
successful	826	836	O
and	837	840	O
complete	841	849	O
coronary	850	858	B-Multi-tissue_structure
revascularisation	859	876	O
.	876	877	O

Of	878	880	O
the	881	884	O
14	885	887	O
patients	888	896	O
who	897	900	O
did	901	904	O
not	905	908	O
complete	909	917	O
the	918	921	O
study	922	927	O
,	927	928	O
3	929	930	O
decided	931	938	O
not	939	942	O
to	943	945	O
undergo	946	953	O
the	954	957	O
repeated	958	966	O
CMR	967	970	O
scan	971	975	O
or	976	978	O
were	979	983	O
lost	984	988	O
during	989	995	O
follow	996	1002	O
-	1002	1003	O
up	1003	1005	O
;	1005	1006	O
7	1007	1008	O
had	1009	1012	O
significant	1013	1024	O
periprocedural	1025	1039	O
injury	1040	1046	O
(	1047	1048	O
new	1048	1051	O
LGE	1052	1055	B-Pathological_formation
zones	1056	1061	O
on	1062	1064	O
repeated	1065	1073	O
CMR	1074	1077	O
scans	1078	1083	O
and	1084	1087	O
clinically	1088	1098	O
proven	1099	1105	O
periprocedural	1106	1120	O
myocardial	1121	1131	B-Multi-tissue_structure
infarction	1132	1142	O
(	1143	1144	O
MI	1144	1146	O
)	1146	1147	O
or	1148	1150	O
MI	1151	1153	O
between	1154	1161	O
both	1162	1166	O
scans	1167	1172	O
)	1172	1173	O
;	1173	1174	O
3	1175	1176	O
had	1177	1180	O
pacemakers	1181	1191	O
or	1192	1194	O
defibrillators	1195	1209	O
implanted	1210	1219	O
in	1220	1222	O
the	1223	1226	O
period	1227	1233	O
between	1234	1241	O
the	1242	1245	O
MR	1246	1248	O
scans	1249	1254	O
;	1254	1255	O
and	1256	1259	O
1	1260	1261	O
was	1262	1265	O
excluded	1266	1274	O
because	1275	1282	O
of	1283	1285	O
dilated	1286	1293	O
cardiomyopathy	1294	1308	O
with	1309	1313	O
secondary	1314	1323	O
CAD	1324	1327	O
.	1327	1328	O

None	1329	1333	O
of	1334	1336	O
the	1337	1340	O
patients	1341	1349	O
were	1350	1354	O
excluded	1355	1363	O
from	1364	1368	O
the	1369	1372	O
study	1373	1378	O
for	1379	1382	O
technical	1383	1392	O
reasons	1393	1400	O
or	1401	1403	O
image	1404	1409	O
quality	1410	1417	O
.	1417	1418	O

The	1419	1422	O
mean	1423	1427	O
interval	1428	1436	O
between	1437	1444	O
CMR	1445	1448	O
and	1449	1452	O
revascularisation	1453	1470	O
was	1471	1474	O
12	1475	1477	O
+	1478	1479	O
/	1479	1480	O
-	1480	1481	O
13	1482	1484	O
days	1485	1489	O
,	1489	1490	O
and	1491	1494	O
none	1495	1499	O
of	1500	1502	O
the	1503	1506	O
patients	1507	1515	O
presented	1516	1525	O
clinical	1526	1534	O
evidence	1535	1543	O
of	1544	1546	O
infarction	1547	1557	O
during	1558	1564	O
this	1565	1569	O
period	1570	1576	O
.	1576	1577	O

The	1578	1581	O
mean	1582	1586	O
interval	1587	1595	O
between	1596	1603	O
MI	1604	1606	O
and	1607	1610	O
the	1611	1614	O
first	1615	1620	O
CMR	1621	1624	O
was	1625	1628	O
3	1629	1630	O
.	1630	1631	O
6	1631	1632	O
years	1633	1638	O
.	1638	1639	O

In	1640	1642	O
46	1643	1645	O
patients	1646	1654	O
,	1654	1655	O
the	1656	1659	O
extent	1660	1666	O
of	1667	1669	O
regional	1670	1678	O
contractility	1679	1692	O
and	1693	1696	O
LGE	1697	1700	B-Pathological_formation
were	1701	1705	O
determined	1706	1716	O
repeatedly	1717	1727	O
by	1728	1730	O
CMR	1731	1734	O
28	1735	1737	O
+	1738	1739	O
/	1739	1740	O
-	1740	1741	O
4	1742	1743	O
weeks	1744	1749	O
(	1750	1751	O
6	1751	1752	O
months	1753	1759	O
)	1759	1760	O
after	1761	1766	O
revascularisation	1767	1784	O
.	1784	1785	O

The	1786	1789	O
study	1790	1795	O
was	1796	1799	O
approved	1800	1808	O
by	1809	1811	O
the	1812	1815	O
Lithuanian	1816	1826	O
Bioethics	1827	1836	O
Committee	1837	1846	O
(	1847	1848	O
Nr	1848	1850	O
.	1850	1851	O
17	1852	1854	O
)	1854	1855	O
,	1855	1856	O
and	1857	1860	O
informed	1861	1869	O
written	1870	1877	O
consent	1878	1885	O
was	1886	1889	O
obtained	1890	1898	O
from	1899	1903	O
each	1904	1908	O
patient	1909	1916	O
prior	1917	1922	O
to	1923	1925	O
inclusion	1926	1935	O
in	1936	1938	O
the	1939	1942	O
study	1943	1948	O
.	1948	1949	O

Authors	0	7	O
'	7	8	O
contributions	9	22	O

EEKN	23	27	O
was	28	31	O
responsible	32	43	O
for	44	47	O
data	48	52	O
collection	53	63	O
,	63	64	O
statistical	65	76	O
analysis	77	85	O
and	86	89	O
drafting	90	98	O
the	99	102	O
manuscript	103	113	O
.	113	114	O

SAGN	115	119	O
and	120	123	O
YW	124	126	O
involved	127	135	O
in	136	138	O
data	139	143	O
collection	144	154	O
and	155	158	O
helped	159	165	O
with	166	170	O
the	171	174	O
data	175	179	O
analysis	180	188	O
.	188	189	O

AS	190	192	O
helped	193	199	O
in	200	202	O
data	203	207	O
analysis	208	216	O
.	216	217	O

EST	218	221	O
and	222	225	O
JL	226	228	O
directed	229	237	O
the	238	241	O
study	242	247	O
and	248	251	O
helped	252	258	O
in	259	261	O
revising	262	270	O
the	271	274	O
manuscript	275	285	O
.	285	286	O

RMVD	287	291	O
helped	292	298	O
in	299	301	O
data	302	306	O
analysis	307	315	O
,	315	316	O
interpretation	317	331	O
of	332	334	O
the	335	338	O
results	339	346	O
and	347	350	O
led	351	354	O
writing	355	362	O
of	363	365	O
the	366	369	O
manuscript	370	380	O
.	380	381	O

All	382	385	O
authors	386	393	O
read	394	398	O
and	399	402	O
approved	403	411	O
the	412	415	O
final	416	421	O
manuscript	422	432	O
.	432	433	O

Figures	0	7	O

Fig	8	11	O
.	11	12	O

1	13	14	O
.	14	15	O

A	16	17	O
view	18	22	O
of	23	25	O
(	26	27	O
I	27	28	O
)	28	29	O
with	30	34	O
displacement	35	47	O
ellipsoids	48	58	O
drawn	59	64	O
at	65	67	O
the	68	71	O
30	72	74	O
%	74	75	O
probability	76	87	O
level	88	93	O
.	93	94	O

Fig	95	98	O
.	98	99	O

2	100	101	O
.	101	102	O

Stereoview	103	113	O
of	114	116	O
the	117	120	O
sheet	121	126	O
formed	127	133	O
by	134	136	O
C	137	138	O
-	138	139	O
-	139	140	O
H	140	141	O
.	141	142	O
.	142	143	O
.	143	144	O
pi	144	146	O
interactions	147	159	O
.	159	160	O

Hydrogen	161	169	O
atoms	170	175	O
not	176	179	O
involved	180	188	O
in	189	191	O
the	192	195	O
motifs	196	202	O
are	203	206	O
not	207	210	O
included	211	219	O
.	219	220	O

The	0	3	O
growth	4	10	O
in	11	13	O
the	14	17	O
number	18	24	O
of	25	27	O
database	28	36	O
publications	37	49	O
per	50	53	O
year	54	58	O
.	58	59	O

Each	60	64	O
bar	65	68	O
shows	69	74	O
the	75	78	O
number	79	85	O
of	86	88	O
research	89	97	O
articles	98	106	O
with	107	111	O
the	112	115	O
keyword	116	123	O
'	124	125	O
database	125	133	O
'	133	134	O
appearing	135	144	O
in	145	147	O
the	148	151	O
article	152	159	O
title	160	165	O
in	166	168	O
the	169	172	O
given	173	178	O
year	179	183	O
.	183	184	O

The	185	188	O
count	189	194	O
only	195	199	O
covers	200	206	O
articles	207	215	O
indexed	216	223	O
in	224	226	O
PubMed	227	233	O
.	233	234	O

The	235	238	O
increase	239	247	O
shows	248	253	O
an	254	256	O
exponential	257	268	O
trend	269	274	O
that	275	279	O
will	280	284	O
produce	285	292	O
nearly	293	299	O
2000	300	304	O
database	305	313	O
publications	314	326	O
per	327	330	O
year	331	335	O
by	336	338	O
2015	339	343	O
.	343	344	O

Cation	0	6	O
binding	7	14	O
to	15	17	O
yolk	18	22	B-Cell
platelet	23	31	I-Cell
phosvitin	32	41	O

In	42	44	O
addition	45	53	O
to	54	56	O
non	57	60	O
-	60	61	O
heme	61	65	O
iron	66	70	O
[	71	72	O
23	72	74	O
]	74	75	O
,	75	76	O
yolk	77	81	B-Developing_anatomical_structure
phosvitin	82	91	O
also	92	96	O
contains	97	105	O
Ca2	106	109	O
+	109	110	O
,	110	111	O
Mg2	112	115	O
+	115	116	O
,	116	117	O
Na	118	120	O
+	120	121	O
and	122	125	O
K	126	127	O
+	127	128	O
[	129	130	O
11	130	132	O
]	132	133	O
.	133	134	O

Partially	135	144	O
relaxed	145	152	O
23Na	153	157	O
Fourier	158	165	O
transform	166	175	O
NMR	176	179	O
spectra	180	187	O
revealed	188	196	O
the	197	200	O
existence	201	210	O
of	211	213	O
at	214	216	O
least	217	222	O
two	223	226	O
major	227	232	O
intracellular	233	246	B-Cellular_component
compartments	247	259	I-Cellular_component
of	260	262	O
NMR	263	266	O
-	266	267	O
visible	267	274	O
Na	275	277	O
+	277	278	O
[	279	280	O
35	280	282	O
]	282	283	O
.	283	284	O

A	285	286	O
large	287	292	O
fraction	293	301	O
of	302	304	O
the	305	308	O
Rana	309	313	O
oocyte	314	320	B-Cell
Na	321	323	O
+	323	324	O
was	325	328	O
NMR	329	332	O
-	332	333	O
invisible	333	342	O
and	343	346	O
could	347	352	O
be	353	355	O
recovered	356	365	O
in	366	368	O
the	369	372	O
yolk	373	377	B-Cell
platelets	378	387	I-Cell
[	388	389	O
35	389	391	O
]	391	392	O
.	392	393	O

During	394	400	O
the	401	404	O
first	405	410	O
meiotic	411	418	O
division	419	427	O
there	428	433	O
is	434	436	O
a	437	438	O
net	439	442	O
increase	443	451	O
in	452	454	O
NMR	455	458	O
-	458	459	O
visible	459	466	O
Na	467	469	O
+	469	470	O
;	470	471	O
by	472	474	O
completion	475	485	O
of	486	488	O
the	489	492	O
second	493	499	O
meiotic	500	507	O
division	508	516	O
(	517	518	O
following	518	527	O
fertilization	528	541	O
)	541	542	O
,	542	543	O
about	544	549	O
70	550	552	O
%	552	553	O
of	554	556	O
the	557	560	O
total	561	566	O
Na	567	569	O
+	569	570	O
becomes	571	578	O
NMR	579	582	O
-	582	583	O
visible	583	590	O
.	590	591	O

Thus	592	596	O
,	596	597	O
phosvitin	598	607	O
not	608	611	O
only	612	616	O
serves	617	623	O
as	624	626	O
a	627	628	O
site	629	633	O
for	634	637	O
energy	638	644	O
storage	645	652	O
,	652	653	O
but	654	657	O
also	658	662	O
as	663	665	O
a	666	667	O
storage	668	675	O
site	676	680	O
for	681	684	O
iron	685	689	O
and	690	693	O
other	694	699	O
ions	700	704	O
essential	705	714	O
for	715	718	O
embryonic	719	728	B-Developing_anatomical_structure
development	729	740	O
in	741	743	O
ponds	744	749	O
and	750	753	O
streams	754	761	O
that	762	766	O
contain	767	774	O
little	775	781	O
dissolved	782	791	O
salts	792	797	O
and	798	801	O
minerals	802	810	O
.	810	811	O

Predicted	0	9	O
methylation	10	21	O
level	22	27	O
of	28	30	O
C	31	32	O
.	32	33	O
gigas	34	39	O
genes	40	45	O
categorized	46	57	O
by	58	60	O
biological	61	71	O
processes	72	81	O
compared	82	90	O
to	91	93	O
measured	94	102	O
level	103	108	O
of	109	111	O
DNA	112	115	O
methylation	116	127	O
.	127	128	O

Mean	129	133	O
CpG	134	137	O
O	138	139	O
/	139	140	O
E	140	141	O
for	142	145	O
10	146	148	O
,	148	149	O
699	149	152	O
C	153	154	O
.	154	155	O
gigas	156	161	O
genes	162	167	O
categorized	168	179	O
according	180	189	O
to	190	192	O
Biological	193	203	O
Process	204	211	O
Gene	212	216	O
Ontology	217	225	O
(	226	227	O
GO	227	229	O
)	229	230	O
Slim	231	235	O
terms	236	241	O
are	242	245	O
plotted	246	253	O
on	254	256	O
the	257	260	O
x	261	262	O
-	262	263	O
axis	263	267	O
(	268	269	O
modified	269	277	O
from	278	282	O
Gavery	283	289	O
and	290	293	O
Roberts	294	301	O
,	301	302	O
2010	303	307	O
)	307	308	O
.	308	309	O

DNA	310	313	O
methylation	314	325	O
was	326	329	O
empirically	330	341	O
measured	342	350	O
by	351	353	O
performing	354	364	O
MBD	365	368	O
-	368	369	O
seq	369	372	O
on	373	375	O
the	376	379	O
SOLiD	380	385	O
4	386	387	O
platform	388	396	O
(	397	398	O
Applied	398	405	O
Biosystems	406	416	O
)	416	417	O
.	417	418	O

Genes	419	424	O
identified	425	435	O
in	436	438	O
the	439	442	O
MBD	443	446	O
-	446	447	O
library	447	454	O
were	455	459	O
associated	460	470	O
with	471	475	O
respective	476	486	O
GO	487	489	O
terms	490	495	O
and	496	499	O
enrichment	500	510	O
analysis	511	519	O
was	520	523	O
performed	524	533	O
based	534	539	O
on	540	542	O
the	543	546	O
entire	547	553	O
transcriptome	554	567	O
(	568	569	O
Fleury	569	575	O
et	576	578	O
al	579	581	O
.	581	582	O
,	582	583	O
2009	584	588	O
)	588	589	O
using	590	595	O
DAVID	596	601	O
(	602	603	O
Huang	603	608	O
et	609	611	O
al	612	614	O
.	614	615	O
,	615	616	O
2009a	617	622	O
,	622	623	O
b	623	624	O
)	624	625	O
.	625	626	O

Results	627	634	O
indicate	635	643	O
the	644	647	O
most	648	652	O
underrepresented	653	669	O
genes	670	675	O
in	676	678	O
the	679	682	O
library	683	690	O
are	691	694	O
involved	695	703	O
in	704	706	O
cell	707	711	B-Cell
adhesion	712	720	O
and	721	724	O
genes	725	730	O
involved	731	739	O
in	740	742	O
DNA	743	746	O
and	747	750	O
protein	751	758	O
metabolism	759	769	O
were	770	774	O
most	775	779	O
prevalent	780	789	O
in	790	792	O
the	793	796	O
MBD	797	800	O
-	800	801	O
library	801	808	O
.	808	809	O

Discussion	0	10	O

We	11	13	O
estimated	14	23	O
the	24	27	O
future	28	34	O
acceptability	35	48	O
of	49	51	O
PrEP	52	56	O
,	56	57	O
examining	58	67	O
the	68	71	O
attitudes	72	81	O
and	82	85	O
preferences	86	97	O
of	98	100	O
potential	101	110	O
user	111	115	O
groups	116	122	O
from	123	127	O
different	128	137	O
countries	138	147	O
towards	148	155	O
hypothetical	156	168	O
and	169	172	O
known	173	178	O
PrEP	179	183	O
attributes	184	194	O
.	194	195	O

Our	196	199	O
results	200	207	O
show	208	212	O
that	213	217	O
participants	218	230	O
were	231	235	O
generally	236	245	O
willing	246	253	O
to	254	256	O
accept	257	263	O
PrEP	264	268	O
and	269	272	O
adopt	273	278	O
it	279	281	O
as	282	284	O
soon	285	289	O
as	290	292	O
it	293	295	O
becomes	296	303	O
available	304	313	O
.	313	314	O

Surprisingly	315	327	O
,	327	328	O
participants	329	341	O
were	342	346	O
also	347	351	O
willing	352	359	O
to	360	362	O
take	363	367	O
PrEP	368	372	O
even	373	377	O
when	378	382	O
reminded	383	391	O
of	392	394	O
potential	395	404	O
side	405	409	O
effects	410	417	O
,	417	418	O
cost	419	423	O
,	423	424	O
condom	425	431	O
use	432	435	O
,	435	436	O
and	437	440	O
frequent	441	449	O
HIV	450	453	O
testing	454	461	O
.	461	462	O

These	463	468	O
findings	469	477	O
indicate	478	486	O
participants	487	499	O
'	499	500	O
motivation	501	511	O
to	512	514	O
overcome	515	523	O
barriers	524	532	O
which	533	538	O
can	539	542	O
have	543	547	O
a	548	549	O
considerable	550	562	O
impact	563	569	O
on	570	572	O
uptake	573	579	O
.	579	580	O

In	581	583	O
contrast	584	592	O
,	592	593	O
participants	594	606	O
mentioned	607	616	O
that	617	621	O
the	622	625	O
thought	626	633	O
of	634	636	O
taking	637	643	O
PrEP	644	648	O
made	649	653	O
them	654	658	O
feel	659	663	O
anxious	664	671	O
,	671	672	O
although	673	681	O
they	682	686	O
also	687	691	O
indicated	692	701	O
that	702	706	O
taking	707	713	O
PrEP	714	718	O
would	719	724	O
not	725	728	O
be	729	731	O
embarrassing	732	744	O
and	745	748	O
they	749	753	O
would	754	759	O
want	760	764	O
their	765	770	O
partner	771	778	O
or	779	781	O
partners	782	790	O
to	791	793	O
know	794	798	O
.	798	799	O

Participants	800	812	O
'	812	813	O
anxiety	814	821	O
may	822	825	O
be	826	828	O
explained	829	838	O
by	839	841	O
the	842	845	O
hypothetical	846	858	O
nature	859	865	O
of	866	868	O
most	869	873	O
of	874	876	O
the	877	880	O
presented	881	890	O
PrEP	891	895	O
characteristics	896	911	O
,	911	912	O
the	913	916	O
stigma	917	923	O
associated	924	934	O
with	935	939	O
HIV	940	943	O
[	944	945	O
34	945	947	O
]	947	948	O
,	948	949	O
and	950	953	O
in	954	956	O
some	957	961	O
settings	962	970	O
,	970	971	O
the	972	975	O
criminalization	976	991	O
of	992	994	O
sex	995	998	O
work	999	1003	O
,	1003	1004	O
injected	1005	1013	O
drug	1014	1018	O
use	1019	1022	O
and	1023	1026	O
homosexuality	1027	1040	O
[	1041	1042	O
35	1042	1044	O
]	1044	1045	O
.	1045	1046	O

Most	1047	1051	O
participants	1052	1064	O
,	1064	1065	O
nonetheless	1066	1077	O
,	1077	1078	O
subsequently	1079	1091	O
indicated	1092	1101	O
that	1102	1106	O
PrEP	1107	1111	O
would	1112	1117	O
give	1118	1122	O
them	1123	1127	O
hope	1128	1132	O
,	1132	1133	O
which	1134	1139	O
suggests	1140	1148	O
that	1149	1153	O
their	1154	1159	O
initial	1160	1167	O
willingness	1168	1179	O
to	1180	1182	O
take	1183	1187	O
it	1188	1190	O
remained	1191	1199	O
largely	1200	1207	O
unscathed	1208	1217	O
.	1217	1218	O

Female	1219	1225	O
participants	1226	1238	O
indicated	1239	1248	O
a	1249	1250	O
higher	1251	1257	O
level	1258	1263	O
of	1264	1266	O
willingness	1267	1278	O
to	1279	1281	O
take	1282	1286	O
PrEP	1287	1291	O
than	1292	1296	O
male	1297	1301	O
participants	1302	1314	O
,	1314	1315	O
which	1316	1321	O
may	1322	1325	O
be	1326	1328	O
explained	1329	1338	O
by	1339	1341	O
women	1342	1347	O
'	1347	1348	O
s	1348	1349	O
difficulty	1350	1360	O
negotiating	1361	1372	O
the	1373	1376	O
use	1377	1380	O
of	1381	1383	O
condoms	1384	1391	O
and	1392	1395	O
awareness	1396	1405	O
of	1406	1408	O
their	1409	1414	O
and	1415	1418	O
/	1418	1419	O
or	1419	1421	O
their	1422	1427	O
partners	1428	1436	O
'	1436	1437	O
risk	1438	1442	O
of	1443	1445	O
becoming	1446	1454	O
infected	1455	1463	O
with	1464	1468	O
HIV	1469	1472	O
[	1473	1474	O
36	1474	1476	O
]	1476	1477	O
.	1477	1478	O

We	1479	1481	O
also	1482	1486	O
found	1487	1492	O
that	1493	1497	O
younger	1498	1505	O
participants	1506	1518	O
and	1519	1522	O
those	1523	1528	O
with	1529	1533	O
fewer	1534	1539	O
children	1540	1548	O
,	1548	1549	O
those	1550	1555	O
who	1556	1559	O
reported	1560	1568	O
adherence	1569	1578	O
to	1579	1581	O
past	1582	1586	O
medication	1587	1597	O
,	1597	1598	O
more	1599	1603	O
frequent	1604	1612	O
condom	1613	1619	O
usage	1620	1625	O
,	1625	1626	O
having	1627	1633	O
been	1634	1638	O
tested	1639	1645	O
for	1646	1649	O
HIV	1650	1653	O
in	1654	1656	O
the	1657	1660	O
past	1661	1665	O
and	1666	1669	O
never	1670	1675	O
injecting	1676	1685	O
drugs	1686	1691	O
,	1691	1692	O
reported	1693	1701	O
greater	1702	1709	O
willingness	1710	1721	O
to	1722	1724	O
take	1725	1729	O
PrEP	1730	1734	O
.	1734	1735	O

These	1736	1741	O
promising	1742	1751	O
findings	1752	1760	O
suggest	1761	1768	O
that	1769	1773	O
those	1774	1779	O
who	1780	1783	O
are	1784	1787	O
currently	1788	1797	O
bearing	1798	1805	O
the	1806	1809	O
brunt	1810	1815	O
of	1816	1818	O
HIV	1819	1822	O
[	1823	1824	O
1	1824	1825	O
]	1825	1826	O
,	1826	1827	O
have	1828	1832	O
higher	1833	1839	O
perceived	1840	1849	O
risk	1850	1854	O
,	1854	1855	O
and	1856	1859	O
are	1860	1863	O
most	1864	1868	O
likely	1869	1875	O
to	1876	1878	O
adhere	1879	1885	O
to	1886	1888	O
a	1889	1890	O
comprehensive	1891	1904	O
PrEP	1905	1909	O
program	1910	1917	O
,	1917	1918	O
are	1919	1922	O
also	1923	1927	O
the	1928	1931	O
most	1932	1936	O
motivated	1937	1946	O
to	1947	1949	O
enroll	1950	1956	O
.	1956	1957	O

Yet	1958	1961	O
,	1961	1962	O
while	1963	1968	O
participants	1969	1981	O
stated	1982	1988	O
not	1989	1992	O
being	1993	1998	O
interested	1999	2009	O
in	2010	2012	O
selling	2013	2020	O
PrEP	2021	2025	O
,	2025	2026	O
the	2027	2030	O
majority	2031	2039	O
reported	2040	2048	O
intentions	2049	2059	O
to	2060	2062	O
share	2063	2068	O
it	2069	2071	O
.	2071	2072	O

Therefore	2073	2082	O
,	2082	2083	O
information	2084	2095	O
and	2096	2099	O
counseling	2100	2110	O
about	2111	2116	O
the	2117	2120	O
risks	2121	2126	O
of	2127	2129	O
sharing	2130	2137	O
PrEP	2138	2142	O
should	2143	2149	O
be	2150	2152	O
readily	2153	2160	O
available	2161	2170	O
as	2171	2173	O
part	2174	2178	O
of	2179	2181	O
any	2182	2185	O
implementation	2186	2200	O
program	2201	2208	O
.	2208	2209	O

Results	2210	2217	O
from	2218	2222	O
the	2223	2226	O
conjoint	2227	2235	O
analysis	2236	2244	O
reveal	2245	2251	O
trends	2252	2258	O
in	2259	2261	O
participants	2262	2274	O
'	2274	2275	O
preferences	2276	2287	O
which	2288	2293	O
deserve	2294	2301	O
consideration	2302	2315	O
.	2315	2316	O

PrEP	2317	2321	O
route	2322	2327	O
of	2328	2330	O
administration	2331	2345	O
was	2346	2349	O
the	2350	2353	O
most	2354	2358	O
important	2359	2368	O
attribute	2369	2378	O
,	2378	2379	O
and	2380	2383	O
bi	2384	2386	O
-	2386	2387	O
monthly	2387	2394	O
and	2395	2398	O
monthly	2399	2406	O
injections	2407	2417	O
were	2418	2422	O
the	2423	2426	O
preferred	2427	2436	O
alternatives	2437	2449	O
.	2449	2450	O

This	2451	2455	O
finding	2456	2463	O
is	2464	2466	O
encouraging	2467	2478	O
from	2479	2483	O
a	2484	2485	O
policy	2486	2492	O
perspective	2493	2504	O
if	2505	2507	O
such	2508	2512	O
modalities	2513	2523	O
become	2524	2530	O
available	2531	2540	O
;	2540	2541	O
since	2542	2547	O
it	2548	2550	O
may	2551	2554	O
reduce	2555	2561	O
users	2562	2567	O
'	2567	2568	O
likelihood	2569	2579	O
of	2580	2582	O
sharing	2583	2590	O
,	2590	2591	O
selling	2592	2599	O
or	2600	2602	O
forgetting	2603	2613	O
to	2614	2616	O
take	2617	2621	O
PrEP	2622	2626	O
,	2626	2627	O
but	2628	2631	O
it	2632	2634	O
also	2635	2639	O
raises	2640	2646	O
questions	2647	2656	O
regarding	2657	2666	O
participants	2667	2679	O
'	2679	2680	O
willingness	2681	2692	O
to	2693	2695	O
take	2696	2700	O
oral	2701	2705	O
PrEP	2706	2710	O
.	2710	2711	O

HIV	2712	2715	O
testing	2716	2723	O
was	2724	2727	O
the	2728	2731	O
second	2732	2738	O
most	2739	2743	O
important	2744	2753	O
attribute	2754	2763	O
,	2763	2764	O
and	2765	2768	O
a	2769	2770	O
test	2771	2775	O
every	2776	2781	O
six	2782	2785	O
months	2786	2792	O
was	2793	2796	O
,	2796	2797	O
as	2798	2800	O
expected	2801	2809	O
,	2809	2810	O
the	2811	2814	O
preferred	2815	2824	O
alternative	2825	2836	O
.	2836	2837	O

Interestingly	2838	2851	O
,	2851	2852	O
dispensing	2853	2863	O
sites	2864	2869	O
were	2870	2874	O
more	2875	2879	O
important	2880	2889	O
than	2890	2894	O
any	2895	2898	O
other	2899	2904	O
attribute	2905	2914	O
for	2915	2918	O
some	2919	2923	O
groups	2924	2930	O
,	2930	2931	O
particularly	2932	2944	O
in	2945	2947	O
Africa	2948	2954	O
.	2954	2955	O

This	2956	2960	O
may	2961	2964	O
indicate	2965	2973	O
concerns	2974	2982	O
about	2983	2988	O
social	2989	2995	O
stigma	2996	3002	O
and	3003	3006	O
access	3007	3013	O
[	3014	3015	O
37	3015	3017	O
]	3017	3018	O
.	3018	3019	O

However	3020	3027	O
,	3027	3028	O
it	3029	3031	O
is	3032	3034	O
encouraging	3035	3046	O
that	3047	3051	O
most	3052	3056	O
participants	3057	3069	O
were	3070	3074	O
willing	3075	3082	O
to	3083	3085	O
receive	3086	3093	O
PrEP	3094	3098	O
at	3099	3101	O
a	3102	3103	O
healthcare	3104	3114	O
facility	3115	3123	O
,	3123	3124	O
which	3125	3130	O
can	3131	3134	O
facilitate	3135	3145	O
synergies	3146	3155	O
between	3156	3163	O
PrEP	3164	3168	O
and	3169	3172	O
other	3173	3178	O
existing	3179	3187	O
prevention	3188	3198	O
services	3199	3207	O
.	3207	3208	O

Time	3209	3213	O
spent	3214	3219	O
obtaining	3220	3229	O
PrEP	3230	3234	O
and	3235	3238	O
frequency	3239	3248	O
of	3249	3251	O
pick	3252	3256	O
up	3257	3259	O
,	3259	3260	O
which	3261	3266	O
we	3267	3269	O
used	3270	3274	O
as	3275	3277	O
a	3278	3279	O
proxy	3280	3285	O
measure	3286	3293	O
for	3294	3297	O
cost	3298	3302	O
-	3302	3303	O
opportunity	3303	3314	O
,	3314	3315	O
were	3316	3320	O
generally	3321	3330	O
less	3331	3335	O
important	3336	3345	O
,	3345	3346	O
consistent	3347	3357	O
with	3358	3362	O
participants	3363	3375	O
'	3375	3376	O
willingness	3377	3388	O
to	3389	3391	O
pay	3392	3395	O
for	3396	3399	O
PrEP	3400	3404	O
.	3404	3405	O

Our	3406	3409	O
findings	3410	3418	O
are	3419	3422	O
broadly	3423	3430	O
consistent	3431	3441	O
with	3442	3446	O
the	3447	3450	O
work	3451	3455	O
of	3456	3458	O
Guest	3459	3464	O
et	3465	3467	O
al	3468	3470	O
.	3470	3471	O
and	3472	3475	O
Galea	3476	3481	O
et	3482	3484	O
al	3485	3487	O
[	3488	3489	O
18	3489	3491	O
]	3491	3492	O
,	3492	3493	O
[	3494	3495	O
19	3495	3497	O
]	3497	3498	O
.	3498	3499	O

However	3500	3507	O
,	3507	3508	O
specific	3509	3517	O
comparisons	3518	3529	O
are	3530	3533	O
not	3534	3537	O
advisable	3538	3547	O
as	3548	3550	O
the	3551	3554	O
composition	3555	3566	O
and	3567	3570	O
size	3571	3575	O
of	3576	3578	O
the	3579	3582	O
samples	3583	3590	O
,	3590	3591	O
recruitment	3592	3603	O
methods	3604	3611	O
,	3611	3612	O
measures	3613	3621	O
and	3622	3625	O
statistical	3626	3637	O
analyses	3638	3646	O
differ	3647	3653	O
greatly	3654	3661	O
.	3661	3662	O

Previous	3663	3671	O
work	3672	3676	O
on	3677	3679	O
PrEP	3680	3684	O
implementation	3685	3699	O
suggests	3700	3708	O
that	3709	3713	O
delivery	3714	3722	O
programs	3723	3731	O
will	3732	3736	O
need	3737	3741	O
to	3742	3744	O
meet	3745	3749	O
a	3750	3751	O
number	3752	3758	O
of	3759	3761	O
requirements	3762	3774	O
in	3775	3777	O
order	3778	3783	O
to	3784	3786	O
be	3787	3789	O
effective	3790	3799	O
,	3799	3800	O
including	3801	3810	O
:	3810	3811	O
prioritization	3812	3826	O
of	3827	3829	O
groups	3830	3836	O
at	3837	3839	O
higher	3840	3846	O
risk	3847	3851	O
of	3852	3854	O
infection	3855	3864	O
;	3864	3865	O
delivery	3866	3874	O
of	3875	3877	O
PrEP	3878	3882	O
in	3883	3885	O
combination	3886	3897	O
with	3898	3902	O
other	3903	3908	O
prevention	3909	3919	O
services	3920	3928	O
,	3928	3929	O
including	3930	3939	O
risk	3940	3944	O
reduction	3945	3954	O
and	3955	3958	O
medication	3959	3969	O
adherence	3970	3979	O
counseling	3980	3990	O
,	3990	3991	O
condoms	3992	3999	O
provision	4000	4009	O
,	4009	4010	O
diagnosis	4011	4020	O
and	4021	4024	O
treatment	4025	4034	O
of	4035	4037	O
other	4038	4043	O
sexually	4044	4052	O
transmitted	4053	4064	O
infections	4065	4075	O
,	4075	4076	O
and	4077	4080	O
frequent	4081	4089	O
HIV	4090	4093	O
testing	4094	4101	O
;	4101	4102	O
and	4103	4106	O
monitoring	4107	4117	O
of	4118	4120	O
side	4121	4125	O
effects	4126	4133	O
,	4133	4134	O
adherence	4135	4144	O
and	4145	4148	O
risk	4149	4153	O
behaviors	4154	4163	O
[	4164	4165	O
8	4165	4166	O
]	4166	4167	O
,	4167	4168	O
[	4169	4170	O
38	4170	4172	O
]	4172	4173	O
,	4173	4174	O
[	4175	4176	O
39	4176	4178	O
]	4178	4179	O
,	4179	4180	O
[	4181	4182	O
40	4182	4184	O
]	4184	4185	O
,	4185	4186	O
[	4187	4188	O
41	4188	4190	O
]	4190	4191	O
,	4191	4192	O
[	4193	4194	O
42	4194	4196	O
]	4196	4197	O
.	4197	4198	O

Our	4199	4202	O
results	4203	4210	O
provide	4211	4218	O
valuable	4219	4227	O
clues	4228	4233	O
that	4234	4238	O
can	4239	4242	O
help	4243	4247	O
countries	4248	4257	O
to	4258	4260	O
deliver	4261	4268	O
PrEP	4269	4273	O
more	4274	4278	O
effectively	4279	4290	O
,	4290	4291	O
should	4292	4298	O
they	4299	4303	O
decide	4304	4310	O
to	4311	4313	O
implement	4314	4323	O
it	4324	4326	O
,	4326	4327	O
by	4328	4330	O
focusing	4331	4339	O
their	4340	4345	O
efforts	4346	4353	O
on	4354	4356	O
the	4357	4360	O
aspects	4361	4368	O
that	4369	4373	O
need	4374	4378	O
more	4379	4383	O
attention	4384	4393	O
.	4393	4394	O

This	4395	4399	O
is	4400	4402	O
the	4403	4406	O
first	4407	4412	O
multinational	4413	4426	O
study	4427	4432	O
,	4432	4433	O
to	4434	4436	O
our	4437	4440	O
knowledge	4441	4450	O
,	4450	4451	O
that	4452	4456	O
integrates	4457	4467	O
different	4468	4477	O
disciplines	4478	4489	O
to	4490	4492	O
shed	4493	4497	O
light	4498	4503	O
on	4504	4506	O
a	4507	4508	O
question	4509	4517	O
that	4518	4522	O
we	4523	4525	O
believe	4526	4533	O
is	4534	4536	O
of	4537	4539	O
global	4540	4546	O
importance	4547	4557	O
.	4557	4558	O

Our	4559	4562	O
study	4563	4568	O
complements	4569	4580	O
previous	4581	4589	O
work	4590	4594	O
on	4595	4597	O
PrEP	4598	4602	O
by	4603	4605	O
examining	4606	4615	O
potential	4616	4625	O
users	4626	4631	O
'	4631	4632	O
perspective	4633	4644	O
and	4645	4648	O
offering	4649	4657	O
insights	4658	4666	O
into	4667	4671	O
their	4672	4677	O
attitudes	4678	4687	O
and	4688	4691	O
preferences	4692	4703	O
.	4703	4704	O

We	4705	4707	O
note	4708	4712	O
that	4713	4717	O
it	4718	4720	O
may	4721	4724	O
not	4725	4728	O
be	4729	4731	O
possible	4732	4740	O
to	4741	4743	O
generalize	4744	4754	O
the	4755	4758	O
observed	4759	4767	O
PrEP	4768	4772	O
acceptability	4773	4786	O
to	4787	4789	O
other	4790	4795	O
settings	4796	4804	O
and	4805	4808	O
our	4809	4812	O
results	4813	4820	O
should	4821	4827	O
be	4828	4830	O
considered	4831	4841	O
within	4842	4848	O
the	4849	4852	O
context	4853	4860	O
of	4861	4863	O
this	4864	4868	O
study	4869	4874	O
'	4874	4875	O
s	4875	4876	O
limitations	4877	4888	O
.	4888	4889	O

Given	4890	4895	O
the	4896	4899	O
sensitive	4900	4909	O
nature	4910	4916	O
of	4917	4919	O
the	4920	4923	O
addressed	4924	4933	O
questions	4934	4943	O
,	4943	4944	O
and	4945	4948	O
despite	4949	4956	O
all	4957	4960	O
our	4961	4964	O
efforts	4965	4972	O
to	4973	4975	O
reduce	4976	4982	O
social	4983	4989	O
desirability	4990	5002	O
bias	5003	5007	O
,	5007	5008	O
there	5009	5014	O
is	5015	5017	O
an	5018	5020	O
unavoidable	5021	5032	O
risk	5033	5037	O
that	5038	5042	O
participants	5043	5055	O
may	5056	5059	O
have	5060	5064	O
felt	5065	5069	O
at	5070	5072	O
times	5073	5078	O
compelled	5079	5088	O
to	5089	5091	O
provide	5092	5099	O
what	5100	5104	O
they	5105	5109	O
felt	5110	5114	O
was	5115	5118	O
the	5119	5122	O
"	5123	5124	O
right	5124	5129	O
"	5129	5130	O
answer	5131	5137	O
.	5137	5138	O

Additionally	5139	5151	O
,	5151	5152	O
our	5153	5156	O
data	5157	5161	O
collection	5162	5172	O
took	5173	5177	O
place	5178	5183	O
in	5184	5186	O
urban	5187	5192	O
areas	5193	5198	O
,	5198	5199	O
where	5200	5205	O
HIV	5206	5209	O
incidence	5210	5219	O
is	5220	5222	O
normally	5223	5231	O
higher	5232	5238	O
,	5238	5239	O
thus	5240	5244	O
current	5245	5252	O
findings	5253	5261	O
may	5262	5265	O
not	5266	5269	O
be	5270	5272	O
generalizable	5273	5286	O
to	5287	5289	O
rural	5290	5295	O
settings	5296	5304	O
.	5304	5305	O

Finally	5306	5313	O
,	5313	5314	O
examining	5315	5324	O
acceptability	5325	5338	O
among	5339	5344	O
users	5345	5350	O
enrolled	5351	5359	O
in	5360	5362	O
pilot	5363	5368	O
programs	5369	5377	O
is	5378	5380	O
much	5381	5385	O
deserving	5386	5395	O
,	5395	5396	O
as	5397	5399	O
actual	5400	5406	O
acceptability	5407	5420	O
may	5421	5424	O
differ	5425	5431	O
from	5432	5436	O
potential	5437	5446	O
willingness	5447	5458	O
to	5459	5461	O
take	5462	5466	O
PrEP	5467	5471	O
,	5471	5472	O
especially	5473	5483	O
if	5484	5486	O
relevant	5487	5495	O
attributes	5496	5506	O
of	5507	5509	O
a	5510	5511	O
product	5512	5519	O
or	5520	5522	O
program	5523	5530	O
are	5531	5534	O
modified	5535	5543	O
,	5543	5544	O
as	5545	5547	O
observed	5548	5556	O
in	5557	5559	O
other	5560	5565	O
comparable	5566	5576	O
interventions	5577	5590	O
[	5591	5592	O
43	5592	5594	O
]	5594	5595	O
.	5595	5596	O

Origins	0	7	O
of	8	10	O
Acquired	11	19	O
Antibiotic	20	30	O
Resistance	31	41	O
Mechanisms	42	52	O

Recently	53	61	O
,	61	62	O
D	63	64	O
'	64	65	O
Costa	65	70	O
et	71	73	O
al	74	76	O
.	76	77	O

(	78	79	O
2011	79	83	O
)	83	84	O
have	85	89	O
reported	90	98	O
a	99	100	O
metagenomic	101	112	O
analysis	113	121	O
of	122	124	O
the	125	128	O
Beringian	129	138	O
permafrost	139	149	O
,	149	150	O
which	151	156	O
is	157	159	O
30	160	162	O
,	162	163	O
000	163	166	O
years	167	172	O
old	173	176	O
.	176	177	O

They	178	182	O
showed	183	189	O
molecular	190	199	O
evidences	200	209	O
of	210	212	O
the	213	216	O
ancient	217	224	O
origins	225	232	O
of	233	235	O
antibiotic	236	246	O
resistances	247	258	O
,	258	259	O
detecting	260	269	O
beta	270	274	O
-	274	275	O
lactamases	275	285	O
genes	286	291	O
,	291	292	O
vanX	293	297	O
-	297	298	O
like	298	302	O
,	302	303	O
component	304	313	O
of	314	316	O
the	317	320	O
vancomycin	321	331	O
resistance	332	342	O
operon	343	349	O
,	349	350	O
and	351	354	O
tetM	355	359	O
,	359	360	O
coding	361	367	O
for	368	371	O
a	372	373	O
protein	374	381	O
protecting	382	392	O
the	393	396	O
ribosomal	397	406	B-Cellular_component
target	407	413	O
from	414	418	O
tetracycline	419	431	O
.	431	432	O

Sequence	433	441	O
analysis	442	450	O
revealed	451	459	O
that	460	464	O
the	465	468	O
beta	469	473	O
-	473	474	O
lactamases	474	484	O
genes	485	490	O
recovered	491	500	O
from	501	505	O
the	506	509	O
permafrost	510	520	O
demonstrated	521	533	O
an	534	536	O
amino	537	542	O
-	542	543	O
acid	543	547	O
homology	548	556	O
(	557	558	O
53	558	560	O
-	560	561	O
84	561	563	O
%	563	564	O
)	564	565	O
to	566	568	O
known	569	574	O
beta	575	579	O
-	579	580	O
lactamases	580	590	O
from	591	595	O
beta	596	600	O
-	600	601	O
lactams	601	608	O
producing	609	618	O
Streptomyces	619	631	O
.	631	632	O

The	633	636	O
tetM	637	641	O
sequences	642	651	O
revealed	652	660	O
a	661	662	O
high	663	667	O
similarity	668	678	O
to	679	681	O
the	682	685	O
genes	686	691	O
coding	692	698	O
for	699	702	O
the	703	706	O
ribosomal	707	716	B-Cellular_component
protection	717	727	O
protein	728	735	O
of	736	738	O
actinomycetes	739	752	O
.	752	753	O

The	754	757	O
vanX	758	762	O
sequence	763	771	O
showed	772	778	O
a	779	780	O
similarity	781	791	O
to	792	794	O
the	795	798	O
vanX	799	803	O
gene	804	808	O
recovered	809	818	O
in	819	821	O
pathogenic	822	832	O
vancomycin	833	843	O
resistant	844	853	O
enterococci	854	865	O
(	866	867	O
VRE	867	870	O
)	870	871	O
and	872	875	O
to	876	878	O
the	879	882	O
vanX	883	887	O
gene	888	892	O
from	893	897	O
Amycolatopsis	898	911	O
orientalis	912	922	O
.	922	923	O

This	924	928	O
environmental	929	942	O
species	943	950	O
,	950	951	O
belonging	952	961	O
to	962	964	O
the	965	968	O
actinobacteria	969	983	O
phylum	984	990	O
,	990	991	O
is	992	994	O
a	995	996	O
natural	997	1004	O
producer	1005	1013	O
of	1014	1016	O
vancomycin	1017	1027	O
,	1027	1028	O
and	1029	1032	O
very	1033	1037	O
likely	1038	1044	O
the	1045	1048	O
progenitor	1049	1059	O
of	1060	1062	O
the	1063	1066	O
van	1067	1070	O
genes	1071	1076	O
operons	1077	1084	O
,	1084	1085	O
responsible	1086	1097	O
for	1098	1101	O
resistance	1102	1112	O
to	1113	1115	O
vancomycin	1116	1126	O
.	1126	1127	O

The	1128	1131	O
integration	1132	1143	O
of	1144	1146	O
the	1147	1150	O
van	1151	1154	O
operons	1155	1162	O
on	1163	1165	O
transposons	1166	1177	O
and	1178	1181	O
on	1182	1184	O
conjugative	1185	1196	B-Cellular_component
plasmids	1197	1205	I-Cellular_component
has	1206	1209	O
enhanced	1210	1218	O
their	1219	1224	O
spread	1225	1231	O
(	1232	1233	O
Courvalin	1233	1242	O
,	1242	1243	O
2006	1244	1248	O
)	1248	1249	O
.	1249	1250	O

Reports	1251	1258	O
of	1259	1261	O
VRE	1262	1265	O
in	1266	1268	O
freshwater	1269	1279	O
have	1280	1284	O
been	1285	1289	O
provided	1290	1298	O
by	1299	1301	O
several	1302	1309	O
authors	1310	1317	O
(	1318	1319	O
Talebi	1319	1325	O
et	1326	1328	O
al	1329	1331	O
.	1331	1332	O
,	1332	1333	O
2008	1334	1338	O
;	1338	1339	O
Lata	1340	1344	O
et	1345	1347	O
al	1348	1350	O
.	1350	1351	O
,	1351	1352	O
2009	1353	1357	O
;	1357	1358	O
Luczkiewicz	1359	1370	O
et	1371	1373	O
al	1374	1376	O
.	1376	1377	O
,	1377	1378	O
2010	1379	1383	O
)	1383	1384	O
.	1384	1385	O

Interestingly	1386	1399	O
,	1399	1400	O
Schwartz	1401	1409	O
et	1410	1412	O
al	1413	1415	O
.	1415	1416	O

(	1417	1418	O
2003	1418	1422	O
)	1422	1423	O
detected	1424	1432	O
vanA	1433	1437	O
genes	1438	1443	O
in	1444	1446	O
the	1447	1450	O
biofilm	1451	1458	B-Cell
of	1459	1461	O
drinking	1462	1470	O
water	1471	1476	O
supplies	1477	1485	O
,	1485	1486	O
in	1487	1489	O
the	1490	1493	O
absence	1494	1501	O
of	1502	1504	O
enterococci	1505	1516	O
,	1516	1517	O
demonstrating	1518	1531	O
the	1532	1535	O
lateral	1536	1543	O
transfer	1544	1552	O
of	1553	1555	O
this	1556	1560	O
gene	1561	1565	O
.	1565	1566	O

Notably	1567	1574	O
,	1574	1575	O
the	1576	1579	O
progenitors	1580	1591	O
of	1592	1594	O
these	1595	1600	O
resistance	1601	1611	O
genes	1612	1617	O
are	1618	1621	O
soil	1622	1626	O
bacteria	1627	1635	O
thus	1636	1640	O
most	1641	1645	O
likely	1646	1652	O
,	1652	1653	O
a	1654	1655	O
shuttle	1656	1663	O
has	1664	1667	O
been	1668	1672	O
responsible	1673	1684	O
for	1685	1688	O
the	1689	1692	O
introduction	1693	1705	O
of	1706	1708	O
these	1709	1714	O
genes	1715	1720	O
into	1721	1725	O
the	1726	1729	O
commensal	1730	1739	O
bacterial	1740	1749	O
community	1750	1759	O
and	1760	1763	O
afterward	1764	1773	O
into	1774	1778	O
the	1779	1782	O
pathogenic	1783	1793	O
species	1794	1801	O
.	1801	1802	O

Results	0	7	O

Supplementary	0	13	O
Material	14	22	O

Crystal	23	30	O
structure	31	40	O
:	40	41	O
contains	42	50	O
datablock	51	60	O
(	60	61	O
s	61	62	O
)	62	63	O
global	64	70	O
,	70	71	O
I	72	73	O
.	73	74	O

DOI	75	78	O
:	78	79	O
10	80	82	O
.	82	83	O
1107	83	87	O
/	87	88	O
S1600536812002796	88	105	O
/	105	106	O
hg5166sup1	106	116	O
.	116	117	O
cif	117	120	O

Structure	121	130	O
factors	131	138	O
:	138	139	O
contains	140	148	O
datablock	149	158	O
(	158	159	O
s	159	160	O
)	160	161	O
I	162	163	O
.	163	164	O

DOI	165	168	O
:	168	169	O
10	170	172	O
.	172	173	O
1107	173	177	O
/	177	178	O
S1600536812002796	178	195	O
/	195	196	O
hg5166Isup2	196	207	O
.	207	208	O
hkl	208	211	O

Additional	212	222	O
supplementary	223	236	O
materials	237	246	O
:	246	247	O
crystallographic	248	264	O
information	265	276	O
;	276	277	O
3D	278	280	O
view	281	285	O
;	285	286	O
checkCIF	287	295	O
report	296	302	O

Results	0	7	O

Images	0	6	O

Figure	7	13	O
1	14	15	O

Figure	16	22	O
2	23	24	O

Figure	25	31	O
3	32	33	O

Figure	34	40	O
4	41	42	O

Results	0	7	O

Images	0	6	O

FIGURE	7	13	O
2	14	15	O
.	15	16	O

Nf	0	2	O
and	3	6	O
GA	7	9	O
-	9	10	O
1	10	11	O
DNA	12	15	O
polymerases	16	27	O
couple	28	34	O
polymerization	35	49	O
to	50	52	O
strand	53	59	O
displacement	60	72	O
processively	73	85	O

The	86	89	O
results	90	97	O
presented	98	107	O
in	108	110	O
this	111	115	O
paper	116	121	O
clearly	122	129	O
indicate	130	138	O
that	139	143	O
Nf	144	146	O
and	147	150	O
GA	151	153	O
-	153	154	O
1	154	155	O
DNA	156	159	O
polymerases	160	171	O
can	172	175	O
account	176	183	O
for	184	187	O
their	188	193	O
genome	194	200	O
replication	201	212	O
without	213	220	O
the	221	224	O
assistance	225	235	O
of	236	238	O
unwinding	239	248	O
and	249	252	O
processivity	253	265	O
factors	266	273	O
,	273	274	O
in	275	277	O
contrast	278	286	O
to	287	289	O
most	290	294	O
replicative	295	306	O
DNA	307	310	O
polymerases	311	322	O
which	323	328	O
require	329	336	O
their	337	342	O
physical	343	351	O
association	352	363	O
to	364	366	O
processivity	367	379	O
factors	380	387	O
and	388	391	O
DNA	392	395	O
unwinding	396	405	O
proteins	406	414	O
(	415	416	O
1	416	417	O
,	417	418	O
70	418	420	O
)	420	421	O
.	421	422	O

Strand	423	429	O
displacement	430	442	O
capacity	443	451	O
has	452	455	O
also	456	460	O
been	461	465	O
shown	466	471	O
for	472	475	O
other	476	481	O
protein	482	489	O
-	489	490	O
primed	490	496	O
DNA	497	500	O
polymerases	501	512	O
as	513	515	O
those	516	521	O
of	522	524	O
bacteriophages	525	539	O
phi29	540	545	O
(	546	547	O
10	547	549	O
)	549	550	O
,	550	551	O
Cp	552	554	O
-	554	555	O
1	555	556	O
(	557	558	O
71	558	560	O
)	560	561	O
and	562	565	O
PRD1	566	570	O
(	571	572	O
72	572	574	O
,	574	575	O
73	575	577	O
)	577	578	O
.	578	579	O

On	580	582	O
the	583	586	O
contrary	587	595	O
,	595	596	O
adenovirus	597	607	O
DNA	608	611	O
polymerase	612	622	O
,	622	623	O
although	624	632	O
processive	633	643	O
,	643	644	O
cannot	645	651	O
couple	652	658	O
polymerization	659	673	O
to	674	676	O
strand	677	683	O
displacement	684	696	O
,	696	697	O
requiring	698	707	O
the	708	711	O
DNA	712	715	O
unwinding	716	725	O
activity	726	734	O
of	735	737	O
the	738	741	O
adenovirus	742	752	O
DBP	753	756	O
to	757	759	O
perform	760	767	O
strand	768	774	O
displacement	775	787	O
(	788	789	O
74	789	791	O
,	791	792	O
75	792	794	O
)	794	795	O
.	795	796	O

Whereas	797	804	O
it	805	807	O
was	808	811	O
possible	812	820	O
to	821	823	O
obtain	824	830	O
GA	831	833	O
-	833	834	O
1	834	835	O
DNA	836	839	O
replication	840	851	O
by	852	854	O
using	855	860	O
exclusively	861	872	O
the	873	876	O
GA	877	879	O
-	879	880	O
1	880	881	O
TP	882	884	O
and	885	888	O
DNA	889	892	O
polymerase	893	903	O
,	903	904	O
Nf	905	907	O
DNA	908	911	O
polymerase	912	922	O
,	922	923	O
although	924	932	O
provided	933	941	O
with	942	946	O
competent	947	956	O
strand	957	963	O
displacement	964	976	O
and	977	980	O
processivity	981	993	O
features	994	1002	O
,	1002	1003	O
required	1004	1012	O
the	1013	1016	O
presence	1017	1025	O
of	1026	1028	O
Nf	1029	1031	O
DBP	1032	1035	O
for	1036	1039	O
an	1040	1042	O
effective	1043	1052	O
in	1053	1055	O
vitro	1056	1061	O
replication	1062	1073	O
of	1074	1076	O
Nf	1077	1079	O
TP	1080	1082	O
-	1082	1083	O
DNA	1083	1086	O
.	1086	1087	O

Results	1088	1095	O
presented	1096	1105	O
here	1106	1110	O
show	1111	1115	O
that	1116	1120	O
Nf	1121	1123	O
DBP	1124	1127	O
strongly	1128	1136	O
stimulates	1137	1147	O
the	1148	1151	O
formation	1152	1161	O
of	1162	1164	O
the	1165	1168	O
TP	1169	1171	O
-	1171	1172	O
dAMP	1172	1176	O
initiation	1177	1187	O
complex	1188	1195	O
by	1196	1198	O
decreasing	1199	1209	O
the	1210	1213	O
Km	1214	1216	O
for	1217	1220	O
dATP	1221	1225	O
and	1226	1229	O
facilitates	1230	1241	O
the	1242	1245	O
transition	1246	1256	O
from	1257	1261	O
initiation	1262	1272	O
to	1273	1275	O
elongation	1276	1286	O
,	1286	1287	O
as	1288	1290	O
it	1291	1293	O
occurs	1294	1300	O
in	1301	1303	O
phi29	1304	1309	O
(	1310	1311	O
76	1311	1313	O
)	1313	1314	O
.	1314	1315	O

These	1316	1321	O
results	1322	1329	O
point	1330	1335	O
to	1336	1338	O
either	1339	1345	O
a	1346	1347	O
specific	1348	1356	O
and	1357	1360	O
direct	1361	1367	O
contact	1368	1375	O
between	1376	1383	O
DBP	1384	1387	O
and	1388	1391	O
DNA	1392	1395	O
polymerase	1396	1406	O
that	1407	1411	O
promotes	1412	1420	O
conformational	1421	1435	O
changes	1436	1443	O
at	1444	1446	O
the	1447	1450	O
polymerization	1451	1465	O
active	1466	1472	O
site	1473	1477	O
or	1478	1480	O
to	1481	1483	O
an	1484	1486	O
effect	1487	1493	O
of	1494	1496	O
DBP	1497	1500	O
in	1501	1503	O
conferring	1504	1514	O
the	1515	1518	O
optimal	1519	1526	O
template	1527	1535	O
structure	1536	1545	O
to	1546	1548	O
direct	1549	1555	O
initiating	1556	1566	O
nucleotide	1567	1577	O
insertion	1578	1587	O
.	1587	1588	O

A	1589	1590	O
similar	1591	1598	O
role	1599	1603	O
has	1604	1607	O
been	1608	1612	O
proposed	1613	1621	O
for	1622	1625	O
adenovirus	1626	1636	O
DBP	1637	1640	O
,	1640	1641	O
a	1642	1643	O
DNA	1644	1647	O
unwinding	1648	1657	O
protein	1658	1665	O
(	1666	1667	O
77	1667	1669	O
)	1669	1670	O
.	1670	1671	O

As	1672	1674	O
in	1675	1677	O
the	1678	1681	O
case	1682	1686	O
of	1687	1689	O
phi29	1690	1695	O
and	1696	1699	O
Nf	1700	1702	O
DBP	1703	1706	O
,	1706	1707	O
this	1708	1712	O
protein	1713	1720	O
stimulates	1721	1731	O
the	1732	1735	O
rate	1736	1740	O
of	1741	1743	O
initiation	1744	1754	O
also	1755	1759	O
by	1760	1762	O
decreasing	1763	1773	O
the	1774	1777	O
Km	1778	1780	O
for	1781	1784	O
the	1785	1788	O
initiating	1789	1799	O
nucleotide	1800	1810	O
(	1811	1812	O
74	1812	1814	O
)	1814	1815	O
.	1815	1816	O

The	1817	1820	O
fact	1821	1825	O
that	1826	1830	O
an	1831	1833	O
adenovirus	1834	1844	O
DBP	1845	1848	O
mutant	1849	1855	O
defective	1856	1865	O
in	1866	1868	O
unwinding	1869	1878	O
can	1879	1882	O
still	1883	1888	O
stimulate	1889	1898	O
initiation	1899	1909	O
precludes	1910	1919	O
the	1920	1923	O
unwinding	1924	1933	O
role	1934	1938	O
as	1939	1941	O
the	1942	1945	O
one	1946	1949	O
responsible	1950	1961	O
for	1962	1965	O
such	1966	1970	O
an	1971	1973	O
activation	1974	1984	O
(	1985	1986	O
77	1986	1988	O
,	1988	1989	O
78	1989	1991	O
)	1991	1992	O
.	1992	1993	O

In	1994	1996	O
this	1997	2001	O
case	2002	2006	O
,	2006	2007	O
contacts	2008	2016	O
between	2017	2024	O
DBP	2025	2028	O
and	2029	2032	O
pTP	2033	2036	O
/	2036	2037	O
DNA	2037	2040	O
polymerase	2041	2051	O
complex	2052	2059	O
have	2060	2064	O
been	2065	2069	O
reported	2070	2078	O
(	2079	2080	O
77	2080	2082	O
)	2082	2083	O
.	2083	2084	O

The	2085	2088	O
effect	2089	2095	O
of	2096	2098	O
Nf	2099	2101	O
DBP	2102	2105	O
in	2106	2108	O
promoting	2109	2118	O
elongation	2119	2129	O
of	2130	2132	O
the	2133	2136	O
initiation	2137	2147	O
products	2148	2156	O
could	2157	2162	O
be	2163	2165	O
due	2166	2169	O
to	2170	2172	O
a	2173	2174	O
decrease	2175	2183	O
of	2184	2186	O
the	2187	2190	O
Km	2191	2193	O
also	2194	2198	O
for	2199	2202	O
the	2203	2206	O
incorporation	2207	2220	O
of	2221	2223	O
the	2224	2227	O
dNMPs	2228	2233	O
during	2234	2240	O
the	2241	2244	O
transition	2245	2255	O
stage	2256	2261	O
from	2262	2266	O
initiation	2267	2277	O
to	2278	2280	O
elongation	2281	2291	O
,	2291	2292	O
to	2293	2295	O
a	2296	2297	O
different	2298	2307	O
type	2308	2312	O
of	2313	2315	O
contact	2316	2323	O
with	2324	2328	O
the	2329	2332	O
DNA	2333	2336	O
polymerase	2337	2347	O
that	2348	2352	O
helps	2353	2358	O
transition	2359	2369	O
to	2370	2372	O
elongation	2373	2383	O
,	2383	2384	O
or	2385	2387	O
both	2388	2392	O
.	2392	2393	O

The	2394	2397	O
similarity	2398	2408	O
in	2409	2411	O
replication	2412	2423	O
rates	2424	2429	O
when	2430	2434	O
comparing	2435	2444	O
M13	2445	2448	O
DNA	2449	2452	O
replication	2453	2464	O
,	2464	2465	O
performed	2466	2475	O
in	2476	2478	O
the	2479	2482	O
absence	2483	2490	O
of	2491	2493	O
DBP	2494	2497	O
(	2498	2499	O
2400	2499	2503	O
nt	2504	2506	O
/	2506	2507	O
min	2507	2510	O
)	2510	2511	O
,	2511	2512	O
with	2513	2517	O
Nf	2518	2520	O
TP	2521	2523	O
-	2523	2524	O
DNA	2524	2527	O
replication	2528	2539	O
in	2540	2542	O
the	2543	2546	O
presence	2547	2555	O
of	2556	2558	O
DBP	2559	2562	O
(	2563	2564	O
2260	2564	2568	O
nt	2569	2571	O
/	2571	2572	O
min	2572	2575	O
)	2575	2576	O
,	2576	2577	O
suggests	2578	2586	O
that	2587	2591	O
the	2592	2595	O
DBP	2596	2599	O
stimulatory	2600	2611	O
role	2612	2616	O
is	2617	2619	O
restricted	2620	2630	O
to	2631	2633	O
the	2634	2637	O
first	2638	2643	O
phases	2644	2650	O
of	2651	2653	O
Nf	2654	2656	O
TP	2657	2659	O
-	2659	2660	O
DNA	2660	2663	O
replication	2664	2675	O
.	2675	2676	O

2	0	1	O
-	1	2	O
Theory	3	9	O

Scanning	10	18	O
holography	19	29	O
is	30	32	O
a	33	34	O
two	35	38	O
-	38	39	O
pupil	39	44	O
interaction	45	56	O
method	57	63	O
[	64	65	O
8	65	66	O
]	66	67	O
by	68	70	O
which	71	76	O
incoherent	77	87	O
imaging	88	95	O
with	96	100	O
complex	101	108	O
point	109	114	O
-	114	115	O
spread	115	121	O
-	121	122	O
functions	122	131	O
(	132	133	O
PSF	133	136	O
)	136	137	O
is	138	140	O
possible	141	149	O
.	149	150	O

The	151	154	O
method	155	161	O
has	162	165	O
recently	166	174	O
been	175	179	O
applied	180	187	O
to	188	190	O
the	191	194	O
recording	195	204	O
of	205	207	O
high	208	212	O
resolution	213	223	O
holographic	224	235	O
images	236	242	O
of	243	245	O
incoherent	246	256	O
objects	257	264	O
and	265	268	O
fluorescent	269	280	O
biological	281	291	O
specimens	292	301	O
[	302	303	O
6	303	304	O
,	304	305	O
7	305	306	O
]	306	307	O
.	307	308	O

A	309	310	O
single	311	317	O
-	317	318	O
sideband	318	326	O
in	327	329	O
-	329	330	O
line	330	334	O
Fresnel	335	342	O
hologram	343	351	O
is	352	354	O
obtained	355	363	O
by	364	366	O
a	367	368	O
2D	369	371	O
raster	372	378	O
scan	379	383	O
of	384	386	O
the	387	390	O
object	391	397	O
with	398	402	O
the	403	406	O
superposed	407	417	O
3D	418	420	O
diffraction	421	432	O
distributions	433	446	O
of	447	449	O
two	450	453	O
pupils	454	460	O
,	460	461	O
as	462	464	O
sketched	465	473	O
in	474	476	O
fig	477	480	O
.	480	481	O

1	482	483	O
.	483	484	O

The	485	488	O
two	489	492	O
pupil	493	498	O
distributions	499	512	O
P	513	514	O
~	514	515	O
1	515	516	O
(	516	517	O
rho	517	520	O
-	520	521	O
-	521	522	O
>	522	523	O
)	523	524	O
MathType	525	533	O
@	533	534	O
MTEF	534	538	O
@	538	539	O
5	539	540	O
@	540	541	O
5	541	542	O
@	542	543	O
+	543	544	O
=	544	545	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	545	630	O
=	630	631	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	631	662	O
=	662	663	O
OqFfea0dXdd9vqai	663	679	O
=	679	680	O
hGuQ8kuc9pgc9s8qqaq	680	699	O
=	699	700	O
dirpe0xb9q8qiLsFr0	700	718	O
=	718	719	O
vr0	719	722	O
=	722	723	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	723	840	O
@	840	841	O
3295	841	845	O
@	845	846	O
and	847	850	O
P	851	852	O
~	852	853	O
2	853	854	O
(	854	855	O
rho	855	858	O
-	858	859	O
-	859	860	O
>	860	861	O
)	861	862	O
MathType	863	871	O
@	871	872	O
MTEF	872	876	O
@	876	877	O
5	877	878	O
@	878	879	O
5	879	880	O
@	880	881	O
+	881	882	O
=	882	883	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	883	968	O
=	968	969	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	969	1000	O
=	1000	1001	O
OqFfea0dXdd9vqai	1001	1017	O
=	1017	1018	O
hGuQ8kuc9pgc9s8qqaq	1018	1037	O
=	1037	1038	O
dirpe0xb9q8qiLsFr0	1038	1056	O
=	1056	1057	O
vr0	1057	1060	O
=	1060	1061	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	1061	1178	O
@	1178	1179	O
3297	1179	1183	O
@	1183	1184	O
from	1185	1189	O
the	1190	1193	O
same	1194	1198	O
source	1199	1205	O
(	1206	1207	O
for	1207	1210	O
example	1211	1218	O
,	1218	1219	O
but	1220	1223	O
not	1224	1227	O
necessarily	1228	1239	O
,	1239	1240	O
a	1241	1242	O
laser	1243	1248	O
)	1248	1249	O
are	1250	1253	O
combined	1254	1262	O
by	1263	1265	O
a	1266	1267	O
beam	1268	1272	O
splitter	1273	1281	O
in	1282	1284	O
the	1285	1288	O
pupil	1289	1294	O
plane	1295	1300	O
of	1301	1303	O
the	1304	1307	O
objective	1308	1317	O
where	1318	1323	O
they	1324	1328	O
interfere	1329	1338	O
,	1338	1339	O
forming	1340	1347	O
a	1348	1349	O
Fresnel	1350	1357	O
pattern	1358	1365	O
with	1366	1370	O
a	1371	1372	O
depth	1373	1378	O
-	1378	1379	O
dependent	1379	1388	O
Fresnel	1389	1396	O
number	1397	1403	O
.	1403	1404	O

To	1405	1407	O
obtain	1408	1414	O
the	1415	1418	O
conventional	1419	1431	O
point	1432	1437	O
-	1437	1438	O
spread	1438	1444	O
function	1445	1453	O
of	1454	1456	O
wide	1457	1461	O
field	1462	1467	O
imaging	1468	1475	O
,	1475	1476	O
P1	1477	1479	O
is	1480	1482	O
chosen	1483	1489	O
as	1490	1492	O
a	1493	1494	O
point	1495	1500	O
source	1501	1507	O
,	1507	1508	O
and	1509	1512	O
P2	1513	1515	O
as	1516	1518	O
a	1519	1520	O
spherical	1521	1530	O
wave	1531	1535	O
with	1536	1540	O
appropriate	1541	1552	O
curvature	1553	1562	O
.	1562	1563	O

The	1564	1567	O
3D	1568	1570	O
specimen	1571	1579	O
is	1580	1582	O
placed	1583	1589	O
in	1590	1592	O
the	1593	1596	O
focal	1597	1602	O
region	1603	1609	O
of	1610	1612	O
the	1613	1616	O
objective	1617	1626	O
,	1626	1627	O
and	1628	1631	O
scattered	1632	1641	O
lights	1642	1648	O
(	1649	1650	O
transmitted	1650	1661	O
,	1661	1662	O
reflected	1663	1672	O
,	1672	1673	O
and	1674	1677	O
fluorescent	1678	1689	O
)	1689	1690	O
are	1691	1694	O
collected	1695	1704	O
by	1705	1707	O
non	1708	1711	O
-	1711	1712	O
imaging	1712	1719	O
detectors	1720	1729	O
.	1729	1730	O

The	1731	1734	O
hologram	1735	1743	O
data	1744	1748	O
can	1749	1752	O
be	1753	1755	O
obtained	1756	1764	O
by	1765	1767	O
heterodyne	1768	1778	O
detection	1779	1788	O
with	1789	1793	O
one	1794	1797	O
of	1798	1800	O
the	1801	1804	O
pupils	1805	1811	O
shifted	1812	1819	O
in	1820	1822	O
frequency	1823	1832	O
(	1833	1834	O
as	1834	1836	O
done	1837	1841	O
in	1842	1844	O
this	1845	1849	O
work	1850	1854	O
)	1854	1855	O
,	1855	1856	O
or	1857	1859	O
by	1860	1862	O
a	1863	1864	O
homodyne	1865	1873	O
method	1874	1880	O
requiring	1881	1890	O
the	1891	1894	O
capture	1895	1902	O
of	1903	1905	O
at	1906	1908	O
least	1909	1914	O
three	1915	1920	O
frames	1921	1927	O
with	1928	1932	O
different	1933	1942	O
relative	1943	1951	O
phases	1952	1958	O
between	1959	1966	O
the	1967	1970	O
two	1971	1974	O
pupils	1975	1981	O
[	1982	1983	O
9	1983	1984	O
]	1984	1985	O
.	1985	1986	O

The	1987	1990	O
amplitude	1991	2000	O
distribution	2001	2013	O
of	2014	2016	O
the	2017	2020	O
illuminating	2021	2033	O
beam	2034	2038	O
,	2038	2039	O
in	2040	2042	O
a	2043	2044	O
transverse	2045	2055	O
plane	2056	2061	O
at	2062	2064	O
an	2065	2067	O
axial	2068	2073	O
distance	2074	2082	O
z	2083	2084	O
from	2085	2089	O
the	2090	2093	O
focal	2094	2099	O
plane	2100	2105	O
of	2106	2108	O
the	2109	2112	O
objective	2113	2122	O
,	2122	2123	O
is	2124	2126	O
the	2127	2130	O
Fourier	2131	2138	O
transform	2139	2148	O
of	2149	2151	O
the	2152	2155	O
combined	2156	2164	O
pupil	2165	2170	O
distributions	2171	2184	O
[	2185	2186	O
10	2186	2188	O
]	2188	2189	O
.	2189	2190	O

Namely	2191	2197	O
:	2197	2198	O

Figure	2199	2205	O
1	2206	2207	O

Experimental	2208	2220	O
set	2221	2224	O
up	2225	2227	O
of	2228	2230	O
a	2231	2232	O
scanning	2233	2241	O
holographic	2242	2253	O
microscope	2254	2264	O
.	2264	2265	O

Sketch	2266	2272	O
of	2273	2275	O
the	2276	2279	O
experimental	2280	2292	O
setup	2293	2298	O
.	2298	2299	O

M	2300	2301	O
'	2301	2302	O
s	2302	2303	O
are	2304	2307	O
mirrors	2308	2315	O
,	2315	2316	O
BS	2317	2319	O
'	2319	2320	O
s	2320	2321	O
are	2322	2325	O
beam	2326	2330	O
splitters	2331	2340	O
,	2340	2341	O
EO	2342	2344	O
is	2345	2347	O
an	2348	2350	O
electro	2351	2358	O
-	2358	2359	O
optic	2359	2364	O
phase	2365	2370	O
modulator	2371	2380	O
.	2380	2381	O

Lens	2382	2386	O
L1	2387	2389	O
(	2390	2391	O
achromat	2391	2399	O
doublet	2400	2407	O
16	2408	2410	O
cm	2411	2413	O
focal	2414	2419	O
length	2420	2426	O
)	2426	2427	O
produces	2428	2436	O
the	2437	2440	O
desired	2441	2448	O
Fresnel	2449	2456	O
pattern	2457	2464	O
in	2465	2467	O
the	2468	2471	O
focal	2472	2477	O
plane	2478	2483	O
of	2484	2486	O
L2	2487	2489	O
(	2490	2491	O
achromat	2491	2499	O
doublet	2500	2507	O
16	2508	2510	O
cm	2511	2513	O
focal	2514	2519	O
length	2520	2526	O
)	2526	2527	O
.	2527	2528	O

L2	2529	2531	O
and	2532	2535	O
the	2536	2539	O
objective	2540	2549	O
form	2550	2554	O
a	2555	2556	O
4	2557	2558	O
-	2558	2559	O
f	2559	2560	O
system	2561	2567	O
projecting	2568	2578	O
a	2579	2580	O
reduced	2581	2588	O
image	2589	2594	O
of	2595	2597	O
the	2598	2601	O
Fresnel	2602	2609	O
pattern	2610	2617	O
onto	2618	2622	O
the	2623	2626	O
specimen	2627	2635	O
.	2635	2636	O

L3	2637	2639	O
(	2640	2641	O
achromat	2641	2649	O
doublet	2650	2657	O
12	2658	2660	O
cm	2661	2663	O
focal	2664	2669	O
length	2670	2676	O
)	2676	2677	O
projects	2678	2686	O
the	2687	2690	O
images	2691	2697	O
of	2698	2700	O
the	2701	2704	O
pupils	2705	2711	O
on	2712	2714	O
the	2715	2718	O
pinhole	2719	2726	O
detector	2727	2735	O
.	2735	2736	O

(	2737	2738	O
Not	2738	2741	O
shown	2742	2747	O
are	2748	2751	O
the	2752	2755	O
beam	2756	2760	O
expanders	2761	2770	O
used	2771	2775	O
to	2776	2778	O
illuminate	2779	2789	O
the	2790	2793	O
pupils	2794	2800	O
)	2800	2801	O
.	2801	2802	O

S	2803	2804	O
(	2804	2805	O
r	2805	2806	O
-	2806	2807	O
-	2807	2808	O
>	2808	2809	O
,	2809	2810	O
z	2810	2811	O
)	2811	2812	O
=	2812	2813	O
F	2813	2814	O
-	2814	2815	O
1	2815	2816	O
{	2816	2817	O
[	2817	2818	O
P	2818	2819	O
~	2819	2820	O
1	2820	2821	O
(	2821	2822	O
rho	2822	2825	O
-	2825	2826	O
-	2826	2827	O
>	2827	2828	O
;	2828	2829	O
z	2829	2830	O
)	2830	2831	O
+	2831	2832	O
P	2832	2833	O
~	2833	2834	O
2	2834	2835	O
(	2835	2836	O
rho	2836	2839	O
-	2839	2840	O
-	2840	2841	O
>	2841	2842	O
;	2842	2843	O
z	2843	2844	O
)	2844	2845	O
exp	2845	2848	O
(	2849	2850	O
-	2850	2851	O
iOmegat	2851	2858	O
]	2858	2859	O
}	2859	2860	O
,	2860	2861	O
(	2862	2863	O
1a	2863	2865	O
)	2865	2866	O
MathType	2867	2875	O
@	2875	2876	O
MTEF	2876	2880	O
@	2880	2881	O
5	2881	2882	O
@	2882	2883	O
5	2883	2884	O
@	2884	2885	O
+	2885	2886	O
=	2886	2887	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	2887	2972	O
=	2972	2973	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	2973	3004	O
=	3004	3005	O
OqFfea0dXdd9vqai	3005	3021	O
=	3021	3022	O
hGuQ8kuc9pgc9s8qqaq	3022	3041	O
=	3041	3042	O
dirpe0xb9q8qiLsFr0	3042	3060	O
=	3060	3061	O
vr0	3061	3064	O
=	3064	3065	O
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	3065	3570	O
@	3570	3571	O
5D95	3571	3575	O
@	3575	3576	O

where	3577	3582	O

P	3583	3584	O
~	3584	3585	O
1	3585	3586	O
,	3586	3587	O
2	3587	3588	O
(	3588	3589	O
rho	3589	3592	O
-	3592	3593	O
-	3593	3594	O
>	3594	3595	O
;	3595	3596	O
z	3596	3597	O
)	3597	3598	O
=	3598	3599	O
P	3599	3600	O
~	3600	3601	O
1	3601	3602	O
,	3602	3603	O
2	3603	3604	O
(	3604	3605	O
rho	3605	3608	O
-	3608	3609	O
-	3609	3610	O
>	3610	3611	O
)	3611	3612	O
exp	3612	3615	O
(	3616	3617	O
ipilambdazrho2	3617	3631	O
)	3631	3632	O
(	3633	3634	O
1b	3634	3636	O
)	3636	3637	O
MathType	3638	3646	O
@	3646	3647	O
MTEF	3647	3651	O
@	3651	3652	O
5	3652	3653	O
@	3653	3654	O
5	3654	3655	O
@	3655	3656	O
+	3656	3657	O
=	3657	3658	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	3658	3743	O
=	3743	3744	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	3744	3775	O
=	3775	3776	O
OqFfea0dXdd9vqai	3776	3792	O
=	3792	3793	O
hGuQ8kuc9pgc9s8qqaq	3793	3812	O
=	3812	3813	O
dirpe0xb9q8qiLsFr0	3813	3831	O
=	3831	3832	O
vr0	3832	3835	O
=	3835	3836	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGH9aqpcuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCcqGGOaakcqWGPbqAcqWFapaCcqWF7oaBcqWG6bGEcqWFbpGCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiaaxMaacaWLjaWaaeWaaeaacqaIXaqmcqqGIbGyaiaawIcacaGLPaaaaaa	3836	4237	O
@	4237	4238	O
53A8	4238	4242	O
@	4242	4243	O

are	4244	4247	O
the	4248	4251	O
generalized	4252	4263	O
defocused	4264	4273	O
pupils	4274	4280	O
[	4281	4282	O
11	4282	4284	O
]	4284	4285	O
.	4285	4286	O

F	4287	4288	O
-	4288	4289	O
1	4289	4290	O
stands	4291	4297	O
for	4298	4301	O
inverse	4302	4309	O
Fourier	4310	4317	O
transform	4318	4327	O
,	4327	4328	O
and	4329	4332	O
Omega	4333	4338	O
is	4339	4341	O
the	4342	4345	O
frequency	4346	4355	O
shift	4356	4361	O
of	4362	4364	O
one	4365	4368	O
of	4369	4371	O
the	4372	4375	O
pupils	4376	4382	O
.	4382	4383	O

The	4384	4387	O
transverse	4388	4398	O
spatial	4399	4406	O
frequency	4407	4416	O
vector	4417	4423	O
rho	4424	4427	O
-	4427	4428	O
-	4428	4429	O
>	4429	4430	O
MathType	4431	4439	O
@	4439	4440	O
MTEF	4440	4444	O
@	4444	4445	O
5	4445	4446	O
@	4446	4447	O
5	4447	4448	O
@	4448	4449	O
+	4449	4450	O
=	4450	4451	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	4451	4536	O
=	4536	4537	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	4537	4568	O
=	4568	4569	O
OqFfea0dXdd9vqai	4569	4585	O
=	4585	4586	O
hGuQ8kuc9pgc9s8qqaq	4586	4605	O
=	4605	4606	O
dirpe0xb9q8qiLsFr0	4606	4624	O
=	4624	4625	O
vr0	4625	4628	O
=	4628	4629	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFbpGCgaWcaaaa	4629	4691	O
@	4691	4692	O
2E85	4692	4696	O
@	4696	4697	O
=	4698	4699	O
r	4700	4701	O
-	4701	4702	O
-	4702	4703	O
>	4703	4704	O
MathType	4705	4713	O
@	4713	4714	O
MTEF	4714	4718	O
@	4718	4719	O
5	4719	4720	O
@	4720	4721	O
5	4721	4722	O
@	4722	4723	O
+	4723	4724	O
=	4724	4725	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	4725	4810	O
=	4810	4811	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	4811	4842	O
=	4842	4843	O
OqFfea0dXdd9vqai	4843	4859	O
=	4859	4860	O
hGuQ8kuc9pgc9s8qqaq	4860	4879	O
=	4879	4880	O
dirpe0xb9q8qiLsFr0	4880	4898	O
=	4898	4899	O
vr0	4899	4902	O
=	4902	4903	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	4903	4961	O
@	4961	4962	O
2E2B	4962	4966	O
@	4966	4967	O
P	4967	4968	O
/	4968	4969	O
lambdaf0	4969	4977	O
is	4978	4980	O
proportional	4981	4993	O
to	4994	4996	O
the	4997	5000	O
real	5001	5005	O
space	5006	5011	O
coordinate	5012	5022	O
r	5023	5024	O
-	5024	5025	O
-	5025	5026	O
>	5026	5027	O
MathType	5028	5036	O
@	5036	5037	O
MTEF	5037	5041	O
@	5041	5042	O
5	5042	5043	O
@	5043	5044	O
5	5044	5045	O
@	5045	5046	O
+	5046	5047	O
=	5047	5048	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	5048	5133	O
=	5133	5134	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	5134	5165	O
=	5165	5166	O
OqFfea0dXdd9vqai	5166	5182	O
=	5182	5183	O
hGuQ8kuc9pgc9s8qqaq	5183	5202	O
=	5202	5203	O
dirpe0xb9q8qiLsFr0	5203	5221	O
=	5221	5222	O
vr0	5222	5225	O
=	5225	5226	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	5226	5284	O
@	5284	5285	O
2E2B	5285	5289	O
@	5289	5290	O
P	5290	5291	O
in	5292	5294	O
the	5295	5298	O
pupil	5299	5304	O
plane	5305	5310	O
[	5311	5312	O
10	5312	5314	O
]	5314	5315	O
.	5315	5316	O
lambda	5317	5323	O
is	5324	5326	O
the	5327	5330	O
wavelength	5331	5341	O
of	5342	5344	O
the	5345	5348	O
illumination	5349	5361	O
,	5361	5362	O
and	5363	5366	O
f0	5367	5369	O
is	5370	5372	O
the	5373	5376	O
focal	5377	5382	O
length	5383	5389	O
of	5390	5392	O
the	5393	5396	O
objective	5397	5406	O
.	5406	5407	O

The	5408	5411	O
two	5412	5415	O
pupils	5416	5422	O
used	5423	5427	O
to	5428	5430	O
obtain	5431	5437	O
an	5438	5440	O
in	5441	5443	O
-	5443	5444	O
line	5444	5448	O
Fresnel	5449	5456	O
hologram	5457	5465	O
are	5466	5469	O
,	5469	5470	O
respectively	5471	5483	O
,	5483	5484	O
a	5485	5486	O
spherical	5487	5496	O
wave	5497	5501	O
filling	5502	5509	O
the	5510	5513	O
pupil	5514	5519	O
of	5520	5522	O
the	5523	5526	O
objective	5527	5536	O
,	5536	5537	O
and	5538	5541	O
a	5542	5543	O
point	5544	5549	O
at	5550	5552	O
the	5553	5556	O
center	5557	5563	O
of	5564	5566	O
that	5567	5571	O
pupil	5572	5577	O
:	5577	5578	O

P	5579	5580	O
~	5580	5581	O
1	5581	5582	O
(	5582	5583	O
rho	5583	5586	O
-	5586	5587	O
-	5587	5588	O
>	5588	5589	O
)	5589	5590	O
MathType	5591	5599	O
@	5599	5600	O
MTEF	5600	5604	O
@	5604	5605	O
5	5605	5606	O
@	5606	5607	O
5	5607	5608	O
@	5608	5609	O
+	5609	5610	O
=	5610	5611	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	5611	5696	O
=	5696	5697	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	5697	5728	O
=	5728	5729	O
OqFfea0dXdd9vqai	5729	5745	O
=	5745	5746	O
hGuQ8kuc9pgc9s8qqaq	5746	5765	O
=	5765	5766	O
dirpe0xb9q8qiLsFr0	5766	5784	O
=	5784	5785	O
vr0	5785	5788	O
=	5788	5789	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	5789	5906	O
@	5906	5907	O
3295	5907	5911	O
@	5911	5912	O
=	5913	5914	O
exp	5915	5918	O
(	5918	5919	O
ipilambdaz0rho2	5919	5934	O
)	5934	5935	O
circ	5935	5939	O
(	5939	5940	O
rho	5940	5943	O
/	5943	5944	O
rhoMAX	5944	5950	O
)	5950	5951	O

P	5952	5953	O
~	5953	5954	O
2	5954	5955	O
(	5955	5956	O
rho	5956	5959	O
-	5959	5960	O
-	5960	5961	O
>	5961	5962	O
)	5962	5963	O
=	5963	5964	O
delta	5964	5969	O
(	5969	5970	O
rho	5970	5973	O
-	5973	5974	O
-	5974	5975	O
>	5975	5976	O
)	5976	5977	O
.	5977	5978	O

(	5979	5980	O
2	5980	5981	O
)	5981	5982	O
MathType	5983	5991	O
@	5991	5992	O
MTEF	5992	5996	O
@	5996	5997	O
5	5997	5998	O
@	5998	5999	O
5	5999	6000	O
@	6000	6001	O
+	6001	6002	O
=	6002	6003	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	6003	6088	O
=	6088	6089	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	6089	6120	O
=	6120	6121	O
OqFfea0dXdd9vqai	6121	6137	O
=	6137	6138	O
hGuQ8kuc9pgc9s8qqaq	6138	6157	O
=	6157	6158	O
dirpe0xb9q8qiLsFr0	6158	6176	O
=	6176	6177	O
vr0	6177	6180	O
=	6180	6181	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpcqWF0oazcqGGOaakcuWFbpGCgaWcaiabcMcaPiabc6caUiaaxMaacaWLjaWaaeWaaeaacqaIYaGmaiaawIcacaGLPaaaaaa	6181	6398	O
@	6398	6399	O
3D5F	6399	6403	O
@	6403	6404	O

circ	6405	6409	O
(	6409	6410	O
x	6410	6411	O
)	6411	6412	O
is	6413	6415	O
a	6416	6417	O
disc	6418	6422	O
function	6423	6431	O
of	6432	6434	O
unit	6435	6439	O
radius	6440	6446	O
.	6446	6447	O

rhoMAX	6448	6454	O
=	6455	6456	O
sinalpha	6457	6465	O
/	6465	6466	O
lambda	6466	6472	O
is	6473	6475	O
the	6476	6479	O
cutoff	6480	6486	O
frequency	6487	6496	O
of	6497	6499	O
the	6500	6503	O
objective	6504	6513	O
,	6513	6514	O
where	6515	6520	O
sinalpha	6521	6529	O
=	6530	6531	O
NA	6532	6534	O
is	6535	6537	O
its	6538	6541	O
numerical	6542	6551	O
aperture	6552	6560	O
.	6560	6561	O

The	6562	6565	O
Fresnel	6566	6573	O
pattern	6574	6581	O
projected	6582	6591	O
on	6592	6594	O
the	6595	6598	O
object	6599	6605	O
is	6606	6608	O
the	6609	6612	O
interference	6613	6625	O
of	6626	6628	O
the	6629	6632	O
Fourier	6633	6640	O
transforms	6641	6651	O
of	6652	6654	O
the	6655	6658	O
two	6659	6662	O
pupils	6663	6669	O
,	6669	6670	O
namely	6671	6677	O
a	6678	6679	O
spherical	6680	6689	O
wave	6690	6694	O
and	6695	6698	O
a	6699	6700	O
plane	6701	6706	O
wave	6707	6711	O
in	6712	6714	O
the	6715	6718	O
paraxial	6719	6727	O
approximation	6728	6741	O
.	6741	6742	O

The	6743	6746	O
Fresnel	6747	6754	O
number	6755	6761	O
of	6762	6764	O
this	6765	6769	O
pattern	6770	6777	O
is	6778	6780	O
determined	6781	6791	O
by	6792	6794	O
the	6795	6798	O
free	6799	6803	O
parameter	6804	6813	O
z0	6814	6816	O
,	6816	6817	O
which	6818	6823	O
is	6824	6826	O
the	6827	6830	O
distance	6831	6839	O
from	6840	6844	O
the	6845	6848	O
objective	6849	6858	O
'	6858	6859	O
s	6859	6860	O
focal	6861	6866	O
plane	6867	6872	O
to	6873	6875	O
the	6876	6879	O
point	6880	6885	O
where	6886	6891	O
the	6892	6895	O
spherical	6896	6905	O
wave	6906	6910	O
comes	6911	6916	O
to	6917	6919	O
a	6920	6921	O
focus	6922	6927	O
.	6927	6928	O

There	6929	6934	O
are	6935	6938	O
two	6939	6942	O
possible	6943	6951	O
modes	6952	6957	O
of	6958	6960	O
operation	6961	6970	O
,	6970	6971	O
depending	6972	6981	O
on	6982	6984	O
the	6985	6988	O
detector	6989	6997	O
geometry	6998	7006	O
[	7007	7008	O
5	7008	7009	O
]	7009	7010	O
.	7010	7011	O

With	7012	7016	O
a	7017	7018	O
spatially	7019	7028	O
integrating	7029	7040	O
detector	7041	7049	O
,	7049	7050	O
the	7051	7054	O
resulting	7055	7064	O
data	7065	7069	O
is	7070	7072	O
a	7073	7074	O
convolution	7075	7086	O
of	7087	7089	O
the	7090	7093	O
object	7094	7100	O
'	7100	7101	O
s	7101	7102	O
intensity	7103	7112	O
distribution	7113	7125	O
with	7126	7130	O
the	7131	7134	O
desired	7135	7142	O
complex	7143	7150	O
PSF	7151	7154	O
(	7155	7156	O
namely	7156	7162	O
,	7162	7163	O
a	7164	7165	O
spherical	7166	7175	O
wave	7176	7180	O
with	7181	7185	O
a	7186	7187	O
radius	7188	7194	O
of	7195	7197	O
curvature	7198	7207	O
z0	7208	7210	O
+	7211	7212	O
z	7213	7214	O
,	7214	7215	O
and	7216	7219	O
a	7220	7221	O
radius	7222	7228	O
a	7229	7230	O
=	7231	7232	O
z0sinalpha	7233	7243	O
,	7243	7244	O
in	7245	7247	O
this	7248	7252	O
case	7253	7257	O
)	7257	7258	O
.	7258	7259	O

This	7260	7264	O
detection	7265	7274	O
mode	7275	7279	O
leads	7280	7285	O
to	7286	7288	O
a	7289	7290	O
hologram	7291	7299	O
from	7300	7304	O
which	7305	7310	O
the	7311	7314	O
three	7315	7320	O
-	7320	7321	O
dimensional	7321	7332	O
distribution	7333	7345	O
of	7346	7348	O
scattering	7349	7359	O
intensity	7360	7369	O
,	7369	7370	O
absorption	7371	7381	O
,	7381	7382	O
and	7383	7386	O
fluorescence	7387	7399	O
intensity	7400	7409	O
can	7410	7413	O
be	7414	7416	O
reconstructed	7417	7430	O
.	7430	7431	O

With	7432	7436	O
a	7437	7438	O
point	7439	7444	O
detector	7445	7453	O
at	7454	7456	O
the	7457	7460	O
center	7461	7467	O
of	7468	7470	O
a	7471	7472	O
conjugate	7473	7482	O
pupil	7483	7488	O
plane	7489	7494	O
,	7494	7495	O
the	7496	7499	O
resulting	7500	7509	O
data	7510	7514	O
is	7515	7517	O
a	7518	7519	O
convolution	7520	7531	O
of	7532	7534	O
the	7535	7538	O
object	7539	7545	O
'	7545	7546	O
s	7546	7547	O
complex	7548	7555	O
amplitude	7556	7565	O
distribution	7566	7578	O
with	7579	7583	O
the	7584	7587	O
same	7588	7592	O
complex	7593	7600	O
PSF	7601	7604	O
.	7604	7605	O

The	7606	7609	O
reconstruction	7610	7624	O
of	7625	7627	O
this	7628	7632	O
hologram	7633	7641	O
gives	7642	7647	O
the	7648	7651	O
three	7652	7657	O
-	7657	7658	O
dimensional	7658	7669	O
distribution	7670	7682	O
of	7683	7685	O
the	7686	7689	O
specimen	7690	7698	O
'	7698	7699	O
s	7699	7700	O
complex	7701	7708	O
amplitude	7709	7718	O
transmittance	7719	7732	O
.	7732	7733	O

In	7734	7736	O
particular	7737	7747	O
,	7747	7748	O
assuming	7749	7757	O
that	7758	7762	O
multiple	7763	7771	O
scattering	7772	7782	O
can	7783	7786	O
be	7787	7789	O
ignored	7790	7797	O
,	7797	7798	O
the	7799	7802	O
phase	7803	7808	O
of	7809	7811	O
the	7812	7815	O
reconstruction	7816	7830	O
is	7831	7833	O
a	7834	7835	O
quantitative	7836	7848	O
measure	7849	7856	O
of	7857	7859	O
the	7860	7863	O
integrated	7864	7874	O
optical	7875	7882	O
path	7883	7887	O
length	7888	7894	O
through	7895	7902	O
the	7903	7906	O
specimen	7907	7915	O
.	7915	7916	O

These	7917	7922	O
two	7923	7926	O
modes	7927	7932	O
of	7933	7935	O
operation	7936	7945	O
are	7946	7949	O
similar	7950	7957	O
to	7958	7960	O
the	7961	7964	O
usual	7965	7970	O
coherent	7971	7979	O
/	7979	7980	O
incoherent	7980	7990	O
imaging	7991	7998	O
modes	7999	8004	O
of	8005	8007	O
a	8008	8009	O
conventional	8010	8022	O
system	8023	8029	O
,	8029	8030	O
which	8031	8036	O
are	8037	8040	O
obtained	8041	8049	O
by	8050	8052	O
using	8053	8058	O
,	8058	8059	O
respectively	8060	8072	O
,	8072	8073	O
a	8074	8075	O
point	8076	8081	O
source	8082	8088	O
,	8088	8089	O
or	8090	8092	O
a	8093	8094	O
large	8095	8100	O
spatially	8101	8110	O
incoherent	8111	8121	O
source	8122	8128	O
.	8128	8129	O

In	8130	8132	O
scanning	8133	8141	O
holography	8142	8152	O
,	8152	8153	O
the	8154	8157	O
detector	8158	8166	O
size	8167	8171	O
plays	8172	8177	O
a	8178	8179	O
similar	8180	8187	O
role	8188	8192	O
to	8193	8195	O
that	8196	8200	O
of	8201	8203	O
the	8204	8207	O
source	8208	8214	O
size	8215	8219	O
in	8220	8222	O
conventional	8223	8235	O
imaging	8236	8243	O
.	8243	8244	O

For	8245	8248	O
simplicity	8249	8259	O
,	8259	8260	O
let	8261	8264	O
'	8264	8265	O
s	8265	8266	O
assume	8267	8273	O
an	8274	8276	O
object	8277	8283	O
with	8284	8288	O
an	8289	8291	O
amplitude	8292	8301	O
transmittance	8302	8315	O
T	8316	8317	O
(	8317	8318	O
r	8318	8319	O
-	8319	8320	O
-	8320	8321	O
>	8321	8322	O
MathType	8323	8331	O
@	8331	8332	O
MTEF	8332	8336	O
@	8336	8337	O
5	8337	8338	O
@	8338	8339	O
5	8339	8340	O
@	8340	8341	O
+	8341	8342	O
=	8342	8343	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	8343	8428	O
=	8428	8429	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	8429	8460	O
=	8460	8461	O
OqFfea0dXdd9vqai	8461	8477	O
=	8477	8478	O
hGuQ8kuc9pgc9s8qqaq	8478	8497	O
=	8497	8498	O
dirpe0xb9q8qiLsFr0	8498	8516	O
=	8516	8517	O
vr0	8517	8520	O
=	8520	8521	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	8521	8579	O
@	8579	8580	O
2E2B	8580	8584	O
@	8584	8585	O
,	8585	8586	O
z	8587	8588	O
)	8588	8589	O
.	8589	8590	O

Note	8591	8595	O
that	8596	8600	O
for	8601	8604	O
an	8605	8607	O
incoherent	8608	8618	O
or	8619	8621	O
fluorescent	8622	8633	O
object	8634	8640	O
,	8640	8641	O
the	8642	8645	O
phase	8646	8651	O
of	8652	8654	O
the	8655	8658	O
transmitted	8659	8670	O
field	8671	8676	O
is	8677	8679	O
a	8680	8681	O
random	8682	8688	O
variable	8689	8697	O
,	8697	8698	O
and	8699	8702	O
only	8703	8707	O
the	8708	8711	O
intensity	8712	8721	O
I	8722	8723	O
(	8723	8724	O
r	8724	8725	O
-	8725	8726	O
-	8726	8727	O
>	8727	8728	O
MathType	8729	8737	O
@	8737	8738	O
MTEF	8738	8742	O
@	8742	8743	O
5	8743	8744	O
@	8744	8745	O
5	8745	8746	O
@	8746	8747	O
+	8747	8748	O
=	8748	8749	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	8749	8834	O
=	8834	8835	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	8835	8866	O
=	8866	8867	O
OqFfea0dXdd9vqai	8867	8883	O
=	8883	8884	O
hGuQ8kuc9pgc9s8qqaq	8884	8903	O
=	8903	8904	O
dirpe0xb9q8qiLsFr0	8904	8922	O
=	8922	8923	O
vr0	8923	8926	O
=	8926	8927	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	8927	8985	O
@	8985	8986	O
2E2B	8986	8990	O
@	8990	8991	O
,	8991	8992	O
z	8993	8994	O
)	8994	8995	O
=	8996	8997	O
|	8998	8999	O
T	8999	9000	O
(	9000	9001	O
r	9001	9002	O
-	9002	9003	O
-	9003	9004	O
>	9004	9005	O
MathType	9006	9014	O
@	9014	9015	O
MTEF	9015	9019	O
@	9019	9020	O
5	9020	9021	O
@	9021	9022	O
5	9022	9023	O
@	9023	9024	O
+	9024	9025	O
=	9025	9026	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	9026	9111	O
=	9111	9112	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	9112	9143	O
=	9143	9144	O
OqFfea0dXdd9vqai	9144	9160	O
=	9160	9161	O
hGuQ8kuc9pgc9s8qqaq	9161	9180	O
=	9180	9181	O
dirpe0xb9q8qiLsFr0	9181	9199	O
=	9199	9200	O
vr0	9200	9203	O
=	9203	9204	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	9204	9262	O
@	9262	9263	O
2E2B	9263	9267	O
@	9267	9268	O
,	9268	9269	O
z	9270	9271	O
)	9271	9272	O
|	9272	9273	O
2	9273	9274	O
is	9275	9277	O
measurable	9278	9288	O
.	9288	9289	O

For	9290	9293	O
a	9294	9295	O
quasi	9296	9301	O
transparent	9302	9313	O
object	9314	9320	O
,	9320	9321	O
the	9322	9325	O
phase	9326	9331	O
is	9332	9334	O
equal	9335	9340	O
to	9341	9343	O
the	9344	9347	O
integrated	9348	9358	O
optical	9359	9366	O
thickness	9367	9376	O
of	9377	9379	O
the	9380	9383	O
object	9384	9390	O
:	9390	9391	O
Phi	9392	9395	O
(	9395	9396	O
r	9396	9397	O
-	9397	9398	O
-	9398	9399	O
>	9399	9400	O
MathType	9401	9409	O
@	9409	9410	O
MTEF	9410	9414	O
@	9414	9415	O
5	9415	9416	O
@	9416	9417	O
5	9417	9418	O
@	9418	9419	O
+	9419	9420	O
=	9420	9421	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	9421	9506	O
=	9506	9507	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	9507	9538	O
=	9538	9539	O
OqFfea0dXdd9vqai	9539	9555	O
=	9555	9556	O
hGuQ8kuc9pgc9s8qqaq	9556	9575	O
=	9575	9576	O
dirpe0xb9q8qiLsFr0	9576	9594	O
=	9594	9595	O
vr0	9595	9598	O
=	9598	9599	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	9599	9657	O
@	9657	9658	O
2E2B	9658	9662	O
@	9662	9663	O
)	9663	9664	O
=	9665	9666	O
(	9667	9668	O
2pi	9668	9671	O
/	9671	9672	O
lambda	9672	9678	O
)	9678	9679	O
integraldzn	9679	9690	O
(	9690	9691	O
r	9691	9692	O
-	9692	9693	O
-	9693	9694	O
>	9694	9695	O
MathType	9696	9704	O
@	9704	9705	O
MTEF	9705	9709	O
@	9709	9710	O
5	9710	9711	O
@	9711	9712	O
5	9712	9713	O
@	9713	9714	O
+	9714	9715	O
=	9715	9716	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	9716	9801	O
=	9801	9802	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	9802	9833	O
=	9833	9834	O
OqFfea0dXdd9vqai	9834	9850	O
=	9850	9851	O
hGuQ8kuc9pgc9s8qqaq	9851	9870	O
=	9870	9871	O
dirpe0xb9q8qiLsFr0	9871	9889	O
=	9889	9890	O
vr0	9890	9893	O
=	9893	9894	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	9894	9952	O
@	9952	9953	O
2E2B	9953	9957	O
@	9957	9958	O
,	9958	9959	O
z	9960	9961	O
)	9961	9962	O
,	9962	9963	O
where	9964	9969	O
n	9970	9971	O
(	9971	9972	O
r	9972	9973	O
-	9973	9974	O
-	9974	9975	O
>	9975	9976	O
MathType	9977	9985	O
@	9985	9986	O
MTEF	9986	9990	O
@	9990	9991	O
5	9991	9992	O
@	9992	9993	O
5	9993	9994	O
@	9994	9995	O
+	9995	9996	O
=	9996	9997	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	9997	10082	O
=	10082	10083	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	10083	10114	O
=	10114	10115	O
OqFfea0dXdd9vqai	10115	10131	O
=	10131	10132	O
hGuQ8kuc9pgc9s8qqaq	10132	10151	O
=	10151	10152	O
dirpe0xb9q8qiLsFr0	10152	10170	O
=	10170	10171	O
vr0	10171	10174	O
=	10174	10175	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	10175	10233	O
@	10233	10234	O
2E2B	10234	10238	O
@	10238	10239	O
,	10239	10240	O
z	10241	10242	O
)	10242	10243	O
is	10244	10246	O
the	10247	10250	O
3D	10251	10253	O
distribution	10254	10266	O
of	10267	10269	O
refractive	10270	10280	O
index	10281	10286	O
.	10286	10287	O

The	10288	10291	O
amplitude	10292	10301	O
distribution	10302	10314	O
after	10315	10320	O
the	10321	10324	O
object	10325	10331	O
is	10332	10334	O
written	10335	10342	O
as	10343	10345	O

A	10346	10347	O
(	10347	10348	O
r	10348	10349	O
-	10349	10350	O
-	10350	10351	O
>	10351	10352	O
MathType	10353	10361	O
@	10361	10362	O
MTEF	10362	10366	O
@	10366	10367	O
5	10367	10368	O
@	10368	10369	O
5	10369	10370	O
@	10370	10371	O
+	10371	10372	O
=	10372	10373	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	10373	10458	O
=	10458	10459	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	10459	10490	O
=	10490	10491	O
OqFfea0dXdd9vqai	10491	10507	O
=	10507	10508	O
hGuQ8kuc9pgc9s8qqaq	10508	10527	O
=	10527	10528	O
dirpe0xb9q8qiLsFr0	10528	10546	O
=	10546	10547	O
vr0	10547	10550	O
=	10550	10551	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	10551	10609	O
@	10609	10610	O
2E2B	10610	10614	O
@	10614	10615	O
,	10615	10616	O
t	10617	10618	O
)	10618	10619	O
=	10620	10621	O
integraldzS	10622	10633	O
(	10633	10634	O
r	10634	10635	O
-	10635	10636	O
-	10636	10637	O
>	10637	10638	O
MathType	10639	10647	O
@	10647	10648	O
MTEF	10648	10652	O
@	10652	10653	O
5	10653	10654	O
@	10654	10655	O
5	10655	10656	O
@	10656	10657	O
+	10657	10658	O
=	10658	10659	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	10659	10744	O
=	10744	10745	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	10745	10776	O
=	10776	10777	O
OqFfea0dXdd9vqai	10777	10793	O
=	10793	10794	O
hGuQ8kuc9pgc9s8qqaq	10794	10813	O
=	10813	10814	O
dirpe0xb9q8qiLsFr0	10814	10832	O
=	10832	10833	O
vr0	10833	10836	O
=	10836	10837	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	10837	10895	O
@	10895	10896	O
2E2B	10896	10900	O
@	10900	10901	O
,	10901	10902	O
z	10903	10904	O
)	10904	10905	O
T	10905	10906	O
[	10906	10907	O
r	10907	10908	O
-	10908	10909	O
-	10909	10910	O
>	10910	10911	O
MathType	10912	10920	O
@	10920	10921	O
MTEF	10921	10925	O
@	10925	10926	O
5	10926	10927	O
@	10927	10928	O
5	10928	10929	O
@	10929	10930	O
+	10930	10931	O
=	10931	10932	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	10932	11017	O
=	11017	11018	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	11018	11049	O
=	11049	11050	O
OqFfea0dXdd9vqai	11050	11066	O
=	11066	11067	O
hGuQ8kuc9pgc9s8qqaq	11067	11086	O
=	11086	11087	O
dirpe0xb9q8qiLsFr0	11087	11105	O
=	11105	11106	O
vr0	11106	11109	O
=	11109	11110	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	11110	11168	O
@	11168	11169	O
2E2B	11169	11173	O
@	11173	11174	O
-	11174	11175	O
r	11175	11176	O
-	11176	11177	O
-	11177	11178	O
>	11178	11179	O
MathType	11180	11188	O
@	11188	11189	O
MTEF	11189	11193	O
@	11193	11194	O
5	11194	11195	O
@	11195	11196	O
5	11196	11197	O
@	11197	11198	O
+	11198	11199	O
=	11199	11200	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	11200	11285	O
=	11285	11286	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	11286	11317	O
=	11317	11318	O
OqFfea0dXdd9vqai	11318	11334	O
=	11334	11335	O
hGuQ8kuc9pgc9s8qqaq	11335	11354	O
=	11354	11355	O
dirpe0xb9q8qiLsFr0	11355	11373	O
=	11373	11374	O
vr0	11374	11377	O
=	11377	11378	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	11378	11436	O
@	11436	11437	O
2E2B	11437	11441	O
@	11441	11442	O
S	11442	11443	O
(	11443	11444	O
t	11444	11445	O
)	11445	11446	O
,	11446	11447	O
z	11448	11449	O
]	11449	11450	O
,	11450	11451	O
(	11452	11453	O
3	11453	11454	O
)	11454	11455	O

where	11456	11461	O
r	11462	11463	O
-	11463	11464	O
-	11464	11465	O
>	11465	11466	O
MathType	11467	11475	O
@	11475	11476	O
MTEF	11476	11480	O
@	11480	11481	O
5	11481	11482	O
@	11482	11483	O
5	11483	11484	O
@	11484	11485	O
+	11485	11486	O
=	11486	11487	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	11487	11572	O
=	11572	11573	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	11573	11604	O
=	11604	11605	O
OqFfea0dXdd9vqai	11605	11621	O
=	11621	11622	O
hGuQ8kuc9pgc9s8qqaq	11622	11641	O
=	11641	11642	O
dirpe0xb9q8qiLsFr0	11642	11660	O
=	11660	11661	O
vr0	11661	11664	O
=	11664	11665	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	11665	11723	O
@	11723	11724	O
2E2B	11724	11728	O
@	11728	11729	O
S	11729	11730	O
(	11730	11731	O
t	11731	11732	O
)	11732	11733	O
is	11734	11736	O
the	11737	11740	O
instantaneous	11741	11754	O
position	11755	11763	O
of	11764	11766	O
the	11767	11770	O
2D	11771	11773	O
raster	11774	11780	O
scan	11781	11785	O
.	11785	11786	O

The	11787	11790	O
incoherent	11791	11801	O
imaging	11802	11809	O
mode	11810	11814	O
is	11815	11817	O
obtained	11818	11826	O
with	11827	11831	O
a	11832	11833	O
spatially	11834	11843	O
integrating	11844	11855	O
detector	11856	11864	O
,	11864	11865	O
leading	11866	11873	O
to	11874	11876	O
a	11877	11878	O
temporal	11879	11887	O
signal	11888	11894	O
proportional	11895	11907	O
to	11908	11910	O
the	11911	11914	O
integrated	11915	11925	O
intensity	11926	11935	O
,	11935	11936	O
integrald2r	11937	11948	O
|	11948	11949	O
A	11949	11950	O
(	11950	11951	O
r	11951	11952	O
-	11952	11953	O
-	11953	11954	O
>	11954	11955	O
MathType	11956	11964	O
@	11964	11965	O
MTEF	11965	11969	O
@	11969	11970	O
5	11970	11971	O
@	11971	11972	O
5	11972	11973	O
@	11973	11974	O
+	11974	11975	O
=	11975	11976	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	11976	12061	O
=	12061	12062	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	12062	12093	O
=	12093	12094	O
OqFfea0dXdd9vqai	12094	12110	O
=	12110	12111	O
hGuQ8kuc9pgc9s8qqaq	12111	12130	O
=	12130	12131	O
dirpe0xb9q8qiLsFr0	12131	12149	O
=	12149	12150	O
vr0	12150	12153	O
=	12153	12154	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	12154	12212	O
@	12212	12213	O
2E2B	12213	12217	O
@	12217	12218	O
,	12218	12219	O
t	12220	12221	O
)	12221	12222	O
|	12222	12223	O
2	12223	12224	O
,	12224	12225	O
which	12226	12231	O
is	12232	12234	O
stored	12235	12241	O
in	12242	12244	O
the	12245	12248	O
computer	12249	12257	O
.	12257	12258	O

The	12259	12262	O
data	12263	12267	O
corresponding	12268	12281	O
to	12282	12284	O
each	12285	12289	O
hologram	12290	12298	O
line	12299	12303	O
is	12304	12306	O
cut	12307	12310	O
from	12311	12315	O
the	12316	12319	O
signal	12320	12326	O
,	12326	12327	O
and	12328	12331	O
band	12332	12336	O
pass	12337	12341	O
filtered	12342	12350	O
to	12351	12353	O
extract	12354	12361	O
the	12362	12365	O
term	12366	12370	O
oscillating	12371	12382	O
at	12383	12385	O
Omega	12386	12391	O
.	12391	12392	O

The	12393	12396	O
lines	12397	12402	O
are	12403	12406	O
then	12407	12411	O
rearranged	12412	12422	O
in	12423	12425	O
a	12426	12427	O
2D	12428	12430	O
format	12431	12437	O
.	12437	12438	O

The	12439	12442	O
resulting	12443	12452	O
hologram	12453	12461	O
amplitude	12462	12471	O
is	12472	12474	O
found	12475	12480	O
to	12481	12483	O
be	12484	12486	O

HI	12487	12489	O
(	12489	12490	O
r	12490	12491	O
-	12491	12492	O
-	12492	12493	O
>	12493	12494	O
MathType	12495	12503	O
@	12503	12504	O
MTEF	12504	12508	O
@	12508	12509	O
5	12509	12510	O
@	12510	12511	O
5	12511	12512	O
@	12512	12513	O
+	12513	12514	O
=	12514	12515	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	12515	12600	O
=	12600	12601	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	12601	12632	O
=	12632	12633	O
OqFfea0dXdd9vqai	12633	12649	O
=	12649	12650	O
hGuQ8kuc9pgc9s8qqaq	12650	12669	O
=	12669	12670	O
dirpe0xb9q8qiLsFr0	12670	12688	O
=	12688	12689	O
vr0	12689	12692	O
=	12692	12693	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	12693	12751	O
@	12751	12752	O
2E2B	12752	12756	O
@	12756	12757	O
)	12757	12758	O
=	12759	12760	O
integraldzI	12761	12772	O
(	12772	12773	O
r	12773	12774	O
-	12774	12775	O
-	12775	12776	O
>	12776	12777	O
MathType	12778	12786	O
@	12786	12787	O
MTEF	12787	12791	O
@	12791	12792	O
5	12792	12793	O
@	12793	12794	O
5	12794	12795	O
@	12795	12796	O
+	12796	12797	O
=	12797	12798	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	12798	12883	O
=	12883	12884	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	12884	12915	O
=	12915	12916	O
OqFfea0dXdd9vqai	12916	12932	O
=	12932	12933	O
hGuQ8kuc9pgc9s8qqaq	12933	12952	O
=	12952	12953	O
dirpe0xb9q8qiLsFr0	12953	12971	O
=	12971	12972	O
vr0	12972	12975	O
=	12975	12976	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	12976	13034	O
@	13034	13035	O
2E2B	13035	13039	O
@	13039	13040	O
,	13040	13041	O
z	13042	13043	O
)	13043	13044	O
(	13045	13046	O
+	13046	13047	O
)	13047	13048	O
[	13049	13050	O
p1	13050	13052	O
(	13052	13053	O
r	13053	13054	O
-	13054	13055	O
-	13055	13056	O
>	13056	13057	O
MathType	13058	13066	O
@	13066	13067	O
MTEF	13067	13071	O
@	13071	13072	O
5	13072	13073	O
@	13073	13074	O
5	13074	13075	O
@	13075	13076	O
+	13076	13077	O
=	13077	13078	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	13078	13163	O
=	13163	13164	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	13164	13195	O
=	13195	13196	O
OqFfea0dXdd9vqai	13196	13212	O
=	13212	13213	O
hGuQ8kuc9pgc9s8qqaq	13213	13232	O
=	13232	13233	O
dirpe0xb9q8qiLsFr0	13233	13251	O
=	13251	13252	O
vr0	13252	13255	O
=	13255	13256	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	13256	13314	O
@	13314	13315	O
2E2B	13315	13319	O
@	13319	13320	O
,	13320	13321	O
z	13322	13323	O
)	13323	13324	O
p	13324	13325	O
*	13325	13326	O
2	13326	13327	O
(	13327	13328	O
r	13328	13329	O
-	13329	13330	O
-	13330	13331	O
>	13331	13332	O
MathType	13333	13341	O
@	13341	13342	O
MTEF	13342	13346	O
@	13346	13347	O
5	13347	13348	O
@	13348	13349	O
5	13349	13350	O
@	13350	13351	O
+	13351	13352	O
=	13352	13353	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	13353	13438	O
=	13438	13439	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	13439	13470	O
=	13470	13471	O
OqFfea0dXdd9vqai	13471	13487	O
=	13487	13488	O
hGuQ8kuc9pgc9s8qqaq	13488	13507	O
=	13507	13508	O
dirpe0xb9q8qiLsFr0	13508	13526	O
=	13526	13527	O
vr0	13527	13530	O
=	13530	13531	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	13531	13589	O
@	13589	13590	O
2E2B	13590	13594	O
@	13594	13595	O
,	13595	13596	O
z	13597	13598	O
)	13598	13599	O
]	13599	13600	O
,	13600	13601	O
(	13602	13603	O
4	13603	13604	O
)	13604	13605	O

where	13606	13611	O
(	13612	13613	O
+	13613	13614	O
)	13614	13615	O
symbolizes	13616	13626	O
a	13627	13628	O
convolution	13629	13640	O
integral	13641	13649	O
,	13649	13650	O
I	13651	13652	O
(	13652	13653	O
r	13653	13654	O
-	13654	13655	O
-	13655	13656	O
>	13656	13657	O
MathType	13658	13666	O
@	13666	13667	O
MTEF	13667	13671	O
@	13671	13672	O
5	13672	13673	O
@	13673	13674	O
5	13674	13675	O
@	13675	13676	O
+	13676	13677	O
=	13677	13678	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	13678	13763	O
=	13763	13764	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	13764	13795	O
=	13795	13796	O
OqFfea0dXdd9vqai	13796	13812	O
=	13812	13813	O
hGuQ8kuc9pgc9s8qqaq	13813	13832	O
=	13832	13833	O
dirpe0xb9q8qiLsFr0	13833	13851	O
=	13851	13852	O
vr0	13852	13855	O
=	13855	13856	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	13856	13914	O
@	13914	13915	O
2E2B	13915	13919	O
@	13919	13920	O
,	13920	13921	O
z	13922	13923	O
)	13923	13924	O
=	13925	13926	O
|	13927	13928	O
T	13928	13929	O
(	13929	13930	O
r	13930	13931	O
-	13931	13932	O
-	13932	13933	O
>	13933	13934	O
MathType	13935	13943	O
@	13943	13944	O
MTEF	13944	13948	O
@	13948	13949	O
5	13949	13950	O
@	13950	13951	O
5	13951	13952	O
@	13952	13953	O
+	13953	13954	O
=	13954	13955	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	13955	14040	O
=	14040	14041	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	14041	14072	O
=	14072	14073	O
OqFfea0dXdd9vqai	14073	14089	O
=	14089	14090	O
hGuQ8kuc9pgc9s8qqaq	14090	14109	O
=	14109	14110	O
dirpe0xb9q8qiLsFr0	14110	14128	O
=	14128	14129	O
vr0	14129	14132	O
=	14132	14133	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	14133	14191	O
@	14191	14192	O
2E2B	14192	14196	O
@	14196	14197	O
,	14197	14198	O
z	14199	14200	O
)	14200	14201	O
|	14201	14202	O
2	14202	14203	O
,	14203	14204	O
and	14205	14208	O
p1	14209	14211	O
,	14211	14212	O
2	14212	14213	O
(	14213	14214	O
r	14214	14215	O
-	14215	14216	O
-	14216	14217	O
>	14217	14218	O
MathType	14219	14227	O
@	14227	14228	O
MTEF	14228	14232	O
@	14232	14233	O
5	14233	14234	O
@	14234	14235	O
5	14235	14236	O
@	14236	14237	O
+	14237	14238	O
=	14238	14239	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	14239	14324	O
=	14324	14325	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	14325	14356	O
=	14356	14357	O
OqFfea0dXdd9vqai	14357	14373	O
=	14373	14374	O
hGuQ8kuc9pgc9s8qqaq	14374	14393	O
=	14393	14394	O
dirpe0xb9q8qiLsFr0	14394	14412	O
=	14412	14413	O
vr0	14413	14416	O
=	14416	14417	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	14417	14475	O
@	14475	14476	O
2E2B	14476	14480	O
@	14480	14481	O
,	14481	14482	O
z	14483	14484	O
)	14484	14485	O
are	14486	14489	O
the	14490	14493	O
inverse	14494	14501	O
Fourier	14502	14509	O
transforms	14510	14520	O
of	14521	14523	O
the	14524	14527	O
defocused	14528	14537	O
pupil	14538	14543	O
distributions	14544	14557	O
(	14558	14559	O
eq	14559	14561	O
.	14561	14562	O
1b	14562	14564	O
)	14564	14565	O
.	14565	14566	O

The	14567	14570	O
superscript	14571	14582	O
*	14583	14584	O
stands	14585	14591	O
for	14592	14595	O
complex	14596	14603	O
conjugate	14604	14613	O
.	14613	14614	O

The	14615	14618	O
hologram	14619	14627	O
is	14628	14630	O
thus	14631	14635	O
the	14636	14639	O
convolution	14640	14651	O
of	14652	14654	O
the	14655	14658	O
object	14659	14665	O
intensity	14666	14675	O
with	14676	14680	O
a	14681	14682	O
spherical	14683	14692	O
wave	14693	14697	O
,	14697	14698	O
i	14699	14700	O
.	14700	14701	O
e	14701	14702	O
.	14702	14703	O
an	14704	14706	O
in	14707	14709	O
-	14709	14710	O
line	14710	14714	O
single	14715	14721	O
-	14721	14722	O
sideband	14722	14730	O
Gabor	14731	14736	O
hologram	14737	14745	O
.	14745	14746	O

In	14747	14749	O
Fourier	14750	14757	O
space	14758	14763	O
,	14763	14764	O
the	14765	14768	O
hologram	14769	14777	O
can	14778	14781	O
be	14782	14784	O
written	14785	14792	O
as	14793	14795	O

H	14796	14797	O
~	14797	14798	O
I	14798	14799	O
(	14799	14800	O
rho	14800	14803	O
-	14803	14804	O
-	14804	14805	O
>	14805	14806	O
)	14806	14807	O
=	14807	14808	O
integraldzI	14808	14819	O
~	14819	14820	O
(	14820	14821	O
rho	14821	14824	O
-	14824	14825	O
-	14825	14826	O
>	14826	14827	O
;	14827	14828	O
z	14828	14829	O
)	14829	14830	O
[	14830	14831	O
P	14831	14832	O
~	14832	14833	O
1	14833	14834	O
(	14834	14835	O
rho	14835	14838	O
-	14838	14839	O
-	14839	14840	O
>	14840	14841	O
;	14841	14842	O
z	14842	14843	O
)	14843	14844	O
(	14844	14845	O
*	14845	14846	O
)	14846	14847	O
P	14847	14848	O
~	14848	14849	O
2	14849	14850	O
(	14850	14851	O
rho	14851	14854	O
-	14854	14855	O
-	14855	14856	O
>	14856	14857	O
;	14857	14858	O
z	14858	14859	O
)	14859	14860	O
]	14860	14861	O
,	14861	14862	O
(	14863	14864	O
5	14864	14865	O
)	14865	14866	O
MathType	14867	14875	O
@	14875	14876	O
MTEF	14876	14880	O
@	14880	14881	O
5	14881	14882	O
@	14882	14883	O
5	14883	14884	O
@	14884	14885	O
+	14885	14886	O
=	14886	14887	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	14887	14972	O
=	14972	14973	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	14973	15004	O
=	15004	15005	O
OqFfea0dXdd9vqai	15005	15021	O
=	15021	15022	O
hGuQ8kuc9pgc9s8qqaq	15022	15041	O
=	15041	15042	O
dirpe0xb9q8qiLsFr0	15042	15060	O
=	15060	15061	O
vr0	15061	15064	O
=	15064	15065	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkdaWadaqaaiqbdcfaqzaaiaWaaSbaaSqaaiabigdaXaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPiabgEPielqbdcfaqzaaiaWaaSbaaSqaaiabikdaYaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPaGaay5waiaaw2faaiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI1aqnaiaawIcacaGLPaaaaaa	15065	15550	O
@	15550	15551	O
58FF	15551	15555	O
@	15555	15556	O

where	15557	15562	O
(	15563	15564	O
+	15564	15565	O
)	15565	15566	O
symbolizes	15567	15577	O
a	15578	15579	O
correlation	15580	15591	O
integral	15592	15600	O
.	15600	15601	O

With	15602	15606	O
the	15607	15610	O
pupils	15611	15617	O
of	15618	15620	O
eq	15621	15623	O
.	15623	15624	O
2	15624	15625	O
,	15625	15626	O
we	15627	15629	O
find	15630	15634	O
,	15634	15635	O
in	15636	15638	O
the	15639	15642	O
paraxial	15643	15651	O
approximation	15652	15665	O
,	15665	15666	O

H	15667	15668	O
~	15668	15669	O
I	15669	15670	O
(	15670	15671	O
rho	15671	15674	O
-	15674	15675	O
-	15675	15676	O
>	15676	15677	O
)	15677	15678	O
=	15678	15679	O
integraldzI	15679	15690	O
~	15690	15691	O
(	15691	15692	O
rho	15692	15695	O
-	15695	15696	O
-	15696	15697	O
>	15697	15698	O
;	15698	15699	O
z	15699	15700	O
)	15700	15701	O
exp	15701	15704	O
[	15705	15706	O
ipilambda	15706	15715	O
(	15715	15716	O
z0	15716	15718	O
+	15718	15719	O
z	15719	15720	O
)	15720	15721	O
rho2	15721	15725	O
]	15725	15726	O
circ	15726	15730	O
(	15730	15731	O
rho	15731	15734	O
/	15734	15735	O
rhoMAX	15735	15741	O
)	15741	15742	O
,	15742	15743	O
(	15744	15745	O
6	15745	15746	O
)	15746	15747	O
MathType	15748	15756	O
@	15756	15757	O
MTEF	15757	15761	O
@	15761	15762	O
5	15762	15763	O
@	15763	15764	O
5	15764	15765	O
@	15765	15766	O
+	15766	15767	O
=	15767	15768	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	15768	15853	O
=	15853	15854	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	15854	15885	O
=	15885	15886	O
OqFfea0dXdd9vqai	15886	15902	O
=	15902	15903	O
hGuQ8kuc9pgc9s8qqaq	15903	15922	O
=	15922	15923	O
dirpe0xb9q8qiLsFr0	15923	15941	O
=	15941	15942	O
vr0	15942	15945	O
=	15945	15946	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCdaWadaqaaiabdMgaPjab	15946	16216	O
=	16216	16217	O
b8aWjab	16217	16224	O
=	16224	16225	O
T7aSjabcIcaOiabdQha6naaBaaaleaacqaIWaamaeqaaOGaey4kaSIaemOEaONaeiykaKIae8xWdi3aaWbaaSqabeaacqaIYaGmaaaakiaawUfacaGLDbaacqWGJbWycqWGPbqAcqWGYbGCcqWGJbWycqGGOaakcqWFbpGCcqGGVaWlcqWFbpGCdaWgaaWcbaGaemyta0KaemyqaeKaemiwaGfabeaakiabcMcaPiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI2aGnaiaawIcacaGLPaaaaaa	16225	16515	O
@	16515	16516	O
67E3	16516	16520	O
@	16520	16521	O

which	16522	16527	O
is	16528	16530	O
the	16531	16534	O
Fourier	16535	16542	O
transform	16543	16552	O
of	16553	16555	O
the	16556	16559	O
Fresnel	16560	16567	O
hologram	16568	16576	O
of	16577	16579	O
the	16580	16583	O
object	16584	16590	O
'	16590	16591	O
s	16591	16592	O
intensity	16593	16602	O
distribution	16603	16615	O
.	16615	16616	O

The	16617	16620	O
coherent	16621	16629	O
imaging	16630	16637	O
mode	16638	16642	O
is	16643	16645	O
obtained	16646	16654	O
by	16655	16657	O
using	16658	16663	O
a	16664	16665	O
pinhole	16666	16673	O
or	16674	16676	O
a	16677	16678	O
point	16679	16684	O
detector	16685	16693	O
at	16694	16696	O
the	16697	16700	O
center	16701	16707	O
of	16708	16710	O
a	16711	16712	O
conjugate	16713	16722	O
plane	16723	16728	O
of	16729	16731	O
the	16732	16735	O
pupil	16736	16741	O
of	16742	16744	O
the	16745	16748	O
objective	16749	16758	O
.	16758	16759	O

This	16760	16764	O
leads	16765	16770	O
to	16771	16773	O
the	16774	16777	O
hologram	16778	16786	O
amplitude	16787	16796	O

HC	16797	16799	O
(	16799	16800	O
r	16800	16801	O
-	16801	16802	O
-	16802	16803	O
>	16803	16804	O
MathType	16805	16813	O
@	16813	16814	O
MTEF	16814	16818	O
@	16818	16819	O
5	16819	16820	O
@	16820	16821	O
5	16821	16822	O
@	16822	16823	O
+	16823	16824	O
=	16824	16825	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	16825	16910	O
=	16910	16911	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	16911	16942	O
=	16942	16943	O
OqFfea0dXdd9vqai	16943	16959	O
=	16959	16960	O
hGuQ8kuc9pgc9s8qqaq	16960	16979	O
=	16979	16980	O
dirpe0xb9q8qiLsFr0	16980	16998	O
=	16998	16999	O
vr0	16999	17002	O
=	17002	17003	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	17003	17061	O
@	17061	17062	O
2E2B	17062	17066	O
@	17066	17067	O
)	17067	17068	O
=	17069	17070	O
integraldz	17071	17081	O
[	17081	17082	O
T	17082	17083	O
(	17083	17084	O
r	17084	17085	O
-	17085	17086	O
-	17086	17087	O
>	17087	17088	O
MathType	17089	17097	O
@	17097	17098	O
MTEF	17098	17102	O
@	17102	17103	O
5	17103	17104	O
@	17104	17105	O
5	17105	17106	O
@	17106	17107	O
+	17107	17108	O
=	17108	17109	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	17109	17194	O
=	17194	17195	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	17195	17226	O
=	17226	17227	O
OqFfea0dXdd9vqai	17227	17243	O
=	17243	17244	O
hGuQ8kuc9pgc9s8qqaq	17244	17263	O
=	17263	17264	O
dirpe0xb9q8qiLsFr0	17264	17282	O
=	17282	17283	O
vr0	17283	17286	O
=	17286	17287	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	17287	17345	O
@	17345	17346	O
2E2B	17346	17350	O
@	17350	17351	O
,	17351	17352	O
z	17353	17354	O
)	17354	17355	O
(	17356	17357	O
+	17357	17358	O
)	17358	17359	O
p1	17360	17362	O
(	17362	17363	O
r	17363	17364	O
-	17364	17365	O
-	17365	17366	O
>	17366	17367	O
MathType	17368	17376	O
@	17376	17377	O
MTEF	17377	17381	O
@	17381	17382	O
5	17382	17383	O
@	17383	17384	O
5	17384	17385	O
@	17385	17386	O
+	17386	17387	O
=	17387	17388	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	17388	17473	O
=	17473	17474	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	17474	17505	O
=	17505	17506	O
OqFfea0dXdd9vqai	17506	17522	O
=	17522	17523	O
hGuQ8kuc9pgc9s8qqaq	17523	17542	O
=	17542	17543	O
dirpe0xb9q8qiLsFr0	17543	17561	O
=	17561	17562	O
vr0	17562	17565	O
=	17565	17566	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	17566	17624	O
@	17624	17625	O
2E2B	17625	17629	O
@	17629	17630	O
,	17630	17631	O
z	17632	17633	O
)	17633	17634	O
]	17634	17635	O
[	17635	17636	O
T	17636	17637	O
(	17637	17638	O
r	17638	17639	O
-	17639	17640	O
-	17640	17641	O
>	17641	17642	O
MathType	17643	17651	O
@	17651	17652	O
MTEF	17652	17656	O
@	17656	17657	O
5	17657	17658	O
@	17658	17659	O
5	17659	17660	O
@	17660	17661	O
+	17661	17662	O
=	17662	17663	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	17663	17748	O
=	17748	17749	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	17749	17780	O
=	17780	17781	O
OqFfea0dXdd9vqai	17781	17797	O
=	17797	17798	O
hGuQ8kuc9pgc9s8qqaq	17798	17817	O
=	17817	17818	O
dirpe0xb9q8qiLsFr0	17818	17836	O
=	17836	17837	O
vr0	17837	17840	O
=	17840	17841	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	17841	17899	O
@	17899	17900	O
2E2B	17900	17904	O
@	17904	17905	O
,	17905	17906	O
z	17907	17908	O
)	17908	17909	O
(	17910	17911	O
+	17911	17912	O
)	17912	17913	O
p2	17914	17916	O
(	17916	17917	O
r	17917	17918	O
-	17918	17919	O
-	17919	17920	O
>	17920	17921	O
MathType	17922	17930	O
@	17930	17931	O
MTEF	17931	17935	O
@	17935	17936	O
5	17936	17937	O
@	17937	17938	O
5	17938	17939	O
@	17939	17940	O
+	17940	17941	O
=	17941	17942	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	17942	18027	O
=	18027	18028	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	18028	18059	O
=	18059	18060	O
OqFfea0dXdd9vqai	18060	18076	O
=	18076	18077	O
hGuQ8kuc9pgc9s8qqaq	18077	18096	O
=	18096	18097	O
dirpe0xb9q8qiLsFr0	18097	18115	O
=	18115	18116	O
vr0	18116	18119	O
=	18119	18120	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	18120	18178	O
@	18178	18179	O
2E2B	18179	18183	O
@	18183	18184	O
,	18184	18185	O
z	18186	18187	O
)	18187	18188	O
]	18188	18189	O
*	18189	18190	O
.	18190	18191	O

(	18192	18193	O
7	18193	18194	O
)	18194	18195	O

Where	18196	18201	O
again	18202	18207	O
,	18207	18208	O
(	18209	18210	O
+	18210	18211	O
)	18211	18212	O
symbolizes	18213	18223	O
a	18224	18225	O
convolution	18226	18237	O
product	18238	18245	O
,	18245	18246	O
and	18247	18250	O
the	18251	18254	O
superscript	18255	18266	O
*	18267	18268	O
stands	18269	18275	O
for	18276	18279	O
complex	18280	18287	O
conjugate	18288	18297	O
.	18297	18298	O

In	18299	18301	O
Fourier	18302	18309	O
space	18310	18315	O
,	18315	18316	O

H	18317	18318	O
~	18318	18319	O
C	18319	18320	O
(	18320	18321	O
rho	18321	18324	O
-	18324	18325	O
-	18325	18326	O
>	18326	18327	O
)	18327	18328	O
=	18328	18329	O
integraldzT	18329	18340	O
~	18340	18341	O
(	18341	18342	O
rho	18342	18345	O
-	18345	18346	O
-	18346	18347	O
>	18347	18348	O
;	18348	18349	O
z	18349	18350	O
)	18350	18351	O
P	18351	18352	O
~	18352	18353	O
1	18353	18354	O
(	18354	18355	O
rho	18355	18358	O
-	18358	18359	O
-	18359	18360	O
>	18360	18361	O
;	18361	18362	O
z	18362	18363	O
)	18363	18364	O
(	18364	18365	O
*	18365	18366	O
)	18366	18367	O
T	18367	18368	O
~	18368	18369	O
(	18369	18370	O
rho	18370	18373	O
-	18373	18374	O
-	18374	18375	O
>	18375	18376	O
;	18376	18377	O
z	18377	18378	O
)	18378	18379	O
P	18379	18380	O
~	18380	18381	O
2	18381	18382	O
(	18382	18383	O
rho	18383	18386	O
-	18386	18387	O
-	18387	18388	O
>	18388	18389	O
;	18389	18390	O
z	18390	18391	O
)	18391	18392	O
.	18392	18393	O

(	18394	18395	O
8	18395	18396	O
)	18396	18397	O
MathType	18398	18406	O
@	18406	18407	O
MTEF	18407	18411	O
@	18411	18412	O
5	18412	18413	O
@	18413	18414	O
5	18414	18415	O
@	18415	18416	O
+	18416	18417	O
=	18417	18418	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	18418	18503	O
=	18503	18504	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	18504	18535	O
=	18535	18536	O
OqFfea0dXdd9vqai	18536	18552	O
=	18552	18553	O
hGuQ8kuc9pgc9s8qqaq	18553	18572	O
=	18572	18573	O
dirpe0xb9q8qiLsFr0	18573	18591	O
=	18591	18592	O
vr0	18592	18595	O
=	18595	18596	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGdbWqaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdsfauzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGHxkcXcuWGubavgaacaiabcIcaOiqb	18596	18938	O
=	18938	18939	O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIafmiuaaLbaGaadaWgaaWcbaGaeGOmaidabeaakiabcIcaOiqb	18939	19022	O
=	19022	19023	O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiIda4aGaayjkaiaawMcaaaaa	19023	19114	O
@	19114	19115	O
5E5B	19115	19119	O
@	19119	19120	O

With	19121	19125	O
the	19126	19129	O
pupils	19130	19136	O
of	19137	19139	O
eq	19140	19142	O
.	19142	19143	O
2	19143	19144	O
,	19144	19145	O
we	19146	19148	O
find	19149	19153	O

H	19154	19155	O
~	19155	19156	O
C	19156	19157	O
(	19157	19158	O
rho	19158	19161	O
-	19161	19162	O
-	19162	19163	O
>	19163	19164	O
)	19164	19165	O
=	19165	19166	O
integraldzT	19166	19177	O
~	19177	19178	O
*	19178	19179	O
(	19179	19180	O
0	19180	19181	O
;	19181	19182	O
z	19182	19183	O
)	19183	19184	O
T	19184	19185	O
~	19185	19186	O
(	19186	19187	O
rho	19187	19190	O
-	19190	19191	O
-	19191	19192	O
>	19192	19193	O
;	19193	19194	O
z	19194	19195	O
)	19195	19196	O
exp	19196	19199	O
[	19200	19201	O
ipilambda	19201	19210	O
(	19210	19211	O
z0	19211	19213	O
+	19213	19214	O
z	19214	19215	O
)	19215	19216	O
rho2	19216	19220	O
]	19220	19221	O
circ	19221	19225	O
(	19225	19226	O
rho	19226	19229	O
/	19229	19230	O
rhoMAX	19230	19236	O
)	19236	19237	O
.	19237	19238	O

(	19239	19240	O
9	19240	19241	O
)	19241	19242	O
MathType	19243	19251	O
@	19251	19252	O
MTEF	19252	19256	O
@	19256	19257	O
5	19257	19258	O
@	19258	19259	O
5	19259	19260	O
@	19260	19261	O
+	19261	19262	O
=	19262	19263	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	19263	19348	O
=	19348	19349	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	19349	19380	O
=	19380	19381	O
OqFfea0dXdd9vqai	19381	19397	O
=	19397	19398	O
hGuQ8kuc9pgc9s8qqaq	19398	19417	O
=	19417	19418	O
dirpe0xb9q8qiLsFr0	19418	19436	O
=	19436	19437	O
vr0	19437	19440	O
=	19440	19441	O
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	19441	19943	O
=	19943	19944	O
f8aYjabc	19944	19952	O
+	19952	19953	O
caViab	19953	19959	O
=	19959	19960	O
f8aYnaaBaaaleaacqWGnbqtcqWGbbqqcqWGybawaeqaaOGaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiMda5aGaayjkaiaawMcaaaaa	19960	20071	O
@	20071	20072	O
6F41	20072	20076	O
@	20076	20077	O

Aside	20078	20083	O
from	20084	20088	O
an	20089	20091	O
inconsequential	20092	20107	O
complex	20108	20115	O
constant	20116	20124	O
(	20125	20126	O
the	20126	20129	O
first	20130	20135	O
term	20136	20140	O
under	20141	20146	O
the	20147	20150	O
integral	20151	20159	O
)	20159	20160	O
,	20160	20161	O
eq	20162	20164	O
.	20164	20165	O
9	20165	20166	O
is	20167	20169	O
the	20170	20173	O
Fourier	20174	20181	O
transform	20182	20191	O
of	20192	20194	O
the	20195	20198	O
Fresnel	20199	20206	O
hologram	20207	20215	O
of	20216	20218	O
the	20219	20222	O
object	20223	20229	O
'	20229	20230	O
s	20230	20231	O
complex	20232	20239	O
amplitude	20240	20249	O
distribution	20250	20262	O
.	20262	20263	O

Thus	20264	20268	O
,	20268	20269	O
the	20270	20273	O
reconstruction	20274	20288	O
of	20289	20291	O
the	20292	20295	O
hologram	20296	20304	O
recorded	20305	20313	O
in	20314	20316	O
the	20317	20320	O
coherent	20321	20329	O
mode	20330	20334	O
carries	20335	20342	O
a	20343	20344	O
quantitative	20345	20357	O
measure	20358	20365	O
of	20366	20368	O
the	20369	20372	O
object	20373	20379	O
'	20379	20380	O
s	20380	20381	O
phase	20382	20387	O
distribution	20388	20400	O
.	20400	20401	O

Results	0	7	O

Here	8	12	O
we	13	15	O
include	16	23	O
data	24	28	O
obtained	29	37	O
from	38	42	O
active	43	49	O
,	49	50	O
oscillatory	51	62	O
brain	63	68	B-Multi-tissue_structure
slices	69	75	I-Multi-tissue_structure
as	76	78	O
well	79	83	O
as	84	86	O
from	87	91	O
recordings	92	102	O
during	103	109	O
cortical	110	118	B-Multi-tissue_structure
slow	119	123	O
oscillations	124	136	O
in	137	139	O
anesthetized	140	152	O
animals	153	160	O
.	160	161	O

All	162	165	O
recordings	166	176	O
included	177	185	O
in	186	188	O
this	189	193	O
study	194	199	O
were	200	204	O
obtained	205	213	O
from	214	218	O
the	219	222	O
visual	223	229	B-Multi-tissue_structure
cortex	230	236	I-Multi-tissue_structure
of	237	239	O
the	240	243	O
ferret	244	250	O
(	251	252	O
in	252	254	O
vitro	255	260	O
)	260	261	O
,	261	262	O
cat	263	266	O
(	267	268	O
in	268	270	O
vivo	271	275	O
)	275	276	O
and	277	280	O
from	281	285	O
barrel	286	292	B-Multi-tissue_structure
cortex	293	299	I-Multi-tissue_structure
of	300	302	O
the	303	306	O
rat	307	310	O
(	311	312	O
in	312	314	O
vivo	315	319	O
)	319	320	O
.	320	321	O

Twenty	322	328	O
-	328	329	O
nine	329	333	O
neurons	334	341	B-Cell
recorded	342	350	O
from	351	355	O
ferret	356	362	O
cortical	363	371	B-Multi-tissue_structure
slices	372	378	I-Multi-tissue_structure
are	379	382	O
included	383	391	O
in	392	394	O
this	395	399	O
study	400	405	O
(	406	407	O
22	407	409	O
regular	410	417	O
spiking	418	425	O
(	426	427	O
RS	427	429	O
)	429	430	O
;	430	431	O
5	432	433	O
chattering	434	444	O
(	445	446	O
CH	446	448	O
)	448	449	O
and	450	453	O
2	454	455	O
intrinsic	456	465	O
bursting	466	474	O
(	475	476	O
IB	476	478	O
)	478	479	O
)	479	480	O
,	480	481	O
27	482	484	O
neurons	485	492	B-Cell
from	493	497	O
cat	498	501	O
visual	502	508	B-Multi-tissue_structure
cortex	509	515	I-Multi-tissue_structure
in	516	518	O
vivo	519	523	O
(	524	525	O
14	525	527	O
RS	528	530	O
;	530	531	O
5	532	533	O
CH	534	536	O
;	536	537	O
2	538	539	O
IB	540	542	O
;	542	543	O
3	544	545	O
fast	546	550	O
spiking	551	558	O
(	559	560	O
FS	560	562	O
)	562	563	O
;	563	564	O
plus	565	569	O
3	570	571	O
non	572	575	O
classified	576	586	O
)	586	587	O
and	588	591	O
14	592	594	O
neurons	595	602	B-Cell
from	603	607	O
rat	608	611	O
barrel	612	618	B-Multi-tissue_structure
cortex	619	625	I-Multi-tissue_structure
in	626	628	O
vivo	629	633	O
(	634	635	O
12	635	637	O
RS	638	640	O
;	640	641	O
1	642	643	O
CH	644	646	O
;	646	647	O
1	648	649	O
IB	650	652	O
)	652	653	O
.	653	654	O

Synaptic	655	663	B-Cellular_component
potentials	664	674	O
were	675	679	O
evoked	680	686	O
by	687	689	O
electric	690	698	O
shocks	699	705	O
(	706	707	O
intracortical	707	720	O
or	721	723	O
thalamocortical	724	739	O
connections	740	751	O
)	751	752	O
or	753	755	O
by	756	758	O
means	759	764	O
of	765	767	O
sensory	768	775	O
(	776	777	O
visual	777	783	O
or	784	786	O
whisker	787	794	O
)	794	795	O
stimulation	796	807	O
.	807	808	O

The	809	812	O
main	813	817	O
results	818	825	O
are	826	829	O
:	829	830	O
1	831	832	O
)	832	833	O
Synaptic	834	842	B-Cellular_component
potentials	843	853	O
show	854	858	O
more	859	863	O
paired	864	870	O
pulsed	871	877	O
facilitation	878	890	O
and	891	894	O
synaptic	895	903	B-Cellular_component
augmentation	904	916	O
in	917	919	O
active	920	926	O
than	927	931	O
in	932	934	O
silent	935	941	O
cortical	942	950	B-Multi-tissue_structure
networks	951	959	O
and	960	963	O
2	964	965	O
)	965	966	O
Synaptic	967	975	B-Cellular_component
potentials	976	986	O
occurring	987	996	O
during	997	1003	O
up	1004	1006	O
or	1007	1009	O
activated	1010	1019	O
states	1020	1026	O
of	1027	1029	O
the	1030	1033	O
cortex	1034	1040	B-Multi-tissue_structure
increased	1041	1050	O
their	1051	1056	O
amplitude	1057	1066	O
with	1067	1071	O
respect	1072	1079	O
to	1080	1082	O
those	1083	1088	O
occurring	1089	1098	O
during	1099	1105	O
down	1106	1110	O
states	1111	1117	O
.	1117	1118	O

Ca2	0	3	O
+	3	4	O
Dependence	5	15	O
of	16	18	O
Slob57	19	25	O
Modulation	26	36	O
of	37	39	O
the	40	43	O
Voltage	44	51	O
Dependence	52	62	O
of	63	65	O
Activation	66	76	O
of	77	79	O
dSlo	80	84	O

Ca2	85	88	O
+	88	89	O
plays	90	95	O
a	96	97	O
fundamental	98	109	O
role	110	114	O
in	115	117	O
regulating	118	128	O
the	129	132	O
dSlo	133	137	O
response	138	146	O
to	147	149	O
membrane	150	158	B-Cellular_component
depolarization	159	173	O
.	173	174	O

One	175	178	O
of	179	181	O
the	182	185	O
three	186	191	O
known	192	197	O
Ca2	198	201	O
+	201	202	O
binding	203	210	O
sites	211	216	O
(	217	218	O
Xia	218	221	O
et	222	224	O
al	225	227	O
.	227	228	O
,	228	229	O
2002	230	234	O
;	234	235	O
Bao	236	239	O
et	240	242	O
al	243	245	O
.	245	246	O
,	246	247	O
2002	248	252	O
;	252	253	O
Zeng	254	258	O
et	259	261	O
al	262	264	O
.	264	265	O
,	265	266	O
2005b	267	272	O
)	272	273	O
,	273	274	O
known	275	280	O
as	281	283	O
the	284	287	O
calcium	288	295	O
bowl	296	300	O
(	301	302	O
Schreiber	302	311	O
and	312	315	O
Salkoff	316	323	O
,	323	324	O
1997	325	329	O
)	329	330	O
,	330	331	O
contributes	332	343	O
to	344	346	O
the	347	350	O
high	351	355	O
-	355	356	O
affinity	356	364	O
Ca2	365	368	O
+	368	369	O
sensitivity	370	381	O
of	382	384	O
the	385	388	O
channel	389	396	O
(	397	398	O
Schreiber	398	407	O
and	408	411	O
Salkoff	412	419	O
,	419	420	O
1997	421	425	O
;	425	426	O
Schreiber	427	436	O
et	437	439	O
al	440	442	O
.	442	443	O
,	443	444	O
1999	445	449	O
;	449	450	O
Braun	451	456	O
and	457	460	O
Sy	461	463	O
,	463	464	O
2001	465	469	O
;	469	470	O
Bao	471	474	O
et	475	477	O
al	478	480	O
.	480	481	O
,	481	482	O
2002	483	487	O
;	487	488	O
Niu	489	492	O
and	493	496	O
Magleby	497	504	O
,	504	505	O
2002	506	510	O
;	510	511	O
Xia	512	515	O
et	516	518	O
al	519	521	O
.	521	522	O
,	522	523	O
2002	524	528	O
;	528	529	O
Bao	530	533	O
et	534	536	O
al	537	539	O
.	539	540	O
,	540	541	O
2004	542	546	O
;	546	547	O
Zeng	548	552	O
et	553	555	O
al	556	558	O
.	558	559	O
,	559	560	O
2005b	561	566	O
)	566	567	O
.	567	568	O

We	569	571	O
used	572	576	O
a	577	578	O
mutated	579	586	O
dSlo	587	591	O
channel	592	599	O
with	600	604	O
substitution	605	617	O
of	618	620	O
Asp966	621	627	O
-	627	628	O
Asp970	628	634	O
by	635	637	O
Asn966	638	644	O
-	644	645	O
Asn970	645	651	O
within	652	658	O
its	659	662	O
calcium	663	670	O
bowl	671	675	O
,	675	676	O
which	677	682	O
greatly	683	690	O
reduces	691	698	O
the	699	702	O
channel	703	710	O
'	710	711	O
s	711	712	O
calcium	713	720	O
sensitivity	721	732	O
(	733	734	O
Bian	734	738	O
et	739	741	O
al	742	744	O
.	744	745	O
,	745	746	O
2001	747	751	O
)	751	752	O
,	752	753	O
to	754	756	O
determine	757	766	O
whether	767	774	O
Ca2	775	778	O
+	778	779	O
participates	780	792	O
in	793	795	O
Slob57	796	802	O
modulation	803	813	O
of	814	816	O
dSlo	817	821	O
.	821	822	O

This	823	827	O
mutated	828	835	O
channel	836	843	O
,	843	844	O
dSloD5N5	845	853	O
,	853	854	O
still	855	860	O
binds	861	866	O
to	867	869	O
full	870	874	O
-	874	875	O
length	875	881	O
and	882	885	O
truncated	886	895	O
Slobs	896	901	O
(	902	903	O
Fig	903	906	O
.	906	907	O
1	908	909	O
B	910	911	O
,	911	912	O
lanes	913	918	O
4	919	920	O
-	920	921	O
6	921	922	O
)	922	923	O
.	923	924	O

During	925	931	O
a	932	933	O
350	934	937	O
-	937	938	O
ms	938	940	O
test	941	945	O
pulse	946	951	O
(	952	953	O
Fig	953	956	O
.	956	957	O
7	958	959	O
E	960	961	O
)	961	962	O
,	962	963	O
Slob57	964	970	O
causes	971	977	O
dSloD5N5	978	986	O
inactivation	987	999	O
(	1000	1001	O
Fig	1001	1004	O
.	1004	1005	O
7	1006	1007	O
B	1008	1009	O
)	1009	1010	O
,	1010	1011	O
consistent	1012	1022	O
with	1023	1027	O
our	1028	1031	O
previous	1032	1040	O
finding	1041	1048	O
that	1049	1053	O
the	1054	1057	O
inactivation	1058	1070	O
caused	1071	1077	O
by	1078	1080	O
Slob57	1081	1087	O
is	1088	1090	O
Ca2	1091	1094	O
+	1094	1095	O
independent	1096	1107	O
(	1108	1109	O
Zeng	1109	1113	O
et	1114	1116	O
al	1117	1119	O
.	1119	1120	O
,	1120	1121	O
2005a	1122	1127	O
)	1127	1128	O
.	1128	1129	O

After	1130	1135	O
deletion	1136	1144	O
of	1145	1147	O
the	1148	1151	O
amino	1152	1157	O
-	1157	1158	O
terminal	1158	1166	O
residues	1167	1175	O
2	1176	1177	O
-	1177	1178	O
6	1178	1179	O
of	1180	1182	O
Slob57	1183	1189	O
,	1189	1190	O
the	1191	1194	O
inactivation	1195	1207	O
of	1208	1210	O
dSloD5N5	1211	1219	O
is	1220	1222	O
eliminated	1223	1233	O
(	1234	1235	O
Fig	1235	1238	O
.	1238	1239	O
7	1240	1241	O
C	1242	1243	O
)	1243	1244	O
,	1244	1245	O
and	1246	1249	O
further	1250	1257	O
truncation	1258	1268	O
of	1269	1271	O
Slob57	1272	1278	O
to	1279	1281	O
Arg16	1282	1287	O
also	1288	1292	O
eliminates	1293	1303	O
the	1304	1307	O
inactivation	1308	1320	O
(	1321	1322	O
Fig	1322	1325	O
.	1325	1326	O
7	1327	1328	O
D	1329	1330	O
)	1330	1331	O
,	1331	1332	O
just	1333	1337	O
as	1338	1340	O
observed	1341	1349	O
with	1350	1354	O
wild	1355	1359	O
-	1359	1360	O
type	1360	1364	O
dSlo	1365	1369	O
(	1370	1371	O
Fig	1371	1374	O
.	1374	1375	O
2	1376	1377	O
,	1377	1378	O
C	1379	1380	O
and	1381	1384	O
D	1385	1386	O
)	1386	1387	O
.	1387	1388	O

Figure	1389	1395	O
7	1396	1397	O
.	1397	1398	O

Slob57	1399	1405	O
causes	1406	1412	O
inactivation	1413	1425	O
of	1426	1428	O
dSloD5N5	1429	1437	O
.	1437	1438	O

Same	1439	1443	O
as	1444	1446	O
Fig	1447	1450	O
.	1450	1451	O

2	1452	1453	O
,	1453	1454	O
except	1455	1461	O
that	1462	1466	O
the	1467	1470	O
mutated	1471	1478	O
channel	1479	1486	O
dSloD5N5	1487	1495	O
was	1496	1499	O
used	1500	1504	O
instead	1505	1512	O
of	1513	1515	O
wild	1516	1520	O
-	1520	1521	O
type	1521	1525	O
dSlo	1526	1530	O
.	1530	1531	O

(	1532	1533	O
A	1533	1534	O
)	1534	1535	O
dSloD5N5	1536	1544	O
alone	1545	1550	O
,	1550	1551	O
(	1552	1553	O
B	1553	1554	O
)	1554	1555	O
dSloD5N5	1556	1564	O
together	1565	1573	O
with	1574	1578	O
Slob57	1579	1585	O
,	1585	1586	O
(	1587	1588	O
C	1588	1589	O
)	1589	1590	O
dSloD5N5	1591	1599	O
together	1600	1608	O
with	1609	1613	O
Slob57DeltaN5	1614	1627	O
,	1627	1628	O
(	1629	1630	O
D	1630	1631	O
)	1631	1632	O
dSloD5N5	1633	1641	O
together	1642	1650	O
with	1651	1655	O
Slob57DeltaN15	1656	1670	O
,	1670	1671	O
(	1672	1673	O
E	1673	1674	O
)	1674	1675	O
pulse	1676	1681	O
protocol	1682	1690	O
.	1690	1691	O

We	1692	1694	O
next	1695	1699	O
used	1700	1704	O
a	1705	1706	O
100	1707	1710	O
-	1710	1711	O
ms	1711	1713	O
test	1714	1718	O
pulse	1719	1724	O
(	1725	1726	O
during	1726	1732	O
which	1733	1738	O
no	1739	1741	O
inactivation	1742	1754	O
occurs	1755	1761	O
)	1761	1762	O
to	1763	1765	O
measure	1766	1773	O
the	1774	1777	O
voltage	1778	1785	O
dependence	1786	1796	O
of	1797	1799	O
activation	1800	1810	O
of	1811	1813	O
dSloD5N5	1814	1822	O
in	1823	1825	O
the	1826	1829	O
presence	1830	1838	O
of	1839	1841	O
110	1842	1845	O
muM	1846	1849	O
free	1850	1854	O
Ca2	1855	1858	O
+	1858	1859	O
,	1859	1860	O
as	1861	1863	O
only	1864	1868	O
at	1869	1871	O
high	1872	1876	O
concentrations	1877	1891	O
of	1892	1894	O
free	1895	1899	O
Ca2	1900	1903	O
+	1903	1904	O
can	1905	1908	O
tail	1909	1913	O
current	1914	1921	O
saturation	1922	1932	O
be	1933	1935	O
achieved	1936	1944	O
with	1945	1949	O
the	1950	1953	O
mutant	1954	1960	O
channel	1961	1968	O
(	1969	1970	O
Fig	1970	1973	O
.	1973	1974	O
8	1975	1976	O
)	1976	1977	O
.	1977	1978	O

As	1979	1981	O
shown	1982	1987	O
in	1988	1990	O
Fig	1991	1994	O
.	1994	1995	O

8	1996	1997	O
,	1997	1998	O
Slob57	1999	2005	O
does	2006	2010	O
not	2011	2014	O
rightward	2015	2024	O
shift	2025	2030	O
the	2031	2034	O
conductance	2035	2046	O
-	2046	2047	O
voltage	2047	2054	O
relationship	2055	2067	O
of	2068	2070	O
dSloD5N5	2071	2079	O
.	2079	2080	O

Because	2081	2088	O
dSloD5N5	2089	2097	O
can	2098	2101	O
still	2102	2107	O
respond	2108	2115	O
to	2116	2118	O
an	2119	2121	O
increment	2122	2131	O
of	2132	2134	O
free	2135	2139	O
Ca2	2140	2143	O
+	2143	2144	O
at	2145	2147	O
high	2148	2152	O
concentration	2153	2166	O
(	2167	2168	O
Bian	2168	2172	O
et	2173	2175	O
al	2176	2178	O
.	2178	2179	O
,	2179	2180	O
2001	2181	2185	O
)	2185	2186	O
,	2186	2187	O
we	2188	2190	O
then	2191	2195	O
increased	2196	2205	O
the	2206	2209	O
concentration	2210	2223	O
of	2224	2226	O
free	2227	2231	O
Ca2	2232	2235	O
+	2235	2236	O
to	2237	2239	O
300	2240	2243	O
muM	2244	2247	O
.	2247	2248	O

As	2249	2251	O
shown	2252	2257	O
in	2258	2260	O
Fig	2261	2264	O
.	2264	2265	O

8	2266	2267	O
,	2267	2268	O
the	2269	2272	O
conductance	2273	2284	O
-	2284	2285	O
voltage	2285	2292	O
relationship	2293	2305	O
of	2306	2308	O
dSloD5N5	2309	2317	O
shifts	2318	2324	O
to	2325	2327	O
less	2328	2332	O
depolarized	2333	2344	O
voltages	2345	2353	O
when	2354	2358	O
the	2359	2362	O
concentration	2363	2376	O
of	2377	2379	O
free	2380	2384	O
Ca2	2385	2388	O
+	2388	2389	O
is	2390	2392	O
increased	2393	2402	O
from	2403	2407	O
110	2408	2411	O
to	2412	2414	O
300	2415	2418	O
muM	2419	2422	O
,	2422	2423	O
but	2424	2427	O
again	2428	2433	O
the	2434	2437	O
V1	2438	2440	O
/	2440	2441	O
2	2441	2442	O
is	2443	2445	O
not	2446	2449	O
modulated	2450	2459	O
by	2460	2462	O
Slob57	2463	2469	O
.	2469	2470	O

Figure	2471	2477	O
8	2478	2479	O
.	2479	2480	O

Conductance	2481	2492	O
-	2492	2493	O
voltage	2493	2500	O
relationships	2501	2514	O
for	2515	2518	O
dSloD5N5	2519	2527	O
.	2527	2528	O

Same	2529	2533	O
protocol	2534	2542	O
as	2543	2545	O
Fig	2546	2549	O
.	2549	2550	O

6	2551	2552	O
,	2552	2553	O
except	2554	2560	O
that	2561	2565	O
the	2566	2569	O
mutated	2570	2577	O
channel	2578	2585	O
dSloD5N5	2586	2594	O
was	2595	2598	O
used	2599	2603	O
in	2604	2606	O
the	2607	2610	O
presence	2611	2619	O
(	2620	2621	O
circles	2621	2628	O
)	2628	2629	O
or	2630	2632	O
absence	2633	2640	O
(	2641	2642	O
squares	2642	2649	O
)	2649	2650	O
of	2651	2653	O
Slob57	2654	2660	O
,	2660	2661	O
and	2662	2665	O
the	2666	2669	O
concentration	2670	2683	O
of	2684	2686	O
free	2687	2691	O
Ca2	2692	2695	O
+	2695	2696	O
was	2697	2700	O
either	2701	2707	O
110	2708	2711	O
muM	2712	2715	O
(	2716	2717	O
filled	2717	2723	O
symbols	2724	2731	O
)	2731	2732	O
or	2733	2735	O
300	2736	2739	O
muM	2740	2743	O
(	2744	2745	O
open	2745	2749	O
symbols	2750	2757	O
)	2757	2758	O
.	2758	2759	O

We	2760	2762	O
next	2763	2767	O
measured	2768	2776	O
the	2777	2780	O
voltage	2781	2788	O
dependence	2789	2799	O
of	2800	2802	O
activation	2803	2813	O
of	2814	2816	O
wild	2817	2821	O
-	2821	2822	O
type	2822	2826	O
dSlo	2827	2831	O
,	2831	2832	O
in	2833	2835	O
the	2836	2839	O
presence	2840	2848	O
or	2849	2851	O
absence	2852	2859	O
of	2860	2862	O
Slob57	2863	2869	O
,	2869	2870	O
at	2871	2873	O
free	2874	2878	O
Ca2	2879	2882	O
+	2882	2883	O
concentrations	2884	2898	O
ranging	2899	2906	O
from	2907	2911	O
20	2912	2914	O
to	2915	2917	O
300	2918	2921	O
muM	2922	2925	O
.	2925	2926	O

As	2927	2929	O
shown	2930	2935	O
in	2936	2938	O
Fig	2939	2942	O
.	2942	2943	O

9	2944	2945	O
A	2946	2947	O
(	2948	2949	O
and	2949	2952	O
by	2953	2955	O
many	2956	2960	O
previous	2961	2969	O
investigators	2970	2983	O
)	2983	2984	O
,	2984	2985	O
in	2986	2988	O
the	2989	2992	O
absence	2993	3000	O
of	3001	3003	O
Slob57	3004	3010	O
,	3010	3011	O
the	3012	3015	O
voltage	3016	3023	O
-	3023	3024	O
conductance	3024	3035	O
relationship	3036	3048	O
of	3049	3051	O
dSlo	3052	3056	O
shifts	3057	3063	O
to	3064	3066	O
less	3067	3071	O
depolarized	3072	3083	O
voltages	3084	3092	O
as	3093	3095	O
the	3096	3099	O
free	3100	3104	O
Ca2	3105	3108	O
+	3108	3109	O
concentration	3110	3123	O
is	3124	3126	O
increased	3127	3136	O
in	3137	3139	O
this	3140	3144	O
range	3145	3150	O
.	3150	3151	O

The	3152	3155	O
V1	3156	3158	O
/	3158	3159	O
2	3159	3160	O
decreases	3161	3170	O
from	3171	3175	O
85	3176	3178	O
to	3179	3181	O
-	3182	3183	O
22	3183	3185	O
mV	3186	3188	O
,	3188	3189	O
a	3190	3191	O
change	3192	3198	O
of	3199	3201	O
107	3202	3205	O
mV	3206	3208	O
,	3208	3209	O
when	3210	3214	O
the	3215	3218	O
concentration	3219	3232	O
of	3233	3235	O
free	3236	3240	O
Ca2	3241	3244	O
+	3244	3245	O
is	3246	3248	O
increased	3249	3258	O
from	3259	3263	O
20	3264	3266	O
to	3267	3269	O
300	3270	3273	O
muM	3274	3277	O
.	3277	3278	O

In	3279	3281	O
contrast	3282	3290	O
,	3290	3291	O
when	3292	3296	O
dSlo	3297	3301	O
is	3302	3304	O
coexpressed	3305	3316	O
with	3317	3321	O
Slob57	3322	3328	O
,	3328	3329	O
this	3330	3334	O
increment	3335	3344	O
of	3345	3347	O
free	3348	3352	O
Ca2	3353	3356	O
+	3356	3357	O
concentration	3358	3371	O
shifts	3372	3378	O
the	3379	3382	O
V1	3383	3385	O
/	3385	3386	O
2	3386	3387	O
to	3388	3390	O
a	3391	3392	O
much	3393	3397	O
lesser	3398	3404	O
extent	3405	3411	O
(	3412	3413	O
Fig	3413	3416	O
.	3416	3417	O
9	3418	3419	O
B	3420	3421	O
and	3422	3425	O
Fig	3426	3429	O
.	3429	3430	O
10	3431	3433	O
A	3434	3435	O
)	3435	3436	O
.	3436	3437	O

Note	3438	3442	O
also	3443	3447	O
that	3448	3452	O
the	3453	3456	O
effect	3457	3463	O
of	3464	3466	O
Slob57	3467	3473	O
on	3474	3476	O
the	3477	3480	O
V1	3481	3483	O
/	3483	3484	O
2	3484	3485	O
is	3486	3488	O
more	3489	3493	O
apparent	3494	3502	O
at	3503	3505	O
higher	3506	3512	O
free	3513	3517	O
Ca2	3518	3521	O
+	3521	3522	O
concentrations	3523	3537	O
(	3538	3539	O
Fig	3539	3542	O
.	3542	3543	O
10	3544	3546	O
A	3547	3548	O
)	3548	3549	O
.	3549	3550	O

To	3551	3553	O
illustrate	3554	3564	O
this	3565	3569	O
better	3570	3576	O
,	3576	3577	O
we	3578	3580	O
plotted	3581	3588	O
the	3589	3592	O
V1	3593	3595	O
/	3595	3596	O
2	3596	3597	O
change	3598	3604	O
evoked	3605	3611	O
by	3612	3614	O
Slob57	3615	3621	O
(	3622	3623	O
DeltaV1	3623	3630	O
/	3630	3631	O
2	3631	3632	O
)	3632	3633	O
as	3634	3636	O
a	3637	3638	O
function	3639	3647	O
of	3648	3650	O
the	3651	3654	O
free	3655	3659	O
Ca2	3660	3663	O
+	3663	3664	O
concentration	3665	3678	O
(	3679	3680	O
Fig	3680	3683	O
.	3683	3684	O
10	3685	3687	O
B	3688	3689	O
)	3689	3690	O
to	3691	3693	O
demonstrate	3694	3705	O
that	3706	3710	O
the	3711	3714	O
magnitude	3715	3724	O
of	3725	3727	O
the	3728	3731	O
modulatory	3732	3742	O
shift	3743	3748	O
in	3749	3751	O
V1	3752	3754	O
/	3754	3755	O
2	3755	3756	O
evoked	3757	3763	O
by	3764	3766	O
Slob57	3767	3773	O
itself	3774	3780	O
is	3781	3783	O
calcium	3784	3791	O
dependent	3792	3801	O
.	3801	3802	O

Figure	3803	3809	O
9	3810	3811	O
.	3811	3812	O

Effect	3813	3819	O
of	3820	3822	O
calcium	3823	3830	O
on	3831	3833	O
dSlo	3834	3838	O
voltage	3839	3846	O
dependence	3847	3857	O
of	3858	3860	O
activation	3861	3871	O
in	3872	3874	O
the	3875	3878	O
absence	3879	3886	O
or	3887	3889	O
presence	3890	3898	O
of	3899	3901	O
Slob57	3902	3908	O
.	3908	3909	O

Same	3910	3914	O
as	3915	3917	O
Fig	3918	3921	O
.	3921	3922	O

6	3923	3924	O
,	3924	3925	O
except	3926	3932	O
that	3933	3937	O
the	3938	3941	O
measurements	3942	3954	O
of	3955	3957	O
dSlo	3958	3962	O
expressed	3963	3972	O
alone	3973	3978	O
(	3979	3980	O
A	3980	3981	O
)	3981	3982	O
or	3983	3985	O
together	3986	3994	O
with	3995	3999	O
Slob57	4000	4006	O
(	4007	4008	O
B	4008	4009	O
)	4009	4010	O
were	4011	4015	O
performed	4016	4025	O
in	4026	4028	O
the	4029	4032	O
presence	4033	4041	O
of	4042	4044	O
different	4045	4054	O
concentrations	4055	4069	O
of	4070	4072	O
free	4073	4077	O
Ca2	4078	4081	O
+	4081	4082	O
:	4082	4083	O
20	4084	4086	O
muM	4087	4090	O
(	4091	4092	O
diamonds	4092	4100	O
)	4100	4101	O
,	4101	4102	O
40	4103	4105	O
muM	4106	4109	O
(	4110	4111	O
inverted	4111	4119	O
triangles	4120	4129	O
)	4129	4130	O
,	4130	4131	O
80	4132	4134	O
muM	4135	4138	O
(	4139	4140	O
triangles	4140	4149	O
)	4149	4150	O
,	4150	4151	O
110	4152	4155	O
muM	4156	4159	O
(	4160	4161	O
squares	4161	4168	O
)	4168	4169	O
,	4169	4170	O
and	4171	4174	O
300	4175	4178	O
muM	4179	4182	O
(	4183	4184	O
circles	4184	4191	O
)	4191	4192	O
.	4192	4193	O

Figure	4194	4200	O
10	4201	4203	O
.	4203	4204	O

Interaction	4205	4216	O
between	4217	4224	O
Slob57	4225	4231	O
and	4232	4235	O
calcium	4236	4243	O
.	4243	4244	O

The	4245	4248	O
V1	4249	4251	O
/	4251	4252	O
2	4252	4253	O
(	4254	4255	O
A	4255	4256	O
)	4256	4257	O
of	4258	4260	O
the	4261	4264	O
conductance	4265	4276	O
-	4276	4277	O
voltage	4277	4284	O
relationship	4285	4297	O
for	4298	4301	O
dSlo	4302	4306	O
expressed	4307	4316	O
alone	4317	4322	O
(	4323	4324	O
O	4324	4325	O
)	4325	4326	O
or	4327	4329	O
together	4330	4338	O
with	4339	4343	O
Slob57	4344	4350	O
(	4351	4352	O
*	4352	4353	O
)	4353	4354	O
,	4354	4355	O
taken	4356	4361	O
from	4362	4366	O
Fig	4367	4370	O
.	4370	4371	O

9	4372	4373	O
,	4373	4374	O
and	4375	4378	O
the	4379	4382	O
difference	4383	4393	O
in	4394	4396	O
V1	4397	4399	O
/	4399	4400	O
2	4400	4401	O
(	4402	4403	O
DeltaV1	4403	4410	O
/	4410	4411	O
2	4411	4412	O
)	4412	4413	O
evoked	4414	4420	O
by	4421	4423	O
Slob57	4424	4430	O
(	4431	4432	O
B	4432	4433	O
)	4433	4434	O
are	4435	4438	O
plotted	4439	4446	O
as	4447	4449	O
a	4450	4451	O
function	4452	4460	O
of	4461	4463	O
the	4464	4467	O
concentration	4468	4481	O
of	4482	4484	O
free	4485	4489	O
Ca2	4490	4493	O
+	4493	4494	O
.	4494	4495	O

Authors	0	7	O
'	7	8	O
contributions	9	22	O

OK	23	25	O
and	26	29	O
MG	30	32	O
analyzed	33	41	O
and	42	45	O
interpreted	46	57	O
the	58	61	O
patient	62	69	O
data	70	74	O
regarding	75	84	O
his	85	88	O
hospitalization	89	104	O
.	104	105	O

SP	106	108	O
and	109	112	O
PK	113	115	O
performed	116	125	O
the	126	129	O
coronary	130	138	B-Multi-tissue_structure
angiography	139	150	O
,	150	151	O
and	152	155	O
were	156	160	O
the	161	164	O
major	165	170	O
contributors	171	183	O
in	184	186	O
writing	187	194	O
the	195	198	O
manuscript	199	209	O
.	209	210	O

All	211	214	O
authors	215	222	O
read	223	227	O
and	228	231	O
approved	232	240	O
the	241	244	O
final	245	250	O
manuscript	251	261	O
.	261	262	O

Authors	0	7	O
'	7	8	O
contributions	9	22	O

CM	23	25	O
,	25	26	O
JRH	27	30	O
,	30	31	O
HJP	32	35	O
,	35	36	O
and	37	40	O
JH	41	43	O
carried	44	51	O
animal	52	58	O
studies	59	66	O
.	66	67	O

CM	68	70	O
performed	71	80	O
the	81	84	O
statistical	85	96	O
analysis	97	105	O
.	105	106	O

JLK	107	110	O
conceived	111	120	O
of	121	123	O
the	124	127	O
study	128	133	O
,	133	134	O
participated	135	147	O
in	148	150	O
its	151	154	O
design	155	161	O
and	162	165	O
coordination	166	178	O
,	178	179	O
and	180	183	O
drafted	184	191	O
and	192	195	O
edited	196	202	O
the	203	206	O
manuscript	207	217	O
.	217	218	O

All	219	222	O
authors	223	230	O
read	231	235	O
and	236	239	O
approved	240	248	O
the	249	252	O
final	253	258	O
manuscript	259	269	O
.	269	270	O

Disk	0	4	O
preparation	5	16	O
phase	17	22	O

o	23	24	O
Adoption	25	33	O
of	34	36	O
a	37	38	O
two	39	42	O
-	42	43	O
stage	43	48	O
sampling	49	57	O
scheme	58	64	O
.	64	65	O

o	66	67	O
Careful	68	75	O
planning	76	84	O
and	85	88	O
choice	89	95	O
of	96	98	O
representative	99	113	O
sampling	114	122	O
groups	123	129	O
and	130	133	O
sites	134	139	O
according	140	149	O
to	150	152	O
the	153	156	O
adopted	157	164	O
network	165	172	O
sampling	173	181	O
technique	182	191	O
,	191	192	O
and	193	196	O
determining	197	208	O
certain	209	216	O
criteria	217	225	O
such	226	230	O
as	231	233	O
control	234	241	O
sites	242	247	O
where	248	253	O
major	254	259	O
sampling	260	268	O
groups	269	275	O
exist	276	281	O
(	282	283	O
i	283	284	O
.	284	285	O
e	285	286	O
.	286	287	O
surface	288	295	O
water	296	301	O
points	302	308	O
,	308	309	O
valleys	310	317	O
,	317	318	O
and	319	322	O
wells	323	328	O
)	328	329	O
,	329	330	O
impact	331	337	O
sites	338	343	O
where	344	349	O
contamination	350	363	O
is	364	366	O
expected	367	375	O
,	375	376	O
such	377	381	O
as	382	384	O
polygons	385	393	O
,	393	394	O
and	395	398	O
outlets	399	406	O
(	407	408	O
e	408	409	O
.	409	410	O
g	410	411	O
.	411	412	O
treated	413	420	O
water	421	426	O
discharges	427	437	O
site	438	442	O
)	442	443	O
to	444	446	O
maximise	447	455	O
understanding	456	469	O
the	470	473	O
quality	474	481	O
of	482	484	O
urban	485	490	O
water	491	496	O
sources	497	504	O
,	504	505	O
and	506	509	O
with	510	514	O
the	515	518	O
least	519	524	O
risk	525	529	O
of	530	532	O
missing	533	540	O
the	541	544	O
correct	545	552	O
representative	553	567	O
sampling	568	576	O
groups	577	583	O
and	584	587	O
sites	588	593	O
.	593	594	O

o	595	596	O
Attention	597	606	O
paid	607	611	O
to	612	614	O
ensure	615	621	O
inclusion	622	631	O
in	632	634	O
the	635	638	O
sampling	639	647	O
frame	648	653	O
of	654	656	O
all	657	660	O
groups	661	667	O
and	668	671	O
locations	672	681	O
(	682	683	O
sites	683	688	O
,	688	689	O
roads	690	695	O
,	695	696	O
venues	697	703	O
,	703	704	O
and	705	708	O
so	709	711	O
on	712	714	O
)	714	715	O
via	716	719	O
screening	720	729	O
,	729	730	O
browsing	731	739	O
,	739	740	O
and	741	744	O
delineation	745	756	O
from	757	761	O
a	762	763	O
satellite	764	773	O
digital	774	781	O
map	782	785	O
of	786	788	O
the	789	792	O
Khamis	793	799	O
Mushait	800	807	O
Governorate	808	819	O
zone	820	824	O
,	824	825	O
because	826	833	O
local	834	839	O
pre	840	843	O
-	843	844	O
knowledge	844	853	O
was	854	857	O
preferred	858	867	O
with	868	872	O
regard	873	879	O
to	880	882	O
accessibility	883	896	O
,	896	897	O
safety	898	904	O
,	904	905	O
and	906	909	O
permission	910	920	O
.	920	921	O

o	922	923	O
Approximation	924	937	O
of	938	940	O
the	941	944	O
number	945	951	O
of	952	954	O
the	955	958	O
target	959	965	O
study	966	971	O
population	972	982	O
in	983	985	O
each	986	990	O
group	991	996	O
and	997	1000	O
sampling	1001	1009	O
location	1010	1018	O
.	1018	1019	O

o	1020	1021	O
Determination	1022	1035	O
of	1036	1038	O
the	1039	1042	O
proportional	1043	1055	O
allocation	1056	1066	O
of	1067	1069	O
samples	1070	1077	O
between	1078	1085	O
different	1086	1095	O
groups	1096	1102	O
and	1103	1106	O
locations	1107	1116	O
.	1116	1117	O

o	1118	1119	O
Training	1120	1128	O
of	1129	1131	O
interviewers	1132	1144	O
\	1144	1145	O
sample	1145	1151	O
collectors	1152	1162	O
to	1163	1165	O
follow	1166	1172	O
and	1173	1176	O
to	1177	1179	O
use	1180	1183	O
the	1184	1187	O
sampling	1188	1196	O
strategy	1197	1205	O
and	1206	1209	O
procedures	1210	1220	O
.	1220	1221	O

o	1222	1223	O
Implementation	1224	1238	O
of	1239	1241	O
ways	1242	1246	O
to	1247	1249	O
boost	1250	1255	O
participation	1256	1269	O
rates	1270	1275	O
in	1276	1278	O
the	1279	1282	O
screening	1283	1292	O
and	1293	1296	O
core	1297	1301	O
interviews	1302	1312	O
and	1313	1316	O
sample	1317	1323	O
collection	1324	1334	O
.	1334	1335	O

o	1336	1337	O
Planning	1338	1346	O
of	1347	1349	O
logistic	1350	1358	O
needs	1359	1364	O
of	1365	1367	O
timing	1368	1374	O
,	1374	1375	O
gathering	1376	1385	O
,	1385	1386	O
handling	1387	1395	O
samples	1396	1403	O
,	1403	1404	O
and	1405	1408	O
laboratory	1409	1419	O
.	1419	1420	O

o	1421	1422	O
Producing	1423	1432	O
sampling	1433	1441	O
cards	1442	1447	O
to	1448	1450	O
be	1451	1453	O
completed	1454	1463	O
to	1464	1466	O
record	1467	1473	O
observations	1474	1486	O
at	1487	1489	O
scene	1490	1495	O
(	1496	1497	O
sample	1497	1503	O
ID	1504	1506	O
and	1507	1510	O
data	1511	1515	O
/	1515	1516	O
information	1516	1527	O
:	1527	1528	O
date	1529	1533	O
,	1533	1534	O
time	1535	1539	O
,	1539	1540	O
temperature	1541	1552	O
,	1552	1553	O
group	1554	1559	O
,	1559	1560	O
locality	1561	1569	O
,	1569	1570	O
problems	1571	1579	O
in	1580	1582	O
the	1583	1586	O
area	1587	1591	O
,	1591	1592	O
sketch	1593	1599	O
map	1600	1603	O
)	1603	1604	O
.	1604	1605	O

o	1606	1607	O
Selection	1608	1617	O
of	1618	1620	O
an	1621	1623	O
appropriate	1624	1635	O
major	1636	1641	O
sampling	1642	1650	O
method	1651	1657	O
[	1658	1659	O
52	1659	1661	O
]	1661	1662	O
(	1663	1664	O
i	1664	1665	O
.	1665	1666	O
e	1666	1667	O
.	1667	1668	O
simple	1669	1675	O
random	1676	1682	O
sample	1683	1689	O
;	1689	1690	O
network	1691	1698	O
sampling	1699	1707	O
)	1707	1708	O
.	1708	1709	O

o	1710	1711	O
Planning	1712	1720	O
of	1721	1723	O
pilot	1724	1729	O
visits	1730	1736	O
to	1737	1739	O
samples	1740	1747	O
of	1748	1750	O
each	1751	1755	O
group	1756	1761	O
in	1762	1764	O
the	1765	1768	O
field	1769	1774	O
to	1775	1777	O
review	1778	1784	O
strategy	1785	1793	O
.	1793	1794	O

Results	0	7	O

In	8	10	O
the	11	14	O
established	15	26	O
adult	27	32	O
rat	33	36	O
NSC	37	40	B-Cell
culture	41	48	O
,	48	49	O
FGF	50	53	O
-	53	54	O
2	54	55	O
promotes	56	64	O
self	65	69	O
-	69	70	O
renewal	70	77	O
by	78	80	O
increasing	81	91	O
proliferation	92	105	O
and	106	109	O
inhibiting	110	120	O
spontaneous	121	132	O
differentiation	133	148	O
of	149	151	O
adult	152	157	O
NSCs	158	162	B-Cell
,	162	163	O
accompanied	164	175	O
with	176	180	O
activation	181	191	O
of	192	194	O
MAPK	195	199	O
and	200	203	O
PLC	204	207	O
pathways	208	216	O
.	216	217	O

Using	218	223	O
a	224	225	O
molecular	226	235	O
genetic	236	243	O
approach	244	252	O
,	252	253	O
we	254	256	O
demonstrate	257	268	O
that	269	273	O
activation	274	284	O
of	285	287	O
FGF	288	291	O
receptor	292	300	O
1	301	302	O
(	303	304	O
FGFR1	304	309	O
)	309	310	O
,	310	311	O
largely	312	319	O
through	320	327	O
two	328	331	O
key	332	335	O
cytoplasmic	336	347	B-Organism_substance
amino	348	353	O
acid	354	358	O
residues	359	367	O
that	368	372	O
are	373	376	O
linked	377	383	O
to	384	386	O
MAPK	387	391	O
and	392	395	O
PLC	396	399	O
activation	400	410	O
,	410	411	O
suffices	412	420	O
to	421	423	O
promote	424	431	O
adult	432	437	O
NSC	438	441	B-Cell
self	442	446	O
-	446	447	O
renewal	447	454	O
.	454	455	O

The	456	459	O
canonical	460	469	O
MAPK	470	474	O
,	474	475	O
Erk1	476	480	O
/	480	481	O
2	481	482	O
activation	483	493	O
,	493	494	O
is	495	497	O
both	498	502	O
required	503	511	O
and	512	515	O
sufficient	516	526	O
for	527	530	O
the	531	534	O
NSC	535	538	B-Cell
expansion	539	548	O
and	549	552	O
anti	553	557	O
-	557	558	O
differentiation	558	573	O
effects	574	581	O
of	582	584	O
FGF	585	588	O
-	588	589	O
2	589	590	O
.	590	591	O

In	592	594	O
contrast	595	603	O
,	603	604	O
PLC	605	608	O
activation	609	619	O
is	620	622	O
integral	623	631	O
to	632	634	O
the	635	638	O
maintenance	639	650	O
of	651	653	O
adult	654	659	O
NSC	660	663	B-Cell
characteristics	664	679	O
,	679	680	O
including	681	690	O
the	691	694	O
full	695	699	O
capacity	700	708	O
for	709	712	O
neuronal	713	721	B-Cell
and	722	725	O
oligodendroglial	726	742	B-Cell
differentiation	743	758	O
.	758	759	O

Stochastic	0	10	O
models	11	17	O

Stochasticity	18	31	O
inevitably	32	42	O
emerges	43	50	O
when	51	55	O
molecular	56	65	O
components	66	76	O
are	77	80	O
present	81	88	O
at	89	91	O
low	92	95	O
cellular	96	104	B-Cell
concentrations	105	119	O
(	120	121	O
McAdams	121	128	O
&	129	130	O
Arkin	131	136	O
,	136	137	O
1997	138	142	O
;	142	143	O
Kierzek	144	151	O
et	152	154	O
al	155	157	O
.	157	158	O
,	158	159	O
2001	160	164	O
)	164	165	O
.	165	166	O

This	167	171	O
physical	172	180	O
phenomenon	181	191	O
generates	192	201	O
noise	202	207	O
in	208	210	O
synthetic	211	220	O
and	221	224	O
natural	225	232	O
circuits	233	241	O
(	242	243	O
Paulsson	243	251	O
,	251	252	O
2004	253	257	O
;	257	258	O
Mettetal	259	267	O
et	268	270	O
al	271	273	O
.	273	274	O
,	274	275	O
2006	276	280	O
)	280	281	O
,	281	282	O
and	283	286	O
its	287	290	O
consequences	291	303	O
over	304	308	O
the	309	312	O
phenotype	313	322	O
are	323	326	O
starting	327	335	O
to	336	338	O
be	339	341	O
explored	342	350	O
(	351	352	O
Suel	352	356	O
et	357	359	O
al	360	362	O
.	362	363	O
,	363	364	O
2006	365	369	O
)	369	370	O
.	370	371	O

For	372	375	O
example	376	383	O
,	383	384	O
noise	385	390	O
constitutes	391	402	O
the	403	406	O
driving	407	414	O
force	415	420	O
behind	421	427	O
differentiation	428	443	O
in	444	446	O
isogenetic	447	457	O
colonies	458	466	O
(	467	468	O
Colman	468	474	O
-	474	475	O
Lerner	475	481	O
et	482	484	O
al	485	487	O
.	487	488	O
,	488	489	O
2005	490	494	O
)	494	495	O
.	495	496	O

Biological	497	507	O
and	508	511	O
theoretical	512	523	O
studies	524	531	O
have	532	536	O
aided	537	542	O
to	543	545	O
delineate	546	555	O
the	556	559	O
regulatory	560	570	O
mechanism	571	580	O
by	581	583	O
which	584	589	O
the	590	593	O
cell	594	598	B-Cell
handles	599	606	O
noise	607	612	O
efficiently	613	624	O
and	625	628	O
effectively	629	640	O
to	641	643	O
carry	644	649	O
out	650	653	O
its	654	657	O
biological	658	668	O
functions	669	678	O
(	679	680	O
Gardner	680	687	O
&	688	689	O
Collins	690	697	O
,	697	698	O
2000	699	703	O
;	703	704	O
Orrell	705	711	O
&	712	713	O
Bolouri	714	721	O
,	721	722	O
2004	723	727	O
;	727	728	O
Raser	729	734	O
&	735	736	O
O	737	738	O
'	738	739	O
Shea	739	743	O
,	743	744	O
2005	745	749	O
)	749	750	O
.	750	751	O

From	752	756	O
a	757	758	O
theoretical	759	770	O
point	771	776	O
of	777	779	O
view	780	784	O
,	784	785	O
stochastic	786	796	O
models	797	803	O
are	804	807	O
the	808	811	O
most	812	816	O
challenging	817	828	O
but	829	832	O
also	833	837	O
the	838	841	O
most	842	846	O
realistic	847	856	O
ones	857	861	O
:	861	862	O
there	863	868	O
is	869	871	O
a	872	873	O
precise	874	881	O
counting	882	890	O
of	891	893	O
how	894	897	O
,	897	898	O
through	899	906	O
individual	907	917	O
chemical	918	926	O
reactions	927	936	O
,	936	937	O
the	938	941	O
populations	942	953	O
of	954	956	O
every	957	962	O
chemical	963	971	O
species	972	979	O
change	980	986	O
.	986	987	O

The	988	991	O
milestone	992	1001	O
to	1002	1004	O
simulate	1005	1013	O
stochastic	1014	1024	O
processes	1025	1034	O
is	1035	1037	O
the	1038	1041	O
Gillespie	1042	1051	O
algorithm	1052	1061	O
(	1062	1063	O
Gillespie	1063	1072	O
,	1072	1073	O
1992	1074	1078	O
)	1078	1079	O
.	1079	1080	O

Because	1081	1088	O
of	1089	1091	O
their	1092	1097	O
analytical	1098	1108	O
and	1109	1112	O
computational	1113	1126	O
complexity	1127	1137	O
,	1137	1138	O
the	1139	1142	O
present	1143	1150	O
models	1151	1157	O
do	1158	1160	O
not	1161	1164	O
surpass	1165	1172	O
a	1173	1174	O
handful	1175	1182	O
of	1183	1185	O
chemical	1186	1194	O
species	1195	1202	O
.	1202	1203	O

Two	1204	1207	O
immediate	1208	1217	O
problems	1218	1226	O
must	1227	1231	O
be	1232	1234	O
solved	1235	1241	O
to	1242	1244	O
model	1245	1250	O
systems	1251	1258	O
with	1259	1263	O
several	1264	1271	O
dozens	1272	1278	O
of	1279	1281	O
genetic	1282	1289	O
components	1290	1300	O
:	1300	1301	O
the	1302	1305	O
systematic	1306	1316	O
determination	1317	1330	O
of	1331	1333	O
kinetic	1334	1341	O
constants	1342	1351	O
and	1352	1355	O
the	1356	1359	O
efficient	1360	1369	O
computation	1370	1381	O
of	1382	1384	O
thousands	1385	1394	O
of	1395	1397	O
chemical	1398	1406	O
stochastic	1407	1417	O
equations	1418	1427	O
(	1428	1429	O
Kuwahara	1429	1437	O
et	1438	1440	O
al	1441	1443	O
.	1443	1444	O
,	1444	1445	O
2006	1446	1450	O
;	1450	1451	O
Sanchez	1452	1459	O
&	1460	1461	O
Kondev	1462	1468	O
,	1468	1469	O
2008	1470	1474	O
)	1474	1475	O
.	1475	1476	O

Model	0	5	O
of	6	8	O
how	9	12	O
estrogen	13	21	O
induces	22	29	O
DNA	30	33	O
damage	34	40	O
.	40	41	O

Estrogen	42	50	O
enters	51	57	O
the	58	61	O
cell	62	66	B-Cell
and	67	70	O
is	71	73	O
bound	74	79	O
by	80	82	O
the	83	86	O
ER	87	89	O
.	89	90	O

The	91	94	O
dimeric	95	102	O
ER	103	105	O
-	105	106	O
estrogen	106	114	O
complex	115	122	O
enters	123	129	O
the	130	133	O
nucleus	134	141	B-Cellular_component
and	142	145	O
induces	146	153	O
AID	154	157	O
expression	158	168	O
.	168	169	O

This	170	174	O
leads	175	180	O
to	181	183	O
an	184	186	O
increase	187	195	O
in	196	198	O
mutations	199	208	O
and	209	212	O
translocations	213	227	O
,	227	228	O
and	229	232	O
potentially	233	244	O
cancer	245	251	B-Pathological_formation

Results	0	7	O
:	7	8	O

In	9	11	O
the	12	15	O
total	16	21	O
population	22	32	O
(	33	34	O
N	34	35	O
=	35	36	O
95	36	38	O
)	38	39	O
,	39	40	O
median	41	47	O
OS	48	50	O
was	51	54	O
significantly	55	68	O
longer	69	75	O
in	76	78	O
patients	79	87	O
with	88	92	O
baseline	93	101	O
CA	102	104	O
19	105	107	O
-	107	108	O
9	108	109	O
values	110	116	O
at	117	119	O
or	120	122	O
below	123	128	O
the	129	132	O
median	133	139	O
than	140	144	O
in	145	147	O
those	148	153	O
with	154	158	O
values	159	165	O
above	166	171	O
it	172	174	O
(	175	176	O
12	176	178	O
.	178	179	O
2	179	180	O
months	181	187	O
[	188	189	O
95	189	191	O
%	191	192	O
confidence	193	203	O
interval	204	212	O
(	213	214	O
CI	214	216	O
)	216	217	O
,	217	218	O
8	219	220	O
.	220	221	O
6	221	222	O
-	222	223	O
16	223	225	O
.	225	226	O
6	226	227	O
%	227	228	O
]	228	229	O
vs	230	232	O
5	233	234	O
.	234	235	O
0	235	236	O
months	237	243	O
[	244	245	O
95	245	247	O
%	247	248	O
CI	249	251	O
,	251	252	O
3	253	254	O
.	254	255	O
9	255	256	O
-	256	257	O
5	257	258	O
.	258	259	O
7	259	260	O
%	260	261	O
]	261	262	O
;	262	263	O
P	264	265	O
<	265	266	O
0	266	267	O
.	267	268	O
0001	268	272	O
)	272	273	O
.	273	274	O

This	275	279	O
also	280	284	O
reached	285	292	O
significance	293	305	O
in	306	308	O
the	309	312	O
Gem	313	316	O
+	316	317	O
A	317	318	O
arm	319	322	O
(	323	324	O
median	324	330	O
OS	331	333	O
,	333	334	O
12	335	337	O
.	337	338	O
5	338	339	O
months	340	346	O
[	347	348	O
95	348	350	O
%	350	351	O
CI	352	354	O
,	354	355	O
8	356	357	O
.	357	358	O
6	358	359	O
-	359	360	O
16	360	362	O
.	362	363	O
6	363	364	O
%	364	365	O
]	365	366	O
vs	367	369	O
4	370	371	O
.	371	372	O
9	372	373	O
months	374	380	O
[	381	382	O
95	382	384	O
%	384	385	O
CI	386	388	O
,	388	389	O
3	390	391	O
.	391	392	O
6	392	393	O
-	393	394	O
5	394	395	O
.	395	396	O
6	396	397	O
%	397	398	O
]	398	399	O
;	399	400	O
P	401	402	O
<	402	403	O
0	403	404	O
.	404	405	O
0001	405	409	O
)	409	410	O
.	410	411	O

Patients	412	420	O
with	421	425	O
any	426	429	O
dBP	430	433	O
>	433	434	O
90	434	436	O
mmHg	437	441	O
had	442	445	O
significantly	446	459	O
longer	460	466	O
OS	467	469	O
than	470	474	O
those	475	480	O
who	481	484	O
did	485	488	O
not	489	492	O
.	492	493	O

However	494	501	O
,	501	502	O
there	503	508	O
was	509	512	O
no	513	515	O
predictive	516	526	O
significance	527	539	O
of	540	542	O
CA	543	545	O
19	546	548	O
-	548	549	O
9	549	550	O
.	550	551	O

Percentage	0	10	O
reported	11	19	O
purchasing	20	30	O
intentions	31	41	O
,	41	42	O
comparing	43	52	O
ITN	53	56	O
-	56	57	O
owning	57	63	O
to	64	66	O
non	67	70	O
-	70	71	O
owning	71	77	O
households	78	88	O

School	0	6	O
environment	7	18	O

At	19	21	O
the	22	25	O
majority	26	34	O
of	35	37	O
the	38	41	O
schools	42	49	O
a	50	51	O
soft	52	56	O
drink	57	62	O
vending	63	70	O
machine	71	78	O
(	79	80	O
91	80	82	O
%	82	83	O
,	83	84	O
n	85	86	O
=	87	88	O
446	89	92	O
)	92	93	O
and	94	97	O
/	97	98	O
or	98	100	O
a	101	102	O
vending	103	110	O
machine	111	118	O
containing	119	129	O
sweets	130	136	O
and	137	140	O
candy	141	146	O
bars	147	151	O
(	152	153	O
81	153	155	O
%	155	156	O
,	156	157	O
n	158	159	O
=	160	161	O
413	162	165	O
)	165	166	O
is	167	169	O
present	170	177	O
(	178	179	O
Table	179	184	O
2	185	186	O
)	186	187	O
.	187	188	O

At	189	191	O
78	192	194	O
%	194	195	O
(	196	197	O
n	197	198	O
=	199	200	O
393	201	204	O
)	204	205	O
of	206	208	O
the	209	212	O
schools	213	220	O
there	221	226	O
is	227	229	O
a	230	231	O
supermarket	232	243	O
,	243	244	O
gas	245	248	O
station	249	256	O
or	257	259	O
a	260	261	O
fast	262	266	O
food	267	271	O
restaurant	272	282	O
in	283	285	O
the	286	289	O
neighbourhood	290	303	O
(	304	305	O
within	305	311	O
1	312	313	O
km	314	316	O
of	317	319	O
the	320	323	O
school	324	330	O
)	330	331	O
.	331	332	O

At	333	335	O
68	336	338	O
%	338	339	O
(	340	341	O
n	341	342	O
=	343	344	O
345	345	348	O
)	348	349	O
of	350	352	O
the	353	356	O
schools	357	364	O
there	365	370	O
are	371	374	O
facilities	375	385	O
at	386	388	O
or	389	391	O
around	392	398	O
the	399	402	O
school	403	409	O
property	410	418	O
where	419	424	O
the	425	428	O
students	429	437	O
can	438	441	O
be	442	444	O
physically	445	455	O
active	456	462	O
,	462	463	O
for	464	467	O
example	468	475	O
a	476	477	O
soccer	478	484	O
field	485	490	O
or	491	493	O
a	494	495	O
basketball	496	506	O
field	507	512	O
.	512	513	O

Table	514	519	O
2	520	521	O

The	522	525	O
school	526	532	O
environment	533	544	O

Total	545	550	O
School	551	557	O
level	558	563	O

Vocational	564	574	O
education	575	584	O
schools	585	592	O
Mixed	593	598	O
schools	599	606	O
Higher	607	613	O
education	614	623	O
schools	624	631	O
Vocational	632	642	O
education	643	652	O
schools	653	660	O
versus	661	667	O
higher	668	674	O
education	675	684	O
schools	685	692	O
#	692	693	O
Mixed	694	699	O
schools	700	707	O
versus	708	714	O
higher	715	721	O
education	722	731	O
schools	732	739	O
#	739	740	O

n	741	742	O
=	743	744	O
515	745	748	O
n	749	750	O
=	751	752	O
216	753	756	O
n	757	758	O
=	759	760	O
232	761	764	O
n	765	766	O
=	767	768	O
67	769	771	O

%	772	773	O
(	774	775	O
n	775	776	O
)	776	777	O
%	778	779	O
(	780	781	O
n	781	782	O
)	782	783	O
%	784	785	O
(	786	787	O
n	787	788	O
)	788	789	O
%	790	791	O
(	792	793	O
n	793	794	O
)	794	795	O
OR	796	798	O
(	799	800	O
95	800	802	O
%	802	803	O
CI	803	805	O
)	805	806	O
OR	807	809	O
(	810	811	O
95	811	813	O
%	813	814	O
CI	814	816	O
)	816	817	O

Soft	818	822	O
drink	823	828	O
vending	829	836	O
machine	837	844	O
present	845	852	O
at	853	855	O
school	856	862	O
91	863	865	O
.	865	866	O
4	866	867	O
(	868	869	O
466	869	872	O
)	872	873	O
90	874	876	O
.	876	877	O
2	877	878	O
(	879	880	O
194	880	883	O
)	883	884	O
91	885	887	O
.	887	888	O
3	888	889	O
(	890	891	O
209	891	894	O
)	894	895	O
95	896	898	O
.	898	899	O
5	899	900	O
(	901	902	O
63	902	904	O
)	904	905	O
1	906	907	O
.	907	908	O
0	908	909	O
(	910	911	O
0	911	912	O
.	912	913	O
9	913	914	O
;	914	915	O
1	915	916	O
.	916	917	O
1	917	918	O
)	918	919	O
1	920	921	O
.	921	922	O
0	922	923	O
(	924	925	O
0	925	926	O
.	926	927	O
9	927	928	O
;	928	929	O
1	929	930	O
.	930	931	O
0	931	932	O
)	932	933	O

Percentage	934	944	O
of	945	947	O
soft	948	952	O
drink	953	958	O
vending	959	966	O
machines	967	975	O
present	976	983	O
at	984	986	O
school	987	993	O
that	994	998	O
contain	999	1006	O
light	1007	1012	O
soft	1013	1017	O
drinks	1018	1024	O
79	1025	1027	O
.	1027	1028	O
8	1028	1029	O
(	1030	1031	O
372	1031	1034	O
)	1034	1035	O
75	1036	1038	O
.	1038	1039	O
4	1039	1040	O
(	1041	1042	O
147	1042	1045	O
)	1045	1046	O
82	1047	1049	O
.	1049	1050	O
2	1050	1051	O
(	1052	1053	O
171	1053	1056	O
)	1056	1057	O
85	1058	1060	O
.	1060	1061	O
7	1061	1062	O
(	1063	1064	O
54	1064	1066	O
)	1066	1067	O
0	1068	1069	O
.	1069	1070	O
9	1070	1071	O
(	1072	1073	O
0	1073	1074	O
.	1074	1075	O
8	1075	1076	O
;	1076	1077	O
1	1077	1078	O
.	1078	1079	O
0	1079	1080	O
)	1080	1081	O
1	1082	1083	O
.	1083	1084	O
0	1084	1085	O
(	1086	1087	O
0	1087	1088	O
.	1088	1089	O
9	1089	1090	O
;	1090	1091	O
1	1091	1092	O
.	1092	1093	O
1	1093	1094	O
)	1094	1095	O

Soft	1096	1100	O
drink	1101	1106	O
vending	1107	1114	O
machines	1115	1123	O
contain	1124	1131	O
more	1132	1136	O
unhealthy	1137	1146	O
drinks	1147	1153	O
than	1154	1158	O
healthy	1159	1166	O
drinks	1167	1173	O
57	1174	1176	O
.	1176	1177	O
9	1177	1178	O
(	1179	1180	O
268	1180	1183	O
)	1183	1184	O
61	1185	1187	O
.	1187	1188	O
9	1188	1189	O
(	1190	1191	O
120	1191	1194	O
)	1194	1195	O
58	1196	1198	O
.	1198	1199	O
5	1199	1200	O
(	1201	1202	O
121	1202	1205	O
)	1205	1206	O
43	1207	1209	O
.	1209	1210	O
6	1210	1211	O
(	1212	1213	O
27	1213	1215	O
)	1215	1216	O
1	1217	1218	O
.	1218	1219	O
4	1219	1220	O
(	1221	1222	O
1	1222	1223	O
.	1223	1224	O
0	1224	1225	O
;	1225	1226	O
1	1226	1227	O
.	1227	1228	O
9	1228	1229	O
)	1229	1230	O
1	1231	1232	O
.	1232	1233	O
4	1233	1234	O
(	1235	1236	O
1	1236	1237	O
.	1237	1238	O
0	1238	1239	O
;	1239	1240	O
1	1240	1241	O
.	1241	1242	O
9	1242	1243	O
)	1243	1244	O
*	1244	1245	O

Vending	1246	1253	O
machine	1254	1261	O
present	1262	1269	O
at	1270	1272	O
school	1273	1279	O
that	1280	1284	O
contains	1285	1293	O
sweets	1294	1300	O
/	1300	1301	O
candy	1301	1306	O
bars	1307	1311	O
80	1312	1314	O
.	1314	1315	O
7	1315	1316	O
(	1317	1318	O
413	1318	1321	O
)	1321	1322	O
75	1323	1325	O
.	1325	1326	O
6	1326	1327	O
(	1328	1329	O
161	1329	1332	O
)	1332	1333	O
84	1334	1336	O
.	1336	1337	O
9	1337	1338	O
(	1339	1340	O
197	1340	1343	O
)	1343	1344	O
82	1345	1347	O
.	1347	1348	O
1	1348	1349	O
(	1350	1351	O
55	1351	1353	O
)	1353	1354	O
1	1355	1356	O
.	1356	1357	O
1	1357	1358	O
(	1359	1360	O
0	1360	1361	O
.	1361	1362	O
9	1362	1363	O
;	1363	1364	O
1	1364	1365	O
.	1365	1366	O
2	1366	1367	O
)	1367	1368	O
1	1369	1370	O
.	1370	1371	O
1	1371	1372	O
(	1373	1374	O
1	1374	1375	O
.	1375	1376	O
0	1376	1377	O
;	1377	1378	O
1	1378	1379	O
.	1379	1380	O
2	1380	1381	O
)	1381	1382	O

Sweets	1383	1389	O
/	1389	1390	O
candy	1390	1395	O
bars	1396	1400	O
vending	1401	1408	O
machines	1409	1417	O
contain	1418	1425	O
more	1426	1430	O
unhealthy	1431	1440	O
than	1441	1445	O
healthy	1446	1453	O
foods	1454	1459	O
63	1460	1462	O
.	1462	1463	O
7	1463	1464	O
(	1465	1466	O
260	1466	1469	O
)	1469	1470	O
70	1471	1473	O
.	1473	1474	O
6	1474	1475	O
(	1476	1477	O
113	1477	1480	O
)	1480	1481	O
64	1482	1484	O
.	1484	1485	O
4	1485	1486	O
(	1487	1488	O
125	1488	1491	O
)	1491	1492	O
40	1493	1495	O
.	1495	1496	O
7	1496	1497	O
(	1498	1499	O
22	1499	1501	O
)	1501	1502	O
1	1503	1504	O
.	1504	1505	O
7	1505	1506	O
(	1507	1508	O
1	1508	1509	O
.	1509	1510	O
2	1510	1511	O
;	1511	1512	O
2	1512	1513	O
.	1513	1514	O
4	1514	1515	O
)	1515	1516	O
*	1516	1517	O
1	1518	1519	O
.	1519	1520	O
6	1520	1521	O
(	1522	1523	O
1	1523	1524	O
.	1524	1525	O
1	1525	1526	O
;	1526	1527	O
2	1527	1528	O
.	1528	1529	O
3	1529	1530	O
)	1530	1531	O
*	1531	1532	O

There	1533	1538	O
is	1539	1541	O
a	1542	1543	O
supermarket	1544	1555	O
,	1555	1556	O
gas	1557	1560	O
station	1561	1568	O
,	1568	1569	O
or	1570	1572	O
fast	1573	1577	O
food	1578	1582	O
restaurant	1583	1593	O
in	1594	1596	O
the	1597	1600	O
neighbourhood	1601	1614	O
of	1615	1617	O
the	1618	1621	O
school	1622	1628	O
78	1629	1631	O
.	1631	1632	O
3	1632	1633	O
(	1634	1635	O
393	1635	1638	O
)	1638	1639	O
76	1640	1642	O
.	1642	1643	O
7	1643	1644	O
(	1645	1646	O
161	1646	1649	O
)	1649	1650	O
79	1651	1653	O
.	1653	1654	O
7	1654	1655	O
(	1656	1657	O
181	1657	1660	O
)	1660	1661	O
78	1662	1664	O
.	1664	1665	O
5	1665	1666	O
(	1667	1668	O
51	1668	1670	O
)	1670	1671	O
1	1672	1673	O
.	1673	1674	O
1	1674	1675	O
(	1676	1677	O
0	1677	1678	O
.	1678	1679	O
9	1679	1680	O
;	1680	1681	O
1	1681	1682	O
.	1682	1683	O
2	1683	1684	O
)	1684	1685	O
1	1686	1687	O
.	1687	1688	O
1	1688	1689	O
(	1690	1691	O
0	1691	1692	O
.	1692	1693	O
9	1693	1694	O
;	1694	1695	O
1	1695	1696	O
.	1696	1697	O
2	1697	1698	O
)	1698	1699	O

The	1700	1703	O
students	1704	1712	O
are	1713	1716	O
allowed	1717	1724	O
to	1725	1727	O
leave	1728	1733	O
the	1734	1737	O
school	1738	1744	O
property	1745	1753	O
during	1754	1760	O
school	1761	1767	O
hours	1768	1773	O
57	1774	1776	O
.	1776	1777	O
4	1777	1778	O
(	1779	1780	O
295	1780	1783	O
)	1783	1784	O
42	1785	1787	O
.	1787	1788	O
6	1788	1789	O
(	1790	1791	O
92	1791	1793	O
)	1793	1794	O
65	1795	1797	O
.	1797	1798	O
8	1798	1799	O
(	1800	1801	O
152	1801	1804	O
)	1804	1805	O
76	1806	1808	O
.	1808	1809	O
1	1809	1810	O
(	1811	1812	O
51	1812	1814	O
)	1814	1815	O
0	1816	1817	O
.	1817	1818	O
6	1818	1819	O
(	1820	1821	O
0	1821	1822	O
.	1822	1823	O
5	1823	1824	O
;	1824	1825	O
0	1825	1826	O
.	1826	1827	O
8	1827	1828	O
)	1828	1829	O
*	1829	1830	O
0	1831	1832	O
.	1832	1833	O
9	1833	1834	O
(	1835	1836	O
0	1836	1837	O
.	1837	1838	O
8	1838	1839	O
;	1839	1840	O
1	1840	1841	O
.	1841	1842	O
0	1842	1843	O
)	1843	1844	O

There	1845	1850	O
are	1851	1854	O
facilities	1855	1865	O
at	1866	1868	O
and	1869	1872	O
around	1873	1879	O
the	1880	1883	O
school	1884	1890	O
property	1891	1899	O
where	1900	1905	O
the	1906	1909	O
students	1910	1918	O
can	1919	1922	O
be	1923	1925	O
physically	1926	1936	O
active	1937	1943	O
68	1944	1946	O
.	1946	1947	O
1	1947	1948	O
(	1949	1950	O
345	1950	1953	O
)	1953	1954	O
63	1955	1957	O
.	1957	1958	O
1	1958	1959	O
(	1960	1961	O
135	1961	1964	O
)	1964	1965	O
70	1966	1968	O
.	1968	1969	O
3	1969	1970	O
(	1971	1972	O
161	1972	1975	O
)	1975	1976	O
76	1977	1979	O
.	1979	1980	O
6	1980	1981	O
(	1982	1983	O
49	1983	1985	O
)	1985	1986	O
0	1987	1988	O
.	1988	1989	O
8	1989	1990	O
(	1991	1992	O
0	1992	1993	O
.	1993	1994	O
7	1994	1995	O
;	1995	1996	O
1	1996	1997	O
.	1997	1998	O
0	1998	1999	O
)	1999	2000	O
0	2001	2002	O
.	2002	2003	O
9	2003	2004	O
(	2005	2006	O
0	2006	2007	O
.	2007	2008	O
8	2008	2009	O
;	2009	2010	O
1	2010	2011	O
.	2011	2012	O
1	2012	2013	O
)	2013	2014	O

#	2015	2016	O
Associations	2017	2029	O
are	2030	2033	O
adjusted	2034	2042	O
for	2043	2046	O
school	2047	2053	O
size	2054	2058	O

*	2059	2060	O
p	2061	2062	O
<	2063	2064	O
0	2065	2066	O
.	2066	2067	O
05	2067	2069	O

The	2070	2073	O
vocational	2074	2084	O
education	2085	2094	O
schools	2095	2102	O
did	2103	2106	O
not	2107	2110	O
differ	2111	2117	O
from	2118	2122	O
the	2123	2126	O
higher	2127	2133	O
education	2134	2143	O
schools	2144	2151	O
with	2152	2156	O
regard	2157	2163	O
to	2164	2166	O
the	2167	2170	O
presence	2171	2179	O
of	2180	2182	O
vending	2183	2190	O
machines	2191	2199	O
and	2200	2203	O
a	2204	2205	O
canteen	2206	2213	O
,	2213	2214	O
but	2215	2218	O
the	2219	2222	O
vending	2223	2230	O
machines	2231	2239	O
and	2240	2243	O
the	2244	2247	O
canteen	2248	2255	O
contained	2256	2265	O
a	2266	2267	O
less	2268	2272	O
favourable	2273	2283	O
selection	2284	2293	O
of	2294	2296	O
foods	2297	2302	O
and	2303	2306	O
drinks	2307	2313	O
.	2313	2314	O

The	2315	2318	O
vocational	2319	2329	O
education	2330	2339	O
schools	2340	2347	O
indicated	2348	2357	O
more	2358	2362	O
often	2363	2368	O
that	2369	2373	O
the	2374	2377	O
vending	2378	2385	O
machines	2386	2394	O
and	2395	2398	O
the	2399	2402	O
canteen	2403	2410	O
contained	2411	2420	O
more	2421	2425	O
unhealthy	2426	2435	O
foods	2436	2441	O
and	2442	2445	O
drinks	2446	2452	O
than	2453	2457	O
healthy	2458	2465	O
foods	2466	2471	O
and	2472	2475	O
drinks	2476	2482	O
.	2482	2483	O

Vocational	2484	2494	O
education	2495	2504	O
schools	2505	2512	O
had	2513	2516	O
fewer	2517	2522	O
facilities	2523	2533	O
at	2534	2536	O
and	2537	2540	O
around	2541	2547	O
the	2548	2551	O
school	2552	2558	O
property	2559	2567	O
to	2568	2570	O
be	2571	2573	O
physical	2574	2582	O
than	2583	2587	O
the	2588	2591	O
higher	2592	2598	O
education	2599	2608	O
schools	2609	2616	O
.	2616	2617	O

Most	2618	2622	O
associations	2623	2635	O
were	2636	2640	O
attenuated	2641	2651	O
after	2652	2657	O
adjustment	2658	2668	O
for	2669	2672	O
school	2673	2679	O
size	2680	2684	O
.	2684	2685	O

For	2686	2689	O
example	2690	2697	O
,	2697	2698	O
the	2699	2702	O
association	2703	2714	O
between	2715	2722	O
school	2723	2729	O
level	2730	2735	O
and	2736	2739	O
content	2740	2747	O
of	2748	2750	O
the	2751	2754	O
soft	2755	2759	O
drink	2760	2765	O
vending	2766	2773	O
machines	2774	2782	O
was	2783	2786	O
OR	2787	2789	O
=	2790	2791	O
1	2792	2793	O
.	2793	2794	O
42	2794	2796	O
,	2796	2797	O
95	2798	2800	O
%	2800	2801	O
CI	2801	2803	O
:	2803	2804	O
1	2805	2806	O
.	2806	2807	O
05	2807	2809	O
-	2809	2810	O
1	2810	2811	O
.	2811	2812	O
93	2812	2814	O
in	2815	2817	O
the	2818	2821	O
crude	2822	2827	O
analysis	2828	2836	O
and	2837	2840	O
OR	2841	2843	O
=	2844	2845	O
1	2846	2847	O
.	2847	2848	O
35	2848	2850	O
,	2850	2851	O
95	2852	2854	O
%	2854	2855	O
CI	2855	2857	O
:	2857	2858	O
0	2859	2860	O
.	2860	2861	O
99	2861	2863	O
-	2863	2864	O
1	2864	2865	O
.	2865	2866	O
85	2866	2868	O
in	2869	2871	O
the	2872	2875	O
adjusted	2876	2884	O
analysis	2885	2893	O
.	2893	2894	O

Background	0	10	O

Over	11	15	O
the	16	19	O
past	20	24	O
decades	25	32	O
,	32	33	O
extensive	34	43	O
comparative	44	55	O
mapping	56	63	O
research	64	72	O
has	73	76	O
been	77	81	O
performed	82	91	O
in	92	94	O
the	95	98	O
plant	99	104	O
family	105	111	O
Solanaceae	112	122	O
.	122	123	O

The	124	127	O
recent	128	134	O
identification	135	149	O
of	150	152	O
a	153	154	O
large	155	160	O
set	161	164	O
of	165	167	O
single	168	174	O
-	174	175	O
copy	175	179	O
conserved	180	189	O
orthologous	190	201	O
(	202	203	O
COSII	203	208	O
)	208	209	O
markers	210	217	O
has	218	221	O
greatly	222	229	O
accelerated	230	241	O
comparative	242	253	O
mapping	254	261	O
studies	262	269	O
among	270	275	O
major	276	281	O
solanaceous	282	293	O
species	294	301	O
including	302	311	O
tomato	312	318	O
,	318	319	O
potato	320	326	O
,	326	327	O
eggplant	328	336	O
,	336	337	O
pepper	338	344	O
and	345	348	O
diploid	349	356	O
Nicotiana	357	366	O
species	367	374	O
(	375	376	O
as	376	378	O
well	379	383	O
as	384	386	O
tetraploid	387	397	O
tobacco	398	405	O
)	405	406	O
.	406	407	O

The	408	411	O
large	412	417	O
amount	418	424	O
of	425	427	O
comparative	428	439	O
data	440	444	O
now	445	448	O
available	449	458	O
for	459	462	O
these	463	468	O
species	469	476	O
provides	477	485	O
the	486	489	O
opportunity	490	501	O
to	502	504	O
describe	505	513	O
the	514	517	O
overall	518	525	O
patterns	526	534	O
of	535	537	O
chromosomal	538	549	B-Cellular_component
evolution	550	559	O
in	560	562	O
this	563	567	O
important	568	577	O
plant	578	583	O
family	584	590	O
.	590	591	O

The	592	595	O
results	596	603	O
of	604	606	O
this	607	611	O
investigation	612	625	O
are	626	629	O
described	630	639	O
herein	640	646	O
.	646	647	O

Introduction	0	12	O

Tea	13	16	O
(	17	18	O
Camellia	18	26	O
sinensis	27	35	O
L	36	37	O
.	37	38	O
)	38	39	O
is	40	42	O
one	43	46	O
of	47	49	O
the	50	53	O
most	54	58	O
widely	59	65	O
consumed	66	74	O
beverages	75	84	O
in	85	87	O
the	88	91	O
world	92	97	O
.	97	98	O

(	99	100	O
-	100	101	O
)	101	102	O
-	102	103	O
Epigallocatechin	103	119	O
-	119	120	O
3	120	121	O
-	121	122	O
O	122	123	O
-	123	124	O
gallate	124	131	O
(	132	133	O
EGCG	133	137	O
)	137	138	O
,	138	139	O
which	140	145	O
is	146	148	O
the	149	152	O
major	153	158	O
green	159	164	O
tea	165	168	O
catechin	169	177	O
present	178	185	O
in	186	188	O
the	189	192	O
leaves	193	199	B-Organ
,	199	200	O
is	201	203	O
believed	204	212	O
to	213	215	O
the	216	219	O
compound	220	228	O
most	229	233	O
responsible	234	245	O
for	246	249	O
the	250	253	O
health	254	260	O
benefits	261	269	O
attributed	270	280	O
to	281	283	O
tea	284	287	O
.	287	288	O

EGCG	289	293	O
was	294	297	O
reported	298	306	O
to	307	309	O
have	310	314	O
antioxidative	315	328	O
[	329	330	O
1	330	331	O
]	331	332	O
,	332	333	O
[	334	335	O
2	335	336	O
]	336	337	O
,	337	338	O
antimutagenic	339	352	O
[	353	354	O
3	354	355	O
]	355	356	O
,	356	357	O
anti	358	362	O
-	362	363	O
inflammatory	363	375	O
[	376	377	O
4	377	378	O
]	378	379	O
,	379	380	O
and	381	384	O
anticarcinogenic	385	401	O
activities	402	412	O
[	413	414	O
5	414	415	O
]	415	416	O
.	416	417	O

Although	418	426	O
the	427	430	O
EGCG	431	435	O
concentrations	436	450	O
required	451	459	O
to	460	462	O
elicit	463	469	O
the	470	473	O
anticancer	474	484	B-Pathological_formation
activity	485	493	O
have	494	498	O
been	499	503	O
shown	504	509	O
to	510	512	O
be	513	515	O
more	516	520	O
than	521	525	O
1	526	527	O
microM	528	534	O
,	534	535	O
the	536	539	O
blood	540	545	B-Organism_substance
level	546	551	O
of	552	554	O
EGCG	555	559	O
after	560	565	O
consuming	566	575	O
the	576	579	O
equivalent	580	590	O
of	591	593	O
2	594	595	O
-	595	596	O
3	596	597	O
cups	598	602	O
of	603	605	O
green	606	611	O
tea	612	615	O
was	616	619	O
0	620	621	O
.	621	622	O
1	622	623	O
-	623	624	O
0	624	625	O
.	625	626	O
6	626	627	O
microM	628	634	O
and	635	638	O
for	639	642	O
an	643	645	O
equivalent	646	656	O
of	657	659	O
7	660	661	O
-	661	662	O
9	662	663	O
cups	664	668	O
was	669	672	O
still	673	678	O
lower	679	684	O
than	685	689	O
1	690	691	O
microM	692	698	O
[	699	700	O
6	700	701	O
]	701	702	O
,	702	703	O
[	704	705	O
7	705	706	O
]	706	707	O
.	707	708	O

In	709	711	O
a	712	713	O
cohort	714	720	O
study	721	726	O
,	726	727	O
daily	728	733	O
consumption	734	745	O
of	746	748	O
ten	749	752	O
cups	753	757	O
of	758	760	O
green	761	766	O
tea	767	770	O
was	771	774	O
required	775	783	O
for	784	787	O
the	788	791	O
cancer	792	798	B-Pathological_formation
preventive	799	809	O
effect	810	816	O
[	817	818	O
8	818	819	O
]	819	820	O
.	820	821	O

Moreover	822	830	O
,	830	831	O
adverse	832	839	O
effects	840	847	O
of	848	850	O
green	851	856	O
tea	857	860	O
,	860	861	O
mainly	862	868	O
hepatitis	869	878	O
,	878	879	O
by	880	882	O
consumption	883	894	O
of	895	897	O
high	898	902	O
doses	903	908	O
of	909	911	O
green	912	917	O
tea	918	921	O
have	922	926	O
been	927	931	O
reported	932	940	O
[	941	942	O
9	942	943	O
]	943	944	O
.	944	945	O

Therefore	946	955	O
,	955	956	O
it	957	959	O
is	960	962	O
important	963	972	O
to	973	975	O
enhance	976	983	O
the	984	987	O
pharmacologic	988	1001	O
effect	1002	1008	O
of	1009	1011	O
EGCG	1012	1016	O
to	1017	1019	O
obtain	1020	1026	O
the	1027	1030	O
health	1031	1037	O
benefit	1038	1045	O
in	1046	1048	O
reasonable	1049	1059	O
concentration	1060	1073	O
in	1074	1076	O
daily	1077	1082	O
life	1083	1087	O
.	1087	1088	O

We	1089	1091	O
have	1092	1096	O
reported	1097	1105	O
that	1106	1110	O
the	1111	1114	O
cell	1115	1119	B-Cellular_component
-	1119	1120	I-Cellular_component
surface	1120	1127	I-Cellular_component
binding	1128	1135	O
of	1136	1138	O
EGCG	1139	1143	O
and	1144	1147	O
its	1148	1151	O
derivatives	1152	1163	O
is	1164	1166	O
involved	1167	1175	O
in	1176	1178	O
their	1179	1184	O
biological	1185	1195	O
activities	1196	1206	O
[	1207	1208	O
10	1208	1210	O
]	1210	1211	O
-	1211	1212	O
[	1212	1213	O
15	1213	1215	O
]	1215	1216	O
.	1216	1217	O

We	1218	1220	O
have	1221	1225	O
identified	1226	1236	O
the	1237	1240	O
67	1241	1243	O
-	1243	1244	O
kDa	1244	1247	O
laminin	1248	1255	O
receptor	1256	1264	O
(	1265	1266	O
67LR	1266	1270	O
)	1270	1271	O
as	1272	1274	O
a	1275	1276	O
cell	1277	1281	B-Cellular_component
surface	1282	1289	I-Cellular_component
receptor	1290	1298	O
for	1299	1302	O
EGCG	1303	1307	O
that	1308	1312	O
mediates	1313	1321	O
the	1322	1325	O
anticancer	1326	1336	O
activity	1337	1345	O
of	1346	1348	O
EGCG	1349	1353	O
[	1354	1355	O
16	1355	1357	O
]	1357	1358	O
.	1358	1359	O

67LR	1360	1364	O
has	1365	1368	O
been	1369	1373	O
shown	1374	1379	O
to	1380	1382	O
be	1383	1385	O
overexpressed	1386	1399	O
on	1400	1402	O
the	1403	1406	O
cell	1407	1411	B-Cellular_component
surface	1412	1419	I-Cellular_component
of	1420	1422	O
various	1423	1430	O
tumor	1431	1436	B-Cell
cells	1437	1442	I-Cell
[	1443	1444	O
17	1444	1446	O
]	1446	1447	O
.	1447	1448	O

It	1449	1451	O
was	1452	1455	O
postulated	1456	1466	O
that	1467	1471	O
67LR	1472	1476	O
plays	1477	1482	O
a	1483	1484	O
significant	1485	1496	O
role	1497	1501	O
in	1502	1504	O
the	1505	1508	O
tumor	1509	1514	B-Pathological_formation
progression	1515	1526	O
and	1527	1530	O
speculated	1531	1541	O
that	1542	1546	O
studies	1547	1554	O
conducted	1555	1564	O
to	1565	1567	O
define	1568	1574	O
the	1575	1578	O
function	1579	1587	O
of	1588	1590	O
67LR	1591	1595	O
could	1596	1601	O
provide	1602	1609	O
a	1610	1611	O
new	1612	1615	O
approach	1616	1624	O
to	1625	1627	O
cancer	1628	1634	B-Pathological_formation
prevention	1635	1645	O
.	1645	1646	O

Indeed	1647	1653	O
,	1653	1654	O
expression	1655	1665	O
of	1666	1668	O
67	1669	1671	O
LR	1672	1674	O
confers	1675	1682	O
EGCG	1683	1687	O
responsiveness	1688	1702	O
to	1703	1705	O
tumor	1706	1711	B-Cell
cells	1712	1717	I-Cell
in	1718	1720	O
vivo	1721	1725	O
[	1726	1727	O
18	1727	1729	O
]	1729	1730	O
.	1730	1731	O

Vitamin	1732	1739	O
A	1740	1741	O
,	1741	1742	O
also	1743	1747	O
known	1748	1753	O
as	1754	1756	O
retinol	1757	1764	O
,	1764	1765	O
participates	1766	1778	O
in	1779	1781	O
physiological	1782	1795	O
activities	1796	1806	O
related	1807	1814	O
to	1815	1817	O
the	1818	1821	O
immune	1822	1828	O
system	1829	1835	O
,	1835	1836	O
maintenance	1837	1848	O
of	1849	1851	O
epithelial	1852	1862	B-Tissue
and	1863	1866	O
mucosa	1867	1873	B-Tissue
tissues	1874	1881	I-Tissue
,	1881	1882	O
growth	1883	1889	O
,	1889	1890	O
reproduction	1891	1903	O
,	1903	1904	O
and	1905	1908	O
bone	1909	1913	B-Organ
development	1914	1925	O
.	1925	1926	O

It	1927	1929	O
comes	1930	1935	O
from	1936	1940	O
animal	1941	1947	O
sources	1948	1955	O
,	1955	1956	O
such	1957	1961	O
as	1962	1964	O
eggs	1965	1969	B-Organism_substance
,	1969	1970	O
meat	1971	1975	B-Organism_subdivision
,	1975	1976	O
milk	1977	1981	B-Organism_substance
,	1981	1982	O
cheese	1983	1989	O
,	1989	1990	O
cream	1991	1996	O
,	1996	1997	O
liver	1998	2003	B-Organ
,	2003	2004	O
kidney	2005	2011	B-Organ
,	2011	2012	O
cod	2013	2016	O
and	2017	2020	O
halibut	2021	2028	O
fish	2029	2033	O
oil	2034	2037	B-Organism_substance
.	2037	2038	O

In	2039	2041	O
vitro	2042	2047	O
and	2048	2051	O
in	2052	2054	O
animal	2055	2061	O
models	2062	2068	O
,	2068	2069	O
it	2070	2072	O
has	2073	2076	O
been	2077	2081	O
demonstrated	2082	2094	O
that	2095	2099	O
vitamin	2100	2107	O
A	2108	2109	O
is	2110	2112	O
involved	2113	2121	O
in	2122	2124	O
the	2125	2128	O
regulation	2129	2139	O
and	2140	2143	O
promotion	2144	2153	O
of	2154	2156	O
growth	2157	2163	O
and	2164	2167	O
differentiation	2168	2183	O
of	2184	2186	O
many	2187	2191	O
cells	2192	2197	B-Cell
[	2198	2199	O
19	2199	2201	O
]	2201	2202	O
.	2202	2203	O

The	2204	2207	O
visual	2208	2214	O
function	2215	2223	O
of	2224	2226	O
vitamin	2227	2234	O
A	2235	2236	O
depends	2237	2244	O
on	2245	2247	O
its	2248	2251	O
natural	2252	2259	O
and	2260	2263	O
synthetic	2264	2273	O
derivatives	2274	2285	O
,	2285	2286	O
retinoids	2287	2296	O
[	2297	2298	O
20	2298	2300	O
]	2300	2301	O
.	2301	2302	O

All	2303	2306	O
-	2306	2307	O
trans	2307	2312	O
-	2312	2313	O
retinoic	2313	2321	O
acid	2322	2326	O
(	2327	2328	O
ATRA	2328	2332	O
)	2332	2333	O
,	2333	2334	O
the	2335	2338	O
active	2339	2345	O
derivative	2346	2356	O
of	2357	2359	O
vitamin	2360	2367	O
A	2368	2369	O
,	2369	2370	O
has	2371	2374	O
been	2375	2379	O
well	2380	2384	O
documented	2385	2395	O
as	2396	2398	O
a	2399	2400	O
growth	2401	2407	O
and	2408	2411	O
differentiation	2412	2427	O
factor	2428	2434	O
in	2435	2437	O
many	2438	2442	O
tissues	2443	2450	B-Tissue
and	2451	2454	O
cells	2455	2460	B-Cell
,	2460	2461	O
and	2462	2465	O
proved	2466	2472	O
to	2473	2475	O
be	2476	2478	O
an	2479	2481	O
effective	2482	2491	O
treatment	2492	2501	O
to	2502	2504	O
many	2505	2509	O
diseases	2510	2518	O
including	2519	2528	O
cancers	2529	2536	B-Pathological_formation
[	2537	2538	O
21	2538	2540	O
]	2540	2541	O
,	2541	2542	O
[	2543	2544	O
22	2544	2546	O
]	2546	2547	O
.	2547	2548	O

Retinoids	2549	2558	O
exert	2559	2564	O
their	2565	2570	O
physiological	2571	2584	O
activities	2585	2595	O
through	2596	2603	O
retinoid	2604	2612	O
receptor	2613	2621	O
nuclear	2622	2629	B-Cellular_component
proteins	2630	2638	O
that	2639	2643	O
belong	2644	2650	O
to	2651	2653	O
the	2654	2657	O
superfamily	2658	2669	O
of	2670	2672	O
steroid	2673	2680	O
/	2680	2681	O
thyroid	2681	2688	O
hormone	2689	2696	O
receptors	2697	2706	O
,	2706	2707	O
of	2708	2710	O
which	2711	2716	O
there	2717	2722	O
are	2723	2726	O
two	2727	2730	O
classes	2731	2738	O
,	2738	2739	O
retinoic	2740	2748	O
acid	2749	2753	O
receptors	2754	2763	O
(	2764	2765	O
RARs	2765	2769	O
)	2769	2770	O
and	2771	2774	O
the	2775	2778	O
retinoic	2779	2787	O
-	2787	2788	O
X	2788	2789	O
receptors	2790	2799	O
(	2800	2801	O
RXRs	2801	2805	O
)	2805	2806	O
,	2806	2807	O
each	2808	2812	O
of	2813	2815	O
which	2816	2821	O
has	2822	2825	O
three	2826	2831	O
subtypes	2832	2840	O
,	2840	2841	O
alpha	2842	2847	O
,	2847	2848	O
beta	2849	2853	O
,	2853	2854	O
and	2855	2858	O
gamma	2859	2864	O
[	2865	2866	O
23	2866	2868	O
]	2868	2869	O
,	2869	2870	O
[	2871	2872	O
24	2872	2874	O
]	2874	2875	O
.	2875	2876	O

The	2877	2880	O
natural	2881	2888	O
ligands	2889	2896	O
for	2897	2900	O
the	2901	2904	O
RARs	2905	2909	O
are	2910	2913	O
ATRA	2914	2918	O
and	2919	2922	O
its	2923	2926	O
stereoisomers	2927	2940	O
9	2941	2942	O
-	2942	2943	O
cis	2943	2946	O
-	2946	2947	O
RA	2947	2949	O
and	2950	2953	O
13	2954	2956	O
-	2956	2957	O
cis	2957	2960	O
-	2960	2961	O
RA	2961	2963	O
,	2963	2964	O
whereas	2965	2972	O
RXRs	2973	2977	O
are	2978	2981	O
activated	2982	2991	O
by	2992	2994	O
9	2995	2996	O
-	2996	2997	O
cis	2997	3000	O
-	3000	3001	O
RA	3001	3003	O
only	3004	3008	O
.	3008	3009	O

ATRA	3010	3014	O
acts	3015	3019	O
through	3020	3027	O
RAR	3028	3031	O
to	3032	3034	O
transcriptionally	3035	3052	O
activate	3053	3061	O
target	3062	3068	O
genes	3069	3074	O
,	3074	3075	O
such	3076	3080	O
as	3081	3083	O
cytochrome	3084	3094	O
P450	3095	3099	O
and	3100	3103	O
CRABI	3104	3109	O
[	3110	3111	O
24	3111	3113	O
]	3113	3114	O
.	3114	3115	O

This	3116	3120	O
study	3121	3126	O
was	3127	3130	O
designed	3131	3139	O
to	3140	3142	O
identify	3143	3151	O
a	3152	3153	O
food	3154	3158	O
component	3159	3168	O
that	3169	3173	O
could	3174	3179	O
be	3180	3182	O
effectively	3183	3194	O
used	3195	3199	O
in	3200	3202	O
combination	3203	3214	O
with	3215	3219	O
EGCG	3220	3224	O
and	3225	3228	O
to	3229	3231	O
investigate	3232	3243	O
the	3244	3247	O
mechanism	3248	3257	O
of	3258	3260	O
action	3261	3267	O
of	3268	3270	O
this	3271	3275	O
combination	3276	3287	O
.	3287	3288	O

By	3289	3291	O
using	3292	3297	O
in	3298	3300	O
vitro	3301	3306	O
and	3307	3310	O
in	3311	3313	O
vivo	3314	3318	O
systems	3319	3326	O
involving	3327	3336	O
a	3337	3338	O
highly	3339	3345	O
metastatic	3346	3356	O
mouse	3357	3362	O
B16	3363	3366	B-Cell
melanoma	3367	3375	I-Cell
cell	3376	3380	I-Cell
line	3381	3385	I-Cell
[	3386	3387	O
25	3387	3389	O
]	3389	3390	O
,	3390	3391	O
we	3392	3394	O
found	3395	3400	O
that	3401	3405	O
ATRA	3406	3410	O
enhances	3411	3419	O
the	3420	3423	O
antitumor	3424	3433	B-Pathological_formation
activity	3434	3442	O
of	3443	3445	O
EGCG	3446	3450	O
by	3451	3453	O
upregulating	3454	3466	O
the	3467	3470	O
67	3471	3473	O
LR	3474	3476	O
expression	3477	3487	O
through	3488	3495	O
RAR	3496	3499	O
.	3499	3500	O

Titration	0	9	O
of	10	12	O
Ab	13	15	O
-	15	16	O
01	16	18	O
inhibition	19	29	O
of	30	32	O
ex	33	35	O
vivo	36	40	O
response	41	49	O
to	50	52	O
rhIL21	53	59	O

Samples	60	67	O
from	68	72	O
4	73	74	O
individual	75	85	O
healthy	86	93	O
human	94	99	O
donors	100	106	O
were	107	111	O
pre	112	115	O
-	115	116	O
incubated	116	125	O
for	126	129	O
2	130	131	O
hours	132	137	O
at	138	140	O
the	141	144	O
indicated	145	154	O
concentration	155	168	O
of	169	171	O
Ab	172	174	O
-	174	175	O
01	175	177	O
or	178	180	O
the	181	184	O
control	185	192	O
IgG1TM	193	199	O
prior	200	205	O
to	206	208	O
addition	209	217	O
of	218	220	O
10	221	223	O
ng	224	226	O
/	226	227	O
mL	227	229	O
rhIL21	230	236	O
and	237	240	O
2	241	242	O
hr	243	245	O
incubation	246	256	O
,	256	257	O
and	258	261	O
the	262	265	O
effect	266	272	O
on	273	275	O
the	276	279	O
6	280	281	O
biomarkers	282	292	O
was	293	296	O
then	297	301	O
assessed	302	310	O
(	311	312	O
Figures	312	319	O
4	320	321	O
and	322	325	O
5	326	327	O
)	327	328	O
.	328	329	O

For	330	333	O
the	334	337	O
first	338	343	O
2	344	345	O
donors	346	352	O
tested	353	359	O
,	359	360	O
even	361	365	O
the	366	369	O
lowest	370	376	O
concentration	377	390	O
of	391	393	O
Ab	394	396	O
-	396	397	O
01	397	399	O
(	400	401	O
0	401	402	O
.	402	403	O
1	403	404	O
mug	405	408	O
/	408	409	O
mL	409	411	O
,	411	412	O
0	413	414	O
.	414	415	O
66	415	417	O
nM	418	420	O
)	420	421	O
resulted	422	430	O
in	431	433	O
complete	434	442	O
inhibition	443	453	O
of	454	456	O
the	457	460	O
rhIL21	461	467	O
response	468	476	O
,	476	477	O
therefore	478	487	O
the	488	491	O
two	492	495	O
subsequent	496	506	O
donors	507	513	O
were	514	518	O
tested	519	525	O
at	526	528	O
increasing	529	539	O
concentrations	540	554	O
of	555	557	O
Ab	558	560	O
-	560	561	O
01	561	563	O
starting	564	572	O
at	573	575	O
0	576	577	O
.	577	578	O
003	578	581	O
mug	582	585	O
/	585	586	O
mL	586	588	O
.	588	589	O

Ab	590	592	O
-	592	593	O
01	593	595	O
inhibited	596	605	O
the	606	609	O
response	610	618	O
of	619	621	O
all	622	625	O
6	626	627	O
genes	628	633	O
in	634	636	O
all	637	640	O
4	641	642	O
donors	643	649	O
.	649	650	O

IC50	651	655	O
values	656	662	O
ranged	663	669	O
between	670	677	O
0	678	679	O
.	679	680	O
003	680	683	O
and	684	687	O
0	688	689	O
.	689	690	O
015	690	693	O
mug	694	697	O
/	697	698	O
mL	698	700	O
Ab	701	703	O
-	703	704	O
01	704	706	O
(	706	707	O
Figure	707	713	O
5	714	715	O
)	715	716	O
.	716	717	O

Control	718	725	O
IgG1TM	726	732	O
had	733	736	O
no	737	739	O
significant	740	751	O
effect	752	758	O
on	759	761	O
rhIL21	762	768	O
response	769	777	O
(	778	779	O
Figure4B	779	787	O
)	787	788	O
.	788	789	O

Figure	790	796	O
4	797	798	O

Average	799	806	O
percent	807	814	O
inhibition	815	825	O
of	826	828	O
the	829	832	O
expression	833	843	O
level	844	849	O
of	850	852	O
6	853	854	O
IL21	855	859	O
-	859	860	O
responsive	860	870	O
genes	871	876	O
.	876	877	O

Percent	878	885	O
inhibition	886	896	O
values	897	903	O
were	904	908	O
calculated	909	919	O
based	920	925	O
on	926	928	O
RQ	929	931	O
(	932	933	O
relative	933	941	O
quantification	942	956	O
)	956	957	O
values	958	964	O
of	965	967	O
untreated	968	977	O
control	978	985	O
and	986	989	O
rhIL21	990	996	O
-	996	997	O
treated	997	1004	O
samples	1005	1012	O
for	1013	1016	O
each	1017	1021	O
of	1022	1024	O
the	1025	1028	O
4	1029	1030	O
donors	1031	1037	O
,	1037	1038	O
and	1039	1042	O
subsequently	1043	1055	O
the	1056	1059	O
mean	1060	1064	O
and	1065	1068	O
standard	1069	1077	O
deviation	1078	1087	O
were	1088	1092	O
determined	1093	1103	O
for	1104	1107	O
each	1108	1112	O
gene	1113	1117	O
shown	1118	1123	O
.	1123	1124	O

A	1125	1126	O
:	1126	1127	O
Percent	1128	1135	O
inhibition	1136	1146	O
in	1147	1149	O
presence	1150	1158	O
of	1159	1161	O
Ab	1162	1164	O
-	1164	1165	O
01	1165	1167	O
.	1167	1168	O

B	1169	1170	O
:	1170	1171	O
Percent	1172	1179	O
inhibition	1180	1190	O
in	1191	1193	O
presence	1194	1202	O
of	1203	1205	O
control	1206	1213	O
IgG1TM	1214	1220	O
.	1220	1221	O

Data	1222	1226	O
for	1227	1230	O
the	1231	1234	O
0	1235	1236	O
.	1236	1237	O
1	1237	1238	O
mug	1239	1242	O
/	1242	1243	O
mL	1243	1245	O
,	1246	1247	O
0	1248	1249	O
.	1249	1250	O
3	1250	1251	O
mug	1252	1255	O
/	1255	1256	O
mL	1256	1258	O
and	1259	1262	O
1	1263	1264	O
mug	1265	1268	O
/	1268	1269	O
mL	1269	1271	O
concentrations	1272	1286	O
were	1287	1291	O
generated	1292	1301	O
using	1302	1307	O
4	1308	1309	O
donors	1310	1316	O
.	1316	1317	O

Data	1318	1322	O
for	1323	1326	O
the	1327	1330	O
higher	1331	1337	O
and	1338	1341	O
the	1342	1345	O
lower	1346	1351	O
concentrations	1352	1366	O
were	1367	1371	O
generated	1372	1381	O
using	1382	1387	O
2	1388	1389	O
donors	1390	1396	O
.	1396	1397	O

Figure	1398	1404	O
5	1405	1406	O

Inhibition	1407	1417	O
by	1418	1420	O
Ab	1421	1423	O
-	1423	1424	O
01	1424	1426	O
at	1427	1429	O
the	1430	1433	O
indicated	1434	1443	O
concentration	1444	1457	O
is	1458	1460	O
shown	1461	1466	O
for	1467	1470	O
6	1471	1472	O
IL21	1473	1477	O
-	1477	1478	O
responsive	1478	1488	O
genes	1489	1494	O
.	1494	1495	O

IC50	1496	1500	O
values	1501	1507	O
of	1508	1510	O
inhibition	1511	1521	O
curves	1522	1528	O
shown	1529	1534	O
in	1535	1537	O
Figure	1538	1544	O
4A	1545	1547	O
were	1548	1552	O
calculated	1553	1563	O
using	1564	1569	O
curve	1570	1575	O
fit	1576	1579	O
(	1580	1581	O
XLfit	1581	1586	O
)	1586	1587	O
program	1588	1595	O
for	1596	1599	O
each	1600	1604	O
of	1605	1607	O
the	1608	1611	O
referred	1612	1620	O
biomarker	1621	1630	O
genes	1631	1636	O
.	1636	1637	O

Values	1638	1644	O
for	1645	1648	O
the	1649	1652	O
0	1653	1654	O
.	1654	1655	O
1	1655	1656	O
mug	1657	1660	O
/	1660	1661	O
mL	1661	1663	O
,	1663	1664	O
0	1665	1666	O
.	1666	1667	O
3	1667	1668	O
mug	1669	1672	O
/	1672	1673	O
mL	1673	1675	O
and	1676	1679	O
1	1680	1681	O
mug	1682	1685	O
/	1685	1686	O
mL	1686	1688	O
concentrations	1689	1703	O
were	1704	1708	O
generated	1709	1718	O
using	1719	1724	O
4	1725	1726	O
donors	1727	1733	O
.	1733	1734	O

Data	1735	1739	O
for	1740	1743	O
the	1744	1747	O
higher	1748	1754	O
and	1755	1758	O
the	1759	1762	O
lower	1763	1768	O
concentrations	1769	1783	O
were	1784	1788	O
generated	1789	1798	O
using	1799	1804	O
2	1805	1806	O
donors	1807	1813	O
each	1814	1818	O
.	1818	1819	O

INTRODUCTION	0	12	O

For	13	16	O
several	17	24	O
years	25	30	O
now	31	34	O
,	34	35	O
virtual	36	43	O
microscopy	44	54	O
has	55	58	O
been	59	63	O
utilized	64	72	O
in	73	75	O
medical	76	83	O
teaching	84	92	O
,	92	93	O
research	94	102	O
,	102	103	O
proficiency	104	115	O
testing	116	123	O
,	123	124	O
American	125	133	O
Board	134	139	O
of	140	142	O
Pathology	143	152	O
examinations	153	165	O
,	165	166	O
pathology	167	176	O
meetings	177	185	O
and	186	189	O
conferences	190	201	O
,	201	202	O
and	203	206	O
quality	207	214	O
assurance	215	224	O
programs	225	233	O
.	233	234	O

In	235	237	O
diagnostic	238	248	O
practice	249	257	O
,	257	258	O
it	259	261	O
is	262	264	O
most	265	269	O
widely	270	276	O
and	277	280	O
routinely	281	290	O
used	291	295	O
in	296	298	O
image	299	304	O
analysis	305	313	O
.	313	314	O

Some	315	319	O
practices	320	329	O
are	330	333	O
beginning	334	343	O
to	344	346	O
use	347	350	O
it	351	353	O
internally	354	364	O
(	365	366	O
within	366	372	O
their	373	378	O
group	379	384	O
)	384	385	O
for	386	389	O
frozen	390	396	O
section	397	404	O
intraoperative	405	419	O
consultations	420	433	O
and	434	437	O
subspecialty	438	450	O
consultations	451	464	O
due	465	468	O
to	469	471	O
geographic	472	482	O
and	483	486	O
time	487	491	O
constrains	492	502	O
.	502	503	O

Although	504	512	O
diagnostic	513	523	O
consultation	524	536	O
for	537	540	O
expert	541	547	O
second	548	554	O
opinion	555	562	O
is	563	565	O
a	566	567	O
well	568	572	O
-	572	573	O
established	573	584	O
practice	585	593	O
in	594	596	O
pathology	597	606	O
for	607	610	O
glass	611	616	O
slides	617	623	O
,	623	624	O
similar	625	632	O
consultation	633	645	O
via	646	649	O
virtual	650	657	O
microscopy	658	668	O
poses	669	674	O
multiple	675	683	O
controversial	684	697	O
issues	698	704	O
such	705	709	O
as	710	712	O
licensing	713	722	O
,	722	723	O
liability	724	733	O
,	733	734	O
security	735	743	O
,	743	744	O
reimbursement	745	758	O
,	758	759	O
and	760	763	O
scanning	764	772	O
quality	773	780	O
and	781	784	O
its	785	788	O
validation	789	799	O
.	799	800	O

Regulations	801	812	O
and	813	816	O
standardization	817	832	O
are	833	836	O
not	837	840	O
yet	841	844	O
in	845	847	O
place	848	853	O
that	854	858	O
pathologists	859	871	O
can	872	875	O
use	876	879	O
to	880	882	O
allay	883	888	O
these	889	894	O
fears	895	900	O
.	900	901	O

Nevertheless	902	914	O
,	914	915	O
if	916	918	O
the	919	922	O
virtual	923	930	O
microscopy	931	941	O
scans	942	947	O
are	948	951	O
of	952	954	O
optimal	955	962	O
quality	963	970	O
,	970	971	O
these	972	977	O
can	978	981	O
be	982	984	O
simply	985	991	O
substituted	992	1003	O
for	1004	1007	O
glass	1008	1013	O
slides	1014	1020	O
and	1021	1024	O
a	1025	1026	O
microscope	1027	1037	O
while	1038	1043	O
maintaining	1044	1055	O
all	1056	1059	O
other	1060	1065	O
practice	1066	1074	O
guidelines	1075	1085	O
for	1086	1089	O
second	1090	1096	O
opinion	1097	1104	O
consultation	1105	1117	O
.	1117	1118	O

Additionally	1119	1131	O
,	1131	1132	O
the	1133	1136	O
cost	1137	1141	O
and	1142	1145	O
maintenance	1146	1157	O
of	1158	1160	O
scanning	1161	1169	O
equipment	1170	1179	O
is	1180	1182	O
not	1183	1186	O
currently	1187	1196	O
affordable	1197	1207	O
to	1208	1210	O
most	1211	1215	O
practitioners	1216	1229	O
and	1230	1233	O
consultants	1234	1245	O
.	1245	1246	O

A	1247	1248	O
practice	1249	1257	O
model	1258	1263	O
that	1264	1268	O
offers	1269	1275	O
tertiary	1276	1284	O
consultation	1285	1297	O
in	1298	1300	O
gastrointestinal	1301	1317	B-Organism_subdivision
(	1318	1319	O
GI	1319	1321	B-Organism_subdivision
)	1321	1322	O
and	1323	1326	O
liver	1327	1332	B-Organ
pathology	1333	1342	O
is	1343	1345	O
presented	1346	1355	O
that	1356	1360	O
eliminates	1361	1371	O
the	1372	1375	O
cost	1376	1380	O
and	1381	1384	O
maintenance	1385	1396	O
of	1397	1399	O
scanners	1400	1408	O
by	1409	1411	O
the	1412	1415	O
consultants	1416	1427	O
and	1428	1431	O
clients	1432	1439	O
,	1439	1440	O
minimizes	1441	1450	O
the	1451	1454	O
need	1455	1459	O
for	1460	1463	O
review	1464	1470	O
of	1471	1473	O
glass	1474	1479	O
slides	1480	1486	O
,	1486	1487	O
facilitates	1488	1499	O
clinicopathological	1500	1519	O
and	1520	1523	O
radiological	1524	1536	O
correlation	1537	1548	O
and	1549	1552	O
serves	1553	1559	O
the	1560	1563	O
need	1564	1568	O
of	1569	1571	O
clients	1572	1579	O
who	1580	1583	O
need	1584	1588	O
timely	1589	1595	O
help	1596	1600	O
with	1601	1605	O
challenging	1606	1617	O
liver	1618	1623	B-Organ
and	1624	1627	O
GI	1628	1630	B-Organism_subdivision
cases	1631	1636	O
and	1637	1640	O
to	1641	1643	O
obtain	1644	1650	O
expert	1651	1657	O
opinion	1658	1665	O
for	1666	1669	O
dysplasia	1670	1679	O
in	1680	1682	O
Barrett	1683	1690	O
'	1690	1691	O
s	1691	1692	O
and	1693	1696	O
ulcerative	1697	1707	O
colitis	1708	1715	O
surveillance	1716	1728	O
biopsies	1729	1737	O
required	1738	1746	O
by	1747	1749	O
the	1750	1753	O
American	1754	1762	O
Gastroenterology	1763	1779	O
Association	1780	1791	O
(	1792	1793	O
AGA	1793	1796	O
)	1796	1797	O
.	1797	1798	O

This	1799	1803	O
model	1804	1809	O
has	1810	1813	O
been	1814	1818	O
practiced	1819	1828	O
for	1829	1832	O
3	1833	1834	O
years	1835	1840	O
and	1841	1844	O
applied	1845	1852	O
to	1853	1855	O
over	1856	1860	O
2000	1861	1865	O
cases	1866	1871	O
by	1872	1874	O
small	1875	1880	O
pathology	1881	1890	O
practices	1891	1900	O
in	1901	1903	O
the	1904	1907	O
50	1908	1910	O
United	1911	1917	O
States	1918	1924	O
and	1925	1928	O
a	1929	1930	O
single	1931	1937	O
consultant	1938	1948	O
GI	1949	1951	B-Organism_subdivision
and	1952	1955	O
liver	1956	1961	B-Organ
pathologist	1962	1973	O
.	1973	1974	O

Click	0	5	O
here	6	10	O
for	11	14	O
file	15	19	O

The	0	3	O
right	4	9	O
eye	10	13	B-Organ
of	14	16	O
a	17	18	O
50	19	21	O
-	21	22	O
year	22	26	O
-	26	27	O
old	27	30	O
patient	31	38	O
with	39	43	O
severe	44	50	O
hypertension	51	63	O
at	64	66	O
the	67	70	O
first	71	76	O
visit	77	82	O
.	82	83	O

(	84	85	O
a	85	86	O
)	86	87	O
Fundus	88	94	O
photograph	95	105	O
shows	106	111	O
serous	112	118	O
retinal	119	126	B-Multi-tissue_structure
detachment	127	137	O
.	137	138	O

The	139	142	O
optic	143	148	O
disc	149	153	O
is	154	156	O
pale	157	161	O
at	162	164	O
the	165	168	O
temporal	169	177	O
side	178	182	O
.	182	183	O

(	184	185	O
b	185	186	O
)	186	187	O
Optical	188	195	O
coherence	196	205	O
tomography	206	216	O
(	217	218	O
OCT	218	221	O
)	221	222	O
shows	223	228	O
retinal	229	236	B-Multi-tissue_structure
detachment	237	247	O
involving	248	257	O
the	258	261	O
fovea	262	267	O
and	268	271	O
cystic	272	278	O
change	279	285	O
of	286	288	O
inner	289	294	B-Multi-tissue_structure
retina	295	301	I-Multi-tissue_structure
.	301	302	O

(	303	304	O
c	304	305	O
)	305	306	O
Early	307	312	O
phase	313	318	O
images	319	325	O
of	326	328	O
fluorescein	329	340	O
angiography	341	352	O
(	353	354	O
FA	354	356	O
)	356	357	O
(	358	359	O
left	359	363	O
)	363	364	O
and	365	368	O
indocyanine	369	380	O
green	381	386	O
angiography	387	398	O
(	399	400	O
IA	400	402	O
)	402	403	O
(	404	405	O
right	405	410	O
)	410	411	O
.	411	412	O

(	413	414	O
d	414	415	O
)	415	416	O
Late	417	421	O
phase	422	427	O
images	428	434	O
of	435	437	O
FA	438	440	O
(	441	442	O
left	442	446	O
)	446	447	O
and	448	451	O
IA	452	454	O
(	455	456	O
right	456	461	O
)	461	462	O
.	462	463	O

FA	464	466	O
shows	467	472	O
window	473	479	O
defect	480	486	O
associated	487	497	O
with	498	502	O
macular	503	510	B-Tissue
cystic	511	517	O
change	518	524	O
.	524	525	O

Note	526	530	O
that	531	535	O
no	536	538	O
active	539	545	O
leakage	546	553	O
is	554	556	O
observed	557	565	O
in	566	568	O
the	569	572	O
area	573	577	O
with	578	582	O
serous	583	589	O
retinal	590	597	B-Multi-tissue_structure
detachment	598	608	O
or	609	611	O
cystoid	612	619	B-Pathological_formation
edema	620	625	I-Pathological_formation
.	625	626	O

IA	627	629	O
shows	630	635	O
decreased	636	645	O
perfusion	646	655	O
of	656	658	O
the	659	662	O
choroid	663	670	O
at	671	673	O
the	674	677	O
macula	678	684	B-Tissue
and	685	688	O
window	689	695	O
defect	696	702	O
with	703	707	O
the	708	711	O
damaged	712	719	O
RPE	720	723	O
.	723	724	O

Hypofluorescence	725	741	O
(	742	743	O
arrow	743	748	O
)	748	749	O
along	750	755	O
the	756	759	O
retinal	760	767	B-Tissue
artery	768	774	I-Tissue
are	775	778	O
observed	779	787	O
.	787	788	O

These	789	794	O
are	795	798	O
unique	799	805	O
findings	806	814	O
.	814	815	O

5	0	1	O
.	1	2	O

Conclusion	3	13	O

RLs	14	17	O
are	18	21	O
new	22	25	O
actors	26	32	O
in	33	35	O
animal	36	42	O
and	43	46	O
plant	47	52	O
defense	53	60	O
and	61	64	O
their	65	70	O
low	71	74	O
toxicity	75	83	O
and	84	87	O
biodegradability	88	104	O
make	105	109	O
them	110	114	O
promising	115	124	O
molecules	125	134	O
to	135	137	O
be	138	140	O
used	141	145	O
against	146	153	O
pathogens	154	163	O
.	163	164	O

In	165	167	O
this	168	172	O
respect	173	180	O
,	180	181	O
there	182	187	O
are	188	191	O
some	192	196	O
clues	197	202	O
now	203	206	O
available	207	216	O
for	217	220	O
the	221	224	O
success	225	232	O
of	233	235	O
RL	236	238	O
applications	239	251	O
in	252	254	O
greenhouses	255	266	O
to	267	269	O
fight	270	275	O
phytopathogens	276	290	O
.	290	291	O

A	292	293	O
better	294	300	O
understanding	301	314	O
of	315	317	O
RL	318	320	O
mode	321	325	O
of	326	328	O
action	329	335	O
,	335	336	O
especially	337	347	O
their	348	353	O
perception	354	364	O
and	365	368	O
the	369	372	O
signaling	373	382	O
pathways	383	391	O
activated	392	401	O
,	401	402	O
will	403	407	O
be	408	410	O
very	411	415	O
important	416	425	O
to	426	428	O
potentiate	429	439	O
their	440	445	O
beneficial	446	456	O
effects	457	464	O
in	465	467	O
plants	468	474	O
.	474	475	O

RLs	476	479	O
have	480	484	O
a	485	486	O
dual	487	491	O
mode	492	496	O
of	497	499	O
action	500	506	O
:	506	507	O
they	508	512	O
are	513	516	O
antimicrobial	517	530	O
and	531	534	O
also	535	539	O
stimulate	540	549	O
plant	550	555	O
defense	556	563	O
responses	564	573	O
.	573	574	O

This	575	579	O
dual	580	584	O
property	585	593	O
is	594	596	O
probably	597	605	O
very	606	610	O
important	611	620	O
for	621	624	O
the	625	628	O
efficiency	629	639	O
of	640	642	O
new	643	646	O
biopesticides	647	660	O
.	660	661	O

In	662	664	O
animals	665	672	O
,	672	673	O
the	674	677	O
use	678	681	O
of	682	684	O
RLs	685	688	O
is	689	691	O
also	692	696	O
at	697	699	O
an	700	702	O
advanced	703	711	O
stage	712	717	O
.	717	718	O

RLs	719	722	O
are	723	726	O
successfully	727	739	O
used	740	744	O
as	745	747	O
antimicrobial	748	761	O
agents	762	768	O
,	768	769	O
especially	770	780	O
for	781	784	O
skin	785	789	B-Organ
disease	790	797	O
treatment	798	807	O
.	807	808	O

Deep	809	813	O
insight	814	821	O
into	822	826	O
the	827	830	O
physiochemical	831	845	O
effects	846	853	O
of	854	856	O
RLs	857	860	O
and	861	864	O
their	865	870	O
biological	871	881	O
importance	882	892	O
would	893	898	O
reveal	899	905	O
new	906	909	O
dimensions	910	920	O
in	921	923	O
the	924	927	O
fields	928	934	O
of	935	937	O
research	938	946	O
like	947	951	O
agriculture	952	963	O
and	964	967	O
medicine	968	976	O
,	976	977	O
precisely	978	987	O
in	988	990	O
plant	991	996	O
defense	997	1004	O
,	1004	1005	O
disease	1006	1013	O
control	1014	1021	O
and	1022	1025	O
pathogenesis	1026	1038	O
.	1038	1039	O

An	1040	1042	O
understanding	1043	1056	O
of	1057	1059	O
bacterial	1060	1069	O
genera	1070	1076	O
producing	1077	1086	O
RLs	1087	1090	O
that	1091	1095	O
are	1096	1099	O
not	1100	1103	O
yet	1104	1107	O
well	1108	1112	O
studied	1113	1120	O
would	1121	1126	O
provide	1127	1134	O
light	1135	1140	O
on	1141	1143	O
these	1144	1149	O
fascinating	1150	1161	O
aspects	1162	1169	O
.	1169	1170	O

Objectives	0	10	O

Evaluate	11	19	O
relationships	20	33	O
between	34	41	O
MRI	42	45	O
and	46	49	O
clinical	50	58	O
/	58	59	O
laboratory	59	69	O
/	69	70	O
radiographic	70	82	O
findings	83	91	O
in	92	94	O
rheumatoid	95	105	O
arthritis	106	115	O
(	116	117	O
RA	117	119	O
)	119	120	O
.	120	121	O

Assessment	0	10	O
instruments	11	22	O

The	23	26	O
SCID	27	31	O
-	31	32	O
I	32	33	O
/	33	34	O
P	34	35	O
was	36	39	O
administered	40	52	O
by	53	55	O
psychiatrists	56	69	O
trained	70	77	O
and	78	81	O
certified	82	91	O
in	92	94	O
the	95	98	O
use	99	102	O
of	103	105	O
all	106	109	O
instruments	110	121	O
in	122	124	O
this	125	129	O
study	130	135	O
.	135	136	O

The	137	140	O
ICG	141	144	O
is	145	147	O
a	148	149	O
self	150	154	O
-	154	155	O
report	155	161	O
instrument	162	172	O
that	173	177	O
can	178	181	O
be	182	184	O
used	185	189	O
to	190	192	O
identify	193	201	O
CG	202	204	O
when	205	209	O
the	210	213	O
total	214	219	O
score	220	225	O
is	226	228	O
>	229	230	O
25	231	233	O
,	233	234	O
that	235	239	O
demonstrated	240	252	O
high	253	257	O
internal	258	266	O
consistency	267	278	O
(	279	280	O
Cronbach	280	288	O
'	288	289	O
s	289	290	O
alpha	291	296	O
=	297	298	O
0	299	300	O
.	300	301	O
94	301	303	O
)	303	304	O
,	304	305	O
and	306	309	O
convergent	310	320	O
and	321	324	O
criterion	325	334	O
validity	335	343	O
[	344	345	O
27	345	347	O
]	347	348	O
.	348	349	O

The	350	353	O
ICG	354	357	O
total	358	363	O
score	364	369	O
also	370	374	O
showed	375	381	O
a	382	383	O
fairly	384	390	O
high	391	395	O
association	396	407	O
with	408	412	O
the	413	416	O
Beck	417	421	O
Depression	422	432	O
Inventory	433	442	O
(	443	444	O
BDI	444	447	O
)	447	448	O
[	449	450	O
32	450	452	O
]	452	453	O
total	454	459	O
score	460	465	O
(	466	467	O
r	467	468	O
=	469	470	O
0	471	472	O
.	472	473	O
67	473	475	O
,	475	476	O
P	477	478	O
<	479	480	O
0	481	482	O
.	482	483	O
001	483	486	O
)	486	487	O
,	487	488	O
the	489	492	O
Texas	493	498	O
Revised	499	506	O
Inventory	507	516	O
of	517	519	O
Grief	520	525	O
(	526	527	O
TRIG	527	531	O
)	531	532	O
[	533	534	O
33	534	536	O
]	536	537	O
score	538	543	O
(	544	545	O
r	545	546	O
=	547	548	O
0	549	550	O
.	550	551	O
87	551	553	O
,	553	554	O
P	555	556	O
<	557	558	O
0	559	560	O
.	560	561	O
001	561	564	O
)	564	565	O
,	565	566	O
and	567	570	O
the	571	574	O
Grief	575	580	O
Measurement	581	592	O
Scale	593	598	O
(	599	600	O
GMS	600	603	O
)	603	604	O
[	605	606	O
34	606	608	O
]	608	609	O
score	610	615	O
(	616	617	O
r	617	618	O
=	619	620	O
0	621	622	O
.	622	623	O
70	623	625	O
,	625	626	O
P	627	628	O
<	629	630	O
0	631	632	O
.	632	633	O
001	633	636	O
)	636	637	O
.	637	638	O

The	639	642	O
ASA	643	646	O
-	646	647	O
27	647	649	O
is	650	652	O
a	653	654	O
self	655	659	O
-	659	660	O
report	660	666	O
measure	667	674	O
developed	675	684	O
to	685	687	O
rate	688	692	O
separation	693	703	O
anxiety	704	711	O
symptoms	712	720	O
in	721	723	O
adult	724	729	O
life	730	734	O
(	735	736	O
from	736	740	O
18	741	743	O
years	744	749	O
of	750	752	O
age	753	756	O
)	756	757	O
.	757	758	O

Principal	759	768	O
components	769	779	O
analysis	780	788	O
revealed	789	797	O
a	798	799	O
coherent	800	808	O
construct	809	818	O
of	819	821	O
adult	822	827	O
separation	828	838	O
anxiety	839	846	O
with	847	851	O
high	852	856	O
internal	857	865	O
consistency	866	877	O
(	878	879	O
Cronbach	879	887	O
'	887	888	O
s	888	889	O
alpha	890	895	O
=	896	897	O
0	898	899	O
.	899	900	O
95	900	902	O
)	902	903	O
and	904	907	O
sound	908	913	O
test	914	918	O
-	918	919	O
retest	919	925	O
reliability	926	937	O
(	938	939	O
r	939	940	O
=	941	942	O
0	943	944	O
.	944	945	O
86	945	947	O
;	947	948	O
P	949	950	O
<	951	952	O
0	953	954	O
.	954	955	O
001	955	958	O
)	958	959	O
.	959	960	O

Further	961	968	O
,	968	969	O
a	970	971	O
receiver	972	980	O
operation	981	990	O
characteristic	991	1005	O
(	1006	1007	O
ROC	1007	1010	O
)	1010	1011	O
analysis	1012	1020	O
against	1021	1028	O
the	1029	1032	O
semistructured	1033	1047	O
interview	1048	1057	O
yielded	1058	1065	O
a	1066	1067	O
high	1068	1072	O
area	1073	1077	O
under	1078	1083	O
the	1084	1087	O
curve	1088	1093	O
(	1094	1095	O
AUC	1095	1098	O
)	1098	1099	O
index	1100	1105	O
of	1106	1108	O
0	1109	1110	O
.	1110	1111	O
9	1111	1112	O
,	1112	1113	O
suggesting	1114	1124	O
that	1125	1129	O
the	1130	1133	O
questionnaire	1134	1147	O
is	1148	1150	O
an	1151	1153	O
adequate	1154	1162	O
alternative	1163	1174	O
measure	1175	1182	O
of	1183	1185	O
adult	1186	1191	O
separation	1192	1202	O
anxiety	1203	1210	O
[	1211	1212	O
29	1212	1214	O
]	1214	1215	O
.	1215	1216	O

The	1217	1220	O
WSAS	1221	1225	O
is	1226	1228	O
a	1229	1230	O
self	1231	1235	O
-	1235	1236	O
report	1236	1242	O
scale	1243	1248	O
of	1249	1251	O
functional	1252	1262	O
impairment	1263	1273	O
that	1274	1278	O
includes	1279	1287	O
five	1288	1292	O
questions	1293	1302	O
rating	1303	1309	O
interference	1310	1322	O
of	1323	1325	O
psychiatric	1326	1337	O
symptoms	1338	1346	O
in	1347	1349	O
work	1350	1354	O
,	1354	1355	O
home	1356	1360	O
management	1361	1371	O
,	1371	1372	O
social	1373	1379	O
or	1380	1382	O
private	1383	1390	O
leisure	1391	1398	O
activities	1399	1409	O
,	1409	1410	O
and	1411	1414	O
ability	1415	1422	O
to	1423	1425	O
form	1426	1430	O
and	1431	1434	O
maintain	1435	1443	O
close	1444	1449	O
relationships	1450	1463	O
with	1464	1468	O
others	1469	1475	O
.	1475	1476	O

Each	1477	1481	O
question	1482	1490	O
is	1491	1493	O
rated	1494	1499	O
on	1500	1502	O
a	1503	1504	O
0	1505	1506	O
to	1507	1509	O
8	1510	1511	O
scale	1512	1517	O
with	1518	1522	O
0	1523	1524	O
indicating	1525	1535	O
no	1536	1538	O
impairment	1539	1549	O
at	1550	1552	O
all	1553	1556	O
and	1557	1560	O
8	1561	1562	O
indicating	1563	1573	O
very	1574	1578	O
severe	1579	1585	O
impairment	1586	1596	O
.	1596	1597	O

The	1598	1601	O
Cronbach	1602	1610	O
'	1610	1611	O
s	1611	1612	O
alpha	1613	1618	O
measure	1619	1626	O
of	1627	1629	O
internal	1630	1638	O
scale	1639	1644	O
consistency	1645	1656	O
ranged	1657	1663	O
from	1664	1668	O
0	1669	1670	O
.	1670	1671	O
70	1671	1673	O
to	1674	1676	O
0	1677	1678	O
.	1678	1679	O
94	1679	1681	O
,	1681	1682	O
the	1683	1686	O
test	1687	1691	O
-	1691	1692	O
retest	1692	1698	O
correlation	1699	1710	O
was	1711	1714	O
0	1715	1716	O
.	1716	1717	O
73	1717	1719	O
,	1719	1720	O
and	1721	1724	O
the	1725	1728	O
WSAS	1729	1733	O
interactive	1734	1745	O
voice	1746	1751	O
response	1752	1760	O
administrations	1761	1776	O
gave	1777	1781	O
correlations	1782	1794	O
of	1795	1797	O
0	1798	1799	O
.	1799	1800	O
81	1800	1802	O
and	1803	1806	O
0	1807	1808	O
.	1808	1809	O
86	1809	1811	O
with	1812	1816	O
clinician	1817	1826	O
interviews	1827	1837	O
[	1838	1839	O
30	1839	1841	O
]	1841	1842	O
.	1842	1843	O

Correlations	1844	1856	O
of	1857	1859	O
WSAS	1860	1864	O
with	1865	1869	O
severity	1870	1878	O
of	1879	1881	O
depression	1882	1892	O
and	1893	1896	O
obsessive	1897	1906	O
-	1906	1907	O
compulsive	1907	1917	O
disorder	1918	1926	O
symptoms	1927	1935	O
were	1936	1940	O
0	1941	1942	O
.	1942	1943	O
76	1943	1945	O
and	1946	1949	O
0	1950	1951	O
.	1951	1952	O
61	1952	1954	O
,	1954	1955	O
respectively	1956	1968	O
,	1968	1969	O
and	1970	1973	O
the	1974	1977	O
scores	1978	1984	O
were	1985	1989	O
sensitive	1990	1999	O
to	2000	2002	O
patient	2003	2010	O
differences	2011	2022	O
in	2023	2025	O
disorder	2026	2034	O
severity	2035	2043	O
and	2044	2047	O
treatment	2048	2057	O
-	2057	2058	O
related	2058	2065	O
change	2066	2072	O
[	2073	2074	O
30	2074	2076	O
]	2076	2077	O
.	2077	2078	O

The	2079	2082	O
MOODS	2083	2088	O
-	2088	2089	O
SR	2089	2091	O
is	2092	2094	O
an	2095	2097	O
instrument	2098	2108	O
developed	2109	2118	O
and	2119	2122	O
validated	2123	2132	O
to	2133	2135	O
assess	2136	2142	O
lifetime	2143	2151	O
mood	2152	2156	O
spectrum	2157	2165	O
symptoms	2166	2174	O
[	2175	2176	O
35	2176	2178	O
]	2178	2179	O
,	2179	2180	O
including	2181	2190	O
manic	2191	2196	O
and	2197	2200	O
depressive	2201	2211	O
features	2212	2220	O
,	2220	2221	O
rhythmicity	2222	2233	O
and	2234	2237	O
vegetative	2238	2248	O
functions	2249	2258	O
.	2258	2259	O

The	2260	2263	O
manic	2264	2269	O
and	2270	2273	O
depressive	2274	2284	O
components	2285	2295	O
are	2296	2299	O
subtyped	2300	2308	O
into	2309	2313	O
mood	2314	2318	O
,	2318	2319	O
energy	2320	2326	O
and	2327	2330	O
cognition	2331	2340	O
domains	2341	2348	O
,	2348	2349	O
focusing	2350	2358	O
on	2359	2361	O
manic	2362	2367	O
or	2368	2370	O
depressive	2371	2381	O
symptoms	2382	2390	O
,	2390	2391	O
respectively	2392	2404	O
.	2404	2405	O

The	2406	2409	O
rhythmicity	2410	2421	O
and	2422	2425	O
vegetative	2426	2436	O
functions	2437	2446	O
domain	2447	2453	O
include	2454	2461	O
changes	2462	2469	O
in	2470	2472	O
energy	2473	2479	O
,	2479	2480	O
physical	2481	2489	O
wellbeing	2490	2499	O
,	2499	2500	O
mental	2501	2507	O
and	2508	2511	O
physical	2512	2520	O
efficiency	2521	2531	O
,	2531	2532	O
related	2533	2540	O
to	2541	2543	O
the	2544	2547	O
weather	2548	2555	O
and	2556	2559	O
season	2560	2566	O
,	2566	2567	O
and	2568	2571	O
changes	2572	2579	O
in	2580	2582	O
appetite	2583	2591	O
,	2591	2592	O
sleep	2593	2598	O
and	2599	2602	O
sexual	2603	2609	O
activities	2610	2620	O
.	2620	2621	O

The	2622	2625	O
sum	2626	2629	O
of	2630	2632	O
the	2633	2636	O
scores	2637	2643	O
on	2644	2646	O
the	2647	2650	O
3	2651	2652	O
manic	2653	2658	O
domains	2659	2666	O
(	2667	2668	O
mood	2668	2672	O
,	2672	2673	O
energy	2674	2680	O
,	2680	2681	O
cognition	2682	2691	O
)	2691	2692	O
constitutes	2693	2704	O
the	2705	2708	O
'	2709	2710	O
manic	2710	2715	O
component	2716	2725	O
'	2725	2726	O
(	2727	2728	O
62	2728	2730	O
items	2731	2736	O
)	2736	2737	O
and	2738	2741	O
that	2742	2746	O
of	2747	2749	O
the	2750	2753	O
3	2754	2755	O
depressive	2756	2766	O
domains	2767	2774	O
the	2775	2778	O
'	2779	2780	O
depressive	2780	2790	O
component	2791	2800	O
'	2800	2801	O
(	2802	2803	O
63	2803	2805	O
items	2806	2811	O
)	2811	2812	O
.	2812	2813	O

The	2814	2817	O
rhythmicity	2818	2829	O
and	2830	2833	O
vegetative	2834	2844	O
functions	2845	2854	O
domain	2855	2861	O
includes	2862	2870	O
29	2871	2873	O
items	2874	2879	O
.	2879	2880	O

The	2881	2884	O
instrument	2885	2895	O
can	2896	2899	O
be	2900	2902	O
downloaded	2903	2913	O
from	2914	2918	O
http	2919	2923	O
:	2923	2924	O
/	2924	2925	O
/	2925	2926	O
www	2926	2929	O
.	2929	2930	O
spectrum	2930	2938	O
-	2938	2939	O
project	2939	2946	O
.	2946	2947	O
org	2947	2950	O
.	2950	2951	O

